<SEC-DOCUMENT>0001193125-13-308167.txt : 20130730
<SEC-HEADER>0001193125-13-308167.hdr.sgml : 20130730
<ACCEPTANCE-DATETIME>20130729215438
ACCESSION NUMBER:		0001193125-13-308167
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		12
FILED AS OF DATE:		20130730
DATE AS OF CHANGE:		20130729

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AxoGen, Inc.
		CENTRAL INDEX KEY:			0000805928
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				411301878
		STATE OF INCORPORATION:			MN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-188597
		FILM NUMBER:		13993921

	BUSINESS ADDRESS:	
		STREET 1:		13859 PROGRESS BLVD.
		STREET 2:		SUITE 100
		CITY:			ALACHUA
		STATE:			FL
		ZIP:			32615
		BUSINESS PHONE:		(386) 462-6817

	MAIL ADDRESS:	
		STREET 1:		13859 PROGRESS BLVD.
		STREET 2:		SUITE 100
		CITY:			ALACHUA
		STATE:			FL
		ZIP:			32615

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LECTEC CORP /MN/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d532389ds1a.htm
<DESCRIPTION>AMENDMENT NO. 3 TO FORM S-1
<TEXT>
<HTML><HEAD>
<TITLE>Amendment No. 3 to Form S-1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>As filed with the Securities and Exchange Commission on July 29, 2013 </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registration No.&nbsp;333-188597 </B></FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>AMENDMENT NO. 3 </B></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="5"><B>TO </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM S-1 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>REGISTRATION STATEMENT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B><I>UNDER </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B><I>THE SECURITIES ACT OF 1933 </I></B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>AXOGEN, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Minnesota</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5047</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>41-1301878</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Primary Standard Industrial</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Classification Code Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification Number)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13859 Progress Blvd., Suite 100 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Alachua, Florida 32615 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(386) 462-6800 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address, including zip code and telephone number,
including area code, of registrant&#146;s principal executive offices) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Karen Zaderej
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Chief Executive Officer </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>AxoGen, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13859 Progress Blvd., Suite 100 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Alachua, Florida 32615 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(386) 462-6800 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Name, address, including zip code and telephone number,
including area code, of agent for service) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Copies to:
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gregory G. Freitag </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Chief Financial Officer and General Counsel </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AxoGen, Inc. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13859 Progress Blvd., Suite 100 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Alachua, Florida 32615 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(386) 462-6800 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Fahd M.T. Riaz</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Andrew D. Thorpe</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Emilio Ragosa</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Orrick, Herrington &amp; Sutcliffe LLP</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Morgan, Lewis&nbsp;&amp; Bockius LLP</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>405 Howard Street</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1701 Market Street</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>San Francisco, CA 94105</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Philadelphia, PA 19103</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Telephone: (415) 773-5700</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(215) 963-5000</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Approximate date of commencement of proposed sale to the public:</B> As soon as practicable after the effective date of this
Registration Statement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any of the securities being registered on this form are to be offered on a delayed or continuous
basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If this
Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant is a
large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2
of the Exchange Act. (Check one): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-accelerated filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until
the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the registration statement shall
become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></FONT></P> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2" COLOR="#de1a1e"><B>The
information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is declared effective. This prospectus is not an offer to sell
these securities and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2" COLOR="#de1a1e"><B>Subject to Completion, dated July 29, 2013 </B></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Prospectus </B></FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>3,658,536 Shares </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>


<IMG SRC="g532389g00k21.jpg" ALT="LOGO">
 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>AXOGEN, INC. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="4"><B>Common Shares </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are offering up to
3,658,536 common shares, par value $.01 per share. Our common shares currently trade on the OTCQB Marketplace, operated by OTC Markets Group, under the symbol &#147;AXGN.&#148; The last reported sale price of our common shares on the OTCQB
Marketplace on July 26, 2013 was $4.10 per share. We have applied to list our common shares on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and expect that, after the
pricing of this offering, our common shares will trade on the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; under the symbol &#147; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.&#148;
</FONT></P>  <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Investing in our securities involves a high degree of risk. See &#147;<A HREF="#toc532389_2">Risk Factors</A>&#148; beginning on page
8. </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Per&nbsp;Share</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Public offering price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Underwriting discounts and commissions(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds, before expenses, to us</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(1)</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>See &#147;Underwriting&#148; in this prospectus for a description of compensation payable to the underwriters. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have granted to the underwriters an option to purchase up to 548,780 additional common shares to cover over-allotments, if any, exercisable at any
time until 30 days after the date of this prospectus. If the underwriters exercise the option in full, the total underwriting discounts and commissions payable by us will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
and the total proceeds to us, before expenses, will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters expect to deliver the
common shares on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>JMP&nbsp;Securities </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="5"><B>Ladenburg&nbsp;Thalmann&nbsp;&amp;&nbsp;Co. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The date of this prospectus is
<B></B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g532389g33w70.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A NAME="toc"></A>TABLE OF CONTENTS </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Page</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_1">PROSPECTUS SUMMARY</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_2">RISK FACTORS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_3">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_4">USE OF PROCEEDS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_5">DIVIDEND POLICY</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_6">COMMON SHARE PRICE RANGE</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_7">CAPITALIZATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_8">DILUTION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_9">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_100">BUSINESS </A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_10">MANAGEMENT</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_11">EXECUTIVE COMPENSATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_12">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">83</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_13">PRINCIPAL SHAREHOLDERS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">84</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_14">DESCRIPTION OF COMMON SHARES</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_15">UNDERWRITING</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">88</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_16">LEGAL MATTERS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_17">EXPERTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">91</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_18">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_19">INDEX TO FINANCIAL STATEMENTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Neither we nor any of the underwriters has authorized anyone to provide you with information different from, or in addition to, that
contained in this prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. Neither we nor any of the underwriters is making an offer to sell or seeking offers to buy these securities in any
jurisdiction where, or to any person to whom, the offer or sale is not permitted. The information in this prospectus is accurate only as of its date regardless of the time of delivery of this prospectus or of any sale of our common shares. Our
business, financial condition, results of operations and future growth prospects may have changed since those dates. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For investors outside the United States: neither we nor any of the underwriters has done anything that would permit this offering or
possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and
the distribution of this prospectus outside of the United States. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>This prospectus includes estimates, statistics and
other industry and market data that we obtained from industry publications, research, surveys and studies conducted by third parties and publicly available information. Such data involves a number of assumptions and limitations and contains
projections and estimates of the future performance of the industries in which we operate that are subject to a high degree of uncertainty. This prospectus also includes data based on our own internal estimates. We caution you not to give undue
weight to such projections, assumptions and estimates. </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">i </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_1"></A>PROSPECTUS SUMMARY </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This summary highlights information contained in other parts of this prospectus. Because it is only a summary, it does not contain all
of the information that you should consider before investing in our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere in this prospectus. You should read the
entire prospectus carefully, especially the section entitled &#147;Risk Factors&#148; and our consolidated financial statements and related notes, before deciding to buy our securities. Unless otherwise stated, all references to &#147;us,&#148;
&#147;our,&#148; &#147;we,&#148; &#147;AxoGen,&#148; the &#147;Company&#148; and similar designations refer to AxoGen, Inc. and its subsidiary AxoGen Corporation. </I></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Company Overview </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a leading regenerative medicine company dedicated
to advancing the science and commercialization of peripheral nerve repair solutions. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of muscle function and/or
feeling. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nerves can be damaged in a number of ways. When a nerve is cut due to a traumatic injury or surgery, functionality
of the nerve may be compromised, causing the nerve to no longer carry the signals to and from the brain to the muscles and skin. This type of injury generally requires a surgical repair. The traditional gold standard has been to either suture the
nerve ends together directly without tension or to bridge the gap between the nerve ends with a less important nerve surgically removed from elsewhere in the patient&#146;s own body referred to as nerve autograft. In addition, pressure on a nerve or
blunt force trauma can cause nerve injuries that may require surgical intervention. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">In order to improve
the options available for the surgical repair and regeneration of peripheral nerves, we have developed and licensed patented and patent pending technologies. Our innovative approach to regenerative medicine has resulted in first-in-class products
that we believe will define their product categories. Our products offer a full suite of surgical nerve repair solutions including Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, the only off-the-shelf commercially available processed nerve allograft, human nerve tissue obtained from a donor, for bridging severed nerves without
the comorbidities of an autograft second surgical site, such as loss of feeling where the nerve was removed and potential pain at the donor site. Our AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> line of products are a natural scaffold ExtraCellular Matrix, or ECM, derived from pig tissue. AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector is used to facilitate the tensionless repair of severed nerves, and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector is used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s products are used by surgeons during surgical interventions to repair a wide variety of traumatic
nerve injuries ranging from a simple laceration of a finger to complex brachial plexus (an injury to the network of nerves that originate in the neck). The Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft provides surgeons with a three-dimensional structure of a natural nerve. This structure is essential and allows for bridging nerve gaps or discontinuities
in the range of 5mm to 70mm. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The January 2012 edition of Microsurgery and November 2012 edition of The
Journal of Hand Surgery each contain an article summarizing study results from patients included in our ongoing
RANGER<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> study, an observational study of outcomes from the use of Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. The most recent presentation of data from the RANGER<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> study found that in 113 nerve repairs, the use of Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft has been associated with meaningful motor and sensory recovery in 87% of nerve discontinuities between 5 and 50 mm. According to Brooks, et al.,
&#147;outcomes of Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft compare favorably with those reported in the literature for nerve
autograft and the processed nerve allograft returned a higher rate of meaningful functional recovery than those reported in the literature for nerve conduits.&#148;</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Additionally, no implant related adverse events have been reported. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft has beneficial product and sales synergies with the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
Nerve Connector. Complementary to our Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, our AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector is used to align and connect nerves with less than a 5mm gap between the severed nerve ends. Our
AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector is designed to protect and isolate the nerve during the healing process after surgery.
Furthermore, our AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products provide the unique features of pliability, suturability, and translucence
for visualization of the underlying nerve, while also allowing the patient&#146;s own cells to incorporate into the product to remodel and form a tissue similar to the nerve epineurium. </FONT></P>
<P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1</SUP>&nbsp;</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">See &#147;Business&#151; Sales and Marketing &#151; Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft Performance&#148; for full citation information. </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft has been processed and distributed since 2007 as a human cell, tissue, and cellular and tissue-based product, hereafter referred herein as HCT/P, pursuant
to section 361 of the Public Health Service Act and 21 CFR &#167; 1271 controls, based on AxoGen&#146;s good faith belief that the Avance Nerve Graft was a HCT/P tissue product. In 2010, the Food and Drug Administration, or FDA, determined that the
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft was a biological product that would be reviewed and regulated by the Center for Biologics
Evaluation and Research, or CBER, under the biologics licensing provision of the Public Health Service, or PHS, Act. We subsequently agreed with the FDA on a transition plan for Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft from a HCT/P product to a licensed biological product. We are able to continue to sell Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft pursuant to a November 2010 letter from the FDA stating the agency&#146;s intent to exercise enforcement discretion with respect to the introduction or
delivery for introduction into interstate commerce of the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft provided we meet the conditions
for the transition specified in the letter. One such condition is that we conduct a phase 3 clinical trial to demonstrate the safety, purity and potency of the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft under a Special Protocol Assessment, or SPA, and the FDA has subsequently agreed to our SPA. In accordance with FDA regulations in 21 CFR &#167;312, we
submitted an Investigational New Drug Application, or IND, to the FDA in April 2013 and we are currently responding to FDA comments regarding it. We expect that enrollment of patients into the phase 3 clinical trial will occur later this year
following approval of the IND. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products are manufactured by Cook Biotech Incorporated, referred to herein as Cook Biotech. Under the license agreement with Cook Biotech, we are the exclusive
worldwide distributor of the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products for use in the peripheral and central nervous system, but
excluding use of the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product in the oral cavity for endodontic and periodontal applications and oral
and maxillofacial surgery solely as they relate to dental, soft or hard, tissue repair or reconstruction. The exclusion results in certain areas of AxoGen&#146;s market expansion into the oral surgery market being limited to the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. The AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products are Class II medical devices that FDA found substantially equivalent to class II predicate devices, and thus, cleared for marketing under FDA&#146;s 510(k)
program. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;5, 2012, we entered into a Revenue Interests Purchase Agreement, which we refer
to as the Royalty Contract, with PDL BioPharma, Inc., or PDL, pursuant to which we sold to PDL the right to receive specified royalties on our Net Revenues, as defined in the Royalty Contract, generated by the sale, distribution or other use of our
products Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
Nerve Protector, referred to as the Assigned Interests. The Royalty Contract has a term of eight years. Under the Royalty Contract, PDL is to receive royalty payments based on a 9.95% royalty rate of our Net Revenues, as defined in the Royalty
Contract, subject to certain agreed upon minimum payment requirements of approximately $1.3 to $2.5 million per quarter which begin in the fourth quarter of 2014 as provided in the Royalty Contract. The total consideration PDL paid to AxoGen was
$20,800,000, or the Funded Amount. The Royalty Contract also contains certain call provisions, including a call right by PDL in connection with a change of control, is secured by our Net Revenues, restricts our ability to pay dividends and grants
PDL a right to a designee on our Board of Directors. Further, on October 5, 2016, or in the event of the occurrence of a material adverse event, our transfer of revenue interest or substantially all of our interest in the products or our bankruptcy
or material breach of the Royalty Contract, PDL may require us to repurchase the Assigned Interests, referred to herein as the Put, at the Put Price which is equal to the sum of (i) an amount that, when paid to PDL, would generate a 20% internal
rate of return to PDL, called the Put Rate, on the Funded Amount, taking into consideration payments made to PDL by us, and (ii) any Delinquent Assigned Interests Payment, as defined in the Royalty Contract, we owed to PDL. The arrangement was
entered into because we could not obtain debt financing under a traditional credit facility with a lender to the extent of the Funded Amount and we believed the cost of capital for an equity transaction at the time was prohibitive. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently promote, market and sell our family of products through our own direct sales force and independent
sales representatives. Following the publication of results from our RANGER<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> study in 2012, we invested in
expanding our commercial capabilities and implemented a number of sales initiatives which we believe position us to further build awareness and drive sales growth of our Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
products. For the three months ended March&nbsp;31, 2013, our total revenue was approximately $2.1 million and our net loss was approximately $3.4 million, with a gross margin of approximately 74%. For the twelve months ended December&nbsp;31, 2012,
our total revenue was approximately $7.7 million and our net loss was approximately $9.4 million, with a gross margin of approximately 75%. For the year ended December&nbsp;31, 2011, our total revenue was approximately $4.8 million, and our net loss
was approximately $10.2 million, with a gross margin of approximately 50%. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Associated with Our Business </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks are described
in more detail in the &#147;Risk Factors&#148; section of this prospectus immediately following this prospectus summary. These risks include the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen has not experienced positive cash flow from its operations, and the ability to achieve positive cash flow from operations will depend on
increasing sales of its products, which may not be achievable. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s revenue growth depends on its ability to expand its sales force and develop new customers, and there can be no assurance that these
efforts will result in significant increase in sales. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s revenue depends solely on three products. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen is a party to the Royalty Contract with PDL which requires it to pay royalty fees that could materially adversely affect its financial position.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s business is subject to continuing regulatory compliance by the FDA and other authorities which is costly and could result in negative
effects on its business. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Failure to protect AxoGen&#146;s Intellectual Property rights could result in costly and time consuming litigation and its loss of any potential
competitive advantage. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The price of AxoGen&#146;s common shares could be highly volatile due to a number of factors, which could lead to losses by investors and costly
securities litigation. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Recent Developments </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On July&nbsp;11, 2013, we announced the following operating results for the quarter ended June&nbsp;30, 2013. The following results have
been prepared by, and are the responsibility of, management and have not been reviewed or audited by our independent registered public accounting firm. We believe the following results constitute a fair representation of the financial status of
AxoGen. Our financial statements for the 2013 second quarter have not yet been finalized and therefore are not available at this time. </FONT></P>  <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Revenue </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenues for the second quarter 2013 were $2.86 million, up 42.2%
compared to $2.01 million in the second quarter 2012, driven by an increase in the number of facilities utilizing our products and increased penetration of existing accounts. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Gross Profit </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gross profit for the second quarter 2013 was $2.23 million,
up 47.6% compared to $1.51 million in the second quarter 2012. Gross profit margin for the second quarter 2013 was 77.9%, up 2.8% compared to 75.1% in the second quarter 2012. The year-over-year improvement in gross profit and gross margin was
primarily attributable to revenue growth and a product price increase implemented during the first quarter 2013, respectively. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Operating Expenses </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Total operating expenses in the second quarter 2013 were $4.42 million, up 42.8% compared to $3.10 million in the second quarter 2012. As a percentage of revenues, operating expenses were up 0.73% in the
second quarter 2013 as compared to the same period in 2012. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second quarter 2013 sales and marketing expense was $2.53
million, up 60.0% compared to $1.58 million in the second quarter 2012. The increase was primarily attributable to increased commissions due to higher sales and the expansion of the Company&#146;s marketing efforts and direct sales force. Direct
sales force personnel require time to become effective in the territory and new sales personnel hired during the first and second quarters of 2013 are not expected to contribute significantly to revenue in the third quarter of this year. </FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second quarter 2013 general and administrative expense was $1.40 million, up 21.8% compared to $1.15 million in the second quarter
2012. The increase was primarily attributable to increased salary expense and benefits, travel and public company expenses. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second quarter 2013 research and development expense was $0.50 million, up 35.7% compared to $0.37 million in the second quarter 2012.
The increase was primarily attributable to costs associated with the Company&#146;s investment in clinical studies that support the use and regulatory position of the Company&#146;s products. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Loss from Operations and Net Loss </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Operating loss in the second quarter 2013 was $2.20 million, compared to $1.59 million in the second quarter 2012. Net loss in the second quarter 2013 was $3.45 million, or ($0.31) per share, compared to
net loss of $1.03 million, or ($0.09) per share, in the second quarter 2012. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Balance Sheet </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2013, the Company had $8.69 million in cash and cash equivalents and approximately $23.38 million in long-term note
payable &#150; revenue interest purchase agreement. AxoGen had working capital of approximately $12.22 million and a current ratio of 8.7 at June&nbsp;30, 2013, compared to working capital of $16.82 million and a current ratio of 12.4 at
December&nbsp;31, 2012. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Corporate Information </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We were incorporated under the laws of Minnesota in 1977. Our principal executive offices are located at 13859 Progress Blvd., Suite 100, Alachua, Florida 32615 and our telephone number is
(386)&nbsp;462-6800. Our website address is <U>www.axogeninc.com</U>. We have included our website address in this prospectus solely as an inactive textual reference. The information contained on, or that can be accessed through, our website is not
part of this prospectus. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The Offering </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="57%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Common shares offered by us</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,658,536 shares (or 4,207,316 shares if the underwriters&#146; over-allotment option is exercised in full)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Common shares outstanding after this offering</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,798,475 shares (or 15,347,255 shares if the underwriters&#146; over-allotment option is exercised in full)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Use of proceeds</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate that the net proceeds to us from the sale of common shares in this offering will be approximately $13,490,000 or approximately $15,582,500 if the underwriters
exercise their over-allotment option in full, in each case assuming a public offering price of $4.10 per common share and after deducting estimated underwriting discounts and commissions and offering expenses payable by us. We intend to use the net
proceeds from this offering to continue our product commercialization and marketing efforts, development of our product pipeline, including product line extensions, and for general working capital purposes. See &#147;Use of
Proceeds.&#148;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current trading on OTCQB Marketplace</B><B> </B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our common shares currently trade on the OTCQB Marketplace under the symbol &#147;AXGN.&#148;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Anticipated Listing</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with this offering we intend to list our common shares on under the symbol &#147;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; .&#148;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risk factors</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">You should read the &#147;Risk Factors&#148; section of this prospectus for a discussion of factors to consider carefully before deciding to invest in our common
shares.</FONT></TD></TR>
</TABLE>  <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number of our common shares outstanding after this offering is based on 11,139,939 common shares outstanding as of July 26, 2013 and assumes no exercise of the
underwriter&#146;s option to purchase an additional 548,780 shares to cover over-allotments, and excludes: </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,986,276 common shares issuable upon the exercise of options outstanding as of July 26, 2013 at a weighted average exercise price of $2.67 per share;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">89,686 common shares issuable upon the exercise of warrants outstanding as of July 26, 2013 at an exercise price of $2.23 per share; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">602,914 additional common shares available for future issuance as of July 26, 2013 under our AxoGen 2010 Stock Incentive Plan.
</FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless otherwise indicated, all information in this prospectus assumes no exercise of the outstanding
options or the warrants described above. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Summary Consolidated Financial Data </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The summary financial data below as of and for the years ended December&nbsp;31, 2012, 2011 and 2010 have been derived from our audited
consolidated financial statements. Our audited consolidated financial statements as of December&nbsp;31, 2012 and 2011 and for the years ended December&nbsp;31, 2012 and 2011 are included elsewhere in this prospectus. Our audited consolidated
financial statements as of December&nbsp;31, 2010 and for the year ended December&nbsp;31, 2010 are not included in this prospectus. The summary financial data as of March&nbsp;31, 2013 and 2012 and for the three months ended March&nbsp;31, 2013 and
2012 have been derived from our consolidated financial statements included elsewhere in this prospectus. You should read the summary financial data together with &#147;Capitalization,&#148; &#147;Management&#146;s Discussion and Analysis of
Financial Condition&#148; and &#147;Results of Operations&#148; and our financial statements and the related notes included elsewhere in this prospectus. Our historical results for any prior period are not necessarily indicative of results to be
expected in any future period. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three months ended March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Statement of operations data:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands, except share and per share data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,143</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,653</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,692</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,849</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,004</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cost of goods sold</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">560</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">439</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,962</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,427</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,379</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gross Profit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,583</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,214</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,730</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,422</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs and expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales and marketing</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,894</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,629</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,884</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,379</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,007</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">407</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">296</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,427</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">697</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">436</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,606</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,230</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,221</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,316</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,664</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Costs and Expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,907</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,155</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,392</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,107</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,324</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,941</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,802</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,970</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,482</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,114</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,354</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(942</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net Loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,438</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,156</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,220</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,424</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss available to common shareholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,438</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,418</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,248</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,990</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average basic and diluted common shares outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,124,633</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,062,339</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,089,425</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,697,390</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">836,645</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss Per Common Share &#150; basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.77</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8.35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Balance sheets data:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and Cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,642</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,907</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,191</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,799</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,852</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,477</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,231</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,495</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,857</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,357</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,060</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,424</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,105</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Temporary equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,412</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total shareholders&#146; equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,005</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,829</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,071</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(27,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD>
<TD HEIGHT="16" COLSPAN="12"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Statements of cash flows data:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used for operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,651</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,478</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,662</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,079</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,943</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash (used for) provided by investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(71</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(72</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,359</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,531</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_2"></A>RISK FACTORS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Investing in our common shares involves a high degree of risk. Before you decide to invest in our securities, you should consider
carefully the risks described below, as well as the other information contained in this prospectus. The risks described below are not the only ones facing us. Additional risks not presently known to us or that we currently deemed immaterial may also
impair our business operations. </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>If any of the following risks actually occurs, our business, financial condition,
results of operations and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common shares could decline, and you may lose all or part of your investment. </I></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risk Related To Company </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen has not experienced positive cash flow from its operations, and the ability to achieve positive cash flow from operations
will depend on increasing sales of its products, which may not be achievable. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen has historically operated with
negative cash flow from its operations. As of March&nbsp;31, 2013, AxoGen had an accumulated deficit of approximately $61.0 million. If AxoGen product sales do not increase as anticipated, then it will continue to experience negative cash flows and
adverse operating conditions. AxoGen&#146;s continuing capital needs and other factors, could cause the Company to raise additional funds through public or private equity offerings, debt financings or from other sources. The sale of additional
equity may result in dilution to AxoGen&#146;s shareholders. There is no assurance that AxoGen will be able to secure funding on terms acceptable to it, or at all. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen&#146;s revenue growth depends on its ability to expand its sales force and develop new customers, and there can be no assurance that these efforts will result in significant increase in
sales. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen is in the process of investing in its sales channel composed of a combination of its direct sales force
and independent distributors to allow it to reach new customers. There can be no assurance that these efforts will be successful in expanding AxoGen&#146;s product sales. AxoGen currently sells products directly through its employees and indirectly
through distributor relationships. AxoGen is engaged in a major initiative to build and further expand sales and marketing capabilities. The incurrence of these expenses impacts AxoGen&#146;s operating results, and there can be no assurance of their
effectiveness. If AxoGen is unable to develop its sales force and new customers, or increase sales to existing customers, it may not be able to grow revenue or maintain its current level of revenue generation. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen&#146;s revenue depends solely on three products. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">All of AxoGen&#146;s revenue is currently derived from only three products, the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
Nerve Connector, for the treatment of peripheral nerve damage. Its ability to generate revenue is dependent on the success of these products. Accordingly, any disruption in AxoGen&#146;s ability to generate revenue from the sale of these products
will have a material adverse impact on its business, results of operations, financial condition and growth prospects. In addition, AxoGen&#146;s expenditures for research and development are minimal and funding to develop, or increase efforts to
find collaboration or licensing opportunities to obtain, additional products will be necessary. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The
AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products are only available through an exclusive distribution agreement with Cook Biotech. Such
contract is for an initial seven year term and following such initial term, the agreement automatically renews for an additional seven (7)&nbsp;year period provided that the parties agree to meet at least ninety (90)&nbsp;days before the end of such
initial term to review whether the purchase price of the products obtained from Cook Biotech need to be adjusted and reasonably agree to such adjustment in writing, where such agreement shall not be unreasonably withheld. However, there are
conditions for continuation of the agreement, including payment terms and minimum purchase requirements, that if breached could result in an earlier termination of the agreement; except that through mutual agreement the parties have not established
such minimums and to date have not enforce such minimum purchase provision. Additionally, in the event that AxoGen and Cook Biotech were to fail to reach an agreement as to minimum purchase </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">
quantities, Cook Biotech could terminate the agreement if it was deemed that AxoGen had failed to generate commercially reasonable sales of AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> as measured by sales similar to a competitive product at the same stage in its commercial launch as verified by a
mutually acceptable third-party. Although there are products that AxoGen believes it could develop or obtain that would replace the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products, the loss of the ability to sell the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products could have a material adverse effect on AxoGen&#146;s business until other replacement products are available. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen&#146;s success will be dependent on continued acceptance of its products by the medical community. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Continued market acceptance of AxoGen&#146;s products will depend on its ability to demonstrate that its products are
an attractive alternative to existing nerve reconstruction treatment options. Its ability to do so will depend on surgeons&#146; evaluations of clinical safety, efficacy, ease of use, reliability, and cost-effectiveness of AxoGen&#146;s nerve repair
products. For example, although AxoGen&#146;s Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft follows stringent safety standards, including
sterilization by gamma irradiation, AxoGen believes that a small portion of the medical community has lingering concerns over the risk of disease transmission through the use of allografts in general. Furthermore, AxoGen believes that even if its
products receive general acceptance within the medical community, acceptance and clinical recommendations by influential surgeons will be important to the commercial success of AxoGen&#146;s products. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Negative publicity concerning methods of donating human tissue and screening of donated tissue, in the industry in which AxoGen
operates, may reduce demand for its Avance Nerve Graft product and negatively impact the supply of available donor tissue. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGen is highly dependent on its ability to recover cadaveric nerves from tissue donors for its Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft product. The availability of acceptable donors is relatively limited, and this availability is impacted by regulatory changes, general public opinion of
the donation process and AxoGen&#146;s reputation for its handling of the donation process. Media reports or other negative publicity concerning both improper methods of tissue recovery from donors and disease transmission from donated cadaver
tissue (allografts) including bones, tendon, etc. may limit widespread acceptance of AxoGen&#146;s Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve
Graft. Unfavorable reports of improper or illegal tissue recovery practices, both in the U.S. and internationally, as well as incidents of improperly processed tissue leading to transmission of disease, may broadly affect the rate of future tissue
donation and market acceptance of allograft technologies. Potential patients may not be able to distinguish AxoGen products, technologies, and tissue recovery and processing procedures from others engaged in tissue recovery. In addition, unfavorable
reports could make families of potential donors from whom AxoGen is required to obtain consent before processing tissue reluctant to agree to donate tissue to for-profit tissue processors. Any disruption in the supply could have negative
consequences for AxoGen&#146;s revenue, operating results and continued operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen is highly dependent on the
continued availability of its facilities and could be harmed if the facilities are unavailable for any prolonged period of time. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Any failure in the physical infrastructure of AxoGen&#146;s facilities, including the facility it leases from LifeNet Health, could lead to significant costs and disruptions that could reduce its revenues
and harm its business reputation and financial results. Any natural or man-made event that impacts AxoGen&#146;s ability to utilize its facilities could have a significant impact on its operating results, reputation and ability to continue
operations. This includes termination of the LifeNet Health facility lease which can occur upon six months&#146; notice from either party. Although AxoGen believes it can find and make operational a new facility in less than six months, the
regulatory process for approval of facilities is time-consuming and unpredictable. AxoGen&#146;s ability to rebuild or find acceptable lease facilities would take a considerable amount of time and expense and could cause a significant disruption in
service to its customers. Although AxoGen has business interruption insurance which would, in instances other than lease termination, cover certain costs, it may not cover all costs nor help to regain AxoGen&#146;s standing in the market.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen must maintain high quality manufacturing and processing. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is processed through its
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Process which requires careful calibration and precise, high-quality processing and manufacturing.
Achieving precision and quality control requires skill and diligence by its personnel. If it fails to achieve and maintain these high quality controls, processing and manufacturing standards, including avoidance of manufacturing errors, defects or
product failures, AxoGen could experience recalls or withdrawals of its product, delays in delivery, cost overruns or other problems that would adversely affect its business. AxoGen cannot completely eliminate the risk of errors, defects or
failures. In addition, AxoGen may experience difficulties in scaling-up manufacturing of its Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product,
including problems related to yields, quality control and assurance, tissue availability, adequacy of control policies and procedures, and lack of skilled personnel. If AxoGen is unable to process and produce its allografts on a timely basis, at
acceptable quality and costs, and in sufficient quantities, or if it experiences unanticipated technological problems or delays in production, its business would be adversely affected. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen relies on third-party suppliers, some of which are currently the only source for the respective components or materials they
supply to it. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Most of the raw materials used in the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Process for the production of Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft are available from more than one supplier. However, one of the chemicals AxoGen uses in the manufacture of Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is no longer provided by the original single source provider. AxoGen has inventory of such chemical
which it believes provides more than one year of production. AxoGen is currently evaluating a new supplier of the chemical. In addition, some of the test results, packaging and reagents/chemicals AxoGen uses in its manufacturing process are also
obtained from single suppliers. We do not have written contracts with any of our single source suppliers, and at any time they could stop supplying our orders. FDA approval of a new supplier may be required if these materials become unavailable from
AxoGen&#146;s current suppliers. Although there may be other suppliers that have equivalent materials that would be available to AxoGen, FDA approval of any alternate suppliers if required could take several months or years to obtain, if able to be
obtained at all. Any delay, interruption or cessation of production by AxoGen&#146;s third-party suppliers of important materials, or any delay in qualifying new materials, if necessary, would prevent or delay AxoGen&#146;s ability to manufacture
products. In addition, an uncorrected impurity, a supplier&#146;s variation in a raw material or testing, either unknown to AxoGen or incompatible with its manufacturing process, or any other problem with AxoGen&#146;s materials, testing or
components, would prevent or delay its ability to manufacture products. These delays may limit AxoGen&#146;s ability to meet demand for its products and delay its clinical trial, which would have a material adverse impact on its business, results of
operations and financial condition. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen relies on third parties to perform many necessary
services for the commercialization of Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, including services related to the recovery,
distribution, storage and transportation. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen relies upon third parties for certain recovery,
distribution, and transportation services. In accordance with product specifications, these third parties ship
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft in specially validated shipping containers at frozen temperatures. If any of the third
parties that AxoGen relies upon in its recovery, distribution, storage or transportation process fail to comply with applicable laws and regulations, fail to meet expected deadlines, or otherwise do not carry out their contractual duties to AxoGen,
or encounter physical damage or natural disaster at their facilities, AxoGen&#146;s ability to deliver product to meet commercial demand may be significantly impaired. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen is dependent on its relationships with distributors to generate revenue. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGen derives material revenues through its relationships with distributors. If such distributor relationships were terminated for any reason, it could materially and adversely affect AxoGen&#146;s
ability to generate revenues and profits. AxoGen intends to obtain the assistance of additional distributors to continue its sales growth. It may not be able to find additional distributors who will agree to market and distribute its products on
commercially reasonable terms, if at all. If it is unable to establish new distribution relationships or renew current distribution agreements on commercially acceptable terms, operating results could suffer. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Loss of key members of management, who it needs to succeed, could adversely affect its
business. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s future success depends on the continued efforts of the members of its senior management team.
Competition for experienced management personnel in the healthcare industry is intense. If one or more of AxoGen&#146;s senior executives or other key personnel are unable or unwilling to continue in their present positions, or if AxoGen is unable
to attract and retain high quality senior executives or key personnel in the future, its business may be adversely affected. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen&#146;s operating results will be harmed if it is unable to effectively manage and sustain its future growth.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There can be no assurance that AxoGen will be able to manage its future growth efficiently or profitably. Its business
is unproven on a large scale and actual revenue and operating margins, or revenue and margin growth, may be less than expected. If AxoGen is unable to scale its production capabilities efficiently, it may fail to achieve expected operating margins,
which would have a material and adverse effect on its operating results. Growth may also stress AxoGen&#146;s ability to adequately manage its operations, quality of products, safety and regulatory compliance. If growth significantly decreases
AxoGen&#146;s cash reserves, it may be required to obtain additional financing, which may increase indebtedness or result in dilution to shareholders. Further, there can be no assurance that AxoGen would be able to obtain additional financing on
acceptable terms if all at. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>There may be significant fluctuations in AxoGen&#146;s operating results.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Significant quarterly fluctuations in AxoGen&#146;s results of operations may be caused by, among other factors, its
volume of revenues, seasonal changes in nerve repair activity, timing of sales force expansion and general economic conditions. There can be no assurance that the level of revenues and profits, if any, achieved by AxoGen in any particular fiscal
period, will not be significantly lower than in other comparable fiscal periods. AxoGen&#146;s expense levels are based, in part, on its expectations as to future revenues. As a result, if future revenues are below expectations, net income or loss
may be disproportionately affected by a reduction in revenues, as any corresponding reduction in expenses may not be proportionate to the reduction in revenues. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen&#146;s revenues depend upon prompt and adequate reimbursement from public and private insurers and national health systems. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Political, economic and regulatory influences are subjecting the healthcare industry in the U.S. to fundamental change. The ability of
hospitals to pay fees for AxoGen&#146;s products depends in part on the extent to which reimbursement for the costs of such materials and related treatments will continue to be available from governmental health administration authorities, private
health coverage insurers and other organizations. Major third-party payers of hospital services and hospital outpatient services, including Medicare, Medicaid and private healthcare insurers, annually revise their payment methodologies, which can
result in stricter standards for reimbursement of hospital charges for certain medical procedures or the elimination of reimbursement. Further, Medicare, Medicaid and private healthcare insurer cutbacks could create downward price pressure on
AxoGen&#146;s products. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen may be subject to future product liability litigation that could be expensive and its
insurance coverage may not be adequate. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although AxoGen is not currently subject to any product liability proceedings,
and it has no reserves for product liability disbursements, it may incur material liabilities relating to product liability claims in the future, including product liability claims arising out of the usage of AxoGen products. AxoGen currently
carries product liability insurance in an amount consistent with industry averages, however, its insurance coverage and any reserves it may maintain in the future for product related liabilities may not be adequate and AxoGen&#146;s business could
suffer material adverse consequences. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Technological change could reduce demand for AxoGen&#146;s products.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The medical technology industry is intensely competitive. AxoGen competes with both U.S. and international companies
that engage in the development and production of medical technologies and processes including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">biotechnology, orthopedic, pharmaceutical, biomaterial, chemical and other companies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">academic and scientific institutions; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">public and private research organizations. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGen products compete with autograft and hollow-tube conduits, as well as with alternative medical procedures. For the foreseeable future, AxoGen believes a significant number of surgeons will continue
to choose to perform autograft procedures when feasible, despite the necessity of performing a second operation and its drawbacks. In addition, many members of the medical community will continue to prefer the use of hollow-tube conduits due in part
to their familiarity with these products and the procedures required for their use. Also, steady improvements have been made in synthetic human tissue substitutes, which could compete with AxoGen&#146;s products. Unlike allografts, synthetic tissue
technologies are not dependent on the availability of human or animal tissue. Although AxoGen&#146;s growth strategy contemplates the introduction of new technologies, the development of these technologies is a complex and uncertain process,
requiring a high level of innovation, as well as the ability to accurately predict future technology and market trends. AxoGen may not be able to respond effectively to technological changes and emerging industry standards, or to successfully
identify, develop or support new technologies or enhancements to existing products in a timely and cost effective manner, if at all. Finally, there can be no assurance that in the future AxoGen&#146;s competitors will not develop products that have
superior performance or are less expensive relative to its products rendering them obsolete or noncompetitive. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen
may be unsuccessful in commercializing its products outside the U.S. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">To date, AxoGen has focused
its commercialization efforts in the U.S., except for minor revenues from the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft in the United
Kingdom, the Netherlands, Switzerland, Italy, Austria and Canada. It intends to expand sales beyond these countries outside the U.S. and will need to comply with applicable foreign regulatory requirements, including obtaining the requisite approvals
to do so. Additionally, AxoGen will need to either enter into distribution agreements with third parties or develop a direct sales force in these foreign markets. If it does not obtain adequate levels of reimbursement from third-party payers outside
of the U.S., it may be unable to develop and grow its product sales internationally. Outside of the U.S., reimbursement systems vary significantly by country. Many foreign markets have government-managed healthcare systems that govern reimbursement
for medical devices and procedures. Additionally, some foreign reimbursement systems provide for limited payments in a given period and therefore result in extended payment periods. If AxoGen is unable to successfully commercialize its products
internationally, its long term growth prospects may be limited. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If AxoGen does not manage tissue and tissue donation in
an effective and efficient manner, it could adversely affect its business. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Many factors affect the supply, quantity
and timing of donor medical releases, such as effectiveness of donor screening (currently performed by donor recovery groups), the effective recovery of tissue, the timely receipt, recording and review of required medical documentation, and employee
loss and turnover in AxoGen&#146;s and its contractor&#146;s recovery department. AxoGen can provide no assurance that tissue recovery or donor medical releases will occur at levels that will maximize processing efficiency and minimize AxoGen&#146;s
cost per allograft processed. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If AxoGen does not manage product inventory in an effective and efficient manner, it
could adversely affect profitability. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Many factors affect the efficient use and planning of product inventory, such as
effectiveness of predicting demand, effectiveness of preparing manufacturing to meet demand, efficiently meeting product mix and product demand requirements and product expiration. AxoGen may be unable to manage its inventory efficiently, keep
inventory within expected budget goals, keep its work-in-process inventory on hand or manage it efficiently, or keep sufficient product on hand to meet demand, and AxoGen can provide no assurance that it can keep inventory costs within its target
levels. Failing to do so may require AxoGen to raise additional cash resources or may harm long term growth prospects. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen is a party to a Royalty Contract which requires it to pay royalty fees that could materially adversely affect its financial
position. </I></B></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;5, 2012, AxoGen entered into a Royalty Contract with PDL, pursuant
to which AxoGen sold to PDL the right to receive specified royalties on AxoGen&#146;s Net Revenues generated by the sale, distribution or other use of AxoGen&#146;s products Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve
Protector and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector (the Assigned Interests as defined in the Royalty Contract). The Royalty
Contract has a term of eight years. Under the Royalty Contract, PDL is to receive royalty payments, currently paid weekly, based on a 9.95% royalty rate of AxoGen&#146;s Net Revenues, subject to certain agreed upon minimum guaranteed quarterly
payment amounts of approximately $1.3 to $2.5 million per quarter that commence in the quarter ending December&nbsp;31, 2014. The minimum annual payment amounts are as follows: 2014&#151;$1,250,805, 2015&#151;$6,781,440, 2016&#151;$9,232,642, 2017
and 2018&#151;$9,000,000, 2019&#151;$9,063,000 and 2020&#151;$6,939,000. Further, on October&nbsp;5, 2016, or in the event of the occurrence of a material adverse event, our transfer of revenue interest or substantially all of our interest in the
products or AxoGen&#146;s bankruptcy or material breach of the Royalty Contract, PDL may require AxoGen to repurchase the Assigned Interests (the &#147;Put&#148;) at the Put Price (as defined in the Royalty Contract). The Put Price is equal to the
sum of (i)&nbsp;an amount that, when paid to PDL, would generate a 20% internal rate of return to PDL (the &#147;Put Rate&#148;) on the Funded Amount, taking into consideration payments made to PDL by AxoGen, and (ii)&nbsp;any &#147;Delinquent
Assigned Interests Payment&#148; (as defined in the Royalty Contract) AxoGen owed to PDL. For purposes of estimating the effective interest rate of the Royalty Contract, we considered that the effective rate of 20% (currently the Put Rate) is
currently slightly higher than the implicit rate of return and, as a result, we assume for accounting purposes that PDL will exercise its put option in order to receive the higher rate of return. However we have no actual knowledge or other
indications of PDL&#146;s intent to do so. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2012, AxoGen&#146;s monthly expenses exceeded its revenues and thus it
operated at a cash loss. Royalty payments to PDL are owed without consideration to any negative affect it has on AxoGen&#146;s cash or loss position. In addition, minimum payments under the Royalty Contract start in October 2014 and if AxoGen is
required to pay an amount greater than the royalty fee, AxoGen would have an even greater cash burden. Finally, there is no assurance that AxoGen will have sufficient capital to pay the Put Price if it was exercised. If AxoGen does not have
sufficient cash to pay PDL, AxoGen would need to raise additional capital. The sale of additional equity to further finance the company may result in dilution to AxoGen&#146;s shareholders. There is no assurance that if AxoGen is required to secure
funding it can do so on terms acceptable to it, or at all. The increasing need for capital as the PDL transaction matures could also make it more difficult to obtain funding through either equity or debt. See &#147;Notes to Consolidated Financial
Statements &#150; Footnote 7 Long-Term Debt/Note Payable.&#148; </FONT></P>  <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>PDL Royalty Contract has Change of Control
provision that could have material impact on price received by AxoGen shareholders in the event of a Change of Control. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event of a &#147;Change of Control&#148; (as defined in the Royalty Contract), AxoGen must repurchase the Assigned Interests from
PDL for a repurchase price equal to the &#147;Change of Control Price&#148; on or prior to the third business day after the occurrence of the Change of Control. The Change of Control Price is the sum of (i)&nbsp;an amount that, when paid to PDL,
would generate an internal rate of return to PDL of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
thirty-two and one half percent (32.5%)&nbsp;on all payments made by PDL pursuant to the Royalty Contract as of the date of the Change of Control Payment (as defined in the Royalty Contract),
taking into account the amount and timing of all payments made by AxoGen to PDL (and retained by PDL) prior to and as of the date of payment of the Change of Control Payment, plus (ii)&nbsp;any Delinquent Assigned Interests Payment owed. For
purposes of example only, the Change of Control payment at March&nbsp;31, 2013 would have been $23,439,186. Payment of the Change of Control Price could materially reduce the consideration to be received by AxoGen shareholders if the Change of
Control event was in conjunction with the acquisition of the Company. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen incurs costs as a result of operating as a
public company, and its management is required to devote substantial time to compliance initiatives. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a public
company, AxoGen incurs legal, accounting and other expenses to comply with relevant securities laws and regulations, including, without limitation, the requirement of establishment and maintenance of effective disclosure and financial controls and
corporate governance practices. AxoGen&#146;s management devotes substantial time and financial resources to these compliance initiatives. Failure to comply with public company requirements could have a material adverse effect on AxoGen&#146;s
business. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our Business and Stock Price May Be Adversely Affected if Our Internal Controls Are Not Effective.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 requires companies to conduct a comprehensive evaluation of their
internal control over financial reporting. To comply with this statute, each year we are required to document and test our internal control over financial reporting and our management is required to assess and issue a report concerning our internal
control over financial reporting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In our annual report for the period ended December&nbsp;31, 2011, we reported a material
weakness in our internal control over financial reporting, which related to an instance in which the accounting for a contract was inappropriately treated as an expense as opposed to a prepaid asset. Specifically, an effective control was not
operating to ensure that accounting for the contract was completely and accurately recorded during the 4th quarter of 2011. This control deficiency could have resulted in misstatement of net loss that would not have been prevented or detected.
Accordingly, we determined that this control deficiency constituted a material weakness. During the first quarter of 2012, in response to the conclusion reached by our Chief Executive and Chief Financial Officers that, as of December&nbsp;31, 2011,
our disclosure controls and procedures were not effective, we implemented a control procedure whereby all significant contracts will be reviewed by the Chief Financial Officer, and at the end of each quarter, the Chief Financial Officer will then
review the accounting with the Company&#146;s corporate controller prior to the recording of all such contracts. Based on its most recent evaluation, management concluded that internal control over financial reporting was effective as of
December&nbsp;31, 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although we believe we took appropriate actions to remediate the control deficiencies we identified
and to strengthen our internal control over financial reporting, we cannot assure you that we will not discover other material weaknesses in the future or that no material weakness will result from any difficulties, errors, delays or disruptions
while we implement and transition to new internal systems. The existence of one or more material weaknesses could result in errors in our financial statements, and substantial costs and resources may be required to rectify these or other internal
control deficiencies. If we cannot produce reliable financial reports, investors could lose confidence in our reported financial information, the market price of our common stock could decline significantly, we may be unable to obtain additional
financing to operate and expand our business, and our business and financial condition could be harmed. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to the Regulatory Environment in which AxoGen Operates </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen&#146;s business is subject to continuing regulatory compliance by the FDA and other authorities which is costly and could
result in negative effects on its business. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen is subject to extensive regulation. Its
products are subject to regulation by the FDA in the U.S., the Center for Medicare Services of the U.S. Department of Health and Human Services and other federal governmental agencies and, in some jurisdictions, by state and foreign governmental
authorities. The FDA regulates the development, clinical testing, marketing, distribution, manufacturing, labeling, and promotion of biological products, such as that of AxoGen&#146;s Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft product. The FDA also regulates medical devices, such as the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products. The FDA requires the approval of a biological product, such as the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft product, through a biological license application, or BLA, prior to marketing. Although the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft product has not yet been approved by FDA through a BLA, FDA is permitting the product to be sold pursuant to a transition plan while AxoGen performs
clinical testing and prepares a BLA submission for the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. See &#147;Business &#151; Government
Regulations &#151; U.S. Government Regulation Review.&#148; The FDA also regulates medical devices and requires that certain medical devices, such as the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products, be cleared through the 510(k) premarket notification process prior to marketing. The FDA&#146;s premarket review process for new and modified existing
devices that precedes product marketing can be time consuming and expensive. Some of the future products and enhancements to such products that AxoGen expects to develop and market may require marketing clearance or approval from the FDA. There can
be no assurance, however, that clearance or approval will be granted with respect to any of AxoGen&#146;s products or enhancements or that FDA review will not involve delays that would adversely affect AxoGen&#146;s ability to market such products
or enhancements. In addition, there can be no assurance that AxoGen products, including the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft,
or enhancements will not be subject to a lengthy and expensive approval process with the FDA. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">It is possible that if
regulatory clearances or approvals to market a product are obtained from the FDA, the clearances or approvals may contain limitations on the indicated uses of such product and other uses may be prohibited. Product approvals by the FDA can also be
withdrawn due to failure to comply with regulatory standards or the occurrence of unforeseen problems following initial approval. Also, the FDA could limit or prevent the distribution of AxoGen products and has the power to require the recall of
such products. FDA regulations depend heavily on administrative interpretation, and there can be no assurance that future interpretations made by the FDA or other regulatory bodies will not adversely affect AxoGen&#146;s operations. AxoGen, and its
facilities, may be inspected by the FDA from time to time to determine whether it is in compliance with various regulations relating to specification, development, documentation, validation, testing, quality control, and product labeling. A
determination that AxoGen is in violation of such regulations could lead to imposition of civil penalties, including fines, product recalls or product seizures and, in certain cases, criminal sanctions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The use, misuse or off-label use of AxoGen&#146;s products may harm its reputation or the image of its products in
the marketplace, or result in injuries that lead to product liability suits, which could be costly to AxoGen&#146;s business or result in FDA sanctions if the company is deemed to have engaged in off-label promotion. AxoGen is seeking a biologics
license through the BLA process for specific uses of Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft under specific circumstances. Its
promotional materials and training methods must comply with FDA requirements and other applicable laws and regulations, including the prohibition against off-label promotion. AxoGen&#146;s promotion of the AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products, which are regulated as medical devices, also must comply with FDA&#146;s requirements and must only use
labeling that is consistent with the specific indication(s) for use included in FDA&#146;s substantial equivalence order that results in marketing the devices. The FDA does not restrict or regulate a physician&#146;s use of a medical product within
the practice of medicine, and AxoGen cannot prevent a physician from using its products for an off-label use. However, the Federal Food, Drug, and Cosmetic Act, referred to herein as the FD&amp;C Act, and the FDA&#146;s regulations restrict the kind
of promotional communications that may be made about AxoGen&#146;s products and if the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
FDA determines that AxoGen&#146;s promotional or training materials constitute the unlawful promotion of an off-label use, it could request that AxoGen modify its training or promotional
materials and/or subject the Company to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, civil money penalties, or criminal fines and penalties. Other federal, state or foreign governmental
authorities might also take action if they consider AxoGen promotion or training materials to constitute promotion of an uncleared or unapproved use, which could result in significant fines or penalties under other statutory authorities, such as
laws prohibiting false claims for reimbursement, or exclusion from participation in federal health programs. In that event, AxoGen&#146;s reputation could be damaged and the use of its products in the marketplace could be impaired. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, there may be increased risk of injury if physicians or others attempt to use AxoGen products off-label. Furthermore, the use
of AxoGen&#146;s product for indications other than those for which its products have been approved, cleared or licensed by the FDA may not effectively treat the conditions not referenced in product indications, which could harm AxoGen&#146;s
reputation in the marketplace among physicians and patients. Physicians may also misuse AxoGen&#146;s product or use improper techniques if they are not adequately trained in the particular use, potentially leading to injury and an increased risk of
product liability. Product liability claims are expensive to defend and could divert management&#146;s attention from its primary business and result in substantial damage awards against AxoGen. Any of these events could harm AxoGen&#146;s business,
results of operations and financial condition. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen&#146;s Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft product is currently allowed to be sold pursuant to a transition plan with the FDA and a change in
position by the FDA regarding its use of enforcement discretion to permit the sale of Avance would have a material adverse effect on AxoGen. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">The FDA considers the AxoGen&#146;s Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft product to
be a biological product, subject to BLA approval requirements. Although the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft product has not
yet been approved by FDA through a BLA, AxoGen&#146;s Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft product is currently sold under the
controls applicable to a HCT/P pursuant to section 361 of the Public Health Service Act and 21 CFR Part 1271 of FDA&#146;s regulations, in accordance with a transition plan with the FDA in which the agency will monitor AxoGen&#146;s compliance with
21 CFR Part 1271. See &#147;Business &#151; Government Regulations &#151; U.S. Government Regulation Review.&#148; AxoGen has continued to communicate with FDA&#146;s CBER since the acceptance of the transition plan on clinical trial design and
Chemistry, Manufacturing, and Controls (&#147;CMC&#148;) for the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. AxoGen can commercially
distribute the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft subject to the controls HCT/Ps until FDA makes a final determination on an
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft BLA submission, assuming AxoGen remains in compliance with the transition plan. In the event
that the FDA becomes dissatisfied with AxoGen&#146;s progress or actions with respect to the transition plan or FDA otherwise changes its position regarding its use of enforcement discretion to permit AxoGen to provide the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft product in accordance with the transition plan, AxoGen would no longer be able to sell the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft product, which would have a material adverse effect on AxoGen&#146;s operations and financial viability.
In addition, if AxoGen does not meet the conditions for the transition plan, fails to comply with applicable regulatory requirements or fails to comply with the ongoing requirements of the premarket submission to transition to a biological product,
the FDA could deny approval of the premarket application, or impose civil penalties, including fines, product seizures, injunctions or product recalls and, in certain cases, criminal sanctions. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen&#146;s AxoGuard products are subject to FDA and other regulatory requirements. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product line is regulated as a medical device under the FD&amp;C Act and subject to premarket notification and clearance requirements under section 510(k) of the
FD&amp;C Act, 21 CFR Part 820 (Quality System Regulation) and other FDA regulations. AxoGen distributes for Cook Biotech Incorporated the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product line and Cook Biotech is responsible for the regulatory compliance of the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product line. Cook Biotech has obtained a 510(k) premarket clearance from the FDA for porcine small intestine submucosa for the repair of peripheral nerve
discontinuities where gap closure can </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">
be achieved by flexion of the extremity. If AxoGen or Cook Biotech Incorporated fails to comply with applicable regulatory requirements the FDA could deny or withdraw 510(k) clearance for the
AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products, or impose civil penalties, including fines, product seizures or product recalls and, in
certain cases, criminal sanctions. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Defective AxoGen product could lead to recall or other negative business conditions.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">If AxoGen&#146;s products are defective or otherwise pose safety risks, the FDA could require
their recall, or AxoGen may initiate a voluntary recall of its products. The FDA may require recall of a marketed medical device product, such as the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products, in the event that it determines that due to material deficiencies or defects that use of the medical device product would pose a reasonable probability of
serious adverse health consequences or death. However, FDA does not have authority to require most device recalls because they do not rise to this level of health significance. FDA may request, but not require, the recall of a biological product,
such as the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. However, if a company does not comply with an FDA request for a recall, FDA can
pursue other enforcement actions, such as product seizure. In addition, manufacturers may, on their own initiative, recall a product to remove or correct a deficiency or to remedy a violation of the Federal Food, Drug, and Cosmetic Act that may pose
a risk to health. A government-mandated, government-requested or voluntary recall could occur as a result of an unacceptable risk to health, reports of safety issues, failures, manufacturing errors, design or labeling defects or other deficiencies
and issues. Recalls and other field corrections for any of AxoGen&#146;s products would divert managerial and financial resources and have an adverse effect on its business, results of operations and financial condition. A recall could harm
AxoGen&#146;s reputation with customers and negatively affect its sales. AxoGen may initiate recalls involving some of its products in the future that it determines do not require notification of the FDA. If the FDA were to disagree with
AxoGen&#146;s determinations, it could request that it report those actions as recalls, and take regulatory or enforcement action against AxoGen or the product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If AxoGen&#146;s products cause or contribute to a death, a serious injury or any adverse reaction involving a communicable disease related to its products, or malfunction in certain ways, it will be
subject to reporting regulations, which can result in voluntary corrective actions or agency enforcement actions. See &#147;Business &#151; Regulation &#151; Education Grants, U.S. Anti-kickback, False Claims and Other Healthcare Fraud and Abuse
Laws &#151; Pervasive and Continuing Regulation.&#148; If AxoGen fails to report these events to the FDA within the required timeframes, or at all, the FDA could take regulatory or enforcement action against AxoGen. Any adverse event involving
AxoGen&#146;s products could result in future voluntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection, mandatory recall or other enforcement action. Any corrective action, whether voluntary or
involuntary, as well as AxoGen defending itself in a lawsuit, would require the dedication of time and capital, distract management from operating its business, and may harm AxoGen&#146;s reputation, business, results of operations and financial
condition. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen&#146;s manufacturing operations must comply with FDA and other governmental requirements.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s manufacturing operations require it to comply with the FDA&#146;s and other governmental
authorities&#146; laws and regulations regarding the manufacture and production of medical products, which is costly and could subject AxoGen to enforcement action. See Business &#151; Government Regulations &#151; Education Grants, U.S.
Anti-kickback, False Claims and Other Healthcare Fraud and Abuse Laws &#151; Pervasive and Continuing Regulation. Any of these actions could impair AxoGen&#146;s ability to produce its products in a cost-effective and timely manner in order to meet
customer demands. AxoGen may also be required to bear other costs or take other actions that may have an adverse impact on its future sales and its ability to generate profits. Furthermore, AxoGen key material suppliers, licensors and or other
contractors may not continue to be in compliance with all applicable regulatory requirements, which could result in AxoGen&#146;s failure to produce its products on a timely basis and in the required quantities, if at all. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales of AxoGen products outside the U.S. are subject to foreign regulatory requirements
that vary from country to country. In the European Union (the &#147;E.U.&#148;), regulations, if applicable, differ from one E.U. member state to the next. Because of the absence of a harmonized regulatory framework and the proposed regulation for
advanced therapy medicinal products in the E.U., as well as for other countries, the approval process for human derived cell or tissue based medical products may be extensive, lengthy, expensive and unpredictable. AxoGen products will be subject to
E.U. member states&#146; regulations that govern the donation, procurement, testing, coding, traceability, processing, preservation, storage, and distribution of human tissues and cells and cellular or tissue-based products. In addition, some E.U.
member states have their own tissue banking regulations. The inability to meet foreign regulatory requirements could materially affect AxoGen&#146;s future growth and compliance with such requirements could place a significant financial burden on
AxoGen. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Clinical trials can be long, expensive and ultimately uncertain which could jeopardize
AxoGen&#146;s ability to obtain regulatory approval and continue to market its Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft product.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen is required to perform a clinical trial for its Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft pursuant to requirements of the FDA to obtain approval of a BLA for the product. This trial is
expensive, is expected to take several years to execute, and is subject to factors within and outside of AxoGen&#146;s control. The outcome of this trial is uncertain. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen has continued to communicate with the FDA regarding clinical trial design, preclinical studies and CMC for
the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, and will have significant work to continue to meet the requirements asked of AxoGen by
the FDA for each of these components to begin its clinical study and receive approval of its BLA approval. If AxoGen is unable to agree with FDA, or unable to meet the standards required of it by the FDA, regarding preclinical studies, clinical
studies and CMC, the approval of AxoGen&#146;s BLA may be impossible, delayed and/or may add significant costs to the ongoing production of Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The
results of non-clinical studies do not necessarily predict future clinical trial results, and predecessor clinical trial results may not be repeated in subsequent clinical trials. Additionally, the FDA may disagree with AxoGen&#146;s interpretation
of the data from its non-clinical studies and clinical trials and may require it to pursue additional non-clinical studies or clinical trials, or not approve AxoGen&#146;s BLA or future supplements, which could further delay the BLA for the
Avance<B><I><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT></I></B> Nerve Graft of AxoGen&#146;s products. If AxoGen is unable to demonstrate the safety and
efficacy of its product through its clinical trials, it will be unable to obtain regulatory approval to market the
Avance<B><I><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT></I></B> Nerve Graft and will not be able to continue to sell it. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen will rely on third parties to conduct its clinical trial and they may not perform as contractually required or expected.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen will rely on third parties, such as contract research organizations (&#147;CROs&#148;), medical institutions,
clinical investigators and contract laboratories to conduct its clinical trial and certain nonclinical studies. AxoGen and its CROs are required to comply with all applicable regulations governing clinical research, including good clinical practice,
or GCP. The FDA enforces these regulations through periodic inspections of trial sponsors, principal investigators, CROs and trial sites. If AxoGen or its CROs fail to comply with applicable FDA regulations, the data generated in its clinical trials
may be deemed unreliable and the FDA may require AxoGen to perform additional clinical trials before approving its applications. AxoGen cannot be certain that, upon inspection, the FDA and similar foreign regulatory authorities will determine that
AxoGen&#146;s clinical trial complies or complied with clinical trial regulations, including GCP. In addition, AxoGen&#146;s clinical trial must be conducted with product produced under applicable current Good Manufacturing Practice, or GMP,
regulations. Failure to comply with the clinical trial regulations may require AxoGen to repeat clinical trials, which would delay the regulatory approval process. If these third parties do not successfully carry out their contractual duties or
regulatory obligations or meet expected deadlines, if these third parties need to be replaced, or if the quality or accuracy of the data </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
they obtain is compromised due to the failure to adhere to AxoGen&#146;s clinical protocols or regulatory requirements or for other reasons, AxoGen&#146;s non-clinical development activities or
clinical trials may be extended, delayed, suspended or terminated, and it would not be able to obtain regulatory approval for, its products on a timely basis, if at all, and its business, results of operations, financial condition and growth
prospects would be adversely affected. Furthermore, AxoGen&#146;s third-party clinical trial investigators may be delayed in conducting its clinical trials for reasons outside of their control. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>U.S. governmental regulation could restrict the use of AxoGen&#146;s Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft product, restrict AxoGen&#146;s procurement of tissue or increase costs. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to the FDA requirements for biological products, the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft will continue to be subject to various requirements for human tissue under 21 CFR Part 1271 controls.
Human tissues intended for transplantation have been regulated by the FDA since 1993. In May 2005, three new comprehensive regulations went into effect that address manufacturing activities associated with HCT/P. The first requires that companies
that produce and distribute HCT/Ps register with the FDA. The second provides criteria that must be met for donors to be eligible to donate tissues and is referred to as the &#147;Donor Eligibility&#148; rule. The third rule governs the processing
and distribution of the tissues and is often referred to as the Current Good Tissue Practices rule. The Current Good Tissue Practices rule covers all stages of allograft processing, from procurement of tissue to distribution of final allografts.
Together, they are designed to ensure that sound, high quality practices are followed to reduce the risk of tissue contamination and of communicable disease transmission to recipients. These regulations increased regulatory scrutiny within the
industry in which AxoGen operates and have led to increased enforcement action, which affects the conduct of its business. See &#147;Business &#151; Government Regulations.&#148; These regulations can also increase the cost of tissue recovery
activities. Additionally, the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is subjected to certain state and local regulations, as well
as compliance to the standards of the tissue bank industry&#146;s accrediting organization, the American Association of Tissue Banks (&#147;AATB&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The procurement and transplantation of allograft nerve tissue is also subject to federal law pursuant to the National Organ Transplant Act (&#147;NOTA&#148;), a criminal statute which prohibits the
purchase and sale of human organs used in human transplantation, including nerve and related tissue, for &#147;valuable consideration.&#148; NOTA only permits reasonable payments associated with the removal, transportation, processing, preservation,
quality control, implantation and storage of human nerve tissue. AxoGen makes payments to certain of its clients and tissue banks for their services related to recovering allograft nerve tissue on its behalf. If NOTA is interpreted or enforced in a
manner which prevents AxoGen from receiving payment for services it renders, or which prevents it from paying tissue banks or certain of its clients for the services they render for AxoGen, its business could be materially and adversely affected.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen has engaged, through its marketing employees, independent sales agents and sales representatives, in ongoing efforts
designed to educate the medical community as to the benefits of AxoGen products, and AxoGen intends to continue its educational activities. Although AxoGen believes that NOTA permits payments in connection with these educational efforts as
reasonable payments associated with the processing, transportation and implantation of AxoGen products, payments in connection with such education efforts are not exempt from NOTA&#146;s restrictions and AxoGen&#146;s inability to make such payments
in connection with its education efforts may prevent it from paying AxoGen sales representatives for their education efforts and could adversely affect AxoGen&#146;s business and prospects. No federal agency or court has determined whether NOTA is,
or will be, applicable to every allograft nerve tissue-based material which AxoGen&#146;s processing technologies may generate. Assuming that NOTA applies to AxoGen&#146;s processing of allograft nerve tissue, AxoGen believes that it complies with
NOTA, but there can be no assurance that more restrictive interpretations of, or amendments to, NOTA will not be adopted in the future, which would call into question one or more aspects of AxoGen&#146;s method of operations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other regulatory entities include state agencies with statutes covering tissue banking.
Regulations issued by Florida, New York, California and Maryland, among others, will be particularly relevant to AxoGen&#146;s business. Most states do not currently have tissue banking regulations. However, incidents of allograft related infections
in the industry may stimulate the development of regulation in other states. It is possible that others may make allegations against AxoGen or against donor recovery groups or tissue banks about non-compliance with applicable FDA regulations or
other relevant statutes or regulations. Allegations like these could cause regulators or other authorities to take investigative or other action, or could cause negative publicity for AxoGen&#146;s business and the industry in which it operates.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Healthcare policy changes may have a material adverse effect on AxoGen. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education
Affordability Reconciliation Act, which substantially changes the way healthcare is financed by both governmental and private insurers, and encourages improvements in the quality of healthcare items and services. This Act significantly impacts the
biotechnology and medical device industries and could have a material adverse impact on numerous aspects of AxoGen&#146;s business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This Act includes, among other things, the following measures: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a 2.3% excise tax on any entity that manufactures or imports medical devices offered for sale in the U.S., with limited exceptions, beginning in 2013,
referred to as the Device Tax; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities and conduct comparative clinical effectiveness research;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">new reporting and disclosure requirements on healthcare manufacturers for any &#147;transfer of value&#148; made or distributed to physicians and
teaching hospitals, as well as reporting of certain physician ownership interests, with the first of such reports due March&nbsp;31, 2014 for calendar year 2013 (&#147;Sunshine Act&#148;); </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the
coordination, quality and efficiency of certain healthcare services through bundled payment models which began January 2013; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an independent payment advisory board that will submit recommendations to reduce Medicare spending if projected Medicare spending exceeds a specified
growth rate; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a new abbreviated pathway for the licensure of biologic products that are demonstrated to be biosimilar or interchangeable with a licensed biologic
product. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Because the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is a biological product and is not a medical device it is not subject to the Device Tax. Cook Biotech is the manufacturer of the AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products and AxoGen is the distributor. As such, Cook Biotech is responsible for payment of the Device Tax on the
transfer price of the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products from Cook Biotech to AxoGen and AxoGen has no further Device Tax
obligations with respect to its resale. Although AxoGen currently has no Device Tax obligations, there can be no assurance that changes in regulations will not subject it to such obligations in the future. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are also a number of states (such as Vermont, Massachusetts, Minnesota) with their own Sunshine Acts that implement the reporting
and disclosure requirements on healthcare manufacturers for any &#147;transfer of value&#148; made or distributed to physicians and teaching hospitals, as well as reporting of certain physician ownership interests. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the future, there may continue to be additional proposals relating to the reform of the U.S. healthcare system. Certain of these
proposals could limit the prices AxoGen is able to charge for its products or the amounts of reimbursement available for its products and could also limit the acceptance and availability of its products. The adoption of some or all of these
proposals could have a material adverse effect on AxoGen&#146;s business, results of operations and financial condition. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, initiatives sponsored by government agencies, legislative bodies and the
private sector to limit the growth of healthcare costs, including price regulation and competitive pricing, are ongoing in markets where AxoGen does business. AxoGen could experience an adverse impact on operating results due to increased pricing
pressure in the U.S. and in other markets. Governments, hospitals and other third-party payors could reduce the amount of approved reimbursement for AxoGen&#146;s products or deny coverage altogether. Reductions in reimbursement levels or coverage
or other cost-containment measures could unfavorably affect AxoGen&#146;s future operating results. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to AxoGen&#146;s
Intellectual Property </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Failure to protect AxoGen&#146;s Intellectual Property rights could result in costly and time
consuming litigation and its loss of any potential competitive advantage. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s success will depend, to a
large extent, on its ability to successfully obtain and maintain patents, prevent misappropriation or infringement of intellectual property, or IP, maintain trade secret protection, and conduct operations without violating or infringing on the IP
rights of third parties. See &#147;Business &#151; Intellectual Property.&#148; There can be no assurance that AxoGen&#146;s patented and patent pending technologies will provide it with a competitive advantage, that AxoGen will be able to develop
or acquire additional technology that is patentable, or that third parties will not develop and offer technologies which are similar to AxoGen&#146;s. Moreover, AxoGen can provide no assurance that confidentiality agreements with its employees,
consultants and other parties, trade secrecy agreements or similar agreements intended to protect unpatented technology will provide the intended protection. IP litigation is extremely expensive and time-consuming, and it is often difficult, if not
impossible, to predict the outcome of such litigation. A failure by AxoGen to protect its IP could have a materially adverse effect on its business and operating results and its ability to successfully compete in its industry. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Future protection for AxoGen&#146;s proprietary rights is uncertain which may impact its ability to successfully compete in its
industry. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The degree of future protection for AxoGen&#146;s proprietary rights is uncertain. AxoGen cannot ensure
that: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">it, or its licensors, were the first to make the inventions covered by each of AxoGen&#146;s patents; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">it, or its licensors, were the first to file patent applications for these inventions; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">others will not independently develop similar or alternative technologies or duplicate any of AxoGen&#146;s technologies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any of AxoGen&#146;s pending patent applications will result in issued patents; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any of AxoGen&#146;s issued patents or those of its licensors will be valid and enforceable; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any patents issued to AxoGen or its collaborators will provide any competitive advantages or will not be challenged by third parties;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">it will develop additional proprietary technologies that are patentable; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the patents of others will not have a material adverse effect on its business rights; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the measures AxoGen relies on to protect its IP underlying their products may not be adequate to prevent third parties from using its technology, all
of which could harm its ability to compete in the market. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s success depends on its ability to
avoid infringing on the intellectual property rights of third parties which could expose it to litigation or commercially unfavorable licensing arrangements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s commercial success depends in part on its ability and the ability of its
collaborators and licensors to avoid infringing patents and proprietary rights of third parties. Third parties may accuse AxoGen or collaborators and licensors of employing their proprietary technology in AxoGen products, or in the materials or
processes used to research or develop AxoGen products, without authorization. Any legal action against AxoGen collaborators, licensors or it claiming damages and/or seeking to stop AxoGen&#146;s commercial activities relating to the affected
products, materials and processes could, in addition to subjecting AxoGen to potential liability for damages, require it or its collaborators and licensors to obtain a license to continue to utilize the affected materials or processes or to
manufacture or market the affected products. AxoGen cannot predict whether AxoGen or its collaborators and licensors would prevail in any of these actions or whether any license required under any of these patents would be made available on
commercially reasonable terms, if at all. If AxoGen were unable to obtain such a license, it and its collaborators and licensors may be unable to continue to utilize the affected materials or processes, or manufacture or market the affected
products, or AxoGen may be obligated by a court to pay substantial royalties and/or other damages to the patent holder. Even if AxoGen were able to obtain such a license, the terms of such a license could substantially reduce the commercial value of
the affected product or products and impair AxoGen&#146;s prospects for profitability. Accordingly, AxoGen cannot predict whether, or to what extent, the commercial value of the affected product or products, or AxoGen&#146;s prospects for
profitability may be harmed as a result of any of the liabilities discussed above. Furthermore, infringement and other IP claims, with or without merit, can be expensive and time-consuming to litigate and can divert management&#146;s attention from
its core business. AxoGen and its licensors may be unable to obtain and enforce IP rights to adequately protect its products and related IP. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>The patent protection for our products may expire before we are able to maximize their commercial value which may subject us to increased competition and reduce or eliminate our opportunity to
generate product revenue. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The patents for our commercialized products and products in development
have varying expiration dates and, when these patents expire, we may be subject to increased competition and we may not be able to recover our development costs. For example, the two U.S. patents covering the formulations used in our AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product line, which are held by Cook Biotech, are scheduled to expire in August and September 2016. Although we
expect that Cook Biotech is using best efforts to take any action possible to extend the life of these patents, there can be no assurance that any action is possible or action taken will be successful. If these patents expire while we have the right
to distribute and market the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products, it could adversely affect our ability to successfully execute
our business strategy to maximize the value of AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products and could likely negatively impact our future
financial condition and results of operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Others may claim an ownership interest in AxoGen IP which could expose
it to litigation and have a significant adverse effect on its prospects. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A third party may claim an ownership interest
in one or more of AxoGen&#146;s patents or other IP. A third party could bring legal actions against AxoGen claiming it infringes their patents or proprietary rights, and seek monetary damages and/or enjoin clinical testing, manufacturing and
marketing of the affected product or products. While AxoGen believes it owns the right, title and interest in the patents for which it or its licensors have applied and AxoGen&#146;s other IP (including that which is licensed from third parties),
and is presently unaware of any claims or assertions by third-parties with respect to AxoGen&#146;s patents or IP, it cannot guarantee that a third-party will not assert a claim or an interest in any of such patents or IP. If AxoGen becomes involved
in any litigation, it could consume a substantial portion of AxoGen&#146;s resources, and cause a significant diversion of effort by AxoGen&#146;s technical and management personnel regardless of the outcome of the litigation. If any of these
actions were successful, in addition to any potential liability for damages, AxoGen could be required to obtain a license to continue to manufacture or market the affected product, in which case AxoGen may be required to pay substantial royalties or
grant cross-licenses to AxoGen&#146;s patents. AxoGen cannot, however, assure you that any such license will be available on acceptable terms, if at all. Ultimately, AxoGen could be prevented from commercializing a product, or be forced to cease
some aspect of its business operations as a result of claims of patent infringement or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
violation of other IP rights, which could have a material and adverse effect on AxoGen&#146;s business, financial condition, and results of operations. Further, the outcome of IP litigation is
subject to uncertainties that cannot be adequately quantified in advance, including the demeanor and credibility of witnesses and the identity of the adverse party. This is especially true in IP cases that may turn on the testimony of experts as to
technical facts upon which experts may reasonably disagree. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen depends on maintenance of exclusive licenses.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen depends fundamentally on keeping and satisfying the terms of exclusive licenses of its nerve repair
technologies from the University of Florida Research Foundation (the &#147;UFRF&#148;) and the University of Texas at Austin (&#147;UT&#148;)where the original technologies are purported to be invented. Though AxoGen makes an effort to follow these
agreements strictly, a disagreement between AxoGen and either party could have negative impacts on its ability to operate its business effectively. In addition, AxoGen could learn that the technologies it has licensed from UFRF and UT do not perform
as purported, are not efficacious, or are not the property of UFRF or UT, or some similar problem with the license, any of which would have an immediate and negative impact on AxoGen&#146;s business. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risk Related to this Offering </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Until our common stock is listed on a qualified national securities exchange or our common stock price exceeds $5 per share, our common stock will be considered a &#147;penny stock&#148; and will
not qualify for exemption from the &#147;penny stock&#148; restrictions, which may make it more difficult for you to sell your shares. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Prior to this offering, our common shares have traded on the OTCQB Marketplace at a price of less than $5.00 per share and, as a result, is considered as a &#147;penny stock&#148; by the SEC and subject
to rules adopted by the SEC regulating broker-dealer practices in connection with transactions in &#147;penny stocks.&#148; The SEC has adopted regulations which generally define a &#147;penny stock&#148; to be any equity security that is not listed
on a qualified national securities exchange and that has a market price of less than $5.00 per share, or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt,
these rules require delivery, prior to any transaction in a penny stock, of a disclosure schedule relating to the penny stock market. Disclosure is also required to be made about current quotations for the securities and commissions payable to both
the broker-dealer and the registered representative. Finally, broker-dealers must send monthly statements to purchasers of penny stocks disclosing recent price information for the penny stock held in the account and information on the limited market
in penny stocks. As a result of our common shares being subject to the rules on penny stocks, the liquidity of our common shares may be adversely affected. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In connection with this offering, we have applied to list our common shares on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. To the extent that our listing application is
approved and our common shares continue to be listed on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and we meet certain minimum financial metrics, our common shares will no longer be considered as a &#147;penny
stock.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The price of AxoGen&#146;s common shares could be highly volatile due to a number of factors, which could
lead to losses by investors and costly securities litigation. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to this offering, our common shares have traded on
the OTCQB Marketplace in limited volumes. In connection with this offering, we have applied to list our common shares on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We cannot predict the extent to which investor
interest in our company will lead to the development of an active trading market on that stock exchange or any other exchange in the future. The trading price of our common shares has experienced substantial volatility while trading on the OTCQB
Marketplace and is likely to continue to be highly volatile in response to a number of factors including, without limitation, the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">trading of AxoGen common shares on the OTCQB; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">limited daily trading volume resulting in the lack of a liquid market; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">fluctuations in price and volume due to investor speculation and other factors that may not be tied to the financial performance of AxoGen;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">performance by AxoGen in the execution of its business plan; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">financial viability; actual or anticipated variations in our operating results; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">announcements of developments by us or our competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">market conditions in our industry; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">adoption of new accounting standards affecting our industry; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">additions or departures of key personnel; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">introduction of new products by us or our competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">sales of our common shares or other securities in the open market; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory developments in both the United States and foreign countries; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">performance of products sold and advertised by licensees in the marketplace; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">economic and other external factors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">period-to-period fluctuations in financial results; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">other events or factors, many of which are beyond our control. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The stock market is subject to significant price and volume fluctuations. In the past, and several recent situations, following periods
of volatility in the market price of a company&#146;s securities, securities class action litigation has been initiated against such company. Litigation initiated against us, whether or not successful, could result in substantial costs and diversion
of our management&#146;s attention and resources, which could harm our business and financial condition. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen does
not meet the criteria to list its common shares on an exchange such as the NYSE &#151; MKT or NASDAQ Stock Market and its common shares lack liquidity and may be difficult to sell. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to this offering, trading of AxoGen&#146;s common stock has been conducted on the OTCQB. Generally, securities that are quoted on
the OTCQB lack liquidity and analyst coverage. This may result in lower prices for its common shares and a larger spread between the bid and asked prices for its common shares than might otherwise be obtained if it met the criteria to list its
securities on a larger or more established exchange. We have applied to list our common shares on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and anticipate that simultaneously with the closing of the sale of the shares
pursuant to this Prospectus our common stock will trade on such exchange. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has provided us requirements necessary to obtain such listing which include, completion of this
offering and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We cannot predict the extent to which investor interest in our company will lead to the development of an active trading market on that stock exchange or any
other exchange in the future. Additionally, listing on an exchange will result in increased costs and regulatory requirements. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our use of the offering proceeds may not yield a favorable return on your investment. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently anticipate that the net proceeds from this offering will be used primarily for continued product commercialization and
marketing efforts, development of product pipeline, including product line extension, and for general working capital purposes. Pending the application of the net proceeds, we intend to invest the net proceeds in investment-grade, interest-bearing
securities. Our management has broad discretion over how these proceeds are used and could spend the proceeds in ways with which you may not agree, and the proceeds may not be invested in a manner that yields a favorable or any return. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>As a new investor, you will incur substantial dilution as a result of this offering
and future equity issuances, and as a result, our share price could decline. </I></B></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The offering price will be
substantially higher than the net tangible book value per share of our outstanding common shares. As a result, based on our capitalization as of March&nbsp;31, 2013, investors purchasing common shares in this offering will incur immediate and
substantial dilution of $3.04 per share, based on the assumed offering price of $4.10&nbsp;per share. In addition to this offering, subject to market conditions and other factors, we likely will pursue raising additional funds in the future, as we
continue to build our business. In future years, we will likely need to raise significant additional funding to finance our operations and to fund clinical trials, regulatory submissions and the development, manufacture and marketing of other
products under development and new product opportunities. Accordingly, we may conduct substantial future offerings of equity or debt securities. The exercise of outstanding options and warrants and future equity issuances, including future public
offerings or future private placements of equity securities and any additional shares issued in connection with acquisitions, will also result in dilution to investors. In addition, the market price of our common shares could fall as a result of
resales of any of these shares of common stock due to an increased number of shares available for sale in the market. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We do not anticipate paying any cash dividends in the foreseeable future. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The continued operation and expansion of our business will require substantial funding. In additional, the PDL Royalty Contract places
certain restrictions on our ability to pay dividends. Accordingly, we do not anticipate that we will pay any cash dividends on our common shares for the foreseeable future. Any determination to pay dividends in the future will be at the discretion
of our board of directors and will depend upon results of operations, financial condition, contractual restrictions, restrictions imposed by applicable law and other factors our board of directors deems relevant. Accordingly, if you purchase shares
in this offering, realization of a gain on your investment will depend on the appreciation of the price of our common shares, which may never occur. Investors seeking cash dividends in the foreseeable future should not purchase our common shares.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Anti-takeover provisions in Minnesota law may deter acquisition bids for us that you might consider favorable.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are governed by the provisions of Sections 302A.671, 302A.673 and 302A.675 of the Minnesota Business Corporation
Act (the &#147;MBCA&#148;). These provisions may discourage a negotiated acquisition or unsolicited takeover of us and deprive our shareholders of an opportunity to sell their shares at a premium over the market price. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, Section&nbsp;302A.671 of the MBCA provides that a corporation&#146;s shares acquired in a control share acquisition have no
voting rights unless voting rights are approved in a prescribed manner. A &#147;control share acquisition&#148; is a direct or indirect acquisition of beneficial ownership of shares that would, when added to all other shares beneficially owned by
the acquiring person, entitle the acquiring person to have voting power of 20% or more in the election of directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
general, Section&nbsp;302A.673 of the MBCA prohibits a public Minnesota corporation from engaging in a business combination with an interested shareholder for a period of four years after the date of the transaction in which the person became an
interested shareholder, unless the business combination is approved in a prescribed manner. The term &#147;business combination&#148; includes mergers, asset sales and other transactions resulting in a financial benefit to the interested
shareholder. An &#147;interested shareholder&#148; is a person who is the beneficial owner, directly or indirectly, of 10% or more of a corporation&#146;s voting stock, or who is an affiliate or associate of the corporation, and who, at any time
within four years before the date in question, was the beneficial owner, directly or indirectly, of 10% or more of the corporation&#146;s voting stock. Section&nbsp;302A.673 does not apply if a committee of our Board of Directors consisting of all
of its disinterested directors (excluding current and former officers) approves the proposed transaction or the interested shareholder&#146;s acquisition of shares before the interested shareholder becomes an interested shareholder. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If a tender offer is made for our common shares, Section&nbsp;302A.675 of the MBCA precludes
the offer or from acquiring additional shares of stock (including in acquisitions pursuant to mergers, consolidations or statutory share exchanges) within two years following the completion of the tender offer, unless shareholders selling their
shares in the later acquisition are given the opportunity to sell their shares on terms that are substantially the same as those contained in the earlier tender offer. Section&nbsp;302A.675 does not apply if a committee of our Board of Directors
consisting of all of its disinterested directors (excluding its current and former officers) approves the proposed acquisition before any shares are acquired pursuant to the earlier tender offer. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_3"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">From time to time, in reports filed with the Securities and Exchange Commission (including this registration statement),
in press releases, and in other communications to shareholders or the investment community, the Company may provide forward-looking statements concerning possible or anticipated future results of operations or business developments. These statements
are based on management&#146;s current expectations or predictions of future conditions, events or results based on various assumptions and management&#146;s estimates of trends and economic factors in the markets in which we are active, as well as
our business plans. Words such as &#147;expects&#148;, &#147;anticipates&#148;, &#147;intends&#148;, &#147;plans&#148;, &#147;believes&#148;, &#147;seeks&#148;, &#147;estimates&#148;, &#147;projects&#148;, &#147;forecasts&#148;, &#147;may&#148;,
&#147;should&#148;, variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product development, product
potential, regulatory environment, sales and marketing strategies, capital resources or operating performance. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth
in the statements. Forward-looking statements in this registration statement should be evaluated together with the many uncertainties that affect the Company&#146;s business and its market, particularly those discussed in the risk factors and
cautionary statements in the Company&#146;s filings with the Securities and Exchange Commission, including as described in &#147;Risk Factors&#148; included in this registration statement. Forward-looking statements are not guarantees of future
performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and the Company assumes no responsibility to update any forward-looking statements,
whether as a result of new information, future events or otherwise. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You should read this prospectus and the documents that we
reference in this prospectus and have been filed as exhibits to the registration statement of which this prospectus is a part completely and with the understanding that our actual future results may be materially different from what we expect. The
information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any issuance or sale of our common shares. Except as required by law, we do not assume any
obligation to update any forward-looking statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_4"></A>USE OF PROCEEDS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate that the net proceeds to us from the sale of common shares in this offering will be approximately $13,490,000, or
approximately $15,582,500 if the underwriters exercise their over-allotment option in full, assuming a public offering price of $4.10&nbsp;per share and after deducting estimated underwriting discounts and commissions and offering expenses payable
by us. Each $0.10 increase or decrease in the assumed public offering price would increase or decrease, respectively, the net proceeds to us by approximately $0.09, assuming the number of shares offered by us, as set forth above, remains the same
and after deducting underwriting discounts and commissions and estimated offering expenses. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to use the net
proceeds from this offering for continued product commercialization and marketing efforts, development of product pipeline, including product line extension, and for general working capital purposes. We have not determined the amounts we plan to
spend on any of the areas listed above or the timing of these expenditures. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Therefore, investors will be relying on the
judgment of our management, who will have broad discretion regarding the application of the proceeds of this offering. The amounts and timing of our actual expenditures will depend upon numerous factors, including the amount of cash generated by our
operations, our cash needs, the rate of adoption of our products by the medical community and efficiency of our product development. We may find it necessary or advisable to use portions of the proceeds from this offering for other purposes.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pending the application of the net proceeds, we intend to invest the net proceeds in investment-grade, interest-bearing
securities. Our management has broad discretion over how these proceeds are used and could spend the proceeds in ways with which you may not agree, and the proceeds may not be invested in a manner that yields a favorable or any return. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_5"></A>DIVIDEND POLICY </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen currently intends to retain earnings, if any, to finance the growth and development of its business, and does not expect to pay
any cash dividends to its shareholders in the foreseeable future. In additional, the PDL Royalty Contract places certain restrictions on AxoGen&#146;s ability to pay dividends. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_6"></A>COMMON SHARE PRICE RANGE </B></FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to this
offering, our common shares have been traded on the OTCQB Marketplace under the symbol &#147;AXGN.&#148; </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following
table sets forth, for each of the calendar periods indicated, the quarterly high and low closing bid prices for our common shares quoted on the OTCQB Marketplace. The prices in the table represent prices between dealers and do not include
adjustments for retail mark-up, markdown or commission and may not represent actual transactions. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>January&nbsp;1,
2013</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>through&nbsp;July&nbsp;26,&nbsp;2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year
Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,&nbsp;2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year
Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,&nbsp;2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>High</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Low</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>High</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Low</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>High</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Low</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Quarter </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.95</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third Quarter (through July&nbsp;26, 2013)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fourth Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The last reported sale price for our common shares on July 26, 2013 was $4.10 per share. As of
June&nbsp;14, 2013, there were approximately 303 registered holders of record of our common shares, based upon information received from our stock transfer agent. However, this number does not include beneficial owners whose shares were held of
record by nominees or broker dealers. We believe that there are a significantly larger number of beneficial owners of our common shares than the number of record holders. In connection with this offering, we intend to a list our shares
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; under the symbol &#147;&nbsp;&nbsp;&nbsp;&nbsp;.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_7"></A>CAPITALIZATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table describes our capitalization as of March&nbsp;31, 2013: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">on an actual basis; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>on an as adjusted basis to give effect to the sale of 3,658,536 of our shares in this offering at an assumed public offering price of
$4.10&nbsp;per share, after deducting estimated underwriting discounts and commissions and offering expenses. </FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">You should read this capitalization table together with our consolidated financial statements and the related notes appearing at the end of this prospectus and the &#147;Use of Proceeds,&#148;
&#147;Summary Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; sections and other financial information included in this prospectus. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of March&nbsp;31, 2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As Adjusted</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,438</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,438</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shareholders&#146; equity (deficit):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Share, $.01 par value; 50,000,000 shares authorized, 11,127,869 shares issued and outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional paid-in capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,170</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68,623</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(61,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(61,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total shareholders&#146; equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,005</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,485</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total capitalization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,923</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number of our common shares outstanding after this offering is based on 11,139,939 common shares outstanding
as of July 26, 2013 and assumes no exercise of the underwriter&#146;s option to purchase an additional shares to cover over-allotments, and excludes: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,986,276 common shares issuable upon the exercise of options outstanding as of July 26, 2013 at a weighted average exercise price of $2.67 per share;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">89,686 common shares issuable upon the exercise of warrants outstanding as of July 26, 2013 at an exercise price of $2.23 per share; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">602,914 additional common shares available for future issuance as of July 26, 2013 under our AxoGen 2010 Stock Incentive Plan.
</FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless otherwise indicated, all information in this prospectus assumes no exercise of the outstanding
options or the warrants described above. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_8"></A>DILUTION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our net tangible book value as of March&nbsp;31, 2013 was approximately $(6.6) million, or $(0.59) per common share. Net tangible book
value per share is determined by dividing our total tangible assets less total liabilities by the actual number of outstanding shares of our common shares. After giving effect to our issuance of 3,658,536 shares at the assumed public offering price
of $4.10&nbsp;per share, and after deducting estimated underwriting discounts and commissions and offering expenses payable by us, our net tangible book value as of March&nbsp;31, 2013 would have been $6.9&nbsp;million or $0.47&nbsp;per common
share. This represents an immediate increase in pro forma net tangible book value of $1.06&nbsp;per share to our existing shareholders and an immediate dilution of $3.04&nbsp;per share to new investors in this offering. The following table
illustrates this per share dilution: </FONT></P>  <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assumed public offering price per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net tangible book value per share as of March&nbsp;31, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.59</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increase per share attributable to new investors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma net tangible book value per share after this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.06</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dilution per share to new investors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.04</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Information in the above table is based on 11,127,869 shares of common stock outstanding as of March&nbsp;31, 2013,
and excludes: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,943,689 common shares issuable upon the exercise of options outstanding as of March&nbsp;31, 2013 at a weighted average exercise price of $2.60 per
share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">89,686 common shares issuable upon the exercise of warrants outstanding as of March&nbsp;31, 2013 at an exercise price of $2.23 per share; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">657,571 additional common shares available for future issuance as of March&nbsp;31, 2013 under our AxoGen 2010 Stock Incentive Plan.
</FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dilution per share to new investors is determined by subtracting pro forma net tangible book value per
share after this offering from the assumed public offering price per share paid by a new investor. If any shares are issued in connection with outstanding options or the underwriter&#146;s over-allotment option, you will experience further dilution.
A $0.10 increase or decrease in the assumed public offering price would increase or decrease, respectively, the pro forma as adjusted net tangible book value as of March&nbsp;31, 2013 by approximately $0.4 million, or $0.02&nbsp;per common share,
and the dilution per share to new investors by $0.08&nbsp;per share, assuming the number of shares offered by us, as set forth above, remains the same and after deducting underwriting discounts and commissions and estimated offering expenses.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_9"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITIONS AND RESULTS OF OPERATIONS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The following discussion of our financial condition and results of operations
should be read in conjunction with our consolidated financial statements and the related notes, and the financial and other information included elsewhere in this prospectus. Among other things, those financial statements include more detailed
information regarding the basis of presentation for the following information. The financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, and are presented in U.S. dollars. </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This discussion contains forward-looking statements that involve risks and uncertainties based on assumptions about our future
business. Our actual results may differ from those contained in the forward-looking statements and such differences may be material as a result of a number of factors. Please read &#147;Risk Factors&#148; and &#147;Cautionary Note Regarding
Forward-Looking Statements.&#148; </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;30, 2011, LecTec Corporation (&#147;LecTec&#148;) completed its business combination with AxoGen Corporation (&#147;AC&#148;) in accordance with the terms of an Agreement and Plan of
Merger, dated as of May&nbsp;31, 2011, by and among LecTec, Nerve Merger Sub Corp., a subsidiary of LecTec (&#147;Merger Sub&#148;), and AC, which the parties amended on September&nbsp;30, 2011 and August&nbsp;9, 2011 (as amended, the &#147;Merger
Agreement&#148;). Pursuant to the Merger Agreement, Merger Sub merged with and into AC, with AC continuing after the Merger as the surviving corporation and a wholly owned subsidiary of LecTec. Immediately following the Merger, LecTec changed its
name to AxoGen, Inc. In October 2011, AxoGen, Inc. moved its corporate headquarter facilities (principal executive office) from Texarkana, Texas to 13859 Progress Blvd., Suite 100, Alachua, Florida 32615. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For accounting purposes, AC was identified as the acquiring entity and LecTec as the acquired entity. The Merger was accounted for using
the purchase method of accounting for financial reporting purposes. The purchase method requires the identification of the acquiring entity, based on the criteria of Accounting Standards Codification 805-10-55-12, Accounting for Business
Combinations. Under purchase accounting, the assets and liabilities of an acquired company (LecTec) as of the effective date of the acquisition were recorded at their respective estimated fair values and added to those of the acquiring company.
Accordingly, the consolidated financial statements and related footnote disclosures presented for periods prior to the Merger are those of AC alone. The consolidated Statement of Operations for the years ended December&nbsp;31, 2011 and 2010 include
the operations and cash flows of AC through September&nbsp;30, 2011 and the combined operations and cash flows of the Company subsequent to the Merger. The common stock of AC has been retrospectively adjusted to reflect the exchange ratio of one
share of AC common stock for 0.03727336 share of the Company&#146;s common shares as established in the Merger Agreement. Historical results for LecTec prior to the Merger are not included in the Company&#146;s consolidated financial statements.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen is a leading regenerative medicine company dedicated to advancing the science and
commercialization of peripheral nerve repair solutions. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of muscle function and feeling. In order to improve the
options for the surgical repair and regeneration of peripheral nerves, AxoGen has developed and licensed patented and patent pending technologies. AxoGen&#146;s innovative approach to regenerative medicine has resulted in first-in-class products
that will define their product categories. AxoGen&#146;s products offer a full suite of surgical nerve repair solutions including Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves without the comorbidities of an autograft second surgical site,
loss of feeling where the nerve was removed and potential pain at the donor site. AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector is
for tensionless repair of severed nerves and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector is used to wrap and protect injured
peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue from the
distribution of these products is the main contributor to AxoGen&#146;s total reported sales and has been the key component of its growth to date. AxoGen revenues increased in the first quarter of 2013 and the twelve months of 2012 compared to the
first quarter 2012 and the twelve months of 2011, respectively, as a result of increased usage in the number of accounts utilizing our products. AxoGen has continued to broaden its sales and marketing focus which is expected to have a positive
contribution to its revenue growth in the long term, even though in the near term revenue growth may lag behind expense increase. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">From May 2009 to December 2010, AxoGen temporarily stopped the
manufacturing of Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft due to adequate inventory. In December 2010, AxoGen resumed the
manufacturing of Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, and as a result incurred higher processing and testing fees, travel costs
and temporary labor costs in 2011 compared to 2012. In 2011 AxoGen reviewed inventory expiration and wrote off inventory for products manufactured in early 2009. Additionally AxoGen reviewed and adjusted inventories and established reserves to
adequately reflect inventory value in 2011. AxoGen believes that such actions will not be required in the future and that it has the necessary inventories, inventory reserves and manufacturing capabilities for its anticipated sales growth.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Critical Accounting Policies and Estimates </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The discussion and analysis of the Company&#146;s financial condition and results of operations is based upon the Company&#146;s consolidated financial statements, which have been prepared in accordance
with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial statements, and reported amount of expenses during the period reported. Management bases its estimates and judgments on historical experience, observance of trends in the
industry, information provided by outside sources and on various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our significant accounting policies are described in Note 3 to the consolidated financial statements contained in F-7 of this
registration statement. We have identified the following policies as critical to our business operations and the understanding of our consolidated results of operations: </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>Accounts Receivable and Concentration of Credit Risk &#150; Doubtful Accounts </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Trade accounts receivable are recorded at the invoiced amount and do not bear interest. If deemed necessary we maintain an allowance for doubtful accounts for estimated losses inherent in our accounts
receivable portfolio. In establishing the required allowance, management considers customers&#146; financial condition, credit history and current economic conditions. To date, we have not reserved for doubtful accounts as they have been immaterial
both in number and dollar amount. Account balances are charged off after all means of collection have been exhausted and the potential for recovery is considered remote. Our internal financial operations have primary responsibility for billing and
collecting our accounts receivable. We utilize various processes and procedures in our collection efforts; these efforts include monthly statements, written collection notices and telephonic follow-ups. In the event the current conditions as to
doubtful accounts negatively changes, management will consider reserving for doubtful accounts. Management judgment as to identifying negative trends is important in its assumption of exposure to uncollectable receivables requiring a reserve and if
revenues expand as expected accounts receivable will rise potentially causing management to reevaluate its underlying assumptions. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>Goodwill </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Goodwill represents the excess of the purchase price over the net
tangible and intangible assets acquired in business combinations. The Company is required to perform a review for impairment of goodwill in accordance with FASB ASC 350, Intangibles &#151; Goodwill and Other. Goodwill is considered to be impaired if
it is determined that the carrying value of goodwill exceeds its fair value. The Company conducts an impairment test of goodwill each year end. In addition to the annual review, an interim review is required if an event occurs or circumstances
change that would more likely than not reduce the fair value of the goodwill below its carrying amount. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Effective Interest
Rate on Note Payable </U></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The PDL Royalty Contract is accounted for as long-term debt. The Company records interest using
its best estimate of the effective interest rate. This estimate takes into account both the internal rate of return (IRR) of the PDL agreement and the rate of return as the result of exercise of the Put option. The IRR of the PDL Royalty Contract is
based on the actual&nbsp;payments to date, projected future revenues and required minimum payments, and is calculated at 19.85%. The PDL Royalty Contract Put option provides PDL a 20% return, if exercised. As a result of the return of the Put option
being higher than the IRR of the PDL agreement, management believes the best estimate of the effective interest rate on this instrument would be the Put rate. As a result, the Company is accruing interest using the specified internal rate of return
for the Put which is 20%. We currently have no knowledge of PDL&#146;s intent to exercise the Put, but will monitor this on an ongoing basis. From time to time, the Company will reevaluate the expected cash flows and may adjust the effective
interest rate. Since inception of the Royalty Contract, if the interest rate utilized were to change by 1% the effect on interest expense through March&nbsp;31, 2013 would increase or decrease by approximately $110,000. Determining the effective
interest rate requires judgment and is based on significant assumptions related to estimates of the amounts and timing of future revenue streams and PDL&#146;s ultimate decision to exercise the Put. Determination of these assumptions is highly
subjective and different assumptions could lead to materially different outcomes. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Income Taxes </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Deferred income taxes reflect the impact of temporary differences between the reported amounts of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws and
regulations. The deferred tax assets and liabilities represent the future tax return consequences of those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. A valuation allowance is
provided for deferred tax assets when management concludes it is more-likely-than-not that some portion of the deferred tax assets will not be recognized. We have a full valuation allowance established on the deferred tax asset upon
management&#146;s best estimate of final outcomes based upon estimated future revenue and changes in business capitalization. Factors used to establish the valuation allowance are complicated and could cause variability in application over time.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Results of Operations </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Comparison of Three months ended March&nbsp;31, 2013 and 2012 and the Years Ended December&nbsp;31, 2012 and 2011 </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>Revenues </U></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenues for the three months ended March&nbsp;31, 2013
increased 29.6% to approximately $2,143,000 as compared to approximately $1,653,000 for the three months ended March&nbsp;31, 2012. Additionally, revenues for the year ended December&nbsp;31, 2012 increased 59% to approximately $7,692,000 as
compared to approximately $4,849,000 for the year ended December&nbsp;31, 2011. Such increases were principally due to a greater number of customers utilizing AxoGen products and increased product usage by existing accounts. For the three months
ended March&nbsp;31, 2013, new AxoGen customers in that quarter represented approximately $149,000 of total revenue for such quarter or approximately 7%. For the year ended December&nbsp;31, 2012 new customers in 2012 represented approximately
$859,000 of total revenue in 2012 or approximately 11%. Each new customer in a defined period has the potential to become an established customer that increases its purchasing. As such, revenue growth occurs from both new customers who purchase for
the first time in a period and increased purchasing from established customers. Each new period of measurement is thus benefited from the additional new customers added in the prior period. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Gross Profit </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">Gross profit for the three months ended March&nbsp;31, 2013 increased 30.4% to approximately $1,583,000 as compared to approximately $1,214,000 for the three months ended March&nbsp;31, 2012, primarily
attributable to the increased revenues in the first quarter of 2013, manufacturing efficiencies and a product price increase instituted in March 2013 which contributed approximately $30,000 or approximately 1.5%, partially offset by an increase in
the inventory reserve. Gross profit for the year ended December&nbsp;31, 2012 increased 136% to approximately $5,730,000 as compared to approximately $2,423,000 for the year ended December&nbsp;31, 2011. This increase was primarily attributable to
the increased revenues and gross margin in 2012 and not incurring inventory write-offs in the aggregate amount of $828,000 or higher processing and testing fees, travel costs and temporary labor costs due to the resumption of the manufacturing of
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft as experienced in 2011. The 2011 inventory write-offs consisted of two items. The first item
was approximately $614,000 for Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft finished goods inventory and the second was related to
$214,000 of raw materials related to the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, both of these items were deemed to be excess
inventory. During the third quarter of 2011 management made certain strategic decisions in response to market demand, and anticipated trends, that resulted in a portion of the finished goods and raw materials inventory to become excess. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Costs and Expenses </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Total cost and expenses increased 23.8% to approximately $3,906,000 for the three months ended March&nbsp;31, 2013 as compared to approximately $3,155,000 for the three months ended March&nbsp;31, 2012.
Total cost and expenses increased 44% to approximately $13,532,000 for the year ended December&nbsp;31, 2012 as compared to approximately $9,392,000 for the year ended December&nbsp;31, 2011. These increases in the first quarter 2013 and the 2012
fiscal year were primarily due to increasing sales and marketing activities and increases in salaries as AxoGen hired additional personnel to meet its current and expected growth. To a lesser extent, these increases were also attributable to
expenses associated with being a public company and research and development costs associated with the Company&#146;s preparation for its clinical trial. For the fiscal year 2012 these increases were partially offset by decreases in certain
professional services and financing costs. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a percentage of revenues, total operating expenses were 182.3% for the three months ended
March&nbsp;31, 2013 compared to 190.9% for the three months ended March&nbsp;31, 2012. As a percentage of revenues, total operating expenses were 175.9% for the year ended December&nbsp;31, 2012 compared to 193.7% for the year ended
December&nbsp;31, 2011. Such lower total costs and expenses as a percentage of revenue in the first quarter 2013 and the 2012 fiscal year were primarily a result of the Company&#146;s revenue increase outpacing costs and expenses increase.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales and marketing expenses increased 16.3% to approximately $1,894,000 for the three months ended March&nbsp;31, 2013 as
compared to approximately $1,629,000 for the three months ended March&nbsp;31, 2012. Sales and marketing expenses increased 57.2% to approximately $6,884,000 for the year ended December&nbsp;31, 2012 as compared to approximately $4,379,000 for the
year ended December&nbsp;31, 2011. The increases in the first quarter 2013 and the 2012 fiscal year were primarily due to an increase in sales and marketing activity as the Company expands support for both its direct sales force and independent
distributors and in fiscal year 2012 increasing the number of its direct sales representatives. As a percentage of revenues, sales and marketing expenses were 88.4% for the three months ended March&nbsp;31, 2013 compared to 98.5% for the three
months ended March&nbsp;31, 2012. As a percentage of revenues, sales and marketing expenses were 89.4% for the year ended December&nbsp;31, 2012 compared to 90.3% for the year ended December&nbsp;31, 2011. Such lower sales and marketing expenses as
a percentage of revenue were a result of the revenue increases outpacing costs and expenses increases. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and
administrative expenses increased 30.5% to approximately $1,606,000 for the three months ended March&nbsp;31, 2013 as compared to approximately $1,231,000 for the three months ended March&nbsp;31, 2012. General and administrative expenses increased
21.0% to approximately $5,221,000 for the year ended December&nbsp;31, 2012 as compared to approximately $4,316,000 for the year ended December&nbsp;31, 2011. As a percentage of revenues, general and administrative expenses were 74.9% for the three
months ended March&nbsp;31, 2013 compared to 74.5% for the three months ended March&nbsp;31, 2012. As a percentage of revenues, general and administrative expenses were 67.9% for the year ended December&nbsp;31, 2012 compared to 89.0% for the year
ended December&nbsp;31, 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The increase in aggregate dollars spent in the first quarter 2013 and the 2012 fiscal year were
a result of increased payroll and benefits, public company related expenditures, travel and other general expenses. As a percentage of revenue, general and administrative expenses decreased in the 2012 fiscal year as the increase in aggregate
dollars spent were absorbed by the increase in revenues. In the first quarter 2013 as a percentage of revenue, general and administrative expenses were slighter higher as the percentage increase rise in revenue was similar to the percentage increase
rise in general and administrative expenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses increased 37.5% to approximately $407,000 in
the three months ended March&nbsp;31, 2013 as compared to approximately $296,000 for the three months ended March&nbsp;31, 2012. Research and development expenses increased 104.7% to approximately $1,427,000 in the year ended December&nbsp;31, 2012
as compared to approximately $697,000 for the year ended December&nbsp;31, 2011. Development includes AxoGen&#146;s clinical efforts and a large portion of the increase in the first quarter 2013 and the 2012 fiscal year in research and development
expenses over the comparable periods related to expenditures for such clinical activity. Because AxoGen&#146;s products are developed for sale in their current use, it conducts limited direct research and product development, but intends to pursue
new products and new applications for existing products in the future that may result in increased spending. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Other Income
and Expenses </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense increased 754% to approximately $1,068,000 in the three months ended March&nbsp;31, 2013 as
compared to approximately $125,000 for the three months ended March&nbsp;31, 2012. This increase was a result of the interest expense related to the PDL transaction. As a result of the accounting treatment for the PDL transaction, interest expense
included approximately $895,000 of non-cash expense that is expected to be paid in the future based upon the terms of the PDL transaction and increases in AxoGen revenues. The $895,000 of non cash expense was derived from taking the total amount of
imputed interest for the quarter on the PDL agreement less the actual cash payment made to PDL in the quarter. Other than the $895,000 non-cash expense, the remaining $173,000 in interest expense for the three months ended March&nbsp;31, 2013 is
related to cash paid for interest on the note payable. The $125,000 interest expense for the three months ended March&nbsp;31, 2012 was cash paid for interest on the previous debt. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense increased 27% to approximately $1,391,000 for the year ended
December&nbsp;31, 2012 as compared to approximately $1,095,000 for the year ended December&nbsp;31, 2011. This increase was a result of the interest expense related to the PDL transaction. As a result of the accounting treatment for the PDL
transaction, interest expense included approximately $780,000 of non-cash expense that is expected to be paid in the future based upon the terms of the PDL transaction and increases in AxoGen revenues. The $780,000 of non cash expense was derived
from taking the total amount of imputed interest for the year ended December&nbsp;31, 2012 on the PDL agreement less the actual cash payment made to PDL for that period. Excluding this non-cash component, cash paid for interest decreased in 2012 by
approximately $381,000 compared to 2011 as a result of accrued interest on convertible debt and an increased interest rate on borrowed money in 2011 not recurring in 2012. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense&#151;deferred financing costs increased 25.7% to approximately $44,000 for the three months ended March&nbsp;31, 2013 as
compared to approximately $35,000 for the three months ended March&nbsp;31, 2012. This increase is primarily due to higher deferred financing cost amortization associated with the PDL agreement when compared to the previous bank debt. Interest
expense&#151;deferred financing costs decreased 19.3% to approximately $987,000 for the year ended December&nbsp;31, 2012 as compared to approximately $1,223,000 for the year ended December&nbsp;31, 2011. This decrease is primarily due to certain
deferred financing costs associated with warrants issued as consideration for several amendments executed during 2010 related to the Loan and Security agreement originally entered into in April 2008 becoming fully amortized by March&nbsp;31, 2011.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Income Taxes </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company had no income tax expenses or income tax benefit for each of the three months ended March&nbsp;31, 2013 and 2012 due to incurrence of net operating loss in each of these periods. Income tax
benefit of approximately $738,000 for the year ended December&nbsp;31, 2012 was the result of the Company&#146;s ability to utilize net operating losses and franchise tax adjustments which resulted in tax refunds. The company had no income tax
expense or income tax benefit for 2011 due to incurrence of net operating losses. The Company does not believe there are any additional tax refund opportunities currently available. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>Effect of Inflation </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inflation has not had a significant impact on
the Company&#146;s operations or cash flows. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Liquidity and Capital Resources </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Long-Term Debt / Note Payable </U></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;5, 2012, AxoGen entered into the Royalty Contract with PDL. Proceeds from the PDL transaction were used to fully repay the MidCap Loan, as defined below, and extinguish AxoGen&#146;s
long-term debt obligations thereunder. The Royalty Contract has a term of eight years. Under the Royalty Contract, PDL is to receive royalty payments currently paid weekly based on a 9.95% royalty rate of certain of the Company&#146;s Net Revenues
(the &#147;Assigned Interests&#148;), subject to certain guaranteed quarterly payment amounts of approximately $1.3 to $2.5 million per quarter that commence in the quarter ending December&nbsp;31, 2014. The minimum annual payment amounts are as
follows: 2014 - $1,250,805, 2015 - $6,781,440, 2016 - $9,232,642, 2017 and 2018 - $9,000,000, 2019 - $9,063,000 and 2020 - $6,939,000. The royalty payment is based on only that portion of Company Net Revenue that is generated by the sale,
distribution or other use of the Company&#146;s products Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector (the &#147;Acquired Revenues&#148;), which at this time represents all of the Company&#146;s Net Revenue with the exception of shipping and handling
fees which represent less than 2.3% of total revenues. Future revenue, if any, from other products or services will not be subject to the PDL royalty payment. Further, on October&nbsp;5, 2016, or in the event of the occurrence of a material adverse
event, our transfer of revenue interest or substantially all of our interest in the products or AxoGen&#146;s bankruptcy or material breach of the Royalty Contract, PDL may require AxoGen to repurchase the Assigned Interests at the Put Price. The
Put Price is equal to the sum of (i)&nbsp;an amount that, when paid to PDL, would generate a 20% internal rate of return to PDL on the Funded Amount, taking into consideration payments made to PDL by AxoGen, and (ii)&nbsp;any Delinquent Assigned
Interests Payment AxoGen owed to PDL. Although we have no knowledge of PDL&#146;s intent to exercise the Put, based on actual payments to date, projected future revenues and the required minimum payments, we currently believe the Put Rate is the
best estimate of the effective interest rate of the Royalty Contract. Finally, in the event of a Change of Control, AxoGen must repurchase the Assigned Interests from PDL for a repurchase price equal to the Change of Control Price on or prior to the
third business day after the occurrence of the Change of Control. The Change of Control Price is the sum of (i)&nbsp;an amount that, when paid to PDL, would generate an internal rate of return to PDL of thirty-two and one half percent
(32.5%)&nbsp;on all payments made by PDL pursuant to the Royalty Contract as of the date </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of the Change of Control Payment, taking into account the amount and timing of all payments made by AxoGen to PDL (and retained by PDL) prior to and as of the date of payment of the Change of
Control Payment, plus (ii)&nbsp;any Delinquent Assigned Interests Payment owed. The total consideration PDL paid to the Company was $20,800,000 (the &#147;Funded Amount&#148;), including $19,050,000 PDL paid to the Company on October&nbsp;5, 2012,
and $1,750,000 PDL paid to the Company on August&nbsp;14, 2012 pursuant to the Interim Royalty Contract. Upon the closing of PDL&#146;s purchase of the specified royalties described above, which was concurrent with the execution of the Royalty
Contract, the Interim Royalty Contract was terminated. There are no financial covenants or other restrictions on the use of capital by AxoGen as a result of the Royalty Contract, however, PDL has a first perfected security interest in the Assigned
Interests. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;30, 2011, the Company, entered into the Loan and Security Agreement with MidCap Financial SBIC,
LP (&#147;MidCap&#148;), as administrative agent, and the Lenders listed on Schedule 1 thereto (the &#147;MidCap Loan&#148;). The MidCap Loan had a principal amount of $5.0 million and a term of 42 months, and was subject to prepayment penalties.
Under this agreement, AxoGen was required to make interest only payments for the first 12 months, and payments of both interest and straight line amortization of principal for the remaining 30 months. The interest rate was 9.9%&nbsp;per annum, and
interest was computed on the basis of a 360-day year and the actual number of days elapsed during which such interest accrues. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The MidCap Loan contained customary affirmative and negative covenants, including, without limitation, (i)&nbsp;covenants requiring
AxoGen to comply with applicable laws, provide to MidCap copies of AxoGen&#146;s financial statements, maintain appropriate levels of insurance and protect, defend and maintain the validity and enforceability of AxoGen&#146;s material intellectual
property, (ii)&nbsp;covenants restricting AxoGen&#146;s ability to dispose of all or any part of its assets (subject to certain exceptions), engage in other lines of business, changes in its senior management, enter into merger or consolidation
transactions, incur or assume additional indebtedness, or incur liens on its assets, and (iii)&nbsp;covenants requiring the Company to meet certain minimum Net Invoiced Revenue, as defined in the agreement, or maintain a cash balance of 80% of the
loan principal amount. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The MidCap Loan was secured by all of AxoGen&#146;s assets. The Lenders also received a ten-year
warrant to purchase 89,686 shares of AxoGen&#146;s common shares at $2.23 per share. Proceeds from the PDL transaction were used to fully repay the MidCap Loan, along with a $172,581 prepayment penalty, and extinguish AxoGen&#146;s obligations
thereunder. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;21, 2008, AxoGen entered into a Loan and Security Agreement with Oxford Finance Corporation and
ATEL Ventures, Inc., as subsequently amended (the &#147;2008 Loan and Security Agreement&#148;), which provided for a loan with an aggregate principal amount of $7.5 million. The loan&#146;s maturity date was October&nbsp;1, 2011. The loan bore
interest at a rate of 18%&nbsp;per month and was secured by all of AxoGen&#146;s assets. On September&nbsp;30, 2011, AxoGen paid in full the entire outstanding balance of the 2008 Loan and Security Agreement, using the proceeds from the MidCap Loan.
</FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;11, 2010, AxoGen entered into Convertible Debt Agreements for an aggregate principal amount of $3.7 million
with 8% interest and principal and interest payable in full on June&nbsp;30, 2013, as amended. The Convertible Debt Agreements were collateralized by a third lien on certain property and were subordinated to the 2008 Loan and Security Agreement.
Immediately prior to the closing of the Merger, the Convertible Debt Agreements pursuant to their terms automatically converted into AC common stock which was then exchanged for Company common shares pursuant to the terms of the Merger Agreement.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On May&nbsp;3, 2011, AxoGen issued an 8% Convertible Note Payable to LecTec Corporation for $500,000. On May&nbsp;31, 2011,
AxoGen issued additional convertible notes payable under the same terms of which $2,000,000 was issued to LecTec and $500,000 was issued to certain AC shareholders. On August&nbsp;29, 2011, AxoGen issued an additional subordinated secured
convertible promissory note in the principal amount of $2,000,000 to LecTec and $500,000 to certain AC shareholders. These notes were collateralized by all of AxoGen&#146;s assets and subordinated to the 2008 Loan and Security Agreement. Immediately
prior to the closing of the Merger, the notes held by investors other than LecTec automatically converted into AC&#146;s common stock which was then exchanged for LecTec common stock pursuant to the terms of the Merger Agreement. Immediately after
to the closing of the Merger, the notes held by LecTec were retired. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company had no material commitments for capital
expenditures at March&nbsp;31, 2013 or December&nbsp;31, 2012 or 2011. Under the Royalty Contract, the Company sold to PDL the Acquired Revenues and PDL is to receive for eight years the Assigned Interests, i.e., a royalty payment based on a 9.95%
royalty rate of the Company&#146;s Net Revenues, subject to certain agreed upon minimum payments of approximately $1.3 to $2.5 million per quarter, and was provided the Put and receives certain payments in the event of a
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Change of Control. The total consideration PDL paid to the Company was $20,800,000, including $19,050,000 PDL paid to the Company on October&nbsp;5, 2012, and $1,750,000 PDL paid to the Company
on August&nbsp;14, 2012, pursuant to the Interim Royalty Contract. Upon the closing of PDL&#146;s purchase of the specified royalties under the Royalty contract, which was concurrent with its execution, the Interim Royalty Contract was terminated.
Proceeds from the PDL Royalty Contract transaction where used to fully repay the MidCap Loan and extinguish AxoGen&#146;s obligations thereunder. There are no financial covenants or other restrictions on the use of capital by AxoGen as a result of
the Royalty Contract, however, PDL has a first perfected security interest in the Assigned Interests. In the event that the Company is unable to generate revenue in excess of its PDL Assigned Interests payments and other expenses, or PDL were to
exercise the Put at a time when the Company did not have sufficient capital to pay the Put Price, AxoGen would need to raise additional capital. There is no assurance that if AxoGen is required to secure funding it can do so on terms acceptable to
it, or at all, and its liquidity would be severely compromised. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Cash Flow Information </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen had working capital of approximately $14.5 million and a current ratio of 11.23 at March&nbsp;31, 2013, compared to working capital
of $16.8 million and a current ratio of 12.4 at December&nbsp;31, 2012. The decrease in working capital and the current ratio at March&nbsp;31, 2013 as compared to December&nbsp;31, 2012 was primarily due to the use of working capital for operations
in excess of revenues. The Company believes it has sufficient cash resources to meet its liquidity requirements for the next 12 months. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s future capital requirements depend on a number of factors, including, without limitation, revenue increases consistent with its business plan, and the corresponding royalty payments of
approximately $1.3 to $2.5 million per quarter due to PDL and pursuant to AxoGen&#146;s licensing agreements in connection with Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, cost of products and acquisition and/or development of new products. In particular, if revenue does not increase by fourth quarter 2014 to a level
whereby the 9.95% royalty owed to PDL on AxoGen&#146;s gross revenues exceeds the PDL minimum royalty payments at such time of approximately $1.3 million, and such differential continues, or grows larger as the PDL minimum royalty payments increase,
AxoGen would face increasing capital needs. Such capital needs could be substantial depending on the extent to which AxoGen is unable to increase revenue. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As a result of AxoGen&#146;s continuing capital needs and other factors, it has decided to raise additional funds through this registration statement. The sale of additional equity may result in dilution
to AxoGen&#146;s shareholders. There is no assurance that AxoGen will be able to secure funding on terms acceptable to it, or at all. The increasing need for capital as the PDL transaction matures could also make it more difficult to obtain funding
through either equity or debt. Should additional capital not become available to AxoGen as needed, AxoGen may be required to take certain action, such as, slowing sales and marketing expansion, delaying regulatory approvals or reducing headcount.
During the three months ended March&nbsp;31, 2013, the Company had a net decrease in cash and cash equivalents of approximately $2,707,000 as compared to a net decrease of cash and cash equivalents of approximately $2,549,000 in the three months
ended March&nbsp;31, 2012. The Company&#146;s principal sources and uses of funds are explained below: </FONT></P>  <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash used in
operating activities </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company used approximately $2,651,000 of cash for operating activities in the three months ended
March&nbsp;31, 2013, as compared to using approximately $2,478,000 of cash for operating activities in the three months ended March&nbsp;31, 2012. This increase in cash used in operating activities is primarily attributed to the net loss generated
in the three months ended March&nbsp;31, 2013, along with an increase in our accounts receivable and inventory. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash used for
investing activities </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investing activities for the three months ended March&nbsp;31, 2013 used approximately $57,000 of cash as
compared to using approximately $71,000 of cash in the three months ended March&nbsp;31, 2012. This increase in use is principally attributable to the purchase of certain fixed and intangible assets. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash provided by financing activities </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Financing activities in the three months ended March&nbsp;31, 2013 provided $1,654 of cash as compared to providing $0 of cash in the three months ended March&nbsp;31, 2012. The Company did not incur any
debt issuance costs in 2013. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Off-Balance Sheet Arrangements </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen does not have any off-balance sheet arrangements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_100"></A>BUSINESS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a
leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can
result in the loss of muscle function and/or feeling. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nerves can be damaged in a number of ways. When a nerve is cut due to a
traumatic injury or surgery, functionality of the nerve may be compromised, causing the nerve to no longer carry the signals to and from the brain to the muscles and skin. This type of injury generally requires a surgical repair. The traditional
gold standard has been to either suture the nerve ends together directly without tension or to bridge the gap between the nerve ends with a less important nerve surgically removed from elsewhere in the patient&#146;s own body referred to as nerve
autograft. In addition, pressure on a nerve or blunt force trauma can cause nerve injuries that may require surgical intervention. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">In order to improve the options available for the surgical repair and regeneration of peripheral nerves, we have developed and licensed patented and patent pending technologies. Our innovative approach to
regenerative medicine has resulted in first-in-class products that we believe will define their product categories. Our products offer a full suite of surgical nerve repair solutions including
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, the only off-the-shelf commercially available processed nerve allograft, human nerve tissue
obtained from a donor, for bridging severed nerves without the comorbidities of an autograft second surgical site, such as loss of feeling where the nerve was removed and potential pain at the donor site. Our AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> line of products are a natural scaffold ExtraCellular Matrix or ECM derived from pig tissue. AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector is used to facilitate the tensionless repair of severed nerves, and AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector is used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while
preventing soft tissue attachments. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s products are used by surgeons during surgical
interventions to repair a wide variety of traumatic nerve injuries ranging from a simple laceration of a finger to complex brachial plexus (an injury to the network of nerves that originate in the neck). The Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft provides surgeons with a three-dimensional structure of a natural nerve. This structure is essential and
allows for bridging nerve gaps or discontinuities the range of 5mm to 70mm. Additionally, the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve
Graft has product and sales synergies with the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector and AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector. AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products provide the unique features of pliability, suturability, and translucence for visualization of the underlying nerve, while also allowing the patient&#146;s
own cells to incorporate into the extracellular matrix to remodel and form a tissue similar to the outermost layer of the nerve (nerve epineurium). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Regenerative Medical Products Industry </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Regenerative medical products
enable the repair, restoration, replacement or regeneration of tissue or organ systems of the body. Regenerative medical products are becoming common in various medical arenas because they have been shown to be effective repairing injured or
defective tissues, such as bone, tendons, dermis and other tissues of the body. Surgeons utilize regenerative medical products because they can provide the complex structure required for implant integration and regeneration in the body. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe the primary driver of sustained growth in the regenerative medical product market is continued favorable
efficacy as compared to autograft and synthetic medical products, and a wider understanding of this advantage by practitioners. Repair with nerve autograft requires a secondary recovery procedure to remove tissue from another location of the body to
repair the injured area and can result in loss of function at the site of donation. Nerve autograft may also be costly and time consuming and may result in complications such as infection. In addition to nerve allograft (Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft), alternatives to nerve autograft include hollow-tube synthetic or collagen-based medical products that
are designed to provide some restoration of function but may </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
be limited by biocompatibility with the body or manufacturing technologies and capabilities. Regenerative medical products often provide more desirable conditions for reconstruction and
regeneration of tissue, creating a superior solution for patients and physicians. AxoGen follows this trend, providing regenerative medical products for peripheral nerve reconstruction. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Regenerative medicine products typically consist of and rely on: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">i.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">A scaffold or ECM to support the cells and/or provide the architecture of the tissue: and/or </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">ii.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cells to regenerate or recellularize the scaffold. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s products are scaffolds, and the patients&#146; own body provides the cells to regenerate or recellularize these scaffolds. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Peripheral Nerves and Their Regeneration </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The peripheral nervous system, or PNS, consists of nerves that either extend outside of, or reside outside of, the central nervous system (the brain and spinal cord). Peripheral nerves provide the pathway
for signals between the central nervous system and target organs, regulating movement (motor nerves) and touch (sensory nerves). Therefore, if a peripheral nerve is crushed, severed, or otherwise damaged, its ability to deliver signals to the target
organs is eliminated, or significantly reduced, and could result in a loss of sensation and/or functionality. The axon portion of the nerve cell, consisting of cell cytoplasm and resembling a hair-like fiber, carries signals from the cell body to
the target organ. Axons can be quite long, even exceeding one meter, but are only a few micrometers in diameter. A typical nerve consists of hundreds of axons that lie within long, thin tubes (basal lamina tubes). Analogous to a fiber-optic cable,
these basal lamina tubes are bundled together in groups called fascicles, and each nerve may contain numerous fascicles. This sheath structure provides protection for the axons and support for regeneration in the event of injury. Nerve injury occurs
when a sufficient number of axons have been crushed or transected (severed), thereby disrupting signals to the target motor or sensory organ. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Given the right conditions, peripheral nerves have the ability to regenerate. Regenerating axons require the proper environmental conditions including; structure and guidance of axons in a tension and
compression free environment. In an untreated severe crush injury or transected nerve, errant axons that are not guided by the nerve sheath structure, or other mechanism, can form painful and ineffective nerve proliferation (neuromas). This can then
require revision surgery to relieve pain or bring back sensory and/or motor functionality. Therefore, the surgical treatment of nerve injuries is typically focused on restoring nerve functionality by providing structural guidance to regenerating
axons while alleviating compression and tension on the nerve. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Peripheral Nerve Regeneration Market Overview
</I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Everyday patients suffer traumatic wounds to peripheral nerves severe enough to require surgical treatment, including
injuries from motor vehicle accidents, collisions, gun wounds, dislocations, fractures, lacerations, or other forms of penetrating trauma. Specifically, military service men and women may suffer severe wounds from explosions and other
military-related injuries. The peripheral nerves commonly injured from these traumas include the digital, median, ulnar, radial, facial, spinal accessory and brachial plexus nerves. Based upon epidemiological studies regarding the number of trauma
patients and incidence of peripheral nerve injury in the population, each year in the U.S. more than 1.4&nbsp;million people suffer traumatic injuries to peripheral nerves resulting in at least 700,000 nerve repair procedures in the U.S. annually.
(&#147;Health&#148;, United States, 2011, Publication of U.S. Department of Health&nbsp;&amp; Human Services; Noble, et al. J of Trauma Injury Infection and Critical Care 1998). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Beyond traumatic injury to nerves, nerve damage also occurs due to surgical intervention.
Some of these nerve cases occur after dental or oral surgery when patients lose sensory and taste function in the mouth, including complications from third molar extractions and dental implants. Also, nerves that support erectile function may be
injured or removed following a surgical prostatectomy to remove prostate cancer. Further, breast cancer patients may have reduced sensation in the tissue used to reconstruct the breast after mastectomy. Finally, nerves are also damaged or
compromised due to repetitive stress or compression injuries. For instance, severe and recurrent carpal tunnel cases may result in complications and damage to the nerve that requires further surgical intervention and protection of the nerve.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peripheral nerve injury is a major source of disability impairing the ability to move muscles or to feel normal sensations.
Failure to treat nerve damage can in severe cases lead to full loss of function and sometimes amputation. Many peripheral nerve injury patients who receive treatment do not optimally recover. They may suffer from both reduced, or no, muscle strength
and reduced, or no, sensitivity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the cases where a nerve is severed, if the gap between the two ends of the nerve is
extremely small, the surgeon can reconnect the nerve without tension through direct suturing. Because a tension-free repair is important, when the gap is more than a few millimeters in length, the surgeon typically needs to bridge the gap between
the nerve ends. Historically, to repair a severed nerve gap, surgeons have relied on an autotransplantation (autologous grafting or autograft). In autograft procedures, surgeons remove nerve from another part of the patient&#146;s body, frequently
from the back of the lower leg, to repair the damaged nerve. Autografting is often effective in repairing a damaged peripheral nerve, but it presents a tradeoff &#150; the surgeon can attempt to fix the damaged nerve but must create an additional
nerve deficit. For example, a patient may opt to get movement and feeling back in their finger while losing some sensation in their foot. Additionally, the secondary surgery to obtain the needed autograft also increases operating time, and thus
medical expenses, and increases the risk of surgical infection and other complications. In the case of extreme trauma where multiple nerves need to be repaired, it may not be possible to recover enough nerve from the patient to complete the repair.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Drawbacks of repair with autograft eventually led to the development of hollow-tube conduits, or hollow-tube nerve cuffs, for
peripheral nerve repair made of, for instance, bovine collagen or polyglycolic acid. The nerve cuff is typically an absorbable hollow tube that, unlike natural nerve, does not have basal lamina tubes to support regenerating axons; as a result, it is
deficient in the qualities that natural nerve possesses to support nerve regeneration. Hollow-tube conduits may also lack pliability and structural integrity needed when used around joints and may be difficult to use in a confined space.
Additionally, hollow-tube conduits do not provide familiar handling characteristics to the surgeon and in some instances are contraindicated for use in infected wound beds. Clinical data has demonstrated that conduits are most effective only when
used in very short gaps and the reliability of successful nerve recovery diminishes as gap length increases. However, we believe with surgeons seeking alternatives to autografts, the annual number of procedures using hollow-tube conduits has grown.
AxoGen believes this demand has resulted in hollow-tube conduits being used for gap lengths where their likelihood of effectiveness is greatly diminished. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The growth of hollow-tube conduit use demonstrates there is market demand for products that do not have the drawbacks of autografting. However, as stated above, the shortcomings of conduits limit where
they may be used effectively. Thus, the nerve repair market needs an alternative off-the-shelf product that provides the natural ECM scaffold and three-dimensional structure of a typical nerve for bridging nerve discontinuities without the
comorbidities of a second surgical site of an autograft. AxoGen believes its product portfolio meets this market need. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AxoGen&#146;s Product Portfolio </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Overview of AxoGen&#146;s Products </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s proprietary products and technologies are designed to overcome fundamental challenges in nerve repair. AxoGen&#146;s Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is an alternative to autografts for nerve gaps up to 70mm in length. AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector is the surgical solution for nerve gaps of less than 5mm in length. AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector completes the product portfolio by allowing a protective wrap in cases of nerves damaged by compression, or where the surgeon wants to protect and
isolate the nerve during the healing process after surgery. This product portfolio, depicted below, provides surgeons off-the-shelf solutions for a wide variety of peripheral nerve injuries. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table provides a summary of certain peripheral nerve injuries for which AxoGen products are used: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g532389g54c00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is intended for the surgical repair of peripheral nerve discontinuities to support regeneration across
the defect (a gap created when the nerve is severed). It is intended to act as a bridge in order to guide and structurally support axonal regeneration across a nerve gap caused by traumatic injury or surgical intervention. Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is decellularized and sterile extracellular matrix (ECM) processed from human peripheral nerve tissue.
AxoGen developed the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft by following the guiding principle that the human body created the
optimal nerve structure. AxoGen, through its licensing efforts and research, developed the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Process, a
proprietary method for processing recovered human peripheral nerve tissue in a manner that preserves the essential structure of the ECM while cleansing away cellular and noncellular debris. Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft provides the natural nerve structure of an autograft and the ease and availability of an off-the-shelf product. AxoGen believes that Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is the first and only off-the-shelf commercially available allograft nerve for bridging nerve
discontinuities. The Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is comprised of bundles of small diameter endoneurial tubes that are
held together by an outer sheath called the epineurium. Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft has
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">
been processed to remove cellular and noncellular factors such as cells, fat, blood, axonal debris and chondroitin sulfate proteoglycans, (&#147;CSPG&#148;), while preserving the
three-dimensional scaffold, basal lamina tubular structure, epineurium and microvasculature of the peripheral nerve. After processing, Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is flexible and pliable, and its epineurium can be sutured in place allowing for tension-free approximation of the proximal and distal peripheral nerve
stumps. The design results in a product that has clean and clear pathways for the regenerating axons to grow through. During the healing process, the body revascularizes and gradually remodels the graft into the patient&#146;s own tissue while
allowing the processed nerve allograft to physically support axonal regeneration across the nerve discontinuity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">With lengths up to 70 mm and diameters up to 5 mm, the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
Nerve Graft allows surgeons to choose the correct length for the relevant nerve gap for repairs up to 70 mm, as well as to match the diameter to the proximal and distal end of the severed nerve. The Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is stored frozen and utilizes packaging that maintains the graft in a sterile condition. The packaging
is typical for medical products so the surgical staff is familiar with opening the package for transfer of the
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft into the sterile surgical field. Such packaging also provides protection during shipment and
storage and a reservoir for the addition of sterile fluid to aid in thawing the product. The Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft
thaws in less than 10 minutes, and once thawed, it is ready for implantation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft provides the following key advantages: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provides a three-dimensional bioscaffold for bridging a nerve gap; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">No patient donor-nerve surgery, therefore no comorbidities associated with a secondary surgical site; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Available in a variety of diameters, 1-2 mm to 4-5mm, to meet a range of anatomical needs </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Available in a variety of lengths, 15mm to 70mm, to meet a range of gap lengths, </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Decellularized and cleansed extracellular matrix that remodels into patient&#146;s own tissue; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Structurally supports the body&#146;s own regeneration process; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Handles similar to an autograft, and is flexible and pliable; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alleviates tension at the repair site; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Three year shelf life; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Supplied sterile. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector is an ECM for tensionless repair of severed nerves. AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector is a tubular, multilaminar extracellular matrix with an open lumen where the severed nerve ends are placed. Typically, the AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector is used to align and connect nerves with less than a 5mm gap between the severed nerve ends. The
AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector material allows the body&#146;s natural healing process to repair the nerve by
isolating and protecting it during the healing process. The patient&#146;s own cells incorporate into the extracellular matrix product to remodel and form a tissue similar to the outermost layer of the nerve (nerve epineurium). AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector is provided sterile, for single use only, and in a variety of sizes to meet the surgeon&#146;s
needs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector can be used to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bridge gaps up to 5 mm; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aid coaptation in direct repair, grafting, or cable grafting repairs; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reinforce the coaptation site. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector has the following advantages: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Only porcine submucosa extra-cellular matrix product to bridge gaps up to 5 mm; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alleviates tension at the repair site; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reduces the number of required sutures (versus direct repair); </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Moves location of sutures away from the coaptation face; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reduces potential for fascicular mismatch; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Allows visualization of underlying nerve; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Strong and flexible, easy to suture; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stored at room temperature with an 18 month shelf life. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector is a product used to wrap and protect injured peripheral nerves and reinforce reconstructed nerve gaps while preventing soft tissue attachments. It is
designed to protect and isolate the nerve during the healing process after surgery. AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> is a multilaminar
extracellular matrix that separates and protects the nerve from the surrounding tissues. The patient&#146;s own cells incorporate into the extracellular matrix to remodel and form a tissue similar to the nerve epineurium. AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector is provided sterile, for single use only, and in a variety of sizes to meet the surgeon&#146;s
needs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector can be used to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wrap injured nerves; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Minimize risk of entrapment in compressed nerves; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Protect partially severed nerves; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Protect nerves in a traumatized wound bed; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reinforce a coaptation site. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector has the following advantages: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Only porcine submucosa bio scaffold used to reinforce a coaptation site, wrap a partially severed nerve or protect nerve tissue;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Isolates and protects the nerve in a traumatized wound bed; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Easily conforms and wraps the injured nerve; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Minimizes the potential for soft tissue attachments and nerve entrapment by physically isolating the nerve during the healing process;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Allows nerve gliding; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Strong and flexible, plus easy to suture; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stored at room temperature with an 18 month shelf life. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Tissue Recovery and Processing for Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft Processing Overview </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Over several years, AxoGen has developed the Avance<B><I><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT></I></B> Process, an advanced and proprietary technique to process the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft from donated peripheral nerve tissue. The Avance<B><I><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT></I></B> Process requires special training over several months for each manufacturing associate who processes Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Grafts. The processing and manufacturing system for Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft has required significant capital investment, and AxoGen plans to make additional investments to continually improve its manufacturing and quality
assurance processes and systems. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Process requires several steps, including peripheral nerve tissue recovery and testing, donor medical review and release, processing, packaging, and sterilization to
meet or exceed all applicable FDA, state, and international regulations and AATB standards. As an FDA registered tissue establishment, AxoGen utilizes both its own personnel and a variety of subcontractors for recovery, storage, testing, processing
and sterilization of the donated peripheral nerve tissue. Additionally, independent certified laboratories have been contracted by AxoGen and its subcontractors to perform testing. The safety of
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is supported by donor screening, process validation, process controls, and validated
terminal sterilization methods. The AxoGen Quality System has built in redundancies so that each Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve
Graft released for implantation meets AxoGen&#146;s stringent quality control and product requirements. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft Tissue Recovery and Processing </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGen partners with FDA registered tissue establishments and AATB accredited recovery agencies or recovery agencies in compliance with AATB standards to recover human peripheral nerve tissue for Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft processing. After consent for donation is obtained, donations are screened and tested in detail for
safety in compliance with the federal regulations and AATB standards on communicable disease transmission. AxoGen processes and packages Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft using its employees and equipment located at LifeNet Health, Virginia Beach, Virginia, an FDA registered tissue establishment, from the donated nerve
tissue. Under the agreement with LifeNet Health, AxoGen pays LifeNet Health a facility fee. Either party may terminate the agreement with six months&#146; written notice. The LifeNet Health facility provides a cost effective, quality controlled and
licensed facility, however, AxoGen could reproduce a manufacturing space that would meet its needs if it no longer continued its relationship with LifeNet. AxoGen&#146;s processing methods and process controls have been developed and validated to
ensure product uniformity and quality. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft Packaging </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">After processing, each Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is visually inspected
and organized by size (length and diameter) into finished product codes. It is then packaged in individual medical grade clamshells and primary packaging. The outer pouch is the primary sterility and moisture barrier. The packaging operation is
performed in a controlled environment at LifeNet Health. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft Sterilization and Labeling </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">After being processed and packaged, Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is then irradiated and returned to AxoGen&#146;s headquarters in Alachua, Florida. There, the product receives its final labels and is released following
a final stringent technical and quality review. Orders for Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft are placed with AxoGen&#146;s
customer care team and product is shipped from the distribution facilities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft Product Release </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
AxoGen Quality System meets the requirements set forth under 21 CFR &#167; 1271 for Human Cells, Tissues and Cellular and Tissue-Based Products, including Good Tissue Practices (&#147;GTP&#148;) and is compliant with the 21 CFR &#167; 820 Quality
System Regulations (&#147;QSR&#148;). AxoGen has established quality procedures for review of tissue recovery, relevant donor medical record review and release to processing that meet or exceed FDA requirements as defined in 21 CFR &#167;1271, state
regulations, international regulations and AATB standards. Furthermore, AxoGen utilizes validated processes for the handling of raw material components, environmental control, processing, packaging and terminal sterilization. In addition to ongoing
monitoring activities for product conformity to specifications and sterility, product biocompatibility, shipping methods and shelf life have been validated in accordance with applicable industry standards. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Manufacturing for the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Product Line </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> is manufactured by Cook Biotech, West Lafayette, Indiana, which was established in 1995 to develop and manufacture tissue grafts utilizing porcine extracellular
matrix technology. AxoGen decided to expand its portfolio of products and felt that the unique ECM material offered by Cook Biotech provided the combination of properties needed in nerve reconstruction. Cook Biotech&#146;s ECM material is pliable,
capable of being sutured, translucent and allows the patient&#146;s own cells to incorporate into the extracellular matrix to remodel and form a tissue similar to the nerve&#146;s epineurium. In August 2008, Cook Biotech entered into an agreement
with AxoGen to distribute its product worldwide in the field of the peripheral and central nervous system, but excluding use of the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product in the oral cavity for endodontic and periodontal applications and oral and maxillofacial surgery solely as they relate to dental, soft or hard, tissue repair
or reconstruction, and the parties subsequently amended the agreement in March, 2012. The exclusion results in certain areas of AxoGen&#146;s market expansion into the oral surgery market being limited to the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">The agreement has an initial seven-year term from the date of the original agreement and following such initial term, the agreement automatically renews for an additional seven (7)&nbsp;year period
provided that the parties agree to meet at least ninety (90)&nbsp;days before the end of such initial term to review whether the purchase price of the products obtained from Cook Biotech need to be adjusted and reasonably agree to such adjustment in
writing, where such agreement shall not be unreasonably withheld. The Cook Biotech agreement also requires certain minimum purchases, although through mutual agreement the parties have not established such minimums and to date have not enforce such
provision, and establishes a formula for the transfer cost of the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products. Under the agreement,
AxoGen provides purchase orders to Cook Biotech, and Cook Biotech fulfills the purchase orders. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Sales and Marketing </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Overview </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The AxoGen portfolio of nerve repair solutions offers a full range of products for all surgical peripheral nerve repair needs. AxoGen is
focused on the developing market of peripheral nerve repair and regeneration and is committed to improving awareness of new surgical peripheral nerve repair options, as well as building additional scientific and clinical data to assist surgeons and
patients in making informed choices. AxoGen believes this approach will solidify its position as a leader in the field of products for peripheral nerve injuries. The following provides the key elements of AxoGen&#146;s sales and marketing strategy.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Increase Awareness of AxoGen&#146;s Products </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to the introduction of AxoGen&#146;s portfolio of products, surgeons had a limited number of options available for the surgical
repair of nerve injuries. AxoGen entered the market to improve the standard of care for patients. It has brought the science of nerve repair to life by developing reconstruction options based on extracellular matrix tissue. Unlike other
off-the-shelf nerve reconstruction options, an extracellular matrix remodels into the patient&#146;s own tissue and provides physical support for the body&#146;s natural healing process. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen intends to increase market share by improving awareness of its products through the use of educational
conferences and presentations, surgical resident and fellow training, scientific publications, and a knowledgeable and professional sales team. AxoGen expects to increase usage with existing customers as well as expand the overall customer base.
Initially, AxoGen will focus on plastic reconstructive surgeons and orthopedic and plastic surgeons who perform surgeries on patients suffering traumatic nerve injuries and who perform hand reconstructive surgeries. In select hospital accounts and
in conformity with AxoGen&#146;s agreement with Cook Biotech restricting certain use of the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Products,
AxoGen is also expanding into the market for the reconstruction of nerve injuries in oral surgery. </FONT></P>  <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Expand Clinical
and Scientific Data Regarding the Performance of AxoGen Products </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Data will be a mainstay of
AxoGen&#146;s marketing strategy. AxoGen will continue to accept patients in its RANGER<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> clinical study (defined
below in &#147;Government Regulations&#148;), a utilization registry of Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. A multicenter
prospective randomized comparative pilot study of hollow tube conduits and Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is in process. A
case series in digital nerve repair has already been published and other studies have been completed. Case series in brachial plexus, military trauma, prostate cancer, neurotization of breast reconstruction and compressive neuropathy are also being
developed. AxoGen also supports outside research and will continue to work with investigators working on grants with a translational focus. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Expand the AxoGen Sales Team for National Coverage </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen provides full
sales and distribution services through both a direct sales force and a team of independent distributors. AxoGen provides support and resources for independent distributors and is increasing its direct sales force in selected territories. AxoGen
provides products to hospitals, surgery centers and military hospitals, calling on plastic reconstructive surgeons and orthopedic and plastic hand surgeons to review the benefits of the AxoGen products. While surgeons make the decision to implant
the products in appropriate patients, hospitals make the decision to buy the products from AxoGen. In today&#146;s budget constrained environment, hospital committees review new technologies for cost effectiveness as well as quality. AxoGen believes
that it has been successful in meeting the needs of these hospital committees by demonstrating the cost/benefit of its products and providing a fair value to the hospital. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>AxoGen Strengths </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen believes that it has the following strengths in
the field of nerve reconstruction and regeneration: </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Established Surgical Nerve Repair and Regeneration Expertise</U>
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen has made a significant investment in understanding surgical nerve repair and regeneration through interaction with
leading academic centers throughout the United States and by striving to build an outstanding internal team of technical and clinical experts. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Surgical Implant Commercialization Experience</U> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The AxoGen commercialization team consists of sales, marketing, and customer service professionals with backgrounds
in the medical device and biotechnology industries. The commercial team has been instrumental in beginning to establish the
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft and the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product line as a new standard of care for the surgical treatment of nerve injuries. AxoGen believes it can leverage these capabilities in expanding the commercial
success of the current AxoGen products and future product opportunities. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft Performance </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen has worked with leading institutions, researchers and surgeons to support innovation in the field of surgical
peripheral nerve repair. To date, AxoGen&#146;s RANGER<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> study (defined below in &#147;Government
Regulations&#148;) is the largest multi-center clinical study conducted in peripheral nerve gap repair. AxoGen&#146;s RECON study will also continue AxoGen&#146;s clinical work, providing a new multi-center, prospective, randomized, clinical study
on the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. The January, 2012 edition of Microsurgery and November 2012 edition of The Journal
of Hand Surgery each contain an article summarizing the RANGER<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> study results. The publication reported on 55
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft nerve repairs and resulted in meaningful motor and sensory recovery in 87% of nerve
discontinuities between 5 and 50 mm. Additionally no implant related adverse events have been reported. (Brooks, D. N., Weber, R. V., Chao, J. D., Rinker, B. D., Zoldos, J., Robichaux, M. R., Ruggeri, S. B., Anderson, K. A., Bonatz, E. E., Wisotsky,
S. M., Cho, M. S., Wilson, C., Cooper, E. O., Ingari, J. V., Safa, B., Parrett, B. M. and Buncke, G. M. (2012), Processed nerve allografts for peripheral nerve reconstruction: A multicenter study of utilization and outcomes in sensory, mixed, and
motor nerve reconstructions. Microsurgery, 32: 1&#150;14. doi: 10.1002/micr.20975 and Cho, et al. 2012, J Hand Surg Am 37(11):2340-9). A meta-analysis of available clinical outcomes data from published papers on the leading synthetic collagen
conduit showed meaningful improvement in only 53% of cases bridging a gap in the nerve. A similar meta-analysis for nerve autograft reported meaningful improvement in 60-88% of nerve repairs. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>International Opportunity for Product Sales </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen currently focuses on the U.S. market, with additional limited foreign sales in the United Kingdom, the
Netherlands, Canada, Italy, Austria and Switzerland. The need for the surgical repair of injured nerves is a global issue. Through its foreign sales, AxoGen has shown the capability to take its current product offering into new geographical markets.
AxoGen does not currently have E.U.-wide approval for the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, but received its CE Mark for
AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products in April 2013. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Research and Development </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen believes it provides
the most extensive product portfolio for peripheral nerve repair available. Our current development focus is to expand clinical data in both traumatic nerve repair and other surgical applications. Additional product line extensions of the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products may be developed. AxoGen&#146;s current intention is to spend limited direct resources on extensive research into new unmet peripheral nerve needs. AxoGen
does, however, work with academic intuitions in the expansion of treatments for peripheral nerve. For the three months ended March&nbsp;31, 2013 and 2012 AxoGen spent approximately $406,000, and $296,000, respectively, and for the years ended
December&nbsp;31, 2012 and 2011, AxoGen spent $1,427,211, and $697,355, respectively, on research and development expenses. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Competition
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The medical device and biotechnology industries are characterized by rapidly advancing technologies, intense competition
and a strong emphasis on proprietary products. As such, AxoGen cannot predict what products may be offered in the future that may compete with AxoGen&#146;s </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
products. Currently, AxoGen competes primarily against autograft and hollow-tube conduits based on product features and performance, price, surgical application, ease of use and healthcare
provider education. AxoGen&#146;s major competitors for off-the-shelf repair option in hollow-tube conduits are the following companies: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Integra LifeSciences Holding Corporation (NASDAQ: IART) (&#147;Integra&#148;). Integra offers
NeuraGen<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, a hollow bovine collagen conduit and NeuraWrapTM, a nerve repair conduit also made from bovine
collagen; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Baxter International, Inc. (NYSE: BAX) (&#147;Baxter&#148;). Baxter acquired Synovis that offered the Neurotube, which is a hollow conduit comprised of
polyglycolic acid; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stryker Corporation (NYSE: SYK), (&#147;Stryker&#148;). Stryker offers the NeuroMatrix and Neuroflex products, both of which are hollow conduits
derived from bovine collagen. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen believes that surgeons use Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft because, unlike hollow-tube conduits, it provides them with the natural three-dimensional structure of a
typical nerve for bridging nerve discontinuities (severed nerves) without the comorbidities of an autograft second surgical site. AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
Nerve Connector provide the unique features of pliability, suturability, and translucence for visualization of the underlying nerve while also allowing the patient&#146;s own cells to incorporate into the extracellular matrix to remodel and form a
tissue similar to the outermost layer of the nerve (nerve epineurium). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen believes any current or
future competitors face the following important barriers to entry as it relates to the market for its products. AxoGen&#146;s intellectual property, and that of its partners, including patents and patents-pending, is believed to be an important
barrier. Additionally, AxoGen has developed knowledge and experience in understanding and meeting FDA regulatory requirements for Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, including having made a substantial investment in validating, testing for, and meeting and preparing a submission for FDA BLA requirements. However, due
to its limited resources, its smaller size and its relatively early stage, AxoGen believes it may face competitive challenges and barriers that are difficult to overcome and could negatively impact its growth. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Intellectual Property </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGen relies on a combination of patent, trademark, trade secret, and copyright, as well as other intellectual property laws, to protect IP rights. In addition, AxoGen utilizes license, non-disclosure,
and assignment agreements to protect these IP rights. Specifically, AxoGen requires vendors, contract organizations, consultants, advisors and employees to execute nondisclosure agreements. AxoGen also requires consultants, advisors and employees
who develop IP to assign to AxoGen any of their rights to all IP conceived in connection with their relationship with AxoGen. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>License Agreements </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen has entered into license agreements with the UFRF and UT. Under the terms of these license agreements, AxoGen has exclusive
worldwide licenses for the underlying technologies used by AxoGen in repairing and regenerating nerves. The license agreements include both the right to issued patents and patents pending in the U.S. and international markets. The effective term of
the license agreements extends through the term of the related patents. In the event of default, licensors may also terminate an agreement (after written notice) if AxoGen fails to cure a breach. The license agreements contain the following key
terms: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payment of annual license maintenance fees, some of which may be credited against future royalty payments; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payment of royalty fees of 1%-3% based on net sales of the licensed products, the level depending on the agreement, which may include a minimum
quarterly royalty payment with discounts off royalty rates when royalty stacking applies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payment of a percentage of sublicense fees received; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reimbursement of certain legal expenses incurred for patent prosecution and defense; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other payments of various amounts based on achieving certain milestones. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Currently, AxoGen pays royalties to UFRF and UT specific to the licensed technologies related to the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Patents </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of the date of this registration statement, AxoGen owned
or was the exclusive licensee of five issued U.S. patents, three pending U.S. patent applications, one U.S. patent application for which a Notice of Allowance has been issued, six issued international patents and nine pending international patent
applications with regard to its peripheral nerve products. Additionally, the granted European Patent No. EP1425390 has been validated in France, Germany, Italy, Spain, Sweden, Switzerland, and the United Kingdom. The following table illustrates the
issued U.S. patents owned or licensed by AxoGen with regard to it peripheral nerve products, including the patent number, a description of each patent, and the estimated expiration date of each patent. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Patent No.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Estimated&nbsp;expiration&nbsp;date</B></FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">US 6,972,168</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Materials and Methods for Nerve Grafting, Selection of Nerve Grafts, and in vitro Nerve Tissue Culture</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 13, 2021</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">US 7,402,319</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cell Free Tissue Replacement for Tissue Engineering</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">September&nbsp;26,&nbsp;2023</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">US 7,732,200</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Materials and Methods for Nerve Grafting, Selection of Nerve Grafts, and in vitro Nerve Tissue Culture</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">December 21, 2022</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">US 6,696,575</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Biodegradable, electrically conducting polymer for tissue engineering applications</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 27, 2021</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">US 7,851,447</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Materials and Methods for Nerve Repair</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">November&nbsp;18,&nbsp;2023</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, AxoGen entered into an exclusive distribution agreement with Cook
Biotech in August 2008, as subsequently amended in March 2012, to distribute its ECM technology in the form of the
Surgisis<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Cuff, the form of a nerve wrap or patch, or the form of any other mutually-agreed-to
configuration in the field of peripheral nervous system and central nervous system use, but excluding use of the
AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product in the oral cavity for endodontic and periodontal applications and oral and maxillofacial
surgery solely as they relate to dental, soft or hard, tissue repair or reconstruction. AxoGen has subsequently rebranded the Surgisis products under the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> name. Cook Biotech holds multiple issued and pending U.S. and international patents covering its ECM technology. The following table illustrates the two
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">
non-licensed U.S. patents held by Cook Biotech that are specifically identified on AxoGen&#146;s AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
Nerve Protector product labeling. The table includes the U.S. Patent number, a description of each patent, and the estimated expiration date of each patent. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>U.S. Patent No.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Estimated expiration date</B></FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,206,931</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Graft Prosthesis Material</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 23, 2016</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,241,981</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Composition and Method for Repairing Neurological Tissue</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">September&nbsp;16,&nbsp;2016</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because of the length of time and expense associated with bringing new products through development and
the governmental approval process, medical technology companies have traditionally placed considerable importance on obtaining and maintaining patent protection for significant new technologies, products and processes. AxoGen intends to seek patent
protection for appropriate proprietary technologies by filing patent applications when possible in the U.S. and selected other jurisdictions. AxoGen&#146;s policy is to seek patent protection for the inventions that it considers important to the
development of its business. AxoGen also intends to use its scientific expertise to pursue and file patent applications on new developments with respect to uses, methods, and compositions to enhance its IP position in the areas that are important to
the development of its business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finally, AxoGen continues to hold IP, including patents, related to LecTec&#146;s original
hydrogel patch technology and hand sanitizer patch. AxoGen has not been able to monetize the IP regarding the hand sanitizer patch and issues regarding the enforceability of such IP has resulted in AxoGen determining that it has no future value.
AxoGen continues to take all action necessary to maintain relevant patents licensed to Novartis Consumer Health, Inc., however, Novartis has discontinued sale of products related to the license in certain countries and as such AxoGen has determined
that the value of the Novartis license has been impaired. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Trademarks, Trade Secrets, Copyrights and Domain Names
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen has registered and filed numerous trademark applications with the U.S. Patent and Trademark Office and
appropriate offices in foreign countries in order to distinguish its products from competitors&#146; products. It possesses trade secrets and material know-how in the following general subject matters: nerve processing, nerve repair, product testing
methods, and pre-clinical and clinical expertise. AxoGen has registered copyrights for training tools and artistic renderings. It has entered into an agreement with an independent artistic creator, under which the artistic director retains copyright
rights to any copyrighted material under agreement with AxoGen and provides AxoGen a license to such copyrights. AxoGen has also registered approximately 50 domain names. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Government Regulations </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>U.S. Government Regulation Overview
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s products are subject to regulation by the FDA, as well as other federal and state
regulatory bodies in the U.S. and comparable authorities in other countries. In addition, its Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve
Graft must comply with the standards of the tissue bank industry&#146;s accrediting organization, the American Association of Tissue Banks. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen distributes for Cook Biotech the AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product line and Cook Biotech is responsible for the regulatory compliance of the AxoGuard product line. AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products are regulated as medical devices and subject to premarket notification classification requirements under
section 510(k) of the FD&amp;C Act that usually result in the marketing of devices, 21 CFR &#167; 820 (&#147;Quality System Regulation&#148;) and related laws and regulations. Cook Biotech has obtained a 510(k) premarket clearance from the FDA for
the use of porcine (pig) small intestine submucosa for the repair of peripheral nerve discontinuities where gap closure can be achieved by flexion of the extremity. We sell the 510(k)-cleared device under the trade name AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">In 2007, AxoGen began to process and distribute its Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve
Graft pursuant to Section&nbsp;361 of the PHS Act and 21 CFR Part 1271 Human Cells, Tissues, and Cellular and Tissue Based Products controls. Such action was based on AxoGen&#146;s good faith belief that the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft product was a HCT/P tissue product regulated solely under Section&nbsp;361. From October 2008 through
early 2010, AxoGen was in communication with the FDA concerning the regulatory status of the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft
product. In April 2010, in response to a Request For Designation filed by AxoGen, the FDA determined that the
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft was a biologic product that would be reviewed and regulated by CBER under the biologics
licensing provision under section 351 of the PHS Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen met with CBER in July 2010 and, between
July 2010 and November 2010, provided information to CBER that resulted in the FDA issuing a letter stating the agency&#146;s intent to exercise enforcement discretion with respect to the introduction or delivery for introduction into interstate
commerce of the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft assuming that certain conditions are met relating to the transition of the
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft to regulation as a biological product under section 351 of the PHS Act. The conditions and
AxoGen&#146;s current status with respect to these conditions are: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen transitions to compliance with the Section&nbsp;501(a)(2)(B) of the FD&amp;C Act, the current GMP regulations in 21 CFR &#167; 210 and 211 and
the applicable regulations and standards in 21 CFR &#167; 600-610 prior to initiation of a phase 3 clinical trial; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen has performed several gap analyses of its quality system for compliance with 21 CFR &#167;210/211 and 600-610 regulations. The gap analyses
indicate that procedural changes are necessary to establish compliance with these regulations.&nbsp;The quality system procedures must be updated to establish compliance with 21 CFR &#167;&#167; 210/211 and 600-610 regulations. We must review the
regulations and update our quality procedures to create appropriate documentation systems, and train personnel on the procedural updates. Once procedures, training, and implementation are accomplished, we will, through internal auditing, verify
compliance with these regulations.&nbsp;After such verification, we will retain an external audit firm with experience in auditing to 21 CFR &#167;&#167; 210/211 and 600-610 regulations to verify quality system compliance to the
regulations.&nbsp;The associated costs for these activities are not material and the Company believes it can appropriately implement all necessary changes; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen conducts a phase 3 clinical trial to demonstrate safety, purity and potency of the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft under a SPA; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen and the FDA agreed to the SPA in August 2011 and in accordance with FDA regulations 21CFR &#167;312, AxoGen submitted an IND to the FDA and we
are currently responding to FDA comments regarding the IND. We expect enrollment of patients into the phase 3 clinical trial later this year; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen continues to comply with the regulations and standards for 21 CFR &#167; 1271 and exercises due diligence in executing the transition;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen was audited by the FDA in March 2013 and the quality system was found to be in compliance with 21 CFR &#167;1271. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen submitted an IND for the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft in April, 2013. AxoGen is working with the FDA to ensure compliance with the applicable regulations by
having continual discussions on the transition of the quality system to 21 CFR &#167;210/211 and 600-610 regulations with the FDA and being audited by the FDA for compliance to 21 CFR &#167;1271 regulations. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA will end the period of enforcement discretion upon a final determination of AxoGen&#146;s BLA future
submission or if the FDA finds that AxoGen does not meet the conditions for the transition plan. Until final FDA action on the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft submission, and assuming AxoGen&#146;s compliance with the provisions in the transition plan, AxoGen will be able to continue to distribute the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. If final action on the BLA is negative or AxoGen is found to not meet the conditions for the transition
plan, AxoGen will not be able to continue to distribute the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The BLA application of the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, if approved, will require a potentially substantial user fee payment to the FDA, although certain exemptions, waivers and discounts of the user fees may
apply, including certain waivers or discounts for small businesses. AxoGen has continued to communicate with CBER since the acceptance of the transition plan on clinical trial design and CMC and continues to move with diligence toward the completion
of the BLA. A SPA has been submitted, reviewed and approved by CBER. In compliance with the transition plan established by the FDA, AxoGen is able to continue to distribute the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Food and Drug
Administration Safety and Innovation Act, referred to herein as FDASIA (Public Law 112-144), which was signed into law on July&nbsp;9, 2012, amended the Federal Food, Drug, and Cosmetic Act. FDASIA includes the Prescription Drug User Fee Amendments
of 2012 which authorizes the FDA to continue to collect the following user fees from applicants who submit certain new drug and biological product applications and supplements: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Application Fee: Each new BLA has a fee required upon submission. In FY 2013, this fee for a BLA requiring clinical data is $1,958,800. The fee is
adjusted each year so we cannot provide an accurate estimate of what our fee will be upon submission of our BLA. For small companies (fewer than 500 employees and no other approved biologic product on the market) submitting its first application, a
waiver of the application fee is available. AxoGen expects to apply for this waiver for the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft
BLA. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Establishment Fee: Establishment fees (for where the biologic product is manufactured) are based on the FDA budget divided by the total number of
establishments. In FY 2013, the Establishment Fee is $526,500. This fee is adjusted each year so we cannot provide an accurate estimate of what our fee will be upon approval of our BLA. AxoGen will have to pay an establishment fee after BLA approval
and then pay such fee annually thereafter. </FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>FDA &#151; General </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">FDA regulations govern nearly all the activities that AxoGen performs, or that are performed on its behalf, to ensure that medical
products distributed domestically or exported internationally are safe and effective for their intended uses. The activities the FDA regulates include the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product design, development and manufacture; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product safety, testing, labeling and storage; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">pre-clinical testing in animals and in the laboratory; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">clinical investigations in humans; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">premarketing clearance or approval and licensing; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">record-keeping and document-retention procedures; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">advertising and promotion; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the import and export of products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product marketing, sales and distribution; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">post-marketing surveillance and medical device reporting, including reporting of deaths, serious injuries, communicable diseases, device malfunctions
or other adverse events; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">corrective actions, removals and recalls. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Failure to comply with applicable FDA regulatory requirements may subject AxoGen to a variety of administrative or judicially-imposed penalties or sanctions and/or prevent it from obtaining or maintaining
required approvals, clearances or licenses to manufacture and market its products. Such failure to comply with the applicable FDA requirements may subject AxoGen to stringent administrative or judicial actions or sanctions, such as agency refusal to
approve pending applications, warning letters, product recalls, product seizures, total or partial suspension of production or distribution of products, injunctions, or civil or criminal prosecution. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>FDA&#146;s Premarket Clearance and Approval Requirements&#151;Medical Devices </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless an exemption applies, each medical device distributed commercially in the U.S. requires either 510(k) premarket notification
submission or a Pre-Market Approval Application, or PMA, from the FDA. Medical devices are classified into one of three classes&#151;Class I, Class II, or Class III&#151;depending on the degree of risk and the level of control necessary to assure
the safety and effectiveness of each medical device. Medical devices deemed to pose lower risks are generally placed in either Class I or II. Pre-market review and clearance by the FDA for Class I and II medical devices is accomplished through the
510(k) pre-market notification procedure, unless the device is exempt. Most Class I medical devices are exempt from the 510(k) premarket notification requirement. Devices deemed by the FDA to pose the greatest risk, such as life-sustaining,
life-supporting or implantable devices, and novel devices, including devices deemed not substantially equivalent to a previously cleared 510(k) device are generally placed in Class III. Class III devices generally require an approved PMA to be
marketed. A PMA must be supported by extensive data, including, but not limited to, technical, preclinical, clinical trials, manufacturing and labeling to demonstrate to the FDA&#146;s satisfaction, the safety and effectiveness of the device.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>FDA&#146;s Premarket Approval Requirements&#151;Biologic Products </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Biologics License Application Pathway </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Biological products require FDA approval of a BLA to be marketed. In order to be approved, a BLA must demonstrate the safety, purity, and potency of the product candidate based on results of preclinical
studies and clinical trials. A BLA must also contain extensive CMC and other manufacturing information, and the applicant must pass an FDA pre-approval inspection of the manufacturing facility or facilities at which the biologic product is produced
to assess compliance with the FDA&#146;s current good manufacturing practice. Satisfaction of FDA approval requirements for biologics typically takes several years and the actual time required may vary substantially based on the type, complexity and
novelty of the product. AxoGen cannot be certain that any BLA approvals for its products will be granted on a timely basis, or at all. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The steps for obtaining FDA approval of a BLA to market a biologic product in the U.S.
include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">completion of preclinical laboratory tests, animal studies and formulation studies under the FDA&#146;s good laboratory practices regulations;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">submission to the FDA of an IND, for human clinical testing, which must become effective before human clinical trials may begin and which must include
independent Institutional Review Board, or IRB, approval at each clinical site before the trials may be initiated; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">performance of adequate and well-controlled clinical trials in accordance with Good Clinical Practices to establish the safety and efficacy of the
product for each indication; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">submission to the FDA of a BLA, which contains detailed information about the CMC for the product, reports of the outcomes and full data sets of the
preclinical testing and clinical trials, and proposed labeling and packaging for the product; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">satisfactory review of the contents of the BLA by the FDA, including the satisfactory resolution of any questions raised during the review;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">satisfactory completion of an FDA Advisory Committee review, if applicable; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with
current good manufacturing practice, or cGMP, regulations, to assure that the facilities, methods and controls are adequate to ensure the product&#146;s identity, strength, quality and purity; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">FDA approval of the BLA including agreement on post-marketing commitments, if applicable. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND
sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. Some preclinical testing may continue after the IND is submitted. The IND must become effective
before human clinical trials may begin. An IND will automatically become effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions about issues such as the conduct of the trials and or supporting
preclinical data as outlined in the IND. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns or questions before clinical trials can proceed. In other words, submission of an IND may not result in the FDA allowing
clinical trials to commence. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Biosimilar Biological Products </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A new regulatory approval pathway for biosimilars was established by The Biologics Price Competition and Innovation Act
(&#147;BPCIA&#148;), as part of the Patient Protection and Affordable Care Act of 2010. An important component of the legislation specified that a manufacturer of a reference biological product would be granted 12 years of exclusive use before a
biosimilar could be approved for marketing in the US. An application for a biosimilar product may not be submitted to FDA until 4 years after the approval date of the BLA for the reference biological product. BPCIA provides for an abbreviated
licensure process for a biosimilar, which is defined to mean a biological product that is highly similar to the reference product, notwithstanding minor differences in clinically inactive components, and there are no clinically meaningful
differences between the biological product and the reference product in terms of safety, purity and potency. At its discretion, FDA can waive a requirement for any required element in an application for a biosimilar product. In addition, the
legislation distinguished approval of a biosimilar from approval of such a product as a substitute for the reference biologic. Where a product is a substitution for the reference biologic it is considered an interchangeable product. Approval as
interchangeable requires that the product is biosimilar </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
and can be expected to produce the same clinical results as the reference product in any given patient, and a demonstration that the risk in terms of safety or diminished efficacy of alternating
or switching between the use of the interchangeable and reference product is not greater than the risk of using the reference product without such alternation or switch. Several states have enacted or are considering laws that also regulate the use
and substitution of biosimilar drugs. For example, Virginia requires licensure as interchangeable by FDA for a pharmacist to dispense a biosimilar in place of a prescribed biological product<BR>
<FONT STYLE="white-space:nowrap">(Virginia&nbsp;&#167;&nbsp;54.1-3408.04).</FONT> </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U></U></I><B><U>FDA&#146;s Pre-Approval
and Pre-Licensing Requirements.</U></B><I><U> </U></I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Before approving a BLA, the FDA generally inspects the facility or the
facilities at which the product is manufactured. The FDA will not approve the product if it finds that the facility does not appear to be in cGMP compliance. If the FDA determines the application, manufacturing process or manufacturing facilities
are not acceptable, it will either not approve the application or issue an approvable letter in which it will outline the deficiencies in the BLA and provide the applicant an opportunity to meet with FDA representatives and subsequently to submit
additional information or data to address the deficiencies. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The testing and approval process requires substantial time, effort and financial resources, and each may take several years to complete.
Data obtained from clinical activities are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The FDA may not grant approval on a timely basis, or at all. AxoGen may
encounter difficulties or unanticipated costs in its efforts to secure necessary governmental approvals, which could delay or preclude it from marketing its products. The FDA may limit the indications for use or place other conditions on any
approvals that could restrict the commercial application of the products. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further
testing requirements and FDA review and approval. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Post-Approval Requirements </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After regulatory approval of a product is obtained, AxoGen will be required to comply with a number of post-approval requirements. For
example, as a condition of approval of a BLA, the FDA may require post marketing testing and surveillance to monitor the product&#146;s safety or efficacy. In addition, holders of an approved BLA are required to keep extensive records, to report
certain adverse reactions and production problems to the FDA, to provide updated safety and efficacy information and to comply with requirements concerning advertising and promotional labeling for their products. Also, quality control and
manufacturing procedures must continue to conform to cGMP regulations as well as the manufacturing conditions of approval set forth in the BLA. The FDA periodically inspects manufacturing facilities to assess compliance with cGMP regulations, which
imposes certain procedural, substantive and recordkeeping requirements. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of
regulatory compliance. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Future FDA inspections may identify compliance issues at AxoGen&#146;s facilities or at the facilities
of its contract manufacturers that may disrupt production or distribution, or require substantial resources to correct and prevent recurrence of any deficiencies. In addition, discovery of problems with a product or the failure to comply with
applicable requirements may result in restrictions on a product, manufacturer or holder of an approved BLA, including withdrawal or recall of the product from the market or other voluntary, FDA-initiated or judicial action that could
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
delay or prohibit further marketing. Newly discovered or developed safety or effectiveness data may require changes to a product&#146;s approved labeling, including the addition of new warnings
and contraindications. Finally, new government requirements, including those resulting from new legislation, may be established that could delay or prevent regulatory approval of AxoGen products that are currently under development or regulatory
activity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA has broad regulatory compliance and enforcement powers. If the FDA determines that AxoGen failed to comply
with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, such as issuing a FDA Form 483 notice of inspectional observations, warning letter, or untitled letter, imposing civil money penalties, suspending
or delaying issuance of approvals, requiring product recall, imposing a total or partial shutdown of production, withdrawal of approvals or clearances already granted, and pursuing product seizures, consent decrees or other injunctive relief, and
criminal prosecution through the Department of Justice. The FDA can also require AxoGen to repair, replace or refund the cost of devices that it manufactured or distributed. If any of these events were to occur, it could materially adversely affect
AxoGen&#146;s business. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Clinical Trials </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Clinical trials are required to support a BLA and are sometimes required for 510(k) clearance. Clinical trials involve the administration of the investigational product to human subjects under the
supervision of qualified investigators. Clinical trials are conducted under strict requirements to ensure the protection of human subjects participating in the trial and under protocols detailing, among other things, the objectives of the study, the
parameters to be used in monitoring and safety, and the effectiveness criteria to be evaluated. Clinical trials for biological products require the submission and FDA approval of an IND and clinical trials for medical devices require the submission
and FDA approval of an Investigational Device Exemption application, or IDE, unless the device regulations would not require an IDE for a study. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA
as part of the IND or IDE, for significant risk devices. In addition, for these studies, an IRB at each site at which the study is conducted must approve the protocol, subject consent form and any amendments for each site at which the study is
conducted. All research subjects must be informed, among other things, about the risks and benefits of the investigational product and provide their informed consent in writing. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials under an IND typically are conducted in three sequential phases, but the phases may overlap or be
combined. In AxoGen&#146;s case, AxoGen believes that the Phase 3 clinical trial study for the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve
Graft represents the only new clinical data that will be required to evaluate safety and effectiveness. Phase 1 clinical trials usually involve the initial introduction of the investigational product into a small group of healthy volunteers (e.g.,
10 to 20) to evaluate the product&#146;s safety, (dosage tolerance and pharmacokinetics if a biologic product) and, if possible, to gain an early indication of its effectiveness. Phase 2 clinical trials usually involve controlled trials in a larger
but limited patient population (e.g., a few hundred) to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">evaluate dosage tolerance and appropriate dosage; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">identify possible adverse effects and safety risks; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">provide a preliminary evaluation of the efficacy of the product for specific indications. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase 3 clinical trials usually further evaluate clinical efficacy and test further for safety in an expanded patient population (e.g., a
hundred to several thousand). Phase 3 clinical trials usually involve comparison with placebo, standard treatments or other comparators. Usually at least one well-controlled large Phase 3 or pivotal clinical trial demonstrating safety and efficacy
is required to support a BLA. These trials are intended to establish the overall risk-benefit profile of the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">57 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">
product and provide an adequate basis for physician labeling. Phase 3 trials are almost always larger, more time consuming, complex and costly than Phase 1 and Phase 2 clinical trials. Phase 1,
Phase 2 and Phase 3 clinical testing may not be completed successfully within any specified period, if at all. Furthermore, the FDA or AxoGen may suspend or terminate clinical trials at any time on various grounds, including a finding that the
subjects or patients are being exposed to an unacceptable health risk, have experienced a serious and unexpected adverse event, or that continued use in an investigational setting may be unethical. Similarly, an IRB can suspend or terminate approval
of research if the research is not being conducted in accordance with the IRB&#146;s requirements or if the research has been associated with unexpected serious harm to patients. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Investigational New Drug Application </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For a biologic product, an IND must be submitted prior to the initiation of the clinical study. The IND application must contain information in three broad areas: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Animal Pharmacology and Toxicology Studies&#151;Preclinical data to permit an assessment as to whether the product is reasonably safe for initial
testing in humans. Also included are any previous experiences with the product in humans (often foreign use). </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Manufacturing Information&#151;Information pertaining to the composition, manufacturer, stability, and controls used for manufacturing of the drug
substance and the drug product. This information is assessed to ensure that the company can adequately produce and supply consistent batches of the drug. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical Protocols and Investigator Information&#151;Detailed protocols for proposed clinical studies to assess whether the initial-phase trials will
expose subjects to unnecessary risks. Also, information on the qualifications of clinical investigators&#151;professionals (generally physicians) who oversee the administration of the experimental compound&#151;to assess whether they are qualified
to fulfill their clinical trial duties. Finally, commitments to obtain informed consent from the research subjects, to obtain review of the study by an IRB, and to adhere to the investigational new drug regulations. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Once the IND is submitted, the sponsor must wait 30 calendar days before initiating any clinical trials. During this time, FDA has an
opportunity to review the IND for safety to assure that research subjects will not be subjected to unreasonable risk. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen Clinical Trials </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGen is currently performing three clinical studies to gather data on the
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. The studies are &#147;A Multicenter Retrospective Study of Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft Utilization, Evaluations and Outcomes in Peripheral Nerve Injury Repair (&#147;RANGER<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>&#148;)&#148;, &#147;A Multicenter, Prospective, Randomized, Comparative Study of Hollow Nerve Conduit and Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft Evaluation Recovery Outcomes of the Nerve Repair in the Hand (&#147;CHANGE&#148;)&#148; and a pilot
study to evaluate the use of Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft in the reconstruction of nerves following prostatectomy.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The RANGER<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> study is an observational study in current enrollment. It is designed to allow enrollment of up to a total of 1000 subjects over the next several years. The follow-up
for the RANGER<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> study is standard of care up to 36 months post nerve repair. At the time of the BLA submission,
if 1000 subjects have not been enrolled and follow-up completed, AxoGen will submit an interim report in the BLA for the enrolled subjects. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">58 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The CHANGE study is being run as a pilot comparative study and enrollment was completed
November 2011. The study has a 12 month follow-up post nerve repair. After the completion of the follow-up period, data management and report development are anticipated to take an additional 9 months. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The study regarding prostatectomy has also completed enrollment as of the first quarter 2013. The study has a 24 month follow-up post
nerve repair. After the completion of the follow-up period, data management and report development are anticipated to take an additional 9 months. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Clinical trials are subject to extensive recordkeeping and reporting requirements. AxoGen&#146;s clinical trials must be conducted under the oversight of an IRB for the relevant clinical trial sites
and must comply with FDA regulations, including but not limited to those relating to good clinical practices. AxoGen is also required to obtain the patients&#146; written informed consent in form and substance that complies with both FDA
requirements and state and federal privacy and human subject protection regulations. AxoGen, the FDA or the IRB may suspend a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the
anticipated benefits. Even if a trial is completed, the results of clinical testing may not adequately demonstrate the safety and efficacy of the biological product or device, or may otherwise not be sufficient to obtain FDA approval to market the
product in the U.S. Similarly, in Europe, the clinical study for a medicine product must be authorized by the Competent Authority in each Member State in which the clinical trial is to be conducted, and must receive a favorable opinion from an
ethics committee. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Pervasive and Continuing Regulation </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are numerous regulatory requirements that apply after a product is cleared or approved. For medical devices, these include, but are
not limited to: the FDA&#146;s regulations for device labeling (21 CFR &#167; 801), medical device reporting (21 CFR &#167; 803), reporting of corrections and removals (21 CFR &#167; 806), establishment registration and device listing requirements
(21 C.F.R. &#167; 807); and compliance with the Quality System Regulation (QSR) per 21 CFR &#167; 820. For tissue and biologic products, these include: the FDA&#146;s registration and listing requirements, donor eligibility, and Good Tissue
Practices (GTP) per 21 CFR &#167;1271 for human tissue products, the FDA&#146;s Good Manufacturing Practices (GMP) per 21 CFR &#167; 210, 211, and 600 for biologic products, and postmarket BLA requirements (21 CFR &#167; 601). Among other things,
these regulations require manufacturers, including third-party manufacturers: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">59 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to comply with labeling regulations and FDA prohibitions against the false or misleading promotion or the promotion of products for uncleared,
unapproved or off-label uses or indications; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to comply with requirements to obtain clearance or approval for certain changes affecting the product, including changes to the product&#146;s
manufacturing, labeling, or intended use; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to report to the FDA certain adverse events, adverse reactions and deviations: (a)&nbsp;for medical devices, a report to FDA is required if the device
may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur; (b)&nbsp;for biologics, a deviation from current GMP or an
unexpected or unforeseeable event that may affect the safety, purity, or potency of the product must be reported; and (c)&nbsp;for human tissue products, FDA requires reporting of certain adverse reactions involving a communicable disease related to
an HCT/P that the company made available for distribution; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to comply with post-approval restrictions or conditions, including post-approval study commitments and post-market safety and annual reporting
requirements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to follow post-market surveillance regulations that may apply when necessary to protect the public health or to provide additional safety and
effectiveness data for the device; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to follow requirements to issue notices of correction or removal, or conduct market withdrawals or recalls where quality or other issues arise.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen has not had any adverse events concerning the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft or the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products and has not had to submit any Medical Device Reports (&#147;MDRs&#148;), biological deviation reports, or tissue adverse reaction reports to the FDA.
Although AxoGen has had no adverse events to date, there may have been other incidents, including patient deaths, which may have occurred during procedures utilizing AxoGen&#146;s products without AxoGen being aware of any such incidents. In
addition, there can be no assurance that in the future AxoGen will not have an adverse event or will not submit any MDRs, biological deviation reports, or tissue adverse reaction reports to the FDA. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The advertising and promotion of medical products are also regulated by the Federal Trade Commission and by state regulatory and
enforcement authorities. Recently, some promotional activities for FDA-regulated products have been the subject of enforcement action brought under healthcare reimbursement laws and consumer protection statutes. In addition, under the Federal Lanham
Act and similar state laws, competitors and others can initiate litigation relating to advertising claims. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen is registered with the FDA as a tissue establishment for the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. The FDA has broad post-market and regulatory enforcement powers. AxoGen is subject to unannounced
inspections by the FDA to determine compliance with the GTP, GMP and other regulations, and these inspections may also include the manufacturing facilities of suppliers. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Failure by AxoGen or by AxoGen&#146;s suppliers to comply with applicable regulatory requirements can result in enforcement action by the FDA or other federal or state authorities, which may include any
of the following sanctions, among others: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">warning letters, fines, injunctions, consent decrees and civil penalties; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">customer notifications, repair, replacement, refunds, recall or seizure of our products; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">operating restrictions, partial suspension or total shutdown of production; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">suspension or termination of our clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">refusing our PMA or BLA for new products, new intended uses or modifications to existing products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">withdrawing premarket approvals that have already been granted; and criminal prosecution. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Education Grants, U.S. Anti-kickback, False Claims and Other Healthcare Fraud and Abuse Laws </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Educational Grants </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A medical product manufacturer may provide financial support, including support by way of grants, to third-parties for the purpose of conducting medical educational activities. If these funded activities
are considered by the FDA to be independent of the manufacturer, then the activities fall outside the FDA restrictions on promotion to which the manufacturer is subject. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The FDA considers several factors in determining whether an educational event or activity is independent from the substantive influence of the product manufacturer and therefore non-promotional,
including, but not limited to, the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the intent of the funded activity is to present clearly defined educational content, free from commercial influence or bias;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the third-party grant recipient and not the manufacturer has maintained control over selecting the faculty, speakers, audience, program content
and materials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the program focuses on a single product of the manufacturer without a discussion of other relevant existing competitive products or treatment
options; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether there was meaningful disclosure to the audience, at the time of the program, regarding the manufacturer&#146;s funding of the program, any
significant relationships between the provider, presenters, or speakers and the supporting manufacturer; whether any unapproved uses will be discussed; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether there are legal, business, or other relationships between the supporting manufacturer and provider or its employees that could permit the
supporting manufacturer to exert influence over the content of the program; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the individuals employed by the provider and involved in designing or conducting the educational activities are also involved in advising or
assisting the company with respect to sales or marketing; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the information about the company&#146;s products is further disseminated after the initial program, by or at the direction of the company,
other than in response to an unsolicited request or through an independent provider; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the provider is compliant with standards for independence, balance, objectivity, and scientific rigor when putting on ostensibly independent
educational programs. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen seeks to ensure that the activities it supports pursuant to educational grants
program are in accordance with these criteria for independent educational activities. However, AxoGen cannot provide an assurance that the FDA or other government authorities would view the programs supported as being independent. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">61 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Fraud, Abuse and False Claims </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen is directly and indirectly subject to various federal and state laws governing relationships with healthcare providers and
pertaining to healthcare fraud and abuse, including anti-kickback laws. In particular, the federal healthcare program Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving or providing remuneration,
directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing, arranging for or recommending a good or service for which payment may be made in whole or part under federal healthcare programs, such as
the Medicare and Medicaid programs. Penalties for violations include criminal penalties and civil sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other federal healthcare programs. The Anti-Kickback Statute
is broad and prohibits many arrangements and practices that are lawful in businesses outside of the healthcare industry. In implementing the statute, the Office of Inspector General of the U.S. Department of Health and Human Services
(&#147;OIG&#148;) has issued a series of regulations, known as the &#147;safe harbors.&#148; These safe harbors set forth provisions that, if all their applicable requirements are met, will assure healthcare providers and other parties that they
will not be prosecuted under the Anti-Kickback Statute. The failure of a transaction or arrangement to fit precisely within one or more safe harbors does not necessarily mean that it is illegal or that prosecution will be pursued. However, conduct
and business arrangements that do not fully satisfy each applicable element of a safe harbor may result in increased scrutiny by government enforcement authorities, such as the OIG. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Federal False Claims Act (&#147;FCA&#148;) imposes civil liability on any person or entity that submits, or causes the submission of,
a false or fraudulent claim to the U.S. Government. Damages under the FCA can be significant and consist of the imposition of fines and penalties. The FCA also allows a private individual or entity with knowledge of past or present fraud against the
federal government to sue on behalf of the government to recover the civil penalties and treble damages. The U.S. Department of Justice (&#147;DOJ&#148;) on behalf of the government has previously alleged that the marketing and promotional practices
of pharmaceutical and medical device manufacturers included the off-label promotion of products or the payment of prohibited kickbacks to doctors violated the FCA resulting in the submission of improper claims to federal and state healthcare
entitlement programs such as Medicaid. In certain cases, manufacturers have entered into criminal and civil settlements with the federal government under which they entered into plea agreements, paid substantial monetary amounts and entered into
corporate integrity agreements that require, among other things, substantial reporting and remedial actions going forward. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AdvaMed is one of the primary voluntary U.S. trade associations for medical device manufacturers. This association has established
guidelines and protocols for medical device manufacturers in their relationships with healthcare professionals on matters including research and development, product training and education, grants and charitable contributions, support of third-party
educational conferences, and consulting arrangements. Adoption of the AdvaMed Code by a medical device manufacturer is voluntary, and while the OIG and other federal and state healthcare regulatory agencies encourage its adoption and may look to the
AdvaMed Code, they do not view adoption of the AdvaMed Code as proof of compliance with applicable laws. AxoGen has incorporated the principles of the AdvaMed Code in its standard operating procedures, sales force training programs, and
relationships with doctors. Key to the underlying principles of the AdvaMed Code is the need to focus the relationships between manufacturers and healthcare professionals on matters of training, education and scientific research, and limit payments
between manufacturers and healthcare professionals to fair market value for legitimate services provided and payment of modest meal, travel and other expenses for a healthcare professional under limited circumstances. AxoGen has incorporated these
principles into its relationships with healthcare professionals under its consulting agreements, payment of travel and lodging expenses, research and educational grant </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">62 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
procedures and sponsorship of third-party conferences. In addition, AxoGen has conducted training sessions on these principles. However, AxoGen cannot provide any assurance that regulatory or
enforcement authorities will view these arrangements as being in compliance with applicable laws. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Regulation Outside of
the United States </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales of medical products outside of the U.S. are subject to foreign governmental regulations that
vary substantially from country to country. The time required to obtain certification or approval by a foreign country may be longer or shorter than that required for FDA clearance or approval and the requirements may be different. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are restrictions under U.S. law on the export from the U.S. of medical devices and biologic product that cannot be legally
distributed in the U.S. If a Class I or Class II medical device does not have 510(k) clearance, and the manufacturer reasonably believes that the device could obtain 510(k) clearance in the U.S., then the device can be exported to a foreign country
for commercial marketing without the submission of any type of export request or prior FDA approval, if the device is not sold or offered for sale in the U.S., is labeled for export only and satisfies certain criteria relating primarily to
specifications of the foreign purchaser and compliance with the laws of the country to which it is being exported, known as Importing Country Criteria. An unapproved Class III medical device can be exported if it complies with the criteria discussed
above for devices that could obtain 510(k) clearance, meets certain other quality and labeling requirements, and has a valid marketing authorization from one of a list of countries listed in the Federal Food, Drug, and Cosmetic Act. If an unapproved
Class III medical device does not have a valid marketing authorization from one of the listed countries, an export permit from the FDA is required in order to export it. An unapproved biologic product can be exported without submitting an export
request to FDA if the product has received a marketing authorization in one of a list of countries listed in the FD&amp;C Act and it meets applicable requirements of the FD&amp;C Act and the laws of the country to which it is exported. An
investigational biologic product may also be exported under an IND if a listed investigator is in a foreign country and certain requirements specified in FDA&#146;s regulations are met. AxoGen currently complies with applicable regulations when
exporting its products and intends to continue such compliance in the event there are any regulatory changes regarding its products in the United States. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The primary regulatory body in Europe is that of the E.U., which has adopted numerous directives and promulgated voluntary standards regulating the design, manufacture and labeling of, and clinical trials
and adverse event reporting for, medical devices. Devices that comply with the requirements of a relevant directive will be entitled to bear CE marking, indicating that the device conforms to the essential requirements of the applicable directives
and, accordingly, can be commercially distributed throughout the member states of the E.U. and other countries that comply with or mirror these directives. The method for assessing conformity varies depending on the type and class of the product,
but normally involves an assessment by the manufacturer and a third-party assessment by a notified body, an independent and neutral institution appointed by a country to conduct the conformity assessment. This third-party assessment may consist of
an audit of the manufacturer&#146;s quality system and specific testing of the manufacturer&#146;s device. Such an assessment is required for a manufacturer to commercially distribute the product throughout these countries. AxoGen has prepared the
Quality System and is ready for an assessment by the International Organization for Standardization, (ISO) 13485:2003 Quality Management System. If a country or international customer requires AxoGen to have its quality system registered for
compliance to ISO 13485, AxoGen will begin the registration process (selecting a registering body, scheduling audits and report completion). This process is expected to take less than 9 months. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">63 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Cook Biotech is responsible for all regulatory filings for the AxoGuard
products including international registrations. AxoGen works with Cook Biotech by providing the countries for Cook to register or get approval for the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products. Cook Biotech prepares the product filing documentation and submits this documentation to the Ministry of Health (&#147;MOH&#148;) for the country. Each
country or region has its own regulations and the documentation required for submission varies. It typically takes less than 9 months from the initiation of the project to obtain AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> clearance in a given country or region. To date, the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product line has been registered in Canada for distribution (May 2013) and has been awarded the CE Mark (April 2013) allowing distribution into the European Union and
other countries that accept the CE Mark. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Tissue products are not currently regulated under the CE Mark
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although some standards of harmonization exist, each country in which AxoGen conducts business has its own specific
regulatory requirements. AxoGen procures and processes its tissue products in the U.S., and markets in the U.S., the United Kingdom, the Netherlands , Canada, Switzerland, Austria and Italy under compliance with the individual country regulations.
These requirements are dynamic in nature and, as such, are continually changing. New regulations may be promulgated at any time and with limited notice. AxoGen will review the regulations at the time of submission of the product dossier for
regulatory review. This review involves reviewing the appropriate MOH regulations, discussion with in-country distributors and use of consultants. It typically takes less than 9 months from the initiation of the product to develop a product dossier
(specific for that country), submission of the documentation and MOH review of the product filing. While AxoGen believes that it is in compliance with all existing pertinent international and domestic laws and regulations, there can be no assurance
that changes in governmental administrations and regulations will not negatively impact AxoGen&#146;s operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA and
international regulatory bodies conduct periodic compliance inspections of AxoGen&#146;s U.S. processing facilities. AxoGen&#146;s operations are registered with the CBER, as a tissue establishment. AxoGen is also accredited by the AATB and is
licensed in the states of Florida, New York, California, Maryland, Delaware, Oregon and Illinois. AxoGen believes that worldwide regulation of tissue products is likely to intensify as the international regulatory community focuses on the growing
demand for these implant products and the attendant safety and efficacy issues of citizen recipients. Changes in governing laws and regulations could have a material adverse effect on AxoGen&#146;s financial condition and results of operations.
AxoGen management further believes that it can help to mitigate this exposure by continuing to work closely with government and industry regulators. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Environmental </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s products, as well as the chemicals used in
processing, are handled and disposed of in accordance with country-specific, federal, state and local regulations. Since 2007, AxoGen has used outside third parties to perform all biohazard waste disposal. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen contracts with independent, third parties to perform sterilization of its allografts. In view of the engagement of a third party
to perform irradiation services, the requirements for compliance with radiation hazardous waste do not apply, and therefore AxoGen does not anticipate that having any material adverse effect upon its capital expenditures, results of operations or
financial condition. However, AxoGen is responsible for assuring that the service is being performed in accordance with applicable regulations. Although AxoGen believes it is in compliance with all applicable environmental regulations, the failure
to fully comply with any such regulations could result in the imposition of penalties, fines and/or sanctions which could have a material adverse effect on AxoGen&#146;s business. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">64 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LecTec Corporation Merger </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;30, 2011, LecTec Corporation (&#147;LecTec&#148;) completed its business combination with AxoGen Corporation (&#147;AC&#148;) in accordance with the terms of an Agreement and Plan of
Merger, dated as of May&nbsp;31, 2011, by and among LecTec, Nerve Merger Sub Corp., a subsidiary of LecTec (&#147;Merger Sub&#148;), and AC, which the parties amended on September&nbsp;30, 2011 and August&nbsp;9, 2011 (as amended, the &#147;Merger
Agreement&#148;). Pursuant to the Merger Agreement, Merger Sub merged with and into AC, with AC continuing after the merger as the surviving corporation and a wholly owned subsidiary of LecTec (the &#147;Merger&#148;). Immediately following the
Merger, LecTec changed its name to AxoGen, Inc. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PDL BioPharma, Inc. Revenue Interests Purchase Agreement </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>General </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;5, 2012, AxoGen entered into a Royalty Contract with PDL, pursuant to which AxoGen sold to PDL the right to receive specified royalties on AxoGen&#146;s Net Revenues generated by the sale,
distribution or other use of AxoGen&#146;s products Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector. The Royalty Contract has a term of eight years. Under the Royalty Contract, PDL is to receive royalty payments based on a 9.95% royalty rate of
AxoGen&#146;s Net Revenues, subject to certain agreed upon minimum payment requirements of approximately $1.3 to $2.5 million per quarter, which begin in the fourth quarter of 2014 as provided in the Royalty Contract. The total consideration PDL
paid to AxoGen was the Funded Amount of $20,800,000, including $19,050,000 PDL paid to AxoGen on October&nbsp;5, 2012, and $1,750,000 PDL paid to AxoGen on August&nbsp;14, 2012 pursuant to an Interim Revenue Interest Purchase Agreement between
AxoGen and PDL, dated August&nbsp;14, 2012 (the &#147;Interim Royalty Contract&#148;). Upon the closing of PDL&#146;s purchase of the specified royalties described above, which was concurrent with the execution of the Royalty Contract, the Interim
Royalty Contract was terminated. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Put Option </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Royalty Contract, on October&nbsp;5, 2016, or in the event of the occurrence of a material adverse event, our transfer of
revenue interest or substantially all of our interest in the products or AxoGen&#146;s bankruptcy or material breach of the Royalty Contract, PDL may require AxoGen to repurchase the Assigned Interests at the &#147;Put Price.&#148; The Put Price is
equal to the sum of (i)&nbsp;an amount that, when paid to PDL, would generate a 20% rate of return to PDL on the Funded Amount, taking into consideration payments made to PDL by AxoGen, and (ii)&nbsp;any &#147;Delinquent Assigned Interest
Payment&#148; (as defined in the Royalty Contract) AxoGen owed to PDL. </FONT></P>  <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Change of Control; Call Option </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, in the event of a &#147;Change of Control&#148;, AxoGen must repurchase the assigned Interests from PDL for a repurchase
price equal to the &#147;Change of Control Price&#148; on or prior to the third business day after the occurrence of the Change of Control. The Change of Control Price is equal to the sum of (i)&nbsp;an amount that, when paid to PDL, would generate
a 32.5% internal rate of return to PDL on the Funded Amount, taking into consideration payments made to PDL by AxoGen, and (ii)&nbsp;any &#147;Delinquent Assigned Interest Payment&#148; AxoGen owed to PDL. In addition, at any time after
October&nbsp;5, 2016, AxoGen, at its option, can call the Royalty Contract for a price equal to the Change of Control Price. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">65 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Board Designee </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Royalty Contract, during the term of the Royalty Contract, PDL is entitled to designate, and AxoGen shall appoint an individual
designated by PDL, who shall serve on the Board of Directors of AxoGen (the &#147;Board&#148;) until AxoGen&#146;s 2013 Annual Meeting of Shareholders (the &#147;2013 Annual Meeting&#148;). For the 2013 Annual Meeting and each annual meeting
thereafter during the term of the Royalty Contract, the Board shall nominate and recommend the PDL designee as a director nominee to serve on the Board until the next annual meeting and shall include such nomination in AxoGen&#146;s proxy statement
for the 2013 Annual Meeting and each annual meeting thereafter, provided that the election of the PDL designee is subject to shareholders&#146; approval. Should at any time there become a vacancy on the Board as a result of (i)&nbsp;the resignation,
death or removal of the PDL designee or (ii)&nbsp;such PDL designee failing to obtain the requisite approval of AxoGen&#146;s shareholders at any annual or special meeting of AxoGen&#146;s shareholders and where no other individual is elected to
such vacancy, PDL shall have the right to designate an individual to fill such vacancy, and AxoGen shall take such actions necessary to appoint, such individual to the Board. AxoGen was required to have taken all actions necessary at or prior to the
Closing to ensure there is a vacancy on the Board as of the Closing to permit the appointment of the PDL designee to the Board as of the Closing. PDL has exercised this right and nominated John P. McLaughlin, PDL&#146;s President and Chief Executive
Officer. On October&nbsp;5, 2012, upon the Closing, the Board approved to increase its size from seven directors to eight directors, and Mr.&nbsp;McLaughlin was elected to the Board to serve until the 2013 Annual Meeting. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Preemptive Rights </I></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under the Royalty Contract, PDL has preemptive rights with respect to new issuances of AxoGen&#146;s equity securities and securities convertible, exchangeable or exercisable into such equity securities,
subject to certain restrictions, including restrictions regarding issuance of securities in a registered public offering by the Company. Therefore, due to such restrictions, the preemptive right does not apply to this offering. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Restriction on Dividends </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under the Royalty Contract, during the period from the October&nbsp;5, 2012 to December&nbsp;4, 2016 (or the payment of the Put Price in the event PDL exercises its put option on or prior to
December&nbsp;4, 2016), AxoGen shall not, nor shall it permit any subsidiary to, declare, pay or make any dividend or distribution on any shares of the common stock or preferred stock of such entity (other than dividends or distributions payable in
its stock, or split-ups or reclassifications of its stock) or apply any of its funds, property or assets to the purchase, redemption or other retirement of any common or preferred stock, or of any options to purchase or acquire any such shares of
common or preferred stock of any such entity (collectively, &#147;Restricted Payments&#148;), except that: (i)&nbsp;each subsidiary may make direct or indirect Restricted Payments to AxoGen; and (ii)&nbsp;AxoGen and each subsidiary may purchase,
redeem or otherwise acquire Equity Interests issued by it solely with the proceeds received from the substantially concurrent issue of new shares of its common stock or other common Equity Interests. For purposes of the Royalty Contract,
&#147;Equity Interests&#148; of any person means any and all shares, rights to purchase, options, warrants, general, limited or limited liability partnership interests, member interests, participation or other equivalents of or interest in
(regardless of how designated) equity of such entity, whether voting or nonvoting, including common stock, preferred stock, convertible securities or any other &#147;equity security&#148; (as such term is defined in Rule 3a11-1 under the Securities
Exchange Act of 1934, as amended). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Guarantee and Collateral Agreement </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the Royalty Contract, on October&nbsp;5, 2012, AxoGen and AC, entered into a Guarantee and Collateral Agreement (the
&#147;Guarantee and Collateral Agreement&#148;) with PDL, pursuant to which (i)&nbsp;AC unconditionally and irrevocably guarantees to PDL the prompt and complete payment and performance by AxoGen when due of the &#147;Secured Obligations,&#148;
which include AxoGen&#146;s obligations under the Royalty Contract, and any other obligations that AxoGen may owe to PDL under the Royalty Contract and other transaction documents; and (ii)&nbsp;each of AxoGen and AC grants to PDL a security
interest in certain collateral as specified in the Guarantee and Collateral Agreement for the prompt and complete payment and performance when due of the Secured Obligations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">66 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Employees </B></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">At July 26, 2013, AxoGen had 67 full time employees which included 13 in administration, information technology and finance, 9 in manufacturing and quality control, 9 in research and development and
regulatory and 36 in sales and marketing. As of the date of this registration statement AxoGen has not had a work stoppage and no employees are represented by a labor union. AxoGen believes its relationship with its employees is satisfactory.
</FONT></P>  <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Properties </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s corporate headquarters are currently located in Alachua, Florida, in a facility with a lease for 4,742 square feet of office space until April 2014. AxoGen also leases 2,224 square feet of
laboratory and distribution space in University of Florida&#146;s Sid Martin Biotechnology Incubator in Alachua, Florida under a one-year lease until September 2013 and leases space and maintains records at certain facilities, which includes
AxoGen&#146;s prior corporate headquarters at 1407 South Kings Highway, Texarkana, </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Texas 75501. AxoGen&#146;s aggregate cost
of such properties is approximately $176,000 per year. AxoGen believes that these facilities are sufficient to operate its business for the next 12 months and that lease obligations will not change materially, although AxoGen will likely require
additional space in the future to accommodate its expansion. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Legal Proceedings </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On July&nbsp;25, 2008, LecTec filed a complaint for patent infringement (the &#147;Complaint&#148;) against five companies, including
Chattem, Inc. (Ticker: CHTT), Endo Pharmaceuticals, Inc. (Ticker: ENDP), Johnson&nbsp;&amp; Johnson Consumer Company, Inc. (Ticker: JNJ), The Mentholatum Company, Inc. (Division of Rohto Pharmaceuticals, Ticker RPHCF.PK), and Prince of Peace
Enterprises, Inc. (Private Company) (collectively, the &#147;Defendants&#148;) in the U.S. District Court for the Eastern District of Texas. The Complaint alleged, among other things, that the Defendants infringed two of LecTec&#146;s patents (the
&#147;Patents-In-Suit&#148;), which related to LecTec&#146;s medicated patch technology. LecTec sought to enjoin the Defendants from infringing the Patents-In-Suit and to recover monetary damages related to such infringement, as well as interest and
litigation costs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2010, LecTec had settlement with Endo Pharmaceuticals, Inc., Johnson&nbsp;&amp;
Johnson Consumer Company, Inc. and The Mentholatum Company. On March&nbsp;23, 2011, LecTec entered into a Confidential Settlement Agreement and Mutual Release (the &#147;Chattem Settlement Agreement&#148;) with Chattem to settle LecTec&#146;s claims
against Chattem that Chattem infringed the Patents-In-Suit. Pursuant to the Chattem Settlement Agreement, Chattem paid a one-time sum of $3,600,000 to LecTec. and LecTec granted to Chattem a fully paid-up, world-wide, non-exclusive and irrevocable
license to (a)&nbsp;the Patents-In-Suit, (b)&nbsp;any patent that claims priority, directly or indirectly, from the Patents-In-Suit (the &#147;Family Patents&#148;) and (c)&nbsp;any foreign counterparts of the Family Patents, for use in connection
with any product or process sold or used by Chattem, other than products covered by exclusive licenses previously granted to other companies. Such settlement proceeds were before payment of contingent legal fees and any applicable taxes. In
addition, under the Chattem Settlement Agreement, LecTec and Chattem entered into mutual releases of all claims. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
April&nbsp;25, 2011, LecTec entered into a Confidential Settlement Agreement and Mutual Release (the &#147;POP Settlement Agreement&#148;) with Prince of Peace Enterprises, Inc. (&#147;POP&#148;) to settle LecTec&#146;s claims against POP that POP
infringed the Patents-In-Suit. Pursuant to the Settlement Agreement, POP paid LecTec a one-time sum of $225,000 and LecTec granted to POP a fully paidup, world-wide, non-exclusive and irrevocable license to (a)&nbsp;the Patents-In-Suit, (b)&nbsp;the
&#147;Family Patents&#148; and (c)&nbsp;any foreign counterparts of the Family Patents, for use in connection with </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">67 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
any product or process sold or used by POP, other than products covered by exclusive licenses previously granted to other companies. Such settlement proceeds were before payment of contingent
legal fees and any applicable taxes. In addition, under the POP Settlement Agreement, LecTec and POP entered into mutual releases of all claims. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have completed, through settlement, our previous material legal action against the five defendants. We currently have no active or pending material legal proceedings. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">68 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_10"></A>MANAGEMENT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Executive Officers and Directors </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Executive Officers </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to the Merger, Mr.&nbsp;Gregory Freitag was
LecTec&#146;s only executive officer serving as CEO and CFO. The following table, except as noted, lists the names and positions of the individuals who have served since the completion of the Merger, and who are, as of March&nbsp;31, 2013, executive
officers of the Company: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="71%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:15pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Karen Zaderej</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President, Chief Executive Officer and Director</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gregory G. Freitag, J.D. CPA</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer, General Counsel and Director</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John P. Engels</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jill F. Schiaparelli</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Business Strategy and Marketing</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark Friedman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President of Regulatory and Quality</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David Hansen</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporate Controller</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shawn McCarrey</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President of Sales</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Biographical information for each of our executive officers is included below. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Karen Zaderej, President, Chief Executive Officer and Director (Age 51) </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Zaderej has served as AxoGen&#146;s President, Chief Executive Officer and a member of its board of directors since September,
2011. She has served as AC&#146;s Chief Executive Officer and a member of its board of directors since May 2010. Ms.&nbsp;Zaderej joined AC in May 2006 and served as Vice President of Marketing and Sales from May 2006 to October 2007 and as Chief
Operating Officer from October 2007 to May 2010. From October 2004 to May 2006, Ms.&nbsp;Zaderej worked for Zaderej Medical Consulting, a consulting firm she founded, which assisted medical device companies build and execute successful
commercialization plans. From 1987 to 2004, Ms.&nbsp;Zaderej worked at Ethicon, Inc., a Johnson&nbsp;&amp; Johnson company, where she held senior positions in marketing, business development, and research&nbsp;&amp; development, as well as ran a
manufacturing business. Ms.&nbsp;Zaderej has a MBA from the Kellogg Graduate School of Business and a BS in Chemical Engineering from Purdue University. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>Gregory G. Freitag, J.D., CPA, Chief Financial Officer, General Counsel and Director (Age 51) </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Freitag, J.D., CPA, has been AxoGen&#146;s Chief Financial Officer, General Counsel and a member of its Board of Directors since September 2011 and was LecTec&#146;s Chief Executive Officer,
Chief Financial Officer and board member from June 2010 through September 2011. From May 2009 to the present, Mr.&nbsp;Freitag has been a principal of FreiMc, LLC, a consulting and advisory firm he founded that provides strategic guidance and
business development advisory services. Prior to founding FreiMc, LLC, Mr.&nbsp;Freitag was a Director of Business Development at Pfizer Health Solutions, a former subsidiary of Pfizer, Inc., from January 2006 to May 2009. From July 2005 to January
2006, Mr.&nbsp;Freitag worked for Guidant Corporation in their business development group. Prior to Guidant Corporation, Mr.&nbsp;Freitag was the Chief Executive Officer of HTS Biosystems, a biotechnology tools start-up company, from March 2000
until its sale in early 2005. Mr.&nbsp;Freitag was the Chief Operating Officer, Chief Financial Officer and General Counsel of Quantech, Ltd., a public point of care diagnostic company, from December 1995 to March 2000. Prior to that time,
Mr.&nbsp;Freitag practiced corporate law in Minneapolis, Minnesota. Mr.&nbsp;Freitag is also a director of the Foundation Board of HealthEast Care System, a health care system in Minnesota. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">69 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>John P. Engels, Vice President (Age 41) </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Engels has served as AxoGen&#146;s Vice President since September, 2011. He is a co-founder of AC and has served as AC&#146;s
Vice President since June 2006, providing operational and financial leadership and managing AxoGen&#146;s strategic and product development partnerships. From 1999 to 2002, Mr.&nbsp;Engels worked as a consultant for the University of Florida,
Saffron Hill Ventures and PA Early Stage Partners, among other companies. From 1993 to 1997, Mr.&nbsp;Engels was an analyst and associate at CACM, a boutique investment banking firm. Mr.&nbsp;Engels is currently a member of the board of directors of
Oxicool, Inc., a privately-held company developing new cooling technologies. Mr.&nbsp;Engels holds a MBA in Management and Operations from the Wharton School of Business at the University of Pennsylvania, and a BA from the University of Chicago.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Jill F. Schiaparelli, Senior Vice President, Business Strategy&nbsp;&amp; Marketing (Age 47) </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Schiaparelli has served as AxoGen&#146;s Senior Vice President, Business Strategy&nbsp;&amp; Marketing since February 2012. From
January 2011 to February 2012 and from June, 2007 to December 2008, Ms.&nbsp;Schiaparelli was employed by JS Strategic Partners, LLC, a consulting firm she founded to provide business strategy, commercialization and marketing services to
biotechnology companies and health care providers. From December 2008 to December 2010, Ms.&nbsp;Schiaparelli was the Vice President, Commercial Strategy&nbsp;&amp; Business Development for ApaTech, a venture-back global orthopedic graft company
based in the UK that was later acquired by Baxter Healthcare. From 1996 to 2007, Ms.&nbsp;Schiaparelli was employed by Johnson&nbsp;&amp; Johnson family of companies where she held several senior positions in strategic marketing, marketing, sales
operations and healthcare analytics within the Ethicon Endo-Surgery, Ethicon and Healthcare Systems operating companies. Prior to working in the healthcare industry, Ms.&nbsp;Schiaparelli worked for 8 years in the investment banking and financial
services industry. Ms.&nbsp;Schiaparelli has an MBA from the Stern School of Business at New York University and a BS in Business Administration from Boston University. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>Mark Friedman, Ph.D., Vice President of Regulatory and Quality (Age 55) </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Friedman has served as AxoGen&#146;s Vice President of Regulatory and Quality since September, 2011. He has served as AC&#146;s
Vice President of Regulatory and Quality since June 2011 and served as AC&#146;s Director of Quality Assurance and Regulatory Affairs from September 2006 to June 2011. Prior to joining AxoGen, Dr.&nbsp;Friedman held several regulatory and quality
leadership positions at Enable Medical Corporation, a medical device company, including Director of Quality Assurance from 1997 to 1998 and Vice President of Quality and Regulatory from 1998 to 2001 and from 2004 to 2005. Dr.&nbsp;Friedman also
worked for AtriCure, Inc., a company that develops, manufactures and sells surgical ablation systems to treat atrial fibrillation, as Vice President of Quality and Regulatory from 2001 to 2004 and as Vice President of Operations in 2004. AtriCure
acquired Enable Medical in 2005. Mr.&nbsp;Friedman has over 24 years of experience in developing and directing regulatory strategy and quality systems for medical products, including 15 years with start-up medical product firms. Dr.&nbsp;Friedman
has a Ph.D. in Chemistry specializing in protein biochemistry from the University of Cincinnati. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">70 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>David Hansen, Corporate Controller (Age 52) </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Hansen has served as AxoGen&#146;s Corporate Controller since September, 2011. He has served as AC&#146;s Corporate Controller
since June 2006. Mr.&nbsp;Hansen was Vice President of Finance&#151;Corporate Controller and Treasurer of Perma-Fix Environmental Services, Inc., a publicly-traded environmental services company, and held other corporate and regional accounting
positions at Perma-Fix Environmental Services from 1995 to 2005. Mr.&nbsp;Hansen was also Controller at Kraft Foodservice, Inc. from 1994 to 1995 and held other accounting and procurement positions at Kraft Foodservice, Inc. from 1985 to 1994.
Mr.&nbsp;Hansen has over 20 years of experience in senior financial positions at both publicly traded and private companies. Mr.&nbsp;Hansen holds a Bachelor of Business Administration degree in Accounting from the University of Oklahoma.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Shawn McCarrey, Vice President of Sales (Age 55) </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;McCarrey has served as AxoGen&#146;s Senior Vice President of Sales since February, 2013. Mr.&nbsp;McCarrey was Executive Vice
President of North American Cardiovascular Sales at Bayer Interventional/MEDRAD Interventional from January, 2009 to May 2012. Bayer HealthCare, a subgroup of Bayer AG, is one of the world&#146;s leading, innovative companies in the healthcare and
medical products industry. Bayer Interventional, now doing business as part of Bayer Medical Care&#146;s Radiology and Interventional business, is the Interventional franchise formerly operated under Bayer&#146;s MEDRAD brand. From 1998 to 2009,
Mr.&nbsp;McCarrey held multiple escalating positions with Possis Medical, Inc., a company that developed, manufactured, and marketed medical devices for the cardiovascular and vascular treatment markets, and served as Director or Sales, VP of US
Sales, VP of Worldwide Sales and EVP of Worldside Sales&nbsp;&amp; Marketing. For more than 15 years prior to joining Possis, Mr.&nbsp;McCarrey served in a series of progressively responsible roles with two divisions of C.R. Bard, United States
Catheter and Instrument Corporation (USCI) which specialized in the treatment of coronary disease in the cardiac catheterization laboratory and Davol, an operating room division that promoted Thoraclex and Simpulse to cardiovascular and orthopedic
surgeons. Mr.&nbsp;McCarrey holds a Bachelor of Science degree in Marketing from Central Michigan University. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen has a
key-person life insurance policy for $3,000,000 insuring the life of Ms.&nbsp;Zaderej. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the Company&#146;s 2012 annual
meeting of shareholders (the &#147;Annual Meeting&#148;), Greg Freitag, Mark Gold, M.D., Jamie M. Grooms, John Harper, Joe Mandato, Karen Zaderej and Robert Rudelius were nominated for re-election to AxoGen&#146;s Board of Directors (the
&#147;Board&#148;) and the AxoGen shareholders approved their election. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;5, 2012, the AxoGen Board approved
the increase in its size from seven directors to eight directors, and Mr.&nbsp;McLaughlin, a PDL designee, was elected to the Board to serve until the 2013 Annual Meeting. See &#147;Business &#151; PDL BioPharma, Inc. Revenue Interest Purchase
Agreement &#151;Board Designee.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Directors </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each elected director was to hold office for a term of one year and until their successors are duly elected and qualified (except in the
case of earlier death, resignation or removal). The following table lists the names, age and positions of the individuals who serve on the Board of Directors of the Company as of May&nbsp;10, 2013, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">71 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Age</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Karen Zaderej</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer and Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gregory Freitag</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer, General Counsel and Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jamie M. Grooms</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director, Chairman of the Board of Directors</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark Gold, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John Harper</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Joe Mandato</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Rudelius</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John P. McLaughlin</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Karen Zaderej, President, Chief Executive Officer and Director (Age 51) </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Zaderej&#146;s biographical information is provided above under &#147;&#151;Executive Officers.&#148; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Gregory G. Freitag, Chief Financial Officer and Director (Age 51) </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Freitag&#146;s biographical information is provided above under &#147;&#151;Executive Officers.&#148; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Jamie M. Grooms, Chairman and Director (Age 53) </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Grooms has served as Chairman of the Company&#146;s board of directors since September&nbsp;30, 2011 and AC&#146;s board of directors since 2002. Mr.&nbsp;Grooms is a co-founder of AC and from
2002 to May 2010 served as AC&#146;s Chief Executive Officer. Since leaving AC in May 2010, Mr.&nbsp;Grooms has provided consulting services to start-up companies and serves on the board of directors of several companies. From 1998 to 2002,
Mr.&nbsp;Grooms served as the founding Chief Executive Officer and Chairman of the Board of Regeneration Technologies, Inc. a publicly-traded company involved in processing human tissue for allogenic grafts used in orthopedic, oral maxillofacial,
urinary and cardiovascular surgeries. Mr.&nbsp;Grooms has extensive experience in all areas of operations of the allograft business and has worked at the Virginia Tissue Bank (now LifeNet Health), Osteotech, Inc., and CryoLife, Inc. in various
positions of leadership. In addition, Mr.&nbsp;Grooms has served as Director of the University of Florida Tissue Bank from 1992 to 1995. Mr.&nbsp;Grooms holds a Bachelor&#146;s degree in biology from Old Dominion University. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Mark Gold, MD, Director (Age 63) </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Gold has served as a member of the Company&#146;s board of directors since September&nbsp;30, 2011 and AC&#146;s board of directors since July 2007. Since 1991, Dr.&nbsp;Gold has been a Professor
at the University of Florida College of Medicine&#146;s McKnight Brain Institute. Dr.&nbsp;Gold has taught medical neuroscience for four decades and has been a pioneer in translational neuroscience research for over three decades. Dr.&nbsp;Gold was
also a Founder of Somerset Valley Bank and served on its board of directors from its formation through its initial public offering to its acquisition by Fulton Financial Corporation, a publicly-traded financial holding company Dr.&nbsp;Gold has
consulted for many major global pharmaceutical companies as well as firms such as the Carlyle Group and Cressey&nbsp;&amp; Company. Dr.&nbsp;Gold has authored hundreds of scientific research articles, chapters, and abstracts on a wide variety of
research subjects and is frequently interviewed for comment by the Wall Street Journal, CNN and other major business and national publications concerned with the strengths and limitations of new technology and treatments. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>John Harper, Director (Age 62) </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Harper has served as a member of the Company&#146;s board of directors since September&nbsp;30, 2011 and AC&#146;s board of directors since June 2006. From January 2012 until present,
Mr.&nbsp;Harper has been Executive Chairman of Xhale, Inc., a company that provides patient-centric monitoring solutions, from patient monitoring to medication adherence to anesthesia monitoring. From June
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">72 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
2005 to January 2006, Mr.&nbsp;Harper was the Entrepreneur-in-Residence at The Innovation Factory, a medical device incubator. From August 2000 to October 2001, Mr.&nbsp;Harper served as
President and Chief Executive Officer of ATI Medical, Inc. and from February 1998 to May 1999, he served as Executive Chairman of Meretek Diagnostics, Inc., which was acquired by American Standard Companies. From November 1995 to March 1997,
Mr.&nbsp;Harper served as President and Chief Executive Officer of Indigo Medical, Inc., which merged with Johnson&nbsp;&amp; Johnson. Mr.&nbsp;Harper also served as Vice President of Sales and Marketing, and then President and Chief Executive
Officer, of Menlo Care, Inc. from June 1989 to June 1995. Menlo Care, Inc. merged with Johnson&nbsp;&amp; Johnson in 1995. Mr.&nbsp;Harper has served on the board of directors for a number of medical device and biotechnology companies since 1999. He
received his BA in Economics from Davidson College in 1971. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Joe Mandato, Director (Age 68) </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Mandato has served as a member of the Company&#146;s board of directors since September&nbsp;30, 2011 and AC&#146;s board of
directors since February 2006. From March 2003 to the present, Mr.&nbsp;Mandato has served as a Managing Director of DeNovo Ventures, a venture capital firm and a shareholder of AxoGen. From February 1999 to September 2000, Mr.&nbsp;Mandato served
as Chairman of Confer Software, Inc., a developer of enterprise software used to automate healthcare business processes. From September 1995 to February 1999, Mr.&nbsp;Mandato served as Confer Software&#146;s Chief Executive Officer. From September
1994 to May 1995, Mr.&nbsp;Mandato served as a Vice President, member of founding management committee and Chief Executive Officer of two of Guidant Corporation&#146;s five operating units, Origin Medsystems and Heart Rhythm Technology. He also
served as President and Chief Executive Officer of Origin Medsystems from May 1991 to May 1995. In March 1994, Mr.&nbsp;Mandato co-founded Gynecare, Inc., a developer of devices used in gynecology, which was spun out of Guidant Corporation., and
served as its Chief Executive Officer until April 1995. From July 1986 to November 1990, Mr.&nbsp;Mandato was Chief Executive Officer of Ioptex Research Inc., an ophthalmic device company. Mr.&nbsp;Mandato serves on the board of directors of several
companies and non-profit organizations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Robert J. Rudelius, Director (Age 57) </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Rudelius has served as a member of the Board of Directors since September 2010. Since 2003, Mr.&nbsp;Rudelius has been the
Managing Director and Chief Executive Officer of Noble Ventures, LLC, a company he founded that provides advisory and consulting services to early-stage companies in the information technology, renewable energy and loyalty marketing fields.
Mr.&nbsp;Rudelius is also the Managing Director and Chief Executive Officer of Noble Logistics, LLC, a holding company he founded in 2002 to create, acquire and grow a variety of businesses in the freight management, logistics and information
technology industries. From April 1999 through May 2001, when it was acquired by StarNet L.P., Mr.&nbsp;Rudelius was the founder and Chief Executive Officer of Media DVX, Inc., a start-up business that provided a satellite-based, IP-multicasting
alternative to transmitting television commercials via analog videotapes to television stations, networks and cable television operators throughout North America. Mr.&nbsp;Rudelius assisted StarNet L.P. with the transition and integration of the
Media DVX, Inc. business through January 2002. From April 1998 to April 1999, Mr.&nbsp;Rudelius was the President and Chief Operating Officer of Control Data Systems, Inc., during which time Mr.&nbsp;Rudelius reorganized and repositioned the
software company as a professional services company, which resulted in the successful sale of Control Data Systems, Inc. to Syntegra, British Telecom&#146;s systems integration subsidiary. From October 1995 through April 1998, Mr.&nbsp;Rudelius was
the founding Managing Partner of AT&amp;T Solution&#146;s Media, Entertainment&nbsp;&amp; Communications industry group. From January 1990 through September 1995, Mr.&nbsp;Rudelius was a partner in McKinsey&nbsp;&amp; Company&#146;s Information,
Technology and Systems practice group, during which time he headed the practice group in Tokyo and co&#150;led the practice group in London. Mr.&nbsp;Rudelius is currently a member of the Board of Directors of ProUroCare Medical, Inc., a
publicly&#150;held medical device company that develops and markets prostate imaging systems. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">73 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>John P. McLaughlin, Director (age 61) </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;McLaughlin has served as a member of the Board of Directors since October 2012. Mr.&nbsp;McLaughlin has been PDL&#146;s President
and Chief Executive Officer since December&nbsp;18, 2008, when PDL spun-off Facet Biotech Corporation and was elected a director of PDL in October 2008. From November&nbsp;6, 2008, until the spinoff, he served as a Senior Advisor to PDL. From
January 2000 to June 2008, Mr.&nbsp;McLaughlin was the Chief Executive Officer and a director of Anesiva, Inc., formerly known as Corgentech, Inc., a publicly-traded biopharmaceutical company. From December 1997 to September 1999,
Mr.&nbsp;McLaughlin was President of Tularik Inc., a biopharmaceutical company. From September 1987 to December 1997, Mr.&nbsp;McLaughlin held a number of senior management positions at Genentech, Inc., a biopharmaceutical company, including
Executive Vice President and General Counsel. From January 1985 to September 1987, Mr.&nbsp;McLaughlin was a partner at a Washington, D.C. law firm specializing in food and drug law. Prior to that, Mr.&nbsp;McLaughlin served as counsel to various
subcommittees in the United States House of Representatives, where he drafted numerous measures that became FDA laws. Mr.&nbsp;McLaughlin co-founded and served as Chairman of the Board of Directors of Eyetech Pharmaceuticals, Inc., a publicly-traded
biopharmaceutical company subsequently bought by OSI Pharmaceuticals, Inc., and co-founded and served as a director of Peak Surgical, Inc., a private medical device company, until it was acquired by Medtronic in 2011. Mr.&nbsp;McLaughlin currently
serves as a director of Seattle Genetics, Inc., a publicly-traded biopharmaceutical company. He received a B.A. from the University of Notre Dame and a J.D. from Catholic University of America. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Director Independence </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company is not a listed issuer and so is not subject to the director independence requirements of any exchange or interdealer
quotation system. Nevertheless, in determining whether its directors and director nominees are independent, the Company uses the definition of independence provided in Rule 4200(a) (15)&nbsp;of the NASDAQ Stock Market&#146;s Marketplace Rules. Under
this definition of independence, Messrs. Grooms, Gold, Harper, Mandato and Rudelius would be considered independent directors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with this offering, we have applied to list our common shares
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and will be subject to certain rules of such exchange. Although we are not currently subject to director independence requirements, we have, nevertheless, in determining
whether our directors and director nominees are independent, used the definition of independence provided in Rule 5605 (a)(2) of The NASDAQ Stock Market&#146;s Marketplace Rules. Under this definition of independence, directors Jamie Grooms, Robert
Rudelius, John Harper, Joe Mandato and Dr.&nbsp;Mark Gold would be considered independent directors. Members of our Board Gregory Freitag and Karen Zaderej would not be considered independent because they serve as Executive Officers, John McLaughlin
would not be considered independent because he is an executive officer of PDL and PDL&#146;s payments to the Company under the Interim Revenue Interest Purchase Agreement exceeded the limit set forth in independence standards under the NASDAQ rules
as to Audit Committee consideration and the Board has not otherwise deemed him independent. The Company believes it complies with applicable independence standards of both the NYSE &#151; MKT and NASDAQ Stock Market. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">74 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Board Committees </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The standing committees of AxoGen&#146;s Board of Directors include an Audit Committee, a Compensation Committee and a Governance and Nominating Committees. Messrs. Rudelius (Chairman), Grooms and Harper
are the members of the Audit Committee. Messrs. Harper (Chairman), Rudelius and Dr.&nbsp;Gold are members of the Compensation Committee. Dr.&nbsp;Gold (Chairman) and Messrs. Grooms and Harper are members of the Nominating and Governance Committees.
The Charters of each of the Audit Committee, the Compensation, and Governance and Nominating Committee can be found on our website under &#147;About AxoGen&#151;Investors&#151;Corporate Governance.&#148; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Audit Committee </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Audit Committee is responsible for review of audits, financial reporting and compliance, and accounting and internal controls policy. For audit services, the Audit Committee is responsible for the engagement and compensation of independent auditors,
oversight of their activities and evaluation of their independence. The Audit Committee has instituted procedures for receiving reports of improper record keeping, accounting or disclosure. In the opinion of the AxoGen Board of Directors, each of
the members of the Audit Committee has both business experience and an understanding of generally accepted accounting principles and financial statements enabling them to effectively discharge their responsibilities as members of that Committee.
Moreover, the AxoGen Board of Directors has determined that each of Messrs. Rudelius, Grooms and Harper is an &#147;audit committee financial expert&#148; as such term is defined in Item&nbsp;407(d)(5) of Regulation S-K promulgated by the SEC.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation Committee </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee is responsible for establishing executive compensation and administering AxoGen&#146;s Incentive Compensation Plan. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Governance and Nominating Committee </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Governance and Nominating
Committee is responsible to provide oversight in relation to the corporate governance of AxoGen and also identifies director nominees for election to fill vacancies on the AxoGen Board of Directors. Nominees are approved by the AxoGen Board of
Directors on recommendation of the Governance and Nominating Committee. In evaluating nominees, the Governance and Nominating Committee particularly seeks candidates of high ethical character with significant business experience at the senior
management level who have the time and energy to attend to board responsibilities. Candidates should also satisfy such other particular requirements that the Governance and Nominating Committee may consider important to AxoGen&#146;s business at the
time. When a vacancy occurs on the AxoGen Board of Directors, the Governance and Nominating Committee will consider nominees from all sources, including shareholders, nominees recommended by other parties, and candidates known to the directors or
AxoGen&#146;s management. The best candidate from all evaluated will be recommended to the AxoGen Board of Directors to consider for nomination. Shareholders who wish to recommend candidates for consideration as nominees should on or before
January&nbsp;1 of each year furnish in writing detailed biographical information concerning the candidate to the Governance and Nominating Committee addressed to the Corporate Secretary of AxoGen at 13859 Progress Blvd., Suite 100, Alachua, FL
32615. No material changes have been made to the procedures by which security holders may recommend nominees to AxoGen&#146;s Board of Directors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">75 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_11"></A>EXECUTIVE COMPENSATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Executive Compensation </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Summary Compensation Table </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth the cash and non&#150;cash compensation for the fiscal years 2012 and 2011 for: (i)&nbsp;each individual serving as the Company&#146;s Chief Executive Officer
(&#147;CEO&#148;) or acting in a similar capacity during any part of such fiscal years; and (ii)&nbsp;the other two most highly paid executive officers who were serving as executive officers during such periods (our &#147;named executive
officers&#148;). </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:97pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Principal Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Salary($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Bonus($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock<BR>Awards($)(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Awards(#)(1)(2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>All Other<BR>Compensation($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Karen Zaderej<BR>CEO (3)(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">291,200</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">252,403</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,646</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,254</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">516,697</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,893</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,537</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">310,739</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">799,891</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gregory G. Freitag(5)<BR>Former CEO and CFO and General Counsel</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">204,069</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">154,808</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,161</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100,000</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">172,859</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,594</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">217,824</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">427,667</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John P. Engels<BR>Vice President(6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">174,888</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">171,138</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,689</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,833</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">121,998</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,600</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,453</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">189,177</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">315,422</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jill Schiaparelli</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">173,654</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">208,672</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,377</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">393,905</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President Business Strategy and Marketing(7)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts in this column are calculated based on the aggregate grant date fair value computed in accordance with Accounting Standards Codification (&#147;ASC&#148;)
Topic 718 as of December&nbsp;31 of the year indicated. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">76 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts shown for option awards relate to option awards granted under the AxoGen Corporation 2002 Stock Incentive Plan, as amended. These amounts are equal to the
aggregate grant date fair value of the options computed in accordance with FASB ASC Topic 718 using the assumptions set forth in Note 10 to AxoGen&#146;s audited consolidated financial statements included elsewhere in this Form 10-K.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms. Zaderej voluntarily accepted reduced salaries for a portion of 2011. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms. Zaderej has been CEO of the Company since September&nbsp;30, 2011 as a result of the Merger, CEO of AC since May 2010 and was Chief Operating Officer of AC from
2007 through May 2010. The amounts include life insurance premiums paid by AxoGen on behalf of Zaderej in 2011 of $365 and $393 in 2012 and also includes amounts contributed by the Company to the SIMPLE IRA plan on her behalf for 2011 of $7,172 and
2012 of $7,500. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr. Gregory G. Freitag is our current CFO and General Counsel and has been serving in such capacity since June&nbsp;1, 2010. Mr. Freitag stepped down as CEO on
September&nbsp;30, 2011 in conjunction with the Merger. On September&nbsp;30, 2011, Mr. Freitag received a one-time bonus as a result of completing the Merger. The amounts include life insurance premiums paid by AxoGen on behalf of Mr. Freitag in
2012 of $411 and also includes amounts contributed by the Company to the SIMPLE IRA plan on his behalf for 2012 of $5,183. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts include life insurance premiums paid by AxoGen on behalf of Mr. Engels in 2011 of $319 and $353 in 2012 and also includes amounts contributed by the Company
to the SIMPLE IRA plan on his behalf for 2011 of $5,134 and 2012 of $5,247. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts include life insurance premiums paid by AxoGen on behalf of Ms. Schiaparelli in 2012 of $167 and also includes amounts contributed by the Company to the
SIMPLE IRA plan on her behalf for 2012 of $5,210. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">77 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Outstanding Equity Awards at Fiscal Year End </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes the equity awards granted to our named executive officers that remain outstanding as of December&nbsp;31,
2012. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="20" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option Awards</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Grant Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Securities</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Exercise<BR>Price&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option&nbsp;Expiration<BR>Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Karen Zaderej</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/18/2008</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">126</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;(1)</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/18/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/9/2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,167(1)</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/9/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/26/2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">206,250(2)</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/26/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/26/2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;(3)</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/26/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gregory G. Freitag</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/1/2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">125,000(4)</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/1/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/26/2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">69,000(5)</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/26/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John P. Engels</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/7/2006</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,727(6)</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/7/2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/6/2007</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">719(6)</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/6/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/18/2008</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">406(6)</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/18/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/9/2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28,554(6)</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,131(6)</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/9/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/16/2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48,750(7)</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/16/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jill Schiaparelli</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/27/2012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90,913(8)</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/27/2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Zaderej received these options to purchase shares of AC common stock, which options pursuant to the Merger have been adjusted and provide for the right to
purchase Company common Shares. The options vest semi-annually and become fully vested and exercisable four years from the grant date. The options were granted under plans previously approved by AxoGen&#146;s shareholders and the exercise price for
the options were issued at a price equal to the fair market value of the AxoGen&#146;s common shares on the date of grant. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Zaderej received this option to purchase 275,000 shares of the Company&#146;s common shares. All shares pursuant to the option will be fully vested on
December&nbsp;26, 2015 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on December&nbsp;26, 2012 (12 months from the option grant date) and an additional 12.5% of aggregate shares each 6
months thereafter and will expire December&nbsp;26, 2018. The option was granted under plans previously approved by the Company&#146;s shareholders and the exercise price for the options were issued at a price equal to the fair market value of the
Company&#146;s common shares on the date of grant. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">78 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Zaderej received this option to purchase 100,000 shares of the Company&#146;s common shares. The shares under the Option are subject to a performance vesting
provision (the &#147;Performance Shares&#148;) whereby all, none or a portion of the Performance Shares, to the extent to which the performance standards established by the Board of Directors are met, will vest as to 25% of the Performance Shares on
March&nbsp;31, 2013, and an additional 12.5% of the Performance Shares each six months thereafter, with all Performance Shares being fully vested on December&nbsp;26, 2015 (4 years from the Option grant date) and will expire December&nbsp;26, 2018.
The option was granted under plans previously approved by the Company&#146;s shareholders and the exercise price for the options were issued at a price equal to the fair market value of the Company&#146;s common shares on the date of grant. These
options were forfeited on December&nbsp;31, 2012 due to not achieving the performance standard. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Freitag received this option which became fully vested and exercisable on August&nbsp;29, 2011 pursuant to the vesting terms of the option. The option was
granted outside of plans previously approved by the Company&#146;s shareholders and the exercise price for the option was issued at a price equal to the fair market value of the Company&#146;s common shares on the date of grant.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Freitag received this option to purchase 92,000 shares of the Company&#146;s common shares. All shares pursuant to the option will be fully vested on
December&nbsp;26, 2015 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on December&nbsp;26, 2012 (12 months from the option grant date) and an additional 12.5% of aggregate shares each 6
months thereafter and will expire December&nbsp;26, 2018. The option was granted under plans previously approved by the Company&#146;s shareholders and the exercise price for the options were issued at a price equal to the fair market value of the
Company&#146;s common shares on the date of grant. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Engels received these options to purchase shares of AC common stock, which options pursuant to the Merger have been adjusted and provide for the right to
purchase Company common shares. The options vest semi-annually and become fully vested and exercisable four years from the grant date. The options were granted under plans previously approved by AxoGen&#146;s shareholders and the exercise price for
the options were issued at a price equal to the fair market value of the AxoGen&#146;s common shares on the date of grant. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Engels received this option to purchase 65,000 shares of the Company&#146;s common shares. All shares pursuant to the option will be fully vested on
December&nbsp;16, 2015 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on December&nbsp;26, 2012 (12 months from the option grant date) and an additional 12.5% of aggregate shares each 6
months thereafter and will expire December&nbsp;16, 2018. The option was granted under plans previously approved by the Company&#146;s shareholders and the exercise price for the options were issued at a price equal to the fair market value of the
Company&#146;s common shares on the date of grant. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Schiaparelli received this option to purchase 90,913 shares of the Company&#146;s common shares. All shares pursuant to the option will be fully vested on
February&nbsp;2, 2016 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on February&nbsp;2, 2013 (12 months from the option grant date) and an additional 12.5% of aggregate shares each 6
months thereafter and will expire February&nbsp;27, 2019. The option was granted under plans previously approved by the Company&#146;s shareholders and the exercise price for the options were issued at a price equal to the fair market value of the
Company&#146;s common shares on the date of grant. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">79 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Employment Agreements </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AC is a party to employment agreements with each of Karen Zaderej, effective October&nbsp;15, 2007 and as amended September&nbsp;29, 2011,
John P. Engels, effective May&nbsp;6, 2003 and as amended September&nbsp;29, 2011, Gregory Freitag, effective October&nbsp;1, 2011, Jill Schiaparelli, effective February&nbsp;27, 2012 and Shawn McCarrey, effective February&nbsp;25, 2013.
Ms.&nbsp;Zaderej and Mr.&nbsp;Engels employment agreements renew for one year periods on each anniversary of the effective date and provide for severance benefits upon termination of the executive officer&#146;s employment: (1)&nbsp;by AxoGen for
any reason other than &#147;substantial cause&#148; (as defined below), permanent disability, or death, (2)&nbsp;by the executive officer due to AxoGen&#146;s breach of the employment agreement and AxoGen&#146;s failure to cure such breach within
ten days following notice by the executive officer of such breach; or (3)&nbsp;by the executive officer within six months of a &#147;change of control&#148; (as defined below) of AxoGen. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon a termination of Ms.&nbsp;Zaderej&#146;s employment for any of the reasons set forth above, Ms.&nbsp;Zaderej is entitled to base
salary in an amount equal to the base salary that she would have been paid for the remainder of the then current employment period had the executive officer&#146;s employment not been terminated or the one-year non-competition period, whichever is
longer. Upon a termination of Mr.&nbsp;Engels&#146; employment for any of the reasons set forth above, Mr.&nbsp;Engels is entitled to base salary in an amount equal to the base salary that he would have been paid for the remainder of the then
current employment period had the executive officer&#146;s employment not been terminated. Both Ms.&nbsp;Zaderej and Mr.&nbsp;Engels are entitled to continued medical and dental benefits (in the form of a reimbursement for the COBRA premiums) and
continued bonus payments to which the executive officer would have been entitled for the remainder of the then current employment period had the executive officer&#146;s employment not been terminated. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under their respective employment agreement, Messrs. Freitag and McCarrey and Ms.&nbsp;Schiaparelli employment are at will. In the event
Messrs. Freitag or McCarrey or Ms.&nbsp;Schiaparelli is terminated without substantial cause either prior to a change of control or 180 days following a change in control the person is entitled to a severance payment consisting of (A)&nbsp;twelve
months of base salary; and (B)&nbsp;an amount equal to any bonuses paid during the twelve month period prior to termination of employment. Messrs. Freitag and McCarrey and Ms.&nbsp;Schiaparelli are also entitled to severance of twelve months of base
salary if the person leaves AxoGen for &#147;good reason&#148; (as defined below) within 180 days following a change of control. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, Ms.&nbsp;Zaderej is entitled to full vesting of her outstanding stock options that were granted prior to the Merger upon a change of control, regardless of whether her employment terminates
on or following the change of control. With respect to Ms.&nbsp;Zaderej&#146;s, Ms.&nbsp;Schiaparelli&#146;s and Messrs. Freitag&#146;s, Engel&#146;s and McCarrey&#146;s post-Merger stock options, if a change of control occurs, such options shall
automatically accelerate and become fully exercisable in the event that within twelve months following the change of control they are terminated without cause or leave for good reason. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of the executive officer&#146;s employment agreements, &#147;change of control&#148; means the occurrence of any of the
following events: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any person who holds less than 20% of the combined voting power of the securities of AC or AxoGen, Inc., becomes the beneficial owner, directly or
indirectly, of securities of AC or AxoGen, Inc., representing 50% or more of the combined voting power of the securities of AC or AxoGen, Inc. then outstanding; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">during any period of 24 consecutive months, individuals who at the beginning of such period constitute all members of the AxoGen, Inc.&#146;s Board of
Directors cease, for any reason, to constitute at least a majority of the board of directors, unless the election of each director who was not a director at the beginning of the period was either nominated for election by, or was approved by a vote
of, at least two-thirds of the directors then still in office who were directors at the beginning of the period; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">80 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AC or AxoGen, Inc. consolidates or merges with another company and AC or AxoGen, Inc. is not the continuing or surviving corporation, provided,
however, that any consolidation or merger whereby AxoGen, Inc. continues as the majority holder of AC securities or a merger or consolidation of AC and AxoGen, Inc. will not constitute a change in control; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">shares of AC&#146;s or AxoGen, Inc.&#146;s common shares are converted into cash, securities, or other property (other than by a merger set forth in
(iii)&nbsp;above) in which the holders of the AC&#146;s or AxoGen, Inc.&#146;s common shares immediately prior to the merger have the same proportionate ownership of common shares of the surviving corporation as immediately after the merger;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AC or AxoGen, Inc. sells, leases, exchanges, or otherwise transfers all or substantially all of its assets (in one transaction or in a series of
related transactions); or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the holders of AxoGen&#146;s stock approve a plan or proposal for the liquidation or dissolution of AC or AxoGen, Inc. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of Ms.&nbsp;Zaderej&#146;s, Ms.&nbsp;Schiaparelli&#146;s and Messrs. Freitag&#146;s and McCarrey&#146;s employment
agreements, &#147;substantial cause&#148; means: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">commission of any act of fraud, theft, or embezzlement; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">material breach of the employment agreement, provided that AC shall have first delivered to the executive officer written notice of the alleged breach,
specifying the exact nature of the breach in detail, and provided, further, that the executive officer shall have failed to cure or substantially mitigate such breach within ten days after receiving such written notice; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">commission or conviction of any felony, or of any misdemeanor involving moral turpitude, or entry of a plea of guilty or nolo contendere to any felony
or misdemeanor; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">material failure to adhere to AC&#146;s corporate codes, policies or procedures which have been adopted in good faith for a valid business purpose as
in effect from time to time; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure to meet reasonable performance standards as determined by AC, which for Mr.&nbsp;McCarrey includes the failure of gross revenue in a calendar
quarter exceed 80% of budgeted gross revenue. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of Mr.&nbsp;Engels&#146; employment agreement,
&#147;substantial cause&#148; means the commission by Mr.&nbsp;Engels of any act of fraud, theft or embezzlement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For
purposes of Messrs. Freitag&#146;s and McCarrey&#146;s and Ms.&nbsp;Schiaparelli&#146;s employment agreements, &#147;good reason&#148; means the occurrence of any one or more of the following: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the assignment of any duties inconsistent in any respect with the person&#146;s position (including status, offices, titles, and reporting
requirements), authorities, duties, or other responsibilities as in effect immediately prior to a change of control or any other action by AxoGen which results in a diminishment in such position, authority, duties, or responsibilities, other than an
insubstantial and inadvertent action which is remedied by AxoGen; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a reduction by AC in the person&#146;s base salary; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the failure by AC to (A)&nbsp;continue in effect any material compensation or benefit plan, program, policy or practice in which the person was
participating at the time of the change of control of AxoGen or (B)&nbsp;provide the person with compensation and benefits at least equal (in terms of benefit levels and/or reward opportunities) to those provided for under each employee benefit
plan, program, policy and practice as in effect immediately prior to the change in control (or as in effect following the Change in Control of the Company), if greater. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">81 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pension Benefits </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen adopted the AxoGen SIMPLE IRA plan in 2007. The AxoGen named executive officers participate in the SIMPLE IRA plan. Eligibility is
immediate upon employment, and enrollment is available any time during employment. Participating employees may make annual pretax contributions to their accounts up to a maximum amount as limited by law. The SIMPLE IRA plan requires AxoGen to make
matching contributions of between 1% and 3% of the employee&#146;s annual salary as long as the employee participates in the SIMPLE IRA plan. Additionally, the matching contribution has to be at least 3% for three of the first five years of the
SIMPLE IRA. Both employee contributions and AxoGen contributions are fully vested at all times. In 2012 and 2011, AxoGen&#146;s matching contribution was 3% of the AxoGen named executive officers&#146; annual base salary. AxoGen contributed
approximately $23,000 and $12,000 in matching funds for the AxoGen named executive officers during 2012 and 2011, respectively. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Director
Compensation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each non-employee director receives a quarterly cash retainer payment of $3,000 for services to AxoGen
starting in the first quarter after election, which cash payment is paid in advance each quarter. Non-employee directors are also paid $1,500 per in-person Board of Directors meeting if they attend in person and $750 for such in-person meeting if
they participate by telephone. No additional compensation is provided for telephonic Board meetings or actions taken pursuant to written minutes of action of the Board. Non-employee directors are paid $1,000 per committee meeting attended in-person
if they attend in person and $500 for such in-person committee meeting if they participate by telephone. The total board and committee member fees cannot exceed $2,500 per day. In addition, all non-employee directors receive an annual calendar year
non-qualified stock option grant equal to 0.1% of the fully diluted stock of AxoGen, rounded down to a 250 share increment, at an exercise price equal to the fair market value of our common shares on the date of grant. Such stock options are for a
term of seven years and are fully vested upon grant. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">82 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Director Compensation Table </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows the compensation earned by all persons serving as members of our Board of Directors during 2012. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fees&nbsp;Earned<BR>or Paid in<BR>Cash ($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock<BR>Awards($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Awards($)(3)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert J. Rudelius</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gregory G. Freitag</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Karen Zaderej(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jamie M. Grooms(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark Gold, M.D.(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John Harper(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Joe Mandato(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John McLaughlin (2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Service as a member of our Board of Directors began on September&nbsp;30, 2011 when their election at the Company&#146;s 2010 Annual Meeting of Shareholders took effect
as a result of the closing of the Merger. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Service as a member of our Board of Directors began on October&nbsp;4, 2012 when Mr.&nbsp;McLaughlin was appointed to the Board pursuant to the PDL Royalty Contract.
Mr.&nbsp;McLaughlin&#146;s director fees were paid to PDL. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts in this column are calculated based on the aggregate grant date fair value computed in accordance with Accounting Standards Codification (ASC) Topic 718 as
of December&nbsp;31, 2012. </FONT></TD></TR></TABLE> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_12"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">One of our directors, Joe Mandato, is a Managing Partner of DeNovo Ventures II, L.P. which is a greater than 5%
shareholder of the Company&#146;s common shares. Another director of ours, John McLaughlin, is an executive officer of PDL, with which the Company has entered into the Royalty Contract. See &#147;Business<B>&#151;</B> PDL BioPharma, Inc. Revenue
Interests Purchase Agreement&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">83 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_13"></A>PRINCIPAL SHAREHOLDERS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth, as of July 26, 2013, certain information with respect to the beneficial ownership of our common shares
(the only voting class outstanding), (i)&nbsp;by each director, (ii)&nbsp;by each of the named executive officers and (iii)&nbsp;by all officers and directors as a group. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:89pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name of Beneficial Owner</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares<BR>Beneficially<BR>Owned<BR>Before<BR>Offering&nbsp;(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage<BR>of<BR>Outstanding<BR>Shares<BR>Beneficially<BR>Owned<BR>Before<BR>Offering (1)</B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares<BR>Beneficially<BR>Owned<BR>After<BR>Offering</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage&nbsp;of<BR>Outstanding<BR>Shares<BR>Beneficially<BR>Owned After<BR>Offering</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">DeNovo Ventures II, LP(2)</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2180 Sand Hill Rd.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Suite 200</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Menlo Park, CA 94025</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,426,392</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,426,392</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">AMV Partners I, L.P.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2750 Premier Parkway</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Suite 200</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Duluth, GA 30097</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,017,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,017,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Utility Service Holding Company, Inc.(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">972,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">972,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.33</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CHP II, L.P.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">230 Nassau St.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Princeton, NJ 08542</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attn: John Park</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">886,556</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">886,556</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.78</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Karen Zaderej</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">278,208</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">278,208</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.79</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jamie M. Grooms(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">473,032</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">473,032</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.06</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John P. Engels</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">154,189</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">154,189</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark Gold, M.D.(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">277,697</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">277,697</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.81</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John Harper</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">184,371</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">184,371</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Joe Mandato(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Rudelius</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68,273</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68,273</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Greg Freitag</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">183,818</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">183,818</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All directors and executive officers as a group (11 persons) (2)(3)(4)(5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,723,695</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,723,695</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE>  <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Beneficial ownership is determined in accordance with the rules and regulations of the SEC. In general, a person is deemed to be the beneficial owner of (i)&nbsp;any of
our common shares over which such person has sole or shared voting power or investment power, plus (ii)&nbsp;any shares which such person has the right to acquire beneficial ownership of within 60 days, whether through the exercise of options,
warrants or otherwise. The percentage of ownership set forth above is based on 11,139,939 common shares outstanding as of July 26, 2013. Our common shares issuable upon the exercise of stock options exercisable currently or within 60 days of July
26, 2013 are deemed outstanding and to be beneficially owned by the person holding such option for purposes of computing such person&#146;s percentage ownership, but are not deemed outstanding for the purpose of computing the percentage ownership of
any other person. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">84 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Mandato is a Managing Partner of this venture capital fund. Mr.&nbsp;Mandato disclaims beneficial ownership of the shares owned by the fund.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">These shares include 218,534 shares of record held by Mr.&nbsp;Grooms, and 132,883 shares held by the Jamie Grooms Trust, of which Mr.&nbsp;Grooms is the trustee.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">These shares include 107,690 shares held by Dr.&nbsp;Gold&#146;s wife and 125,523 shares held by MJSK, Ltd., an investment trust held by Dr.&nbsp;Gold&#146;s family.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 5,665 shares held by Mark Friedman and 5,750 held by Jill Schiaparelli. Also includes a number of shares underlying options equal to 22,728, 21,311 and 23,653,
for Jill Schiaparelli, Mark Friedman and Dave Hansen, respectively. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">85 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_14"></A>DESCRIPTION OF COMMON SHARES </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following
description does not purport to be complete and is subject in all respects to applicable Minnesota law and to the provisions of the AxoGen Amended and Restated Articles of Incorporation and bylaws, as amended to the date of this prospectus. AxoGen
shareholders are urged to read the Amended and Restated Articles of Incorporation and bylaws for a more complete description of these provisions and other information that may be important to AxoGen shareholders. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Capital Stock </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s authorized capital stock consists of 50,000,000 shares, par value $0.01 per share. The authorized capital stock is divisible
into the classes and series, has the designation, voting rights, and other rights and preferences and is subject to the restrictions that the AxoGen Board of Directors may from time to time establish. Unless otherwise designated by the AxoGen Board
of Directors, all shares are common shares. The holders of AxoGen common shares: (1)&nbsp;have equal ratable rights to dividends from funds legally available therefor, when, as and if declared by the AxoGen Board of Directors; (2)&nbsp;are entitled
to share ratably in all assets available for distribution to holders of AxoGen common shares upon liquidation, dissolution or winding up of its affairs; (3)&nbsp;do not have preemptive, subscription or conversion rights and there are no redemption
or sinking fund provisions applicable thereto; and (4)&nbsp;are entitled to one vote per share on all matters which shareholders may vote on at all meetings of shareholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">All shares of AxoGen common shares now outstanding are fully paid and nonassessable. The holders of shares of AxoGen common shares do not have cumulative voting rights, which means that the holders of
more than 50% of the outstanding shares voting for the election of directors can elect all of AxoGen&#146;s directors to be elected, if they so choose. In such event, the holders of the remaining shares will not be able to elect any directors.
</FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After consummation of this offering, AxoGen expects to have
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; common shares outstanding. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wells
Fargo Bank, N.A. is the transfer agent for AxoGen common shares. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Minnesota Anti-Takeover Laws </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen is governed by the provisions of Sections 302A.671, 302A.673 and 302A.675 of the Minnesota Business Corporation Act. These
provisions may discourage a negotiated acquisition or unsolicited takeover of AxoGen and deprive AxoGen security holders of an opportunity to sell their shares at a premium over the market price. In general, Section&nbsp;302A.671 provides that a
corporation&#146;s shares acquired in a control share acquisition have no voting rights unless voting rights are approved in a prescribed manner. A &#147;control share acquisition&#148; is a direct or indirect acquisition of beneficial ownership of
shares that would, when added to all other shares beneficially owned by the acquiring person, entitle the acquiring person to have voting power of 20% or more in the election of directors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, Section&nbsp;302A.673 prohibits a public Minnesota corporation from engaging in a business combination with an interested
shareholder for a period of four years after the date of the transaction in which the person became an interested shareholder, unless the business combination is approved in a prescribed manner. The term &#147;business combination&#148; includes
mergers, asset sales and other transactions resulting in a financial benefit to the interested shareholder. An &#147;interested shareholder&#148; is a person who is the beneficial owner, directly or indirectly, of 10% or more of a corporation&#146;s
voting stock, or who is an affiliate or associate of the corporation, and who, at any time within four years before the date in question, was the beneficial owner, directly or indirectly, of 10% or more of the corporation&#146;s voting stock.
Section&nbsp;302A.673 does not apply if a committee of the AxoGen Board of Directors consisting of all of its disinterested directors (excluding current and former officers) approves the proposed transaction or the interested shareholder&#146;s
acquisition of shares before the interested shareholder becomes an interested shareholder. If a tender offer is made for AxoGen common stock, Section&nbsp;302A.675 of the Minnesota </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">86 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Business Corporation Act precludes the offeror from acquiring additional shares of stock (including in acquisitions pursuant to mergers, consolidations or statutory share exchanges) within two
years following the completion of the tender offer, unless shareholders selling their shares in the later acquisition are given the opportunity to sell their shares on terms that are substantially the same as those contained in the earlier tender
offer. Section&nbsp;302A.675 does not apply if a committee of the AxoGen Board of Directors consisting of all of its disinterested directors (excluding its current and former officers) approves the proposed acquisition before any shares are acquired
pursuant to the earlier tender offer. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Trading </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our common shares currently trade on the OTCQB Marketplace under the symbol &#147;AXGN&#148; In connection with this offering, we intend to list our common shares
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; under the symbol &#147;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Transfer Agent and Registrar </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The transfer agent and registrar for our
common shares is Wells Fargo Shareowner Services. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">87 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_15"></A>UNDERWRITING </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and the underwriters for the offering named below have entered into an underwriting agreement with respect to the shares of common
shares being offered. Subject to the terms and conditions of the underwriting agreement, each underwriter has severally agreed to purchase from us the number of common shares set forth opposite its name below. JMP Securities is the representative of
the underwriters. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:46pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Underwriters</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">JMP Securities LLC.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ladenburg Thalmann&nbsp;&amp; Co., Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,658,536</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters are offering the common shares subject to each underwriter&#146;s acceptance of the
shares of common stock from us and subject to prior sale. The underwriting agreement provides that the obligation of each underwriter to pay for and accept delivery of the shares of common stock offered by this prospectus is subject to the approval
of certain legal matters by its counsel and to certain other conditions. Each underwriter is obligated to take and pay for all of the shares of common stock if any such shares are taken. However, the underwriters are not required to take or pay for
the shares of common stock covered by the underwriters&#146; <FONT STYLE="white-space:nowrap">over-allotment</FONT> option described below. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Over-Allotment Option </B></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have granted the underwriters an option,
exercisable for 30 days from the date of this prospectus, to purchase up to an aggregate of 548,780 additional shares of common stock to cover over-allotments, if any, at the public offering price set forth on the cover page of this prospectus, less
underwriting discounts and commissions. The underwriters may exercise this option solely for the purpose of covering over-allotments, if any, made in connection with the offering of the shares of common stock offered by this prospectus. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Commission and Expenses </B></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The underwriters have advised us that they propose to offer the shares of common stock to the public at the initial public offering prices set forth on the cover page of this prospectus and to certain
dealers at that price less a concession not in excess of $4.10&nbsp;per share of common stock. After this offering, the initial public offering price, concession and reallowance to dealers may be changed by the underwriters. No such change shall
change the amount of proceeds to be received by us as set forth on the cover page of this prospectus. The shares of common stock are offered by the underwriters subject to various conditions as stated herein, including receipt and acceptance by it
and its right to reject any order in whole or in part. The underwriters have informed us that they do not intend to confirm sales to any accounts over which they exercise discretionary authority. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows the underwriting discounts and commissions payable to the underwriter by us in connection with this offering.
Such amounts are shown assuming both no exercise and full exercise of the underwriter&#146;s over-allotment option to purchase additional shares. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">88 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Per<BR>Common<BR>Share</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total Without<BR>Exercise
of<BR><FONT STYLE="white-space:nowrap">Over-Allotment</FONT><BR>Option</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total With<BR>Exercise
of<BR><FONT STYLE="white-space:nowrap">Over-Allotment</FONT><BR>Option</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Public offering price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Underwriting discounts and commissions payable by us</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate that expenses payable by us in connection with this offering (including the reimbursement of
the underwriters&#146; expenses described in this paragraph), other than the underwriting discounts and commissions referred to above, will be approximately $460,000. We have agreed to reimburse the underwriters for reasonable fees and other
disbursements of counsel to the underwriters and other reasonable out-of-pocket expenses actually incurred by the underwriters in an amount not to exceed $150,000 in the aggregate. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Indemnification </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, and liabilities arising from breaches of representations and warranties contained
in the underwriting agreement, or to contribute to payments that the underwriters may be required to make in respect of those liabilities. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Lock-up Agreements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We, our officers and directors and our significant
shareholders have agreed, subject to limited exceptions, for a period of 90 days after the date of the underwriting agreement, not to offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of,
directly or indirectly any shares of common stock or any securities convertible into or exchangeable for our common stock either owned as of the date of the underwriting agreement or thereafter acquired without the prior written consent of JMP
Securities LLC. This 90-day period may be extended if (1)&nbsp;during the last 17 days of the 90-day period, we issue an earnings release or material news or a material event regarding us occurs or (2)&nbsp;prior to the expiration of the 90-day
period, we announce that we will release earnings results during the 16-day period beginning on the last day of the 90-day period, then the period of such extension will be 18 days, beginning on the issuance of the earnings release or the occurrence
of the material news or material event. JMP Securities LLC may, in its sole discretion and at any time or from time to time before the termination of the lock-up period, without notice, release all or any portion of the securities subject to lock-up
agreements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Electronic Distribution </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This prospectus in electronic format may be made available on websites or through other online services maintained by the underwriters, or by their affiliates. Other than this prospectus in electronic
format, the information on any underwriter&#146;s website and any information contained in any other website maintained by any underwriter is not part of this prospectus or the registration statement of which this prospectus forms a part, has not
been approved and/or endorsed by us or the underwriters in their capacity as underwriters, and should not be relied upon by investors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Price Stabilization, Short Positions and Penalty Bids </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with
the offering the underwriters may engage in stabilizing transactions, over-allotment transactions and syndicate covering transactions in accordance with Regulation M under the Exchange Act: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum.
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">89 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Over-allotment involves sales by the underwriters of shares in excess of the number of shares the underwriters are obligated to purchase, which creates
a syndicate short position. The short position may be either a covered short position or a naked short position. In a covered short position, the number of shares over-allotted by the underwriters is not greater than the number of shares that they
may purchase in the over-allotment option. In a naked short position, the number of shares involved is greater than the number of shares in the over-allotment option. The underwriters may close out any covered short position by either exercising
their over-allotment option and/or purchasing shares in the open market. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Syndicate covering transactions involve purchases of shares of the common stock in the open market after the distribution has been completed in order
to cover syndicate short positions. In determining the source of shares to close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at
which they may purchase shares through the over-allotment option. If the underwriters sell more shares than could be covered by the over-allotment option, a naked short position, the position can only be closed out by buying shares in the open
market. A naked short position is more likely to be created if the underwriters are concerned that there could be downward pressure on the price of the shares in the open market after pricing that could adversely affect investors who purchase in the
offering. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These stabilizing transactions, syndicate covering transactions and penalty bids may have the
effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in
the open market. Neither we nor the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common stock. In addition, neither we nor the
underwriters make any representations that the underwriters will engage in these stabilizing transactions or that any transaction, once commenced, will not be discontinued without notice. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Listing and Transfer Agent </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We intend to list our common shares on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;under the symbol
&#147;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.&#148; The transfer agent of our common shares is Wells Fargo Bank, N.A. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Other </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriter and/or their affiliates have provided, and may in
the future provide, various investment banking and other financial services for us for which services they have received and, may in the future receive, customary fees. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_16"></A>LEGAL MATTERS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain legal matters in
connection with the securities offered hereby will be passed upon for us by Morgan, Lewis&nbsp;&amp; Bockius LLP, Philadelphia, Pennsylvania and Kaplan, Strangis and Kaplan, P.A., Minneapolis, Minnesota. Certain legal matters in connection with this
offering will be passed upon for the underwriters by Orrick, Herrington &amp; Sutcliffe LLP, San Francisco, California. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">90 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_17"></A>EXPERTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The financial statements of the Company as of December&nbsp;31, 2012 and 2011, and for the years then ended included in this prospectus
and registration statement, have been included in reliance of the reports on Lurie Besikof Lapidus&nbsp;&amp; Company, LLP, an independent registered public accounting firm, given on the authority of said firm as experts in accounting and auditing.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">91 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_18"></A>WHERE YOU CAN FIND MORE INFORMATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have filed with the SEC a registration statement under the Securities Act of 1933 that registers the distribution of the common shares
offered under this prospectus. The registration statement contains additional relevant information about us and the common shares. The rules and regulations of the SEC allow us to omit from this prospectus certain information included in the
registration statement. Statements contained in this prospectus as to the contents of any documents that we have filed as an exhibit to the registration statement are qualified in their entirety by reference to the exhibits for a complete statement
of their terms and conditions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, we file annual, quarterly and current reports, proxy statements and other
information with the SEC. You may read and copy this information and the registration statement at the SEC public reference room located at 100 F Street, N.E., Washington D.C. 20549. You may obtain information on the operation of the Public
Reference Room by calling the SEC at 1-800-SEC-0330. Any information we file with the SEC is also available on the SEC&#146;s website at http://www.sec.gov. We also maintain a website at <U>http://www.axogeninc.com/secfilings.html</U> through which
you can access our SEC filings. We have included our website address in this prospectus solely as an inactive textual reference. The information contained on, or that can be accessed through, our website is not part of this prospectus. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">92 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_19"></A>AXOGEN, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="index"></A><A NAME="toc532389_22"></A>INDEX TO FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Audited Consolidated Financial Statements </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin532389_1">Report of Independent Registered Public Accounting Firm</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin532389_2">Consolidated Balance Sheets as of December&nbsp;31, 2012 and 2011</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin532389_3">Consolidated Statements of Operations for the Years Ended December&nbsp;31, 2012 and
2011</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin532389_4">Consolidated Statements of Shareholders&#146; Equity (Deficit) for the Years Ended December&nbsp;
31, 2012 and 2011</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin532389_5">Consolidated Statements of Cash Flows for the Years Ended December&nbsp;31, 2012 and
2011</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin532389_6">Notes to Consolidated Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Unaudited Condensed Consolidated Financial Statements</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin532389_7">Condensed Consolidated Balance Sheets as of March&nbsp;31, 2013 and 2012</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin532389_8">Condensed Consolidated Statements of Operations for the Three Months Ended March&nbsp;31, 2013 and
2012</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin532389_9">Condensed Consolidated Statements of Cash Flows for the Three Months Ended March&nbsp;31, 2013 and
2012</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin532389_10">Notes to Condensed Consolidated Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U><A NAME="fin532389_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
</U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the Shareholders and </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Board
of Directors of </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen, Inc. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have audited the accompanying consolidated balance sheets of AxoGen, Inc. as of December&nbsp;31, 2012 and 2011, and the related consolidated statements of operations, shareholders&#146; equity
(deficit), and cash flows for the years then ended. These consolidated financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these financial statements based on our audit.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an
audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of
expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures
in the consolidated financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall consolidated financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In our opinion, the consolidated financial statements referred to above present fairly, in
all material respects, the financial position of AxoGen, Inc. as of December&nbsp;31, 2012 and 2011, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the
United States of America. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ LURIE BESIKOF LAPIDUS &amp; COMPANY, LLP </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Minneapolis, Minnesota </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;12, 2013 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AXOGEN, INC. </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin532389_2"></A>CONSOLIDATED BALANCE SHEETS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2012 and 2011 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,<BR>2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,<BR>2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current assets:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,907,401</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,190,781</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,050,089</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">797,654</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventory</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,151,109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,760,540</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid expenses and other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">187,256</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">133,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total current assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,295,855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,882,475</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Property and equipment, net</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108,534</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">247,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Goodwill</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">169,987</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Intangible assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">573,731</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">899,480</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Deferred financing costs</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,252,443</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">295,276</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,230,563</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,495,042</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Liabilities and Shareholders&#146; Equity (Deficit)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current liabilities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable and accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,479,752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,585,100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current portion of long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151; &nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">434,734</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total current liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,479,752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,019,834</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Long-term debt</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,403,737</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note Payable &#151; Revenue Interest Purchase Agreement</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,580,252</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,060,004</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,423,571</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Shareholders&#146; equity (deficit):</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock, $.01 par value; 50,000,000 shares authorized; 11,122,573 and 11,062,188 shares issued and
outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">111,226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">110,622</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional paid-in capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,908,226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,391,784</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(57,848,893</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(48,430,935</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total shareholders&#146; equity (deficit)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,829,441</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,071,471</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,230,563</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,495,042</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:237px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-3
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AXOGEN, INC. </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin532389_3"></A>CONSOLIDATED STATEMENTS OF OPERATIONS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Years ended December&nbsp;31, 2012 and 2011 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Revenues</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,691,704</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,849,470</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cost of goods sold</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,961,877</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,426,544</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gross profit</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,729,827</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,422,926</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Costs and expenses:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales and marketing</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,883,953</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,378,694</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,427,211</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">697,355</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,220,599</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,315,604</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total costs and expenses</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,531,763</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,391,653</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Loss from operations</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,801,936</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,968,727</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other income (expense):</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,391,342</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,094,657</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense &#151; deferred financing costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(986,844</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,223,126</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in fair value of warrant liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,305</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,972</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,985</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total other income (expense)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,354,214</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,250,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Loss before income taxes</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,156,150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,219,220</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Income tax benefit</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">738,192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net Loss</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,417,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,219,220</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preferred Stock dividends (assumes all paid)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,028,351</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss available to common shareholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,417,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,247,571</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted Average Common Shares outstanding &#151; basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,089,425</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,697,390</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss Per Common share &#151; basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.77</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:235px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-4
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AXOGEN, INC. </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin532389_4"></A>CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#146; EQUITY (DEFICIT) </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Years ended December&nbsp;31, 2012 and 2011 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Series A Convertible</I></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Preferred
Stock</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Common Stock</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Additional<BR>Paid-in</I></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Capital
</I></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Accumulated</I></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Deficit</I></FONT>
</TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Total<BR>Stockholders&#146;</I></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Deficit
</I></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Shares</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Amount</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Shares</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Amount</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance,</B> December&nbsp;31, 2010</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,544,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,125,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,205,624</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,056</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,934,980</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(38,183,364</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(27,111,328</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">250,044</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">250,044</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercise of stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">98,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">987</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,480</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director Stock Compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,275</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">273</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">74,727</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Conversion of preferred stock, debt, and accrued interest into Common Stock and shares exchange in Merger</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,544,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,125,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,001,854</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,447,936</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,372,955</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preferred Stock dividend payable forfeited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,076,729</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,076,729</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrant Liability forfeited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,607,510</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,607,510</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Merger Closing &#151; LecTec shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,305,026</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43,050</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,804,866</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,847,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">423,709</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,237</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">995,763</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">173,736</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">173,736</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series B preferred stock dividends</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(292,330</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(292,330</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series C preferred stock dividends</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(515,577</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(515,577</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series D preferred stock dividends</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(220,444</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(220,444</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,219,220</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,219,220</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance,</B> December&nbsp;31, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,062,188</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">110,622</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,391,784</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(48,430,935</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,071,471</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">495,077</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">495,077</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercise of stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58,340</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">583</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,069</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,652</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock Grant for Services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cancellation of shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,455</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,946</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,999</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Merger Closing &#151; Fractional shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,417,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,417,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance,</B> December&nbsp;31, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,122,573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">111,226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,908,226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(57,848,893</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,829,441</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:50px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-5
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AXOGEN, INC. </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin532389_5"></A>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Years ended December&nbsp;31, 2012 and 2011 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from operating activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,417,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,219,220</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjustments to reconcile net loss to net cash used for operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">187,749</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">273,528</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amortization of intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">127,080</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67,147</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss on impairment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">299,654</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss on abandonment of license</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">147,826</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amortization of deferred financing costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">352,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,223,126</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amortization of debt discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">161,529</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,643</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">495,077</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">250,044</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Directors Stock Compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock grant for service</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cancellation of shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,999</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in fair value of warrant liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(62,305</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest added to note payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">780,252</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,562</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in assets and liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(252,435</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(368,954</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventory</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,390,570</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">142,249</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid expenses and other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(53,757</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,070</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable and accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(105,348</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500,820</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash used for operating activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,661,858</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,079,290</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from investing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchase of property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(48,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,610</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acquisition of intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(78,825</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(68,856</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash acquired with Merger</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,201,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash (used for) provided by investing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(127,284</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,112,172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from financing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from issuance of long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from issuance of note payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,961,294</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from issuance of common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repayments of long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(161,292</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,732,857</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Debt issuance costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,309,834</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(434,772</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from exercise of stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,652</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,480</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Merger</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash provided by financing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,505,762</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,358,851</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net increase in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,716,620</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,391,733</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash and cash equivalents,</B> beginning of year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,190,781</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,799,048</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash and cash equivalents,</B> end of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,907,401</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,190,781</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Supplemental disclosures of cash flow activity:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash paid for interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">649,108</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,029,753</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Supplemental disclosure of non-cash investing and financing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payments of long term debt with proceeds from note payable (this amount represents a payment made by PDL directly to MidCap
Financial SBIC, LP)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,838,706</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> &#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Conversion of preferred stock, convertible debt and accrued interest into common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,497,955</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accretion of dividends of Series B preferred stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">292,330</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accretion of dividends of Series C preferred stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">515,577</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accretion of dividends of Series D preferred stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">220,444</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preferred stock dividend payable forfeited with the Merger</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,076,729</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrant Liability forfeited with the Merger</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,607,510</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Debt discount related to warrants issued with debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">173,736</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net assets acquired on Merger</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,847,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Note and accrued interest retired with the Merger</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,555,562</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Directors stock compensation included in prepaid expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-6
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AXOGEN, INC. </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin532389_6"></A>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2012 and 2011 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Basis of Presentation </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying consolidated financial statements include the accounts of AxoGen, Inc. (the &#147;Company&#148; or &#147;AxoGen&#148;)
and its wholly owned subsidiary AxoGen Corporation (&#147;AC&#148;) as of December&nbsp;31, 2012 and December&nbsp;31, 2011 and the years then ended. The Company&#146;s consolidated financial statements have been prepared in accordance with
accounting principles generally accepted in the United States of America. All significant intercompany accounts and transactions have been eliminated in consolidation. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Organization and Business </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Business Summary </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;30, 2011, LecTec Corporation (&#147;LecTec&#148;) completed its business combination with AC in accordance with the terms of an
Agreement and Plan of Merger, dated as of May&nbsp;31, 2011, by and among LecTec, Nerve Merger Sub Corp., a subsidiary of LecTec (&#147;Merger Sub&#148;), and AC, which the parties amended on September&nbsp;30, 2011 and August&nbsp;9, 2011 (as
amended, the &#147;Merger Agreement&#148;). Pursuant to the Merger Agreement, Merger Sub merged with and into AC, with AC continuing after the merger as the surviving corporation and a wholly owned subsidiary of LecTec (the &#147;Merger&#148;).
Immediately following the Merger, LecTec changed its name to AxoGen, Inc. In October 2011, the Company moved its corporate headquarter facilities (principal executive office) from Texarkana, Texas to 13859 Progress Blvd., Suite 100, Alachua, Florida
32615. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the Merger, </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">all outstanding AC convertible securities were converted into shares of AC common stock and exchanged for shares of AxoGen, Inc. common stock;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">all outstanding AC warrants expired unexercised; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">all outstanding shares of AC common stock, including those issued upon conversion of AC convertible securities, were exchanged for shares of AxoGen,
Inc. common stock at a ratio of one share of AC common stock for 0.03727336 share of AxoGen, Inc. common stock; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">all outstanding options to purchase shares of AC common stock were exchanged for options to purchase shares of AxoGen, Inc. common stock at a ratio of
one option to purchase shares of AC common stock for an option to purchase 0.03727336 share of AxoGen, Inc. common stock. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A
total of 6,221,077 shares of the Company&#146;s common stock were issued in share exchange, and an additional 558,267 shares of the Company&#146;s common stock were reserved for issuance upon exercise of AC stock options which were converted into
the Company&#146;s stock options. Upon completion of the Merger, all AC securities were cancelled. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Immediately following the completion of
the Merger, former AC shareholders owned approximately 56.8% of the outstanding common stock of the Company, LecTec shareholders owned approximately 39.4% of the outstanding common stock of the Company, and certain investors owned the remaining 3.8%
of the outstanding common stock of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For accounting purposes, AC was identified as the acquiring entity and LecTec as the acquired
entity. The merger was accounted for using the purchase method of accounting for financial reporting purposes. The purchase method requires the identification of the acquiring entity, based on the criteria of Accounting Standards Codification
805-10-55-12, Accounting for Business Combinations. Under purchase accounting, the assets and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-7
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
liabilities of an acquired company (LecTec) as of the effective date of the acquisition were recorded at their respective estimated fair values and added to those of the acquiring company.
Accordingly, the consolidated financial statements and related footnote disclosures presented for periods prior to the Merger are those of AC alone. The consolidated Statement of Operations for the year ended December&nbsp;31, 2011 includes the
operations and cash flows of AC through September&nbsp;30, 2011 and the combined operations and cash flows of AC and LecTec subsequent to the Merger. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The common stock of AC has been retrospectively adjusted to reflect the exchange ratio of one share of AC common stock for 0.03727336 share of the Company&#146;s common shares as established in the Merger
Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company is a regenerative medicine company with a portfolio of proprietary products and technologies for
peripheral nerve reconstruction and regeneration. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. In order to improve surgical
reconstruction and regeneration of peripheral nerves, the Company has developed and licensed technologies which are used in its products. Its product portfolio includes Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, which the Company believes is the first and only commercially available allograft nerve for bridging nerve discontinuities (a gap created when the nerve
is severed), AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and
AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector that protects nerves during the body&#146;s healing process after surgery. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Summary of Significant Accounting Policies </B></FONT></TD></TR></TABLE>

 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Revenue Recognition </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds.
Revenues for manufactured products and products sold under a distribution agreement are recognized when the product is delivered to the customer, at which time title passes to the customer. Once product is delivered, the Company has no further
performance obligations. Delivery is defined as delivery to a customer location or segregation of product into a contracted distribution location. At such time, this product cannot be sold to any other customer. Fees charged to customers for
shipping are recognized as revenues when products are shipped to the customer or end user. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Cash and Cash Equivalents and Concentration </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to
be cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances and does not believe it is
not exposed to any significant credit risk on cash and cash equivalents. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Accounts Receivable and Concentration of Credit Risk </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts receivable are carried at the original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts on
a monthly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer&#146;s financial condition, credit history and current economic conditions. Accounts
receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received. As of December&nbsp;31, 2012 and December&nbsp;31, 2011, there were no amounts deemed uncollectible and there
was no allowance for doubtful accounts recorded. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Concentrations of credit risk with respect to accounts receivable are limited because a
large number of geographically diverse customers make up the Company&#146;s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals, credit limits and monitoring procedures. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-8
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Inventories </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">Inventories are comprised of implantable tissue, nerve grafts,
AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector, AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector, and supplies that are valued at the lower of cost (first-in, first-out) or market and consist of the following: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,<BR>2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,<BR>2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finished goods</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,143,176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,374,817</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Work in process</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">145,156</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">145,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Raw materials</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">862,777</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">240,423</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,151,109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,760,540</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventories are net of reserve of $537,798 and $433,706 at December&nbsp;31, 2012 and 2011, respectively </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Property and Equipment </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets as follows: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furniture and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2-5&nbsp;years</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Leasehold improvements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5&nbsp;years&nbsp;(or&nbsp;lease&nbsp;term&nbsp;if&nbsp;less)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Processing equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5-7&nbsp;years</FONT></TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Major additions and improvements are capitalized, while replacements, maintenance and repairs, which do not improve or extend the life
of the respective assets, are expensed as incurred. When assets are retired or otherwise disposed of, related costs and accumulated depreciation and amortization are removed and any gain or loss is reported as other income or expense. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Intangible Assets </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Intangible assets consist primarily of license agreements for exclusive rights to use various patented and <FONT STYLE="white-space:nowrap">patent-pending</FONT> technologies described in Note 6 and other
costs related to the license agreements, including patent prosecution and protection costs. Such costs are capitalized and amortized on a straight-line basis over the underlying terms of the license agreements or estimated useful life of patents,
ranging from 5 to 20 years. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Impairment of Long-lived Assets, Including License Agreements
</U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount
of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted cash flows expected to be generated by the asset. If such assets are considered to
be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. For the year ended December&nbsp;31, 2012, the Company recorded an impairment loss of $129,667;
there was no impairment for the year ended December&nbsp;31, 2011. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Goodwill </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Goodwill represents the excess of the purchase price over the fair value of net assets acquired. Goodwill is not amortized, but is tested for impairment annually. The Company utilizes the income approach
in estimating fair value. The Company&#146;s 2012 annual goodwill impairment analysis indicated a significant decrease in the carrying value of goodwill, due to declines in the associated revenues, resulting in a $169,887 impairment loss being
recorded for the year ended December&nbsp;31, 2012; there was no impairment for the year ended December&nbsp;31, 2011. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-9
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Deferred Financing Costs </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company capitalizes all third-party costs incurred, including equity-based payments, associated with the issuance of long-term debt. The costs are amortized to interest expense over the term of the
debt using the effective interest method. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Advertising </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Advertising costs are expensed as incurred. Advertising costs were approximately $56,000 and $17,000 for 2012 and 2011, respectively, and are included in sales and marketing expense on the accompanying
consolidated statements of operations. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Research and Development Costs </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and Development costs are expensed as incurred. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Income Taxes </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company has not recorded current income tax expense due to the generation of net operating losses. Deferred income taxes are accounted for using the balance sheet approach which requires recognition
of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not
that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that future tax benefit will not be realized. In addition, future utilization of the available
net operating loss carryforward may be limited under Internal Revenue Code Section&nbsp;382 as a result of changes in ownership. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company
identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing
authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax
benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company&#146;s remaining open tax years subject to examination by the Internal Revenue Service
include the years ended December&nbsp;31,&nbsp;2009 through 2012; there currently are no examinations in process. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Preferred Stock </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company accounted for its preferred stock under the provisions of Accounting Standards Codification on <I>Distinguishing Liabilities from Equity</I>,
which sets forth the standards for how an issuer classifies and measures certain financial instruments with characteristics of both liabilities and equity. This standard requires an issuer to classify a financial instrument that is within the scope
of the standard as a liability or temporary equity if such financial instrument embodies an unconditional obligation to redeem the instrument at a specified date and/or upon an event certain to occur. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to conversion in connection with the Merger, all or any number of the Series B, Series C, and Series D preferred stock was originally redeemable by
a majority of preferred shareholder approval at any time after January&nbsp;7, 2015 at a redemption price determined in accordance with the Company&#146;s Certificate of Incorporation, plus accrued and unpaid dividends. The Company has determined
that its Series B, Series C, and Series D preferred stock required temporary equity classification as its obligation to redeem these instruments were outside the control of the Company. Permanent equity classification was not currently applicable as
the preferred stock was not currently redeemable but may become so in the future. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-10
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Fair Value of Financial Instruments </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these
instruments. These financial instruments include cash, accounts receivable, accounts payable and accrued expenses. The fair value of the Company&#146;s long-term debt approximates its carrying value based upon current rates available to the Company.
</FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Stock-Based Compensation </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation cost related to stock options granted under the AC 2002 Stock Option Plan and AxoGen 2010 Stock Incentive Plan (see Note 10) is
measured at grant date, based on the fair value of the award, and is recognized as an expense over the employee&#146;s requisite service period. The Company estimates the fair value of each option award issued under the Plan on the date of grant
using a Black-Scholes-Merton <FONT STYLE="white-space:nowrap">option-pricing</FONT> model that uses the assumptions noted in the table below. The Company estimates the volatility of its common stock at the date of grant based on the volatility of
comparable peer companies which are publicly traded, for the periods prior to the merger, and based on the Company&#146;s common stock for periods subsequent to the merger. The Company determines the expected life based on historical experience with
similar awards, giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining
term approximately equal to the expected life of the award. The Company has never paid any cash dividends on its common stock and does not anticipate paying any cash dividends in the foreseeable future. The Company used the following
weighted-average assumptions for options granted during the year ended December&nbsp;31: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:86pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Years ended December&nbsp;31,</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected term (in years)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected volatility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">117.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk free rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected dividends</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company estimates forfeitures when recognizing compensation expense and this estimate of forfeitures is adjusted over the requisite
service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative catch-up adjustment, which is recognized in the period of
change, and also impact the amount of unamortized compensation expense to be recognized in future periods. The Company did not apply a forfeiture allocation to its unvested options outstanding during the years ended December&nbsp;31, 2012 and 2011
as they were deemed insignificant. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U><B>Earnings (Loss) Per Common Share</B> </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Earnings (loss) per common share (EPS) is calculated for basic EPS by dividing net income (loss) available to common stockholders by the
weighted average number of common shares outstanding during the period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The basic loss attributable to common stockholders was computed as
follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Years Ended December&nbsp;31,</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,417,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,219,220</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less preferred dividends</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,028,351</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss attributable to common stockholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,417,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,247,571</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">There were no dilutive instruments as of December&nbsp;31, 2012 and 2011. The basic and diluted weighted average shares outstanding
were 11,089,425 and 3,697,390 for the years ended December&nbsp;31, 2012 and 2011. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-11
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Use of Estimates </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual
results could differ from those estimates. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Recent Accounting Pronouncements </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s management has reviewed and considered all recent accounting pronouncements and believe there are none that could potentially have a
material impact on the Company&#146;s consolidated financial condition, results of operations, or disclosures. </FONT></P>
 <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Merger </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;30, 2011, LecTec completed its business combination with AC pursuant to the terms of the Merger Agreement (see Note
2). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition. The
total acquisition price of $11,847,916 has been allocated as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> 7,201,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,483</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notes and accrued interest receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,555,562</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Goodwill</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">169,987</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">260,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable and accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(379,754</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total purchase price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,847,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth the unaudited pro forma results of the Company as if the Merger had taken place on the first day of the
period presented. These combined results are not necessarily indicative of the results that may have been achieved had the companies always been combined. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Year
Ended</FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,</FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1">2011</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,914,938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net Loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,610,775</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic and diluted net loss per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.79</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average shares &#151; basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,957,705</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-12
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Property and Equipment </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property and equipment consist of the following: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,<BR>2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,<BR>2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furniture and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">572,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">535,183</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Leasehold improvements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,564</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,564</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Processing equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">995,815</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">988,716</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less: accumulated depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,502,304</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,318,639</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108,534</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">247,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Intangible Assets </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s intangible assets consist of the following: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,<BR>2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,<BR>2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">License agreements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">772,230</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">899,231</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,429</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">291,907</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less: accumulated amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(261,928</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(291,658</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Intangible assets, net</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">573,731</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">899,480</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">License agreements are being amortized over periods ranging from 17-20 years. Patent costs are being amortized over three years.
Pending patent costs are not amortizable. Amortization expense for 2012 and 2011 was approximately $127,000 and $67,000, respectively. As of December&nbsp;31, 2012, future amortization of license and patent agreements is expected to be $58,400 for
2013 $55,300 for 2014, $46,000 for 2015, 2016 and 2017. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2012 the Company determined that the carrying value of certain patents were not
recoverable and exceeded their estimated fair value. As a result, the Company recorded an impairment loss of $129,667 to reduce these patents to their estimated fair value. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>License Agreements </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has entered into license agreements (the
&#147;License Agreements&#148;) with the University of Florida Research Foundation (&#147;UFRF&#148;) and University of Texas at Austin (&#147;UTA&#148;) and Emory University (&#147;Emory&#148;). Under the terms of the License Agreements, the
Company acquired exclusive worldwide licenses for underlying technology used in repairing and regenerating nerves. The licensed technologies include the rights to issued patents and patents pending in the United States and international markets. The
effective term of the License Agreements extends through the term of the related patents and the agreements may be terminated by the Company with 60 days prior written notice. Additionally, in the event of default, licensors may terminate an
agreement if the Company fails to cure a breach after written notice. The License Agreements contain the key terms listed below: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen pays royalty fees ranging from 1% to 3% under the License Agreements based on net sales of licensed products.&nbsp;One of the agreements also
contains a minimum royalty of $12,500 per quarter, which may include a credit in future quarters in the same calendar year for the amount the minimum royalty exceeds the royalty fees.&nbsp;Also, when AxoGen pays royalties to more than one licensor
for sales of the same product, a royalty stack cap applies, capping total royalties at 3.75%;</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under one of the agreements, if AxoGen does not achieve certain regulatory milestones, which AxoGen has not achieved, AxoGen would owe an annual
license maintenance fee starting on August&nbsp;31, 2012 of $120,000, escalating to $240,000 on August&nbsp;31, 2013 and August&nbsp;31, 2014. In 2012, AxoGen decided to abandon the license and as a result recorded a $147,826 loss on abandonment of
license. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-13
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">If AxoGen sublicenses technologies covered by the License Agreements to third parties, AxoGen would pay a percentage of sublicense fees received from
the third party to the licensor.&nbsp;Currently, AxoGen does not sublicense any technologies covered by License Agreements. The Company is not considered a sub-licensee under the License Agreements and does not owe any sublicensee fees for its own
use of the technologies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen reimburses the licensors for certain legal expenses incurred for patent prosecution and defense of the technologies covered by the License
Agreements; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Currently, under one of the License Agreements, AxoGen would owe a $15,000 milestone fee upon receiving a Phase II Small Business Innovation Research
or Phase II Small Business Technology Transfer grant involving the licensed technology. The Company has not received either grant and does not owe such a milestone fee.&nbsp;Other milestone fees are due if AxoGen develops certain pharmaceutical or
medical device products under the License Agreements. No such products are currently under development. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Royalty fees were
approximately $167,000 and $115,000 during 2012 and 2011 and are included in sales and marketing expense on the accompanying consolidated statements of operations. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Long-Term Debt / Note Payable </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long-term debt / note payable consists of the following: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,<BR>2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,<BR>2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loan and Security Agreement with financial institutions for aggregate of $5,000,000 with 9.9% interest payable monthly through
September 2012; principal and interest payable monthly for the 30 months thereafter maturing on April&nbsp;1, 2015, collateralized by all the assets of the Company and subject to certain financial covenant restrictions including minimum revenue
requirements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> &#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue Interest Purchase Agreement with PDL for aggregate of $20,800,000 with amounts payable monthly at 9.95% of Net Revenues
through September 2014; and the greater of (i)&nbsp;9.95% of product revenue or (ii)&nbsp;specific quarterly amounts varying from approximately $1.3 million to $2.5 million per quarter through September 2020. The minimum annual payment amounts are
as follows: 2014 - $1,250,805, 2015 - $6,781,440, 2016 - $9,232,642, 2017 and 2018 - $9,000,000, 2019 - $9,063,000 and 2020 - $6,939,000.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,580,252</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,580,252</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less unamortized debt discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(161,529</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(434,734</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Long-term portion</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,580,252</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,403,737</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Note Payable </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;5, 2012, AxoGen entered into a Revenue Interests Purchase Agreement (the &#147;Royalty Contract&#148;) with PDL, pursuant to which the Company sold to PDL the right to receive specified
royalties of 9.95% on the Company&#146;s Net Revenues (as defined in the Royalty Contract) generated by the sale, distribution or other use of AxoGen&#146;s products Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve
Connector and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector. The Royalty Contract has a term of eight years. Under the Royalty
Contract, PDL is to receive royalty payments based on a royalty rate of 9.95% of the Company&#146;s Net Revenues, subject to certain agreed upon minimum payment requirements of approximately $1.3 to $2.5 million per quarter which begin in the fourth
quarter of 2014 through the third quarter of 2020 as provided in the Royalty Contract. The total consideration PDL paid to the Company was $20,800,000 (the &#147;Funded Amount&#148;), including $19,050,000 PDL paid to the Company on October&nbsp;5,
2012, and $1,750,000 PDL paid to the Company on August&nbsp;14, 2012 pursuant to an Interim Revenue Interest Purchase Agreement between the Company and PDL, dated August&nbsp;14, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-14
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
2012 (the &#147;Interim Royalty Contract&#148;). Upon the closing (the &#147;Closing&#148;) of PDL&#146;s purchase of the specified royalties described above, which was concurrent with the
execution of the Royalty Contract, the Interim Royalty Contract was terminated. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company records interest using its best estimate of the
effective interest rate, currently the Company is accruing interest using the specified internal rate of return of the put option of 20%. From time to time, the Company will reevaluate the expected cash flows and may adjust the effective interest
rate. Determining the effective interest rate requires judgment and is based on significant assumptions related to estimates of the amounts and timing of future revenue streams. Payments made to PDL consist of interest and principal. Based on
current calculations of repayments, using actual payments to date, an estimate of future revenue streams and an estimated effective rate of 20% (calculated using the put rate in the agreement), principal payments are scheduled to begin in April
2015. All payments made prior to this date are interest only payments. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Put Option </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Royalty Contract, on October&nbsp;5, 2016, or in the event of the occurrence of a material adverse event, our transfer of
revenue interest or substantially all of our interest in the products or AxoGen&#146;s bankruptcy or material breach of the Royalty Contract, PDL may require AxoGen to repurchase the Assigned Interests at the &#147;Put Price.&#148; The Put Price is
equal to the sum of (i)&nbsp;an amount that, when paid to PDL, would generate a specified internal rate of return to PDL of 20% on the Funded Amount, taking into consideration payments made to PDL by the Company, and (ii)&nbsp;any &#147;Delinquent
Assigned Interest Payment&#148; (as defined in the Royalty Contract) the Company owed to PDL. </FONT></P>  <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Change of Control; Call
Option </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, in the event of a &#147;Change of Control&#148; (as defined in the Royalty Contract), the Company must
repurchase the assigned Interests from PDL for a repurchase price equal to the &#147;Change of Control Price&#148; on or prior to the third business day after the occurrence of the Change of Control. The Change of Control Price is equal to the sum
of (i)&nbsp;an amount that, when paid to PDL, would generate a specified internal rate of return to PDL of thirty-two and one half percent (32.5%) on the Funded Amount, taking into consideration payments made to PDL by the Company, and (ii)&nbsp;any
&#147;Delinquent Assigned Interest Payment&#148; (as defined in the Royalty Contract) the Company owed to PDL. In addition, at any time after October&nbsp;5, 2016, the Company, at its option, can call the Royalty Contract for a price equal to the
Change of Control Price. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Board Designee </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under the Royalty Contract, during the term of the Royalty Contract, PDL is entitled to designate, and AxoGen shall appoint an individual designated by PDL, who shall serve on the Board of Directors of
the Company (the &#147;Board&#148;) until the Company&#146;s 2013 Annual Meeting of Shareholders (the &#147;2013 Annual Meeting&#148;). For the 2013 Annual Meeting and each annual meeting thereafter during the term of the Royalty Contract, the Board
shall nominate and recommend the PDL designee as a director nominee to serve on the Board until the next annual meeting and shall include such nomination in AxoGen&#146;s proxy statement for the 2013 Annual Meeting and each annual meeting
thereafter, provided that the election of the PDL designee is subject to shareholders&#146; approval. Should at any time there become a vacancy on the Board as a result of (i)&nbsp;the resignation, death or removal of the PDL designee or
(ii)&nbsp;such PDL designee failing to obtain the requisite approval of the Company&#146;s shareholders at any annual or special meeting of the Company&#146;s shareholders and where no other individual is elected to such vacancy, PDL shall have the
right to designate an individual to fill such vacancy, and AxoGen shall take such actions necessary to appoint, such individual to the Board. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Preemptive Rights </I></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Royalty Contract, PDL has preemptive
rights with respect to certain new issuances of AxoGen&#146;s equity securities and securities convertible, exchangeable or exercisable into such equity securities. </FONT></P>  <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Restriction on Dividends </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Royalty Contract, during the period
from the October&nbsp;5, 2012 to December&nbsp;4, 2016 (or the payment of the Put Price in the event PDL exercises its put option on or prior to December&nbsp;4, 2016), AxoGen </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-15
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
shall not, nor shall it permit any subsidiary to, declare, pay or make any dividend or distribution on any shares of the common stock or preferred stock of such entity (other than dividends or
distributions payable in its stock, or split-ups or reclassifications of its stock) or apply any of its funds, property or assets to the purchase, redemption or other retirement of any common or preferred stock, or of any options to purchase or
acquire any such shares of common or preferred stock of any such entity (collectively, &#147;Restricted Payments&#148;), except that: (i)&nbsp;each subsidiary may make direct or indirect Restricted Payments to the Company; and (ii)&nbsp;the Company
and each subsidiary may purchase, redeem or otherwise acquire Equity Interests issued by it solely with the proceeds received from the substantially concurrent issue of new shares of its common stock or other common Equity Interests. For purposes of
the Royalty Contract, &#147;Equity Interests&#148; of any person means any and all shares, rights to purchase, options, warrants, general, limited or limited liability partnership interests, member interests, participation or other equivalents of or
interest in (regardless of how designated) equity of such entity, whether voting or nonvoting, including common stock, preferred stock, convertible securities or any other &#147;equity security&#148; (as such term is defined in Rule 3a11-1under the
Securities Exchange Act of 1934, as amended). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Guarantee and Collateral Agreement </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the Royalty Contract, on October&nbsp;5, 2012, AxoGen and AC, entered into a Guarantee and Collateral Agreement (the
&#147;Guarantee and Collateral Agreement&#148;) with PDL, pursuant to which (i)&nbsp;AC unconditionally and irrevocably guarantees to PDL the prompt and complete payment and performance by AxoGen when due of the &#147;Secured Obligations,&#148;
which include the Company&#146;s obligations under the Royalty Contract, and any other obligations that AxoGen may owe to PDL under the Royalty Contract and other transaction documents; and (ii)&nbsp;each of the Company and AC grants to PDL a
security interest in certain collateral as specified in the Guarantee and Collateral Agreement for the prompt and complete payment and performance when due of the Secured Obligations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>Long-Term Debt </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;30, 2011, the Company entered into the Loan and
Security Agreement with MidCap Financial SBIC, LP (&#147;MidCap&#148;), as administrative agent, and the Lenders listed on Schedule 1 thereto (the &#147;MidCap Loan&#148;). The credit facility under the MidCap loan had a principal amount of $5.0
million and a term of 42 months, and is subject to prepayment penalties. Under the MidCap Loan, AxoGen was required to make interest only payments for the first 12 months, and payments of both interest and straight line amortization of principal for
the remaining 30 months. The interest rate was 9.9%&nbsp;per annum, and interest was computed on the basis of a 360-day year and the actual number of days elapsed during which such interest accrues. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The agreement contained customary affirmative and negative covenants, including, without limitation, (i)&nbsp;covenants requiring AxoGen to comply with
applicable laws, provide to MidCap copies of AxoGen&#146;s financial statements, maintain appropriate levels of insurance, protect, defend and maintain the validity and enforceability of AxoGen&#146;s material intellectual property,
(ii)&nbsp;covenants restricting AxoGen&#146;s ability to dispose of all or any part of its assets (subject to certain exceptions), engage in other lines of business, change its senior management, enter into merger or consolidation transactions,
incur or assume additional indebtedness, or incur liens on its assets, and (iii)&nbsp;covenants requiring the Company to meet certain minimum Net Invoiced Revenue as defined in the agreement, or maintain a cash balance of 80% of the loan principal
amount. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The MidCap Loan was secured by all of AxoGen&#146;s assets. The lenders also received a ten-year warrant to purchase 89,686 shares of
AxoGen&#146;s common stock at $2.23 per share. The fair value of the warrant was $173,736 and was recorded as debt discount and was being amortized through interest expense using the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-16
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
effective interest method over the term of the debt. Amortization of debt discount was $12,207 for 2011. The Company also recorded $317,990 in deferred financing costs which were being amortized
over the term of the loan. Amortization of the deferred financing cost was $22,714 for 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;21, 2008, the Company entered into
a Loan and Security Agreement with two different lenders, as subsequently amended (the &#147;2008 Loan and Security Agreement&#148;), which provided for a loan with an aggregate principal amount of $7.5 million. The loan&#146;s maturity date was
October&nbsp;1, 2011. The loan bore interest at a rate of 18%&nbsp;per month, as amended, and was secured by all of the Company&#146;s assets. Upon the execution of the 2008 Loan and Security Agreement, the Company recorded $155,556 in deferred
financing costs which were being amortized through interest expense on the accompanying consolidated statements of operations over the life of the term note. Amortization of the deferred financing costs was $12,963 for 2011. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In conjunction with the 2008 Loan and Security Agreement, the Company also issued warrants to purchase a combined 280,803 shares of the Company&#146;s
Series C Preferred Stock, immediately exercisable at $0.7345 per share, expiring on May&nbsp;1, 2018. The fair value of the warrants was recorded as debt discount and was being amortized through interest expense using the effective interest method
over the term of the debt. Amortization of this debt discount was $11,436 during 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2010, the Company executed six amendments to
the 2008 Loan and Security Agreement, resulting in the issuance of a total of 28,561,272 additional warrants for the purchase of the Company&#146;s Series D preferred stock, immediately exercisable at $0.1198 per share, expiring on varying dates
during the year 2020. The total fair value of the warrants of $2,160,879 was recorded as deferred financing costs during 2010 and was being amortized through interest expense &#151; deferred financing costs on the accompanying consolidated statement
of operations. The Company recognized $990,792 in amortization of these costs for 2011. See additional discussion related to the accounting for the warrants at Note 9. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;11, 2011, the Company entered into a waiver and seventh amendment (the &#147;Amendment&#148;) to the 2008 Loan and Security Agreement. The Amendment waived the event of default resulting
from the failure to pay the balance due under the 2008 Loan and Security Agreement by March&nbsp;31, 2011, increased the annual interest rate to 18% beginning April&nbsp;1, 2011, and extended the maturity to the earlier of an acquisition event
(including the Merger discussed in Note 4), or October&nbsp;1, 2011. In connection with the Amendment, an event of default would occur if the Company fails to receive proceeds from equity and/or convertible subordinated debt financings of at least
$2.5 million by May&nbsp;31, 2011 and an additional $2.5 million by August&nbsp;31, 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;30, 2011, the Company paid the
entire outstanding loan balance under the 2008 Loan and Security Agreement. The Company also paid a loan pay off fee of $109,436 which is included in the amortization of deferred financing costs for 2011. The warrants issued to the holders of the
2008 Loan and Security Agreement (see Note 9) expired upon the effective date of the Merger. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>2010 Convertible Debt and Warrants
</U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 2010 Convertible Debt is convertible automatically into shares of conversion stock, defined in the agreement as a future
&#147;qualified next equity financing&#148;, or its Series C preferred stock. The debt is also convertible at the option of the Company in the event of a future equity financing which is not considered a &#147;qualified next equity financing&#148;.
The conversion price is 65% of the price per share paid at the next equity financing, as defined in the agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon issuance of the 2010
Convertible Debt, the Company recorded a total of $122,900 in deferred financing costs which were being amortized through interest expense on the accompanying consolidated statements of operations over the debt term. Amortization of the deferred
financing costs was $87,221 for 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the Merger on September&nbsp;30, 2011, the 2010 convertible debt of $1,338,455 and
$2,359,091 and accrued interest of $263,371 were converted into 2,581,963 shares of AC common stock using a conversion price of $0.0572 (65% of price per share paid at the next equity financing or $0.088) and 0.03727336 exchange ratio. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-17
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>2011 Convertible Debt </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On May&nbsp;3, 2011, the Company issued an 8% convertible note payable for $500,000 to LecTec related to the Merger. On May&nbsp;31, 2011, the Company issued additional convertible notes payable under the
same terms of which $2,000,000 was issued to LecTec and $500,000 was issued to certain AC shareholders. The notes were collateralized by all assets of the Company and subordinated to the Company&#146;s 2008 Loan and Security Agreement. Principal and
interest accrued under the note was due upon the earlier of June&nbsp;30, 2013 or a change in control other than in connection with the Merger. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;29, 2011, the Company issued an additional subordinated secured convertible promissory note in the principal amount of $2,000,000 to
LecTec and $500,000 to certain AC shareholders on the same terms as the $3,000,000 notes issued by the Company in May 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The $4,500,000
notes to LecTec were retired on September&nbsp;30, 2011 after the closing of the Merger. The $1,000,000 notes to certain AC shareholders were converted into 423,709 shares of AxoGen, Inc.&#146;s common stock using the $0.088 conversion price and
0.03727336 exchange ratio. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Stockholders&#146; Equity (Deficit) and Temporary Equity </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>AxoGen, Inc. Classes of Stock </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGen, Inc.&#146;s authorized capital stock consists of 50,000,000 shares, par value $0.01 per share. The authorized capital stock is divisible into the classes and series, has the designation, voting
rights, and other rights and preferences and is subject to the restrictions that the AxoGen Board of Directors may from time to time establish. Unless otherwise designated by the AxoGen Board of Directors, all shares are common stock. AxoGen has not
designated any shares other than common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the Merger, 32,709,676 shares of AC common stock were converted into
1,219,199 shares of AxoGen, Inc.&#146;s common stock using the 0.03727336 exchange ratio. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;30, 2011, AxoGen sold to certain
investors in a private placement 423,709 shares of common stock at $2.36 per share. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;10, 2011, each non-employee director of
AxoGen was granted 5,455 shares of AxoGen common stock, valued at $2.75 per share, in lieu of a cash retainer payment for the director&#146;s services through December&nbsp;31, 2012. The Company recorded $15,000 of directors fee included in general
and administrative expenses and $60,000 in prepaid expenses related to issuance of 27,275 shares of common stock to five directors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>AC
Classes of Stock </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>General </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">AC had authorized 133,000,000 shares of common stock with a $.00001 par value. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">AC had authorized
103,408,891 shares of preferred stock with a $.00001 par value which the Board of Directors is empowered to designate and issue in different series. At December&nbsp;31, 2010, the Board of Directors had designated and issued 2,544,750 shares of
Series A Preferred Stock; 17,065,217 shares of Series B Preferred Stock; 16,798,924 shares of Series C Preferred Stock and 67,000,000 shares of Series D Preferred Stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In connection with the Merger, on September&nbsp;30, 2011 each share of Series A, B, C and D convertible preferred stock, for a total of 53,555,857 shares, were converted into shares of AC common stock
and exchanged for 1,996,206 shares of AxoGen, Inc. common stock using the 0.03727336 exchange ratio. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-18
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Series A Convertible Preferred Stock </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2004, AC issued 2,544,750 shares of Series A Convertible Preferred Stock (&#147;Series A&#148;) at $0.4421 per share for an aggregate price of
$1,125,000. No dividends accrued or were payable on the Series A, except upon the declaration of dividends on AC&#146;s common stock, payable at a rate per share of Series A equal to the amount the holder would be entitled to receive had all of the
Series A been converted to AC common stock. Upon liquidation, Series A holders have preference to any distribution of any of the assets of AC to the holders of AC Common Stock after Series B, Series C, and Series D preferences have been paid. Series
A has no redemption option. Each share of Series A is convertible into AC common stock at any time at the option of the holder by dividing the Preferred Original Issue Price by the Conversion Price at the time of conversion, which as of
December&nbsp;31, 2010 is equal to the purchase price of $0.4421. The conversion price is subject to adjustment, as defined. The only election right for Series A is to vote along with AC common shareholders to elect two directors to the Board. Each
share of Series A has voting rights equal to the number of AC common shares as if converted. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Series B Convertible
Preferred Stock </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2006, AC issued 16,847,826 shares of Series B Convertible Preferred Stock (&#147;Series B&#148;) at $0.46 per share
for an aggregate price of $7,750,000. The holders of the Series B are entitled to receive a cash dividend in preference over shares of AC common stock and Series A shareholders of AC at a rate of 8% of the issued price, per annum. Upon liquidation,
the Series B holders have preference to any distributions of any of AC&#146;s assets equal to the Preferred Original Issue Price plus any unpaid dividends after Series C and Series D preferences have been paid. At any time on or after
January&nbsp;7, 2015, the Series B shareholders have the right to redeem shares equal to the redemption price upon written request of at least 55% of the holders of Series B. Each share of Series B is convertible into AC common stock at any time at
the option of the holder by dividing the Preferred Original Issue Price by the Conversion Price at the time of conversion, which as of December&nbsp;31, 2010 is equal to the purchase price of $0.46. The conversion price is subject to adjustment, as
defined. The holders of a majority of the Series B, C and D Preferred Stock have the right to elect three directors to the Board. Also, Series B, C and D will vote together with Series A and AC common shareholders to elect two directors to the
Board. Each share of Series B, C and D has voting rights equal to the number of AC common shares as if converted. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">AC is accreting dividends
on the Series B, based on the stated dividend rate of 8%&nbsp;per annum. The Series B dividends accreted for the year ended December&nbsp;31, 2011 was $292,329. A total of $3,152,603 in Series B dividends had been accreted as of September&nbsp;30,
2011 and were forfeited in accordance with the Merger. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;11, 2010, 7,065,217 shares of Series B, representing $3,250,000, were
converted into 263,344 shares of AC&#146;s common stock at the election of the shareholder. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Series C Convertible
Preferred Stock </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2007, AC issued 16,518,121 shares of Series C Convertible Preferred Stock (&#147;Series C&#148;) at $0.7345 per
share for an aggregate purchase price of $12,132,559. The holders of the Series C are entitled to receive a cash dividend in preference over shares of AC common stock, Series A and Series B shareholders of AC at a rate of 8% of the issued price, per
annum. Upon liquidation, the Series C holders have preference to any distributions of any of AC&#146;s assets equal to the Preferred Original Issue Price plus any unpaid dividends after Series D preferences have been paid. At any time on or after
January&nbsp;7, 2015, the Series C shareholders have the right to redeem shares equal to the redemption price upon written request of at least 60% of the holders of Series C. Each share of Series C is convertible into AC common stock at any time at
the option of the holder by dividing the Preferred Original Issue Price by the Conversion Price at the time of conversion, which as of December&nbsp;31, 2010 is equal to the purchase price of $0.7345. The conversion price is subject to adjustment,
as defined. The holders of a majority of the Series B, C and D have the right to elect three directors to the Board. Also, Series B, C and D will vote together with Series A and AC common shareholders to elect two directors to the Board. Each share
of Series B, C and D has voting rights equal to the number of AC common shares as if converted. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-19
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">AC is accreting dividends on the Series C, based on the stated dividend rate of 8%&nbsp;per annum. The
dividends accreted for the year ended December&nbsp;31, 2011 was $515,577. A total of $3,403,651 in Series C dividends had been accreted as of September&nbsp;30, 2011 and were forfeited in accordance with the Merger. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;11, 2010, 5,445,882 shares of Series C, representing $4,000,000, were converted into 202,986 shares of AC&#146;s common stock at the
election of the shareholder. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Series D Convertible Preferred Stock and Warrants </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;7, 2010, AC issued 39,156,876 shares of Series D Preferred Stock (&#147;Series D&#148;) at $0.1198 per share for an aggregate price of
$4,661,326, net of issuance costs of $29,667. Of the total shares issued, 16,694,489&nbsp;shares were issued for $2,000,000 in cash. The remaining 22,462,387 shares were issued in conjunction with the conversion of $2,617,000 of principal and
$73,994 of accrued and unpaid interest under the 2009 Convertible Debt (see Note 7). The holders of the Series D are entitled to receive a cash dividend in preference over all other shareholders of AC at a rate of 8% of the issued price, per annum.
Upon liquidation, the Series D holders have preference to any distributions of any of AC&#146;s assets equal to the Preferred Original Issue Price plus any unpaid dividends. At any time on or after January&nbsp;7, 2015, the Series D shareholders
have the right to redeem shares equal to the redemption price upon written request of at least 66 2/3% of the holders of Series D. Each share of Series D is convertible into AC common stock at any time at the option of the holder by dividing the
Preferred Original Issue Price by the Conversion Price at the time of conversion, which as of December&nbsp;31, 2010 is equal to the purchase price of $0.1198. The conversion price is subject to adjustment, as defined. The holders of a majority of
the Series B, C and D have the right to elect three directors to the Board. Also, Series B, C and D will vote together with Series A and AC common shareholders to elect two directors to the Board. Each share of Series B, C and D has voting rights
equal to the number of AC common shares as if converted. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">AC is accreting dividends on the Series D, based on the stated dividend rate of
8%&nbsp;per annum. Dividends accreted during the year ended December&nbsp;31, 2011 were $220,444. A total of $518,426 in Series D dividends had been accreted as of September&nbsp;30, 2011 and were forfeited in accordance with the Merger. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;11, 2010, 9,000,617 shares of Series D, representing $1,078,274, were converted into 335,483 of AC&#146;s common stock at the election
of the shareholder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In conjunction with the issuance of the Series D, AC also issued warrants for the purchase of 8,347,236 shares of
AC&#146;s Series D Preferred Stock, immediately exercisable at $0.1198 per share, expiring on January&nbsp;7, 2015. The investors paid additional consideration totaling $10,000 for the purchase of the warrants. The warrants are considered offering
costs related to the Series D issuance and their fair value of $517,529 was recorded net against proceeds on the issuance of the stock during 2010. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-20
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Preferred Stock Warrants and Warrant Liability </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Preferred Stock Warrants </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">At September&nbsp;30, 2011, the outstanding warrants to purchase the Company&#146;s Series C and Series D preferred stock which were issued in connection with certain financing arrangements and amendments
to existing financing arrangements were expired unexercised in connection with the Merger. Information relating to these warrants at December&nbsp;31, 2010 is summarized as follows: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:33pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Warrants</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Remaining<BR>Number<BR>Outstanding</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exercise&nbsp;Price</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series C Warrants-2008 Loan and Security Agreement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">280,803</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.7345</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series D Warrants-2009 Convertible Debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,368,948</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series D Warrants-Series D Preferred Stock Issuance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,347,236</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">*Series D Warrants-1</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Amendment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,243,362</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">*Series D Warrants-2</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">nd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Amendment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,694,558</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">*Series D Warrants-3</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">rd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Amendment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,462,227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">*Series D Warrants-5</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Amendment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,260,440</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">*Series D Warrants-6</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Amendment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,900,685</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,558,259</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrants issued to lenders in conjunction with amendments to 2008 Loan and Security Agreement (see&nbsp;Note&nbsp;7). </FONT></TD></TR></TABLE>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Warrant Liability </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The warrants issued in conjunction with the 2008 Loan and Security Agreement (see Note 7) are issuable for Series&nbsp;C preferred stock. The warrants issued in connection with the 2009 Convertible Debt
(see Note 7) and the Series&nbsp;D Preferred Stock (see Note 8) are issuable for Series D preferred stock. Both the Series C and Series&nbsp;D preferred stock are considered contingently redeemable based on the shareholders&#146; right to redeem the
shares on or after January&nbsp;7, 2015. In accordance with Accounting Standards Codification on <I>Distinguishing Liabilities from Equity</I>, since the warrants are indexed to contingently redeemable securities of the Company, they are classified
as liabilities upon issuance. As liability classified derivative financial instruments, the warrants are initially and subsequently required to be measured at their fair values as defined in Accounting Standards Codification on <I>Fair Value
Measurement.</I> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The change in fair value of the warrants between each reporting period is recorded in the statements of operations and was
estimated by the Company using a binomial lattice valuation model. The following assumptions were incorporated into the valuations for 2011 and 2010: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercise price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">$0.1198&nbsp;&#150;&nbsp;$0.7345</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Market value of stock at end of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">$0.01</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected dividend rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.00%</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected volatility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33.47%&nbsp;&#150;&nbsp;62.86%</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk-free interest rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.03%&nbsp;&#150;&nbsp;3.18%</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected life in years</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.40&nbsp;&#150;&nbsp;9.90</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shares underlying warrants outstanding classified as liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,558,259</FONT></TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company recorded income of $62,305 for 2011, as a result of the change in the fair value of warrant liability between reporting
periods which was recorded in other income (expense) on the consolidated statements of operations. The total balance of the warrant liability as of September&nbsp;30, 2011 of $2,607,510 was forfeited in accordance with the Merger. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-21
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Stock Options </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">AC has a 2002 Stock Option Plan (&#147;the AC Plan&#148;), which allows for issuance of incentive stock options and <FONT
STYLE="white-space:nowrap">non-qualified</FONT> stock options to employees, directors and consultants at an exercise price equal to or greater than fair market value. Under the provisions of the AC Plan, AC authorized for issuance 18,144,658 shares
for purchase pursuant to options. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen, Inc. has a AxoGen 2010 Stock Incentive Plan (the &#147;AxoGen Plan&#148;), which allows for
issuance of incentive stock options and non-qualified stock options to employees, directors and consultants at an exercise price equal to or greater than fair market value. On September&nbsp;27, 2011, LecTec amended and restated the AxoGen Plan to,
among other things, increase the number of shares of common stock authorized for issuance under the plan by 2,300,000 shares. The total number of shares authorized for issuance under the AxoGen Plan is 2,750,000 shares. As a result of the Merger,
options granted under the AC Plan were assumed by the Company so that each stock option pursuant to the AC Plan so assumed continued to have, and be subject to, the same terms and conditions of such stock option immediately prior to the Merger,
except that (i)&nbsp;each AC Plan stock option is exercisable for that number of shares of Company common stock equal to the product of the number of shares of AC common stock that were issuable upon exercise of such stock option immediately prior
to the Merger multiplied by the Closing Ratio (&#147;as defined in the Merger Agreement&#148;) and (ii)&nbsp;the per share exercise price for the shares of Company common stock issuable upon the exercise of such assumed stock option will be equal to
the quotient determined by dividing the exercise price per share of AC common stock at which such stock option was exercisable immediately prior to the Merger by the Closing Ratio. The options to employees typically vest 12.5% every six months over
a four-year period and those to directors and certain executive officers have vested 25%&nbsp;per quarter over one year or had no vesting period. Options issued to consultants vest over the service period ranging from three to ten years. Options
have terms ranging from seven to ten years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation expense was $495,077 and $250,044 for 2012 and 2011, respectively.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following is a summary of stock option activity: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Options</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Weighted<BR>Average<BR>Exercise&nbsp;Price</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Weighted<BR>Average<BR>Remaining<BR>Contractual<BR>Term(Years)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding at December&nbsp;31, 2010:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">447,659</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,141,952</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LecTec stock option from Merger</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">464,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Forfeited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,223</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.06</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercised</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(98,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding at December&nbsp;31, 2011:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,945,688</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">267,576</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Forfeited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(354,932</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercised</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(58,341</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding at December&nbsp;31, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,799,991</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercisable at December&nbsp;31, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">941,876</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.71</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The average fair value of options granted at market during 2012 and 2011 was $2.99 and $0.42 per option, respectively. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The intrinsic value of options exercised during the years ended December&nbsp;31, 2012 and 2011 was approximately $173,000 and $190,000, respectively.
The intrinsic value of options outstanding at December&nbsp;31, 2012 and 2011 was approximately $288,000 and $1,126,000, respectively. The intrinsic value of options exercisable at December&nbsp;31, 2012 and 2011 was approximately $0 and $391,000,
respectively. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-22
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the Merger, all outstanding options to purchase shares of AC Common Stock were exchanged
for options to purchase shares of AxoGen, Inc. common stock at a ratio of one to 0.03727336. The Company recorded $19,769 and $38,521 incremental cost in 2012 and 2011, respectively, related to this modification. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total future compensation expense related to nonvested awards is expected to be approximately $1,405,000 at December&nbsp;31, 2012 which is expected to
be recognized over a weighted average period of 3.04 years. The following table represents non-vested share-based payment activity with employees for the year ended December&nbsp;31, 2012 and 2011: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Number of<BR>Options</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Weighted<BR>Average&nbsp;Grant<BR>Date&nbsp;Fair&nbsp;Value</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nonvested options &#151; December&nbsp;31, 2010:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">325,575</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,141,952</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vested</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(195,099</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.87</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Forfeited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,223</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.004</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nonvested options &#151; December&nbsp;31, 2011:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,263,205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">267,576</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vested</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(317,734</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Forfeited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(354,932</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nonvested options &#151; December&nbsp;31, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">858,115</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Income Taxes </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and their
respective income tax basis, as measured by enacted state and federal rates as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Deferred tax assets:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net operating loss carryforwards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,182,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,065,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Charitable contributions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventory Reserves</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">365,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">163,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">361,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total deferred tax assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,602,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,592,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Deferred tax liabilities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(154,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(160,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(51,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(51,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total deferred tax liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(206,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(211,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net deferred tax assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,396,100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,381,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Valuation allowance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(18,396,100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(15,381,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2012, the Company had net operating loss carry forwards of approximately $48.3 million to offset future taxable
income which expire in various years through 2031. A valuation allowance is recorded to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that a portion or none of the deferred tax assets
will be realized. After consideration of all the evidence, including reversal of deferred tax liabilities, future taxable income and other factors, management has determined that a full valuation allowance is necessary as of December&nbsp;31, 2012
and 2011. The valuation allowance increased by $3,015,100 and $3,572,000 during 2012 and 2011, respectively. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-23
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The net income tax benefit of approximately $738,000 for 2012 was the result of the Company&#146;s ability
to utilize net operating losses and franchise tax adjustments which resulted in tax refunds. The Company had no income tax expense or income tax benefit for 2011 due to incurrence of net operating losses. The Company does not believe there are any
additional tax refund opportunities currently available. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Employee Benefit Plan </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company adopted the AxoGen Simple IRA plan in 2007. All full-time employees who have attained the age of 18 are eligible to
participate in the Plan. Eligibility is immediate upon employment and enrollment is available any time during employment. Participating employees may make annual pretax contributions to their accounts up to a maximum amount as limited by law. The
simple IRA plan requires the Company to make matching contributions of between 1% and 3% of the employee&#146;s annual salary as long as the employee participates in the Plan. Additionally, the matching has to be at least 3% for three of the first
five years of the Plan. Both employee contributions and Company contributions vest immediately. In 2012 and 2011, the Company match was 3% of the participating employee&#146;s annual salary. The Company contributed $102,189 and $66,687 in matching
funds during 2012 and 2011, respectively. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Commitments and Contingencies Operating Leases </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Operating Leases </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Company leases its lab space under one-year lease agreements, currently expiring in September 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Its corporate office space lease
agreement expires in April 2014. Estimated future minimum rental payments on the leases are as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Year ending December&nbsp;31</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">145,964</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34,015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">TOTAL</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">179,979</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total rent expense for the Company&#146;s leased office and lab space for the years ended December&nbsp;31, 2012 and 2011 was
approximately $176,000 and $171,000, respectively. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Service Agreements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In 2008, the Company entered into a biostorage and management services agreement with a vendor. The agreement specifies monthly administration fees, storage fees based on volume, and retrieval fees per
specimen based on lead times. The agreement can be terminated with 90 days written notice. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2009, the Company also entered into a two-year
tissue processing agreement with another vendor. Tissue processing fees are based on a per donor batch rate. The agreement requires minimum annual purchases of $160,000 and either party may terminate this agreement with six month written notice. In
2011 and 2012, the parties agreed to an extension for an additional twelve months and amended the agreement to provide for automatic twelve month renewals. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">In August 2008, the Company entered into an agreement to distribute the
AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product worldwide in the field of peripheral nerve repair, and the parties subsequently amended the
agreement in March, 2012. The agreement has an initial seven-year term from the date of the original agreement and following such initial term, the agreement automatically renews for an additional seven (7)&nbsp;year period provided that the parties
agree to meet at least ninety (90)&nbsp;days before the end of such initial term to review whether the purchase price of the products obtained from Cook Biotech need to be adjusted and reasonably agree to such adjustment in writing, where such
agreement shall not be unreasonably withheld. The Cook Biotech agreement also requires certain minimum purchases, although through mutual agreement the parties have not established such minimums and to date have not enforce such provision, and
establishes a formula for the transfer cost of the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-24
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In December 2011, the Company also entered into a Master Services Agreement for Clinical Research and
Related Services. The Company was required to pay $151,318 upon execution of this agreement and $20,416 per month for 42 months starting in January 2012 through August 2015. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Certain executive officers of the Company are parties to employment contracts. All such contracts have severance payments in the event of a Company change of control, provided certain conditions are met.
One&nbsp;contract has a severance provision in the event of termination without cause.</FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-25
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin532389_7"></A>AXOGEN, INC. </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONDENSED CONSOLIDATED BALANCE SHEETS </B></FONT></P>
 <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">March&nbsp;31,<BR>2013</FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1">(unaudited)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,<BR>2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current assets:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,200,447</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,907,401</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,179,138</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,050,089</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventory</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,420,253</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,151,109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid expenses and other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">142,033</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">187,256</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total current assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,941,871</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,295,855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Property and equipment, net</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">111,401</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108,534</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Intangible assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">590,458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">573,731</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Deferred financing costs</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,208,227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,252,443</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,851,957</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,230,563</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Liabilities and Shareholders&#146; Equity (Deficit)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current liabilities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable and accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,418,938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,479,752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total current liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,418,938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,479,752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note Payable &#151; Revenue Interest Purchase Agreement</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,438,404</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,580,252</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,857,342</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,060,004</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Commitments and contingencies</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Shareholders&#146; equity (deficit):</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock, $.01 par value; 50,000,000 shares authorized; 11,127,869 and 11,122,573 shares issued and
outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">111,279</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">111,226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional paid-in capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,169,737</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,908,226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(61,286,401</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(57,848,893</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total shareholders&#146; equity (deficit)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,005,385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,829,441</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,851,957</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,230,563</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>See notes to condensed consolidated financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-26
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AXOGEN, INC. </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin532389_8"></A>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(UNAUDITED) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Three Months Ended</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">March&nbsp;31,</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">March&nbsp;31,</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Revenues</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,142,932</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,653,430</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cost of goods sold</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">560,243</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">439,158</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gross profit</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,582,689</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,214,272</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Costs and expenses:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales and marketing</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,893,541</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,628,608</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">406,943</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">296,131</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,605,759</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,230,608</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total costs and expenses</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,906,243</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,155,347</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Loss from operations</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,323,554</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,941,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other income (expense):</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,067,621</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(125,125</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense &#151; deferred financing costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(44,216</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(34,951</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,117</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,174</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total other income (expense)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,113,954</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(168,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net loss</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,437,508</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,109,325</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss available to common shareholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,437,508</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,109,325</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted Average Common Shares outstanding &#151; basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,124,633</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,062,339</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss Per Common share &#151; basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>See notes to condensed consolidated financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-27
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AXOGEN, INC. </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin532389_9"></A>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(UNAUDITED) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Three Months Ended March&nbsp;31,</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from operating activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,437,508</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,109,325</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjustments to reconcile net loss to net cash used for operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,140</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,691</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amortization of intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,687</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,419</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amortization of deferred financing costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44,216</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,713</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amortization of debt discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,238</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">259,912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">157,860</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest added to note</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">858,151</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in assets and liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(129,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(96,329</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventory</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(269,144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(365,796</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid expenses and other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,223</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(106,033</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable and accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(60,814</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(78,727</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash used for operating activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,651,186</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,478,289</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from investing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchase of property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(26,007</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(29,313</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acquisition of intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(31,415</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(41,236</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash used for investing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(57,422</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(70,549</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from financing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from exercise of stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,654</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payment of fractional shares from Merger</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(59</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash provided by financing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,654</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net decrease in cash and cash equivalents</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,706,954</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,548,834</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash and cash equivalents,</B> beginning of year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,907,401</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,190,781</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash and cash equivalents,</B> end of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,200,447</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,641,947</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Supplemental disclosures of cash flow activity:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash paid for interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">172,527</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">125,125</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>See notes to condensed consolidated financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-28
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AXOGEN, INC.</B> </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin532389_10"></A>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(UNAUDITED) </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. Basis of Presentation </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying condensed consolidated financial statements include the accounts of AxoGen, Inc. (the &#147;Company&#148; or
&#147;AxoGen&#148;) and its wholly owned subsidiary AxoGen Corporation (&#147;AC&#148;) as of March&nbsp;31, 2013 and December&nbsp;31, 2012 and for the three month periods ended March&nbsp;31, 2013 and 2012. The Company&#146;s condensed
consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and should be read in conjunction with the audited financial statements of the Company for the year
ended December&nbsp;31, 2012, which are included in the Annual Report on Form 10-K for the year ended December&nbsp;31, 2012. The interim condensed consolidated financial statements are unaudited and in the opinion of management, reflect all
adjustments necessary for a fair presentation of results for the periods presented. Results for interim periods are not necessarily indicative of results for the full year. All significant intercompany accounts and transactions have been eliminated
in consolidation </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. Organization and Business </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Business Summary </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company is a leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. Peripheral nerves provide the pathways for both motor
and sensory signals throughout the body and their damage can result in the loss of function and feeling. In order to improve surgical reconstruction and regeneration of peripheral nerves, the Company has developed and licensed, patented and patent
pending technologies. The Company&#146;s innovative approach to regenerative medicine has resulted in first-in-class products that will define their product categories. AxoGen&#146;s products offer a full suite of surgical nerve reconstruction
solutions including Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, which the Company believes is the only commercially available processed
nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site,
AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector, a porcine submucosa ExtraCellular Matrix (&#147;ECM&#148;) coaptation aid for
tensionless repair of severed nerves, and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector, a porcine submucosa ECM product used to
wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. Summary of Significant Accounting Policies </B></FONT></P>

 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Revenue Recognition </U></B></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds.
Revenues for manufactured products and products sold under a distribution agreement are recognized when the products delivered to the customer, at which time title passes to the customer. Once a product is delivered, the Company has no further
performance obligations. Delivery is defined as delivery to a customer location or segregation of product into a contracted distribution location. At such time, this product cannot be sold to any other customer. Fees charged to customers for storage
and shipping of products are recognized as revenues when products are shipped to the customer or end user. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Cash and Cash Equivalents and Concentration </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to
be cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances and does not believe it is
exposed to any significant credit risk on cash and cash equivalents. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-29
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Accounts Receivable and Concentration of Credit Risk </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts receivable are carried at the original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts on
a monthly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer&#146;s financial condition, credit history and current economic conditions. Accounts
receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received. As of March&nbsp;31, 2013 and December&nbsp;31, 2012, there were no amounts deemed uncollectible and there was
no allowance for doubtful accounts recorded. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Concentrations of credit risk with respect to accounts receivable are limited because a large
number of geographically diverse customers make up the Company&#146;s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals, credit limits and monitoring procedures. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Inventories </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">Inventories are comprised of implantable tissue, nerve grafts,
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector, AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
Nerve Protector, and supplies that are valued at the lower of cost (first-in, first-out) or market and consist of the following: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">March&nbsp;31,<BR>2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,<BR>2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">(unaudited)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finished goods</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,246,213</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,143,176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Work in process</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">149,561</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">145,156</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Raw materials</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,024,479</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">862,777</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,420,253</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,151,109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventories were net of reserve of approximately $459,000 and $538,000 at March&nbsp;31, 2013 and December&nbsp;31, 2012, respectively.
</FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Income Taxes </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company has not recorded current income tax expense due to the generation of net operating losses. Deferred income taxes are accounted for using the balance sheet approach which requires recognition
of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not
that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that future tax benefit will not be realized. In addition, future utilization of the available
net operating loss carryforward may be limited under Internal Revenue Code Section&nbsp;382 as a result of changes in ownership. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company
identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing
authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax
benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company&#146;s remaining open tax years subject to examination by the Internal Revenue Service
include the years ended December&nbsp;31,&nbsp;2009 through 2012; currently there are no examinations in process. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Share-Based Compensation </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s 2010 Stock Incentive Plan is measured at grant date, based on the fair value of the award, and is recognized as an expense over the
employee&#146;s requisite service period. The Company estimates the fair value of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-30
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
each option award issued under the Plan on the date of grant using a Black-Scholes-Merton option pricing model that uses the assumptions noted in the table below. The Company estimates the
volatility of its common stock at the date of grant based on the volatility of comparable peer companies which are publicly traded for the periods prior to October&nbsp;1, 2011, and based on the Company&#146;s common stock for periods subsequent to
that date. The Company determines the expected life based on historical experience with similar awards, giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on
the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. The Company has never paid any cash dividends on its common stock during the periods reflected
herein and does not anticipate paying any cash dividends in the foreseeable future. The Company used the following weighted-average assumptions for options granted during the three months ended March&nbsp;31:</FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:100pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B></B>Three months ended March&nbsp;31,<B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B></B>2013<B></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B></B>2012<B></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected term (in years)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected volatility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">84.90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">118.17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk free rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected dividends</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company estimates forfeitures when recognizing compensation expense and this estimate of forfeitures is adjusted over the requisite
service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative catch-up adjustment, which is recognized in the period of
change, and also impact the amount of unamortized compensation expense to be recognized in future periods. The Company did not apply a forfeiture allocation to its unvested options outstanding during the three months ended March&nbsp;31, 2013 and
2012 as they were deemed insignificant. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Use of Estimates </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from
those estimates. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Recent Accounting Pronouncements </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s management has reviewed and considered all recent accounting pronouncements and believe there are none that could potentially have a
material impact on the Company&#146;s consolidated financial condition, results of operations, or disclosures. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. Intangible Assets </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s intangible assets consist of the following: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">March&nbsp;31,</FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1">2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,</FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1">2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B></B>(unaudited)<B></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">License agreements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">802,994</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">772,230</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64,079</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,429</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less: accumulated amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(276,615</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(261,928</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Intangible assets, net</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">590,458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">573,731</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-31
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">License agreements are being amortized over periods ranging from 17-20 years. Patent costs are being
amortized over three years. Pending patent costs are not amortizable. Amortization expense for the three months ended March&nbsp;31, 2013 and 2012 was approximately $15,000 and $29,000, respectively. As of March&nbsp;31, 2013, future amortization of
license agreements is expected to be approximately $44,000 for the remainder of fiscal 2013, $55,000 for 2014, $46,000 each year for 2015 through 2018. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>License Agreements </U></B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has entered into multiple license agreements (the
&#147;License Agreements&#148;) with the University of Florida Research Foundation (&#147;UFRF&#148;) and University of Texas at Austin (&#147;UTA&#148;). Under the terms of the License Agreements, the Company acquired exclusive worldwide licenses
for underlying technology used in repairing and regenerating nerves. The licensed technologies include the rights to issued patents and patents pending in the United States and international markets. The effective term of the License Agreements
extends through the term of the related patents and the agreements may be terminated by the Company with 60 days prior written notice. Additionally, in the event of default, licensors may terminate an agreement if the Company fails to cure a breach
after written notice. The License Agreements contain the key terms listed below: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen pays royalty fees ranging from 1% to 3% under the License Agreements based on net sales of licensed products.&nbsp;One of the agreements also
contains a minimum royalty of $12,500 per quarter, which may include a credit in future quarters in the same calendar year for the amount the minimum royalty exceeds the royalty fees.&nbsp;Also, when AxoGen pays royalties to more than one licensor
for sales of the same product, a royalty stack cap applies, capping total royalties at 3.75%; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">If AxoGen sublicenses technologies covered by the License Agreements to third parties, AxoGen would pay a percentage of sublicense fees received from
the third party to the licensor.&nbsp;Currently, AxoGen does not sublicense any technologies covered by License Agreements. The Company is not considered a sub-licensee under the License Agreements and does not owe any sublicensee fees for its own
use of the technologies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen reimburses the licensors for certain legal expenses incurred for patent prosecution and defense of the technologies covered by the License
Agreements; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Currently, under one of the License Agreements, AxoGen would owe a $15,000 milestone fee upon receiving a Phase II Small Business Innovation Research
or Phase II Small Business Technology Transfer grant involving the licensed technology. The Company has not received either grant and does not owe such a milestone fee.&nbsp;Other milestone fees are due if AxoGen develops certain pharmaceutical or
medical device products under the License Agreements. No such products are currently under development. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Royalty fees were
$47,031 and $37,265 during the three months ended March&nbsp;31, 2013 and 2012, respectively, and are included in sales and marketing expense on the accompanying condensed consolidated statements of operations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-32
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. Notes Payable </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notes Payable consists of the following: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">March&nbsp;31,</FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1">2013</FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1">(unaudited)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,</FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1">2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue Interest Purchase Agreement with PDL for aggregate of $20,800,000 with amounts payable monthly at 9.95% of Net Revenues
through September 2014; and the greater of (i)&nbsp;9.95% of product revenue or (ii)&nbsp;specific quarterly amounts varying from approximately $1.3 million to $2.5 million per quarter through September 2020. The minimum annual payment amounts are
as follows: 2014 - $1,250,805, 2015 - $6,781,440, 2016 - $9,232,642, 2017 and 2018 - $9,000,000, 2019 - $9,063,000 and 2020 - $6,939,000.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,438,404</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,580,252</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Long-term Notes Payable</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,438,404</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,580,252</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Notes Payable </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;5, 2012, AxoGen entered into a Revenue Interests Purchase Agreement (the &#147;Royalty Contract&#148;) with PDL, pursuant to which the Company sold to PDL the right to receive specified
royalties of 9.95% on the Company&#146;s Net Revenues (as defined in the Royalty Contract) generated by the sale, distribution or other use of AxoGen&#146;s products Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve
Connector and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector. The Royalty Contract has a term of eight years. Under the Royalty
Contract, PDL is to receive royalty payments based on a royalty rate of 9.95% of the Company&#146;s Net Revenues, subject to certain agreed upon minimum payment requirements of approximately $1.3 to $2.5 million per quarter which begin in the fourth
quarter of 2014 through the third quarter of 2020 as provided in the Royalty Contract. The total consideration PDL paid to the Company was $20,800,000 (the &#147;Funded Amount&#148;), including $19,050,000 PDL paid to the Company on October&nbsp;5,
2012, and $1,750,000 PDL paid to the Company on August&nbsp;14, 2012 pursuant to an Interim Revenue Interest Purchase Agreement between the Company and PDL, dated August&nbsp;14, 2012 (the &#147;Interim Royalty Contract&#148;). Upon the closing (the
&#147;Closing&#148;) of PDL&#146;s purchase of the specified royalties described above, which was concurrent with the execution of the Royalty Contract, the Interim Royalty Contract was terminated. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company records interest using its best estimate of the effective interest rate, currently the Company is accruing interest using the specified
internal rate of return of the put option of 20%. From time to time, the Company will reevaluate the expected cash flows and may adjust the effective interest rate. Determining the effective interest rate requires judgment and is based on
significant assumptions related to estimates of the amounts and timing of future revenue streams. Payments made to PDL consist of interest and principal. Based on current calculations of repayments, using actual payments to date, an estimate of
future revenue streams and an estimated effective rate of 20% (calculated using the put rate in the agreement), principal payments are scheduled to begin in April 2015. All payments made prior to this date are interest only payments. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Put Option </I></FONT></P>  <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under
the Royalty Contract, on October&nbsp;5, 2016, or in the event of the occurrence of a material adverse event, our transfer of revenue interest or substantially all of our interest in the products or AxoGen&#146;s bankruptcy or material breach of the
Royalty Contract, PDL may require AxoGen to repurchase the Assigned Interests at the &#147;Put Price.&#148; The Put Price is equal to the sum of (i)&nbsp;an amount that, when paid to PDL, would generate a specified internal rate of return to PDL of
20% on the Funded Amount, taking into consideration payments made to PDL by the Company, and (ii)&nbsp;any &#147;Delinquent Assigned Interest Payment&#148; (as defined in the Royalty Contract) the Company owed to PDL. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Change of Control; Call Option </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, in the event of a &#147;Change of Control&#148; (as defined in the Royalty Contract), the Company must repurchase the assigned Interests from PDL for a repurchase price equal to the
&#147;Change of Control Price&#148; on or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-33
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
prior to the third business day after the occurrence of the Change of Control. The Change of Control Price is equal to the sum of (i)&nbsp;an amount that, when paid to PDL, would generate a
specified internal rate of return to PDL of thirty-two and one half percent (32.5%) on the Funded Amount, taking into consideration payments made to PDL by the Company, and (ii)&nbsp;any &#147;Delinquent Assigned Interest Payment&#148; (as defined
in the Royalty Contract) the Company owed to PDL. In addition, at any time after October&nbsp;5, 2016, the Company, at its option, can call the Royalty Contract for a price equal to the Change of Control Price. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Board Designee </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under
the Royalty Contract, during the term of the Royalty Contract PDL is entitled to designate, and AxoGen shall appoint an individual designated by PDL, who shall serve on the Board of Directors of the Company (the &#147;Board&#148;) until the
Company&#146;s 2013 Annual Meeting of Shareholders (the &#147;2013 Annual Meeting&#148;). For the 2013 Annual Meeting and each annual meeting thereafter during the term of the Royalty Contract, the Board shall nominate and recommend the PDL designee
as a director nominee to serve on the Board until the next annual meeting and shall include such nomination in AxoGen&#146;s proxy statement for the 2013 Annual Meeting and each annual meeting thereafter, provided that the election of the PDL
designee is subject to shareholders&#146; approval. Should at any time there become a vacancy on the Board as a result of (i)&nbsp;the resignation, death or removal of the PDL designee or (ii)&nbsp;such PDL designee failing to obtain the requisite
approval of the Company&#146;s shareholders at any annual or special meeting of the Company&#146;s shareholders and where no other individual is elected to such vacancy, PDL shall have the right to designate an individual to fill such vacancy, and
AxoGen shall take such actions necessary to appoint, such individual to the Board. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Preemptive Rights </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Royalty Contract, PDL has preemptive rights with respect to certain new issuances of AxoGen&#146;s equity securities and securities convertible,
exchangeable or exercisable into such equity securities. </FONT></P>  <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Restriction on Dividends </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Royalty Contract, during the period from October&nbsp;5, 2012 to December&nbsp;4, 2016 (or the payment of the Put Price in the event PDL
exercises its put option on or prior to December&nbsp;4, 2016), AxoGen shall not, nor shall it permit any subsidiary to, declare, pay or make any dividend or distribution on any shares of the common stock or preferred stock of such entity (other
than dividends or distributions payable in its stock, or split-ups or reclassifications of its stock) or apply any of its funds, property or assets to the purchase, redemption or other retirement of any common or preferred stock, or of any options
to purchase or acquire any such shares of common or preferred stock of any such entity (collectively, &#147;Restricted Payments&#148;), except that: (i)&nbsp;each subsidiary may make direct or indirect Restricted Payments to the Company; and
(ii)&nbsp;the Company and each subsidiary may purchase, redeem or otherwise acquire Equity Interests issued by it solely with the proceeds received from the substantially concurrent issue of new shares of its common stock or other common Equity
Interests. For purposes of the Royalty Contract, &#147;Equity Interests&#148; of any person means any and all shares, rights to purchase, options, warrants, general, limited or limited liability partnership interests, member interests, participation
or other equivalents of or interest in (regardless of how designated) equity of such entity, whether voting or nonvoting, including common stock, preferred stock, convertible securities or any other &#147;equity security&#148; (as such term is
defined in Rule 3a11-1under the Securities Exchange Act of 1934, as amended). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Guarantee and Collateral Agreement
</I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the Royalty Contract, on October&nbsp;5, 2012, AxoGen and AC, entered into a Guarantee and Collateral Agreement (the
&#147;Guarantee and Collateral Agreement&#148;) with PDL, pursuant to which (i)&nbsp;AC unconditionally and irrevocably guarantees to PDL the prompt and complete payment and performance by AxoGen when due of the &#147;Secured Obligations,&#148;
which include the Company&#146;s obligations under the Royalty Contract, and any other obligations that AxoGen may owe to PDL under the Royalty Contract and other </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-34
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
transaction documents; and (ii)&nbsp;each of the Company and AC grants to PDL a security interest in certain collateral as specified in the Guarantee and Collateral Agreement for the prompt and
complete payment and performance when due of the Secured Obligations. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. Stock Options </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company granted 153,000 shares of stock options pursuant to its 2010 Stock Incentive Plan for the three months ended March&nbsp;31,
2013. Stock-based compensation expense was $259,912 and $157,860 for the three months ended March&nbsp;31, 2013 and 2012, respectively. Total future stock compensation expense related to nonvested awards is expected to be approximately $1,437,000 at
March&nbsp;31, 2013. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-35
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>3,658,536 Shares </B></FONT></P>
<P STYLE="font-size:24px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g532389g90w05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>AXOGEN, INC. </B></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Common Shares </B></FONT></P> <P STYLE="font-size:24px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Prospectus
</B></FONT></P> <P STYLE="font-size:24px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>, 2013 </B></FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>JMP&nbsp;Securities </B></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="5"><B>Ladenburg&nbsp;Thalmann&nbsp;&amp;&nbsp;Co. </B></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART II </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;13.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Expenses of Issuance and Distribution. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth the various expenses to be incurred in connection with the registration of the securities being registered hereby, all of which will be borne by the registrant. All amounts
shown are estimates except the SEC registration fee. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">SEC registration fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;2,353</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">FINRA fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,088</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Listing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Legal fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">300,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounting fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transfer agent and miscellaneous expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,559</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">460,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;14.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Indemnification of Directors and Officers. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Minnesota Statutes, Section&nbsp;302A.521, subd. 2, requires the Company to indemnify a person made or threatened to be made a party to a proceeding by reason of the former or present official capacity of
the person with respect to the Company, against judgments, penalties, fines, settlements, and reasonable expenses, including attorneys&#146; fees and disbursements, incurred by the person in connection with the proceeding if certain statutory
standards are met, unless the Company amends its Amended the Restated Articles of Incorporation, or the &#147;Articles of Incorporation,&#148; or its Amended and Restated Bylaws, or the &#147;Bylaws,&#148; to prohibit or condition such
indemnification rights. In addition, Minnesota Statutes, Section&nbsp;302A.521, subd. 3 requires payment by the Company, upon written request, of reasonable expenses in advance of final disposition of the proceeding in certain circumstances unless
the Company amends the Articles of Incorporation or the Bylaws to prohibit or condition such expense advancement rights. Under Section&nbsp;302A.521, subd. 4, the Company may amend the Articles of Incorporation or the Bylaws to prohibit or condition
such indemnification or expense advancement rights. A decision as to required indemnification is made (i)&nbsp;by a disinterested majority of the Company&#146;s Board of Directors present at a meeting at which a disinterested quorum is present,
(ii)&nbsp;by a designated committee of the Board of Directors consisting of two or more disinterested directors, (iii)&nbsp;by special legal counsel selected by the board or a committee by vote pursuant to clause (i)&nbsp;or (ii)&nbsp;above,
(iv)&nbsp;by an affirmative vote of the shareholders, in which the shares held by parties to the proceeding is not counted in determining the presence of a quorum and are not considered to be present and entitled to vote, or (v)&nbsp;by a court in
Minnesota. For purposes of clauses (i)&nbsp;and (ii)&nbsp;above, a director is disinterested if he or she is not a party to the proceeding for which indemnification or expense advancement is at issue. Section&nbsp;302A.521 contains detailed terms
regarding such right of indemnification and reference is made thereto for a complete statement of such indemnification rights. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Article 7 of the Articles of Incorporation provides that, to the fullest extent permitted by the Minnesota Business Corporation Act as
the same exists or may hereafter be amended, a director of the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Company shall not be personally liable to the Company or its shareholders for monetary damages for breach of fiduciary duty as a director; provided, however, that Article 7 shall not eliminate or
limit the liability of a director to the extent provided by applicable law (i)&nbsp;for any breach of the director&#146;s duty of loyalty to the corporation or its shareholders, (ii)&nbsp;for acts or omissions not in good faith or that involve
intentional misconduct or a knowing violation of law, (iii)&nbsp;under section 302A.559 or 80A.76 of the Minnesota Statutes, (iv)&nbsp;for any transaction from which the director derived an improper personal benefit, or (v)&nbsp;for any act or
omission occurring prior to the effective date of Article 7 or any predecessor of this provision. Neither the amendment, modification or repeal of Article 7 nor the adoption of any provision in these articles of incorporation inconsistent with
Article 7 shall adversely affect any right or protection of a director or officer of the Company with respect to any act or omission that occurred prior to the time of such amendment, modification, repeal or adoption. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Bylaws provide that the directors and officers of the Company shall have the right to indemnification provided by Minnesota Statutes,
Section&nbsp;302A.521, as now enacted or hereafter amended. Under Section&nbsp;302A.521, subd. 2, indemnification will be available only where an officer, director or employee can establish that he or she: (i)&nbsp;has not been indemnified by
another organization with respect to the same acts or omissions; (ii)&nbsp;acted in good faith; (iii)&nbsp;received no improper personal benefits; (iv)&nbsp;in the case of a criminal proceeding, had no reasonable cause to believe the conduct was
unlawful; and (v)&nbsp;reasonably believed the conduct was in the best interests of the Company or, in certain circumstances, reasonably believed that the conduct was not opposed to the best interests of the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company maintains, on behalf of its directors and officers, insurance protection against certain liabilities arising out of the
discharge of their duties, as well as insurance covering the Company for indemnification payments made to its directors and officers for certain liabilities. The premiums for such insurance are paid by the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">With respect to possible indemnification of directors, officers and controlling persons of the Company for liabilities arising under the
Securities Act pursuant to such provisions, the Company is aware that the Commission has publicly taken the position that such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;15.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Recent Sales of Unregistered Securities. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following list sets forth information regarding all securities sold by us in the three years preceding the filing of this registration statement which were not registered under the Securities Act:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;30, 2011, the Company sold 423,709 shares of the Company&#146;s common shares at $2.36 per share to certain investors who were
accredited investor (as defined in Rule 501(a) of Regulation D promulgated under the Securities Act). The proceeds of this sale of approximately $1,000,000 was used for general working capital purposes. This offering was completed in conjunction
with the Merger. Purchasers of Company securities were certain shareholders of AC prior to the Merger and included AC&#146;s Chief Executive Officer and certain members of its Board of Directors. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;29, 2012, the Company issued 7,500 shares of its common shares to an individual who is an accredited investor (as defined in Rule 501(a)
of Regulation D promulgated under the Securities Act) as compensation for investor relations services this individual rendered to the Company. Such party had no relationship to the Company except as a service provider. The aggregate value of the
shares issued, determined based on market value of the Company&#146;s common shares was $21,375 and was reported as an operating expense in the Company&#146;s consolidated statements of operations. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The above-described transactions were exempt from the registration requirements of the Securities Act pursuant to Section&nbsp;4(2)
thereof or Regulation D promulgated thereunder, as a transaction not involving a public offering. With respect to the transaction listed above, no general solicitation was made by either the Registrant or any person acting on its behalf; the
securities sold are subject to transfer restrictions; and the certificate representing the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
securities contain an appropriate legend stating that such securities have not been registered under the Securities Act and may not be offered or sold other than pursuant to an effective
registration statement under the Securities Act or an applicable exemption from the registration requirements thereof. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;16.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibits and Financial Statement Schedules. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibits: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Underwriting Agreement (to be filed by amendment)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Agreement and Plan of Merger, dated as of May 31, 2011, among LecTec Corporation, Nerve Merger Sub Corp. and AxoGen Corporation (Incorporated by reference to Exhibit 2.1 to LecTec
Corporation&#146;s Current Report on Form 8-K filed on June 2, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 1 to Agreement and Plan of Merger, dated as of June 30, 2011, among LecTec Corporation, Nerve Merger Sub Corp. and AxoGen Corporation (Incorporated by reference to
Appendix A2 to the Proxy Statement/Prospectus included as part of LecTec Corporation&#146;s Amendment No. 2 to Registration Statement on Form S-4 filed on August 29, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 2 to Agreement and Plan of Merger, dated as of August 9, 2011, among LecTec Corporation, Nerve Merger Sub Corp. and AxoGen Corporation (Incorporated by reference to
Appendix A3 to the Proxy Statement/Prospectus included as part of LecTec Corporation&#146;s Amendment No. 2 to Registration Statement on Form S-4 filed on August 29, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Articles of Incorporation of AxoGen, Inc. (Incorporated by reference to Appendix B to the Proxy Statement/Prospectus included as part of LecTec
Corporation&#146;s Amendment No. 2 to Registration Statement on Form S-4 filed on August 29, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen, Inc. Amended and Restated Bylaws. (Incorporated by reference to Appendix C to the Proxy Statement/Prospectus included as part of LecTec Corporation&#146;s Amendment No. 2 to
Registration Statement on Form S-4 filed on August 29, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;#5.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opinion of Kaplan, Strangis and Kaplan, P.A. regarding the validity of the common shares being registered</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">**10.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent License Agreement, dated as of August 3, 2005, by and between AxoGen Corporation and the Board of Regents of the University of Texas System (Incorporated by reference to the
Company&#146;s Current Report on Form 8-K filed on October 6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">**10.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Standard Exclusive License Agreement with Sublicensing Terms, dated as of February 21, 2006, by and between AxoGen Corporation and the University of Florida
Research Foundation, Inc. (Incorporated by reference to the Company&#146;s Current Report on Form 8-K filed on October 6, 2011)</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-3
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">**10.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sid Martin Biotechnology Development Institute Incubator License Agreement, dated as of September&nbsp;26, 2006, by and between AxoGen, Inc. and the University of Florida Research
Foundation, Inc. (Incorporated by reference to the Company&#146;s Current Report on Form 8-K filed on October&nbsp;6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">**10.4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Nerve Tissue Processing Agreement, dated as of February&nbsp;27, 2008, by and between AxoGen Corporation and LifeNet Health (Incorporated by reference to the
Company&#146;s Current Report on Form 8-K filed on October&nbsp;6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">**10.4.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Amendment to Amended and Restated Nerve Tissue Processing Agreement, dated as of August&nbsp;9, 2011, by and between AxoGen Corporation and LifeNet Health (Incorporated by
reference to the Company&#146;s Current Report on Form 8-K filed on October&nbsp;6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">**10.4.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third Amendment dated March 12, 2012 to Amended and Restated Nerve Tissue Processing Agreement, dated as of February 27, 2008, by and between AxoGen Corporation and LifeNet Health
(Incorporated by reference to the Company&#146;s Annual Report on Form 10-K for the year ended December 31, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">**10.5.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Distribution Agreement, dated as of August 27, 2008, by and between AxoGen, Inc. and Cook Biotech Incorporated (Incorporated by reference to the Company&#146;s Current Report on
Form 8-K filed on October 6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.5.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment dated March 14, 2012 to Distribution Agreement, dated as of August 27, 2008, by and between AxoGen, Inc. and Cook Biotech Incorporated (Incorporated by reference to the
Company&#146;s Annual Report on Form 10-K for the year ended December 31, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">+*10.6.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue Interests Purchase Agreement, dated as of October 5, 2012, by and among AxoGen, Inc. and PDL BioPharma, Inc. (Incorporated by reference to the Company&#146;s Annual Report
on Form 10-K for the year ended December 31, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">+*10.6.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Guarantee and Collateral Agreement, dated as of October 5, 2012, by and among AxoGen, Inc. and AxoGen Corporation and PDL BioPharma, Inc. . (Incorporated by reference to the
Company&#146;s Annual Report on Form 10-K for the year ended December 31, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.6.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interim Revenue Interests Purchase Agreement dated August 14, 2012, by and between AxoGen, Inc. and PDL BioPharma, Inc. (Incorporated by reference to the Company&#146;s Quarterly
Report on Form 10-Q for the quarter ended September 30, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;+10.6.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment dated July 26, 2013 to Revenue Interests Purchase Agreement, dated as of October 5, 2012, by and among AxoGen, Inc. and PDL BioPharma, Inc.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">LecTec Corporation 2010 Stock Incentive Plan, Amended and Restated on September 27, 2011 (Incorporated by reference to Appendix E to the Proxy Statement/Prospectus included as part
of LecTec Corporation&#146;s Amendment No. 2 to Registration Statement on Form S-4 filed on August 29, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.8.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Employment Agreement, effective as of October 15, 2007, by</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-4
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">and between AxoGen Corporation and Karen Zaderej (Incorporated by reference to the Company&#146;s Current Report on Form 8-K filed on October&nbsp;6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.8.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment to Executive Employment Agreement, effective as of September&nbsp;29, 2011, by and between AxoGen Corporation and Karen Zaderej (Incorporated by reference to the
Company&#146;s Current Report on Form 8-K filed on October&nbsp;6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.9.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Employment Agreement, effective as of May 6, 2003, by and between AxoGen Corporation and John P. Engels (Incorporated by reference to the Company&#146;s Current Report on
Form 8-K filed on October 6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.9.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment to Executive Employment Agreement, effective as of September 29, 2011, by and between AxoGen Corporation and John P. Engels (Incorporated by reference to the
Company&#146;s Current Report on Form 8-K filed on October 6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.10</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease dated as of February 6, 2007, by and between AxoGen Corporation and WIGSHAW, LLC, its successors and assigns (Incorporated by reference to the Company&#146;s Quarterly Report
on Form 10-Q filed on November 14, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.15</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Employee Incentive Stock Option Agreement (Incorporated by reference to the Company&#146;s Current Report on Form 8-K filed on September 26, 2007)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.16</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Employment Agreement, effective as of October 1, 2011, by and between AxoGen, Inc. and Gregory G. Freitag (Incorporated by reference to the Company&#146;s Annual Report on
Form 10-K for the year ended December 31, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.17</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Employment Agreement, effective as of February 27, by and between AxoGen, Inc. and Jill Schiaparelli (Incorporated by reference to the Company&#146;s Annual Report on Form
10-K for the year ended December 31, 2011)</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-5
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.18</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Amendment dated February&nbsp;27, 2013 to lease dated as of February&nbsp;6, 2007, by and between AxoGen Corporation and WIGSHAW, LLC, its successors and assigns
(Incorporated by reference to the Company&#146;s Annual Report on Form 10-K for the year ended December&nbsp;31, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.19.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loan and Security Agreement, dated as of September&nbsp;30, 2011, by and among AxoGen, Inc. and AxoGen Corporation, as borrower, Midcap Financial SBIC, LP, as administrative agent,
and the Lenders listed on Schedule 1 thereto (Incorporated by reference to the Company&#146;s Current Report on Form 8-K filed on October&nbsp;6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.19.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Amendment to Loan and Security Agreement dated August&nbsp;14, 2012, by and between AxoGen, Inc. and Midcap Financial SBIC, LP. (Incorporated by reference to the
Company&#146;s Quarterly Report on Form 10-Q for the quarter ended September&nbsp;30, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.19.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subordination and Intercreditor Agreement dated August&nbsp;14, 2012, by and between AxoGen, Inc., PDL BioPharma, Inc. and Midcap Financial SBIC, LP. (Incorporated by reference to
the Company&#146;s Quarterly Report on Form 10-Q for the quarter ended September&nbsp;30, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.20</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Employment Agreement, effective as of February&nbsp;25, 2013, by and between AxoGen, Inc. and Shawn McCarrey (Incorporated by reference to the Company&#146;s Quarterly
Report on Form 10-Q for the quarter ended March&nbsp;31, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;21.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subsidiary of the Registrant (Incorporated by reference to the Company&#146;s Annual Report on Form 10-K for the year ended December&nbsp;31, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;+23.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of Lurie Besikof Lapidus &amp; Company, LLP</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;#23.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of Kaplan, Strangis and Kaplan, P.A. (included in Exhibit 5.1 above)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">++24.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Power of Attorney</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;101.INS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Instance Document (to be furnished by amendment)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;101.SCH</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Schema Document (to be furnished by amendment)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;101.CAL</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Calculation Linkbase Document (to be furnished by amendment)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;101.DEF</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Definition Linkbase Document (to be furnished by amendment)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;101.LAB</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Extension Labels Linkbase (to be furnished by amendment)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;101.PRE</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Presentation Linkbase Document (to be furnished by amendment)</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidential treatment has been requested as to certain portions, which portions have been omitted and filed separately with the Securities and Exchange Commission.
</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-6
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">**</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidential treatment has been granted for portions of this Exhibit pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 as amended. The confidential
portions have been deleted and filed separately with the United States Securities and Exchange Commission. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">+</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filed herewith. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">++</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Included on signature page. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">#</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financial Statement Schedules </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All schedules have been omitted because either they are not required, are not applicable or the information is otherwise set forth in the
financial statements and related notes thereto. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;17.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Undertakings. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
undersigned registrant hereby undertakes to provide to the underwriter at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery
to each purchaser. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to
directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public
policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its
counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final
adjudication of such issue. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The undersigned registrant hereby undertakes that: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration
statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b) (1)&nbsp;or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the
time it was declared effective. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a
new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-7
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Act, the Registrant has duly caused this Amendment No.&nbsp;3 to Registration Statement to
be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Alachua, State of Florida, on the 29th day of July, 2013. </FONT></P>  <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AXOGEN, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;/s/ Karen Zaderej</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Karen Zaderej</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>POWER OF ATTORNEY </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Each person whose individual signature appears below hereby authorizes and appoints Karen Zaderej and Gregory Freitag, and each of them, with full power of substitution and resubstitution and full power
to act without the other, as his or her true and lawful attorney in fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any
and all amendments to this Registration Statement, including any and all post effective amendments and amendments thereto, and any registration statement relating to the same offering filed pursuant to Rule 462(b) under the Securities Act of 1933,
as amended, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys in fact and agents, and each of them, full power and authority to do
and perform each and every act and thing, ratifying and confirming all that said attorneys in fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following
persons in the capacities and on the dates indicated. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:33pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Signature</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:15pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Date</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Karen Zaderej</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer and Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">July 29, 2013</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Karen Zaderej</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(Principal Executive Officer)</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Gregory G. Freitag</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">July 29, 2013</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gregory G. Freitag</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(Principal Financial and Accounting Officer)</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chairman of the Board</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">July 29, 2013</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Jamie M. Grooms</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">July 29, 2013</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Robert J. Rudelius</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>*</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">July 29, 2013</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Mark Gold, M.D.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>*</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">July 29, 2013</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>John Harper</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>*</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">July 29, 2013</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Joe Mandato</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>*</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">July 29, 2013</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>John McLaughlin</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">*By:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;/s/ Gregory G. Freitag</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gregory G. Freitag</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Attorney-in-fact</B></FONT></P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Underwriting Agreement (to be filed by amendment)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Agreement and Plan of Merger, dated as of May 31, 2011, among LecTec Corporation, Nerve Merger Sub Corp. and AxoGen Corporation (Incorporated by reference to Exhibit 2.1 to LecTec
Corporation&#146;s Current Report on Form 8-K filed on June 2, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 1 to Agreement and Plan of Merger, dated as of June 30, 2011, among LecTec Corporation, Nerve Merger Sub Corp. and AxoGen Corporation (Incorporated by reference to
Appendix A2 to the Proxy Statement/Prospectus included as part of LecTec Corporation&#146;s Amendment No. 2 to Registration Statement on Form S-4 filed on August 29, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 2 to Agreement and Plan of Merger, dated as of August 9, 2011, among LecTec Corporation, Nerve Merger Sub Corp. and AxoGen Corporation (Incorporated by reference to
Appendix A3 to the Proxy Statement/Prospectus included as part of LecTec Corporation&#146;s Amendment No. 2 to Registration Statement on Form S-4 filed on August 29, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Articles of Incorporation of AxoGen, Inc. (Incorporated by reference to Appendix B to the Proxy Statement/Prospectus included as part of LecTec
Corporation&#146;s Amendment No. 2 to Registration Statement on Form S-4 filed on August 29, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen, Inc. Amended and Restated Bylaws. (Incorporated by reference to Appendix C to the Proxy Statement/Prospectus included as part of LecTec Corporation&#146;s Amendment No. 2 to
Registration Statement on Form S-4 filed on August 29, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;#5.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opinion of Kaplan, Strangis and Kaplan, P.A. regarding the validity of the common shares being registered</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">**10.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent License Agreement, dated as of August 3, 2005, by and between AxoGen Corporation and the Board of Regents of the University of Texas System (Incorporated by reference to the
Company&#146;s Current Report on Form 8-K filed on October 6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">**10.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Standard Exclusive License Agreement with Sublicensing Terms, dated as of February 21, 2006, by and between AxoGen Corporation and the University of Florida
Research Foundation, Inc. (Incorporated by reference to the Company&#146;s Current Report on Form 8-K filed on October 6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">**10.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sid Martin Biotechnology Development Institute Incubator License Agreement, dated as of September 26, 2006, by and between AxoGen, Inc. and the University of Florida Research
Foundation, Inc. (Incorporated by reference to the Company&#146;s Current Report on Form 8-K filed on October 6, 2011)</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">**10.4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Nerve Tissue Processing Agreement, dated as of February&nbsp;27, 2008, by and between AxoGen Corporation and LifeNet Health (Incorporated by reference to the
Company&#146;s Current Report on Form 8-K filed on October&nbsp;6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">**10.4.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Amendment to Amended and Restated Nerve Tissue Processing Agreement, dated as of August&nbsp;9, 2011, by and between AxoGen Corporation and LifeNet Health (Incorporated by
reference to the Company&#146;s Current Report on Form 8-K filed on October&nbsp;6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">**10.4.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>Third Amendment dated March 12, 2012 to Amended and Restated Nerve Tissue Processing Agreement, dated as of February 27, 2008, by and between AxoGen Corporation and LifeNet
Health (Incorporated by reference to the Company&#146;s Annual Report on Form 10-K for the year ended December 31, 2012)<B></B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">**10.5.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Distribution Agreement, dated as of August 27, 2008, by and between AxoGen, Inc. and Cook Biotech Incorporated (Incorporated by reference to the Company&#146;s Current Report on
Form 8-K filed on October 6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.5.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment dated March 14, 2012 to Distribution Agreement, dated as of August 27, 2008, by and between AxoGen, Inc. and Cook Biotech Incorporated (Incorporated by reference to the
Company&#146;s Annual Report on Form 10-K for the year ended December 31, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">+*10.6.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue Interests Purchase Agreement, dated as of October 5, 2012, by and among AxoGen, Inc. and PDL BioPharma, Inc. (Incorporated by reference to the Company&#146;s Annual Report
on Form 10-K for the year ended December 31, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">+*10.6.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Guarantee and Collateral Agreement, dated as of October 5, 2012, by and among AxoGen, Inc. and AxoGen Corporation and PDL BioPharma, Inc. (Incorporated by reference to the
Company&#146;s Annual Report on Form 10-K for the year ended December 31, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.6.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interim Revenue Interests Purchase Agreement dated August 14, 2012, by and between AxoGen, Inc. and PDL BioPharma, Inc. (Incorporated by reference to the Company&#146;s Quarterly
Report on Form 10-Q for the quarter ended September 30, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;+10.6.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment dated July 26, 2013 to Revenue Interests Purchase Agreement, dated as of October 5, 2012, by and among AxoGen, Inc. and PDL BioPharma, Inc.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">LecTec Corporation 2010 Stock Incentive Plan, Amended and Restated on September 27, 2011 (Incorporated by reference to Appendix E to the Proxy Statement/Prospectus included as part
of LecTec Corporation&#146;s Amendment No. 2 to Registration Statement on Form S-4 filed on August 29, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.8.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Employment Agreement, effective as of October 15, 2007, by and between AxoGen Corporation and Karen Zaderej (Incorporated by reference to the Company&#146;s Current Report
on Form 8-K filed on October 6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.8.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment to Executive Employment Agreement, effective as of September 29, 2011, by and between AxoGen Corporation and Karen Zaderej (Incorporated by reference to the Company&#146;s
Current Report on Form 8-K filed on October 6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.9.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Employment Agreement, effective as of May 6, 2003, by and between AxoGen Corporation and John P. Engels (Incorporated by reference to the Company&#146;s Current Report on
Form 8-K filed on October 6, 2011)</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.9.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment to Executive Employment Agreement, effective as of September&nbsp;29, 2011, by and between AxoGen Corporation and John P. Engels (Incorporated by reference to the
Company&#146;s Current Report on Form 8-K filed on October&nbsp;6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.10</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease dated as of February&nbsp;6, 2007, by and between AxoGen Corporation and WIGSHAW, LLC, its successors and assigns (Incorporated by reference to the Company&#146;s Quarterly
Report on Form 10-Q filed on November&nbsp;14, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.15</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Employee Incentive Stock Option Agreement (Incorporated by reference to the Company&#146;s Current Report on Form 8-K filed on September&nbsp;26, 2007)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.16</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Employment Agreement, effective as of October 1, 2011, by and between AxoGen, Inc. and Gregory G. Freitag (Incorporated by reference to the Company&#146;s Annual Report on
Form 10-K for the year ended December 31, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.17</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Employment Agreement, effective as of February 27, by and between AxoGen, Inc. and Jill Schiaparelli (Incorporated by reference to the Company&#146;s Annual Report on Form
10-K for the year ended December 31, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.18</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Amendment dated February 27, 2013 to lease dated as of February 6, 2007, by and between AxoGen Corporation and WIGSHAW, LLC, its successors and assigns (Incorporated by
reference to the Company&#146;s Annual Report on Form 10-K for the year ended December 31, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.19.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loan and Security Agreement, dated as of September 30, 2011, by and among AxoGen, Inc. and AxoGen Corporation, as borrower, Midcap Financial SBIC, LP, as administrative agent, and
the Lenders listed on Schedule 1 thereto (Incorporated by reference to the Company&#146;s Current Report on Form 8-K filed on October 6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.19.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Amendment to Loan and Security Agreement dated August 14, 2012, by and between AxoGen, Inc. and Midcap Financial SBIC, LP. (Incorporated by reference to the Company&#146;s
Quarterly Report on Form 10-Q for the quarter ended September 30, 2012)</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.19.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subordination and Intercreditor Agreement dated August&nbsp;14, 2012, by and between AxoGen, Inc., PDL BioPharma, Inc. and Midcap Financial SBIC, LP. (Incorporated by reference to
the Company&#146;s Quarterly Report on Form 10-Q for the quarter ended September&nbsp;30, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;10.20</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Employment Agreement, effective as of February&nbsp;25, 2013, by and between AxoGen, Inc. and Shawn McCarrey (Incorporated by reference to the Company&#146;s Quarterly
Report on Form 10-Q for the quarter ended March&nbsp;31, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;21.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subsidiary of the Registrant (Incorporated by reference to the Company&#146;s Annual Report on Form 10-K for the year ended December&nbsp;31, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;+23.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of Lurie Besikof Lapidus &amp; Company, LLP</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;#23.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of Kaplan, Strangis and Kaplan, P.A. (included in Exhibit 5.1 above)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">++24.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Power of Attorney</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;101.INS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Instance Document (to be furnished by amendment)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;101.SCH</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Schema Document (to be furnished by amendment)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;101.CAL</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Calculation Linkbase Document (to be furnished by amendment)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;101.DEF</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Definition Linkbase Document (to be furnished by amendment)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;101.LAB</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Extension Labels Linkbase (to be furnished by amendment)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;101.PRE</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Presentation Linkbase Document (to be furnished by amendment)</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidential treatment has been requested as to certain portions, which portions have been omitted and filed separately with the Securities and Exchange Commission.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">**</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidential treatment has been granted for portions of this Exhibit pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 as amended. The confidential
portions have been deleted and filed separately with the United States Securities and Exchange Commission. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">+</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filed herewith. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">++</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Included on signature page. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>#</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed.<B></B> </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>Financial Statement Schedules<B></B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">All
schedules have been omitted because either they are not required, are not applicable or the information is otherwise set forth in the financial statements and related notes thereto. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6.1
<SEQUENCE>2
<FILENAME>d532389dex1061.htm
<DESCRIPTION>REVENUE INTERESTS PURCHASE AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Revenue Interests Purchase Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.6.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked &#147;***&#148; and has been filed separately with the Securities and Exchange Commission pursuant to a
Confidential Treatment Application filed with the Commission. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Execution Version </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">REVENUE INTERESTS PURCHASE AGREEMENT </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dated as of October&nbsp;5, 2012 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">between </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen, Inc. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">PDL
BioPharma, Inc. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Table of Contents </U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Page</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>ARTICLE I DEFINITIONS</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>ARTICLE II PURCHASE OF INTERESTS</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;2.01</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Purchase</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;2.02</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Payments by the Company</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;2.03</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Closing; Payment Purchase Price; Closing Deliveries</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;2.04</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>No Assumed Obligations</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>ARTICLE III REPRESENTATIONS AND WARRANTIES OF COMPANY</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;3.01</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Organization</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;3.02</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Authorization</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;3.03</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Governmental Authorization</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;3.04</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Ownership</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;3.05</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Financial Statements</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;3.06</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>No Undisclosed Liabilities</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;3.07</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Solvency</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;3.08</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Litigation</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;3.09</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Compliance with Laws</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;3.10</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Conflicts</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;3.11</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Subordination</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;3.12</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Intellectual Property</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;3.13</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Regulatory Approval</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;3.14</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Material Contracts</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;3.15</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Place of Business</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;3.16</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Broker&#146;s Fees</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;3.17</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Other Information</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;3.18</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Insurance</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U><B>Section&nbsp;3.19</B></U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Taxes</U></B><U>.<B></B></U><B></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>ARTICLE IV REPRESENTATIONS AND WARRANTIES OF PURCHASER</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;4.01</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Organization</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;4.02</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Authorization</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;4.03</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Broker&#146;s Fees</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;4.04</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Conflicts</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- i -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Table of Contents </U></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(continued) </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Page</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>ARTICLE V COVENANTS</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;5.01</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Consents and Waivers</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;5.02</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Access; Information</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;5.03</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Material Contracts</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;5.04</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Confidentiality; Public Announcement</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;5.05</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Guarantee and Collateral Agreement</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;5.06</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Efforts; Further Assurance</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;5.07</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Change of Control; Put Option</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;5.08</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Remittance to Deposit Account</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;5.09</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Intellectual Property</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;5.10</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Negative Covenants</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;5.11</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Insurance</U></B><U>.<B></B></U><B></B><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;5.12</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Notice</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;5.13</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Use of Proceeds</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;5.14</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Taxes</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;5.15</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Board Designee</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;5.16</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Rights to Future Stock Issuances</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>ARTICLE VI TERMINATION</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;6.01</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Termination Date</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;6.02</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Effect of Termination</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>ARTICLE VII MISCELLANEOUS</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;7.01</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Survival</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;7.02</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Specific Performance; Limitations on Damages</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;7.03</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Notices</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;7.04</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Successors and Assigns</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;7.05</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Indemnification</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;7.06</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>No Implied Representations and Warranties</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;7.07</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Independent Nature of Relationship</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;7.08</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Federal Tax</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;7.09</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Entire Agreement</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;7.10</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Amendments; No Waivers</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- ii -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Table of Contents </U></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(continued) </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Page</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;7.11</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Interpretation</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;7.12</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Headings and Captions</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;7.13</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Counterparts; Effectiveness</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;7.14</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Severability</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;7.15</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Expenses</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;7.16</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Governing Law; Jurisdiction</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;7.17</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Waiver of Jury Trial</U></B><U>.<B></B></U><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- iii -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBITS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit&nbsp;A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Guarantee and Collateral Agreement</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit&nbsp;B</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Assignment of Interests</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit&nbsp;C</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Deposit Agreement</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit&nbsp;D</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Legal Opinion</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>REVENUE INTERESTS PURCHASE AGREEMENT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This <B>REVENUE INTERESTS PURCHASE AGREEMENT</B> (as amended, supplemented or otherwise modified from time to time, this
&#147;<U>Agreement</U>&#148;) is made and entered into as of October&nbsp;5, 2012, by and between AxoGen, Inc., a Minnesota corporation (the &#147;<U>Company</U>&#148;), and PDL BioPharma, Inc., a Delaware corporation (&#147;<U>Purchaser</U>&#148;).
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS,</B> the Company wishes to obtain financing in respect of the commercialization of the Product (as hereinafter
defined) and to sell, assign, convey and transfer to Purchaser in consideration for its payment of the Purchase Price (as hereinafter defined), and Purchaser wishes to purchase from the Company, the Assigned Interests (as hereinafter defined), all
upon and subject to the terms and conditions hereinafter set forth; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS,</B> the Company and Purchaser entered into
that certain Interim Royalty Purchase Agreement, dated August&nbsp;14, 2012 (&#147;<U>Interim Royalty Purchase Agreement</U>&#148;), pursuant to which, Purchaser paid $1,750,000.00 (the &#147;<U>Interim Payment</U>&#148;) for the acquisition of
certain of the Company&#146;s revenue rights; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS</B>, the parties desire for this Agreement to amend, restate and
replace the Interim Royalty Purchase Agreement in its entirety. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOW, THEREFORE,</B> in consideration of the mutual
covenants, agreements representations and warranties set forth herein, the parties hereto agree as follows: </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE I
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DEFINITIONS </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;1.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Definitions</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following terms, as used herein, shall have the following meanings: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>2013 Annual Meeting</U>&#148; shall have the meaning set forth in <U>Section 5.15.</U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Accounts</U>&#148; shall mean, collectively, the Deposit Account, the Joint Concentration Account, the Company Concentration
Account and the Purchaser Concentration Account, each established and maintained pursuant to the Deposit Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Affiliate</U>&#148; shall mean any Person that controls, is controlled by, or is under common control with another Person. For
purposes of this definition, &#147;<U>control</U>&#148; shall mean (i)&nbsp;in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%)&nbsp;of the stock or shares having the right to vote for the election of
directors, and (ii)&nbsp;in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%)&nbsp;of the equity interest with the power to direct the management and policies of such non-corporate entities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Aggregate Deposit Funds</U>&#148; shall mean any and all financial assets, funds, monies, checks or other items deposited into
the Deposit Account. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Agreement</U>&#148; shall have the meaning set forth in the first paragraph hereof. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 1 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Applicable Percentage</U>&#148; shall mean 9.95%. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Assigned Interests</U>&#148; shall mean the following amounts of the Company&#146;s Net Revenues: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) from the Closing Date until September&nbsp;30, 2014, an amount equal to the product of the Applicable Percentage multiplied by the
Company&#146;s Net Revenues; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) for each of the following twenty-four (24)&nbsp;Fiscal Quarters, the greater of (i)&nbsp;an
amount equal to the Applicable Percentage of the Company&#146;s Net Revenues for such Fiscal Quarter or (ii)&nbsp;the following amounts: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(i) for the quarter ending December&nbsp;31, 2014, $1,250,805; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) for the
quarter ending March&nbsp;31, 2015, $1,452,146; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) for the quarter ending June&nbsp;30, 2015, $1,558,610; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) for the quarter ending September&nbsp;30, 2015, $1,769,395; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v) for the quarter ending December&nbsp;31, 2015, $2,001,289; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(vi) for the quarter ending March&nbsp;31, 2016, $2,323,434; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vii) for the
quarter ending June&nbsp;30, 2016, $2,182,055; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(viii) for the quarter ending September&nbsp;30, 2016, $2,477,153; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ix) for the quarter ending December&nbsp;31, 2016, $2,250,000; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(x) for the quarter ending March&nbsp;31, 2017, $2,250,000; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(xi) for the quarter
ending June&nbsp;30, 2017, $2,250,000; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(xii) for the quarter ending September&nbsp;30, 2017, $2,250,000; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(xiii) for the quarter ending December&nbsp;31, 2017, $2,250,000; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(xiv) for the quarter ending March&nbsp;31, 2018, $2,250,000; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(xv) for the quarter ending June&nbsp;30, 2018, $2,250,000; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(xvi) for the
quarter ending September&nbsp;30, 2018, $2,250,000; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(xvii) for the quarter ending December&nbsp;31, 2018, $2,250,000;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(xviii) for the quarter ending March&nbsp;31, 2019, $2,250,000; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(xix) for the quarter ending June&nbsp;30, 2019, $2,250,000; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(xx) for the quarter ending September&nbsp;30, 2019, $2,250,000; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 2 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(xxi) for the quarter ending December&nbsp;31, 2019, $2,313,000; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(xxii) for the quarter ending March&nbsp;31, 2020, $2,313,000; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(xxiii) for the quarter ending June&nbsp;30, 2020, $2,313,000; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(xxiv) for
the quarter ending September&nbsp;30, 2020, $2,313,000. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Assigned Interests Collateral</U>&#148; shall mean the
property included in the definition of &#147;Collateral&#148; in the Guarantee and Collateral Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Assignment
of Interests</U>&#148; shall mean the Assignment of Interests pursuant to which the Company shall assign to Purchaser all of its rights and interests in and to the Assigned Interests purchased hereunder, which Assignment of Interests shall be
substantially in the form of <U>Exhibit B</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Audit Costs</U>&#148; shall mean, with respect to any audit of the
books and records of the Company with respect to amounts payable or paid under this Agreement, the reasonable out-of-pocket cost of such audit, including all fees, costs and expenses incurred in connection therewith. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Bankruptcy Event</U>&#148; shall mean the occurrence of any of the following: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) the Company shall commence any case, proceeding or other action (i)&nbsp;under any existing or future law of any jurisdiction,
domestic or foreign, relating to bankruptcy, insolvency, reorganization, relief of debtors or the like, seeking to have an order for relief entered with respect to it, or seeking to adjudicate it bankrupt or insolvent, or seeking reorganization,
arrangement, adjustment, winding-up, liquidation, dissolution, composition or other relief with respect to it or its debts, or (ii)&nbsp;seeking appointment of a receiver, trustee, custodian or other similar official for it or for all or any portion
of its assets, or the Company shall make a general assignment for the benefit of its creditors; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) there shall be commenced
against the Company any case, proceeding or other action of a nature referred to in clause (a)&nbsp;above which remains undismissed, undischarged or unbonded for a period of sixty (60)&nbsp;days; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) there shall be commenced against the Company any case, proceeding or other action seeking issuance of a warrant of attachment,
execution, distraint or similar process against (i)&nbsp;all or any substantial portion of its assets and/or (ii)&nbsp;the Product or any substantial portion of the Intellectual Property related to the Product, which results in the entry of an order
for any such relief which shall not have been vacated, discharged, stayed, satisfied or bonded pending appeal within sixty (60)&nbsp;days from the entry thereof; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) the failure of the Company to take action to object to any of the acts set forth in clause (b)&nbsp;or (c)&nbsp;above within ten (10)&nbsp;days of the Company receiving written notice of such act; or
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) the Company shall generally not, or shall be unable to, or shall admit in writing its inability to, pay its respective
debts as they become due. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 3 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>BLA</U>&#148; shall mean a biologics license application and
all amendments and supplements thereto, submitted to the FDA with respect to Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Board</U>&#148; shall mean the Board of Directors of the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Business Day</U>&#148; shall mean any day other than a Saturday, a Sunday, any day which is a legal holiday under the laws of
the State of New York, or any day on which banking institutions located in the State of New York are required by law or other governmental action to close. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Call Closing Date</U>&#148; shall have the meaning set forth in <U>Section&nbsp;5.07(c)</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Call Option</U>&#148; shall have the meaning set forth in <U>Section&nbsp;5.07(c)</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Change of Control</U>&#148; shall mean: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) the acquisition by any
Person or group (within the meaning of Sections 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended) of beneficial ownership of any capital stock of the Company, if after such acquisition, such Person or group would be the
&#147;beneficial owner&#148; (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended), directly or indirectly, of securities of the Company representing more than fifty percent (50%)&nbsp;of the combined voting power of the
Company&#146;s then outstanding securities entitled to vote generally in the election of directors; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) a merger or
consolidation of the Company, with any other Person, other than a merger or consolidation which would result in the Company&#146;s voting securities outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by
being converted into voting securities of the surviving entity) more than fifty percent (50%)&nbsp;of the combined voting power of the Company&#146;s voting securities or such surviving entity&#146;s voting securities outstanding immediately after
such merger or consolidation; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) during any period of two (2)&nbsp;consecutive years, measured from the first Business Day
after the Purchaser Designee appointed pursuant to <U>Section&nbsp;5.15</U> hereof takes office, individuals who at the beginning of such period constitute the board of directors of the Company (together with any new directors (other than a director
designated by a Person who has entered into an agreement with the Company to effect a transaction described in clause (a)&nbsp;or (b)&nbsp;of this definition of &#147;Change of Control&#148;), whose election by such board of directors or nomination
for election by the Company&#146;s stockholders, as applicable, was approved by a vote of a majority of the directors then still in office who either were directors at the beginning of such period or whose election or nomination for election was
previously so approved) cease for any reason to constitute at least a majority of the board of directors of the Company then in office, <U>provided</U> that for purposes of determining a Change of Control pursuant to this clause (c), the
directorship held by the Purchaser Designee shall be disregarded. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) the bona fide sale, lease, transfer, exclusive license
or other disposition, in a single transaction or series of related transactions, by the Company or any of its Subsidiaries of all or substantially all the assets of the Company and its Subsidiaries, taken as a whole, or the sale or disposition
(whether by merger or otherwise) of one or more Subsidiaries of the Company if substantially all of the assets of the Company and its Subsidiaries, taken as a whole, are held by such Subsidiary or Subsidiaries, except where such sale, lease,
transfer, exclusive license or other disposition is to a wholly owned (direct or indirect) Subsidiary of the Company. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 4 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Change of Control Payment</U>&#148; shall mean the sum of (i)&nbsp;an amount that,
when paid to Purchaser, would generate an IRR to Purchaser of thirty-two and one half percent (32.5%)&nbsp;on all payments made by Purchaser pursuant to the Interim Royalty Purchase Agreement and <U>Section&nbsp;2.03</U> of this Agreement as of the
date of the Change of Control Payment, taking into account the amount and timing of all payments made by the Company to Purchaser (and retained by Purchaser) pursuant to <U>Sections 2.02</U> and <U>5.08</U> of this Agreement and, if applicable, the
Interim Royalty Purchase Agreement, prior to and as of the date of payment of the Change of Control Payment, plus (ii)&nbsp;any Delinquent Assigned Interests Payment owed (it being understood and agreed that in calculating the Change of Control
Payment, in no event shall Purchaser be required to repay any amounts previously paid to Purchaser pursuant to <U>Sections 2.02</U> and <U>5.08</U> of this Agreement if such payments exceed the IRR required pursuant to this definition). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Closing</U>&#148; shall have the meaning set forth in <U>Section&nbsp;2.03(a)</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Closing Date</U>&#148; shall have the meaning set forth in <U>Section&nbsp;2.03(a)</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Company</U>&#148; shall have the meaning set forth in the first paragraph hereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Company Concentration Account</U>&#148; shall mean a segregated account established and maintained at the Deposit Bank pursuant
to the terms of the Deposit Agreement and this Agreement. The Company Concentration Account shall be the account into which the funds remaining in the Joint Concentration Account after payment therefrom of the amounts payable to Purchaser pursuant
to this Agreement are swept in accordance with the terms of this Agreement and the Deposit Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Company
Indemnified Party</U>&#148; shall have the meaning set forth in <U>Section&nbsp;7.05(b)</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Confidential
Information</U>&#148; shall mean, as it relates to the Company and its Affiliates and the Product, the Intellectual Property, confidential business information, financial data and other like information (including ideas, research and development,
know-how, formulas, schematics, compositions, technical data, specifications, customer and supplier lists, pricing and cost information, and business and marketing plans and proposals), inventory, ideas, algorithms, processes, computer software
programs or applications (in both source code and object code form), client lists and tangible or intangible proprietary information or material, or such other information that either party identifies to the other as confidential or the nature of
which or the circumstances of the disclosure of which would reasonably indicate that such information is confidential. Notwithstanding the foregoing definition, Confidential Information shall not include information that (a)&nbsp;is already in the
public domain at the time the information is disclosed, (b)&nbsp;thereafter becomes lawfully obtainable from other sources who, to the knowledge of the recipient, have no obligation of confidentiality, (c)&nbsp;can be shown to have been
independently developed by the recipient or its representatives without reference to any Confidential Information of the other party, or (d)&nbsp;is required to be disclosed under securities laws, rules and regulations applicable to the Company or
its Affiliates or the Purchaser or its Affiliates, as the case may be, or pursuant to the rules and regulations of any securities exchange or trading system or pursuant to any other laws, rules or regulations of any Governmental Authority having
jurisdiction over the Company and its Affiliates or Purchaser and its Affiliates. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 5 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Controlled</U>&#148; or &#147;<U>Control</U>&#148; shall mean, with respect to
Intellectual Property, the right, possession of the right, whether directly or indirectly, and whether by ownership, license or otherwise, to grant a license, sublicense or other right to or under such Intellectual Property without violating the
terms of any agreement with a third party related to such Intellectual Property. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Daily Amount</U>&#148; shall have
the meaning set forth in <U>Section&nbsp;2.02(b)</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Default</U>&#148; shall mean the occurrence of any event or
circumstance that would, with the giving of notice, lapse of time, or both, be an Event of Default. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Delinquent
Assigned Interests Payment</U>&#148; shall mean, with respect to any Assigned Interests Payment and, if owed by the Company to Purchaser, any payment due under <U>Section&nbsp;5.08(g)(iii)</U> that is not paid when due shall, in each case, be an
amount equal to the product of the amount so owed multiplied by the lower of (i)&nbsp;the highest rate permitted by applicable law, and (ii)&nbsp;one and one-half percent (1.5%)&nbsp;per month, compounded monthly. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Deposit Account</U>&#148; shall mean collectively, any deposit and segregated deposit account established and maintained at the
Deposit Bank pursuant to a Deposit Agreement and this Agreement. The Deposit Account shall be the account into which all payments made to the Company in respect of the sale of the Product are to be remitted. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Deposit Agreement</U>&#148; shall mean the agreement entered into by a Deposit Bank, the Company and Purchaser, substantially in
the form of <U>Exhibit C</U> attached hereto, pursuant to which, among other things, the Deposit Account, the Joint Concentration Account, the Purchaser Concentration Account and the Company Concentration Account shall be established and maintained.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Deposit Bank</U>&#148; shall mean Silicon Valley Bank or such other bank or financial institution approved by each
of Purchaser and the Company and a party to any Deposit Agreement (it being understood that the parties intend to engage a new bank within 120 days of the date hereof). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Dispute</U>&#148; shall have the meaning set forth in <U>Section&nbsp;3.12(e)</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Event of Default</U>&#148; shall mean the occurrence of any Put Option Event (other than pursuant to clause of (a)&nbsp;of said definition) and any material breach by the Company of the
Transaction Documents, whether or not constituting a Put Option Event. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Excluded Liabilities and
Obligations</U>&#148; shall have the meaning set forth in <U>Section&nbsp;2.04</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Existing Agent</U>&#148; shall
mean Midcap Financial SBIC LP, in its capacity as agent for the lenders under the Existing Credit Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Existing Credit Agreement</U>&#148; shall mean that certain Loan and Security Agreement, dated as of September&nbsp;30, 2011
among the Company, its Subsidiary, the Existing Agent and the lenders party thereto, as amended, restated, supplemented or otherwise modified from time to time. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 6 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>FDA</U>&#148; shall mean the United States Food and Drug Administration or any
successor federal agency thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Financial Statements</U>&#148; shall mean (a)&nbsp;the audited consolidated
balance sheets of the Company and its Subsidiary as of December&nbsp;31, 2012 and 2011, and the related audited consolidated statements of operations, cash flows and shareholders&#146; equity for the Fiscal Years then ended and (b)&nbsp;the
unaudited consolidated balance sheet of the Company and its Subsidiary as of June&nbsp;30, 2012, and the related unaudited consolidated statements of operations, cash flows and shareholders&#146; equity for the three (3)&nbsp;and six (6)&nbsp;month
period then ended. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Fiscal Quarter</U>&#148; shall mean each three (3)&nbsp;month period commencing
January&nbsp;1,&nbsp;April&nbsp;1,&nbsp;July&nbsp;1 or October&nbsp;1, provided however that (a)&nbsp;the first Fiscal Quarter of the Term shall extend from the Closing Date to the end of the first full Fiscal Quarter thereafter, and (b)&nbsp;the
last Fiscal Quarter of the Term shall end upon the expiration of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Fiscal Year</U>&#148; shall mean
the calendar year. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>GAAP</U>&#148; shall mean generally accepted accounting principles in the United States in effect
from time to time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Governmental Authority</U>&#148; shall mean any government, court, regulatory or administrative
agency or commission, or other governmental authority, agency or instrumentality, whether foreign, federal, state or local (domestic or foreign), including the United States Patent and Trademark Office, the FDA, or the United States National
Institutes of Health. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Gross Product Revenues</U>&#148; means, for any period of determination, the sum of the
following for such period: (a)&nbsp;the amounts invoiced and recognized as revenue in accordance with GAAP by the Company, its Subsidiaries or any of their Affiliates with respect to the sale of Product to a Third Party by the Company, its
Subsidiaries or any of their Affiliates, (b)&nbsp;the amounts invoiced and recognized as revenue in accordance with GAAP by the Company, its Subsidiaries or any of their Affiliates from a Third Party with respect to the sale, distribution or other
use of the Product by such Third Party in connection with any marketing, royalty, manufacturing, co-promotion, co-development, equity investment, cost sharing or other strategic arrangements, and (c)&nbsp;any collections in respect of write-offs or
allowances for bad debts in respect of items described in the preceding clauses (a)&nbsp;and (b). For purposes of prevention of duplication, &#147;Gross Product Revenue&#148; shall not include amounts invoiced by distributors, wholesalers or other
Persons acting in similar capacities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Guarantee and Collateral Agreement</U>&#148; shall mean the Guarantee and
Collateral Agreement between the Company and Purchaser providing for, among other things, the grant by the Company in favor of Purchaser of a valid continuing, perfected lien on and security interest in, the Assigned Interests and the other Assigned
Interests Collateral described therein, which Guarantee and Collateral Agreement shall be substantially in the form of <U>Exhibit A</U>. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 7 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Intellectual Property</U>&#148; shall mean all proprietary information; technical
data; laboratory notebooks; clinical data; priority rights; trade secrets; know-how; confidential information; inventions (whether patentable or unpatentable and whether or not reduced to practice or claimed in a pending patent application) and
improvements thereto; Patents; registered or unregistered trademarks, trade names, service marks, including all goodwill associated therewith; registered and unregistered copyrights and all applications thereof; in each case that are owned,
Controlled by, generated by, issued to, licensed to, licensed by or hereafter acquired by or licensed by the Company, in each case relating to, or otherwise relevant or desirable, now or in the future, for the manufacture and sale of the Product.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Interim Payment</U>&#148; shall have the meaning set forth in the Recitals. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Interim Royalty Purchase Agreement</U>&#148; shall have the meaning set forth in the Recitals. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>IRR</U>&#148; shall mean the internal rate of return utilizing the same methodology utilized by the XIRR function in Microsoft
Excel. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Joint Concentration Account</U>&#148; shall mean a segregated account, subject to a control agreement in
favor of Purchaser, established for the benefit of the Company and Purchaser and maintained at the Deposit Bank pursuant to the terms of the Deposit Agreement and this Agreement. The Joint Concentration Account shall be the account into which the
Deposit Bank sweeps the funds held in the Deposit Account. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Knowledge</U>&#148; shall mean the actual knowledge, or
that which would or should have been known after reasonable inquiry, of any officer, director or employee of the Company or its Subsidiaries relating to a particular matter. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>License Agreement</U>&#148; shall mean any existing or future license, commercialization, co-promotion, collaboration, distribution, marketing or partnering agreement entered into before or
during the Revenue Interest Period by the Company or any of its Affiliates relating to the Product and/or under the Intellectual Property. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Licensees</U>&#148; shall mean, collectively, the licensees, sublicensees or distributors under the License Agreements; each a &#147;<U>Licensee</U>&#148;. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Liens</U>&#148; shall mean any lien, hypothecation, charge, instrument, license, preference, priority, security agreement,
security interest, interest, mortgage, deed of trust, option, privilege, pledge, liability, covenant, order, tax, right of recovery, trust or deemed trust (whether contractual, statutory or otherwise arising) or any encumbrance, right or claim of
any other person of any kind whatsoever whether choate or inchoate, filed or unfiled, noticed or unnoticed, recorded or unrecorded, contingent or non-contingent, material or non-material, known or unknown, including, without limitation, any
conditional sale or other title retention agreement, any lease having the same financial effect as any of the foregoing, and the filing of, or agreement to give, any financing statement under the UCC. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Losses</U>&#148; shall mean collectively, any and all claims, damages, losses, judgments, awards, penalties, liabilities, costs
and expenses (including reasonable expenses of investigation and reasonable attorneys&#146; fees and expenses incurred in connection with investigating, preparing for or defending any action, suit or proceeding). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 8 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Major Countries</U>&#148; shall mean the United States. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Material Adverse Change</U>&#148; shall mean, with respect to the Company and its Subsidiaries, any event, change, circumstance,
occurrence, effect or state of facts that has caused or is reasonably likely to cause a material adverse change on the business, operations, assets, condition (financial or otherwise), results of operations or prospects of the Company and its
Subsidiaries, taken as a whole. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Material Adverse Effect</U>&#148; shall mean (a)&nbsp;the effect of a Material
Adverse Change, (b)&nbsp;a material adverse effect on the validity or enforceability of any of the Transaction Documents, (c)&nbsp;material adverse effect on the ability of the Company to perform any of its obligations under the Transaction
Documents, (d)&nbsp;the inability or failure of Company to make payment of the Assigned Interests or any other amounts in violation of this Agreement, and (e)&nbsp;any material adverse effect on the Product or the ability of the Company to
distribute, market and/or sell the Product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Material Contract</U>&#148; shall mean: (a)&nbsp;any marketing
agreement, co-promotion agreement or partnering agreement related to the manufacture, sale or distribution of the Product in any of the Major Countries; or (b)&nbsp;any agreement relating to any Material Patent, including any license, assignment, or
agreement related to Control of such Material Patent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Net Revenues</U>&#148; shall mean, for any period of
determination, the difference of </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Gross Product Revenues for such period, less </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) the sum, with respect to the items described in clauses (i)&nbsp;and (ii)&nbsp;of the definition of Gross Product Revenues, of
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) cash, trade discounts and rebates actually granted or paid Third Parties in accordance with customary industry standards,
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) allowances and adjustments actually credited to customers for Product that is spoiled, damaged, outdated, obsolete,
returned or otherwise recalled, but only if and to the extent the same are in accordance with sound business practices and not in excess of customary industry standards, </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(iii) charges for freight, postage, shipping, delivery, service and insurance charges, to the extent invoiced, </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(iv) taxes, duties or other governmental charges to the extent invoiced, </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v)
write-offs or allowances for bad debts, </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vi) rebates and chargebacks and other price reduction programs granted to managed
care entities, Governmental Authorities, group purchasing organizations or pharmaceutical benefit management companies, and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vii) other payments required by law to be made under Medicaid, Medicare or other government special medical assistance programs.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 9 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net Revenues shall be determined in accordance with GAAP as applied by the Company and its
Subsidiary on the date of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>New Securities</U>&#148; shall mean, collectively, equity securities of
the Company, whether or not currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such
equity securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Obligations</U>&#148; shall mean any and all obligations of the Company under the Transaction
Documents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Offer Notice</U>&#148; shall have the meaning set forth in <U>Section&nbsp;5.16(a)</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Patents</U>&#148; shall mean all patents, patent rights, patent applications, patent disclosures and invention disclosures
issued or filed, together with all reissues, divisions, continuations, continuations-in-part, revisions, term extensions, substitutes, supplementary protection certificates and reexaminations, including the inventions claimed in any of the foregoing
and any priority rights arising therefrom, covering or related to the manufacture, use and sale of the Product that are issued or filed as of the date hereof or during the Revenue Interest Period, including, without limitation, those identified in
Schedule 3.12(a) in each case, which are owned, Controlled by, issued to, licensed to or licensed by the Company, its Subsidiary or any of its Affiliates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Person</U>&#148; shall mean an individual, corporation, partnership, limited liability company, association, trust or other entity or organization, but not including a government or political
subdivision or any agency or instrumentality of such government or political subdivision. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Product</U>&#148; shall mean Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, AXOGUARD<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve
Protector and AXOGUARD<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector, regardless of the purpose for which such products are marketed or sold,
and any and all future iterations of such products developed or licensed by the Company as a solution to repair or protect nerves as marketed in any jurisdiction. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Purchase Price</U>&#148; shall mean $20,800,000 less the Interim Payment and any additional amounts due and payable under the Interim Royalty Purchase Agreement as of the Closing Date.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Purchaser</U>&#148; shall have the meaning set forth in the first paragraph hereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Purchaser Concentration Account</U>&#148; shall mean a segregated account established for the benefit of Purchaser and
maintained at a bank specified in writing by Purchaser pursuant to the terms of the Deposit Agreement and this Agreement. The Purchaser Concentration Account shall be the account into which the funds held in the Joint Concentration Account which are
payable to Purchaser pursuant to this Agreement are swept by the Deposit Bank in accordance with the terms of this Agreement and the Deposit Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Purchaser Designee</U>&#148; shall have the meaning set forth in <U>Section&nbsp;5.15(a)</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Purchaser Indemnified Party</U>&#148; shall have the meaning set forth in <U>Section&nbsp;7.05(a)</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Put Option</U>&#148; shall have the meaning set forth in <U>Section&nbsp;5.07(b)</U>. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 10 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Put Option Closing Date</U>&#148; shall have the meaning set forth in
<U>Section&nbsp;5.07(b)</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Put Option Event</U>&#148; shall mean any one of the following events: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) the anniversary of four (4)&nbsp;years from the Closing Date; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) any Bankruptcy Event; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) occurrence of a Material Adverse Effect; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) any Transfer by the Company of
its interests in the Revenue Interests or substantially all of its interest in the Product; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) any material breach of any
representation or warranty made by the Company in this Agreement or any material breach of or default under any covenant or agreement by the Company pursuant to a Transaction Document, which breach is not cured within thirty (30)&nbsp;days after the
earlier of (1)&nbsp;written notice thereof being delivered by Purchaser to the Company and (2)&nbsp;the date the Company becomes aware of such material breach. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Put Price</U>&#148; shall mean the sum of (i)&nbsp;an amount that, when paid to Purchaser, would generate an IRR to Purchaser of twenty percent (20%)&nbsp;on all payments made by Purchaser
pursuant to the Interim Royalty Purchase Agreement and <U>Section&nbsp;2.03</U> of this Agreement as of the date of payment of the Put Price, taking into account the amount and timing of all payments made by the Company to Purchaser (and retained by
Purchaser) pursuant to <U>Sections 2.02</U> and <U>5.08</U> of this Agreement and, if applicable, the Interim Royalty Purchase Agreement, prior to and as of the date of payment of the Put Price, plus (ii)&nbsp;any Delinquent Assigned Interests
Payment owed (it being understood and agreed that in calculating the Put Price, in no event shall Purchaser be required to repay any amounts previously paid to Purchaser pursuant to <U>Sections 2.02</U> and <U>5.08</U> of this Agreement if such
payments exceed the IRR required pursuant to this definition). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Quarterly Report</U>&#148; shall mean, with respect
to the relevant Fiscal Quarter of the Company, (a)&nbsp;a report showing Gross Profit Revenues for such quarter and the adjustments and other reconciliations used to arrive at Net Revenues for such quarter, reconciled, in each case, to the most
applicable line item in the Company&#146;s consolidated statements of operations as most recently filed or to be filed with the Securities and Exchange Commission or furnished to Purchaser pursuant to <U>Section&nbsp;5.02(h)</U> and (b)&nbsp;a
reconciliation of all payments made by the Company to Purchaser pursuant to this Agreement during such quarter, including all amounts deposited into the Purchaser Concentration Account during such quarter. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Regulatory Agency</U>&#148; shall mean a Governmental Authority with responsibility for the approval of the marketing and sale
of pharmaceuticals in the United States or other regulation of pharmaceuticals. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Regulatory Approval</U>&#148; shall
mean all approvals (including, without limitation, where applicable, pricing and reimbursement approval and schedule classifications), product and/or establishment licenses, registrations or authorizations of any Governmental Authority necessary for
the manufacture, use, storage, import, export, transport, offer for sale, or sale of the Product in a regulatory jurisdiction. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 11 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Revenue Interest Period</U>&#148; shall mean the period from and including the
Closing Date through the earliest of: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) expiration of eight (8)&nbsp;complete years following the Closing Date; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) payment of the Put Price; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) payment of the Change of Control Payment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Revenue
Interests</U>&#148; shall mean all of the Company&#146;s interest in the Gross Product Revenues. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Secretary&#146;s
Certificate</U>&#148; shall mean the duly executed Secretary&#146;s and Officer&#146;s Certificate, dated as of the Closing Date, in form and substance reasonably satisfactory to Purchaser, (W)&nbsp;attaching certified copies of the Company&#146;s
organizational documents (together with any and all amendments thereto); (X)&nbsp;attaching certified copies of the resolutions adopted by the board of directors of the Company authorizing and approving the execution, delivery and performance by the
Company of the Agreement and the Assignment of Interests and the transactions contemplated herein and therein; (Y)&nbsp;setting forth the incumbency of the officer or officers of the Company who have executed and delivered the Agreement and the
Assignment of Interests; and (Z)&nbsp;attaching copies, certified by such officer as true and complete, of a certificate of the appropriate Governmental Authority of the Company&#146;s jurisdiction of formation, stating that the Company is in good
standing under the laws of the State of Minnesota. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Subsidiary</U>&#148; shall mean, with respect to any Person, any
other Person controlled by such first Person, directly or indirectly, through one or more intermediaries. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Tax</U>&#148; or &#147;<U>Taxes</U>&#148; shall mean any federal, state, local or foreign tax, levy, impost, duty, assessment,
fee, deduction or withholding or other charge, including all excise, sales, use, value added, transfer, stamp, documentary, filing, recordation and other fees imposed by any taxing authority (and interest, fines, penalties and additions related
thereto). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Tax Return</U>&#148; shall mean any report, return, form (including elections, declarations, statements,
amendments, claims for refund, schedules, information returns or attachments thereto) or other information supplied or required to be supplied to a Governmental Authority with respect to Taxes. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Term</U>&#148; shall have the meaning set forth in <U>Section&nbsp;6.01</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Term Sheet</U>&#148; shall mean the Term Sheet between the Company and Purchaser, dated July&nbsp;26, 2012. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Third Party</U>&#148; shall mean any Person other than the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Transaction Documents</U>&#148; shall mean, collectively, this Agreement, the Assignment of Interests, the Guarantee and
Collateral Agreement, the UCC Financing Statements, the Deposit Agreement, the Secretary&#146;s Certificate and any related ancillary documents or agreements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 12 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Transfer</U>&#148; shall mean any sale, conveyance, assignment, disposition,
pledge, hypothecation or transfer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>True-Up Amount</U>&#148; shall have the meaning set forth in
<U>Section&nbsp;5.08(g)(i)</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>True-Up Statement</U>&#148; shall have the meaning set forth in
<U>Section&nbsp;5.08(g)(i)</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>UCC</U>&#148; shall mean the Uniform Commercial Code (or any similar or equivalent
legislation) as in effect in any applicable jurisdiction. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>UCC Financing Statements</U>&#148; shall mean the UCC-1
financing statements, in form and substance reasonably satisfactory to Purchaser, that shall be filed at or promptly following the Closing, as well as any additional UCC-1 financing statements or amendments thereto as reasonably requested from time
to time, to perfect Purchaser&#146;s security interest in the Assigned Interests Collateral. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>United States</U>&#148;
shall mean the United States of America. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Year-to-Date Assigned Interests</U>&#148; shall have the meaning set forth
in <U>Section&nbsp;5.08(g)(i)</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Year-to-Date Net Revenues</U>&#148; shall have the meaning set forth in
<U>Section&nbsp;5.08(g)(i)</U>. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE II </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>PURCHASE OF INTERESTS </B></FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;2.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Purchase</U></B>. <B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Upon the terms and subject to the conditions set forth in this Agreement, the Company agrees to sell, assign, transfer and convey to
Purchaser, and Purchaser agrees to purchase from the Company, free and clear of all Liens (except those Liens created in favor of Purchaser pursuant to the Guarantee and Collateral Agreement, the Assignment of Interests and any other Transaction
Document), all of the Company&#146;s rights and interests in and to the Assigned Interests on the Closing Date. Purchaser&#146;s ownership interest in each of the Assigned Interests so acquired shall vest immediately upon the Company&#146;s receipt
of payment for such Assigned Interests pursuant to <U>Section&nbsp;2.03(a)</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The Company and Purchaser intend and
agree that the sale, assignment and transfer of the Assigned Interests under this Agreement is a true sale by the Company to Purchaser that provides Purchaser with the full benefits of ownership of the Assigned Interests. The Company waives any
right to contest or otherwise assert that this Agreement is other than a true sale by the Company to Purchaser in any bankruptcy or insolvency proceeding relating to the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) The Company hereby consents to Purchaser recording and filing, at Purchaser&#146;s sole cost and expense, the UCC Financing
Statements and other financing statements in the appropriate filing offices under the UCC (and continuation statements with respect to such financing statements when applicable) meeting the requirements of applicable law in such manner and in such
jurisdictions as are necessary or appropriate to perfect the purchase by Purchaser of the Assigned Interests. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 13 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;2.02</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Payments by the Company</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Payments in Respect of the Assigned Interests</U>. In connection with the assignment of the Assigned Interest, Purchaser shall be entitled to receive (i)&nbsp;the Assigned Interests in respect of
Net Revenues earned during the Revenue Interest Period and (ii)&nbsp;any Delinquent Assigned Interests Payment, as and when due. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Interim Payments into Deposit Accounts</U>. Subject to <U>Section&nbsp;5.08(a)</U>, within 120 days of the date hereof, the Applicable Percentage of the Aggregate Deposit Funds in each Fiscal Year
shall be swept from the Deposit Account into the Purchaser Concentration Account on a daily basis (the &#147;<U>Daily Amount</U>&#148;) pursuant to <U>Section&nbsp;5.08</U>. Prior to the establishment of Purchaser Concentration Account as
contemplated by <U>Section&nbsp;5.08(a)</U>, the Company shall promptly pay to Purchaser upon demand the aggregate Daily Amount. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Payment Procedure</U>. Other than payments made pursuant to the Deposit Agreement, any payments to be made by the Company to Purchaser hereunder or under any other Transaction Document shall be
made by wire transfer of immediately available funds. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;2.03</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Closing; Payment Purchase Price; Closing Deliveries</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Closing</U>. The closing of the purchase of the Assigned Interests pursuant to this Agreement (the &#147;<U>Closing</U>&#148;) will take place concurrently with the execution of this Agreement on
the date hereof (the &#147;<U>Closing Date</U>&#148;) and will be held at the offices of PDL. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Payment of Purchase
Price</U>. At the Closing, Purchaser shall pay to the Company the Purchase Price by wire transfer of immediately available funds to the account designated by the Company prior to the date hereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Closing Deliveries</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(i) At the Closing, the Company will deliver to Purchaser: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A. its duly executed
counterpart to each of the Transaction Documents to which the Company is a party; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">B. a duly executed Secretary&#146;s
Certificate, dated as of the Closing Date; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">C. a payoff letter in form and substance reasonably satisfactory to Purchaser and
duly executed and delivered by the Company and the Existing Agent which provides for the payment in full of the obligations owing under the Existing Credit Agreement and release of the liens thereunder; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">D. copies of the UCC Financing Statements in respect of the Assigned Interests Collateral in form for filing in each appropriate
jurisdiction; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">E. a legal opinion reasonably satisfactory to Purchaser from Morgan, Lewis&nbsp;&amp; Bockius LLP
addressing such matters with respect to the Transaction Documents as set forth on <U>Exhibit D</U> hereto. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 14 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) At the Closing, the Purchaser will deliver to the Company: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A. payment of the Purchase Price consistent with <U>Section&nbsp;2.03(b)</U>; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">B. its duly executed counterpart to each of the Transaction Documents to which Purchaser is a party. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;2.04</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>No Assumed Obligations</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding any provision in this Agreement or any other writing to the contrary, Purchaser is acquiring only the Assigned Interests and is not assuming any liability or obligation of the Company or
any of its Affiliates of whatever nature, whether presently in existence or arising or asserted hereafter, whether under any Transaction Document or otherwise. All such liabilities and obligations shall be retained by and remain obligations and
liabilities of the Company or its Affiliates (the &#147;<U>Excluded Liabilities and Obligations</U>&#148;). </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE III
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>REPRESENTATIONS AND WARRANTIES OF COMPANY </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of all the representations and warranties contained in Article III, the term &#147;<U>Product</U>&#148;
shall mean Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, AXOGUARD<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector and AXOGUARD<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
Nerve Connector as such products currently exist and are marketed in any jurisdiction, and no broader definition shall be implied. The Company hereby represents and warrants to Purchaser, as of the Closing Date, the following: </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;3.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Organization</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Each of the Company and its Subsidiary is a corporation duly incorporated, validly existing and in good standing under the laws of the States of Minnesota and Delaware, respectively, and has all corporate
powers and all licenses, authorizations, consents and approvals required to carry on its respective business as now conducted and as proposed to be conducted in connection with the transactions contemplated by the Transaction Documents. Each of the
Company and its Subsidiary is duly qualified to do business as a foreign corporation and is in good standing in every jurisdiction in which the failure to do so would have a Material Adverse Effect. The Company has no direct or indirect
Subsidiaries, other than AxoGen Corporation, a Delaware corporation. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;3.02</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Authorization</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company has all necessary power and authority to enter into, execute and deliver the Transaction Documents and to perform all of the obligations to be performed by it hereunder and thereunder and to
consummate the transactions contemplated hereunder and thereunder. The Transaction Documents have been duly authorized, executed and delivered by the Company and each Transaction Document constitutes the valid and binding obligation of the Company,
enforceable against the Company in accordance with their respective terms, subject, as to enforcement of remedies, to bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&#146; rights generally or general equitable
principles. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 15 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;3.03</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Governmental Authorization</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The execution and delivery by the Company of the Transaction Documents, and the performance by the Company of its obligations hereunder and thereunder, does not require any notice to, action or consent
by, or in respect of, or filing with, any Governmental Authority, except for the filing of the UCC Financing Statements. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;3.04</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Ownership</U></B>. <B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The Company owns, Controls, or holds a valid license under, all of the Intellectual Property and the Regulatory Approvals which it
currently purports to own related to the Product free and clear of all Liens, and no license or covenant not to sue under any Intellectual Property has been granted to or exists in any Third Party. Neither the Company nor its Subsidiary has granted,
nor does there exist, any Lien on the Revenue Interests, the Assigned Interests or any other Collateral (except those Liens created in favor of Purchaser pursuant to the Guarantee and Collateral Agreement, the Assignment of Interests and any other
Transaction Document). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The Company, immediately prior to the purchase of the Assigned Interests, owns, and is the sole
holder of, all the Revenue Interests; and the Company owns, and is the sole holder of, and/or has and holds a valid, enforceable and subsisting license to, all of those other assets that are required to produce or receive any payments from any
Licensee or payor under and pursuant to, and subject to the terms of any License Agreement, in each case free and clear of any and all Liens, except those Liens created in favor of Purchaser pursuant to the Guarantee and Collateral Agreement, the
Assignment of Interests and any other Transaction Document. The Company has not transferred, sold, or otherwise disposed of, or agreed to transfer, sell, or otherwise dispose of any portion of the Revenue Interests other than under the Interim
Royalty Purchase Agreement or as contemplated by this Agreement. No Person other than the Company has any right to receive the payments payable under any License Agreement, other than Purchaser&#146;s rights with respect to the Assigned Interests,
from and after the Closing Date. The Company has the full right to sell, transfer, convey and assign to Purchaser all of the Company&#146;s rights and interests in and to the Assigned Interests being sold, transferred, conveyed and assigned to
Purchaser pursuant to this Agreement without any requirement to obtain the consent of any Person. By the delivery to Purchaser of the executed Assignment of Interests, the Company shall transfer, convey and assign to Purchaser all of the
Company&#146;s rights and interests in and to the Assigned Interests being sold, transferred, conveyed and assigned to Purchaser pursuant to this Agreement, free and clear of any Liens, except those Liens created in favor of Purchaser pursuant to
the Guarantee and Collateral Agreement, the Assignment of Interests and any other Transaction Document. At the Closing, and upon the delivery of the Assignment of Interests to Purchaser by the Company, Purchaser shall have acquired good and valid
rights and interests of the Company in and to the Assigned Interests being sold, transferred, conveyed and assigned to Purchaser pursuant to this Agreement, free and clear of any and all Liens, except those Liens created in favor of Purchaser
pursuant to the Guarantee and Collateral Agreement, the Assignment of Interests and any other Transaction Document. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) As of
the Closing Date and upon the Company&#146;s execution and delivery of the Guarantee and Collateral Agreement, Purchaser shall have valid, continuing, first perfected lien on and security interest in the Revenue Interests, the Assigned Interests and
the other Assigned Interests Collateral described in the Guarantee and Collateral Agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 16 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;3.05</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Financial Statements</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Financial Statements are complete and accurate in all material respects, were prepared in conformity with GAAP and present fairly in all material respects the financial position and the financial
results of the Company and its Subsidiary as of the dates and for the periods covered thereby. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;3.06</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>No Undisclosed Liabilities</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Except for those liabilities (a)&nbsp;specifically identified on the face of the Financial Statements, (b)&nbsp;incurred by the Company in the ordinary course of business since June&nbsp;30, 2012, or
(c)&nbsp;in connection with the Obligations under the Transaction Documents, there are no material liabilities of the Company or its Subsidiary of any kind whatsoever, whether accrued, contingent, absolute, determined or determinable. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;3.07</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Solvency</U></B>. <B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company and its Subsidiary, taken as a whole, are not insolvent as defined in any statute of the United States Bankruptcy Code or in
the fraudulent conveyance or fraudulent transfer statutes of the States of Delaware, Florida, Minnesota or New York. Assuming consummation of the transactions contemplated by the Transaction Documents, (a)&nbsp;the present fair saleable value of the
Company&#146;s and its Subsidiary&#146;s assets and the fair value of the Company&#146;s and its Subsidiary&#146;s assets are each greater than the total amount of liabilities (including contingent and unliquidated liabilities) of the Company and
its Subsidiary as such liabilities mature, (b)&nbsp;neither the Company nor its Subsidiary has unreasonably small capital with which to engage in its respective business, and (c)&nbsp;neither the Company nor its Subsidiary has incurred, nor does
either have present plans to or intend to incur, debts or liabilities beyond their respective ability to pay such debts or liabilities as they become absolute and matured. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;3.08</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Litigation</U></B>. <B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There is no (a)&nbsp;action, suit, arbitration proceeding, claim, investigation or other proceeding pending or, to the Knowledge of the
Company, threatened against the Company or its Subsidiary or (b)&nbsp;any governmental inquiry pending or, to the Knowledge of the Company, threatened against the Company or its Subsidiary, in each case with respect to clauses (a)&nbsp;and
(b)&nbsp;above, which, if adversely determined, would question the validity of, or could adversely affect the transactions contemplated by any of the Transaction Documents or&nbsp;could reasonably be expected to have a Material Adverse Effect. There
is no action, suit, arbitration proceeding, claim, investigation or other proceeding pending or, to the Knowledge of the Company, threatened against the Company, its Subsidiary or any other Person relating to the Product, the Intellectual Property,
the Regulatory Approvals, the Revenue Interests or the Assigned Interests. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;3.09</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Compliance with Laws</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Neither the Company nor its Subsidiary (a)&nbsp;is in violation of, has violated, or to the Knowledge of the Company, is under investigation with respect to, and, (b)&nbsp;has been threatened to be
charged with or been given notice of any violation of any law, rule, ordinance or regulation of, or any judgment, order, writ, decree, permit or license entered by any Governmental Authority applicable to the Company, the Assigned Interests or the
Revenue Interests which would reasonably be expected to have a Material Adverse Effect. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 17 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;3.10</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Conflicts</U></B>. <B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neither the execution and delivery of any of this Agreement or the other Transaction Documents to which the Company is a party nor the
performance or consummation of the transactions contemplated hereby or thereby will: (a)&nbsp;contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, in any material
respects any provisions of: (i)&nbsp;any law, rule, ordinance or regulation of any Governmental Authority, or any judgment, order, writ, decree, permit or license of any Governmental Authority, to which the Company or its Subsidiary or any of their
respective assets or properties may be subject or bound; or (ii)&nbsp;any contract, agreement, commitment or instrument to which the Company or its Subsidiary is a party or by which the Company or its Subsidiary or any of their respective assets or
properties is bound or committed; (b)&nbsp;contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, any provisions of the articles or certificate of incorporation or bylaws
(or other organizational or constitutional documents) of the Company or its Subsidiary; (c)&nbsp;except for the filing of the UCC Financing Statements required hereunder and filings with the United States Patent and Trademark Office, require any
notification to, filing with, or consent of, any Person or Governmental Authority; (d)&nbsp;give rise to any right of termination, cancellation or acceleration of any right or obligation of the Company, its Subsidiary or any other Person or to a
loss of any benefit relating to the Revenue Interests or the Assigned Interests; or (e)&nbsp;other than pursuant to the Guarantee and Collateral Agreement, the Assignment of Interests, or any other Transaction Document, result in the creation or
imposition of any Lien on (i)&nbsp;the assets or properties of the Company or its Subsidiary or (ii)&nbsp;the Assigned Interests, the Revenue Interests, or any other Assigned Interests Collateral, except, in the case of the foregoing clauses (a),
(c), (d)&nbsp;or (e), for any such breaches, defaults or other occurrences that would not, individually or in the aggregate, have a Material Adverse Effect. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;3.11</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Subordination</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The claims and rights of Purchaser created by any Transaction Document in and to the Assigned Interests, the Revenue Interests and any other Assigned Interests Collateral are not and shall not be
subordinated to any creditor of the Company or any other Person. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;3.12</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Intellectual Property</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Schedule 3.12(a)</U> sets forth an accurate, true and complete list of all (i)&nbsp;Patents and utility models, (ii)&nbsp;trade names, registered trademarks, registered service marks, and
applications for trademark registration or service mark registration, (iii)&nbsp;registered copyrights and (iv)&nbsp;domain name registrations and websites, in each case with respect to clauses (i), (ii), (iii)&nbsp;and (iv)&nbsp;above in this
subsection (a)&nbsp;that the Company owns or licenses and which are necessary to make, have made, use, sell, have sold, offer for sale, import, develop, promote, market, distribute, manufacture, commercialize or otherwise exploit the Product in the
jurisdictions where the Product marketed and sold. For each item of Intellectual Property listed on <U>Schedule 3.12(a)</U>, the Company has identified (x)&nbsp;the owner, (y)&nbsp;the countries in which such listed item is patented or registered or
in which an application for Patent or registration is pending and (z)&nbsp;the application </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 18 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
number, the Patent number or registration number. To the Company&#146;s Knowledge, except as disclosed therein, each Patent and trademark listed on <U>Schedule 3.12(a)</U> is valid, enforceable
and subsisting and none has lapsed, expired, been cancelled or become abandoned. The Patent applications listed in <U>Schedule 3.12(a)</U> have been prosecuted by competent patent counsel in a diligent manner. After due inquiry, the Company has
determined that there are no published patents, patent applications, articles, prior art references, public uses, undisclosed information (including best mode) or other grounds, factors or circumstances that could adversely affect the validity or
enforceability of any of the Patents listed in <U>Schedule 3.12(a)</U>. After due inquiry, the Company has determined that all Persons relevant to the prosecution of any of the Material Patents or applications related thereto have complied with the
duty to disclose information and/or the duty of candor, including obligations to the United States Patent and Trademark Office specified under Rule 56. To the Company&#146;s Knowledge, each of the Material Patents and Material Patent applications
correctly identifies each and every inventor of the claims thereof as determined in accordance with the laws of the jurisdiction in which such Material Patent is issued or such Material Patent application is pending. To the Company&#146;s Knowledge,
each Person who has or has had any rights in or to the Intellectual Property listed on <U>Schedule 3.12(a)</U> that are owned by, or licensed to, the Company, including, each inventor named on the Patents and Patent applications listed in
<U>Schedule 3.12(a)</U>, has executed an agreement assigning his, her or its entire right, title and interest in and to such Intellectual Property, and the inventions embodied, described and/or claimed therein, to the purported owner and no such
Person has any contractual or other obligation that would preclude or conflict with any such assignment or otherwise conflict with the obligations of such Person to the applicable owner of each listed Intellectual Property. To the Company&#146;s
Knowledge, all Persons having a claim to inventorship to any pending or issued claim of the Patents are currently listed as inventors with respect to such Patents, and that the Company has performed an appropriate inquiry with respect to such
inventorship. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Except for Intellectual Property licensed to and owned by the Company and set forth on <U>Schedule
3.12(a)</U>, no other Intellectual Property is necessary to make, have made, offer to sell, sell, have sold, use, import, distribute, commercialize or market the Product in the Major Countries. The use, manufacture, import, export, offer for sale,
distribution, marketing and sale of the Product does not infringe any patents that are owned by a Third Party in the Major Countries. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) The Company has the full right, power and authority to grant all of the rights and interests granted to Purchaser in this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) To the Company&#146;s Knowledge, there are no unpaid maintenance, annuity or renewal fees currently overdue for any of the Patents
that cover the manufacture, use or sale of the Product or which cover compositions of matter and/or processes which relate to the Product or alternatives thereto (&#147;<U>Material Patents</U>&#148;). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) There is, and has been, no pending, decided or settled opposition, interference proceeding, reexamination proceeding, cancellation
proceeding, injunction, claim, lawsuit, declaratory judgment, administrative post-grant review proceeding, other administrative or judicial proceeding, hearing, investigation, complaint, arbitration, mediation, International Trade Commission
investigation, decree, or any other filed claim (collectively referred to hereinafter as &#147;<U>Disputes</U>&#148;) related to any of the Material Patents, nor, to the Knowledge of the Company, has
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 19 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
any such Dispute been threatened challenging the legality, validity, enforceability or ownership of any Material Patents or which would give rise to a credit against the revenues or royalties due
to the Company for the manufacture, sale, offer for sale, use, importation or exportation of the Product and the Company has no notice of any facts that would form the basis for such a Dispute. There are no Disputes by any Person or Third Party
against the Company, its Licensees or its licensor, and the Company has not received any written notice or claim of any such Dispute as pertaining to the Product. Neither the Company nor its licensor has sent any notice of any such Dispute to a
Third Party. The Company is not subject to any outstanding injunction, judgment, order, decree, ruling, charge, settlement or other disposition of Dispute which relates to the Product or the Patents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) There is no pending or threatened action, suit, or proceeding, or any investigation or claim by any Governmental Authority to which
the Company is a party (i)&nbsp;that would be the subject of a claim for indemnification by any Person or Third Party under any agreement, or (ii)&nbsp;that the marketing, sale or distribution of the Product worldwide by the Company or its by
Licensees pursuant to the related License Agreement, as applicable, does or will infringe on any patent of any other Person, and there is no basis for any such action, suit, proceeding, investigation or claim of the type described in clause
(i)&nbsp;or (ii)&nbsp;above. To the Company&#146;s Knowledge, there are no pending published or unpublished United States, international or foreign patent applications owned by any other Person, which, if issued, would limit or prohibit, in any
material respect, the use of the Product or the licensed Intellectual Property relating to the Product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) The Company has
taken all commercially reasonable measures and precautions necessary to protect and maintain (i)&nbsp;the confidentiality of all Intellectual Property that it owns and (ii)&nbsp;the value of all Intellectual Property related to the Product, except
where such failure to take action would not have a Material Adverse Effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(h) No material trade secret of the Company has
been published or disclosed to any Person except pursuant to a written agreement requiring such Person to keep such trade secret confidential, except where such disclosure would not have a Material Adverse Effect. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) Each Product, or its manufacture or use, is covered by one or more claims of an issued Patent in the United States. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;3.13</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Regulatory Approval</U></B>.<B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) The Company and its Subsidiary have made available to Purchaser any written reports or other written communications received from a Governmental Authority that would indicate that any Regulatory
Agency (A)&nbsp;is not likely to approve the BLA, (B)&nbsp;is likely to revise or revoke any current Regulatory Approval granted by any Regulatory Agency with respect to the Product, or (C)&nbsp;is likely to pursue any material compliance actions
against the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The Company and its Subsidiary possess all Regulatory Approvals issued or required by the
appropriate Regulatory Agencies, which Regulatory Approvals are necessary to conduct the current clinical trials relating to the Product, and neither the Company nor its Subsidiary has received any notice of proceedings relating to the revocation,
suspension, termination or modification of any such Regulatory Approvals. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 20 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) The Company and its Subsidiary are in material compliance with, and has materially
complied with, all applicable federal, state, local and foreign laws, rules, regulations, standards, orders and decrees governing its business, including all regulations promulgated by each Regulatory Agency, the failure of compliance with which
could reasonably be expected to result in a Material Adverse Effect; the Company and its Subsidiary have not received any notice citing action or inaction by any of them that would constitute any material non-compliance with any applicable federal,
state, local and foreign laws, rules, regulations, or standards, which could reasonably be expected to result in a Material Adverse Effect; and to the Company&#146;s Knowledge, no prospective change in any applicable federal, state, local or foreign
laws, rules, regulations or standards has been adopted which, when made effective, could reasonably be expected to result in a Material Adverse Effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) Preclinical and clinical trials conducted on behalf of the Company or its Subsidiary relating to the Product were conducted in compliance with applicable laws and, in all material respects, in
accordance with experimental protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards; the descriptions of the results of such trials provided to Purchaser are accurate in all material
respects. Neither the Company nor its Subsidiary has received any notices or correspondence from any Regulatory Agency or comparable authority requiring the termination, suspension, or material modification or clinical hold of any clinical trials
conducted by or on behalf of the Company or its Subsidiary with respect to the Product, which termination, suspension, material modification or clinical hold could reasonably be expected to result in a Material Adverse Effect. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;3.14</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Material Contracts</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Neither the Company nor its Subsidiary is in breach of or in default under any Material Contract which default, individually or in the aggregate, could reasonably be expected to result in a Material
Adverse Effect. To the Knowledge of the Company, nothing has occurred and no condition exists that would permit any other party thereto to terminate any Material Contract. Neither the Company nor its Subsidiary has received any notice or, to the
Knowledge of the Company, any threat of termination of any such Material Contract. To the Knowledge of the Company, no other party to a Material Contract is in breach of or in default under such Material Contract. All Material Contracts are valid
and binding on the Company or its Subsidiary and, to the Knowledge of the Company, on each other party thereto, and are in full force and effect. The Company is in compliance with all obligations of the Amended and Restated Standard Exclusive
License Agreement with Sublicensing Terms between AxoGen Corporation and the University of Florida Research Foundation dated February&nbsp;21, 2006, and the Patent License Agreement between AxoGen Corporation and the Board of Regents of The
University of Texas System dated July&nbsp;19, 2005. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;3.15</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Place of Business</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s principal place of business and chief executive office are set forth on <U>Schedule&nbsp;3.15</U>. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 21 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;3.16</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Broker&#146;s Fees</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company and its Subsidiary have not taken any action that would entitle any Person to any commission or broker&#146;s fee in connection with this Agreement except fees, commissions and expenses to be
paid to JMP Securities LLC, all of which will be paid by the Company. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;3.17</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Other Information</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">No written statement, information, report or materials prepared by or on behalf of the Company or its Subsidiary and furnished to Purchaser by or on behalf of the Company or its Subsidiary in connection
with any Transaction Document or any transaction contemplated hereby or thereby, no written representation, warranty or statement made by the Company or its Subsidiary in any Transaction Document, and no Schedule or Exhibit hereto or thereto, in
each case taken in the aggregate, contains any untrue statement of a material fact or omits any statement of material fact necessary in order to make the statements made therein in light of the circumstances under which they were made not
misleading. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;3.18</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Insurance</U></B>. <B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are in full force and effect insurance policies maintained by the Company with an insurance company rated not less than
&#147;A-&#148; by A.M. Best Company, Inc., with coverages and in amounts customary for companies of comparable size and condition similarly situated in the same industry as the Company, including product liability insurance, directors and officers
insurance and insurance against litigation liability, subject only to such exclusions and deductible items as are usual and customary in insurance policies of such type. All material insurable risks in respect of the business and assets of the
Company and its Subsidiary are covered by such insurance policies. The Company has named Purchaser as an additional insured party with respect to its general liability and product liability insurance policies. A schedule of the Company&#146;s
insurance policy or insurance policies is attached hereto as <U>Schedule 3.18</U>. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;3.19</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Taxes</U></B>. <B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has timely filed (taking into account all extensions of due dates) all Tax returns required to be filed by, or on behalf of,
it and has timely paid all Taxes required to be paid with such returns. All Tax Returns filed by the Company (or on its behalf) have been true, correct and complete in all material respects. Except as set forth on Schedule 3.19, there is no
outstanding or, to the Company&#146;s Knowledge, threatened action, claim or other examination or proceeding with respect to Taxes of the Company or its assets (including with respect to the Assigned Interests and the Revenue Interests). Except as
set forth on Schedule 3.19, there are no Taxes of the Company that form or could form, individually or in the aggregate, the basis for a material encumbrance (other than encumbrances for current taxes not yet past due) on any of its assets
(including the Assigned Interests and the Revenue Interests). </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE IV </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>REPRESENTATIONS AND WARRANTIES OF PURCHASER </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Purchaser represents and warrants to the Company the following: </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;4.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Organization</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Purchaser is a corporation duly incorporated and validly existing under the laws of the State of Delaware. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 22 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;4.02</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Authorization</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Purchaser has all necessary power and authority to enter into, execute and deliver the Transaction Documents and to perform all of the obligations to be performed by it hereunder and thereunder and to
consummate the transactions contemplated hereunder and thereunder. The Transaction Documents have been duly authorized, executed and delivered by Purchaser and each Transaction Document constitutes the valid and binding obligation of Purchaser,
enforceable against Purchaser in accordance with their respective terms, subject, as to enforcement of remedies, to bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&#146; rights generally or general equitable
principles. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;4.03</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Broker&#146;s Fees</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Purchaser has not taken any action that would entitle any Person to any commission or broker&#146;s fee in connection with the transactions contemplated by the Transaction Documents. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;4.04</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Conflicts</U></B>. <B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neither the execution and delivery of this Agreement or any other Transaction Document to which Purchaser is a party nor the performance
or consummation of the transactions contemplated hereby or thereby will: (a)&nbsp;contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, in any material respects any
provisions of: (i)&nbsp;any law, rule or regulation of any Governmental Authority, or any judgment, order, writ, decree, permit or license of any Governmental Authority, to which Purchaser or any of its assets or properties may be subject or bound;
or (ii)&nbsp;any contract, agreement, commitment or instrument to which Purchaser is a party or by which Purchaser or any of its assets or properties is bound or committed; (b)&nbsp;contravene, conflict with, result in a breach or violation of,
constitute a default under, or accelerate the performance provided by, any provisions of the organizational or constitutional documents of Purchaser; or (c)&nbsp;require any notification to, filing with, or consent of, any Person or Governmental
Authority, except, in the case of the foregoing clauses (a)&nbsp;or (c), for any such breaches, defaults or other occurrences that would not, individually or in the aggregate, have a material adverse effect on the ability of Purchaser to perform any
of its obligations under the Transaction Documents. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE V </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>COVENANTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">From the date hereof through and including the end of the Revenue Interest Period, the following covenants shall apply: </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;5.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Consents and Waivers</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company shall use its commercially reasonable efforts to obtain and maintain any required consents, acknowledgements, certificates or waivers so that the transactions contemplated by this Agreement or
any other Transaction Document may be consummated and shall not result in any default or breach or termination of any of the Material Contracts. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 23 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;5.02</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Access; Information</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) <U>License Notices</U>. Subject to any applicable confidentiality restrictions, the Company shall promptly provide Purchaser with copies of any material written notices received or given by the
Company under any Material Contract, and to the extent the Company is barred from providing Purchaser with copies of such notices due to any applicable confidentiality restrictions, the Company shall (i)&nbsp;inform Purchaser of the existence of
such notice accompanied by a written description of the substance contained in such notice and (ii)&nbsp;promptly seek the removal or waiver of any such confidentiality restrictions so as to permit a free exchange of information with the Purchaser
regarding the substance of such notice. The Company shall promptly notify Purchaser of any breaches or alleged breaches under any Material Contracts and of any other events with respect to any Material Contract or the subject matter thereof which
could reasonably be expected to have a Material Adverse Effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Litigation or Investigations</U>. The Company shall
promptly notify Purchaser of (i)&nbsp;any action, demand, suit, claim, cause of action, proceeding or investigation pending or, to the best knowledge of the Company, threatened by or against the Company, or (ii)&nbsp;proceeding or inquiry of any
Governmental Authority pending or, to the best knowledge of the Company, threatened against the Company, related to any Material Contract, the Product, the Patents or any Transaction Document. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Maintenance of Books and Records</U>. The Company shall keep and maintain, or cause to be kept and maintained, at all times
accurate and complete books and records. During the Term, the Company shall keep and maintain, or cause to be kept and maintained, at all times full and accurate books of account and records adequate to correctly reflect all payments paid and/or
payable with respect to the Revenue Interests and Assigned Interests and all deposits made into the applicable deposit accounts. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) <U>Inspection Rights</U>. Purchaser and any of Purchaser&#146;s representatives shall have the right, once a year (and at any other time a Default or Event of Default shall have occurred or be
continuing), to visit the Company and its Subsidiaries&#146; offices and properties where the Company and its Subsidiaries keep and maintain their books and records relating or pertaining to the Revenue Interests, the Assigned Interests and the
other Assigned Interests Collateral for purposes of conducting an audit of such books and records, and to inspect, copy and audit such books and records, during normal business hours, and, upon five (5)&nbsp;Business Days&#146; written notice given
by Purchaser to the Company (provided one (1)&nbsp;Business Day&#146;s notice shall be required if a Default or Event of Default shall have occurred and be continuing), the Company will provide Purchaser and any of Purchaser&#146;s representatives
reasonable access to such books and records, and shall permit Purchaser and any of Purchaser&#146;s representatives to discuss the business, operations, properties and financial and other condition of the Company or any of its Affiliates including,
but not limited to, matters relating or pertaining to the Revenue Interests, the Assigned Interests and any the other Assigned Interests Collateral with officers of such parties, and with their independent certified public accountants. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) <U>Audit Costs</U>. In the event any audit of the books and records of the Company and its Subsidiaries relating to the Revenue
Interests, Assigned Interests, and the other Assigned Interests Collateral by Purchaser and/or any of Purchaser&#146;s representatives reveals that the amounts paid to Purchaser hereunder for the period of such audit have been understated by more
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 24 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
than five percent (5%)&nbsp;of the amounts determined to be due for the period subject to such audit, then the Audit Costs in respect of such audit shall be borne by the Company; and in all other
cases, such Audit Costs shall be borne by Purchaser. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) <U>Quarterly Reports</U>. During the Term, the Company shall,
promptly after the end of each Fiscal Quarter of the Company (but in no event later than forty-five (45)&nbsp;days following the end of such quarter), produce and deliver to Purchaser a Quarterly Report for such quarter, together with a certificate
of the Company, certifying that to the best Knowledge of the Company (i)&nbsp;such Quarterly Report is a true and complete copy and (ii)&nbsp;any statements and any data and information therein prepared by the Company are true, correct and accurate
in all material respects. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) <U>GAAP Accounting</U>. The Company shall maintain a system of accounting established and
administered in accordance with sound business practices to permit preparation of financial statements in conformity with GAAP. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(h) <U>Periodic Reports</U>. In the event that the Company is not subject to the reporting requirements of the Securities Exchange Act of
1934, as amended, the Company shall deliver to Purchaser the following financial statements: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) Within forty-five
(45)&nbsp;days after the end of each Fiscal Quarter, copies of the unaudited consolidated financial statements of the Company and its Subsidiaries for such Fiscal Quarter; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(ii) Within forty-five (45)&nbsp;days after the end of each Fiscal Year, copies of the audited consolidated financial statements of the Company and its Subsidiaries for such Fiscal Year. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;5.03</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Material Contracts</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company shall comply with all material terms and conditions of and fulfill all of its obligations under all the Material Contracts. The Company shall not amend, modify or supplement any Material
Contract in a manner which would adversely affect Purchaser or issue any waivers, consents, or other approvals under any Material Contract in a manner which would adversely affect Purchaser without the prior written consent of Purchaser. Upon the
occurrence of a material breach of any Material Contract by any Third Party thereto, which is not cured pursuant to the express terms as provided therein (disregarding any rights of waiver or extensions of time or other rights or consents that are
excisable at the discretion of the Company), the Company shall, in its discretion but in accordance with its sound business judgment, use its commercially reasonable efforts to enforce its rights and remedies thereunder. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;5.04</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Confidentiality; Public Announcement</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) All Confidential Information furnished by Purchaser to the Company or by the Company to Purchaser in connection with this Agreement and any other Transaction Document and the transactions contemplated
hereby and thereby, as well as the terms, conditions and provisions of this Agreement and any other Transaction Document, shall be kept confidential by the Company and Purchaser. Notwithstanding the foregoing, the Company and Purchaser may disclose
such Confidential Information to their partners, directors, employees, managers, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 25 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
officers, investors, bankers, advisors, trustees and representatives, <U>provided</U> that such Persons shall be informed of the confidential nature of such information and shall be obligated to
keep such information confidential pursuant to the terms of this <U>Section&nbsp;5.04(a)</U>. The Company will consult with Purchaser, and Purchaser will consult with the Company, on the form, content and timing of any such disclosures of
Confidential Information, including, without limitation, any disclosures made pursuant to applicable securities laws or made to investment or other analysts. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) Except as required by law or the rules and regulations of any securities exchange or trading system or the FDA or any Governmental Authority with similar regulatory authority, or except with the prior
written consent of the other party (which consent shall not be unreasonably withheld), no party shall issue any press release or make any other public disclosure with respect to the transactions contemplated by this Agreement or any other
Transaction Document; <U>provided</U>, <U>however</U>, that the Company and Purchaser may jointly prepare a press release for dissemination promptly following the Closing Date. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;5.05</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Guarantee and Collateral Agreement</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">During the Revenue Interest Period, the Company shall, at all times until the Obligations are paid and performed in full, grant in favor of Purchaser a valid, continuing, first perfected lien on and
security interest in the Revenue Interests, the Assigned Interests and the other Assigned Interests Collateral described in the Guarantee and Collateral Agreement. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;5.06</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Efforts; Further Assurance</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Subject to the terms and conditions of this Agreement, each of Purchaser and the Company will use its commercially reasonable efforts to take, or cause to be taken, all actions and to do, or cause to
be done, all things necessary under applicable laws and regulations to consummate the transactions contemplated by this Agreement and any other Transaction Document. Purchaser and the Company agree to execute and deliver such other documents,
certificates, agreements and other writings (including any financing statement filings requested by Purchaser) and to take such other actions as may be reasonably necessary in order to consummate or implement expeditiously the transactions
contemplated by this Agreement and any other Transaction Document and to vest in Purchaser good, valid and marketable rights and interests in and to the Assigned Interests free and clear of all Liens, except those Liens created in favor of Purchaser
pursuant to the Guarantee and Collateral Agreement, the Assignment of Interests and any other Transaction Document. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)
Purchaser and the Company shall execute and deliver such additional documents, certificates and instruments, and perform such additional acts, as may be reasonably requested and necessary or appropriate to carry out and effectuate all of the
provisions of this Agreement and any other Transaction Document and to consummate all of the transactions contemplated by this Agreement and any other Transaction Document. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) Purchaser and the Company shall cooperate and provide assistance as reasonably requested by the other party in connection with any Third Party litigation, arbitration or other Third Party proceeding
(whether threatened, existing, initiated, or contemplated prior to, on or after the date hereof) to which any party hereto or any of its officers, directors, shareholders, agents or employees is or may become a party or is or may become otherwise
directly or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 26 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
indirectly affected or as to which any such Persons have a direct or indirect interests, in each case relating to this Agreement, any other Transaction Document, the Assigned Interests or any
other Assigned Interests Collateral, or the transactions described herein or therein. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;5.07</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Change of Control; Put Option</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Change of Control</U>. In the event that a Change of Control shall occur during the Revenue Interest Period, the Company shall repurchase the Assigned Interests from Purchaser for a repurchase
price equal to the Change of Control Payment on or prior to the third Business Day after the occurrence of a Change of Control. The Change of Control Payment shall be made by wire transfer of immediately available funds to the account designated by
Purchaser. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Put Option</U>. In the event that a Put Option Event shall occur during the Term, Purchaser shall have the
right, but not the obligation (the &#147;<U>Put Option</U>&#148;) to require the Company to repurchase from Purchaser the Assigned Interests at the Put Price. In the event Purchaser elects to exercise its Put Option, Purchaser shall deliver written
notice to the Company specifying the closing date which date shall be forty-five (45)&nbsp;days from such notice date (the &#147;<U>Put Option Closing Date</U>&#148;), which notice must be given within sixty (60)&nbsp;days of Purchaser&#146;s
receipt of written notice from the Company of a Put Option Event. Failure to provide notice by such times will be deemed an irrevocable waiver of the right to exercise the Put Option. On the Put Option Closing Date, the Company shall repurchase from
Purchaser the Assigned Interests at the Put Price in cash, the payment of which shall be made by wire transfer of immediately available funds to the account designated by Purchaser. Notwithstanding anything to the contrary contained herein,
immediately upon the occurrence of a Bankruptcy Event, Purchaser shall be deemed to have automatically and simultaneously elected to have the Company repurchase from Purchaser the Assigned Interests for the Put Price in cash and the Put Price shall
be immediately due and payable without any further action or notice by any party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Call Option</U>. At any time after
the fourth anniversary following the Closing Date, the Company shall have the right (the &#147;<U>Call Option</U>&#148;), exercisable upon ten (10)&nbsp;days&#146; written notice to Purchaser, to repurchase the Assigned Interests from Purchaser at a
repurchase price equal to the Change of Control Payment. In order to exercise the Call Option, the Company shall deliver written notice to Purchaser of its election to so repurchase the Assigned Interests not less than ten (10)&nbsp;days prior to
the proposed closing date (the &#147;<U>Call Closing Date</U>&#148;). On the Call Closing Date, the Company shall repurchase from Purchaser the Assigned Interests at the Change of Control Payment, the payment of which shall be made by wire transfer
of immediately available funds to the account designated by Purchaser. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <U>Obligations of Purchaser</U>. In connection
with the consummation of a repurchase of the Assigned Interests pursuant to the Change of Control Payment or the Put Option, Purchaser agrees that it will (i)&nbsp;promptly but no later than three (3)&nbsp;Business Days execute and deliver to the
Company such UCC termination statements and other documents as may be necessary to release Purchaser&#146;s Lien on the Assigned Interests Collateral and otherwise give effect to such repurchase and (ii)&nbsp;take such other actions or provide such
other assistance as may be necessary to give effect to such repurchase. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 27 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;5.08</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Remittance to Deposit Account</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) On the Closing Date, the parties hereto shall enter into a Deposit Agreement in form and substance reasonably satisfactory to the parties hereto and the Deposit Bank, which Deposit Agreement will
provide for, among other things, the establishment and maintenance of a Deposit Account and Joint Concentration Account in accordance with the terms herein and therein. Funds deposited into the Deposit Account shall be swept by the Deposit Bank on a
daily basis into the Joint Concentration Account. The parties understand and agree that the current Deposit Bank cannot accommodate multiple Deposit Accounts; and accordingly, so long as the Company has not established a separate Company
Concentration Account and Purchaser Concentration Account as required pursuant to <U>Section&nbsp;5.08(b)</U>, the Company shall be responsible for computing the Daily Amount and shall retain at all times (subject to any payments of the Daily Amount
paid to Purchaser, which payments shall be made promptly upon Purchaser&#146;s request) an amount equal to the aggregate Daily Amount owed to Purchaser pursuant to this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Notwithstanding any provision herein or in any other Transaction Document to the contrary, the Company shall no later than one
hundred twenty (120)&nbsp;days after the Closing Date to enter into a new Deposit Agreement (in form and substance reasonably satisfactory to Purchaser) with a bank or financial institution approved by Purchaser, which bank or financial institution
shall thereafter serve as the Deposit Bank pursuant to the terms hereof. Upon engagement of the replacement Deposit Bank and the entering into the new Deposit Agreement in accordance with the immediately preceding sentence, such Deposit Agreement
shall provide for, among other things, the establishment and maintenance of a Deposit Account, a Joint Concentration Account, a Company Concentration Account and a Purchaser Concentration Account in accordance with the terms herein and therein. Any
Purchaser Concentration Account shall be held solely for the benefit of Purchaser, but shall be subject to the terms and conditions of this Agreement, the Guarantee and Collateral Agreement and the other Transaction Documents. Funds deposited into
the Deposit Account shall be swept by the Deposit Bank on a daily basis into the Joint Concentration Account and subsequent thereto, the Daily Amount shall be swept into the Purchaser Concentration Account. Purchaser shall have immediate and full
access to any funds held in the Purchaser Concentration Account and such funds shall not be subject to any conditions or restrictions whatsoever. After the Daily Amount is swept into the Purchaser Concentration Account, the amounts remaining in the
Joint Concentration Account shall then be swept, at the direction of the Company, into the Company Concentration Account. The Company shall have immediate and full access to any funds held in the Company Concentration Account and such funds shall
not be subject to any conditions or restrictions whatsoever other than those of the Deposit Bank; <U>provided</U>, <U>however</U>, that nothing herein shall (i)&nbsp;affect or reduce the Company&#146;s obligations to pay in full all amounts due to
Purchaser under this Agreement, or (ii)&nbsp;in any manner limit the recourse of Purchaser to the Assigned Interests Collateral to satisfy the Company&#146;s Obligations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) The Company shall pay all fees, expenses and charges of the Deposit Bank (including the replacement Deposit Bank contemplated by <U>Section&nbsp;5.08(b)</U>). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) The Company shall use commercially reasonable efforts to amend each License Agreement, within thirty (30)&nbsp;Business Days after
the engagement of the replacement Deposit Bank contemplated by <U>Section&nbsp;5.08(b)</U>, to contain a provision providing for all payments in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 28 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
respect of sales of the Product and in respect of royalties received from Licensees to be remitted directly by the applicable party into the Deposit Account and the Company shall cause such
payments to be remitted directly by the applicable party into the Deposit Account. If the Company is unsuccessful in amending the License Agreements in accordance with the foregoing sentence and at all times prior to the engagement of the
replacement Deposit Bank as contemplated by <U>Section&nbsp;5.08(b)</U>, the Company shall instruct each Licensee to such License Agreement to remit to the Deposit Account when due all applicable payments in respect of sales and licensing revenue in
respect of the Product and in respect of royalties received from such Licensees. Without in any way limiting the foregoing, commencing on the Closing Date and thereafter, any and all payments in respect of sales of the Product received by the
Company shall be deposited into the Deposit Account within two (2)&nbsp;Business Days of the Company&#146;s receipt thereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) With respect to any License Agreement (excluding License Agreement that do not call for direct payment to the Company) entered into
by the Company from and after the engagement of the replacement Deposit Bank contemplated by <U>Section&nbsp;5.08(b)</U>, the Company shall (i)&nbsp;at the time of the execution and delivery of such agreement, instruct any party thereto under such
agreement to remit to the Deposit Account when due all applicable payments in respect of sales and licensing revenue in respect of the Product and in respect of royalties received from Licensees that are due and payable to the Company in respect of
or derived from such agreement during the Revenue Interest Period and (ii)&nbsp;deliver to Purchaser evidence of such instruction and of such applicable party&#146;s agreement thereto. Without in any way limiting the foregoing, commencing on the
Closing Date and thereafter, any and all payments in respect of sales of the Product received by the Company shall be deposited into the Deposit Account within two (2)&nbsp;Business Days of the Company&#146;s receipt thereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) Prior to the termination of this Agreement, the Company shall not have any right to terminate the Deposit Bank without
Purchaser&#146;s prior written consent. Any such consent, which Purchaser may grant or withhold in its sole and absolute discretion, shall be subject to the satisfaction of each of the following conditions to the satisfaction of Purchaser:
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) the successor Deposit Bank shall be acceptable to Purchaser; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) Purchaser, the Company and the successor Deposit Bank shall have entered into a deposit agreement substantially in the form of the
Deposit Agreement initially entered into; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) all funds and items in the accounts subject to the Deposit Agreement to be
terminated shall be transferred to the new accounts held at the successor Deposit Bank prior to the termination of the then existing Deposit Bank; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(iv) Purchaser shall have received evidence that all of the applicable parties making payments in respect of sales of the Product have been instructed to remit all future payments in respect of sales of
the Product to the new accounts held at the successor Deposit Bank. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 29 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) <U>True-Up</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) Following the end of each Fiscal Quarter, as soon as the Company shall have determined the Net Revenues for such Fiscal Quarter and
for each other Fiscal Quarter in the Fiscal Year in which the then most recently ended Fiscal Quarter occurred (the &#147;<U>Year-to-Date Net Revenues</U>&#148;) and in any event no later than forty-five (45)&nbsp;days after the end of such Fiscal
Quarter (unless such Fiscal Quarter is the last Fiscal Quarter of a Fiscal Year in which case no later than ninety (90)&nbsp;days after the end of such Fiscal Quarter), the Company shall present Purchaser a certificate, in reasonable detail with
supporting calculations and information, detailing the Year-to-Date Net Revenues (the &#147;<U>True-Up Statement</U>&#148;). The True-Up Statement shall include a calculation of (A)&nbsp;the year-to-date Assigned Interests as of the end of such
quarterly period, which shall be the product of the Applicable Percentage multiplied by the Year-to-Date Net Revenues, with a separate calculation taking into account any mandatory minimum payments as provided in the definition of Assigned Interests
(&#147;<U>Year-to-Date Assigned Interests</U>&#148;) and (B)&nbsp;the difference between (X)&nbsp;the amount Purchaser has received on or prior to the last day of the most recently ended Fiscal Quarter in payments from the Company under
<U>Section&nbsp;2.02(a)</U> or this <U>Section&nbsp;5.08</U> in respect of the Fiscal Year for which Year-to-Date Net Revenues is calculated less (Y)&nbsp;the Year-to-Date Assigned Interests (the &#147;<U>True-Up Amount</U>&#148;). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) If the True-Up Amount calculated pursuant to clause (i)&nbsp;above is positive, Purchaser shall pay such amount to the Company
within five (5)&nbsp;days of receipt by Purchaser of the True-Up Statement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) If the True-Up Amount calculated pursuant
to clause (i)&nbsp;above is negative, the Company shall pay the absolute value of such amount to Purchaser within five (5)&nbsp;days of the receipt by Purchaser of the True-Up Statement. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;5.09</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Intellectual Property</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) The Company shall, at its sole expense, either directly or by causing any Licensee to do so, take any and all actions (including taking legal action to specifically enforce the applicable terms of any
License Agreement), and prepare, execute, deliver and file any and all agreements, documents or instruments which are necessary to diligently maintain the Material Patents. The Company shall ensure that all patent applications corresponding to the
Material Patents are diligently prosecuted with the intent to protect the Product. In the exercise of its reasonable business discretion, the Company shall diligently defend or assert such Intellectual Property and such Patents against infringement
or interference by any other Persons, and against any claims of invalidity or unenforceability, in any jurisdiction (including, without limitation, by bringing any legal action for infringement or defending any counterclaim of invalidity or action
of a Third Party for declaratory judgment of non-infringement or non-interference). The Company shall not, and shall use its commercially reasonable efforts to cause any Licensee not to, disclaim or abandon, or fail to take any action necessary or
desirable to prevent the disclaimer or abandonment of, the Material Patents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) In the event that the Company becomes aware
that any intellectual property licensed by it to a Licensee under any License Agreement infringes or violates any Third Party intellectual property, the Company shall, in the exercise of its reasonable business discretion, use commercially
reasonable efforts to attempt to secure the right to use such intellectual property on behalf of itself and the affected Licensee and shall pay all costs and amounts associated with obtaining any such license, without any reduction in the Assigned
Interests. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 30 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) The Company shall directly, or through a Licensee, take any and all actions and prepare,
execute, deliver and file any and all agreements, documents or instruments that are necessary or commercially reasonable or desirable to secure and maintain, all Regulatory Approvals in the United States. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) The Company shall notify PDL regarding any material developments with the Material Patents, including new filings, allowance and
issuance, abandonment, or the initiation of any interference, reexamination, reissue, post-grant review proceeding and litigation, and shall provide PDL with an updated patent schedule upon request, but at least once per year. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;5.10</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Protective Covenants</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) The Company shall not, without the prior written consent of Purchaser: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i)
Forgive, release or compromise any amount owed to the Company or its Subsidiary and relating to the Assigned Interests outside the ordinary course of business; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(ii) Waive, amend, cancel or terminate, exercise or fail to exercise, any of its material rights constituting or relating to the Revenue Interests (including any rights under any License Agreement)
outside the ordinary course of business; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) Amend, modify, restate, cancel, supplement, terminate or waive any material
provision of any Material Contract, or grant any consent thereunder, or agree to do any of the foregoing, including, without limitation, entering into any agreement with any Person under the provisions of such Material Contract; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) Enter into any agreement that would be reasonably expected to have a Material Adverse Effect; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v) Create, incur, assume or suffer any interference with the direction of payments set for in <U>Section&nbsp;5.08</U>; or </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vi) Create, incur, assume or suffer to exist any Lien, or exercise any right of rescission, offset, counterclaim or defense, upon or
with respect to the Assigned Interests, the Revenue Interests or the other Assigned Interests Collateral, or agree to do or suffer to exist any of the foregoing, except for any Lien or agreements in favor of Purchaser granted under or pursuant to
this Agreement and the other Transaction Documents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) During the Term, the Company agrees that, within five
(5)&nbsp;Business Days of any Person becoming a direct or indirect wholly owned Subsidiary of the Company, the Company shall cause such Subsidiary to deliver to Purchaser an Assumption Agreement (as defined in the Guarantee and Collateral Agreement)
executed by such Subsidiary, pursuant to which such Subsidiary shall become a guarantor of the obligations hereunder and grant a security interest in the Assigned Interests Collateral. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;5.11</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Insurance</U></B>. <B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company shall (i)&nbsp;maintain the current insurance policies with its current insurance companies or with companies having at the
least the same rating from A.M. Best Company, Inc., </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 31 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
including product liability insurance and directors and officers insurance and insurance against litigation, liability, subject only to such exclusions and deductible items as are usual and
customary in insurance policies of such type, and (ii)&nbsp;maintain Purchaser as an additional insured party with respect to its general liability and product liability insurance policies. From time to time (with reasonable frequency) the Company
will revise its insurance policy so as to maintain coverage in amounts customary for companies of comparable size and condition similarly situated in the same industry as the Company. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;5.12</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Notice</U></B>. <B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company shall provide Purchaser with written notice as promptly as practicable (and in any event within two (2)&nbsp;Business Days)
after becoming aware of any of the following: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) any material breach or default by the Company of any covenant, agreement or
other provision of this Agreement, or any other Transaction Document; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) any representation or warranty made or deemed made
by the Company in any of the Transaction Documents or in any certificate delivered to Purchaser pursuant hereto shall prove to be untrue, inaccurate or incomplete in any material respect on the date as of which made or deemed made; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) the occurrence of a Change of Control; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) the occurrence of a Put Option Event. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;5.13</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Use of Proceeds</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company shall use proceeds received from Purchaser in support of the business plan for the Product, including sales operation and expansion and additional clinical studies. The Company shall take
commercially reasonable measures to support the sales of the Product. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;5.14</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Taxes</U></B>.<B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)
The Company shall timely file (taking into account all extensions of due dates) all Tax Returns required to be filed by it and will pay all Taxes required to be paid with such returns. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Each payment made by the Company pursuant to the Transaction Documents shall be payable free of any Tax, withholding or other
deduction except for any Tax, withholding or deduction imposed by applicable law. The Company and Purchaser agree that to each of their knowledge such payments are not subject to any deduction or withholding under current applicable law. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;5.15</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Board Designee</U>. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective immediately after the Closing, Purchaser shall have the right to designate, and the Company shall appoint an individual
designated by the Purchaser (the &#147;<U>Purchaser Designee</U>&#148;), who shall serve on the Board until the 2013 Annual Meeting of Shareholders (the &#147;<U>2013 Annual Meeting</U>&#148;). For the 2013 Annual Meeting and each annual meeting
thereafter </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 32 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
during the Term, the Board shall nominate and recommend the Purchaser Designee as a director nominee to serve on the Board until the next annual meeting and shall include such nomination in the
Company&#146;s proxy statement for the 2013 Annual Meeting and each annual meeting thereafter, provided that the election of the Purchaser Designee is subject to shareholders&#146; approval. Should at any time there become a vacancy on the Board as
a result of (1)&nbsp;the resignation, death or removal of the Purchaser Designee or (2)&nbsp;such Purchaser Designee failing to obtain the requisite approval of the Company&#146;s shareholders at any annual or special meeting of the Company&#146;s
shareholders and where no other individual is elected to such vacancy, Purchaser shall have the right to designate an individual to fill such vacancy, and the Company shall take such actions necessary to appoint, such individual to the Board. The
Company shall have taken all actions necessary at or prior to the Closing to ensure there is a vacancy on the Board as of the Closing to permit the appointment of the Purchaser Designee to the Board as of the Closing. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;5.16</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Rights to Future Stock Issuances</U>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Subject to the terms and conditions of this <U>Section&nbsp;5.16</U> and applicable securities laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New
Securities to the Purchaser. The Purchaser shall be entitled to apportion the right of first offer hereby granted to it among itself and its Affiliates in such proportions as it deems appropriate. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The Company shall give notice (the &#147;<U>Offer Notice</U>&#148;) to the Purchaser, stating (i)&nbsp;its bona fide intention to
offer such New Securities, (ii)&nbsp;the number of such New Securities to be offered, and (iii)&nbsp;the price and terms, if any, upon which it proposes to offer such New Securities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) By notification to the Company within five (5)&nbsp;days after the Offer Notice is given, the Purchaser may elect to purchase or
otherwise acquire, at the price and on the terms specified in the Offer Notice, up to <B>***</B> of such New Securities. The closing of any sale pursuant to this <U>Section&nbsp;5.16(b)</U> shall occur within the later of one hundred and twenty
(120)&nbsp;days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to <U>Section&nbsp;5.16(c)</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in <U>Section&nbsp;5.16(b)</U>, the Company may, during the ninety (90)&nbsp;day period
following the expiration of the periods provided in <U>Section&nbsp;5.16(b)</U>, offer and sell such New Securities (including any portion of New Securities Purchaser declined to acquire pursuant to <U>Section&nbsp;5.16(b)</U>) to any Person or
Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement
is not consummated within thirty (30)&nbsp;days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Purchaser in accordance with this
<U>Section&nbsp;5.16</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) The right of first offer in this <U>Section&nbsp;5.16</U> shall not be applicable to
(i)&nbsp;issuance of options under the Company&#146;s equity compensation plans, where such plans have been approved by the Company&#146;s shareholders; and (ii)&nbsp;issuance of equity securities to one or more counterparties in connection with the
consummation, by the Company, of a strategic partnership, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 33 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
joint venture, collaboration or acquisition or license of any business products or technology (it being understood and agreed that the primary purpose of any issuance pursuant to this clause
(ii)&nbsp;shall not be to raise capital). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) The Purchaser shall agree to treat the Offer Notice as confidential, and it
shall not trade any securities of the Company while the terms of the Offer Notice remain as material, non-public information. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;5.17</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Dividends</U></B>.<B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the period from the Closing Date to sixty (60)&nbsp;days after the fourth anniversary of the Closing Date (or the payment of the
Put Price in the event the Put Option is exercised on or prior to 60 days after the fourth anniversary of the Closing Date), the Company shall not, nor shall it permit any Subsidiary to, declare, pay or make any dividend or distribution on any
shares of the common stock or preferred stock of such Person (other than dividends or distributions payable in its stock, or split-ups or reclassifications of its stock) or apply any of its funds, property or assets to the purchase, redemption or
other retirement of any common or preferred stock, or of any options to purchase or acquire any such shares of common or preferred stock of any such Person (collectively, &#147;<U>Restricted Payments</U>&#148;), except that: (a)&nbsp;each Subsidiary
may make direct or indirect Restricted Payments to the Company; and (b)&nbsp;the Company and each Subsidiary may purchase, redeem or otherwise acquire Equity Interests issued by it solely with the proceeds received from the substantially concurrent
issue of new shares of its common stock or other common Equity Interests. For purposes of this Agreement, &#147;<U>Equity Interests</U>&#148; of any Person means any and all shares, rights to purchase, options, warrants, general, limited or limited
liability partnership interests, member interests, participation or other equivalents of or interest in (regardless of how designated) equity of such Person, whether voting or nonvoting, including common stock, preferred stock, convertible
securities or any other &#147;equity security&#148; (as such term is defined in Rule 3a11-1 of the General Rules and Regulations promulgated by the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended).
</FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE VI </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>TERMINATION </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;6.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Termination Date</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This Agreement shall terminate upon the earlier of expiration or termination of the Revenue Interest Period, in each case after full satisfaction of any amounts due under this Agreement by Company to the
Purchaser (the &#147;<U>Term</U>&#148;). </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;6.02</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Effect of Termination</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In the event of the termination of this Agreement pursuant to <U>Section&nbsp;6.01</U>, this Agreement shall forthwith become void and have no effect without any liability on the part of any party hereto
or its Affiliates, directors, officers, stockholders, partners, managers or members other than the provisions of this <U>Section&nbsp;6.02</U> and <U>Sections 5.04</U>, and <U>Article VII</U> hereof, which shall survive any termination as set forth
in <U>Section&nbsp;6.01</U>. Nothing contained in this <U>Section&nbsp;6.02</U> shall relieve any party from liability for any breach of this Agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 34 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE VII </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>MISCELLANEOUS </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;7.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Survival</U></B>. <B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) All representations and warranties made herein and in any other Transaction Document, any certificates or in any other writing
delivered pursuant hereto or thereto shall survive the execution and delivery of this Agreement and shall continue to survive until the termination of this Agreement in accordance with <U>Article VI</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Any investigation or other examination that may have been made or may be made at any time by or on behalf of the party to whom
representations and warranties are made shall not limit, diminish or in any way affect the representations and warranties in the Transaction Documents, and the parties may rely on the representations and warranties in the Transaction Documents
irrespective of any information obtained by them by any investigation, examination or otherwise. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;7.02</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Specific Performance; Limitations on Damages</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Each of the parties hereto acknowledges that the other party will have no adequate remedy at law if it fails to perform any of its obligations under any of the Transaction Documents. In such event,
each of the parties agrees that the other party shall have the right, in addition to any other rights it may have (whether at law or in equity), to specific performance of this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Notwithstanding anything to the contrary in this Agreement, in no event shall either party be liable for special, indirect,
incidental, punitive or consequential damages of the other party, whether or not caused by or resulting from the actions of such party or the breach of its covenants, agreements, representations or warranties hereunder, even if such party has been
advised of the possibility of such damages. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;7.03</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Notices</U></B>. <B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All notices, consents, waivers and communications hereunder given by any party to the other shall be in writing (including facsimile
transmission) and delivered personally, by telegraph, telecopy, telex or facsimile, by a recognized overnight courier, or by dispatching the same by certified or registered mail, return receipt requested, with postage prepaid, in each case
addressed: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If to Purchaser to: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">PDL BioPharma, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">932 Southwood Blvd. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: General Counsel </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Facsimile No.: (775)&nbsp;832-8501 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 35 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">with a copy to: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Gibson, Dunn&nbsp;&amp; Crutcher LLP </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">333 South Grand Avenue </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Los Angeles, CA 90071-3197 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Attention: Dhiya El-Saden </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Facsimile No.: (213)&nbsp;229-7520 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If to the Company to: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGen, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen Corporation </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13859 Progress Blvd. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Alachua, FL 32615 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: Karen Zaderej </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fax: (386)&nbsp;462-6803 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">with a copy to: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Morgan, Lewis&nbsp;&amp; Bockius LLP </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1701 Market Street </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Philadelphia, Pennsylvania 19103 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: Fahd M.T. Riaz </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fax: (215)&nbsp;963-5001 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">or to
such other address or addresses as Purchaser or the Company may from time to time designate by notice as provided herein, except that notices of changes of address shall be effective only upon receipt. All such notices, consents, waivers and
communications shall: (a)&nbsp;when posted by certified or registered mail, postage prepaid, return receipt requested, be effective three (3)&nbsp;Business Days after dispatch, unless such communication is sent trans-Atlantic, in which case they
shall be deemed effective five (5)&nbsp;Business Days after dispatch, (b)&nbsp;when telegraphed, telecopied, telexed or facsimiled, be effective upon receipt by the transmitting party of confirmation of complete transmission, or (c)&nbsp;when
delivered by a recognized overnight courier or in person, be effective upon receipt when hand delivered. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;7.04</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Successors and Assigns</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns. The Company shall not be entitled to assign any of its
obligations and rights under the Transaction Documents without the prior written consent of Purchaser. Solely upon the consent of the Company (which consent may not be unreasonably withheld, delayed or conditioned), Purchaser may assign any of its
obligations or rights under the Transaction Documents without restriction; provided, however, that Purchaser, notwithstanding such assignment, will remain liable under <U>Section&nbsp;5.08(g)</U> (to the extent of any amount subject thereto during
the Fiscal Quarter as of the date of such assignment) and <U>Section&nbsp;7.05</U>. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 36 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;7.05</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Indemnification</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) The Company hereby indemnifies and holds Purchaser and its Affiliates and any of their respective partners, directors, managers, members, officers, employees and agents (each, a &#147;<U>Purchaser
Indemnified Party</U>&#148;) harmless from and against any and all Losses (including all Losses in connection with any product liability claims or claims of infringement or misappropriation of any Intellectual Property rights of any Third Parties)
incurred or suffered by any Purchaser Indemnified Party arising out of any breach of any representation, warranty or certification made by the Company in any of the Transaction Documents or certificates given by the Company in writing pursuant
hereto or thereto or any breach of or default under any covenant or agreement by the Company pursuant to any Transaction Document, including any failure by the Company to satisfy any of the Excluded Liabilities and Obligations. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Purchaser hereby indemnifies and holds the Company, its Affiliates and any of their respective partners, directors, managers,
officers, employees and agents (each, a &#147;<U>Company Indemnified Party</U>&#148;) harmless from and against any and all Losses incurred or suffered by a Company Indemnified Party arising out of any breach of any representation, warranty or
certification made by Purchaser in any of the Transaction Documents or certificates given by Purchaser in writing pursuant hereto or thereto or any breach of or default under any covenant or agreement by Purchaser pursuant to any Transaction
Document. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) If any claim, demand, action or proceeding (including any investigation by any Governmental Authority) shall be
brought or alleged against an indemnified party in respect of which indemnity is to be sought against an indemnifying party pursuant to the preceding paragraphs, the indemnified party shall, promptly after receipt of notice of the commencement of
any such claim, demand, action or proceeding, notify the indemnifying party in writing of the commencement of such claim, demand, action or proceeding, enclosing a copy of all papers served, if any; <U>provided</U>, that the omission to so notify
such indemnifying party will not relieve the indemnifying party from any liability that it may have to any indemnified party under the foregoing provisions of this <U>Section&nbsp;7.05</U> unless, and only to the extent that, such omission results
in the forfeiture of, or has a material adverse effect on the exercise or prosecution of, substantive rights or defenses by the indemnifying party. In case any such action is brought against an indemnified party and it notifies the indemnifying
party of the commencement thereof, the indemnifying party will be entitled to participate therein and, to the extent that it may wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel
reasonably satisfactory to such indemnified party (who shall not, except with the consent of the indemnified party, be counsel to the indemnifying party), and after notice from the indemnifying party to such indemnified party of its election so to
assume the defense thereof, the indemnifying party will not be liable to such indemnified party under this <U>Section&nbsp;7.05</U> for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense
thereof other than reasonable costs of investigation. In any such proceeding, an indemnified party shall have the right to retain its own counsel, but the reasonable fees and expenses of such counsel shall be at the expense of such indemnified party
unless (i)&nbsp;the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel, (ii)&nbsp;the indemnifying party has assumed the defense of such proceeding and has failed within a reasonable time to
retain counsel reasonably satisfactory to such indemnified party or (iii)&nbsp;the named parties to any such proceeding (including any impleaded parties) include both the indemnifying party and the indemnified party and representation of both
parties by the same counsel would be inappropriate due to actual or potential conflicts of interests between them based on the advice of such counsel. It is agreed that the indemnifying party shall not, in
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 37 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable fees and expenses of more than one separate law firm (in addition to local counsel
where necessary) for all such indemnified parties. The indemnifying party shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the
plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such settlement or judgment. No indemnifying party shall, without the prior written consent of the indemnified party,
effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified party, unless such settlement includes an
unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) To the extent that any breach by the Company of this Agreement does not trigger a Put Option Event, Purchaser&#146;s sole remedy
shall be to recover any monetary damages associated with such breach, subject to the other terms and provisions contained in this Agreement. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;7.06</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>No Implied Representations and Warranties</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Each party acknowledges and agrees that, other than the representations and warranties specifically contained in any of the Transaction Documents or certificates given in writing by a party hereto or
thereto, there are no representations or warranties of either party or any other Person either expressed or implied with respect to the Assigned Interests or the transactions contemplated hereby. Without limiting the foregoing, Purchaser
acknowledges and agrees that (a)&nbsp;Purchaser and its Affiliates, together with its and its Affiliates&#146; representatives, have made their own investigation of the Product and the Intellectual Property and are not relying on any implied
warranties or upon any representation or warranty whatsoever as to the future amount or potential amount of the Assigned Interests or as to the creditworthiness of Company and (b)&nbsp;except as expressly set forth in any representation or warranty
in a Transaction Document, Purchaser shall have no claim or right to indemnification pursuant to <U>Section&nbsp;7.05</U> (or otherwise) with respect to any information, documents or materials furnished to Purchaser, any of its Affiliates, or any of
its or its Affiliates&#146; representatives, including any information, documents or material made available to Purchaser and its Affiliates and its Affiliates&#146; representatives in any data room, presentation, interview or any other form
relating to the transactions contemplated hereby. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;7.07</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Independent Nature of Relationship</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) The relationship between the Company and its Subsidiary, on the one hand, and Purchaser, on the other, is solely that of seller and purchaser, and neither Purchaser, on the one hand, nor the Company
and its Subsidiary, on the other, has any fiduciary or other special relationship with the other or any of their respective Affiliates. Nothing contained herein or in any other Transaction Document shall be deemed to constitute the Company and its
Subsidiary and Purchaser as a partnership, an association, a joint venture or other kind of entity or legal form. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) No
officer or employee of Purchaser will be located at the premises of the Company or any of its Affiliates, except in connection with an audit performed pursuant to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 38 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
<U>Section&nbsp;5.02</U>. No officer, manager or employee of Purchaser shall engage in any commercial activity with the Company or any of its Affiliates other than as contemplated herein and in
the other Transaction Documents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) The Company and/or any of its Affiliates shall not at any time obligate Purchaser, or
impose on Purchaser any obligation, in any manner or respect to any Person not a party hereto. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;7.08</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Federal Tax</U>. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding the accounting treatment thereof, for United States federal, state and local tax purposes, the Company and Purchaser shall
treat the transactions contemplated by the Transaction Documents as debt for United States tax purposes. The parties hereto agree not to take any position that is inconsistent with the provision of this <U>Section&nbsp;7.08</U> on any tax return or
in any audit or other administrative or judicial proceeding unless (a)&nbsp;the other party to this Agreement has consented to such actions, which consent shall not be unreasonably withheld, or (b)&nbsp;the party that contemplates taking such an
inconsistent position has been advised by its tax advisor in writing that it is more likely than not (i)&nbsp;that there is no &#147;reasonable basis&#148; (within the meaning of Treasury Regulation Section&nbsp;1.6662-3(b)(3)) for the position
specified in this <U>Section&nbsp;7.08</U> or (ii)&nbsp;that taking such a position would otherwise subject the party to penalties under the Internal Revenue Code of 1986, as amended. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;7.09</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Entire Agreement</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This Agreement, together with the Exhibits and Schedules hereto (which are incorporated herein by reference), and the other Transaction Documents constitute the entire agreement between the parties with
respect to the subject matter hereof and supersede all prior agreements (including the Term Sheet and the Interim Revenue Interest Purchase Agreement), understandings and negotiations, both written and oral, between the parties with respect to the
subject matter of this Agreement. No representation, inducement, promise, understanding, condition or warranty not set forth herein (or in the Exhibits, Schedules or other Transaction Documents) has been made or relied upon by either party hereto.
None of this Agreement, nor any provision hereof, is intended to confer upon any Person other than the parties hereto any rights or remedies hereunder. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;7.10</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Amendments; No Waivers</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) This Agreement or any term or provision hereof may not be amended, changed or modified except with the written consent of the parties hereto. No waiver of any right hereunder shall be effective unless
such waiver is signed in writing by the party against whom such waiver is sought to be enforced. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) No failure or delay by
either party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or
privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by law. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 39 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;7.11</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Interpretation</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">When a reference is made in this Agreement to Articles, Sections, Schedules or Exhibits, such reference shall be to an Article, Section, Schedule or Exhibit to this Agreement unless otherwise indicated.
The words &#147;include&#148;, &#147;includes&#148; and &#147;including&#148; when used herein shall be deemed in each case to be followed by the words &#147;without limitation&#148;. Neither party hereto shall be or be deemed to be the drafter of
this Agreement for the purposes of construing this Agreement against one party or the other. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;7.12</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Headings and Captions</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The headings and captions in this Agreement are for convenience and reference purposes only and shall not be considered a part of or affect the construction or interpretation of any provision of this
Agreement. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;7.13</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Counterparts; Effectiveness</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This Agreement may be executed in two or more counterparts, each of which shall be an original, but all of which together shall constitute one and the same instrument. This Agreement shall become
effective when each party hereto shall have received a counterpart hereof signed by the other parties hereto. Any counterpart may be executed by facsimile or pdf signature and such facsimile or pdf signature shall be deemed an original. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;7.14</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Severability</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If any provision of this Agreement is held to be invalid or unenforceable, the remaining provisions shall nevertheless be given full force and effect. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;7.15</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Expenses</U></B>. <B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company will pay all of its own fees and expenses in connection with entering into and consummating the transactions contemplated by
this Agreement. The Company shall, promptly (and, in any event, within five (5)&nbsp;Business Days) upon demand, reimburse Purchaser up to <B>***</B> for its reasonable legal fees and expenses incurred in connection with the transactions
contemplated by the Transaction Documents, less any amounts reimbursed in connection with the Interim Royalty Purchase Agreement, not to exceed <B>***</B> in the aggregate. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;7.16</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Governing Law; Jurisdiction</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) This Agreement shall be governed by, and construed, interpreted and enforced in accordance with, the laws of the state of New York, without giving effect to the principles of conflicts of law thereof.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Any legal action or proceeding with respect to this Agreement or any other Transaction Document may be brought in any
state or federal court of competent jurisdiction in the State of Nevada, Washoe County and city of Reno. By execution and delivery of this Agreement, each party hereto hereby irrevocably consents to and accepts, for itself and in respect of its
property, generally and unconditionally the non-exclusive jurisdiction of such courts. Each party hereto hereby further irrevocably waives any objection, including any objection to the laying of venue or based on the grounds of forum non conveniens,
which it may now or hereafter have to the bringing of any action or proceeding in such jurisdiction in respect of any Transaction Document. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 40 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Each party hereto hereby irrevocably consents to the service of process out of any of
the courts referred to in subsection (b)&nbsp;of this <U>Section&nbsp;7.16</U> in any such suit, action or proceeding by the mailing of copies thereof by registered or certified mail, postage prepaid, to it at its address set forth in this
Agreement. Each party hereto hereby irrevocably waives any objection to such service of process and further irrevocably waives and agrees not to plead or claim in any suit, action or proceeding commenced hereunder or under any other Transaction
Document that service of process was in any way invalid or ineffective. Nothing herein shall affect the right of a party to serve process on the other party in any other manner permitted by law. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;7.17</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Waiver of Jury Trial</U></B>. <B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Each party hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any action, proceeding, claim or counterclaim arising out of or
relating to any Transaction Document or the transactions contemplated under any Transaction Document. This waiver shall apply to any subsequent amendments, renewals, supplements or modifications to any Transaction Document. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[SIGNATURE PAGE FOLLOWS] </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 41 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>IN WITNESS WHEREOF,</B> the parties hereto have caused this Agreement to be duly executed
by their respective authorized officers as of the date first above written.<B> </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">COMPANY:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AXOGEN, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Karen Zaderej</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Karen Zaderej</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">PURCHASER:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PDL BIOPHARMA, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ John P. McLaughlin</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">John P. McLaughlin</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[Signature Page to Revenue Purchase Agreement] </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit A </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Form of Guarantee and Collateral Agreement </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[A copy of the execution version of the
Guarantee and Collateral Agreement has been filed as Exhibit 10.6.2 to this Amendment No.&nbsp;3 to Registration Statement on Form S-1.] </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit B </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Form of Assignment of Interests </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[See attached.] </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FORM OF ASSIGNMENT OF INTERESTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">THIS ASSIGNMENT OF INTERESTS (&#147;<U>Assignment of Interests</U>&#148;) is made as of August&nbsp;13, 2012, between AxoGen, Inc., a
Minnesota corporation (the &#147;<U>Company</U>&#148;), and PDL BioPharma, Inc., a Delaware corporation (&#147;<U>Purchaser</U>&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A. The Company and Purchaser have entered into that certain Revenue Interests Purchase Agreement, dated as of October&nbsp;5, 2012 (the &#147;<U>Revenue Purchase Agreement</U>&#148;), pursuant to which
the Company is to sell and Purchaser is to purchase the Assigned Interests. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Revenue Purchase Agreement; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">B. The Company has agreed to execute and deliver this Assignment of Interests to Purchaser for the purpose of transferring to and vesting
in Purchaser title to the Assigned Interests as set forth herein. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In consideration of the foregoing and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.
The Company does hereby sell, assign, transfer, convey, deliver and vest in Purchaser, its successors and assigns forever, all of its right, title and interest in and to the Assigned Interests. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. The Company hereby covenants that, from time to time after the delivery of this instrument, at Purchaser&#146;s request, the Company
will do, execute, acknowledge and deliver, or will cause to be done, executed, acknowledged and delivered such further acts, conveyances, transfers, assignments, powers of attorney and assurances as Purchaser may reasonably require to convey,
transfer to and vest in Purchaser, and to put Purchaser in possession of, any of the Assigned Interests. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. Nothing in this
Assignment of Interests shall alter any liability or obligation of the Company or Purchaser arising under the Revenue Purchase Agreement, which shall govern the representations, warranties and obligations of the parties with respect to the Assigned
Interests. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4. This Assignment of Interests shall be binding upon and inure to the benefit of the parties hereto and their
respective successors and assigns. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5. This Assignment of Interests shall be governed by, and construed in accordance with,
the internal laws of the State of New York, without giving effect to the principles of conflicts of law thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6. This
Assignment of Interests may be executed in counterparts, each of which shall be deemed an original and all of which, when taken together, shall constitute one and the same instrument. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[The remainder of this page has been intentionally left blank.] </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the parties have executed this Assignment of Interests as of the date
first written above. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AXOGEN, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Karen Zaderej</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PDL BIOPHARMA, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">John P. McLaughlin</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A<SMALL>SSIGNMENT</SMALL> <SMALL>OF</SMALL> I<SMALL>NTERESTS</SMALL> &#150; I<SMALL>NTERIM</SMALL>
R<SMALL>EVENUE</SMALL> I<SMALL>NTERESTS</SMALL> P<SMALL>URCHASE</SMALL> A<SMALL>GREEMENT</SMALL> </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit C </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Form of Deposit Agreement </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[See attached.] </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Form of Deposit Agreement </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Account&nbsp;Numbers:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="53%"></TD></TR>

<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DEPOSIT ACCOUNT CONTROL AGREEMENT </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Customer:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Creditor:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Deposit Account Control Agreement (&#147;<U>Agreement</U>&#148;) is entered into as of the above
date among Silicon Valley Bank (&#147;<U>Bank</U>&#148;), Creditor identified above (&#147;<U>Creditor</U>&#148;), and Customer identified above (&#147;<U>Customer</U>&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">All parties agree as follows: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;
</P><DIV STYLE="position:relative;float:left; margin-right:1%; width:48%;padding-right:9px;padding-bottom:8px;overflow:hidden;padding-top:3px">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. <U>Deposit Account</U>.</B> Bank maintains one or more demand, time, savings, passbook, certificates
of deposit or other similar accounts that are identified above in which Customer has an interest (collectively, the &#147;<U>Account</U>&#148;). The Deposit Account (as defined below) is subject to Bank&#146;s Deposit Agreement and Disclosure
Statement (the &#147;<U>Deposit Agreement</U>&#148;), provided that, in the case of any conflict between the terms of this Agreement and the Deposit Agreement, the terms of this Agreement will prevail. The parties acknowledge that the Deposit
Account constitutes a &#147;deposit account&#148; within the meaning of Section&nbsp;9102 of the Uniform Commercial Code of the State of California (the &#147;<U>UCC</U>&#148;), and Bank is a &#147;bank&#148; within the meaning of Section&nbsp;9102
of the UCC. Bank&#146;s jurisdiction for purposes of Section&nbsp;9304 of the UCC is California. The provisions of this Agreement constitute &#147;control&#148; over the Deposit Account within the meaning of Section&nbsp;9104 of the UCC. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. <U>Security Interests</U>.</B> Pursuant to a security agreement or similar agreement, Customer has granted to Creditor a security interest in the
Account and in all cash, funds, items, instruments, and any other amounts now or later deposited into or held therein (collectively, the &#147;<U>Deposit Account</U>&#148;). Bank acknowledges the lien on and security interest in the Deposit Account
granted by Customer to Creditor.<B> </B></FONT></P></DIV><DIV STYLE="position:relative;float:right; width:48%;padding-right:9px;padding-bottom:8px;overflow:hidden;padding-top:3px">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:27px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[For Bank use only - Bank representative to check box, if necessary, and insert
initials.] </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:27px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> Other than as set forth in Section&nbsp;6 below, Bank does
not have a security interest in the Deposit Account. <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> [DLM initials] </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:27px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> Bank has a security interest in the Deposit Account. <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> [DLM initials]
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the box is Section&nbsp;2(b) above is checked, the priorities of Creditor&#146;s security interest and Bank&#146;s security interest in
the Deposit Account are governed by an intercreditor or other similar agreement between Bank and Creditor. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. <U>Other Deposit Control
Agreements</U>. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:27px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[For Bank use only - Bank representative to check appropriate box below and insert initials.]
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:27px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> Bank has not entered into any other control agreement governing the
Deposit Account with any other party. <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> [DLM initials] </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:27px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> Bank has entered into other control agreement(s) governing the Deposit Account with the following party or parties: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> [DLM initials]
</FONT></P></DIV><div style="clear:both; height:0px; font-size:0px">&nbsp;</div>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<DIV STYLE="position:relative;float:left; margin-right:1%; width:48%;padding-right:9px;padding-bottom:8px;overflow:hidden;padding-top:3px">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bank agrees that it will not enter into a control agreement with any other party with respect to the
Deposit Account without Creditor&#146;s prior written consent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. <U>Customer&#146;s Rights in Deposit Account</U>. </B>Creditor has
control over the Deposit Account, provided that, until Bank receives a Notice of Exclusive Control (as described and set forth in Section&nbsp;13(b) below). Customer will be entitled to draw items on and to withdraw or otherwise direct the
disposition of funds from the Deposit Account. So long as this Agreement is in effect. Customer may not close the Deposit Account without Creditor&#146;s prior written consent. Bank may close the Deposit Account in accordance with the Deposit
Agreement and as may be required by applicable law. After Bank receives a Notice of Exclusive Control, Bank will notify Creditor not less than thirty (30)&nbsp;calendar days prior to closing the Deposit Account in non-emergency circumstances and
substantially contemporaneously with closing the Deposit Account in emergency circumstances (for example, in response to fraud or returned items), unless prohibited by law. Customer will notify Creditor promptly if Bank closes the Deposit
Account.<B> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. <U>Creditor&#146;s Control of Deposit Account</U>.</B> Except as permitted in Section&nbsp;6 hereof, after Bank
receives a Notice of Exclusive Control and has reasonable opportunity to comply with it, but no later than two Business Days (as defined below) after the Notice of Exclusive Control has been validly given (in accordance with Section&nbsp;13(b)
below). Bank and Customer agree that: (a)&nbsp;Bank will comply only with Creditor&#146;s instructions as to the withdrawal or disposition of any funds credited to the Deposit Account and to any other matters relating to the Deposit Account, without
Customer&#146;s further consent, and (b)&nbsp;Bank will not comply with any instructions from Customer concerning the Deposit Account or any funds therein. Bank shall have no duty to inquire or<B>
</B></FONT></P></DIV><DIV STYLE="position:relative;float:right; width:48%;padding-right:9px;padding-bottom:8px;overflow:hidden;padding-top:3px">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>
</B>determine whether Creditor is entitled to send a Notice of Exclusive<B> </B>Control. Creditor&#146;s instructions may include the giving of stop payment orders for any items being presented
to the Deposit Account for payment. Bank will be fully entitled to rely upon such instructions from Creditor even if such instructions are contrary to any instructions or demands given by Customer. Customer confirms that Bank (x)&nbsp;should follow
instructions from Creditor even if the result of following such instructions is that Bank dishonors items presented for payment from the Deposit Account, and (y)&nbsp;will have no liability to Customer for wrongful dishonor of such items in
following such instructions from Creditor. For purposes of this Agreement, &#147;Business Day&#148; means a day on which Bank is open to the public for business and is measured in a 24 hour increment.<B> </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. <U>Priorities of Security Interests; Rights Reserved by Bank</U>. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:27px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Creditor agrees that nothing herein subordinates or waives, and that Bank expressly reserves, any and/or all of Bank&#146;s present and future rights (whether described as rights of setoff,
banker&#146;s liens, chargeback or otherwise, and whether available to Bank under the law or under any other agreement between Bank and Customer concerning the Deposit Account) with respect to: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:54px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) the face amount of a check, draft, money order, instrument, wire transfer of funds, automated clearing house entry, credit from a
merchant card transaction, other electronic transfer of funds or other item (A)&nbsp;deposited in or credited to the Deposit Account, whether before or after the date of this Agreement, and returned unpaid or otherwise uncollected or subject to an
adjustment entry, whether for insufficient funds or for any other reason and without regard to the timeliness of the return or adjustment or the occurrence or timeliness of any other person&#146;s notice of nonpayment or adjustment, (B)&nbsp;subject
to a claim against the Bank for breach of transfer, presentment, encoding, retention or other warranty under Federal Reserve Regulations or Operating, Circulars, clearing house rules, the
</FONT></P></DIV><div style="clear:both; height:0px; font-size:0px">&nbsp;</div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<DIV STYLE="position:relative;float:left; margin-right:1%; width:48%;padding-right:9px;padding-bottom:8px;overflow:hidden;padding-top:3px">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
UCC or other applicable law, or (C)&nbsp;for a merchant card transaction, against which a contractual demand for chargeback has been made (&#147;<U>Returned Items</U>&#148;): </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:54px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) service charges, fees or expenses payable or reimbursable to the Bank in connection with the Deposit Account or any related
services (&#147;<U>Account Charges</U>&#148;); and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:54px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) any adjustments or corrections of any posting or encoding errors
(&#147;<U>Adjustments</U>&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:27px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Creditor agrees that notwithstanding receipt of the Notice of Exclusive Control, Bank
may exercise Bank&#146;s rights and remedies in connection with any liens or claims it may have in or on the Deposit Account as described in this Section&nbsp;6. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>7. <U>Statements</U>.</B> At Customer&#146;s expense, Bank will send copies of all statements sent to Customer for the Deposit Account to Creditor at Creditor&#146;s address set forth below
Creditor&#146;s signature at the end of this Agreement. Until this Agreement is terminated, Customer authorizes Bank to disclose to Creditor at Creditor&#146;s request any information concerning the Deposit Account, including but not limited to the
identity of any other party with which Customer and Bank have executed control agreements.<B> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8. <U>Returned items, Account Charges,
and Adjustments</U>.</B> Bank may debit the Deposit Account for Returned Items, Account Charges and Adjustments. If at any time after Creditor exercises exclusive control over the Deposit Account (a)&nbsp;funds are not available in the Deposit
Account to cover the amount of any Returned Item. Account Charge or Adjustment, and (b)&nbsp;Customer fails to pay such amount within fifteen (15)&nbsp;Business Days of Bank&#146;s written demand therefor, then Creditor agrees that it will pay,
within ten (10)&nbsp;Business Days of a written demand by Bank, amounts owed for each such Returned Item, Account Charge or Adjustment that is not paid in full by Customer up to the amount of the proceeds received by Creditor from the Deposit
Account, provided that Bank must<B> </B>make a demand from Creditor<B> </B>within 180 days of termination of this Agreement.<B>
</B></FONT></P></DIV><DIV STYLE="position:relative;float:right; width:48%;padding-right:9px;padding-bottom:8px;overflow:hidden;padding-top:3px">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9. <U>Indemnity and Hold Harmless of Bank by Customer</U>.</B> Customer hereby agrees to indemnify and
hold harmless Bank, its affiliates and their respective directors, officers, agents and employees (each, an &#147;<U>Indemnified Person</U>&#148;) against any and all claims, causes of action, liabilities, lawsuits, demands and damages (each, a
&#147;<U>Claim</U>&#148;) asserted by Creditor or any other party (other than an Indemnified Person), including without limitation, any and all court costs and reasonable attorneys&#146; fees, in any way related to or arising out of or in connection
with this Agreement, <U>provided</U> that no Indemnified Person shall be entitled to be indemnified to the extent that such Claims result from the gross negligence or willful misconduct of such Indemnified Person.<B> </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10. <U>Indemnification and Hold Harmless of Bank by Creditor</U>. </B>To the extent that an Indemnified Person is not promptly indemnified by
Customer, Creditor shall indemnify and hold harmless such Indemnified Person against any and all Claims (including reasonable attorneys&#146; fees) asserted by persons other than an Indemnified Person and arising from any Notice of Exclusive Control
from Creditor except to the extent such Claims result from the gross negligence or willful misconduct of Bank or any other Indemnified Person; <U>provided</U> that in no event shall Creditor be liable for any special, indirect, consequential or
punitive damages, or lost profits. Creditor agrees that Bank is released from any and all liabilities to the Creditor arising from the terms of this Agreement except to the extent such liabilities arise from Bank&#146;s or another Indemnified
Person&#146;s gross negligence or willful misconduct.<B> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11. <U>Limitation of Liability</U>. IN NO EVENT SHALL BANK BE LIABLE FOR ANY
SPECIAL, INDIRECT, CONSEQUENTIAL, OR PUNITIVE DAMAGES RELATING TO THIS AGREEMENT WHETHER ANY CLAIM IS BASED ON ANY THEORY OF LIABILITY (INCLUDING WITHOUT LIMITATION ANY THEORY IN CONTRACT OR TORT)
</B></FONT></P></DIV><div style="clear:both; height:0px; font-size:0px">&nbsp;</div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<DIV STYLE="position:relative;float:left; margin-right:1%; width:48%;padding-right:9px;padding-bottom:8px;overflow:hidden;padding-top:3px">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>
AND WHETHER THE LIKELIHOOD OF SUCH DAMAGES WAS KNOWN TO BANK AND REGARDLESS OF THE FORM OF ANY CLAIM OR ACTION. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>12. <U>Amendments</U>. </B>This Agreement and all exhibits attached hereto may be amended only by a written agreement signed by Bank, Creditor, and Customer.<B> </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13. <U>Notices</U>. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:27px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Any notice, <U>other than</U> a Notice of Exclusive Control, or other communication provided for or allowed hereunder shall be in
writing and shall be considered to have been validly given (i)&nbsp;when received if delivered personally (whether by messenger, hand delivery or otherwise) or by overnight delivery or by facsimile to the recipient to the address or facsimile number
set forth below the signature of the applicable party hereto, or (ii)&nbsp;72 hours after being deposited in the United States mail, registered or certified, postage prepaid, return receipt requested, if sent to the address and addressee as set
forth below the signature of the applicable party hereto. The addresses and facsimile numbers to which notices or other communications are to be given (including statements delivered pursuant to Section&nbsp;7 and a Notice of Exclusive Control
pursuant to Section&nbsp;13(b) below) may be changed from time to time by notice given as provided herein. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:27px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) A Notice of
Exclusive Control shall be in writing, must be in the form set forth in Exhibit A hereto, must be delivered to the address listed below Bank&#146;s signature at the end of this Agreement via hand delivery, messenger, overnight delivery or facsimile,
and shall be considered to have been validly given when actually received, <U>except</U> that a facsimile will be considered to have been validly given only when acknowledged in writing by Bank (Bank agrees that it will use its good faith effort to
promptly acknowledge receipt of such facsimile). To the extent Creditor does not deliver the Notice of Exclusive Control as set forth in this Section&nbsp;13 or to the address listed below Bank&#146;s signature at the end of this Agreement, Creditor
(a)&nbsp;acknowledges that Bank may not be able to
</FONT></P></DIV><DIV STYLE="position:relative;float:right; width:48%;padding-right:9px;padding-bottom:8px;overflow:hidden;padding-top:3px">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
respond to such Notice of Exclusive Control pursuant to Section&nbsp;5 above, and (b)&nbsp;agrees that Bank will not be held liable for any failure to respond to such Notice of Exclusive Control.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:27px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) If deemed necessary, by Bank to enable Bank to comply with the provisions of &#167;326 of the USA PATRIOT Act, Creditor
agrees that it will provide Bank with a copy of its formation documentation when delivering a Notice of Exclusive Control, unless such documentation has previously been provided to Bank, and Bank can verify that such documentation is still
maintained in Bank&#146;s files (provided that no such request by Bank shall delay the effectiveness of any such Notice of Exclusive Control). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14. <U>Integration Provision</U>.</B> This Agreement constitutes the entire agreement among Bank, Customer and Creditor with respect to
Creditor&#146;s control over the Deposit Account and matters related thereto, and all prior communications, whether verbal or written, between any of the parties hereto with respect to the subject matter hereof shall be of no further effect or
evidentiary value.<B> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>15. <U>Counterparts</U>.</B> This Agreement may be signed in counterparts that, when signed by all parties,
shall constitute one agreement.<B> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>16. <U>Relationship of the Parties</U>.</B> Nothing in this Agreement shall create any agency or
fiduciary relationship between Customer, Creditor and Bank.<B> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>17. <U>Governing Law and Jurisdiction</U>.</B> The parties hereto agree
that this Agreement shall be governed exclusively under and in accordance with the laws of the State of California. All parties hereto each submit to the exclusive jurisdiction of the State and Federal courts in Santa Clara County, California.<B>
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>18. <U>Jury Trial Waiver</U>.</B> CUSTOMER, CREDITOR, AND BANK EACH WAIVES ITS RIGHT TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION
ARISING OUT OF OR BASED UPON THIS AGREEMENT, OR ANY CONTEMPLATED TRANSACTION,
</FONT></P></DIV><div style="clear:both; height:0px; font-size:0px">&nbsp;</div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<DIV STYLE="position:relative;float:left; margin-right:1%; width:48%;padding-right:9px;padding-bottom:8px;overflow:hidden;padding-top:3px">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
INCLUDING CONTRACT, TORT, BREACH OF DUTY AND ALL OTHER CLAIMS. THIS WAIVER IS A MATERIAL INDUCEMENT FOR ALL PARTIES TO ENTER INTO THIS AGREEMENT, EACH PARTY HAS REVIEWED THIS WAIVER WITH ITS
COUNSEL. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">WITHOUT INTENDING IN ANY WAY TO LIMIT THE PARTIES&#146; AGREEMENT TO WAIVE THEIR RESPECTIVE RIGHT TO A TRIAL BY JURY, if the above
waiver of the right to a trial by jury is not enforceable, the parties hereto agree that any and all disputes or controversies of any nature between them arising at any time out of or based upon this Agreement or any transaction contemplated herein
shall be decided by a reference to a private judge, mutually selected by the parties (or, if they cannot agree, by the Presiding Judge of the Santa Clara County, California Superior Court) appointed in accordance with California Code of Civil
Procedure Section&nbsp;638 (or pursuant to comparable provisions of federal law if the dispute falls within the exclusive jurisdiction of the federal courts), sitting without a jury, in Santa Clara County, California; and the parties hereby submit
to the jurisdiction of such court. The reference proceedings shall be conducted pursuant to and in accordance with the provisions of California Code of Civil Procedure &#167;&#167; 638 through 645.1, inclusive. The private judge shall have the
power, among others, to grant provisional relief, including without limitation, entering temporary restraining orders, issuing preliminary and permanent injunctions and appointing receivers. All such proceedings shall be closed to the public and
confidential and all records relating thereto shall be permanently sealed. If during the course of any dispute, a party desires to seek provisional relief, but a judge has not been appointed at that point pursuant to the judicial reference
procedures, then such party may apply to the Santa Clara County, California Superior Court for such relief. The proceeding before the private judge shall be conducted in the same manner as it would be before a court under the rules of evidence
applicable to judicial proceedings. The parties shall be entitled to discovery which shall be conducted in the same
</FONT></P></DIV><DIV STYLE="position:relative;float:right; width:48%;padding-right:9px;padding-bottom:8px;overflow:hidden;padding-top:3px">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
manner as it would be before a court under the rules of discovery applicable to judicial proceedings. The private judge shall oversee discovery and may enforce all discovery rules and order
applicable to judicial proceedings in the same manner as a trial court judge. The parties agree that the selected or appointed private judge shall have the power to decide all issues in the action or proceeding, whether of fact or of law, and shall
report a statement of decision thereon pursuant to the California Code of Civil Procedure &#167; 644(a). Nothing in this paragraph shall limit the right of any party at any time to exercise self-help remedies, foreclose against collateral, or obtain
provisional remedies. The private judge shall also determine all issues relating to the applicability, interpretation, and enforceability of this paragraph. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>19. S<U>uccessors</U>. </B>The terms of this Agreement shall be binding upon, and shall inure to the benefit of, the parties hereto and their respective corporate successors or heirs and personal
representatives. Customer may not assign this Agreement without the prior written consent of Creditor and Bank. Creditor may assign this Agreement upon written notice to Bank; provided, that such assignee must assume in writing or by operation of
law all of Creditor&#146;s obligations under this Agreement. Bank may assign this Agreement upon written notice to Creditor (which shall be given to Creditor at the same time such notice is provided to Customer); provided, that such assignee must
assume in writing or by operation of law all of Bank&#146;s obligations under this Agreement.<B> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>20. <U>Attorneys&#146; Fees, Costs
and Expenses</U>.</B> In any action or proceeding between Bank and any other party to this agreement, the prevailing party will be entitled to recover its reasonable attorneys&#146; fees and other reasonable costs and expenses incurred, in addition
to any other relief to which it may be entitled. <B> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>21. <U>Termination; Survival</U>.</B> Customer may terminate this Agreement only
with the written consent of Creditor. Creditor may terminate this Agreement by giving Bank and Customer written notice of termination. Bank may
</FONT></P></DIV><div style="clear:both; height:0px; font-size:0px">&nbsp;</div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<DIV STYLE="position:relative;float:left; margin-right:1%; width:48%;padding-right:9px;padding-bottom:8px;overflow:hidden;padding-top:3px">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
terminate this Agreement by giving Creditor and Customer thirty (30)&nbsp;calendar days&#146; prior written notice of termination <U>unless</U> termination is a result of Bank&#146;s closure of
the Deposit Account pursuant to its rights set forth in the Deposit Agreement or in accordance with applicable law, in which case, Creditor&#146;s receipt of notice shall be governed by Section&nbsp;4 hereof. Subject to the
</FONT></P></DIV><DIV STYLE="position:relative;float:right; width:48%;padding-right:9px;padding-bottom:8px;overflow:hidden;padding-top:3px">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
foregoing, this Agreement automatically terminates when the Deposit Account closes. Sections 9, 10, 11, 17, 18 and 20 shall survive the termination of this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[Signature page follows.]
</FONT></P></DIV><div style="clear:both; height:0px; font-size:0px">&nbsp;</div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>BANK:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SILICON VALLEY BANK</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deposit Liability Management</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Address for Notices</U>:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">Silicon Valley Bank</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deposit Liability Management</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">3003 Tasman Drive, Mail Sort HF 184</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">Santa Clara, CA 95054</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">Telephone: (408) 654-5071</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">Facsimile: (408) 496-2409</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CUSTOMER:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">,</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">a</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">TIN*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Address for Notices</U>:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">Telephone:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">Facsimile:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CREDITOR:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">,</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">TIN*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Address for Notices</U>:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Telephone:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Facsimile:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to &#167;326 of the USA PATRIOT Act, Bank is required to obtain a Tax Identification Number (TIN) from all parties to this Agreement. </FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit A </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Notice of Exclusive Control </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="63%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Silicon&nbsp;Valley&nbsp;Bank&nbsp;(&#147;Bank&#148;)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">From:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(&#147;Creditor&#148;)</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Re:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(&#147;Customer&#148;)</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the Deposit Account Control Agreement dated
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&#147;Agreement&#148;) entered among Bank, Customer and Creditor, Creditor hereby notifies Bank of Creditor&#146;s exercise of
Creditor&#146;s rights under the Agreement and directs Bank to cease complying with instructions or any directions originated by Customer or its agents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Creditor agrees that it will provide Bank with a copy of its formation documentation when delivering a Notice of Exclusive Control if deemed necessary by Bank to enable Bank to comply with the
provisions of &#167;326 of the USA PATRIOT Act (provided that no such request by Bank shall delay the effectiveness of any such Notice of Exclusive Control). </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">CREDITOR:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ACKNOWLEDGED BY:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">SILICON VALLEY BANK</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(for facsimile only:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Time:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit D </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Form of Legal Opinion </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[See attached.] </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Form of Legal Opinion </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">October&nbsp;5, 2012 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">PDL BioPharma, Inc. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">932 Southwood Blvd. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incline Village, NV 89451
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Re:</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Revenue Interests Purchase Agreement dated as of October&nbsp;5, 2012 of AxoGen, Inc. and AxoGen Corporation</U> </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ladies and Gentlemen: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have acted as
counsel for AxoGen, Inc., a Minnesota corporation (the &#147;Company&#148;), and AxoGen Corporation, a Delaware corporation (the &#147;Subsidiary&#148;), in connection with the Revenue Interests Purchase Agreement, dated as of October&nbsp;5, 2012
(the &#147;Revenue Interests Purchase Agreement&#148;), by and between the Company and PDL BioPharma, Inc. (&#147;PDL&#148;). Terms defined in the Revenue Interests Purchase Agreement are used as therein defined, unless otherwise defined herein.
References in this opinion letter to the &#147;Delaware UCC&#148; and &#147;Minnesota UCC&#148; are to the Uniform Commercial Code as currently in effect in the State of Delaware and the State of Minnesota, respectively. The terms in paragraphs 9-12
that are defined in the Delaware UCC or the Minnesota UCC and that are not capitalized have the respective meanings given to them in the Delaware UCC or the Minnesota UCC, as applicable. This opinion letter is being delivered to you pursuant to
Section&nbsp;2.03(c)(E) of the Revenue Interests Purchase Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with this opinion letter, we have examined originals, or
copies certified or otherwise identified to our satisfaction, of the Amended and Restated Articles of Incorporation and the Amended and Restated Bylaws of the Company, and the Certificate of Incorporation and Bylaws of the Subsidiary, and such other
documents and records, and other instruments as we have deemed appropriate for purposes of the opinions set forth herein, including the following documents (the documents referred to in clauses&nbsp;(a) through (g)&nbsp;below are referred to herein
as the &#147;Transaction Documents&#148;): </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) the Revenue Interests Purchase Agreement; </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) the Assignment of Interests; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) the Guaranty and Collateral Agreement; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) the Deposit
Agreement; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) an unfiled copy of a Uniform Commercial Code financing statement (the &#147;Minnesota Financing
Statement&#148;) naming the Company as debtor and PDL as secured party, to be filed in the Office of the Secretary of State of the State of Minnesota (the &#147;Minnesota Filing Office&#148;), and </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) an unfiled copy of a Uniform Commercial Code financing statement (the &#147;Delaware Financing Statement&#148;) naming
the Subsidiary as debtor and PDL as secured party, to be filed in the Office of the Secretary of State of the State of Delaware (the &#147;Delaware Filing Office&#148;). </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">PDL BioPharma, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">October 5, 2012 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 2 </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have assumed the genuineness of all signatures, the legal capacity of natural persons, the
authenticity of the documents submitted to us as originals, the conformity to the original documents of all documents submitted to us as certified, facsimile or photostatic copies, and the authenticity of the originals of all documents submitted to
us as copies. We have also assumed that the Transaction Documents constitute valid and binding obligations of each party thereto other than the Company and the Subsidiary party thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As to any facts that are material to the opinions hereinafter expressed that we did not independently establish or verify, we have relied without investigation upon the representations of the Company
contained in the Transaction Documents and upon certificates of officers of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In rendering the opinions set forth herein, whenever
a statement or opinion set forth therein is qualified by &#147;to our knowledge,&#148; &#147;known to us&#148; or by words of similar import, it is intended to indicate that, during the course of our representation of the Company in the subject
transaction, no information has come to the attention of those lawyers in our firm who have rendered legal services in connection with such transaction that gives us actual knowledge of the inaccuracy of such statement or opinion. We have not
undertaken any independent investigation to determine the accuracy of facts material to any such statement or opinion, and no inference as to such statement or opinion should be drawn from the fact of our representation of the Company and the
Subsidiary. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have relied upon a certificate of an officer of the Company dated the date hereof, certifying that the items listed in such
certificate are (i)&nbsp;all of the material indentures, loan or credit agreements, leases, guarantees, mortgages, security agreements, bonds, notes, other agreements or instruments (the &#147;Other Company Agreements&#148;) to which the Company or
the Subsidiary are a party, and (ii)&nbsp;all of the judicial or administrative orders, writs, judgments, awards, injunctions and decrees (the &#147;Company Orders&#148;) binding on the Company or the Subsidiary. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based upon and subject to the foregoing, and to the limitations and qualifications described below, we are of the opinion that: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. The Company is a corporation validly existing and in good standing under the laws of the State of Minnesota. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. The Subsidiary is a corporation validly existing and in good standing under the laws of the State of Delaware. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">PDL BioPharma, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">October 5, 2012 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 3 </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. Each of the Company and the Subsidiary has the corporate power and authority to enter
into and perform the Transaction Documents to which it is a party, has taken all necessary corporate action to authorize the execution, delivery and performance of such Transaction Documents and has duly executed and delivered such Transaction
Documents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4. Each Transaction Document to which the Company or the Subsidiary is a party is the valid and binding obligation
of the Company or the Subsidiary, as applicable, enforceable against the Company and the Subsidiary in accordance with its terms. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5. The execution and delivery by the Company and the Subsidiary of the Transaction Documents to which it is a party do not, and the performance by the Company and the Subsidiary of their respective
obligations thereunder will not, (i)&nbsp;result in a violation of the Amended and Restated Articles of Incorporation and the Amended and Restated Bylaws of the Company, or the Certificate of Incorporation and Bylaws of the Subsidiary,
(ii)&nbsp;result in a breach or default under any Other Company Agreement, (iii)&nbsp;result in a violation of any Company Order or (iv)&nbsp;result in or require the creation or imposition of any lien or encumbrance upon any assets of the Company
or the Subsidiary under any Other Company Agreements (for the avoidance of doubt, any liens and security interests created pursuant to the Transaction Documents are excluded from this clause (iv)). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6. The execution and delivery by each of the Company and the Subsidiary of the Transaction Documents to which it is a party do not, and
the performance by each of the Company and the Subsidiary of its obligations thereunder will not, require any approval from or filing with any governmental authority of the United States, the State of New York, the State of Minnesota or under any
provision of the General Corporation Law of the State of Delaware or the Delaware UCC, other than the filings and records contemplated by the Transaction Documents to perfect security interests. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7. The execution and delivery by each of the Company and the Subsidiary of the Transaction Documents to which it is a party do not, and
the performance by the Company and the Subsidiary of its obligations thereunder will not, result in any violation of any federal law of the United States, the law of the State of New York or any regulation thereunder, the law of the State of
Minnesota or any regulation thereunder, or any provision of the Delaware General Corporation Law or Delaware UCC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8. Neither
the Company nor the Subsidiary is, or will be after giving effect to the sale of the Assigned Interests and the use of proceeds therefrom, an &#147;investment company&#148; within the meaning of, and subject to regulation under, the Investment
Company Act of 1940, as amended. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9. The Guaranty and Collateral Agreement is effective to create in favor of PDL, as security
for the Secured Obligations, as defined in the Guaranty and Collateral Agreement, a security interest (the &#147;Article&nbsp;9 Security Interest&#148;) in the collateral described in the Guaranty and Collateral Agreement in which a security
interest may be created under Article&nbsp;9 of the New York UCC (the &#147;Article&nbsp;9 Collateral&#148;). </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">PDL BioPharma, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">October 5, 2012 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 4 </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10. Upon the filing of the Minnesota Financing Statement with the Minnesota Filing
Office, the Article&nbsp;9 Security Interest in that portion of the Article&nbsp;9 Collateral in which a security interest may be perfected by the filing of a financing statement under the Minnesota UCC will be perfected. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11. Upon the filing of the Delaware Financing Statement with the Delaware Filing Office, the Article&nbsp;9 Security Interest in that
portion of the Article&nbsp;9 Collateral in which a security interest may be perfected by the filing of a financing statement under the Delaware UCC will be perfected. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12. The Article&nbsp;9 Security Interest in the Deposit Account as defined in the Deposit Agreement will be perfected by control upon the execution and delivery of the Deposit Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The opinions expressed above are subject to the following limitations, exceptions, qualifications and assumptions: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A. The opinion expressed in paragraph 4 is subject to bankruptcy, insolvency, fraudulent transfer and other similar laws affecting the
rights and remedies of creditors generally and general principles of equity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">B. Provisions of the Transaction Documents
relating to indemnification or exculpation may be limited by public policy or by law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">C. The opinions expressed in this
opinion letter are limited to the laws of the State of New York, the laws of the State of Minnesota, the General Corporation Law of the State of Delaware, the Delaware UCC (subject to the immediately succeeding sentence) and the Federal laws of the
United States of America, and we express no opinion with respect to the laws of any other state or jurisdiction. With respect to the applicable provisions of the Delaware UCC and Minnesota UCC we have, with your permission, confined our
investigation of the laws of such jurisdiction to an examination of the relevant provisions of the Uniform Commercial Code as in effect in such jurisdiction as set forth in a standard compilation such as the <U>CCH Secured Transactions Guide</U>.
<B>To the extent that our opinions involve the laws of the State of Minnesota, we have relied, with their consent, solely on the opinion letter of Kaplan, Strangis and Kaplan, P.A., dated the date hereof. We express no opinion on any matter covered
by laws, rules or regulations applicable to (a)&nbsp;patents, copyrights, trademarks and other proprietary rights and licenses, (b)&nbsp;the U.S. Food and Drug Administration or (c)&nbsp;health care regulatory matters or health care reimbursement
matters.</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">D. For purposes of our opinions in paragraphs 1 and 2 hereof as to the valid existence and good standing of the
Company and the Subsidiary, we have relied solely upon good standing or similar certificates issued by the appropriate authorities in the subject jurisdictions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">E. For purposes of the opinion in paragraph 7, we have considered only such laws and regulations that in our experience are typically applicable to a transaction of the nature contemplated by the
Transaction Documents. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">PDL BioPharma, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">October 5, 2012 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 5 </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">F. Certain waivers by the Company and the Subsidiary in the Transaction Documents may
relate to matters that cannot, as a matter of law, be effectively waived. Without limiting the foregoing, you should be aware that under applicable law guarantors may be entitled to certain rights or protections which as a matter of statutory or
common law may not be waived or altered. We express no opinion herein as to the enforceability of any provisions of the Guaranty and Collateral Agreement which purport to waive or alter such rights or protections, except to the extent permitted by
law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">G. The enforceability of the Transaction Documents, may be limited by the unenforceability under certain circumstances
of provisions imposing penalties, forfeitures, late payment charges or an increase in interest rate upon delinquency in payment or an occurrence of default. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">H. For purposes of the opinion in paragraph 6, where any Other Company Agreement states that it is governed by laws of a state other than the State of New York, we have not made any investigation of the
laws of such other state but have merely assumed that they would be interpreted in accordance with their plain meaning. We have not reviewed the covenants in the Other Company Agreements that contain financial ratios and other similar financial
restrictions, and no opinion is provided with respect thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">I. We express no opinion as to: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) The enforceability of any provision of the Transaction Documents insofar as it provides that any Person purchasing a participation
from PDL or other Person may exercise set-off or similar rights with respect to such participation or that a lender or other Person may exercise set-off or similar rights other than in accordance with applicable law. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) The enforceability of any provision of the Transaction Documents permitting modification thereof only by means of an agreement in
writing signed by the parties thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) The sale, assignment and transfer of the Assigned Interests being a true sale.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) The enforceability of any provision of the Transaction Documents purporting to waive the right to trial by jury.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">L. In connection with the opinions set forth in paragraphs 9-12, we have assumed that the Company or the Subsidiary has, or
has power to transfer, rights (to the extent necessary to grant a security interest) in the Article&nbsp;9 Collateral existing on the date hereof and will have, or will have the power to transfer, rights (to such extent) in property which becomes
Article&nbsp;9 Collateral after the date hereof. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">PDL BioPharma, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">October 5, 2012 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 6 </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">M. In connection with the opinions set forth in paragraphs 9-12, the perfection of a
security interest in any collateral consisting of &#147;proceeds&#148; (as defined in the Uniform Commercial Code of the applicable jurisdiction) is subject to limitations set forth in Section&nbsp;9-315 of the Uniform Commercial Code of the
applicable jurisdiction. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This opinion letter is effective only as of the date hereof. We do not assume responsibility for updating this
opinion letter as of any date subsequent to its date, and we assume no responsibility for advising you of any changes with respect to any matters described in this opinion letter that may occur subsequent to the date of this opinion letter or from
the discovery, subsequent to the date of this opinion letter, of information not previously known to us pertaining to the events occurring prior to such date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This opinion letter is furnished by us solely for the benefit of PDL and its respective successors and permitted assigns and participants pursuant to the Revenue Interests Purchase Agreement, and this
opinion letter may not be relied upon by such parties for any other purpose or by any other person or entity for any purpose whatsoever. This opinion letter is not to be quoted in whole or in part or otherwise referred to or used or furnished to any
other person, except as may be required by any governmental authority or pursuant to legal process, without our express written consent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Very
truly yours, </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6.2
<SEQUENCE>3
<FILENAME>d532389dex1062.htm
<DESCRIPTION>GUARANTEE AND COLLATERAL AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Guarantee and Collateral Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.6.2 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked &#147;***&#148; and has been filed separately with the Securities and Exchange Commission pursuant to a
Confidential Treatment Application filed with the Commission. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Execution Version </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GUARANTEE AND COLLATERAL AGREEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">DATED AS OF OCTOBER 5, 2012 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">BY </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">AXOGEN, INC., </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">AND </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">AXOGEN
CORPORATION, </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">AS GRANTORS </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">IN FAVOR OF </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">PDL BIOPHARMA, INC., </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">AS PURCHASER </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Section&nbsp;1.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Definitions.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>1.01.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Definition of Terms Used Herein Generally.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>1.02.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Definition of Certain Terms Used Herein.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>1.03.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Rules of Interpretation.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Section&nbsp;2.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Guarantee.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>2.01.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Guarantee.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>2.02.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Right of Contribution.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>2.03.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Subrogation.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>2.04.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Amendments, etc. with respect to the Secured Obligations.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>2.05.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Guarantee Absolute and Unconditional.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>2.06.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Reinstatement.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>2.07.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Payments.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>2.08.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Waiver of Subrogation.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Section&nbsp;3.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Grant of Security Interest.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Section&nbsp;4.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Authorization to File Financing Statements.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Section&nbsp;5.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Reserved.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Section&nbsp;6.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Representations and Warranties.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>6.01.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Grantors&#146; Legal Status.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>6.02.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Grantors&#146; Legal Names.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>6.03.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Grantors&#146; Locations.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>6.04.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Representations in the Purchase Agreement.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>6.05.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Title to Collateral.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>6.06.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Nature of Collateral.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>6.07.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Compliance with Laws.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>6.08.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Validity of Security Interest.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>6.09.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Reserved.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>6.10.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Investment Property in lieu of Payment.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>6.11.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Account Receivables.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>6.12.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Accounts.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>6.13.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Reserved.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Section&nbsp;7.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Covenants.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>7.01.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Grantors&#146; Legal Status.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-i-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(continued) </B></FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>7.02.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Grantors&#146; Names.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>7.03.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Grantors&#146; Organizational Numbers.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>7.04.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Reserved.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>7.05.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Covenants in Purchase Agreement.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>7.06.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Promissory Notes and Tangible Chattel Paper.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>7.07.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Deposit Accounts.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>7.08.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Pledged Stock.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>7.09.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Reserved.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>7.10.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Reserved.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>7.11.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Reserved.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>7.12.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Reserved.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>7.13.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Reserved.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>7.14.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Maintenance of Collateral; Compliance with Laws.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>7.15.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Reserved.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>7.17.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Periodic Certification.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>7.18.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Other Actions as to any and all Collateral.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Section&nbsp;8.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Reserved.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Section&nbsp;9.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Collateral Protection Expenses; Preservation of Collateral.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>9.01.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Expenses Incurred by the Purchaser.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>9.02.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Purchaser&#146;s Obligations and Duties.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>9.03.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Reserved.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Section&nbsp;10.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Deposits.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Section&nbsp;11.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Notification to Account Debtors and Other Persons Obligated on Collateral.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Section&nbsp;12.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Power of Attorney.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>12.01.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Appointment and Powers of Purchaser.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>12.02.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Failure of Grantor to Perform.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>12.03.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Expenses of Attorney-in-Fact.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>12.04.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Ratification by Grantor.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>12.05.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>No Duty on Purchaser.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Section&nbsp;13.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Remedies.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>13.01.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Default.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>13.02.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Remedies Upon Default.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(continued) </B></FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>13.03.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Reserved.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>13.04.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Waivers by Grantors.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>13.05.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Application of Proceeds.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>13.06.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Surplus, Deficiency.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>13.07.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Information Related to the Collateral.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>13.08.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Sale Exempt from Registration.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>13.09.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Rights and Remedies Cumulative.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>13.10.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Reserved.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Section&nbsp;14.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Standards for Exercising Remedies.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>14.01.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Commercially Reasonable Manner.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>14.02.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Standard of Care.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Section&nbsp;15.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Waivers by Grantor; Obligations Absolute.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>15.01.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Specific Waivers.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>15.02.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Obligations Absolute.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Section&nbsp;16.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Marshalling.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Section&nbsp;17.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Interest.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Section&nbsp;18.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Reinstatement.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Section&nbsp;19.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Miscellaneous.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>19.01.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Notices.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>19.02.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>GOVERNING LAW; CONSENT TO JURISDICTION; SERVICE OF PROCESS.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>19.03.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>WAIVER OF JURY TRIAL, ETC.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>19.04.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Counterparts.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>19.05.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Headings.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>19.06.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>No Strict Construction.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>19.07.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Severability.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>19.08.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Survival of Agreement.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>19.09.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Fees and Expenses; Indemnification.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>19.10.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Binding Effect; Several Agreement.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>19.11.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Waivers; Amendment.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>19.12.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Set-Off.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>19.13.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Integration.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>19.14.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Acknowledgments.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>19.15.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Additional Grantors and Guarantors.</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(continued) </B></FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">SCHEDULES </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.01</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;Information for UCC Filings </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.06</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;Nature of Collateral </FONT></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">ANNEXES </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">I</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;Form of Assumption Agreement </FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">GUARANTEE AND COLLATERAL AGREEMENT, dated as of October&nbsp;5, 2012 by AXOGEN, INC., a
Minnesota corporation ( the &#147;<U>Seller</U>&#148;; and together with any other entity on the signature pages hereto or that may become a party hereto as a grantor as provided herein, each a &#147;<U>Grantor</U>&#148; and collectively, jointly
and severally, the &#147;<U>Grantors</U>&#148;), in favor of PDL BIOPHARMA, INC., a Delaware corporation, as Purchaser (in such capacity, the &#147;<U>Purchaser</U>&#148;) under the Revenue Interests Purchase Agreement, dated as of October&nbsp;5,
2012 (as amended, supplemented or otherwise modified from time to time, the &#147;<U>Purchase Agreement</U>&#148;) between the Seller and the Purchaser. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>W</U> <U>I</U> <U>T</U> <U>N</U> <U>E</U> <U>S</U> <U>S</U> <U>E</U> <U>T</U> <U>H</U>: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, pursuant to the Purchase Agreement, the Purchaser has agreed to purchase the Assigned Interests (as defined in the Purchase Agreement) upon the terms and conditions set forth therein; and
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, it is a condition precedent to the purchase by Purchaser of the Assigned Interests that the Grantors shall have
executed and delivered this Agreement to the Purchaser; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, in consideration of the premises and for other good
and valuable consideration the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1. D<SMALL>EFINITIONS</SMALL>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.01. <U>Definition of Terms Used Herein Generally</U>. Except as otherwise provided herein, all capitalized terms used herein (including in the preamble hereto) but not defined herein shall have the
meanings set forth in the Purchase Agreement. Except as specifically provided herein, all terms used herein and defined in the NYUCC shall have the same definitions herein as specified therein as of the date hereof; <U>provided</U>, <U>however</U>,
that if a term is defined in Article&nbsp;9 of the NYUCC differently than in another Article of the NYUCC, the term has the meaning specified in Article&nbsp;9 of the NYUCC as of the date hereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.02. <U>Definition of Certain Terms Used Herein</U>. As used herein, the following terms shall have the following meanings: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Agreement</U>&#148;: this Guarantee and Collateral Agreement, as the same may be amended, supplemented, replaced or otherwise
modified from time to time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Collateral</U>&#148;: as defined in <U>Section&nbsp;3</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Event of Default</U>&#148;: the occurrence of any Put Option Event under the Purchase Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Fully Satisfied</U>&#148;: with respect to the Secured Obligations, at any time that (a)&nbsp;all amounts constituting Secured
Obligations shall have been paid in full in cash; and (b)&nbsp;all fees, expenses and other amounts (including contingent obligations, including those in respect of indemnification provisions contained in the Transaction Documents, but excluding
obligations in respect of such indemnification provisions for which no claim has been made and for which no notice of claim has been given) unpaid as of such time which constitute Secured Obligations shall have been paid in full in cash. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Grantor</U>&#148;: as defined in the preamble. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Guarantors</U>&#148;: the collective reference to each Grantor, other than Borrower. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>NYUCC</U>&#148;: the Uniform Commercial Code as in effect in the State of New York from time to time. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Person</U>&#148;: any natural person, corporation, limited liability company, trust, joint venture, association, company,
partnership, Governmental Authority or other entity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Pledged Stock</U>&#148;: the shares of capital stock or other
equity interests owned at any time by any Person, together with any other shares, stock certificates, options, rights or security entitlements of any nature whatsoever in respect of the capital stock or other equity interests of any Person that may
be issued or granted to, or held by, any Person. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Proceeds</U>&#148;: all &#147;proceeds&#148; as such term is
defined in Section&nbsp;9-102(64) of the NYUCC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Purchase Agreement</U>&#148;: as defined in the preamble.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Purchaser</U>&#148;: as defined in the preamble. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Secured Obligations</U>&#148;: means the &#147;Obligations&#148; of the Seller to the Purchaser, as defined in the Purchase
Agreement, and any obligations owed by a Grantor other than the Seller to the Purchaser pursuant to the terms of the Transaction Documents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Security Interest</U>&#148;: the security interest granted pursuant to <U>Section&nbsp;3</U>, as well as all other security interests created or assigned as additional security for the Secured
Obligations pursuant to the provisions of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Seller</U>&#148;: as defined in the preamble. Any
references herein to &#147;each,&#148; &#147;either&#148; or &#147;such&#148; Seller or to the &#147;applicable&#148; Seller, or to the &#147;the Seller&#148; shall mean and refer to Seller. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>UCC</U>&#148;: the Uniform Commercial Code as in effect in any jurisdiction (except as otherwise contemplated in
<U>Section&nbsp;7.18</U>). References to particular sections of Article 9 of the UCC shall be, unless otherwise indicated, references to revised Article 9 of the UCC adopted and effective in certain jurisdictions on or after July&nbsp;1, 2001.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.03. <U>Rules of Interpretation</U>. The rules of interpretation specified in Section&nbsp;7.10 of Purchase Agreement shall
be applicable to this Agreement. References to &#147;Sections,&#148; &#147;Exhibits&#148; and &#147;Schedules&#148; shall be to Sections, Exhibits and Schedules, respectively, of this Agreement unless otherwise specifically provided. Any of the
terms defined in this <U>Section&nbsp;1</U> may, unless the context otherwise requires, be used in the singular or the plural depending on the reference. All references to statutes and related regulations shall include (unless otherwise specifically
provided herein) any amendments of same and any successor statutes and regulations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2. G<SMALL>UARANTEE</SMALL> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.01. <U>Guarantee</U>. (a)&nbsp;Each of the Guarantors hereby, jointly and severally, unconditionally and irrevocably, guarantees to the
Purchaser and its successors, indorsees, transferees and assigns, the prompt and complete payment and performance by Seller when due of the Secured Obligations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) Anything herein or in any other Transaction Document to the contrary notwithstanding, the maximum liability of each Guarantor hereunder and under the other Transaction Documents shall in no event
exceed the amount which can be guaranteed by such Guarantor under applicable federal, state and other laws relating to the insolvency of debtors (after giving effect to the right of contribution established in <U>Section&nbsp;2.02</U>). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Each Guarantor agrees that the Secured Obligations may at any time and from time to time exceed the amount of the liability of such
Guarantor hereunder without impairing the guarantee contained in this <U>Section&nbsp;2</U> or affecting the rights and remedies of the Purchaser hereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) The guarantee contained in this <U>Section&nbsp;2</U> shall remain in full force and effect until all the Secured Obligations shall have been Fully Satisfied notwithstanding that from time to time
during the term of the Purchase Agreement Seller may be free from any Secured Obligations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) No payment made by the
Seller, any of the Guarantors, any other guarantor or any other Person or received or collected by the Purchaser from the Seller, any of the Guarantors, any other guarantor or any other Person by virtue of any action or proceeding or any set-off or
appropriation or application at any time or from time to time in reduction of or in payment of the Secured Obligations shall be deemed to modify, reduce, release or otherwise affect the liability of any Guarantor hereunder which shall,
notwithstanding any such payment, remain liable for the Secured Obligations up to the maximum liability of such Guarantor hereunder until the Secured Obligations are Fully Satisfied. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.02. <U>Right of Contribution</U>. Each Guarantor hereby agrees that to the extent that a Guarantor shall have paid more than its
proportionate share of any payment made hereunder, such Guarantor shall be entitled to seek and receive contribution from and against any other Guarantor hereunder which has not paid at least its proportionate share of such payment. Each
Guarantor&#146;s right of contribution shall be subject to the terms and conditions of <U>Section&nbsp;2.03</U>. The provisions of this <U>Section&nbsp;2.02</U> shall in no respect limit the obligations and liabilities of any Guarantor to the
Purchaser and each Guarantor shall remain liable to the Purchaser for the full amount guaranteed by such Guarantor hereunder. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.03. <U>Subrogation</U>. Notwithstanding any payment made by any Guarantor hereunder or any set-off or application of funds of any
Guarantor by the Purchaser, (i)&nbsp;no Guarantor shall be entitled to be subrogated to any of the rights of the Purchaser against the Seller or any other Guarantor or Grantor or any collateral security or guarantee or right of offset held by the
Purchaser for the payment of the Secured Obligations, (ii)&nbsp;no Guarantor shall seek or be entitled to seek any contribution or reimbursement from the Seller or any other Guarantor or Grantor in respect of payments made by such Guarantor
hereunder, and (iii)&nbsp;each Guarantor hereby expressly and irrevocably waives any and all rights at law or in equity to subrogation, reimbursement, exoneration, contribution, indemnification or set off and any and all defenses available to a
surety, guarantor or accommodation co-obligor, in each case, until all </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Secured Obligations are Fully Satisfied. If any amount shall be paid to any Guarantor on account of such subrogation rights at any time when all of the Secured Obligations shall not have been
Fully Satisfied, such amount shall be held by such Guarantor in trust for the Purchaser, and shall, forthwith upon receipt by such Guarantor, be turned over to the Purchaser in the exact form received by such Guarantor (duly endorsed by such
Guarantor to the Purchaser, if required), to be applied against the Secured Obligations, whether matured or unmatured, in such order as the Purchaser may determine. Each Guarantor acknowledges and agrees that this waiver is intended to benefit the
Purchaser and shall not limit or otherwise affect such Guarantor&#146;s liability hereunder or the enforceability of this <U>Section&nbsp;2.03</U>, and that the Purchaser and its successors and assigns are intended third-party beneficiaries of the
waivers and agreements set forth in this <U>Section&nbsp;2.03</U>, and its rights under this <U>Section&nbsp;2.03</U>, shall survive payment in full of the Obligations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.04. <U>Amendments, etc. with respect to the Secured Obligations</U>. Each Guarantor shall remain obligated hereunder notwithstanding that, without any reservation of rights against any Guarantor and
without notice to or further assent by any Guarantor, any demand for payment of any of the Secured Obligations made by the Purchaser may be rescinded by the Purchaser and any of the Secured Obligations continued, and the Secured Obligations, or the
liability of any other Person upon or for any part thereof, or any collateral security or guarantee therefor or right of offset with respect thereto, may, from time to time, in whole or in part, be renewed, extended, amended, modified, accelerated,
compromised, waived, surrendered or released by the Purchaser, and the Purchase Agreement and the other Transaction Documents and any other documents executed and delivered in connection therewith may be amended, modified, supplemented or
terminated, in whole or in part, as the Purchaser may deem advisable from time to time, and any collateral security, guarantee or right of offset at any time held the Purchaser for the payment of the Secured Obligations may be sold, exchanged,
waived, surrendered or released. The Purchaser shall not have any obligation to protect, secure, perfect or insure any Lien at any time held by it as security for the Secured Obligations or for the guarantee contained in this <U>Section&nbsp;2</U>
or any property subject thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.05. <U>Guarantee Absolute and Unconditional</U>. Each Guarantor waives any and all notice
of the creation, renewal, extension or accrual of any of the Secured Obligations and notice of or proof of reliance by the Purchaser upon the guarantee contained in this <U>Section&nbsp;2</U> or acceptance of the guarantee contained in this
<U>Section&nbsp;2</U>; the Secured Obligations, and any of them, shall conclusively be deemed to have been created, contracted or incurred, or renewed, extended, amended or waived, in reliance upon the guarantee contained in this
<U>Section&nbsp;2</U>; and all dealings between the Seller and any of the Guarantors, on the one hand, and the Purchaser, on the other hand, likewise shall be conclusively presumed to have been had or consummated in reliance upon the guarantee
contained in this <U>Section&nbsp;2</U>. Each Guarantor waives diligence, presentment, protest, demand for payment and notice of default or nonpayment to or upon Seller or any of the Guarantors with respect to the Secured Obligations, except as
required pursuant to the Purchase Agreement. Each Guarantor understands and agrees that the guarantee contained in this <U>Section&nbsp;2</U> shall be construed as a continuing, absolute and unconditional guarantee of payment and performance (and
not of collection) without regard to (a)&nbsp;the validity or enforceability of the Purchase Agreement or any other Transaction Document (other than this Agreement), any of the Secured Obligations or any other collateral security therefor or
guarantee or right of offset with respect thereto at any time or from time to time held by the Purchaser; (b)&nbsp;any defense, set-off or counterclaim (other than a defense of complete payment and performance hereunder) which may
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
at any time be available to or be asserted by the Seller or any other Person against the Purchaser; or (c)&nbsp;any other circumstance whatsoever (with or without notice to or knowledge of Seller
or such Guarantor) which constitutes, or might be construed to constitute, an equitable or legal discharge of Seller for the Secured Obligations, or of such Guarantor under the guarantee contained in this <U>Section&nbsp;2</U>, in bankruptcy or in
any other instance. When making any demand hereunder or otherwise pursuing its rights and remedies hereunder against any Guarantor, the Purchaser may, but shall be under no obligation to, make a similar demand on or otherwise pursue such rights and
remedies as it may have against Seller, any other Guarantor or any other Person or against any collateral security or guarantee for the Secured Obligations or any right of offset with respect thereto, and any failure by any Secured Creditor to make
any such demand, to pursue such other rights or remedies or to collect any payments from Seller, any other Guarantor or any other Person or to realize upon any such collateral security or guarantee or to exercise any such right of offset, or any
release of Seller, any other Guarantor or any other Person or any such collateral security, guarantee or right of offset, shall not relieve any Guarantor of any obligation or liability hereunder, and shall not impair or affect the rights and
remedies, whether express, implied or available as a matter of law, of the Purchaser against any Guarantor. For the purposes hereof, &#147;<U>demand</U>&#148; shall include the commencement and continuance of any legal proceedings. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.06. <U>Reinstatement</U>. The guarantee contained in this <U>Section&nbsp;2</U> shall continue to be effective, or be reinstated, as
the case may be, if at any time payment, or any part thereof, of any of the Secured Obligations is rescinded or must otherwise be restored or returned by the Purchaser upon the insolvency, bankruptcy, dissolution, liquidation or reorganization of
the Seller or any Guarantor, or upon or as a result of the appointment of a receiver, intervenor or conservator of, or trustee or similar officer for, the Seller or any Guarantor or any substantial part of its property, or otherwise, all as though
such payments had not been made. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.07. <U>Payments</U>. Each Guarantor hereby guarantees that payments hereunder will be paid
to the Purchaser without set-off or counterclaim in Dollars in immediately available funds to the account of Purchaser and that all such payments will be subject to the provisions of the Transaction Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.08. <U>Waiver of Subrogation</U>. Notwithstanding anything to the contrary in this Agreement or in any other Transaction Document, and
except as set forth in <U>Section&nbsp;2.11</U>, each Guarantor hereby expressly and irrevocably waives until all Secured Obligations have been paid in full any and all rights at law or in equity to subrogation, reimbursement, exoneration,
contribution, indemnification or set off and any and all defenses available to a surety, guarantor or accommodation co-obligor. Each Guarantor acknowledges and agrees that this waiver is intended to benefit the Purchaser and shall not limit or
otherwise affect such Guarantor&#146;s liability hereunder or the enforceability of this <U>Section&nbsp;2.08</U>, and that the Purchaser and its successors and assigns are intended third-party beneficiaries of the waivers and agreements set forth
in this <U>Section&nbsp;2.08</U>, and its rights under this <U>Section&nbsp;2.08</U>, shall survive payment in full of the Obligations. The foregoing waiver shall not be deemed to limit or prohibit the payment of indebtedness or other obligations of
any Guarantor to any other Guarantor or other Person which is otherwise permitted under this Agreement or any other Transaction Document. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.09. <U>Election of Remedies</U>. If the Purchaser may, under applicable law, proceed to realize its benefits under any of the Transaction Documents giving the Purchaser a Lien upon any Collateral,
whether owned by any Guarantor or by any other Person, either by </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
judicial foreclosure or by nonjudicial sale or enforcement, the Purchaser may, at its sole option, determine which of its remedies or rights it may pursue without affecting any of its rights and
remedies under this <U>Section&nbsp;2</U>. If, in the exercise of any of its rights and remedies, the Purchaser shall forfeit any of its rights or remedies, including its right to enter a deficiency judgment against any Guarantor or any other
Person, whether because of any applicable laws pertaining to &#147;election of remedies&#148; or the like, each Guarantor hereby consents to such action by the Purchaser and waives, to the extent permitted by applicable law, any claim based upon
such action, even if such action by Purchaser shall result in a full or partial loss of any rights of subrogation that each Guarantor might otherwise have had but for such action by the Purchaser. Any election of remedies that results in the denial
or impairment of the right of the Purchaser to seek a deficiency judgment against any Guarantor shall not impair any other Guarantor&#146;s obligation to pay the full amount of the Secured Obligations. In the event the Purchaser shall bid at any
foreclosure or trustee&#146;s sale or at any private sale permitted by law or the Transaction Documents, the Purchaser may bid all or less than the amount of the Secured Obligations and the amount of such bid need not be paid by the Purchaser but
shall be credited against the Secured Obligations. The amount of the successful bid at any such public sale, whether the Purchaser or any other party is the successful bidder, shall be conclusively deemed to be the fair market value of the
Collateral and the difference between such bid amount and the remaining balance of the Secured Obligations shall be conclusively deemed to be the amount of the Secured Obligations guaranteed under this <U>Section&nbsp;2</U>, notwithstanding that any
present or future law or court decision or ruling may have the effect of reducing the amount of any deficiency claim to which the Purchaser might otherwise be entitled but for such bidding at any such sale. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.10. <U>Limitation</U>. Notwithstanding any provision herein contained to the contrary, each Guarantor&#146;s liability under this
<U>Section&nbsp;2</U> (which liability is in any event in addition to amounts for which such Guarantor is primarily liable under Section&nbsp;2 of the Purchase Agreement) shall be limited to an amount not to exceed as of any date of determination
the amount that could be claimed by the Purchaser from such Guarantor under this <U>Section&nbsp;2.10</U> without rendering such claim voidable or avoidable under Section&nbsp;548 of Chapter 11 of the Bankruptcy Code or under any applicable state
Uniform Fraudulent Transfer Act, Uniform Fraudulent Conveyance Act or similar statute or common law after taking into account, among other things, such Guarantor&#146;s right of contribution and indemnification from each other Guarantor under
<U>Section&nbsp;2.11</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.11. <U>Contribution with Respect to Guaranty Obligations</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) To the extent that any Guarantor shall make a payment under this <U>Section&nbsp;2.11</U> of all or any of the Secured Obligations
which it has agreed to guarantee pursuant hereto (a &#147;<U>Guarantor Payment</U>&#148;) that, taking into account all other Guarantor Payments then previously or concurrently made by any other Guarantor, exceeds the amount that such Guarantor
would otherwise have paid if each Guarantor had paid the aggregate Secured Obligations satisfied by such Guarantor Payment in the same proportion that such Guarantor&#146;s Allocable Amount (as defined below) (as determined immediately prior to such
Guarantor Payment) bore to the aggregate Allocable Amounts of each of the Guarantors as determined immediately prior to the making of such Guarantor Payment, then, following indefeasible payment in full in cash of the Secured Obligations, such
Guarantor shall be entitled to receive contribution and indemnification payments from, and be reimbursed by, each other Guarantor for the amount of such excess, pro rata based upon their respective Allocable Amounts in effect immediately prior to
such Guarantor Payment. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) As of any date of determination, the &#147;<U>Allocable Amount</U>&#148; of any
Guarantor shall be equal to the maximum amount of the claim that could then be recovered from such Guarantor under this <U>Section&nbsp;2</U> without rendering such claim voidable or avoidable under Section&nbsp;548 of Chapter 11 of the Bankruptcy
Code or under any applicable state Uniform Fraudulent Transfer Act, Uniform Fraudulent Conveyance Act or similar statute or common law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) This <U>Section&nbsp;2.11</U> is intended only to define the relative rights of Guarantors and nothing set forth in this <U>Section&nbsp;2.11</U> is intended to or shall impair the obligations of
Guarantors, jointly and severally, to pay any amounts as and when the same shall become due and payable in accordance with the terms of this Agreement, including <U>Section&nbsp;2.01</U>. Nothing contained in this <U>Section&nbsp;2.11</U> shall
limit the liability of Seller to pay the payments owing from it to the Purchaser for which Seller shall be primarily liable. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) The parties hereto acknowledge that the rights of contribution and indemnification hereunder shall constitute assets of the Guarantor
to which such contribution and indemnification is owing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) The rights of the indemnifying Guarantors against other Grantors
under this <U>Section&nbsp;2.11</U> shall be exercisable upon the full and indefeasible payment of the Secured Obligations. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3. G<SMALL>RANT</SMALL> <SMALL>OF</SMALL> S<SMALL>ECURITY</SMALL> I<SMALL>NTEREST</SMALL>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each Grantor hereby grants to the Purchaser a security interest in, and mortgage on, all of the following property now owned or at any
time hereafter acquired by such Grantor or in which such Grantor now has, or at any time in the future may acquire, any right, title or interest (collectively, the &#147;<U>Collateral</U>&#148;), as collateral security for the prompt and complete
payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of the Secured Obligations: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">a. all accounts, including health-care receivables, all instruments, chattel paper, and promissory notes evidencing such accounts and all
Pledged Stock delivered to a Grantor in respect of settlement of any account; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">b. all deposit accounts, all claims now or
hereafter arising therefrom, all funds now or hereafter held therein, all amounts now or hereafter credited thereto and all certificates and instruments, if any, from time to time representing or evidencing such bank accounts; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">c. all cash, provided that such shall exclude any deposits given for security of any lease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4. A<SMALL>UTHORIZATION</SMALL> <SMALL>TO</SMALL> F<SMALL>ILE</SMALL> F<SMALL>INANCING</SMALL> S<SMALL>TATEMENTS</SMALL>.
Each Grantor hereby irrevocably authorizes the Purchaser at any time and from time to time to file in any jurisdiction in which the UCC has been adopted any initial financing statements and amendments thereto that (a)&nbsp;indicate the Collateral
(i)&nbsp;as &#147;all accounts receivable, including health care receivables, and all instruments, chattel paper, and promissory notes evidencing such accounts and all Pledged Stock delivered to a Grantor in respect of settlement of any account; all
deposit </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
accounts, all claims now or hereafter arising therefrom, all funds now or hereafter held therein, all amounts now or hereafter credited thereto and all certificates and instruments, if any, from
time to time representing or evidencing such bank accounts; and all cash of such Grantor or words of similar effect, regardless of whether any particular asset comprised in the Collateral falls within the scope of Article&nbsp;9 of the NYUCC or such
jurisdiction, or (ii)&nbsp;as being of an equal or lesser scope or with greater detail, and (b)&nbsp;contain any other information required by part&nbsp;5 of Article&nbsp;9 of the UCC for the sufficiency or filing office acceptance of any initial
financing statement or amendment, including&nbsp;whether such Grantor is an organization, the type of organization and any organization identification number issued to such Grantor. Each Grantor agrees to furnish any such information to the
Purchaser promptly upon request. Each Grantor also ratifies its authorization for the Purchaser to have filed in any UCC jurisdiction any like initial financing statements or amendments thereto if filed prior to the date hereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;5. [R<SMALL>ESERVED</SMALL>]. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6. <U>Representations and Warranties</U>. To induce the Purchaser to enter into the Purchase Agreement and to induce the Purchaser to purchase the Secured Obligations from the Seller
thereunder, each Grantor hereby represents and warrants to the Purchaser that: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.01. <U>Grantors&#146; Legal Status</U>.
(a)&nbsp;Such Grantor is an organization as set forth in Schedule 6.01; (b)&nbsp;such organization is of the type, and is organized in the jurisdiction, set forth in Schedule 6.01; and (c)&nbsp;Schedule 6.01 sets forth such Grantor&#146;s correct
legal name, prior organizational names within the previous five years, chief executive office, organizational identification number or states that such Grantor has none. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">6.02. <U>Grantors&#146; Legal Names</U>. Such Grantor&#146;s exact legal name is that set forth on the signature page hereof (or, in the case of any Grantor that becomes a party hereto after the date
hereof, on the signature page to the applicable Assignment and Assumption Agreement). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.03. <U>Grantors&#146; Locations</U>.
Schedule 6.01 sets forth such Grantor&#146;s place of business or (if it has more than one place of business) its chief executive office, as well as its mailing address if different. Such Grantor&#146;s place of business or (if it has more than one
place of business) its chief executive office (if such Grantor is an organization) is located in a jurisdiction that has adopted the UCC or whose laws generally require that information concerning the existence of nonpossessory security interests be
made generally available in a filing, recording or registration system as a condition or result of the security interest obtaining priority over the rights of a lien creditor with respect to the Collateral. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.04. <U>Representations in the Purchase Agreement</U>. The representations and warranties set forth in Section&nbsp;5 of the Purchase
Agreement as they relate to such Grantor to the Transaction Documents to which such Grantor is a party, each of which is hereby incorporated herein by reference, are true and correct in all material respects, and the Purchaser shall be entitled to
rely on each of them as if they were fully set forth herein; <U>provided</U> that each reference in each such representation and warranty to the applicable Seller&#146;s knowledge shall, for the purposes of this <U>Section&nbsp;6.04</U>, be deemed
to be a reference to such Grantor&#146;s knowledge. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.05. <U>Title to Collateral</U>. The Collateral of such Grantor is owned by such Grantor
free and clear of any Lien, except for Liens expressly permitted pursuant to the Purchase Agreement. Such Grantor has not filed or consented to the filing of (a)&nbsp;any financing statement or analogous document under the UCC or any other
applicable laws covering any of its Collateral or (b)&nbsp;any assignment in which such Grantor assigns any Collateral or any security agreement or similar instrument covering any Collateral with any foreign governmental, municipal or other office,
which financing statement or analogous document, assignment, security agreement or similar instrument is still in effect, except, in each case, with respect to Liens expressly permitted pursuant to the Purchase Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.06. <U>Nature of Collateral</U>. None of the Collateral of such Grantor constitutes, or is the proceeds of, farm products and none of
the Collateral has been purchased or will be used by such Grantor primarily for personal, family or household purposes, and as of the Closing Date, except as set forth on Schedule 6.06: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) none of the account debtors or other persons obligated on any of the Collateral of such Grantor is a Governmental Authority subject
to the Federal Assignment of Claims Act or like federal, state or local statute or rule in respect of such Collateral; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)
such Grantor has no deposit accounts or other bank accounts; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) such Grantor has no securities accounts or securities
entitlements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.07. <U>Compliance with Laws</U>. Such Grantor has at all times operated its business in compliance with all
laws, except as could not reasonably be expected to have a Material Adverse Effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.08. <U>Validity of Security
Interest</U>. (a)&nbsp;The Security Interest granted by each Grantor constitutes, to the extent possible under applicable law, a legal and valid security interest in all of the Collateral of such Grantor securing the payment and performance of the
Secured Obligations and (b)&nbsp;upon the giving of value, the filing of financing statements describing the Collateral in the offices listed on the Schedule 6.01, and the taking of all applicable actions in respect of perfection contemplated by
<U>Sections 7.06</U> and <U>7.07</U> in respect of Collateral (in which a security interest cannot be perfected by the filing of a financing statement), the Security Interest will be valid, enforceable and perfected in all Collateral of such
Grantor. The Security Interest is and shall be prior to any other Lien on the Collateral, other than Liens expressly permitted to be prior to the Security Interest under the Purchase Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.09. <U>Reserved</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">6.10. <U>Investment Property in lieu of Payment</U>. No account exceeding $50,000 has been settled with the Grantor&#146;s receipt of Pledged Stock that has not been delivered to the Purchaser.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.11. <U>Account Receivables</U>. No amount exceeding $50,000 and payable to such Grantor under or in connection with any
account is evidenced by any instrument, promissory note, chattel paper, and no account exceeding $50,000 has been settled by the account debtor granting to such Grantor Pledged Stock which has not been delivered to the Purchaser. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.12. <U>Accounts</U>. (i)&nbsp;Each account of such Grantor is genuine and in all material
respects what they purport to be, (ii)&nbsp;each account arises out of (A)&nbsp;a bona fide sale of goods sold and delivered by such Grantor (or is in the process of being delivered) or (B)&nbsp;services theretofore actually rendered or to be
rendered by such Grantor to the account debtor named therein, (iii)&nbsp;no material account of such Grantor is evidenced by any instrument, promissory note or chattel paper other than any such instrument, promissory note or chattel paper that has
been theretofore endorsed over, assigned and delivered to, or submitted to the control of, the Purchaser (accompanied by such instruments of transfer and assignment duly executed in blank as the Purchaser may from time to time specify), and
(iv)&nbsp;no surety bond was required or given in connection with any account of such Grantor or the contracts or purchase orders out of which they arose and the right to receive payment under each account is assignable. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.13. <U>Reserved</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7. C<SMALL>OVENANTS</SMALL>. Each Grantor covenants and agrees with the Purchaser, in each case at such Grantor&#146;s own cost and expense, as follows. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.01. <U>Grantors&#146; Legal Status</U>. Such Grantor shall not change its type of organization, jurisdiction of organization or other
legal structure except upon not less than twenty (20)&nbsp;days&#146; prior written notice to the Purchaser. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.02.
<U>Grantors&#146; Names</U>. Such Grantor shall not change its name except upon not less than twenty (20)&nbsp;days&#146; prior written notice to the Purchaser. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7.03. <U>Grantors&#146; Organizational Numbers</U>. Without providing at least twenty (20)&nbsp;days&#146; prior written notice to the Purchaser, such Grantor shall not change its organizational
identification number if it has one. If such Grantor does not have an organizational identification number and later obtains one, such Grantor shall forthwith notify the Purchaser of such organizational identification number promptly upon obtaining
such identification number. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.04. <U>Reserved</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7.05. <U>Covenants in Purchase Agreement</U>. Each Grantor shall take, or shall refrain from taking, as the case may be, each action that is necessary to be taken or not taken, as the case may be, so that
no Default or Event of Default is caused by the failure to take such action or to refrain from taking such action by such Grantor or any of its subsidiaries. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7.06. <U>Promissory Notes and Tangible Chattel Paper</U>. If such Grantor, together with the other Grantors, shall at any time hold or acquire any instruments, promissory notes or tangible chattel paper
in an aggregate principal amount of more than $50,000 payable to such Grantor under or in connection with any account, such Grantor shall forthwith endorse, assign and deliver the same to the Purchaser, accompanied by such instruments of transfer or
assignment duly executed in blank as the Purchaser may from time to time specify to be held by the Purchaser as Collateral pursuant to this Agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.07. <U>Deposit Accounts</U>. For each deposit account that such Grantor at any time opens
or maintains, such Grantor shall, at the Purchaser&#146;s request and option, either (a)&nbsp;cause the depository bank to enter into a written agreement or other authenticated record with the Purchaser, in form and substance reasonably satisfactory
to the Purchaser, pursuant to which such depository bank shall agree, among other things, to comply at any time with instructions from the Purchaser to such depository bank directing the disposition of funds from time to time credited to such
deposit account, without further consent of the Grantor, or (b)&nbsp;arrange for the Purchaser to become the customer of the depository bank with respect to the deposit account; <U>provided</U>, <U>however</U>, that notwithstanding the foregoing,
the requirements of this <U>Section&nbsp;7.07</U> shall not apply to any zero balance payroll or similar disbursement account maintained by any Grantor (and each Grantor agrees not to deposit in any payroll account or similar disbursement account
maintained by it any funds, except funds needed at the time of deposit (or within three days thereafter) to meet payroll needs of such Grantor). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7.08. <U>Pledged Stock</U>. If such Grantor, together with the other Grantors, shall at any time hold or acquire any Pledged Stock granted to such Grantor by an account debtor to settle an account in an
aggregate principal amount of more than $50,000, such Grantor shall forthwith deliver the same to the Purchaser, accompanied by an executed blank stock power and such other instruments of transfer or assignment duly executed in blank as the
Purchaser may from time to time specify to be held by the Purchaser as Collateral pursuant to this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.09.
<U>Reserved</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.10. <U>Reserved</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7.11. <U>Reserved</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.12. <U>Reserved</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.13. <U>Reserved</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7.14. <U>Maintenance of Collateral; Compliance with Laws</U>. (a)&nbsp;Such Grantor shall not use the Collateral in violation of any law to the extent that such violation could reasonably be expected to
have a Material Adverse Effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.15. <U>Reserved</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.16. <U>Reserved</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7.17. <U>Periodic Certification</U><I>. </I>From time to time on demand (which demand, absent an Event of Default, shall be no more frequent than once every four months) from the Purchaser such Grantor
shall deliver to the Purchaser either (a)&nbsp;new Schedules setting forth the information required pursuant to Sections 6.01, 6.03 and 6.06, and a certificate from an executive officer of the Seller certifying as to the accuracy of the information
set forth therein or (b)&nbsp;a certificate from an executive officer of the Seller confirming that there has been no change in the information set forth on the Schedules delivered as of the date hereof or since the date of the most recent
certificate delivered pursuant to <U>Section&nbsp;7.17(a)</U>, as applicable. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.18. <U>Other Actions as to any and all Collateral</U>. Such Grantor further agrees to take
any other action reasonably requested by the Purchaser to insure the attachment, perfection and, first priority of, and the ability of the Purchaser to enforce, the Security Interest in any and all of the Collateral provided by such Grantor
including, without limitation, (a)&nbsp;executing, delivering and, where appropriate, filing financing statements and amendments relating thereto under the UCC, to the extent, if any, that such Grantor&#146;s signature thereon is required therefor;
(b)&nbsp;causing the Purchaser&#146;s name to be noted as secured party on any certificate of title for a titled good if such notation is a condition to attachment, perfection or priority of, or ability of the Purchaser to enforce, the Security
Interest in such Collateral; (c)&nbsp;complying with any provision of any statute, regulation or treaty of the United States of America as to any Collateral if compliance with such provision is a condition to the attachment, perfection or priority
of, or the ability of the Purchaser to enforce, the Security Interest in such Collateral; (d)&nbsp;obtaining governmental and other third-party consents and approvals, including without limitation any consent of any licensor, lessor or other person
obligated on such Collateral; (e)&nbsp;providing to the Purchaser &#147;control&#148; over such Collateral, to the extent that perfection can only be achieved under the UCC by control or where obtaining perfection by control provides more protection
to the Purchaser that perfection by filing a financing statement; and (f)&nbsp;taking all actions required by the UCC or by other law, as applicable in any relevant UCC jurisdiction, or by other law as applicable in any foreign jurisdiction;
<U>provided</U>, <U>however</U>, that nothing contained in clause (d)&nbsp;or (e)&nbsp;shall require such Grantor to pay any consideration (other than any governmental application, processing, filing or recording fees) in order to obtain any consent
or waiver referred to in such clauses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.19. <U>Treatment of Accounts</U>. Subject to Section&nbsp;5.10 of the Purchaser
Agreement, no Grantor shall grant or extend the time for payment of any material account, or compromise or settle any account for less than the full amount thereof, or release any person or property, in whole or in part, from payment thereof, or
allow any credit or discount thereon, other than as normal and customary in the ordinary course of a Grantor&#146;s business. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8. [R<SMALL>ESERVED</SMALL>]. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9. C<SMALL>OLLATERAL</SMALL> P<SMALL>ROTECTION</SMALL> E<SMALL>XPENSES</SMALL>; P<SMALL>RESERVATION</SMALL> <SMALL>OF</SMALL> C<SMALL>OLLATERAL</SMALL>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.01. <U>Expenses Incurred by the Purchaser</U>. In its discretion, the Purchaser may, if the relevant Grantor fails to do so, discharge
taxes and other encumbrances at any time levied or placed on any material portion of the Collateral and pay any necessary filing fees. Each Grantor agrees to reimburse the Purchaser on demand for any and all expenditures so made, and all sums
disbursed by the Purchaser in connection with this <U>Section&nbsp;9.01</U>, including reasonable attorneys&#146; fees, court costs, expenses and other charges relating thereto, shall be payable, upon demand, by such Grantor to the Purchaser shall
bear interest at the per annum rate specified in <U>Section&nbsp;17</U> and shall constitute additional Secured Obligations. The Purchaser shall have no obligation to any Grantor to make any such expenditures, nor shall the making thereof relieve
any Grantor of any default. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.02. <U>Purchaser&#146;s Obligations and Duties</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Anything herein to the contrary notwithstanding, each Grantor shall remain liable under each contract or agreement comprised in the
Collateral provided by it to be observed or performed by such Grantor thereunder. The Purchaser shall not have any obligation or liability under any such contract or agreement by reason of or arising out of this Agreement or the receipt by the
Purchaser of any payment relating to any of the Collateral, nor shall the Purchaser be obligated in any manner to perform any of the obligations of any Grantor under or pursuant to any such contract or agreement, to make inquiry as to the nature or
sufficiency of any payment received by the Purchaser in respect of the Collateral or as to the sufficiency of any performance by any party under any such contract or agreement, to present or file any claim, to take any action to enforce any
performance or to collect the payment of any amounts which may have been assigned to the or to which the Purchaser may be entitled at any time or times. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) The Purchaser&#146;s sole duty with respect to the custody, safekeeping and physical preservation of the Collateral in its possession, under Section&nbsp;9-207 of the NYUCC or otherwise, shall be to
deal with such Collateral in the same manner as the Purchaser deals with similar property for its own account. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Neither
the Purchaser nor any of its respective officers, directors, partners, employees, agents, attorneys and other advisors, attorneys-in-fact or affiliates shall be liable for failure to demand, collect or realize upon any of the Collateral or for any
delay in doing so or shall be under any obligation to sell or otherwise dispose of any Collateral upon the request of any Grantor or any other Person or to take any other action whatsoever with regard to the Collateral or any part thereof. The
powers conferred on the Purchaser hereunder are solely to protect the Purchaser&#146;s interests in the Collateral and shall not impose any duty upon Purchaser to exercise any such powers. The Purchaser shall be accountable only for amounts that it
actually receives as a result of the exercise of such powers, and neither it nor any of its officers, directors, partners, employees, agents, attorneys and other advisors, attorneys-in-fact or affiliates shall be responsible to any Grantor for any
act or failure to act hereunder, except to the extent that any such act or failure to act is found by a final and non-appealable decision of a court of competent jurisdiction to have resulted from their respective gross negligence or willful
misconduct. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Each Grantor acknowledges that the rights and responsibilities of the Purchaser under this Agreement with
respect to any action taken by the Purchaser or the exercise or non-exercise by the Purchaser of any option, voting right, request, judgment or other right or remedy provided for herein or resulting or arising out of this Agreement shall, be
governed by the Purchase Agreement and by such other agreements with respect thereto as may exist from time to time among them. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.03. <U>Reserved</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10. D<SMALL>EPOSITS</SMALL>. The Purchaser may after the occurrence and during the continuance of an Event of Default demand, sue for, collect, or make any settlement or compromise which it
deems desirable with respect to the Collateral. Regardless of the adequacy of Collateral or any other security for the Secured Obligations, any deposits or other sums at any time credited by or due from the Purchaser to any Grantor may at any time
be applied to or set off against any of the Secured Obligations whether or not due and owing. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;11. N<SMALL>OTIFICATION</SMALL> <SMALL>TO</SMALL> A<SMALL>CCOUNT</SMALL>
D<SMALL>EBTORS</SMALL> <SMALL>AND</SMALL> O<SMALL>THER</SMALL> P<SMALL>ERSONS</SMALL> O<SMALL>BLIGATED</SMALL> <SMALL>ON</SMALL> C<SMALL>OLLATERAL</SMALL>. If an Event of Default shall have occurred and be continuing, each Grantor shall, at the
request of the Purchaser, notify account debtors and other persons obligated on any of the Collateral of such Grantor of the Security Interest in any account or chattel paper, promissory notes or instruments payable to such Grantor under or in
connection with any account, or Pledged Stock delivered to such Grantor to settle an account, or other claims constituting Collateral that payment thereof is to be made directly to the Purchaser or to any financial institution designated by the
Purchaser as the Purchaser&#146;s agent therefor, and the Purchaser may itself, if an Event of Default shall have occurred and be continuing, without notice to or demand upon any Grantor, so notify account debtors and other persons obligated on
Collateral. After the making of such a request or the giving of any such notification, each Grantor shall hold any proceeds of collection of accounts and other claims constituting Collateral received by the Grantor as trustee for the Purchaser
without commingling the same with other funds of the Grantor and shall turn the same over to the Purchaser in the identical form received, together with any necessary endorsements or assignments. The Purchaser shall have no liability or
responsibility to any Grantor for acceptance of a check, draft or other order for payment of money bearing the legend &#147;payment in full&#148; or words of similar import or any other restrictive legend or endorsement or be responsible for
determining the correctness of any remittance. Without limitation of the foregoing, during the continuation of an Event of Default (1)&nbsp;the Purchaser shall have the right, but not the obligation, to make test verifications of the accounts in any
manner and through any medium that it reasonably considers advisable, and the Grantors shall furnish all such assistance and information as the Purchaser may require in connection with such test verifications, and (2)&nbsp;the Purchaser in its own
name or in the name of others may communicate with account debtors on the accounts to verify with them to the Purchaser&#146;s satisfaction the existence, amount and terms of any accounts. The Purchaser may apply the proceeds of collection of
accounts and other claims constituting Collateral received by the Purchaser to the Secured Obligations or hold such proceeds as additional Collateral, at the option of the Purchaser. The provisions of Section&nbsp;9-209 of the NYUCC shall not apply
to any account as to which notification of assignment has been sent to the account debtor or other person obligation on the Collateral, whether under this <U>Section&nbsp;11</U>, <U>Section&nbsp;12</U> or <U>Section&nbsp;13</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;12. P<SMALL>OWER</SMALL> <SMALL>OF</SMALL> A<SMALL>TTORNEY</SMALL>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.01. <U>Appointment and Powers of Purchaser</U>. Upon the occurrence and during the continuance of an Event of Default, each Grantor
hereby irrevocably constitutes and appoints the Purchaser and any officer or Purchaser thereof, with full power of substitution, as its true and lawful attorney-in-fact with full irrevocable power and authority in the place and stead of such Grantor
and in the name of such Grantor or in its own name, for the purpose of carrying out the terms of this Agreement, to take any and all appropriate action and to execute any and all documents and instruments which may be necessary or desirable to
accomplish the purposes of this Agreement, and, without limiting the generality of the foregoing, each Grantor hereby gives the Purchaser the power and right, on behalf of such Grantor, without notice to or assent by such Grantor, to do any or all
of the following: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) in the name of such Grantor or its own name, or otherwise, take possession of and endorse and collect
any checks, drafts, notes, acceptances or other instruments for the payment of moneys due under any account or with respect to any other Collateral and file any claim or take any other action or proceeding in any court of law or equity or otherwise
deemed appropriate by the Purchaser for the purpose of collecting any and all such moneys due under any account or with respect to any other Collateral whenever payable; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) pay or discharge taxes and Liens levied or placed on or threatened against the
Collateral, effect any repairs or provide any insurance and pay all or any part of the premiums therefor and the costs thereof; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) execute, in connection with any sale provided for in <U>Section&nbsp;13</U>, any endorsements, assignments or other instruments of conveyance or transfer with respect to the Collateral; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) exercise all rights of such Grantor as owner of the Pledged Stock or as party to any partnership, limited liability company or
similar agreement, including, without limitation, the right to sign any and all amendments, instruments, certificates, proxies, and other writings and exercise all voting and consent rights with respect to the Pledged Stock; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) (1) direct any party liable for any payment under any of the Collateral to make payment of any and all moneys due or to become due
thereunder directly to the Purchaser or as the Purchaser shall direct; (2)&nbsp;ask or demand for, collect, and receive payment of and receipt for, any and all moneys, claims and other amounts due or to become due at any time in respect of or
arising out of any Collateral; (3)&nbsp;commence and prosecute any suits, actions or proceedings at law or in equity in any court of competent jurisdiction to collect the Collateral or any portion thereof and to enforce any other right in respect of
any Collateral; (4)&nbsp;defend any suit, action or proceeding brought against such Grantor with respect to any Collateral; (5)&nbsp;settle, compromise or adjust any such suit, action or proceeding and, in connection therewith, give such discharges
or releases as the Purchaser may deem appropriate; and (6)&nbsp;generally, sell, transfer, pledge and make any agreement with respect to or otherwise deal with any of the Collateral as fully and completely as though the Purchaser were the absolute
owner thereof for all purposes, and do, at the Purchaser&#146;s option and such Grantor&#146;s expense, at any time, or from time to time, all acts and things which the Purchaser deems necessary to protect, preserve or realize upon the Collateral
and the Security Interest therein and to effect the intent of this Agreement, all as fully and effectively as such Grantor might do; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(f) to the extent that such Grantor&#146;s authorization given in <U>Section&nbsp;4</U> is not sufficient, to file such financing statements or similar documents under the laws of any jurisdiction with
respect hereto, with or without such Grantor&#146;s signature, or a photocopy of this Agreement in substitution for a financing statement or such other document, as the Purchaser may deem appropriate and to execute in such Grantor&#146;s name such
financing statements, other such documents and amendments thereto and continuation statements which may require such Grantor&#146;s signature. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anything in this <U>Section&nbsp;12.01</U> to the contrary notwithstanding, the Purchaser agrees that it will not exercise any rights under the power of
attorney provided for in this <U>Section&nbsp;12.01</U> (other than under paragraph (e)&nbsp;of this <U>Section&nbsp;12.01</U>) unless an Event of Default shall have occurred and be continuing. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.02. <U>Failure of Grantor to Perform</U>. If any Grantor fails to perform or comply with any of its agreements contained herein, the
Purchaser, at its option, but without any obligation so to do, may perform or comply, or otherwise cause performance or compliance, with such agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.03. <U>Expenses of Attorney-in-Fact</U>. The expenses of the Purchaser incurred in
connection with actions undertaken as provided in this <U>Section&nbsp;12</U>, together with interest thereon at a rate equal to the lower of (i)&nbsp;the highest rate permitted by applicable law, and (ii)&nbsp;one and one-half percent
(1.5%)&nbsp;per month, compounded monthly, shall be payable by such Grantor to the Purchaser on demand. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.04.
<U>Ratification by Grantor</U>. To the extent permitted by law, each Grantor hereby ratifies all that said attorneys shall lawfully do or cause to be done by virtue of this <U>Section&nbsp;12</U>. This power of attorney is a power coupled with an
interest and is irrevocable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.05. <U>No Duty on Purchaser</U>. The powers conferred on the Purchaser, its directors,
officers and agents pursuant to this <U>Section&nbsp;12</U> are solely to protect the Purchaser&#146;s interests in the Collateral and shall not impose any duty upon any of them to exercise any such powers. The Purchaser shall be accountable only
for the amounts that it actually receives as a result of the exercise of such powers, and neither it nor any of its officers, directors, employees or Purchasers shall be responsible to any Grantor for any act or failure to act, except for the
Purchaser&#146;s own gross negligence or willful misconduct as determined in a final and non-appealable judgment by a court of competent jurisdiction. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;13. R<SMALL>EMEDIES</SMALL>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.01. <U>Default</U>. Grantors shall
be in default under this Agreement (a)&nbsp;whenever any Event of Default has occurred and is continuing (and each of the Grantors shall thereupon be in default hereunder without regard to whether or to what degree any Grantor individually may have
caused, participated in, or had any knowledge of the occurrence of such Event of Default) and (b)&nbsp;at all times after any Secured Obligation has become due and payable and remains unpaid beyond any applicable grace period. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.02. <U>Remedies Upon Default</U>. At any time when any Grantor is in default under this Agreement as set forth in
<U>Section&nbsp;13.01</U>, the Purchaser may exercise and enforce, in any order, (i)&nbsp;each and all of the rights and remedies available to a secured party upon default under the NYUCC or any other applicable UCC or other applicable law,
(ii)&nbsp;each and all of the rights and remedies available to it under the Purchase Agreement or any other Transaction Document, and (iii)&nbsp;each and all of the following rights and remedies: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Collection Rights</U>. Without notice to any Grantor or any other Loan Party, the Purchaser may notify any or all account debtors
and obligors on any accounts, chattel paper or instruments evidencing an account, or other claims constituting Collateral of the Purchaser&#146;s Security Interests therein or the issuers of Pledged Stock delivered to settle an account and may
direct, demand and enforce payment thereof directly to the Purchaser. The provisions of Section&nbsp;9-209 of the NYUCC shall not apply to any account or chattel paper, promissory note or payment intangible as to which notification of assignment has
been sent to the account debtor. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Foreclosure</U>. The Purchaser may sell, lease, license or otherwise dispose of or
transfer any or all of the Collateral or any part thereof in one or more parcels at public sale or in private sale or transaction, on any exchange or market or at the Purchaser&#146;s offices or on any Grantor&#146;s premises or at any other
location, for cash, on credit or for future </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
delivery, and may enter into all contracts necessary or appropriate in connection therewith, without any notice whatsoever unless required by law. Where permitted by law, the Purchaser may be the
purchaser at any such sale and in such event, the Purchaser may bid part or all of the Secured Obligations owing to it without necessity of any cash payment on account of the purchase price, even though any other purchaser at such sale is required
to bid a purchase price payable in cash. Each Grantor agrees that at least ten (10)&nbsp;calendar days&#146; written notice to such Grantor of the time and place of any public sale of Collateral owned by it (or, to the extent such Grantor is
entitled by law to notice thereof, the public sale of any other Collateral), or the time after which any private sale of Collateral owned by it (or, to the extent such Grantor is entitled by law to notice thereof, the private sale of any other
Collateral) is to be made, shall be commercially reasonable. For purposes of such notice, to the fullest extent permitted by law (i)&nbsp;each Grantor waives notice of any sale of Collateral owned by any other Grantor and (ii)&nbsp;each Grantor
agrees that notice given to the Seller shall constitute notice given to such Grantor. The giving of notice of any such sale or other disposition shall not obligate the Purchaser to proceed with the sale or disposition, and any such sale or
disposition may be postponed or adjourned from time to time, without further notice. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Voting Rights</U>. The Purchaser
may exercise any and all rights of any Grantor as the owner of any Pledged Stock delivered to a Grantor to settle an account, including, without limitation, voting rights, rights to give or withhold consent under any agreement under which such
Pledged Stock is issued. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <U>Appointment of Receiver</U>. Without limiting any other right or remedy of the Purchaser in
this Agreement, upon the occurrence and during the continuance of any Event of Default, the Purchaser may by instrument in writing appoint any person as a receiver of all or any part of the Collateral of each applicable Grantor. The Purchaser may
from time to time remove or replace a receiver, or make application to any court of competent jurisdiction for the appointment of a receiver. Any receiver appointed by the Purchaser shall (for purposes relating to responsibility for the
receiver&#146;s acts or omissions) be considered to be the Purchaser of each applicable Grantor. The Purchaser may from time to time fix the receiver&#146;s remuneration and the Grantors shall pay the amount of such remuneration to the Purchaser.
The Purchaser shall not be liable to any Grantor or any other person in connection with appointing or not appointing a receiver or in connection with the receiver&#146;s actions or omissions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.03. <U>Reserved</U><I>. </I> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">13.04. <U>Waivers by Grantors</U>. Each Grantor hereby irrevocably waives (a)&nbsp;all rights of redemption from any foreclosure sale; (b)&nbsp;the benefit of all valuation, appraisal, exemption and
moratorium laws; (c)&nbsp;to the fullest extent permitted by law, all rights to notice or a hearing prior to the exercise by the Purchaser of its right to take possession of any Collateral, whether by self-help or by legal process and any right to
object to the Purchaser taking possession of any Collateral by self-help; and (d)&nbsp;if the Purchaser seeks to obtain possession of any Collateral by replevin, claim and delivery, attachment, levy or other legal process, (i)&nbsp;any notice or
demand for possession prior to the commencement of legal proceedings, (ii)&nbsp;the posting of any bond or security in any such proceedings, and (iii)&nbsp;any requirement that the Purchaser retain possession and not dispose of any Collateral until
after a trial or final judgment in such proceedings. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.05. <U>Application of Proceeds</U>. Except as expressly provided elsewhere in this
Agreement, all proceeds received by the Purchaser in respect of any sale of, collection from, or other realization upon all or any part of the Collateral may, in the discretion of the Purchaser, be held by the Purchaser as Collateral for, or then,
or at any other time thereafter, applied in full or in part by the Purchaser against, the Secured Obligations in the following order of priority: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">FIRST: to the payment of all reasonable costs and expenses of such sale, collection or other realization, including reasonable compensation to the Purchaser and its agents and counsel, and all other
reasonable expenses, liabilities and advances made or incurred by the Purchaser in connection therewith, and all amounts for which the Purchaser is entitled to indemnification hereunder and all reasonable advances made by the Purchaser hereunder for
the account of any Grantor, and to the payment of all reasonable costs and expenses paid or incurred by the Purchaser in connection with the exercise of any right or remedy hereunder, all in accordance with <U>Section&nbsp;19.09</U>; </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">SECOND: to the payment of all other Secured Obligations then due and payable in the manner and order provided in the
Purchase Agreement; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">THIRD: to any payments required by Section&nbsp;9-608(a)(1)(C) or 9-615(a)(3) of the NYUCC
or other applicable law; and </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">FOURTH, to the payment to or upon the order of the Grantor entitled thereto, or
to whomsoever may be lawfully entitled to receive the same or as a court of competent jurisdiction may direct, of any surplus then remaining from such proceeds. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">13.06. <U>Surplus; Deficiency</U>. Any surplus proceeds of any sale or other disposition by the Purchaser of any Collateral remaining after discharge of the Purchase Agreement and after all Secured
Obligations are paid in full and in cash and any payments required by Section&nbsp;9-608(a)(1)(C) or 9-615(a)(3) of the NYUCC are paid in full shall be paid over to the Grantor entitled thereto, or to whomever may be lawfully entitled to receive
such surplus or as a court of competent jurisdiction may direct, but prior to termination and discharge of the Purchase Agreement, such surplus proceeds may be retained by the Purchaser and held as Collateral until termination and discharge of the
Purchase Agreement. The Seller and each Guarantor shall be and remain liable for any deficiency. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.07. <U>Information
Related to the Collateral</U>. If, during the continuance of an Event of Default, the Purchaser determines to sell or otherwise transfer any Collateral, each Grantor shall, and shall cause any Person controlled by it to, furnish to the Purchaser all
information the Purchaser may request that pertains or could pertain to the value or condition of the Collateral or that would or might facilitate such sale or transfer. The Purchaser shall have the right, notwithstanding any confidentiality
obligation or agreement otherwise binding upon it, freely (but not in violation of any law, including federal securities laws) to disclose such information, and any and all other information (including confidential information) pertaining in any
manner to the Collateral or the assets, liabilities, results of operations, business or prospects of the Purchaser, freely to any Person that the Purchaser in good faith believes to be a potential or prospective purchaser in such sale or transfer,
without liability for any disclosure, dissemination or use that may be made as to such information by any such Person. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.08.
<U>Reserved</U>. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.09. <U>Rights and Remedies Cumulative</U>. The rights provided for in this Agreement and
the other Transaction Documents are cumulative and are not exclusive of any other rights, powers or privileges or remedies provided by law or in equity, or under any other instrument, document or agreement. The Purchaser may exercise and enforce
each right and remedy available to it either before or concurrently with or after, and independently of, any exercise or enforcement of any other right or remedy of the Purchaser against any Person or property. All such rights and remedies shall be
cumulative, and no one of them shall exclude or preclude any other. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.10. <U>Reserved</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;14. S<SMALL>TANDARDS</SMALL> <SMALL>FOR</SMALL> E<SMALL>XERCISING</SMALL> R<SMALL>EMEDIES</SMALL>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.01. <U>Commercially Reasonable Manner</U>. To the extent that applicable law imposes duties on the Purchaser to exercise remedies in a
commercially reasonable manner, each Grantor acknowledges and agrees that it is not commercially unreasonable for the Purchaser (a)&nbsp;to fail to obtain third-party consents for access to Collateral to be disposed of, or to obtain or, if not
required by other law, to fail to obtain governmental or third-party consents for the collection or disposition of Collateral to be collected or disposed of; (b)&nbsp;to fail to exercise collection remedies against account debtors or other persons
obligated on Collateral or to remove any Lien on or any adverse claims against Collateral; (c)&nbsp;to exercise collection remedies against account debtors and other persons obligated on Collateral directly or through the use of collection agencies
and other collection specialists; (d)&nbsp;to advertise dispositions of Collateral through publications or media of general circulation, whether or not the Collateral is of a specialized nature; (e)&nbsp;to contact other persons, whether or not in
the same business as such Grantor, for expressions of interest in acquiring all or any portion of the Collateral; (f)&nbsp;to hire one or more professional auctioneers to assist in the disposition of Collateral, whether or not the collateral is of a
specialized nature; (g)&nbsp;to dispose of Collateral by utilizing Internet sites that provide for the auction of assets of the types included in the Collateral or that have the reasonable capability of doing so, or that match buyers and sellers of
assets; (h)&nbsp;to dispose of assets in wholesale rather than retail markets; (i)&nbsp;to disclaim disposition warranties; (j)&nbsp;to purchase insurance or credit enhancements to insure the Purchaser against risks of loss, collection or
disposition of Collateral or to provide to the Purchaser a guaranteed return from the collection or disposition of Collateral; or (k)&nbsp;to the extent deemed appropriate by the Purchaser, to obtain the services of other brokers, investment
bankers, consultants and other professionals to assist the Purchaser in the collection or disposition of any of the Collateral. Each Grantor acknowledges that the purpose of this <U>Section&nbsp;14</U> is to provide non-exhaustive indications of
what actions or omissions by the Purchaser would not be commercially unreasonable in the Purchaser&#146;s exercise of remedies against the Collateral and that other actions or omissions by the Purchaser shall not be deemed commercially unreasonable
solely on account of not being indicated in this <U>Section&nbsp;14</U>. Without limiting the foregoing, nothing contained in this <U>Section&nbsp;14</U> shall be construed to grant any rights to any Grantor or to impose any duties on the Purchaser
that would not have been granted or imposed by this Agreement or by applicable law in the absence of this <U>Section&nbsp;14</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">14.02. <U>Standard of Care</U>. The powers conferred on the Purchaser hereunder are solely to protect its interest in the Collateral and shall not impose any duty upon it to exercise any such powers.
Except for the exercise of reasonable care in the custody of any Collateral in its possession and the accounting for moneys </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
actually received by it hereunder, the Purchaser shall have no duty as to any Collateral or as to the taking of any necessary steps to preserve rights against prior parties or to protect,
preserve, vote or exercise any rights pertaining to any Collateral. The Purchaser shall be deemed to have exercised reasonable care in the custody and preservation of Collateral in its possession if such Collateral is accorded treatment
substantially equal to that which the Purchaser accords its own property or if it selects, with reasonable care, a custodian to hold such Collateral on its behalf. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;15. W<SMALL>AIVERS</SMALL> <SMALL>BY</SMALL> G<SMALL>RANTOR</SMALL>; O<SMALL>BLIGATIONS</SMALL> A<SMALL>BSOLUTE</SMALL>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.01. <U>Specific Waivers</U>. Each Grantor waives demand, notice, protest, notice of acceptance of this Agreement, notice of any
purchase pursuant to the terms of the Purchase Agreement, Collateral received or delivered or other action taken in reliance hereon and all other demands and notices of any description other than those required pursuant to the Purchase Agreement or
any other Transaction Documents to which such Grantor is a party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.02. <U>Obligations Absolute</U>. All rights of the
Purchaser hereunder, the Security Interest and all obligations of the Grantors hereunder shall be absolute and unconditional irrespective of (a)&nbsp;any lack of validity or enforceability of the Purchase Agreement, any other Transaction Document,
any agreement with respect to any of the Secured Obligations or any other agreement or instrument relating to any of the foregoing; (b)&nbsp;any change in the time, manner or place of payment of, or in any other term of, all or any of the Secured
Obligations, or any other amendment or waiver of or any consent to any departure from the Purchase Agreement, any other Transaction Document, or any other agreement or instrument; (c)&nbsp;any exchange, release or non-perfection of any Lien on other
collateral, or any release or amendment or waiver of or consent under or departure from or any acceptance of partial payment thereon and or settlement, compromise or adjustment of any Secured Obligation or of any guarantee, securing or guaranteeing
all or any of the Secured Obligations; or (d)&nbsp;any other circumstance that might otherwise constitute a defense available to, or a discharge of, any Grantor in respect of the Secured Obligations or this Agreement other than the prompt and
complete performance and payment in full of the Secured Obligations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;16. M<SMALL>ARSHALLING</SMALL>. The
Purchaser shall not be required to marshal any present or future collateral security (including but not limited to this Agreement and the Collateral) for, or other assurances of payment of, the Secured Obligations or any of them or to resort to such
collateral security or other assurances of payment in any particular order, and all of its rights hereunder and in respect of such collateral security and other assurances of payment shall be cumulative and in addition to all other rights, however
existing or arising. To the extent that it lawfully may, each Grantor hereby agrees that it shall not invoke any law relating to the marshalling of collateral which might cause delay in or impede the enforcement of the Purchaser&#146;s rights under
this Agreement or under any other instrument creating or evidencing any of the Secured Obligations or under which any of the Secured Obligations is outstanding or by which any of the Secured Obligations is secured or payment thereof is otherwise
assured, and, to the extent that it lawfully may, each Grantor hereby irrevocably waives the benefits of all such laws. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;17. I<SMALL>NTEREST</SMALL>. Until paid, all amounts due and payable by each Grantor hereunder shall be deemed to be a debt
secured by the Collateral and shall bear, whether before or after judgment, interest at a rate equal to the lower of (i)&nbsp;the highest rate permitted by applicable law, and (ii)&nbsp;one and one-half percent (1.5%)&nbsp;per month, compounded
monthly. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;18. R<SMALL>EINSTATEMENT</SMALL>. The obligations of each Grantor pursuant to
this Agreement shall continue to be effective or automatically be reinstated, as the case may be, if at any time payment of any of the Secured Obligations is rescinded or otherwise must be restored or returned by the Purchaser upon the insolvency,
bankruptcy, dissolution, liquidation or reorganization of such Grantor or any other obligor or otherwise, all as though such payment had not been made. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;19. M<SMALL>ISCELLANEOUS</SMALL>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.01. <U>Notices</U>. All
notices, requests and demands to or upon the Purchaser or any Grantor hereunder shall be effected in the manner provided for in Section&nbsp;7.03 of the Purchase Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">19.02. <U>GOVERNING LAW; CONSENT TO JURISDICTION; SERVICE OF PROCESS</U>. THIS AGREEMENT SHALL&nbsp;BE A CONTRACT MADE UNDER AND GOVERNED BY THE INTERNAL LAWS OF THE STATE OF NEW YORK APPLICABLE TO
CONTRACTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE, WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES (OTHER THAN SECTION 5-1401 OF THE NEW YORK GENERAL OBLIGATIONS LAW). ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION
WITH THIS AGREEMENT OR ANY OTHER TRANSACTION DOCUMENT, MAY BE BROUGHT IN ANY STATE OR FEDERAL COURT OF COMPETENT JURISDICTION IN THE STATE OF NEVADA, WASHOE COUNTY AND CITY OF RENO; <U>PROVIDED</U> THAT ANY SUIT SEEKING ENFORCEMENT AGAINST ANY
COLLATERAL OR OTHER PROPERTY MAY BE BROUGHT, AT PURCHASER&#146;S OPTION, IN THE COURTS OF ANY JURISDICTION WHERE SUCH COLLATERAL OR OTHER PROPERTY MAY BE FOUND. EACH PARTY HERETO HEREBY EXPRESSLY AND IRREVOCABLY SUBMITS TO THE JURISDICTION OF THE
COURTS OF THE STATE OF NEVADA, WASHOE COUNTY AND CITY OF RENO FOR THE PURPOSE OF ANY SUCH LITIGATION AS SET FORTH ABOVE. EACH PARTY HERETO FURTHER IRREVOCABLY CONSENTS TO THE SERVICE OF PROCESS BY REGISTERED MAIL, POSTAGE PREPAID, OR BY PERSONAL
SERVICE WITHIN OR WITHOUT THE STATE OF NEVADA. EACH PARTY HERETO HEREBY EXPRESSLY AND IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY SUCH LITIGATION BROUGHT
IN ANY SUCH COURT REFERRED TO ABOVE AND ANY CLAIM THAT ANY SUCH LITIGATION HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.03.
<U>WAIVER OF JURY TRIAL, ETC.</U> EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING, CLAIM OR COUNTERCLAIM ARISING OUT OF OR RELATING TO ANY
TRANSACTION DOCUMENT OR THE TRANSACTIONS CONTEMPLATED UNDER ANY TRANSACTION DOCUMENT. THIS WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO ANY TRANSACTION DOCUMENT. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.04. <U>Counterparts</U>. This Agreement may be executed in counterparts (and by different
parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">19.05. <U>Headings</U>. The headings of each section of this Agreement are for convenience only and shall not define or limit the provisions thereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.06. <U>No Strict Construction</U>. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In
the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the
authorship of any provisions of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.07. <U>Severability</U>. The illegality or unenforceability of any
provision of this Agreement or any instrument or agreement required hereunder shall not in any way affect or impair the legality or enforceability of the remaining provisions of this Agreement or any instrument or agreement required hereunder.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.08. <U>Survival of Agreement</U>. All representations, warranties and agreements made by or on behalf of any in this
Agreement and in the other Transaction Documents shall survive the execution and delivery hereof or thereof and the payment of the Secured Obligations. In addition, notwithstanding anything herein or under applicable law to the contrary, the
provisions of this Agreement and the other Transaction Documents relating to indemnification or payment of costs and expenses, including, without limitation, the provisions of Sections 7.05 and&nbsp;7.14 of the Purchase Agreement, shall survive the
payment in full of the Secured Obligations and any termination of this Agreement or any of the other Transaction Documents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.09. <U>Fees and Expenses; Indemnification</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) The Grantors, jointly and severally, agree to pay upon demand the amount of any and all reasonable expenses, including the fees, disbursements and other charges of counsel and of any experts or
Purchasers, which (i)&nbsp;the Purchaser may incur in connection with (x)&nbsp;collecting against any Grantor or otherwise enforcing or preserving any rights under this Agreement and the other Transaction Documents, (y)&nbsp;the exercise,
enforcement or protection of any of the rights of the Purchaser hereunder or (z)&nbsp;the failure of any Grantor to perform or observe any of the provisions hereof, and (ii)&nbsp;the Purchaser may incur in connection with (x)&nbsp;the administration
of this Agreement (including the customary fees and charges for any audits conducted by it or on its behalf with respect to the accounts receivable) or (y)&nbsp;the custody or preservation of, or the sale of, collection from or other realization
upon any of the Collateral. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each Grantor agrees to pay, and to save the Purchaser harmless from, any and all liabilities,
obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind or nature whatsoever with respect to the execution, delivery, enforcement, performance and administration of this Agreement to the
extent the Seller would be required to do so pursuant to Section&nbsp;7.05 of the Purchase Agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The agreements in this Section shall survive repayment of the Secured Obligations and
all other amounts payable under the Purchase Agreement and the other Transaction Documents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Each Grantor agrees that the
provisions of Article III of the Purchase Agreement are hereby incorporated herein by reference, mutatis mutandis, and the Purchaser shall be entitled to rely on each of them as if they were fully set forth herein. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.10. <U>Binding Effect; Several Agreement</U><I>. </I>This Agreement is binding upon each Grantor and the Purchaser and their
respective successors and permitted assigns, and shall inure to the benefit of the Grantors, the Purchaser and their respective successors and permitted assigns, except that no Grantor shall have any right to assign or transfer its rights or
obligations hereunder or any interest herein, except as specifically permitted by the Purchase Agreement, without the prior written consent of the Purchaser (and any such assignment or transfer shall be void). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.11. <U>Waivers; Amendment</U><I>. </I> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) No failure or delay of the Purchaser in exercising any power or right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any
abandonment or discontinuance of steps to enforce such a right or power, preclude any other or further exercise thereof or the exercise of any other right or power. The rights and remedies of the Purchaser hereunder and of the Purchaser under the
Purchase Agreement and other Transaction Documents are cumulative and are not exclusive of any rights or remedies that it would otherwise have. No waiver of any provisions of this Agreement or consent to any departure by any Grantor therefrom shall
in any event be effective unless the same shall be permitted by paragraph (b)&nbsp;below, and then such waiver or consent shall be effective only in the specific instance and for the purpose for which given. No notice to or demand on any Grantor in
any case shall entitle such or any other Grantor to any other or further notice or demand in similar or other circumstances. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Neither this Agreement nor any provision hereof may be waived, amended or modified except pursuant to an agreement or agreements in
writing entered into by the Purchaser and each affected Grantor. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.12. <U>Set Off</U>. Each Grantor hereby irrevocably
authorizes the Purchaser at any time and from time to time while an Event of Default shall have occurred and be continuing, without notice to such Grantor or any other Grantor, any such notice being expressly waived by each Grantor, to set off and
appropriate and apply any and all deposits (general or special, time or demand, provisional or final), in any currency, and any other credits, indebtedness or claims, in any currency, in each case whether direct or indirect, absolute or contingent,
matured or unmatured, at any time held or owing by the Purchaser to or for the credit or the account of such Grantor, or any part thereof in such amounts as the Purchaser may elect, against and on account of the obligations and liabilities of such
Grantor to the Purchaser hereunder and claims of every nature and description of the Purchaser against such Grantor, in any currency, whether arising hereunder, under the Purchase Agreement, any other Transaction Document or otherwise, as the
Purchaser may elect. The Purchaser shall notify such Grantor promptly of any such set-off and the application made by the Purchaser of the proceeds thereof; <U>provided</U> that the failure to give such notice shall not affect the validity of such
set-off and application. The rights of the Purchaser under this Section are in addition to other rights and remedies (including, without limitation, other rights of set-off) which the Purchaser may have. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.13. <U>Integration</U>. This Agreement and the other Transaction Documents constitute the
entire contract among the parties relating to the subject matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.14. <U>Acknowledgments</U>. Each Grantor hereby acknowledges that: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) it has been advised by counsel in the negotiation, execution and delivery of this Agreement and the other Transaction Documents to
which it is a party; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) the Purchaser does not have any fiduciary relationship with or duty to any Grantor arising out of
or in connection with this Agreement or any of the other Transaction Documents, and the relationship between the Grantors, on the one hand, and the Purchaser, on the other hand, in connection herewith or therewith is solely that of seller and
purchaser (or, in the case that a Grantor owes Secured Obligations to the Purchaser, that of debtor and creditor); and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)
no joint venture is created hereby or by the other Transaction Documents or otherwise exists by virtue of the transactions contemplated hereby among the Grantors and the Purchaser. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.15. <U>Additional Grantors and Guarantors</U>. Each subsidiary of the Seller that is required to become a party to this Agreement
pursuant to Section&nbsp;5.10(b) of the Purchase Agreement shall become a Grantor and Guarantor for all purposes of this Agreement upon execution and delivery by such subsidiary of an Assumption Agreement in the form of <U>Annex&nbsp;I</U> hereto.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[Remainder of Page Intentionally Left Blank; Signature Pages Follow] </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, each of the undersigned has caused this Guarantee and Collateral
Agreement to be duly executed and delivered as of the date first above written. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">GRANTORS:</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">AXOGEN, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Karen Zaderej</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Karen Zaderej</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">CEO</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">AXOGEN CORPORATION.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Karen Zaderej</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Karen Zaderej</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">CEO</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[Collateral Agreement &#150; Signature Page] </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="78%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">PDL BIOPHARMA, INC.,</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">as Purchaser</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ John P. McLaughlin</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">John P. McLaughlin</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[Guarantee and Collateral Agreement &#150; Signature Page] </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Annex A to Guarantee and Collateral Agreement </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">ASSUMPTION AGREEMENT, dated as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 20&nbsp;&nbsp;&nbsp;&nbsp;,
made by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, a &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(the &#147;<U>Additional Grantor</U>&#148;),
in favor of PDL Biopharma, Inc., as Purchaser (the &#147;<U>Purchaser</U>&#148;) party to the Purchase Agreement referred to below. All capitalized terms not defined herein shall have the meaning ascribed to them in such Purchase Agreement.
</FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">W I T N E S S E T H: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, AxoGen, Inc. (&#147;<U>Seller</U>&#148;) and the Purchaser have entered into the Revenue Interests Purchase Agreement, dated as of October&nbsp;5, 2012 (as amended, supplemented, replaced or
otherwise modified from time to time, the &#147;<U>Purchase Agreement</U>&#148;); </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, in connection with the Purchase
Agreement, the Seller and certain of its Affiliates (other than the Additional Grantor) have entered into a Guarantee and Collateral Agreement, dated as of October&nbsp;5, 2012 (as amended, supplemented or otherwise modified from time to time, the
&#147;<U>Guarantee and Collateral Agreement</U>&#148;) in favor of the Purchaser; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the Purchase Agreement requires
the Additional Grantor to become a party to the Guarantee and Collateral Agreement; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the Additional Grantor has
agreed to execute and deliver this Assumption Agreement in order to become a party to the Guarantee and Collateral Agreement; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, IT IS AGREED: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1. <U>Guarantee and Collateral Agreement</U>. By executing and delivering this Assumption Agreement, the Additional Grantor, as provided in <U>Section&nbsp;19.15</U> of the Guarantee and Collateral
Agreement, hereby becomes a party to the Guarantee and Collateral Agreement as a Grantor and Guarantor thereunder with the same force and effect as if originally named therein as a Grantor and Guarantor and, without limiting the generality of the
foregoing, hereby expressly assumes all obligations and liabilities of a Grantor and Guarantor thereunder. The information set forth in Annex I-A hereto is hereby added to the information set forth in the update to the Schedules to the Purchase
Agreement most recently delivered pursuant to the terms of the Guarantee and Collateral Agreement. The Additional Grantor hereby represents and warrants that each of the representations and warranties as to the Additional Grantor contained in
<U>Section&nbsp;6</U> of the Guarantee and Collateral Agreement is true and correct on and as the date hereof (after giving effect to this Assumption Agreement) as if made on and as of such date. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. <U>GOVERNING LAW</U>. THIS ASSUMPTION AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE
STATE OF NEW YORK. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the undersigned has caused this Assumption Agreement to be duly executed
and delivered as of the date first above written. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">[ADDITIONAL GRANTOR]</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule 6.01 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Name: AxoGen, Inc. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jurisdiction of Organization: Minnesota </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Identification Number: 41-1301878 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief
Executive Office: 13859 Progress Boulevard, Suite 100 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alachua, Florida 32615 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Prior Organizational Names: LecTec Corporation </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: AxoGen Corporation </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jurisdiction of Organization: Delaware </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Identification Number: 55-0805988 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief
Executive Office: 13859 Progress Boulevard, Suite 100 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alachua, Florida 32615 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Prior Organizational Names: None </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule 6.06 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Nature of Collateral </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:32pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Guarantor</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Bank</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:55pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Account Number</FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen, Inc.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Silicon Valley Bank</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen Corporation</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Silicon Valley Bank</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6.4
<SEQUENCE>4
<FILENAME>d532389dex1064.htm
<DESCRIPTION>AMENDMENT DATED JULY 26, 2013 TO REVENUE INTERESTS PURCHASE AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Amendment dated July 26, 2013 to Revenue Interests Purchase Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.6.4 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">July&nbsp;26, 2013 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGen Corporation </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">13859 Progress Blvd. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Alachua, FL 32615 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: Karen Zaderej </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ladies and Gentlemen: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reference hereby is made to that certain Revenue Interests Purchase Agreement (the &#147;Revenue Purchase Agreement&#148;), dated as of
October&nbsp;5, 2012 by and between AxoGen, Inc., a Minnesota corporation (the &#147;Company&#148;), and PDL BioPharma, Inc., a Delaware corporation (&#147;PDL&#148;). Capitalized terms used herein but not otherwise defined herein shall have the
meanings set forth in the Revenue Purchase Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;5.16 of the Revenue Purchase Agreement entitles PDL to
receive notice and to participate in the sale of New Securities. PDL hereby agrees that its right of first offer under Section&nbsp;5.16 is not applicable to the issuance of securities in a registered public offering of securities of the Company. As
such, the parties agree that Sections 5.16(d) of the Revenue Purchase Agreement is hereby deleted, and is replaced and superseded in its entirety by the following: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) The right of first offer in this <U>Section&nbsp;5.16</U> shall not be applicable to (i)&nbsp;issuance of options under the Company&#146;s equity compensation plans, where such plans have been
approved by the Company&#146;s shareholders; (ii)&nbsp;issuance of equity securities to one or more counterparties in connection with the consummation, by the Company, of a strategic partnership, joint venture, collaboration or acquisition or
license of any business products or technology (it being understood and agreed that the primary purpose of any issuance pursuant to this clause (ii)&nbsp;shall not be to raise capital); and (iii)&nbsp;issuance of securities in a registered public
offering of securities of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except as expressly set forth herein, all other terms of the Revenue Purchase
Agreement remain in full force and effect without modification or amendment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No amendment or waiver of the terms hereof shall
be effective unless the same shall be in writing and signed by each of the signatories to this Letter Agreement. This Letter Agreement shall be governed by, and construed, interpreted and enforced in accordance with, the laws of the state of New
York, without giving effect to the principles of conflicts of law thereof. This Letter Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an
original and all of which taken together shall constitute one and the same agreement. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Very truly yours,</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PDL BIOPHARMA, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Danny Hart</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Danny Hart</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deputy General Counsel</FONT></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acknowledged and agreed as of the</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">date first above written</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AXOGEN, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Greg Freitag</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Greg Freitag</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">General Counsel</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>d532389dex231.htm
<DESCRIPTION>CONSENT OF LURIE BESIKOF LAPIDUS & COMPANY, LLP
<TEXT>
<HTML><HEAD>
<TITLE>&lt;![CDATA[Consent of Lurie Besikof Lapidus &amp; Company, LLP]]&gt;</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P>&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right">


<IMG SRC="g532389g60e21.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit 23.1 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We consent to the use in this Amendment
No. 3 to Registration Statement on Form S-1/A of our report dated March&nbsp;12, 2013, relating to the consolidated financial statements of AxoGen, Inc. and Subsidiary as of and for the years ended December&nbsp;31, 2012 and 2011 appearing in the
Prospectus, which is a part of this Registration Statement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also consent to the reference to us under the heading &#147;Experts&#148; in
such Prospectus. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g532389g23b45.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Lurie Besikof Lapidus&nbsp;&amp; Company, LLP </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Minneapolis, Minnesota </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">July 29, 2013 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g532389g42z24.jpg" ALT="LOGO">
 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g532389g00k21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g532389g00k21.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X00C:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C,M8S`Q,2`V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M
M,30Z-38Z,C<@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z044P,C(Y1C9$.4-&,3%%,CE&-35"-T0P0S0V
M0S`R-4$B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z044P,C(Y1C5$.4-&
M,3%%,CE&-35"-T0P0S0V0S`R-4$B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#HP,S,P-C=C9BUC9#<P+30Y-F4M83,S,"UA
M,3$P93-B9C=B9#<B('-T4F5F.F1O8W5M96YT240](G5U:60Z93EC-V)C-60M
M,&$P,"TT8S5B+3DX-C(M8V4W9&0P835C.64X(B\^(#QD8SIC<F5A=&]R/B`\
M<F1F.E-E<3X@/')D9CIL:3YR<C$U-#$T,#PO<F1F.FQI/B`\+W)D9CI397$^
M(#PO9&,Z8W)E871O<CX@/&1C.G1I=&QE/B`\<F1F.D%L=#X@/')D9CIL:2!X
M;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9"`M($%X;T=E;B`M
M($9O<FT@4RTQ05]T<F%C:V5D+F1O8W@\+W)D9CIL:3X@/"]R9&8Z06QT/B`\
M+V1C.G1I=&QE/B`\+W)D9CI$97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B`\+W@Z
M>&UP;65T83X@/#]X<&%C:V5T(&5N9#TB<B(_/O_M`$A0:&]T;W-H;W`@,RXP
M`#A"24T$!```````#QP!6@`#&R5''`(```(``@`X0DE-!"4``````!#\X1^)
MR+?)>"\T8C0'6'?K_^X`#D%D;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#
M`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`-`"V`P$1``(1`0,1
M`?_$`+````$$`@,!`0`````````````'"`D*`00"`P8%"P$!``$$`P$`````
M``````````@!!@<)`@,%!!````4#`P(#!@,&!`<!`````0(#!`41!@<`$@@A
M$S$4"4%182(5%C(C%W&!0B08"I'1,T/PH>%2-%0F&1$``0($!`,&`P4)``,!
M`````0(#`!$$!2$2!@<Q01-182(R%`AQ@161H4(C%K'!X5)B<C-#%]'Q@J+_
MV@`,`P$``A$#$0`_`+_&D(-(1UJ"&T?F``#\0U"A0`!$1$1&@``>/PUQ\*B.
M!D?O^7.*$I"2I7D`Q^$,2SESSQ5BJ;+8%G,Y7-67'*AFC#'^.MLHJB\&I>S,
MRB`+M8[:(5.!054*%:@%-92TCM+J#45(J\7)35KTX,5U%22$!/\`2F0*B>0'
M'E$?=PO<5H[1E=^G+.'+YK,CP45'XR>'^1P32B7.9PQG*&G3^=LU7DL9SG'E
M)BGB!`K@!BXZL)S&W?E%LW4Z]F;EE!>I1;PZ8T,4I2G3$>I`'60J+2NFJ5*4
MZ)L%QU-6(5C5O@LT@('E0T<JE#GF/$$#E&&KMN#KB\@5>OM5VS1MK4K-Z&ER
M5%?TS^!U8S!!X\,1"PX<QGQ)R>\[-J\E<B9;NPI!554=9FG6DX<2AO66;PS0
M\3^7N^>A$C[0U;NJ+YN58&5BZV:EMUM)(!32(R@?RYR%<.$RK&+UT5I39;5[
MZ56+4UQNMU2)E/U%U"R>9Z8*?L`A\UEV%-6,LFS9WQ<]R6W0"EB[Q<I3<BP$
M`HF:/N`2-Y%1`/XDG0KB/\(EUAZKKD7`^HJ&&6Z@GS-S`/>1P$^.`B1]FLE1
M8VA3T]2^]0##+4*ZJT]R5^:0X#-,]L*WKX(N2#2$&D(-(0:0@TA!I"#2$&D(
M-(0:0@TA!I"#2$&D(-(0:0CXT[.Q%NQ+^;FY)G$P\6U7?24G(."-63-FV()U
MUW#A02E3(0H=>M:]/'IKMIF'JVI;HJ1"W:MU02A"`5*43R`[><?)7W"AM5&[
M<;DZAFA905+6L@)2E(F22>7_`*BOGRT]1BX\M/)JP,)3SK'V*&!UF-R9'$ID
M;DN](PF1496ZBF`.631V4H]HI#%7<%'<<Q"5K,W;/8N@T\RS?]6TZ:W4+@S,
MTQF&V%8%*G!^)0_$#@"><:S]YO=1<-:./Z>V^J#1:.02EZL`/5J$B:5H0)>!
M!GX5`A1`[YQ&B;+,K;D=(6_BXKFQ8>22\O,S+95,U]W6!A-WEI^YR%*\:-G0
MF&K)F=)N4.AA4&IAD2C15-<7D5VK5)K:IL30R$AND:'()8&"E##Q*G,B8E$1
MW->U=II3;='$T5*Z9./HPJWDGS]1Y0*BE6'A24SX'A"1J`!U#JG#O.#F$RJJ
MGYJRAS#43F64$55#&$:C4?'5Z,MI9:2T@)2V!@$@)`'+`8=T6`^XJI?-6\EQ
MRK)\3BUJ)P[CA*4H^I`7!-6A,Q=U6O(.82XH)XC)Q,LP5,@Y:O6:A543;TS%
M,9(PEH8@U(<HB!@ZZZ+E;;=>Z!VUW=M+UN6TL+2I(5)2A))3\.,>E9KW=K!<
MV+]9WET]WIGD+;4VHI2N1FI+@'(IPBZ!@V_U<H8>QMD!PD"+J[;.@9E\0H?(
M1^Y9)@_`@=*$%V0^T/=K4CJ>UIL6I*ZRI.9%+4+0#S("B!]HC?EH._KU1HJU
MZC<3E<K*-EQ0[%*0"?\`]0K>O%B[HQ4/?JDQPYP@`P#X"`ZK/ESBDP<`1&=(
MK!I"#2$&D(-(0:0C%0\??I",Z0@TA!I"#2$&D(-(1KN'*#9!=PNH1%!!%19=
M98P)HHHID,HHJJH80*FDF0HB8P]"@%1U09U8(22HR``XDG@/C'6ZMMIM3CI"
M6D@E1.```F23R`$5FO4,YMN\X7(_Q/CB551Q';$@*,D_:*&3-?DXT5$BCDRI
M#!NMUBL42MT_!4Y>X;IM#4^-@]HF=.6Y.JM0LY[_`%"`M@'#HI(P4F8\W(]T
MXU.>Z7W!NZYO+^B=+.A&DZ565;@)RU2TX&1!Q;2J0EV@$\XC'`SM^HS8MDUW
M!S'!NP8M4E%E5%E?D*FV;MR'44=.5#4':43&&@`/34EWGJ>G"KC7O)2V`,RU
M2XRQ))D`,.V(=L"NKW10-EQQQ20<B$'QD83"4X'C+`3P[845UC5U;J8+9"G&
M-E*F`!);@D/+WH<FT=A5K>9&`(<API_YBR*GMV"&K3;U@BZU:F]-TJZP<.O/
M+3"7(K/'Y"7?%U.:)5::,56JJE%"I6*61XZA23P/3!3E']QGW"4:EK0MBW%=
M$);3J3NJ)0G9AC#-YX["->D:.))TDR9NG42@H199`CE<FX$E-Y2C4/#2[W'5
MMKMCMY52T+C-.RMQ:$.',I(3/#"7AD3/[HXV*V:2NU\IK&Y5UM*JJJ&VD/+:
M24%3BLJ4D)4I1S$C`\.,XU+YQ[<5C9$N3%LBDFM=%OW.XM%5)K51%W)`\!DT
M,W`?G,G(&.F8@"&X`.`#UU]5IU51773+>JJ:2:!VAZHF9Y59,Q"CPP,Y1TZA
MTA>=/ZPJ-"UZ`;FS7AGPXYOS9)*?[DD&7+ARBY)A2QQQQB/&]BF`.[:UEV]#
MN:"/5ZUCD"OC^`?B=B<?#6JW4UR%YU'77<8IJ:E:Q\"HD?MC>YH6QG3>CK78
MC@:6A9;(_J2E,_L,*@?\(^-:#3:%1K\->+.6,783(3'&(GN3_J<1F!<JR.,+
M6L-ID):WVK8MRRYK@^FH1TRX`530R!$6CL%5&B`E%4PB&TX[:5#4B=N/;_6:
MYTXC4-?6&A2XLA">EF)3_-,D8?MB&F[WNXHMM=8KTG:[<BY&G0GK.]<-R<,R
M4!("IR`,SVX0[GB'R.6Y/8G+DI>V4;4<A<DU;SB%0D#29$311T!3<>;,@W$1
M<).`,)=H4UC/<W0SFW.J_P!-N/BJ;].ET.R"<%&0!$S(]T9LV4W3_P"O:(3J
MY%(*1SU+C*F@K/(HEB%83&(^^'3@<!]@^[X5_;6FK"[N<9?F!S$HSO#X^ZE.
MOCKCG25909JBHQ$X-X=?$*>\*?\`759B>7G",`<H_`?<-`$?V=>M=5.''AVP
M&/"<>;O"\K4L"UYZ]+WN&(M2T[9C',O/W%//D(V'B8UHF*B[MZ]<'(BDD0H4
M\:F-\I0$1`-(16=Y%_W*V.[1NB5MSCAA%YE*&C'*S)"_[UGE;2@YM9$1(9U"
M031D[F5XPXE'MJ+&1,J3YM@:K+"<(\)@_P#N94I6\(6(Y`<=V-JV?)23=G*W
MECRZG<RK;31RH1(95[`3#)%5^U8B<#K@DL50J=1`!I35(1:HMNXX.[;>A+KM
MJ3:3-NW)%L)R#EV"@+,Y**E&R3Q@];*]-R3ELN4X5H/7KI"/MU`1$/<-!_PK
M^[II"#<'7X#3]H_#2$8W%]__`!2O^'Q\-(1D#`/@/^?M]GC[-(1G2$1*^J7R
M:>XKQU'8>M!\=M>&4VCL)IX@<0<0]CICY:1H<H[D'$XL/ER#T'8"E-2)]M^W
M:-4ZF5J"YHZEHMW^,*Q2M\8E*N1RC&(:>[S=Y[0VEV]'V=THOEU!#A2?$A@S
M3,#CXS-,^[OBOOC#&-Z9@O6'QY8$0:8N*9,*:20&!!E',D`W/)24>F#M1D5'
MI5.JJ>FT/"IA#4Z-5ZIL^C+$J]7=X,VY`_+P\2U$@!IM/&:R<HYB<XU?Z/T3
MJ'7.HV-,:8IU+NBPHC.)-M`S4MQU1F$A(!7-1D2`(>0_MB'Q-8N3GV"3*W-)
M8L;1\'ESD.:/*Z3-=$^\+&?9N(T%2*I0<1'G$YG<SU<K$(`E.0#:P@U<[EK"
M_P!N9UPLM4EQ65V^V)5ER,HQ#M6K`N*(G)*^V)&O62WZ&TK=E;=A=75V9M"+
MG=B@'JON3"FJ$$$(2VH26L$<)IA@C<KR:?`DU*[F960<`!$VY7,D_>N%3>)"
M)E<.W2QQ$>M#&-J0?4H;50YF^C3VUH89@EMN2<#Q.7X3B*P:N%WNLP'ZFYOK
MPDE;JE+5B.U:OC@)SB5+CAQ))A""_JSY5-0M:S+"0)<-E8\D*)W+<]SE'?;H
MR;`P@9G5WM,@U&JIS4.<`(749MQMU#K:O_YCMFXNIN=<L(<J4H"$LH_V(21@
MI!3,%<Y<HFKM'L>G;2@3O5O&TB@M]O;+K-*HYUO/$?DDHP*59I201/G'9P)P
MY+\IN3%W<C+[8"I:=L7>^O1V5<@F;RM\2KM1_"0R=2"1=&$3,594`J!1(F'M
MUT[UZFH]N-O*3;FPK!N-53(0J1Q2VF0<43R)7F`[1'9[;-!5F[NZ];NEJ!HF
MST]2I\`@Y55"EE32`>!"42*^,C%DTM=I:^.T*^/C3KX]=09D!@.$;3SQALW+
M+/\`%\=,+W+?[H2*3HI?1K-C!4`%92Z9%-1..3*2M3H,Z"NL(A0$TQKXZO;;
MO1]3KK55/8F@?3EQ*GE#'*T%"9P_FX#'[8Q)O5N51;6Z!J]2O*`N!26J9'-3
MZP0CY)\QPX"*S[G#L_.<;;VY278J[<24YE>*M^*>.#'`)49$TDZNV9.``/<*
MK*J)(IC7:`$&FI\,:OIZ'<2AVQLB0U;::@>4X@I$TJ3@`>SA/&-3U3MY6W?:
MZY[S7[/ZRIN[+314?,F2^LJ9P(ZA`!X&)3_2LN*XU^->;8&T#L_NZW;JD).V
MDY%)1PQ/*RMLH.(U-XB11(YT'+M@)3`!@$*_#4<_<Q;Z5G<2WO5H5Z!ZF:"R
MD"8`\Q[,)_;$Q?9A=*S_`)1>Z&U957.CJ7'&@J925J9!2"!C(J^V$ZP=ZH67
MIO,]JV/FB-L*WK1?33^!NB2CV+Z-=P;U!)TF1RLNZ?*I)-&S]OM5W!^$??KW
MM8>W:QV[1CE^TD[7U-P]*V^A+@24+2N4P,N(E/G.+>V_]WVL:[<2FTKKFFMM
M+:EU3M.^MH+"FRVDG,K,<.$OB<(4R-Y^YOSGGR3L#CE!6@TQC"`=Q,7Y>T:\
M7;Q-M11E33EYRKE)XW191RR21A9-S4.J8`"M!$0M2JV9TQI+1(ONN*NI_4#Z
M`:>F:`S.+6!E0.9D3)6$7A;_`')ZVW#W-7I?:^DIDZ.HU$U594)(2TPB>=Q2
MB<LS(Y1.9F(\EDSU/,I7E?">,^*]C-;I>BLI&,[D?Q3J5EKK>-$Q!W(PEMME
M4T6$2H9(YTS.%#CVZ"-.FO?L'M^L5HLJ=3;F5QHJ-:9AH8*02,P03S,B)G#&
M+<UI[MM67K4GZ-V<MOJZY*RA+ZDYU/Y<%+:;\H3.<LY$P.R/!V'ZH'(7'F2T
M[)Y&6C"K,6DPUA[J:HPJMKW1:XN%$B&<@B5=5JZ(@FL54Q#E`3I]2FU[%Z]N
M^D+[I?\`4&WU:MUTMJ<2%N`I6$@D@`#B)1;>FO=WN1IC6"-+[KT;207TM.`,
M])UK,1)2RE13(SX2^<,+_N)^;,U+W+9?#*QI99M9S>W8/)V656B@E)<CV<VO
M[%MYV8@[QC&#%/Z@JD/1519+<%"!6&Z6E-3;='YB<P(["DRC913OM53*:AD@
MLJ2%)/:%`$?MAW_H7>G)B.V^.5J\JLL6+;U[Y3S`F[F;//=42SFF-DV`D[58
MPY(B,DD5F+:9FQ;*.EG7;[O:.F0H@`#7K/'#A'="6^J7Z*>6.2_)F'R1Q.L_
M$EA6C.6,BWR*O)3:5HQJ][-)%PFE)M[<AXIV)G+B&.0%U$DB%5,4!-4U1%"'
MC9`YEVOZ-_!CCKA_-"[#*W(J(Q\2U[<L2SI11-I.'A7#DII]]*2"!745:$8B
MX11%=5'N+G(*:11,`B5"(K9WU;?67D<8+<KXC`5FVQQH1=%<$G5,<NI"WC11
MGOE4W1Y:0FTKC<PQES@B,BFB5L)ZB!PURD,N:>/9")4N.7K#L<^<!.2G)A6R
M&%I9=XT6H\6N^SQ=+/K4DI]]%K+6A*PKE0R3Y6$FGA.VJB<>Z@=,Q-XU`=<8
M1%5Q^_N">:^0KHF;;<\>K2R[<SVT),UBV%B:V+J4F9&\:MO+2,PJ@\E7*=JP
MR`J*.NTEW%?E*!R5W:Y9>TR,(3"UO[@WGO9N:&D5F*Q\<N8!I=S2%O'%YK(D
M;3N6$05D4F<C'-9)=\>4:S+!,XBF5RF8#G`-P"!M5RS3FG"+J7W`V^U?NKL.
M_)_;_P!P^5[?\_Y;Z=]2\OVO_;[7R[:_CZ:X0BIMS$OB6SWRSR(ZC3+OTV\\
M>S;:2$3G3;05M$\J*H$+NV-A6[RRE/$QQ#Q'6RO:NUV[0.U5)<:S\IWI!Y\&
M0(?=)&17.:DR*?OC2AOKJ"X;E[YW$6XJJ$M.BC91B9-)E)Q/]"%DS/&</2R?
M8J'!/A>WCXNK;.7(QTE"W#<Z1`3DX*V`9D>R<%'N*"LT31CQ(@8";1%58U?P
M@(8CTU=G-Z]VUUM4>IH^RCJM4Y\JEI,FY@X'Q3)^`E$@=66-GVQ[!)H[<HC<
M'4#X0Z^KQ.A!D74H5*8DGAB1QG#I?3'N#"[WBT>R)"4M,TZ:X;C6R!;MQN8@
MJ\@9\Z+Y)=TRD#_SL<JP(0$S4.4I@'J`ZQI[@J/4;>Y:KRVU4HITH2:=36>3
M8(\2$Y.`GRC,'M,N&A'MH&['4N48N2WWE5C-0MHJ?<69YU)60")$2[#"L9&S
MUP8XG,'DI#1>-ONX"'48VUC>(@9"Y73HGX"'>,TU4(=/>;JHLJF`!6@&'H-M
MV#1N[FY#B*$+N)MG%3KREH90G\1.;`B7$2)PB]=4;B>WS9IIRK0W:$7M1D&*
M9+;CRU"9`44!63^XGN$XBMO:<Y">H9ENW(%ZR5MB#<J@[M''X&<GB[-M<U".
M\@WF;\LRI^P;^6%<I5'JPE30(5,!-J1-FI]!;%:<>J&B*ZX?[*M)\[HQ##$_
M.E2I9U)P2,#C$-K[=MT/<SK2EMKP-NMSBB:>ARDFGI5S2NKJ9C+BC%L*`4"1
ME'.+!N#L-6A@K&MN8VLQH5",@6P%</3)D(\FI94H&DIN1,7JH\DG(F4-41V`
M(%#H`!J&FIM3W?6-^JM17E9-54N%03^%M'!+:>P``3[YQLMV_P!#6+;K25'I
M#3S?3H*-L(S'S.+&"G%GFI9F3.>$ARA6A4`H4"G0`"@]`#V=1'W4U;JEY<L@
M2DF6'&+T'"0QE^R*O_J2\B?UJS:M94)(J'L#%3EQ`LE&BA5&TG<1Q*G<4ZF`
M'[*XM"D%JA40Z$&GCK8+[?=`KTQH[ZZ\T#?KDE1F0066Q_C"L"1GP5SC45[K
M]TCK;<'].43I.E;6YT<!F"W<`ZL&>4E`GE'$RCT>=>8>#;WXF07&[&UF7C!*
MVV-HC'2$HUBD(]12#6(XE7;KRCU=8%Y-0RJE1`3"8_6FO.T3M+KRU;HKUYJ!
MYEQ+ZWPH)6LKS.`R\R1,`2XG`<!./7W'WTVVO^RK&T^EZ*L;?IDL26ZE"&ST
MC-2IA4RM9GRX]T+OZ-UQ%1F,YVRHJ4I5(VU+D`3F*5,@-%Y!@NIN-0HAVW)-
MQN@``>S5F^ZZB4X[::XG%8<;ES)D"!]T9#]A]V0'-0VX**6)LO2.`2!X53/#
MO^&,1P<QE,>N>2>77>,)-.5M5_<CEZ5RW0V,0GG!:W"VCSE$0<,4I@JFQ4M"
M'$P[:@%=2!V;3J5K;FW_`%]LH.7*"J<^D/(%)/(]AX1%+W"#39W@NKVDE]2W
MN/9BM*AD6X3^:I!'X$8@GFJ)!)R0QWACTP&,GB@YOKV='D;;EWW"X!/ZZZE'
M:SD+GCE'".U1NVBV\<9!!+P(D>M!$U=8"M=/>-9^XLT^J\SE!;7"M#>(;#:0
M<A2.\\3$HKG4Z6V_]H;%1H@RJ;^I+#KY_P`CBEE6?Q>:0"</XQGT>L<-9.\\
MI90<H$.M;43%VC#*G`IC-G<T87TH=$:#VS&9MTR=.H`(^_7=[IKZ\AJWZ=2L
M])16ZH?,A/QPD,>R.CV):38?N=WUBI"%>F0VPW/%746C,I6/*7.&-<MYDN5.
M8F3AA:+$F<D,+.C12`#BHJS796\)R[-V_>Z(:H_`=9DVNIOH&SU(_4DAQNVN
MN*F990J:A/O*>/?$<]\[BWJW?F["EDEQRY,,M"4\RT*2DC#CB(@C]1*?E[JY
ML\CQF%CF>Q.1'5BIG7.8?+,;19L;49)DWB)B((-V`"!?``#IK7#7.AZK?<3P
M6\M4^Y2B0/AC&ZFUT?T^W4]$OSM4[:?L2F<_G.+FG,SB[R4RAZ>&#..G#25C
M;5N"/C,0IRTZ-YO+`58VA;-LHN%R1<Q&%%R963DBI`HF00WD$1$1#Q^&/1BF
MPI*<L(_DBUXT/^0V4YJ\D\NQ6)9)>U,OWI-PR\\M<36`D2Q4F252+(MVCA50
MHG*4H"8@AUI759>&<(]OZBM\W1R7Y[Y'MB#+*7,K;]VP/'+%\2HY.Y=O(ZQ0
M;61%-DUG"WS.I^<26756.<!,HL)S#4!'51()F1/&$3+Y-9^NMDSC/*\3I7A_
MC2WL42U@1.-C!;;FU6,NUMJ';1[1NBS<*WNLS2=KI1Y-YQ1#<8QA``$>G$XP
MB/VZ.//(C@-Z=G*2W,_V4[QI=/)_*^$<>VG#.)J$DUIBU+02N.Z[ND0"$D'I
M2I(`1NW/O$M>X/B%!US"DSQ&$(DI_MFL-L$8CDMR)E6*)702-OXNM^2<()B9
MO'L&9KGN4S)V<HF13.JX:%5VB%0"ANFN*CF,X1!T0CWF#ZHP]I,7ALR<OE#E
M!,@*)FMYO?AS&.!25*"2%NQ%1$:U(41'0"8,(_2#[*/:%OVR>7[78[.T.UVM
MH)]K92@$V]*>%-4A%<C$>&V^-,J9YOW(+8&R=C<B\:V!(.WA2G;QMLW=<QIN
M5GE3J%[1&$@@DS3,L:A02.-1H(ZFGKS6*-5Z:LMNM#@`K[54U61)\SS*0VA"
MI?B$E%*3]D:NMOM`C1NK]1:FU(TO+1:GI*$K*22AIY?46X)_ZE`I25\L9&)4
M>;/%'^K;'<'%05P-+=NNU)5Q.6E+/4CK0KQ-\U(W>,'OEA45!J];E**:R93"
M0Q0&@@.H_P"T>Y*ML=0.U[M*X]1OIZ;R"<JTD&>83[^1B8&_^S2-Z=,TU!0U
M;=-=Z-U3K"U24AS.B4@4S\('/''C$-[OTKL\6Z*DC>]_8@L6WT*@[N&4NM^"
M9$"B`G%)!*/0<+J"'4J8"`F&@=-2FJ?<SHBN3DM]LK*NK)$DJ0V9*EPS$3R_
M.(-H]F.Y%M4M^]76ST5O"9N/%QPJEVA*9>*7+A"AXFX>VR^F4(/!L6OE2\F;
MQ(TWG/(4.>+Q+81=P$.ZMFRU@.O=T\4!$S;SQCDW_-VZ=0LW4>\%VJJ+U&IG
MDVZPX]*W4JI/ND^4NN<$-JX+`,Y8#C%WZ*V"L(N/T_0S;MZU`@A3EUKD9:"G
M(.)IV')J==3^`F8)E$WN!L`VA@NVUXV'.ZF[FGE@D+VOJ:$KBY+PF=@`9[(.
MJ?DLT`^1LT3H@V2`"E*&HN:HU5<]5U25ULD6]@*2PPG!ME*N(0.U7XE'%1Q,
M3YV[V\M&W]I-/1DU%VJ3GJJI>+U0X<"I1.*4``!#8DE(X"%[(4"%`H>`:MH`
M`2'`1D`!*1)(DF&8<Y<NW;B?!L[^G<'<$Y?]Y'/:UM!`0[Z67B3/DQ+)SBX,
MD5!;A'L#&[0FH`JB7QIK(FUM@M.H-7,MWZH:I[(T<[JEF7`X)^9'QC"._P#J
M^^Z/V[K'=,4S]1J.J`:8#22HI*L"X>."!B0<(B]].SA#%9*^^K^Y"V"_=P:9
MTK?MFWKL;2L2[>2HJ$>R]PJHF%HZ5(4#@D0YA$#G,8=2+WRW@7;%T-AT#7%"
MVFD]5UJ64I2)(3S`('.4XB![9O;Q1:I3<M0;KVSJTRRE#3#^>:G!-3E1.8,U
M$D'E#K>7W!;`5I\=\DW%BC#K1K?L1%M'=OK083$C*@L22:`NFS9>:<]XRK<Y
MP$-AAIU]FL;[;;OZUJ=<V]C4=W>597'Y.AS+ERE)$YRPEV\HS#O?[==MK;M;
M>*[1MB;1J1NF!8Z165!84F65)40<)S$HA;QHPY.8^0O&#Q_C[)42ZR=!M['E
MW:%I3J#X\6ZDD%SM6CT[5,L=YY6B2BPB42)";J`:ECJ>IVUU0NDJK[76]]NV
MN*=0!4-I49`F92>,@`1S)B!NC*7>C22*RVZ=H+G3&[L-T[A33.>%)FA7C`\,
MR9%7(0]O-/IT2&*>),+=T?&O[FS4PN*,F+W0A4G4D9."ED#,#V[#LD2&.X)!
M+JIJJJ`GN54`P^`!K#VE]_6-0[I.MONII=&.-EEI*_"D%HB3G9XY2PPC/FL?
M:E4Z1V6I[A2-+J]P&GDN5!:2IW,RO--A*/--!,UJXD\3",8QQ?F;*G&C(F!B
MV#>+2>L6[(_,]@L9F!DHE.<;*-E(>\+<CW#YLB@>7,F=)RV2$2]RA@#KJY-1
M:NT9IK<^BUS35;#]NK&E4M3TU3+6/Y:Y<^<^46-H[2.X&L]E+EH!RW5S-=:*
MABXT+3S:D%\&:'Z9LKYI22I/9&EQPY*YVXJ6UD?&ULX>EI&<O5\1XV<2]OW*
MA)V[+)QXQ@JIL6[`22`)I!O(0PE`%`#J8*Z^W7^W>B]RKI1ZD>O;":"E2"4I
M6U-:9YA,%0(&/BYQ\VU&ZFO-E;%=-(TUAJ'+G7/20OI/3;RI+8D0D@D),B9\
M<8<]P'X+9#FLDQ6>\[0CVWXJ'DEKFMN"GDRI3MSW,Y6,\1FI*.&IF46S<+"L
M!5?F65$`V@4*ZQ[O+O)86]/*T#HA?62IH-.OIP;"$RFELC$DRX]D9:]M7MVU
M+<-4C<S<ID,(%4JI88<FIUY9GXU@^1"29RP),1+^M=Z8N;[3Y%W_`,GL08^N
M#(N(<P2"=R7,2S6#B:GK&O5T0$KA3E8*/2.^"#EETP<-W2)#IDWF(<0$`K#Q
M)`!':!]W"-E4O&7/QD2^4)=AKU*_6(NW',#QEP_:EU7*\9P;>Q8.YFV&9%3(
MD;$(-@BVB;BYY-LA%-'+)F4"%?N2%63`H&$X"&[7&*QZ_A-Z:G([#7JE<;+<
MS+:<O)A;A&6?;XO2/C9>5LN-EPBI:;2MN0O)1J6+D;I0G%$?,"140\P8:;OQ
M:K,RERA"2\\>(7)G@ISVF>0-H8ON*^<?!FLN=<87E'6Y*73:[I5S<!;H/:]T
MEBD'#B,?L))15NJ10"B=,2*)F&HZ3,I<H0X#.O*WU,/5[DL>XCP]Q[O/#%IP
M,XC-2,I;3J]K9B%9LR)X\9V\+^DTH,&T%"H.53I,D0,8YA`1[A]FJ0CY_JO\
M5,X88Q=PTXI6E%9JY#N[)M:^,HY4R,SB+TOTDIDR\7\?#]E&353DS1T;&L(U
M9)DS$Y#$;"4PEW'$=(1,#P2L2\>(OHHW1-)V/=A,JW#CO+N15+*2@),M[!=M
MX^>@;<CS096QI<9%LW29*=KM;BE`1I2ND(A<]"WB1F!QSYM;(64<29&LR!Q9
M9%WWB$M>]GSMNLG5T2C4EO1"35Q+,VQ'#X#2SE78`B8"EW:J#*$6I6O*7)ZN
M5).SSXV:*PS:XF\(@W02F#7`BU/<K>$7=O!*"C=(R+90JW=.1-LH#I(2',!%
M=4A"^7U^A7DLM_?/VI]+^U8_]8?J7:\C]![#OZ3]QU^3S7E>YY>OY^VFW^'5
MP6G]0^HH?I'7]7U#Z7+/S3\73Y2GYY8=L6!?_P!#]"[?7/3^C],GU\_Y)?E]
M26.:7D_%PE$<]G?9/ER?HE_^A'Z9]\WTW[2^H_:/E=_S?0?NO_Z#Z=M_TNU_
MMTV=*:RW6>JZ*/K/Z4^K2,^IDZV:>/4Y9I\9\XC58/H/IE?HS_H'Z8ZIR]#J
M>GE/_3G\73X^7E'NXK^E_P"X0^^?U+\SW`\[^J_W1]R][<3?]9^Y_P"?\COI
MO^G_`)-*[NFK<KOU9Z8^B]+T^?I<F27_`,X?#G%WT/\`RWU3?ZB^I>OZF/K>
MMU/Z<W4Y<>'*)*+-^S/MYE]D?0?MOM%\E]O^4^FTV%W[/*?+W?#=O_,KX]=8
MOK?4^H/K\_J9XYYS^^))6CZ/Z!OZ)T?IV&3IRR]W#G\<8]:790-NVG6E*?OI
MKH,^<>G\8Y:I".K\FO797K7PK[:_&E==*NCF7.6;#-^Z?[HX?ER$\LL93EV^
M*4^_C&2]K<.W9NH'A2M.M/\`GKMPF9\</X?PCD,LAEEEQE*7SCD;;3YJ4]M:
M4_?7IJARS$^/*"LN4YY9><^$'RT]E.O[/CK@>EE&:66453_3V\HXAVJA396H
M4I3Q]FN/Y'4/EZF'Q[OWRA\../\`'^,<5.QM#N[-M0IOI2M0I2OMKKDGIS&7
MCC+[,?NBJ9YAD\_+M^4:IOI7F0W^0\Y[-WE_->'LK^=X:[DYNGX,W2^<H^17
MHL_CZ74GSRSGS^<;?Y-0_!7]U?`/W^%-5\4NZ/I,IF?FE]W_`(CG\G7\/AU\
M/#X_#7&*QH,OI.Y?Z=].W[OYGR7EMVZO^_V.NZO_`':0C?#9MZ4V_#PTA'2Y
M\KV%?.>7\K3\[S/;[&VH?ZO=_+INIX^W2$<&7D.P'T_RGE:CM\EV>Q7^*G8_
M+K[](1MZ0CC\N[^'=^[=_GX:0CEI"-)/Z=YYQVO)?4NTCYOM]CSO9Z]CS.W\
+_M5KLW=/=I"/_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g532389g23b45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g532389g23b45.jpg
M_]C_X0EG17AI9@``34T`*@````@`"`$2``,````!``$```$:``4````!````
M;@$;``4````!````=@$H``,````!``(```$Q``(````>````?@$R``(````4
M````G`$[``(````&````L(=I``0````!````N````.0`+<;````G$``MQL``
M`"<0061O8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q,SHP-3HQ-"`P
M.3HP-#HQ,0!E<FEC:``````#H`$``P````$``0``H`(`!`````$```$8H`,`
M!`````$````@``````````8!`P`#`````0`&```!&@`%`````0```3(!&P`%
M`````0```3H!*``#`````0`"```"`0`$`````0```4("`@`$`````0``"!T`
M````````2`````$```!(`````?_8_^T`#$%D;V)E7T--``'_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``2`*`#`2(``A$!`Q$!_]T`!``*_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#TK/SG8-8O=0^W':'&^QCF#TFM&[UK!<^K]#I[_3_2?\%_HZ/2CU;,
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MQP.$6M#&`-VUV;K-^/5<W^?MIJ]-O4'[[L=F9^K8_P#1LI:]EM=98'F-Y+6F
M"1(:ZSW$?0]C'>YZY=O2_K;39ZN&,7&.V][,876?9V76&MC/T-=%7J55T4_H
MO9_2\C*SK?\`!T)9G2/KA=TNWI[,FCTK<9M+GOL?;=%;7MN9ZCZ<?U<CJCG;
M;\WU,?['5_1L/UJ_M5J4]'@9V/GX-.?CD_9\A@MJ<\%I+'>YC]K_`'-WL]Z*
M+6.I%U9]6MS=["R';@1N;LCZ6[\U<?U%GUF<&=(?9353G[,2K#;!<<9C6OS;
M_MK*V>A<_']3'LV8EG\Y7]DHH^S_`&W(U[+NOXU=.)1CTBUX)8*6DX]31%=.
M)ZCC3MJJ;^DR,IU;+/3_`*#T^VS^BI3#)^L'VZVK"Z'87Y+MMF2162:&D^RG
M+;:&LP[;';_5KR=F1]GHR?1I^U_9JUOKC79G5NGT_;3NOQ<7(<[-NJ<P'+O+
M[L#TZV7/-C=MS<*FK$_FZ:OT5&1FW48]2MX^1]>FU/==B4NMW.]A>S;)'Z/T
M!6ZO]3K:[_M1=]MOOI]+]6HR?M&(E/25VLM8U[9AS0X!P+7`.^CNK?M>S^VU
M37)]+H^MF$^^VS"INR\VQEV9DES*P]XWT^E7Z=MSJ\.C'JPJ,?>RR_[/]JSK
M:OMOZAD6JZOKC9TRYV0ZAF>ZI]=%=;H:+;K)%US_`/!T8%7Z.GTO6R+:?4O_
M`*39Z#$IZ$D`$DP!J25C=/Z^[J?5/0Q&#[&VKU?4<';WUN)9CY3#_-U8][Z[
M?LOJ?ILVOU,JOT<>JO[7+J.+GV]+Q,6ZM^6-[&]1KJ<S=;4UKMS=V1]DJ?7D
M7-I^UU^SU,9^12LP8?UEP;[3TNK6ZP.OORS7>_(MM8QWVC)?39C^AB]/V_96
MTX[/YNCTL;&M^T5W8B4]6DN3N^LOUC?8[`Q>F_Y3I9ZV36S9<RMKBYF)0Y[L
MG$K];+]*R_>ZUGHT_HJOM=OIJU7UGZT/K:\](+7.N_2UN<T&J@CV!KO6<W,R
M65_I[MGV>GU+&8%7J65Y.52E/1)+FJ?K3F?;7TY>,,:K%>Y_47':[[/6\.;T
MW%<:[[/M.?F_HLC]4;=Z?K58GHVV6LR4NO9O4<BG-QQC^E@4Z76O8X6N:W:X
M?L^Q[Z:_M]]KMG3?3]:JFYGKWWUW^EB)*=5O6\`V9K9<*^G[1?=$L+W%[?0J
MV;K+;ZW,VOK;7_.6U55^I:GLZYTRL4[K23D5MN8&L>XBIWT<B]K&.=C8_P"]
M?D^E4Q<_3@>L'XS>EMJQNEXPOP.C5W%@OLL=;Z%G4`[T\=EGJ8GZ+UOM7OLN
MRKOTJT.E_59M'Z;J-_VG(ML;DY#*QLI=>V/0<YONMLIPFM93A8[[/LM5=--O
MV;[7^L)*?__0],ZA_1O\#_.5?TG^;_G*_P#P;_N-_P!V?25E?*J22GZJ27RJ
MDDI^JDE\JI)*?I9W_BG9_1OZ"[G^E_SM?\U_W2_T_P#P_P!G6HOE5))3]38_
M\TWZ'?\`F_H\_FHB^54DE/U4DOE5))3]5)+Y5224_4.-_2,O^9_G6_S7T_YJ
MK^E_\/\`N?\`=;[.K*^54DE/T=@_S>5_R9_RH[^8X^FS^D_^;O\`?_X7TEN+
MY5224_4X_G3]'Z(_K<NY_D*:^54DE/\`_]G_[1%>4&AO=&]S:&]P(#,N,``X
M0DE-!`0``````%$<`5H``QLE1QP"```"```<`E``!65R:6-H'`(%`#-#3TY3
M14Y4($]&($E.1$5014Y$14Y4($-%4E1)1DE%1"!054),24,@04-#3U5.5$%.
M5%,`.$))300E```````0,>V2H?QN[I3/$,CQ%3Y39#A"24T$.@``````Y0``
M`!`````!```````+<')I;G1/=71P=70````%`````%!S=%-B;V]L`0````!)
M;G1E96YU;0````!);G1E`````$-L<FT````/<')I;G13:7AT965N0FET8F]O
M;``````+<')I;G1E<DYA;65415A4`````0``````#W!R:6YT4')O;V93971U
M<$]B:F,````,`%``<@!O`&\`9@`@`%,`90!T`'4`<```````"G!R;V]F4V5T
M=7`````!`````$)L=&YE;G5M````#&)U:6QT:6Y0<F]O9@````EP<F]O9D--
M64L`.$))300[``````(M````$`````$``````!)P<FEN=$]U='!U=$]P=&EO
M;G,````7`````$-P=&YB;V]L``````!#;&)R8F]O;```````4F=S36)O;VP`
M`````$-R;D-B;V]L``````!#;G1#8F]O;```````3&)L<V)O;VP``````$YG
M='9B;V]L``````!%;6Q$8F]O;```````26YT<F)O;VP``````$)C:V=/8FIC
M`````0```````%)'0D,````#`````%)D("!D;W5B0&_@````````````1W)N
M(&1O=6)`;^````````````!";"`@9&]U8D!OX````````````$)R9%15;G1&
M(U)L=````````````````$)L9"!5;G1&(U)L=````````````````%)S;'15
M;G1&(U!X;$!RP```````````"G9E8W1O<D1A=&%B;V]L`0````!09U!S96YU
M;0````!09U!S`````%!G4$,`````3&5F=%5N=$8C4FQT````````````````
M5&]P(%5N=$8C4FQT````````````````4V-L(%5N=$8C4')C0%D`````````
M```08W)O<%=H96Y0<FEN=&EN9V)O;VP`````#F-R;W!296-T0F]T=&]M;&]N
M9P`````````,8W)O<%)E8W1,969T;&]N9P`````````-8W)O<%)E8W12:6=H
M=&QO;F<`````````"V-R;W!296-T5&]P;&]N9P``````.$))30/M```````0
M`2P````!``(!+`````$``CA"24T$)@``````#@`````````````_@```.$))
M300-```````$````>#A"24T$&0``````!````!XX0DE-`_,```````D`````
M``````$`.$))32<0```````*``$``````````CA"24T#]0``````2``O9F8`
M`0!L9F8`!@```````0`O9F8``0"AF9H`!@```````0`R`````0!:````!@``
M`````0`U`````0`M````!@```````3A"24T#^```````<```____________
M_________________P/H`````/____________________________\#Z```
M``#_____________________________`^@`````____________________
M_________P/H```X0DE-!`@``````!`````!```"0````D``````.$))300>
M```````$`````#A"24T$&@`````#.0````8``````````````"````$8````
M`@`P`#$````!``````````````````````````$``````````````1@````@
M``````````````````````$`````````````````````````$`````$`````
M``!N=6QL`````@````9B;W5N9'-/8FIC`````0```````%)C=#$````$````
M`%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<````@
M`````%)G:'1L;VYG```!&`````9S;&EC97-6;$QS`````4]B:F,````!````
M```%<VQI8V4````2````!W-L:6-E241L;VYG``````````=G<F]U<$E$;&]N
M9P`````````&;W)I9VEN96YU;0````Q%4VQI8V5/<FEG:6X````-875T;T=E
M;F5R871E9`````!4>7!E96YU;0````I%4VQI8V54>7!E`````$EM9R`````&
M8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P``````
M````3&5F=&QO;F<``````````$)T;VUL;VYG````(`````!29VAT;&]N9P``
M`1@````#=7)L5$585`````$```````!N=6QL5$585`````$```````!-<V=E
M5$585`````$```````9A;'1486=415A4`````0``````#F-E;&Q497AT27-(
M5$U,8F]O;`$````(8V5L;%1E>'1415A4`````0``````"6AO<GI!;&EG;F5N
M=6T````/15-L:6-E2&]R>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N
M96YU;0````]%4VQI8V5697)T06QI9VX````'9&5F875L=`````MB9T-O;&]R
M5'EP965N=6T````115-L:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET;W!/
M=71S971L;VYG``````````IL969T3W5T<V5T;&]N9P`````````,8F]T=&]M
M3W5T<V5T;&]N9P`````````+<FEG:'1/=71S971L;VYG```````X0DE-!"@`
M``````P````"/_`````````X0DE-!!0```````0````".$))300,``````@Y
M`````0```*`````2```!X```(<````@=`!@``?_8_^T`#$%D;V)E7T--``'_
M[@`.061O8F4`9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5
M$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.
M#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`S_P``1"``2`*`#`2(``A$!`Q$!_]T`!``*_\0!/P``
M`04!`0$!`0$``````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!
M``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!
M,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?2
M5>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'
MEZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12A
ML4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+R
MLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'
M_]H`#`,!``(1`Q$`/P#TK/SG8-8O=0^W':'&^QCF#TFM&[UK!<^K]#I[_3_2
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ME^A9^?U#)R,BQP.$6M#&`-VUV;K-^/5<W^?MIJ]-O4'[[L=F9^K8_P#1LI:]
MEM=98'F-Y+6F"1(:ZSW$?0]C'>YZY=O2_K;39ZN&,7&.V][,876?9V76&MC/
MT-=%7J55T4_HO9_2\C*SK?\`!T)9G2/KA=TNWI[,FCTK<9M+GOL?;=%;7MN9
MZCZ<?U<CJCG;;\WU,?['5_1L/UJ_M5J4]'@9V/GX-.?CD_9\A@MJ<\%I+'>Y
MC]K_`'-WL]Z*+6.I%U9]6MS=["R';@1N;LCZ6[\U<?U%GUF<&=(?9353G[,2
MK#;!<<9C6OS;_MK*V>A<_']3'LV8EG\Y7]DHH^S_`&W(U[+NOXU=.)1CTBUX
M)8*6DX]31%=.)ZCC3MJJ;^DR,IU;+/3_`*#T^VS^BI3#)^L'VZVK"Z'87Y+M
MMF2162:&D^RG+;:&LP[;';_5KR=F1]GHR?1I^U_9JUOKC79G5NGT_;3NOQ<7
M(<[-NJ<P'+O+[L#TZV7/-C=MS<*FK$_FZ:OT5&1FW48]2MX^1]>FU/==B4NM
MW.]A>S;)'Z/T!6ZO]3K:[_M1=]MOOI]+]6HR?M&(E/25VLM8U[9AS0X!P+7`
M.^CNK?M>S^VU37)]+H^MF$^^VS"INR\VQEV9DES*P]XWT^E7Z=MSJ\.C'JPJ
M,?>RR_[/]JSK:OMOZAD6JZOKC9TRYV0ZAF>ZI]=%=;H:+;K)%US_`/!T8%7Z
M.GTO6R+:?4O_`*39Z#$IZ$D`$DP!J25C=/Z^[J?5/0Q&#[&VKU?4<';WUN)9
MCY3#_-U8][Z[?LOJ?ILVOU,JOT<>JO[7+J.+GV]+Q,6ZM^6-[&]1KJ<S=;4U
MKMS=V1]DJ?7D7-I^UU^SU,9^12LP8?UEP;[3TNK6ZP.OORS7>_(MM8QWVC)?
M39C^AB]/V_96TX[/YNCTL;&M^T5W8B4]6DN3N^LOUC?8[`Q>F_Y3I9ZV36S9
M<RMKBYF)0Y[LG$K];+]*R_>ZUGHT_HJOM=OIJU7UGZT/K:\](+7.N_2UN<T&
MJ@CV!KO6<W,R65_I[MGV>GU+&8%7J65Y.52E/1)+FJ?K3F?;7TY>,,:K%>Y_
M47':[[/6\.;TW%<:[[/M.?F_HLC]4;=Z?K58GHVV6LR4NO9O4<BG-QQC^E@4
MZ76O8X6N:W:X?L^Q[Z:_M]]KMG3?3]:JFYGKWWUW^EB)*=5O6\`V9K9<*^G[
M1?=$L+W%[?0JV;K+;ZW,VOK;7_.6U55^I:GLZYTRL4[K23D5MN8&L>XBIWT<
MB]K&.=C8_P"]?D^E4Q<_3@>L'XS>EMJQNEXPOP.C5W%@OLL=;Z%G4`[T\=EG
MJ8GZ+UOM7OLNRKOTJT.E_59M'Z;J-_VG(ML;DY#*QLI=>V/0<YONMLIPFM93
MA8[[/LM5=--OV;[7^L)*?__0],ZA_1O\#_.5?TG^;_G*_P#P;_N-_P!V?25E
M?*J22GZJ27RJDDI^JDE\JI)*?I9W_BG9_1OZ"[G^E_SM?\U_W2_T_P#P_P!G
M6HOE5))3]38_\TWZ'?\`F_H\_FHB^54DE/U4DOE5))3]5)+Y5224_4.-_2,O
M^9_G6_S7T_YJK^E_\/\`N?\`=;[.K*^54DE/T=@_S>5_R9_RH[^8X^FS^D_^
M;O\`?_X7TEN+Y5224_4X_G3]'Z(_K<NY_D*:^54DE/\`_]D`.$))300A````
M``!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````
M$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`$,`4P`V`````0`X
M0DE-!`8```````<`"`````$!`/_A$(!H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C`O`#P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ
M<F53>DY48WIK8SED(C\^(#QX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C`Q,B\P,B\P-BTQ-#HU-CHR-R`@("`@("`@(CX@/')D9CI21$8@
M>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D9BUS
M>6YT87@M;G,C(CX@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SIP
M9&8](FAT='`Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B('AM;&YS.F1C/2)H
M='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(@>&UL;G,Z>&UP34T]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T179T
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V5%
M=F5N=",B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C`O<U1Y<&4O4F5S;W5R8V52968C(B!X;6QN<SIP:&]T;W-H;W`](FAT='`Z
M+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B('AM<#I#<F5A=&5$871E
M/2(R,#$S+3`U+3$T5#`Y.C`R.C4W(B!X;7`Z0W)E871O<E1O;VP](DUI8W)O
M<V]F=,*N($]F9FEC92!7;W)D(#(P,#<B('AM<#I-;V1I9GE$871E/2(R,#$S
M+3`U+3$T5#`Y.C`T.C$Q*S`U.C,P(B!X;7`Z365T861A=&%$871E/2(R,#$S
M+3`U+3$T5#`Y.C`T.C$Q*S`U.C,P(B!P9&8Z4')O9'5C97(](DUI8W)O<V]F
M=,*N($]F9FEC92!7;W)D(#(P,#<B(&1C.F9O<FUA=#TB:6UA9V4O:G!E9R(@
M>&UP34TZ26YS=&%N8V5)1#TB>&UP+FEI9#I&0S<X0T4V-S0S0D-%,C$Q038T
M0T)!.#(X1$,V1C`S-B(@>&UP34TZ1&]C=6UE;G1)1#TB>&UP+F1I9#I&0C<X
M0T4V-S0S0D-%,C$Q038T0T)!.#(X1$,V1C`S-B(@>&UP34TZ3W)I9VEN86Q$
M;V-U;65N=$E$/2)X;7`N9&ED.D9"-SA#138W-#-"0T4R,3%!-C1#0D$X,CA$
M0S9&,#,V(B!P:&]T;W-H;W`Z0V]L;W)-;V1E/2(S(B!P:&]T;W-H;W`Z24-#
M4')O9FEL93TB<U)'0B!)14,V,3DV-BTR+C$B/B`\9&,Z8W)E871O<CX@/')D
M9CI397$^(#QR9&8Z;&D^97)I8V@\+W)D9CIL:3X@/"]R9&8Z4V5Q/B`\+V1C
M.F-R96%T;W(^(#QD8SIT:71L93X@/')D9CI!;'0^(#QR9&8Z;&D@>&UL.FQA
M;F<](G@M9&5F875L="(^0T].4T5.5"!/1B!)3D1%4$5.1$5.5"!#15)4249)
M140@4%5"3$E#($%#0T]53E1!3E13/"]R9&8Z;&D^(#PO<F1F.D%L=#X@/"]D
M8SIT:71L93X@/'AM<$U-.DAI<W1O<GD^(#QR9&8Z4V5Q/B`\<F1F.FQI('-T
M179T.F%C=&EO;CTB<V%V960B('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z
M1D(W.$-%-C<T,T)#13(Q,4$V-$-"03@R.$1#-D8P,S8B('-T179T.G=H96X]
M(C(P,3,M,#4M,314,#DZ,#0Z,3$K,#4Z,S`B('-T179T.G-O9G1W87)E06=E
M;G0](D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I(B!S=$5V=#IC:&%N
M9V5D/2(O(B\^(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)D97)I=F5D(B!S=$5V
M=#IP87)A;65T97)S/2)C;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N
M861O8F4N<&AO=&]S:&]P('1O(&EM86=E+VIP96<B+SX@/')D9CIL:2!S=$5V
M=#IA8W1I;VX](G-A=F5D(B!S=$5V=#II;G-T86YC94E$/2)X;7`N:6ED.D9#
M-SA#138W-#-"0T4R,3%!-C1#0D$X,CA$0S9&,#,V(B!S=$5V=#IW:&5N/2(R
M,#$S+3`U+3$T5#`Y.C`T.C$Q*S`U.C,P(B!S=$5V=#IS;V9T=V%R94%G96YT
M/2)!9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S*2(@<W1%=G0Z8VAA;F=E
M9#TB+R(O/B`\+W)D9CI397$^(#PO>&UP34TZ2&ES=&]R>3X@/'AM<$U-.D1E
M<FEV961&<F]M('-T4F5F.FEN<W1A;F-E240](GAM<"YI:60Z1D(W.$-%-C<T
M,T)#13(Q,4$V-$-"03@R.$1#-D8P,S8B('-T4F5F.F1O8W5M96YT240](GAM
M<"YD:60Z1D(W.$-%-C<T,T)#13(Q,4$V-$-"03@R.$1#-D8P,S8B('-T4F5F
M.F]R:6=I;F%L1&]C=6UE;G1)1#TB>&UP+F1I9#I&0C<X0T4V-S0S0D-%,C$Q
M038T0T)!.#(X1$,V1C`S-B(O/B`\+W)D9CI$97-C<FEP=&EO;CX@/"]R9&8Z
M4D1&/B`\+W@Z>&UP;65T83X@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`\/WAP
M86-K970@96YD/2)W(C\^_^(,6$E#0U]04D]&24Q%``$!```,2$QI;F\"$```
M;6YT<E)'0B!865H@!\X``@`)``8`,0``86-S<$U31E0`````245#('-21T(`
M``````````````$``/;6``$`````TRU(4"`@````````````````````````
M```````````````````````````````````````18W!R=````5`````S9&5S
M8P```80```!L=W1P=````?`````48FMP=````@0````4<EA96@```A@````4
M9UA96@```BP````48EA96@```D`````49&UN9````E0```!P9&UD9````L0`
M``"(=G5E9````TP```"&=FEE=P```]0````D;'5M:0```_@````4;65A<P``
M!`P````D=&5C:```!#`````,<E120P``!#P```@,9U120P``!#P```@,8E12
M0P``!#P```@,=&5X=`````!#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U0
M86-K87)D($-O;7!A;GD``&1E<V,`````````$G-21T(@245#-C$Y-C8M,BXQ
M```````````````2<U)'0B!)14,V,3DV-BTR+C$`````````````````````
M`````````````````````````````````````````````%A96B````````#S
M40`!`````1;,6%E:(`````````````````````!865H@````````;Z(``#CU
M```#D%A96B````````!BF0``MX4``!C:6%E:(````````"2@```/A```ML]D
M97-C`````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@``````````````!9)
M14,@:'1T<#HO+W=W=RYI96,N8V@`````````````````````````````````
M````````````````````````````9&5S8P`````````N245#(#8Q.38V+3(N
M,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="```````````````N
M245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M`````````````````````````````&1E<V,`````````+%)E9F5R96YC92!6
M:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$``````````````"Q2
M969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ````
M``````````````````````````````!V:65W```````3I/X`%%\N`!#/%``#
M[<P`!!,+``-<G@````%865H@``````!,"58`4````%<?YVUE87,`````````
M`0````````````````````````*/`````G-I9R``````0U)4(&-U<G8`````
M```$``````4`"@`/`!0`&0`>`",`*``M`#(`-P`[`$``10!*`$\`5`!9`%X`
M8P!H`&T`<@!W`'P`@0"&`(L`D`"5`)H`GP"D`*D`K@"R`+<`O`#!`,8`RP#0
M`-4`VP#@`.4`ZP#P`/8`^P$!`0<!#0$3`1D!'P$E`2L!,@$X`3X!10%,`5(!
M60%@`6<!;@%U`7P!@P&+`9(!F@&A`:D!L0&Y`<$!R0'1`=D!X0'I`?(!^@(#
M`@P"%`(=`B8"+P(X`D$"2P)4`ET"9P)Q`GH"A`*.`I@"H@*L`K8"P0++`M4"
MX`+K`O4#``,+`Q8#(0,M`S@#0P-/`UH#9@-R`WX#B@.6`Z(#K@.Z`\<#TP/@
M`^P#^00&!!,$(`0M!#L$2`15!&,$<01^!(P$F@2H!+8$Q`33!.$$\`3^!0T%
M'`4K!3H%2058!6<%=P6&!98%I@6U!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[
M!HP&G0:O!L`&T0;C!O4'!P<9!RL'/0=/!V$'=`>&!YD'K`>_!]('Y0?X"`L(
M'P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)$`DE"3H)3PED"7D)CPFD";H)SPGE
M"?L*$0HG"CT*5`IJ"H$*F`JN"L4*W`KS"PL+(@LY"U$+:0N`"Y@+L`O("^$+
M^0P2#"H,0PQ<#'4,C@RG#,`,V0SS#0T-)@U`#5H-=`V.#:D-PPW>#?@.$PXN
M#DD.9`Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1`F$$,081!^$)L0
MN1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C
M$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]%>`6`Q8F%DD6
M;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA`&&48BABO&-48^AD@&449:QF1
M&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:'`(<*AQ2''L<HQS,'/4=
M'AU''7`=F1W#'>P>%AY`'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$
M(/`A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\)*LD
MVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G&"=))WHGJR?<*`TH/RAQ**(HU"D&
M*3@I:RF=*=`J`BHU*F@JFRK/*P(K-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78M
MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C
M,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V`W
MG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC
M/2(]83VA/>`^(#Y@/J`^X#\A/V$_HC_B0"-`9$"F0.=!*4%J0:Q![D(P0G)"
MM4+W0SI#?4/`1`-$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?`2`5(2TB1
M2-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/
M`$])3Y-/W5`G4'%0NU$&45!1FU'F4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U
M5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<
MAES672==>%W)7AI>;%Z]7P]?85^S8`5@5V"J8/QA3V&B8?5B26*<8O!C0V.7
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MRHTQC9B-_XYFCLZ/-H^>D`:0;I#6D3^1J)(1DGJ2XY--D[:4()2*E/257Y7)
MEC26GY<*EW67X)A,F+B9))F0F?R::)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?
MBY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DW
MJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[``L'6PZK%@L=:R2[+"LSBS
MKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*
MOH2^_[]ZO_7`<,#LP6?!X\)?PMO#6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S)
M.LFYRCC*M\LVR[;,-<RUS37-M<XVSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)
MU,O53M71UE76V-=<U^#89-CHV6S9\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@
M-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[
M[(;M$>V<[BCNM.]`[\SP6/#E\7+Q__*,\QGSI_0T],+U4/7>]FWV^_>*^!GX
MJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X`#D%D;V)E`&1``````?_;
M`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``
M$0@`(`$8`P$1``(1`0,1`?_=``0`(__$`:(````&`@,!``````````````<(
M!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+$``"`0,$
M`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,74G&!&&*1
M)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R9(-TDX1E
MH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8F9JDI::G
MJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1``(!`P($
M!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B%C,)L23!
MT4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756-X2%H[/#
MT^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>WQ]?G]TA8
M:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:``P#`0`"
M$0,1`#\`W]G=(T>21UCCC5G=W8*B(H+,[LQ"JJJ+DG@#W[KW7:LKJK*P96`9
M64@JRD7#*1<$$'@^_=>ZJ'W]\TNW-U=Y8.?IC<6T,5T9MWY%;9^-NS]KS;1J
MMT]@_-CM.DW#3X/Y(IU[E)JFB@V'TQ\6<)-DI,EN:EIJY:O<FVLI#//34%`%
MR?NO=6\^_=>Z][]U[KWOW7NO>_=>ZK@^2?\`,`FZ7W1GJ/KWI^L[?V!TINOK
M;"?+#LU-XT6S]O\`3R=G[CVQM_![0V7%5X?+-V[W51T6\*'.5^VJ63'PXW"S
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MW[ZV&CJ*.KI\A'3S4$]-/#70U:QO22T<L3I4QU23`Q/3O"S!PWI*DWX]^Z]U
M1%V[\=NQ]F;RV3\.?@'\X?EGUIE-^8VAW1EL$F:ZK[HZD^(?QGCR4&-R6XL;
MN/M?K/>O9>"GW)AJ&KVUU=MV/<KDY?56PA,1@J[P^Z]U8]\5?@=\<OA[@]OT
M'5>W,_FMR[<V50]>4/9_:>[L]V?VB-F4%2U:FVZ7=^[*NNJ=OX"LR#?=5>/Q
M$>.H*VM`JIX)*F\I]U[HX0J*<U#T@GA-5'#'424PE0U"4\SRQ13O"&\BPRR0
M.JL1I9D8`W!]^Z]T'F"W5OS*=F[_`-K9/K*IV]UWM7#[.FVIVA6[IPE6.QMQ
M9V'*U>Z<1B-FT`GS.$Q>QZ>"ACDR&0DA_B%76R1T\)2E>:3W7NA)]^Z]T17^
M9)\V]E?R^/AYVO\`);=U51'*8"CQ^U>L=O5,-57U.].WM\5T6V^N]L4.#QI.
M<SZ/G*U:W(4^/CFK8\-15E0B$0-;W7NJW?AF,7\OLOU_T-CJ'?\`L+HCXE[E
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M3*XS%[EH*>EJZ[;V1KZ">EHLY1TE:DE%55>)J95J(XYE:)WC`<%2??NO=4==
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M=VI52XRM\8BR%`T53%>*5"?=>Z'?W[KW7O?NO=>]^Z]T47Y:_)'-](X?9&PN
MIMK8WLOY0]]YK);*^//5^4KJF@P5=F<90Q5VZ^SNRLAC8Y\KM[H[IW$5<64W
M5DX(GG$<M+C:,293*8Z"?W7NJB.C<34]J_-7=_Q-Z\W3+WI@>M:[;_9/\UGY
MA[IPE%4;A[R^0&!S6-W#U5\;MD5,-358KK3JWKG.;>:%-G8ES0X7#)4XY0]7
M_%:_(^Z]UL8^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZK$^6_\TGXV
M=!];5+;`[AZ?WQWSNOL[*_'WJ_JZJW+7Y7(P]VXV?)4N?I^Q-E;(HLYV?B]K
M]9TN*J<KGHZ;%FOJ*."&EH5DK<EC4J/=>Z2/QT[<W1\2?AOW-\B?F'V/VUN[
M+9KL_.=EX[:W:U?A'[HHU[%@V;MGJ3I^CZYQU?'MGJ;=G:^Y6I*C;W7U-.E/
MMAMS4N,JYWJH*ZL?W7NH?Q^_F$9?"=#?)'Y-?,[>W4F"ZBZQW;@J'#;LZAQ6
M<R^R:;<F5QF.H,]T%UGN=<MGLE\G=T;.WWD*+;-/N+`X^BAW7NZKJ\?C*`&E
M2,>Z]UUO?Y&_-?9F?Z*[;[#_`-#O36S^X^_NL.F^OOA!5[>R787?_8&UNQ\_
M0XS/[BW+VOAMRT.!VQVOUULH9#>==@\+B,IM["87#5L-?EZRWWM-[KW7_]'8
M;R72OR*[MW+D\9VE\=-P]G?(^;=V?R=3VG\F]R05'P$^/FVCG<C3[3@Z2Z4V
M/O):CNX+LVCI66BKL73Y7+9!V;/YK&I(:>+W7NB[86CZ'_ES_(?JK`?&?I?Y
M?1?)+=_R0K>J?DUM##=,YPX3YS[`WCUWOS>5!WC1U])%B/CF^'ZRW/0156U*
MG&9C`2[#PM+F\.V/I\4*F'W[KW4]>]?YD':6RNX)<KT/\K<5F=Q?,/;-?\E]
MH;#=,+EOC+\;=A[PP.TMO_&SX3[BK\]LG%?([LKLW`[/I=P;]WUAJJ#:N.QV
M\,L*6LJ)Z2A@C]U[J7OWL3^9CTCW=\Q.Z,9\6^VNR._/D-\/>HZWK'";)H=M
M[U^-WQ(IMA;P[SH:?:<78=?DJ&M[9[+ZFV_N^#=^Z=L8?%U>0['W)DOX;M^*
M#'TD=8WNO=(/<.Y-S9;LK^6OCM]57\P/'_!3X=XVK[`@[W[#Z;[UW)W)\^?F
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MONN#8.=V!ENT\=M;8E"L7>?7O4^[]D9W,YFLW+D:#'UV\67^`X9VAFR&3B]U
M[JQ[,?.;YD[-[^['[OW!\"/GUD.CJ;XU8+;OQ"^,'6>P]I;HK>T]V93=4F6W
MOVC\BZBARC4/QVW_`(Y\;@\)@MNY7)5E?0[9FR>1>EFKJB7&4/NO=5L_%/??
MR`^('SD_F%?);Y6;`W3W'\^,]M/<TF9^.7QD_P!+.]*'M_:=3L'KCM?JJLIM
MU[WVCMWI?H[XL_&W:N'EV+M[.5V0K<_N+<L^X9ZCRS1X[&5/NO==UO\`,4_F
ML=+_`!1^2/RIK.Z?C_W9M#O?M3IW`_'7=]+U3V?EJKKS?/;.(VU%VWUC\2>G
M]O[?IQW_`-2_$K"Y+)UE/N_<>5H_[V9/:626>D>5Y(W]U[JWOX%5<W5VP?CW
M\0_A'T#\@<'\;^J:BHSO<WRR^76Q<]UU5]H4^<ES>\=XYO:.`W]/MCMCLKN?
MN_LO-3Y'*Y>;`8S;N$AGJG1B10T'OW7NE'WO_,&[=HL#2[ZZ&VCUYC.OMP[A
MRNQNB).U,/O3>?;?S6[%B6IIL1M_XR=)[%SFT<K3[!K<E2%VWKG\K3XQ<.SY
MMZ6+!0_Q2;W7NBU[(^0G<GQMP7R,R?R*HNIL3_,Y[<[HZ?ZHS/8F;W5+3_$/
M:6R>P-A;W['Z<KMA[GW4=H9_$?''XU=0[)WUE,S@Z^2ES>Y-\X'.M'4>3<-#
M4K[KW19NH?YNNU/C1\,OE[VKN/L;N;OKY)[A[A[Z/QC^./9NY:G?_P`EM[P]
M>;3V=MO!]C;PZEQ.UMOCXY=9=G;NJ%W=1;?IL=38##;3SF)IL3]_6UD$=;[K
MW35U-_/#['&RMX5%%WUT5\K=U;@QOPMVE1]E[<ZJSO6WQ@^+O;?=5,8^^-T=
M[[VQ.Y,Y4[5^/G3F&R&$EJ:G<&3HMP9'?N6;;-'%#IE..]U[J'\TOYKG8WS/
MW54?#_XD=F=%=$_'#O'L3+_%;MCY,=O1;WQO;>W.N9MD9S<?R`[RP&/R<VT.
MO/CGMS#[+Q-?M_8*=B54&?[,W#5FIP%!'BJ!\K)[KW0Z[-_G`?';I;K>#H?X
MMX_I'973_7/;W3OQ`^,&7WGO6KIL/M3JO9F.QF-[D^3WR:PAAVZ_1/2>.CBJ
M<-ULN:R%/GNU=PTD4N/A-'E*>I7W7NN6P_YZM)WA\X<[M;K';/:B?''J7JS<
MM$G1F/\`CIV3E/F#\H>[=TY_#T^P*[9VQL[MS#P[!ZSQ&UL3D<K3UU?D,=1_
M85\%9G*J@CG@IZ;W7NA_^9O;?R3^.O\`+O.6WG@-W97Y(?)3Y'X+$87XL]*=
MC5M7W-78/NCM*7<69^+70G:^`QRR0[YVQU%39"3-;LHHH:3"T-'G,GC)84I:
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ME?)+?NTL%B*/<NS^J=E]D97_`$C=@=:]==MUJ[0SO<U)2T?7/\6R%##`WED5
M)?=>Z/[\E_YF.#ZOWYMCXU]6+TWFOE54=6[A[L[ZQ79'<6%V]TY\(.D-HX.D
M;>'=GR7WQBXJB9=O8/>>>Q.(Q^%I!0Y+<#5IJ4FHJ**6K3W7NB?_`!R_GK8;
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MU-N;>?\`"R])M?>V^>O4QV<R.WS)+4[?FR7\/J6^ZIY@/=>Z+O\`(K^8Y#U:
M^^9NK^L(^PMK=9[N;J_=79&ZMU5FR]K[H[WDFBAQ/QMZ"V]AMI[V["^0O>>;
MR*R8MJ#`XL8K&Y4_;U.0\]-D(*3W7NB>=+=Y["ZR[*[W^:_S-Z/EVI_,*R)F
MZDSGQ_Z_Q76'8.X_BY\:]F;7Q7;6&QP[QP\NW=HUW667VCNNDW5OKLW<V:Q&
M"DSTR[=CEC7!8Z@]^Z]U/^/?4'QZ_FS_`"+ROS\[:^-V-PG6O2M6W4O3_2G>
M/6S;<[9W9V/C,'A\MDN]/E3UWD*BLV]EIL%M/<]-!U+BLG'E#C-MYFHW`)5F
MS-!!B_=>Z+=L+`_(_P#FV?)?;'REZ,B^/&Q?Y</PA[+W7U[\`Z#L;;FYM];,
M[1[QZWR51USN;YX;2ZOV-D=D;3WAA^J!29C;G5E-7Y>/'XVLCJ<I`L%4OOW7
MNKO>COAOM7K'L"K[W[+WUO/Y'?)K*8-]MS]X=J-BQ5;1VQ5K2R939'2VP=OT
M>-V)TKL3*Y&F^YK*3"T:9#*RE#E*[(&"G:+W7NO_TM_CW[KW10-Z]=[Z[!^:
M?2NZLI@\A2=-?'KJ;L+>V"SR9NGCQVY>_>V:D=:8ZCDP",U742]==14&XRU1
M(J1`[NC5&9E<+[KW1O\`W[KW7O?NO=>]^Z]U[W[KW0)YKXT_'3<F](^Q]P]"
M=,9[L&&MAR<6]\SUALK)[L3*4TU/44V47<%;A)\J,G2STL;Q5'E\T;("K#W[
MKW0V>_=>Z][]U[KWOW7NO>_=>ZI4[,ZO[P^5/\T6GP.X.IMT[5^,/Q#VKU1E
M<1W#N?')BMH;XS6ZZJD[5WALGIN*JI9SOC/;KW1L_:&+W7D0@H=N[<VY78R.
M05FX)0GNO=75$!@58`@@@@BX(/!!!X((]^Z]T6GI[X=?&CH3=&3WMU5U-@]N
M;OR=#)ATW+5U^X-TYK`[<EJI:U]G[*R&\,OGZC8&Q?NI=8P6#;'X=2D=J8"*
M,)[KW0?;5^*V-WKV?\B.RODML?K+L>'L+M+K2NZJV9GL1C>P=N[,V)T#@JNB
MZGW0]'NO;PI\7V?4;NW7N3-2STJR?P],C3P0S%XI9']U[H/MQ_!&I[#_`)@$
M7RZ[&W=M3+=:[+V!UK1]8]2XK8M!0;AE[8V7DMZ5B[[[)WX9#4[IP>U3N"GK
M-OXKPD09F"GKI90^+H$'NO='JP?7VP=L8C(;?VULC:&WL#EZ^MRN5PF#VUA<
M3B,GE,C,*C(9+(8V@HJ>BK:^OJ!KFFD1I)7]3$GGW[KW43=75W6>^\;E<-O?
MKO8N\L1G,MB<]F\5NK:.W]PXW,9S`)0QX+-96AR^/K*7(9;"QXRF6DJ9E>:F
M6GB$;*(UM[KW3@^Q-D2U>XJ^39NU9*[>%5A*[=M:^WL0]7NBMVU%2P;<K-Q5
M#49FS=5M^&A@2BDJ3*](L*"(J$6WNO=*G2+EK#40%+6%R%+%03]2%+&W]+GW
M[KW4.HQV/JZJ@K:J@HJFMQ4L\^+JZBE@FJL;/4TTM%4S4%1(C2T<M11SO"[1
ME2\3LINI(]^Z]U-]^Z]T%2=%=(Q]C5/<,?3O5J=M5G@-7V@O7^U%[#J6IJ%,
M9`\^\QB?[QRO%C8DIE8U)(IT6.^A54>Z]U/J^G^J:VE[+I)NM]D+%W-0U&-[
M<:EVQAZ&I[,HJK"U&W)H-]5M%24]9NF^`JI*(-6R3,E,YC4A#;W[KW0?[R^)
M?QCW]L>3K?=G0?5&5V.>J\?T?2[:39.!QU!B>G<17X;+8CK#;W\+HZ&;;6Q\
M5E=N8VJI<;CWIJ6FJ<=22QHKTT#1^Z]U3C\%_P"1Q\?:7#[M[V_F`_%/XP;Y
M^3';'9VY^P&ZQQ6TL-O?ISH'93YZH.P>IMMOF,<M-V358W;]'0SYS+YB"K^^
MR*K#'JIZ.&67W7NK`1_*2_EIK6YK(K\+.AUJ]Q]KY7NK/2)L^%4R^_L[24M%
MFY,A3K.*>JV=F8J*%ZO:[H=L5%1$D\F/:91(/=>Z&[>'P@^'O8-3N2KWY\9^
ME-Z2[OR?6V6W(NZNO-M[@I\K5].X&JVQU;'-1Y6@JJ2/'[#V]D*JCQE'&B4E
M-!6U2K'_`)54>3W7NJ4_EO\`RE,;\XOYB&WMJY/XS;"Z.^"O5=!U=VOWSV9@
M(*#$[F^;'8=+2R8_%]!8O;^%K_M-N]5[:VUMC$TVZ<E'1XS)UT2K1Q5$BB%Z
M?W7NK3.JOC#N+8GR<R^3Z_V-UQ\8?B1UE1C);'ZKZ+H\)M0?)+N;>VS:#;NZ
M>T^XMO;4Q6&P6W]F]3[5HX<)MK`QI-/E<Q+59BO=10X=![KW0A]1?!;X\=-=
MB5/:V"P&X=T[[ILOOK(;$S/9.[L]OZ/IO&]CY>NSN\-L=*XO<%74XCK+!YS*
M9:L>J?&P19&MCJY(:JJG@T1)[KW098;^75TINSO/N/Y'_(W9&PNX^U>PNRJ7
M*;7K:K&YV/;NW.HMDX/:.#ZGZYW'M*NS=5M;?DNU*_:K[B,V4H:F&GW'D9JJ
MCC@:.)E]U[H;?C_T]O+KO>/RPW#OZJP>8/>/R&J^RMM5F(K\C4D[`3J+JGK?
M;>#S6-KZ.FBQ.8P=/L.6FF2GDJ8*A`DXD4RF&+W7NA[V7LG9O7&U,!L3KS:>
MVMB;(VKC:?#;8V?L[!XS;.U]NXBD732XO!X##4M%BL3CZ=>$A@BCC7\#W[KW
(2G]^Z]U__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g532389g33w70.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g532389g33w70.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X0,K:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C,M8S`Q,2`V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M
M,30Z-38Z,C<@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87`O,2XP+R(@>&UL;G,Z>&UP34T](FAT='`Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V52968C(B!X;7`Z0W)E
M871O<E1O;VP](D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I(B!X;7!-
M33I);G-T86YC94E$/2)X;7`N:6ED.C!!0C%&1$$R1#E$,#$Q13(X.3%"030V
M,4)!,3)&.3`Y(B!X;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.C!!0C%&1$$S
M1#E$,#$Q13(X.3%"030V,4)!,3)&.3`Y(CX@/'AM<$U-.D1E<FEV961&<F]M
M('-T4F5F.FEN<W1A;F-E240](GAM<"YI:60Z,$%",49$03!$.40P,3%%,C@Y
M,4)!-#8Q0D$Q,D8Y,#DB('-T4F5F.F1O8W5M96YT240](GAM<"YD:60Z,$%"
M,49$03%$.40P,3%%,C@Y,4)!-#8Q0D$Q,D8Y,#DB+SX@/"]R9&8Z1&5S8W)I
M<'1I;VX^(#PO<F1F.E)$1CX@/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0]
M(G(B/S[_[@`.061O8F4`9,`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#
M`0$!`0$!`0(!`0("`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"`,J`G(#`1$``A$!`Q$!_\0`_0`!
M``$#!0$!``````````````@&!PD"`P0%"@$+`0$``04!`0$!````````````
M`P$"!`4&!P@)"A````8!`P("!08)"`4'"``7`0(#!`4&!P`1"!(3(0DQ05%A
M%/"1H=$B%7&!L>$R4B,6"D)B<I+2,U07P?&B)!B"LD-3-"498W.3U3:6EUB#
MU#555M;"9)3%)F8W5Z-TE6?7&CA(.1$``0,"!`(%"00%!P<*!0`+`0`"`Q$$
M(3$2!4%187$3!@?P@9&AL2(R%`C!T4)2X6*B(S/Q<H*2LE,5TD,D-)06&,)C
M<X.3H]-55A>S5&34)41T">*D1?*T-28V_]H`#`,!``(1`Q$`/P#WV`J;8/1Z
M`]6I"`K:!?>Z;W?-JE`JT"=TWN^;2@2@3NF]WS:4"4"=TWN^;2@2@3NF]WS:
M4"4"XXMV8B(BR:B(CN(B@EN(CZ1'['I'4G:R_F=Z2HNPA_*WT!?/AF7^!:?^
M@2_L:=K+^=WI*?+P_E;Z`GPS+_`M/_0)?V-.UE_.[TE/EX?RM]`6ZF":("""
M*2)3#N8$TRD`P^C<0*``([:M<YS\7DGK5S8V,P:``MSNF]WS:MH%?0)W3>[Y
MM*!*!.Z;W?-I0)0)W3>[YM*!*!.Z;W?-I0)0+C+M&;T2F>(E5,F`@01%0-@-
ML(_H&`/$0U+'-+%41&@*@EMXIB#(VI"V/N>'_P`*3^NO_;U?\W=?F/H'W*+Y
M*V_(/7]Z?<\/_A2?UU_[>GS=U^8^@?<GR5M^0>O[T^YX?_"D_KK_`-O3YNZ_
M,?0/N3Y*V_(/7]Z?<\/_`(4G]=?^WI\W=?F/H'W)\E;?D'K^]/N>'_PI/ZZ_
M]O3YNZ_,?0/N3Y*V_(/7]Z?<\/\`X4G]=?\`MZ?-W7YCZ!]R?)6WY!Z_O3[G
MA_\`"D_KK_V]/F[K\Q]`^Y/DK;\@]?WI]SP_^%)_77_MZ?-W7YCZ!]R?)6WY
M!Z_O3[GA_P#"D_KK_P!O3YNZ_,?0/N3Y*V_(/7]Z?<\/_A2?UU_[>GS=U^8^
M@?<GR5M^0>O[T^YX?_"D_KK_`-O3YNZ_,?0/N3Y*V_(/7]Z?<\/_`(4G]=?^
MWI\W=?F/H'W)\E;?D'K^]/N>'_PI/ZZ_]O3YNZ_,?0/N3Y*V_(/7]Z?<\/\`
MX4G]=?\`MZ?-W7YCZ!]R?)6WY!Z_O3[GA_\`"D_KK_V]/F[K\Q]`^Y/DK;\@
M]?WI]SP_^%)_77_MZ?-W7YCZ!]R?)6WY!Z_O3[GA_P#"D_KK_P!O3YNZ_,?0
M/N3Y*V_(/7]Z?<\/_A2?UU_[>GS=U^8^@?<GR5M^0>O[T^YX?_"D_KK_`-O3
MYNZ_,?0/N3Y*V_(/7]Z?<\/_`(4G]=?^WI\W=?F/H'W)\E;?D'K^]/N>'_PI
M/ZZ_]O3YNZ_,?0/N3Y*V_(/7]Z?<\/\`X4G]=?\`MZ?-W7YCZ!]R?)6WY!Z_
MO3[GA_\`"D_KK_V]/F[K\Q]`^Y/DK;\@]?WI]SP_^%)_77_MZ?-W7YCZ!]R?
M)6WY!Z_O3[GA_P#"D_KK_P!O3YNZ_,?0/N3Y*V_(/7]Z?<\/_A2?UU_[>GS=
MU^8^@?<GR5M^0>O[T^YX?_"D_KK_`-O3YNZ_,?0/N3Y*V_(/7]Z?<\/_`(4G
M]=?^WI\W=?F/H'W)\E;?D'K^]/N>'_PI/ZZ_]O3YNZ_,?0/N3Y*V_(/7]Z?<
M\/\`X4G]=?\`MZ?-W7YCZ!]R?)6WY!Z_O3[GA_\`"D_KK_V]/F[K\Q]`^Y/D
MK;\@]?WI]SP_^%)_77_MZ?-W7YCZ!]R?)6WY!Z_O3[GA_P#"D_KK_P!O3YNZ
M_,?0/N3Y*V_(/7]Z?<\/_A2?UU_[>GS=U^8^@?<GR5M^0>O[T^YX?_"D_KK_
M`-O3YNZ_,?0/N3Y*V_(/7]Z?<\/_`(4G]=?^WI\W=?F/H'W)\E;?D'K^]/N>
M'_PI/ZZ_]O3YNZ_,?0/N3Y*V_(/7]Z?<\/\`X4G]=?\`MZ?-W7YCZ!]R?)6W
MY!Z_O3[GA_\`"D_KK_V]/F[K\Q]`^Y/DK;\@]?WI]SP_^%)_77_MZ?-W7YCZ
M!]R?)6WY!Z_O3[GA_P#"D_KK_P!O3YNZ_,?0/N3Y*V_(/7]Z?<\/_A2?UU_[
M>GS=U^8^@?<GR5M^0>O[T^YX?_"D_KK_`-O3YNZ_,?0/N3Y*V_(/7]Z?<\/_
M`(4G]=?^WI\W=?F/H'W)\E;?D'K^]/N>'_PI/ZZ_]O3YNZ_,?0/N3Y*V_(/7
M]Z?<\/\`X4G]=?\`MZ?-W7YCZ!]R?)6WY!Z_O3[GA_\`"D_KK_V]/F[K\Q]`
M^Y/DK;\@]?WI]SP_^%)_77_MZ?-W7YCZ!]R?)6WY!Z_O0(B(`0$&I-P'</M+
M^D/$/Y?MT^;N3FXTZA]RJ+*VK\`]?WKL.Z;W?-K'H%ET"=TWN^;2@2@3NF]W
MS:4"4"=TWN^;2@2@3NF]WS:4"4"=TWN^;2@2@3NF]WS:4"4"=TWN^;2@2@7P
M3]13%.4IR&`2F*8`$I@'P$!`=P$!#U:J,#48%4+010Y+C_#,O\"T_P#0)?V-
M7]K+^=WI*C^7A_*WT!/AF7^!:?\`H$O[&G:R_G=Z2GR\/Y6^@)\,R_P+3_T"
M7]C3M9?SN])3Y>'\K?0$^&9?X%I_Z!+^QIVLOYW>DI\O#^5OH"?#,O\``M/_
M`$"7]C3M9?SN])3Y>'\K?0%]`P;!]KU!Z]4(-575TIU!^L'SZ4*:NE.H/U@^
M?2A35TIU!^L'SZ4*:NE.H/U@^?2A35TIU!^L'SZ4*:NE:M_?JE%75TIO[]*)
MJZ4W]^E$U=*^"8`](_3JM%35TKYU!^L'SZ4*:NE.H/U@^?2A35TIU!^L'SZ4
M*:NE.H/U@^?2A35TIU!^L'SZ4*:NE:@,`^O?5"%<'!?=]**NH)OI1-03?2B:
M@F^E$U!-]*)J";Z434$WTHFH)OI1-03?2B:@F^E$U!-]*)J";Z434$WTHFH)
MOI1-03?2B:@F^E$U!-]*)J";Z434$WTHFH)OI1-03?2B:@F^E$U!-]*)J";Z
M434$WTHFH)OI1-03?2B:@F^E$U!-]*)J";Z434$WTHFH)OI1-03?2B:@F^E$
MU!-]*)J";Z434$WTHFH)OI1-03?2B:@F^E$U!-]*)J";Z434$WTHFH)OI1-0
M3?2B:@F^E$U!-]*)J";Z434$WTHFH+1U!^L'SZK0JS5TIU!^L'SZ4*:NE.H/
MU@^?2A35TIU!^L'SZ4*:NE.H/U@^?2A35TIU!^L'SZ4*:NE.H/U@^?2A35TI
MU!^L'SZ4*:NE?0,`^@=*)JZ5]W]^J45=72F_OTHFKI3?WZ435TIO[]*)JZ4W
M]^E$U=*X'<'V?3^;63I6-J*=P?9]/YM-*:BG<'V?3^;32FHIW!]GT_FTTIJ*
M=P?9]/YM-*:BG<'V?3^;32FHK[W`]@_+\>J:5744[@>P?E^/32FHIW`]@_+\
M>FE-17SN>P/E].FE-13N#[/I_-JNE4U%.X/L^G\VFE-13N#[/I_-II344[@^
MSZ?S::4U%.X/L^G\VFE-16X10=AV\/'W#_HU8YHJK@XA:^X;V_0&J:0JZT[A
MO;]`::0FM.X;V_0&FD)K3N&]OT!II":T[AO;]`::0FM.X;V_0&FD)K3N&]OT
M!II":T[AO;]`::0FM.X;V_0&FD)K5.VJY56BPCJRW:T5^GUUB43/)VSR\=!1
M+<``1V4?R2[9N!Q`H[%`PF,/@`".L[;MIW'>+MMAM%O/=7S_`(8XF.D>>IK`
M3Y\@M9O._P"S=W=O?NW>"\MK':XQ[TUQ*R&-O6^1S6UY"M3P6-S*'G!<-<>+
MN64'8K=E>0;=1#!CVLF&'%8O@)2V&T.:[&N$@'_I&PN"#ZA'7O/=[Z7O%3?&
M-FO(+7;8'8_Z3+[]/^CA$K@>AVDKY3[X?7)X$=UY'VVWW5[O5TPTI90?NZ\N
MUN'0,</UH]8Y$JQ<+YTK&VN1)1N(6;;@R`^WQ$)(-9-QT[[;BVAJW+H`?;U=
M_;WZ["[^E"7;(Z[QWGVFUEIE(TM'I?*P_LKSW;_KVM][E([N]R=^OK<'XHGA
M[OZL5O(*]&KSJ2-&\T;"<LX:,<N4'-O'!P\4(BG*9=QU+L:=WE!*5,JMKC4'
M3>/2$X["J\0;(E])CE#7!;Q]._>VV8Z;NS>[3OK&"I997+'3T&=(7$%Q_58Y
M[CP!7J_=WZO.X-[(R#OKMN_]UI)'!HDW*RD9;%QP`[=@=H%?Q2LC8,RX!9%X
MB;BK!%Q\Y`2T;.0DLT1?Q4S#O6DG%2;%P4#H/(^19*+M'C58@[E43.8I@]`Z
M\,NK.XLKA]G>Q20W<3BU['M<Q['#-KFN`<TCB"`5]0V.XV6YV<6X[;-%<;?.
MP/CEB>V2.1CL0YCV$M<TC$%I(*['N&]OT!J#2%DZT[AO;]`::0FM.X;V_0&F
MD)K3N&]OT!II":T[AO;]`::0FM.X;V_0&FD)K3N&]OT!II":T[AO;]`::0FM
M.X;V_0&FD)K3N&]OT!II":T[AO;]`::0FM.X;V_0&FD)K3N&]OT!II":T[AO
M;]`::0FM.X;V_0&FD)K3N&]OT!II":T[AO;]`::0FM.X;V_0&FD)K3N&]OT!
MII":T[AO;]`::0FM.X;V_0&FD)K3N&]OT!II":T[AO;]`::0FM.X;V_0&FD)
MK3N&]OT!II":T[AO;]`::0FM.X;V_0&FD)K3N&]OT!II":T[AO;]`::0FM.X
M;V_0&FD)K3N&]OT!II":T[AO;]`::0FM.X;V_0&FD)K3N&]OT!II":U\[AO;
M]`::0FLK9[@^SZ?S:DTJS44[@^SZ?S::4U%.X/L^G\VFE-13N#[/I_-II344
M[@^SZ?S::4U%.X/L^G\VFE-13N#[/I_-II344[@^SZ?S::4U%.Y[0^7T:II5
M=17WN![!^7X]-*:BG<#V#\OQZ:4U%.X'L'Y?CTTIJ*=P/8/R_'II344[@>P?
ME^/32FHKB=TORV^O4E%'4IW2_+;Z]*)4IW2_+;Z]*)4IW2_+;Z]*)4IW2_+;
MZ]*)4IW2_+;Z]*)4K5W"^W\OU:434G<+[?R_5I1-2=POM_+]6E$U+X*I0^7U
M[:42I7SNE^6WUZ42I3NE^6WUZ42I3NE^6WUZ42I3NE^6WUZ42I3NE^6WUZ42
MI6LIP,&_R_TZ45:\UJW#5$J$W#1*A-PT2H3<-$J$W#1*A-PT2H3<-$J%P9.4
MBX2-?S,W)1\-#Q319_*2TL\;QT9&L6Q!4</'[]XHBU9M4$RB)E%#E*4/2.IK
M>VN+NX9:6D;Y;J1P:QC&ESW..`:UK02XG@`"5CWE[9[?:27^X3106,+"^221
MS61QL:*N<][B&M:!B2X@!8..6'G,U2IK2-)XKQ#.^SZ9E&3C*=C:N0I3%SN9
M$PU.`ZFTC;5R*#^S<N!;,A,`"0CD@[C]>^&WTK;EN3&;OXBRNLK(T<+2(CMW
M#/\`?28MA'-C=4E,"8R%^>/C3]>>R[))+W>\'8&;EN8)8Z_F:[Y5CLC\O#@^
MX(X2/T15`+6S,-5$S&W`SFYSQFV.4^3E_LE)ISXQ7;"3R(1P[LSF/<"54"43
M%J)XV/K<<LF;]FHX)&HB`@<B:P>GTK?O&7PC\&[1_=WP^LH+O=&8.9;4$0<,
M/](NSJ=*X',-,KN!+%XKW4^G#Z@_J/W"/OAXO;G=[?L4GO,?>ASIW,=0TM-O
M!C9!&X9%X@9B',;(%F5P=Y9G$G!R#-TSQBADBT-BIG/<,JII7!\=P0`'OLH1
MPV2J<3L?<2=AB"A0V`5#;;Z^5^]_C_XF=[WOCEW`V&WNK^XLR8&T/!T@)F?T
MZI*'\H7W?X>?27X)>'<<<L&T,W7=V`5N=P`N7EP_$V)S1;QXX@LA#AQ<:54[
M63=M%MDF,:V;1C)N4$T&4>W18-$"%#8")-6I$4$B@`>@"AKQV5\EQ(9KASI)
M7&I<XESCUDU)]*^C;>*"TA;;VK&16[10-8T,:!R#6@`>8+<<D2>MUFCU--ZT
M<)F2<-7B9'39=(X;'36;KE4153,`["4Q1`=6QET+Q+"2R1IJ"TT(/,$4(/4K
MI6QSQNAG`?"X4<UP#FD',$&H(Z"%;"H8FJ>-Y5Z[QLQ;TN!FW*KNQ46'2^%I
M+J27'J4L4)7TMF%4L*BGBY/'D0;2!1$7"1U@(L3H=S[R[EOULR+?GNN[R%H$
M5P\UN`T9122'WIHP/A$A<Z/\#@VK#R.Q]R]D[J7LDW=2-MAMMP\NFM(AIM'2
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MA"J'`YK[U^_\FJ:5=5J=?O\`R::4JU.OW_DTTI5J=?O_`"::4JU.OW_DTTI5
MJ=?O_)II2K587D3R8Q+Q=HBM\RO8`8(+=Y"N5J/!)W:[E*)$ZONNM1)E4S.3
ME$2]]RH9-HT*8#+*$`0`>S[C>'_>7Q#WD;-W;@UO%#+*ZHA@8?QROH:<=+15
M[S@UIQIYKXI>+7<CP?[MN[R=\[GLXS400,HZXNI!_FX(Z@N.(U/=ICC!!D>V
MHKYD<R\FN5?F79088HH<%)-*B]?"YKF(*N\43@(]@U4*`VK)5@4!JVDSQY#%
M.L]?=I@T,/2W1(<P=S]!.ZOA_P"''@#W>?WDWF:-VYM926]F:#(YQ'\&UC%2
MS5DV./5(_-[B![OY$]_/%SQF^K7OA'W+[LV\T>Q22ZH-NMW$0L8T_P"L7TQT
MM>68%TLNF*,T$3&.=[U\:?8>$OETBF\<DCN8?+6-`17<0:K8,18MF"`('80\
MZ^;/62THP7#I4>HMWTCU%$"@P$1+KD-TL?%OQTK$PR=UO#.3(2`_.W;/S/C:
M6N#'#$1N='%0XF;`KT38MT^GOZ5P)IA%WY\:XLW0EO\`AMA*/P1S/:]ID8X4
M,K&335%`+8DA6!RYYKW,K*+IT6)OK3$L&L<_9A<91B$4Y32,.Q"N+3)A*6AP
MN4OI.1T@41\0(7T:[3NS]-OA7W=C:;FR=N=X`*R7;R\5XTA9HA`Z"QQZ2O,>
M^_UI^.W?"=XL-QCV7;7$TBL(Q&X#A6X?VEP7`9ELC03B&C)1+6Y-\DG#P9!;
MD%FQ1Z)^Y\0.4KL!^O??J`"S92!X^K;;7IC/#[N$R+L6;)M`BI2GRD'_`(:\
M1D\7_%F6X^:D[S]X#<5KJ_Q"[K7_`+53,XZ^:YR>P[.QR.0K0_SCCT5T4YBO
M79=)S:$&74!5G%:NAD?O=M)))^)$WIW;100Z3$+OUE\I[]?3;X>]Z;.1^QV[
M-HWRA+)(`1"7<!+!706'B8PQXS!-*'WSPK^M+Q<[B[E%'WINY.\/=?4!+#=.
M#KAK.+H+H@RB0#(2F2,TH6@G4/4UB?*])S;CNJY2QU+A,U"WQQ9",<F("+ML
MJ0YV[^)E6O4<S&9AWR2C=T@(B*:R8["8HE,/YT]Y>[6[]TM\N>[N^Q=EN=K)
MI>,P1FU[#^)CVD.8[BTC(U`_9/N7WS[N>(/=>S[X]UIQ<;'?1:XW9.:0:/CD
M;4Z98G@LD;4T<#0D4)N'U^_\FM'I74U:G7[_`,FFE*M3K]_Y--*5:G7[_P`F
MFE*M3K]_Y--*5:G7[_R::4JU.OW_`)--*5:G7[_R::4JU.OW_DTTI5J=?O\`
MR::4JU.OW_DTTI5J=?O_`"::4JU.OW_DTTI5J=?O_)II2K4Z_?\`DTTI5J=?
MO_)II2K4Z_?^332E6IU^_P#)II2K4Z_?^332E6IU^_\`)II2K4Z_?^332E6I
MU^_\FFE*M3K]_P"332E6IU^_\FFE*M3K]_Y--*5:G7[_`,FFE*M3K]_Y--*5
M:G7[_P`FFE*M3K]_Y--*5:G7[_R::4JU.OW_`)--*5:G7[_R::4JU.OW_DTT
MI5J=?O\`R::4JU.OW_DTTI5J=?O_`"::52K5HWU=16ZRF^E$UE-]*)K*;Z43
M64WTHFLIOI1-93?2B:RF^E$UE.K2B:RG4.E$UE.H=*)K*=0Z4364ZATHFLIU
M#I1-97`[YOD(ZET!0=IT)WS?(1TT!.TZ$[YOD(Z:`G:="=\WR$=-`3M.A.^;
MY".F@)VG0G?-\A'30$[3H6KX@?9^3ZM4T*O:!/B!]GY/JTT)V@3X@?9^3ZM-
M"=H%\%<P_P"OZMM-"IVG0OG?-\A'5=`3M.A.^;Y".F@)VG0G?-\A'30$[3H3
MOF^0CIH"=IT)WS?(1TT!.TZ%N$6\!ZO;[1_/JTMIDKFNJMSO%^0C]6J:2KJA
M.\7Y"/U::2E0G>+\A'ZM-)2H3O%^0C]6FDI4)WB_(1^K324J%";F?SEQOP_J
M)32`-[;E>P,E5:1C9L[[2[@H]:2=BM2Z74M"5-NN4?MB`+O3E%)N`B!U$O6_
M"CP@W[Q0W.D&JV[MP/`N+HBH'$Q0@X23$</AC!#GGX6N^?/'SZA^ZG@9L>J[
MTWO?*YC)M+%KJ.=F!-<$8Q6X/'XY2"R,8/>SRV3EBS%S0RK/Y`RE>&:"+!J6
M3N=^LIUV&/\`%%+*Z%-NU91[4%Q9L2JG[$7$,2*R$L],":95ESJ*:_1.TL>Z
MWA1W;AV3N[9N<][M$%M%1US>3TJ2YQIJ=0:I9I"(X8Q5Q8P`+\<[[<^_?U`=
M\[GO-WQW%C((F"2ZO)R66>W6NJC6L8VNEH)T6]M$'37$ITL;)*]SCWEWY)L:
MM1Y'!G&-I+8\Q5(`1*]7AWVF67<[/$2F3/(WF78*'/6Z@;K/\#66"WPC9$X@
MY4=*F.;6'M'<*;<=W9WP\0717W>1F-O;MJZRV]IQTV['`=K-EVEW(W6YP_=M
MC:`%L>\GBW;;+W?E\.?"".;:^YDE!=W;J-W+=W#`ONY&$]A;8GLK&%YC8PGM
M7S/<YRB`````````'H``V`/P`&O4<\UX.FB)HB:(O0!Y'^8WX/<R8%D79U8L
M(^.RK56JJAC%9/$GC6LV])L4PB":;])W&K&*4`#K1,;TF'?XH^KONM#V.U=\
M[=@%QK=9S$?B:6F6$GI:6RMJ>#@."_3G_P#9X]^[ETV^^&UW(76HC9N%NTD^
MXX.;;W(;4X!X=`Z@PJPG,E>@_O%^0C]6OB/25^GM0G>+\A'ZM-)2H3O%^0C]
M6FDI4)WB_(1^K324J$[Q?D(_5II*5"=XOR$?JTTE*A.\7Y"/U::2E0G>+\A'
MZM-)2H3O%^0C]6FDI4)WB_(1^K324J$[Q?D(_5II*5"=XOR$?JTTE*A.\7Y"
M/U::2E0G>+\A'ZM-)2H3O%^0C]6FDI4)WB_(1^K324J$[Q?D(_5II*5"=XOR
M$?JTTE*A.\7Y"/U::2E0G>+\A'ZM-)2H3O%^0C]6FDI4)WB_(1^K324J$[Q?
MD(_5II*5"=XOR$?JTTE*A.\7Y"/U::2E0G>+\A'ZM-)2H3O%^0C]6FDI4)WB
M_(1^K324J$[Q?D(_5II*5"=XOR$?JTTE*A.\7Y"/U::2E0G>+\A'ZM-)2H3O
M%^0C]6FDI4)WB_(1^K324J$[Q?D(_5II*5"^=XORW^K324J%L=\WR$=7Z`H^
MTZ$[YOD(Z:`G:="=\WR$=-`3M.A.^;Y".F@)VG0G?-\A'30$[3H3OF^0CIH"
M=IT)WS?(1TT!.TZ$[YOD(Z:`G:="^@N8/]?U[ZIH3M.A??B!]GY/JTT*O:!/
MB!]GY/JTT)V@3X@?9^3ZM-"=H$^('V?D^K30G:!/B!]GY/JTT)V@77]?\[_:
MUD:5CZD[G\[_`&M-*:D[G\[_`&M-*:D[G\[_`&M-*:D[G\[_`&M-*:D[G\[_
M`&M-*:EJZQ]OT!JFD*NH)UC[?H#32$U!.L?;]`::0FH+2)Q]8_3MJNE4U)W/
MYW^UII34G<_G?[6FE-2=S^=_M::4U)W/YW^UII34G<_G?[6FE-2U%4_'^/5"
MU5!6KN>[Z?S:II5:A.Y[OI_-II2H3N>[Z?S::4J$[GN^G\VFE*A0FYP<SZMQ
M"QP60*FQG\K6Y!VUQM3%U1,DLNB':<VJPII&*LC5H-4X=8`)3O7'2W3$-U#I
M>M>$7A1N/B?OW8$OA[MVQ:;J<#$`XB&(G`S2#+,1MJ]P^%KOG[ZAO'O9O`WN
MG\Y2.Y[Y7K7-L;4G`D8.N)@#46\1(J,#*^D;2/?<SR0V:U7/--^GKSD2UN9>
MQV%XK-6RWSASK%:M^HI#*]A("@FT9I="#)@V*4O@F@B0`V`/TSV_;=J[I[+#
ML^QVS8K&!HCA@CPJ>53F7&KI)'$GXGO)Q7X@[MO6_P#B%WFN>\7>F]?-N5R\
MRW-S*2=+<B:#)K11D43`!\$4;0*!;=KO!I2(CZ57$%X/'T([,_90QCD^-GYP
MR(MEKC;UD-DY2R.4#"FB4>IO&-3?#-@`HJJ+7;;LXM[I^[7Y;-O<S=+G_ACC
MK400`XLB!Q<?BE>.TDQTM;9OG>4WMC%W>VAKK;NM;OULBJ-<TU-)NKDC"2=P
MJ&#%D$9[*+`O=);W6\7*)HB:(FB)HBRK^3>NNES&$B0F[3C$.0DG0!OL9$BM
M?73`_JV!RD00]^OF_P"J=C'>%E7?$W=+8CKI(/82OM/Z"WO;XZN#/A=L=X'=
M587#]H-7JF[GN^G\VOSDTK]FJA.Y[OI_-II2H3N>[Z?S::4J$[GN^G\VFE*A
M.Y[OI_-II2H3N>[Z?S::4J$[GN^G\VFE*A.Y[OI_-II2H3N>[Z?S::4J$[GN
M^G\VFE*A.Y[OI_-II2H3N>[Z?S::4J$[GN^G\VFE*A.Y[OI_-II2H3N>[Z?S
M::4J$[GN^G\VFE*A.Y[OI_-II2H3N>[Z?S::4J$[GN^G\VFE*A.Y[OI_-II2
MH3N>[Z?S::4J$[GN^G\VFE*A.Y[OI_-II2H3N>[Z?S::4J$[GN^G\VFE*A.Y
M[OI_-II2H3N>[Z?S::4J$[GN^G\VFE*A.Y[OI_-II2H3N>[Z?S::4J$[GN^G
M\VFE*A.Y[OI_-II2H3N>[Z?S::4J$[GN^G\VFE*A.Y[OI_-II2H3N>[Z?S::
M4J%M]S^=_M:NTJW4G<_G?[6FE-2=S^=_M::4U)W/YW^UII34G<_G?[6FE-2=
MS^=_M::4U)W/YW^UII34G<_G?[6FE-2`?V#].^FE-2U=8^WZ`U32%74$ZQ]O
MT!II":@G6/M^@--(34$ZQ]OT!II":@G6/M^@--(34%UW<]WT_FUDZ5CU"=SW
M?3^;32E0G<]WT_FTTI4)W/=]/YM-*5"=SW?3^;32E0G<]WT_FTTI4+[UA[_E
M^/5-*K4IUA[_`)?CTTI4IUA[_E^/32E2@G]WSC_KU72J5YKYW/=]/YM-*5"=
MSW?3^;32E0G<]WT_FTTI4)W/=]/YM-*5"=SW?3^;32E0MPBNP#Z/3ZQU:YBJ
M'46ON_T?G_/JW1UJ[4G=_H_/^?31UIJ3N_T?G_/IHZTU*U6;<T4S`.+[9EB^
MNNQ`55@*Q6:)R%D)Z8<"*,+6X@B@@"LI-OQ*BF'B"91,J;8B9Q#I.Z7=/=>^
MG>&V[M[,VM[<OIJ/PQL&+Y7TR9&VKCS-&C%P7&>(/?W8?#3N?>]]>\C].V64
M5=((#YI'8101USDE?1K>#15[O=:XCQBYZSA>>1>4K-EC(#SO35@<`1G'(J*&
MC*U`M1.2&K$*F<?V$7$-3=!?`#*J"=8^ZBAQ']6.YG=#:.XO=VW[M[(VEI`W
MWG$#7+(?CED(S>\XG@!1H]UH"_`CQ,\1N\/BKWSN^^O>5];ZY=1D8),<$+:B
M*"('*.-N`XN=J>ZKW.)M'WU>P+8#"5$5`6.0O@"BA2B5,ZGZXI%,(%W\"]0[
M>(CKIM#=>O\`'2G4.-.OCSPY+ANU?V78@TC+JD<SD">=!6G*IIF5LZO4::(K
MBX_Q%E'*R[A#'%`M5R!EXR#R#B'3B)BR[;BI+SAR)PT0D`>(G<N$B@'KUHM[
M[S]W>[;&OWZ]MK77\+9'@/?T,CQ>\]#&DKK.Z_</OGWUE='W4VR]OQ'\;XHG
M.BC&=99:"*(?K2/:.E7''B]D-%;X)_:L%14P)NV$%)\A<--Y8%O0#=1).Y+-
M$%^KPZ5%B"`^`[:T(\0]C<WMH;;>)+7/M&;;?%E.=>P#B.D-*ZS_`-F^]$;_
M`)>ZO>[D&X5IV,F][4)*_E(%V6M/0YPZ5;S)>(,FX=E&,1DRES-2<RS,)&$<
M/DT'$/8(T>G:2KE@CEWL%88\>L/VS)RNF&X;B&X:WFP=Z.[_`'IMWW.P7<5S
M'$_3(&DA\;ORRQN#9(G?JO:T]"Y7O?W#[X=PKN*R[W;?/92SQ]I$YX#HIF8>
M_!,PNAG9B/?B>]N.:MMK?KD5F9\E"JJ/\]Y5N@I[MJGB@(@%1#[)'UOM$3V2
M=7J.=E7W`_@`=?*GU9[DV'N9MNTU_>7.Y:Z?JPQ/K^U(U???_P"SYV1USXD[
MUWA(K'9;+V5>3[FXBT^<LAD]!7I8[O\`1^?\^O@71UK];-2=W^C\_P"?31UI
MJ3N_T?G_`#Z:.M-2Z&TVZNTBM3MQMTPPK]7K,8YF9^<D5#)L8N+9DZW+QR9,
MJB@D3#8`*0ICG,(%*43"`#F[=M=]N]_#M>V1/GW&XD#(XVCWGO=DT5H/.2`!
MB2`M;O&];7W?VJXWS>YX[;:+2%TLTKR0V.-HJYSJ`G#D`230`$D!1/-YBO"<
M@[#R(I9O`!W)'VXY?'WEK@AOKT@>!GBR?_Y'=_UH?_%7BY^J/Z?AGWHL/ZES
M_P"`KTXAY%86SVE/K8>R##7Q*K*1R-@/%-Y=L$8I+$=GC2K!+1T<8_Q96"PE
M%,#@';'?;PWY3O-W&[U]S'0M[T64MFZX#C'K+#K#-.JFASJ4U-SIG@N_[D>*
M'<'Q(9<R=Q=S@W)EF6"8QME;V9DU%E>TC975H=334>Z:T5Y>[_1^?\^N5T=:
M[O4G=_H_/^?31UIJ3N_T?G_/IHZTU)W?Z/S_`)]-'6FI.[_1^?\`/IHZTU)W
M?Z/S_GTT=::D[O\`1^?\^FCK34G=_H_/^?31UIJ3N_T?G_/IHZTU)W?Z/S_G
MTT=::E1N0LEX^Q)3YC(65;U3L:T*OH]^<N=[L<55:S%I[")0=S,T[9LB+*](
M@FD!Q55'P(4P^&K'ED8JXT5S0YYTL!+NA86,D?Q)7E,8\FEX-GFR]Y/5:K&1
M7E<58=NUAKO60PE,9K.S;:L,9)$!#P4:BLF8/$IA#8=8;[V%I]W$>?[`1ZUG
M,VV[<*EH'60JHQ/_`!$?E,98EV<$3D>_QC(OU4T&Q\S8TO-`AA65,!"$<VA6
M+DZO'%$P^*CIXBD7UF`-59>0N^(T/ES`'K5'[?=LQ#:CH(]F:S-5^S5^VP41
M::G/0=IJ]@8(2L!9:W+,)VOSD8Y+U-Y&'F8MPZCI)BN7]%5%0Y!]NLUH:\5:
M:A8!)::$4(7;]W^C\_Y]5T=::D[O]'Y_SZ:.M-2=W^C\_P"?31UIJ3N_T?G_
M`#Z:.M-2=W^C\_Y]-'6FI.[_`$?G_/IHZTU)W?Z/S_GTT=::D[O]'Y_SZ:.M
M-2=W^C\_Y]-'6FI.[_1^?\^FCK34G=_H_/\`GTT=::D[O]'Y_P`^FCK34G=_
MH_/^?31UIJ3N_P!'Y_SZ:.M-2=W^C\_Y]-'6FI.[_1^?\^JZ%34MCN>[Z?S:
MOTJVH3N>[Z?S::4J$[GN^G\VFE*A.Y[OI_-II2H3N>[Z?S::4J$[GN^G\VFE
M*A.Y[OI_-II2H3N>[Z?S::4J$!3W?,.FE*K[UA[_`)?CU32JU*=8>_Y?CTTI
M4IUA[_E^/32E2G6'O^7X]-*5*=8>_P"7X]-*5*ZCO>[Z/SZR])6*<U\[WN^C
M\^FDHG>]WT?GTTE$[WN^C\^FDHG>]WT?GTTE$[WN^C\^FDHM7Q']+Y]-'4E2
MGQ']+Y]-'4E2GQ']+Y]-'4E2O@K[^H?Q^/\`ITTI5?.][OH_/II*)WO=]'Y]
M-)1.][OH_/II*)WO=]'Y]-)1.][OH_/II*+>26\!]`>CT_Z]6N;S5S74R6[W
MO>7Y]6Z`JZRG>]Y?GTT!-96HJIC&`I=A,80*4`](B([``>/I$="UH%3DJASB
M:#,KRT>:-RU/G;+8XLITGW\4X?D7L<DJT5ZF5LOY`.RL-D$Q#"FZ91`@>.CS
M>(=!%U2CLOK]$OIX\-!W.[L_[Q[I'3O'ND;7$$>]#;?%'%S#GX2R=)8T_`OQ
ML^LGQN=XC=]O]RMBFU=S=BE<RK3[ES>#W9I^3F1XPPGD)'M-)5BVU]$KXS31
M%7F-L8W_`"_;6%&QI596WVB1`ZB,;%H@8K9HEL+F2E'JQDF$/$,B?:7=NE46
MZ)?$QPUIM^[P[+W7VQ^\;_<QVNW1YO><R<F,:*N>]V36,#G..073=T>YO>CO
MYO<7=WNC937V\2U(9&,&M'Q22/-&11MS?)(YK&C%S@I.NX7C;QL,=K8S0_*O
M-C,1(YKT1)OV?'&A2:>W4UF;!&J,;!F.58K!LJ@P480O4`D,NX`!`?/8[OOY
MW]`DL1+W<[I/RD>QKMSN&'BR-X='8L<,G2"2?(AC"O9)]O\`"7PC)AW4P=\_
M$./XH8I'MV.SD%/=EFC+)MSD8?B;"Z&UK5IEF`(-C\G<A,N9<00B[=;%D:DP
M^S#8[JS1I3L:P"!1_9-X:B5M&.KK8$B[!W3H*.#[;G4.;<==?W?[D=V>[+S<
M[9;`[F_^)<S.=/=2'B7W$I=*:\@X-'!H"\X[X^*G?GOQ&VSWN]<S8XOX5C;M
M;:V$`!P$5G`(X&TRU:"\YN<XU*LJ!2@&P%*`>P`#;YO1KK*E>>4"R[\<:Z;,
MGEF<L*Q;P/)L\'V5'(>*7[XPKJU.6:U]*;GXV"76ZC,6$DU:*D7;IB5,POSF
M$.H0'7S'W[OAW6\?^[>X;72.;=X#;7C6X"9AD,<;I`/B<PN!:XXCLP`:!?=?
MA1M9[_?2)WTVG?@9H.[UT+[;WO\`>-M(V'M9F0DUT,D:UP>QM`3,YQ%358B=
M?3B^%%Z=?)XQ2M2..=@R5(M^S(YCN*KR/%0@D4&I4LCB!B5`ZMC"F[FEI)0H
M^@Q.@0U^?7U1=Y&;OWZ@V"!U8-KM0UU#AVT])'CK$8B!Y&H7["?0EW*D[N>%
M-SWKNF:;O?KXO944/RUJ'0QG'@Z9UP1P(#2LM/>]Y?GU\TZ`OMK64[WO+\^F
M@)K*=[WE^?30$UE84O.0Y#C7:%4N.5??`27R"LA<[X5NH'<;TR#>F+7HEP!3
M=1"V"R-C.#%'TIQP;^!]?67TL]Q_GMYN>_5ZRMK9`P6]1@9Y&_O7C_HXB&]<
MO,+\^_KS\4SM/=FR\*]LDI?;HX75X`<6VL3Z01NQJ.VG:7]4`K@Y><[7W2OR
ME6<_R1)KL6_D17Q.``]JE`G$TQ'TFBYN>CE3@'N"8('X]?'_`-6]H'[9L=[3
MX+FYCK_/CC</[!7Z._\`[/"_,>]=Z=M)PDL[.4#_`*.69A/_`'P7H/[WO+\^
MOB30%^H.LIWO>7Y]-`364[WO+\^F@)K*=[WE^?30$UE.][R_/IH":RG>]Y?G
MTT!-93O>\OSZ:`FLIWO>7Y]-`364[WO+\^F@)K*A]SIYPX:\OWCK;.1.:7BJ
M\;$F)"4JDQ2[=.TY0R!(H+J0%%JR;CJ3*[?BW.L[=G**$:P16<J[E3`IL>YF
MCMV:G9^7E^@&F1;12W4HBCSXGD.:_,BYZ^8IR:\Q?*;K(N?[>N-=8/G2F.<-
MU]V\;8MQ7$JJ#\,PK4"HIVG\T#?I*\FWI59-^H`F.H1/H13YN69\SJO/EY>5
M,%UUO;16S-,8QXGB?+DH(*N6Z(@59=%$P@)@!54B8B4/2(`<P"(!J%9*W2F*
M<H&*8IRF`!*8H@8I@'T"`AN`@(:JJ+T:_P`.SYE=^XO\K*)Q*NUK?R/&/DK9
MDJ4RK4P]47BL79BG]T:3<JD5P<Q(%E:YP$HB9:H]#9U\8BZ,3O-^HV=8SNCE
M$9^`G+[LL_:M9NELV6`S-'[U@KUCC7JS7Z*@JB41`=@$!$!`?`0$/`0$/:`Z
MZ/0%RFLKYWO>7Y]-`364[WO+\^F@)K*=[WE^?30$UE.][R_/IH":RG>]Y?GT
MT!-93O>\OSZ:`FLIWO>7Y]-`364[WO+\^F@)K*=[WE^?30$UE.][R_/IH":R
MG>]Y?GTT!-93O>\OSZ:`FLIWO>7Y]-`364[WO+\^F@)K*=[^C\OQZKH":RN)
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MUMYK2*YO:`?@#Z]]5TJFMO-?.^;];Z`^K32FMO-.^;];Z`^K32FMO-.^;];Z
M`^K32FMO-.^;];Z`^K32FMO-.^;];Z`^K32FMO-;J:W@/4(C\VJ%JJ'`Y+7W
MB^_5M"JU/).\7WZ4*5/)0)\Q7DX/'7`,DC77PM<EY1%[2Z.9(X%=Q+=5J'[T
MVQ(`'J(:"BG()MS_`,E\Z0'^2.O9_`SP_'?KOI&Z^9JV#;M,]Q7)Y!_<PG_I
M'BKA_=L>.(7S1]57B\[PH\,9F[9)V?>W>-=I9T/O1@M_TBY'$=C&X-8>$LD9
MX%>2_P#&(^T1$1$1]8B([B(B/I$?3K]+%^'N)Q.::(I4\7N)]XY,STFJR>LZ
M3BZFI&D,E99L101K-1BFZ)GCM--591NC)SHL4S*$;%4(5-,.XN=)+8P^<>(?
MB3M'A_9QME8Z[[Q71TVMG%C+,\G2"0`2R/40"^A)/NL#G8+VSP8\#^\?C!N4
MTL$C-N[F;>W7?[E/[MO;1M&MP!):))=`+A&'`-;[TCF,]Y7+SER*IM8J$IQ^
MXA1<C2\'`X+%WO)BX'1R-R`EFY#&5=VJ>*DW>,:>?8QVD,CV4C(F`RJ92F!$
M-!W/[C;KN.Z1]]O$Z2.[[WZ==O:C&UVUAR;#'4M=,,`^=VIP=@UQ(U'L?$GQ
M5V'9=AF\+_`N&7;_``ZU=G>;@:B^WF1H-77$U&N9;'$QVK=+=)J]@U=FV!8`
M```````>``'@`![`#7LR^8DT1<R/CW\O(,(F*9.I.5E'C6.C(UB@HZ?2$@]6
M(V9LF;9(IE7#ITX4*1,A0$QC&``U%//#:P/N;E[8[:-A<]SB`UK6BKG.)P``
M!))R"R+.SNMPNXK"QC?->SR-CCC8"Y[WO(:UC6BI<YSB```22:!>@/*]*0X.
M>6!+XQEE6R>4,T/FT19R(J$.)K/=#M'MFCT%""/Q+:I4>"%@90NY#+`)@'90
M-?%'=O=G^+_U"1=X+8./=[:F%\1(_P`U!5L3B.!FN).T`.(;AFTK]1.^_=Z/
MZ<?H[G[HWIC'?#?Y&Q7`!!K<71:^X8"*ZFV]I#V)<,"_$8/"P38WH,_E2_TW
M&U71,O/W>QQ=;C``HG*BK).2(JO5@+XE:QS83N%C>@J21A]6OL7?MZLN[FR7
M6_;B=-E:0/E?TA@J&CI<:-:.)("_-?N?W7W/OMWIV_NELS=6Y[C=QP1X5`,C
M@"]WZK!5[CP:TG@O;+0ZA`8VI%0Q[64>S7Z16X>KQ!.D"F.SAF23,KE4`]+A
MZ=,RRH^DRBAA]>OR5WG=+S?MWNM[W`UO;N=\K_YSW%U!T-KI'0`OZ&^[7=_;
M^Z?=VQ[K[0W3MFW6D5O$.;8F!@<?UGD%[CQ<XE57WB^_6MH5NJGDG>+[]*%*
MGDN!+3D37XF5GYQZE&PD%&/YF9D7`@5!A%1;15](/%3"(`!&S1`YQ_!J>VM+
MF]N8[*S89+N:1L;&C-SWD-:T=)<0%BWU_9[78S;GN,C8=NMH7RRR.-`R.-I>
M]YZ&M!/F7BYY*9KE.0F;<@Y;D^\FA99E7]WX]4QC#$5*,*$?5X@A1$0(9I#M
MTNX`;`9<RAO28=?J[W![IV_<CNE8]V;>A?;Q#M'#\<S_`'I7^=Y-.30!P7\_
M/B]XA7GBEXB[IWVN]0BN[@B!A/\`"MH_<MXQC0:8FMU4P+RYV9*IG+6,)W#U
MR&BV<HISS:LTJ?DVPIBF9@XN%2AK7]V*%$1$5XQ.8!NH/ANHF;PUG]V>\-GW
MIVK_`!C;\;)UQ/&PUKJ$$SX=8Z'EFH=!"TW?KN9N?<'O!_NWO`IN3+.TFD;2
MFAUU:Q7/9GIC$H8[]9I627R:YOX#DI>H8QMB3V&YH0+^NK#VFJO2[!ZQ*DH<
M?P:\&^JBT[;N#9W8SAW6/T/AF;[0%];?0)N!@\6MRVZONW.P2GK,5Q;.]E5G
MIS'R3PGQ_P#W?_S@NZ-*+:@D?N!1U#6&21D1B!:!(ID6A(F2215;`_1$2*B0
MQBG`2@(`(A\9]UNX7>WOKV_^Z]F;LVVGM`)(F%NO5I-)'L)!TNQ%1A0T7Z8=
M_?%CP_\`##Y4]^]P;M[;WM.Q+HIY`_LM.L5ABD`+=;<'$$@U%<59$?,CX3``
MB.=8G8`$1VJU\$?#W!5A$===_P"PWBT</\'D_P"VMO\`QEYW_P`6/T]_^I(/
M]FO?_ME,2O66$M<!"6FNOTI6OV2)CIV#E&X*`A(Q,LT2?1[U$JI$U2IN6JY3
M@4Y2G+OL8`$!#7EM]8W>VWLVW7S#'>V\KHY&&E6O8XM<TTJ,"","1RP7O.U[
MI8[UMEOO.U2-GVN[@9-#(VNE\4C0]CQ4`@.:0:$`C(@'!1RR'S<XKXIMTQ0[
M]F&#@K=7SH)34*$79956-<.&R3M-JZ<PT)(,2/"H+$%1$%142$W2<"FW#7=;
M'X2>(W>3;(MYV7:YIMLG!,<FN)@<`2"0))&NTU!HZE#F"0O*.]/U"^#7<K?9
M^[7>??;:VWRU($L79W$AC+FAP:YT4,C`ZA%6ZM3:T<`<%66'>36$<_KSK?#]
MU"ZFK*+)>=6:5^SQS..+(J*IL4EG\U#1K([IT*"@D1(<RHD(8W3TAOK5]Z>X
M'>[N4R%_>BT^4%P7",.DA<YVD`N(;'(YU!45<0!4@5JM_P!P_%OP]\3I+F+N
M)N'^(&T:QTQ;!<1L9K)#`7S0QL+G:748UQ=1I-*"JIS,W,?C=@%XI$Y-R=$Q
MUD2(4ZE1A&[VT6M$#AU)_&0T$@\5BNX7Q+\89OU!XAN'CK/[J>%O?SOK$+GN
M_M\LE@<II"V*$TSTR2%H?3CHU46I\0/'CPG\,9S9=\-XMX=V%*VT0?<7(KEK
MBA:\Q5X=J8ZC')17-YO7$,'0(`7+1T!-TB]"ALP0`-]NOM&LH.Q+MX_W>_NU
MZ,/IB\3C'K__`!H?^7YAU?3V5/6O%S]<_@8)NR'^-&.OQ_*,T]=/F-5/Z->A
M3`PCRGP-R)0<FQ+D".L,DP0^*DJR\0=P=LCFP"!3.G-=ET6K]1F0X@!G"`+-
MRB(`)]Q#7E_>[PZ[Y=QGM'>:RD@@>:-E:6R0N/(2L):'<FNTN/)>[^'?C+X;
M>*L3W=Q]TAN[N-NJ2W<'0W+&Y%SH)0UY8#@7L#V`T&K$*0!#@H<B9`$3',4A
M0'8`ZC"`!N(B``&X^D=<4105*]-J>2_,\\]WS"7O.KFE9H*HSJCSCQQMD)S%
M>'F+9<YHF?F(]Z#/(^4NT`]IP\N-BCQ;LUA`1+#,&H%$.M3JY._N#/.<?<::
M#ET^7GXKLMLM?EK8%P_>OQ/V#S>U06X$\+LC<_>4./.-6.%PAU+,LYFKS=EV
M9GL=CG&L!V7%PNT@W`R97)X]JL1NQ;"<GQDFZ;-^HH*"8L$$#[B41LS^SR]:
MR;JY9:PF9^-,AS/`>7!?IE\5_+IX7<.<:1F,L-X&Q^9!NQ;M[%>+M4ZY=,D7
M^132*1W.72VST8]?/G3Y4!/\*B*$<U`W;;H)I@!==1#8PQ,TTQ\N(I7S^:@P
M7'3WES</UR./4#0#J"\='\31P-Q!QCS5A'D'@FDP6-ZGR-876$OU*J<:VA:D
MRRE0U(60/98&"8)HQL%^^%<L1#/&S9-)N9VP.N4@'64$=)N=JV"0/;32ZN'E
MY8<ZKH-FNI)XW12DES*4/0?NIZUYJ*=9I"E7&G72(74:RU-MU8ML6Y2.9-5O
M(UF=CYMBLF<H@8ATG+$I@$!\!#6M:=+@X9@U6X<`YI:<B"/2OV0F$NG,QT;,
ME#I"9C8^8`H>@H2C)!^!0]P`XVUVS&C2`W*B\^-0:*/W)+F!QCX?U)"[<F<U
MT7#T$^[H0R=HE!-8;*JA_>MZG4(M&0M=H73'P,#%FN!!$.L2ZCEGA@%97`>7
METJ6&">X=IA87'RS/!8=97^)\\K2/FSQ322Y&SD>FJ9(;+%8/52AU``W3WT6
MTS:HFP'0-Z0$613[?R=_#6O_`,6MQ7.OGI[*^I;`;-?$5HP?TEDVXB>9-PHY
MU)/4.,^=*]=;/%LADIG',NTDZ7DZ(CR;`K(.J+:6D9-/(QN8P`H[9$=M$Q$`
M,J&X;YD%W!<?`X:N7\M#ZEAW%I<VW\9A#>>8](4X2J`<Q2AZ3"`!N(`'CZQ$
M1```/6(^`:RJ%8M2L/[[S\_*4C)&2BGW+F*1?1,B^BGR08PS*LFF]C7:S)XF
MDX0Q\JW<IIN4#`"B9C)G`.HHB40'6$=PL@:=H*]1^Y;`;7?D5$>'6/O4NN/7
MF#<..5&-\E9AP?G.N6;%F'7B3#*%^G8ZQ8]J]*<+17WX'WU+9#AZNU103BA*
MLHJ4QDDP.0IC`8Y2C)'=6TH+F/!`SS'MZU!+:W,#Q'(PA[LA@:^BJQCY<_B8
M/*\QC8W=;KMFS)F\S!P=LYL6),8@O3E%$C"0YXR?O4_2/OIOU%^RLU0504#Q
M(<Q=AUB.W6V:ZF)'1Y`>@E9D>SWKQ4AK>LX^H%3@X->;%PF\PM:4@N/N1I)#
M(T%'J3$QB+),">D9)1AD3$(YG(J(7=OXRU0K-10I7#B*>/0:]117!(#%$<BW
MO8+DZ6&CN1S\O2.E8US8W-IC*WW#Q!J/+K61SO%]^LRA6'4\D[Q??I0I4\D[
MQ??I0I4\D[Q??I0I4\D[Q??I0I4\D[Q??I0I4\D%8OO^;2B5*X_?-^M]`?5J
M_2K=;>:=\WZWT!]6FE-;>:=\WZWT!]6FE-;>:=\WZWT!]6FE-;>:=\WZWT!]
M6FE-;>:=\WZWT!]6FE-;>:=\WZWT!]6FE-;>:=\WZWT!]6FE-;>:^@N;]8!_
M"`?Z-M-*:V\UJ^('^;]/UZII5=;>:?$#_-^GZ]-*:V\T^('^;]/UZ:4UMYI\
M0/\`-^GZ]-*:V\T^('^;]/UZ:4UMYKJ>\'M'Y_SZRM'4L(O%4[P>T?G_`#Z:
M.I-83O![1^?\^FCJ36$[P>T?G_/IHZDUA.\'M'Y_SZ:.I-83O![1^?\`/IHZ
MDUA:NX'ZP_3IH5=03N!^L/TZ:$U!.X'ZP_3IH34%\%4`]8_/]>FCJ5-07SO!
M[1^?\^FCJ36$[P>T?G_/IHZDUA.\'M'Y_P`^FCJ36$[P>T?G_/IHZDUA.\'M
M'Y_SZ:.I-86X17T[;^KU_P"O5KF*YKSP*W.Z/R'\VK=`5W:.YKZ50QC`4H")
MC"!0`!\1$1V``\/2(Z%H`J<E4/<30'%>4+S(<ZGS;R;M3>.>_$T[%@*8VJQ4
MU!.U65AG*@VJ62`/L&-*64RY0.'Z;=NCZ@#7Z2>`_<X=TO#^VDG9IW3<:74U
M1B`\#L6'^9%IPX.<[FOQ,^K;Q)?XA>+]Y!:R:]AV6MC;T-6DQ./S$HX5DG+P
M",XV1\E`C7LZ^8E+CA[Q*M_+'(Q*_''<PE"KZC1YD*Z$0!0L1'+J#V(B)!4H
MH/+3.`F8C1$=RI@!EU`[:8@;S+Q0\2]L\-MB-[.&S;U.'-MH*TUN&;WTQ;#'
M4%[LS@QOO.P]U\!?`W??&[O6-MMB^V[L6I:Z]NZ5[-A.$45<'7$M"(VY"AD=
M[K367',3-<?//ZIY?W$*)3CL95Z?CJ;,(UY83J9)R"O(I-3QCJ33'NRL3&2_
M[20=JF-]X2!#JG'L-TM_,O"[NE-9PW/C7XGRF3O!/"Z=AE&%K;!I.L,.#'O9
MA&P4[.,AH]][E[MX\^(5MN-U9?3!X$PB'NC;7,=K*(#4WUZYX:8W2#&2..7&
M:5Q/;3!SW'LXXU'+G7B%CQXNF+\%Q/2NRI^)8*=EYLJ0I_O;>KA)2SJY643"
M'4=`7$:@P:E$1[+)@B3T@81[OP=[SS=^-IW'OA<U$UUN<D;(ZU[&W@8P01==
M'.D>?Q22..5%Y+]2G<6V\+-_V7PWL*.MK#9(9I90*?,WEU)(ZZN*YEI<QD,8
M_#%"QIQ!)@YKU]?-RJVC4.Z9,LT=3,?UB9M]HEE`38PL&S4>NU`W`#KK=``B
MS9(;[JN%C)H)%^T<Y0\=:S>-YVKN_M\FZ[W<16NW1BKI)'!K1T#BYQX-:"XG
M``E;WNWW8[P]\-WBV#NO9SWV\3&C(H6ESCE4G@UHK5SW$,:,7$#%>D/@MY>$
M/QX68Y0RF:,M.:E$!&'9M3D>5O&A7*0IK!%N#E!.7M9TCBFK(;`BV*)B-M]S
M+G^#O&'QPNN_+']W>[G:6W=,'WW'W9;JAPUC-D(.(C^)QH9.#!^M7TW_`$K;
M?X5/C[Y=\C#>^(1;^Z:VCH+`.%#V;LI+D@T=/\,8JV&N,CL5/F5\GFW(#-I:
MS4Y$K[&F(BR%:@'3=43LK!95UTPMMG0$!!-=JLY:)LFB@`(&;->X4=EAU]'>
M`7A[)W)[I?XAN4>C?]STRR`CWHX@#V,1X@@.+WC@Y^D_"OBKZO/&*+Q.\0AL
MVR3=KW2V(/@A<T^Y/<.(^9N!P<TN:V*)V-8XP\&CRI2>4!QZ.]F[1R6L;$?@
MH,CZC8U^(3V*O-/$"%M]A;=9?$L7&+%CTE"^`J.EP#[28Z\Z^I_ON(K2W[@V
M#_WLQ;<75#E&T_N8C_/>#(1R8S@Y>S_0CX6.FOKSQ<W:/]Q;A]I8:AG*\?Z3
M.VH_S<9$+7`T)ED&;%GU[H_(?S:^+]`7Z;=H[FG='Y#^;30$[1W-.Z/R'\VF
M@)VCN:Q2^;)R!''F$H_#L&]%&TYH<*(RX(J;+LL=0:Z*TR8_3]HA;%*]AB7?
M8%$".2^H=?2'TU]R1OG>U_>F\97;MI:"RHP=<R`AG7V3-4AY.,97Q5];GBB[
MNIX=Q=Q-NE+=Y[P.(DH<66,)!EKR[>31$*_$P3!89N"6$0SQR9Q]5W[3XJJ5
MQX-^NP&+NB:N5-5![\`ON`EZ)N8,U8[#Z2N!]@Z^J_&/O=_N;W`O=PA=IW*=
MOR\'/M9@6ZA_T;-<G]$+\_\`Z:O#L>)7B_M>T7+->RVC_G+OEV%L0_0>B:7L
MX?\`K.A75\U-H+?F?>W`E`HRE5QU(^`;`835-@S,(````!U,Q#P]&VN;^G*3
M7X4V<?\`=W-RW_OG._Y2[7ZU8#%X_;C,?\_9V3__`.&C;_R5J\JR9^Z>9=,;
MB;I">J&0X00WVZQ-67,JF7W_`+2)`?Q:I]1MI\UX5W3^,-U;2?\`>AGL>KOH
MJW'Y'Q[L(:T^:L;V+_\`AWR`>F,++]YIN+1R/Q5FK&S;]^:Q%/1E]:&*'4K]
MR*",!:D@$`W[18V2(Z.'H_W,!]6OF#Z=>\7^`^(\5C*ZEIN<+[=W+M/XD)Z]
M3"P?SU]W?6;W,/>WP6N-T@:7[AL=S'>-IGV1_<W`Z@R02G_H@>"\M6OT47XP
M+/?B/GE&X7\N2FR"+UG(9?A9"U8<H,&N<BQR/H=<LG&V>2:"(G-!U6LS[0X]
M6Q5W!44-]CF$OQAWF\&I^]?CM=0.8]G=B5D-]<R##W7C0Z)CO[R:6-XYM:7/
MX"OZ<=Q_J7M.X'TH6%XR6.7OU;R7&UV<)QH^(]HR=[<^RMK>>(FN#WAD>3B1
MA6IE0R!G?)T55*^F]MF0\C6-7=P]6.JN_E91PJ^EIR9?'`XI-6Y3*NWC@_@F
MD0YQ]&VOK'==TV3N=W?DW*]++;8["`8-``:Q@#61L;Q)P8QHS)`7YZ]W]A[T
M>)O?*'9=L$E[WIW:[-7.))?)(XODFE>:T:WWI)7GX6ASCDLW/)#)T)Y</'>G
M<9<%2")<Q7B-<3MNOB*:9)5@D[#X&:O/08#F0FIQXW.Q@R'W^[V+4R@?M"$,
M;Y([A]WKOQW[\W7B!WQ8?]UK.01PVY)+'%OO1V]>,<;2)+@C^)(\#X20/T4\
M6>^6W?2;X5V'A#X;RL_W[W&)TUS=@`2,#O<EO*8D2S/:8;0&O8PQEP.MK2<"
MB"$U9IM)NW3E+#8[%*)HHI$!U+34Y-2KH$TR%#]N^DI.1>+``?IJJJ&]8CK[
M,>^TV^T+WF."P@CJ3@R..-@Q/!K6-:.@`!?F7''N.];DV*,37>[W<P``U22S
M2R.P`S>^1[STN<X\25?;+/$WD/@RL15RRKC&7J5:F'R,6VDUWT+(IMI-P@JY
M;1\LE#R4@O#O'**!Q3(Y*EUB0Q0^T`AKCN[7B5W'[X;A)M7=S<(KF_B87E@;
M(TE@(!<PO8T/:"14L)I4'(U7I/?CP/\`%7PWV>'?^^FSSV6T3R"-LA?%(&R.
M!<UD@BD>Z)S@TD"0-K0C,$*T="OELQA<J[D"C3#F!ME5DD)6&DVJAB&370-N
M=NX*40*YCWR(F1<H'W370.8AP$IA#73;ULVV]X=JGV3>(FS;;<QECVGD>(Y.
M::.:X8M<`1B%P_=?O/OG<SO!:]Z.[D[[;>K*9LD4C32A&;7"HU,<*M>P^Z]A
M+7`@D+T+>8USN##_`)3&3N5M/=%@[AD[$T#3<:E26V6A\E9E[=+$69M^L7-,
M,[DWJ8@/4`QH&]6OR7[\[-+W0WG<-@F=JFL[E\0=Q<`[W'_TFEKO.OZ$_#'O
M-!XA]V-G[V6PT6^Y645PYE:Z'%M98_Z$@='YE^8@0@)D(0!,($*!0$YA,<=@
MVW,8VYC&'UB/B(Z\O7M2]UO\*KQG8T[C?G'EI+1Q/WHS9D(<4U"062`%VN-\
M4D0<S96:AB]16\_D"86*OTCL<8=+?]`-=)LEN.S=.?B)H.H?IKZ`N3[P7),[
M+9IP:VIZS]P]J]6/='Y#^;6]T!<]VCN:Q*>;+Y7O_BD4[`U%<YJ#"L3A^_6R
MZ2LHA1OWZEI]&R5IE7THR*;*V2MLHQ1L9L94ZJQUBF`2@!/`1UK[W;OG"WWM
M('17GT]*V.W[D;%SW%NLN`&=./45`K%O\++P!J7PR^3\F\C\S.TA3.NV4M%7
MQK`N#D$#&*+"HUM>;(@<0\2A)]6P_I>O6,S8X`/?+B[U>JA]:RI.\-V[^&V-
MHZB3ZS3U+(IYJ_F2TGRPN,;6WM(Z-M&9;J16A\>,:2#E06<K-Q$8W3>6NSE1
M4(^_<3'\>H@N_,0Q5'CA5NS(<IW`J)Y-_<LLH</XAR'EY>D+%VZTEW"?34B(
M8N/V#I/#TK\U'.&=<U<I<L3N7\Y7JSY7RM=9`A'4U+G6?.S&=.`3C:U5H5H0
M6L'!-%%2H1\3'(I-T0Z2)IB81$W(R223/UR$EY\J!=Q%%%!&(X@&QCRJ?O*R
M.V3R(/,_J6`9/D5/\?VC&KPE6<7>;H87FM.,SQ%39,32C^6?XT;N%)%->.C"
M&<.(\JQY5%(ANIJ!RF(&4[;KMD?:N;1M/+H\U:UPI58+=WV]TW8-?[Q-*T]V
MO7]N2Q;8QR=?\-Y`IF7<2VV6H^1Z!-L;12KA`NCM9&'EV*A5D%DU$S`5RQ=$
MW2=-E.I!VV4.BJ4Z9S%'#:YS'![#1P6P>QDC#'(*L(H0OT]Z%STC<N^4[(<_
M2(M(-ZYXDY&R38(UH?I:0.3:;4;)"6:&9[F$2-FV1855-J41Z@1.D`^(Z[%D
M^O;_`)G(Z*^C,>HCUK@WV[X]Q^2J3^\`\Q(IZBORSTC+'23.X.*C@Y"J.%##
MN91<X=:RAA'Q$QU1$1'VCKC%WZF9BN=Y=9[P@APAX]4')V1:"UR%.9VOF/</
M5.RVF1NUMDHZ`K4)8LCH5YHZ[\%3(JO)-X=!WTLT72ZZX`9P<@IY$?;2L["%
MI=0DF@J<:9]&`6+)\M#+\U.YK74#07$"@%3ATFN*C-?L>W[%5NF:!E"DVS'-
MZKJZ;:?IMXK\I5[-#K*HIN$"2,+,-FC]L#ALJ51(QB="J9@.03%$!U$]CXW%
MD@+7C@<"IV2,E:'QN#F'(@U"O;PHR-<,2<Q>+.1:#)/8JVUO/^)QC7+!91%=
MPVF+M"P,U$*]L0%=A/P<FY9.43;D6;N#D,`@.VI+=Q;<,<W/4/;1173&R6TC
M'_#H/J%?4OUQW9@2=.4B!L1-PLF0.K?8I%#%*'H]0!KN6-U,#CF0%YSVCN:X
M_='Y#^;5V@)VCN:=T?D/YM-`3M'<T[H_(?S::`G:.YIW1^0_FTT!.T=S3NC\
MA_-IH"=H[FG='Y#JNA.T/-<?O![1^?\`/J_1U*/6$[P>T?G_`#Z:.I-83O![
M1^?\^FCJ36$[P>T?G_/IHZDUA.\'M'Y_SZ:.I-83O![1^?\`/IHZDUA.\'M'
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MUP^C30>2:PG>#]</HTT'DFL+<(J`[_:`?1Z/S:H6D*H=7);G6'M^C\VK?>5U
M2K)<D<JDPM@?*N32JD3?U>H22D%UCT]RS2@$AJTF7?TF^_)%`VWIZ2CKKNX7
M=UW>SOEMO=\@F&XNF"3_`*)G[R7_`+MKAYUYYXL]]!X?>&N]=\`X-N+.PD,-
M>-Q)2*W'_;/8>H%>,Y159=11=PJ==PNH=9PNJ83JK+JG%1990YA$QU%5#"8P
MCXB(Z_51K6L:&,`#`*`#(`8`#H`7\_\`)))+(Z64ETKB222222:DDG$DG,E5
MYB[&ELS!?ZKC:DL!?V.W2[>)8@8#`U:%4`ZSR3D%2@/8C8E@BJY<'_D(I&$-
MQV`=-WBW_;>Z^RW._;N_18VL1>[FZF#6-'%SW$,:.+B%TW<KN?O??[O19=T>
M[T1EW6^G;&S\K0:E\CS^%D;`Z1YX,:30Y+T"<E+-4_+PX>0^(,1N0;7^^E?5
MR+L!2D0FY"4<,T!R#D]Z)?VA'J#59-JP#<0:'<-R$^R@.OBCN#8;IXX^*,O>
M?O,W5LMEIE?'G&U@<?EK1O#22"^3\X;(3B]?J)XN;QL?TK>`T'<7N.[1WFW(
M/@CFP$SY','SNX/QKJ:TMCAQ/9%\36X1%0:\HK%[*VY\M.2)1`KE'$U0%S$=
MXHJ`G:KDX7A63WJ-ONNTAD)`Q1_2!0Y3>D->O_4WWBFVSN9;;#;$M?N5U1],
M*PP`/<WJ+S$#T`A?.'T+=SK???$R][W7C0]NR6.J.HK2YNB8F/ZVQ"<CB"05
MF5Y/\/,1\K6,'^_9IN!LU9(NW@;G5E6:,TVCG2G?<P[Y"0:/&$K$G<_M2IJ$
M!1%43&34)UG`WRMX>^*7>?PWFF_P?L9MON"#)!,'&,N`H'M+7-<Q],"0:.%`
MYIH*??GC'X#=R/&NUMQWE^8MMVM`1#=6Y8)6L<:NB>'M<R2,N]X-(#FN)+'-
MU.#H>USR>,!1K])U9,DY3M3)-0#FBT?W<K:+@@#OVG#QI&R#WH$/`12,D;V"
M&O4;_P"J/OK/`8["PVZVE(^,]K*1TAI<UOI!"\'VKZ"_#&TNFS[KNN\WD#37
MLQV$`=T.<UDCJ<]):>1"R.XFPGB;!L&-<Q-18.G,5RIE?+Q[<Z\W,G3V`BDW
M/O3.9F85W\0!=8Y2C^B4H>&O">\O>[O-WOO/GN\MY-=3"ND.($;*\(XVTC8/
MYK03Q)7UCW(\/.Y/ASMW^%=R-MMK"V<`'EC2Z66F1FF>72RGEK>0/P@+&%YC
MW/!G38F=X]8;FR.+O+(+Q.2K?%.`,G3(IP04GU3B'J!A`;7)HG%-ZJF;_NY`
MQDP$'!Q[/T)X$>#DVZW,/??O5"6[1&0^U@>,9WC%LSVG_,L.+`1^]<`[X![_
M`,=_5E]2MOW=L+GPN[A7(?WCG8Z._N8W86L;A1]M&\?_`*0\5;*X']RPE@/:
MN/9X3<583N&7,BT'%U8;[6.^.&QT2*)',G`UU0GQ+BS3`%V%LP:0Z2KWI'8Q
MFY2&#^^3`?K7O'WMVONSL5[WBW!W^@632#0XR2C`1,YN+R(ZY!Q(_"ZGYW]R
MO#G?^_7>W;.YNTM__+;FYIH02(8"-1N)?RL$0=+3,QAI'QMK[",8X]K&(L?5
M#&=-;_"UNEPC6%C@,4`7=F1`5'LJ]$H;*2,P_55=.#?REE3>K;7Y=]X-]W'O
M-O=UO^Z.U7]W*9'<A7!K&\FL:`QH_*T+]X^Y_=7:.XW=>Q[H[`S1M.WV[8F8
M"KJ8OD?3-\KRZ1YXN<5776'M^C\VM/[RZ2I3K#V_1^;3WDJ5H4<(HIJ+N%TF
M[=!)1=PX7,":#=NB0RJ[A90VQ4T4$B"8YA\"E`1'56MD>X,8"YY(``Q))P``
MXDG`=*M=(R-ADE<&1-!+G'`-:!4N)X``$D\`%Y`.8N=UN17(&\9!0744K"+L
M*O0T#B/2VIE>46:12I">@AYA459!4/3W79@]6OU`\+>YS>XW<FSV1X`W`M[:
MX/.>2A>/Z`I&.A@7X0^/WB6_Q6\4-Q[SQ.)V9C_E[,'\-K`2V,@<#*=4SA^:
M0K,MY1V%@IN'++F66:]J;RS+?=L$HJ0052HU2<+M4U$NH-RI35D,Y..W@<C1
M(WB&VOE;ZFN]AW7O3;]U;5U;3;(M4E,C<3`$@],<6@=!>X+[^^AGP]_W?[@7
M??Z]9IW'?)]$)(-1:6SG-!%<A+/VA-/B$49Q%%`;S;VG8Y8H.0#8)+$]&<[[
M;=0H.K#'B/H\=@9@&O:/IFEU^&KF'_-[E<#TB)W_`"E\Q?7-#V7C:R2G\79+
M1W71TT?_`"%83@%+_<O,C`3H3]!75R7ACCOL`EGH"9AP(/M`QWH!KL_&JV^:
M\+-ZC`J6VH?_`-G(Q_\`R5YG]+][\AX^=V9R:!U\Z+_MH98J>EZ]8MFKT5<J
MW8J?.)D7A;7!2]:ED3EZBGCIR/<1CS<!#81*@Y$0]A@`=?FOM]]=;5?P;I:$
MB[MIF2L/ZT;@]OK"_;K=]JL]_P!HNMBW(!VWWMM+;R@\8YF.C=ZG'SKQ1WFG
MRF/;K;J'-IF3EZ999NKR!3%$@F<PDBXCSJ@4?'H<=@%"CZRF`=?K/L^Z6^^;
M3:[S:&MM=V\<K>J1H=3S5H>D+^>;O/L-YW5[QW_=K<`1?6%Y-;OPI[T3W,)'
M0:5',$%4L)AV`!$PE*(B4NXB`";I`W27Q^T?I#?;Q'8-;&G%:2I(#<:5RZ_O
MP7ID\MKB$E@:B#EK(C`C3*^0XE-4J#Y$"N,?4-P";U"),"@=36:FTB$=20^!
MDDRI-QV$BO5\`>/7B>_OEO/^[6Q/+N[=C)2K3A<W`JTOPSCC)+(N!.I_%M/V
M"^DKP(9X9]VO]]N],09WVW6`&CQ[UE9NH\1&N+990!)/D6M#(C0MDK@6Y09?
M>9VSWDS)BZZBK"9L;ME6DCG,<C.HPAAB*PU1`?!,GW2T35,`;`*JIS>D1'7V
M9X>=UXNYW<S;]@8`)XH&NE-/BFD]^4GG[[B!^J`."_,SQG[^3^)7B;N_>Z1Q
M=:SW3F6XJ2&VT7[NW:`<OW36D@?B+CQ4XO*/Q"RNF=;)E"8:D<L,/UU%Q"@L
MGUI$NEL5<QL2[+U`)17BX=H_63'TD6%,X;"`#KR#ZF>\\VT]S[?N]:N+9]TG
M(DH<>PA`<\=3WNC:>;=0XKZ-^ACN+;]X/$>\[Y7S`^VV*U!BJ*@75R71QNY5
MCB;,X<6OT.&("RF>9N=D/"_*(.P*8PRN/_@>H`W+(?OO"=HZ8B'@<$.Z'AX]
M(CKYU^GT3?\`NOMW9Y=G<ZOYOR\E?71?9_UA.@_X?=Z[<5/;66CH?\W#0C^C
MJ\U5Y5=?HZOQ376>=+F%_'>61Y;6!2NU"?OK?\V94EFG6(=^$QO,2]4J_<+O
M]I$LC?W9B;^'4CX>C7Y;?4N]C?%3<XHB-+I(7$?K"VBK[5^\GT4-GD\`]CGN
M/B;#<M;_`#3>W%/4%Y:#F`A3',.Q2%$QA]@%`1$?Q`&OGM?7"_4Q\HC%9,+>
M69PLI!VX-9!SA&OWV;3[?0<TWE1R^R5(*+!L`BMU6HI1$?'8@>S7>;=$Z*RC
M:?R@^G'VE><;I-VNX3/X:R/1A]BP!>:[Y]W,?B1SNS%QRX[%PFKCG%C&@PZR
MEXQP[M,^>Y2M*AK/;.[+H6F(*+5N\G2()H]G]EV1^T.XZTVX;I<07;HHBW0`
M.?*O`]*WNU[-:W-DR>XU]HZN1&52!PZ%CR)_%`>9H7?JC>+RGAZ#8;FR[>_[
M&0RZP_\`&KS]7]K_`"EG?[O6'.3TC[ED0\K3ST_,#YQ<Z<%\:;U7^/*-#NSF
MVR5]>U/&=CBK*VJU/I4]97BT1(N+]),X]XX?QS9`%#ME2%[PAT[B&V99;I>7
M%RV)V@,-2<^`)_,L#<MGLK.R?<,+]8I2I%*D@<EA`\\/F`^Y?^8;F*182QW^
M,<&23S`.)FJ:PJ1Q(:@R+EE;[`T3`>UW[A?@D'9U0\5&Q6Q1$03+MK-SG,]X
MX_A::#S9^OU`+;[/:_*V+`?XCQJ/GR'F%%7/D!8BQ/D3S#Z9?\W6K']6Q]QT
MJLUF=(<C6BM5>&FLA,'#&OXUCVZEGD(]G).XJQ3/WR")!.8HQ93B&P;ZKM;(
MWW0=*0&-%<>?#[^L*S>Y966)9"'&20Z<`3AF<O1YU^@=8^6_%*-@[&^E.2O'
MMRU804Z]DFA<TXS=N'35K%NW#QJ5HG9U%G:SE`AB`D4ICJ&-T@`B.VNO==6X
M;4O;I\O+H7$-MKHN`$;ZU_*?N7Y)3Q=NZ>OG3-+X=F[?O73-OT]'89N72R[5
M#H\.CLMU"EV]6VVN`.>&2].&`H<UZQJ1EEWC/^%&M[51XHF\R?FRYX6@BF4,
M4QHZX9[;2DVU;[^(HF@X&4$Q0\-CG]^MVV0LV4@\30>=QKZJKF7Q]IWE')K`
MX^9N'KHO)AK2+IE^DC_#Y<98'CMY;.)KBG%-V>0>3A7><K]-=@I)20BYEZ\C
M\:0CEST]\\7`T=FV601$>V1P_<*`'4J81[+9[<16@?3WW8GSY>JGK7`[Y<NG
MW!S*_NX_='FS]:\S'\3_`&N!L'F5Q,)%MFQ9>D<:<40EK?I%*#A_*RTM=;5&
MIO3E`#*JQU<FV:9!,(F*D8I?0``&DWLM-YI:*$-QZZDU\^:Z'NZUPV\N<<#(
M:>@#VK&EY5F+#YF\R#A70!0%PT<\@*1:98G2)REA,<NE<C3!U``!V3!A5#@(
M^CQUA6+#)>1M&/O5]&/V+8;E+V-A,_CH(].'VK]5!1?N*'4,/VE#F.;P]9S"
M8?5[1UWP!&`R7FU2M'6'M^C\VGO)4IUA[?H_-I[R5*=8>WZ/S:>\E2G6'M^C
M\VGO)4IUA[?H_-I[R5*=8>WZ/S:4<E2N/W@_7#Z-7Z#R5FL)W@_7#Z--!Y)K
M"=X/UP^C30>2:PG>#]</HTT'DFL)W@_7#Z--!Y)K"=X/UP^C30>2:PG>#]</
MHTT'DFL)W@_7#Z--!Y)K"^@L'ZQ1^;_1IH/)-87WNA[2_+\>J:#TIJ;S3NA[
M2_+\>F@]*:F\T[H>TOR_'IH/2FIO-.Z'M+\OQZ:#TIJ;S3NA[2_+\>F@]*:F
M\UU(J^(^`>D?7K-#,%!K'0OG=]P?/IH5-8Z$[ON#Y]-":QT)W?<'SZ:$UCH3
MN^X/GTT)K'0G=]P?/IH36.A:NX7W_1JF@J[6$[A??]&F@IK"=POO^C304UA?
M!5#V?..JZ%36.A?.[[@^?30J:QT)W?<'SZ:$UCH3N^X/GTT)K'0G=]P?/IH3
M6.A.[[@^?30FL="W4U1\=A`/F'\NK7,'%7!P/%;G=-^M^3ZM6:!R5:CFL47F
M\7I:%P%2*.@OT'OV1D7#U,!V%6)IL4XDCD,`>)D_O>29F]FY`U](_3'LS+KO
MI=[N]N%E8D-/)\[PT?L->/.OB3Z[.\;]N\,-O[O0NH_<]U!>.<5K&YY'_:R1
M'S+SM,6+V4?,HR-:K/I&2=MH^/9-B"HY>/GJY&S1HW3+]I1=RX5*0A0])C`&
MON2::*WA?<3N#((VESG'`-:T5<2>0`)*_*.UM;B^NH[*S8Z2[FD:QC&BKGO>
M0UK6CB7.(`',KT/>6+QWC:/"6?,#Y)N\E7KF1Q]4I,H$5369PSLJ&0+'&J[?
M::3-J:#%LU2_IQ\3UAX.3[_#WU!=^+C>+NW[L1%S;9C6W,S,11SVUMHG#\S(
M7=J\'*2:G^;"_5KZ//"BR[M[;>=^KD,DO9'R65M)@0YL3@+V>,_EEN6FWB<,
MX;;5_G7+&WYFF4W>1N5-K@RN3*P>*F,?CZ(0`_4B1XU1+*69R0@#T@LXGY!5
M(X^D2MR`/Z(:]Y^G_NY%L7AS;79:!=[D]UR\TQTDZ(AU"-H(Z7'FOD7ZP^^D
M_>KQIO=L:\G;=EC991"M6ZVCM+AU.9F>]I/$,:."DEY.EZB8N]YCQZ[<HMY>
MW5NMV."34,4JDA^Z#R50F&C?J_O%D&<^1QT!X]I)0VVQ1'7!_5)L]S<[-M>]
MQ-+K6UGEBD/Y>V#"QQY`NC+:\RT<5ZW]`O>.PM.\F_\`=:X>UM_?6D$\(.!?
M\JZ42M',ALX?3/2UQR!6?;NF_6_)]6OB[0.2_3RHYKJ)^RP=3A9"R6F=BJW7
MHE`SF3G)Q^UC(I@@0!$5'+UV=)!/<`^R7?J./@4!'8-95EM]WN5VRPVZ&2>^
ME-&1QM+WN/0UM2?8.*P=TW7:]DV^7=]YN8+3:H&ZI)IGMCC8!Q<]Q`'0*U)P
M`)6#3F!YHSJ>;2N-N,SM]%Q3@JS"<RXLBJPF)%N<#).&M#9+%3=0K1<@B49)
M<I'ABC^P31\%1^OO##Z=XK.2/?N_[627+:.CL@0YC3F#<.%0\C/LFDL!^-S_
M`(1^;WCS]9DFXQ3]TO!]\D-FX%DVYD%DKVG!S;-AHZ)IR[=X$I%>S;'@\XLZ
MI4F\973Y;OK4R]9-(/&%,@WQE?B<HW%J8JCIJF'4#I:HUU98BTX]*.QS&(Q3
M/\0X$R/T5N6Y/N+X=V=E=3<-#73R-I2T@.1/`32@%MO'P`,SAH91WQCL6Q1V
M>UGOYWI87;097,M(7UU;C=-Q<T?B-K`2'7<PP)+;=CNUEU1^@_R].+\IB&I2
M69,FMQ/FK+K8CYZ1Z@FF\I]0>*)OV,#V0(4K"3ES%3<ODDRD*W3(@U`"]DP#
M\2>-_B%;]Y]RC[J]WS3NGMCM+=));/.T%KI*_B8S%L9).HE\E3K"_4SZ6?!N
M[[B['-W^[Y-KXA[ZT/?K`#[6U<0]D-*#1)+[LDK0`&-$4-!H<#D?[IOUOR?5
MKPC0.2^L:CFG=-^M^3ZM-`Y)4<T[IOUOR?5IH')*CFL>/F6Y]/A_CU(56&?B
MWN>8U'5*BNRIT.F58!`BMUER"02J)A]V+D8$.`@(*/\`</$HZ]P\`NY8[T=]
MV;C=,U;5M0$[ZC!TM:0,_K@R$<HZ<5\K?5YXFCN%X5R[-82:>\&_EUI%0T<R
MWH#=RC$'^&YL((R,U1\*\P&P;=/B4NVWV=@$`]'V=_`!`/1K]"NGBOQJZ\EF
MHI'FW5['U,J=$KG'%=K`TZNQ%:B4`R4B`@RB&2+--53:F;"NY%(551_E*',/
MKU\G;O\`3/?;WNMSO%_OK77MU.^5Y^5/Q/<7$#]_D*T'(`!?H;W=^N7:.[&P
M67=O:NZ;V;;86L4$0_Q`?!$P,!/^B?$ZFIQXN)/%0'YA<FD>5F283(:5*/1C
MQ--8U)6,/.EL`NQ82TQ)$?@[+%Q/:`Q97M]OMFVZ-^KQV#V?PN\/W^'&PS;&
MZ[%X);MTP<(^SIJ8QFG3K?7X*UJ,Z4P7S#X]^,,7C7WNMN],>W';3!M[+8QF
M;M]6B660/U=G%3"33ITG*M<:"W7&R9&O<A\&30'[81^6\?J'.([`5)2SQK=8
M1'V=I8=_=K>]_;47W<?>+0BNO;+D><1.(]87*^$.X':O%;NW?@T$>^61)Z#<
M1@^HE>R8YC@J=,#!N"AB_P`D`\#"'I'8`#PU^6(:W2#3@OW\<!K+0<:TS7DN
MYY7''E]Y4Y2LV-'!GT&Z?1K*4E4^V,=,VJ'BVL18I6&,G_>Q3IZR^PJ/]^H4
MZI?L'*(_I7X-;7O>S>'.W;?O[=%VUCG,8:ZF0O>7Q,?7)X:[$?A!#3B"OPY^
MIO?NZG>7QJWG=^Z#C)MSY(V22"G9RW$4;8IY(J9QN>S!WXW:GCW7!61PA;(.
MB9DQ;<K-%,)NNUJ^UB7G(R30*Y9+Q366;&>J+-S[IJF9H"9=,#`)>XD7<!#<
M-=;WOVV\WGNMN.U;?(^*^N+.5D;F&C@\L.D`YC4?=-,:$T7G7AMOFV]VO$#9
M=_WF&*XVFTW.WEFCD&IAC;(TO)&1+6U<T'#4!7!>K?EED%3'W&G-UV8/0%RU
MQY--8=XF<!!1_:4DZ[%.D3E\3"*\T14H@/CMOK\W_#79&[WW^VC:9F?NW7T9
M>WDV$F5X/FC(*_;;QN[S?[K^$7>+O#;2#MF;5*V)X/X[D"")P/\`.F#@5X]2
MATE*4/04``/Q!MK]0SB:K\$UZ-?*(J1H3CW=+@HF!%KSDQZDBH)0`RD;4H>/
MC4-A$-Q(61?NP]F^^OA3ZF]S%YWWM-L::LL]O:2.3YGN<?V6L7ZS_0IL/^'>
M%=_OL@`DW'=WAIYQVT3&-_[R25;?F\78T/@"D4I)<`7O62FSEPD`@!E(NGQ#
MU^L(E#Q$@2<FT]VX:N^F/:!==];O=G#W+.P(!Y/G>UH_88]6?79WA_P_PNV_
MN_$X=KN6[M<X5SCM8GN=_P!Y+$O.<80*4QA]!0$1_``;Z^Z1B:+\FU%7S^VC
M^HW;R_\`%+PIT?W&X-5V><-3;@5&:R7DBY6*9W(.VRO<:)$./I^P`>K7Y$>-
M>Z,WGQ*W7<(S6)]W*&GFV-W9-/\`5C"_HF^FO8']V?!;8-GE;IN8]M@=(.3Y
MF"=XZPZ4A>?EV3N-7*>^W<053W]G60Q=_P`6^O*3DO=U^O\`X@BVE<Q-B*NM
M`!*.@,78VA&Q$RE`",HFF03!$I"^``!4&X;!KTZ",-A:T#(+R29X=*YQ.)<?
M:O&3S`_AZO,9Y,<J^17()K;N,I6F9,R7F]0C&3R;;T)1K79J<<?NNP?I$QLX
M;H/6%<3:HJID54(0Y!*4Q@`!'E;K8KZ:=\S3&&N<2,3EP_#R786G>';;:UCM
MR)*L8`<!G3'\7->87,.,IK"F6<EX=LLG7IJR8KO-FQ[8I6IR"\K6'L]4I5S"
M3"D#)NF4<XD(TDBS4(FJ=!$3]&_2&N?EC=#*Z)U"YI(-,JA=-#*V>)LS00U[
M017.AQQ6<G^'C:#1LQ<V^5JB0`3BMP3R[;(IV<"]#:T61,JL5TJ&#8BRD=4'
MQ0]?28?;K:;0VDDLY_S<=?/75[&E:7?R'PPVO][.T>;R(7GQ,\>2)U)*164<
MR,DJK(R+E4PG5<OWZAG;URJ<PB8RJ[I8YS"/B(B.M14G$YK?4`P&04F<)<(.
M6W**M2UNX_\`&K*F;*G79T:W,S]&JIIZ)B;$$>UDS0[IR*J9$I$L:^16$@;B
M":I1'TZGBM;B<5A8YPZ/+I"QI[VTM7!EQ*QCR*T)I@KRAY1'F6`("'`7D0`@
M("`ACK80$/$!#_>/`0'4O^&WW]R_T!0_XMMO]_'Z5R__``EO,Z_^1'DG_P"X
M2O\`]-Z?X=?_`-T]/\5VS^_C]*R3>8M6\A<6O)<\L#B#D^LS./<FVW+6>LX9
M$H%A;@PL,#]S3EE1A&DXP`YQ;NNWDI!3I$1V$`]8:S;UC[?;8()`6O<22..!
M<?\`E!:[;GQW6\7-W$0Z,-:T$98@9?U5YT4F+N360BX\AE9"470C&"1`$QU7
MT@J1FS2(4/$QU'*Q2@'K$=::A.`S*Z`D`5.07Z\N#L?(8CPMAK$D>F5%MC/%
M6.<>H(D*4I2FJ-0AH!0`#;P$[AB8P^\=>FP0]E"V,_A:!Z%Y-/*)9GRD_$XG
MTFJ_,[\X+*@9D\SCFA<470/(]AF65Q]#K%/UI_=.*HV+QNV(D8/#M=VL*&#;
MPW,.N`W-YDOY7'@ZGHP^Q>D;1%V.V0LXEE?ZV/VJ>?\`#*XQ&Z^9,M>UF_=9
M84P%DVW`L8@&(VF;8K!8WB#;B`@54S6T/1+Z_L#[-9FP1=I?ZOR,)])`]E5@
M]Y91'MVBN+Y`/14_8%^@_P!TWZWY/JUW&@<EP%1S3NF_6_)]6F@<DJ.:=TWZ
MWY/JTT#DE1S3NF_6_)]6F@<DJ.:=TWZWY/JTT#DE1S3NF_6_)]6F@<DJ.:^=
MTWZWY/JU70.25'-<?N^X/GU)H5FL="=WW!\^FA-8Z$[ON#Y]-":QT)W?<'SZ
M:$UCH3N^X/GTT)K'0G=]P?/IH36.A.[[@^?30FL="=WW!\^FA-8Z%]!4/9\P
MZ:%76.A?>X7W_1JF@JNL)W"^_P"C304UA.X7W_1IH*:PG<+[_HTT%-83N%]_
MT::"FL+J!<^(_H^D?;]>L@`T6!J:OGQ/]'Z?KU6A34U/B?Z/T_7I0IJ:GQ/]
M'Z?KTH4U-3XG^C]/UZ4*:FI\3_1^GZ]*%-35K^(]WTZI@JU'-/B/=].F"5'-
M/B/=].F"5'-:1<?T?QC^?2G)4+@OGQ/]'Z?KU6A34U/B?Z/T_7I0IJ:GQ/\`
M1^GZ]*%-34^)_H_3]>E"FIJ?$_T?I^O2A34U;R;@!`=Q*'CZMQ^O5I:KVO(^
M%;G?+^L'S#JFD*[M'="P6^<?)JJV#`,2!Q^'1@;_`"G0&_2*[J3KC/J_""3/
M;\>OL'Z6H&MLMZN?QF:V9Y@R5WM<OS9^OR[E?N?=>R)_=-MKV2G2Z2!OL8H!
M\=:B\9UO*V<P;F46QO$Q5/QV`EW!WF?*KL:K3U6_4`D4<5.-</9@OI$CALW-
MKVCOSN<4M_MO<_51M_*^>YZ+&S;VTX/(3/$<)YM<\+YC\(^[]Q!M.]^).@N?
MM,$=K8_K;IN+OE[9S:X%UM&9KH9Z9(XBO4MB^F1>+L<T+',44I&%'JD%6R;%
M$!66C&**3]T<0#[2SZ0!58YO28Z@B/B.OSM[P[M/WAWV\WVY-9KNYDE/0'N)
M:.IK:-'0`OV@[G=W[?N;W4VSNI9@"VVZRA@'28V`/<>E[]3R>)<2O*%RRC9&
M)Y.Y\92I5"O?\UKD\'N`(&4:R<NO)QRP;^E->.>)'(/H$A@$-?I%X:W$%SX?
M;++;$&+_``V!N'-C`QPZPYI!Z0OQ#\<[.\L/&/O/;WX(N/\`&KI^/%LDKI&'
MJ<QS2.@A6;J]IL=)L,1;*A-R5;LT"\(_AIR'=*,Y&.=I@8H+-W"8@8.I,YB'
M*.Y%"&$I@$HB`]5N.W6.[6,NV[G#'/M\S=+XW@.:YO(@].(.8(!%"%Y]LN];
MOW<W:#?=AN9K3>+60/BFB<6/8X<6N',$@C(@D$$$A3V8^:7RZ9Q)(U6P4:1<
MII`D$[(4**/,'$"](+*_"J-(I5?UB86OB/I#7C,WT[>&<MR9VPWD<9->S;</
MT=0J"\#^FOIZV^M/QTM[$6;[G;II@VG;/LXNUZSITQD])C42,L9]S%G!ZF_R
MMD*P6XK90564<]<D:0$:<=PZHVO1R;.$8G`!VZTT`4$/28=>F=V^Y?=;NC$8
M>[EC#;%PHYS072._G2.+I'=1=3H7A7?CQ0[_`/B/<BY[Z[K=7P8:LC<X-AC.
M/\.",-B8:&E6L!/$E7PQUQLBJG1V^?>3YI.F8I$W72J`BI]V9)SA+$("[6%K
MC1<H.:]55MRF>S*Q`[;41,@41,137(;YW]N-RW=W<OP][.Z[R?Y^Y/OVM@S(
MOE<,)9AB(X&G%^#R*$+TGNGX066Q=VV^*'C+VVW]R:UM+('L[[=Y`*MB@:?>
MAMS@9;IX]V,UC!+FN&0/AEQWGL_7B*Y59QKT="46OI,V6`\3M&!F=781$*J<
M8!Q&PJQ1*A2JVH(J,^X`JS$D)WBXG#J,MXIXJ=^;+N7M$GASW1G?-O$Y<[<;
MQSM4KGR#]X'2#.>48/IA#%IB8&X!GU+X`>%>Z>*'>.#QK\1;2&V[M6H:S9=M
M:S1;LBA)[%T<1^&U@-71:JNN9]4\A=[SI<U`N0,(F,?<QA$1$=Q$1$=Q$1]8
MB.OE`,`%!DOT),KR:G-?.^7]8/F'32%3M'="=\OZP?,.FD)VCNA?2K`8P%`P
M;F$`#?<`W$=O$1\`#0@`550]Y-!2I7E8Y[YY#//(>S/XIZ+JE4/KH-*Z#B+9
MPQAG*P3$VB7<2#]_3QEUBG#Q,V*B'\D-?HSX,]S?]S>X]O#<,T[M>?Z1/S#G
M@:(S_P!''I:1P=JYK\4OJ>\3?_<SQ4NY[.37W>VRMG:4/NN9$X]K*.![:8O>
M'<8^S'`*RF,^.^;LR1<G-XNQK8[K$PT@G%2<A#IL_AVDDHV(\*R,=V[:BHO\
M*H500(!NDIBB.VX;]9W@[\]T>ZMQ':=XK^"TN96:V->75<T'3JP!PJ",:5(-
M,EYWW.\)O$;Q!L9MS[F;1=;A86\HBD?$&Z6R%H=H]YS:NTD$@5H"*TJ%<?\`
MX&>77_Z@[U_Z*)_]::T'_O#X8_\`G5GZ7_Y"Z[_AK\=?_3.X^B/_`"U:')N%
MLK89<P[/*=%G:.ZL#=V[A49M)NF:2;,%DD'BS;X=PX*8C=9<A3;B`[F#74=W
M^]G=OO7'++W<O(;R.!S6R&,DZ2X$M!J!F`:=2X+OEX==]_#V6W@[Z;;<;=-=
M-<Z(2@#M&L(#RVA/PD@'K5&U:2&&M%9F"CTFB;'!28&#PZ182K1V`[^K;LZV
MNY6XN]NN+4Y2P2,_K,(^U:#8KP[=O=GN`P,%W#)_4D:[[%Z%/,JY?ABZG*8;
MQ]*]O(^2(HR]ADF*W2YIE#E"'*H)%4Q`[:=MB1C(M]MCHLNXMX&.B;7Q'X">
M&'^\6Z#O3O4==BL)*1L<,)[AF6!SCA-'.X.DTMQ`>%^J/U=^/)[E;`>X/=B;
M3WLW:`F:1AHZULY`0:$8MFN15K*8LBUOJ"Z,KSY0--L]EB[7,0,(]DHBBPB-
MAMC]LENU@H9Q*,85L[>JB(%("\E())D(&YS;F,`=)#B7[9O=UV^PN+:UO9F1
MW-Y,8H6DXR/#'2%K1T-:23D,!6I%?RRVSN]O6\V5]N.UVTLUCMMN)[E[1[L,
M3I&0M<\],DC6@8DXFE&N(ID0`P"4?0("`_@$-AUL,L5IEG8R1EIQEKRF$IP[
MHSF;A/W"Q];#";K7%Y3;O!Q8+.1`=^I_$),7(B/I%;?7QYL/=J/NU]2ILPT-
MM)OF;F'EIGMY'T'\UYD;_17Z6=[^_$_?CZ'!N;GE]_;BRL;DUJ[5:WD,=7=+
MXA#(?YZP4:^PU^::]4WEXLV<7PYPT1J8G^_,K3*NA+X]3U]=+"9?J$/Y903*
M4?7]G7YS>-\TEQXI;J9?P/A8/YK8(J??YU^V'TK6T5CX!]WV6]*21W,COYS[
MN>M>D4`\RQ8>;3D]M:\XU+'$>Y(NVQ=4.J5*F?J(E9KFLC+.VYR@.P+-H-I'
M]6_B45!#VZ^B_IJ[OOV[NA<[],TA^XW7N5XQ0`L!ZC(Z2G.E5\5?7+WRBWKQ
M%L.Z5L\.BV:QK)0Y7%V1*YI',0M@Z14A01X[8K=YJS;C;&K=(ZC:Q69C]^*$
M*8Q6E8C3_>EE>*B4!Z"(0K-;81V`3B4/2(:]B[\]XXNZ?=*_W^0@206[NSZ9
M7>Y$T=<CF^:IX+YH\)NY4_B'XC;1W1B:70W5XSMC0T;;Q_O+AQY:8FOI7"M!
MQ5C?XJO'KB+Y)\4\H-6G:@;9@BRX_153()6Z,ECJ^.98L>`[`4IDX>^-Q*7]
M0OL#7Y#=Z&/^:CF?4ES34\R#4GSER_HK[H2,^4EMV`-:Q[=+1P;IH`.@::+R
MM.$S+(+)%-TF5243*;]4QR"4IO\`DB.^N777#-?JG>73RLQUS$X@82RKCNPL
M)J09X[IM2R7`-G*2\Y1,D5BN1T):JY9HY(QG48X&38J.&AU"E3>,EDETA,0^
M^O3=LN(KNT8]AJZE#T'B/+ACD0O)-S@GL;U\,HH-1+3P+2<"/+-<#S#N>^*O
M+VX]6G+=_FF`7Y_$RT9A+&XKD"S9'R*=BJ6#:Q\6(_%!6X9^HDZF)`Q0:LV:
M9@,853HIJ-RO8;"V,CR-9P:WF>5/;R5=LLKC<KD0QC]V#[SN#1QQY\AQ*_+5
MEY>5L,O+V&=>*24[8):3GIR16$15D)F:?+R<J^5$1$14>2#I10WO-KS0DN)<
M[XB:GSKU@-#0&MP:!0=0R7IO\J;'$K7_`"3/.3S/%H'3F+]39['D2Z(F(JJ0
M&.<:FE+$1$VWBGMD9P!MO0*8^S70[9"\;1=3MX@CS!I_RBN5W><'?;*W/PM(
M)ZW.P_LKS`!ML&WHV#;\'JUSJZM?H:?PV52BZOY7]8G6BS=5_D3..:;3-&2V
M,HBZC)F-I#)FX$/$%D(NJ(GZ1\0*J'MUWW=R.FW`_F<3ZZ>P!>;]YYGG=2S@
MUC1ZJ^TJ8/FH^8Q#^6UQQC<OI5F!R)D.X7V#HV.<:3DZ\KR%G4.!Y.XRRK^.
M:/Y!O'52MMS+**$1.3XIPV2,(=T-9>ZWXVZW$@&J1QH!6G7SX5X+#VBPDW2Z
M,-=,36DN<!6G(9\3ZJK!GC/^*7ON0KA3\?Q_`!G8KA>K-`TZLPU2ST_*ZEK%
M99-K#P\>U1DL6N1`SJ1>$*(B80(41,/@`CK21=Y7O>(Q!5[B`*.S)P'X5OYN
MZPBC=*;FD;0226<!C^90C_B@LIN;=SCQ#C!8Z*9L.\;JTI+1[5T+QI'VK)UE
MG;1+MTG`I(?$@G%1\<4JO;(*J8%-TEWV#![QRZ[UK,M+,>LG[@%G=U(R+!\Q
M_'*:=30`/758??+KQ67-G/3A]B]5O\2RLW(7&BTNB).LAH&LV!M<)\5"["`I
M!"U]?JW\.G?6JV^/MKZ*,X@R"O4,3Z@MUN<WR^W3S#,1NIUD4'K*_5!M=QCZ
MA`6J\RJJ:,;4H&Q7*24/]E-)A7(M[//3F$?`"D;L3".O37AD<1+O@`]2\E8Z
M1[PP4U$@>G!?D*6^UO[[;[=?)10ZTG>;79;I(JJ&$RBCZUS;Z?=F.8PB83"X
MD#;[Z\I>\R/,AS<2?2:KV5C!&QL8R:`/0*+V"_PHF-"MX/FCFYPAL9]+XFQ!
M$NC$]*46RLEYL**9]O1W):,$X!ZP+OZM=9W7A![68YU`'F!K[0N+[WW!:Z"!
MM,G./J`]A7K[[Y?U@^8===I"XSM'="=\OZP?,.FD)VCNA.^7]8/F'32$[1W0
MG?+^L'S#II"=H[H3OE_6#YATTA.T=T)WR_K!\PZ:0G:.Z$%<NP_:#T>P=-(3
MM'="XOQ/]'Z?KU?0J+4U/B?Z/T_7I0IJ:GQ/]'Z?KTH4U-3XG^C]/UZ4*:FI
M\3_1^GZ]*%-34^)_H_3]>E"FIJ?$_P!'Z?KTH4U-3XG^C]/UZ4*:FKZ#C^C^
M(?SZI3F@(6KXCW?3I@JU'-/B/=].F"5'-/B/=].F"5'-/B/=].F"5'-/B/=]
M.F"5'-=*98=Q\/6/L]OX-90C%%`7"J^=X?EM]6G9A-03O#\MOJT[,)J"=X?E
MM]6G9A-03O#\MOJT[,)J"=X?EM]6G9A-03O#\O\`5IV834$[P_+_`%:=F$U!
M.\/R_P!6G9A-03O#\MOJT[,)J"=X?EM]6G9A-03O#\MOJT[,)J"=X?EM]6G9
MA-03O#\MOJT[,)J"=X?EM]6G9A-06ZFOZ=_#T>S\VK71JH-<EN=\/;^3Z]6=
MFJU/-85_."@'"S;!%Q(03-6ZMXJKE0`^R1=R6!F6)#"'H%5-LX$/;T#KZQ^E
MZ]8R3>=K)_>.%O,!T#M&.]!+?2OSQ^O?:)GV_=K?V@]@QUY;./)SNQE8/.&R
M4ZBJ.K=-98[XF<&VK\B;=#*_+:EY$MZI@`I7*"SM\WKJ3HP_I(HPC-L8`-X!
MN8?7K:7^Z2[YXE]\)827/VWNS/;0#D0UIE(Z3(YX]"T6S]WH.Z7@=X;PW`#&
M;WWYM+ZZ.0>TN>V`.Z!`UAY9E9W55Q[JO4/VNX?J]'IZAW]?MU\<MC]T4RHO
MTM>7:S4XU*QC<X^"*W(.52REB]_$Q&3D8]M&S\/,K"QAKLRCT^U&N0DDTUBQ
M=B8-0!`%%2BW<H$3*<R8I@8WT'X0>,;>Y%L>[O>%DLO=XO+XWL&I\#G&KQIP
MUQ./O4!U-<7$!P=0?'/U(?3+)XJ7C>^?<V6"#ODV)L<T4IT17;&"C'=H`1'.
MQON`N&B1@:'.86U=B86X!\OD79V?^2LRJ8AQ)\2A/4]5B?8=@.F\"P@B9,?2
M`[^C7TLWQI\,'1"7_%H@",C'.'=1;V5:KX8D^EOQ[CG,'^[L[B#34V>U+#TA
M_;Z:>=7CHGE:<D;,X0-;G%)QO&G,'Q"TK/)V*53(/I[$36`?H*J[>@JCM$-_
M6&N5WGZBNX>WL<-L;=W\XR#(^R8>M\ND@=3'=2]![L_11XN;Q*QV_/V[:+0_
M$9)A/*!^K';]HTGH=(P=*E&IB#B3P:`'DHU-R&Y",(X9J-@["I'-X2J$1*0Q
M;188LHNX*A5YHL)3%=RAWK]4P@5H05#!MYV.\_B9XP'LK=W^!]R'R:'21!QD
MFK_FHW^[)<2D5&B(,C`J930+VL^'_@;]-P[>\9_O5XIQ0]K'#.6-BMJ4_P!(
MGC&N&S@:ZA$EP9IG&@@;J-1U^#N.V2.961T>2W*EZ[?8^2.0]"I*K=U$1]I8
M(+"JS1BH1<X.H+&:*@`8!4V>S0AUG'I,<XS=[^_.P^%>PGN!X<,:S>R/](N`
M0]T+B*.+Y!A)=$88?NX,@*@`8GAOX3=[OJ![VM\7_&J1\G=5I!LK,M=$RY8T
MU8(X2=4.W@XC526Z^)QHYSCFB1,@W11;-DD6S9LBDV;-FR2:#9LV;IE1;MVZ
M"0$20;H(D`A"%`"D*`````:^47-?(\R2$ND<22222234DDXDDXDG$E?H/&QD
M4;8H@&0L:&M:T!K6M:*-:UH``:``````!08+<[X>W\GUZM[-7U/-.^'M_)]>
MG9I4\T[X>W\GUZ=FE3S4.^=.>!P9Q\M$A%O?A;G>"J4.E]LX%<H/IEJJ68FD
M=MS%&"@@65*?;8K@Z(?R@UZEX/=S!WP[[V\%RS5M5F1<3UR+8R-##_TDFD$<
M6A_)>!?4IXE'PT\*[V\LY-'>#<0;*TH?>#Y6GM91G3L8=;@>$ACYKRR`40`"
MD*8P^!2$*`F.8?04I0#<3&,/@`>D1U^BY/$X!?BD`20UHJXY+UD\0L1EP7Q[
MQ]1W+<K>PN([]ZKCX%!0UJLY4Y&006,&PF-$MS(,0W]!6H:_-7Q/[S'OCWWO
MMW8=5DV3L8.78Q5:TC^>=4G6]?N9X$=P1X;>%FU=W)6Z-T=#\S=<_F;@![VG
MF8FZ(>J-26[X>W\GUZX#LUZ]4\UA%\X5'KD./[X-O&/R*R$?Z#JIN"A_^T'7
MUS]+CM,&]P_KVKO5,/L7YQ_7U"?FNZUS_P`U?L]#K5WVK"W[/<(#\WCKZO7Y
MXJM965O.7[ZI(2"TG<K_`'J::-2;%[\E,R[TR$=&L&J)`*0A2E*D@@F4"II)
M$*4``I?#4VUML_=?91!`([79;.%QY-8QM7.<3Z7.)J223B2NDO;WO+W_`.]!
MNKITVX=Z-RN&M'&265Y#(V-`P'X6,:*-:T!HH`O2C@SA]6L7<9;5A.0(S>VS
M*E5EFV2IY("J`[LDS#KLV#%FN.QC0]167(FT]`'4(HOL!E1V^".^'BA?]XO$
M&V[VPE[-MVVY8;6,_ABC>'.<X?GF`)?R!:S)J_7[PV\`=I[E^#U[X=7(9)O>
M]64K;^88ZKB6)S&,:[^ZM2X"*E`7!TM`7E>861CGL/(R$/)(F;R,2^>1<@@<
M!`Z#Z/<JLW:)@'80,FX1,4?P:_0B">*Z@9=0'5!*QKVGFUP#FGS@A?C->V=Q
MMUY+M]VTLNX)71O:<VO8XM<#U$$+)-P34/EK%?)_B:LZ23>9#I!;W02.3@5%
M.XUA9HFHF`F$"D!VX2C#*"'H30.8?1KP3QC:.[7>/N]XE-:3%8W?R]S3/L)0
MXC^J#*!TN`7U_P#3,YW?KN3WR\#I'M%QNFW?.V0=@WYJW+017]=PMR>36./!
M8V9&.D(>1?Q$NR<QLM%/74;)QSQ(Z#MA(,ECMGC-TB<"G27;.$S$,40W`0U[
MW!/!=0,NK9[9+:1@<QS35KFN%6N!&8(((*^0+VRN]NO)=OOXWPWT$CHY&.!#
MF/82US7`XAS7`@@Y$*9N#^?6=<`XX'&%.3ILG`M7DB]@'5GA7<G(UM255,Z>
MHQQF\HQ:.69WRAW!$G22Q4U3GVW*;IUY5WO\%^YW?7?O]X=T-U'>.:UL@BD:
MQLH8*-+JL<X.T@-)86DM`XBJ^@_#?ZH/$KPO[H_[F["W;YML9(]\#KB)TDD!
MD.IXCTR,:YI>2\-D:\!SG<#11"LUEG[I8YNV6B4=SEDLLH[F)J5>&[CN1DY!
M8RKA<X$*4H"=0^Q"$*!"%`"E`"@`!Z?M]A9;380[;MT;8;"WC:R-C<`UC10#
MT9DXDU)-5X-O.\;KWCW>XWS>II+G=[R9TLLCL7/D>:N.',G````4````6?SR
MV^*<EA^MO\QY#BU(W(-\BTV%=A'R7;D*G25SI/#J/D3@"C.;M"R22BB1ME&[
M1),A@`ZBA"_%?CUXCP=Z;]G=;8Y!)LEE(72R-/NS3BK:-(P='""0'#!SW.(J
M&M)_4CZ1O`^\[@[/)W][U0NA[U;G"&00O%'VUH2'$O!%62W!#7.:?>9&UH-'
M/>T4'YW/!F;YT\+I:*QU%??&<,'3ALN8GBT0)\=:3,XQ>-O&/V)C"&[^W5A0
M3,DQ'9:48M4_#JW#Y=WS;'7MD>R%9V'4WIYCSCUT7W7W?W)NW7X,QI;2#2[H
MY.\QSZ"5^;ZLBNV67:NF[AH[:+KM';-V@JU>,W;54Z#IF\:KD37:NVKA,R:J
M2A2G34*)3``@(:\UQ!H<UZMGB,E7>.\L94Q!+N;!B7)N0L6SKQN#1[,8ZNED
MI4B^:%$1*V?.ZW)1JSUN01$2D5$Y2B(B``.KXY987:H7.:[H)'L4<L,,XTS,
M:]HX.`/M7!NV0,AY3L);)D>\7G)EL=%0CDIN[V:PW:QKD45*1K&M7TZ]E)(Y
M%7!P!)ND;8RA@`I1,.CY))7:I'.<_I))]:K''%"S3$UK&<@`!ZE?+DWQ!S-Q
M$3PDSSE!C4;;F[$Z68X^CO"*)6.H5E_:)VN0L=<&Z@`$=97[>#^.69;=UDDY
M326Z5P4(2>ZLY[/LQ<#2^1FJG$"I&/3AEPXXK&L[ZWONT-L=4<;]->!-`33H
MQI7CU+W2>2QQWK[KR:\;XNN#7MPW)FI9QG[>';`55(3,<S9JJW=@0W]XJE46
M;-1+?]4NN[V2S:[9FL=E*'5_I$_91>==X+MPWY\T9QA<P#K:`?;5>![D/@'(
M7%K-N2>/N5(MQ%7?%ME?5R0!9(Z:$S'(J"I`6N)4.4"O(&V0AT'[)<FY%$%P
M\>H#`'`7-O):3NMIA21AIU\CU$8A>DVES%>VS+J$UC>*]7,'I!P*FYP.\WCE
M_P"7E5K)CW#+ZA6O&5FFUK0MC[*=<?V&$A+2Z:MF;^?J[R&G*[-PCF5;LT0>
M(E<G:.3(D.9(%-SCF6&[7>W@LATF,\'5(KS%"%@;CLEEN;Q+/J;*!34TT)'(
MU!!Z%'#F1S?Y%\[<G)Y8Y'75"P2D3&JPU3KD+'IUZAT&OG7^+<1-0K:*RR,:
MB[<%!5VY65</7BA2F774Z"`3'N[VXO9>UN#4\!D!U?><5EV.WVNW0]C:MH":
MDG$D])]@R'`+T@?P[GE:V-M9X;S!^0%7<PL=&,G1>+--GV1VTG+R,LV6CW^;
MW\<[(1=I$,HQPJUK8J%*=TLNJ_(`)I-5%.F[N;.]SOG[@$-I[@(SK^(]%,O3
MR7)]Z-Y9H.V6KJD_Q".%/P#IXNY9<U@\\X[*09?\SGF+9T7(.X^#RF?&D0J4
M_6F$;BJ!AL?@1(0$0!/X^`<&V#PW,.M%O,G:[I,[D[3_`%0![0NBV&'L=H@8
M<RS4?Z1+OM4L_P"'#QE^_?F9U>V+M^\PPOA_*V1%%#%ZB-Y22BV6.80XCZ"*
M?$7=0Q/>F.WHUF=VH3+N8<!@QCC[&_:L+O5-V6T%@SDD:W_E'V+V,^;+E<</
M^6SS,N:#KX606PG8*/#J@<"'^^,GN&..&14AWW[N]H,8`#Q^R.NRWAQM]LFD
M&>@C^MA]JX398NWW:",XCM`3U-][[%^8$0I2%*0H;%(4"E#V%*```?B`->7+
MU]?H7_PX.,QHGEG4VP*H`A(9IS#E7(:BIB@4SB/:S++',(H8V^YDOA:08Q!]
MA_#7HG=NW+-K$A'QO<[UT^Q>7]ZI^TW=S`<(V-;ZM1]J^9+YDYEL.1Z1(,\G
MW/'U;S!9K'%81I&-)6CPDBQKD!R<8\78B4FXJZX5R;'Y>R-9;`9S:'\3+SU1
M@6D&D2-:J"_ZG2D<EY*^<!I>`YY:T-TBGO!H)#FG434&E0`#3.I58K&!D+@6
MM<]C07EU3B8^T(!:YNEH'N@@.-<3A@LLO'#*-FRCBY.6O;:%;9"J%WR;B/(A
MZPDY0JTG>,/WZP8[G[%5FSY=R]95VU+P!9-JU65559)N_ACJ*&1$YMW:E\L5
M9`.T:YS33*K202.@TKT9+27<;89J1D]DYK7-KG1S0X`](K2O&E5?;OA[?R?7
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MK3O>\WR_'II":T[WO-\OQZ:0FM??B/>/S!JF@*O:)\1[Q^8--`3M$^(]X_,&
MF@)VB^"OOZS?+\>JZ0J:T[WO-\OQZ:0FM.][S?+\>FD)K3O>\WR_'II":T[W
MO-\OQZ:0FM.][S?+\>FD)K6ZFJ`[^GU>G_7JUS>2N:_!;G<#Y?Z]4TE7:U%G
MF7A-?/V`K93HA`J]NB3-[A22#T@9>Q0)%S!%D.80`AIV+<.691$0#NK$$?`-
M>B^%?>QO<KOI;;K<NIMDE89^B*2GO_\`5O#7GH:>:\6^H'PYD\4O#"^[OV30
M[?8"VZM!A4SPAW[L$Y&:-TD0X:G-)P"C;DO%4MFWR\<4,:.T=&NM`I./[G6H
MUNF=*5&=H\4K#62$;H[`LE-II_&D32V!07B!4]NH==YL'>.V[I>.&Y3;NYO^
M$WMW<P2N.+.SN'A\4A.1C)[,DY:'%V2\B[W]R+[Q$^E/8[;NXQQ[Q;5MUC=6
M\;:B3M[.(PW$+0,1*!VP#?B,K`W,JM^,7/O%F5ZK%0V3;/#X[RQ%M48ZPLK0
MZ2@X6QOVA"MU9J"EGYD8])5^<G6NQ742<-UQ,4I3I@4VM1X@^"_>/NWN,EWW
M?MY;[NW(XNB=$#))$TXB.1C:N(;DV1H+7-H20:A='X-_5!W+[[[+!MW?&]M]
MI[\P,;'.RY<(8IWM&DS0RO(C!D(U/A>YKV/+@T.;1RF@KDK'*+87JV0J&DS`
MO7\4I<ZT1OT;;]7>-*`GT[>O?7E+=@WU\G9-LKPR\A!+7T:*KZ$?WO[IQP_,
M2;KM;8*5U&[MPVG.O:44>,@<Z^,>/]VHY%:WF>.<46E:QHU6N<J]="/2FU2<
MQXA")*J'^R'<=E'<?0.NXV7P>\0-Z_>?(NL[,"IENB(&-'$D._>$#/!A7E7>
MCZE/![NQ^Y_Q:/<MR)HVWV]INY'NX,#F4A!)P]Z48\%&K(W(WD'=FL<B>*D^
M,%.M8F1J=>8QY;ORQRJD?P!K0Z,F5%.H(.2#TJ2;Q-J@R`>OXE3;I'O=B[B]
MR=HDD<V2/O#NEMC-*YW8;/9GG<7!KVQ'")A>Z3+LVYCR/O7XL^*7>*&*-\,W
M<[8+["V@8SYOO+N0_+9V8T_+!PJ'7$K8F0X.$[_A-48/X5-7#EI;,TP3>.B$
MY%*P1&&#S)[8XD)TIA51N&>;PM^VR;=@.<3%9%Z89@8QBI);"<@Z[O=XKRL8
M[;>ZDSGW)88WWVCL0V/(P[=;C"T@PIK-9Y``7.J`5NO#GZ>H996;YX@VS8K$
M2":+:3+\RY\U21=;S=G&_NZDD1"EK"2X,8`Y[%DD`Y2@4I2E(4A2D(0A2D(0
MA"@0B:9"[%(F0@`!2@```!L'AKP<M)-3B3Y57UL'```4#0*`#``#``#@`,`.
M`7WN!\O]>FDIK3N!\O\`7II*:T[@?+_7II*:T[@?+_7II*:U%#D7Q%H')R7K
M4I?[5?HY"IQSQA#PU8D85E%)J2+DKF0DEDI"$DUU)%X"**1C]P"@D@0`*'B(
M^D=Q?$S>O#ZVN+?9;:R>^YD:Y[Y6R.>0T4:T%LC`&MJX@4K5Q).5/#_%KP'[
MK>,M[9W?>F^W2**QB<R**WDA9&"]VI\A#X9'&1]&M)U`:6-`&9-EJGY8O'2I
MV>O6A*6R5,KUR;C)UO%S4Y`KQ#]Q%.TGK=K)MVU::KN&*BZ!>Z0JI!.7<N^P
MCKK-R^H'OSN6WS[<Z.PB9/"^,OCCD#VA[2TEA,K@'`'`D&AQHO.]B^C7PGV+
M>;3>H[C=[B6TN8YFQS30&)[HW![6R-;;M<YA(&IH<VHPK0E9&3+=1C&-XF,(
MF$?#Q$1W$?3[=>%!E!09+ZU,A<23F5\[@?+_`%ZKI*IK4:>1?%O'')U"HM\@
M2-LCBTQ:96BCU:0C6"BPSA(Y-X1Z,A%2H*D($8F*?0"8@(FWWW\.^[B^(>^^
M'S[E^RLMGF[#`_MFN=3L]6G3I>RGQFM:\,EX_P"+7@KW2\98K&+O3->Q-V]T
MIC-L^-A/;",/#^TBEJ!V;=---,:UJHMF\J3CH/Z-LRZ7V_\`?U8-O\]3\->B
M#ZC^_0SMML/_`%<O_C+Q0_0_X2G*_P!^'_76W_VJO%@W@9@W`E\;9&K*]OL5
MDCH]TSACW"1B)!G"N7I`0<R\<W80L89.5%F)T2*',<$DU3](`80,'+=[_&3O
MAWSV9VQ7XM8+"1X<_L&O:Z0-Q#'%TCZLU4<0`*D"N&!]!\-?IC\-O"_O,SO9
MLSKZ[W>*)S(C=/BD;"YXHZ6,,AC(ETDL#B2&ASJ`.H1-@%0`0$-P$/$!]X?C
MUY+H7T7KHL=V0O+4P/D6]6V^R%BR/#R%QGI"QR,9!R5<0B&LA*+"Z?`P1=UQ
MVY206='.ITG5.(&./CML`>Y;'X^=\MBV>VV6""PE@M86Q-?(R4O+6"C=1$H!
M(%!@!@%\G]Z_H^\,>]O>6^[T7EWNUO=[A=/GDCAD@;$U\AU/T!UNYP!<2ZA<
MXU)QI14=@KC1Q'Q#RF&FX\SU8I'D7C"I(WZP8@D;'7%IU#'UN:J0;>9FX5"L
ML7+BNR829"@H@OU)J&3$W3N7?6=Z?'3?N^6TW'=7<[?;1'*UCG:&R"1FEX<U
M[:RN`((&8(H2.*W?A_\`2?W,\,^\MGW\[OWV]&YMGR-;VLD#H9`^-\;XY`V!
MKB"UQ-`YIJ`0<%<#-'&?BARKR9D&O(64D%GO&[6H+Y1&A.T"6"&;W6+<2='<
MWR`?LU8E^K8(=@HJU<$$CI1%+8ZNQ2@&!W&\8^]7<N,[19OBN]KBH>PFJ>SU
M5/[M[2'L!Q.GWF9D-!)6W\5_IG\/?%.X'>#<XI]N[P38&[M2QIGT>[^^C>'1
MRN;@"\:)"*`O(`I'</*(JWQ0&-G:Q"RZ_%(*'%@[Z/8"XV040/[^WM[M>J'Z
MF]Q[.@V>#M:9_,/TUZNRKZU\_CZ#MC[>I[RW7RU<ODX]5/YWS%/V5+3!W`KC
M[@^39V5K$R5]N,>H5=A9+VJTD"13D@@8CN&@&C9K"L7:1@`4UE$W"Z0AN10H
M^.O-.]_C+WV[WV[K"26.RVIXHZ*W#FZQR?(XF1P/%H+6GBTKW3PV^F'PL\-K
MR/=[>"7<]_B-67%Z6O$;LPZ*%K6Q,<#BU[FR/;FUP.*FN*NXB(B(B(B(B/B(
MB/B(B(CN(B.O)M%,!DOHHO)-3FO@*["`@(@(#N`AX"`AZ!`=_`0U72536L"O
MFH^6+Y7F26[SD?R/OZ7#*Y6JQ,Z_*9OJ+YA$0=XN4JT>NX]&YTI_$RM>L=FD
M&L6N<7B";!^Y*B85G"@@`ZYK>=GVIX-W<N[%[C34"`"3S!P)P/2>:ZC9-[WJ
M(BSLV?,1M%0PXD`9T-00,<L1T+#%@OR/^`/(Z_J47"WF[5'*DXBS<S)J13L9
M5Y"_NH-D("]?1S":OR'W@DQ3,`KJMFBY$0^T<I2ZT-KW?VZ\E,5O>!SZ5H&B
MI']8^?!=!==Y=ULHNUN;!S&UI4N.FO31N%>&*]#O"OR6N#7"6=B[_5ZA-9?S
M##F(O%94S0[CK))5QZ4-OCZ55&$?&TZIR!1_0>)M%Y%+^0Y+KJ+#N]86#A*T
M%\X_$[&G4*4'72O2N4W'O)N6XM,3W".W/X68`]9K4]5:="J/GEY2/&'S$LB4
MO)V=+'F*$LE%I"U!B"XWM5>@8]S"K3\E8Q7DD)JI6-9Q(D?RBH%4(HF7M[`)
M!'<PW[CL5INDK9K@O#VMTC20,*UX@\U9MG>"\VJ)T-L(RQSM1U`G&E.!')3]
MPUBVI8)Q'C+"E$(^)2\346M8^JWWHNBZE#PE6BV\4Q<2CIN@S0<R;I-OW7"A
M$DBJ+',8"%`=@V4%LRV@9;Q_PV-#1U`4QZ5J[BY?<SON)*=H]Q<>52:X*)'.
M7RS^)GF#1,8&=J?(L;[7&!XVI9AH$@A6\E5^..H=<(=6359R$99:X1RH94L?
M*-7:"2AC&1[)CF,.%N&S6>Y`?,-(D&3A@X='2.@U"SMMWJ^VMQ^6<.S)Q:[%
MIZ:<#T@A807O\*QB<\FHI&\T\GMH051%)H^P]37LLFCU;@F>2;V^/9*J@7PZ
MP:$`1\>GU:Y__<R*N$[Z?S1[:CV+I!WXFTXV[-7\\T]%/M4\^*O\/KP%XVV*
M*O%LC;ER8N\(Y0?1+G-3F'4HL9(MCE5;OF^,JZPCZ])N&ZQ0.F$L>42(8`$"
M=0`.MC9]U]OM7"22LL@_-EZ``/35:R][V;G=L,;"V&,YZ*ZC_2)KZ*+.>BN"
M!T#)$3*#;L@BD4A2(ID;@0J*)$B=)$T$B$`I2%`"E*``&P!KH=&%."YK75>?
M2Y_PW?!7(%TN%\L62.4KJR7NV6.YSRR5_HA4UYRUS3V>E3H)FQBJH1$\A(*=
MLHF,8I=@$1$-]<W)W3V^61TCWS:W.).(S)K^5=3'WPW**-L3&0:&M`&#L@*#
M\2D'PEX"<"O+$LK[)F*LQV64?\E):K\=:U,Y(OU2M\5/7#]X):5C*#2'E/K$
M0W_>F8FH-PFX1454V/'"F;MG3,`SV&U[=M+NVAD<3*X,!<0:FIP%`,:@^A8N
MX;MN>\L[&:-H$(,A#6D$"@]XU)P`/K4WN9?$K''.+`\WQVRQ/7JO42PV*JV.
M7=8\EHJ%L+M>GR83,7'F?3$+/L_NQ6233473^'ZSBB38Q=AWV-]M\>X6YMIB
MX1D@G2:'`UX@K6[?N,NVW(NH`PR@$#4*C$4.1"P\?_VQ_E]?_K"Y3_\`Q!H/
M_P#2_6D_W0VW\\WI'^2M_P#[Y[I^6#^J[_*6<;CC@RC<7,%XMX]XS/,J4;$=
M6;U2M.K`[:OK`\:(NW<@M(33YDSC6CN5?/WRJRRB3=$ACG\"!KH+6T99V[+:
M*O9L%!7-<W=WDEY<ONIJ=K(ZIIEYNA1=NG!IV[L5_<8TR56JI3,F*O'<G5;U
MBY[D5WCB0E\GP^:YYWAJ8CLD4-I!,9/,4&A:DHZ:93;1A/"HJWZ6BJC$<&;:
M=;RZ-S0TFH#FEVDDU)80YM*G&A#@"33#!9L>Z@,:)F%TC.+7:=0#=`U@M=7W
M3IJ"TD9XXJ8^*<;5O#M`@,=U966>QL($H[=S5A>ED[-:;'8IF0LUNN5IDRHM
MB2-GN%IF'DD_6(DDF9RY.":::8$3+L(+=L$8B94@<3F2<23TDU)Z5@3W+[B4
MROH":8#(`"@`Z```.A7#[@?+_7J;25#K3N!\O]>FDIK3N!\O]>FDIK3N!\O]
M>FDIK3N!\O\`7IH*%ZXW>]YOE^/5^D*/6G>]YOE^/32$UIWO>;Y?CTTA-:=[
MWF^7X]-(36G>]YOE^/32$UIWO>;Y?CTTA-:=[WF^7X]-(36G>]YOE^/32$UH
M"^WK'Y?CTTA-:^_$>\?F#5-`5>T3XCWC\P::`G:)\1[Q^8--`3M$^(]X_,&F
M@)VB?$>\?F#30$[1=,9P/4/VO6/K#VZRQ&*+#,V.2^?$#^M](:=F%3MNA/B!
M_6^D-.S"=MT)\0/ZWTAIV83MNA/B!_6^D-.S"=MT)\0/ZWTAIV83MNA;GQ`_
M(-4[(*[M6I\0/R#3L@G:M3X@?D&G9!.U:M)G`[^G;Y@U41A4,HX+3\0/ZWTA
MIV85.VZ$^('];Z0T[,)VW0GQ`_K?2&G9A.VZ$^('];Z0T[,)VW0GQ`_K?2&G
M9A.VZ%NIK^`[[CZ/6&K71\E(R35T+=[X>P?GU;V95VKI3OA[!^?3LRJZNE<=
MHDS8$438M46::KIT^43:ID0(=X]7.Z>.A(F!2]]VZ4,HH8`W.H83#N81$;Y#
M+,0Z9Q>X-#17'W6BC1CP```'``#(*&"&"V:66S6QL<]SR&@`%[W%SW4'XG.)
M<X\7$DXDE1KRGP_XX9BD74W<<;L4;$]4,L]L=7>O*M+OES_I.)$T2JDQDG)O
M291P@JH8?28==]W=\3^_G=:!MIM=^\V+!1L4K6S,:.3=8+F#H:X#H7D'?7P!
M\)._]V_<M_VB)N[2$E\]N]UM*]QS=)V1#)''BZ1CG'B596/\LSB@S<@X<0M[
ME4P-U`S?W=9-L(;[])AC(Z.=&+_]%`??KJYO'[Q)ECT,ELHW?F;;BO[;G#U+
MSZU^COP1MY>TE@W.=E?@?>$-ZOW<<;J?TE?VL\>*#C@@,\.56E8IZD@2<W.,
MKC>T9&.00V.2*FK5\>C%*B`B`+K_`!X`/B"`#L.N+W#OOO6^GM>]-S=[EC40
M/E,-K7]>.'27C]5O9]+UZ=M'A-W8[I-$'<"RV[9"6T==QP-N;^G*.:YUB,_K
MO[8<1&#BKB4C&-'Q^\DYB#BUW=KG=OWBO=C?N;'>[$(>(%E[3*'6D3M"C^@T
M0%!DD'@FB0``-:/=]_W?>HH[6\D:W;8?X5O$T16\7\R%E&UYO=JD=^)Y*ZON
MYW*[N=UIYMPVV%TF^77\>]N'NN+V?_I;F0F0MY1,+(6Y,C:,%<7OA[!^?6C[
M,KK-72G?#V#\^G9E-72G?#V#\^G9E-72G?#V#\^G9E-72G?#V#\^G9E-72G?
M#V#\^G9E-72G?#V#\^G9E-72G?#V#\^G9E-72G?#V#\^G9E-72G?#V#\^G9E
M-72G?#V#\^G9E-72G?#V#\^G9E-72G?#V#\^G9E-72G?#V#\^G9E-72G?#V#
M\^G9E-72O.CR+QCD5UYD/-'E?@"/=RW(OAEBGA/DZGU%JNJF3,6*)>FY9C\^
MX&>HD,";E3(5&CP7BQ$!,E.1K,2>)M<?=6LQW:XO+4$W=NV)P'YFD/UL_I`8
M?K`+L;.YA&S6UA=FEG<OF:7?D>"SLW_T7&A_5)0G.BNTB?\`-VYT8'^`O<9+
M8&\NNW8A^\FSMW'.9S(F.YFGU8MFBXX0D5!J]CL90E8](2N168K-0Z5!\*C<
M&QF_W.VHYO90%O\`2:0*@5R)Q&?#-5.V/E;MVU756.$MP'TY-<":$\P,#EB"
MK^<7.07(=ERAPGCQSE+ESR=QAENO7YAG"9Y"\*+%QVA\)9#KM5_>FI6[&]N2
MQC0HMG0+?*,7D*>`E%I%RW,HU53<"H)@-DV%Q??.QPO=-+"\.U%\3F!A`J"#
MH8`#2FDZJ88\\2^MK(V,LP9;P3QEI8(YQ(7M)H0X:W$N`H[4*`XU"MQB7(7F
M%W+RU<C\V@Y0RESR\>@S60,8XDB,7XYC:HRJN",PV*0M<=)N2P*\I9;WE['-
M5D8Q^J!6[9D11L5BFDLD9=2.!^[2;._<NVU2Z-36Z6@48\U&6)<T4KTX`4J9
MKB/9X][9M9@#;?6&N<7.)K(P4(QH&L<01SQJ:8*ZN<O,2N,=+Y]Y`X3D6UAX
M[\6?+XJ&=92IF:,',-DGD+RB,QL."(">G2-%9]E$X^QV@G)2#9BY;F5++D[O
M4()[7W.[2@R75M4VD-N'$4&+WU+*\:!HKA3!X*@M=IC<V&TNL+R>[+`:XMCB
MPD(&57.P%1^%4=QLY(\EF/(/C77W65N6O)BI9K4G:[R289IX.6;`6/<*3ZM&
MD+36<BX>O!,84U"$HJ-MCON):'F'TJHY:/$'!5P6*8=66-SN'SD3'NFEBDJ'
MZHG-#30D.:3&V@P`H2[//"IDO;6Q-G.\,MX)(J&/1.'N>-0!:]NMU74.JH`H
M0117O\W&8L$/3.#LO4:6&1[3%^8_QI?U['YIR)K);I+MH_(2C&M#8IY-:$@P
MEE@!+XIV0S='JZC@(!K-WT/9';.C;K?\W'1M0*GWL*G`5YE8O=_0^2Z;(_1&
M;*6KJ$Z1[M308FG(*Q>0KME_+?F`>67!<A.(S;ANPKN7<OW/&^1&.1<>9GF,
MGWZ)P[86AL'#*XS91A:'`3,%(N)9XK(BND_^[2())@?<X85P^>7=+3YV'Y<-
M<]P<'!^HACO=]WX:BI).>FG!94++:#:+U]G<?,DQL#FEKF!K2\>_1WQ$&@%*
M4K51ZG>?_)_),%G'D/B7)7*%I=J'ES)];P#Q)Q]PBM63N-F0J/A^\OJ9^[&3
M\R1N-)F9E\@923@'JR\K&6!@WK+M=%`$?V*H#B/W+<93)=6YE]V1P9&(G.8X
M,)!#G",U<ZF8>-->C',;M=A`Z*SN&P=F^-IDE=.&R-<]H=5K"\`-;7(M)<,:
MXK(.>Z\GN6W)S/E#Q+R#L'$RC<7*9@1-C7X7'%"NTWD7,^;<;FRRZ2RV?(4/
M).$<<4J)=,H@\3%#&/G2XNE3.DSE3`NWK?WU[+#!+V#(6LP`!+G/&KWJ@X`$
M#2*&M?>R6HT6.WV,4UQ$+B6=TF)<YH:QCM'N:2/><:FIJ!A@H3L?,!Y"6O`?
METT6VY3R32\A\F*-R"RAR"SIQYP`;-&4V]<PID!]3F%8Q+C:`IMLAH`]GFI-
MHDZG7,.\2BXMEU"47#D%!U@W2\EM;:(N<V>4/+WL87.HP@4:`UU*U&.DT`YF
MJVCMJLX[N\E8QCH8'1MC9))H;5[:U>XN!-`#1H<*D\@JHE^87,V(XE9S)`6_
M(B5[Q[S&XJ8CX^\D<_<<)##]BRUB7.N0*##/5<AXKLE6JT9*2U1D)B2@Y=[%
M,V!7[<B2R/PRR@*:O-]N;;)X]X2-FC:R1["W4'N8*%I:VM*N!(#:@5%"HVV&
MVNW"+4&=D^VE?)''('ACHVN/NN!)`-`X`DTR-0KVSV>N0/!S.?)*FY8SW:^7
M-#J?E[9`YI5\,A4['E%L5<R%BR].:C+T^%>8W@:\R3QW;B.4%$VKE-PYC`3'
MI7/]HQ\LSW>W7$T=Q*9HVVAF%0`0YIH0-('NGIRYK%9;6FZ6L,EO$VWE=>-A
M.ESG`M>VH)U$^\.8P/)66XY<KN4SC)?$6P.<H\K.0@Y[N-2@.3V++UP8MF),
M#8DKF1JV[DV]_P`%9.)C*O.8.N8OLZK)FH:9FI9*?BE3.A.4^Q@Q+2\W$S0N
MU32B0@/:8G-8W4"=37:!0--!BYVH8K)O+*P$-PP,MX>R:3&YLX>]Y:::7MU&
MI<*GW6C2<%=W!F8>54[C+F]RHR3RWI-8I.%LC<V</8;I&0Z/7H;#M.)C3(DC
M%4W*V<+?`1*MYL`TE=J2/91T<F4J\:GLL5V]<]89-O+?/BN;R6=K8HGRM:'`
M!HTN-'/(%32E*"F',FHQ[J"Q9/:V$-NYTLK(7O<UQ+SJ:"YK`3I&K,D\>0"H
M'C'R4S1-<K^/^%8KE#RRS!0^2.%,ZNK-D3D#Q6KV#HBLY-H-1K-@KF0>+SF9
MQ?07TQ#-74VN=2)E&$M&IM!9F544.<Q1Q[2ZO'7D=MVLKXIHW^\^/2*M`(<R
ML;<,<B'`89\9KVSM6V$MT8;>.6&6.C8Y2\EKB06RT>ZAPS!!K56CX;V'*>$.
M&G!9&)RM*VYMF+S6WV,)=C;J5C5PW@*3)YJY"Q%QBJTHTJB#A@]N\_7_`+[<
MR75]Y,7KM9%BNW:=*(661GM-MMGAY<U]Z6D%K<!KD!`PXD5KF"32@4^XBWNM
MRNM3`TQ6`>*.=B[1&03C^$'33(@`D$XJ^DOE/F#F7"7+_G1CKE-.8@B^/F0.
M2D9@KCBRHF.9K#MFI'%"6FH*=2SL\GJ\]O\`/V'+4G4)(QW$=+1@0B"[?X<A
MA(;?)=)N%Q;W&Y13:&PND#&4;I(B)!UU!<2XM.3A0'#)8K8MNMKJWVN:`2.F
M9&7R:G!X=*`1V=#I`8'#`@ZL:JNHW)7*#F-RP3QGC7DK;.+&%IK@/Q;Y-.F=
M$HF.;5D:-OF:9N[))Q4%8<@5V<:Q<-V&J?WKWF[E9PG'H)-A:]UPH>X2WU_=
M]E#*883;,D]T-)JXNH*N!IEC@>BF*B=%8[;8=M/"V>Y%W+%[SG!I:P-Q(:14
M\L1F:UP4N?+JS;D7/?#_`!?D/+LJQL63$Y7*%!N5GC(IK!-+9+8IRM=,:A:_
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M#VCII*:^E.Z'M'324U]*=T/:.FDIKZ5NIK"`#MX^CTZH13-7!X.>*W>^;V!J
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M><['K)]D_'"DDS85VE+,QGGH?Y5.8Q@UEJP!+'8EY9KW%G`,'Q$A0`B9`)K!
MBV*PB%RP!QBNC[S:X-S^&@%,22.1R6PE[Q7\QM7G2)K048[B[+XZFAP%#E49
MJX6'.(EEH>3J?EC,'*G.G*"Q8KJ<[2L.,,F-J)5J]0(JSM64989Y_$8XK]=0
MR#D27A(Y%BI/3/?7(W[G:3346.<9;7;##.VXN)I)I&-+6:M(#0<R0T#4XY5-
M>/,J&YW6.:!UO;6\4#)'!S].HEQ&(%7$Z6@FNEOG."O3QSP74^-6#J/@*JOY
MBST^BL+!&,WMO^[W$M+,K+99ZS22$P$:S81RR9G%B70`I$2`+<"@;<VXCE6=
MI'96K;2,ET;014YFI)QX<5BWM\^^NWWL@#97D'W:T%``*5KR4?<$>7=QUP-Q
MPS'Q8CV=FOF*L[RES<9#1O4H@ZG'U?M<$QJ<73&,K%M(X["O8]J$4TC:_P!)
M>^Q1:IGZS*!U:Q+79K.ULY+$:GP2DZM1QH10`$<&@`-Y469=[[>WE]%N#M++
MB$-TZ1A4'474-:ESB2[G5;N(>%TY1+_C.\Y3Y6Y]Y)-L#PLO!8%J&2R46`K]
M`),P9:HO8[(>@5VOO\L7QK4@&-;2T\HL9NBHHH5+XA05=6VNT]A,R:::27L@
M0P.T@-KQ.D`O=0G%U<R<S5+G>&30R0V]M#`9B#(6ZB74-:#43H;7$AN?.F"O
MEGC`-5Y!CA8;7,V&&_R-SYCWD-6?W>/'$^]K9C@DR2(A9W[Q9/>NNO@FU/B2
MH=ER/07H4+X[YMU9QW?9=H2.RE;(*<2VM`:\,<>*Q+._?9=KV;0>VA=&:UP:
MZE2.G#!:<R8#KV:+WQOR++6*R5RP\8\NNLPTK[@+$G9S<M(TV=HLK7[,E*,'
MJBD#(P5A7`PM3MW2:Q2'*H&VPVW5E%=R0RO)#H9-0I2AJTM(-1D03E0I:W[K
M2&>!C6N9/%H=6N`#@X$4.8(XU"BM8?+EB9-YD:H5CDOGS''&',F19;*>5>*U
M+4I+*F6*T6B8;V*^1M=R,O7E<I8_HV1IYN+J:AHJ0227.LN5%1`BYRZU[]CC
M<][62R,LY'ZG1C30DFI`=36UKB34`\32E2M@S?W-#)'P0OOXF!C)7:M0`%&D
MMKH<YHP:XC@*UHH]<MH(:+R?R5:X"J>81B9+*6&L>5B:N7".FP>6:5RC0JS2
M=AX_&MFBW-'M$AQ]RC0H]R$2RLX.8TSJ&?E.1VF+<!+A[E&Z&^>^)ETQLD;0
M3$-0DI7W2-+M#VY!U6X?B%,,[;91-81QO=92=G*XAL[BQT5:'4#J`D8XXEM#
M1PRQ5=\>_+[L,7P[X,UF7O5VXU\I>+-,L2]2R-CA6KVV;H`Y6=RLG?\`%%GB
M[:QGJAD:J/(N2:L9)NZ(<IW\<1R@L4Y>L\UILI_PVU8]QAOH`2'-H2TNQ+2"
M"'#('I`(."AO=\C=N=W(QC9]ON'"K75:':*!KP6T<TUJ13@:$*_B/`FEO\2S
M^.;UES+V2+;>^06+N3&3LSVJ0KYKS>LC8DMU2M53CRQ#.&1IE/H;)"ELHM"'
MB6+9%K'@?MF[YS+#EC9H?ES#(^1\CI6R.>:5+FN:X"@&D-]T"@&`RQQ6'_C<
M@N1/%%&R-D+XF,%=+6O:036NISO>)U$DD]&"O+>N,>-LE9NFLVW8).><6;C3
M<N*MEH+L60TF=QG?+>G;[&=ZD5J6:"9=+%,T`Y'14BMCB($[@`<,J6P@FN3<
MRU.J$Q%O`M)J>FO#/)8L.Y3P6@M(J-#9VS!WX@]K=(Z*<<L^A6)Q)P0=XZM.
M&75SY5\A,W8RXTN0><=\,W]2D1E9HCUE!NZM6)"XV2H5Z%MV9)"B5AZHQA3S
M[E5-J406.FJN4J@8=OLPA?'VDTLD$/\`#8=(`P(&HM`<\@$TU'ISQ67<;T)H
MY1%;PQ3SC]X]NHEV-2&AQ(9J.+M(QRP"K)?@WB.0XT\@.+$U,726QYR+O^9,
MDVV3-(1K&TP5DS+>39%?J59^RC4FC9&I6DB*T7\0@N;I0*5P*P";>8[3;&SF
MLG%QBF>]Q-14%[M6&'`Y5\ZC_P`9N!?0[@UK1/`QC6C@0QNG$5XC.GFHJ'JG
M!:U1^;<#\C,C<R>0>8\NX"4L</7I.V0>)H6H2^-[;!MX2S8]=T.KTV.AXQ:R
M&8MG,A84#C/.%6Y"%732*5,L$>S.$\5U+<2ON(J@&C`"TBA&D-I4T!+OBJ,Z
M*63>HG6LUE#:PQ6TU"0"\D.!J':BZIIB`WX<<JK72/+UHU*JM$HA<O99L%)Q
M/S`0YB8IKTR2D%)1+(2:N=F=8V:R4?6&DE,T"0LM\D'JBCY1:5*<Q")N2)EZ
M1OCV:*.-L7:2.BCN.V:#IP-2=-:5+:N)QQZ527?999'S=E&)9+;L7D:O>%&C
M50F@=1H&%!T*F+WY;<);7V9*M7^26<\:\;>1MUE\@YWXP4]O0#4NYV&V+M'.
M1FU<O,O67V1<;5K*B[,#V".B7A$W1EEQ2,AWCZCEV-DCY&LFD99S.+I(QIHX
MGXJ.(U-#OQ`'B:4JI(=_=$V*1\$4E]`P-CE=JU-`^&K0=+BS\)(PPK6BES4,
M!TNC\@K1R(KSB393]GPGBS`P4](L>E2X*EXBL-GL%64A&J30DF@_$]H5;*@H
MX.@#9!("$*8#&-GQV,$5TZZ94.=&UFG@`TN(IT^\5KI+^26S;92`%C97R:OQ
M%SP`:\.%>LE:N-^"*OQCQ+%X>I<O/SU?B;/D2U(25G/'J3"C[)5_LF1)ANJ:
M+9Q[,6C&7LZR+;9(#@V3(!Q,?J,-UE:1V-N+:,DL#G&IS]YQ<<NDX*E]?/O[
MDW4K0'EK109>ZT-&?0,>E7T[YO8&LI8FH<D[YO8&B:AR3OF]@:)J').^;V!H
MFH<D[YO8&B:AR3OF]@:)J')?!7-[`T34%QNZ'M'5VDJS7TIW0]HZ:2FOI3NA
M[1TTE-?2G=#VCII*:^E.Z'M'324U]*=T/:.FDIKZ4[H>T=-)37TIW0]HZ:2F
MOI7T%0]HAII*:^E?>[_/'Z=4TE-72G=_GC].FDIJZ4[O\\?ITTE-72G=_GC]
M.FDIJZ4[O\\?ITTE-72NE,L'4/B;TCZ_?^'6<&8<%C%XJOG>#VF^?\^FCJ36
M$[P>TWS_`)]-'4FL)W@]IOG_`#Z:.I-83O![3?/^?31U)K"=X/:;Y_SZ:.I-
M86KO_P`\?I^K3L^A4UA._P#SQ^GZM.SZ$UA._P#SQ^GZM.SZ$UA?!7]XC\_Y
MM-%.2:POG>#VF^?\^FCJ5=83O![3?/\`GTT=2:PG>#VF^?\`/IHZDUA.\'M-
M\_Y]-'4FL)W@]IOG_/IHZDUA;R2_@/@(^CTC_KU8YE54.KDMSO\`N_VOS:M[
M-7:CS6H%P'TAM^`=]4,?)-17WO%]^F@IJ*=XOOTT%-13O%]^F@IJ*=XOOTT%
M-13O%]^F@IJ*=XOOTT%-13O%]^F@IJ*=XOOTT%-13O%]^F@IJ*=XOOTT%-13
MO%]^F@IJ*=XOOTT%-13O%]^F@IJ*=XOOTT%-13O%]^F@IJ*=XOOTT%-13O%]
M^F@IJ*=XOOTT%-13O%]^F@IJ*=XOOTT%-13O%]^F@IJ*=XOOTT%-13O%]^F@
MIJ*=XOOTT%-13O%]^F@IJ*=XOOTT%-13O%]^F@IJ*=XOOTT%-13O%]^F@IJ*
MU`XZ=^DQR[AL.PB&X>P=A\0TT%-16GO%]^F@IJ*=XOOTT%-13O%]^F@IJ*=X
MOOTT%-13O%]^F@IJ*=XOOTT%-13O%]^F@IJ*=XOOTT%-13O%]^F@IJ*=XOOT
MT%-13O%]^F@IJ*=XOOTT%-16D5_8'TZKV::CS7SO^[_:_-IV::CS3O\`N_VO
MS:=FFH\T[_N_VOS:=FFH\T%?P'P_VOS:=FFKI7%[P>TWS_GU+HZE9K"=X/:;
MY_SZ:.I-83O![3?/^?31U)K"I^T7"O4N$=V.SR9(J'9G;(J.#(NG:RSM\X39
ML(^/CV"#J1E).1>+$2;M6R2JZRA@*0@CJV0LB;KD(#1Y=9/0%<S5([1&*N/E
MGD!TE4_0,L47)[1X[IDT:1&.^%%^S<LGT7(M47PNBQ[T6<@@W4<1D@=BN1!V
MAW6JJK=9,JG=15(2R*2*<$QD&GF]O#IR]"OECD@($@I7S^1Z,U<#O![3?/\`
MGU+HZE%K"=X/:;Y_SZ:.I-83O![3?/\`GTT=2:POH+^\0^7X]-%>2IK"^]_^
M>/T_5IV?0FL)W_YX_3]6G9]":PG?_GC]/U:=GT)K"=_^>/T_5IV?0FL)W_YX
M_3]6G9]":PNF,L7J-^$?;[=9(8:+`,PJK8YKR_5,"8<RMG"[J@G4,0X[M^1[
M"'7VSN8ZHP;V9-'(&W*/QDLLU(T0`!W,NN0H>(AJ&ZE99VTEW+_#C87'S"OK
MR4]HQ]Y=1VD(_>RO:T=;C2OFS6-3A-RVY+3F&>1M7S(VK'*#EG@..Q]F!O2L
M1S-%JAL@8USWCR-R55<>5E]"(/*HG<,:V-G::607!2'E']?;_$JIJ/.\&@VK
M<;V6TG%P!/?PT=1M&ZFO%0T84JTA[`<G:0:T=5;W=;.QCNH)+?5;[=,7,U/#
MCI=&XM+C7'2X:'X9!QH,**YS+S+J?<L>265\08?O.2*#8<E8=P%Q^FGTHQQZ
MMG_D3E946\WCB*C+5&$=4>N86>]QG;+'(=U!M)QTHS:M7*L>?N3C>XY(3<6T
M3WPE[(XR3I[21V;17X0S)SCQ#@`2TJ$[/)%,+>ZD9',(WR2#XNSB9DXD'WB_
M-C1F"TD@.5'7'FYE^\3-1XQU2JQG&SE9:N4T;QMR))R[^$SE5<35=3`-BY/K
MY:QK(?=]8@\FN;IBJO?"UM"7CF";2:66^\&2I&8I+VR[E=2EMC$T0[BZ?LW5
M(>U@[,RZFF@U:F"C:@4=6K<*&2+;[:)CK^1QGVYMN96TK&7GM!%H=B2W2\U<
M035M-)QPXQ>5F-.+4OR-F[[YA5LY/QO'W%-GM.2^/MWQ]B&-S!6+'`7"K55K
M+U2ZT.A8<B3Q;RR6%"`<,)!%Y'HOI1JO\<W324`]/G8;!\[I;QT[88R71N:S
M6"'`5!:&85(;0@BI!J*8A:7&X-@;#9-@,T@#)&N>6$%I-"'.>:T!=44-`10U
M75,/-M@TJCFJ0G,-P<[>L0QF`;&TJ6#>1^.<W52[07(3,T3@V"BFV58R%KE=
MK&1*?<I9,)>'D&Y6WPZB"[=\JV6%=.P;\SLY2Z)IFC$9HR1KPX2/$8&L``.#
MCBT]!!(-5(=B>9(FLD<(I3(*R1NC+3&PR$Z"22US1@1C6H(J**:>`N1UMRAD
MG/&%<IX@_P`E\M8#4QE*3L%'9(B<K5F>I68H2?FJ)8H>WQ5?JH$DBGJDDRE(
M]1E_NCIJ`I+N45"*:V5C>/NY9;>:+LIXM)(KJ!:\'20:--?=(((PI@2#5:N\
MMXK>"&Z@D,MM-K`.DL(<P@.!!)PQ!!KB#D"K)9?\P)WC"T9WD8G`\Y>./_$R
MU4BF<H<VMLCUR`E:+.6^$I]IF#T'%3Z(=RF3XK%M3O\`$2-D6&3AU$TG*B;%
M-ZJW4*.+=;J;>673"Y]I`X-E?6FDD!QHVAU!K7`NJ6YT;J(67;;8+B.%KI@R
M\N6N=%'I)U`%P&I]:-+W-<&X.RQH"L<W('E?S]C9KS!+[2D[+!5[$/*+$/#'
M$\;!9BPHC1::PR9/<;X<]\:4ZQ84G+/.9?G6.6#OV,](S#B%A#32:"L4Y"+4
M%?37=]O`?=S1:FQ1SLA:`YH`U&(:J%A.LA]022!J^$Z37<V=GL[FV<,I:7RV
M[YWDL?J.@2G34/`#!HH6@5=IKJ&K"1ED\T>"XU/9?$=ZKJU]D>-Q\;TGDM9,
MA<GL/K9_2O%XCZY8IN/QMCV%HM3'DDZQA!79@>9DXYG5&[\"*)1S=TX06+K,
M&^MM&"&4=HZ(,$KG2-$FIP:3H90%^D.%?AY"I!6%'LC[X"XA.AL^MT0;$_L]
M+20"YQ<>RUEIT@E],W$`A7YN'F'3=4C.7%X0XMWRQ8>X:WS*F.LD9*B\D40C
MJQV+'%:JT\T"C8^50/:G\7*.+<T2E'KP&32`:];P5'J:2Y$LM^\O8R>;Y>0V
MUNY[7.J*U:T.P:*\P"30#.I6'%M3)'6T)N&-N;IC',:6NP#B1[SLJC2:`5+C
MAA4*17%CD'.\BJ5,764K6(XF(;RK1E6[#A#DI2N3U"MC1=@#QZHC<*=7JL:!
MF8-<Y$';!ZR*<14(HD=1,1$,_;KM]_&Z0MC#0Z@+)!(UV%<'`-RXX=16#N,#
M+&41-=(7$5(DB=$YO]%Q-0>!!ZU&C(7F55C%W+2I\9K36,8/VEUS/2\&Q<K2
M.1]7N688*RY"9$/5;#D#`+"F(N:35W4NH1HY3<6(\NU152=BR,B?8,&;>60;
MBVPD;&0Z41C3("\%V1='IP%</BKQI19\.T27&VNOXS("R)TA#HBUA#<PV35[
MQIC\-#E5=SYE67.0>.,>X`JO')K)HVK/G*C%N"YRSUN\4FA7.`K]G9V2=7C*
M5/Y"H^0ZM"3]S_=@\>$RZB7J<*B*BH(***)BF[P3WUM;Q-L:B268,)%*BH)P
MJ'"II3(GEBK-B997$TTE[3LX;=\@!!<TD4%7!KFDAM:TJ*\UW<7S=BJCA:Y6
MV;IEQG7N%^7^/."=E&:MD`^LEJN\WD'$.)'>3G\W$UJ'A%D0F<H$?NT&[!N5
MR+17L@@"R94[QN89:NE<UQ,=PV`U(J27,9JR`S=4B@RX*X;>Z2Y;&QS6B6V=
M<"@-`T->_32I.3*"IPKC51WP_P`E\Z6#DCA*D3N1962K%F\P'S9L/V&)5:1!
M&\ICCCW5WSW#=56.E')N2,*(\1*HU.0Y5U!#]NHJ'AK5VE]>2;LVV?(3";BX
M;2@R9VFD95PTCT+87-K:,L9)F,`D;:6KP:G!TA&LY_BX^JBE'RTYQ(<9<B8B
MQ.PIU#F[AF&O7>T0,YF?/E3XRXG*VHDA6HQU4&63;C7;1'365+"YM"2D;`IM
MDS*,F[ARJNFFF`&V>Y[H-OECATM,DC7$%[Q&WW:"@=1U7FN#0,@2L#;=O-_#
M)<:GB.-S00R,RO\`>!-2T$48*8NKF0*)<.=T=1:=S:LUCQ1.M9/@[AK&>7+W
M6F]R@9$]J5R+AM_E]6H0,]','42@YK:<<I&'D2B[:/5=G"(`D(%&CMU:R*ZD
M?&0ZUC:\BH-:LU4!Z,E='MKI9+5C)`6W4CF--#AI?HJ1GC6M,QDHPYXYT9^H
M^3+'6L'4\^3'S3G;PJX_RU2O-EH%-@HNG\@>/,1D]W5:-/DJ#B606M\F_*1Q
M,2ZD@XAWO=40#X,R;<FLO]VNH+DQ6@U/^8C9I<!2CHVNP(%<S0U)-3A@*#/L
M]MM9H&R73M#3:S2`M!)K'(6U<*TP`R%`12N.*[?-OFVUO!EPO51L^*JJ,C@:
M'QN[Y*03CDMCB(OU6L5^KL+;Y.FX&H$A!$F>2$KCZJ6!J^D5VYJ\V>BJ#5@+
MEV!TB9-SO[+61T<D;:Q!O:#M&AP+@"6QM(K(6@@GX:Y"IP5EKL,EU&R1DCM,
MQ=V1[-Q:0TD`R.K2,.(('Q$9F@4_>1_(*,X\XN1R#^Z\QD6:LEUQOB_&-"K[
M^/A9/(63<OVJ+IN/*RE-SG1%UMA(RTL19[(.BF3CV"*RPIJ&("1]O>W+;.#M
MM.MSG-:UHP+G/(:T5.`Q.).0JM196[KR?L=08UK7.<XXAK6`N<:#$T`P`S-`
ML9_*GG+R96QK*XDQYB9]AGE'#\O>*?'#*D76LT8^F30%&Y*+I6"DW?"V5[9C
M.4JS\^3XABZ@T9&5JZ:]7?)NG"S)<$$3*<_N&[WAC-K!'V=_V\;'`.!HUY%'
M,<64][X?>;4&ITFE3O+#;;+MA<32=I8&WED:2QPJZ/!S7L#@?=-'4#O>%`"*
MJ=&?>19N&7%JO90R!&6"^R\*IB+'<LO<+W5X=)&WWR5A:>:UYCS`A6HJE5:F
MP$R_,XL-I3AD&":1!629%!5-$-S=W7^&V#9Y@7O&AIJ0,7$"KWT#6M!-7.I3
MC1:FTMO\2OS!"0QIUN%&DX-!-&,J7%Q`]UM:\*\5TN+.9,A=;CQGH-JQS48F
M:Y-&Y`+U:S8HSY3L^XN3@L#5NHV-6QPU]J<##-K*RN(6H6J2!F[!W&N&2H+I
MG*=,1AMMS[:2&)\;09S)0M>'MHRF(-!4&O(9<5?/8"**>6-[BV#LZA\9C=60
MD4+232E*YD&N"M=&>8O-7:1Q!5L1<9+;DN^YIFN:4)6ZT.5J-2(R&-PLS`PQ
M%:IBTVNT1Z3-E!W%Z_*\:F:MWCQIU)H?#.1.95.+_&'/[-MO`Y\LIF`%0*=B
M\,))/`UK@"1RXC(=M+8A))<3M9#$(23I+B>V87@`#B,C6@.=0OCOS#[42=CY
MR*XT/I3`*W+:D\)WN8'&:*U&SO\`G9/Y(BL16Y]!8M)4G[V?QG0LD/74.>5&
M69NY-Q'+*H,R-1(N-#O#^U&F"MK\PV'7J_&7!AH-.+6NJ/B!-":4Q5!M3-!:
MZ>EW\NZ;1H--`:7BKJX.<VAI0@5%37!=31.=-UG$*[CG&6-[%R#SM?\`.'-^
M&@H"]7JB8=KE3Q9Q2SJ_QI:+-:+Q!4B39M*U%R<O#PE=:HPDE.29G29GZYCI
M.78H]TD=2&",S73Y9@`2UH#8I-!)(!P!+0/=)-<3@2KI=MC:3-.\0VC(H"2U
MKGDNECU`!I<,2`7.]X-%,!B`NJY3^:&GQ"7JZN7,58XADU:#1[SD+'ZO*V@*
M\A*N%FF!AK%'4W#</3IM/(3*F+?M"2:TU!L9PA%"LC"HF)=6WV]_X>1\Q'&/
M<:YS>U;V@J:'2P`ZJ<]30>"NL-E.XAPMI)"=;FM=V3NS-!45>2-->6EQ;Q4D
MN,^3[S=\Z>8-5;59'<Y7<0<GJ+1L9QSA)HBA5:A+<6<$WY]#L#-VR#A9L[MM
MLD'XBX,LJ"CHQ0,!`*4N=8RR2W5VQYJR.=K6CD#%&ZGI)/G6%>LBBM;.2,4?
M)`YSCS(ED;7T-`PY*S5@\Q"QU^S91DU^-4PKQ^P=RTB.(N5LV!EZJ$FHJU6.
M?QU4XB\US$85X\U/4J-LN4HA&8%:38NFB*QEFI'Q4E0)B.W=[9'N,!^3BN!$
MY^H5!):`X-IB`7#5B",P"LEFTM>R-HG'SDMN9F,T&A`#B6E]:!Q#3IP(.1HJ
M6K/FNXXM?(&M8IB*E67F/K=R4E>*$+=V.=:)(Y=+DN*LDW1CV^6XSM(\UQB<
M+O+]7G$4E-J2GQY2&1?*QR;)8JNHQO\``;GL@QI@,QB!#VE^H$BO99AA<"`X
MFN1(`Q4C]CG9:.G<YPF;`)2TL<&:2`Z@E^$OTFNFE,QJJ%PVOF"9`R;AC%^;
M8S!V0,*XGR%R/P?B.LY!_P`QL0VVPW*4LW*Z/P)/U\U!=5^<=P^/YY%!TJO+
MK_`3'PA52,TVCCX=V>C=VFGMX[@1.C@?,Q@=5I))E$9%*&C3S-'4K0#`JIVN
M*"YDM72LEN&0O>6Z7@`"(R`ZJBKAAAB*YU%0J_K/F&V"4MT#*S7&B7@>.\CS
M1LG!M[F@^7ZI*333*\9EJ:PQ6;&.)6E?2F!QG:;[%(QJKU641D8]P_3-\&X;
M$%R:0;P\R8VY^6^8=#KU#XP\L'NTI1S@!BX$5R(Q43]J:V,M;.#>"V$^C00-
M!8'D:JTU!IK2E"!F#@K*<.>=F<7M1XWL>0.,9*9J'(#D?R2X^U3DBODNH.9E
MW>*9DKD+,4EG.X@AJXV>0V/T:)BA>#0E3R7QX.XXAUV`(K$<'@V[=+HQPB[C
MK'+-)&)-0J7!TA:"V@HVC"T&M:C$4-5D;CMMLV28V<@$D,,<ACTFFES8PZCR
M<7:GZJ4I0X'"B[O#7F\8VS)?J/"0]&@"T',3#+#O#MD@<\4*ZY-=FQ93K3?6
MZ^9,'0,:,_A2'R15Z:^7A'*\C*J(*BW;R*+-PX(F%]MO\-S*QK6-[*37H(>T
MN]T%WOL&+`X`D8G@"`316W.P3VT+W/>[MHBS6#&YK?><&^X\X/+2X:J`<2TD
M!5:AYC-X<<9*%RGF./-`P[CS+$1B>?QD\Y%\P\88Q:62)R959*S*JN5X6G7N
M18RL<#9H2.BD&3V6F&[[XDS9C\,X1)>-XE-DR^?"R.*0,+>TE:T$.:79@.Z*
M``DUR!!"C.TQB^?8-F?)-&7AW9PN=0M-.);AG4U`%*5-05T.&.=TKRBS!Y?M
MGQXI+4G&>:ZYY@T3E''2DG#V2.D;UQK=X_J,:LUM;2.;C8(&%LII)U$2#8C$
M'S-Z0Z[<AOV2=EON9OKBS?#[L4HG#VX$5C+6Y\0#6A%*@XA7W.VBPMKQDU'3
MQ&W+78CW9=1RX$BE0:T(P/%2ESCR=R'C_-^-^.N'\"#FW)^3\190S#%&E<MU
M_$=/@8/%EJQ_5)1M8IR7K5JD#*R[W(34C06+%VKWP`JB143*.$-A=WDL%TRT
MMX>UF?&Y_P`0:`&EH-30G'4*4!]&(P+6TBFM7WMS-V4#)&L/N%Y)>'$4`(RT
MFM2/3@8C6'S><?FIF!)B@X_K3FYYLP$[Y'/J;F[D)CSCU%4>FQ]JDZ"K4PNU
MCC+(RNV2IF^5Z5CXMA'LRLED8U1X[>,D#I=>M=WAA,<9A8WM9(NT(D>V,`94
M#C74XNJ``*>Z22%L6;!-VLK9GN[**;LZLC=(7&FJND$:6AI!))KC0`E7@QQY
M@DQGF[TJG\>N-5RR*UM_'+CWR=?6:TY,HF+(RET+/U@OE>:PUC8SJ,K+.[G5
MG-`=B+2-2>H/Q*H'?;%(F=QDQ;LZYE9':0.>'0QRU)#=+9"X4(Q-1I.50>8P
MKC3;6VTB=)>3M86S214#7.+G1AIJ*4&DZAB:4Y'&FW'>9=C)Q0\.WN4H]IA$
M+IBSE!F'-,(O)L7<UQJIW#Y%["YM"Z-D&1362:C<JHMZG'-6P,QD'[D%RF*D
MF8HAO,/91RN80'1RO>.,8AP?7F0^C0,*DU1VSSB:6)KVDMDB8PTPD,V+-/(%
ME7DXT`HN-Q+\QZ!Y.Y7;8D>4.JU"<L^'WF<:,YHF?J#GQ$M2BYJN0TU4LL$H
MT;')8IRO$EM\<Y-$BM+,'*1W!6\@JHT5*+;]W9?7'RQ8UKW1ZVZ7MDP!`(?I
M^!XJ#3$'&CC0JNX;2^QM_F`]SF-DT.U1NCQ()!9J^-AH17`Y5&*O%=N5-SB>
M3CWC!CGC]-Y/G8+$>-<WW&]*Y1I./:=4*'?LB7B@NU9`EC;.YJ4FH4*(Y>MV
M;!NY&0*)DCG9]`*JSS7TK+[Y&&$O<(VO+J@`-<YS<>.&DD<\JCCCQ6<;K'YZ
M:81L,CF!NDN<YS6M=A3``Z@"213I44L.>;MC7,F0J/!0E(@!Q]F)KEE;#EG@
M<[4.YY->&Q94+5>VSO,>"X.-&PX4A<DUBF/EX1RO(RJB"IFS>119N')$PP;?
M?X;B5C6L;V4NK00]KG>Z"[WV#%@<`2#4\`0":+/N=AGMH7.<YW;1EFL&-S6^
M\0WW'G!Y:2-0H.):2`KBX2\PNT9-6P&_OG&UUARH<L,`W#.O'"SRN<*3:260
MU"H$'DRP4G)B+*`AF&*'KZESI9*/D57DDS%BV<&>@R72,W"2VWETW9&:#LXY
MX2^,ZP:T:':78`-P-0:NP!K0X*&ZVID`F$,_:26\P9(`PBFIQ:'-Q.OWA0B@
M-2*5&*C>Y\W*%O.*N8+1C'URIY`P%QB'D5&73C7G/'O)>LKUE6X$I#QI$6Z<
MQI!4Q#(%>G#H]35U$S$,[:.2K(N%>DQ0PW]XHWPSMHULT<.L.B>V44QKB6@:
MA3+2X&HQ6:-A?%<6Y)<Z&6?LRV1CHC6E<0'%VDCB"T@BE%/BC<J+KDCD1F#"
M-.X^3SZH8#R76L;92S=)Y.I,-`Q[JU8:IN78QY6Z*LW7N=I?HHW5JR>-$R-T
M&Y1*X([5$QFR6WBO99KV2TCA)CB>&N?44Q8UXH,R?>`IAS!.(&IELXX+..ZD
MF':3,+FL#23@]S#5V0^$D''E09J@^3O.T^`\WT/C]7:!0K)?+SCIWDR,?9DY
M&4GC%3;$Q0MAJ>C0L9VF\5VQ,LAY:<2!!<*PR8,DV3)5!99P`."`$.X;J+&X
M;:M8QTCF:O>>(P<=.EE0[4^OX12@H2<5+8[:;NU?=O>\1-?I.B,RN&%=3@TC
M2SIQJ:@#!4_>_,+D:58,I3Q>/D[+<<N/>7*+@CD+G$,FU=A-T/)=O#'Z,_\`
MNMB88AV_R%2,3RF4(9G8Y5.7CU@44<G8-'J;4YC62[OV;GO$)-E%(UCY-0JU
MQTUHVGO!NINHU'&@-%?%M0E9&SM@+V:-TD;-)HYHU4J^ONN>&N+10\*D573<
M=^7UJ/D^0Q#DH9F[S65?,2\P'`>/;`9Y&,6>.:)QK@%;Y7H%RR;QJ:LS&I0T
M>I'M1ZR."'4!1514`VU#M^Z.DNS:25<7W,K6G#W6M#G`4ZFT\ZOO;%@MQ<0T
M:V.S@D</S.D(:36N!J:E6^L/F#9_MF>^.=+X_<?H>Y5&\96\P+#E\KUKRS5Z
M3+6"Q\.IUG4D9:$LTE4I8M:C!526FNCLJF>HN2L3&`Z0K&AFWB[?>PP6<37-
M,DS'`FE>S=IJ#3"M">CC@I6;7:1VDTMY,6R-CMWM(:2`)AJH0#B>'12O%5Y6
M><ER=RCW&./,>6'/.=KMRVYC8GH=-N=XHN):O6:+Q>EX<+U/3N0(:E2*4?0J
MF6QQD;#`I$2]ADW4DB5TJ<"JN$\ANZO#S!%&Z6Y=/*UH-&M#8S1QU-:31M0!
M[I<=0J<R(G[;&&B>9XBM6V\+W$`O)=*#I`:7"KC0DXAH`-!P7,@?,1M639/"
MM%P?QAG+KE[+E2Y*RDW1+MF*G8SBL0W+BAE6J8;RW2+K<ON&WH30(7>S]B.D
M(9F\!ZF5%7X=-%915M<-X?*8X[:`NG>V0EI<&Z#$YK'@D!U?>-`0#7.@!J*/
MVID#99;J<-MXW1@.:PN+Q*PO8YHJ*>Z,02*8BM1C0#GS8H6:BN-1L?XDK+>S
M\C<,R^8HN%Y"<D<?<;*\T<5V_O,73V(*9?K/7[-`Y.S"RN<4Z#[N:%9-@C2H
M/%%TR.2$+`>\,;FQ&*(:Y(RZCWB,5!#2QIH[6\'@`,,:T*F&Q/:Z;MI':(9`
MPF.-TAQ;J#W-!!8RG$UQJ*8*8O,/,\MA'B_<LMI.+/5):#=8B27&KA3Y:R0S
MFZY8QY3G\8V&UQ-BI[X$PLRC1TL=LL4S855&IB+=E4FVW*=UK8NN,6N!9E0D
M:GM%,:CC0X998T6LVV$75^VWP<TA^=0#I8XUP(/"HQZ\*JP-S\P^R56YY75#
MC/+O,%X.YB5CAQD_,)<OU9O,L[?=[#C*J5^V4[$YZ\XG++6(RPY:B$I8CJ2C
MEVZ"AE&HOA(J1/7#>G&L@@/RC)VQN?J%07Z`"&TQ`+Q7$$<*K,CVEKXXQVX^
M;EMC,UF@THT.)!?6@)##2@/315:ERVRODI;-SS$N`'3K!>-)[/V(G'(I]EZI
MP]@2R1A2"M<5;+;6L+/*\YD9S'5:R9`*09'QYA&1=.T#N$XT[0@J&G%_<3F7
MY>'_`$9A>WM"X`ZF!P)#*8M#AIKJK7'32E8ODH(>R%Q-_I3Q&_LPPD:7D$`O
MK0.+3JIIH!AJJK?\6N<4E8<#5U/(41/7#(F,?+#XT\W<DWA:3BV@Y'?Y/Q[D
M"3FH=O'MHM%&'G7$MBAZX5<[&:B:2(!$"`D8#1V.Y%UJ!,"Z9EC%,YWYB]KJ
MCH-6FIRQR4U_MP9=GL2&POOI8&MI\.ES:&M<11XZ<,U:/DWYB>6IWC/R*L/%
M+#T@O8,9\%*]R0R)E68RK6*<.`)S.6#9G*^+(6H0DG4+(.7K_4JVV+-R#<Q(
MB.*W!NF591=P"!,2[WF:6QF?M\=7LM>T<XN#>S+FES0`0=9`%3D*4Q)-%DV.
MTP,OH67\GN271C:P-)[0,>&N)((T-)]T9G/"@JKC27.^<QI.988.*G>LUS\+
MECR^L%UBB)36.:4R"Z<M\/PLXWD*Y9'<(P53CG5@>B\EAGW;GM+G,#-1NW*"
M.I/\9=#,^(M?+)KB8![@%7AN1H.+J^\2L<;:R=D;@]D3#'</+J.=[L+R,17D
M*#2!TU*J4GF$V5JQME#G..3QKRJ@>4-4XF0>"(;+M?FJ?;;_`'G$;7/M<MC3
M-SFJPS*)QRRPX=U+S#MQ`_'L%(]9JDS<JG1Z\C_&'M:Z-\#OGFSB(1AP(+BP
M2`Z](.G14GW:BA%":5C_`,+87-E9./\`#S`9C(6D$-:_LR-%35VNC0-5#6M1
MBI'<8>14[GYAF9K;<8!B2\8(SC8<"WBKHWMADB)7LU<IU$N3B:K]LCH"L)OX
M)\QOC<J`*LD5P[1NX4AA$A<W;[M]ZR0O9V<D4I816N(:UU0:#"CAF`>86%?V
M[+-T1CD[2*6(2--"TT+G-H14X^Z>-%!/(O.K(%;\Q"&I[#(E#8\2Z!E#$G#/
M+U'=_NH-VEN1W(>AV*_UK)4:_<J!;VU9Q?.O*15'S=OLP5=6AP=8.XUW+J9]
MVECWMMN'CY%KVQ.%!4R/%0[5P#28VTKCJ)I[IIMH-MBDV8S%CS?OC?,QV.D1
MQN#2TC*K@)'@YT:.:E`/.>'"0=4L<8SX9@;<WV?"7_*O]XH\9-63?Q*61F^8
MB2P1G:_R\-Q].>\"7X<5@:HG8]??#N:V'^)MKV>AWS'S78Z:CEJUY?#V?OY9
M89K`.W.T]KVC?EC:=OKH:4KIT4K\7:?N\\\:45GJ5YFU6G^5S+BS.U7&!Y6S
M/LU152G<1\D:MFZ5C9?"E<F;E(Q.7*G`TN":XVD+)5X!RH@DWEYQ6/?IBR>$
M24^UJ*'>F2;@+!S6:G%X!9('D%@).MM!IJ`>+J'`JZ79I&;<=P8Z30T1DA\9
MC!$A#06$N.H`D9AM1B*KCXE\S)2WQV"+YEWCU+8+POR4X]Y2Y"XIR$XRO5\D
M3!8#"V.H_+%]C+W2*Y7XU6J"XQ^[6D(==)^_4>%:F2=-V*YRI!'#OH<V*6ZA
M=%;31%[':@[!H#C4`"GNFH()RQ`."NN=F$;IH;:8374$S8WMT%HJ]Q8TM<3C
M[V!P%*X$C%=O+^85=,>X"<<E\W\77>*<6VV$Q;(8*,ZS[CB7LM\GLV6:"KV,
MZ1DM@[BJ]"80FY-E9&TO)/5Y&;AH>-2==]T9PW!!65V[2Q6?SUU!V=NX-[/]
MXVKB]P#6NJ`&'$$FKF@5J:BAL;M<4][\A:3B2X:7B3]VX!HC!+W--29`*$`4
M:YQI04-5O8IY$-^>M.S+1(>*H]0R=@:U03.8_<_+,-G/#%MB\IXQMT7&2%1R
M]4ZY$%="YJ]CEVBX*PJ3ZOSS%(ZK9RW$O>NMKG_%XY86!C9X7"NEXD80]I`H
M]H'`N'PU:X8@C.VYM_\`!Y8I7E[K>9IIJ88W@L<*AS"3Q`/Q4<TY@Y7FXG\;
M'''MC*-5G::44#-Q$U:#5F$[98&;&4D&,U/O[C=T:[4D;-).I:.13CB$CR?=
MT<GVE%W*AS'+E;=MS[-I#LJ4`K4XFIJ:"IKEA@.)6+N&Z-O""![V9-*#"H`:
MVIH*9XXG@%%J?Y99LQ_YC.7:5:;/'O.(<$QXSX:^XU*[!-7>+,T<C,=V^V8U
MR4\MJ#%*=?5NZ7VF?N@\:OG"K-H^G8U1(J8=S?6/W"ZAWJ2"1P^0'9LI0#2Z
M0$M<74K0N&BA-*N;2F*V++.UGV2*:-O_`.1)E?6I]]D3@'M`RJUKM8(Q(:[H
M5J:#YK,E5^.G#Y.Y1M`R;R,RKP\JG)W*+S(^;L;<7JH,-)/'L`W1K\C.P$E'
M3^1;U88A^G&0<?&M6""3)19X[9IF2[D,._.99VXE#'WK[82NUO;$T@X8$@U<
MXU`:`!@:D"E<F;8Q)>W/9:V64=T8FZ8W2FHQQ`(HUH(JXDG&@!Q4K<=\_)?.
MM[K%-X]<:[AD9E8>/7''DL_M=HR51L5QE2H?(M_>F,9#S\;/(2LTYNM94H;G
MN,H]%X@\$%/]X;`FD+C81;J^ZF;%9P.>UT,<M2X-HV35@1B:C2<J@\QA773;
M8RSA=+>SL86SRQ4#7/)=%IJ010:3J&)I3D>'$8^9CBM7'^(<AR5)M4/'W'"?
M)7/6:(E608N9OC=2^)Y%*_EUE<FB31,;)9&V703J$>T;_!_&R`G7`Q4DC%U;
M_C4'8QS.8X!T4DCQA6-L6#Z\R'^X`*5->5%<=GN!/)"'-);+%&P\)738LT\A
MH]\G&@ZUKXF>8K!\F\K#B)_1:I3[#,XA5SC37%`S]0\_L?W093T#`353R>O1
MHV-1Q?EB#5M4<NK$BI*,'**J_P`+(+&:K!JNW;LR_N/EBQC7F/6-,C9,*@$.
MTCW7BHPQ!QH30IN.UOL+?YD/>Z,2]F[5&Z/WJ$@LU'WV&AQP(PJT5"R/=[^<
M/];\^MUH6D[8=*=[^</];\^FA.V'2G>_G#_6_/IH3MATIWOYP_UOSZ:$[8=*
MZ(RX=1O'UCZ_?^'62&FBQW/Q.6:LAR$P;4.2N-_\IL@2$PA1']UQU;+="1/W
M:+>]Q&.[I#7HF.[0G*,9!%S1K=*P#9"9;ID(LZ8@=`%"%4/OC7MBR^@^7FKV
M1>TD"GO!K@[2:@^ZX@!PXC!9-E?R6$_S,(;VP8X-)K[I<TMU"E/>`)TG@<59
M:S\%<0C;;-><*O9'B=8[M@RWX!MCWC55<;XY2FJM;+5!VMO:3,VM/48MLD4M
MQ&O6\%-$3%Q'H3+H0`RA6YDL-VR6XD=+:$V[WPF,F,-%02#7(^\VATNX:B<\
M5ELWNY[-L5T!<L9,V0=J7.H0"*9_"ZH+FY'2.E4@'ERX2@ZC;J!B^TY%PY1I
M.ZX>R_C6JT1_7U(G`6?<+)M$(7-F*$+)!38-K'=4(UM^]<=)_>$-8%@<.%FQ
M7+YXLM%_N_:MC=%`Z2.(N8]H;2D;V4H]@((J:#4'5#L2<7.)D_Q^[?(V:X;'
M+,&/8XN!K)&_.-]",&U.@BCFX`&@`'8DX!428J-P;W/*^8+=G*Z9IJW(IURB
M8.:?2\P5G,6/ZHVH6/;%C^-JU5;X\JE>I>/VQH-&!&(=Q3Z+>/$GZ;H7:IAN
M_P`"B=$YLLDK[IT@D[6H#P]HTM+0!I`#1ITEI!!<#7453_'96RM,4<3+1D1C
M[+WG,+''4X.).HESO>U:@00"VE`N!-\!83*KN\2?)_/^7N2,K<<$V?CFQ<R\
M-BG%#2CXYM=QJ609%Y4V&):-7#IWQ"[4.'DFLNZ7<?"N&!.TW*03%&AV)D[I
M'WTLDSY(C'6C&4:2TU&AH]ZK6D.-:4%`JMWQUN&-V^&*!K)A+@7OU.`<T5UN
M/NZ7.!:*5!S522_#JRY`QQ9\99UY:9RS?"3TUAN9BW,[5<'TIS6W&%<IUG+,
M,]22Q[C6OH6"Q6N;J;1K-R,AWC+L@,#9)JJ85!O=M4DT#H+NXEE:2PBH8VFA
MX>/A:*DD`.)X9`*QFZQ03MN+.VAB>`\&CGNKVC"P_$\T`!):!D<R5(6N8?KE
M9SMFSD"RE)M>V9VK6'ZO:(AT=B-?BF.%FMW:5M>!329IR*;J33OCH7HN%UR&
M%)+M%3`#]69'9LCNY;P5[29K`1P&C52G''4:UZ*+"DNW26D5D6M[*%SR#Q)?
MIK7AAI%*>=1HROP*J&5+EE:14S'EFFXGY$V&B6SDOQ_K"5$4H>;+#CZ/K<*Q
M>O;'-U.3R%1&UMKU-B(VS-H*3:)3C&/3(;LG.LHI@W.R17$TCS)(VWF+3+&-
M.EY:`,R"YM0T!VDC4!PJ:Y]MO3[>*-O91/N(&N$4AU:HPXDX`.#74+G%I<#I
M)XX*K+=PMQI<(#/]<D;1=VS/D5R<Q?RKMZK%:`37A;UBE]A-_`U^M`K#*HHU
M)^K@F+*Z3<E<.Q*[==M8@BEVY';/"^.:,N?IFG9*<JAS.SH!AD>S%:U.)QR4
M<>\31/A>UK*P6[X6UKBUXD!)QS_>&E*#`8+19N)<M_F_DG+&).2F9>/Z6<+#
M6[AFNAT6"Q'9*Y=KA68*(J:=QK\ADJ@6ZP8UL]@I]?81DLYB7`)O4&:2H)).
MBBN-7[4X7#Y[6:2!LI!>UH80X@!M1J:XM):`#0X@`X'%49NK/EH[:Y@AF,((
M8YQ>"T$DZ2&N`<`XD@$8$G&F"KB#X[,*=6>1<+CS*&1<?S_(S,USSM(WVOA3
MW=FQY=KJQIL>]2I+6Q5F:K3J!:-J2@F5K+L9'OHN7":IC`<HDDCVWL89HHI'
MM?-(7EWNES7$-&%6EM/=&8.943]Q,LD#YXXWL@B;&&G51S6EQ]ZA!K[V;2,A
M1=1QIXN0''&6S!<0O$QD;)&=['5+'DJY2%.QMC:.D7%&KIZM5F\1C[$E6J%*
MAS-(I947;SX9>2DW"HJ.7!P(B1.W;MJ;MYD>'.DFF<"YQ#16@H*!H`&?6>=`
M`+K_`'1]\V*+0UD$+2&M#G.IJ-35SR7''(5H!D,U9DWEZUG]]#RC7/F98_&!
M.7D9S>88,CXO%"-4+G=O;RWF6<S5S4H*^4+/49>RF571C'4O_P!V][H05%--
M`B6+_@$?S':B63LA<"<,HR@?JU''3J()X5Y8T`IE?X])V6DPPFX^6,!D)?7L
M].D4;JT`@85`QXC$UOGR>@\43;3"\[EBUS=83P_GRE9XIS6`12=/K!<,:1ED
M1;14HR/'2*PU5)E9UE9)<HM`;=*0F<H]8`?,W"&![8GW+BT1S-D%,R6@X'`X
M8XG"F&(6)M\UPTRLMFM=VL+HW5R#7D8C+'##.N.!4:B\*<<9KD;S;*CR4S5&
M89R-R?HO*^T8,@HK&[&N)<A<=VC'5S>.)6:LV.W658ZO6.6Q[%O'M?._0;@J
MO\8V4[2J.M>=H@NG.DCGE%L^=LIC`;3M&EIQ);K`):"6UXU&!"V'^+SVH9'+
M!#\U';NA$A+R>S<'-P`=H)`<0'4/(Y%7WJ/##&]-R52\H1UFN[F;HO('EGR-
MC&#U>"-%NK?S#C%XK(4,_(A"HNS5NMH.!-#%35(Y(<`^)57#PU/%LMM#=B\:
MYYD$DCZ&E*RZJC*M!J-,>55BR[M/+;NMW!@8^&&,X&NF$U:<\S^+AR`50<F.
M.DYR0B0K*>>;MC"ER=8GJ?>*+%8XP7D^H7B)L("DO)NHC-&.;R%?N48R46;L
M91@=/L)+&ZT%3%3,6_<=L_Q!H89GQQTHX`,(<*UQU-=0]6%,""K-OOVV+M8B
M9)*'!S7%TC"TCA5CFU!S(/I"C=?/+$Q[9:UD7'='SWGC#F)LR\>,7<;,OX]I
MI\:V`;Y3L+4%[C'',RI=,A46U6ZNV)K2'H,)8\>X13F444^X5(W68V'+W>A>
MQ\,4TL=O+"V-[1H.IK&Z6G4YI(.G`T^*@KBL^'O!/'(R>:&&6YBG?*QSM8TN
M>[4X:6N#2-6(K\*N=D#@E1+JOE&<B<EY)H=[R%F[CAR(@KQ`H4R5=XTRIQ=Q
M]7<;8[E*Y`V.N24!.PLC7J__`-[1\NB[2='>+`F9$O;`DL^Q6\TCYFR/9.Z1
MCPX:3I=&&M!`+:$$-%0:UJ<ECP[S/$(V.9&^%D4L9:2X:V2N+G`D$$$$X$4I
M09KZXX;VJ/O%FR+CWEWG3%=HRM&4$G(1S5*?@>09YEN./JRPIC#*;6-MN,[`
MQQ)D2:J<6VCI!Q6R-V*S9JWZ6I%D2+:O.TR"5TT-S+')(&]I01^^YHTZJ%A#
M'$4!TX8#"HJ@W5AA;!/;0R1QEW9U=(-#7'465#@7M!)(#JFI.-#12"Y`X3K'
M(O&;K'-EE[/51;V:E7VG7FE.V+.Y8\R1C:SQMRQ_?*PYEV$O#J3%:L<2BMV'
MS1TR>(BJW<)'25.&LR\L8[V#L7ES?>:YKFGWFN:06N%014$<00<BL*RO);&X
M$\8:[W7-<UU=+FN!:YII0T(.8((S!JH\1O!.HN".YW(N7,GY3RO8.2F!.3UX
MRY.,:#7)FUVCC3\.AB2AH52HU>*IE4QA7XQ`[<6$<T3=J&=.7!G0KK&.&O9L
M4%1+-)))<]LR0O.D$EA&EM`*!HIP%<2:U*S7;S,/<@CCCMA!)$U@+B`)?C=4
MDN+R<:DTP`I0*4>7:;9,DTIU6*EE:WX8G%9*-D&]WID)1+.^!!BJH9Y7YBL9
M)K=MJ%CJU@;JF1?LW#0#J)["FJD<H'ULKJV=<1=FR1T3ZUU-#2>JC@00>/J(
M6OMIFP2]I)&R5E"-+BX#K!:0X$<"#YBH35ORX:G0V-`FL9YVRACG-%%S-F3.
M!LTUBF82;JSUEY!5>%IF7((^(#8[##-<J$_7JQ%@S9QD.W/'O8\CSN+.%7)E
M]3%W>A@:PV\TC+EDCGZZ,))>`'`M+=-"`.%:BM22:[:3?99G/;/#$^U?$R/0
M728",ES#KU:R02:DNQ!I@*4N3@W@WC?`\[A&R0=]R?;IK!;7E@C!R5V?5AX^
MM;GF'DR&RKDJ5N2\-7(1-U*1=CA"%C3LTV20(JJ=Y-0W2)<FTV>"T=$]CWN=
M%VM"XC'MG![BZ@&((PI3IJL>[W>XO&2L>R-K9NQJ&UP[%I8T-J3@0<:UZ%#:
MY\+L^6/D=&0-):7S'7%=ASAHW,Z<:2V=L1V'%$M8:O<8[*MMD*9BF*Q*EGF,
MLN2\@L!4-"2EI+689XZ=221E3&1;%U<NT7<E^&Q!S+$739C5["PD.#SI:&=H
M"YWX2_0#5W(+:1;K:,L2^4L?N)M'0"D;P\`M+&ZGE_9D-:?B#-;@`T\2I3&X
M#UFOFJ=BQ%F[+&'<KTC)G)W(5>RM!QF-[9(GB>7.15LGY?QA8Z==JC,4NRT)
M6TD9+Q8+-22,>O%MEBNCG[W=V/\`@D;"V2WFDCN&OE<'#2<)G:GM(<T@MK2E
M<1I!KG77_P"-2OU,N8HI;=\<32PEX%86Z&/#FD.#J5KC0U(IE2B\E^6U$9-;
M9KB9#E/R&AX'DWCK&U%Y*-8Z+P@ZG\R2F+*RUJ->NDE<)/%KJ9J+F4A&2)):
M(@_@(9X=/J20;=Q8%(+CN]'<F37/,&S,:V3X*O+0`'5+,#04(;09TI4UEM]^
MDMS$YMO`7P/<Z*IDHP/.HM#0^CJ'(NJX<2<%-#&>'*SBR\<@+[!R<X_E>1F3
M(#*=O:2IV!X^%G*]BNB8C:,*V5HT:N$XI:`Q\T<*`Z.X6%XLJ)3@F)$R[6"S
MCMY9IF$ETT@>:TP(8UF&&5&@X\5JI[N6XAAA>&AL$98*5J07N?4]-7$8<**!
MU%X'7FQ9&Y%2F:,O75A@_(//.:Y307'2KH8R6I.1FE?)BN>QC.7FY$JSG*<8
MR+>:&D^DJVG+(-G:D6U[@$1.JFMIX-EF?-,;J1PM771E$8TZ74T%I<=.JFIH
M);7&@R%:[F;>8F00-M8V&[99B(RDOU-)UAX:VN@G2Z@=IJ*GC2DC<;<3I?$&
M15YK%G)+,M1PU(9<LV:GO&MM`XCEJ2:X7FQO[G=X**OLQ07V68+&UMNDLZE7
M4$UEB@FY=*D;.$&YQ1#-CVIT,I-O<2LMG/<_LP&$:G&IHXM+@TN)=IKGD:8+
M`GW,7,`;<00NNA&&=K5X=I:-+26AP87!H`#B,AB"<5MP_"G&,+QUQ!QF0M%Z
M/2L,9IH><:].++P`VB2LV/L]N>0L5%32A(8D6>#=VUT9FX*@V1<#'``$4*M^
MUU<W:+=MG'8ASNRBE:\'"I+9.T`.%*5PRK3I57[M<OOI;\M9VLL3HR,:`.C[
M,D8UK3'//H4>N/G!.^Q<V_FL\Y<NCRB5[G=G[EYC_C7#H8S/C)Q9)W.%SR%A
M>\6:YQ%6+DV8)$HSC><&NNI<6C:=(0ZH"1`C<NOM-DEU.=>2O[$74DK8P6TJ
M9'.8ZH;JPJ'4U?%2OP@+-O=XB<P-LXV=LZSCA=*2[501M:]H:3I%:%NH-J6Y
M9U4A:GPJQE4*1QQH;*S7=[$\9>1ETY,4YQ(JU]5W8;C>9#-4C+5^V`E#(M7%
M414SI*$23:IMG70U;`=8P@J*F>S9[=D,,`<_3#,Z0&HJ7.UU!PR_>&E,<`L*
M3=KF2:>8M8'3P-B=G@UH8`1C\7[L9U&)PRIU&(.&CW"C%KCZH<F\W*<<8&'O
M->H_'24A<0.:]4*]=HR>CD:H&22X^)EFPTVB&L*JU>CWLJ8S(R#9-==T@@5(
M:6VTFU'8QSR_)`.#8R&4`=44U:=9#:^Z"<,*D@*ZYW7YH]M)!#\\2TNE!?5Q
M;3'3JT!SJ>\0,:F@!-5IEN#]<1QIPXH^/LN9'QC:^#41&0.$,JL(/&]QL1HE
M'%@8=G4K75;W4IRAR[RR4T`$723!LO'O2@LU,F43I'H_9H^PMHH9'QR6H`8^
MC2::=!J'-+34=`H<D;N\OS%U+-'')'=DE["7M%=>L4+2'"CN%348%;^&>#>.
M\+V+#5KCLA92NEAPO9>75NC)>[O:HZD+?/<S[6PN647]R5@JS!-G"\7,L`&,
M%BBQ(0JAP6(K]GII:[+!:OB>U[W.B=*14MQ,SM3JT:,CE2B76\7%TR6-S(VL
ME;"TANKW1`-+--2<QG6O0K_2.'ZU)\B*!R46DILERQUB+(^&8B$2.P"LO:YD
MVX8[NLU)R*9VAI0TTQDL:LTFIDG":`(+K`=,YA(8F<ZSC=>,O23VK(W,`PI1
MSFN).%:U:*8\UA-NY6V3[$!O9/E:\G&M6-<T#E0AQKAR42:UY>E?Q?"X9+@+
MD#F+"E]PWBF>P83(T5"8HO3K(V)YW(,QE!*KY$IE_I$W2Y![5[K.NGD+),FK
M%Y'F<+$$RR2RB8ZR/8(K<1FSFEBF8PLU>Z[4TG50M<TMP.((`(J<ZE;*3?)+
MA\OSD,4L,L@DTDO;I>&AM6N:X.%6@!P)(.&5%>B(QQCS`.39?.UTRE>K-?K]
MAC#_`!ZE7]Q;QTQ-W%OA.6R/;6-I0@*%4F4E(7:==9&D7$S\"R)&H((I"DV:
MIE,)LQMK!9SF[ED<Z5\3(S6A+M!<:T:VNHZCJH*=`6*ZXN+VW%I%&QL+)7R#
M22`WM`UM*N)&D:1IJ:])5!X]X=<8I2S\L\KPZDM?X/FS"RM,R;5I62$*E68"
M592L7E:I4>)(QBYVC+Y'M<BZF;.W<&!Z,_LJ((F3*0(8=IL'27%PWWVW0(<"
M<`""'AHH"W422[CJ4T^Z[@V.VMG48^T(<TC,D$%A<<0[2`&MIAIPQ5R,!8"O
MV$EF+&?Y5YKSA2ZU3F]%HU(R17L.QC>OPS`\8G%2EAM-#Q]5[?D2WQ,3%)L$
M9*4>?:;*+'515<*BN$]G82VI`?<2RQ-;I:UP8*#"A):T%Q`%*D\ZBIJH+V^B
MNZEEO##*YVISFN>:DUJ`'.+6M)-:`9TQH**OHW#E8C.0MQY()2$RO;[MA:A8
M,E8%R,>I5D:MCV[7R]1<BV0!H63&9D)+(3Q!UW'!VYFR20$3*?K,:5ME&V\=
M>U/:.B:PC"E&N<X'*M27&N-*44#KN5UDVQ(;V;)72`XUJYK6D<J`-%,*UJHY
MXTX<3^#Z\[HF-N2F9'F"JY5<E0N+^-5AB,1*U"M-[G`65E"TMWDY.A(9;G,?
MTV2L`GA&#N7ZV!44"+.'""!4]84&TNM&&*">0VK6N#(CHTBH-&ZM.LM%?=!.
M&%20%G3[JV[>)IX(A>.<TOE!?4Z2*NT:M`<X#WB&XXT`)4>./WEH*J\<\/8Z
MY=9=R3E28IG"R1XKQ>.DSXUKU0P2QRIBZO8^S3^X5AQY4H>2O%G6BH<L1&3\
MVXD5&T4D)"E4,X765PK+N_\`Z''%N,CY'MM>RTU:!&',#7Z2UH).%`230=))
M.=>[_2]EFVR..-CKKM2[WRZ30\N9J#B0T5.HM:!4]05QY+RVZ_=(')43E_DG
MG#*TADKB>'#1:7?0&%J0UIV'T+I&79@:E5?'^.("!C[.C(Q29%W+I-XDZ`QC
M"D39,I+W=VX)0\W$\KWOA[*M&-HWA0-8,1EC7AD``H&[_+$Z-UM!#&V.X[:E
M9'5?0CWBYQ)&.0I13+QGAJM8KO.?[_!R<Z_E>1>2*YD^WM)8[`T?#3=9Q51<
M1LF-;*T:-7"<6O`4!HX5!RHX5%XLJ)3@F)$R[>"RCMY9IFDETSPXUI0$,:S#
M#*C0<>-5J[B[EN(887AH;!&6"E:D%[GX]-7$84P5G.5G$UQROBI2EV'/%_I6
M)K=2WM#R'B:*Q_@N\UFTQ4DI(DDIV#D\IXWN-DQS?G<5)G8_?,0Z34112041
M23<HD7UB;CM(W$:'S/9`YNES0&$.&/%S20:$BH/(@5%5E;=N?^'.$K(8WW+7
MZFO+Y&D$4H"&.:'-J*Z2.=30T5N[%Y>&/9N>L\='9<R]6<`Y'O6,\GY>XQQI
MZ3(8^R=?<4L*/'P,M)W.=J\EE6`B;,3&=?5L\;'3"+>?<1@'4%(7#H%HI-B@
M?(:22-M'O:Y\51I<YND`DD%P!TMU`'WJ=)K,S?+AC&ET<3KQC'L9*=6IK7ZB
M0&@AA(U.T$M]T'C04[F?X)5A9S'V:@9ERCBW)]?Y79SY<U3)D)%XZL[^OW+D
M;"2-9RM2C56Y527J,Y0I>NRBC=ND\:J/FJI$E@<&.00-0[#`UW:V\DD=P)G2
M!PTFFL.#FT<T@MHX@5Q&!JK6;S+0QSQ1R6YMXX2TEPJ(R"QU6D.#@14T-#E1
M4U%>7G!U"#Q8;'/(S.%0RAB/-'([-4!FJ0C,37:WS<IRO?OW^:ZY;J[8:#^X
M,M#3RSTAFBJ,8T=,%6R1TS#L8AK6[!''H?#/*VY9(]X?[CB>T)+P06Z2"3RP
MH%([?))7R=O!"ZWDBC865>T`1`!A!#M0(ICB0:E5"^X'U=@[96W&.9\J8FS!
M!\@.0O(.JY=@X['=FE823Y1*LCYBQV^J%QJ<M2K1C:<"+9'0:O6AGK5TP;."
M.@42'KO=L<0=VT,LD=SVKWAXTFG:?&W21I+3AF*@AIK@HV[S*1V=Q%%):F&.
M,L)<`1%\#M32'!PJ:D&A!(IBJRPIPPQ?@JY87OE7LE]FK+AN@Y[III*UR,/(
MN\DSO)?)]-S%E[)F07+.'CCN+O/WZG%=)A'@QCFZ3Q5$C8$R(`G/:[1;VDD<
MK'/+XV2-Q(]XRN:][G8#WBX5PH!4BE*4BNMUN;N*6&0,#)7QNH*C2(F.8QC<
M3[H:ZF-2:`US5F+%Y<,'+8`J_%J'Y&Y;@<"1=#N&.K;C^1H/'O(36[PUYN%P
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M=4CD/F*GX6RO=<I9+M_'".B<6/J(>^9FC9A'(;V&N4Q1W^3X.J3]CG%[`I!(
M2H-`FS&4(<K8ZC4U6;3V<C^SGD;:R.<YT?N$:G@ZCJ+=0!)U:0::NC!5?NAD
MBC$L,3KJ-C&MEJ\.TL(TU:'!A(`TZJ5T].*M;(^7%5D(*LUO'?(?.F)8IKP[
MI'!S(YZBSQ3*2F6L(XWBI^+I2TM(W*@6(*7>8I.V2H*2D$DT%PC(*I=LG2DH
MGCOV"(M:R*:6-HMVPNII.MC00VM6FCA4XCGE4`C);OLNMTDT,,CC<NG;4O`8
M]Q!=32X:FF@P=6E.M<.\>6G3K-5;C0:?R%SGB.AY:XSXXXN9UK5(9XHD/\W*
M=B3'3[%=$M+N6NE!LK^DW=O29`\?).806B,HR(FB=-/ME4U;)W=@,;H89I8X
MI(1'(&Z#K`!:#5S26FAH=-`13#`)#OTT<C9I8899HYW2QEQ>-#GN#W"C7`.;
MJ%0'5H<5=.6X-8NF+;.7!>UWQ*0GLU\/LZNFR#BO`R1L_"VIQ]/QQ$MRG@SK
M!`V:.C2*393',X.L8?A56Y=BA,=AM3<?,:Y-?:1OIA2L>F@RR.D5]2QV[S<-
MB$-&:1%-'QRG)+CGF*^[PYU5M^1_#]5VWRIEC#S+)5GSM>.2>'>2E9<5+)F,
M<86/&%]QGB&/P*$YCR=R71+?0)2,>8U9N&\I!V1D\;2Y)-TF"R&R/19?[57M
M+FV[1UVZ=D@HYK2US6".K2YI:?=!!:X$'4<L*36.Z`&.VN3&VT9`^(ZF/>'M
M<\R4<&N:X'50AS2"*#`XJON`F#<J8'H.7I/-LJ[E\F9XY&7O/MB93-N@[_-P
M;>QUZCT^%@K/=*I4J'4K#9/N>B(N7QH:(8Q#11U\(S*=%N54\VS6,UG!(;D_
MOY9G2$5#B*AK0"6AK2:-QTM#16@P"AWF]MKR:)MI06\,#8Q1I:#0N<2&ESB!
M5U!J<7&E3B53,OY:7%ZQ8BRACBR5AI/7S+%OR+D:>Y-251QXMR1B<C9`R$[R
M4UNE7R.-1%Y"25`GCM$8!),OPS1A&MVYTU"=SKC?W?V^2!\4@K/(YSC+0=H'
M.<7:@:8%I/NX4H!G12-[P7[+F.=CZ0QM:T1`N[(M:W3I+=6(<*ZN)))5YT^*
M.,PY<-.:#E_9WN56V*D<:.(=9ZR2HDA+(HJQ`Y;=0#=@DJ3*AZ2Y7KGQZ:Y$
MB0:YFY4@\#!EC:[;_$1N=7?,=GII^&OYZ?GT^[7\N%%BG<Y_\-.UC3\OVFJM
M#JIGHK7X-5'4_-C51]Q1Y==6Q5,X,['(#,]HQYQCELOOL!XCEXO$L74J3'YG
MIMTI%C83DS6\?Q5UR#)Q45>77P$K*R*CT`(0%^\8RRBF+;=WX[:6)XEE='`7
M]FTAE&A[2T@D-U.H'&A)SQ-223EW._R7+)JPPMFN`SM'@O)<6.:X$`N+6@EH
MJ`*<J8*X,#P5PU$4GB?CN0E+;:*CQ'P_DO!]5BIU>&%+(-&ROB)#"MM0R&9A
M%LS*NUJ@B8R9HT6!2N53")1)L4)AL=MV-M`\N=%;1E@!I[P<T-.J@Y#A10/W
MNZ=+<SM#&RW,K9"17W7,?K&FIY\ZX*CFG`<CS$9\&7SE5R)R'CJKQ>-V6"4)
M-+$<!:\`R^&[1"6S$U\K=TK6.8^9O>0Z(]K3%JWD++]XMW4:B=!TU6%PNJ>,
M;%6W^5EN)WPM#>SP8#&6$%K@X,JYP(&+JUIB#4UD.^4N?FX;:!D[B[M*:R)`
M\$/:6EU&M=4DAM*$U!%`I38=Q_?\=L;`3(W(&_<@)J=?L'+>7NE3Q;16-:9Q
M[11J$96JSBJH5.);DDE%1</EW0NW#AP!1*9),I4@V-K;3P!W;S/F<3FYK&TZ
M`&-`QS-:U*U]S<P3EO801PM`R:7NK7B2\DX9"E**\7?#V_3^?65I*Q=?4HI7
M7B%BG(<ART=VUY99)MS%HN,*)D2-(\8-$:PWQ%69ZNTNQ4%XW8ED8FTQKJ<+
M*I.UU7`MY1BV61`@$$IM=+M,$QN3)J(NF-:X<M`(!;A4$5K7&A`HMC%NUQ`V
MV$0:#:O>YIQQUD%P=P(-*4PJ"05:"O\`E^PV-('!*&!^0^8L+7K!O'^%XP_Y
MD1D)BF]OLI8>KTJI88.*R74,A4F>IKZQ5^R.G4A&RK!JQ<LEWSD@@J@L9+6*
MS8A`R+Y2:6*:*$1:J-=J8,0'-<TMJ#B"`*$G,%93]]=.^;YR"&6&68RZ27MT
M/(H2US7!U"*`@D@@#(BJD;CG`4)CS*ULS.I>;U=[[>,+X4PK:9:Y+UU529C<
M'R&0I6'N#L("!@D2V^TR&2GZLJ**:+`132!LV;E`P&SX+`07#KK4]\SXF,)=
M3'LRXAV`'O'4:\,J`+!GW!T]LVUT,9"R5[P&UP,@:"W$G`!HIQSJ2K7U_@AQ
M^A[?R_M#YA8+.RYJQ#^M91IT[*IFJU;JMDCIDF0:UC=NP;,W]6C<E6FQ/K',
MB"ZJJTZX^((8G00I<9FR6;);F1P+A="CFDX`$'4&<1J)+G?K&JR'[W>/CMHQ
MI:;0@L<!B2"-)=7`E@`:W]7!5Q@;!&0<,+MVMEY5YHSI4X*H-:12ZADBNX=B
M4(&*8*QQ8Z7G['C_`![5K3D&YL(R,(Q))R;H0.W45.H@=PJ98)+.QFM322XE
MFC#=+6N#!084)+6@N<`*5)YX5-5%>7UO="K+:*&0NU.<TO-2:U`#G$-;4UH!
MGQI@I-]_WCK8:>A8%6\D[_O'33T)5O)._P"\=-/0E6\D[_O'33T)5O)=.9<O
M4;[7K'\NLH-P6$Z4U.>:A[SMR]>,.<;YNQ8UGFM0NELR/@W#<1D![',99IC$
MF<LRT?$\EDT\9*)JQ+YS1XNVK/FB;PAV8ODT.^0Z760VKWF>:UL#);D-E=)'
M&'4KH[21K"^AP.D.J*X5I7!;79(HKO<!'<`OA;')(6XC7V<;GAE1C[Q;0TQI
M6F*L`+;$'&KDIC^A!FKS"W.3)AM=&\83+MNS/D[CER"G(?$5OR!(UV?M-WC)
M7%L;;8:%KSB7[=74@5V+QB+?M]D3-QP=%K87\<(FOC<$.IK=(^*4B-SB"YP+
M*@`N]S30BF6"SNUO-QVZ2?L;$6S2VNAL;)8@9&L!#6D/+22&^_JJ#7/%45#<
MZN1LGQ:P5R'ML;Q;Q1)\GH7%4MA/'[2)Y/<AKU/K6RE3%SM<(WQSB:J1]KM5
ME1BV[5\T:Q9S,XF.!V:2?'%),ZD+-WOW;=!?2MMXW7(88VTEE<=32YPTL`<3
M2E`W!HKJ.%5,_:K!NYS[?$;J5MLYXD=6&)HTN#6G6]VEHK4$G%QII&-%'>S\
MB.2?.)/R^:M`1]8Q.TR?R)YBXUSE1'=ZY)X8):+IQ1A+>R8D=2N/EZ9FNJT9
MX6'4F"0#U9M)(396[22!9N@H)M;+?[AN[K.&)H87S3-D9JDCU.BU@8@MD`]W
M5I<00Z@-:%;".SV_9OGI9"^4Q00/C<&Q24;.6G`.U1N=CIU`$::EM"0IR>6/
MDOE-EW`#6Z<BI_&%M1?6_,L'4YRGC=%+^\7I>?LJ4MXTN:<TR:5P8.&C*ZW9
MPIF!1=G8-TS/!%<3F'>=WI=RNK+MKXQO!<\-(KJ]V1[3JKA0``-IC08XK2=X
MX]MM+XPV`E:0R,N#M.D:HF.JVAK4DDNKA4FF%%+KD+FVN<<<#YCS[:^A:`P[
MC>V9`>,S&*495>O1+AW$P*/4(`9U8IH&S!$OI,LY*`>(ZVE]<QV%E+>R_!%&
MYQZ:#`><T'G6LL()-POH;&(_O)I&M'14XGS"I\RQ/>7-R;S'<,><F,'0.>J#
MS#Y+8WI>,N0V/++<KJ^=4^><YOI+:0N^%9:U0Y!D("OXKSI6YZOQZI$U$XJ+
MDHHRA#(E$H\QL&X7D]O<6C96W.X1M;(TN=4'6/>82TFC6R-<&\6M<VH&(73]
MX+*UAN+:]DA?:;=(]\3@UOO#LW>[(&G,OC+7'\S@ZBNG5?,MN.7,-N,Y8?Q'
M52U#(&;<)\2^/L=D.W.&\Y,\E+_-MJ_E9WE4U/--LZUB+#<TY69('9`K+696
M+7<->TS=L%E,B'?I[JU^;MH6]E),R&+4[.5SJ.UTR8S+"I<6FAH6DX\NQ16E
MW\E=S.[:.&2>4M;@(6BK-&JE7R#'&@9J`-2'`=+?^4_("W7:N<,K;.U_"V7I
M3F'C'C]E+./']S*$B7.(<A<<KWR9KTQB`V16LS+8[R7D6/HJE3$KX9->'='5
M=LEE%%&QDJ3;A>RRMVJ8MANC=,C?)'6FAT3I@6:JZ7N#=&-=)J6DX*Z&QLHH
M7;O"'36@M'RLCD`KK9*V$A^F@>QI=KPH'"@(P*X=VSAB[AA(<GY''5UYKV?)
MF&.+F;,QM<)<I;)G*WX%RLSQ))5)*2R#C_(^6FTQ(O5XJ9G&<>HZK4T1@Z;2
MIS&;&,FDHFFNK?:77!@?=NN(;:1_9S&1T;]!;5S7O!K0D"K'4H[+*B"WNMW;
M;-N&VC;::YCC[2$1ME89`ZC7L90"H!-'MJ"W/-2FS+S'5Q5D?(5&E%,:TN`J
M/"!KRG0R7DEY;?W8C+9*98-BZ+J]ECJDUD+`_K*KM5`2)13=>:>/%B-FQ#J*
M$*.?>;H;2X?"[LVL;:=MJ<3347%H:0`21U8G(8T6ML]M^:MXYF=J^1]YV.A@
M;4M#-9<"Z@!ZSI`Q*B##^9YFMG1^0Y+!ANJ3N3L+WGA="U+XVFYZXXU7)-:Y
MB972Q;&NGU,SG`K9/I;FJ2#1Z8DEVY&.?D[2A$MTUV^M:W?[L0SZXFFXB?`&
MU;)$'"=^@>[(-;:&N.(/I"VKM@M#-;Z)GMMIF7!=1T4I8;=FL^]&=#M0IA@1
MB*Y%7DRYG[F4[D\P<?*O7^,D'E'%G%RV9XS)=S3^:'U-CZY>G>4*QB2G8C*T
M85ZWCD%1ACJ5D)2=D"ECX]RW;%;LU16'LY%W=[N3)8Q,@%S'`9)'`NH&N+PP
M,R-:,<7.X8:02<,2TMMI#8K^5UR;:6Y$4;:1ZB6AA>Y^;=-7M`:,2":D4Q[G
M'>+)[D5P7X>2$E/R<],3_%3CZ2]+S-LDH:UVQI(0^#\JOYAED,8NTOXB[N+=
MCEF==\NT=?&(NG'6=-<$5B306<E_LUHXN)>ZVCU5<0341O)U4-':FC$@UJ>-
M"H[B]98;U=M#=+6W4NFC06MH9&4TU%6Z7'`$4H,Q4*4_'_$TA@_%3^MO9-B[
MDD(AL@U+$)E(SAX6GTMA4JBP.\2CH4DW8$(6"15DY0K%@1\_.<Z;9%(J9`S[
M2R=:6W9N(U4X<`UH:W@*F@Q-!4\`L"[OVWESVC00VO'B7.+G<305.`J:#B2L
M(7&CE%R,AL$<!<991S/D"U7[/.=^`^<:/DZQV)ZYM64\"9WL:U?SMB*RS1SE
M<6%MB_*0`U<-U1.)JU88<IP,"8CKB[+<;V.SLXKF5[GRRV\@>3[SHY".T8>>
MAU:X_"Y@YKM-PL;%][>W%O$QL,$-S&Y@'NLDC%8W@<-;,0?S->IOX@\Q/+V8
MLQT4M4PJ2<X_W_D3<,"(IP>+>2R^4*;6ZI;+?C[_`(@K5E)S0$^-CBE'N=//
M]X0C21%U%1KQ)0S]9TBX:DW$&]W5S<M,,!?9NF='@R76`TN;VA?I[*A<W%H/
MN@CWB00M1<[-:VMJ_MIM-ZR!LF+XM#BYK7=FUFKM=6EV#B*$@^Z`05O43GCR
M6E>,=#YH7O$."8+`,[;:>RN,75KID>>R?4L9R>:W^(;EEEXF_@(RI,HZIMQ;
M3*D<#A^JBP0=&57$>DJ58-UOWV#-UFBA%D7-#J.<7M:9"QS\0![N#J8T%:GD
MFVK;F[B_:899G7P:[22UH8YXCUM8*$N)=BVN&-*!<C)OF+7R&ECU_'^/JJN7
M(?*O,''7`UYEJ[F3)4%)U/C31$Y3/N8;11<*5^Q7ZTL&>3&DC6Z]'PB;9%T5
MF=Z\>H-R&,-)][E#^SAC%7SOCC<6O<"V-O[QY;&"XT>"QH;RJ7`);[+`]NN=
M[AV=LR61H+&$.E=2)@=(0UI+"'N+JTK0`E30XDYKOV=,0HW3*6,I+&EVB[O>
MZ1+P@UZ_U2(M[:F3JT?#Y&H4)E.O5C(+"D9&AA0?QJ4LQ3>-C*J(',J*/=/N
M-LGFO+7M;B,QRA[FD4<`[2:!S0\!VEPQ&H5&6*U&YP6]E==C;R-DB+&N!JUQ
M;J%2UQ87-+FFH-#0YX54->)&*;;S!P)BOE??^2_*.NYCS:H]R3%-<4YKL%*Q
MGB*,-=9=M!8?K^&623G%\[!5*(B4XJ;/8(J5DY1Z1VJNX(<Q`2U6V6C]TLH]
MRGN)VW,OO>Y(6L8*FC`SX"&@4=J!)-23RVNZ7D.U7TFV0V]LZVA]PZXPY[SI
M%7E_Q@N)JW20`*4'/OJASES)8Y_&65Y#'6*&?$G,W,68X;T].-FKH?D'!S:6
M2KKAJLY:L*+I`<>NZO9,G45RW5@&R:<C&1+I!V9XX4(LW*;N]T7,NC%'_ADE
MP86T)[2H<Y@<?PT+VTTTJ&D'4<0K9=JLXVR6HDD.YQ6HG=4-[(C0V0L'XM08
MX'4<"X$4&!5.X$YU<B<BON'=WR)C;!D'AGF-EC+N$JS'4>PY$D,JTJSXZB\S
MSM?N-@=V!JWIS^OVEGA9ZW<Q39(74>HZ16*]<`)T4Z66ZWT[K66>.)MI=2/C
M&DN+@6B0@FN%#V9!%*BH(<<A?>[586XNX8))G7=I$R1VH-#'->8P6BGO5':`
MAQP-"*#-=3A+S!L\V:(XAY9S/C?"5>PCR^K>;7<"PQG.9#F,HX]D\,XRO^6P
MEK$M9V[.JST1;JOC620^[F::;F,=G;[O'93'Z++/>+V06UQ=Q1-L[EKZ:22Y
MI8QSZFN!!#"*4!!IB[%77FSV4;[JVM))77EJZ.NL-#'"1[64%,06N>,3@17`
M*B<;>:AE5_42YQR5@4ZV`Y[C3EKDLW<8[QIR4@[#A^*Q]C\F4:;3<G9)RSCR
MN8=R"\RK5Q,R:2M9<(,VLX0$DTWK11-T,4&_W+H_FYX/]"-N^6K6R@L#6ZPU
MSGM#'%S<`6T&K`5!JII^[]JV7Y."<?.BX9%[SXB'ESM#G,8QQD;H=B0\$EN)
MH<%5'(W,WF25'"^%+L<W$R@SF3.3?#"NQZ%*E<R21XN%S%DF.B+'B:].9F*<
MM['#+HRL>TDYV)!@JZ8G??"LVZQ6RAY+Z??H[6*8_+QODN(0`TO.#W@%KJUJ
M,15PI4$^Z#116$'=^6[FA_TE[([><G4&"IC82'MID<"0UU:&E2155AE/F?RF
MHI>2\G"8XX[6"&X&8SHEXY4).+%D^-?Y(G['CYSF*V5?CDLJT%&LL*EBQ-%R
MUD+2D]^]9=?X/LMDDSN=27&Y;C!VY;'"YMG&UTV+@7$LUN$?*C,07`U<:4`%
M5';[;MDWR[7R3M?>R.;#@TAH#NS!EYES\"&4HW&I."O=A_DGF[.&?\V4^GT;
M$,5@?!>2J%4)RZ62SWD,L6Z'R%Q[QUFF.4K5,C8%:K1<M$N\AH(N5I"2*@LV
M**::!5B&5/FVMW=WE]-%$R(6<,C6EQ)UD.B9(*-`H"-7$^98=U:65G90RROD
M-Y-&YP:&MT-+97QFKB:D'2:4%:\:*DN</,#(/'F5@:YA]7&5KO9\;7;*,IBF
M;Q3R4S!D2<KM663092;%EQ\AY-EC6COWJ#EBO9+&;X5)Z!2H(+@DN!8MWW":
MQ>V.U[-TW9N>6%DKW$-Z(@=#3B-;L*\#0J79]NM[]CI+K6V'M&L#P^*-H)X?
MO2-;LCH9C3,BH5G93G[R*R#'V*>X^XPP4R@JAY>^"^?<V&9[-D)S,/F66H7*
M5C<XA@TJ&S;Q_P`<G'XV.BA/.%2(M55>L[)T50"(XC]WOIFF2QBBT-LH[@ZR
M:T>'G0--.#/BX?E/#*;M%A`YK+V28O??26P[-K:586#6=6-*O^'C^8<;;\K.
M9F?LT\:.8SKC/%4''=0Q'P+K&9,D7B]3^06^5FUDY$<=YW,E;K>%'&/E(QE7
M)_'-&%N\-/R*BR;B7720101(DJX+C7^Z7E[873MO:R.**TUN<XNUU?&YX#--
M*:6@'4:U<0*"A*R-NVVQM-PM6[@7R2RWIC8UH;HI%*(R9-5:ASJC2,FBI)K1
M94;1F&N84XV2N<[\Z5/6,6X))D^U.'"QE'3]G5\?H6%Z@*JAA.O)32[;L)[B
M)U7"Y0W$QM=-+-':6!O)C^[CAUGS-KZ3[5S<<+KS<!90`=I+-H;AQ+J>@9]2
MQ,^6ARKR_D:'Y"X70S]1.4/(Q?$N.>7&,G-NMTC)TRLV;,\(X8Y&XU3$O!$^
M^(.F85S#$)1K4&Q53QT7/-C@4Y2]`\SL%_<W#)[;M6SWW9MF9J-0"\$.C);4
MAK'B@IB&N%1P73=X+"UMG07;H'V]AVKH7T;1Q$9JV4`X%TC#4US+2KM5?S.;
MIDS#%VSICG"U:0K##(^$^*%"K]TO.T_,<U,F7VMX\R!6+;(U$9V*@\&8:L5M
M;-CS+=-:1LPMG#A@F1J9LHMD1;[-<6K[N&%HC$C(6@NQ,[G!I#B*T8PN%2`2
MZAIAI)QI=BAM[MEG<2N[0QR3.+6X"W8TN:X!U"9'AI.DT#*@'&H'7Y4Y7\CW
M-F+PYN,Q3<09OE^5'%S"-JS_`("&84KC7"O)&A90R4PMF.(W*+:<D*+EJ6-A
MV3J#<DB:5292#YM(-3'.HDDG2?<+XN_PR;3#=FXBC=(S(,E:]P<W5JTO/9EF
M.JA(<.`5;:PV\1?XK$'2V8MII!')2O:1.8PAQ934P=HUYIIJ`6GBMRWY5Q9P
MXN&=CT>_\Y)[)^+>+W)/+\;B/DK:\YWOCKG`F#ZC!6R8M-2R/E=K-IN96M/I
M2/:K.JK+M&YTY54BC90Q$^U=++;;7+-V+[MUQ';2O#)3(Z.3LVAQ+7/KB"0*
ML<!CD52&&XW6*'MF68MY;B*,OB$;98^T<0`YC*8$`FCVG(8J2&1.9[B@7&)K
MLVECBDUR2X`W3F-)9&R#*65M5*A8ZY:\<51A7K$6#;O)1>D&<7[N.3LT5I=4
MR1$FQ#JJ%*;.N-R["0,?H:PV3IRYQ-`06``T_#[W#'DL&WVUL\1D9K?(+YL`
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M>6AA<6M`R<7&CM1H``,`2<-=%;;1\N-PD?<&U=,V)@HP/+PT.>YV):&`%M&X
MDU()%*FUF%L67'DSY=7".5FIJ:N$M:^*6!T,B/I2<A7U^FBGD<098>V2)L&2
M8VRU:7L\M-X\3:219Y!PV?-GG>4[IVQ6[B*TLY=PV.T>XESW6T>HD@N/P/J"
MZH));0ZL"#7A0Y%Y>P[?OMXQH:QK+F330'2/C90AM"``ZHTX@BF%:B>_&+%D
MUB#'D=5K(XC%I0QX!N=I$"N=DRC*K3*KC^"!XX66<%?V21A*BW=RSA$P-3/U
MU$VX?#I)".YL+-]K`(WTU89<@T-'6:`$\*Y8+2[A>QW4YDCKIQSS)+BX]0!=
M1HSH,<2L#&!N57)"L\9N,50R9FO(=GN7(O/G#+-6),HV"R/E[5:,87CEY5,0
M<F<`R4\<Y7,I&421=,5TFBACB>KVY)`0,DT/MQ=EN%\VR@BFE>Z2::![7DG4
M6NF:R2.O$-J#_->!^$KM+VPV]]_<RV\4;8H(9XWL`P#VP.?%(!PU`$5_.PGB
MI\T[S$<O9&SFPC:-A5.S8)<\KI[B^\90N+>2\EEB.AJMD&5Q1:.0CO)[7'Y^
M-C2E5N\0ZZ[V`-(F>MH%,SA5^1X4[(NYCWFZGO`R"#5:&X,6#)=7NN+#(7Z3
M&&APJ6XD-Q+M7NK2R[+:069=--IO!;";%\0826A[8PS5VI<6D`.I0NPTTQ6J
MN\[^33WC;+<Q[#AS!;'`M2OUCAK;#0%TR/-Y9;XQQ_R4EL,9)RJDS6@&%2C$
M*M1H5[8?NP73]8P,%!,H4BI4T;H]TW`V!W1\4(LF/(<`YQ?H;*8WORH-+074
MJ<L^`2;5MPW`;2R68WKF`M):T,UNB$C&9EQU.(;6@S'+'L,N>8I<JO,V2$QY
M0:O,,;-RTE.)>!;W(0^6;_"6"2Q5B20R1R,RE9:;AVOV6]VFKT:?BGE<A8^`
M0(K)2#)PJZ=M6R2BQ+;C?)&O<R",$.N.RC)#W5+6%TCBU@+B&D.8`W$N!J0,
M52VV6&1C7SO<TMMA-(VK&D![PR)@=(0UI<"'N+C@"*`D@*7G$#.&1,[8UD[%
ME;&[K'-QK&3+=CUR!:IDJE5;(<175XY:"RG0*YEZOUG(T73+E%2J8IMI1J*[
M1\W=-^\N5(JIMMM=Q/>VQDN8S'*UY;\+FAP%*/:'@.#7`Y'(@BII5:K=+>VL
MK@1VT@DB=&UV;7%I-:L<6$M+FD9@X@@T&2Q.\9LEYSON8:]*8[O_`#/NE_C_
M`#!.5%2Y!,[T&1I;AC#\1Z+EW,U;2B8R6O4.7&C"Y0$3$P#*NHTU^>83E4S)
M.DP0*Y*7F]ODO9[QKH'W+Y!>3-EU:S"(FO>*`N&BH`:&AAU:L\*TZ7<(K*"U
M<VX9:,A-E"Z+3I$YF<R,U(:=>DDN+NT&G3B,:*1./^=O*R^X$XOY;'$7'*"G
M^;EHQ[CGCS7/WZRC,LZO9K'$7ZYVR[YG=%KD8!*A#X^QV_>L(6$77DW#\46B
MKXH*&62S8=UW*:RM[KLH`^[<UL3=3C0D.<XOP&`:TD-!J30$\1@S[5MD-[<V
MO:SEEFUSY3I8*@%K0V/$XESP"YPH!4TX*@[QR\YKV;,?'?#U%)@&DY6IW-/,
MO&C/4<^?9,>89RHO#\/I7D+C:<BCLV#F\0M&DZG--I%U'G5/*QUE8H(?$.&7
M>.>&;<-VEN(+:$0LNFW3XI![Q8XB`RM(S(&D@D5)#P!4M4T.W[1':3W4W;/M
M7VD<L9`;K96<1.!_"7!P(!R+"30%5N_\Q+.3W,=MK=!PE'7R@XKY'5[C)>J]
M6<7<H+-DJXSC26J%9R_E"@Y#KF/G^!JK4,:3UI7=(0T[(*R3^&B5UW+F/56;
MI&F.\W;KIT<,.N&.<1.`9*7DU:'N:X-,8#"[)Q)+6DDMJ`HALUDVU9)--HFE
MMS,TE\+6-%'%C'-+A(7/#:%S10.<``ZA*J*=Y.<PLK8"Y,9_PM"\>*=AFI5W
ME[7L9/+1+Y/<9P1=\?$,E4EKEUVM$,'./T?O;(E!<*L:\+;NM6)FZZ[Y13N-
M1ODO-TN;.XO;00LM&MF#"2[M/W>MNO\`+BYI]VF`H=1."C99[3;7UO8W9G?=
MO=`7@!O9_O=#M&/O8-<*NKB:@-IBMK%_)/FI+T_AGAXS#C//<B^26#'N<4<A
MV%QET^-H'$6/\>X=7F)J\P<<G%V>Q9DNUZRJS0.UB5V<*R1.NZ`QP3(@I9;7
MF[F"UMBV%]_/$9`XUTB-H94D`BKW%XH`0`,3C@:W-GL[9;NZK<-L+>81Z0&:
MB]SI*!I-0&-:PXD%QP'&J8\YY\A,[6C!^.L/8>PM#7K(6&>0]XR6OE._WS]T
ML>7KC/R.A>.-Z@:PXIE5>S-]K<[9EW:T4J=&-7^',@LNH7H404O@W6^O)8H+
M:*(3/BE<[6YU&NBE$3@*-JX%U:984)/!)]IL+*.:XNY93"R6)K-#&ZG-FB,K
M2=1HTAM*YXU`YK*\*BA/L+$%-4H`"I!ZPZ%``.X4`.4IMBGWVW`!V].NE[-<
MSVC>A?._\MQ^K3LU7M&IW_EN/U:=FG:-3O\`RW'ZM.S3M&IW_EN/U:=FG:-3
MO_+<?JT[-.T:M(K#[/RZNT!6]HOG='V?+Y]-`5.T3NC[/E\^F@)VB=T?9\OG
MTT!.T3O#\O\`7IH"=HN-WR_K:DTJ'M3TIWR_K::4[4]*=\OZVFE.U/2G?+^M
MII3M3TIWR_K::4[4]*=\OZVFE.U/2G?+^MII3M3TIWR_K::4[4]*^@L4?Y7S
MZII3M3TK5W`_6#Z--*KVO2G<#]8/HTTIVO2G<#]8/HTTIVO2G<#]8/HTTIVO
M2G<#]8/HTTIVO2N@,Y-U&\`_2'\NLL,%`L(RXG#BJ.R#2*7E>CVO&F2:O$76
M@WF$>5RVU2=;BYBIR&?D`KAFZ(0Z2R9@,4JB2R1TUVZY"*I'(J0ARQ3VL%U"
MZWN&A\#Q1S3D0?+S'$8J2"]FM9FW-LYS)V.JUP.((\NHC`X*-52X2XAJ]JIU
MND[CR)R>]QJA8D,6Q69^0^2\G5S&G[U5&6H,V[JD/8)8Y%I9Q2IUY&$?2IY-
MZBU<'!-4IAZM:Z+8K.*9LSG3R.C!#!)*]X95I::`G/22`75(!.*V,O>"[EB?
M$UEO$V0C68XF,+]+@X:B!EJ`-&Z149+NIGA[A>3QE@/%<0?)&/XKB\VBV6!K
M;C3)EGI>3<>L8RF.,=K,8^^1[@\H_9S]'=JQLHD\!<CY`_48`5*10M\FR6,E
MM!:#6R.V`$9:\M>T!NFFKB"W`UK7K5C-]O&7,]TX1R/N23*U[&N8\EVNI;D"
M'8MI2AZ,%R\;\0\#XG6Q6YI=?LJ#O#&0\UY5H3^<OEMM4FUOG(9K+-,LSLY+
M624DY6U+V1.<=&+]X+.!;JJ]P@]8;ZK;[+M]JZ-\+7:XGO<TESG'5)762236
MNHY\U2YWV^NQ*V8M+9HXV.`:UHTQ4T```!M*#*E5:BR<&*VTIEFQSB')&5<=
M4+)N::=D7(U+6RA=9*IP5/:Y95S-E:I80A$W:9\8/<Q6HYV\FHW<@@5B_=D3
M!,HD3'&DV&(1.@M))8X))FO>W6X@-U]H]L8_!VCL\:4)IR65'WAD,S;B[BBD
MGCA<QCM#0XNT=FQTA_'V;<149@*666L7T3.%7;4K)$2YF*JWNE$OBD(UDWL4
MRD9S&UNB;U4VTP5@JD:5K[:SP31PXCU1%L\!`J:Q3$W*.RNK*"\C[&X%8M;7
M4K2I8X.;6F8J`2,CQ6MM=PELI.VMS270YM:5H'M+74KD=)(!S%<%168>.6*\
MYSSBTWIO;FUE>XDR#@I_8*5>+'19B0Q3E&6KDW=*D\D:X\9NE&\A(U=L=!<I
MB.F7<<?#J)_$*B,5UM=K>/[28.$AB=&2UQ:2QY!<VHYEHQS&-*5*FM-WN+)@
MBA+3&)6R@.:'`/8"&N`/(.-1D<*@T"H2;X1\9IF.R)#(4)[58/)S#$24]!4*
MTV&CP\/8L")1[;#V2J&PKCYBE0<L4-C#1[5K8HOX>06:1K1%P99-`@:QW;#M
MKA(T1EK9`RH:XMH8Z:'-I\+VT`#FT-&M!J`%.SO!N#'1O,FI\1?0N:'$B6O:
M,<374QU22UU14DBE5H;\)N/)L97G%UC@[GD%GDR]Q.4[[D#(.2+E8,TV+*5:
M1BFM.R0&7492-N5?N-#903)O`.HA>/+#MVQ4FQ$R&5*H;L.W"V=;/:YX>\.<
MYSG&0N%-+M=0YI;I&G21I`H%1W>"_P#F67,1:PQL+&M:QHC##74SLZ%I:ZI+
M@X'43BNNC.#F#>_<WM_D\SYXD[WB.YX%F93D!FN]9/=L\.Y#5CG%UH==2?OV
M,=`,+(ZAF:SIV@W"446:(G%UN0-&;#8@O=,99G21.C)DD<_W'4U-&(`K05-*
MX#%5=WAO:,;`V&!K)6R@11M9^\972XT!)(J:`FF)P5/-_+QXWJ1EW8VI7-63
M7^0L2P6#[#:\IYVR/=[BCCFI7)AD&D1E:GI"734I\G1[E%-9"+?QB;5TBZ;$
M54.LJ)U#Q#NWMFES9.VD<^,,+GR/<[2':A0UP+78@C&N)J<5(>\VXZF.B$,;
M8Y3(&LB8UNMS=+B0![P<TD.!J*&@H%WS#@K@)$M[<6%7+F1K!D^8P/8,A77*
M.9+S>[I:ICC3>%LB8<=O)R8D#?=Z-:M"PJ*-6*31D[1#M*(B`G$TD?=_;HVO
M:1(\O,9<7/<XGL7:H^.`:>``!&%%&[O%?G1H$4;(Q*&-9&UK6B9NF3`#&HXF
MI!QJJOS7Q.Q)GJY%OUP>91K=I=T"4Q-:Y#%&6+KBD<CXKEG[R66QUD<*;)1R
MEHJ[26DG3EH43HNFAW;@J2Y4EUDSRWNS6=],)YNT;+H+"6/<S4PU.EVDXC$T
MXBIQH2%%9[W=V,/80B)T6L/:'L:_0\`#6S4#1U``>!H*BH"O?0*?7<84*D8S
MIC)6.IV.J?6:)4HYPZ7?KL*S4(5E7X%DN_=&.Y>K-8J/2(990144,43&$1$=
M9T%M%;0,MH12*-@:T9T#108]06%/>27,[[F;&:1Y<XY5<XDDTX8E5AUE<(.6
MZP[).45FRI0$2B9%PD=%4H&#Q*(IG$-P\0U5\8.'"BM9+QY%185X4\:5ZQQ/
MJ2U(=J1?"*Q5FT\;'!K+-_?5%E:E')1<41W-`Y!_9(U9JV0%VU?&51=JMD5%
M`$Z11#5'8]O,5M"8SHLW`Q8FK2!05/$<P<Z!;<;YN`ENI0\:KUI;-@*.#C4T
M&0/(C$5(XKEU+B'BBAY+6R11;-FZG-'&1)7+;O#]:SAD"(X_.\F3[MS)3]O<
M8>;2A*X9:?F7:LB^CBB6%=22AG2C(RYA.-&;):17!N(C,RKRXL;(X1ZCB3H!
MIB221\.KWJ5Q23>KJ>V^7F;"\]F&=H8VF70,`WM"*X#`'X@,*T5?U3C]B.F8
M#'C'#5H5<*GIUNH*]2EY1],'=U6]+SSFS1CN6>JJ2*_QRME>"503]Q'N%Z!#
MH+M/%MMK%9?X>QI^4TN;I))P=6HKGQ*@EW.[FOO\1>__`$S6UVH4'O-I0T&'
M`*WLEPRP$\PWAG!\3$V^D5CCLO'2&#+3CW(-HIV5<83;",DX=>Q5O)<4^)8S
MS5BC)M\C-'>'=(S1'JX/4E^OP@?LEBZTBL@U[8H/X9:XA[30BH<,:D$AU:AU
M34%9#=[OVW<UZYS'RW%1('-:YCP2#0L(I0$#32A;04(5\,7T*.Q-4VM1AK-D
M*V)H24I,N;/E*_V+)5ZEY68=B]?/):VV=VZD5B]X0*W;)=EFS1*5)NBDF4"Z
MS+:T9:Q")AD<`2:O<7.)/,G'J&`'`!85S=NNI3*\1M-`*,:UC0!@*-`IUG$G
M,DJ-3K@=@DTW8'L'/9[HE.MUQ>Y!MV%<;\A<H4+!5CN4M+%GYZ:=XWK<XQ:1
M2=GG0%Y*L(MQ'Q<FY454<ME!65Z]>=ALM;G,,[(GOU.C;(]L9<34G2#A4XD`
M@$UJ,2MB-_OM#6O$#Y6,#6R/B8Z0-`H!K(-:#!I()`I0X!=_"\+<#5_+K/,,
M<UOWQ<1E&?SG7<8.\F6QW@2J9QM24BG8LQ5C#*SX:A$7V55F7SD5R)BT;OWS
MAXW;HNECK#5NP[>VX^9#9#[Y>&%[C&'FM7AE::C4GD"20`22K'[Y?/M#:.+*
M&,1E^AHE,;:489*:BT4`YD``D@454U;BSA&F5S`54K]=DFL)QDR!9<H8<;+6
M:8=*U^YVZ/R)%SLC(N5W!UK`V<LLJS92-W8J(I"Y()0`44]IX]ILXHX(F-=H
MMWE[,3@YP<#7G\;L#SZ%%+N]Y-)/*]PUW,89)@,6M+"`.7P-Q'+I6BJ\5L&T
MRN\<ZG`UAZE`<4G-I=84CWUAE)-."4NE0M=$LB<X+U94;8VD*O=I)OVG_=(4
M5P.`=1"[(MILXHX(V-.BV)[.I)IJ:6FOYJAQ&*2[O>S27$KWC7=!O:&@%=+F
MN%/RT<T'!49COA%@[&2#JOP,EF27Q8>IW&AQ''Z[9NR#<^/=3I-]8.8FS5.L
M8HG)9Q!M:^M$/5F;)JZ,\1B&BIDH\K4FP!!!L-C;U:SMC;EI;V9D>8PTX$!E
M:4I@`:@#`4"FN-]O;DA\G8BYU-<96QL;*YS34.+P*UKB2*:CBZJZ-OP%P:3'
M,QBN2MW(VT5%V.-QJ)+AR/R=9IC#QL.V1M;L6N,+3,G+JNZ!(TBP,D%FKXGQ
M+]9-ND@Z7<-TRI!:-@LA;NMBZX=$=.FLKR6:#J88R3[I::$'$F@!)"O/>"]^
M8%RUMNV4:]6F)@$G:#2_M`![P<*U&`%20`<5KN?`7`.0W@/;G+9NG%)JGT^A
M9;14SE>V++DI5:"\=O:G&\EV$6^8M,N'BS2"Z!EW!&Z[J/6,Q<&59;-P3=W[
M"<@R]L?=:U_ON_>AM:=K3XZ5(K@2"6FK<$A[P7\`I$(11[G,_=MK$YWQ&$D5
M96@-!4`C4*.Q4E:3C"CX\L^6+A4HQ6-G<V7*&ON0UC/W#EI)66`HE7QK$N8V
M/5,+2#9M:=38]L#9J5-$3(BIT]9S".QALH8))98@0^9X<[/$AH8*<O=:!@M=
M->SW$<44KJLA86MRP!<YYJ>)U.)J5:C,?$[$V<+JAD&TR>5:Q:%<=R.(;.]Q
M1ERZXK3R+BB2E'<VICO(I*=)1ZMEK32:D'+IJ`';NFRCI<I%P2643-B7FS6=
M],+B;M!*&%M6/<S4TU]UU,QB:9$5(K0E95GO%W90F"+LG1=H'@/8U^EX%-3=
M0-#0`',&@PJ%O57B9@FE1<[#5VM2;./LG&BA<0Y=%6SS+H5\#XSBKC"4ZL)*
M+.#&;2D?'7V3(I)DV>N!6*8YQ%,FUT>T64+7,C:X-=;M@.)_AL#@T=8#CCF5
M23>+V9S7R/!<VX=.,!_$>6EQRR):,,AYU:V^>7?QGR%'.8.22RU7*S-X/I_'
M2^53'N;,@T&N98Q-CRO/*K0('*\=6Y9F-U>TZ"D5VS-\L=-RH@J9%R9PWV1#
M%F[N;;,W01*V,Q"-P:]S0]C00T/`/O$`FASQH:C!94'>/<H':VF)T@F=*USX
MV.+'N(<XL)'NAQ`)&6%10XJ263<.8\S#C$,.7^+>2V.CK40[ROMYA_&%E6N.
MK!`6:N1$P[8JHNI&#4E:PS^/:*&[,@W(=%<#)J'*.QN+""ZM_E9P3![N%2*Z
M2"`>8J!4<1@5KK;<+BTN?FX'`7'O8T!IK!!(KD:$T/`XA=+E[C_C;-UAC;?<
MPMD?;HC'>5L3L+51;K/4.Q(8_P`U-H)MD.O%EJXZ:.@2DC5IDNU6`0<1KM`%
MVITE1$VK+O;;:]>))@\2!CV`M<6G2^FH5'4"#F"*BA5]IN5Q91F*$M,1D8\M
M<T.&J.NDT(X5->!!H:A6RD."_%M[#7FM-<<FK=6R)CW%.-[-5:99K!4*\+#!
M2K17#-RA(Z`?L0K>6,9ECFB45:F)D)I-!DV3475*@D!<8[#MI:]C8RV-[&M(
M:YP'N?`10X/9AI<*$`-'X13(;OVYAS)#+JECD>\.<&N-9/XC22#5CZG4PU;4
MG#$K6PX2<>BXZR?C:V1%SRLUS38J]<,I7K+62+=<\NVZV4I"-;8^LILHGD8^
MU5R9QHE#M?W;6AEHT811+NM0(JHJ=0S8MO;;R6[VOD$I!<Y[G%Y+::3KJ"W1
M0:=---,,4=OM^;B.XB<R(PM+6-8UK6-:ZNH:*%I#ZG7JKJR.%%Q8#A#A1A-2
MMANT]F[.\Q*8QR!A=-UR%SC>\L)0F*\JM(UAD>F5^.EG[6,CFMT90S1)^\,B
MK*+D;)[NMR[B9L5FUY?,9IG&-S/WDCGT8^FIH&`]X`5.9IFJR;[>.8(X1#`P
M2-D_=1L95[*ECB0*G34T%:8G!4G%^7-QD;1=CBK*&8\H)V?!;_C4^>Y;SMDB
M_P`G'82=SM<LK"DUEW*3)`JI*S-U*.<QCZ/(WD6ZS4JBBZROV]0L[M[:UKF/
M$L@="8O?D<ZC"0Z@QPH0""*&N))*F=WDW(N:Z,PQELPE]R-C09*$%QH/>J'$
M$&H-<@%W*'`?CZLVR0%M>YERA-9>K^):OD>Y98S;?+[=+-"X-R&OE'&+,TY+
M2/3#I5ZXN#+"2/1:(N4A$BQ#B=0Y[V]WMO:U[7B5YD:P.+GN<2(W%[,>%''@
M`#Q5A[P7]8^S[&-D3GN8UD;6M!D9H?@!C5O,FG!7)S3Q?Q?G:[0>1K5)Y.JE
MWAZG/X\>V3$65;AB:4N&,[1)(34YC2\NZ;(1Z]CI3J:;%=I(&,DY9N#*&;+H
M]Y4#Y%YM-K>RMGE[1LS6EM6/<PEI-2UVG-M<1Q!R(J5CV>[75C"ZWB[-T+G!
MU)&->&O`H'MU#!U,.1&8-`KI8LQY4,+XSQ]B#'C%:(H.+J=7J%2XIU(.I5S&
MU>K1J$1",7$F_45>R"S9@V(0RRQC**"'481$=95M:16EO':P`B&-@:T9T`%!
MCQ6+<WDUY<R7<[JSRO+G'`5+C4X#+%5\1V<ABG*<H&*(&`?LCX@.X>&IM"@U
M]*B$_P"#G&23QWQMQ:_HKQS4N(V1*WE/`)3VF=";I5RJLH]F8QVI/E=EDYR-
M7?OC&>,G9U6SPJ:0*D'LIB75G8]O=!;VY8>SM9`^/$U:YIJ,<R,<0<"MJW?M
MR;<7%RV0=K=1EDN`HYKA0X4H#A@1B,>97:Q'$7%=:RI(96J%FS=2#S>2C9DL
MF+:7G"_UK!%HRHNZ0?R5WGL21THG7G,A8)-L1W*M$A1BI9X`KO&BZISF-5NR
MVC+HW41F87/UEK9'-879EQ:#3$XD"@)Q()5KMYNI+46LK87AL?9A[HV&0,R#
M0\BM`,&GXFC`$!7'HN#L78ZQ$^P36JZ`XLDT,CM).L34@ZG4Y%GEJPVFT7YD
M]=R*BKIPSFY:YR(]L3;(HK@F38I"@&3#M]M!:FSC;_HQUU!J:ZR2[/F7'V+'
MGW&ZN+H7LCO])&BA%!30&AN7(-"M4?A3QX2P/BOCI"U^T5&AX,EX^S8;G:7?
M[55\IXUN4<M-K$O%7RA%R"5K0ML@:RR1)!TNLN231D'"+M-9)4Q-8IV.P-C'
MM[6N;!$:L+7$/:<?>#\ZFIJ?Q`D$$%97^.;A\]+N#W-?/,")`YK2Q[33W2PC
M3I%!0"E*`BA"O?BK'D;B*L?NQ$6O)-T[LU(V&0M&7,AV+)]WE9:3^&!RL^LU
MF<N'";))-HF1NQ:D;,&A"[(H)]1NK,M;-EI%V3'2.%2:O<7N)/2>'("@'`+"
MNKQ]W)VKVQLP``8UK&@#H`SYDU)XE,78QI6&ZS+5#'[!U%P$W>\D9*D6CR4>
M2RBMORU<YJ_WI^FY?**K(MY.TV%VNDW*()-DS@FF`$*4-5MK*&TC,4`(87O>
M<2?>>XN=Z23AP2YO9KN02SD%X8Q@I0>ZQH:T8<@!CQS*M*]XB8+=<?\`''&E
MO$6>#QOAQ6I/\1R%;O%C@LCXSL-$=.7E0M],R.P>)V:*M<&H]7(5V*J@+MW"
MJ"Y%4%5$S8KMGLG6,>WZ7"WBIHHXAS2W(M<,014X\02#4%90WF]%])N)<UUQ
M+JU@M:6/#OB:YA%"TX8<"`10BJH]UP1P&O0:_2&CW+\)-5K+\QG^/S3!YCN+
M'D(OFJR0$C4K/DB7RZ=TYG9B=L=.E5H9VDX(=A]T]MJDW2211*G"=@L/EVVX
M[4%LAD#P]PDUD%I<7YDEITD'#3A2@"F&_P!\)W3GLBQT0B,98WLNS!#@P,I0
M`.&H4QU8DDDKNC\-<3(Y$DLE0-NS[2)*S6*K7/(E6H&?LC4['>6;Q4&,+&QM
MWR;3(:60C[%:I1C7&2<TZ2,T"P%;E"2(ZW-U7_X):?,?,L,['%P<X-D<UKW`
M`:G-!Q)`&JE-5/>JK/\`&[LVXMGM@>UK7-:71L<YC7$DM8XBH:*G2,=-?=HM
MR)X:83@[K<+9$N\J,*]?9C(EEM>$&V7[PAQUE;5EN)EH;)=E4PRC)IUA.2N;
M>>>KNT2[1P2#I1\DV3>#WP,V2SCF?*SM0QY<71ZW=F2\$..BM*FI)X5)<!7%
M4?O=Z^%D3^R+V!@;)H;VH#""P=I2M&T`'&@#2:8*D6?`;"L=2,=TJ/O?)1@Y
MPX]D38:R,SY$7Q#+V)*U+5:*I4EC:B9$(O\`>[+%KVKP;-JK!NRO&QS-DG`B
M+I)-<D0[O60@9`'7'[HG0[M':V`@`M:[/00![IKB`<\5,>\%XZ:29S+<B4#M
M&=DW0\@EP>YF6NI)U"AQ(R-%=&@<5,$8M>4)]0*DZK:^-,*W/`%0,ULL\X,S
MQSD*V1%[NI9!P_?NGLW;K'<X1&3=3KM5:45>G65,L)UCB.3!M%E:N8Z!A:61
M.C&)^%Q#G9G%Q<`2XXUJ<R5BS[O?7(>V=X<))FRNP'QM:6MI04#0TT#1A2@I
M@KO8]IT)C&B4_'%77FEJY1:[%U:"6LU@E+78E8N';$:,SSEGG'#N:GY0R)`[
MSMTJHNL?<QS"(ZRX+9EO"R"/5V;&@"I+C0<R<2>DK%N+I]S.^XDIVCW%QT@-
M%3G0#`#H&`58_$&_6#Z-2Z%#KZ4^(-^L'T::$U]*?$&_6#Z--":^E/B#?K!]
M&FA-?2GQ!OU@^C30FOI6T+GQ']IZ_:.KM"IK3XG_`,I](Z:.A4UA/B?_`"GT
MCIHZ$UA/B?\`RGTCIHZ$UA?!<^`_M/5[1TT)K"X7Q)_8&I=`4/:CDGQ)_8&F
M@)VHY)\2?V!IH"=J.2XZTHW;F`B[A!(PAN!3G`#;>W;Q$`U>VWD>*L:2%8^[
MBC-'D`]:VOOMC_C6W]?\VKOE)OR.5GSUO^8>E<HCXJG]VHDIX;_8.0X[>W8H
MB.VHS$1F"/,5*)V.^&A\ZU_$G]@:IH"KVHY)\2?V!IH"=J.2^@Y,`^(:IH51
M*.*U?%>[\NJ:%=VPZ4^*]WY=-"=L.E/BO=^730G;#I3XKW?ETT)VPZ4^*]WY
M=-"=L.E=$=<>LWVOY1O5[QUEM8=(ZEKC(:K3WQ_6^C5=!3M"G?'];Z--!3M"
MG?'];Z--!3M"G?'];Z--!3M"G?'];Z--!3M"M?Q`^TOSZII5W:E/B!]I?GTT
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MOZ-U2!_IU41..0/H*IV[1FX>D+:4E6:8;G<I![@.!Q_$4@&'5[;:5V`:?0K'
M74;<2X>E<4;!'`(AW%!V]8)'V'\&X`.I/DIN0]*B-_"#2I]"T&L3``$2BN<?
M44$MA'\9A*&JBQF)QH!UJAW"+@7>A<<;,WV'I;KB;U`)DR@(^\0$P@'XM7C;
MW\7"GG5IW)E,`ZOF7%4LZPALDU3(;VG4,H'X@*">I!M[*^\XD=2B=N4A^%H'
MG7'_`'DD!V`I&X#ZQ!,X[_B%00U?\A!Q+O3^A6?XA<'*GH_2M7[P2H^()([>
MWX<^WS]6J?)6W,^E/G;O.GJ7"<7,S,!,\?1#0`WW%VX;-@#;<1W[S@FVP`/S
M:E9M0E_A,E=U`GV!8TN]-MQ6XFAC'ZSFM]I"Z<N9L?L5%$IZ]TB/V*8P**66
M(2$HDWZB'3^-4-N(%';8-]PVUDGNOO$K0ZTM+M__`%3SZ]*UKN_G=>U<6[AN
MFW18<;B(9=&M=0\Y+X&8[@OE6I'$H["#1VY?COOMX?`LW`#X^SU>/HUDQ=Q>
M]TOP;?<TZ6AO]IP6MG\7/#:VPDWNR)_5<Y_]AKE1[WF/Q]9B(%NKE_L&_P#W
M=6;&XW\!'8#*QS<@CX;>GTCK91>&??&08VK6?SI8A['%:&X\>?"^#+<'R']2
MWG=ZS&T*F77.?!:&_84NCX0WV!O5Q2`WV=PV%[)-=MQ\/'U^[QUG1^$_>Q_Q
MBU9URU_LM*U$WU&^'$7\,[A*?U;>G]M[>K]"H]WY@>.4TU!942\NU2J"5,BZ
M\`R(HGN/[4RA9!X*0B'CT])O3Z=9T?@]W@<*R7%FP]<CO9&%J9OJ:[EL-(++
M<Y!STPLX=,IXX>M=0X\PJK%`?A,8V94>D-OB;!$-PZ]_$![35T/3T^OT[^K6
M<SP9OS_$OX`.B-Y]I"U,OU1;,/X&SWCC3\4\3<?,UWEP72.?,-)L8&6)SB.X
M=`O+@4OV?Y745O`&V-OZ-A$-94?@P:_O=Q]$/WR+7S?5(VA^7V1U>&JZX=-(
M%3[CS!K(/7\+C"`3W$.T+FRR:XE#PW[@)1K<#B(;^CIUF,\&[+#M-PF/.D3!
MZ*N*U<GU0[L2>QV>V`X:KB0^FD;:^:BZM7S`;\8P"CCZFI%V\04D9U81-N/B
M!BJH@`;>K8=9#?!W:`/>O;HG^;&/L*Q7_4]WE)_=[78`=,DQ^T+@&Y]Y/$QA
M)3:&4HB(E*(6`XE+Z@$_WL7J$`]>P;ZF'@_L-,;J\K_U?^0L8_4WWPK5NW[:
M&\OWY]?:JG''-S*3A=5<]?HP&5.8XA\#-"!0$?`H",WN(%+X!^#6<SPL[OL8
M&":[H!^9G^0M;)]1G?21Y>;3;<3^2;_QEM?\:V4/_L?HW_X!,_\`KO5__M=L
M']]=_P!9G^0K/^(GOG_\KMO]2;_QEK3YM941.51.!HY#D'<IBL)D!`?_`.->
M(#].K7>%O=]PTNFNB/YS/\A5;]17?1IU-M=M#A^I-_XR^?\`&SE3_P"L=*__
M``.<_P#7FG_M;W?_`+VZ]+/\A5_XB^^O_P`MMO\`4F_\9;Z?-W)A2@"E:IBI
MMQW.!)Y+</4'2$N</#\.K'>%>Q$^[/=`?]6?^0I&?4;WP#:/L]N+N=)AZNU*
M[R/YZ9$8]!3TJG.D]]U2&=3R?5_YDWQJO9W]>X'#W:Q)_"+9IC475RT_S8SZ
M<!59]M]3'>F`4?MU@\<?>F'H]XT]:J1OY@]H#;XK&-<4#K#?X:Q2R`]OPZ@#
MNL7/V_3L/H]VL%_@W8'^'?SC#C$PX^9P6SB^J+>1_&V>U<*_AGD;AYV.Q\J+
MOFWF$D\/CL5*`/VM_@K>0WA_(V!Q`%\=_3X_@UB/\&C_`)K<!_2A^Z1;.'ZH
MQ_\`I&RN_H70\WQ0^E5&U\P2FGV![CFVM_:+:6A'8?HAZ`5^"$=S>'X/'W:P
M9/!S=!_"OK9W6R0>S4MK!]4&PN_UG:KYG\V6%_MT*K6/._#;G;XV-O48/K[L
M)'/"AZ?'J932IA_J^O6NF\).\S/X3[23J>YO]I@6[MOJ3[AR_P"L1;E">F%C
MO[$I]B[W_C;P-_\`7>S_`*'5_P"R4C^E_P!7_>?I_P"S[]8G_M9WO_NK?/\`
MOF^GRQZ%L_\`B&\-?[^]R_\`EG^C//U=*DB=P'6?^D;U^\=<.V,Z1U+UTR8G
M%:?B0]GTZKV95.TZ4^)#V?3IV93M.E/B0]GTZ=F4[3I3XD/9].G9E.TZ4^)#
MV?3IV93M.E;GQ`>TWTZM[,J[M"GQ`>TWTZ=F4[0I\0'M-].G9E.T*TF<![Q_
M".JB,JAD6GXD/9].J]F53M.E/B0]GTZ=F4[3I3XD/9].G9E.TZ4^)#Y#IV93
MM.D+;2=G.4142%$W6H4""J101(4XE(H(D^R7NE`#=/B)0'8?'?5SHJ'W344Y
M4\WF5K)G.%7#2:GC7"N!PYYTX+EHN/`WJ\0_E;:B<PC-2MD6]\1[_P#;_-JW
M1T*[M%J*X]/K_'O]6VJ%BJ)%J^(^6P?7JF@*O:)\1\M@^O30$[1/B/EL'UZ:
M`G:)\1\M@^O30$[1/B/EL'UZ:`G:)\1\M@^O30$[1/B/EL'UZ:`G:)\1\M@^
MO30$[1/B/EL'UZ:`G:)\1\M@^O30$[1/B/EL'UZ:`G:)\1\M@^O30$[1/B/E
ML'UZ:`G:)\1\M@^O30$[1/B/EL'UZ:`G:)\1\M@^O30$[1/B/EL'UZ:`G:)\
M1\M@^O30$[1/B/EL'UZ:`G:)\1\M@^O30$[1/B/EL'UZ:`G:)\1\M@^O30$[
M1!<@'I\/P[?VM-"=I3-;9WR2>W6<I=_1N(>/XM]]7"%SL@50S-&9HMD\LV)_
MTG5[B%$WT[[:N%M(>%%8;A@XU7%&<3W'9$XAZA$2AO\`BW';4OR9XD*/YP<C
MZD^_2?\`4'_K%T^3/Y@GS@_*?4GWZ3_J#_UBZ?)G\P3YP?E/J3[])_U!_P"L
M73Y,_F"?.#\I]2U%F@-^BV5-_1$!_(&J&TIFX*HNB<FN*IB8F6;<ZCB3?LX]
M+^2#]ZW:$(0/0`?$JI%V#UC[=9]M;2.:&0,<]WZK2ZOH!6MN[VWA)DNY8XF_
MKO:T`?TB%:R8S;BN",<DA>:P50GZ22$PS>*A[NVR.Y/O[MM;J#NYWANO]7L;
MIPYZ"T>EU`N5O>_G<?;B1>;OM['#@)F//H87'U*V\GRXP_'B8J,A)2I@W\(R
M->*%'\"KANV2\?Z6MQ!W`[VSXFV;&/UY&#U`N/J7,7GC7X:6>`OWSN_YJ"9W
MK<UC?6J+><W*$CN#*GVU_P"P3K1+$@_C.X7.`?\`)UN+?PNWV3_6)K6+SO>?
M4T#UKEKSZB>Y\.%E:;A<.Z6Q1#UR./[*HV0YS*[&"(QJD`^/2>6LISA[A%)C
M%)[_`(.O6YA\*&__`*3?'^A%]KGGV+EKOZDW_P#Z!M`_ZVX)]3(Q[50S_FMD
MYQU!'U^E1@#OTB9G*R)R^SQ<2B1#"'O+^+6UA\+MB9_&FNI/Z3&^QI]JYJZ^
MHCOE+7Y6UVZ$?S)7G]J0#U*B'_*[.+[JZ+0PC2FWV+&5V%1Z`'U%.X:.U?#V
MB81UM8?#WNI#2MN]Y'YI'GV$!<Y=>-_B1=?#>Q0C_FX(AZW-<?6J*D,ZYDD]
MP=Y*MG2;?<C21&.)L([[`2.3:``:VD/=/NS;XQV-O7I;J_M$KGKKQ*\0+S^/
MO%]3DV3LQZ(PU46^N-OD^H)&V6=^!O`Q7=@EW!1`0V$!*J\,40V]VMI%MNVP
M?P+>!G5&P>P+GKG?]^O/];OKV6OYIY7>URIU0QEAW6,981\1%8QE3"(^D1%0
M3"(COK-%&X-P'1@M2XF0UD)<>DU]JT`0A?T2%#\!0#\@:K4G,JT-:,@%JU17
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB]!1U]CF`=@'J'<!
MW`?3[-M?';6"@ZE^HSGN#B#2M5H^(#VAJN@*W6[F$^(#VAIH":W<PGQ`>T--
M`36[F$^(#VAIH":W<PGQ`>T--`36[F%J^)]_TCJF@*[6[H3XGW_2.F@)K=T)
M\3[_`*1TT!-;NA?!<>\/G'5=`5"]W0OGQ`>T--`5-;N83X@/:&F@)K=S"?$!
M[0TT!-;N83X@/:&F@)K=S"?$![0TT!-;N86\DX#[7H]7^G5CHZJ1DI`QHM[X
M@/=\^K>S5W;%:BN/3_H'5#&KA-U+5W_>/S_GU3LU7M>KTIW_`'C\_P"?3LT[
M7J]*=_WC\_Y].S3M>KTIW_>/S_GT[-.UZO2G?]X_/^?3LT[7J]*=_P!X_/\`
MGT[-.UZO2G?]X_/^?3LT[7J]*=_WC\_Y].S3M>KTIW_>/S_GT[-.UZO2G?\`
M>/S_`)].S3M>KTIW_>/S_GT[-.UZO2G?]X_/^?3LT[7J]*=_WC\_Y].S3M>K
MTIW_`'C\_P"?3LT[7J]*=_WC\_Y].S3M>KTIW_>/S_GT[-.UZO2GQ'O_`-K\
M^G9IVO5Z5H%T0/2;YA$?R;Z=D4[7J077V!,4=_#P\1]/O]>G98T*=MU+A"[<
M#_T@A[@`OU:E[)G)1]H_FOGQ3@?^E-]`?D#3LV<D[1_-:176'TJJ?UA#\@ZK
MH9R"IK<>)6V(F,/B(F$?:(B.KL!DK<2M"QR-DQ5<J)MDBAN95RH1ND4/:918
MQ"`'X]58#(=,8+G<@*GT!6R/9"W7,0Q@XN(:/2:!6_F<M8OK_5]\9!J+,Y!$
M#(EFV;QQN'J^&8*.G`C_`,G6YMN[N_WG^K6=RX<]!:/2Z@]:Y?<._7<O:O\`
M7]UL(W#AVS'N_JL+G>I6NE^6F$HO<&\[+SB@;[%AJ_('(80W]"\B6-0V';T]
M0ZWUMX=]Z9_CBCB'Z\C?8W45Q5_XY^'5E417,]R\<(H'D?UI.S'K5L9?G#5T
M>HL%0K!("'Z*LK*1L4F/O%)JG*J[;^\-;ZV\*K]V-W>0L')C'//I.@+CK[ZD
M-EC)&V;9=2],LD<8]#1(5;.6YN7QR)@A:A4X@GCTG>*2LRN'L$?]YC4!$/Z&
MVM[;^%FT,%;JYN)#T:&#V./K7'7WU&=YY:C;K"Q@;^N9)3_:C'J5MI7E5G"4
M$W1:FL00WH)"P40TZ0]RSAL\<?[>^MW;^'_=6WSMW2']>1Y]0+1ZER%[XV>(
M]X3IOF0-/"*&)M/.YKW>M6UELK9.G>K[WR!;WI3_`*28ST@W1V'T@"#19N@`
M#[`+K>6W=_8;3_5K.V:>?9M)])!*Y"^[[]\MSK\]NM_(#P[9[1_5:6CU*A7"
MZ[LXJ.UUW:@^E1TLJY4'\)USJ&'Y];9C61C3&`UO(`#V+FI9)+AVNX<Z1_-Q
M+CZ225M``!X```'L`-OR:NJ3FK``,E]T55N%06/^BBJ;^BF<?R`.K@QYR!/F
M5ADC;\3@/.%MK!\,43N1*V('B)W!BH%``V\1,J)"@'B'SZM=[@J_W1TX>U71
MGM3IB]]W)N/LJJ3DK]08;?[XOM&B1*.Q@D[C6V!BCUBEL8KN31,`]P.GT?I!
MMZ=:R?>MEM32YO;.,_KSQ-Z/Q/''!;JU[M]Y+[_4=NW"8?\`-VT[^%?PQGAC
MU8JWLGR8XXPW5]Z9^PPQZ>GJ!7)=/,8O6<2%W*E+J&\3E$/1X:TD_?\`[AVO
M^L;UM+.N[@ZN#RNDM?"GQ1OJ?)]V]]DKRL;G@*\8QP5`2'.?AY%@87/(O&BG
M2'4(1\D^EQVZ^WX?=,<]ZAZO4'CT_:]'CK2S^,/A=;_Q-]V\_P`U[G]'X&N\
ML<ETEK]/GC?=_P`+NONH_GQLCX5_SCV?RX9X*B)#S)N$T<)BJ9RCG0E%0O\`
MW;4;\_`12#<>DR-6Z#`?^0.^QO;K43^/7A)!\6\,=G\$-R[+JA]'-=!;?2QX
M^7(!;W>E8#3X[FS9GT&XKAQY*C'OFL\)VA3&1O\`;),2I@<"1^.+24QS".W:
M*,HUC"@J`>(]0@3;^5OX:U,WU(>$L0)9>W,AI^&UF]'OAF/7ATK>V_T=^/<Q
M`?MME$":5?>V^'3^[=)AU5/0J1?>;YQ!:]SX;_-B3Z"E$GPM&CT`6$VVY""^
MM#42B3?QZ@`!V\!'6LF^I_POCKV?^)24Y6[17^M,/6MU;_1/XV34[7_!HJG'
M5=O-.DZ+=V?053#KSE^+R)C%;4S-+TH)]13EK]0;`8^P_LME;J)B^(!]K;;Q
MUKY/JJ\/&&D=INSQ3^[@&/+&=;:'Z&/%R1M9;[88S7+MKEV'/"U]2IU?SJ,`
MD*46N)<P+F$1ZRKJTMH4I=O`2F3G7HG$1]0@7\.L!_U8]RP/W>V;HX])@;[)
M'?8MI']!WB02>UWK8VCA073O;$VGI*Z5UYV.(R*[,\&Y'<(])1[CJT5EFKU^
M/47LI,WQ.D/#8W<W'V!Z\63ZM>[`=2+9[]S>9FB:?0&N]JSH?H)[ZN96?O!M
M;9*Y-MYW"G67,->BGG73./.WHA53`UX^6Q5`.GH.XR%#H+#]D.KJ23JJY"[&
MWVV..X>S6(_ZM]G#B(]DN2SIN6`^@0GVK/C^@7O"6`S=Y;(2<0VSD(])N`?4
MNO=>=S60(7X+CK.'4ZOM@[R6Q3(!-O`2"C2U#";J]NP;:AD^KC;P/W6Q3%U?
MQ731[("LF'Z!-V+C\QWHMPVF&FQ>37SW07"_\;N+_P#EQ>__`!01_P#M%U#_
M`,7-M_Y"_P#VL?\`VZG_`.`.\_\`5,?^P'_[M/\`QNXO_P"7%[_\4$?_`+1=
M/^+FV_\`(7_[6/\`[=/^`.\_]4Q_[`?_`+M:D_.[A^LG=XXR`)=1>X*>3VYE
M`)N'6)`-1RE$X%]&X@&^KA]7-K4:MA?IXTNQ7_\`MU1WT!WVDZ.],6NF%;`T
MKT_Z6NU_\;BF?_+Q9O\`XCQ?_P!I^LC_`(N-J_\`([C_`&IG_@+#_P"`3??_
M`%/:?[%)_P#<KM$O.TQB)$Q7P+?"*"4O=*E=*^J0AQ`.L$SGA$C*%`?0(@41
M]VLAOU;=WZ#7LMX'<:3QD>;]V*^I8C_H'[V!Q[/O'MQ;7"MK,">50)33TE5"
MAYU6!C'$'.(<NH)](B!T'5-='ZMPV**:DLS*!1#?QZ]P]@^K.9]67<TG]YM>
MYAO08#ZM;?:M9)]!OB*&UBWO9'.KD6W31Z1&[T4\ZJ)EYS/&)QVP>4?-,>)R
MF%01@Z<\*D8-^DNZ-S(93JV#Q`H;;ZSHOJK\/GT[6SW9E<_W<#J>B<56LN/H
M6\68Z]AN&PRT.'[VY;7TVII3K57Q_F\\/G8%^*6RK%")`,(.Z(S7Z#"8`%,1
MCK*\W,4!W$0#;;T#OX:VD'U/>%TH_>'<HC3\5NT^;W97+27/T4>-T->R;L\P
MK^&[<//[\#>KFJZC_-)X2/S=)LIS$:/V_P#ZIX[O"0;$`!WZV<*^3`#[[%#?
M?<!W`-;B'ZBO".8T.XRQG]>VN!_9C<%SUS](GC[;"HV>"48?P[VT.?0Z5APX
MX45PXOS`N&,N)0;<@Z8V$P[`$JTM$/L/40OVCR=?:ID#<X>(B`;`(^@!'6\M
M_&SPIN?X>]VC2?SMF9_;C`]:YF[^FSQULJF7NU?N`_NW6\OJCF<>'+ES"N?#
M<H>-5AZ0A>0&&WYC[=*9<BU9LMN.P@`H/9)LN4VPAX"4!UT-KXA]P;ZGRF][
M4\GA\U"#Z'/!]2Y*^\)/%7;*_/\`=K?8P./R5PX>EK'#T%75B;;4I\I30-MJ
MLZ!P`2C"V2$ENH!Z1`2A'OG`B'V@^</;KI+;<]LO?]2N;:;_`*.6-_\`9<5Q
MU[LV];:2-QLKRW(_O8)8_P"VQJJ7X=?;J[*O3Z>KMGZ=OP[;:S]#Z5H:=2U7
M:QUIJ;7K"VO1JU7KYHJJ0-$Y-97HQ4&@S)+5#(])`B;4521$B0?]&UE@43EV
MP`'H`53D#]77';MW%[O;L3)V1M[D_CBHW'F68L/H!Z5ZCW:\8>^_=MK;?Y@7
MVWMP[*YK)0<FRU$K>CWB!R4P*9S"QQ/@BVM323H\@?8IUUBGFH$Q]]MROV*0
M/FQ!_P#*M@*'K-KSC<_#;>[.K]O='=P\A[DG]5QTGS.\R]Y[O^/?='=`V+>X
MYMMNCF2#-!7^>P:VC^='0<U)R%G(BRLRR%<F(J?8&`!!W#R+9^B`"&X`H+=0
MYD3;?R3@4P>S7"W5K/8R=C?1R0R\GM+3YJC'S+V/;MPL-WMQ=;1<075L?Q1/
M:\>?233J-"NS-W2!N8A@#V@.^WX=M]M0#030'%9C@]HJ1@M!53&'8H"(CZ@$
M=7%@`J<E8'ZC1N)6X/>#TD-\^_Y-6^X>(5Y;(."`H<0W`IQ#V@&X?.&A8T&A
MI5`YQ%0"0M(KB'IW#\.P:KV8.2M,E,U\^(]X_1IV:=H.?K7P5_?].WY-5$:H
M9`OG?'Y".G9JG:!.^/R$=.S3M`G?'Y".G9IV@3OC\A'3LT[0+Z90Q!Z3`)3`
M`"("([[&`#!\Y1`=`P$5&2J7T-#FMQ)<?';W>L??JUT:O9+A@MWOF^0_FU9H
M5_:E:@<#\O'ZM4+%42E:OB!^0!IH*KVG0GQ`_(`TT%.TZ$^('Y`&F@IVG0GQ
M`_(`TT%.TZ$^('Y`&F@IVG0GQ`_(`TT%.TZ$^('Y`&F@IVG0GQ`_(`TT%.TZ
M$^('Y`&F@IVG0GQ`_(`TT%.TZ%\^('Y`&F@IVG0M0+''T%$?Q:IIIQ50YQR"
MU=Q3]4?]GZ]4H.:K5_Y5]*<X^D-OF_/JAIP5S:GXA0+5U#[?R:HKZ!.H?;HE
M`%\T55JZ3=(FZ1Z0])MAZ0_";T!JE16G%5H:5X!49-Y$H-:ZPG[M5H@Q`'K1
M=SD>5P&WI`6B:ZCH3>'HZ-];.UV;>+ZGR=K<2`\1&ZGII3UKGMR[U]U]HK_B
MFXV4#AP=-'J_JAQ=YJ*T$URPPG$`<$+!)3ZI?`$X&"?K$./\US(%C6NWOZ]=
M):^'G>FYIKACA:>,DC1ZFZCZEP6X^./AU8`B*ZFNGCA#"\@_TGB-OK5I)KG%
M");DKF/Y5X/CLO.3#..3']4?AH]O)*#O[.X&NCM?"FZ=C>WD;>B-A=ZW%OL7
M"[C]2.W,J-IVJ>0\YI6QC^JQLA_:"M-,\T,IOQ.$/%U&OI&\"=N/=RSD@>T5
MI%X*!C?_`$$`]VNBMO##N_$!\S)<S._G!@]#6U_:7#;A]0O?6Y)%A#86K.%&
M.E</.]]#_45IYCD%FB<!0KS(<\W24WZD(@[6$1`!_DE");M%"E_Y6NAMNYW=
MBTH8K*$N'%]7G]LGV+B+_P`4_$+<JBXW6Z8P\(BV$?\`=-:?6K52<[)RAQ/-
M3<C)',.XFE91V],(B.^^[QPKZ]=!!:00"EK$Q@_48&_V0%Q%YN=Y>NU;A<S3
M./\`>2N?_;<5T$A+0L*W!W+RT/"M!*)P<RTFPBFQB%$0,<J[Y=ND8I1`0$0$
M0`0U;<WEI:-UWDT43!QD>U@]+B%6SV^^OWB+;K>>>0Y"*)\A/4&-<K03W)OC
ME6!.$_G?$L<<@;F2-?*\[6#W`A'OG:PC[@*(ZY.^\1O#_;?]>WO:HR.'S,3C
MZ&N<?4N\VSP?\5]XH=L[M;Y*TY'Y.=H]+V-'K5EYOS%N&D'W`/F=E,'3$0$E
M<J]QFA,("(?850@2-C[B'I[FVWKUR%[X_>$=E4'=V2N'"*&XD]8BIZUZ#MWT
MI>/VXTT]WY(&GC/<6L5.L.FU>I6=G/-JXL1HG+$1^5[.8HB!3,:?'Q2"GB(?
M94G;`P6`!VW\4@_!OKD[WZI/#.V-+5FZ7)_5@8P'SR2M/J7>;=]#_C1=@&^E
MV2S!_/=/D(\T,#Q^TK/6'SE:&W`0JF!;K+GV'I/8;G7J^GOL.PF3CXVQ'VWV
M_E!X;_CY6]^K?86#_P#';+>R'_G)XH_4ULOM7<[=]`O>F2AW?O)MT(Y0VT\Q
M]+WPCU*SDSYS>1U"F"`P'08TP[@F:;NUBFQ`?4)B,(VOE-M[`$-<O=?5OO+J
MBRV2T8>':3RR?V6QKMK+Z!>[K"#N7>2_E''LK:&+T%[YE9N;\WCEJ],?[I@,
M,0"1M^CX2K3,BLGOU;?M9FSO4S"&X>E/;</>._+W7U3^(\Q/RT&UP-.5(9'$
M>=\SAZEVUC]#?@];@?.7.]W+QGJN8F`^:*W8?6K1S_F=<X)D#@EE"(KI#B/V
M*]1Z.T,4!ZAV(NY@7[D``#!_TF_@'OWYN\^HOQ:NZZ-QC@'_`#5O;M]9C<?6
MNRV[Z0?`6PH9-HEN7#^^N[IWI#9F-]2M-,<ZN8\P4Y9#D;D=,IP$#%B9<D&'
MV@,`@7[E;QO0'VQVVVV\/1L&W.77C-XIW@(FWR_`/Y'B/_X8:NOLOIS\#;`@
MV_=C:B1_>1F7_P"*Y]<N/VE6@F.06>9TQS36;\M2HJ"8QP?9$MKA,PF,<P_L
MU9<R8!U*&\`#8-QUS5UWX[Z7I)N]WW.2OYKJ8CT%].*[.R\,_#G;@&V&P;-"
M!EHLK9IX#,1UX!6WD;-8I<3#+6*=E1-^D,A+/WHF\"A]H72ZF_@0`_$'LUHI
M]PO[K_69YI/YSW.]I*Z>UVG:K+_4K:WAI^2-C/[(',^E=)U%WWV$PCN(B8?'
M_3K#6P7S<OZOTZ(FY?U?IT1?-P_5#Z?]`Z(FX>LH?./UCHB^_8]@A^`=_G]>
MB+<`$Q]6_P#RA`?FT1:^A(0]!@_`(_Z=]$6H&Y#>A00]G@`^/X=PWT1?19G_
M`))B&]V^P_3X:(M@R*I?20?PAL(>ST@(Z(M(D,'LW]FX?ZM$7WM&]I?ZP:(O
MO9/[OGT1;0AL(@/I`=A_%HB:(FB)HB:(FB)HB:(MQ)55`Y545%$5"#N51(YD
MSE$/0)3D$#`.JM<YIU-)#AQ"M>QDC2QX#FG@14*X<%F++E8$@UO*61:^*>W1
M]RW:RQ8%V'J#8&4F@```^.M[9]Z>\VW$&PW&^@I_=SRL_LO"YG<.Y'<O=P1N
MNT;9<@Y]K:P2?VV%7ZKW/[F5603+'<A+^Y(EMTIS[QC:B"!=OLG+9F,OU@.W
MCOKL['QJ\5-O`$&^7KFCA(YLP_[UKUYSN?TW>!F[$NNN[.VM<>,+7VY_[A\:
MNG_XJG-C_P#67"?]D^&__1U0?[S_`!O_`+/?]L]_Z'\W71?\1WBU_P"80_#3
M_5;;^M_"^+U="Y#_`(/?`3_RJX^/5_KMYE^3^-\/1GTKUD:_2I?C4FB+L8J7
MEH%X20@Y21AGZ9@,1Y%/7+!R42^(?MFJB1S![A$0U#<6UO=Q&&[C9+"?PO:'
M#T$%95C?WVV7`N]MFEM[H'!\;W,=Z6D%2-J7+?+E;!)"5>1ES8I[`9.P-`3D
M#$#^268C1:N1-MZ#*E6_'KB=Q\.N[E]5UNV2UE/&,^[_`%'5'H+5ZUL7CKW[
MVC3'?20[A;#A.VCZ?]+'I=7I<'J2E4YH8^D3)DM5<G:JZ.`%5=LNU8(L#>L1
M%`&DDF01_P#O<XA[1UQ&X^&.\P@G;YXKB,9-=6-_KJW]H+UW8_J$[K73@-[M
M+FQF(Q<RD\?[.F0#^@2I&UG*V-;D!"UR[UV165#P9&D4F,EX^'2,=(_"/@-X
M^@"#KB;[N]OFV5-[:3L:/Q:2YO\`6;5OK7K>S]]^Z'>``;1N-I+([\':!DG5
MV<FE]?Z*N!T=!2[$Z2"'V/`>G;U=(CZ0UIZU.)J5U0;I:`!1O!?!*4W@8`$/
M>`#^70$C)4(#A0@$+8,U1-_)$O\`1,(?1XAJ03/'2H76\3N%.I=/("#51,I!
M'8Y!,/4(CX@80\-@UE0ETC233`K7W8;`YK6\17UK@?%#[?RZFT%8O;)\4/M_
M+IH*=LGQ0^W\NF@IVR?%#[?RZ:"G;+61=10P$3`3G,.Q2AON/K_)JA&D5=@%
M<U[GNTL%7%=BDW>;B!TMO1L(G+M\X".H#+%G7U++9#<5H6T\X7)!JMOXF3`/
M;U&'Z.@-6]M'TJ46\U<2`M\C78/M*&$?YO@'T[B.HW35R&"F;;T^-U2M?PQ?
MUU/G#ZM6]J>05W8-YE/AB_KJ?.'U:=J>03L&\RM/PP?]8?Z!^K5>U/(*GRX_
M,5\%J/J5-O[P^H=5$O,*AMSP=ZEI^&4_ZP/F-]>J]JWDK?EW\QZ%I%LMZCD'
M\9@_T:KVK.15I@EYM]:U@V/_`"E-OZ("/TB(:H96\`KQ;N_$1YEN`W('I,<?
M^5M^35AE=T*00,&=2M783]@C[Q,;Z]4[1RKV,?)!03'T`(>\##_I$=!(Y##&
M<A1:RD*3]$`#W^D?G'<=6EQ.:O:QK<@M>J*Y:@*8V_24P[>G8!';\.WHU2H&
M:J&DY!4A/WZC58IAL=PK4*)0$12?S+%-SL'B.S,JQW9A]P$$1ULK/9]VW`TL
MK:>7I:QQ'II3UK0[IWH[M[("=VO[.W(X/E8'?U:EWH"L=8.7>&X;K)'OIRT+
MEW`I(2&61;'$/8]F#QJ73[R@;75V?AQWFN:&9D5NS]=X)_JLU'V+S;=/'CP_
MV^K;62YO91_<Q$-/].4QBG2`592>YQNQZRUC'S5`OB!'-BFE7!O<86<6W:D#
M\'?'\.NHM/"F/`WUXXGE&P#UN)_LKSO<_J2G-1LVU,:W@ZXF+C_4C:T?ME6;
ME.5^;;,H9M%SC&*%01*5K5(%H9V&_@!"+N"2K_J]Y3`.NF@\/>ZUB.TGB?)3
MC-(:>@:&^I>?WWC?XC;NXPVES%!7\-M"W5YG.[1_H-5\9XRY<Y<Z%6=!S[=T
ME_[M0:[=%(TY3CN`D.X;-HHJ8[^D!`NVJ2[]X<=VZMEO-GM'#,=I`'>HE]5B
M1]V_&GOJ0YECWDW!CLB8KHL/54-CIZE=JM>6AS1LG0H7#9JVFKL85K=:ZA`F
M*!MOM*MCS+F0*(>L!1ZO=KG+[QV\+K&H.Y]N1PAAFD]!T!OK76[5]+?CCNE'
M#8S:M/&XN+>'TCM'/_9JI"5OR;^1DF"9[-?L15(I@`3I)2-EL[I/</$.B/@&
M30Q@]R^WOUQ=]]3G<B`D6%GN5R>9;%$#_6D<?V5Z1M?T3>)MT`=UW'9K,',!
M\\[A_4B:T^9RD!7/)3B"%2-<N0THX/\`9%9"I8_9LT_YQ4WDY87QQ#;T"*`?
M@UQU]]4UR21MFRQ@<#-<./I$<;?[2]%VSZ%[,`'?.\LSG<1;V;6CS.EF>?.6
M>97ZKGD_\5XDJ8S\UENX+%VZQ>6N+@6RH_\`[O`5]HL0H^P%Q'WZX^^^I;Q!
MN*BSBVVV:>4+Y"//)(1^RO0]L^B_PDLZ'<9]YO7C/5<1Q-/]&&%I']97XKGE
MS<+:T!.S@V%FU$]OV]LG;795#B`[[J)2,X=F81]?[(`]VN0O?&[Q2OB=6[2Q
M-/"&.&(>8MCU>M>@[9],W@;M8&C8()W#C<2W$Y\X?*6_LJ_57XZX#J1TB5/!
M^)H1;J(1)1CC^K_$]8B!2;.W$:LYZMQ](GUR&X=]N^&Y`G<=VW&5O$.N):>@
M.`]2]"VKPU\.]E(_PC8=GMW\"RS@U?UBPN]:_*P\_OEVQYC>9]R"G:VX9.,4
M80DT^-^)F\>F@E"_N[B9T^C+--QS=N1-H"=IR.YF7Y52%#N(*H^(@4NWG5[<
M2W<YDN'ND=S<XN];J\?4O5-MMH;&V;':L9$"*T8UK!Z&@#)88@[2?@0I"^XA
M2A^0`#6(&@9"BSB]SL7$GSIW0]11^7SZNHK:KYUB/L#Y>CQWTP1-]]_'?Q]H
M^SQ`-_#3I"HM@P>/NV#\7I^C555;9P#8-O7[?'U?7HJ+K%Q\!]GU^CY]45<*
MKI%Q\1]_^GQ\=41=>([COHJKYHB:(FB)HB:(FB)HB:(OO4(>L=$6Z10?1_J'
M1%RRJ#L'C\OP^G146RHJ.W@/R'ZM$7%$1'TCHJKZ!Q`-O#1%][AO=]/UZ(M(
MCN(C[1WT1?-$31$T1-$31$T1-$31$T1-$31%^PMD_P`G+"=B%R]Q3D"Z8T>G
M*)D(F;(WOE9(KZB@9TI%61NB8?:\<"7U`/HU]?[!]3?>JR#8N\-G:W\0S>RM
MO+3S!\1/]!J^`N]?T3]Q-R+I^Z.XWVUSG*.4-NX`?Z1CF:/^L?3@%C^R-Y2_
M*VFF<+U-"DY7C4@$Z:E4L24--*D`!'88&VDAQ[OA^BDY7W'T;Z]DV3ZC/#S=
M`&;B;K;ISPFC+V#_`*R'7ATEK5\Y]YOH\\7MD+I-G;8[Q:MR-O,(I3_U-P(\
M>AKW="@M?,)9DQ<L='(V*\@4L2".[B?JDPSCS``B`F3E0:GBUB[AZ2+&`=>M
M[1WJ[L=X&A^R;C975>$<S"[SLKK'G:O`.\/<3OMW3>8^\VT;C8D<9K>1K/-)
MI,9\SBK6D434\2'(<`](D,!O1X#Z!'UZZ`M<W,$+DPYKOA(*U:HKE\$H#L(@
M`B`[AN`#L/M#V#I4JA`.:KJNY.R+4N@*W=[-$I$'<K5&5<K,?5X"P=F<,A*.
MWB';VUJKW8MEW&OSUK!(X\2P!W]84=ZUTNT]\>]FQ4&T;C>0,'X1(XL_J.U,
M_95\X'F+EV*Z"2H5JSHEV`?O*)%@[,`>UU#+L2=0AZQ2-KD[OPT[N7%3;]O`
M[]5^H>AX=[5Z3MGC]W\LJ-O?D[V,?WD6AQ_I1%@KUM*O'"<XXHX$+9<?2+8W
M@!UX":;/4_5N8K:2;,5`_!W1_#KF;KPIN!C8WC'#E(PM/I:7>Q>@;=]2-DX!
MN\;5*P\702M>/ZLC6']HJZ,?RIP7.BD,A*S$*L)>GIF8*1(1+<=Q*=Q%&D4-
M@$?3OMK0S>'_`'MM*B&.*5OZDC<?,_25V=KXV>&NYEINIKBWDR_>PR`#^E%V
MC?/57(BLEX:FQ(6+OE/<'4VZ$E)Y%DL(CZ`[,@LT5`WNVWUI+C9.\]K4W%I<
MM`X]F7#TM!"ZVQ[X>'VY$"RW/;WN/`SAA]#W-/J58$:MGQA/$J1#UN(!T';O
MOBQ'[(=0]39=4HAU>CW:UW:OB%+GM62=+:>T!;\0PW)U6)@DB.1:_5_9)7:(
MPR!4DP<M`!8"[*"!UMA,'AU`(B7TA[M8[[MY<3&[W.&2S8]OB;&.W9^\ICB5
MU*D*Y$YQ(5`A!,82%[R@])1$>D-Q((^`:R6W<8`!+B>I8+]NG+B6:0VN`J<E
MSXV.5:*G46!,1$G202',80$1^UX&*&VX!J&XG;*T-97/DLJSM)()"^6F5!0U
MZUW6L1;%?0`1$``!$1]```B(_@`/$=4RS1?3D.F;I4(=,P``B50IB&`!#<!$
MI@`0W#0$.%6D$*I:6FC@0>E<147?=3[)4!1\.Z*AC@I^EX]L"AMX%]OKU(WL
MM)UDZ^%,E!)V^MO9AO9\:Y^;S+DZL4R:(FB)HB^@41]`"/X`$?R:H@!.2'**
M9>M0.V0/293[!0_Y1]@T!!-&XE5<"P5?@.G#VJFI.YTZ%*)I>VUB,`OZ7QT_
M%-S!_P`A1V53?\6LZ#;-SNC2VMIW_P`V-Y^Q::\[P[!MXK?WUE"!^>>)OJ+J
MJW4IR*PG$`;XC(<,Z.7<!2B4Y"84$0]1?NYFX3'^MMK=V_<OO3<GW+*5HYOT
ML'[3@N4O?%CPZL0>TW6W>X<(@^4_]VQP]:MC,\T<11H&"/;6N;.&X%%*,:Q:
M!A]`?MI5^@J`#_YK?6]M?##O)/\`QG6\0Z7%Y]#&D>M<;N'U#=Q+2HM67UR[
MHC;&WTR/!_95,-.560[HX*SQ;@6SV==4>E$46UALBAA-^B/PM9A!(`?_`$;;
MWZSI/#_9=K9VG>#=[>W8,ZF.(>F5_P#R5HH_'+O-OL@@[G]V[JZD=EA-.3_1
M@BI^VK@1N/?,MR08/W?PG)4EDX`13<RT+7ZD1(@^@3.;W+&?`.WK!+?W:TT^
M^>!>QC_3-UCNY6YACY)J^:W9I]:W,&W?5=WH(_PS8I-OMW9.?%#;T_I7<A?^
MS55FQ\LOG-D'8<D9<J-9:J["JV?WNPV$Y2F'<Y/NFJQ)(D1*`_H]\"^K?;6J
MF\>?";9L-DVVYG>,BVWCC_;E?K\^E;*/Z7_J$[S_`/\`U6^6MM"<VONYIL_^
M;MXQ'ARU45V*KY*<242K7SD%(N53;"LA2Z(T9@8=OM`$E89M^H8=_086P?@U
MSFX?5/<D:=HV9C6\#/<%W[,<;1^TNKVCZ%K,'7WA[QRO><Q;6C6_MS2O/GT*
M2=5\H_B1`E3-.DR9>7!=A.>;NOW2V4$!W_['58R$$I1]G=-^'7"[A]1_B/>$
MBT-A:,_YN#61_2E?)[%ZAM/T;^#FW@'<!NM_(.,MUV;3_1MV1?VE)"K\&N(-
M/!/[GX]XZ763$!*ZL4<ZMSL3!ML8RUI>R^X^'L`-<1N'BUXE;F3\SO5Z&GA&
MX0CT1-8O3=I\`O!C90/DN[>V.>/Q3,=<.],[I%(F!IU.JJ)&]7J%4K*"0`":
M5>K4)"$(`>@"EC&+7;;7$WFY[GN+B_<+FXG><S)*]_\`:<5Z7M^R;)M#!'M-
ME9VL8R$,$40']1C54QU55/TU5#_TSF-^41U@!K1D`%M2]SOB)*V]7*U-$31$
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M7+Z0_#MHBZ1<@[C\OEX:M55UYBB`^[VZ*JTZ(FB)HB:(FB)HB:(FB)HBU$_2
M#1%R2@/XORZJJ%;"GJU156WHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+]Y
M;75+DDT1?3")TCH'V404`0404`%$5`'T@HD<#)G`?8(#J@P<'C!XR(S'GS52
M=3#&[&,Y@X@]8.!5A+SQ9XVY*%<]VP9C*;=.-Q5D2U6/AY8QQ'<5/O>!3BY,
M%=_'J[NXZ[#:?$'OSL5!M6[7\4;<F]JY[.K1)K;3S+SS?_"3PO[T:G;[L&U3
MRNS>(&1R=?:0B.2O3JJHD7+RE^(ME$ZL"PR%CUP?J$HUFYK2+$@CZ/\`N^W,
MK"'24?454FO2-L^HSQ(L:-O'V5ZS_G8`UW]:%T?K!7C>]_1WX-[H2_;X]RVV
M0_W%R7M']"X;-ZG!1?M?DJ,#&44H?(-X@4=Q2:76B(.A#]4IY&O3C/</:(-?
MQ:[[;OJFF``WC9FD\3!<$?LR1N_MKRC=_H7MR2[N_P!Y'M'!MU:!WI?#*W_X
M:CI9O)XY.Q)CC6[1B.Y(EWZ.U89JN.SAZMV\W`%;$,/L^($/?KMK#ZF.X-P`
M+ZWW*U=TQLE'I9)7]E>:;I]%?BM9N/\`AEWLU\P94FEA<?-+#I']=6&L/EM<
MU*Z)^O"KV>3)N/?JEHI\^F<`#?<B3>=3>#OZ@%(!'V;ZZ^R\<O"V]`INK(2>
M$T4T9])C+?6O/=R^F#QSVPFNQ27#1QMY[:;U"4._95EY[BIR;K`&-.\?LP,$
MR!N94M"L+]`H>'B*\8R>H[>/ZVNIM/$+N'?FEIO.V/<>'S$;3Z'N:5P^X>$?
MBIM0)W#NYO4;1Q^4F>/2QKAZU:>1I=TAS&)+TRX1)B#L<LG5IZ/$H[].Q@=Q
MZ(E'J\/'UZZ*#=-KN16VNK:0'\LL;O8XKC[G8]\LC2]L;V$C^\@E9_:8%2ZQ
MDTA$C@2)#X;D7V3'Q#<-RJ;#XAK/:'.Q94CHQ]BU+W,:=,E`>G#VK6W?_#&`
MS-\+8X#N!VCLR!P$/89!0A@'5'Q:Q21FH=(K[0KHKCL3J@D+'?JN+3ZB%6<?
MDS(,6!?NR_V]H4H;%*A9I;H``#;8"&>&)L`>[6LFV+9[C^/9VSCTQ,_R5T%K
MWO[TV0`M-TOXP.5Q+3T:Z*LV7(?-K$`!')%@5*&^P/?N^1]._P#*?,7!Q_2]
MOL]@:U<O<SNK+BZQA!_5U-_LN"Z*W\5O$:V%(]WNG#]?1)_;8Y5*WY6YR;[=
M5J8NM@'_`+76X)0?';QW39(CX;>'X=83_#[NH_*W>WJED^UQ6WA\;_$F(4-[
M$_\`G6\)]C`N^0YCYF2#94]0=?:`=U:V*8@`>DH?#2"`;&]?AO[-8;_#3NP[
MX1<MZI:^UI6SC\?_`!!8/?-@_KMZ?V7A=JES4RJ0W4>&I"H;>!0C)9(0'<-C
M`<DV)O`/RZQW>%_=YPH);H?TF'_D+-9]0_?=IJ^WVUP_Z.4>L3+=-S;R;N)C
MP%&$?68S6:$?9XB,WOJT>%>Q9":[]+/\A7GZB^^.9M=M_JR_^,OA.<&1$U"&
M5K]!5(4P&.D9&:2!0H#XD$Y)P#D`WM`0$-#X5;*00V:\!YU8?^0@^H[O:UP+
M[7;"`<1245_[ZJJA#S`KB@5(C;%>&%U$S&,=21)?Y(RX"``!3I!?FJ)2E'Q#
M8@>G6`_P=VUY)?N.Z!IX-^7;3S_+D^M;!OU.]YF@-BVK8RX9EPNWU\WS8'J7
M)4YN9QG#"6$Q'BY(1$H(EA<<W>4,GTF(4P?M[=(%<"<P[#W"FVZM@V\-1CPK
M[J6@K=;EN!''7<P,]D+:>8C)7N^H;Q(OS2PVG:@>'965S(1ESN'UY8@YTY+D
MH99YN7'=.NXBL!@74.9,:W@6=/T]:9P!-%R[C'^R9`(8Q=SB(&#TCZ-6/[O>
M%>V8WNY0X#'M=PC])`<W'@<%+'W_`/J#WHZ=MVFY.HX=AM$AS!P#G1OPP)&.
M8S51L<5^9I:-BL\;9?9D5'8#N*W6JHF7?[(B*LJG%F2`.G?<1#;T^O6#-WB\
M"+#&6_VUQ'*66;U,U56R@V#ZLMWPAV[>XVGB8+>W'ID$9&7-5K'<$?,GMH%/
M++OJ^FJ(=063,4/'F(!@ZA$[2OR4FJ3IW\0`FX#X;:U4_B]X&[::6X;,X?W5
MD]W[4C6CUK<V_@/]5&]BM[+-;M/]]N<;*?T89'GU*O8CR@^3%B,"M[S3CV'`
MP@*A/O:\W5T`#^D&QX^+:&,`?^6V'6GN?J5[B60T[1M=[+R]R"`?VGN_96\M
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MOZ]<C7OKTZJJ^2`%:)`W:$(T;E`"E;M$R-D"E#P`I44"IIE*`>H`VUR;R9':
MY"7/YG$^DXKOHP(6=G"`R,<&C2/0*!?=455\U5431$T1-$31$T1-$31$T1-$
M31%XS_XQODNI6^//%GB#"R)D7^8LCS^;;RT;K="AZ9B..+7JFV=D*;<6DG=;
MFJX(`^!E8@!\1+X8-R!(='`>GG]RV6WMHXO/*GI\BO!U0LW9NQ.Y*ZQME:^T
MXZ(@H5.#LLLT;")?']HR(X%F<ON$@ZQ*/:<"ML".&"R28D\\'FYCM)G'7"4I
MV:*Z@0J"T9D.MMG+ARW+X'34DV'PRICF`1#J4(?Q'QWT$KVXT]&"KCSPZ<5+
M%GYI?ET<@E^WRNX-,JI)/NVD]M>+B1ZG8$?!5R#=`(AZ&QAWVV4$??J9MU4:
M9*$=(KZ\U9V;*U`H>@_8JM8<(?*`Y7MG#CCSS!:XDMS]?=E3,H*HQADS+#^S
M;E"6+&+&V.(%W(HKJ[3:2FFFG\T_85:6R-Q#AYQ]H5@<K>0;RGK8R#[$<Q2\
MV0;1NJ\2>TN=:N7"S4A1.44VBITU%#F)ML4@F$1'P].H'VD9QB>.HX'[E<#(
M/C::<QB/5]RQ.Y-XM9]Q(Z6:W_%MPKIVZATSGD(-^W3`Q!$#?M%$2D$/#<!`
M1#;6.^UF9F,%5LC3D<58!=LX0,9)=%5$Y1V,50AB"`@/HV,`:@+7#-7CH77*
M%$0'</'?Q_#MMJU5ZUUJJ6_J]6BJN`=`?9\OR#HBV!1'V!\PAHBT"C[OI^O1
M%\[/X?G#153L_A^<-41.S^'YPU5$%+W#^(0'5$6GM#[_`)M%1?.V.JT54[8^
MWZ-45%O$3]WUCHBY0)^'U:JBXZJ8Z(N(("'@.J*J^:(FB)HB:(FB)HB:(FB)
MHB:(FB)HB:(FB+]Y;75+DDT1-$31$T1-$31$T1:RG.3Q(<Y!]I3"7\@AJA`.
M85P<YN1(6HZRJ@=*BAU"_JJ&$Y?F,(AJ@:UN+0`>C!5+WN%'$D=.*Z!]6:Q*
M?_52KUF3\0'_`+RKT,_\2E$A1_WMDMXE((@'L`=M9D5_?P?P+B>/^;(]OL<%
MKKC:MJN_];M+67^?#&_H_$T\%13[!^$Y,#%D<-XG>@=,$C`YQQ3E>I,#"8""
M)H;?I`P[[>W6UA[U]ZK<U@W/<6$&N%S,,?ZZT5QW"[B70(N=DV>2HI[UE;'#
ME_#5+N>+7&=XIW7/'S#"JG2!.L<;U0@])=]@V3C"%\-_9OK/9X@=^XVZ8]YW
M0-__`%F;[7K52>$WA9,[7+W;V-SJ4K\E;_8Q=#_P9\2M]_\`AOP][?\`V+C?
M[&LS_P!T/$?_`,\W/_MW+7?^R'@Y_P"F-D_V9BZH_!CATH<ZAN-^+NI0YCFZ
M(=TF7J,(F'I33?D33+N/@4H`4`\```UD#Q:\36@`;YN%!^N#ZRVJPW>`/@HY
MQ<>[&TU)K_"</4'T'4,%I+P7X<E,4P<;\7[E,!@WB'A@W*.X;E-("4P;AX@(
M"`^O0^+7B:13_'-P_KM_R50>`'@F#4=V-IJ/^;=_EKMQX9<21_\`];\/>/\`
M^9D:'Y"^&L?_`-T/$?\`\\W/_MW+-_\`9#P<_P#3&R?[,Q=VVXK<8V9TU&W'
MK#"1T0Z4S?Y<U902AT"3_I8T_4/0.VX[C^/6(_Q"[^2`A^];H0<_])E^QRV$
M7A)X50D.B[M[&'-R_P!"@/1Q854C+`^#(WH^[\*XC9]HXJIBWQM32"10W@8Y
M1"&W*80]>L&7O?WMGKVVZ[DZHH:W,^7]=;.#P][@6M/EMBV9E#44LK;`\_X:
MJYC1J+%@4(RC4F-`I1(7[OJ-=9=)#'[AB!\-&I"!3'^T(>@1\?3K6R[MN]P:
MSW=T_P#G32.]KBMQ;[!L%H*6EA81`#\%O"WI_"P<<55"(%;ALW(1N'CX-R$0
M#Q'<?!(I`\1#6`XE^+R7'I-?:MLP"/\`A@-'0`/8MXRZY@V,LJ8/890XA](Z
ML#&#(#T*\R2'-Q/G*VM7*Q?-51-$31$T1-$31$T1-$31$T1-$31$T1-$31$T
M1-$31%X&?XC3R_/,$YD<]+)F;&V$KA<L(8XQ50<58V?PJ*;\CEE!H/[+=)5!
MDFJ*R8/;Q9WZ>_2`J$:D'Q\-83XKA[M49!'*HKU4KYO,MQ:F..$:P03C6A7E
M@N?"+E!C]PHVM^&\@0"B8F!096JRS0A1+OU_;,VZ1`/PZA++AGQM(\RS6N8[
MX2%9R0PMD6)1,=S498J8"/4/P+@@E$/2(@9(-O$/0.K-5!0A5H3D<%1;JGRC
M0Z82$6]:=XHB4BB!BB8"^!O5X>G5P;$X^^:!6.=(![HJ5TKJO`'VFQS$.F(C
ML(&*8NWK]`"40U5]K&16)P*C;<.KIE:0KMXLY,<E<#R!)'$V:<C4A9(.GM0M
MIDR,%4]P$4EXU==9@ND(`&Y3)B&L?3*PX%9(+3B%DIQIYZW+RN,"US,-=Q?R
M"K)]DGC.^U1FC*N$!V!0OWDP3*B)S$#;<R!O?H)I!AEU*N8QH1TJOIGFAY77
M(PZG^<7%BRX$L$ET%=V'&SAO)PB2P@/6X!DU314(3K\=@:".VKS,UP]X`GI%
M/8J:6\*CU^U4\\\OGAEG)E][\8.9%$<2*I3')2;^H%;G`,;]!`H.1:JF5$1`
M/[G;?5O90O&%0>C']*>\#@01Z/+TJ*N5_*HY<8U9O)MO05;E6FY15+-T]VUG
MVQT!#J*J!&2IW.PE\?[O4;K1_P"`@H'G-P(Z_P!"Q_6/'MQJKD[.Q5N8B')!
M$#(OV#EJH&PB`_863(;4#HGL-"#55#FG(JCCMC%$0,02B'I`0$!`1_TZCIS5
MRT"A[O\`1HF*^?#^[Y?-HB^_#>[157WX;W:JJ+2+;W:HBVQ;^'HT1;9D=O5\
MOQZ*JT"B(^@/'U!^'V?AT1;G9,01*8IBB'I`P"!@W]H"`#IUHMT"^'H\/:/U
M[>C1%H4(!O1[OR:*BXHM]Q\0\`]VBKDN.LF)?``_-^#\.B+B^C5%5-$31$T1
M-$31$T1-$31$T1-$31$T1?O+:ZI<DFB)HB:(FB)HBP%><3YY%;\L6VXQQ!CS
M&]7SOG&WQZURN]1G;?(U>(QQCM8B[6MOI9]!QTL^&T7&415.Q9'3(!8YJJX4
M$`5;]>NNKSLG!C,^L?<?O^W:6.WFZ:9'DM8,!AF?2%D:\N3EI,\Z.%^$^5=A
MI$1C>8RRQMSMY2H*:?6&*A!K-]M%,2(UF9)E'/7H/$:\5P83HDZ#JB0-P*`C
ME6TAEA$AS-?;U#V+#NH1;W#H0:@4]8JIMZG6.ONJ(OFJHFB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBZR<GHFJ
M04Y:Y]P1I`U:$E[-..U3`1-K#5^.<R\JX4,.P%(BP9J&$?4`:L>X-:233]."
MN:"XT&:_.4JG\5SR\K]BGGX+UR>K$K8IU_#P<Q!M^F-@I"9>O8J.!5-))?=E
M'N");B.X].X^.M=\W$2#(UI'H/I"Z)L18T-8XB@4\J3_`!7E+MS)HRS9QRH-
M@3!/I>G120$RICAL8Q$W31RF!3!ZM3LN+<'W>T:>AU?450M?^J?,KR5_SW_*
M0R"7JR5Q3@HAP]4*FY,V@X5TF5,Y@`ZFZ;9N82[#X@`;ZJ7QO_SI%>8'V*HJ
MT8L'I5P/^,+^'&SEUQUEQO`T]R;]D1^I65V($!0-Q,DZ9"<"AN/K`/'46IPX
ML<.D*H#:UHX+KR>6Q_#X<B&:[K'V=H6H/)L3"8_[TD9&:"8?`O8E2HII&`1]
M8ZJ7#C$T_P`TT0L!R=Z0K$WS^%KXF9&$Y^.G,BGR(G*8R+1[)PLGMW/[H3+Q
MTBH?Q$?9XZ%D5*N;(T>E4H[@6GU*%.2/X1SE76P^\*-=:7DACVG)4BQ$FG'/
M3K=(BV.1-X?MG3W_`$OM:C#+<FHD%:<00JG7D0?,L8V5_P"'E\S#'2;L7''J
MT3Z33N'.O7DF\J7ME`1!0#,UU.L!*'X?'0P.<VHTGJ(JJ:Z.ICZ"L<%^X(\K
ML3J"%ZP1DVM+)J"4BCRK3+8P&*/@<B@-=BA[P'5GR\C1BQWF3M&GB*^A;-)S
MCS%P5NWI&2LJU5JW$#*PCJ1D7D2()?R%8:8^+9"0-O$.V&HW=H.?G5X=PX="
ME#%^:OE^18DA<^8;Q'FR-%J#0SJ<JJ$!8.SX`*J<@Q050,L(>OLAX^.J"5[<
MZT\O,KL"<:%;C3+'EEY=`Z=^Q;DK`LZZ(/=DJRL6SUQ-T??]I\.GUN4T"F'T
M`B7PU7M(7?$*%*"F9]JWC\!^/^4TC/..O*W'-G75*=1"MVAV%6G"^CMHF;R!
MRB*PF';]$H;Z&")V+3BJ"HRH?+I4?,B^73RBQTBXD'6/'\U"(`8_WU7C(3<>
MHD'Z*A%HU5R(%,`>&X!J-UJ^GNXJNJF>"A_+4ZS0*ZK:8@92.70$062=,'*1
MDQ`=OM@=,!+M[]0F-[<P56H.2IXR>WAZ]_6`^'X=6'I5<%I$H;>KY_3MX>CT
M:8>=*+8,4/9ZO:&WTZ=2I7FN*9/?_6'XP]FJ*JSB^6!P1B,JU"?SAD>H%G(9
MO(),:@A(AU,1^'-TNI(6PF`JXBO]@FX"'AK96-J)CJ=\(6)=7'8MZ5E;F?+!
MXZ93M+6P2F/3$E&[=)%4C!9:-C7)D]C%.Z9-A316.0`VW$/$/3K*DL^TFK0!
MJPFW89'0$EY4$>9ODPR$?'2V0..IB"M$QZ[R9QVN!Q4>F;%ZS'KJXFV*L9,H
M_LC!L8?1K%N;4->=.`]2GAN32CL?:O.Y)PDG#2#V*E6#J.D8YRJS?,7J*C=P
MT=(&$BJ"Z2A2F35(8!#8=:X@A;`$$8+A]H`#;_0'TAJBJN$HAU"([?+V:K1*
MKKE40#Y?+;5.I57#'P$0]^J*J^:(FB)HB:(FB)HB:(FB)HB:(FB+]Y;75+DD
MT1-$31$T10QY_P#-K&7E\\6\A\E<F&1D/W=;%A<>TD'9&LCDO*$TBX)3Z-&&
M,/61-\Z0,XD'!0,#&*;.7(@();#C7,XACK^+AY>750%9-K;NN9A&WS]`7B+R
MSPQRC;?*?YC^<!S-[]@Y/\PLB88E<5IS34Z*U%Q#8LQU(B]IBXUSN:""_1S-
MO'P;8`+]WT]DV(3[+Y0-:<QN[)TS\R,/2,O,?13I70,GC%VRS@_ALK7I-#GY
M9UZ%Z?\`R-<B4/%GDN\0[?DFX5ZCUEE!98.M,6220C6R@ESCDO\`8,DU3?%2
M;PXAL1NU367.;P*01\-=5W7V/>>\<L>U[#:SWFX/)HR)I<1CFXC!C>;GEK0,
M20N'[[=Y^[G<Z";?.]=]:[=M+`"99Y`QIP'NL!]Z1YX,C:Y[C@&DKLC^8KR%
MY+YM=8BX.8[K2]71!!)SD_)$!*NE(I@54Z<C=9EH$DVAZS7O$/@FKM%R_<B0
M`!,55`0)]5#P,[D=P>Z3>\WB]?7#=Q-2+2UD8`]U*M@8=)?+)^=[',C;6NH-
M;K/P;_Q2^)WBUX@O[D_3SM=H_96Z0[<+Z&1QC94A]U(W6(H(?[IDC))7T`TF
M1XB;E^Q_69VIU6-B+3=YG(UH`GQ%BN4VW91ZDQ+K@472D9!Q:#:)KD&B8.AF
MQ;I@5%$H=9E5145/\P[WN%GN>XR7.W6D5AMU:101ES@Q@RUR/)?+(<WR.-7.
M)H&M`:/N/NSM&X[)LT5EO&X3[KO%-4]U*UC#+(?B,<,8;'!",HH6-HUH&HO>
M7/=6>M4M\FB)HB:(FB)HB:(FB)HB:(FB*Q^?.0^,N-M1C;;DI_*F-8Y]M4:1
M4:M$J6&\Y`M[QJZ?H5JG5])9L#YXE&L'#QVY<KM(V,8-U73URV;IG5"&69L0
MQQ<<AY>7FK26*%\SM+>&?0J2P+RRQMG^8G*A%0M\QUD>O0;6V/L;92AX2*L<
MC27TDI"MKY4)FHV6[4#(%-+.HFCW3Z"FI`L;(`5J^*V742(>D<XD.DBCN'3Y
M=%5=+`^+$D%N51SY8T(\X"D[J=0)HB:(FB)HB:(FB)HBX#>3:.WKY@V%996-
M%--\L5!0K-!RJ0BI&0.C@5)P\*@<IU")"?M%,`*"4P@4:<:*M,*KGZJJ)HB:
M(FB)HB:(FB)HBQ<^=AFPO'[RH>=F0R2/W7(N\#V#&D$\*?MK)SV9GD=B:.%L
M(>(N$QN1U"@'C]@1]6H9M&FDATQG,\A3[Z*>W!,PTBK@:TZL5^0.2`@CID!O
M.HEZ2E`I5!)OL4`#T"8OLUC#;[&05CN6><46T-U<@T="ZG0?T+Z-84Z0%K+M
M%0'<0_:@7YMCFT.T.(K%-$X'IH@OP![\<C?-5;1Z_/I>*:Q%0]J;@/R#MJ)V
MTWS<@'#H(*O;?6Y-"2#TA;7P]I:>)0>[>G]FH)R^`>D.DWIUCNL;UF)C=[5(
MVZMW8![?2JEC,DY`@42-FLE*M4R'Z_L'<)F$?1XB`AOMMJ(B=GNN:X>93!S7
M?"0?.KHU3EMG.B_'?NQ?;1!C(IHI.C,)1XU4,"!NM(R2B:I3HG*8?240$0T$
M\S12I`*NH%*O'OG`<_\`'"[5>J<ILNPI&0`+=H%K?/&A!*("&[9V=9(P>'H$
M!U47,W/#TJFD'$K))AS^*7\SO&Y/AIW*5?R8S`I2]J\U*'=K_9V\3/F2#1T(
M"'IW-IVS3BYK3ZE=C3`E9$\;_P`7UDZ1;)QV>N)V&<CM3=*:[N*7=12YTQ'9
M4?@Y!"5:"8Q1';P`-]2"X8![H<T]#E;2IQH1U*3;?SYO)@S[6^GD=Y?K>$.[
M5,U=+U^N5687ZE0W46268%A)(""`CN(CK(9>'/M33DYH<HS"W+0*\P:+B+S7
M\*=R,8)F>DL&#WQA('2[C;=!*M"F]!`[99QF"9!'QV]&J&5KC4]DX>=JKV?(
MOKZ53+GR-_(?Y"INW>`/,8K->=OB]V/C9RV517X3N$W(4[>97@9!3I]@_:U6
MD;LXS3]5P*4<,G"O2**/%V_A%I^:[LKQPYG8,R,W[97$4FK,),'CGK\4@!Q%
M/I1LGU;^!@-MJPQVQS+V];?M"H>V'!IZC]X5GY#R"?.ZX\H*(8M<R-ICD""9
M-&FY28S$8X!J'6GM"S;D$A*8"^!13#<?#5X:T#W)&D=)(]H":G$XM<#YC[%&
MZ\X9\U[$K@%^2_!&2RO#)`9)\I)XL=@\70+]DYBS559N4^L2AN!^G5X$N!`#
MAT4/WJSM&'!V?2*?<HEV>O\`"FZNS,\R<=\[\6K&J<Z;J5A(J0G:^U<>@YU(
MR0:-WZ:9#^D`)N`:M<R,BDC"#SH0KVG5BT^PJU$KY=5$OC-W+<;>4F*\A@"A
M0:5"U/PH]T."OZ"(Q\N8A5%0$>GT@&XZQW6T9^!WI5]7"F`/ETJ*64^#_*?$
M`*K7/#-R3C4@ZOON&C%K#"'3$.H%"2<*#UKT"7QW$P>&H3;2-X5'0FH#!V!Z
M58S'N-;/D7(=5QQ"QCQ2PVF>CX)HQ%NL1P15VX(DHH=$Q0.4&Z8F,;<`V`/'
M40:=6FAJKB0!@O?MA?!T/@/"..L.1+%H52!BHLTLX0Z3'!VF@F95,QR#]HZK
M@PG.`[^(ZWT%+>'0/B*T5T_M9:9T4QZ94(]%N=T4@&.<I3B<2[;B(!U`'L`!
M'4IN,*\5C,BPJ>)7(EZK&JJJ`0FPJ@;J.4OV@W+X@(>@0#6MGG+AI=Q*SX(B
MQVMN0"AWG#RZ^,W(NLR]:N6/8=JZEG?WF>V0+)"+L:4MT&(#X)%L0BJA@W\0
M,(E-Z!U1L#2RO!2&<]IA@.:\A?.3RKL_\/G%LN*T,:SX6CYX[2%N3%4%WJ42
MY'=@YG6"1.MD)>H$SJ!N3J#?PWUA21:7:1DLR.;4VKLZT\N55BT$@;"'L#Q]
MON_#J)3KJG!=M_EXZ*H72CZ1_"/Y=6JY?-$31$T1-$31$T1-$31$T1-$31%^
M\MKJER2:(FB*@LD93QOA^N*VW*5WK=#KR?44DC8Y))E\:L4!$6L4R_:2,R]'
M;P0:(K*C^KK<[#W<W[O1?#;.[MG/>7Q_#$TNTCF]V#6-_6>YHZ5S?>OOCW4[
MC;6=Z[X;A:[;M8K1\[PW61^&-F+Y7_J1M>X\EBSR!YPN._CY*$X^X<R!FA_&
MM7CUQ./TEZI7&[!@@JZ>RRC%HPGK+]T,FJ!UE5G2$>5-(@F,)0`1#Z&VGZ8]
MV@M!N??[=]OV6PI5PU-D<T<G2/=%"T_S72+X]W_ZX>[]UN#MD\)N[N[]Y=TK
M1I#'PL?C0%D4<<UR\=#F0GJ7F)MENYG?Q&G+IC)U/'4,[XJ</5&BJ57CI)*$
MQN[EK$_.N5Y.O;E,E3L-LR8$("2B11,HUK+(2@DEWSBKXEM>W>&5[XD/MMRO
MKIOAO:/=65['NGO!'AIC;!'^Z;.^I:2`60BI<97!?36_;QXV[7X-,O-EVNQ?
MXT;E&T""-\;+7;NUJ[5*^ZEI.^UCHUP!(EN2`&=BTJ=7G68U\R"&\M[*$[R,
MR70RX=AK3A>-<XUJ+BJM$BB:_P`!'5=FPB*?38V,0CX-X5`4T@>E3231`"%-
MT@77H'B9O7@`[N=/M7A[MEU'WC=)%V=Q(V6C6-D:91JFF<X%[<,(\:XD9KR7
MP1[L_5I#XD6F]^+V]V,W<QD-P);2)\&MTCH7MA.FWMF-(9(0XUEH`,`<C;7A
M'Q\X[8=\GK#/F!<PLDYGL6&*TR?H_P"5&)(>,<3T8C/9ZL&/F,?&/K'/IH&;
MOI]T#IR1F6/$B2AS%.90/M4[G_4-NG</P]M.Z_=O;;2.]A;)VEU)5[I'/E>X
M.[)HC!+0\-!DD?EE3!7>(OT@;#XK>+VX=^.^F];A-MMP^(PV$-(V1,C@B88S
M.\RD->Z-SR(HHS5WQ5J3Z@_+MR7QHS7Q.QSF3B3CN7QKA7(2EB6@(FSU]I`7
M&37JEDEZ;(S%I!":L;J4>.9*#7[+ER_<JG0Z1^P`]`>3[]WLW[OG?G>N\-W-
M=WK@0'2'!K:_#&P49&ROX6-`XG%>_P#=3N#W4\-MJ'=KN?86VW[8P@EL0-7N
MH!KED<3)-)3#7(YSN`(&"D_E/*%`PEC:\Y?RK:8NDXWQM692WW2U3*P(1\-!
M1#<R[E<_I4<.5S`5%LW2`Z[IRHFBD4ZBA"CHY'MC;J=DNH8QTCPQ@JXE8QL<
M>=[P3R!QDOW,>2DLR8KXW4&[0.,QR1E?$TC`(7O(UA%8&]&Q9!P4I9[#?K!'
M%2ZGY6C7L,@$>ZJ44U@2Q&WT987D4'G^[[/85F/VZX;*(1I=(16@.0YGR^Q1
MQE/XC/B<=JO+4+BKYB^4:PW`RI[A5N*LDRK1FI-Q.\2?3MF8J_#`F'5U'33\
M/2`:I\^RE=+J]`J/L4G^%S5HY\0ZW8_:I9\"?.2X1>8M;)G&V#;->*SEN#@W
MEF<XJRW4`IUKD:_%KMVLS+5QPQE+!7+$C!KNDP>HMWPO&Q3@H=$$P,<)(;R*
M9Q:,#T^7VE0W-A<6K0Z0`L/$8A7,R5YGW$/%7,BH<"[/:[D[Y)7-E79%E7*U
M0IF?K4&RLL7)V%LZN-S;&)!U-K%56(6F))5X<B4?%=+E4P$,&J/NV,E$5*GS
M^RBI'9320&X%-'21]ZAGG_\`B.?*CP%:9.ECFRRYIL,*[682W^0='<WJMLWC
M=045FZ=WDY&L4Z7%-0H@)X]Z\1$0\#CJQ^X0M=3,<?++UJ:/:KR1NK2&]>'Z
M?4K^<'?.?X$>8'>%,58,R%:H7+?W3(3L?C'*]+=T6S6*)B$`=3#NJ.2O)FM6
M12(:;KN&S5^=XFW*9;LBD0YRWPWD4SM(SX>7\JBN+"XMFZY`-',&H62F]WZB
MXMI\_D+)MSJV/*%561I&RW2ZST;6:Q!,2CM\3*34NY:L&I3F^R0IC]:AQ`I`
M,80`<E[VQBKC18K&.>[2P$N/)8/LB_Q+GE(8_GW5?:9HR)DE1DJ*3B8QGARW
M2]<^R82F5:2]B"J$D6H;;@JW(JF</$AC!MK!=N,0/NXCS_<?:M@S:;MPJ0!U
MD*?'!KS+^('F,1]V>\5+W9+<YQNG7U+S$67'UMI4E72VE232K_=5FXXD-(FD
MU(5T!"LWCDY01,)BE+L(Y$%S'.#3,=?MH%C7-I-:D"44!RQ"I7E;YN?EU<++
M"YI.?N3=.B,BLS=#W&5*93>3<@QJPAN5M-UVB1TV>MO#`.X(R2C-80'<"[>.
MK9;R&,D$^]Y=9]5%=#8W4XU1M.CGD/6K5\:O/3\L/E9D:$Q'C/D,K!Y'M$FW
MA*I6<K42WXP-:9MX(%8P<%-62-2KCB<D%!`C9FJ\1<NE#%(B0YS%*-D5]%(=
M)P=7RX#[2KYMNNH6EY;5@&)%#[%9;SO*/.6&B,.N'0DH;(^!<N<;:7)RY(8*
MM4,Z9+S+QGNE8"TOK,^BZQ`-,B4'%]@B&[N2=-&;EV@2*,L523235CO&ESAR
M(-//3CZ_5Q4FWN#23Q#@?,`[TYY>?@K;^7YAQ]CWF5.8YC25"9N&(>0'*[+.
M5[OAJLT6BX%;X-RUA/$.,<$0]'H.,Y"5J>+Y'+TO6&,O)U=5R>55G*7)RRY?
MAUF:RL-NU_:-:!2AK[,/5QQJ#S"FO)(W0EU2:@`5XT)-?-CCD`0!B"O1)K<+
M3)HB:(FB)HB:(FB)HB^[CX!Z@]`>H-QW'8/5N([_`(=41?-51-$31$T1-$31
M$T1-$7E4_B_LNFH_EBT#&#5<2/,Z<HZ%$.VY3](N*[CJL6^^2(G)Z3HI3S2)
M$?4!Q+[M:W<'#0&_B^P__P!*V.W-)E+N`'Z/M7YG.M0MPOOHT1;I5UR?H++$
M_HJG+^0P:N#G#(D>=4(!S`7*)*22?@F^=%_^C''_`)PCJ5MU<MP;(\#K*L=%
M$[XFM/F"W0FY7PW>JGV_7`A_^<0=]7&\N3\3R>M4$,(R:!U+=^_GX@`*?#*A
M_P"4;ICO\W3J[YR<BCM)'4$[%@Q%0>LI][E.``M&L%-O6"9DQ'^J8?'5/F0?
MBC8?4J]F>#G!:@D(LP""T04!'QZD7!RB`^O8#!MJHFMB/>BQZ"J:)0:M?Z0%
MK!S!^'2A(MQ]J:Q#A^'81#359$?"\'K"I_I`XM/F*YB$FS1V*E)R:)0\0*9,
M#E`?Q&'5M+4_B>/,KZS#@T^==^TM:K8Q>B835*7;P=LSB`_TAVT[.#(2>D('
MR4Q;ZU6#2^ID[?4M$G,7?]JBLJT/XC[MA`0U=V#/PRL]BH)W9NC=579J.?96
ML+HKPUUN%=<("`I+5NYRD<=(0$-A(9J]0,&P^C;5!#*''2]AI^LK^W93%KAY
ME/;%7FI<N,=_#A2^<'(BI@V`"HMUKU)33`@;AN4R$HY?)&)ZMA+XZJXWG-KA
MU@^U`^'I'I"R18F_B*O,GI@H)#RSI>1FA#`7X/*E!KL@99+[/V%GK)M'.]]O
M#<%-]1ZIVXNB!ZJ?9175CR#O+SJ9$;_$7Y0OS`\3G?B;PGSL@XZR21UF:L*]
MD6Y@'<J(.TIA-)90!'<?'U:N^>EC%"R0-ZS3T&JM[&-SJ^Z37D/L7>LN<GDV
M9L9,%\R^4#'5Y^H'5(3V&[?7CJMSF((&4:IM)*IOU!Z@\`$0.'MU"[<&U]^H
M/2T>T44@@%,/:KX8W_\`#7L`)J\09SD/4ZW-D,6S8QRI-RTHTJ+]$QB+LF"$
MI(RZ8LE$#`(=M=4GL-Z@W^SE]S(#&R-\8SK^E:[<'PP0GM9)&..5/T9JC'?&
M+C*^R*:PTB4J],O;-95Q$VE>':-Y!-P4!,J<CT$A%(ZR91#?;<1';707$5C<
M4;)#22N;>'25H8'S,),-P"RE:/\`L*G+B##MTR#$+2T<099.+3Z9!^X730!4
MR0")3!W!+U*.2!U%`/3OKF9HBV9S&FH::5YK8QU>S70@D5*OFE7W];!2&?LS
MMG)$B"=,?24AB[E'[.X"4P>O6/(XC#BLF*$&E<`NI6;%ZC?8\=S``D'J^SX>
MW6M>_M)`T<#BLL,:,`%W</&DWWV`2[AN`AZ"B.X[CZA`=;*-P#0.2P7LU.IP
M5`<A,55W,F+KMC&?;(K1=NK<E!.!52(H"0/VJB*3@I3E,'<05$#%'T@(;ZOG
M+9`,*%(ZM;IKG7]"\(69/)YY9XM<W5PC!PT["5Q\^/$G9R8&D)R%1.=1N[:M
MQ2`O?^'`.M,1WZM]M87RSC4MQ"S6W#<`_!_EDL2LJS=1[MTP?-U6KUDNLU=M
MEB"FLW<(',FLBJF;82J)G*("'MUCD$&G%90-<52YO2/X1_+JTYJY?-41-$31
M$T1-$31$T1-$31$T1-$7[RVNJ7)+44HF$"E`3&,(`4H`(B(B.P``!XB(CJA(
M`J<E4`DT&)*Q7\B_,)F4[\OQSX9TP<WYV66<QLG/,VX2M)I#M`W9?]OMJI,I
M]_#''9TY<+H0S!0-EE5C`=(OT9W%\$;5VRCOUXJW7^$=S@`YD;CHGN`<6UP+
MHVO_``,:UT\@^%K`0X_&_BG]3M^WO([PL\!;#_>'Q&+G1R3-;VEK:.;@^E"&
M3/B/\21[VVL)^-TA#F"AL;>6!,Y'L:66N=N5K#F:_/.AP>CP\Z\0J\00P]PL
M2^L*!6CE=F@/V?@H5*,8IB`@114OB.WW_P"H6UV*Q/=KP=VV#:ME9@+A\;3*
M_P#7;$:@./\`>3F60\6M*Y[NI](-]WJW4=]?J-WJZW_O+)0FTBE<VWC&?9OF
M&EQ:W^ZM6P1--0U[VK%MYY7*I>O*8]\ECRZJ7!1><N3#VMU[,D9C5@R@SUZC
MVLQ%:_B^1E(U,KIM)7YB4TK9GCI0RC"I(&%<W0^,)?EOO+WCWKO)>FXWJ[N+
MR\<<7S/<\CJU&C1R#0UH&0I1?<O<GN?W9[F[:+;NU86FV[5&,([>)L0-.+M(
M#I'?K/+G%V9K59\_+OX-XZ\O'BKCWC;01:RDC#H&L64;TBV!NZR5E>;0;FMU
MP<@(`L1@99`C*+;G$?@XEHV1])3":"V@$,8'XCY>7Z%F75RZZF,CLN`Y!8^?
MXE0YB>47FP"CL"N4./B9P\/M$'*L(?I\?1]H@#^+4&X?PO-]K5D[3_KC>H^P
MK$'DUU\%_"%XK3*.WWC-TID;<?TN[S)LCLP![Q%I\VL1_P#J#1T'^T%G,QWI
MQ\OA7H`\C"(+!>4=P8;F`J!76(Y:P+'4,"292SV0[Q/*.%5%1(1-+M/>LQS"
M!0+XB.WCK.LG`6PU9#[@?M6NW$$WK^D_H6&CE#D7(_\`$%<SC<%^--GF*OY:
MG%VU1T_RIS[7S=+++MPBGJZ;2,JSXQ19S"0NFCAG46H]Q%54CFPN"';MV)=8
M<CGWLVA@/9CR_E^V@6="UFVP=O+C<O\`A'+R_1A4KTNGQCQ#XRX<Q74Y^N8*
MQ-A/`4>W8XG#)JE*B*OC\6;%5B>6@IJ^*)MV]I?(.%S/),BOWB[6<KJ**&.L
MH)L_1!$T-=3`C'I\V7G6JUSRO+AJ+W9TXJ!&;_/\\N#$2$S#8\S9*<JLEQ,7
M+OH_%'%JOV')DH^"$CW$@[.]MC%BWQ_7(!BV:'4>2*\B9%FV3.L)3E)L,$EU
M;8Z6M=)CP!\^%?60LJ+;[LD%]61\R:?IKYBL"7D0$99EY>>8OYW&<8*%Q7B?
M'<9EV;0CX$@-ZQ#6+(C4]_R(TAEC)-229J-BZ)1;*K=*9WTC/$5,4%#B76%;
M4+W3NR'MS\],*XBHJMCN!+(8[)F+W$?<.JIKU45EO*QX+WOSIN7_`"H\P;DW
M,W&I<<+7D2U1=JKU8EY"N3F9G=D!@Z;\?V5F8J)2,-B^D8^;Q$?9562J;AXV
M%&.2.0%W*B5;>$W,A>:AGEAY8GTJZ\N&V,++>(`R@#S=-.=:TY>A>V&@<0.*
M6-*6SQCCSC)@*K45%DG$I52-Q)1!BW302`AV9,'L&Z7F5%RCLJJ]4766$1%0
MYA$1UM/EX&-Q'N@<R/4/N6A=<3O=J+B75\LUXL?+6P;A>\_Q!'*+.>!6T%C7
MACP>M.>\ONIB-4"/H5:AXZ`G<9M&D6N'^ZQU3D[2\G9AJW(((I0L:H5,H)$*
M`:>(#Y@N/P"M:89X8<.9X9<%O[N1PV]K'U[62@^W[AY^*O\`T6$RI_$P\T+U
M:[Y9+OC7RHN*=J0C:G0X)ZO!R.5+"KW%H0KHX`=N.1;K#I?>DM(J$64JD$X;
M,60)NG0N33-#[V:I/[L>7D.G.I)43C'M4```-TX>CR]>?`!>L?#G#[BEQ]I;
M+'F%^.6&,?5!BU*S",B,>UMRZD"%(!#KS\Y+,)&?LT@XVW6<R#IRX6,(B<XC
MK9MMHFC2!ZR/91:5]Q-([4]Q)7FH\[;GYC;@C:'/!G@0QPWQ3S_RC<TR?Y8\
MAJ;`0V.6.**5-$5@JF[EG]/BTU&%[EJ\_<OG4HBV4D8BO?M&Q1>/D%4===/;
M&_LHO=)S/ECZ>OE3;;?;ON&_,7%7QMKI&=3]W1^E7*X`9@_AQN!-&B&%0Y=<
M9LF9O?-DW>2>1V58:=L.2KM:W1?B)J082%DITB%(KZ[]0XMF#!1/]GTF<K.G
M`G7.@?:1-JZI=UBOMKYLO:;;J/<KAQ&DB/@!6E/+S^Q8S?/^Y$\#N;]^X)PW
M`"\8ES!R;G<MR=0EK;A2/*QGB1LU(4F+QM7[(\;0\,[DY(UZ>?%Q(G!95F1N
MY,0Q"G'JAN9(YI&F&M:^>OI/0LO;XY[>-_S`(C`KCZ_+I"]VDI78V>KSJJ7.
M-A[?%R<0G"VB+L,8QG8.R)BV20DTI:)E&[J/DV3]=,QSI+I'3/OXAK=AK7L#
M78M]'\F&"YL$M=5N!7343'6/,65\E3Q?0*/C6JD=KORUG'U2K]*KX/W($!R^
M^YJU'1D<+UP5,H'5%,5#@4`$1``U5L;&?"**KGO>:O))Z56.KU8FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB+P6_QJ.3%5;+Y?V%T'.R#&NYVRQ*-`-Z
M5YF5H=+@ESE]?2G7Y$I1'T;FV](ZT^X.!>&\1]P/VE;?;FD-<_@:?:O##K7+
M9)HB:(OF^WB/@&B*LL=X\O>7+?#T#%]1G[_=9]?X>(K%4C7$Q+/#E#J54!NU
M*?L-6R>YUEU1(BBF`F4.4H".J@$F@Q*'`5.`4VLB^57SPQ3AZ6SC>,$2D;2Z
M\5T[LC1C/5N?MM<@F13&=VJ9J\!*2<@VK+,2#WW1>OX<H"=4I$@$X2&"5K=1
M&"C;-$XZ6G%8\P$!`!`0$!#<!#Q`0'T"`^L!U$I%]T1-$31$T1-$7S1$V#1%
MK`YP]!SE_HG,7\@AJM2,BBWB/'B0@9-X[3$/0)'*Y!#;T;"4X"&JZG<RJ4"[
M)"RV-K_V6P33;U_L)1ZE_P`U8-4..:K4KU%>1S$ST_A/)-LL#Y_*$"ZJQT8Y
MD%EG"R:+9BCWR(N%A,82"N;VZVFU/,4KG5HTCUK7[FT20M:14ZEFRB,>.72J
MTJC$J+%34W6="@;L-RF.&W<7$O2!S!ML&^_NU?-<2:R\$J&"WCTAA#?0LJ/%
M^,D9*%;0"Q6*+2-5^,31,L=DB_$A#*B5Z*(E5<J=6P%$?`H>&HXI'.:2[GY=
M:R'L:"-.05:Y"7.K*OS/HXK$`3.HFL*1Q15%(G0'8<B`&6Z0V*'I``U#<2T:
M0>"DBC.HO)/5Y>HJP3-L9\Y,1(2$,83G`##TE``\=MQV].M9`3KJ,U-F.A5:
M1%PP:H%5%(HK$,L5,H!UE+U"!14\`$>K;</=K-;(:5-!BK"QN=%U2PB[$PG\
M=A]/AXAMX>&WNU(V3M!56EC1DHE\CHU)&I2CHJ15%R,W!T]P#<Q@(;8`W#^4
M.IQ,6-.G-0F#603S7YS_`"0*Z-F_*2CR.^ZW"MSFE3,@)T`D4[HXE,4-MME0
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M`R=(13M)"-3C@*,#6CT[P>\&NZ/@OW89L/=R-LFY2-:;N\<T":ZE&9<<V0M-
M>RA!TL&)U2%[W6!\T3S":)Y;7%*V9SL!8V<R-,&7I>!\=O7`)GOF4I!BLM&E
M=HD,#@*C4FY!E)Q<NP)LD.R4P+.$`-YM=W`ACP^(^77Y%>RV5JZZF#!@P8D]
M"P_?P[_`J\BUO/FP<MCR-KY+\KW-BF\6R-K0ZIJ#QU;WBCFS9/5;KEZHV<RZ
MN4$8PA`(#&JMT4T0*B^,0,2Q@)/;OSX>7EPZ5F[I<MPLX:=DW/K'#S>VJ]2N
MMLM,L"_\2R82^4;F4`_E96X]E'\'^:$2;P]^Y=:[</X?F^UJV>T_ZX.H^PK"
M[GMZ2/\`X1SC:EX_]Z9'HC0/$/`P<F<H29@V]8=+`=M8DAI9,Z0?[06?$/\`
M\P_H_P`E5TORAS1R*X=>7OY(WEXR9/\`.?)'$?$+SF7FB.67"O\`'O#E@J47
M/VJKRDW&B!XV7DXJ?*I8!1.#H&SIO$("+Z24!N#WEC;>(Y@5]`'\@_12G91Q
M327]R/<#SI',U-*>7J&,^>=&;\<_P\GET8<XX\+:C&RN<<N3\I3\;S]GBV4@
M]G+FVC8M7)O(+(,<3M-K+9`<2,<RB(Q4WP"*[MHVV%BR,B>>4_)1!C/XAX^7
MKYX<,!C01NW.Z=+,?W;1C]@'+RXXJK>-WD%8TOC:!SSYKF0<F<[^55H8LK!;
M(/).0;,7#6-Y.003>*4NM5:#D(H9I&O*+"V54.HWB5%$Q!M'HH@4#7166MH=
M.23Y9<!Z_-DK9MR<PF.S`9$.0Q/6<_+,YJQ_G^WK!W`/@;%<1N(F&L7X?R;S
M9GT\5MZ[AVAUJH6%YB""<QKJ_D57K\>UF9,UQE'L56DOB%51<A*."@)A(;4=
MZ(XF".,4<<,/N''S<5)MHDN)S-,XEC,<37'S^GS=*ACYG<-)>7?Y4W"?R:\,
M(%D^2W+J0K\MFN.@A`96?D)RTQ$C;8]?X;J540OF:I..KC,PCTJ0M>73'[`#
MJ"4=G"V%OQNS\O/@0<B05D6I^8NY+V3^$S+H_D&)Z5ZN^#G%2K<(^)N#N,%4
M*V53Q;2F+"SS#9(J8VG(DL8\WD6VKF*4IE5+!<9!VLF)MS$;=I/?I(4`VUM$
M(H@!G3RX#UY56EN9C<3NE/$J,?G*\U2<$O+\S7EB'E$X[*%SCO\`)G"@=P".
MBY)R*S?1R,\V+U%,(46LHR,X8P;@4T>0H_IAJ.]F[**@^(^7EU%2V$'S%RUA
M'N#$]7Z<EY?97#=F\NG^&?M%K^$>0F:/,FR;BY/($DKWD)R*PY=@E)2G55VN
M;9RF66Q947"[@AA`14M#DIMQ$0UK#&^*UUG)Q]OMPKZUN!(RYW0-_#$#3K'Z
M3Z@O2AY#.*:;BCRGN(9*>,>X4R73)7,ERE6`IJ?>MZR#8I1Y.?&+)[BH\K[5
MFUAS%,/4B6-*F.W1L&QL`!!49U^ROVK5;DYSKMVJM!@.H8+,"@!!52[@"*7<
M)W.D!WZ-P$X%V])A*`[!K,=72=/Q4P6!UY+Q$^06M6N:WFW>8WRTS2SA[;D!
MG$VR>I$#9F;.71BH[(>5W%2.[9Q4DDY;BG3*%58Z"0'H$&S=[TAMUAK26H;)
M<G5EUGIY=070[AJM[*.*/X:8^C[23YU[+E\0XA<F,9SB3%3@Q]NLR^-J4L8_
M2``7J%2#,)M@`-M_1MK;?+Q<CZ3]ZT(ED&1*^Q^(<11$DSF(G$F+(F8C7*3R
M.EHS'%,CI6.>(#N@\82+.$0>LG:(^)%4CE.0?0(:"WB!J!CUG[U4S2D4+C0J
MX.IU$FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(OS._XP.^J67S1
M:!2RKB=GC#B3B^+!#K$2H2-NN&1KF]$">@AU&<HT$?6(;>P-:*]?JFZJCUD?
M8MY8-TP=;OL"\J>L-9J:(I0<1^(V7>9N6XK%6*8HX%$[=Y<[L_:N#57'M;.J
M)%Y^QNT@*0#&`AB,V93@X?N`!-(/TSDOC89'4&7/DK'O#&U.?+FO9-Q]\FS@
M_A.LQL'.XIALW7($$5)_(.7&9IYS)//TE%(FJ*.3U6NQ_4`@B@FW65*3^\75
M-N;66V*(>Z!4K"?+,[,Z0?+R^Q9,X'&=)I+<"4NCTRII$;)L2A5JE7ZZ)612
M%3(W`\-',C]@B9``""(E#8!VW#62P,;FL:3M"*@DT\ZE="UMD=K8JN[8+R]:
M6HX(RP&8(/56*"$;)NTV+UFHX08.*K*JR9TWA1%4AFRP`;J$P`.7J9BW,45S
M&N&.2\/7G)>4M"<<W-BY1\8F(H8&?R:#B]XU*10'&*G\W)?"(S%<)NL7]P'L
M@Z23,S,H92'56(4@G;&#LZBX@:SWXS[G+DMA%+K]QWQ<^:\[NL13IHB:(FB)
MHB:(FB)HB:(NV@("8M4Y$5FO,'$K.S\BTB8B.:)F6<O9!\L5!L@DF0!,83*'
M#?V``B/@&J@$F@S0D#$Y+]!7R[>(C+`''S%F(Y9RA#OW+1O,7N64(!BH2LF!
M7DPJIL'4L9N)Q(4/2(E`-;*&,-:!6E5K;AW:/H/A"R@W56#GDH6D41@:.Q]5
M@Z&ZATBDDK+(^'Q,S*J%`#CWSAN0@CL4OLU;,\./9QX,'K*EB:?B_$</+I4A
M\,IR4='/X6L1\7\6[%))Y,/5"=]LF!0.*3,FW<3$`WW-Z`VU&UQ`TLI53%HK
M5V:Z#)-=E4XA*1^*4DD%Y"19F<F<J*E!1N;K.FVZA`G;+TFWV]8;#K&N8G%E
M1CY>M7,-<QU=*L6U4*4H"4@$43,;=81-N8O3L)-A\-@`=8`=04&=5=057,FK
M.YDW#=54J91;-$&101(!"&3;DZ""(%#Q,(>D?7J]\[G45P;Q75(R(I$4.J80
M*/B!1]?M_`.IH9'-!KDK2!6BAKR:O#5"NOVYE2B'95`@`;TCTFV``W\=A'5'
MW('O$^Z%>V,DCFO!1SC68.N0]W68=&QUTS..C80%P8!$XB(>`CXZ1.UQARN(
MH:*$I_TS_P!(WY1U<KEIT1-$31$T1-$31$T1-$31$T1-$7[RVNJ7)+$)SYE)
M;`7*KB9S%D861GL6TM*6QM?#1R`NEJZ$XK.E*_(E^BFY?1%F<JM>H2E7<1_9
MZ@,H3?Z=\&+>V[Z>'/>7PM@FCA[Q799=6^HT$O9B/W:\0U\3`^E2ULFJA`*^
M(/J4O+SPU\8^Y7CI=V\MSW/V\26-YH&HP=KVPUTX%\5Q(Z.M`Y\.@D$BN52E
M7:GY(JT3=Z!9(FWU&=;D<Q4_!NR/&+DAB@8R1Q+^T:/D!'I6;+%3<('`2*$*
M8!#7SENVT;IL.XR[1O5O+:[G"ZCXY!I<.D<'-.;7-):X8M)"^R-@[P;'WKV>
M'O!W:NX+[9+ANJ.:)P<QPY'BUXR=&\->PU:YH((6)?G/Y+V&?,.Y*8WSYR,S
MKF^6J.+6D!$UKCK"$I<=B<L!'R;:9M40NZ/"+VH%,E2#8H3;TCHKQ5J5-ND=
M)-!("Z":S,TNMQ]SRZ/M73VU^ZVA,4;1K-?>X^0X+,.S9,8UFSC8QBSC(R-9
MM8Z,C(YLDSCHV.8-TVC".CV:!2(-&+%HB1)%(@`1-,@%*```:S6M#1I&06`2
M2:G$KD:N5%##G]PGI7F$\9;-Q>R%=[?CRJVFTT:TOK/1FL&\L2"]%L"%A9,F
MR-B:/8OX=^Y;E36,=,QBD\2[#K&N(.W9IX_I!Y'DLFUN#;2B4`$BOLHH89>\
ME[&.3/+,Q-Y8L5GC)%5QSB6[0URCLH.JQ5+'>9S[HLEYM01<K$IJ5ZNHI+RE
MX4#NHE`2)-4PZ3&,8VH7V9=`V('%OER^Q3LOW,NW76D$N&7FHKW^6/Y7."_*
M_P`462C8SE)+(>0,@39IG)N:K5#QL1;KB@R57"KUI-A'+O&L#4ZHS7,#=BBN
MH59XLNZ5,914`));6K8!7-_EY>14=W>RW;JNP8,@K>^;5Y2E#\U&AXOC93*D
M]A;)N%I6RR&/;W&0*%LAE6%P0AT[#7K165)2"=NF3EU7F+ELZ9OFSIFN@.W<
M(H8FJ75K\P!0T(\ONX_INLKUUFXFFICLQU*PN,O+O\XB$2JE-R/YV$O)XL@E
M85A,$I/&NFM\N3E3C5VY'L*TRE:%'TQ%3,C$HF;EEUC/GB!S]X>ZH7Q@;;W)
M'9N=1G4W[RI7W5D27M@]_P#G&@\W1R5T<U>3VUY&^9?A+G[E;/\`,6RE<>D*
M0VQCQG<X^^,B(Q''S!_)U]64R(_N3Y],/G.3WXV2075BP4>JI)MSCTD!35[[
M1IE$LC\/1ZR?1GA@D5X]MJZVAC]YV9'W`<L/253%V\K>KROFNQGFC\DN6%6G
MH_'Y$`Q+@6R5J'IL-CQ.M55S7\?":Z3F07(2IJI+RC^?4$(QM\7-.@6_9@0"
MCG67=_=-TN0;"WN+DDX-BADD]&@'IZEJ=R[U;)L5@Z'=KNSLHZ>\^>XBBZZ]
MHYO5U+(O9N<O#VHBJ6:Y&XO%9(1!1O"3BEJ7`Q?27MU=K,[F_'KTBP\(/%#<
MZ&UV+<-)R,D8A'IF+%X]NOU#^!NS5%[WIV@O;F(93<GT6[95Y]O-5@>(?F;9
M=XTNK=SO1HW'C`TI]ZV+#<=Q]RA8I'(DK-V&-<7J3-<BNH=C#KR](AT82/,:
M.="Q!9RL/7WA(&ZE^FKQANR)?\,8UH&3KBV!ZOXOMZ5S$'UI?3OM^J(;U*^1
MV&IME?%H_P#X=3YYH9A\K?G_`,7K?Q/R1FU:ETV=2K[FG3L)1+G'2N,K12SD
M5H]DK3=Y5%(Q4E?!/X8[-4"H.H]59L82`H!RV7GTY^+K8=#MH+B!AHGMCZA+
MQZE?MWUA?3ZZX$L?>`,=7_.6E\T4Z2;<^U82.+/#CGSQ0:R&-.#_`)ZG$>#P
M^_EWLA%T_(S:=C&;5W(K"JZE(_'62:/?(:K2LB<04=!&/TDUUQ$ZG4<>H>,O
M/!WQ6VBKKC9-Q$;>+83*/3%V@]:](L/J*\!.\+FBV[R;,Z=V37W+8''S3]B?
M4O2QY<V`^5&)J]D"Y<MN<ZO.+*M[EH@T++5(K*(Q!C*G0S85482EU"#3:0XS
M<W,N57$C*G:)++((M4"`4B9^YR#MNOMO>Z+=(Y89C@6R,=&>61I]_4O08MTV
MK>(FS[%)!/:`5UPR,F!KQU,+A3SK"]F_^'SY-8CY>VSF/Y57,&N\<[+;K!9+
M0ICZ^,I^.;5AU<Y$TO;ZG$6*"A;E"VS&TQ+',NG#3D*<C4.A/N*]E$Y=<^QE
M;+KA(`)KCEY>9;J/<XG0""[87`"E1Z.C&F&:OVVX@_Q(.3&R,!E#S1.,V&:\
ML";:4G,)8>CY2^G9F$".EHYZ.(Z@BVDNP)A34(];@500'P`-7&&^>-+W`M/0
M/MIZE%V^UL-8XG%W233VE>AFDU=*D4VJ4Q";LEE3JE=AZ\%EN4R[L5NL9XE@
M@S6G[3//U%7DQ89I9(SEXX.;=1=4P@`%V*&Q8W2T-))*U;CJ<74`J>&2J;5Z
MM31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$7'>.TF#-V^7*X,@R;+NEBM6K
ME\Z,DW3,JH5LR9)+O'BXD(/0DD0ZJAMBE*)A`-7Q1NFE;"S3K>X`5(:*DT%7
M.(:T<R2`,R0%%/,RV@?<2!QCC87'2USW4:*G2QH+G&@P:T%SC@`2:+?(8#D(
M<N_2<A3EZBF(;I.4#%ZB'`IR&V'Q`P`(#X"`#JP@@D',%2-(<T.&1%>6?0<1
MU'$<5]T55^3[_$WW(UN\Z?EFAWNZC2XW!]%0#JZ@1^Y<(4%TY0+^KTOI141#
M]8PZY^Z(,Y+<L/6*_:N@LP1;-KGC[5@1UC+)7P1`H"(^@`$1_`'B.B+WK^4%
M@Z!PIP?PZ>.AD&EERA#(95O$F=,IGTK.VPHO(HRZG00XH0]7^#:-TQW*D!#B
M7[1SB,['EC:#-0R,#C7'!93VYNDYCJ=1U!-L!S#N(`4-MMQ`/'??4@D`%?Q*
M(LQZ%5,,\C"O6R<LD!X\5B&=B4JO>%$I#AVD^V<@_M3B`>D``1`1'8!U5LN(
MU9552T::`+MQMDJV0DVR#A12*>HI,4DE`:K+(-V9CECT#N%$3JJ=AJ/:,8!`
M3I^&_@&KS(X5+<6GU*T,&`XJT-[H]7R=2+10;S!,;+4+C!2-=LT#(($<L92)
MEFQVCULJ5<I]C"FINF?]--0"G*('*`A82Y[#7@KVC25^>1SWX?V'A1R)M&)G
MRCR4IKWKL^++0Z2Z%+#1'[M=)B5X8H=L9R`<(G8/REV`5T.Z4`(J36'A7!97
M2H7Z*B:(FB)HB:(FB)HB^:(O4)Y(?ERN'"\5S`RY%D!JH@J.)8%\@/60#B9)
M6TNDE2[%.L0-FOAN4HB;UZR8F"FMV2QIY2T:&?$5ZL(JOKO%R"&Z:)1*`$$.
MGJW';^J`:N<XO-:^Z%;'%I%3\15Y&T>E%I-F+=L@M(NP,B50ZH=HG<.4I%A\
M0!/H*`^(^G4$LPCP;FL@"F2O"[AK+BZMISK8J<A'RJA(]U+(B":`.7"/6HV;
MHG,#@2I$,.Z@``;AJ)SGQM[3-G%4P."M03[WM70Q0DE2Q+`5A9)NE3E12%PI
MW%^DN_2*BRAAW-OHT27>+31@5I+8\_TJ@Y@B;$RK?JV%,YDS%+X[G`>G<1#T
M[CZ-02L9'4<E(*E4F50QE!ZMP*3P#V^/T;ZA8"X]"J7`#J5`7NX-H5FL`JE(
M)2>D#@`F$`$1)L'Z(^`?/I-*UHIDT*2-FI8+.=O)^,H]:G9%R]*"J*"Y6R`J
MANLX,0W:2(7?Q'JV]&M)\U)>70MH:Z1G^E;$1"&+M'#%>06\V=_<K+-6>3.*
MCZ9?KO5A$=^D%3B)">X"%\-=2UH8P,&0"UM234YJUZG]X?\`IF_*.J*HR6C1
M531$T1-$31$T1-$31$T1-$31%^\MKJER2Z.S5BN76O3%2M\%%V>KV!DK&SD!
M-LTG\7*,5MNMN[:K`)#@!B@8A@V.FH4IR&*<H&#+V_<+_:;Z+<]KFDM]P@>'
M1R1N+7L<.((]!&1!((()"U^[[1M6_P"V3[+OEM#=[1<QEDL,K0^.1AS#FGT@
MBA:0'-(<`1BHGO+:R+AZQR5XX*\B+'AIT_5,Z=XTN#Q[,4A\H`@)6OWB5O*$
M=LR@'2F25C)%0A?#XC7T?9^/6Q]Z+&/:/&'8X-UC8*-NH&M9.T?FTU9I=Q)A
MEB!_(OC/<?I1[T=Q=TE[P_3IWHNMAFE.IUA<N?+://!NL-DU-%*-;<6\[A7^
M*B7(/S2,0=37*7$RI9RC690*>SXID@0?O$R>!G`MJR^G"]PQ0WV&%;?T0T=W
M(^G?O/23N[WEN=HG?_FKQM6M/*LK8\/^O?UJK/$WZPNX]8>^'<JR[PVD8_UC
M;GT>\#,TMWS8\:?*1]2W@\V"-K@%2RKQ&Y(8_=$^RY_[F1?MDCAX'$AYQA45
M3D`0]F^K#]-L]\2[NYWFV&]CX>^6D_\`9NF"O_XT+7:F@=\NY'>K;)1\7[L.
M`/'^.RU)'F7=M/.)XA*!M),\QP:NWVD7]"CE3$'?82B+*U.-Q#\&L27Z7/$Y
MI_</VN9O-MP\?VH0MA;_`%T^!\@I=,WVWDY/M(R1_4N7+MQ\WSA1V^O]XLD"
M?;?L_P"73ON;[[=.XRG:W_Y6VL3_`(8O%C53L+"G/YH4_L5]2V'_`!O>`6G5
M\SNU>7R3J_\`Q*>M4Y(><AQ/2W)!P&:;.O\`R$8^F0;05!]0`+^W)G#<?#]#
M6P@^EGQ)?C=S[3;LYNGD=3^K"?:M/>?7=X+0G186V_W<O!K+6%M?Z]R#ZEU1
M/-1GK2`$Q1PFY#WA54>ENLY:N&;4XC^B)S0-9LQ0*/\`YS;WZR3].=GMQKWD
M[V['9M&8!#C_`-Y+%[%A_P#&/N6[M'^Y?A_WGW%[OA):YK3UF&WN!^UYUV!.
M2_F=7SI+0N#E6H+=?^[D<G69<AD"F_1460E;#2E/L@.XA\,(^[4![@?3[LU3
MO/>^XO7MS;:1#'H!9%./VUE#Q9^KGO'I'=OP\L]LC=^._G/N])$L]H?-V9ZE
MST\=>;;?]QL>><"849K;=;:F5QI/2C8AOTBIJA6)C]H4!V`0D=_YWKU"[??I
MHV7_`%#9MYW:4<9Y71L/6.V9A_U7F62WNO\`6OWE_P#\KWC[N;!;N_#:P-FD
M;U'Y:7_X_G717+@Y>6=/M60>4?F(9[D:52:U.W&[.JVH^JE=A:Q6XMU-6&5<
M(%F)[J91L4R56."4>902$'I(([%U$[QS[K[,TGNEW,V2UTC!\X$S\..$;#_W
MBE;]+G?GO$X?[_\`B1WFOR[`QVI=;1FO`!\\K*</X0Z@NDPSPG\LC)C^BA4[
M3.Y]FLD8?BN0=)=S61[4^_?##LU,-(&-R"T&"8UEJ:(>S;])MV5CD=D5/L=$
MNQMM5=?4UXFW8[';[BQL82,&P6T8`%*T!E[7(<0MY8?11X(6#OF-WL]TW.Z#
MO>?=WLM7$?F%OV%?6IWUS@[Q)JW06%XUXM[K<0*"LK5BV9T0Y0#]-6RJ3"HG
MV\1W'?7&WWB[XF;C4W6_;CI=P9-V0]$08%Z3MGT^^!^T:?DNZNRZFY&6`7#O
M3<&4J[L=AK$T:F"<5B'&3%(J9A`C+'-11("11V,.R4*`=!3!L(^@!US,_>KO
M-.[5<;IN#W5_%=3''SR+M[;N+W'M&Z+39-GB8!DVRMF^R)1AY1Y5X`\6H.MS
M/*5O@VA1MV?RT=6&\WB9E:9:?/`QP2]F?,J_4J58[`:#JT08'4M)&;%81C8Q
M5'*R13%$3.^7>BP(=#NNY1GAINIQEU2>7%5E\..XVZ@QW&P;+.WCJL;4YX<8
MN/K7?K\*N$F5("*LK#`F(YRO6N)C9V`LU(8&AH^<A9QFA(1$Q#2U-?QC=XQD
MV+I-9!9(QB*)G*8NX#KJ]O\`&7Q0V^CK7?K\M&-)'B8>B9K\%P&[?3GX&;N'
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M2'`![2&L8"[#&-@KAVK31:#>-H^J7P3LG[ULV[P]^^Z-H-<UI=PN9N+86XN,
M3P7RR%K022)Y7`8BW<`0J-K/G"1]P;`LGA8N/8Y1;X(;Q>K%>+)263X"$.H@
MX#'&*YF4<+MR*%.9`3-3&((?;)ON&_W#Z7IMKDT.W8WTX&KY>WBMXIW-YCYJ
M\C8`:$!WOBO`Y+D]H^N>UWV#M6[`-KM"[0;N\GNY[1CZ`EI^1VZ61Q:"'%O[
MLT(]YM:J7,!YAO$YM7([[YS]%7.QHLA6FEZ?C3))`<O![CAT:.K36MRCZ-C6
MH&[:)5UU5013`RJICB8P^97O@?XE27\GRFRR6E@7TC$]U:X-P`U2F5C7O.;B
MUK1J)#6@4"]LVWZH_!2+:XOG^\T%_NK8ZRFVL+\:G8EQ9`V"1\<;<FA[W.#0
M"][G5*ZJL>8[AO*4^>HX&IN3,R6HI@($>U:U''4<0YA$I1<RF2[77%TT^H/M
M=IHNH4/Y`CX:R=P\".]/=VR_Q/OE=[?M6V_F)FN7>9EK#**];VCI6)M'U5=P
M^^&Y_P"!^&]ANV_;SP8UMK9,_I27]S`X#GIC>X?E4H*>USK-SC&PY*6J&.X)
MBFY.VQ72G"]RE)!RY;*-T%[UD>6CXALJ2.!7NIL(2.02%P4IE7JY"]L?/=TD
M[G6EF^QV`75]>/(K>3@0,:`02+>U8YY&JE#)/*YVDD-B83J'K^Q0^(VX;C'N
MG>QUCM>W1AQ;MUHXW4CW.:6@WE](R)I#*ZFPVL#&ZP"^XD:-!O)KE5WB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(ONJ(FB)JJ+\?;SWI_]Y/.&\PJ1$PG^'Y#S
M\``FZMP"J0T%5RD^T)AZ4PA^D/5L'AL'AKFI/CQY#V!=)!3L6TRI]I6)?4:E
M6\V:F?NFC`@&$[YVU8E`A>HXF>.$VP`0H;B8^ZO@'K'1%^FWBFNLJOCVBP$.
MBD5C!U*MQ#1N!0*FFSBH=FP;I"1/I$HD20`-O=JZ-P<T%6/!!Q5R%P9E;N02
M,[!5)P55%14J!"`U[(BH"X%%10SHSC8";&$G0`[^(AM20M;&:X8X*S$XA<=G
M\2_(@#9NLX<.5%4T&3=NX7>N.P03JJ)(HI'[A$P*/4`")@](AMXZBK(148_:
MK]+1G@5H^.433.W52,D8!$YNZ4Q!'H'[0?:`HAT]([^S5S)R&Z'5"H6XU')5
MU66S.2K[Q1%J[?/G.R8+BN@QC(9L"Z1$W;I95%8ZXNSB("(F;D1(3?<_4/3F
MP/#FEP%0?8HWMYFA6!OSEN*SOD/Q]<+P$(C)92QF]<WF@OD$4Q?3#%`AF]MI
M:#D-C",S#B5=)'<2J/6:.P?:W#!D]R6H^`K)C]YM.*\1?CZ!`2B`B`E,`E,4
MP#L8IBB`"4Q1#80'Q`=7JB:(FB)HB:(FB)HBGOY=G#J?YA\@:W5QCW'^7-:?
M,YS(LSVC?!I135<BR<,"O@47DP8G;`@#OT;CJYHJ:G)4)P7Z)=`H416*Y`P$
M5&-HR$@XQG&Q46V2(B@U9,T"(H$*F0`(4I4R!X:R-56XGW5"UC=6LYE71;-T
M6_<*F9-,2DW)N)0'K]73ON.P:QI)=)PJI0"5?;!&.XVTR`6>T+I%@(UX<J[3
MXHB;QZN@4%4TDR'$#J@<0#[)?3J&&,RG4[X57!O6KR\@;9&IPK"NF@(MNSDE
M3/H=NL?9RW:-"&1.1\5,Q11,IL4P%W]&LR1S2PMH*4JK*$E0#4GQ:MQ:-]B%
MZC"<Y0$H&*(]7;*'AL4!]NL".X+8]#<!52%E<5;>5G.MV<P`)U`]OZ(;!ZP#
MTB.L9\G:/)X*X-H.A4I,W`(ULJ90")@4AA[GKWV'U#Z_'?53*YK?>."J(P<5
MCCY#YM8PL?)/7#T$&[9)8YA.H!0$"E,83>(^K7.[CN`#>SCQ><!TE;6VM\GG
M^1>/WF5R,?YIOSQHR=G-7(9TNDV*!C=#MP4X@=<WCL8I1#8-;K9;`V<':2_Q
MWXGHZ%B7D_:OTM^!JA&N(;#[Q'W>O6Z6(J74_3/_`$S?E'5BN6C1$T1-$31$
MT1-$31$T1-$31$T1?O+:ZI<DFB)HB^ZHJK=%=<2]`K*B3T"05#"00]@E$1*(
M:MT,K6@JKNTD(TEQT\JX+I7<%`O]_CX"!?\`5N!OCH2+>=0#XB!OB6BN^X^W
M67'>WL/\&>9G\V1[?80L";;MMN?]9MK:3^?%&[^TTKI#X[QVH<JBF/*`=0GZ
M*AZ35S'*.^^Y3FBA,'CK+&^;X!I%]>AI_P#J)O\`+6O/=;NL3J.U[87#_P"D
MM_\`PUW3&!@(L`"+K\!&`7]'[MA(IAT_@^$:([>G6)->WMQC<3S2?SY'N_M.
M*V%OMNV6=/D[:VAI_=Q1L_LM"[L7"XEZ165$H>@HJ'Z0_`7?8-8FA@-:"O4L
M\R2$4+C3K*VM7*Q?-5110YZF5+P5YJF0`QEB\2N1ID2D*)SBJ&(+@*8$(`")
MS";;8``1$=0W'\!_\T^Q3VO^LQ_SV^T+RVVR/S?Q8EN0&%L=_?%(H6->$'&^
MSXMR&A)VFLLZSQ$Y6<U,+7K-<.M:Z8DK;JE7L//IB]14A)Q0?>,+5NATW[9V
MY#DTP]VM,"!APXT/JKYL>"WITRZ7.(=5YJ,Z$-J,\JDMZW5&-<9+88Q;E'E-
M;*IAB,Y:9.F*:QX@>83<L!3^`\S\@([&SJRPO)B*QY@-NED:^JP]_P`ZTK"S
MZW/VE?L+Q=TWGF+-FJ5T[;MR",S!(_!KC723F>8&?0..76L>1T,-7E@^-H-0
M*_#4X<*X5&!SR*B[DSD-R6S!C;#^?\@9PF.-]4Y+43E#E?&TED/(_(6E,*=R
M%PFGQZX_8MAL>UG":$A,9%RLQ7H=ELM:Q\Z;J15J7FY)51FY<#N%LDDCP'5I
MJKQRR'Z:<>2DBB@:]T0:'%FD9`U!J36N0Q`+N%!B%EJY\91=\=^8^%<WY1M>
M-Z#'W'RW.0F#L99*S/2+39<*Q_)J1R/B*^VJA62KUV0K\Z,UE['<2[:Q,.D]
M82$FHS,S1[BI10-),2V74^A!&'JIQ'+GC3"JQ;5HDA,;*@B0$T..FCAR//'"
MF.."QT5K*DI)88S%R`MSK*F'JO3N%'E4X_I''W#.9\@\:N-F"7'*E5_1<ES<
MT"*5PE,88ZI\5`-&<Y*$37EX&`*_^&7;OUP>I4U.+2XDAH:W`8`5]E//@.>*
MG+&A[8Q1SB^0DD!SCIQ'63ZST8*E\08[-R(<TAS;+9D^]258XQ^>CCC'4A1<
MV<B"Q+FEXQR_CQAANN567G+:SOUKI00V0'",6,ZHX>SL42,^.%T#)GVK/>+0
M<2ZCAQ_,T<#C@?8I/=8YS<`W4PY#/0X\L,1CY\B2O1MY8#_&;WR^.'KC#]N/
M<Z:C@C'K?[]-<9J\KH6]M`LBY`@5I^P2,I+(N*K>OO".&..J"<-\*#!%)!%L
MFB396M'6[1F*=?WK47>MEV\G!^JO+JY>7$YJR]TXJS^+.59[_@C+4U@&)SZT
M6(V:,(-A9\3.\U1:BTJ]I]^H3Y9FQ=1&3((KAY$JH*(K-95HZ10'J<-R!]+;
M3XC67>/PX&R]\=LAWJYV5P)+I'17@L'@,;/;7#0YP?:R:63!P<U\+XWOP8\K
MXMW[P;W'N=XS'O-X=;U<=VK+O*R@:R)D^W.W6,F1]M>6;BUCH[^$226SFEKH
M[B.9D>,D0$K(;)F?<?%^&R]Q_1LK=(`(MD7C$];VR-=I!N4SN3Q99#U_(T.)
MRAU'28FG"AN(%$0\-><7?=_N7O9[3NQO9MWG$6N[-,+@>3;R(26K^@R?+GFO
M9+#O=XE]V1V/?CNRV[B&!OM@>+ECA^:3;IS#?1<RV$W8Y%43<Y/@1F]3X'*,
M7B%6?4^Q\+E"I.,5Y"9KB.W0BZM433;>V>$/Z!06$>K]$1\-;;:K?QG[HM[;
MN])N8LAC6TF%Y;.'2(7SP%O\YO6%H-]O/IM\0G?+][H=D.YN%"V_MG;=>M)X
M!UQ':W375_(_/(E5Q`X&NF*$B*X'S#:#UU)(JK;$N;).0R=C]9#H`Z;.NW!V
M?_,ZB$53V*DHF^E6B6X&,R5`-AU%YWRVGO(XM[Y;7;B^)H;RP8VTN0>+I8&_
MZ)<4X@QPO.0E;FNAV[PWW_N8T2>'&^WAVL`%NV[K(^_LBVF#8+IW^GV=1@US
M9KF)N9MWY&3K)1VJR9JR#5%C(*-6ZCYDV>#(-F;TZ1#.FK=^9JQ,^0;KB8A%
MA11%4H`82$WZ0\]E;$V5S8'%\(<0UQ;I+FUP);5VDD8ENIU#A4YKUVW=.^W8
M^Z8V.Y+&E[&NUM:X@:FM?I9K`-0':&ZACI;6@Y.K%*FB)HB:(FB)HB:(FB)H
MB:(FB)HB:(FB)HBUIANH0/:<H?.(:HB_&:\W&14E?-+\P]\H4"G4YCY_2Z0$
MQ@`K3(DVS)XFW'Q(@'X-<[/_`!W_`,XKI(/X#/YH6/'4*E78P[TL;,PTD<>D
MD=,14@H;Q^RFQ?MW1S>&X_9*D(ZH14$*HS7Z.V#,M,;10JG)-'S5TB\@(AXB
MZ25(H1VT=,&ZS99)8H_;`R9P$HAZ0UJK>Y--)P(61)&*T.2O`:P_>"BJ9%-D
MBF(0PEVV$3%,/2/HZC!MX`&WCK([4NSRZ5"&`99JHXN:>11DWC%^NT7;-UF[
M==,_0X:I+'$ZP-5A$5&QE3&,!A3$IA`PAOL8=Y1*6XM.-**TM)-%4U0CJY,*
MOQN,^:(%=B\5CA=)/'#05!3$Q3+J,`6?$<J&$13*"1RG-^F)0W,%8@V0GM#B
M0:*TX?",`MH9IS68Q_%,II!5F_:),GPL]CLI=FFH59NH5-RD1=OLH0#=)B)+
M)FW*;80VUD,>8X]-:8>D*S3J<:8@J/EW(2V.H2NH`=W(/I<`9-4$U5SF.1DZ
M.?<$MA22*B0RAE!^R0J8B(@`".KK=GS%VR`8DE2._=1&3DO%AYG7#N(P[F^U
MWC#<W`6['EQEU9>;KL!)M',YC>W3#E=:4B'D,0Y79ZY)/NM=BY1*=-$5#(*=
M'0F)\V\LC;N]QP<WD"*@\C]ZAAF,S:N:6NZ1FL9+:G6QZ8B;.M3CM113M$3;
M1KE<YE/M?8`B29C=>Q!\-O4.L/0_D5,NY=8KR@P1(Y?8XO;)LJB#A)R\J<ZU
M;JMS`4P+I+KL4T5$!*<H]93"78P#OL.ACD&;3Z$!!R75I4BYKF,1"I618Q1$
M![4)(G#P()Q$#`WZ3`4@;B("(`'IU30_D47#4J]F2#=6O321?'[2D:[(3P'8
M=SF2`H>/M'TZ:7<BJT*ZXT>^)N!V;DHAON!D3@(;!N/J]6J4.24*N'B[$UFR
MS;(^HP;RMP2[U1,%IBYV.(J<$P0.<"F<.9&;=LD3B0!W!,@F.;;P#56M+C14
M."]V7EH84XX<9<0U^G5[*.'I&9401?VJ;:Y%I"S^R65=,AG3M04YPZHH(&^P
MB7T`0/#1Q_"/A&:L()Q67,MNJIVX?=]DKDAN'V#1T]$/>KT;=(M7BH#^+4,D
MII17`8XJO*Y7(2R5R1EU9<Z\X#INQA:U')*.W\@NK]HRNZ8&*5#IV#</'?43
M6A[2YQ_><N:NKC2F"O%5*X>@5\]GN+M:O=#@A8^!,H*LFX6`W0=V=B`]:1$P
M+XB8-NGQU<UG9T?*2T#@JDC)HQ5A<L9&5N<\K))D72;)MTFB":H[`()EZ5%2
ME`.E,%S_`&M@U!/<=I\.#4:P#-6&?29O2(](@.VP"/2/OV].L)KB7`<%(17$
M*CI.62:"=54Q0$"B)CF'VAX>CT[ZR"0$`J%$/-&5V<<U<-R.-MBG,80.`>``
M(B(^._JV_!K6WUXQC2.2RX(7.-0,."\RWF%\J73PKFB5^0-\7)]9'BB"H]39
MCN)3[B4=P,KZ`UK=CLG7MR;^<'L6GW>M95[,((Q"RFLC'J6$943&4.8VX[F$
M=Q\1'?Q$1'U^.NX"TN6"ZITIMO[-OEX:*O2NA-XF,/\`.'\NK5<M.B)HB:(F
MB)HB:(FB)HB:(FB)HB_>6UU2Y)-$31$T1-$31$T1;B:2JHB"2:B@E#<03(8X
M@'M$"@.P:M+FM^(@*JT:N5%\T1-$7PQ2F*)3E*<I@$IB'*4Y#%$-A*<A@$IB
MF#P$!#80U1%I,DD8#`=%$X'1.V.!T4C@=LH`E4;'`Q!`[90IA`R8[D$!\0T(
M!S55I1;MFY$$VS9LV3:H$:M4VS=%NFU:I@`)M6Q$4R%;M4P*'2F0"D#8-@\-
M``,DS7Q1JT6*@19FS6(U<)/&I%FC=4C5X@)A0>-2*)&*V=HB<PD5(!5"B8=A
M#<=4+0<TJ5]7;MW12$=MFSM--=%VFF[;HNB)NVQ^XV=ID7(H5-TV4^TFH``=
M,WB40'0M!S2I&2TJ-&:R*[=9DR6;NDC(.FRK1LJW=(&`P&0=('2,DX0$#"'0
M<#%V$?#QTTBE."5.:W")))F`Z:**9R]72=-%),Y>KIZ^DY"%,7KZ"]6P^/2&
M_H#5:#+@BT-VK5FB5NR:M63<ACF(V9-D&C<AE3F55,1!NFDD4RJIQ,80#<QA
M$1W$1'0``4&29YKK+#78.V0[J`LD8VF(=Z9JJX8N@4`GQ#!VA(1[Q!9$Z3EF
M_CI!JDX;.$3IKMUTRJ)G*<H"&78WUYMMTV]L)'173`0'#DYI:YI!J'-<TEKF
MN!:YI+7`@T6OW3:]NWJQ?MF[0LGL9"TN8ZM-3'!['`@AS7L>UKV/:6O8]H<U
MP<`5W(>KQ$1``\3")C#MZS&,(F,8?6(CN(ZQ5GKZKLX`A7`%<%3$#)E7*58$
MS%\2F3!4#`0Q1#P$-A#1ON$EGNDYTPKUT57_`+T`2^\!E7&G57)/3XCXB.J(
MOFJJB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBWF_]^A_YY/\`YY=6N^$]
M2JOQ9_,T4.KYD'/Q0XB8QN9?)/<1$1$=LN6LH;B(B([`&N=F_C/_`)Q]JZ2'
M^"S^:/8H0ZB4B^"&X"`^@0$/GT1>Q?RW<F?O%QDPRFF]-\5%41A%'.!B`8QH
M11>&,W4V$0*9%9D(!X;](!OXCKG9267;V\=1]!Q6:![C2,J>L+*Y4)(`[8S"
MK\S!V8PN5&Q_]Z;J]DY6[A(I@.F)DES)B<H@/43</2.MC$&D#758[B:X*ZY5
M3$[JF[LS'X=LX9F=@BFY61403$[A<C=9=(2`Z[A2&(/2H0I3;!U;!21N@\=-
M*HTUZU7]!N$=4YYC*2L<249$*JF[2Z$CN2(.$C('<-0<I+)BX13.(D`Q0W'T
M&+Z=9EL]K"'''FHWM)R7-),TFXY"43;H'JE03B947KE-HWL;YH#."?KH2`LY
M>09QH3,E)))(HE,LF@FJ8IB@)OLFS&Z9'>X,**+X1CS6)'F_R>Y!\9<DX\G^
M,-T;0#V#;2\A,*.H^/L+"TQTH@2'2:S$=)QS]F9H:/07*9N=,Z/[<WAZ]<MO
M6ZR6%_%'"2&EA)+<>@`UZ`5O-MM6W$#W/`KJ%`<.G[5&=SYZ.93L%3YTX#\-
M<YQD>P7;2LC(8@0K4B5B4J"KAR65HSZ&!DOU-2J"X,U,*(AU%Z>G8=C8[]%<
M:8W/I(<AB/4:CT*&XL)82YP;[@XYI6?-9\D'(X)_\0_E,/\`&LLY17;/[/A&
M]HSZ1TUB*%%1O$W0(,R9-ESF`P.3F!4W6`=7V@W[9G$5P/6W[11:Z@K0X*2F
M))WR$,A]AK@[S(^:7$%S)+IO(NKY+L&0?N2NR!QZ2L_CX.0DH$D>!2E(3O+'
M33$G6!B@(EU=VV&(KU.(]10-`RP62O&O&[DG/-FJW$/SL^,/(-)<$U8Z%RK7
M^/.1I1R]45!(6[E&:I<Q:>VLQ*9(1%QWCB4>KV:H2QQ_SK?6K]1'Y2>I5C=\
M!^>'CZ+*Y+QM\L3D>T*NH4R3?CS#PLA)$$B#Q!Z8M2GX-N8BQT0)U%2*)3AN
M(;=&U`UCL!+ATU^U-9`R]"B):<E\^:*J9AG+R(.%M^1;H$[*]4IEUAB-FX&.
MLJW40=_O400%<1-U`($WVWZM@VO$+ZU:]I/,$?<J:\*.!HHYS_*?BFQ7>MLV
M?P[]/C'A#++R*]6EY6';F,X*54Q69C1311R[.98P@&Q=O$`Z=M]5=;3@5`/J
M5.T:<\U;1YS'\E%P9RXNGDI7ZG_#HD9KFKEI^,335;J("V$ZSR-9HI](I&*(
MF.H8Q=]A/U'`8C%+R=_5_2KP]N`%%O/.3'\,[-B4\MPOY.8S=N4#**%KC%B@
MHP.0X$.5L#>6<IF,)@$1ZRE)N7[(;ZL.&8']4JX"O$*K6&??X95N=DA#2_-6
ME&4604<2S<ULC20J#1J<R8J"P>LRK$.IL14J7<.8P`IOMOO:-&%0P5ZQZU6@
MKS*OM'Y2_AVK&*7W-YBG)2H-E5TR&:3V1\IF()5BIF*D9%>24?LV:`EV4`W2
M`FW]/I&QVG/W#CY<DH*8CUJ[L*MY+#K<T%YS>3V9E')2H(RN8\I%133'H`$B
MD=S;E,H$!/<#"!@^T/4'CX6]G`3BQI\ZKIZ/8KOQ]%\L&40$T#YTE@,H&Z;<
M'V9&4@18YS`"8N`F(-RHV2#81ZMC;E\1``#<:MBMJ:NR(X9\E1S2#3#+G^E5
M_$<1N+MN((0WG#5J60,9--J9QD+#$B*Q5F?6W!RF_JZ)A<&'J5,!3AML`"'I
MWJ;>V=DQV/G^U4&I=38O*'PM>4>TGYD5%LQWQ5>HPVO#2)E-U#E*DD$:Q2$N
MZ0>([B/6`AZ-8DVR[7.*31R4KS(^U2MN9V$%A]BA1?/X4OC[?7LI90YAI/9U
MXHNN)D+-3G#51MUE(D;NFGD2($((&`VR73U;@&VVVLZ"TL[:+L8P]L;<L/:H
M)'R2NUOQ<5!G//\`"T4S&<"K*07)EY)NT6_=602?X_E$&QP+X@<$9U)RH4QB
MB8`*7P)[P$-7ED%<W#K!5A!7F_Y.<!YWC])/&2]Q0G$6IUB@L#1NEW"D,($$
M`;NUP^V7V#J%PC_"254:N.:QPN4A0<+H&'<R*RJ0B'H$4SF((A^$0U$JK9T1
M-$31$T1-$31$T1-$31$T1-$7[RVNJ7)+AR,E&0L;(S4U(-8F%AH]],3,L^4*
MBRBXB+:K/Y.2>+'$I4FC!BW454,(@!2$$=6O<&-+CP50"309K'GQ(\S'!O*'
M`E^Y!62/E>-58QO>ZM5;1'9OE8F(=1U;RI!4*X8"R,^?("FRCJOG*E90@G\.
M*W2*:KT6RINXD<=8T5TUS27X4]GIZ1Z5D2V[F/#6XU'#'$9\.8*E-E#DUQ[P
MHI=F^5\Q46B/,;U2I7J^QTW+#]ZU.GWZUOJ+1;#,1+%%Y)(,+E<XQS%Q>R1E
M'SUNHFB4XD-M*Z9@!.8`!PIQ\ZB;$]Q``.)IZ,_0J(C.<W#:6Q$?/C3DYAE+
M#"%W;8R?9(E;I'P-;ALD/%$4FE`L2T\,:ZK-R<G<I=N-D$FKLQ5DS`3I43$U
M!<1ENJM,>C[^D>E7&"4.+*$D>7EU+7$\X>'LYA&Q\D8SDEB5;!5.L2U/MF3%
M[.C'0%;N2#R/8!2YI"229S$?<W;R6:)M8A1J$B\%XA\.BJ"R0F"XCT:_N^^G
MKXCFA@D#^SI[WG5.S'F'<&8#%=6S;,\J,/1^+;O8+!5*E:UK$H8)ZSU`IE+E
M`,8!%FI:OO6E)$%2:1.Q(:'2V4>=DABF&TW,0:'<3PJ*^W[546\I=IH>NAI[
M%$#G9:,BWEO1[9A6Z567IECBJC=,76E[<Z\VPY<,?.\=91G+#+U2PO8FR5"W
M9&FKL-1^[&A%8Z2D(=9%.+EX=)Q)2:$;W%SJM\AC3/S9=.*OB`&#JUX\ZU'Z
M?N63/`REDD<7T]2SA9TWSQ2:^Z1O2"S>\_N8M:)@,>*7ALY46>HVXU$&-&1*
MY.=Y\3U?$F%QW1U,QQ;#K=P!/\GZ5"\`R4;DL:>'_.*Q+ESB_=^2*>'\AU%]
M0LXX,Q%,8DGYJO*6MW6^1^:*GAK$.9XB7:)C$O\`'UI?6-VZ(($*N1>!DF!M
MG#<1U"RZU-)/Q`CAP)`Y]//S8+(?;:9`T'W2#Z0"2,NCERYJ>4]S#XI5G/+#
MC!.\AL4QG("4D8Z%C\5N[2T2M"\]-1YYB`K*Q/M1T?;[%#$^,CX9RX2E7S40
M50;J$,4PRBYC)`RJ.C#U_8H>PETE]#0%4VMSTX2-[X]Q:MRRP`3)498EZA*T
M+_,RMGML/:6V0XW$BT!-0:;P[Z%DPRA,M(`J;LB/<E'*:)!,8X:KV\8=IKC6
MG#G3GY=:=A+IU:3II^GV*X.0^3?';$A,F*9.S9C:B?Y,Q5'FLKIV6SL(YQ06
M&3G4BPQJ-C:G.+EJ^R$_B7*$(S*0[V461$C=)0PE`:F>,`FM0.5./\G&BM;%
M(Z@`..2J+#>:\1\AZ-'Y,P9D6JY4H4G(2<.ULU.DBR3$DW"/#1\W`2"(D1?P
MUAA7Q11>1[Q%N\:J;`JD41#>YDK'MU`X<<L%1['1NTN%"H:&YNYIR3,Y*=<1
M^%5JY+8KQ-?KCBR=RM(9YQ9@]CD+(6-95>O9*K^"*Y=6DL\R`QI-J9N81>7E
MG-9AW<RS<(-'*Z2)W&L5US(7$1C`=!/L-/33K4[8&`#M74<16G0<O(5ZE?>0
MYH<:*C/8ZH&7,P8^P9FO)<-C&0A^/^6;Q4:]F1G+Y;)((U"I.:HUFI$)*P.9
MJ$D8T1C5GK,SV/6*FN<G0<\XG94"N)IQ''S^7"JB[&2A(!+03CU*A(7S).#%
MJJ>8+A2^2^-+I'X*QC9<R9&80,JNG.1V-JHBJ,K;HN*FFD2XL%=!Z0C,D@Q!
MPP^,712,L4RI-[1<L()`-0*\/3GEY9JXV\H(!'Q8<<^66:@UQ7\\CCOFRUX1
MHV7)W!F*+-R3H$OD_%2%$SPIE:.KT8G+8N@:QB;+[^3QYCM2M\A;+,9+.B$+
M$(S,0F,,[`)(Y@(48V78+@'4]X<".CG3T8]:E?:.:'%M:-.-13GEGAAG@LXI
MBF(8Q#`)3$,)3%'T@8H["`^\!#68""*C)8BAS)\YN/5$J=^NV;<D8ZPY7*7R
M%R!QTCGDKD2NW!Q;;A0A247:1D32_O6;:VQTP[SIW6C-E9F&;MSJ/4TR?:#&
M%RT`EU/,1]_\O#)3_+O)`:#B.1^Y7J:9VQ#+81<\CJ_D&KV3"*./YS)Z&2(6
M41=U5]2J]&2$I)SC65+^R^#;(1:Y5#&`HI*)F*<"F*8`F$C3'V@Q%.C[Z>M1
M=FX/T$4=6BQKP/G1\4+CC3A-FRKVFG-\3<J+X^H>39ZV7J/BY+C).)\9KQR(
MCZO=VL:RE(^<O[I>JM8$8ELX(91U(%,V.NH":*N,+L%K74P/2,Z$Y5-.&9&:
MR3:/#G-)]X#IY@<O/A53<D></#Z*P=6N2K_DABE'!%SF#5JH9))8RN8>TVI)
MY)Q[JGUY@T07L$O<V#Z$>I.H=!F>3:&9..\@F"*@EF^8CT:_5A7VT]?`\E#V
M$FOLZ8A7SQQD:@9BH]6R9B>Z5K)&/+O&)3-/NM,EVD_6[)&+*J-RNXF38**H
M.2D=(*(J$W!1%=,Z2A2J$,4)&O:YNL'W5&YKFNTN%'*S...9_$O,&3+7AG%G
M(O$M^RG2$;"XLE'K-L92,RU;U"1)#W%Q'"3I8V1"FRZA6DP>+6>EBG1@2="B
MH/3J-MQ&YVD'V>7IIC@I'02M:'$&A728NYW\-\ZV=[1,&\E\-Y<O:%#D\CL*
MM1KDRFG<W4HE!NI(2\$Z;%,PG6T2L^:IR)6*KE>+,Y3!TFB)R@-!<1N-!GYO
MO*J8)6BK@:576\0.96/^4^!\)90>/JG0,C92XQ8WY3VG#0VY"8F\=XYR,C))
ML;`\>.V4*Y?T]"8A'[(LL9JW1,LS4`Y4S!MI'.US07^Z2`<2,:^7)4DA<QQ`
MJ0'$5IR4E*ID6@WK'\#EBG7.MV+&%HJK:]5[(,=+-35"7I+R.&7:VYG.K'18
M&K:\2'Q17ACE0^&_:]71]K4HD:6:ZT;11EK@[01[U5&BJ>8AP3O%*R7DBJ<L
M\'S-!P['PLQDRW)7)JT@JI"V>17AZI..'DBFS+)P=PF6QV<,]8`[:R[PO89J
M+JB!!B%Q&6EW`=7W^VBE-O*'!I!J>ORP51L^<7#E]A]ER!2Y-X90PH_N@8U2
MR5)72.AJRWR.85BACV67F#,'4#>>IN8/NE\DV?\`Z/[+[9.JHN(RW56F/1]Z
MH8)0[1I-1T*D:GYC_`F]3F.ZS4.7.#I^QY7L!ZE0H!E<$"S,Q;BRCJ$1J3Z-
M<H(.ZK:9":8K-&4=,$CWK]RF*;9-8_AJ@N8R0!F>K[_955-O*T$D&@ZUVEJ\
MP;@Q1<@2.*KIRVP)5,APM@G*E8*M8,A0L4[K%KKD8,U+UBV/'BJ435;"E$E,
MNBSD7#5P]3*;X8BPE,`#<Q`TKYZC[^*?+S4KI/H7=0O.#A]8<*VCD;#\D<3N
ML'4FQ*T^WY)4LJ3""K5Q3<QK1.G3*$BBSF&5O?N)ID5G%F:_'O\`XUN+9)4%
MTA/47$99K^[[Z>OB.:H8)0_10ZCUK9'G9PN3Q-6\[O.4^#(G#5NL4_3Z]DJ>
MR#!UVJ/[E5(J<F[/359"=7CONNX5Z)K,@N\BGA6[]N5HH!T0-L47S$6D.KAY
ML,^GH\J%.PEU%NDU'1U?>%Q'7/GA*QN6,<?N^4^%T[?F6&H-BQI"(V]J]<6F
M`RL=`F+9=%=D1PQBF>2SN4RUX9!5F::,<I6@+"(!JAN&5#1B3U<<N/LJG82:
M2ZAH.OS^CBNA7Y]<;Z;BV#RKG#)%$PS"VC)^8\65E%U=(_(Z4_.88OUIH]A"
M-DL;M)Y%=\@G6#/))CVP<0!U#LWW;<MU0`;AK&U=BZIRIS/3T*H@>YU&@TH,
MZ\@>72NJN/.2GL<I<?:?C)M5<NX\Y"\7N5')JIY;J=X;/JZ[A^.+3$3N+C8$
M\7'RD=/QE\)E(P&?%=)FCQ8=/:6,H8$[7W`;0MQ!Z>EH^WRJKX[9SP=7ND='
M0X_\FBK/C%S!QIR&P7B[*DE/4VAW2V<5L*<L,DXN6MS:1D<18]S32G%OB)N?
M?O&L0NI3D5(>5:HS"K9N@N,4N)BIF(8@7MG86@N-#I!Q(XJ-\3FO+0"0'$9<
ME):HVVL7ZJ5B]TF>C;33+I7X>UU&SPK@'<-8ZS86"$K!3T0[`"E=Q<O&.DG#
M=4`Z5$5"F#P$-2M(<`X9$*(@M)!S"J9$=EDA]BA!^8P#JI%1147XO7FF,"QG
MF8^8*Q()C%0YE\C>DQP*4P@KE2S+>(%`"^E37.3X3/\`YQ]JZ2#^"P_JCV*!
M^HE*FB+-SY2&:G;)>U8E>/0VBGA+=`HJK"!PB942LI]HV*.^Y&LH5!?I`/`S
MDP^O6BW9ACECN&_"<'>;+U56;;'4PQ\1B%ZI*)-1SV-:K]U)1!1(A^YL!PV$
MI2B!MM^D^_I]^LJ-[7Q@L.04+V$''-7!-,LD6#Q))4QCF-\.B7J'<$>D2[`(
M@(`3Q]`^C?5K7![RPJE*"HXJB++8CM6$>A"?%(+?"]B2.NN*Y5W1%#G%XU$P
M&.V1.B8I3)B)@`Q=R[;[!.YH!`CK3RQ5O25RXM\YC:-,RRCMB"CQ5I&N&J4E
M*ISSILHJY>"]49!TQ[R)9"@F53K``$XE\.H.K6:T]C`9#[<5'0E]."QTYE2&
M\VAZ9V3XD6[%%@4IB=1A$ICJCTE#JZ2"940`/?KCW$7=[)VH#B``MPPF*$!F
M`.*QN9)QJPBG[Y@[(=.#L#)_#2B94P,HFQE6BS-Z9-,^Q#JIMUS&(`^`F``U
M!<6C;*9LD=<'`CS8K+@G==1N8["K2#YU@@ROCV[8$R-9L76-T<LC6G2!4UD3
M"M%340_:HR$)-LDEP.DHREHMRFL7<NY#&,0WVBB`=M%,)&"6(^ZX57//:6N+
M79@JB$;`EX`\C6X[!M\1'J*QSDI?$?2F8R1@W'T"`!MK($O![6N'50^D449:
M:U:2#ZO05-/CEQ.Y9\AF"U@XY4C)TNTC5`$DJD!H:(.Z;F$Y48FQ/7C",7=D
M,/@`+E$!]>^I`8G#W2]A\SA]A]JMK*TXZ7#S@_:%)E3/_G(\$G!?O.[<M</,
MVA@*5S*R-Z1KO[%<5R_"S:JSJOF3[XB<.RY,4VX^D!'>ZDF37,?AD3CZ'4]2
MN[7\P</9Z153<PK_`!5WFJXF:HL+3?JQEN/3*0G<R/3HJ3>J"3K`>_*LD6$@
MX*<I@Z@!8IC=`?:`1,(QN]W^)'3IQ"O#P3@:K);C#^,6DI+X1OR&X28>N@=H
MZ3V3J+UU#/UQ6Z2K*%0L+.R-T04)U`8H>G</'TZ![*>ZY[?.KJ\U/[&_\0SY
M&V=46L=F3C3-XC?OQ(V<J/:'6+1#LQ7Z15$\A`O6;@S<#!]H09#]CU>K5_;S
M-'NR5'(JNEIY*3#:1_AP>2KE)M`9JPC79V5.4P)2IE:0X[KM4J@%=/9B$A&0
M"H<2_I._L]0;"`B`ZD%S<<0US:*FAOD5<AMY$'EF9<:$=8;L>-[.@Y-\2D[J
M%GJ=G,*`@<RB22B1;2?M*'.`&`%""`>D=]MK'3L=A)'3J5PJ#4$J.V2?X6OC
MA."Y5BX8J@'*395A,RD>YWZ![HIHN)23BDE5E!\3A'G*4I?!,1],9=;O'%I]
M*N!QQ(*@3D[^$LQ^NV<KT^U9*KSY)13MHNV$-.Q8)`'4!_B(^NTIR]$RFVPB
M<HE*.VQC`(:!D)=34*)0$98]:Q[Y#_A8LQPB;LU7R6U<&3,4J2,Y"2T,*2BR
MH)E!R+1K;4U!3)U"(`HF)BE$?#T:O^79P*MTE04M_P##K^8M!F<GI-2K>0T&
MS;XQ0M;ML8U>$;&5%NU$S.:<PRYEWIRCV4RD%50`$W2`!J%T3FN^$T/&H]?%
M7`'23JQ\ZB3=_*M\S7$R1W,]QNSO&M$NZ<SJ$CI]^S(FVZ046^,AC+L"I%ZB
M_;[O3L(>.JAA.%316$/`J0HN6"M<M<>N#-)Q+/57=H)%`Z*[N[-5$T#CL!0[
M+HVQ##_)#\8:K21K<''2J5/$8JVS_-^>8TQFZV7,G-E`$W=1=V^QE4$X[`;N
MINGW68WA_*`?1JA?+^8JE0<%:N:R%>ITYAFK=8)43>D7TH[="/O$55#;B/TZ
MB)=6IS551AC"81,81,8PB8PB.XB(CN(B/K$1U:JKYHB:(FB)HB:(FB)HB:(F
MB)HB:(OWEM=4N24->?\`B++W(7B?DWCSA:0;5^?SZ>KX;N]T6F&D.[Q_@V_V
M>+A,^W.!%VBN65MD=B%:70B6)2"9Q(ND=_L%/K'N&O>S0VN)_1[*GH("F@<U
MDFMW#'SC+UJ%T/Y8MMK^8\S5*SY>N7(+BMS,X42G%OD,KDB.PG2+;C69Q,08
M3C7.4.KX8QABZOSC9C0KY98Q1V=FK)L',?%G%<4$DB)8KK9X=09$='^2!D3T
MK(^9&G53WVG#/[23P'1T*U4!Q`\QNM<4,D7.6M[=]SKS1G#CT3D`XPKE2&QU
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M9@J;-=]#-A57;E7(X1DE@=1VEN`=_P`D#`4Q\W+T0QS,HT/<[46D$_TB<_T<
M3U'B\@,"<Q<NYYP9S41X]Y&J\Q`8BS7@&[\;,,\W:?B;,U8B;ADBA7VF9?:9
M=ATH3$]N>VE*EFC[76AF`^&1)'+MW\@=LH@%KXY'4?I-,J4.&60X9<Z<E?'-
M&RK"[IKQ.=:FAY\J\"`LG7#S$S7C]QAPIAV'H"V(&5$I:,6GC'_,^0S&I1CN
MI23FEZXIE-^QBG-X48.I,^[T&Z2/484T0[)$Q',AC:(P"T>0'/+E18<S]<A(
M-1YOL4E&RA4W+=4XCTIKI*''Q$>DJA3&'VB.P:E>TN86C,@A1`T(*\T%F\I[
ME"VXA\#ZMCTU&BL]8KM6+<;<LJN\MC8:M?\`C93^;<7RXA'4382"2.D;QAVV
M59%[!EVW.SLDXT+NHN4HZT6\K0'<W"N>51]HY88\ULC<Q.>X<-)H<,Z$>PT\
MP'!7:3X`9GAN0V8JW=\,Y,SWA'+7/\.:%6R36><R^(,3U)O+Y1I^6(TV5./+
MA#]Z)?(F#+'5TDXDL*UDV-E8QL>DNZ8`*Q4Z,@>R1H<WB,:'V@X=&?2JNN8W
M1G2YP-#@:=52*8DC,U'0I28[\O@T]Q(YW\<LO157K,WRSY.\W\JQ5VJR<4]G
M8R.S/F2?R#@/([F7CVZ3PMQHIDX.21054.M'N(Q%#?9(H!D"W<YKQS.&?,\.
MJGG6.ZX#7,+<0UHY<AA7S>52HE6?R]N8U[XX43,.2B5V=YY/.<].YN<AZ#C'
M,SW%D5>&-!Q78^.5,Q#BO.[6.7_="6Q]BAQ'3M?=NDDHW]X2.D5E6Y71G)(3
M!(8]9'O5RIT4H!G3+##+EB)FW$;9=`)$=*5Z:UKRK6N/3YEDLX#X:D\-4S*\
MW/X:ON%;AE[-TCE2V0V5.2#?D]D.WS!:51J8A>[C=HE5Y6H&9E8NGMV9HF-?
M2**;=@DX4<F7<*)IY-O'^Z+7`BM1Q&%`,C58]S('R!S34`?;7D*^A8_K-Q:Y
M@8JP?E;AI1L$VK,V+'&7L[Y<XN<@<&<X'W$.ZT$V<[GD+)D=4N0+*-G*1>WJ
M&*;[DZ1*"T"[LD;8HULR6<1R3M$4Q@<)V`QM!TU)%`>)/$$<^GA@%,Q\#G"5
MYHZ@!!IP'2#RZ.M7YX_\.N2..LK90RO=9S'EAS',^5_POXO4S.5C7+?WRG)[
M",1GI;)EQEQG(W][75.D;]=8"77<+D34G.T8RJ0JH[!<R"8&M?W@`QQYN)Z_
M+)1R2QN:`!^[UDTPRH*=2A'AW@;SCL&3J+E#--2R<WNT#P+YF<=<I7O/'.-/
MD<\R-G7.M6Q0SA)W%U`B0+0,+X@E[-3Y%PBG%-(98&ZR";Z+:%:(">!L$KA2
MAZ<".+2<\.'"E>2RS<P@U!P\W)PZ^/&M.:EY3..'*#!%Z\J[(M=Q/$Y<_P"'
M;@')\'^0-9A,ITZGRE!G;>SXJNG&3X1];CM(B_4VLR&#Y1N\:1ZWWJN59NHU
M07`QBEE;"^,L(%>>%:?#]W\JQ3)&_M&O-`75'[77S_D68PP`!C`4W64#"!3[
M"7J`!\#=(^(=0>.PZV(RQS6$L!E[X,YUA(Z]6:/PODFZ9)7\Q[F5R>Q!DKC'
MRUH''G.6'Z%GN)A(6!FX9[DR(D,87)A>X1!W'62NSG6#5$B"H-W)@Z2ZAUO(
M`:MJ<.%<J\//F<.M;6.YC&GWB`&Y99TXXGAR]"RL\9JCR$C^*..*1RIMM>M/
M(Q7&LI!95M]<1C!B'EFF?OM%J[6/7H*K0<I,1T,_:)2KR.C(YE(R:+ARV;(I
M+$(&?&R3L=+\\#[#3AY<LEKY',,I<RNFJQH\9^)_*QCCKR?\>Y;PU7<?./+0
MR"^K-^FARK1[Y$Y)IU?X799P-7LN8W0@1/)L6<W>[5&G0BY1!E-L43J+*)$*
MB!C8T4+C36,C3(Y!I%>FM>A94DL8+W1DU<*YY'4#YJ=95JKMY=W*:`ND!FZJ
M04S;7F/_`#`O,;S@CB3$'(U'C[D>S88YI.*X%3O5"RH;X6LP>1*@>N&^-@)9
MU'(OHZ8?I&>)K=)5HG6\HQI499$\3PPKT<.E2QW48:&DD'2,<.0Z_/ARP65C
MAC@[_)WC*CC93'%DP1)6BS9HN<[3YG-BG(.X5ZR9?N]IM4[:9;*G9:L)BUV&
M5GU)MTV9&581S]T=N@NN1/O'SH8R(<J.\XXD\<OTK"G>'2EP-1ARY=%%CEXV
M</>7,,EY;N#<F89QUB^A>6-%Y);J<@*SE:MVG_B8<2&`,@<>ZFRQ[0XB-;W.
MBQ624;V6UW4+.5B9O*1Y&R`2)C@\)BPQ2-D&%-.9H16@(SXY]'++%94LT3F.
M(<XEW#,#&N`X94S//H5<8"X)9RQKCOR7*U-Q%.92O!K!6><>Y\+&6*-51C[!
MDKC*KC2,1JZ[9(A+2RD[^"9W:J&Q>DH.5-]M]6MMI`YCJ?E]6?D4=<M(D!)Q
M)IY_/Z5#?,'#++6.^-'D]<6X.TQ./^6=XPM+>6IGM*M.59T)7B+<L2M+9RYG
MH>P1(I-P7PPWQBQD:_*K"#9*5ERH)_M7Q0-:Z(M#6_C<`*=%`./&HPY$<*JY
MLP<^1Q_AM-1UU-/,:FJS=\MN,Y<[<(,_<0L6R$1BY+(_'2V8,QPY^'<IUJFM
M7-.-6*C%O6L:4SPM2;-6S=@\30*97[N,H!"F-L4<^2$F'LV8$`^L&OMJL*.7
M3,)'8XU]:A)E^D<V>1^,,,O)3A?C[#5VX?9ZXO9^J>+I/D?C>TU;D4YPRYL[
M"XXIJ4Y4:VYC<<4^$C)E*9I<C8RMA//LV97<='II'<AB.CE?&0&Z2,<`17IZ
M3TY]`"RFOB9(#J+FD4QQIEZNC$4XE6X7X2\G,N9+D^1UUQQ4,3S>4?-"X1\K
M)W`KG(E8NCK'^&.*6*D\83-PM=KKJ!Z59<R7QRS3D'#"'5>I(M4&*(/'"Z*A
MBV?+RN]^E*DX8BF5.H8=0%,5)\S$UI9B<,\ZY^G/SFN"JW)/`_-]DQ]SN@(&
M%IA)WD)YKG%[F'CU8U@BV8O,1XDM?"F9M<K-/>R4\79VK;!]E,U8JB*ZQ^V!
M!`7(:E;`YK<1[P</^1EZ"H>W!<TDFF@UZSJS]*^6S@7FJ<QWR#K2<#2'4IDW
MSL,.\[8,KJ<B3(/L`T?+W'*W3$E*++H&*E:D:QC.7(C%*@+@X@FB`@"H!J..
MVD%-8R+>?`MK[,Q@KY+ECI"6DZ2UWKU4KZ50/*#R^>2=^RER0S-C]HA)G7\Q
M;C1S+QK0*WFE;#5IRU1\8\)87C-?(2/R7',7A<69+BK.]>2\"YD`(T=.(E`B
MZS=)T#A&]\#P"`T:01P/Y0/.#QIR'F17#1IUN.H@C]HFI//S<?,:DH?`Z[2\
M_P`5;T]X^RN-?W3\R>T\P<\UK/7)*$Y0W^R,#<.,@8'KN3Y>Q`25JI+NK;7L
M`BE"Q+N0!DA&IR(NA<&4*E5D3C&UM*>^3Q'X2!Q-.'1[%;).TN<6FM6`#+\P
M)Y5X\%?_`!GCOD_QGY0<I@J'&RH9WPYR]Y-4+/:69@S/1\?/<3P0XTQ)BRW4
M;)U#LT*^MEH;XO;8R5E*@%=1DD7Z;XC14(Q0AUQKV<C)--*@D>]0U&`%:\,N
MGI5ID9)%4G2X#+@:$G+S]%.%5$AIQ!YX8PQQ@*@5YID*S8MBN0/F%Y!SAB;C
MARQC^+&0[.\S]RCMV6N,USELW,UH>PN<:UNCV>0+9*["3#"5))2+=44I$&9F
MVK98Y"T``D:G5P)XFF&!\^&?%2,FB#W%V9:T<.0!&1'I!\RW^*GEV<DL1T[@
MW"7"&J,<[P%Q6\U#$5^9L\E&NH1=LY;9JI]ZPO&QEHDVK:8O#(]<A%BR,PX2
M27(L0#NB%55,`4;!)I:*8U)X\V\^H]:K\Q&'O=C0TY?E<.?,JS&;^&F18/''
ME`<38VRQ=.S[EGBDS\N+F-$5]=Q+_?G"FD8IH&0N3,_$6.+%-FBOCFRX\)`0
M,FJ()'6R(NDCN=R`:MDB(T`?&6@'APH<3ED!Y^E&2@F1Q^`.+AUUPP'I\W0O
M2@QCXZ)8,(F&8-8F'B6+.*B(I@B1NQBXJ-;),HV-9-TBE309L&2!$DB%`"D(
M0``-@ULF-#&AHX+7DEQJ5S"CL(#[!`?F'5RM7XXOG20IX#S:?,2CCE$@FY8Y
M:DB@)2DW2G)]6;1,!2")>DZ4@40]8@.X^.N<F.J5SN9KZ5TD&$#!R:L8^HE*
MFB*\.`LM2&#\NTK)3+K.W@I5`DXT)N(OZV\4(A.LP(`@!U!8B91(!\`63(/J
MUCW=NVZ@="<SB#R(R*DBD,4@>."]A6/\FD/#QLI"2`/:_.LVDU&2350RS8\:
M^13=MW10*(G^'504`VP;B4!V$-]<B)G0_NG5&)\W\BVSHVR'6VGWJ_\`$7PI
M2,W3AR(IN16!0Q1ZBEZ>@Q1#K$#>.XB(ZR;2Z:)27&J@ECJP$9KM)+(,<]<(
MMT50#82@02%,/<-N'4`B<"&WV`?0&M@Z^87!K,2L?L7::G)=XZNT>$2/PZJ?
M21/H5*<Y1WW'I$B0"`CXG';T;^[5+B^<82QE:#B5)'!1WO44"+!:RQ-RF'BP
MJN&_Q*I!(8PD%4I1Z!`F^Y0$#I^/I';U^O7*07;[6[,SL8R35;1T(EAT#!P4
M9,CR2E@46.HF4"F4,L!2E#8-Q-L0NWB`$*.WXM9\UV;IGO"BI;PB)WNYUITJ
MY%CX'57S',!TERG8F5%S7BN66J*=V)"_?+N2K!FRJ[.%L[-!VR=OHP#F35:J
M]9EFY^Z!`$#"0=ULES6$Q./PFGW+7[C%IG+P,'"JH'AYY`5@K^:%)3EA9*;8
MZ#7W22U9@:L\?+1M^4`>LB\JJZ19KL&;<0^VS.'=4,&P[E]._#F\<%K3T8KU
MBT/']/QO6(NI4VO1%>@85LFTCHR&8-H^/:H)$`A"(MVZ9$R@`%].VX^O5SKB
MC=,>?-6Z*D%RK)8A'C,\>NU2=,EP,FY:.4$W31T4_@<CENNF=!9(Q?#I.42Z
MQJR2"IQ'EQ5WNM/2H29E\LOA!GD'2^1..&.22;P3'7L-)BCXZL_</ONJ>7I"
ML$+D^YM_VY%@$?2`ZD8^YA'N/<&\LQZ,E0M8XU<!7RXK$_F;^&GX]VDKE_@S
M-=_QH_.*AT82\149D6OE,;<2)IR,8>GV)LD`^`F4,],`>H?7<+O&DC&/\Q:?
M5AZE7LQ^%SAZQZ_O6*+,'\.]SWQ\=RZQK'4K.\:@"JJ?^7-L:L;"9-+[0"-3
MO2=4?**B4/T&R[L=_`-]3-ELI,^TC=YG#U4/J5")FBOND>=OWA8G<L<=N2''
MR6-$9?Q5DG&;Y(QM@NE4L%8;JB!A*86LC(LT(MZ43_RD5U2#ZAU=V8<:1/8Z
MO(T]1HG:.`J]KAZ_6*JG:IG3-&/%R/:C>KI5EP,!R/(*P2\:I]@>HG0Y8.TO
MLD/]H``=M_'57">/X@X*HD#A[I!61C#WGJ^9YA4K5.I\OLP+,FPI`$18;*\L
MT8":)2%`AFD^,BV5!7H#TE'8-_`!$1&S77,`J36LM^&OXP+S!*;\$UR/7<19
M49(E;IJJ356&#E%BIIE(L87E:=0X&46,3J`RA#"7J'<1\-`8CF#Z4U`G@LM>
M&/XQ;!MO^%C^0'%AS$*&%$JDK4[,S?,`=`K^FG&S\<X6(FB78P&%SN(^ST:O
M#(S\+B$KZ5E9PK_$%>4UFGX9)U,O,;R+LITSDMM2B4DD^LXHJ`=[`2$BX6*/
M:W$>R(`7;?;<`U<8I?PN!KT_>JZEDTQGR%X/YB;D5Q1GS&LN+PQ1*G#79A'O
M?`@*?"?!R2C5TD@'2`F2`H%$0#<!U863#,8*_6ZM<*JLKIQ@Q;?(A1U(1E4M
M8`@LHU?3=<KME`%ED114=(NG[&3(!@+OT](=)=QV]NJ"6AJX*A.%"O*CYL'#
M/CG#0D\NZPCC$KHA5>P_@ZU%PKE`.T("*R\:6..KTB43F'M[B8_\K;5[I6$9
M8JU>!'D=3*?6;7)-JW%)Q:"3A0B:*"IC)@!3B`>GW?AUCDU5%%@?`1#WZHB^
M:(FB)HB:(FB)HB:(FB)HB:(FB+]Y;75+DE1>1K_7L64>RY#M:5F<5VJ,"R,H
MWIE+M^1K6Y24=MF*+:OT6@PECN5HDW#MVF1-K',7+@W5OT=)3&"US@T5/L)]
MBN:TN-!GZ/:HT57S`.*]J8.'1KM;:3)1N9<7<?[%3\L8?R]B3(-,ROFX$AP]
M7[S0LATBNVFGQ633.$B0LT_;(P;Y94B1'G=-T:A^9BR=4'J/W=(^Q2_+RTU`
M5;S!!''IZ"JING,;!=*>Y.B1=Y-OEAPYD.FXHR)5<,X+S1FRTP.0[Y0T<GUV
ML%@L6T2TO9)T%#=(2+]9L55K$INFZ;U5NNX12/4SQBM#4CD"?8"K1$\T)H`1
MQ('1Q*I>L\V,1Y*E^*YL36BLV&K\D<QY7PRJ%P;9*Q]D6OW##^/<@VZZTQMC
MJ8QR>5B,F5*9H#EK-PMM-5Q8,TEU4U5W)6[1S&ZX%*LI4`FAZ`[A3HY@_;(V
MW>31P(&&(H1B1QKT\%9'`7F.P%IXD8"Y#9MHF3$K1FE#+SM2M<;^._(+/T;"
M1V*<HVNCOY:4:8MI^296JQ9(B(9N#JRJR7Q+A58&H*`F<B:.X)9J?GJI@#T<
M@>:26Y;)I812@S(&?60NIR#YH^(J/GSC_7V#QUD;CGR"X7Y)Y2TC(&&\69AS
M;D.T/ZEDC%==A6U:I>*ZY:)W]T#4>[2,G*J.HA-9@JQ*559`P&0/0759*#%E
M/L:>%>95WRKNSJ<'ZJ8X#B./2%<*,Y^8\F>0L1`1=QQDOQ0EO+L?<\TN0"TH
M\9M$Z\TRU'T\9)S*O';>)84A"DNU)!P5=F200=)B0YBB4R.K?F_WM/\`-_HK
MY<*>E#:N$>K'M*TIYZ>U7OP%S#P+R6FK15\7SEV;V^GU^LW*7I64<0Y9P?=%
MJ#=E9%O3<D054S%3*3.V7'-I<Q#I%E-,$'#$ZZ!T3G(J`$'(9,QYTC/T>VG)
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M%7Y>2M,*]8X>?RSX%<HOF-<334<]U"VY$!^GE@<$'Q`?`F="<DRYE"I&R#_E
MN/&DV/0S<%C-CPAK"'_<GP@P)1?][X4!4T%PPBHK6M,CRKRKZNFE,53L)*TP
MRK6HI3+/+U^M+)YB_%FKQ%%DGDKF>6DL@TZQ9%BZ'4>+G):Y99KV/:C:7%'L
MUYR1B.LXID\D8NJT/<6BL89W/QD>1R[2.1J"_2(Z?,,R%:]1P]54$#S7+`TS
M%*]=:'S+M,D^8/Q,Q)<4Z3><BS[)\U8XZD[E88?%&6[1CO$##+IVA,7.,]9,
MK5(E*'@H;V#]`[!.U2$4MV%DUUB)('(H(W$8.%:#/`X</-YZ=%5402$9#TC'
MJY^96(Y>^9SC+`\T3&&+OO#)&9(CDWQ4X^W]`N*LPV##]!D,^YDQE3;'5[9F
MVK5Y+%-9RU"XWOIIEC"/IY-T18S4J[<XK$;JV.N1AV>(J!7'B1YLJ\:]"N9;
MN-2_#W2>%<`>&>8IDIU9]SUB'C#CV2RSG*Y)T3',59:C4GEE7AK#/E1GK]:X
MND4Z/"*JL3-S;A:;L\TU:$%%JH4AU@,?I(`F"9TK6,#W\1]WWJ%C'/=I;FK#
MPWF&<2YC'&4,GJ9`LU:AL,WFM8RR-5+UB'+]$R_!Y#O*,(YQS3&F#[51HK+M
MBL>46UD8*5AK&0SQ6>*Z+\("@E4`EGS$=,:UKE0U]&?$?952=A+44%01GPX\
M<N!XKJ9#S*^%L#BXV8+CER0Q[46N:&W'2=CLC8NRU1\AT[.C^MNK?%XNO&*;
M!1V>2JC:YNL-0>QR3V*23DD7#86IUA=-P4I\U%IJ3Y>>GV>L)\O+JT@5-*X9
M4ZU4T+S]XE3N*,Q9L;Y4<QN/<`0]/GLPN[3CS)U,L](B\@U6$NE$5?X\MM-A
M<@NW-O@K"T^[VS6,7<N7AS,B)B\250)<;F$9G'J*IV$M0*8GJ]N22_/CBQ!9
MA1P=*7VP(6\<A5O#TA8D\5Y6=8>K>:+BP8R-5PI;\[M:8MARI9?GD)1J1"NR
M$VWD@=.T&JB9'2Z2)Z?,QUH*D5\O+/D,0G82@5(IA6G'#HS5\<Q9BJ6#:BG<
M[G%9)FX]Q.QE:90V)\29,S9=I&9ERNU&39C1,3U:WVQ9OVV*IEG0M"LVQ2@*
MRJ?47JD>\,%37T$^P%6,87F@IYR![5$.6Y]TZV6#A";`RS"Y4WDSS$O/%7)@
MW.K7JB7_`!9,8^P3G#)EIK\I0[:RJ=KH^3*];,6,V+V/GHT!39NSG!$>X@L&
M-)=4%69BM:]3CUYCH*R(K8N=IDJ!A0CI<T9Y9%49A?S,\<R'&O$68>01'T#D
M7,V2>3M(I&)L&8ORUFB[VN-XZYSR5C67L%:QKCJ#R'D%W#P51IS"0L$D=`(U
MBY?%**B7?;H#>VX&D:JEY)R!X$\AY<<PK'0'66L^$`8D@9@',T"O99_,0XAU
MNJX<N+3)LOD.*S]4IG(.*66%L797S=:K#CJL&9(V_(;^D8KI5LN-5I%*?2"+
M.9D)9BQ2C9$_P2W2[`R`7?,QFFFIKRQIZ*^6=%3Y>6IJ*4YX>W-='8?,TX-U
MB+P3.RN:^\CR8Q@SS!@-O!XORY:[%DK&DE+U^&"QU^MU>@S-F;MT7=C9*O6[
MELV<,F8G=.4TFS=95-\S"2`#4GH/('[0J_+3XX8#I',CGT%5G"<Z^.DOE5'#
M3QYF*I723=Y#85`<@<:N0U`K&4I'%$?*3&08C#-TM^,X>JY=G8*#A'C])A`.
MWSN38ME'#!-TB43Z.G:'%H!+N&!Q]7LKSR"M$#RW5AIXXC#U^WJS6);CYY["
M-ZD\"6?+&-)9GB[EED;+U>Q=&8PXS\TI*_XBIV*ZQD:RL)"ZRSO$]@K7(RS7
M1&KQ2;A"AM&;:M&>/3NC.$F"RA<>.Z<7>^#I<<,.OD*G[.E9,EH`WW'#4!CB
M.CT>D^99H>4V?4.-O'R^9I;UIU>)V(:5N#QS0&ZXQ;W(>5LEV:"Q[B&@E=+)
M'4B?WOR+;8QBY7,F8S)NJJL8@]H2ZRII"R/4W-8D;-;PTF@^P9^I1#RAS_D^
M+W)3$O'SDM',)8;-PDMG(&Z3?'O#6=,IV%]EVBY0H](M<-C['U%9Y'MR>*(J
M!G9*24=2#55R@DT2.LZ()Q1/CBY>)-#Q44X`\@:\^/+#UJ<V[71ZV9ZJ8D<S
MQRX<U,"C<K./639.OQ./\GPUN=6OCM"<L:VK"LIMS'3/'JQRB\+"Y(8RIHQ.
M..R>RC91$&0JEDR&*(G;%#QU.+B$D"N)^W%0NAE:*N%!6GV>U60MOF9<,J=!
M8OGW.2+?9D,T8&3Y08QBL;X.SGE"T6O``J1Q'>44:K0<=6&>B:Y#(RJ"\A]X
M(-%V+<_<63*`:H;F+)M2:5P!RH#RY$*_Y:;B`,:8D#&I'M!518E\PCB3G2VF
MIF+,E3-FDG>+9W-=1E3XKRU!4_*^+*HM%-;;<L(7.Q4B)K6:HVJ/)UBA(%K+
MF36;K/$2]!A.&C;B,\Q4?HZCF,B5:8)&Y@9\QAU\O.MBI^85Q;M;3*#EU8<G
M8X<X>PW-\B+O`9PX^9YP7;2X(K9'0SV6JO4LKXZJ=AO5+AU6AD72\,W?*MG)
MTD54R*K(E/43L)(-105R.0ZP$,,@I2AJ:8$''S%5+@7G!QJY+W*5Q_B*Y6:2
MM<?C^$RU'1MPQ1EC%A+MB>PR00L7E'&;O)]+J+7)./SS9BLE92&,\:H.E$R*
M&*"J0GJR9CW:16I%<O+U5"H^)[!5V5:9@X\E++4RB7SI+U`?H)W`*8@*=!14
M*0PE,8A5-NLI#&*`B`#L(@&_H#5$7W5431%^1G_$25L]6\Z+GBR,GVR2N1:;
M:T/#I[B-NQ)CZP"KX``?;7?G_".N<G;IE+3G0>P+HK5VN!KNOVE86]0J=-$3
M1%EJX$\Q3UB/9X-OSQ4\4F=8M(DU5SE%)JKUK+5M54?$H-S"<[7<0*8@BEX=
M)-^9WNP>T_/0"K/QM_Y0^WTK:V$[7#Y>0T?^$_8?L69B&OS16,2^[Y3NH"&Q
M1[XJB01\2D53^T*>P?H_K`&N8,^D:V'W:^CH*SC$6^ZX4/EDJE9VA#ND7>/5
M2&)N`'.IN'H#T;&]`D]&WB'A[]9$5PUKZR.%1S\LE'V9I1O%<I;)D:4ZK<[P
MIVYO!7I*<3G*7PVZ2E`3F-M[M4EW2#X7$!BO9:O!JT5\ZM)-R:-@<2#AJGW#
M*.CF;I%^R9,ZJH=13]7ATG*&^_CXZQ6$7#B&BK7'#HZ_-@I2TQ4)-"!Z52T_
M`'!L8RB)BG*78X%`!(38H[[]._2._AXZW?R>F-I/(+&;.0[#@5>S@QD]6@Y8
MEJLJX(FSN#(I6X*F$A/O:)4^(:%$HGZ1W244#T=0FV\=@U':O-O=:0<'?9^A
M37;&S0=H!BU>@^"GH*?;I(KJ)D.Z1;B1)7MB55P<@@J9`P;#N)B[F*(`(&\0
MUV,+XYF@29'VKG'`MK15>P%1@8S,S@RJ0"!T>LPF.1/P`4BF$PB?8?1OX@&J
M21=D<#5BI6O717-BQ25*78?#^4!_L"`[`.P@(>!MA_!JH+>"4/#-5M'I,E$U
MV[AH5<YP`K90%@3[)CB&YE/$""41V#?P`/7J=CA\-,U8`?B.=51RXE9KJI'^
MR9(XE$NX#^B80$`$NX#^$/#6.]A:[I4[2%O?>OP;EN^9J?#KI`0Q%$?L_;)X
M`?U_:]OMU$!0Z@:4XJ\BN'!4]97;">:.X^>;1\S&O@.9Y&S#)I*1KL%=Q4*O
M&OD5V2Q3;^(&3$-5+P,7D$E6D4P"Q?9[\L[R^\VG=OK/QRJ-;G'8*=VR8I5D
M,5S!E#"(BNHG3',9!.UNH1'=RQ7`?6`ZM_Q%\>#'D=%<$[#6<6@GJ^U88,[^
M0+B?=[)X2Y`6:L@/6=I7,JU:.MK),=A$J!;35%:O+$)X;=:C%R<`\1ZA],;M
M]C9A.QKAT8%3-L7.'NN(/I6&[,GE@\FL2.7?1`U[($8W,?M2>.;0RDU%DBB.
MRAJ_825VP)F$OI(1)80]`".K6=X=C>=,DAB=TXCTJIVZ^`JUNL=&!]"@7-UB
M;K,JXA9A!Y"3#(_;<Q4TU=0TBW-OX%4:ODTQ#<?0._2/J'6XC,,[!);2L?&<
MB#G]BPW:XSIE:YK@MM"3F(X=U"'4#N)J=8])_P"[]!07)UB!#`/CX^/XM7EL
MK,P4:X')74K7(;(E3.<8&PS$.DH'2HV82+M)J<.HA@,9N"_010O1MU$`!Z1$
M/6.@F>%537Q;YNW-?%0)I4SD1DJ!;MTR)MFJ5CE%V38A>C]FBS7=F0%,I2`!
M2FZB@&X[".I!."/>`]"K5QXE7?R'YT_*G*U95@LFWA*[H*-A0,O,1[)S('.*
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MUD^U=O9_+PY.K\9\%5-[;,;9<RS(<C\E\H.?V-@S!F;C?AWEQ?\`,<+:49*(
M;Y3Q=6IC),10\.V"0@CUZ$?1*L;+Q-::-'Z*?;3``M9&MI49X@8<^.//ED!5
M/FHR\DC"F!.)X9Y<N=:DD%<CB=Y9&6,!R7%!_-2V$H2/P-Y@G,SEU/4_&<ID
M*1K4?C[DGAS*F/*=0*"]ND"C/RDS496_-A>J2JB!%6K=54BQU#%1U1MI(`:D
M8@^L.'`4_$%(^]C.0.8]1;T_JE6P8^5YR:K6+>(&*Y5YA3D+CG"N/L_5'(&"
M;QGKD+A'#J62<I9WD\H4?D$D7$]1>2&:W]-I<JY@5JS86;%N@9VJNQ=)JG.K
MI\K*W"M1CD>KF#RXX=*M^;B)K2AH.%:Y]((S&(/!55Q_X%\WN&\=P?L&%DN*
MV6+SQFX"9)X;W6O7[*&6,84]]9KOF/'&4(6\4Z9@L.Y`EI6IUX*$"3F/?MF#
MQRFKT)JE.`*Z"UE8/PG"GI#1R/(I)=0R9ZA[U<@>+CS'-=$IY+EE>8<5P,\S
M5`DKDAY6%HX0R=Z:1,TE,!G&U<AD>0CW(#*H$.@B3$:=B%5`L>$NG)@P$K8.
MD?VX6_)24K4>3:>0\U>*N^>;P;Q]6JOZ/7T*97"3BSD;$62+;D[+F`N.>+[D
M^Q7"8Q2O&)>2W)SDA;[FDVM`VB;056Y!0$"AC;&B\JD5\RA6JDH_*^4,*[H2
ME$59X87M?J?CUFO/+`?:,UCSS,D8&QX"O*GVFOJ47<ZXPYBW_G;YC5&X\47$
M:=0Y$<".'^$[#ES.5CR+68&D'F7?,2MSMCH<!5L;6R&S3-4V"N2KA[7U9>`.
MFX68`HZ(BY.)87PO>]P`S_RG'D?:.&.*OBD9'&QSB:ASL!T@#F*>OJ4DL6>7
M::AN.:%%?7L5L/\`);AIQ8X>524CE79LE0D!@G`>5L&V2TV1)=HWAPDY%K?F
MSZ/!N[<`=9%7N]G[/5>VS(:0ZF(PXTQKR\U522[+G-<VH(SZ<`/1ADHQ3WEM
M\I^3E`Q_AOE?:<!XUI?'_@UR+X<8UN/'N;OERLF4K'R`Q'4,'*9BMM5N5-HD
M9BVJUBDTI!Y^Y[20L!WDL[.4TB1NU1%6UMM)2F`]TCTUZN?,CIPQO==,!U-J
M27`X\*4ZZY='5RN7G?BOSNY?\>*YBC.</Q'Q]:\#9`XZYAQ&XQOEW/\`-4_,
MN3,&3BJL^PR*M&X_QA<<'XTOU544;,20#J>G8&27(Y[[E-F1)Q5UO*YHP`<.
M5.=3P'VC,XG.C)X8W$BI:<ZCHH/Q>66`RH:5\O;(TMBR5!7AAQ!97Z;SY5\I
M/*]#\\>;$3D*/3IV*I#'=<R/6.:33'A,K5;+T,G*+Q:+5A#H1)JHLHS5744-
MT:N$#Z5-2=5<^BF8:#ZJ]-$-PPNPP;II\/37(N(]?F5&9%\NKFY8\1X5AEK-
MC;(G*&C8>R/CV-YM'YD<K\$<A\'R=SR5:;A2($+ICG'\H]Y>8DQ'7Y&%;%97
M<D<\LDI"JNWB:0R*HI6?+2`98D$9\_-CRH30YG$FE1<Q5XTJ#D#EY\.=0*C(
M8`+L\D>5YF%WF//=G<4_CSR[IW*P,06'*$IGS/')G`#FKY%I>'\=8:R1(2V(
M,'QEFQQF>@7YKC=M/,HM=2#>1S]VX8J+JLP;J(U=;2U..!Y8#EE0\!T#S9&7
M40:!2CA7ISQSJ*8D\_OJN_\``?EX['+.#*%(<<5^-^2?,CQCY@Z.3+=<\EQ^
M:(UC&<A<3Y_R#AA;'$/CJ7JDA*-+!072$)85;)\.K%JMFBS%%5,7*;Y:7M-1
MI4N!)ZC4\.?3YE;\Q'H`-:AI%.L4SKRIP\ZR&\W,!6KDUB6KT"ES,#`RT#R;
MXGYO7?65:108J5[`7(_'.9;-&-U(IA)N?OR6@*<X;1Y13*@9ZHF"JJ28F4+D
MOA+V-;AA3U$'[%C1/#'ZCR/K!'VJ!7+/RR<G9]RARDRY7+CCU*8OG('@IR,P
MM4[//Y)K<).3/$K&%JQQ;Z!ENTX[2C;G2(F^Q]P>!&3-=7D'L8Y*W=G04[)F
MRF(;.0'4TC/"G6.CRZ<EF1WC6L#'`GGZ#Y</M79TSR^\B*AA*S+XKX]\?+)1
MO,)Q!RWR!`T+.6=^0K^[4C%>#+YB5`+#E;,%1A9VQ9.!:U-48]LFP81+.%9)
MIBY,L0`&XVKW#&E<<SS%.0]85/FVAWNUTZ>&&-:Y5/M5V>3/`6R9TYCX9SG"
MW6N0>%)-/&(<T,8RK617F<Y*\5;_`">:>(BD(9NU6B#_`+L96GG9+%]X')\7
M!)-VZ?<Z.@)7VQ+ZL(##F.K$4\^.*A9<!L9#@2\9'KP->.7)1LB_+*R'4^0F
M3GZV+N/.>,+93YEO.7C#(.4^17**F7S%SNU9*A<MV>MK\<J?&2^%\IVJDWF.
M5=U":4DX9'[++[Q;BHT,HO&+9XD_4U5PP&8.5#[1EZ9?FF&.A'[S32M*\*9U
M'L*FUYA''K,_)&BXH@\32<+,0]/S.QN^8L'VS,64./U3Y'XV+4+=`ACJS9@P
MU#6&\UIC`V^;C;(5F5@[C)I:(*S?)]E3<)YHGN`#/A'#+@>-#T<#EDH()&1N
M)>.'*O$<,/:#R4,.,/EA99PFI@!>4?X-J['%7FCYPYV2=)QE-9&F:O"XPRGQ
MEON%87'%-E;M76MAFK9`V2VHKN5I+X9LY:IJKD5(H8C4N,+.32:D5/W.'`=(
M64;R,N!H:"GM:>?ZJ[+$'`WE?Q3'C)EC"KO`&5<R83KW.?%5VQUD>]7_`!UC
MNUXRY<\KEN3E7L=/R3!8TO,[7+UCZ4AHIK)M'-=69RS5=VBFX2,@W65N-JX9
M4-=5?/YCR'`\<E'\RQQ(=4#W2.?NCH(]N"B[8\096\KF3PGD>O7>CY+S%D7C
M?R/Q+ERN.,!\O;S1G]KRCR?M_+5]+8(7XYXJRS(Q[N!R-F24@XRIV96MGL\0
MDS7)(M%6CGHB?$Z/23B1R&7'D0<SEYLE*R5DVIE*--,2>0PY?E'.AK7`X3,\
MNKA9F+"S7RY\HY'"'J\A@?RHF7$C(^/W:SHUYA<I6JZX,R,Y3%!NU<P/W97V
M>/7K"0`7XK$?F(F5-5,#J%E@MS34ZA:6Y=-&C[#B.L*.XN&N!8RM=1Q\[O\`
M*"L#Q^\KODQ3N3O$?.F8W.$;9;N-F>LN9)RKR;>YYY$Y2SURB@[[BW,]`KK@
MF/K]5&N.<%H12F0XP[BM1DB]C6Q8_HCUT&Z)$7%@M92<3P(Q/,$#AAGS(]2O
M^;B#:-'$9"F1!YXY9T!5WJ9P+Y0X,P-Y8[#&$AA#(F;.`.0LW3UCJMRO5ZQ_
MC7)-:SK2\T4*5"`R%$XXN5C@YRJ,<F,WR)7->40>F:KMQ,EU)JC<VT<PZO=)
MKET4IR/L5C[IDE6NU!A&''B#E7HYJ:'F`4/(%YXO2TIC6M+73)N&<D8$Y-U;
M'\8?K>9!E^->8Z-F>6QY!F7!(KB:N4#47\=$@H!`5D5VP&Z=QVR;@.T:FBK@
M?M!^P=2QH"T24)HT@CT@A<:NXR=Y5Y?8UYV4N?9#B&Q<";9A*(@IR,L]:R&>
M9R7F/'V7X25E:O.0<>M!,HZ!K:S20:OC-Y-I)"")VVQ3F+$V)TD@F?3'ATT`
M^Q7NDTQ=@*U#O,0"5`7"_E[\Q^+<-Q@6Q%)<:,AVNF>6VAY?F8D<BW3)M/K%
M;D8:_.L@5[,&/EZWC6R3&0H@CB:?LWL"]2KCE8I6ZB3U+]J`0_*2M((()PRY
M@`<1U\N&*R'W44C=+@0*_:3S%.'/C@KV\7/+\RG@M[QI<6*Y4&53PKY13+R]
M[&$&YL)C2V5&MIH<X:XPQ'T"S*?'QFU47*"BXHR(**$#X7;J,%PLWAP)+<*>
MH`?8K);H/;I;J'O$^:KC]H5'Q/ES\AX'$G`FFU#-M0QUDGB'Y9_)'ADXRC7#
MV-^_@<T9>Q!@>@T'*V.6SB%8*OZ_2+-B9Q(*B\-'O@3,V%%$RG6"=YM7:`T4
MJ&TY8T;CZ17'/BJ-N6]H]QK1SZ\\/>P/IIT9A1GH_E'9Z[V=YV2J_''#<YEW
MRPN2W!UY^[?(3DAR.M%XS)FAQ2EXW-.3\FYFHT7.K5UPZKCI9=LW1=2+('0]
M1GQCAV*1V\@+B>+",ZXGS`^FO65>^ZC(:`/A>#E3`=%2*]5!T!93*?Q:NU>Y
M5\=<]/;!6'%:P]Y?=CXD6"*07E33\E>YG(>#;@A8H<BL6FQ5J2;'%[U,ZB[A
M%YWG".S<2BH8E\%N8GEV%,<NFE/8H9;CM(])K6H]0/WJ=.LQ8J:(FB)HB_+6
M_BO*7^ZOG%9(F02[1<C8,X_W8ING8%A0I9J*LL7P#JW<4HY1'Q\2CK07=3.2
M>/V$C[%OK*GRX`X']*\W&L59::(FB+EQ[]U%OV4DR4%%Y'ND'C54/Y"[=0JB
M8B`[@)1$NPAZP';5KV-D86/Q:X4/455KG,<'-P<#59?,(9R/*PC"6BY!1)<S
M<$Y2*64$X)G2V*NET[F[R15`]`?M"E$#%W#PUPM]MKK=Q`)J,ND<Q]H/%=3;
MW$=S&"1AA7H/EQ4J4,BGG$BN&SDR'H$R)%04*F8`VZ0$1,(D';P'UAKFY+=Q
M))S]JV+!"!I/K7:HV)0Y4Q56.943]!C"7M]10\=^OP\2CJ$6SLCF3YE>`P5(
M&"O-%O4@BFZP'+U%[0&,D<P&*H`AONH4`*H&WB;80`-_QZW]LUL4>@TK@?.%
MIIJO>1C]_);<S<R=LR2*J9_B@**J1P*(G,0H%(<3"/6B<W0("(#]K;QUF2WX
M:RC2:UY*QEJ][E92&LKZ$O$=9&1U$'$9*M7J)B&^V!4E`,<H;`'V3%$2^KTZ
MUAG<Z3M"?>!JMEV`+#'^&E%Z.<;W^,LT)`3*0(@=[&,EP4Z`!<J_9264("A`
M[A%3',`CL/I\==5:W8<P.&>!7,S0ECB*85*DF6TF<-$EP4^T7H`1_E$.'IWW
M\3%,/COK9B8R-SP6*&4*NA7[01TW1.90O<*78Y=]A^R`>(E'U;#JWM'5H**I
M%#0Y*M@F!,D)TE!*3<0$"F$=@V#</'QVWU)VX`%:U"I1=6Z?ALIU*&W$NY3!
MZ=Q`?Q!XAHZ6HS]U*45%C.J'%1NHJ<!3$=B[>DN^X&$=:U]SI!U5P4[6%V2Z
M:4GB`0=E``>@-QWW$HA[O1K"FO=;<*!OEDLB."AJ#BK,VJ\MV""@@L43@`AT
MB("(C[@`=_7K1W%\]M2S/DME!:@BKL&J'%[R%(/`<`#CMI$`PG#K$!*`B(>'
MJ`1UIY9YW@Z\,%GMAC:*MH5AIYL\LX3$<"_1:.4Y"WR::C:%CRJ`8Z:PE$`7
M4`HCT)([[F,/@'X1U-L^SR;M=5(I:-.)Y_RJ.]NVVD&/\8Y>70O-E9K+-6^<
MDK'87RTC+2K@[ETY6.8X[G$1*DGU#]A%$H])2^H`UZQ##'!$(8@!&T4`7)/>
MZ1Y>\U<5TJ:JB0@9)0Z8AML)#"7T#N'H$/7J4.<W%I(*L(!S7(%^L(&%4C=?
MJ](JH)]6_@&_<3!-0!_'J3MG'XP'=8"MTCA4+B*JM#E$3-C)>C<4%C"4/P$6
M*<?$?YVJ%T9S;3J/WJM'<ZKIW':]*2R@"/\`)4)TC_6(8X#]&K2&<"?.%<TG
MB%P?$?3XZL5Z:(FB)HB:(FB)HB:(FB)HB:(FB)HB_>6UU2Y)64Y&\@,=<5\(
M9#Y"9:5GT,<XOBH^9M2E6@75HL7P<G/Q%::%AZZQ.1[,O5)2<0*#='=8X"/0
M4YMBFBEE$3=1YJ2.-TK]#<U&=IYE.`&<1R`>Y'J6?,(3_'*,Q9/V_'&7<2O(
M;)UMKN=Y^4I^#)?%]-K4Q;'EU5RY>89S`1$84[>:3FTQ:/6;-3T0MNFN:33+
MSYY9#CY8T"E=:R-<&GCYJ4SSY#'JQR71R/FD<=*I1,G7'*=,Y$8=G\,Y+P5B
MW)F'+YA]T]S37IGDM-LZ_@^;CZ7CN<OC6ZU7($BY43:.(!]*.!79NFPMP=H'
M;ZH+MI&(][EGQ`X#I5?E7U%"""#CU`GC0\,^KF%5\1YB^`%:OG6S7F"S9@];
MCG@6-Y,9-IN>,4RN,\A-,.2[K(\='V2&ITH^<2<LY7F,62C'X/9-P#Q1HF)?
M][1$:MNFEM7"F%<\\^@<E0VS]0#<1JIU9?>J;O/F=<?L>S\G'3])Y"'J=&=X
MFAL\9;C,3B\Q3QDM>:8NJ3-+I6=K">Q(2L+:64;>H9:?1A8^>0K"4D@>46:D
M/U`-T`:4-*T/0?+'JQ-$%LXC`BM"0.8\O*JK3S"^6UBX28*KN7*[BJRY=E)G
MD-QUPPXJ]9A7$Z[:1>8\O5?'\Y+`V9S,(K][)1<PJW@R"L9%Y8G#!JL`(KG.
M2MQ/V<8>VE"1T8>C^14MXA+(6.PH"?0K?V+S%<>8ZL&;)7*K"YTJJ8PPIQ*R
M(AB.3Q)8&O(N/N/*K)N3<4T.B3;)&VRM3FK5>KI4V$7%P[4C,8IR95:0?G;K
MIF;4%Q[NLT.`P'22,_-3+]%QMR':17XB*G#(`Y<,.E5/8/,&J%2@J!^]/&SF
M'7<M97R3:<7XOXV2N)*JAG'($S1Z,7)-OL-8;ER8IBY]0J_31,Y<3)K2FU[R
M1VI.IT44=4^;:6ZJ"M<JC+G7R'2J_*2!VD\NGB:`<_4KMT7EOCN\WB&Q8XK.
M6<?Y(D>.;WE&[H&4*&O3[+5\;L;ZZQK(,K/'*R;TL7<T+0P.7X%,ZZ2S7H<)
MN#IG((U9<QN=E1Q'Z?1T\_2K)+=\;:G$`T^STJP<KYG^``HV(+QCZ@\B\YCF
M+CO%<LX^FX6Q,E;+S1..4R3_`+NRCDR)DK37HVN,I!TDX;,8ML]?SLJZ8NTV
M#)U\*L)!N@`*"I(!](KAACY4KBJBV=4@D``T]=.&7ES"O3FGEA5:'P?R5S<Q
M9'.\U4FN\:I[D?CIE5&SA4V0JVG0%;S572+=<T>^:0SU@HBYD#'[;EE'E<'$
MG=2[8WR3:8.U9CY>5.FBLCBU3")U0:T4">,GF73<11L'T_E!7^3.6.4'(BA*
M9UJ./L4<')VJR4+BX\[1:9*.?W4IN0,FHL<=5NSVHSQG9IZ38G?PJA3*%%T5
M-%?&BNM+/>Q)-<SAB!TT]*RI;6K_`',&@<:8X$X95R4KL=^8]@')F4*7C^$K
MN:HNG95R3=<-X3Y'67&IXCC7F_*^/?WF_>6C8TR*6:=RCU\H-)FRQ+V1B8V)
ML1HAT$4[>"0@'E%XS401[HKQY8Y?IZJJ(VDH&%"33#K-./FZN-%:2O\`F]\>
M;:KC7]U,*\R[''YQDLB57`,Y%<>7"L/G3(^*7LXWO6-,=.5;8BM]_0S"KR<B
M,K,)Q%44C8UVL67'X98I*?.-K2@]/Z,.LX*ILI1CP\O3P&%3T*<?&[D)0>4N
M*(C+V.6UJAX5]8[O29NLY`@1JEZHM^QG<IK'V1*)=Z_\7(H15EI]QKSMDZ*@
MY=-3BD"B"RJ1R'-/%*)6:AZ/+J6/)&8W:2K&0O/C&KCD54.,]WQ1R&PU=<FV
M2^5'$-DRU0ZO!T;+%BQW"SEIF8^IO*_?[3:XH)2H5I_+Q"T_#PJ$LP;&,W.9
M02IFL;<5>&D4:2:&O+R_E5[H"&%X(-`"1Q%>?IZ5=+D'RFH?'.0Q=6IBH93R
MODO-%@FX'%N&<(5-G<LFW0E0B$[#>IYLQEYVK5N#J-'@UD5I25E)-BT0.Z;(
M$,HY<H(J5GG$(H/B.5<!Z?+V500.F=0?",^/J4#>-?F=J6;C;AF\94QOE[)O
M(//67^9=;QU@#!6*6#O++K'W&WD3D3'KN;LE4F;77:K36N.J9&0+*PO9.:;)
MJSSU-NW[[IR1(8&W6F(.<*DD\>D\3Y>H*9UJYTI8S(`>D@'(8\^"OJ[\S;CZ
M\B,!.\;4SD+G&Q\EZ;F&XXKQQB/$#N4R&<N`+-6J9F2L7J$MDW36.,;;CVW6
M=.,DF\\[8MT)!LNV%?O=A->1UVT-#@,_-E3B1T]'+-6-M9'.+>(\^=:95/#I
MPQR6V'F<X`GJ5@NUXCHW(?D+/\@L<V[+M-Q)A+$IK%EVOXUQW/MZ=D2UY&J]
MCL52C*0A3+ZY"NK-',@:0?SQ3LXY!ZH0VU#>,T@M%3QQI3T^;^7!/E)-1#J`
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M(L2\Q/08F!Q<,;$/(NOS<O-VM1TS!$J;9,%X99W=OH!`:T<^@\./4IX[<.M^
MTH2]QH.C$#[<U?U/S0L`1-*SC<<J8_Y'X`>8"P0/)^TT#.&(RU'(MGX^`Z5C
MC92QY!1MFL,?98QG+)%9/XY1ZTG(AZL@C(,FIW"('O%XRAJ*$#G7A7R]=%8;
M.6HIBT\?/3CU]7(YJ7_'K.L+R$JJ]VJ])S7C^O#:7-=8-LUXLMF&;':HUNUB
MWS2YUZJ7%!A8G-'GV<L48]\Y;-E%C)JD,BF=,Q=2:Q)$Z32*MK2O1UA1.C,;
MPPG,"M.GJ6-?R^_,^+R`Q[QA@L^T+*]/RIR&>9=JU.RZ[Q)^Y_'+*62,86/)
M$B]QSCZR_?SN1"T(XUHZ[UL=S&MHJ9&,>_`/7*R1T@A@N:G0_GG7VU\YZLJJ
M>XMM`,C/A\LNC+I!S5:5+S3,39OJN$;WA*"R[7<?Y;Y`\><2PF2,W\<,E5C'
M^2D<T6:VUE]5,0V129K[2;N</(551%S,I#)P$4<Y#G*^(H'17YL'$4`'6?NP
M_0J?*N!+<WXX`CS5SSY*F,J^9F,IF?B]CCCQ0,IRU`R)Y@4+Q-R#R)L6,&(<
M>[BV@:YF!'+%*Q9>75H2L,A:JY?:$G'%F"0Q(==S'/T&CMP9(^UDUV0[2R@H
M3QY`\.5?,KX;,N:7/X@4'61QX8>?JXWQIOF78%O.5L:X[@*+R$<U',N;;;QY
MP_R'5Q>U9\>,IY5H$7?9:YPE)O"]H"PO8N'+C">;HRRT(C%R;F-6!@NZ3(90
M)#>-J13#'CR%<O-SIR*C%I(6UXX8=9`^T?:%258\RJB)8_P?*V.OY(S3DSD9
MD_EKCW$].XX8;GGLE;)'BUDNXU6TQBL)<[N8E86AH2OIINIB5EVL*\>(KN04
M8MED$2U-RV-H%!QZ!F0/9T(+5[W'3EATY@'ACQX`JJ&GF8X&L-#P;:\=47D'
MEBY\@GV6(^DX!QYBU![GF%6P#:%:/GQ7(=4L%GK=:H;'#5V3)#3#E]-%06E'
M#=M'F>JN$2G&[:&!],3TT]?7Y95HVUD<\L'"GKQZ\E)KCSR*QMR;P33.1F-U
M;`RQM>(NR2\:>[0:M6L<8UJ-CL%5L1+%`J+O5HAW%3%7>D52$YS%*EOZ1V":
M.9LD>L>7L44D9CD,9S4:,=^99@N_8NMG(![CWD7C/C17<2R><H+DID_$R<+A
M_)F,H]VQ:M)C'C^`L]HMKR:M!9-NM"0DI#Q4W,(J@+9J<^Y`A;=M-:B@`KGG
MYNK'GR!4KK61M.))I]^.6!\W2%U[;S/\!QS.[&RCC[D7@&?QVO@F0M])S;BM
MG5[=%8XY&Y&+B;&>:U&D+;K/%&Q.6_`I'SKP'GWC6E43A)L6P@`#7YH#![=)
MPX\_(^@UHGRSB*L(<,<NCR'I%*JXF4.?>!L5VK*M"?,\G72_8JR/B#"RM*QO
M1%K7/9#SAFZE2&2J;AS%Y`DV#"QWJ.QU'C/SP.EX^-K\.JF[?/$D>LQ!NV8Z
M02.'MY888_H!5HMGD`F@SKT4PZ\\,L\,Z*V4EYI_&N$HE2MTS4^1C.SVOD);
M^*)\&Q^#+';,_5GD52\=S&59'%UAQK27=E75DY.CQ2;Z.?1CJ2B'C5^T<@[*
MT44<)/FVZ-5,:]/(G.G1CUU5PM7EVFHRKF.8'/I]."W+%YHO'VJRRR$WC_DH
MSJ-6D\2UC.&5%\-+ML;<8K[FIA49&FXWY`2;RPMK!6+O&H7Z$"QMXJ,FV]5/
M*(!++M`,(E&Z`(P]TTQKSQY8^5:*GRS\14:L:#B:>7W55IN2WF8'KE[Q]C;C
MWC_*=B02\P7CAP]RQGV1Q@R><<V$M;LM0%+S9BV$NC^SL9Q[D"M,)12--),X
M=Q$,)Y,[('AG:2B)8WW6J5K&4TZAQH<QPSY_;C@I66I$;GR9AI(XC(\<N1'1
MCDLO1@V,8`]`"(?,.LY8*_.D_C-L>?<_-7B3E(B(D)?^+LI4EE^G8J[W&N4[
M(Z.7J_E'187UL`AZ@,'MUI;_`/C>KV'[5NMN/[DCIKY>A>.C6"L]-$31$T17
M'QK?7-(FB****C$/%4ROR)B(G;&W*4L@@7^4HB7P.7_I">'I`-8EY:MN8M/X
MQE]RRK6Y=;R5'PG/[UDRJUM*Z0:OVBR"@+)$61604%5D_1'P[B1P,<.VKMX@
M/H'WAKA[F!T;S3!U<1Q'WKJ6%KVC$%E,".*O;#6A)XB)5_LD4\`$>G=NJ(@)
MQ'I$>D`$/QAK'.'#$\5=0CCARXJX,9:GK1-1F"@+(.0Z@*(`8`V\.M$PB4``
M0^C5&BN`KJ\O*JC<0XU<`:?H]*V'<D5-(0^(,9PH80.0PF_9)G,'0!3^@QQ+
MMN;PWU!.`QNIOQT\J*>-XR-`"<O+[URHIIU+]Y78Y!#8#@4=@V`!*`G$/$W4
M;;T>&VL")XD-!@0LET>C'`UHLF_'#(+IM#HPKAT8"1Z9!2-U#^R*!`[291$0
M`PB)MA$?U=;JRF(;HKB%H[F.DA('NE9%*O=$W;)N0RY%TQ3(HL<#_:`?1V]P
MV#J*(?-MKH+9[I&TKB%JYV:#49%7AAIPP$[K9<#%./\`)\1#80'Q'?T[#K.C
M.%''WJJ"E>I5HTMCQL8W<ZC$$H"/B(@4?;X#X`(!JTD\2J:0MMU<3*"L7J$H
MB7]'<1V\/`2@.^P?@U%(V45(50&\\%1CFV(]1S"L4#DW`P]7CTF]/XM_?K5R
MEX)+N2SH@'-]U6UM&14V+=R!%`.H!3!MOX;!Z]]_4&M-//@0Q9T</O#7Z%%^
M3O"LBLY=JJ&!LCU"9P?Q2*.P^``(@`CJ."(!AGE/N\U)*_6[LVX^62QN<O.7
M=9Q%4Y5<'A#OEDU$6+-)0GQD@\.`]E-,@&ZBEZO7Z@\=0VUG/O%X((,(!\1Z
M%-)+'9P=I(??I@.E>77).1K)E.V25NL[M1P]?*G%!`3F,@P:]0BDT;@(CL4@
M?I#Z3&\1]6O3[.TAL8&V\`HP>L\URL\[[B0R29GU*@]9*A31%MG'U?/HBXRI
M@Z1#</$/;[/'15"ZDX[CJBN"T:*J:(FB)HB:(FB)HB:(FB)HB:(FB)HB_>6U
MU2Y)1;YK<<77+GBWEOCDRMS:ANLG,*JR1MSR'6L#:&&MY`J5W,HK#MY"+6>@
M[3K`M@`KA/H,L!_$"B48)XNU9I'`U]HZ.:FAE[)^JE<%%KF#Y:+#EQ?>3MUE
M\EQ-=+G/#W#VF4N*E<>-;U%4C(_#C/V3^05.METK\O,LX7)=!MD]>VL;+UU0
MK(7$8W=$^**=PF=&$VSJ%H(R;PY$GGY9<:B1EP&4J,:N.?Y@!RY>O'AC1T)Y
M;UUE,<*U:S-^#V$YW_B?X;Y_`W#?C!/XG@IB)XGYCB\LN("[/IR_3%AMTU<U
M&2K.+54%!G62.%!(F\%54QK60/+1JH,1A0"M"#4T-.?2KGSLU5;J/ND8N)I4
M$85%>7']%\>97`.#Y=9?X\9.=7M:DQF-98U=SM44(-.6;<D./Z60*#FJ/PA8
MG9G;48B+9YIQ1`R?Q70OU1RDHRZ.A^H.KY;;M'AP\^'Z>H?RJR&X,3',Q-1S
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ML(WG&^2<#6_(_&1X^X^7[,EQN)):E2^1&-LEJ?D&.RP5G&]3\LE`O8\C_J=&
MZ$"P"W=H/%Q:,Z9U->-./5UJ83L:X`"C`YQP/`T\_#KZE&Z-\IW),-QQ>X3<
M/N$V48F>S[8LTA@_-F%<ZWKC?A&/DZ)6*;`53BJ^=YS6S/AU[`RD$]G'3Y&3
M.W?/9Y\@U:1C<4]1_*R=GS=7D*CUTZLZ5-*54OS3.UU4(;3GGZJ^O@*UHKC4
MKRX^2N$G''ZQ8:Y74FR9"HG#NV<+<O7'D5C/(.2_WBHUAR@.68"Z8W;L,NQ5
MC93N.)5VYA8N-L<S,(NH(K0KMX=PW.HN^4D!#@:FOV4Y^S''HJ:&ZC>TM<RC
M>%.NO+RIYE:U/R=)JDPG%R0I$SQ#S/?,(<)L2<),A1W,;C3+97Q?<H+#+Z5F
M*7EK'+""N\-:\975G)V>71?1XNGS"9C7:2*QT%6J;@USK>0!I;0D-`Q`-*=9
MISX\:<*J@N6$N#@0"XG`D9]7FITCS+*!>..JMRX5WCB4VE:13G-TXNW#CPG.
MT/'R-.QQ5WMNQ7*8[/-T_%4;,+HUFF0[R3%RQ@49`_PK-,C8KDPE[HY3X]4)
MC&&'`?9^E8S7TE$F)HZN?3S5&8SXDOL><B\(9X/?&4JWQ!P+CN%J]7)7W+1:
MP/V%_P`<7;_,-.4-*KI,(]0E",V^[3(JJ@9T!_B-B"4T#+72_43F#PRKAS4L
MEQK9HI3$'/E518Q#Y;^7:$_XQ8>MF>,=V7AAPOS[)\A<"TN$Q?8X3D%/33)?
M)#O%%!RUD-[>I.B.:EB%WE!Z<KV'@VLC8BQ[`KH&W2Y,XC^4<26'"/&AZQ3G
MU<`,,.-9OG`*2`?O,*^8UY<<?2>BE>X3\NV3Q%4O+CK"V6HV>/P+R[R)RA)/
M$:@]CR9/1SM3\^55M"1R"D\Z-5E:R;-::RBZQGI718XQ2D3%8ID[F6I:0:\>
M701SZ5#)<!^H4S`&?(@_8I1\1^/3GC!0K[2WEK;712Z\FN3?(0DBTB%H0D<U
MY"YLMN76U4.V</9(SEU5$+.#!1X!BD=J(BJ5),I@3">.(M#OUJ^TG@>GH44D
MFL@TR`'H`'V+%[QW\GRXX:S=QGR;.W_C#,DXQY]RQF17*U;XY3\;R^Y.(9/H
M&8J47_B.S[.Y'FE9&Q0Y\J).'!&;-6-D%8TBA2-`*@W1QF6KQ)J/`G'#B#TX
MY\<>H+)DNFNC+&@XM`SP%".'FX>LK(-R9XYY<OV9.-W)7COD/&U$S5QW:9AI
M:3#,M)M%ZQC=\6YYCJ6WO,+)L*5;*9:8>S0DYCJ%E(EZV>"D<S99JX3[3CNI
M37,+Y:%O#RXTY>5<(8)6QU:\5:?:*T]JB-C+RW^0?'N!XY7G"W(;#TOR:P0_
MYIQ=AL64<-W#_)'+..^;/(!7D/<8!U2:ADIK=J'.T:\1L0XB7C29?I*D:.6S
MA,Z3DBB$3K>70-)]X5Z\37B:>73A*+B-SB'M_=FG'D*#)7?XU>7B[X^9-XK9
M/=Y>2O4[@RC\X$,HN%*::NFRSESG3FK'.=\B7J`9MYV19T.K0%PJ#Y!A#'&1
M5!@[;$,Z,H@JHM=\LXM#">#L:<R#SZ/+,VFX!K0<6\?R@CER5FL5^6UR`XN-
ML(77B_R!PZEFW&V*<[X'O+W-N([K9L67S&F7^2UGY-567BX*EY&K%MK%[Q/;
M[(JBD)I!U'SK5=PDN1L(H*I1FT>WWFXN)-<LCASY=-<>!Q$OS@?[KQ[H`IUC
M'ES]F-16M[.*'ETL.*>2,#7"!RFZN$7AWAA>.+<NWFJXG%S=ZN^2N0<!R'N>
M75G3&34B:^PE;8SD03A4T5@:D?$*1R8B/VY8K7LI`^M:#ET`'IX<E%-=&9FB
ME,?5C]_J5Q..]5OEMY3<N^3]UIMAQ_7;,RQ-Q@PA7[=&*PEHL6,>.S_)-BL>
M7)&%<#\9%0F2\KY=F"5]-P5-PX@8=J^,F0CY,H7Q![Y72.^'(>8G[S7S*.0M
M$;6-SS/6:?=]BHS/OEZP?(J[<W)FXY$>1%4YD\/,+\5SQL!!E&R8YDL/6K.%
MNC\E-)-\^4BY]127RTS60C5&R)`-$&*JJ<CC9.V2V[0G',?Y7^5_*KH[@Q-`
M:,CZ1[I_Y*L)E3RX^1_*:L\C7_*CD7AM]EO*?"BX\',7S.%,-W*IX^I-0R%;
MX.^9"RK=*_<,D6FPV>\W>S5&&$8UB^81<.SCQ10.N=PHL$7RTCZN<:.H1PQP
MISZN/#'FI1<Q,+0QON@@Y\1YNOTX4H`LRK$1:?`=8BL+,C,AC;B`JBU(D0QO
M'J$O<%/?QWVWUG.9J8695!"PP:.!Z5AQXS>6_GG%(\/L>9@SWA^]X`X+Y"R1
MF3#L'CG$MTIN3KSE&\,,N0-;=95LMFR/:ZXA6<;P6:YH44(9@W6F7_PRJXMT
MD#(K84=M('4=_#K7'JIP/+[^@Y<ERQS3I;1Y%":\*UZLU=*F>7A*5/B+Y?7%
M]3+,:_><'LX<=,P/[J6H/4&F2$,#6*R3J]?80AIY5Q65K*2?*DDX5<O"M12$
M3$4`P``VA,8;7U<P!SZ/6JB\I*9`,^GI)^U6KI7EM9[J4[QVQRER%Q$IQ1XJ
M<X;!S'Q-5?\`)VWCG6996R=S;:EL3WC()\E!2$F%/GLY21&$LR@1<R+)!`'2
M:2B9S+4=:O=5E?W=33S@]/M\W%5;=,:1)I_>T%<>5.CH]?52).#>._)^*Y*\
M*>-U6@<K&XA<#^86<<W0]CRMQ5<X=6A<>.J)R-KE0@3Y_?9PM5<SZY4LN:$V
M-9_=:IQJCR"$9":4:KMP25B[+4XPL/%U>C`@<<?1^F4RM9^_<*NHWCG0AW+#
MCF3T+(/@7R[)/"UIX8V-?+,;82\3LE>8/?WK1"H/(TUZ2YQWBVW"/BF:RL\[
M"!4QL2S@W<*J%<EDS(B<A6X&`H3FU+B#7GP_6)Y]*QC<U:YM,Z<>@#ET*)M^
MXN9?X,2V",R8,GLEY%R_!Y$\P1A*N\><.K-R;ISO$G-'D:WY1.:C;:#5\XXH
MME1M])M;*+;P-B)*J0S]RR>)R*#9LX3,E9,SLR-1H#JX9U-:8'[J>?"6*02U
M%,1I.?Y109@^C&OFQGMY96#\J\>O+]X[X<RX@G7LPP5+N4K<62J42^/6K5D?
M(=ZR.5A+-(.1?0"\I`C<DDI!JR>N&172*J*+A1("JFGMF/;#0X$FOJ'EZUCW
M#VOF+F_#]R@%$>2Q)VR+Y,5W*%YX^8@J?(3C_8L-35(X1X:OV*<86[(,ID*F
MY-KO)')F'LBY6ON-E;Y2;)2B`RB89BS0=-)>4;O7[A%=)-&%MJXZ@[`4PP'I
M%"?7CUU60Z\`TE@-0<:GU?R88"@%%*;#?EWF1Q[R,QIR#Q_P,BZYR`PL^P;/
MJ<,N+<I@.PS\),MIIO.66YV6P7>VO5U#+R:3V)@V2:3*$D$3.".7!S$%.]EN
MYS2'@"I_*WU4)^_-1ON`'-,9=AS<2/+CRZ%:N5\I24F^)^(<97',-`S'RBQC
MR=D.8]OS5G##"-YQ#R#S=/P%GQ[:V&8L*C9FCEQ0YS$-@0KS4C*53?PQHE@\
M;*&.W[)Z?*N#*UK)6N(Z^!-.)]7+%\R.T)`I&12@S`PXTKPKZ>:O#C?@#9(%
M]Q2LLVKQ7Q9,<=N65^Y,35*XF\?Y3$.,;8RN'&C(''=C6"M9&XS,S)7-D%V)
M(O;-(;F>-6B;$C-%-))0+FP.(;JH*'D!P(K@:<1DK7S-.L-J0YM,37B#QQHK
M7W;RMY(W)G-69*%%<&+K3.1N7JUFZ])<K^)*^;<OXONS*`I=8N:.(;NPO-9B
MY:KVMC1FK^.CIYL8E=FEUW"1W2)P;%M-LYLGN@&.O('@!Q->'#KZ!>+D&.C]
M6L"F!(XD]7'&JY$CY;^?1G66/('D)B..XHU_S%(#S$Z[5I3#]PE<\%LBF>C\
MB;MAI]?TLEL:06H.,AR<DO%S`0BTF5LZ2:N$Q*@99:@MI!-J)]W57UU/&N?D
M<U4W$>C!IUEM,^%*#ARY4Q\U,QIAW$1]HB/SCK/6"O%+_&D8O"2P!P7S4FW$
M3TW,>5\6O792B/0AD6E05KC4%#`'V2&7QLY$NX[=0^W6KW$8@TP'VU^X+:;:
M15S>)'L_E7Y\^M6MJFB)HB:(FB*X5%R1/T9RD#1=5Q$"N"KB+,H(%*(B'<68
MG-N#5P8/3Z4U/Y0#Z0Q;FTBN6^^!KI@?O\NI9-O=2VY]TG17$+(90LA,;7')
M2<2Z(IU`4CA(H])@4V`3).6XFZD'28>DOS"(;#KD;JR?;O+'8`^6!Y+HH+AM
MRT.;GDKW1\TY,1+^4/H*<#"!0V`?#8VYRAX?H[CK7/>1AQI[%DMC:7=2J%!X
MZ*J0SDXGZQV*0P]1"B.P%'IV]`>KWZU\LAD=5N84K6:0KO1)R?#),RF*<Q3)
M@/3X&ZE"E,;T[B8=QW'6KF>835F?D?Y%GL:'MZ*##[:*4%`D0@FI#D/W.Z8H
MG,81`#`0?$H;>(B&X[:RK*Y:*F0TJ<?0M=<1%QJP54TL>W(@10*BY[0+G+T(
MF/X@0!$H;#N/5U&-\VMI#>R,I0^[7#I6"Z!E*<5)RAW?LE736,':$Q1^V/K`
M1`?'?T^CQ]FMU;;@'_&:%:^6UH<,U>!C;&CHQRF,4"'W`!*;<1V\2^'HWULF
MO8_(YK%,<C<2,%Q)B5;'3,9NX*5<``.HP;!T#ON4P[^L=2ZG4S]*C`]ZA&*M
M99)0A-U$U0ZC`!3`F?[!OL_:$OC[=8=Y22A%*^U9=N'"M>*C[8IT`555>O0;
MM$QWW,?8QP#](H^H0VUHI(XF$O=@`,1S6:TO)TA8V.7G-NDXGB7$(PD6ZTB<
M#E;,&ABJ+J*](AN*:9NL=S>/CZ/7JD-E=;L_LX1IMAF<@IWRPV;-4A_>'AQ/
MES7FMRSEFUY?M+NR69ZJJ!E5/N]AUF%LP;F,/24A-Q**QB_I&]/J#PUW=A86
M^WP""`4YGB2N=N;F6ZD[20]0Y*U^LU8Z:(M(F`/P^S1%PS&$PCX_-Z-O].B+
MBJCZ?F^O15"X0^D?PZHKQDOFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+]Y;75+
MDE'GEAR/JW$3CME+DE=:U:KC6,4Q$3+RM6HR<2M;YT)FTP%291]?2G9*'AU9
M%21L*(E*X=()F*`AU@.VH9I1"S4>?Z>CDI8HC*_0*!0]MOFETK#[#/+#DE@/
M*V`,H86:8.F(+$MFMV%['+9C@.2]]G,5X2?TF]5W(2N+H-U-Y*K3Z'G$YR8C
MVM9.U.Z=.CL@!P,`NB&DN&.%.HX#CCYL^@8J8VI+@&D$'/H(%3P\LL\%1,7Y
MQ>)5L>W2Q26$LH2>2\><B^/G&RS85P_=<)Y[G)&T\H"IJ8;L6/K_`(YR$ZQE
M>("P%[R*Z(23*0CWK-P@Y02!,%#V"]&GWA[W53B.9PS5YL7UP(T^G@3P'0NY
MMOF2*XA5Y7W_`#5B?,](CN-G#OC[R0MO&9]`X=DLB5-?*&5<[T!6/89)I^4K
M%5[G;;&GCAJJ:.^(1B(YN5`Z+]=9TY2:W&XT5<[.@ZOQ=)Y>7"UML9``PC,X
MXX_".73Y<;2\S/,CRK2>.O,:$C,.Y:XH<J,#43CMF:D0-J?8;R9)WS#.6^1U
M<Q82T4YU4;%=:,%A<.8B9KTI"22I'$6^<MS%7.FJFZ)')=/TD#!U>7"AZ^6?
MG&"OBM6EP-0Z.F..1PZN8^W%2`LWFCT;%L9R>_XB,"Y6X_WWC:&!Y#_*RQ6K
M#EJF,GPO*>W3^/\`CX>F7&KY!=8VAY6W7VL/HB30FIABUKRK51RZ>&8E%UJ1
MET>S)<*D4QP%:X5SYCAAU#%6/MJO`81I->9I3$@X<`>5?/@J`BO.+Q*ICO)-
MEFL)9-=Y'Q/G3C7@BU89Q#>,)9_FIB8Y9S:4%A:QXZOF,\@OL;W:,FY`'3=T
MR^\&4FQ>L%T%D"AVE5:-O?=Q'O=5.('$X9^W!7.LG!V!&GKZ">71ZPM7)7S;
M(_B%6ZM=>1?%RVXAKK^D%OET@+[R?X8069ZG&(V>9@)B/JF%"YP?6K-$Q`1D
M6E*K)UE5VDZ;/$V[)1T^(LV)5]TYA;6E"*G^4.(]OGR5L=KVH):02#09_=7R
MQ4CN.^:;[D'FEYA>,IJT'F\9X:-PU7Q'"#&QK-&ML\L8%D;M<E$'C>/:S$@%
MBG4DW9@?++F0$.A+M$W)JL,KWSN:3[N/+@:*DT360L=2CSGZ*JU7(;S.XO`E
MTY20#?BYG+*%*X3PF*KKR>RQ4K#A^'JM$Q[E.E!?T['7(.VWN)NN0)>IUHJS
MN1B6$>506[8YDEC*&115H^[TO+0,`<<.5:\>C/[4CM2]H<2!JRZ^'#U?8"J7
MY"^<+@#CYEG(M!D:E,6^E8*L./*OR"RG&9/P?6%,<S&2HVIST>C5L/7?($#F
M3,J%0K-ZB).QJUZ(6+'MG@IM_C7;=RV1K)=Z'Z:8#/\`E!P]?IP%8[1SX]=1
M4Y#R\N>"J>^>9ZRJ$YR^0@>'?*7)%"X.S][@<]YAJ1,0-\?Q[C'^+J9E^63J
M3>?R5%WFZ2AZ9;P6,SCX=8S0S8`<'2^);]5/FZU+1[H%>'('+5TJAM:$-+FZ
MG'#/F1R54YO\SWC[A&1R@W=1UGO,/C+'7&RVC;*G)T9E5K?>>7UPEJKQXPS7
MYZX6FM0S"XW6/B@L#N0E'+""A*ZY1?/7::9]7.NV"NG'#UUIS&1]HQIBJ-M)
M7`%V'IY5X#E["K"_^-#AM"BS[R0Q7*M<RP'(3&O&M3$S3.W'"9H[F[Y@QQ9,
MLXYL9N4,;D97`D909ZE4Z5*9R[DD91*:8FB@CU'BK<BM@O#V>JGO5IE]E:^7
M560V;NTTU&FE<_3[>I91\0WJUY*QI`7>T8JL&)[3,MI-5;&D];*!=))HHS>O
M&L:HRNF.+%9J'/Q%H;MTGD<\:O1*9HZ3%<B"H*)$RF/+H];L#3'A]JQ7LTR%
M@QQ6.J-\XOC(\KE-L;ZL91A$;;PDRSS;<M9&,@=ZG#X="U&LF"[(_0FE(Y#.
M<@ECNU*L(Y-0[5=&L/U.\!2%$V/\X.(/PUR_3PQ]!Q4YM'@YMSIG^CJ](5H>
M6WF39FP_C[F)<L0T&P6"^80HGEKW"-Q'=:MCJ+9XW;<PKO)PMJ++6U7)$>XO
MDT+%D:-<M3ILTH65%LJU.]:F=J(1.N'Z26UU5`]9%/BPR]6.:D9;-JUKR*$$
MU'4#RZ?*BJ"_\[>5&/>8MNK1.)N:KE5(+R[*KR,L_&*(O7&AI8<4V>.Y$YLJ
MMPMT_DQS?1K-CGK!CVFL$HJ'A9>70=*)]!B-%"N'`'7,C7`\V@Y#&M>%:^OA
MR56V\1:X<0XBM3A0#HQIED*UPX!7?LOFA5=ZPCYSCUQPSCRBKL5Q;Q5S+RY*
M8_D,8TY?$F",UUN<N6-@7B<DW.N/+]EFR5&JRTFE587O.`:1X]3@JKAJDO*Z
M[R+![M`3U'SX5X5^ZL3+4FH>0#4@=)%*\.%?MR!5>.?,DP6I1>6^2ZU#7.X4
M;B/Q7Q+R^FY^'1B&Z.3\5YHQ!>LUTM/'R$G(M'*,VM4:(L54DH5DD1P[1`#B
M4%#%N%TUS7.%<&URY5Z<<L,E:ZV>QS6DBKC3JRS]/M5$8DYJYSR1YA&;>-2'
M'>>?\?Z?A'B5DZO98:67%,:M229WJ^7[%+6.\1;[();I9H2PR5+:PL6QB8A9
M_'/8UXX=$!FY:KFI',]\Q`Q9_+S=S%*TQ]"ND@;'"'.-)#P]%.'(USXKO\\\
MM\^XO\P?BKQ?QYQYF,P8PS/@3-^2[K*0-FQ97)Z-E\?9*PC4DIN/?7[(%550
MK>.8*_N'4XR(V7>R_P![,0C`74:/$R)Y9&2`-^&AQI6F7"HKGY8JV*.-T+GO
M-""/8>@\O5P4:.(/F.93>-*'7N1&(LJ3]4RYS_Y;</Z'RM^\</,J.>Z5GD3R
M!A<)4,^.(&?9Y*_=-M1,9I5X+&M#)!][M`*X*L"AGIHVW18XA_P5=PY$^5*>
MVJF=:M=A%371N%>8'VFN=/0KG8=\W_`N:,YXQQ77JA+M*%G?(U\Q'@K,QLI8
M,G!OU]H#"ZR;A.<P?6\@RF<\8U"YM<<S(UV9G89ND_\`AD1<),BOF8K7MNP9
M*'X.?Z:XY<E8ZT>V+7^(9CRZ_N4J^3/+)3CW>./>*JYA#)&>LI<FYO*-=QE4
M<?S>/*PV0DL4T`^19]Y<;/DFTU>%KU>-")&`79#.E4SEV*W5,8A#233]F[0/
MB(^_I'++CP4<4!D!=4!H/W??]ZB=,>;QBAGC'"UAC<36H<SYHMW(2B(<?[WE
M3!6('N/[)Q0O:N,^007W,&1K[#8D0B*A>Q:QL:O'/Y!>P+2#<S1OV@<J-HW7
M1:P&GOFO#D:'"OV\L\:2,M2Z0MJ-(ICUBHX+N:IYJU,S)7,./>,7'G+W(:ZY
M.Q-?,XVW'4':L.4=YA3&V,,F3&%KJ[OEUN5\:X_F+(?+=:E8.#804A))3QXI
MT\1<IL"`Y-0W=0`T>\>CV8C[<CP%4^5(+M9`:/Y>7E4#,T73Y2\VFDX[XT\<
M.6#/"SF1Q-R+P>SSQ&C?^2_%3`=J@(-Y!L+(G1HJN9CRE6G63,EC#/14*Q@1
M79"H0J1GA5%4@/1]V0&D#`]'0#^;#/CZ55EH7.<TD:F]?,CECEP6O&WF%92S
M!SBJ&)<78#LMWXJY,X*<;^656RFG+8OK,]5HO.UNO:(Y%M\-9LAL+4ZJ<?!0
M[2+/`1\8[FTI=DZ6*FHT605&X3O=,`!1C@/74\^0KE7@50V[&PN<7#M&DCT4
MPRZ>KC7!5!QJ\R/'=OQ3@:8RR]MS!3)?`FS<Y4LSVRIU*@UFY4O%LNW89EB@
MJ59M=I:U>]X_B)J)F'T:W=/&/W9)IJ(.E#)+E3I'=-`HZI;08TZ!TXYCTI):
MOU$MI\5*5Z^@<CZ.I6FR7YV&&\:P<?./L(Y!54KO'O%_)K/]7L&5..V-[Y@G
M'>7:N_OE5KA*7D3*%=G,S9>;8_C%IJ1K=33>G9-A1;BX,_<MVBEIO<B!AQP_
M3AQYJX63S4$BO#IRQZL5E.OF4VM7PM8,TU.#-DB,CJ`ED2O0S.TTZ@DMD([C
M&LU'J_OEDV:JM(J+)Q$NRN57LR^9M&J!3&5,`ATCE.EI'VC,<_5YQR6*V,F0
M,=@:K%G7O.VP!*8JSK>9.AN4KA@;)/'K%<Y3J3GCC?E2@6"R\II=Y`8:?L.2
MM-R2O@NLU=Q,13Y"P/;!)Q0UPS,PN$C]YKW\9MZ"PDCWAT8<N?VCV5RG63@\
M-!%#Z<,^'EZ5(.Q\_K;4JWQR)-<.<NN\N\I<I9!Q1BC$E1RSQRN#.4?4'%=D
MRZ>]'R]%9,#&G^64S6:L[`K_`.*"1:JHG*HP$P%(I7YIU`*>^>CH)RK7AUE6
M?+#4:.;I'W@9TIQSR5K)WS><61%+QX5/$-K:\@[SDC/N)ICCA?<KX'Q*^QG<
M^+LU#P.<?W[S-D&_1&(`K\'(VB%+#.HU_(+V,LXS.T;]OXH[6AO/<!`][J^R
MOV\1YKFVA+R"1H^_+A[>2J"H>:?5<VU["Y^*?'3+O)#)>6\7WG,<QBJ%M^&L
M?N,0T7&F4)7"-P5R'D.[7QMCAU/+YAK\E`032$?RB4\K'.'B*Z<>G\4-WS1<
M`&#WST>S$>0/`55/E2TDR$!@X^0\J@9FBM<S\S_*U(SAYAA,X<5\FUOC-PSQ
M9AW+4A<8F0PV\N^/86T\=)#,-A@KS5H_+$A/V^RVRQ-/NV+)$ME&4.=)0TDY
M0:A\3JQMTX2NU?!0\.0ZSEETJXVK3$TM/[PFF?Z//T##%3YXI<CK3R6J,K<Y
MO!TAB."(,(YI\ZEFO`^=ZCD*)FFCIVHZKMOP1>+E%-)&O]A-.1:/`0Z#ND3-
ME720F4+D02NE!+AZJ?:5!/$(G``U\O+[5*C60H%YVOXIO$)LH^3IF2P-F?QD
MA@[*&%<PMND@&4;LV]O+CJ=<$'83%(C"Y%6.?;^23Q\-8%^TF*O`>W#[*K.L
M'!LX'$@CU+\K36E6[31$T1-$31$T1593+G,4>:;S$4J)BE,4KY@<Y@:R+;?[
M:*Q0'8J@%$134#[29O$/#<!@N+>.YC,4@PY\BIH)Y+>021^C@5D_QQD"!N,.
MVFF"YW+7<B<@BF0A'T8OTAUI/&WB'<('I,'@</M`(AKBKRT?;7&B84:<B*8]
M2ZJ"Y;<Q:X:%W$'@KR)ND7`@=N'6F/3V3`;K$Y>G[/6.Q=S?@#6GFB;J/9X-
MZ?Y/2LV.I:-=*JX-><+@JFX4.")6YA'J.80$QNK<`+X;;](ZU\]J7L<^M6\5
M/%*6N`*D%5YU)-D<%"%4V$W00R@E`2*#N02;;@(AZ]<[-VD3M53V:F>P5',C
M^57FKMM%`B2769,$RAN4#!X>`?H[[;%W'6SL[UKVC&A`6#-"X$\ZJ0U*R.FB
M@9-5<I@%P4W4(B)NWT%W*(;_`&=A`?QZVD4[)`:$:B5B/A(I49<%=DF16:*?
M=3>G3,;82@10/'?T`/LWWU4W,\/O,=B.2=DQV85.S.75629Q(]3<B8-P#<0,
M3WF*'MWU8[?)8L#6O2JC;VOQ&`4?KMR.:0;1[(R\HUC8]HF*B[IT[3;H(E#Q
M$3'5,4A?].K6;M=W$@AA:YTAR`%5>;."(:WFC1SP"Q'<C?,TB'["1@<;.'$Q
M(F%9NG(IIG1C4AVZ.Z5R?;NDW_4`1';P]NNKLM@OKEP?N)#(L#IK5W5T+5S;
ME:P-+;4:GUSX?I6%RT6F=N4T\L%CD%Y*3?*&4566.82D`1W!)$@F$$DB^H`_
M'N.NTAABMXQ%"`U@6ADD?,\R2&KRJ?U(K$T1:3&`/P^SZ]$6SHBXPB`>G1*+
MBJ"`[[>W174]BXFJ*Y-$31$T1-$31$T1-$31$T1-$31$T1-$7[RVNJ7)*!GF
M?X4R=R,X$<C\)88B33>4L@5VFQU-CR/()@<TC%Y3H=B<O".;,]CZ_P!<3%PS
MAV";M8B2XH=H>H3@4<6ZC?)&`S.O5P*R;:1D<NI_PT5F[MY7O^=C/-MGY'\E
M+/E3D%E!?C^2CYMK&)Z#CN+P<QXJY$F\MX/:T;$3U>]5:Q$0R799*5LP3[A^
MC9"/CM!29M2I)IQLMG=F=1H\@4QK2F(Q/(]?L5[KH!X+`-`)X4K7`Y4X>1S5
M=M>!EOLE1IE?S1R$AKI)T3E/QYY/U]UB_C5C+`%79O>/%@+98JE#5:K+STE(
MH722ZCR4G(2[Y=OU=+-%!,!3$VU?@7G(\R>7/'AE[%5UT""&MI4$>T<*#CR5
MK/,8X)W#,^)?,*N^%G<M:LY<JN(N$^.-8QT8:U$Q3)QA+)>0+M"SD?/V&181
MQI*4#*CT5TGYT6A"QR0`8PJF+I<6[G5+,:_<[[7);7#8Z-?\./M:?^2N\O'E
ME2.;87D4]Y(\F[#EK+N?J5A/$B&3*_B6HXPA,98<P1F-'.5=I=/QS%SLXU>2
MENOIW3NP2[Z254=J+)`W0:(-4T!H+1Q%7GWZCB3ZSCQZ>&2J+L-=^[%&8UP&
M-:<L.`]>:N+R4\N?'/)J\\B;_:,@6^LSV=J)Q0KT&Z@(>L/U<27KAOE?(V9L
M19/KZ%E93$+:GO[YY!$)&(EF*L:\8-!;*`8CE02W_*^Z6@X4'I!)Y88E1MN2
MVAIC5Q/]*@/L76(<"KE::)"U'-7(B$NKVN<E^,_(^!>8MXS8PX_UR.>\:+['
M9!BZJ>LU68GY*8_?V7CP+*24A+.CM2#LQ;MR]1#VMMG@@N.1'$GB#QQX9>Q7
M.N6G)M*M(]((X4''E56PY4>523DAD+EK;(/D8^Q17>;>(:OB7.T07`^,<FWM
MO'TZBR&/(@,498N;HDSC>KRD`]`\I#%9/B*ON\[8N(YTY56TEM7.>YS3@X<R
M/8*>FOI2*Z[-C6$5TFOEQ]!'G4W,0\:8'$&:>1F:HRSRTS*<C&>`&<U!/F+-
MM'UDN`,8K8QB#Q;M!4[E\:QL5OBW(+%)V%0Z"=1?'4L4'9R%]<Z^LU4<LYE8
MUA&7V"@5E\M<`:=EJ'\QF'D<B6:'3\QK&=#QG=5V4-%N3XS84/#[W#S24JQ%
MW*99UW(1KT7JB;L42$7*!`$2COJ-UK5SG5SK3S^;[U<VXTA@I\)KZ%05B\NJ
M<89QR3E_"'(6.Q/%YSL5$NN9J9:^,^'<ZO7=]I=/J6/'MUQ+=K\9O(XOEKO2
M:/&-95N[:6*-*Z;_`!C1LV<**B<^V>9-;3@34XD>P4RYU5S+D!FAS0<"/-Y^
MGE12OPUQNJ^()SE/+%E'5Q8\K<_6+/%Q@)^-9$C(9:SXKQKB>4I+8J1UOO>`
M7A<;)*G4<%*HH9ZJF)>@I1&6.#1&8R:@_<!6GFJH9)=;FN`I0?:3SKQ4(:CY
M0N%Z=Q$M/%5CD_(KZ1D\UT;/5-SG-1]6L.0:!<\'NZ4SXT1J$-96,W5+;3<&
MX_QK`U5O$RJ"S.6A6K@BY$SNSF)$+2C""??X'EZN@<\E,;MQD#J>YQ'/.O'F
M3Z5<)]PESQ,X=LF-Y[E/B*9E[/=X2P2Z+SR_L`+8+FJ=$5^0B5\>6G`[JP.U
M[,WEIAZG,J2R]G+(MG[1)-L*+,RS92GRTACT$BM>9R]OK5?FF]H)`W(4X<^J
MGJ4B.&7%VM\+^/E.P!4+&^L\95IR]VE287@H6H199O(UZG\A3L;3*)64TZUC
MG'L+,V-9K`UV.`S.&BTD6Y#J"0RAIXHNSCT.Q]GECR6/+(9'Z_+!0DL?DV<?
M[+CO+F.W-[OS=EE?FDGR\/)MDHXCVH0*\I-*3_&NO$*J1,N&['6;Y<(ARD<0
M5%"W/E!(8W248/E,ZG\5?,<_MPZ3CBIVW3A3`?#3+C3/V>@<E>WD'Y>-+Y!.
M>;K^2R7;*E(\T:!QCJ#MY"0L&]_RJG.*%@LMPQK;Z^WDCG;68SFV3B#E_'O2
MI(*H,NP!P!8QRU-K[KFU..77CGATJUMR6EIH/=KZ#0>P*LZOQ#GQR?<,X99S
M6ODK+>1.'C;B'>)R#QM$8WK$A&-,D9.R$A?H:I-;+:#PDH0,DF8?=YGSI$Q&
M!%C+BHJ<I0M2:%QR`]5>?7]BH;C`@#-Q/II]W)1G0\K.P42HU^H\>>7U[P:C
M,<.L'<),^RB.)J%D"1R]C;C_`$Z;H5!R#51L4BU1P_FEC4;9+QX2J(3<9\.[
M2%2.56:(K:M=:N(`:0/=`.)&7M\^'0I&W0!)<T'WB1T5S^SIZ5Q\J>4VRL$1
ME_'N">2MOXYX4Y!\/\6<,<QXWCL74?*,G*8XP?CZYXLQA*4:\W-^W>4:90H%
MW<1<UU,I'[R0234;'CW8?$@=9N&$9P+:9D<^O#'C7#IQ1MV*@R-!<#7V>O"O
M#T&BD[6.($_C[E2WY'XYS>\K]?M.$,+8.SEB.9QM!6AIDZ(X^-LB(XNL-8O2
MD]%S6+9EJIDM[]Z$2:R[>0111(4K<X&5&1MNYDFII]W&N?2?/GQ4;[CM(]#A
MCP/F`]@7?9TXP6G)7(#CGR7QCFI?#>2\!PN3L?O2/,<0F3ZQD3$.9)?&LY?Z
M8^B)6>K3FLV%62Q3%J1DZU<K&8B*P*-')#@4+IH#(X.'#/$CERZ@K8I1&US2
M*@^T5YUY_P`BMK!^7I2H''.%,;MLC6A:/PGSZN'/J(D58:*!W-VVX9;S+EQQ
MCJ12*Y%)M6V,AF5RR(^3$SHZ#%(XI@=0X!8^UUM`)IB[T$D\E(VY+).T`QT@
M><`=/0J7XT>7E.<5KE6([&_(&-4XW46U76QTG#$OQJP^YR;#Q-Q>6*81QL\Y
M-@;]])+'M1GK*HO%B6*;V`K5NW9N)5=N0X*4CMWLDJ#[G6?9EY9E)+D21Z2T
M:CQP_E]=.A2NR3Q\A<E9[XM9[?6.4BYCBS+9HEH"O-&31>-MJF:,8*XPDT9A
MXLJ1U'$@V"HNT!0*<55@Z#])?'4LD':2!]<OLK]ZB;*6Q.CY^7V*#LSY5<&R
M"D6O%V;W%-S)CK-/,7*5<O%XPS0\RTB6JG-K+JF9,JXAO&)K._C&D[78FT-8
MQ2'E&,M$R[1>+(IW13<.6ZD3[9Q%6G&IX\R3F,>6'1GSF;=!IQ:"*#U"G&HY
M\./52T_)CB]RGQG.8AR%QQ>9_P`HY^/QWR+QURSE/!U0X+XTI-VILE?G&1Z5
M5KCB[-E@J]:Q.G`VJR/AA++565C<1<<9V2192;E=,YXW6[Q0G47#D1[2:T\Q
MXYJ]EPPEP.D,)X@^J@/+HX4HM..?**MM6QOQ<19\BH['64\9>7GBW@9F.00P
MEC[.#*1K5,9RDE)3F#I_)/P+C%%G6L=JDT'<E\#),YQBDR.YCBKM$3DK\J\A
MI!H=(!S&75GY^JF"I\TT%PTU:YY/#R]&/2I,XJ\O>1P3D3C%>\1<@I>!9X/X
M>8@X/Y0K%DQA7K:VSIAG"4@[F:6_:2I[#$OL37K[VEY$73YJ$NW5;/.V#8%$
M4UPD^7<'L<#\(`]`IPSXY\U&;@%KVD?$XGT_R#)45;_*6P_>.(O#OB-.Y)OB
M<#Q!4@(5A?8=E$Q5GREBQ6$D:EE[#=R;)JJM6=#SO2Y'[LGD6ZASE30143W.
MF&K39C2!^+"O52E/(*HNB)'/X&M.O,'K"KC-?E_S-RY`Y!Y$X,SI"8+M6::A
MC^HYEA+7QKQ-R+KLTMBMA*05`OF/$,B.(MSC3($+598T6L?KEH-^U:M#.(LZ
MK<#G/M"#6(T\Y'LS/7AT*L=UI;I>*TZLO+E3K5_N6_%F`Y<<9+AQJLMMDZNQ
MLR6/7;:W-*_7;"5M8L7W2J9!K#NQ466:I5"Y5.1LE.;$FJ\Y22C92-579B"2
M9RF)D2Q&2(QUQ\CY8*"*3LI1(!DHH0'ER9(@C<C[:7EA$/\`+/)>`X\U6W2C
MWB+A1UA&-IW'X^2DVN/6_'I[)/867H%V8Y*73?)/)@\TW5;)J(R8`)4D\<6T
MFD@G$TXGA7C2OKXT61\TW4UVGX:\N-/-PY=-*J-SSRO,QX/?\'(#BSDV%@).
M@\S^4/)S+N6&N%<:Q&)\3.,S\7LB8[2B\=<66-NK4#`8OE[$]CXI*"AI-=ZV
M=2+F45==U198(OE96D:*5ZR/S>?B/3GF5)\VQ[7=H.&7/%OFX>CAD%?1QY44
M9&Q>++E2^0$BSY1T*_\`(C)5RSYD;"F-LK5?-E@Y83U;L^=(S(.")):"K4=5
MG\U28`]=;PDI&O*XC!MD2.W*9W0.)#:.#`&GWAYACGECRY9#IK&+OWB2T:#3
MU99U'/@<^JEQY3@CEJ.L>+LP8IY>KXUY*5##-BP!D7)X\:L33F.\NXQF\A/\
MH0T>[P+%R-.K-&F\:VZ2<'K;Z-D3"FW<KIR9),5U%!&UDP<'>^.D^W/R-:J@
MN6^\'-K&36F'EY<%VQ^$>6H/,F9<P8UYA6*F2/(G#6+J#FE&:P1BR^REBR?A
MG'4SCJCYJKKV67CJO6%'S&5*XGJPI!2$/)BCV4#,4U#ZK\J\.+@<2#QXG'@*
M?R5P5/F&EH86B@=4=7GQY\5V_";@A$</K)GF_GN=2M%YY#/\>N;DRQ3@NE<9
ML.QA,:1=@C(62K^&Z'*S\6G>;"%F<J3]@=/W+Z5[31+9%!HDGJ2W@,52:5/*
MOVJR><S4PR\O1YN:GYK*6.H?^8/A,.2'!'F+@DC?XE[D[C=EZNPB0$ZS?O.6
MFRDK4U$R[&W51L\:T.38!$#%#;QUCW+0Z(CCPZSA]JF@>62M=EBOQ3""82%$
MX;'Z0ZP$-A*?;[11`?$!`WAMZM<\NC6O1$T1-$31$T1-$564VZS]%ETIB!="
MDH`E*[9J"8S*0;@8#&;NT0,7J*.W@8-CD'Q`=0SP17$9CE%1ZQU*6&:2!XDC
M-#[>M3"H?*>$.Z21LL4>`/U]8.6RZSR*Z^H!V$O2#AL`C^L4Q0_6US]UL+G-
MK`[5T'/T\5N[?>&UI,W2>8Q'HS4S*EDRLVI#_NJ;CWI1,502-W22PIG$0$?!
M,0.41`/8.N8N]ON;8>\US12G05MX+F";X'`DJ],-9`(42"<3$((`AX='CON(
M;B.PE+[=<O=VS\*98U\N:VT$M6ECZ98*XK.WG3`HE\1`H=8B.W@```;;[[B`
M@(^_6J,!&#:@U_D4[H&$G$UZ>A=_'WQ=J.Y7`E*)A'[8@)=S>T1\?#?4S6RC
M%M0H'VX`+B12GD%1EWY7T?&IT4+;<XI@\<@!V['X@7+PR8#T]TS9L"QTDRC_
M`"C`'NUN;/:-VOP3;QO,?$G`>:OV+7SSV5L0)I&@\!F?0%'&]^8;B]BBH:'D
MYBTO-A`C:)9+((F/MN'4[?%03*3<=MPWUM;7N;NLSJW1;&SI-3Z`L6;>MOB'
M[O5([H!`]:Q;YRY#W3-\J!Y-9>*K34P_=];;NU%&_5O_`-KD3AT`^>&#T=0=
M!`_1#UZ]`VK9[7:HM,7O3'-Q&/4.07-WU_+>OJ?=B&31]O,JP&MLL!?=$31%
MH,;8/?\`+QT1;6B+:.?;T?C'_0&BJ/6N"8^V_P"715ZUQS&W^OY>C5%6BT:*
MJ:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(OWEM=4N24<.67(MAQ7PA-Y;<4^5R)
M.'M>-<9X\QU#2;""?Y`RQF?(=:Q5B^G_`+Q2B:\;68^9NEL:%?2:Z:R<>Q*L
MOVEC)E2/%+)V;:C%W+U?:%)%'VC]-:#$GJ`JL2O.#GAR^@\"\BL&,<45C!',
M*@9$X*5V;E,9<B',Y4G.`N:N?F>'8?).&<N3>#XZ>A;RK8X*8J;TDE54'%;5
M5&;9G?`@W06PI9Y'L+0.7H)IR'3P&2RHH8VR->35E'<.+17@2.G/HP64!U9;
M#Q2X7N;=>'E<:6S$.,7$U8U.1O*>8G*DPGBOCKN8[(O+FZT,+#,04<ZD?AD[
M`\K0OG"*:*)&1E1(0<ACC%`'&GI(&(Z1A]V*@<T23EK:TKP`/L-/0L=%0\Z-
M"=PMRUOA\(5.[W_BG9.)T4,!A[+MM>XOR]$\OLE1V,:"_IN1LPX-Q!9X21@9
MQ1X61(_K1HT_PZ1V[]1%<ZB%HN7!KC0$MIZ\N`]GM4IM1J8VI`=7,8B@KP)]
MJR`<:N3>2LI9DY)\=\XX;K&'LP<<V^&[2];T#*CS,%$MF.\\P]QDJ+,,+1*8
M]QC+1]GBI"@2T?,1ZL6*":R":S9RNBL`EO@F,I(I@../'K`Z?1Q44T/9`$&M
M:\N'42./-1`YR^;-&\(LM353G*S@2_4ZEML7R5YK<#R`N2O*:/@\B2\5$/)U
M#"E=P#;:%6&<$66!XR):[M7AGV2"BC<Z74EUVRW!C<1AATX^BGVA216W:M!!
M-3T"GIK]BO7DWS$6&-\:\\,C*8G=RZ?!_DYC/C:\B27))D;)#C(\=QK?IV]L
M]-6G(59*(#D4F46)DGXK?=)A[Y/B`!&GS8T:]/$#/F`>72J&VI((]6)!X<B1
M]BC6EYA')'#64/-AM6<<55:X\:>'&;JO2\;JT_*,>GE$C^X81P#(XHQ/7J2?
M$L+&SJF9+YE-L]>34S9BC67DRHQ`KUHQ(NI"V[?BXC"F`\S3R^T9TZ5,ZU95
MK`??Q!\Q<*XGHX#+'H5R[GYE>2<!K98QWRAXP1%3Y%U:AX,ON',:8:SBCE*D
MYT+R+S@QXTX_IS7)5IQOC%U0[57<Y2[&+L9WT,YCVL<[)),UGB8&0+(+IV.%
M<!Z\N`YCAZ<:1_*BHH[W:FM1RSR)Y'CP74W;S-LNX3IW-E3.?%2K(96X6M^'
MCJ0HN&>02U]K>64^8=Y4I=7:U2Z7?$6+E:W*UMPF(*I23#X=TXV*+AN@;O@%
MX:'W:D>7$!#:C4T!V#J^:@KP)S"IWE7YI&8^(=7B)/,6!>,5#R"6@Y#RE8>/
MMAYHV.S9O?TRES4LE&#CZO8CXN9%92SBPUR+!123F5(2NL9HYXX7ZQ$3O=5-
MR=`=0`TKQ%>H4R\_GXHVU:YY:"2*TJ`*><ZO+DH<<L.6W,[(V:>1.6N.Y9^!
MPQQL\J?%7./#42TY0/L0LD)O--&SY>&F2<RXCB\*7Z#SW,0[C'"46E2IF7)7
MF[>(!R"ZBLJ<K/&DF<]_:-R#<,\\>OESIASRGCACC:&28N<ZG#]7F1P/#'S#
M'.GQ,R%FS(G&S&N1>0-"K-/R).T&LV5S#X[OBV44+1%OJ/`SK2SD>J8_Q@E%
MV:W.7;A0\$@P.W8+"1))VN0P&+G0R.=%K=B?T]0RYK"F8UDFEF6'EF?+@L9>
M./.2D+UQMY,<I3XCP&M4N/O'ZW9SD,,T[ER6Q<IJ1*5N1;M6>(^2^$I;"E9D
M\(7.2:"Y%TZ;KSK".?LSL]W`F(N,(NZ"KJ9$TKC4<#AAU$E3FT]X-!.+@*TP
MQXC'$*7')3S%:7Q?O>8ZK=<=6.=B\1<+Z?RW"1K,NQ4F[E*W[-DM@JGX;@X*
M09LV+.:G[BT9)I2SF0*U3,_`%42$2,H-TMUV;BRF/Z"?L_D5D5LZ5FH$#'[O
MO4;N7_(3G]2,:<?)>UX)I&'LBS'F#<(:37:GACE6ZNL-F*IY'M=G9WG#M_N$
MYB'&R]*;-U&+5I-G&.F(F0;K]QH*XI"B.//-*0TY`BO$\1T#)30PPZG--217
M.@I0'I/I4YN)?)6Z9Z><BZ'E?%T!B7,O%S-;;#.2J]2LA/,IX^EU9[&-"S#3
M+;1[O*4O'<W(14W2<BL@<-GT*R<LGZ*R0@H3H4-F12EY+7"CA^CH',<%BR1A
M@:YIJUPKRXD<SR4-<W^;%&8)Y;0O'V<KN`KE4)3D'AKCQ)K8WY`7*W<@J--Y
MMF:Q4ZW:LC8KC\`GQ11F43:K6V!]"2606\\$48KQ%%4YR-31NN2'`-TFI`SY
M^;UURQH5*RVU1ZJFNDG+##IK]BN#QL\Q>9Y(<H+_`((C*)@JF1>/,@YDQ_8J
M5:N30QG-2N-\1S$S7FN2;+Q+E,3Q>V-LBR<6BYBGD;:)`4H629OU3&!0Z)*L
MG+WZ<*5(SQZZ4X\#7'SJU]OHCUU.0.6&/`&N)'4KF<[>:+_B"RQE]RDXW/YK
M(CNV(M('.^=[SBJ?F?W99Q+DC/&E,Q=@?D!?\C/7)Y$Q7RZ,6V80Q01,X6-\
M00H232]G0"E3TT^PJR*+M*UK0<A7TU(HKH<:^6%<Y,<,\:\RZK1KDS@,CX9>
M9=:XT;(MY^]I+1,=+KRM'B$VP,F]AL"DM!N&,>)2MOCE#)"*:(J"0E&3A\7:
M`$G#[/O22$QR]F2.M8Z,=><U$SO&#+_+.[47CXI0L>T[&4M%T'"'+ACE'-5>
MR5F*[0&/Z%@KD=0+/B/&3G`-U&RV=JA*2*YY.,CSH/BAWOA0%:'YIP;JH#@,
MCE7`5P''A6O'(*<VGO:036IS&=,21B:BF-?O7<5'S>GLQ!Y'KCK!M)NN>(7*
MG&S#N':[@C.DA?,#9LNW*E_;8NC1C?.USQ%C=_2%\=.*!-.+JFYK3Q6-C6B+
MID1]\8@EH;IS0:@&E,:U&/F'3PPZ506NIS0":$',4(IT5XUPQ]"D%9>7/+6L
MVW$/'A?BAAUWR\S(?,5L@*JTY23)^/,9@O"3''7[SY@G,N#@0,A,W,M;,HQ=
M>CZX6EJ/C2`J.%5R,B=TUSIY&G21[U3SZ/U>D</O5K88W`O#OW8`Y5J:X4K3
MAS5NZ]YEF3,LO^,6/\#\6HB<S;R#9\RX>VTS*^>&^/:C@?)7!S(]-Q1F&K6>
MZ5G&>1'U[@EKI:%$HR1AHL%G;8C=<6J9%EOA+771#`2*5KSPIAR/$\CZ\+A:
M@N<-6`I3+'4*C,@<.?Z=&,O,PR+R*B..%=XW<9J_8\Z9CQ'E[-63Z)E?.1L=
M8^P?3\&9E=<=;LR/DFO8OR#*WZPV;-$>[C:T1I`-&[IBS5?O5&9"E2/1MVZ0
MAK1[V/JQY'V<\D?:B(%SW>YA2@K6M>D<N?I5V/+*R[?+SY77%#.&4Y.Z90R)
M+<;$+]='ZCA:VY`N\]'I6"1>LVSARHDO8[-)_``T:=9R"Y6%,NY0'POMI"("
MXU)!'L'WU5MPQHG+6T`QZLRHG8[\XV2N7%O.'+)?%7':;J.)<=4&^J8RQ+S"
M+?LZ4J9OE[K-/1Q1R/QI+80ITSA3(,&UL*B[LQ2RS'XZ/<L2',)2N#6?-D`$
M@&O(Y8'/#`X98E2_)U);5PIS&>66.6.?WJ5/*WS#V'%V;YJPSC$KZ\'X<</\
M4\LW*C2X-X-3(K?*.0LNT%&@,D5Z](DK;R*4Q09P$@HH[3<"_*F**0)"H>]U
MV&@'3P!SYAQ_Y/K4<5KV@KJIB1ER+1_RO4J=<<U^6CW)=6X^PG"6C0O(R:Q_
M>>0-BHM_Y8QK:E4/C96K/`4FH6.PY'H>';PF[S#DNY2KN.;5F.CGL7%C$.G#
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M`'+ACCZE"=7S,[1R>QOBM]1TS8CNV-?-WX1\7\M+XNNUTG\>Y)H>2WM4NKXE
M7L=WQOAJ^R=%N].N2#.2CIBM1QP<-E2!\2W%)<^/)</>0,B#_D]7/E]YG;;-
M8QSCB-.%<\G=?+FLD_//F,3A5C&B7TU3K,Y_F%EVNXC):\FWM_BC!.*#V"$L
MLZ7(.=\JQ=*R(]H%!2_=K[M0=$AW0.9F09-C&0*L98F9-*8Z4IB<SD/+[N:Q
M88^U<1C@*X8D]0XJ--AYI96F9CC@K765+-=<R\.O,`S-6:YAOD-2,L<7;C8,
M`AB-''L]_G"3"BUDM,?*?O>1U%OH]*+0B0=/6\E'2:A43-H'SG2UP^+'+'BT
M<17&N8ZP#@IV0#4YIQ`IGGB"3D<Q3+F*<U';&'FM9PHG#_R_9SD3C_!2?)'F
M3A^!OE(L]TY$NZ5B&QT&JX;QS=LAYSR_8JSQ\<OL7V2PV2_,63&E5VNV(H/7
MX=+Y-J@J<AMR\L;JIJ/,TX`\NGD?N.MV&1X87:&GECF13/'+,D+*YPUY,,^7
MW':EYX:TR0QZYL$G=ZS/T]])A/MX>T8[NT]0[$>N6DD9"I7*DR\G7SOH*9(S
M:%E(ATW<"@B8YDB9,4AD;4BA\A]GVK&EC[-Y96JD_J51IHBW43$*JF94@*)`
M<O=3,`&*HGN'<3,40$#%.3<!`?`0'5K@7-(&!(51@:K\5?S%\"+<7>>G,#`!
MVOP;+&/(;*$'7T0(*91J#JSOINE+D(/H3=5&59*E]0E.`AX#KFY`&R$#X:X=
M7#U+I8G:XVN.9`4,#&*4!,80*4/2(^`!JQ7K@*2!0'9,G6'ZQA$H#^`-M]*J
M[2N4@N5<G4`;"`[&+[!]P^L!T5"*+?T5$T1-$31$T1;K=PX:*E7:.%VBY1`2
MK-5E&ZI1#Q`041,0X"`^_0@.%#B%4$C$8%7:KV>LM5D$DV-SDG39(2=+26[<
MHATD]!-W13+E*(>`])PUKI]HVVXQDA9J/$"A]2RXMPO(<&2.IR./M4BH/G):
M&<8=M.4Z.E9$H?L7C.06CVYS`&P"X;'1<G#;^8?6AF[G63Y0^*1[&<J`^@X+
M:1]X;EK"V1C7.X&I'JQ5A[MR+RO>%W/Q5F=PT<N<W1$P1S,&Z2([@")G"8@\
M6`"^`B)PW]@:W=ILNW6;0(XVEX_$[$]?):VXW*\N2=;R&'@,%9)999PJ9=PL
MLX7/XG6<*J++'_IJJF,<WXQUM``!08!8.>:V]$31%\WV\1\`T1<<[I`@["H`
MC_-`3;?C`!#15H5N$724`1*<!``W'U"`>T0'80#14H5Q3.D>H?M[_@`1#YP#
M8=%6A6D[A("AL<!W]GB/S>D-$H5Q#K`(>`_B\=45U/0N,(B/IT55\T1-$31$
MT1-$31$T1-$31$T1-$31$T1-$31%^\MKJER2LOR%P!0^4&(K/A3(X6)"O65S
M6YAE.4V84KMWIERHUGA[S0+_`$:P)(.QA;E1;I76,I'.#(KHE<-2E6251,HD
M>*5C7L(<:#FI(WN8\.;FHI$\M?&$[`9.)EW,.>,YY,S'D+C/?<A9PO\`+8ZC
M<@2+7B)DJ'RM@S'D)$4+'%1QM4\<5ZVQCA=VQCX-%S(JRS]=9R+E<BJ43;9@
MK4G&G+@01D`.'(9E2&Y>2"```#SXBAS).73R4H>3O'ND\L,-6["F1)"S0<':
M).H61G9*2_8QEMJ%TQY=Z_DF@7*M.9>,G84TM4[Q5F#])"08OH]SV!1<MUD3
MG(,CX@Z,1U(`IZO+RR4;'F-^L9_>HG+^6/C*RL\^K98SGR-S1<N2Z_%AUE7(
M-[G\9,)Q97B!DYSEC$[6H0M&Q94J93896R.CIR3)K&BBX;&.*?9<**.#QLM6
M-:1^8CD,L>`IZE*ZZD<6N-/=K3,YBAS->I2^K."J95,_YNY(QCJ>/?L^U##-
M*NS)V]9JUEI$8++D$M-5KT>G'HOV3YT&2I#X\Z[IR1;H1[9$N@_<DBA;%\-<
MN/G^]1OE=(`'4P)]=/N4-\Y>5KC//$SR35?9UY+X^QERUFZ;<N0V&<93^,HV
MAWO(='KU,J,-=%YVQXIM.1X07U9Q[#-9&(9SB$*_^"*<[4!46!2%]M$Y]'&E
M3@,*X4RPKPX'K"ECN9(VT:,`*<<L<Z&G$YK>S3Y76,<Y6W/,P^SAR6H^.N2>
M0<79DS?@S'%DQW&8RN.7<1I8\9UJ_.GTYC"R9"BRR45BF";R\0UFT(62&/(L
MHV!7<PT=:Q@@%U&DBF7"F6'ERXHVYE&(`+@#CCD34UQIFJMR-Y=F)LHWOE1/
MV;(67R8UYH0<0CR!P!%2U-9XVL60:U2JM0*EF>LV`])<9;H>2:G7Z-"G9'B[
M&A&!(Q;9VHT.J0>JORC*$5-".CA0<JY"AH1Z<4%T_`D`N!)KCQJ>=,S7'V*T
MF2?+6C)G%?(9_8KSFSF=R.RCCW%U*JU\S?EVFX8N=:A\%9";Y7Q'`XUO^'L*
M,JIB65J.3"&M8SXU.8>RMA;HJ27Q#<H))VOMFM:75K@.C++(8\,*>G!5;<.<
M\<!4Y"N>>9KUX_:K3<??+3R/=*WS.>\V;G>G4UR_M?$]ZXC"9MK^9LE5V!X@
MS#>YTU[8LIQ6$\1XY+(6V]@H9:&K]0:1,;#I%3354>N'#@ML-L34R8`\A3[!
M3IP5TUS[S2S$M!Q/2*'B3U8J7O(7@%3\_P"4<G94;9TY!X1DL\8/C>._(&$P
MM-XYC8O,&+Z\M>EZG'2<C>L:WRRTJ7K?^94TB1_6GL0NZ;/13<"H)"'+(ZT8
M1I'PTIP//F.DY45C+J2/*E:D\1G2N1&&'&J[NM\`\"5UED2)/^^D[!Y3X58D
MX#W*%F)U@5F^P/AR!R76Z\9JI%0L:]8W26B<KRA)%\17L',5`R#=`2&Z[_E8
MPW2"?(D_:5:ZXD>0XTJ#7V#[`KO\?,'R&!L,P>&9#-.6,U-*S%EK==O>4AH#
M*_1%0804?6ZU6D'^,J-C^$<$JL3&D!L_78JR:[@QUW+A8XATWQQ:&:*FGF^P
M#/BHY)#(_60`?/\`:2HC*^5IBRZ*Y/D.0^;>0_*63R1QIR%Q!+9,MR.)H.R5
M#!N57T)*W.'CK!AW$N,GUIN,I)U6,<)SUC-,/FQX\@H=ON.>_%\N/A+OPD#+
M+S`>7%3&Y?\`$T`>\'<3CYR5J;>5QB2Q&RZ[S_FKD=RDF\W<:83BA=9W+]JH
M,.Z98KJUP?WNJ.*2TQ#C?&K"FW:O6=\#Y*8;)F<JR")':W<<!UZI\FPU+B=1
MZN1&-`*Y]"J+N1H#6`!H/3S!XD\0K@LN"B4Q&4MCFKE1RBY&N<<YVP3GZBR>
M59?#[!:N6?CR_FI*EQ"+#&N'Z'$OHRP/)LY[(\<H*S$R9!`1>(]H`&ORK3\1
M.`IP^P*PW#L:-:*UKGQSS*D-C'`]+Q-D/D5DRL.[`O8>3N2ZOE7(:,N]9.HM
MC9:CB>C8;BT*LW;1S)Q'1*E4Q\Q562<*NU#/3K*%4*F8J1)FQ-:\O%:G[@/L
M"B<\N:UIR:*>LG[5#F?\KW&$];;.^_SXY)0V*+3RPJW-M[QT@K#C%GB<.1==
MR;5<O/K.YDG&*WN5)BL6>^5%N^=P#RQK1C=954S0C<00[$/RK"_436CJ\*^F
ME?73/`*<7<@9H&6FG'*E,JTRXT5R8?@E#DY$8_Y$9+Y!<@\X2V&K)DNY8'H^
M5'&(U*YB.:RW`SM5L1XFT4[$U0RM<H>-J%F>Q<.PL5@E63!HL4PIK+HHKIW-
MA`<"#[K2:##CGD/;7TJUTSBTMH!4"IQJ0,LS3T!57G/B%$YCS#CG/M;S5FSC
M_ES'V/KIAY2Y87?8[*]M^'L@6"LVRS8_G6F3,>9'C8TA[-4&+UG+Q*,?-,5B
M&!-R)#=):R6[9':N)SR/+G7D.76J1SOC&D9><4SY4YE5E@#C-1^-?&6D<5<:
MV+("5$Q[1)B@5FV2UB;.<G-6,RXFWBE@-:V<2P;#;V+V>57;/BLR]#A--0Q#
MF*8359`UD9C:30_<!]BH^9TDG:.I7R*B<MY5V(+F.6)3D#F?D)R3O65<153!
MPY2R!,8OHV0Z'0Z)D:-S!2GE+FL$XMQ2V4R+6LKP4;8&UFEV\K*IR$:W`AR(
M=Y%:,VH<*.)RH.KAE3#HYTQ4@NG@U:`,:\34G/.OJZ57\[P))D3&<_C[.7+;
MECG&96N.*\B8TRE:Y_#]3OV`LA85F'<]CN^8>2Q=AVCTZ.MK:5>&-+.I>*F"
M3J`?#/$SM3&1-3Y1FDC"IIP'#J`]G748)\W)J#N5<*GCUD^73BN+/<!7=D)C
MNWRG,?E@KR/Q58LARM(Y4)NL$)9*B*QE:#JT!?<2_N*GA`,$NL132%)BGI8A
M:K**M9ED212<E<]1C5-L'8D^]6N0^ZGJ^]4;<%N`:`VE*8]/&M>)XJL\,\#<
M'X)LO'*W4AYD!Q/\::ER,K=;DK/9FT^_R!,\KKA3\A9RR/E>17AT7]GR%<+S
M3R29G;92/:I+O'!"MNSV$T*_*L+`PDT%?70_9[5:;AY).&)'JR"M3$>6'BZC
MM</K87SCR,P3;L00^=*6AD7'%AQNK<+SBSD5F*1SOD7&-U_?3&%LK2D,UR3(
M?'04E'QS&<@S)@+=YU*+&4I\HP&K2:X\CGYO+F,:WFZ>[!X!&&&.%.6*E3@/
MCA2>-_&G'?%C&\Y>$J%B_&IL7U2RRDZU6R,VA_AG[="<5LS"+CFG[VLSR!ET
M7J;-,"."$4[8B`[RMA:R/LVDT^X`?8HGRNDD[1U*U_2H@/\`RJ\2WMEFL_(+
M-_(;DE;LU\??^%]]DC(TAB*JWJG8A2M[#(3-M6Y##>(\:1LQ=FE^AH^7+/V!
MI,O_`(F/1(42(&726B-HUP]XDT%!EAGR`Y_I4PNY&_``*FIS-3GC4E<V1\K[
M&]T@N3;+,_(+DQG2U\ML#8_XZ9;R'?[!BR.L"./,9V6Z6BK)T2&H>)ZA2Z=(
M)R%[??$=N-70<G-WCIBX4654I\FPUU$X\J#@1RZ3P""[D;\(:!YSQ!XGH"ZW
MGQQJSIDG(^*LQ\7:Q8FV78+'&1</6;(E,Y;1W%Z4'&]LE:W86-`N;6:X[<@6
MUZH#JSQ9I([N))"6J`<HB:+=;O%>W;<Q5<'-'O'/,\N@TZ^'#BEO*&-+7GW.
M7D1Z.*UX/\KC#=+P1QXQ1F-Z_P`J2.)/+YM_E]7EFV=J16/L@8WRT;'LKEEY
M]W*-`M35^]G<?H$B7A9!!=JT4,91,SD2J)71VH#/>)U$4/H`^SV]:273WN]V
M@`=4<\R1[5VLEY;2-EQ]%4.^\TN9.1EL>VO#MYX_W*XS^#7=FX^W+!,N[E,?
M6VJHQN#8NO9!M/8>J,)9_=65C6EV&Q%>E4!6&ORK=-":TRP'W<>-:^=4%TX.
MU-`'//'U\.%*47<USRUL31CJ>G+9EG/N5+K;N6V`^:ENON0K-1E[%8,S\<ZU
M5:I1&ZB%8QW6*]%4%>)I[--S#L6+<J2913:*MDP*4H6<8XG.O`<NCH"JZ\E<
M"TTH13B>?,])4J<Y8ELN7Z["Q-2SUF#CS.0-A">0M^'O\N'KV90/%R$2[J]P
MK.6,?Y+H]LJ3U*1[QFCF-[B;M!%9-4ADQ`TTD>NA!H0:\/M!]B@C?HK@""*$
M8_80HXX=\N/CWA1QA1W775^FG6%*EROJ[56Q3$#VK\ZYJW*L9`Y`6F\,*]6*
M_&(3=@M57(NP;P2,+$Q23E5%!F"0)%2C%LR@!)-"3Z2#[1[?-)\S)4D4!-/4
M"/85;RK>5Y5Z3C3!%+J?*?E7"6?B<ZDX?BIFAI)86-DC!V*9FGPM&DL`I%4P
MR>C92Q/)5NLQY7+>XP\Y*K.HYJZ!Z1=LD<MAMF$!A.(RRRP'+JS!5PN7AQ>`
M!JSSQ.=<\#U45X(_`.>(;,?%8/\`B*RU=<*X0J^?+7EN>OEUC`R/R'S'D)>%
MA,80.18:CU>F5!]C3&\+,V*5:LF[%HP:/D(E%)L;X<RFJMA<V1H::,%>KT"@
MKB1Y@:*CI@]KBX`R$CS><U/`>M3:UEK&31$T1?F^?Q<G`7)V,^71_,#@*LU-
M@3D!"XJQ]9;6SDHXSR-S[7:A/P[F)E(`BWWNW:S-"H#-XC(&2^%6<`HCW.Z'
M2.CO8G,DU_A/Z:>H+=V$K'1]E^(5]&'VE>.X3G-^D8P[^G<PCO\`..L%;)<I
MLP<NR'.B0HD3$`.8QR$*`B&_I.8OJT1?$7'PW67H*<1-XF`WA]GP\!`!W#WZ
M*A%5NFD#B'V4R@/M$1-]&Q=5JJ:5H!\OO_('W=/U#I5-(6O[P4_ZLGSCI5-(
M3[P4_P"K)\XZ532%\&05]1$P_$8?_N@U2JKI"T_'K^Q/^J;^UHE`GQZ_L3_J
MF_M:)0)\>O[$_P"J;^UHE`@OU_8F'X"C_I,.E4H$!^L`@(@00]8;;;_C`?#2
MJ:0N<#UO^N(?\DW^@-55M"OOQC?_`*SU?JG^;Q+Z=$H5U*RYUC")A$"[_9)Z
M@#_2/OU17`46SHJIHB:(FB+GM8J3?"!64<_>&$@J`5JS<.!%,!`!.`))G$2`
M(@&_H\=31VUQ+A%&]QIP:3[`L>:\M+<5GEC8*T]YS1CRQ(Q54L<99)DQ2"-Q
M[>)`5T^Z@#&ISSL5D@+UBHD"#!05$^GQZ@W#;6QA[O[]<$"WLKMY<*C3#(ZH
MYBC34+47'>SNM:`FZW+;X@TT.NXA;0\C5XH>@JI6O'_/+XG=983RX[2ZQ3[K
M;&]Q73[@;;D%1*&,0#`!@W#?<-]9\?<KOE*W5%M&YN;7,6LY'JC6JE\2?#NW
M=HGW_96/I6CKZV!ISH91@JR4X?\`*1.,:2W^0&6E&SUTZ:(I(42R+OBF:MF#
MLRZ[!&..[;,UDY$@(K'(5-8Y%"$$3)*`7/;X;^(3FAXV/=M)_P#I)_\`(6K=
MXQ>$S'%CN\VPZ@:'_3K;/_M%S@X5\MS`!@XY9AV,`&#_`/(6=#P,&X>`M`$/
M`=9H\)O$PBHV+=*?_J\G^2M:?'GP7!H>]&R5'_U</^4OO_!5RW_^7',/_N-.
M_P#TII_[3>)O_D.Z?[/)]R?^_/@O_P"J-D_VN+_*3_@JY;__`"XYA_\`<:=_
M^E-/_:;Q-_\`(=T_V>3[D_\`?GP7_P#5&R?[7%_E)_P5<M__`)<<P_\`N-._
M_2FG_M-XF_\`D.Z?[/)]R?\`OSX+_P#JC9/]KB_REU3KB+RF9KG;N..V9RJD
MZ1,!,<6M8H=90.791&+43-]D?4([:QI/#+Q%B>8W['NVH?\`TLQ]880LR'QJ
M\(9XQ+'WGV(L/.]MQZC(#ZE33SCIR!CQ<?&X,S"U!J)@<F7QI<TTT!(.QNXH
M:%!,@%'UB.VL"7N+WV@U=ML^Z-TYUM9Z#K/9T6U@\3_#6YT_+]X=D>7_``@7
MUJ2:\AVM2J4?XOR7%=?WICR\QO;2[ZGQ]2GV?0AX_MC_`!$>GTI?9'[0^'AK
M6S]WM_MJ_,V-Y'05.J&1N'/%HPZ5N;;O;W5O*?*;GM\M30:+B%U3R&EYQZ,U
M23J/?L3"1ZQ>,SEZ>HCILLW,7K#J)N58A!#J+XA[0UK)()H325CFGI!'M6YA
MN;:X&JWD8]IXM<'99Y$KAZB4Z:(FB)HB:(OWEM=4N26-SS?+#/U3RW.45AJT
MY,5J?C83&AXZ<@)-[#3#`[C..+V;@S*3CEVSUJ9=FY42.*9RB9-0Q1W*80'$
MO"1&*&GO?85E6@!EQ%</N5ELX>8CR$I3CF%GRC8PPE)</>"N?6&"\T15IF+Z
MVY&Y'5B&F+Y',=[Q:YBNG'-488[1RRT+#P\JTD7%H-&N?]ZC@7;".,+J0`$'
MW0`#EF17K]&=."G^49J,9/[W$CEG0>6%*\5RJKY@>;97FM>..EV@L)8A90>3
M<MTC&F",GU'D'3^1'(FG8\JLS.4_)>!LUSL9'<8,BN\K?=J<@SK<<9RYBX8Z
MPNW@.FRR1;Q<R=IC@W'E3TFA-,SR&9&2M^6C[+4TU=AZ^@5ZL\>`R*J#R[>=
MN5^6-NLU9S([X_X_O41C2*O=DXO15%Y)8JY0X(FI*=:1;JM9%@L^Q$+%93JE
M?575C7=OK+5G%*S*294$U&[E)0)+>:1[R'G"F1`'Z?/@%9<0LB8',QJ<\_T"
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M<7===)GO;<DFM`*CE@">>5!CTUIFENQCK:@`U$T//$@9T../5YU4#7S9N2&,
M,:YHROR`XSH6*HU+C*PSK3)W%V&.8&(*I`Y4G<A8_P`<UKC'?K7R+Q;%I7F:
ML,EE&.?,;15&@E>Q\9*')"E,FU*M>)YF@EX.6%13T88_RFF%#8;>%S@UCL2>
M8/GSPI3IX8\K:<G.8W*V]\2>7E,RI0GE*D,?K\(;A1>0^)L.<M>.5&FU[US(
MQA4,@8=&.Y.U>IW=6]4EO'IJ.'T8Z783,'-D%1LR4*LV&R26?11^KXAC2G/J
MY>L99*L<,6L.:1D[`D&N&%*=?J*E+DOG!E/%%WYG,L:TN%NMRB/-'X?\-:9$
MY<R=?5<>MDN1^'..*BL^P1CV<RZQI`P+[(AW"D9"M%FKEVFN\.B=R[5'563O
M#6M;740./0SG7FKWV["YSC@T:LATOZORK96\P;E%`RM_XV3N.>/DYS$B^<F*
M>%]`M$`]R5!\:I5','&<O+5AE>UP,J_F,F1R5%Q7%3#1Y!-I1168FFC8C=XU
M1='.A<ZXG8PAWQ5I7##"N667LSQPB%O$YP<TGLZ5X\]/7G3AYL,9C<*.0.8,
MX%Y15/.D#C&'R'QBY13_`!SDI+$`6]"E7)M#XGQ#DQM;F49>'\I/PCA^7)XH
MJ,SN7)$/AP`JRP?M3Y%M(Z5A<XU->CD#PZU#<QMC<`S(MKZR/LZ%$FV>:39<
M>YL>89N.)ZX1U0.;5IPMG:?83\@W98MXDNV>"V^)N33]-\<Y@7M%HY3T1D_1
M.(L4T@F%TMB,A$F,ZZE:2*8UR-.61ZL/7BIVVL;F!VK`MY$TZ?4<.KFK$PW(
MSF-R4Y,>6YDC#45B''%RS[P@Y_Y#;TW+$OE*0Q#'8^;9_P",3?#]VG*A3GL?
M.76^2..GL8L"1GL6DP-.OCHN`33*V<6.FD-'@N!`/++W2,,N/M5[88FAS'D:
M:MYX&C@>=,17CPK@M^/\WG-.5Z=QCA\/8DHU4S'E?C'<.2&6'%KQCRHY%8ZJ
M)Z;F&>X_MJ#3J_Q@I4UD$4;QDNGRZZ-AG3L64-$((`9O(/'`(%N%U+)1K*AP
MSPKRZ.G^7(6NM&1^\XU:<L0.)YGD/Y%?ZE<[N8F9LQX,Q/CSC%C'$[^W<)\0
M<R,^Q7)RUY3J%ZPJA:,Q6C&N1,80M-KU$=2]LM;)E4W2D,,FC`D(J!5'VQ5"
MMPN^8F=(&4(.'WG@>'5EAR5I@B9&7DAPJ<O0*X\Z<\^2HOAMYFO(+E-DSC[.
M?\/F_&GE&C?9&L259PIRNAKAQ]JD76[!;,57C,V:K]0(KC?D>$R<QKY(YV6J
MNVR<--RK-!LXED057U=%-,]X)!+#T4'L\N9S5)H(HVFCAK'2.KRZN&2NWS"R
M1S&K_F$>7IB_CC;<315#R?CGF!+9`J.4CY"&"MLACAAAQ]\;.-:2HF+I6L05
MC,>NFW`49)T[%?=(R0!2Y=*)VAIH.BG,<_7PIYTMVQ.A>7C$=?(\E$3CCREY
M68:?6VQR\=B>^\9<@^=QR(X@N2V.R9)D>0L,&9N65JQO3;+6Y%<Y,>P5.QM9
MG;%F2NG;OA=0Y%%47;$Y2-1B[=\4KCB14X<*5(ZQCY<%*8(Y8Q3"32/[(/5^
MDJZ^"_,_SYG?,^-WU.X__O!QDRCR0R+@-LWK^$>61\IXYIE(M-_QZRY*7C.4
MEC]OQ4E*0^O%`$LI7XY\#F%CY1`PR;IXW=-22B>8OU-!+*G"G+IIT?I.2B=!
M&UI:2!(`#F..-*5KQ_1Q4W>8?(;,^';OQ`Q3@BJXJG[URPS;><0I3.8I&X,J
M?16=0P)DW-"UK5:4<AIN?<(!C[LA'%.V*][O:^*:=7Q*4T\DC7!C,SU<G<^K
MH44$;'ASI#1H'V@?;T]2@"^\U3.J-<QEB@<9XT8<J;1R;YG\=+M:(+'O)'->
M"Z]&<(96*9WS*E:Q-A>%LF?;$WO:-QKZ<=#JNFJ,2J]=*O94R35,'.,+J5P#
M&UU\Z5.9X>77ACD?*QT,E?W=.K,"F)\_W8X5M#^8#S=R`IPXQG0N+>)J9G_D
ME`<TG%RC^1LOG;$%!J9.)%OQY7(O)]4@Y#&YLQ2>.LRPUW2EX:,E(5C+%;O6
MY5G*8-UU%9'33!K6XAYJ,J<0!F./4,U8(8:O<35C:9=()(SX4YE7-A?,$R8Z
MO4%QUE\:41IRE1YXV+C3>ZDQE;&XJ$+QSJ6-_P#B0EN3\0"QD["YBI/C?(Q0
MQZ*QBMU+A)$8F'H*)`I\S)713W]7$@'G3+###K*?+L/O@GL]-<CU>VIZ@K1\
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M=;M&=\@9$L69&7*F\8%C,@Y1I%(QM.R<?C!E4<?RLLO"5D9VT24@R30;`@1\
M4&L'S$PZC4#S.IR^\'KRR/EX2:`X@`GJTUIG3V455)>8WR[8T.'BY+CY1%,L
M63G9@7B)C_(=SQ[R>X[8$RS3L\TF6M*.5:S3\RU-KFF!D,;S$2ZAYF-$LLT6
M>,MV[SH=$,A1US,P4=6O.E,J<QT^K-&6T+S75A3*H)&>=#T>O)=8T\PSF]6$
M[[9,EXSXENZ+QM\P+$G`K/2E%E<R-K?DF1S3=L)UF#RMAV.L#IW"XVCJC'<A
M:^N[AIQW9EI1=G($3>,B`V,J9/.:$_#6ARXT^\9>E4=;PBH:3J+21GP!].71
MF,"KAF\POD*FO_Q#JXRPI_P/!SL-P5-'DF+]_P`4)79>1QN(G^?'Q([XT&"'
M.Y=_W1^`^\0K/^^_>?Q7^YZN^8E[2HIIK2F%*UIRKGT98]"H+>*FDN/:::Y<
M*:NK+ISPZ5W-=\RBY.YBA8KLF,JO'9WKG(?ES0.5U6BGEB?0F*L$<.ZK)9!M
M>:*BFJ<DQ)'RA2KCC8]81?F*V5=W<A5#F(W-M07;C0#.N=,.CTX<!@0JFTH2
M?PTP'&N%>/#WN.-"HY8H\X'.;ZB!R-RUQL7=\:K%Q)S1RT1<XTPURNJ,]@R)
MQOC5',%"H64\OYKQS7<(Y8>9CIYSQ[*:J:K)BUL*94T47[%5-X)MQ,*O()92
MN5`..=,</NZ4=;15T!U'ZJ9@UX95PQ]7H5V\!7?F'/\`F<X;)RC=X<@T;KY8
M.6\E0&.,"2>35ZA6W<CR-XZF&/N1[W*.H^YW.IM)H6*%A8M8\CM%9R!6;5,Q
M2G6SWOG.LGX3RZ.23MB;;CL_S#'C^+GY98E9I];%8":(FB)HB\MG\7!1<FSO
MEFUV\4BTV&/I-%SK3XW-E,8N#&K=NH]Z34BZW+V*,.11LN\I>2HR'/'NA`JS
M0T@MVSE[AM];N(=I!!P\J_9Z%LMM+>U+2,:8>755?F`KI&0651/^DD<Q!_Y(
MB&_X]:=;M:-_L[=0^G]'QV]'I]FB+3HB:(FB)HB:(FB)HBWV[5R\5*W:-UW2
MYQV(BW2475.(B`;%32*8YAW'U!J^..25VB)I<\\`"3Z`HY9HH&&29S61C,N(
M`])P5VZWQXSW<3)!5L+94GBK;=M:,H-H=-C=1ND!^+3BQ;%`1]8G`-=-8=Q^
M^>Z$#;MIW*8'(LMIB/2&4]:XO=?$SPYV,$[OOVSVQ;F)+RW:[^J9-7J5_(#R
MX.:MB%(6^!['&)*B'[>R2M7K)$P$!$#*)3DXQ=%#P]28B`Z[2R\!_%F^IHV:
M>-IXROBB](DD:?4O.-R^J/P&VRHE[Q6LKQP@CGGKU&*)[?6KY07D^<N)7MFE
M%,5U8AQ+W`E[R9\LD41+U"*=:AYTAS%`1\`/X]/I]&_7V?TN^)MS0W)VZV!_
M/<:B/-$R3VKS_<?K<\%K.HLQO%VX9=G::`?//)$1Z.*O7!>27D=P4AK-G>@Q
M(CT]Q.#K-EL!B^!>H"F?'K1#"41,`>(`.P>C?PZVS^DG?G@'<-YLHO\`HXI9
M?[79+@MP^OCNM&2-J[N[E-R,L\$/]@3GEY#&\D#Y)5`1`@VC/MPD3!T]PD!2
M(:&*;]#J!-:1GIP2[[&`!%,=MP';P$!ZJR^DG9&4_P`1WJZDY]G;QL];Y).G
MAR7#;C]?'>20D;1W<L8AP,UU++SS#(8NCCSYU%WH3R<>*T;TC+6/,5C,`?:!
MQ9JW%HG'I(`_LXVHE5*7J*([=P1`#;;CL`ZZ>T^EGPX@_P!9GW2<],L3!^S#
M7U\5Q6X?7%XP75196NQVHZ()Y",^+[FAX#X>%:*[$1Y6O":),0ZF+YJ:.0Q3
M`:<R#<UBF$IQ.!3I1LK%(&((#TB'3XE#Q\=Q'I;;Z=?"2VH3MTLI']Y<SGU-
M>P=&62XR]^KSQ\O`6MW>"W:1_FK.U'"F!?'(>G//T*Z,1P+X;PH)@TX[X_7%
M,$^DTNG-SQA[1C&**GWW,ORJ"(F^UU`('#8#;@`:Z&U\&?"NTIV6QV3J?G$D
MF7/M'NK]O%<E>_47XY7Y)G[S[DVM?X9BASY=E$RG13+A17&BN,?&V#Z/NGC_
M`(99"0I"D.3&M154`$S]Q/\`:N8I=4QB*>("(B;?UZWMMX>]PK/_`%;9=J81
M_P#2PDX8C$L)S7+WGBSXI[A7YWO)OL@))QOKD#$4.#9`,1PI17$CZ!0(CI^Z
M:#18OH,<Y!C:;6F`D.J'2H<HM8Q(2F4+X&$/$P>`ZWT&R[+:_P"K65G'0_@@
MB;GGDP+F+GO+WDO:_.;EN$U0`==S._`9#WI#EPY*IVZ#=H!2M&S9H4A>@A6K
M9!L4A/3T%*BF0"DW]0>&M@QD<8I&UK0!P`'L"U$DDLQ+IGO>2:G4XNJ>>).*
MYH.G(!L#A<`#P``54``#V``&V`-2B1XR<?2H>RB.):VO4%I%PN/B*RPC[14.
M/_W6J%[SF3Z4$<8R:WT!:.L_B/6;<?2/4/C^'QU2IYJ[2WD%IW'VC\^J*M`F
MX^T?GT2@3<?:/SZ)0)N/M'Y]$H%]ZS!Z#&#\8_7JM2J:6\@M8+K!MLLJ&WHV
M4.&WX-A\-5#WC(GTJACC.;1Z%J%TY$!`7"X@/I`55!`?P@)MAU7M)#FX^DJ@
MBB&(:VO4%P'+-D]`0>L6+T!$IA!XS;.P$Q0V*80<)*`)B@.P#Z0#4$D44O\`
M%8Q_\YH=[05D13SVYK;R21G]5SF^PA4'+X?Q#/@(3N)L83`"!0'[SQ]47HB!
M>OI#J<0YS?9[AMO'PZA]NM/==U^[%Z*7FV[?+_/MH7>UAYE=%9]]N^NW8[?O
M.[0?]'>7+.7Y91R'H5IIGA5Q&GP-]X\=,4@8^W4I%UM.OJ>'1ML>O+19@\$P
M#P]6_M-OS-WX3>&5[_'V+;:G\D0C/IB+.7E4KL['QY\:=N_U7O1O%!PDG,PX
M\)A)S\J"EEI_RM^%$[W#)8PF*ZJH`AW:W?;<W[8B4"@9-O+24RS*)>G?84Q#
M<1\-<G>_3MX2WE2W;Y8''C%<S"G4'O>WU+O-N^KOQZV^@?NT%TP<)[.V=7K,
M;(G?M*PEE\F#CQ)"JI6,D99JYS`;M)/5:M9V:0B.Y?V9H:"=G*7T;"ON(>O7
M&7_TI=QYZG;[_<[=W`.,,K1YM$;OVEZ+M7UV>)MJ`W=MKV6[:,RP7$#CY^UE
M:/ZGF5JO_!%@?_F-EO\`M6__`.C!I_V+]3_VY_[5_._0_FZYO_A&L_\`SV3X
MO_E!\/+^/GTY="[+_C\W'_TO#\'_`,^[XN?^J?#T9]*_60U\HK[Y5J<XX3QS
MR,Q3<,*9;AW5@QS?&\2UL\.QEY*!=/48.Q0]JC2HR\0X:R+(49N";*B*2A1.
M4@D-N4Q@&.2-LK=+N:O8]T;M3<U'+(WEV<8<J9:L67+9$Y(!2^W*C9(RSBB`
MR]D"N<?,V9&QD$$6A7O,.$8F9;T:]6.O%JL2!CN&Y4),L2R"12>`V2Z83:LU
M`C!HX8_?T#@<NI3"ZE#2TFI/'T_>?2>:[%?@3@Z3RXEF"TV7D)?)"+NETR53
M<?7[D=ERV8=QIDC($)::Y8[YC/'$G9%(JFV-*$N\PWBC-SBWKY9%8T6DS/T&
M)46[>U[4GRZZ_9APHJ?,/[+LAEYO+KYKM<#<*\-8#O\`(Y0@+3G#*62_W$#$
M\5=.06>\AYXLU#Q>K,1UG<8[I[V^34FM7(.7FHEB\?',"DE)'9-3.7*Q44@!
M%;MC<79N\_WFJI+.^5H:[X1Y>0X+J.0?`#CMR8N<I?,@DRQ7YVWT!CB3+">(
M\TY'Q##YWQ'&/I=_&XPSA#T2<B6F0ZC'J6*210*N";U)E)NVA7(-7*J)DENV
M1VK+GY5',\\^DI'</C:6C+AT9?</0%?*C8"Q/C7(^0,K46JI5NWY-I6(,=6H
M8YX[2@!IF!V%KB\604'605^Y:ZTK,==9!$/@T4A734("G4"2?3(R)L9);Q_2
M?M5CY7R`!YK3]`^P+B6/C?ANV9*NN6+=26UDMF2L`EXQWA&><O9"KVG!IK)9
MK6O2Y.IN5303AM(2UPD0<..UWUV[@43'%,I0"UT,<CB\YY>7#CE1&RO:W2#A
M6OL^Y1]I?EQ\;ZE1[QBN8D<_9=Q#><5O\'K8?SSR0S%F#&=3Q+(*QJAJ91*O
M;K2Z1K81X0S)-A*@=:>C46B*;5\B0FVK&6K&U!Q:>O[SCTJ1UR]Q:<`YO5]V
M70N1'>7A@H^.K[BNZW#DYFNGY!3QLA+M,Z<G<PY7>0T3B"]162:'%5)W9+$L
M-9:Q=NA&KAXY0)]XRR:!$G[IRF4I2T%LQK2''-P/$8^G$E'7$A<'"@(%,A]V
M`]BN+/\`"_CW9)ZZ6J9ITJO+Y%Y-8@Y?6EV2UV-LC(Y\P)"T2NXSM39!)^5N
MRC(**QO#IKQ2(%8/#-S&73.95037"WB#O=S!'/#+I_5"&XF(Q.!KP&.=?[1]
M*L?RLX,5')M.S%,8LJ5$_P`Z\RYNPEG.:L^3,JYPQHSCLDX8J<)C2FW;'61,
M)2S3(^'\A05"@V[".>013(.#G7(\;N$W:Y#V3P5.MHJ:]->`Y]'EBKH9W-]Q
MQ_=TY`\^C',Y_<JB\OGA_-\.\7Y1A;E:HRVY%SGGR[\A,A.8&<R1:J]#6"V0
M%-J#*M0URS%8;3E2\EBZW0V)GDY///CY636<K]ELB9)NE);QNC:=69-?(U-?
M+S63R"1PT_"!3R%`J[OW!CBWD^Q\G;;>,8MYJP\QL*UKCWR$DQFIMHO<L5U&
M-L43`0K'X1\D6K2;)G9EMY*-!L_44;,SF5$S-N)#K:)Q<2,3U]/3TE4;/*T`
M--`W]'W*XE=XV8?J]YPGD>NU5Q'6GCEA.Q\?,2+MI>6&-JV([2IC4\U75H@S
MDT?*J*&Q-`@F\=$4<H`U,!#AWE>IV$0H#E0CCC6G3T*G:2&O6"<.7'UJ.COR
MT>+J%8P_7Z&7,V%9;!$'?:EC3).#LZ9&QCE>,HV4+BO?[]C^<O4%+@_N5'L-
MR7"1^[I<CU%D\226:?#JD`^K'6D9;04!\_W]`XJ47<H=4FOHZ>CI*D#CSC/B
M7%]_ALI5=A:G.08/`]5XV-[7;K]<;W-O\44RWS%\A6%ADKA,3+^RV8]KGW;M
MW-/U7$F],L(++'*``$@@8':_Q4YGE3GR41E>YNC#237(!6LPUP)P=@*\,;?B
MB>S_`%NK5V5ML]4,#AR&RQ(<9J!+WL9<;*ZI^#7EA5ID0P<N;"]691ITUHB(
M<NC*Q[5JH!#$M9`R*34#GP\C0]5,%<^=[V:'4Z\/N]?%5]GKBGC'D;/XCN%N
MD<GU._8*G[#8<99!P[DNU8LN\"E;XMG#WJMKSE6=('EJ9=X>,;(RL<Z(JBN5
MLD<HIJ)E.%9H62$.-`01Y9CR\RI%*Z.H;D1BNI#AOQU&M?N.G57Q81ORQ+SB
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MUI:,B/M!^Q1PMWE[<8+='NFC6.R!1;:VY`9.Y1P>3L5Y=N]`S%0<TYN3<(Y0
ML=-O=>ET9JOP5^C7"C1_`J%6@GC,03.T.":8D@-K&00,'>?[^D_:IFW4K:"O
MNCJZ/N"N11^).'Z)8\+W5!7)=QOF!*[F>LT&^Y0RS?<F715AR"DZQ,977MMA
MN$U)OK<^GW]-CA;&=B9.*1;@@Q3;H?LPD$+0&@XZ>OF#SZ%&9GG5P#L\!PK]
MZ[UGQAP<PY/27,AI1T$N1<OB!A@I_?@D9(P+8WC;%^\[:."`,Y&!3F3/R)HJ
MRA6X2"S!!)H=46Z94PKV$?:=I3&GEY<U0RO,?9D^Y6JM5AW@7@S`E[87#%4_
MGVL5F!F;?8JA@4G(?*SSC-1IR]C,J6AY3\%N[$K3(IDZ=6)\X:1ATUHB)=.C
MK,&C50"&)9';MCDU@X>?[Z>:BO?.^1FAU.O#RX9YE7ES1QVP[R$5Q$MEZH(V
MU3!.9Z?R!Q?W7\@P+7LJT-M+M:Q/JDCW#<LJT9)3BXJ,7/=9N#=!E4S"F3:2
M2-LE-7`U4;)'1UT\13S*S%A\O7BM9:UR"K1:#-5X>2V=J_RBR=9J5=K95;PT
MY`TX]1=U++="M\/)(3&.[/59>DL)%F:,.@V)(?$+'2.+MP"D1MH@TC`5.'JP
MSZ!Y54K;B:H-20!ZL?O*IJ,\MW`==C,C%@+MRKKUYRY;L;9"R!FN+Y79M;YQ
MLEQQ54)>BTV9=9%5M"S\8Y*I3KEFYA^T,`Z1,F!F(=E'HM^586D`XY<>C"E>
MC+@KOFI=0)I2M<A[:9]*DG@#`F-^,]$_R^Q8SGTXQW;K5D.R3]RM4]?;W>\B
MWJ84L%TR!?;M:7LC/6JW6B75[KITX5V`I2))$31333+-'`R-A9P(H?+SE122
MOD?K<<5:Y_P<XTR7'1]Q5=TB5'#CJ]V+*3!@UNUOC+C5LFV/+DSG8^0Z1D6*
MF&-VIMS@,L3SB7AY".>H+Q:O0DB((E[8C"TLT'I]M>O/I02O#]=<:4]5/8N!
M7N#>&8N(J,;:;-GS,3^CYWH?)&NVO.6?LE92MK+*V,HI_"T=\C*6&9.U95J$
MCI-<HPK1NVC'*RIEUTE5S&5-$+5@:&NQH>G(YBE5(ZZE))&%>@>VB[Z<X8<>
M+%!Y6KDM495>(S7R2H?+;(K=.VV)NI+YVQI+8JFZ=:6CA%\1:(CHZ2PK7#GC
M&PIL'`,SE43,#A8#2=@P"@RJ#QX4Z>@*/MI*@UQ`(\QK]Y5!CY=G&(V:39L&
M*R4+@V9#<CQP^.8,@CQM#D:<XN#9Y#`@S0T#_,P90PR?Q/P_P?WV/WI\-]X_
M[UJ/Y5G::Z^VOIK^GC6N*D-U*8^SX>;V4\AADKR0/%W!-9Y#93Y50]!8H9TS
M5CVIXLR7<%W3UZC9*13.DD3%*0#M9:#:*NVS=HA(N$D"K2;:-9).3*$:H@63
ML(]9>1B>O[_Y/12,RO+!&3[@5C<:>7#QJQ6UE:Q7W&<YG#[ZD7K&L5QMO/(;
M+=VXU4W'^2HQU"7"FT[#,]9G-9C*XZ@WR[%BT7!TC",EC(1A6:8@4+&VK&DX
M^Z13B/3C0]5*<,L%(ZZD<!EJ'&@^[#KYXYKN^/W`/`7&W(,7E6E2><;?D*`Q
M$]P%6[/FG/N4<R.:SA5U8ZY:FN-ZZSO4_)QD/`PTM4V`M5$4"O1(D(+KKF.)
MM716[8G:AGCS^\JV6=\HTNRPY<!3DIJZR%`FB)HB:(H@>8#QI:<QN$?*;C(X
M027>Y?PM<Z[5Q5*4X-;ZRCS6#';\H'`0*HPO4-'J@/I#I\-8]RSM(2T>77U9
M^9302=E*U_`%?B?SK!_&2\@QE&BS"1:.W#5^R<$%-9F_:JG;OV:R9@`Q%F;Q
M(Z1RCXE,00'7.KIUU&B+Z`"80*4!,8P@!2@`B(B([```'B(B.F>`S5"0!4Y*
M[=/P#G+(!T2TG#^2[05<0[3B%I-B?,QW]`F?(QYF:9?>90`UTVU]R^]^]D#:
M-KO[@'(QP2N;_6#=(\Y7&;WXD>'W=L.._P"][59EN;9;J%COZA?J/F"E'4_+
M!YIVLR9CXE"JMU-O]YN5JJL#T`/K48J2Z\N3;V?#;^[7HFV_3UXL;D17;/EF
M'C/-#'Z6EY?^RO(MY^K7P'V<$-WKYR4?AMK>XFKU/$8C/]=29J?DL9QD03/<
M\K8MJA#``J(Q)+-;7B?\WH")@F)SA[G'3[]>@;;])W>^>AW7<MNMAQ#.UF</
MV(V_M+RC>?KQ\/[:K=BV?=[QPR,G86S3Y^TF>/.RO0I)U7R3\8M2)&NV<KU.
M*AL*R56J\#643;#X@FO+/;4J`"'K%/?7?;=])7=Z,`[MO%Y,[B(88XAZ7NF/
MJ7E>\?7MWLF<1L'=_;[=G`W%Q-.?.(VVX]:D=6/*?X95X$C2-3NMS63$!%2S
MWR5234,'K.VJR5:2$HCZO$-=WM_TV>%5B`9[:[NGCC+</`/FA$07EV[?63XZ
M[D2+:\L+%AX06D9(ZG7!G/G4BJUPOXF5+MC"<><6`JCTBFXF*VE:'("3;I-\
M1:5)E7JW+OOOXCKNK#PI\--LI\IL>W:AD7Q"4^F8O*\QW7QV\9MZJ+_O-N^@
MYB*<V[?1;B(*_D)5:K64RI5JK5BN)%`"E3K]>AH4A0`=P`"QC)J```^/X==I
M:;;MNWM#-OMK>!HX1Q,C_L-"\XO]XWC=GE^ZWEW=//&::67_`.(]RJ(ZRR@;
M'55.'L.H8P?,(CK.+WG,D^=:P1L::M:`>I;6K5>FB)HB:(FB)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+W=:_(Q?T"J+_,W-B/'SC?D
M#)9+LM0)]->GTVASS+$LGGB9=9)R-=("C4&KUG#<18Z@]R+:[C99U"+C8X96
M/0%XZ(JNN1!)0=07#]$9(-#Y<B#G130,[24-I4+#BS\Q_G54<5\R:K=JQ`P^
M>./F>/+FHN-K+GG"%<QU(RU(YT9;J>/)%QE3#F%N0N5JRFYJ:;B24CW$5:F+
MMR@HC\2S;+HCW<%EQ+I+>.'&N;@,Z]//S9US'VT0>#B`:X99`GB,.'Z5=JZ<
MV>8V'+YR#XG6&YX7R5G2,Y1\"\`82Y!JX<E:'1*O%\ZHBSRCF?R3AZ,R3.%L
MKS$(8^F"1"#:?8%GW+V-;.E$S=Y12@NI`TM/&IX\P.?7Q'"E%=\K$\"1M=-!
MAYJ^6!XE7L\N&$R36^3/FT0.7,A1.4[_`!?*GCPA-WN#H*6+XZ>(IP:P`O&J
MA1&]EMS2!>-HQ5%%SV7QT7*Z9ER)H@IVB3VU>U-34T.(-1DSCQ4%S30W2*#'
M`Y_$[APZE9'DIS4YI8]D_,SRY0;O@B)POY;.2<,M4,06/#4W.7+/E5MF"L(Y
M9O\`493+),G1:-*L#P^27;6LN(Z"<K_>1FR;DJR/[,\<T[V2D`X`\SR!RK]E
M.M7PV\;XP2'5<,^`]X@=67G7.R'SGY80D9R/Y;5Z=Q$SXS\7N=41PYE^+<KB
MZ6?98R16&.7L580NM^/FU.^,UJCE26LN333%6@4*XYC%HEFV1<"NJ^^(0H;B
M37J!%104%2,>(%<1GF.7.HN%O$&AI#L<:Y9"M#AAA3GQY8QUIW)SF9QAP[YB
MN:)'*];SN(>:SD#B=AG'TEAFPN7-#R!ES.F%\:U>ZJ33S.__`'KC2CP-Q4^`
MH;<(-!Y)%3*$PU(Z-VXXYWBM":FAS)I4CF>%<\^D*6:W87-;3`5J0`*T'0.-
M,N')7OF>7WF3XTQ5.,[W2X"#MLUS0X/8`P;G+/''I#&#.]T;E%D"/H>3QM>`
M<>Y]N1T)W$$J=0&<BRL,>WEF[UK^P(JBX.:]D\Q`94$$C&M>('.O'CT>>.2W
M@!)]X&A-*4R!/+F!ZU9CDWG;G!,Q]JX\.>1%"B<L<;?-X\MO$;?/%0PI,59A
MDO&_(QCB;(U>@[ABJ'S$V:HI5*R7T[2;9HS)V-KA696BI&JCA1P6KWR`B)YH
MX.&-32GN]()SXGAA1&11%IF:"6%IP-*_BQRP^'TGC12)OG)^\8%ROYB$)<+_
M``L-EFAT'RQ<?5'*-%P+>\J6'*N<\\M\FUF/K]1XNKYG"MK3%NL+3X&`B6,K
M$HLSO>_,2+])H"A:]N&AP!&6!J<<2*UKQ/72O$*T0:BS`Z:FHPPP!Y?RTX*)
M-\Y3<D<U8GR7A?DY69:#O?&?S4/)\C86;M&-J9AS(%EI>8N0&"\A187W&^-L
MQ9VH,+,Q3L[I%%>-L`@]8'0,X9M'!5"&C$KGN:UQK0CC7\3.-3[?,%(Z!D=9
M&U!TN%/Z+^@<A]Y69[S"LZ9=X^X0JEKP8K16N2+SREXHX%BG^2:U+W"H1<;G
M_/\`2L3STM(5R!L=3EY->+B+.JNW(C(-C=XA?M;:S9Y',:W305I[6CF.:P8&
M-D>0ZM`"<.@$J`]UYL\E<2ON3O&'(688FS\BL9<AN-6+<$9/PCP_"^V[-Q>1
M>&[#F[_*9GQR?YM@Z3"9-HU;HLXX>3LA;&D$RKB;:1>)%4,)5</YB306UPYU
M.=>=>OS4R6:+>,O:0#0C+B`.BG5ASKFJ&Q3S4S]EI'B]`\@:)&,<IX]\ZA?A
MQ9W4U7'.,+&XK<7Q-R+E^NW>9Q]BO-^0J%`9#-%65JQ>1P6&TUE4I3.0:D<&
M2*SO,S_E]1H:.(X_E)SKCY=%*"WC[?0*AKF@^EP'$8>7GJK%?-OFG++\:,X7
MF[8*E<+9T\R_-W`)_A"MX5G("U0]0K66^26-:'E8,P/<H32KJ\Q3S"K([^/)
M!HQ+UDY5V!-QLH`SRL=K/PU=ACP)Z:>7#!1]C":QBNO2#7K`^\_I4ZN?.?KG
MANKX@IV(;E;('.F;LEO*IC2HX[XYQ?)K(>16=5IT[<+S&5FFVC*.':%4VU=A
M6:4E(V.P3B,:P:(BB":B[E(23W<NANEIH^HXTY\</+S**UB[1]7`E@'EAQ6(
MV!Y,<\.5=S\LGX7*5<XW9>C.</F/<8LKQ\MA1S8(2Y3_`!ZPSF1I"6+(.(JK
MR(-6$79J[5C@[K;:T3D7'658DDRD5$V:2"N,)7/<T%VFE:FII^*F3NC.IK7.
M@64861QN=34#2@XCX>-*\>0RRQ61WS=9+-4+Q9Q4YPMEA+$MT<<W^!%8E+46
ML2DZ$C'7'E%C.GKQAXZ)NM-=%@'4W,MG,K'F>J(S$.@YB5!3(\%TCE7).EH!
MH:C''*H'/I\JK$M@TR'4*C2[V%0?S),<S\.\M_,WRCC/.^%6>1..?EE<.<P9
M/E;/QUF)B!S;9<6M^;UR0K$#44\S-2X<J%L1@G;=\J1_8)-J99N9LJ`)*=W$
MU/`,D>0`XG'%W34U/,E9($9:UD@()>13`4KIZ,*=0]:[_)/F(\\LJY%RO%<-
M,./Y<^`<-\8<@_Y9,,%Q>7V><<A<A,)P^?%:-<\L3.=L2N\&TA&`GFU?BI6-
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MW''F`Y+)1WC'(F&:]DQP:-R-C(8:35ZHNP-4'\>[C7`HMU#J=4S9Y?X8(.(Q
MK7\0&&.(S]62B=;Q?&0X"APRR!..&%<,.O$K=FN:_,7']TRSQ$FKSA:Y9Z:<
M\N*W$C&O)EWAR0J5&KU.Y1\=W?(IS<KI@Z/R0^:3]QH$=5I>!AFB%B8LIN2>
M1@N1*/?*K0W$C`8W9U../1TUY\1PR5&V\4E)&AVFF7G(X95PPH>.:X-UYR\V
MZ%)3?&F,G>/5VY&T;S*.-O"Y;.-CQ=;(#%%UQKR1X[/,^1EEG\65B_N).KY3
MH;9=-C)LHZ<%B\.V14(#,CX?ASKF5@#*@T.8J<@.-<<^/\ES;6)]9,0VF1P-
M:D>;+EZ:8Y*\TS_+C%G#.[S^.8:B\C>9-1QJ"T''5ZHKT2C9'R`21:-Y"1KN
M.IK(BCAJ1M"+KOF->7M29I)XU(R^\4OB`6)F2&6.&HH7#V4Z2>/3EZ5AQMCD
MF#<0PGK/L^Q8N&?,*_6^JX-AK]D@<M9*@/-*X1XBO%'RCQ-RQP@S%A-AE-M*
M3K-.ZXS)E9XSM3J28#]XUV616>U>19*&2<-I$4!4U@&9Q8,03CQ=T=/Z.7%9
MYMF!SC0AM.C'.O`TR^_@K/XRY/\`-;C7QKY+9*DLLU[/L[D'S:<V\-,,UMU@
MR=DI/&MXOG,":H1K^HM(9_1+=*3`5U!PE6,?D7KS5%\=DQ&8[)A'5W;21O<P
M&IJ>?YB.>'7_`"JG81R-:[20W2,N/N@\L?3T\UEKX.9-Y9V^)S'#<N:1,UX*
M1?*VPP[E:WXQKF`YW,=&LM2CY*24L&)(/*F68NKV*C7CXV'%RWE$VTRV%JND
MV14%4NLJUD>X$.Q:.-:\L.)X^I8MU$R-PTU!/`BGGR4]-9BQ%\T1-$31$T1-
M$31$T1:BE,<0*0IC&'T`4!,(_@`-QU0D#$Y*H!)H!4JGK';*I3FQGEOM-9J;
M0@"8SBSS\1`(@`!N(@>6>-`-X>S?6;8[=N.YR"+;;>>YD/"*-\A_8:5K=SWC
M9]DB,^]7=K9PC\4\T<(],CFJ*=S\PCAO1A63D<YUN==(B8IV-'9S5U<"<H>)
M"K5^-=QNXCX`(N`#?UZ]#VOP8\3MVHZ':9X8S^*=S(!Z)'!W[*\BWSZD/!+8
M*MN=_M;B9OX+5LMT>JL+',_;`Z5%"W><Q@>%.<*)C7*-T<)&ZF[J3_=^E1QE
M""(D.)G#Z=DP)U`'I:@.WJUZ)MOTP=[[H`[O?;?:L.8;VD[J>9L;?VUX_O7U
MN>'MG5NP;7NU\\9.?V-JP^E\KZ?T*KQ5\@/+"XY9[Y)YLSVZD\@TFOY<RG=,
MF,,455]7D8FF?OM..K%(5YK8GL$\>23%O*OUS)'!LU$B1RD`OV-S=MMOTG]T
MX7=IO&YW]R[,B)D4#?6)G4\X7F&\_7AW[N&&+N]LNUV;:4#IGSW+_0TV[:^8
MA553?+5X74P2*)8>1M#H@%W=7>RV6Q=9B_RCQXR3.&'J]8?"](^S7H^U^`7A
M/M1#F[6+B0<;B666O]'6UG["\<WSZJO'??:M?OCK2$_AM8((:=3^S=+_`-Y5
M2DJ.'<0T!,B='Q5CBH@F``12O4FMQ;DNWH'XQM&D=F-[Q4$=>B[9W6[L;*`-
MGVVPM:?W5O$P_P!8-U>M>1;UWX[Z]Y'%W>#>-TO:YB:ZGD;_`%7/T^I7*,JJ
M8H$,HH8A0V*03F$I0#T`4HCL`!KH"YQ%"31<H&,!U`#5SHMO5JO31%]`!$=@
M`1'V`&X_1IFJ$@9K=^'7`O4*"P%#TF%,X%``\1$1$-@``U=H?2M#3J5G:QUI
MJ;7K"Z*1L5<ABB:8L=>ARE\##+3L3&`4>HI=C"^>(;#U'`/'UB`>O6'<7]A:
M"MW<01#]>1C/[3@ME:[7NE\:6-K=3D_W<,DG]AI5L9?D9Q[@!$)K.N'XTP"4
M!(XR/414`3&.4H"FE+*J!N9,P>CTAKG;KO[W&LL+O>=JC/3=0>P//)=;9>%G
MB=N6-AW=WR4<Q8W-.'$Q@<0K9R?.WAU$]7Q7(C':PE$@"$8ZEID?M@82[#$1
M+XI@#I^UL/V?7MN&N?N/&7PKM?XF^V)_F%\F?\QCOT<5UEI].GCG>_P>Z^Z-
MK7^(V.++_I9&>;GPJK;R7F=\*8[<"Y7D940`@[0]`O+K?K,)1`#N()FGU)[;
MF`3!X>C?7/W'U$>$<&6YR2']2VN#[8VC#CBNKM/I&\?;KXMFBA&/\6\M&Y=#
M9G''AAGR5`R?FW<1&/5\&KE69$`6$OP-!2;E.*?]V`&E)]@8`<_R1$O@'Z73
MZ-:6X^I[PNA_A'<I<_AMP,LOCE;GP]=%TEI]%'C=<?QV[-!E\=X74KG_``X7
M_#QQQX55!O\`SE..Z'7]VXVS))B!""05F5.BR'.(_;(83VAX=/ME\=^DP&'P
M\/3K2S_5=W$946]ANTF'%L#!T_YYQ%.HU71VWT)>*$E/F]UV*'$UHZZD('`X
M6[0:\JBBHZ0\Z7&B?=^ZL#7]X("3LC(W"M1P*`/3W!5*VCI3M"7<>G83]6P;
M[;^&JG^K;N^VORVS7KN6J>)M>=:,?3UUZ%O;;Z".]KJ?.]X]M8,:Z+:=].5-
M3XZ]-:4Z523WSK60&5",XY.S$[?[$TCDY$AN]T?],1K2SAV@/^J;J$/8.M5-
M]7,()^7V%Q%,-5V!CTTM\NK%;RW^@.<@?-]ZF!U<=%@3AT%UT,:<Q2JI=UYU
M=L,!/@>/%61$!-W?C<A33H#!X=/;!O7&0D$!WWWZM_=K72?5SN1`[+8K8'CJ
MN9'>BD3:>M;>+Z!-E%?F.]%XX<--E$WTZIWU\U%//RX,^\S_`#-N0</AK!_'
M7'T97$5VKG(>1968N3V`Q_7NLOQLC(/TA9M5WYDQ$6S7I*=4VP>.LW;_`*H.
M\=\)+R3:=O@VF+XWNDF<:_D9BT.>>`I@,2>:Y^ACN99,;#)WAW:6_>3I:V"V
M;7I((=I:.)+EZCLI^7CA2ERE;Q;0,AY,RSG6;%JU&N0O[I,H0[HZR"$E(E($
M.[=QL%"]_O.57+C]F@01ZA$!`.6W_P"KWO/LT>MFU;>ZYG=2""L[I#R,A$@`
M!Z`*5QPQ6^V'Z!^XV[']]O>\-M816::EL&5Y1@PDFF6).HY*%?F71'!SRO\`
M%+>%R3EBZYCYB6.%*O7\+42=K,-!0#QTV6<-YZY&4K,Q-QU52/T$3!55%T_'
M8Q"HIF$Q>9/U@>)]XYNW;;MFQG>`1V[@RY=!;M-,'N-P"^2AJV-I#G9G2VA=
MV%C_`/L^O"-@=N6Z[SWB;L>4?OVC99G#-L;1:D8\7FK6<23@O+@;S0<\F4$$
MJ;BP`.ITHI?=%H65'K/TI)!T6<!55,(@4-B[F-Z`UU8^J'O\&^]:;34#$]G,
M!TG^/@/.M.[Z%?"1\A$-_P!X0TGW1VUJ3T"HM!4]0S7HX\N3B3R>Y$8WF^1_
M-61QMQ4XX0L4M+K3LJS>5N<;Q3=(KA::F7MIL+J-ATCHB`(,SI"X4$Y3'$FY
M2&X#=?K5[^MG,&S6FR.@B=26>6.X,0)R9&&W`=+(>#65+LF@YKJ[;_\`9X^$
MC(FMW#<.\CMQE'[NWBFM==/S2$VA#1SJ/=&)/!88?,*\VCCGCO,"F/O+QA)[
M*U`J:ZL?9LO9O>]<;?))NH*3A6@5RK,:J]BJ\!R#V73Q999<H]0)D#8-;S:?
MJS\5+@_,;CM^S1VI`T1]E.V4\WR?Z4X1ZOPQ#4YH^-VJK1IMU^@KP7LX3:VV
M[=X)-TK[SFSVCH8_U`?E`97#\3P6LX#5FH`./.BSV@)0_P`J,.?:`?\`HKN;
MT;?_`)UDV].N@_XL>^G_`);M7HN/_&7-_P#`=X<<-YWWTVO_`-N5V27G99:*
M"0+X0Q>J(`GWA2EKBCW!#;NBF!I-8$>OQZ=^OIW]>WCEM^K7O,*:]HVXY5H^
M<5YT]\T]=.E8#_H([EDGL]_W<#&E8[8TY5_=BM..5>A5"V\[JVE.87G'>J+)
M]/V"M+_.-%"GW#Q,HM`OBG+T[AL!2COX[^K6>SZN=S!_>[%;%OZMS(T^DQN]
M@6KE^@/92T=AWGO&NKCJLXG"G0!,RG74]2JR/\[M@(IA+<<'!`[0]XT9E`A_
MV_AL"1'='+LB([_I&$P:V4'U<PFGS.PN&&.B[X]`=;Y>=::Y^@.Y%?DN]+3[
MV':6%,.DMNL^H45=QOG88B5`OWO@_([$W0D)_NVRUB5`%!']N!`=-H83$3#Q
M((["?T"!?3K<6_U:=V'#_2MHOV&@^"6)_7F&9<.?0N>NOH)[ZL)^2[P;7(*G
MXX)X\.'PNEQ/'EPJK@Q/G)\6GVP254S-!B/7N*U<JLB0.DQ0)N9C<^O<Y1$?
MT?#;;V:W=M]5'AU-_K%MNL/7%"[^S/\`8N:O/H:\7K?_`%6\V*XRRGN&'I^.
MUIAEGC571B?-5X429B$7R#:(,QS=/_?6.[0!""*@$`5%(=K,D*40'JWWV`OI
M\?#71VWU'^$MP0'WUQ"3_>6TWK+`_KZNG!<C>_1[X]6@)CVRSN`!_FKVWKE7
M`2NB/1U]&*N]!<\N'%A*06/(?'[85.GI).K2]:.'4"8@!_WAB8PA!#N@`[F\
M!`?U3;=/9^,OA9?`&'?+)I/"0OBY?WK&4S]O(KB=P^G7QQVPD7'=G<G@<8A'
M...78R2$Y<N7,*]==S5AFW]'[JY>Q=8A5`!3)#Y`J;Y8X"4I@Z4$)8R^_2<!
MVZ=_'766/>SNIN8!V[=-NGKEHN87'T!]?4N#W3N%WZV2O^,;)N]J!F9+.X8!
MYS'3UJYJ)1<)@LW#XA$0W!9N(+I"'M!1+K((?CUT+07MU1^\WF,1Z0N3>1$[
M1+[K^1P/H.*^"`@.P@(#[!#8=42H.2^:*J:(FB+W<)G3611<(J)KMG"95F[A
M!0BS=PB<-R+-UTC&272.`[@8HB40]`Z_(QP+7%C@0]IH0<"#R(.(/05_0(US
M9&-EC(=$X5:X&H(.1!&!!X$8*W&7\.XPS]CFR8CS+2XG(&.;<DP3GJO,F>HM
MW"T3)LIR%DF4A%NX^9A)R!G(UN^CY!BY;/F#UNFNW635(4P6/8V1NEV2D8]S
M':FYA6+J'`7AU1(&XUNLX(K3>,R+9\2W;(2LK-W>TSM\N>";&A;L16VYVJUV
MF;M-FLE%LK5)VU>O'BRZBB1"KF53(4@1"VC;SKARX&O+H"O,\AI4Y5]8HJVR
M9Q,XW9C0S`WR;B&KV[_/U'&R67'3T\RTD[>MAQ5PXQ/*?>\5*Q\I7;!CAVY.
MXAI*)682#%SLLFL"I2G`;:(UPI7U>7\B-FD;2A."[+!/&7`W&6.MT7@G&\9C
MUM?Y]C;+XX:2MEGI>ZVN/@F%:;VFUV"VS=@GI^QJ0D8@BN^=.5'+H4^XL=14
M3'&^.)L>(Q/\GW*V25\E-7!15C_+$X[3'*+D+RES#`,<P6G,>9,1Y?J%=G'%
MSCJICU]A[$..<<5EE8*8SNQL=97?1=EH(V*+>S4(J>)>.P!`@*(E6&(VP=*9
M'$T-,.H#[ON4OS#A$(F@"@./'$G[U>^P<%^(]JSFAR3L.#*M*9F2LU=O*]F6
MD+4G#2V0*?'I150R18L=-K`AC*T9,J<:W21C+')0SJ;8D01[+H@HI"2[Y:/5
MJ%1T</+V<%9V\NDM)P->O'I6F9X)\1+'9,[VFP8*JTX^Y.Q"D-GZ)EI*UOZ/
ME`BX5WXB9L&-7-A4QVA<W!JC%&4L+.+:SQU(YN<7@G3*8*_+QX\G#+"GHHG;
MRX8XM.'/TYK:H?!'B9C:`5K56Q`W/&+Y)QKE]=>VWC)N1YY?)&&I%*6Q19U[
M7D:ZVNTJJX\D4"JQ34ST6#4=P!`2F,`T;;QM-<2:\?-]P^RBJ;B4BA.%#T9U
MY=:JK(W$3C5EN'S%!9$Q#6[(PS_8J!<,NG4=3\7*6ZXXICJ_$XSMY)Z#F8R=
MK5KH3"J1I8J1AW,>\9G9)*$4!0!.-SH(WDDYG]'W!6MFD:`&G`?I^\KH)O@[
MQ/LU,NE!L>%X.?K>1*SA^I709F>NLG9)Z)X_?$FPDZ<7EY9UKPUM.,7#Q1Q$
MSK>11G$'9_B!=F7V4"AMXW#&M:`5XX*HGD!!!I0D^GHR7#I?`SA_CV%GJ_4L
M$5>/C[7D/%66[8H^EKC8IFV92P?*1TUBC(5JLMELLQ9+';Z;+1+9PB^>NUEG
M"J!!<BMMMJ@MHQCC6N>'0>70.E5-Q(10G"GWC[2MSFOQ1@^:>&8;"EIG_N"M
MM\Y\?<NV(PL)!\-BA<)9;J^3I2D@I$3M;E(<]V:5T\:62;.RKQIG`.$R*&3`
M@UFA[4`5H!]X/V*V*7LG:@*FA]8HNF_\/+AA_E(YP>7!447'SO)R&:W!OWQR
M4.1%LQM&X,&>5E<U_OI_G2?(K2'`(Y*8_>#XY.+_`-Q*H#011U3Y:/3IJ<ZU
MX^73GTJO;RZM=<:4Z*=2JW'_``KXIXKBZW"X\P=3JM&U'-8\D*ZW8J3K@\?G
MD],7QZOE@[N2F7SV0N;VFNE63ERZ47!T"JBJQ3KG,J-1;QAN@XMK7ARIR_2G
M;R:M=?>I3UU]JJUAQFP%%U^EU6/Q966M<QUFB6Y%T>(3"2^$K6<9VR6^WS&2
MX\#R!E?WAD+-?IEZIW#*-N](J[)`7H*6I@C(H>9/#CF/+%4[5]2ZN)%/+T)G
MCC1@WDW"5B!SA0D+HUI%F"XTJ1:V*WTJU4VSC&/81Q,5.\8^L-4NM<<24').
M&+TK.012?,ESH."JI&$NJR1-DSP/,9JC)'Q_#Q5I9'R\>%4EBFO82#C]5X;&
M50R=-9HJ$#4)V]4>1J.5+*241LMXJMRIMK@KQ79JR-9QZA("SDD4GK9XLBL0
MZ2IR#9\M'2F-:YX5X]'25?\`,2UU5X4YCASZ@K^9=PIBK/>,)[#&8J3&7W&-
MF;0[:8JLLO)MDE1KLE'35=D&4M$OXZ?AIRNS<0U>L)%D[;OV3QLFNBL14@&U
M(^-KVZ'9*-KW,=K;@Y47!\4>/-=@KO7([&4>M&9+PW7>/N13SD];[3,7K#=3
M872+K]%MMEL]BF+)/,H]AD6<3^*<.SR*WWFL95P<PE$MO8LH6G$$`>BOWJO:
MO)!Y&OGP^Y6YR?Y>O##,<O6I[(6!X*2F*K0:_BAA(05HR'0W$MBVJ%$M8QO>
M1Q_<*L7)=&@"F.#2+L82K1`%50*0`54Z[#:Q'*HZO+U9="O%Q*.-<>./\BD1
ME'$N,\UXUM.'<L4F!OF+[K"DKUGI,ZV.I#2D2BJV<,T`!JJV=L',8\8H.&3E
MJJBZ9.FZ2[=1-5,ARS/8U[2QV2C:]S'![?B"C[6O+ZX85.@Y=QA%<?JDZI6?
MF5699MCK/*7&\2>4S4<KD*;*W6UW:S6&WS-FJQW0J,)<[\)1JNFDJFX*H@@9
M.(6T8!&)KU?=[:J0W$I(=7%N2[ND<'^*&.J.?'54PM`MZNXRS3,[R?WW-7*X
M6>Q9DQU+P<[0LCVV_7*R3]^N%GI\E68XT<K*2;PC9%DB@0@($!+56V\;<16M
M:UXY@_9U]*H9Y2<3A2E.''AYRJBR%Q*XUY88Y@C\BX=J5K;Y\EZ#8LMJOPE4
M)&VV7%47&0V,K228CY-G+5JU4"/AFA8B3AUX]^Q4;D525*J7KT=;QNJ2,3Y?
M9Q5&S2-`#3@/+[2NMHW#3B]C:H4RC4S#=<BZ[0<Q(<A:T5V_LU@G2YV;M9!B
MEEZP7"R3LO<+KD#X&360/)3;^1740$J9A%-)(I*"VBH&G''R\L^E5,TA)=7$
MBBNWE/%F/LVX^M&*LJUAI<L?7-DA'V6MO74FP1D6[209R[$Z<C"/HN9C7L?+
M1S=TV<M'*#ENX0(HFH4Y0'4KV"1NEV2C8XL<'-S"LG1.#W%#&L#'UVI89A46
MD=EZH9\)*6"P7>\7"0S+C]J1C1<AV"_WFT6.]VF=IT>D1M&!)23MLS:D*BDD
M5,`+J(6T7&I->/L]77TJ0SRGCA2G(>@8<5UTMP'X=SS_`#T_G,#UB82Y/J?%
MYX@).7N+VE9`FADXF<4MBV/U[*>CUJ^+ST`QD%;##1T=.*OV:+D[L5TRJ`-M
M&:YT/H\NNJ">04H<LOY<UNUC@CQ+J-`E\81>'FK^F6#(]`R[/LK?=<EY"F9S
M)&*IB#G\;6N8N-^NEENDB\I$M66"L<BK(&:(`U(0$A3$Q#!;Q@<2:YG/A]P5
M?F)2:UX4Y<^`ZRI<G.90YCG'J.<QCF,/I$QA$3".WAXB.IP`!09!0+3JJ)HB
M^^GP#Q$=455UDW-0M:9GD;+-0]<CTRB<[ZP2K"$9E*`"(F%U)N&J```!^MK(
MM;6ZOY1!8Q2SS'\,;'2.]#`2L2^OK':X3<[I/#;6P%2^:1D3?ZSRT>M1,O?F
M`\/,>BLE+9QK,X^0$0/&45&3O3P3AO\`8!6MLGL84VX;?;<D#?TCKT7:/!OQ
M,WJCK;:9XHC^*X+;=OHE<U_H:5X]W@^HSP5[N:F7>_6MQ.W-EH'W3NJL+7,]
M+PH:7CSF\/1?=1QWB7(5R6+U`D]LLA!TB,.(>!3BBW/:)0R8^G84DC;:]0VG
MZ7^\UQ1V][E96K>+8FR3N])[)GK*\0W_`.M_N7:59W:V;<KY_!T[XK5GH!GD
MI_1:5#J\></R2GA62I-2QACMJ?J!)4(J3N4ND4?087DZ^1BS*![?@`#W:],V
MGZ9^XUF`[=;G<+V09C6V!A\T;2^G_6+Q3?OK4\3]QU,V*SVG;(CD>SDN9!_2
ME>(Z_P#54Z%#V\<V>661`62LV>\A`S7Z@4C*[*DIL9TF])`9U%O"$,3;PV-U
M>&O3-I\*_#K9"'6&SV7:C\4K.W=_6F+_`%47BV_>.OC#WE#F;KWBW+L'9LAD
M%LSJTVXB%.NJC+(O7LPY,]F'SZ8>G$3'>2SQS)NSF'Q$3.GRJZYA$?:;7>01
M16T?96S&11#\+&A@]#0`O++F>>]E,][))-.<W2.<]W]9Q)]:X9E4D_TU$R!X
M!]HY2_@](AJ0-<[($J`O8WXB`N\AZY9+$H5&NURPV!4X@4B<#!RLR<PCZ`*6
M-:.A$1VUB7-]8V3=5[/!"T<9)&,_M$+866V;GN;@S;;:YN7GA%%)*?V&N5`\
M@+A7>*+>JN>2SUQ@PMZ:RSVE-\DP\Y79"V,X)1DC,NZ_%.8T923:QBTDW(LH
MFB)"'6(7?<=M<=N/BAX<[547V][:UPS#9FR._JQ:SZEZ)M'@CXP;[0[7W:WA
M[3Q?;NA;C^M/V;?6H.6'S1^&$#W2MLA6&TJI]0`2KT*SN"*"4=MDW4RT@VA@
M-ZAZ]M<1??4;X3651'?3W+APAMI37J,C8V^M>D[9]'_CSN5#+MEK9L/&XO(&
MD=;8G3.]2L;8/.5P$Q%0E:QAEJQB7?MJOPJE:;J"`[!^E,33DA1#Q\4MP]FN
M-O?JO[DPDBPV[<Y^1=V,0/[<A]2]$VSZ$?$JX`=NN[[+:@YAGS$[A_W43?VE
M8Z?\ZN7.)RU3CS%-R[#VUK-D)\^,!ND=A.UAZY&E$`-X[`L'@'I\?#C[WZN+
MDDC;=BB`X&6Y<[]ED3/[2]"VWZ!+%H!WGO/,X\1!9,9Z'2SR?V?TV5GO.)Y,
MR)CA!5##]83$1Z!)7[%.."%W-M^TE+.+<Q@`0#<4=O#T>/AR-[]57B#.2+*U
MVJW;_P!%+(?2^:G[*[[;?H8\);4`[E?;Y=OX_OH(6GS1P:OVO.K-3WF><TIP
M3@EE1A7DSCN!*W1:6P,F'A]DB[J$?N@#P]9Q'T^/CKD[WZB?%N\)T;DR`'A%
M;V[?68W'UKO-M^D7P#VZA?LTETX<9[NZ?7K#96-]2L[.\T.6=C`Q97D1E82'
M`0,G'6IY!I"`@4-@3@_NXA?T0]`!KE;WQ;\3=P!%SONY:3P;,Z,>B/2%W.W>
M`O@MM1!L^Z^S:AQ?;ME/IEUE6?F,HY/L/5]_Y)R#.=>_6$O=;-)`;<#@/4#R
M36`0$%3!^`P^T=<M==Y>\=__`*[N%]-7\\\K_P"T\\SZ5W-CW/[H[93_``W:
M=LMZ9=E:P,Y?EC'(>@*AEC&<'%1R=1PH81$5'!SKJ&$?`1$ZHG,(CMX^.M,X
MN>=3R2X\2:^U="P-C;IB`:T<&@`>@4"VP33#T$('X"E#\@:MH%?J=S*UZ*U-
M$31$T1-$31%/7R\?+OSYYD&?:[A#"4(J*;ETBYN=V=MU!KE%K*2Z`2<Y..R_
MLVX(MU![!##U+J[$*`B.MWM6SF^:Z\NG]CM<7QR4K7+W&#B\@X!:^_W!EDT-
M:-=T_!C.9YGDT<3R7Z:?&/C1BORZ,+U7@QP8J"-QS%-1A'.1<A"GVGL_-G*D
MG)W&[6!)-0L5`,72O@`G'MI[(I`8YM]6]XN\D6W-BM+2+5<`$6UKA5O_`#LW
MZQS<78-'F"Q-EV27=I'WEX_1:8=M-C0C^ZB!X#A0>^>A0!\R+S6L->4U4;M@
MGC[9(S.OF%Y`C'!,E96.+*0AL.N9)(XHLC$*+E!NXACG$S2$()3)F`JSPPJB
M"1?,[:UW'>KY[X)=5PXEMQ>#*,<;>UK6KQDZ3)F9J^C6^H-CL=OLHYKZ/L]O
M:*V]K^*8\)9LB(^/ZWPMPQ/A`G)[,7)/*SR:GY&X9@S#DF<7=.G;I5W/VBR3
M+Y51RN8.LQU.@IC&-L'2DBF'\DH:[N*+:N[^VD,T6^W1`N<2?2YSCBYSN)-7
M.*YZ27<^\%^UOO2W3L&M:*-:T9-:T8,8T>8#,KU`\9?+3XD>5IAB`Y[>;5>8
MEI/*,6UAQ%QTC3&>WBVR:C4R["+K]7<?`OG$D5PJB<TN;]@V+OL"(=*JGG&Z
M[[?]XY18V0DCVZ3X8F^[/<-_.]QPM[8_WCL79,:]Q`79;;MUMLS'S1F-]]%A
M+<OQ@MC^6,"IEFS`:`7'A05*P0>:]YW7)#S-+#^YJ0&PCQ/JKKM8XX\5!X9"
M(39M!,FRF+T^:D;&M5D51V,<RA001,802(4-Q'?[5L$-B63W(8^[C!#`T4B@
M!S$+3CJ/XYGUED-:EK?='/;COQ?')9[9K9;R?Q97']]<?SR/@C_+$PZ1^(N.
M*PHZZ!<TNLD?2E^`_P"4NA5S5UNJ*Y-$31$T1-$31$T1-$575^_WRI'*I5;M
M;:RH00$IZ_9)B&.40]`@:.>-A`0UL['>MYVPZMMN[FW(_NY7Q_V7!:7<^[?=
MW>FEN\6%E=M/":"*7^VURD95.>G,.F%23AN060G"*73TM[')(7!#8FVQ3)6Q
MK-%$H@&P^T-=UMOC-XH[4`VUWN^<P<)7"<>B82+R_>/IT\$-])=?=VML:\\8
M&&V/IMW1*3U1\X7E;`F1)9&6,;XV)L"OWQ45(5\J```"(.ZG)P:!#C[10,&_
MJUZ%MGU1>)%D0+]FWWD8SUPF-Q\\+XQ^R5Y+O7T0^#FXASMJDW;;I3EV=R)6
M#^C<1RDC^F.M2QI/G:5Y<2)9)P)*QX?9!20H=Q;28".P=9R0UBC(XQ0W]!1?
MC^'7I6T_5M8OHW?MED9S=;SA_P"Q*QOH[3SKQO?_`*!]RC!?W5[QPR<F7=LY
MGIEAD?Z>Q'4K]_\`C%\3O_K'F7_L/Q/_`+)5O_M7_P!;?_;3^^_\K_=>_7:?
M\4OAK_<[K\%?X,6?Y?X^?3DO.?\`@>\9/_F-B_B:?]8G^'^\_P!5R_5^+H6=
M_#'*_D)@!5(F+\G3\1#)J`HI4914MBI;G8?$BE8F@=QS8#^L[4&ZOL.`^.O7
M.]'AWW,[XM)W^PAENB*"9@[.<=4K*./4_4.A>!]Q_%[Q(\.G-'=/=;B&R!J;
M=Y$UL[K@EU,;7FP,=^LLL^'/.8C%P:1F?<6.(]41(FO<L7K_`!K(?49R\ID\
MZ(]0#UF!K(+CZ>E/T!KYS[S_`$P3LU7'<[<&O;F(;H:7=39XQI/].-O2Y?8?
M<GZWK60,M?$3:'1OP!N;`ZV_SG6TS@X=/9S/Z&\%E+Q+RJX[YQ(B3&>6:G-R
MBQ2F_=I\]&NVU(Q@_NSUFP$C9=4Y1\!%%-4F_H,.OG[O'X>]]>Z9)WW;KF*W
M!_BM;VD)Z>UCU,'](@]"^M.YWB[X:]_0UO=;>+.>[</X#G=C<#H,$P9(3_-:
MX=*D(<ATS=)RF(8/24Y1*8/Q"`#KC`0148A>D%I::.!!6C55:FB)HB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(M12F,(%*`F,/@`%
M`1$1]P!XCJA(`J<E4`DT&:M_>\K8OQ>U.\R1D:D45`A1.(6FS1$.Y,`!O^Q8
M.G1)!P80]`)I'$?4&MSM'=W?]_D[+8[&[NWG^ZB>\>=P&D><A<YW@[W]T^ZD
M1F[S[G8;?&!_GYXXW>9CG!Y\S25!O('FL\1*7W4(&?MV4'Z?64J-'JKM&..<
MNX`'WY:U*ZR%,PA^FD"P;#N&^O6=F^GCQ)W2C[R&VV^$\9Y07?\`9P]H[S'2
MO`^\?U>>#6QZH]ON+W=K@<+6!P8?^MN#"VG2W5S4'K_YT=R>=YOBO"5;@$Q`
MQ496_P!AD+*]+X[$5^YX!*OL"&`/'I,Y6+OZQUZQLWTN;7%1_>'=9YG<66\;
M8F]6N0R.\^EJ\%[Q_7'ODVJ/NCL-K;-X27DSYW=![.$0L'47N"A'?_,8YBY`
M!=-YF.2J,>L!BFCL=QD52FY4S;[I@_C6PSPE`H[;F>&'W[Z]5V;P2\,MFH8M
MK9<S#\5RY\YK_-<>S]#%X1WB^ICQK[QAS9][EL[9WX+-D=J*<M;&]KZ9"HBR
M,S;\BR@N)>6M>0)I=01[DB_F[A*J*F,(_9^(5DG8F$P^@/7KTB"UVW9+?1;1
MV]G:@9-:R%@'F#0O&KF]WGO+=]I>37FXWSCF]\MS(3YR]RO+4.)'*"]%3-5<
M`94D&ZFW0[<U&1@F&P^@WQUA3B68$\?3U[:YC<O$?N#M)(W'>=N8\<!,V1W]
M6/6?4NWV;P<\5M_`.T=W=WDC.3G6[XF?UYA&WUJ355\J7F/8^V>2J]*I*!^D
M3'ME]B!<)%,&XB=E62V1SU%]9=@'7![A]0_AE8U$%Q=73Q_<V[Z'^E+V07J>
MT?2'XV;G1UU:6%A&>-Q=QU'6V`3.\RDC5O)8OKCMGN^>*9#D$`%5M5*E.V)<
MH^'44CN7?5I`1#Q\>V(:X?</JEV=E1M6T74IX&::.,>AC93ZUZ?M/T,]XI:.
MW[O#8PCBVWMY9B/Z4CX!^RI'5?R:<`QH)'MN3<L6Q0NPJI1YJO4V:@^L"D1B
M9MZ0@C_]\"/OUP^X?4]WQGJ-NL-NMAP+NUF</2]C?V5Z;M/T1>'=K0[SNN\7
MCN(9V%NT^81RNI_3KTJ1-8\LSA;6>V8V)%;.JGT[K7*XVV;[@E]:C1.681QN
MH?2'8Z?=MKBK_P`>/%*_J!N0MVGA!##'3J)8YW[2]+VKZ6/`W:J$[,Z[>.-S
M<W$M>MHD8S]E2*J_&_CS2NV-4P9B:#41_NUVM"K:SL@^'B#U['NG@F\/2*@C
MKB;_`+\=]-UJ-QW;<90<P;B4#^JUP;ZEZ5M/AAX;;%3_``?8-GMW-R+;2$N_
MK.8YWK5Y6:*,>D5"-;H1R!0`"-X]!)B@4/0`%1:$23`/P!KF)7/G=JG+GOYN
M)<?2:E=O"R.V9V=LUL48X,`:/0T`+\K#^*!Y9*\FO-?RM4(R4._H_%.NU[CC
M6B$<=UE^\5>*O9,I/DDP,8I71LB6-ZP5/^D8D8F`^!0USMR\/E-,AT4\J9>9
M=%:,+(!JQ)QSKY<_.O/#K'62FB)HB:(FB)HB;?+Z]$7WV;^OW>CZ]555\U14
M31$U5$U1$T1-$4RN"'!7/7F'<AJGQVP#75).?G'";FQV1VDL6LT&K)*!]ZVN
MTR!"&28QS!OU&*4P@==0`(0!,.VMGMNVNOWN?(X1640U22$5#1D``/B>XX,;
MF3T+#O;QEFP5&J=YHQ@(!<?/D!FXG`!?IP<0^*F,O+OQ!6^!O!&#C[CFB=8H
MR&=<Z2++I!_))HD2E[A;YYMWC15=CUW!TF#),PGW`$TB"83GT[Q=Y8]O;'86
M4=;MK3\O;DX1CC/<&E-1^)Q.#<AR4&S[*_=7.O[Y^FQJ!+*!B_E!"/R](^/X
MCA18>O-/\ZNC\-:C;.&GE]7EID#/=B([CN2?+UF=%VI'3"J(MWU>QQ*M556Z
MDJR,HHD5=N8[2**'2@*C@3K%\_VO;+K>WON)I'&TE/[ZXQ#[G_FH#FRW;D7_
M`!2?AP]X^D3/M=E8QUS$T7+!^XM?PQ`_YR<<7G`M8?Z5!@O(E@SC_GKF!EEC
M0L25&UY1R-<YH!>.&S=_,.E9"3<=3B3G)(W=,7K65ZUEUU`(0!ZU3D)N<.LW
M'==J[MV<<;P&B@;##&/??3`-C8/;D%J++;=S[Q7,EY*^D.JLMQ*2(V8$XNXF
M@.EC<3@``L^!\O<'/X?NHR<21&C\UO-4DF"8.:^Q=,)_"'%J=1.1=J6WSK(5
M26"\0+G831[)8R)%D_$Q#%!8_GVG=.^%PV\N0&6;#[C3[T,1KB0W`7,XIGC;
MQ&F,I!8.LFEVON[:?+0F1D;VU=3W;FY!&%3B;:V-<`1VKQDVAJO+;RPY?\B>
M;V8)[.G)G)<[DO($XH<I'4FN*<3`1@*'.U@*M"H],=`04>0W0BW;D(0I0\=Q
MW'7:V.WVVWQN9;@F1YU/>XZI)'4IJ>\XN-,`,`T8-```7#;ANESN):V32RVC
M%(XF#3'&..EO$G-SW$O<<7$J-.LU:Y-$75R/I2_`?\I="KFKK=45R:(FB)HB
M:(FB)HB:(FB)HB:(FB)HB][FOV=7\YJ:(@!L<B@>"B1@.DH41*HD<H[E.F<-
MC)G*/H$!`0TX$<#GT]:I3$._$#4'B#S!X'J4J\5\W>5&&R-VM-S'9W,,VZ03
MK5Q52O%>!,!W[*;&S$D%V20^C9LL@(!Z!#7GO>'PI\/N\Y=)NFV6[;IV<L(,
M$G7JBTAQ_G!R]=[I>/'BWW)#8=DWN[=8LR@N2+J&G(,G#RT?S',61/&OG0V=
MH#=IF'"\-.D*!2KSN.)QQ7WQ_0!EC5ZQ!+QZAMMQZ2/4"[^@`UXIOOTNV$E9
M.[.Z2PGA'<QB1O5VD>AP\['+Z5[K_7%NT(;#WTV."X;QELI70NZ^QF[1AZA*
MP=2GQCWS/^'E\!NB^OTKCB17`H&8Y&K<C$MD53`&Z9IZ)";K_2!AVZS.4R^&
MX[:\>WKP#\3-GU.BLX[Z!OXK:5KR1_T;^SD\P:5]#=V_JN\%>\`:RXW&;;+E
MWX;V!\;0>7:Q]K#YR\!36J&0:!D)H1]0KS3KLT4*!BK52S0T_P#9$`$!.G&/
M7*R0["'@<I1#?7EFY[+O&RR&'>+2ZM9!PFB?'_;:`?,O==E[R=W>\<(G[O;A
M97T)%:V\\4WI#'.(\X"K`Q#$'I.4Q#!Z2F`2B'XA`!UK`0148A;H@M-"*%:=
M55$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1:Q3.5,RQBF*B4!$RI@Z4
MB@`;B)E#;$*`!ZQ'5*@NTCXN7'T*XM<&EY%&#CP].2LA>>2G'K&G=+>\V8RK
MBZ(&[C!S;HEY*@)?20(>*</Y4RG\T$=]]=7M/<7OIOM#M&U7\[#^(0O:S^N\
M-9^TN"W_`,4?#?NL#_O!ONU6LC<V.N(W2?\`9QE\E>C2H;7OS:>)=4[R-:<W
M[)KU+J*0M7JBD1%JF*.P;2UO<07[(WJ,1!3P]6O3MH^G+Q&W&CK]MG81'^]F
M#WC^A")/07!>(]X?K$\'MG#F;4_<=UG&0@MS'&?^LN718=(8Y0DOGG0Y!E%5
M(_%&&*G73*]1&KVYS<I<YCJ$=B')#0B=<8`I_,$ZX;^W7JVS_2YLUNT3=XMT
MN9P,2V"-D#/Z\AE=3IHU>$]X?KC[QW;S;=S]CL[4G!KKF62YDZ*11"%E>BKU
M8&3S#YG_`"6(HA$)YV<PK\!(+#'=+?XYK)D5=OL&E8R.@^Z@)3!XKOU-P](C
MKL8.[/@'W%(?<G:&W3/Q7,[;F6H_4<Z2A_FQA>=77?7ZK?%$&.R'>!]C)^"S
MMGV4%#P[1C(JCI=*<.*XU:\J_F=>'?WI9*]6*BN[,"CF3R#D"/>3!A./VE'*
M,$-JE%50](@H(&'5]_\`4'X7[3'\O8SW%RUN`;;V[FL\QD[)@'5@H]J^DGQP
MW^;YO<[:TLWO-7/O+QCI,>)$7S$A/7BI15#R5K"J"2F0<_0C`!$HK,Z12I"6
M4`/#J(22L,K#)`;WBU$/=ZM<!N?U2V3:MV;9Y7\G3SM8/ZL;'G]M>L;+]#&Y
M/H[O)WB@CYMM;9\A_KS21#S]F5*6I>4#Q9@^T>S3&5;XN383ED+0PKC!4P>G
M=I68=D[*0?9\4(^_7G^Y?4KX@W=181;=9M/Y8G2N'GE>X?L+UG9_HO\`"6PH
M[=9]WW"09ZYV0L/]&"-KO^\4I*CP9XAT@4E(3C]CYPY1VZ'ME8.[D\ZB^@YE
M;8]F2]6_CX%#7G^Y>+7B3NM1=[S>MC/X8G"%OHA:SVKUG9O`+P9V&CK#NYMK
MI6Y.G8ZY=Z;ATOL4DX.MUNKH%;5BN5ZM-R`!2H5V#BH-(H`````2+:-"[``:
MX6[OKZ_<7W\\\[SQDD?(?VR5ZAM^U[7M,8BVJUMK6,<(8HXAZ(VM7>'.=0=S
MG,<?:<PF'YQ$=8H`&`%%L"YSC5Q)*T:JK4T1-$31$T16NSCEVO<?L*9@SQ;5
M4TJSA;%]\RK.&5.5,AX^A5>3LRK;K,(`!WHQH(D#?<QU``/$=13.#8B3E3JP
MX^I21M+Y`T9DK\0[(-\L>4[_`'K*%P=GD+;DFY6B_P!H?*"83O+%<IQ]8IIR
M<QA$PF6D9%0VX^/CKG"222<RND`#0&C("BI'5%5-$31$T1-$31$T1-$31$T1
M5WC/%V2,SW6(QSB2C6C(]\GE#)Q%3IT.[G)MX"8=2RQ6C--0R+1L3[2JZ@D1
M2('4<Q0\=2Q0RSNT1"II4\@.9)P`Z258^1D8U/(`KZ^0YE>AC"'\*QYFF7ZB
MQMLW,\;L.C(M2/&]8R!E!](VAND)0,L$NSHU;M+")4;;@"@'<F`AAV$0$-M4
ME$,+@QS]3S^1I<!UNP'HKUJ,3AP)TD-'%Q`]`Q/L7)OW\*#YJ]19/']<'C/D
M\K3P,RJ6:TX625-L80*DC?ZY46!S'V`"@#K[0CL&_CM*+=K@"'M%1Q#A[`59
M\Y%4BA-.5/O"@)7?)&\S5]R&QGQPM/$[)M,MN4["\K]=L<LQ9/<<E",;J/)J
M;>9#@7LO4TH.`CTQ=.U?BA.5`OV2B82@.9M^V.NIJ3N$=HUI<]^!#6@8&F9J
M:``"I)`&:LGOH88B]OOOJ`&C,DY#D.)).``).`7Z`W!7A'COR],4(\)>&+2&
MN6=K1%M)GE+RBEVB+9FE]@A9:6<R!.A>,I,$HJHE$1A5"JN#`*@^/68,?O'W
MG9M@9M.U,'S;&ES(W$`1#C/<N&':4QQPC;1K:E4V?8G;LYVZ;FXBQU!M0*F0
MYB*$''1P+J5>?>-!0+"EYOOG(U'"52MO`#RZKU]\)S"+QERFY:Q,A\19K_9G
M.[6=J5*L+14Q&S`A2*(/W+4Q42)'%LU$$^\HOQ.S;-)N[W7MX7NL9'`O<X$/
MNR.@XLM1^!HQDQ)]T^]Z#<WL6SL`T-&Z,%(HQ0LM!A1SAD^<\C\&;O>H&X7/
M+A\J3+'/1S:\BV"S0V".+V+VA)W*W(')"IH:I1D:50%73:.DGQF[=Y(*-2J*
M%V/]K8`W*!NX79[[WHCV][MNVH127T;1VCG&D-LTX-[0M!+I"<(X&`O=T!6;
M3W?-WHW+>S.8YW'LHF"MQ=.S);7X(A^.9V'Y03E?+F/YP.!N).++EP5\F:$<
MTFGS;,U7SESB?H'99;S/VD092\?C#K,=Y0:1**E.(N`.#YRD8!^P83**:#;N
M[\UW*Z_WA\DCY0`_M/XDK?RN:,((,?\`5V8N%.V<?X8SMWWZ*S#;6R$7;0DE
MD<=#;VQ/%IQ^8N,!69WNM=\&HT(\OKITZ?.G+Y\Y</7KU=5T\>.UE'+MVZ7.
M*B[ERX6,=5==90PF,<PB8PCN(Z[1K6L:&,`#`*``4``R``P`'`+A9999Y'33
M.<^9Y)<YQ)))S))Q)*V-54::(FB+JY'TI?@/^4NA5S5UNJ*Y-$31$T1-$31$
MT1-$31$T1-$31$T1?L%Y*\FO#LV+AWBK)MVQ\Y/N9")LK9C?(`AAW$"`XZH&
MP(I;^&YG#@P![=?8FQ?4[WFM=,?>&PM+V,9OB+K>3T?O(R>IK5^??>CZ(^Y5
M^73=T=UO]ME.4<[6W<(Z*_NI@.M[SUJ!N0/*3Y6U(5UJH6A928)"(IFK-E+!
MS"Q`WV'[FMZ$,F"FP?HINE?'T".O7MF^H[P\W(!NX_.;?,?[V+M&#^G"7^DL
M"^?.\?T=>+VS%S]H&W;M;C+L)^RD(_Z*Y$8KT"1WG4)[WQVSWC`ZA<@8:R35
MDTNKK>OZE+K16Q1$!.69CV[R(43\/TBKB&VO5-H[Z]S]_`.S;I8W#C^%LS`_
M^HXM>/.U>$]X/#7Q#[J.([Q[)NEHT9N?;R&/_M6!T9'2'T5F`4()S)@<O<*(
M@9/J#K*(>D#$WZBB'O#74:74K0T7$!S2=((U#AQ]"U:HKDT1;S-RYCG1'T:Z
M<QSU,0,F]CW"S%XF8!W`R;IJ=%<@@/CN!@U;*QD\9BG:U\1S:X!S3YC4>I7P
M22VTHGM7.BG&3F$L<.IS2"/2I+4GF?RNQX5!&KY\R.DS;`!4HV;FQML84A0`
M`3^!MB,V@"8`&VP`&WJUPFZ^%WAWO1+MPV>Q,KLW1Q]B[KU0EA7J&Q>.'B]W
M;#6;3WBW,0MR9++\PRG+1<"444K:CYO'*V![2=C98NOJ!.D#C+5)Q`OE2AZ>
MIY5I:*;E.;V_##X^K7GFY?3;X=WE38NW"S>?R3"1H_HRL>?VEZ]LWUF>+VW4
M;N;-IW&,9]I;F)Y_I6\D;?V%):L>=87I3)=^/(]7@"KBFY`^SZ?$R;&?KVX;
M!ZA<C^'7"W_TL9G:MZPX">W]KHY/^2O4MJ^NC`-W[NUCQ=;7GL9-#ZM?G5_J
M]YP_&&3[9;!5<P5-0VW6*M=@+`V3$?3^UA[(+@Y0]O8`1]FN.O?IF[_05-E<
M;9<CHDDC)\SXJ?M+T3;?K5\*KJ@W*SWJS=QK##,T>>.>O[*O1"^9OPIF@()L
MMNH,YP']G8J+=XXQ-@WV.HA!/FX;^CP.(;ZY:Z\!O%.UK3;6S`<8KB!WMD:?
M4NXL?JJ\"[X`G>7VY/":UNF4ZR(G-]:NE%\W.(,R`"QY'8J`1`P]+^P_<Y]B
MG!,=R3#9@8-S&#;P^T'B&X>.N?N/"GQ*M?XVQ[C_`$8]?3^`N776GCQX+WO^
MK]Y]HK^O-V?&G^<:S].8P5PV'(;`$H`#'9SP\]ZEBMP[.2J<(BN;IZ4@`TP4
M1.;K#;;VZTLW<OOE;_Q]IW-N%<;6;+G\"Z2W\2?#J[_U;?\`97^]3"^ML^7\
M3I56M<DXV?'.FRR/CUXHF7K.FTO%6<G(3<"]9R(RQS%+U#MN/AOK6R;'OD0#
MI;&]:T\3!*/:Q;B'O1W7N'%L&Z;:]P%2&W4#B!YI"N=^^U(_^S:F?^]E>_\`
M66HO\*W7_P"4NO\`L9/\E9'^/;#_`//V/^T0_P"6G[[4C_[-J9_[V5[_`-9:
M?X5NO_REU_V,G^2G^/;#_P#/V/\`M$/^6N&ZR-CEAT?'9%Q^R[O5VOB[M5VW
M<Z-NOM]Z5)U]/4&^V^V^I8]DWN:O8V5Z^F>F"4TZZ,4$W>?NQ;T^8W/;8ZY:
MKJ!M:<JR"JI:1S_@:([OWIF[$+#L'*DL#C)--(9)0^W20Y`F3'*8V_LUL(.Y
MO>^YI\OM.Y/J*BEK-B/ZBU-SXB^'MG7YK?MECTFAK>VV!Y']ZJ!E.9_$F&Z_
MO#D;B,IDQ6*<C2V,Y50#(!NH4I(D'QCF#^2!0'K'P+OK<6_A=XCW5.QV3<C6
MF<+F9Y?'I_1QHN>N_''P<L:_,]Y]F!%:AMPV0X9X1Z_-SX55M)CS)>%,-U@;
M-K*6,01#HK]3O$N)A*)`'MJ(5PB!P'KW`0/L(`/LUO;;P-\5+JG_`.*?&#_>
M30,](,M?4N5O?J@\"[&M=^CF(_N;>ZDY9$0T.?/@>2M!.^;OQ*B^H(A#+%I.
M7T?=U':QB1Q^SX`K8)^+.'I'^1ZO>&NEL_IM\1[C_67;=;C]:<O/HCC=[5Q>
MX?69X.VF%FW>+MWZEJU@],TT9]7!6.L7G4T9`%"U'`-QDC``]M:SW6"A$A'Q
MV%1O$1=@4`/1Z%/S]99?2SNSR#N6\VS!Q$4$DA]+WQ^Q<%N?US["P$;-W=O9
M3P,]U%$/.(XYCZU8*9\Y#/\`9')H_'V(,9Q#I41(W1%.WWR6ZC#L3I:MG\.D
MLH`^H&X@(^KU:[&U^F/N;8L[;>MROY(QF:PV[/26O('])>=WWUM>(NYR_+=W
M-FVJ&4G`4N;N3H]UKXP3_0\RU,LO^;]G$I1JT!D2L1CSQ3>0N.ZQB^-(F?T&
M).6UBQ?=L`'](KDQMO'<=4E[M?35W3PW":RN)V_A?<RW3O\`LX7.;7K:%6#O
MG]9_?X5VBWW.UM'Y.BLX+!@!_P"=N&,?3I#R5V:/EP<^<Q*%<YJSDSB6ZX@9
M="VY1M]_=D*;P,`0L$#F"Z@*(_9!R4OJW`-0/\</![NR"SNKM+I'C(PVD-N#
M_3DI)Y]!66SZ8_J'[ZN$O?K?V0QNS%Q?W%V[_LHJQ>;6`KXTCR6,:1XIK9!S
M5<K`I]D5V-,K4%46BAO#K#XZ55M+TQ1'?80(0=M<GNOU2[[-5NS;5:PMX.GE
MDF=_58(F^LKO=A^AGNO;4?WCWV^N7<6VT$5NT_TY#.[ST!4N:9Y9_#&F@B<V
M*%+DZ2`-W5^M%AL0*'#;[9XY-]'0HB(^KX7I]VO-]T\=_%#<Z@;B+6,\+>*.
M.G](M<_]M>R[']+7@?LFEQV@WTP_%=SS35Z2P/9%_P!W12TJ&*<6X^2(A1,:
MT&G)I@4"#6JA`0ZX=(;%W=,F"3LX@'K,<1UYSN7>+O!O+B_=[Z\NB?[V:1X]
M#G$>I>Q;+W0[I=W&!G=_:]NLFC^XMH8S_6:P./6357!.JJIMW%#GV\`ZSF-L
M'L#<1VUI0UHR`"Z-SW.^(DK;U<K4T1-$7SJ+U='47KZ>OHZB]?1OT]?1OU='
M4.V^VV^E#2O!*BNFHU<N*^Z(FB)HB:(FB)HB:(O/3_%#<A38(\H3,U>8/P8V
M+D==\;\?HCI/TKK1<Y-*7B[II%`0,=->ET-ZV5]0$=;#X#K`OW4BIS]7D*K.
ML&:IZ\A7R\]%^5+K2K=IHB:(FB)HB:(OI2B80`/$1]'B`?2.P:KG@$7S5$31
M$T197O+C\KRS\X5WUOM5K>XUQ#%2`Q24NPB@?V6YRB:9SNFE8(^[42TC8XY2
MD<OW!CE*H;H334.4P!!=WEM8,:Z>KI7_``L!H2!^)Q-=+>`P))K2@%5>R*24
M%[:")N;CSY`<3SX#U+VY\&N%>%.*=;9T?`E%KD(=2.[<Y=%(YD^R-<OB#@L^
M<6:[+%2FI-`CE,I2MDQ3:MR@`$1Z0`-664UYN+M4GNVP'NM;4-Z*\7&HS)JL
M"ZDC@`IC-7$G,=7+J"SJ8^BU4&1`J"SMPZC(@575?<`U*]632*4K@0[9$_O-
M$Z1A[A2F4-N/B&WHW`MRTTOF4C)P<#@.DCGU_H6I,CC4VIJ\#$4Q/Z.."JN\
M3<6O6HDC15]*15@E&*::+2-4/.N),>J)-$,(-NH4[EP[>G3.5-02@4>HPGZ2
M";6QL[<6\QDP$K&F@J#6N(J<JTX^=03RF=@B!JQY%3E2F8IB:?R8U464&LK%
MV&S8\QI+MH^T/(A]+9ZSA-6`J]`X^8W8'!Z]IL-,R#@&A9$[=N*S]W]DCYPD
M<ZB@-FZ)`U'>CO6+)ORMKV7^+AE1A1D#1G-,<:$9,9G4@Z2\T&]V#N_\Y2>X
M[0[9JH!F^=YR9&!FW\SOZ(.G%WDP\SOSC$;W'SGE_>6.:40P[+2*D7FOD(W!
MTGD3DM9`.JUFD(V31.F]CL=.EB["L42K2"(=!"IMC&(KP]GM<++23>N\CW,L
M321PEPDF<,0^:M:1U_A6^63I/>]T>F6[+QUXRPV2-DN[M!:-%##:L_*PY&48
MZY,=)P94^\HNX6\K[CWQ*PJ3G+YL^4PJF&&<C\%BSC5B@XS>7<^7)LU^\4ZL
M\<K(MV=0C!`2&7.XZ2F2$W4H7[(&L=WR=WF9\KW=UQPOJ"\%G;.`H':,7-@8
MVH#II`78TBC<[$(^[T.S2ON-S='/<Q'4YSM781U)HYU0'W,CB#IB8-)S>ZE5
MBQ\Q+S?,]\[&D1B"MQ<9QLX98^.1GB;BCBIRXC*5$1C$3)QDI>WB`H.<@7`4
M1ZU7CT#)D5.<4B%W$1VNT[#;;<QCGAK[AM2*`Z&$XN+`227FOO3/+I7\7`4:
M-)NW>.XO7O9:E[(Y!1[W$=K*,@'D8,CI33!'2-HH#J(JL2?H\`\`#U:WRYI?
M=$31$T1-$75R/I2_`?\`*70JYJZW5%<FB)HB:(FB)HB:(FB)HB:(FB)HB:(O
MWEM=4N231%N%44(4Q2J'*4P;&*!A`I@'T@8H#L8!]^K2UI-2!57!S@*`FA5J
MKE@["N1"*%O>(\:VTRH""B\W2Z^[>FW'<1^\?@"2!3"/K!4!]^NBVOO;WIV0
M@[1N5];`<(YY`W^KJT^I<CO?<'N+WE!'>#9MKO"<S+:PN=_7T!_H<HL6SRQ^
M%UK%0Z>+'M174W'O4>XV>$(0P[^)&+J0E(LH`(^``@!?=KT';O'KQ1VX!IW!
MERP<)X8I/V@UC_VEY)O'TJ^!V[U<W:9+*0\;6YGB]#'/DC_8HHY6;R9<&/Q4
M/4\L95JYAZA30E&]5M;8@C^B`C]W0#LQ0'VJ[^_7;6/U0=[(:#<=NVZX'$L,
ML)_M2-]2\SW3Z(.X-Q5VS[QN]H>`D;;W#1^Q"[]I6&L'DJ6]+K-5.0=5?``"
M*:-EHDU$G,/2.Q3N(F;FR%W-X;@F.P#Z/#QZ^S^J;;74&X[+<,Z8KAC_`%/C
MC]J\]W'Z%]Z94[1WCM)!P$]I+&?.8Y91ZE9N:\GKE,P$_P!SV+#MC(7?H[%K
MG8=50-S[?LY:K(ID$0*7P%3P$VV_@(ZZ>U^I?P^F`^9@W.`],,;P/.R4GU<%
MQ-]]%GBU;$_)7.R731E2XEC)SX20`#AQX]!5K93RN.:L8(]O&D#,%`?TH7(E
M*<=6R?<$2D>2\>J(;_8_1`1/X!X>.N@M_'_PLN,[^:(_KVTXXT_"QPZ<\ER5
MW])WCI:_#M5O,/\`FKRU/"OXI&'HRS]*M[(^7YS0C.L5N/-W<@0A#B,8XK,M
MN"@@``0L;/NCJ'*(_:*4!$H>([!K=0^,OA=/0-WJT:3^<2L_M1BG17-<Y<_3
MGXXVE3)W;OW``']V8),^6B5U3S`RXJDW?#'ELR4.DXXX9?`Y"`H;LT]^[(!1
M+U[@JS!PD<>GT@!A$/1MOK8Q^*'AQ*T.9OFV4)IC,T>HT*TTO@AXQP.+).[&
M]:@*X6SW#TMJ/053P<6^3`[;<>\T>/\`_+6V_P#JO6;_`+_]Q/\`SG:_]JA_
MRUKO_:;Q2_\`3>^?[%<?^&NF-Q]SV4QB&P=F`#%,)3%'&=T\#%$2F`=H00W`
M0UDCOGW/(J-VVRG_`.M0?Y:P#X<^(8):=@WNH_\`H;K_`,):"\=L[KJ$3+@C
M+JBBABID+_E?<A$QCB!2D#J@]OM&'\&KCWV[HL!)W?;0T8_ZU#_XBH/#7Q!D
M<&#N]O1<30?Z!<\?^J7:_P#"ER/_`/ESS#_\,+3_`.J=8_\`[A]R/_.]L_VJ
M+_+69_[0>)O_`*9WK_89_P#PU4+7A/RN>*D1;\:,L"H<HG+WJ2[:I])2]0[K
M.R((E'I]`"8!'T!XZPI/%3P\B:7/W[;J`\)P?4*E;&+P*\7IGAD?=;>-1'&U
M<T>EP`])551_EZ\QI+M=GCA<VX*B<"FD@K,4!!)U;]X)*;:F1`W3]D3@`&W#
M;?<-:Z;QG\,H*ZM\M7$?E[5_HTQFOFR6WMOIO\:[JG9]V+YH-?C["/+GKE;3
MHKGP5<1GE=<SI/H$V'HJ**<I3[S5YH+,2`8_0)3II3KI4IR!]H0Z=^GT;CX:
MU5QX_>%]O6FYR2$'\$%P[AS,8'1UK?VOTG>-]W0G988JC_.75HVF-,0)7&HS
M(IDKF0_E`\L7HD^\!Q!72B(`87MW</CIE[G08>W"5R1`VR?VP`#>(>'@;PUH
M;GZE?#J('L?\3G/ZL`;P_P"<D;U9>I=39?1?XP3D?,?X+;#]:Z+J8TRBA?PQ
MS]:NS!^2YEUQVQL.;,80Y1V[B<1!6V?4(&P;@0SE&OI'$!\/2`>OW:YR[^J/
MNVRHLMJOY3P+Y(8QZC(5V-C]#??.2AW+?=I@'$1Q7$Q'5J$(/J5Y8#R5*FF*
M9K7R$L[W;854:S0H>**;Q#<".)>=FC%W#?Q%(?3Z/#QYB\^J;<75&W;+;LZ9
M;A[_`%,C9[5VVW?0OM#"#N_>2ZDYB"TCC]#I)9?[)5\ZYY0G%"([9IV0RS<5
M"=(G^\+BQA&Z@AL(@*%<@8Y8I3;>@%MP#U^O7)7WU*>(ES46C-NMA^K"YY'G
MED</V5W^U_1CX0V5#N$N\7KAGKN61-/FAA8?VE(:K>7[PUJ`IJ1^`ZA*+I"4
MQ75M7G+@L)B^@QB6.5D&@B/K_9`'NUQ>X>,OB?N51-O%S&P\(1'"/^[8T^M>
MD;1].7@CLU#;=WK*60?BN#+<GT32/;^RI.U>D4FCH`UI5,J-.;@`%!*K5J%K
MX"4OH`PQ+)H8^W\X1UP6X;MNN[/[3=;JYNG\Y97R?VW%>J[3L&P[!'V6Q6-G
M91\H((H?_AM;7SJJ3'.<>HYC',/I$QA,(_C$1'6O``P&`6W)+C4FI6G551-$
M31$T1-$31$T1-$6GH3Z^[VT^[T=ON]!>[VNKK[7<VZ^WUAOT[[;^/ITJ:::G
M36M.%>=.:II;JUT&NE*TQIG2N=*\%JT54T1-$31$T1=3/R8PL#.3)4?B#1$/
M*2I4``YN^,<Q7>`CLF`J#W!1V^SX^/AJA-!55`J0.9754:TIW:I0=J2:"P"7
M;+**,_B$WB:#AF]=1SLK9\D4B3]B9TS.9NX*4I5T!(H`!U;!1KM0JJN;I<6K
MPR_QI6<5#R?!/C.Q=AV6T;EC/EF9`<=S+2+N%QQ25U$@\/V:<5/`0P^(=PP!
MZ=:G<'5>&\1Z^7M*VNW-(:Y_#+R]2\*FM<MDFB)HB:(FB)HB:(FJHFJ(IB\(
M>'EUYG9GC<>5\CJ.J46*$KD2WIME%F]>@>X(%:HF#8BDY.'(*#-+??J$R@AT
M$'44\[+:/M7@NX!HS<[@!]IX#S*YC#([2"!Q)Y#G]W,K]`#CCQGK6'J15,>U
M2(8P5=K\8SAHN,9"*)TA:M5C*K*@80(HHN<IN\<QQ$XG$WVC#KG;:UN;V[-Q
M<@.G>?,,,N0`&`'+I4EU>,CB$<.$3<O5YZG.O-91<?U>+@F#)(R#8ZI")';M
MDVS@%$@,7MF.!ER=9C&4$!2`=B;%$0VZMQ]#L;66V8UHTAO)<?=3-E<7BM>?
ME]BN*K9SQ2@/S/309X],5OO%L"RTOWP$$4VZ0('46,JX4$$BI)[*&$W24HG$
M`UOHX8@W5/[S'8::8=?2M89)2\"WKK:<Z^GJ5N+KEJ1K\/.%DK95\7)X[KDK
M9<OYDM3DC:J\<,8S:_<DS/)$QO@U\M6IF0$`:(&46:F'X5$IC&<&5X/O?WGM
M]E>;+:Z2;M*6@"FIL-<`XM;4EQ_S;*$N.-#0+M>['=Z;=&-N;T._P\$T`-'3
MNS(#C33&W\;B:`5)(JO)?RYYW9S\SNP'X">737[;3^'J5B.G8K(Z5<Q][Y+3
MQ'F[V\9*F'"C=5A6)9ZG\4WACJI(@02&=@)BD2)Y[=76V]SH#O7>B5\NXRN#
MV6Y(<XR4PDEI6KZXM%2R+)NIU7+U?;MKGW<=G8%L%@QNA]R!1K6?W-J,R.#I
M,'/Z&X&??%SR[<(^6ZWAI&V-JEF7E2F5HK*K+%:V*D8B>.DTG+(L>F"`MYJW
M%`2"55;K:(=1OL?8^UXUWK[V[YWMO3%.>SL0<(FFHRK[Y!HYPY5(''%=KMMO
M86-@+;:V.BM,?>(TR2$8$DG$`^8]0*O9-U4>0$39*-F"H,LDXXLIWQ[)%9`C
MVED;2BS]9\]7<MFQTTS1+Z/4<"+5Y']I1B782`7I\,/:FW6TR-N;&5T=RW(M
M.5/:#^(<1S5E\VUN8^RF:QS3A3AR\_W]*\</FC^57<>#4ZED_'XR%SXOW264
M;U^?5.+V=Q?+O%U!:4/("A2E.<3`42QTKT%1?$)T'$J_@?Z"[I][(M^B^5N@
M(]W8WWF\'@9O9]K<QPJ,O(M^V%VV/-Q;U=8DY\6GD>CD?,>G#]KLUS::(FB)
MHB:(NKD?2E^`_P"4NA5S5UNJ*Y-$31$T1-$31$T1-$31$T1-$31$T1?O+:ZI
M<DFB)HB:(FB)HB:(FB)HB:(ONJ*M2M76?]<W]8?KTH%74>96OOK_`/7*_P#I
M#_7JFEO(*O:/_,?2G?7_`.N5_P#2'^O32WD$UOYGTK1UG_7-_6'Z]5H%34>9
M6G14J5\U5431$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$3
M1%M.&Z#MNNU=(IN&SI%5LY;K%`Z2[==,R2R*I#;E.DJD<2F`?`0';5%5?&S9
MLS;MV;-N@T9M$$FS1HU13;MFK9`A4D&[=ND4B2""*90*0A0`I2@``&VF29XK
M\M+^*OR]_F=YP>3JJBZ%RQP/B#"N(FQ`/U)-7BE5')TXB0H")2*EE\CJE4]8
MF(&_HUH+MQ=.<:C[#B/:M[8M`MP0*5-?L^Q><+6,LM-$31$T1-$31$T1-$5W
M<%X+R5R-R57\4XJK[F>M$\X3*<Q$U/NZ"C`5(1[/SSPI13CX>.(?J44,("8=
MB$`QS%*-LCV11F60TC;F?+,G@,RKF,<]P8P5<?+S#F5^@=Y>G`:D\6\5U.DU
MV$*Y<-DD):Z6D[;MRMVM"R9%74P_$@"L[:E5(9)HV()@01*5,"A]L1T+G/OK
MKMGM(A:*-;R'#K).=..&04LKQ'$8(SB<SS/'J`X?I6:^G8\8M6A%G2:K9H17
M;9!P@+APZ42*519PHE\6X.44]_T=R%'[`%$2B7756$3H@-+:M!KGGUTK5<[>
M/#L`17J.'1CDKGMX485NJ8_<9%:(*O3E=N$A=/F11(H41.H8W9:$!40.JH"*
M@E,84R=)1-KI8;AOPN`I6@Z#T^70M'-&2=5?>IRX='W=`45N06=L;X2JMFR?
MD.^1&,*Y36#:=M.0)Y!NY3QLWEVJJT8]BH9!1J]N^;+LDF=O3:\@0SE(%?O!
MR1(@$42T/>OO2[:6LVG;FB??YA2.-OO:0<GN'`<6@T%15Q#`2NB[K=VG[L]U
M]<U9M,9]XDZ=9&;0XY-&`D=CGI:'.("\RMVDN5/G+65OBR@0D]QS\O+&DXXM
M:</:'Z[)]:E!<"=7-/)*T@8!LUTED]UVT<'>!B"@)-$?2N/@.Z][MM[FO<_M
M&[CWRD)+G5U1PDYT.3GC)S^'PMH,#[]9;`+JW;+?-=;;/0!L8&F6<#$-#?\`
M-P\0S`N^*4UH!DHXZP6$^+[(<.\;XI"=:)-W$):LJ.&!6CFR2`MUR)KP:3HR
M"Z$&JL'40@KICN8INH1W$?*K@[OOMV_==SD,EP\G$Y`<@.`Y+IIW,BMVPM:(
MH&#W(Q2C1TTX\,/8K^N[#*/$7,*YAV3F6=BP6<3!BHGD'$8@!7#8DJ_<=I85
MVQ$A225,<5#``EW$PCOL8;%L8#CGY>52M4Z6IU8Z!Z/-]RY+5=FQBEW*#-LD
MJZ8[HH&%9HZ:!\.9%90J?6'V%DE.HQ1`?L=8>&VPYHA`!=QY\E&YQ+AJJ:%6
MRR$[I.1*A(XYRY%Q=SQU<:A+1%KB)%%,S1PS?@B4Z*K%0IV;<QE&ZGBB.Z:J
M)'")TSAU:B9+>6URV^M7%EY$X%I;Q(X>?\0R(5S[>*9CHI&@QNP(.((X_H]"
M\#'/KB+-<+>25QQ&L=W)4EP8MHQ79W`]XMBH$PHHI%BH](FFW=2T&J4[!\)`
MV^(0$X!TJ$$?HONUOD/>':8]PCH)?AD;^60?$.KB.@KQ[>]L=M5^ZWQ[$XL/
M-I^T9%0OUOEJ$T1-$7P1`/3HBZI^;J,G[@-^4-"KFKK]45R:(FB)HB:(FB)H
MB:(FB)HB:(FB)HB_>6UU2Y)-$31$T1-$31$T1-$6H"F-OTE,;;Q'8!'8/?MJ
MB)T&VZND>D/2;81+\X>&JHM.B)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(MU%,554D@]*BA$P_"<P%#\NK7$-
M:7'(!5&."_&8\VW*0YH\S[GQD4%Q<M9?E3F&*C%A-U@>%IEL?4B$Z#>M(L37
M$2DV\.@`V\-<Y+3M'`9`T]&"Z.$$0MKGI'KQ6/'4:E31$T1-$31$T1-$7>5>
MLSUTLD#4*O&.9FR6>7804'%,TSJN'TI)N4VK1!,B93&V%10!,;;8A`$P^`#H
M2UH+G$!H%23D`,R>I5:USB&M%7'(=*]_GE:>7!4N).,(Z+=),YG*EI%"2R/<
M6:[=PM)/CMRF2B(4Q$?B$*W%"/;:HG,45%`,J?<RFQ>6DN'[I<:F`_*M-&"N
M>'QD#"IX5R%!G59T@%K%V51K</?-,OU:G@.C,XK/]C>JHKD*B:)9MF)$"II*
MO"BV=HJ)D-N*PF,0P`F783$.`@.X>'B.MU8Q`"KA[O5CA[.I:>Y>6G]V23GA
MY>SDI%'9-X=@8H*M%5B`D5J9-)$7"RBG4<$DG.X`4J92[#T&*D`>HV^NDLB'
MX^\(\NGT^6"T5SJ!H*$Y]"QS\Z?,%QIQ3KT>TM<HXF,CV-)VA3:-%,5;#,6F
M?B4F4J2)C8]DC\&O]TLI%HL9-TH1J"SEO\2H5OW`-K=[WZSV6"5UHV*2]CP&
MIU(X:@'M;AYP:P5J&@%[S0-::E=!W<[J[AW@N&=J7LL"<2![\@!(T1#-SC0@
MN^%@J2:T6&3_`(?\N<TIF#Y5>8#,!COC[0Y)X]P;QEC9)N:4?.)I^[7&3$KQ
M)!&]Y-L+HP%FK>_(=!J(]IFF1!--,OR_O_?R:<S6/=^1\MW.2+B\=A++4XLB
M`QCAK@`,2*:CDT?0VW;+9[6V.-T3#-&`61#&&'2``Z0Y/D`-0,AB1B2\WBN5
M\LMBC8NG8]@QQ)A&OJ/4ZICBL+O'[5D4RZBCQS,SQ#-G=FG'IB=Q9=P"IP$P
M`F($`I!U&T;!&]WS-Z"YV>)IGU_H65<;@R,'4[M+IP%74I6F`H,0`.0\^*O/
MA&A&AF+=91L1=1@Z06.@V%,554DB`LD85EMEDW(D4*8`(D;<.H`'70W$3->B
M('0T84HM+)<NDJYQP/7@?N4_(,&[^-N#MQ78J;2L:<>Z[9(]DW?IRC,169@@
M^:-V)(ELZ,NLDX(Q^&!9)0W\LA1`TD!YTM.JG`8$98X4Z:4J#BL2A<6@%PT5
MXFAKG@:UZ*U49\]@PBD@^Z8H&#..74^[&"[D7J3M1RY%19,\E(%9KHMTT6_;
M74#],2=?203AJ`EH>`T:65XXK,@!)&HU=3@*<.7V+&IDO(\5&18,F\/(,K/W
M"-I=:5.11I'L&B))<YOA&R"S>32=@GV2E2,04E"G,8?1OD6]F^60S2.'84KQ
MK6M/,:XK8TQSJTGRQ.76L9'.'%K;G1@V0CBKLHC.6`H.<R!CXR;90S"XP1(\
MSNVT!%ZJJX705?,V"2[%(Q@!!VW*4VX*^'4=U;W_`'=W'2=3MKNW-:2<-+ZT
M:\CIJ03RZES_`'GVMFZV),7^MPU<.JF(\_,<:+RC`.X`.PAN&^PAL(>X0]0A
MZ]>UKQU?=41?!$`#Y>/NU5%L"(B.XZHBZ][Z4_P&_*&A5S5P=45R:(FB)HB:
M(FB)HB:(FB)HB:(FB)HB_>6UU2Y)-$6P[=M8]HZ?OEBMV3%LX>O'!Q`"(-&B
M)W#E8PCX`5)%,QA_!JA(`J<E4`DT&:QE2'-')IWSY2)B:@E%F>.AC"/(J16=
M$8"LH+(KM8DND51S\-T]P0*4!-OL`:UQO)*X`4\NE;<;?%3WB[5QR60.G6.1
MNN-Z_:(X6+>;L53;R+;N(J*1J$ZNQ$!(HW!8JIF*<H02F)W.KMAMU;^.LYKB
M^,.&9"UDC!'*6&ND.]2ASC;E3?Y?)D#3+Y&UF.82$TO7)(6$<]9O6$N85V30
MHJN)-RF4A)<A$E`$@[E,/B&L6.Z>9`QX%*T6?+91-A,D9)(%?,KS<C,[.L1-
M(.+K:48]MLTJ=Z="325<M8^";"=([E=N@X:JBN_>?LT-S@&R:AMAV#4MQ.8J
M!M-16/:VPG)+ZA@]JIJ"S_;H/%:>1<DQD2K)VQ\6/QC3H!@[8R5@,4!(,@[%
M9X_6+'N%SE$HD)U=H"B4#&63#5HG>(];P*G(!7.M6.F[*$FC?B)X*,DE?Y>W
MVNT(9]R)9*K$UQ/MA3**H"*KF;46(4*^P9H&48@:/(!P=N':BAB*E`@J=0CM
MC&1SG'MG$`<`LP1!C&FV:'./$\N?W45&4^2"1OA&N/<AR>(H[HZFDE>[F\74
M<JE/LF5R:,C6\8*KD1`.RJ042EWW4-Z!L:ZKZ1DM'2?(*21NF*LK`]WZH\BI
M[XJR]8UK*;%66FK%C>BM?C*Y88LZ)Z_?(PI#G*[C5V_^YG>'02,H44=DU@(<
M.A-4AB#G13.)[.7X^!YK630,T=M!4Q\1Q"DBLL@V16<N5T6S9LBJX<N7*J:#
M=LW03,JNX<+JF(DB@@D03'.80*4H"(B`!K(.`J<EBK%MFKS,*]6Y)[`88K+.
MZ'9*G;KW:R.';*L++)F$AC044R%"3EVH'#[+A59JFH'B0IRB!APY+L#!@6?%
M8EPK*:='%1H-YB_*1N)9)S#4@D88>LH+X_ED(XR>^_260-+D4$HA_*[HCJ'Y
MF7/#U_>IODH,JFO6L@3[DOD-CPP4Y%RM;K$)=7[5DXKT.F23>P#EK*6MI`Q$
MDY:N7:+\I9)@=1R"(.!`I1(('$!VUE=L[L.T--7Z5B"!AN>Q!);^A;'"7D=D
MOD4SR/(WUC56;.J.ZU'Q(UJ+?1QE7<JA+.G_`,89Y*2(*E20:(]`%`FPF'??
M<-EO*Z6NJF"74#(2T,KC7-5WS&SM9N/N+(RWT]M!N[#*W.*KK9&P-'+Z/^#7
MCI:1D%`;M7K!8RY$X\H%'N=)>H=P'PU=/(8F:FTK566T39I-+JTI5:.'&:KW
MGO%TM>;ZTK[1ZE=).OQ:=<CW<>T/'QL9$+J*+)NY"145<"]?J%Z@.4H%*`;;
M^.D$CI6:G4K55N8F0R:&5I2N*B9R;Y\Y`QGF*R8]QC'4N0A:@DRBY=_/1<C)
MNU[,5#XF;20593$>BDSC3+IMA*)#""R*@B;T`$$MRYKRUH%`LB"T9)&'OK4^
MQ2EX8\A+-R(Q]9YZY-H)G8ZU;S0BR->:.6+$\6ZB&$C&KF;.WK]8%S*G<$,;
MN=)@(&P!L.IH)3*WWJ:JK'N86PO`;721Q5L.:?+J]\>;13:G0XFIOG%@K+RP
MRKVRLI%^JSZ996-8(LV[*4C40(J5HJ8XJ=8B(!ML&^K)YW1NTM`Q"DM;=DS2
MYY.!40%>?_+J+8-K%*TJM)5UP"*J$F_QC96$([2<=(H"C,C*(-SIN"F#MG(J
M/7N&PCJ#YF48D8>=9(L[<G2":]8JI\\2N8,?R0^^:U-5]O4\A5]@G++L(]TL
M\@YZ&,X29K24.=T'QK19BZ72*X;*F5$H*D.10P"8"9,$_:^Z?B6'<6Q@HX&K
M"HAYI\P/-57RW?,?4&`HJD96+?*U:'67K\S.S<H:,="Q$ZB:<TDBLZ6<IG`"
M(H!OX``".H9+F0/+`!@>E9,5G$Z,/>34BJH,WF)\HJNY;GM](IY&ZQ@Z&DY1
M;-5S.@#Q,1LZ-+-E!.(>L"GV]FK/F96YCVJ[Y.!WPN->@@J<F'.<M/RY3+0[
M3@/W=R358UF]7I3^5`\3+)2$K'P2$S%S_P`,17[B824HB:1[B`.63?=3I4+L
M;60RY#F_K+%EM'1N&-6'BKR8/S',Y,<3<;8(1O%/XV/93#95JS>19CL7CI9F
M*$C#OY&5=,53'3(LT6%?I>MCB<I"@GU*21R%QH5%+&&`$'BI":F4*:(FB)HB
M:(FB)HB:(FB)HB:(FB)HBXK^50@H^1GG1BD:P4;(3;DYAV*5M#LUY%<QA\-B
ME2;"(^[4<E-!#LCAZ<%<VNH4SJOPQ+[:7-ZO=XN[U057ERN=JMCI4P[F5<6.
M>D)A901]8J*/1'\>N;)J:KI@*`#D%2FJ*J:(FB)HB:(FB+6FFJLJD@@DJNNN
MJFB@@@F=9==98Y4T444DP,HJLJH8"E*4!,8P@`!OHB]=OD^>5D_Q0E$\C,VQ
M@H96EV1'-3K3IF5P3&L"\*0P*R)U-D&]PF4#;+FW$&*'[$!`YE1UPV\;Z+R0
MV%DX_*"NMX_$0?@'ZGYCD[AAGO;6T^59VTP!N'#W6G\((S/ZW(<.M>L_%E*,
MD=!W%NE#MU"@84S$39()E%4H*%533$4RM@'?8Q#]6P#T`8WCK/VMHIV@^`9C
M(>KA7I\Q*U-VXBK'_'Z3Z\_1UJ:$!32Q?P`*[NI11`HB9BBF+(.M0ZB:>R[U
M/H=%3$3G.8J1C%+L.VP&UTK'LCIII]U3E^G-:5^IY)-0WUG#/++HYKNY,K-J
M4!>)+?"(I*"=HBL!>YW2`1198ZRZAND"I%,;[90'P)X`(ZSX)&",AKO>)J#P
MISZUBR1O+A4>[2G3U#^18(^1O'.CRO)2P9]&"C;1:7\-'5>'A)-56081/W`W
M0-\6JFW(EVHNPGZ$Y!NFZZ7`(](%)UGW^>/$R*YWG?9K/;VO9:2.8]Y!-'/:
MP,U$5+:@#W3PQPQ7N'<7=)=LV2*&=S:QZJ8#5I>XN+:TU`5QZZ<`%L.L?V>P
MM&]AR#($EIHC%O$0M8*FFQ;Q<2BL1N6*BFJ9/@H:(9("8[9L@'2)0\1ZMQ'G
M]G[K_(.:V%A:"<7NJ23F*UZ5M[[O`V8D-P&=![>GK*N)B;&=87L,/"V$\JSJ
M\X(1@/6XIE.S63$>A%!T"*C$Z*A^@R@*`79,HB/3MU%W5Q%(SW7ANH'AQK]U
M5K!/VAU`_>I`AQYME48`XDH-TW?1A5I1HY1=%EE9B&92A?C4T7<8[7^'<BP,
M"C<`*<KH`,4.@Q2[X#M;06N`P&%./HR/$+)U`.JTG'[NGIS5-2>3E:HLZ^),
MB[A7K3M1P&:*1#IH@18PJH**JO'IUW+-V!@*I]D`*J('\0':&-[M>D8@CR\Z
MR6AKV4;@\9\?N4,>2N3VD9`+*K,FZ$Q&*@L94SE<'$NWE$P1>5]!DW^P/:^*
MZC+F.!5!Z0(.PCJ>UMG3RB-PPY_;YCZ5E0D8EA-/+'R\ZPHY)R%,/+`BF^=)
MMF((.G)7+[]JY%,RQ&GP3XT>Z!(Z98Y($W&Y0W)N0/M`.NF991=DXQ?Q>C'A
M6HZ>(5S[O0\!U.RIQ]GZ5UV(LBJU;,4)/G192,*S=O*PY8LD0!*20G")-I-P
MI#.%4R$5=M%"I%,;TI;%-X[#K3;J1+8"&-VF8D/J<ZM.&/"A]"S+=ADE<'`:
M*:<,L:'[NM>:3E7B9U@SD?FC%;ADO'MZI?YY*%07252,>LR;LTQ6'"95@`YD
M5X%^W,0WCN'KU[CLU^S=-IM[^,U$L32?YU*.]#@0O#]WM#8[G-:Y-;(:?S3B
MWU$*P&MFM<MDX[C^#Y#HBT".WB.B+K79MS$_`/Y0T5P7$U17)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB+]Y;75+DDT119Y<7S]U<9&KK1;MRU\=##E`IME$X-H";
MJ<6\!`0(N44FV_K!<?9K%NGZ8](S*S;&/7-J/PMQ\_!0QL>-SP'&ZE7)PW[<
MA9+ZYDEC&+LJ2$?0[IC!D$1#<$UABSK@'K!<!UANC+8`\\2M@R;7=NC&0;3S
MUQ4XN)DU][84@FYC=2L!+3T&<-_$J:;X9)L`_@;R1=O<&LVU=6$=!6MO6Z;@
M](!40>65)6I>4T;=%D,U8W(J5@:KHEZ2M;+&*HDE2D,'@54ZY478>L16,/JU
MBW+-$FH9''SK/LI.TA[-V;</,5M42NSW*',DA9K0F=.O-3LG]E%$RGPS6+:$
M*A%UA@J(!TJR0HB`[;&!/O*^`[;F--Q+J=\/E@DKVV<`8SXSE]I59Y8R66M<
MC49]:#"3K&)636KQ$>FD4&$3,/*X\=Q[END.S=%=*5,`I@/_`$33[/B0NKI7
M@3U(JQHIZE'!#JM-`-'R8]8KY>E1TRUFZ"X>XKI.05ZE"9#Y`YQ-,6.LEMJ2
MKNO4VMHN"'<V%VR3.DL[?/W3Y,4R$41.J=0P=PA$3%4]V\"O!L>*6XW%QN<T
MEOL%EH[5T=.TD?)4LBC+@6M]UI<]Y:Z@T@-JZH^3/JR^I@^`.QV=ILEM%>=[
M]S,@MV2ZNPBCATB2>8,+72>^YK(X@]FHA[G.HS2ZUW'CGJ?DI?H7"')>DT7M
M9`>A`4G)%+A!K<W4K6_`R<(@\1,[>HNXR1>B1N!B&2Z%3D!4JJ9C"3V#Q<^F
M;8]@[K7'>;N9-=%]E&9)H)W-DUQ-^-\;PUKFO8*O+3J:YH(&DTK\U_3C]=?>
MKOGX@6?<7Q,MK!L>Z3"&VNK5CH>SG?A%'-&7O8^.5](VO8&/C>YI.MM=-^&U
M"EJW%WN<9VARUN>`[<T47@%"&%HM&C,H,V\["+`N!F0A(H@+A$4Q(HF8GV@$
M=A^(PW2"X'WF'RHOU/,C7N:QS?W<HS\V15Q_,1SD]CL14"D5UT=BMF5B6PV`
MZ!Q36"F,FL<Z-$@8H@)4)B6D4R*^/VT6QR#N4Y@UE7,ON`#BL&SA':N+OP&G
MG7$\OCC)4"46.SA=()A8K/9WCW]R&LNU1?,*Y!1SQ:-)+-F+DBC92;EWS94Q
M%SE,9!N4@)])CG$:6T0T]HY+R=VLQ--&C-2[DN6W&!LJ_A);,5)ZV3AU&2$8
M[3DG""2[-91H[9K-S1"K8X(K)F(8-C%\/#<-3F>+(E8PMK@XAI46^=^0Z58^
M)5<=8YEHJ4J%JR'7H:%<P2!FD2HRK"4ZZ=-&+86[0$6S!W$E3Z"IE(42;%\-
M0W#VF$%N5?+V+(M&/;<$/!U!I]:[/RPX7X'!]QG#$Z36');],I]O%1""@(5F
M3Q_5(X=*_CWU6T`T%W&JI?&LH')JH3S4)KMU?#5<*;Q>6.V3RA=_22,BHR-1
M,(>SJES^.J7F0\O+-76`]YQZ`KF\8K9'X+X%MLE214]F+&\W!JW/L'WC+R5E
M?15;8``[=PT@_0:I?T1$?0&JQ$1V^ORXJR<&6\[,<P/5BL>O'?$LME:A\K<M
M3Q#R3R)QI:D(Y^X*)S/KU.=5MFGJ8F`=UVL7%G`1#Q+\<76-&PO#G]!\O8LR
M:01OCC&6H>C+RZE('RL+."5GR]3CJ?8DZ[6K4U3$?TE8>2>1+LY?'T]F<1W]
MP:FLS[Q:H;]ONM?TD*S/F33`RO)!U%D/U!7<?5*)*&_@FN]3DIQ0ON$0EB".
MH[DDRTY!2V(I#7FXJ?\`E?D[Q[J'&]]1F5\JU^E7.*F]$B*=77I)\74@:KH0
M2!Y#X<BS*-CXUQLLHJL8@E[7[,#*=(:F?)&V/3@74Z%AQP3.FU4(&JM3AQ47
M?*^QC83W:SY@>M7#2HQ=:=4^,D%TS)HSLS)/XQW)@Q.<`!RVAF49^W4+N0JR
MQ";]0&`([5CJE_"BR+Z0:1&/BK51YXR==]YMU&9/NI\9E"YW90Q=Q_9LBV2P
MHJ=7I`"J$3\=1QC7-UDJ:?W+4C]4#V+T"7*FUO)-<DZ9=(IK/U^=;*,'C.02
M*X[8."BF1XS44`RC.09G,"B"Z8E424*!BB`AK8O8TM((P6H8]S'!S3B%YRN.
M"*M5Y6X_KR8)2C4N2W^/Y5NNDDY:3<!).)2IS+5\V4*=NZ9R$:L<RJ9BB0P>
MD/#6LCPE`Z:?8MS/[UN3^K7[5Z-:Y4*O4$73>L0;"&3?*(JO3-2JG7>':H_#
M-/B7;E5=VNFS;!VT"&.)$$_LIE*7PUM0T-R6E<YSOB*J+5RM31$T1-$31$T1
M-$31$T1-$31$T1-$4=N8-J-1>(G*ZZD4[)ZCQFSY9$E=]NVM#8HMK]$^^X;"
M55`OCJ&X!,+J<,?0:J6'^*T<S3TX+\1-#^Y1_P#-)_\`,#7.+I#FMW1$T1-$
M31$T1-$7HT\EGRYT+\[A^6^88A4T*SEU4<%UF1:G!O,2T8?MO<B23942@ZBF
M+@1;113%%-5R!W`;]M+?B.]F\21TVBT-))&UD<,PTY,'(NXG@WK6]VFT`!OI
M14-^$<"?S'^;PYGJ7M4H&.6\0T;1CQ!<OQ!&YF#A-B+M-7N'[CB,?F1$I54-
MNH`(`E.(AX;=6X:3;[%X#6XAN0H,*\G'B#RSY9JES/K<9#2O&IH>L?>L@E&H
MJD&QB44&*\4T71,Y154:JIG%PX*`J@1DX<"RCU%B#L8H=0`D)0Z=QUV-BPM;
MV1JUH-3A3S`5H.E:&Z=J)=\3\AC@1SK2I5^3UY9G$KN6_::.$>@YR/P`RZBQ
MB@!7!W94"$%!3P-N7J#8.D=M3.N"':F4,/"F9\_6H1`2*N)#^(.7F"I!6H./
MAGK^3*QD%6G=.VCC+"?K<N"G03.DMXMO@TEPV$Q^D.YT]0].L:^OY^R_=Z@7
M#,?:LRTM(R[WZ%HS!\O2H5.<:#+((%>O&D:=RX>-TI!$T<=5D[>'4=K+S2+Q
MP3J476(5$I@$I$BAN4=AW'DKQLDK^UHX=8Y5PYXKIK8MC;H!QKPR\@M*>$(%
M9D8;(E-&=,I1P[2(:7@0*>,,W.BD0(Y%\FYCU5C"4Q2G.9)=/Q(!O#6FGDD#
M,1@,*5'D#T\5M(6M)P./4:>GET+FUA$*S#,(-`B3JEMIM.?C49FM-)%\J_1<
M&!,H*I'2>PKET!#`1-45.CJ$0$`'PU;KC'1)D:FF!Q^PE9[8P[WFG'FN%<[=
M:[%.J33V6=-W,6Z>C"LR`FU38E^)Z6R:S5,$FBRS95$@B4Y=Q4*!@\-]:RY+
MG$O9\0.'ET+,B]WW*"B@/D]:4%M+2;GI,F[^\)-NT4`7H,E2N^E0SHAP%42O
MG1#K`01V$W6&^X`&L"*5X=J-=1^T^D56>"VE!P`'JX]06,;+UQC[-%$9L8LR
M=@5E#D5?O!%@A'IM_CB@^0;=9"JR()$`H'*0W:,7J$HB.X;J`&#WGO\`W=.%
M#4\J^55G1,<`0WR*AVPQW#6X+:B>-[]QF&#YM563I)R]1D9$Z"IUE&23!J/P
M;AHGTK%.X%$A1W`0,)A$&X;K+;-C8QVFW%"XC#2T'&M3D<1AB5D0VK'ZGR#W
MB#GS.1\RM?3Z&JPFG#F=8]"R782>E035.G]\HI_92Z@,F83I*(IB<!V$!V*'
MH'7([SO;9(!!:NHS4:4STDUZZFI`6^L+(L=VDN+R!7D32BQU>>*RA%>1^(K:
MU;_`6>V8`K'[XL3`0'`N:Y,S,'!2+KI'[;AY"()IB8?$Q4`W$=M>U>%<D[N[
M1CEQB9</##6N!#21YB3YRO&^_L,4>[-?'\3H\>FCCC]GF6%D1V#?7I2X=;&B
M+9.;Y@_+HJ]"ZY<=S!^`=45P6QHJIHB:(FB)HB:(FB)HB:(FB)HB:(FB+]Y;
M75+DE]`!$0`/$1'8`]HCZ-418D.1]L?9/S$_AX)%U+MJ^8*=7V,<DJ[7?.FA
MU#RZS-NW*=1=5U*"J`=(")DT2^H-:N=QDEHW&F"WEHP0VX<["N)KZEMWVWY_
MF*(6MW:K24;2(D(<2F4H9X1M'%BNVTB@&1!FE\.0G65(-S!U]6P^G1YG+-+P
M=`Z$B9:MEU1.!D->-5(7A!.IA`Y$@G"Z:2<=)1-A`RRA4TD&SQBZ9O5U#&$"
MII)?=9#',/@`>(ZGLW>ZX'@L7<6^\QPX@CR]*LODNT3_`"9R\PJM.$RD"P,_
MCZNFKUE:_"-4S.):T/BE`1)]XBW#H$0W*B"1/TA'>&1SKB72WX1Y561"QMG`
M7R?$<_N7,XBWI6I9)<TV3.=LPNJ9HLR"P](-;1%"NI&]11\"*KE[[4WK$YR!
MZM5M7Z)-!R/M5+Z+7%V@S;["JDS`I6ZWD?/-4NWQ+)GDV$K5FJ,TFS4>(,+#
M%(BO'*.BH[N$V:[TKAJHHF4_0`CU!L.X72Z6R/:[)P!'F5D&M\4;X\V$@CH*
MB/RGP/;N6F$<17/$+0MER3@R!?4.Z8\;.&Z<])5A9=%U$SL`V<*I$D%&YVXB
M9$I@.L58Y4^I1+H-]3?3-XK[!W(N;WN_WGE%MMM\Z.1DY!+(YF-+"V0@$M9(
MW31]-+7-HZ@-1\`_75]/?>_Q6L-L[W=Q(#>[YM398I+5I`DFMY7"0/A#B`^2
M%^O5$#K>QX+`YS=)C9PWX29?0R[5,L9GITYB3%&))YA>;!-7EDK7GDL\K#I.
M3BH&"BGX(R;Y=]*-T@45!($2I`8"F,J9-,WOOC1XX=R;'N5>[-W?O[?<-\W"
MV?`UL#Q(R-DK2Q\LCVU8W2PG2RI>YY;[NFI'R!]+WTI>*.Y^*&U]Z>^>TWNT
M=UMHO8[I[KJ-T$L\MN\210PQ2!LCM4K6ZY-(C9&'DOU:6NG1<U+=,(6?+C!/
MX>$S3;;73D(LQ1%VZ;`[C))D0R.X=8G<MB$(8H#T+MC`/@8-?FLZN+VY.P\W
M#V+]QFEE1"_XV`&OM5OO,BK$E7;!@1)P4YF3'$9*P1;8>U]ZUZ13"32*;T=S
MMOD#;>GIVU+<M+=/*E%C6;@[6>;J^E9#^"UZ@KCQMQ]'PSMN>6H4:>HV6-2.
M3XR+D6#UVHT<N&P"*A$)5BLFX15$.A03&`!ZBF`,FV<TQ@<5A7;'-G<3D<0L
M3_-3CO4./5DIC.MV6S6)]>&=GLDR:QA%%%IV95JBW%H$8R:#TN7#EP)Q4ZA^
MP&VWCOAS1MC=09K86LSIFG4``*#!5]R1BW5>X4<-8D$S)MWIIZ?>@!1`HOIF
M-5F6HJ#Z.LS>85$`'U;^S59`1$T*V$AUU(5/[R[SQQ^+E9(P4(HX1MEX3ERD
M$!.C)GFSK%25*'B0YHQ1L<H#Z2&`?1K*M:=GTK#O:]N:\@H&>9M>&$_F2JT^
M-<%>*X^IQT)A-`_=^&G;-(?>9XXP$WV>(Q;9H8Y/TBBJ!1\0VUC73@Y]!D%E
MV+"(RX\3[%R.8EI<8ZP1QRXQI+=B1BJ/7KKD)L4W0*#H6BH0\4[*`@)3!+.W
M[DY3>M%(WLTE=IC;&//Y>626S=<SY^%:!6VQI;^:&-\=+T"A8PM2-'G4Y9^X
M*KAQW*K2R5I9%1>NU)9>+.NY3=1QB$2.!MBHE*!?``U1O;-;I`.D]:N>VU>_
M6]PU#I6QY>]A_=GD_4XY0PHHVF!ME153,(EW74B3RS-(X#L(G![!D*`#X]0^
MW2W.F4*MX-4!/(@^7I75\DVYLG<UKI6R+*`2<RE6:`FLATF5000+`598Z`'`
MR8J-A34,7J`2]0>(;:I)5\Y!S)`58?W=J'<FD^TJK.8O#R)XWQM3LU4M<U9:
MY8Y=]7GB-@:QZ,E%RK=D:19JI.8Q-NV=,W[1!8-A2(=)1+TF`WV4L/94/`^7
M0K;:Y,Y+7`!P'!9(.,&8WELX</;A+@R1E<=UB_UU^=@T:1K94:?"N7L8\^"8
MHMV;5=S&.6XJ]M,A3K`8^VYAUEPO)@)XA84\0;<Z1DXCUK'3Y:D,:3Y&%E%"
M]7[NXYM4B<PAOTKR!XF$(;?U"8)(^L:U%9.H+-OC2&G-P69C.N8ZY@K'$[>;
M"\;I/$63IO5(A14A'UCLRB!RQ4;'MQ$%5R%="51PH4!(@W(<YA``#?.ED$;:
M\5K(HG2O#6^?J6%[R^\<RV0N0[*\O45%XG'"4C<)N1,0W84LDLB]90+,#B'2
M+IU(/%G8%WW!-J8?9K`MV:Y:G(+9WCPR'0,W8>9>@#6T6G31$T1-$31$T1-$
M31$T1-$31$T1-$31%CW\VN9/7O*W\Q"82,<JC7AOGY(AB!N8#2&/IB+`0#J)
M_C?:&P:QKIVF$](/]DJ>V%9V?SA[5^,HF'20A?U2%#Y@`-<^NB6O1$T1-$31
M$T194_*^\N&S<WLE)62UL)6-X\4250->)AHFJB]ND@@7XHM"JR_2`&77(4HR
M3HNX,VQP*'[95,`T^\;M'MD/NT=>/'N-_P"4[]4?M'`<5F6EHZY=4FD0S/V#
MI/JS7Z`&"<+P<3&Q,)$0+:O1D3',HV#B`8E8Q49&,2ILXZ+BTDBG0:L6J+<"
M@!2@8.WX@41UQVW[:;B1UW=ESI7DN).;B3S6RN[H,`BCIV8%!3,`<PLKF,<;
M1M?:QKV12`Z#\ZG=<"E\.DDX[IQ`A"K`!E"D15$I!$I"B4?'PUT3F-T4A.@C
M'@M.YP+Z2>]7)2.;L(B/BDDP^(<HD.KVG"Z14P*@(`54BBH@1<Y!*4!$2'V*
M)?9XZ@9),0.VH#RK0?I*JYD8KHJ3U>6"IN2/,2RB"R*"7W.FJC'.%%'#ULTZ
M3@LW$Q"(D,Z44.FI]D_B7Q`!W#5]Q)'V>D.:UO3]E%=`PEQ>02:</O5LB2-C
MB)F=KS%"$F'16*A81F[1,N5XW;'(?[AF&:"_2J19H<54URBCW!W#N&$O2'/S
M3AI)#M9SXBGWK=PP`@$@M&7\AQ\N"[-]'5[)964;+-6=4C&*:).Q",$X@Z,V
MJU.5XS/)&(J+L.D0*"/5T"'H$1W#6MN-SFF-2VF&6/IJLQMDV!A+/>?UUP_0
MJ`M:55Q^$Q4XN8GI*2D&Z2\D8$6;UJBV5)\.#!TL_1.)RG:=*B0DZE""0OV1
M`VX\Y/.7RFE>G$TKU&N"VUJUSXVO>T-'"N)(YX9&M<%:R>E:PA6%8]%S*J.1
M*U(<KQFF1TV140>J+,V"K?MD*CV"%%,G2)@$#`!R[=.L1SG.&E_`4R]BSVZ0
M>;?+RJHG7JXP7[=)X9?M@<H*N7"9R'=-U7!SL#D1$HJM5P24$3'.)OT`$#>&
ML.1NJM0>ORR4K7&M&Y!0SO<L=Z]EF4%('8J@91`K=*3:$7<,P4^*4666>*]:
MC4#"<I>E/J#I,82CL(ZU\LIMW!U#V)P-036OW+-A;K%10N'EY>909OT0NNHF
M]0<H3@K)+IJF=F:&<@NLN42)'00^#513[272"A$Q3,8NVX>&\PG-*2@L#:$4
M'(8\Z9\5LX<O=S*C,RA9)E-N7C)H[CY955P1F8%UDS-"*CVDUA2(NHJF8"''
MK,8Q>HI=A]NM1N=]#+"(II"8&MQ`IC3/'A7ETK?VT5#K:/?/$_=Y!2;Q7B"-
M(8)B678/4ECB0C-82J*G>I(B=PX<(J[@DY(<ACB._24!#Q\-<0RZ%Y-VHP;J
MP%*8#(4\N:GN[AT,79,J'<37/RY+R*>9]F=MFWF9E*6BEA6KE'58XPK:A'8.
MVRT=3"*-7+MH)!%%%![++N%`(3[.X[CXB.OL3N1MK]K[LVT$HI.]O:.%*4+\
M0#U-H%X%WJNQ=[U+IQ9'1@Z=.9_K$K'T<?0'XQ_T:ZM<XMDP[!OHBXBAMM%=
M[2N$H.XA^/5%4+;T54T1-$31$T1-$31$T1-$31$T1-$31%^\MKJER2IJYKV)
MM4["K46'WE:/NIVE`,_B&S4IY1P3X=JL=P[50;ID9G5[P]1@W!/8/$0U8_4&
M'2*NI@KV:2\:\&5Q4+^-G'Z[T^_N+CD*')'!$Q;H(/JDXV15=S4H86SAX;X!
MTY%,S1@=8>H_3N=8!#<0';$MX'MDU2#(+87=U')%V<1K4XX4P"EOE:M.KGC:
M[5=BD#B0F*^\;QJ)U")%5DDNAW'D%54Q4DNMXW('480*7?<1`-94K2^,MXD+
M!@>(Y6O.0*QT0.".2-:C+3%P]6(S;W&(0@YHR=BKP+*1J3U)\=NBH65#M?$B
MF*2@AN)D3G+X`8=:\07#00!GTA;9US9O<USG&K348%2KXP82D\81DS/VYDBT
MN4VK\`DV(X;/!B8!H<JA$BN6BBS<5Y1V'=4Z##LFDF`^.X:RK:$Q@N?\9]BP
M;RX;,X-C/[L>L_H5ALL<<LH#E><M6-H)-S%/)=K:(EZE+Q$>9A,*F2?NTBMW
MCULN7X:8(=0H@7I$I@V'TZ@EMY>U+HQA6O!9,%W#V`CF/O4H<#E_(I)9BQ-+
MY9J-7L;=BR@LJUIFVD&K%^+%Y'N'"J:2\M5I!0?BHYPS4>D$R!S=:.XB4_V%
M#B&1+$96AV4H\J+$@G;!(6'&`^0*@E<Y^OP+Q@,#2+;AC,#-R5M.?=L^K"U1
M+[92K.6+)SW9!NU>C]OH36(T2+X@94NPZPG$-.`+9?0/+RQ6RC:]X]YPD@X8
M5*Y-]=MY&EB[N>=W63+JJJR2@*;!OI.4A(I154@N9"5D7;5!DZ<-6H&*1-!,
MAS*F*`',4!T>:M]Y^H\N'EZ$CJ)/W<>B/B3F5)+!6*+59G-'M^0XPT#4\=Q:
M+;'%*<)G37<R)S?%.K9,-5BE5(J[D#"Z`52E455[8`4J*1>O)@B<ZCGX-;D/
MM6)<3L8',B-9''WC]@5ZN16`:QR*H)Z?/.E(B5CW8R]3L[=`KES`379,@911
ML8Z?QT7((&[3MOUD%0G28IBJ$(8)Y8A*VG%8<,SH7ZAB.(6(%7A3S'Q+8%9'
M':+EVN3J00L^-+TVAUWC4#=12N&CZ1@90B9A^T**J9R%-ZQ].L+L)V&K?45L
MOFK:04?Z"%R'O#/FMF*4;2&1Q5^+1:BP0G,EY`922T>R,H=84&S:.=ST@1N"
MR@G%--(H"<1'T^.AAG>:O]95!<VL0HS+D!_(LH>9N,C'+''JM8="3:Q<_1X:
MKA49\R2RD<VL%:@DX90':1"?%##S3<RR2HE+W4RJ%4`HF)TCEOAUQ!G$+`BG
M,<QEX$FHZ"L5M?XX\\\0/9:'Q]$7B$;RJI22+NA7.%""EA2**2+P5`F&P%4*
MD;8JJB*+@A?`>G;8,,13LP;4>=;`S6DHJ^AIS&*D?QHX`VQK=X_)_(ATS.K&
MRA)]G2RRA;))S4^1<':$I<I@BB[,Z#9V`+F;)K.%'2Q0[IRDZBGFCMG:M<F:
MAGO&Z.SA]/W*C;-Q-Y$9MY-N,@Y/I)82A6*_-7<PY6M%9?J1M!AER)QT4FR8
M2[IXHLXA(])N)2)CLLN8P[!N.K3!*^2KA[M?4%5MS#'!HC-7@<CFLTR9P3.G
MT%!-)(4P(BG]E--)/8")$('@5,A"@4`]``&LZF%%K5A$J7#[D/0>3,-?X2B)
MN*57LRC8&<FC9ZLD9:FJ6E951P1BK,)OB;UYT?\`8F3!7^3T[^&L$6\@EK3W
M:^I;-US"^`L)]\MY'.GWJH*/Q,SZIRXCLK6^D),:6.99J]OI8;)6G9DXL)B5
MEXE;X!K*KR!Q5/\`#%Z`2$Y>KQ`-AV"&7MM=,*U5'7,/R_9M/O::<5-CF[AZ
MWYKPNC6Z'%I3-KB;K`6!A'J/6,=WVJ3>3C93H>23AJS3,FUDNYL8X"8""`;C
ML&LBXC=(RC<ZK%M96Q2ZGX-HH\X-P/GNC<4.16*9JF%8W"XB]-1XX+'75TY,
M+!!1\++E^/:RBS)B9NFR$P]]1/KZ@`-]1,CE;$YE,_N4TLT+[AD@/NC/`J&E
M*XQ\YL92KR1Q_3[A3Y219_=CV2KUJJ30[J/!=-S\(NY+/&*9M\0B0^WZQ0'4
M`BG:<!CYEDOGM9!1Y!'4?N5TX?@3R@RY8&\YG&\(PB6Q2N).R6A?(%J(U$P&
M4;1<:R=N(UJ)@]!3O$4@-L(E';;5XMY7FLA^U6&[@C;2(5]066G#N'*/@RE-
M*/1&*J#!-4SV4E'QR+S-BEU4R)N)B9=)II%6<J$3*1,A"E102*":92E#QS8X
MVQMH%KI97S.UOS]BNGJ11IHB:(FB)HB:(FB)HB:(FB)HB:(FB)HBQ?>=DJ*7
ME&>8F<I^@1XMY!2WZNG<%RL$3$WW#^\*H)=O7OMK#O/X/I_LN659_P`=O6/:
M%^.?K1+?K[HB:(FB)HBF-P9X>V_FMG:&Q7`JNHFKL$D[!DFWH-CKEJ]01<IH
M+'0V3.D,U,+G!LQ(?P[AC*&`2)'UK=VW.+:;)UU(-3ZT:W\SCD.@<2>0YT67
M9VINYA'72VE2>0'+IX#IZ%^C/P\XG8VQ+CBK8<Q]#-JM3ZA'H(1,.W65;&=O
M%>X*S]S("05W<W,OE#.WZ_VP65ZS&W\`UPEKVE_*^[OW%\Y%<:AHY-;R`KEE
M0<5MYW]B&Q6P`CR&1PPJ3SZ\Z\EENQ_C]"O,`(>.<R2Z:3<SEV)2KG*8@&!'
MLIF1(U;(]&ZFR@@``(@8-_'6_B<=(8VM1Z3]PZ."U$N+BYQ'V#GUE7I-(O&B
M"G4\3*":!5VZ22;=P9$P)F30*1R4X-VZ2Q@$IRCX"8=BF'8=I6N!=@,*\Z5I
MFH'`@=/EY>U<Y&4?3#)NV<&<2%99N_BG<N105%VXJIB50O0W,18S1BHH!E@!
M3I(E]D.H1`-03@25((IC@,QT^8<EE0@T#'5KS(]2YM>E(BN@I&QBC]K-`M^P
M+9W9TH?I65()%VD<Z56=L0<MS"+;8`[@^!A'Q#6L?<10D-C#>TJ*5Y'C3GR6
MP9%(\5>28^('W\N:Z"[S`IJJHPCN,=F6<B)3?!.BMECD!-P].NX9+(;KI)F%
M4@=8)G'J(4.K6LN+IKO=+P6UX##^5;"WMW#$M(=3F/8>"M]+L+`Q,R;S\O%S
M4"NZ64B&BR::*3<AVZBI%FI"-C.F9UC)J=O8J@&]([^G6CN']J^C9':*8`\/
MY<5M;<-:*E@[2N/7T]2XI`KR7Q+!R$%"=:I"0\@Z:`8J;8J":!06(5%$'"RQ
M%!WZS`D7PZ0\!UKW1T]YIP'#@LT'GB>CCZU%?($6FU5</6L[]ZO$C]DJQNPD
M=)(5%14<IMTB*B1<@GV('5MTB/V_3K&<QI_>$T>!G7]'2KG&ATC%1<EJVI/Q
MKH[CO6$YFHLW2Z@MDI2N`@!A(\.Q*3M2;!$IQ*L03%$>L!$H>G6#>-,<GON+
M:`4)RZCTJ:%P>W4UM<<@?6HKV.O*Q2*S=.62.BJ==ND[B2BV7107$Y7*"[8C
M(Z_:<IAN5,H@!=P#P'6!*(G3UEQ9IU#+2XC$4QP\_)9<4C@VC0=5:$<156)L
M%0ATVS6/8-=D&@+I$45;]E^X2'_M"8JF^V9)8RPF#<IA$1#80\0UJYK_`%3F
M<OH7UP!J,L,,@?/Z5N8`]K-(X<:=*J#'./JTU<,7J[1&05774*Y!P1(4DFR;
ME%-4YBG,94R8[%^PGMT``^'COKD]SG=+.685-/TGSGTE;2.1W9ZB2!Y46&OS
MAO,,AL)U*6XL8'?MF64+D59;(4_#"B53'E5D!."D2S<(&,HQL]H1$#"4#=;5
MH/4/290NO7/"[N*+N5N^[FRMC&ZL;2,))!^*A_"P^8NPX%<1WK[Q.LHC:6KO
M].>VE>+&GCT.</AX@>]R7DH,8QS&.<QCG.8QSG.8QSG.<1,<YSF$3'.<PB(B
M(B(B.XZ^C%Y,<34YKCF'<1'1%LJ#]&BJN"H;Z]%7I7%$=QWU17+YHB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB_>6UU2Y)-$31$T1-$31$T1-$723M9K=G0*ULM?
MA;`W(`@FE,1C.1!(!]((F<I*'1W_`)@AJTM:X4<`0KFO>PU82#T+IH/&^/:R
MX!Y7Z/58=X4>HCQE",$W:9O:DY,B==(?Z)@U1L<;<6@`JYTTK\'N<1UJV/*[
M*$MAGCGES)D`[29V6M5<35IVX:MWZ2-BEI./A(=91D[(JV>`D]DBG[:A3$/T
M["`AX:[[PP[MVO>[O_M7=V^:7[?<7/[YH):3$QCI'C4T@MJUA%0017`KR+QW
M[[WWASX/[_WTVJ1L6[V5E_H[W-:\-GEECAB<6/!8ZCY`=+@6FF((P4'7_,7,
M;;!+NCS:L;4.8E7S)B;#]@;*1$0Y9S#/(LVDZA+_``<*Z;'B5XNQU=-1,PD1
M!%!P'64J8*)`'LT'A-W2D[ZLWJS$EWX3W.T7M]$0^0.C=:QELEM)(TZP^*8@
MBKM3F^Z2XM<5\RW7U"^(D/A<_NQN;X=N^H6R[P[9M,[3%"YLS;^77!?0PN:8
MG1W-NUS#2,-8_P!\-8'Q@7,M'F7X6KM@FD&E=G[#0*S</W(GLC,K3CMFJ$DF
M_1BW4M`XV?V5#(=FK+-VK^T?MV1$C$`QTP,4`WYW;?IU[W[A80OEN((-]N;3
MYB.T=#=.&@M+VLDNVPFUAF<T81ND)J0'$%=EO?UH^&^S[Q<P06EU=]UK+</D
MY[]EUM['=H'MC=+!MS[@7]S;-<ZKIXX0W2'%H(`K<EWS0AU+%F.%JV&,MW6(
MP4YMS>^WJ$:U]*F(&I]9<V-VA'2;Z525=RLC\,+9NS%(BO68%%!(0Q1-ST7A
M#=MV_:;S<]WVNSN]Z;`;:VD,IN#V\PB:7,:PAK&UUNDJ10%K:D&G:3_4=MS]
MX[P[;LG=W?\`<MO[KNNQ?7L+8!9M^4MW3O;'*^0%TK]!C9#I#JD/<6M+:[LC
MSEP]&-8.5<,[,I`N\&1W("USC5O'N6F/JA/&:M:I"V),CWO.KC;9EXFQ8,6O
M<%14P*&,5'=0+(/!CO9<2S6S'VPO6;T_;(8R7!UU/%J=-)$=-!!!&TR22/I0
M#2`7T:9+OZF_#ZSM[6_FCO3M<G=B/?+F9K6%MA:SZ6VT-P-?O7=U,]D,,$9)
M+G![B(ZO'586YTT/,62X'%QJ=,TZ;N5?E++2'3BY8YNK::8PS3[P?,9M"A62
M==4NP$CBF7*R?@"@E(8HB!@`#97?#P5WONEW=G[R?-PW=G:3LBN&BWN[<QND
M=H:Z,W,48N(M=&F2+"I!`(K37^&OU0=UO$;OE;=RAMUQM^X[A:R7%FXWFWWC
M961,[1[)VV-Q,ZSG[,.>(9QJHUP)!H'=UR"RWDXF6<3\:<(2$%6+_E"'L=SL
M61;'$$L33'^/JQWDG;^)KBRB329L<H[;JI-RN!%%,4PZ@_:=Q+#[B=UN[A[K
M[IXB=\HY[G8MMEBMXK6)YB==74U"&OE`+HXF-+2XM]XU-#[NEVS\6>_O?5O?
MO8O!KPTFM;'O7O=O/=W%_<1"X;86-N'!TD5NXADT\CV/:P/JP:0"!K[2/JT9
MS-O&%.]7OD1F^MY9X_PM7;OV<^YI;.JYA97-S(-H]A78NO55B2NV"/F7:X((
M]QR1;O*D$.@B:HFRGV7<WQ(-ELO<+9KC:^_4UR6NB%PZ:P=;AI<Z5\LSC+$Z
M-H+G486Z6GXBYM-?%N?B9X)-W/O/XN]YK/?_``HMK%LC;A]HRUW9EXZ1L<=O
M%;VT8MYXY7NT-+Y0[6]I]QK'EW+B^9"#*V-:CEG"&3L)/+!C^ZY)HSFXO:G*
M(6R`H$&O8[&R6)7Y1TI6K`VAVYE?A'?B0VQ%#$,8G5%<^$CYMK=NO=?>=MWF
M*"^M[2Y$#9V&"6YD$43@96`31&0@:V9YM!`-,FR^HF*VWYFP=_>[6]=VKB[V
MJ\W"R==OM9!=06,#KBX8X02.-M.V%I=V4M2T^Z\M)9JX-,YN1%JF\&MI3".7
M*-4N0IU6F.K]:?W/^Z'TFE''E.PO$Q-@D)MO&J,R`=-ZHDF54AP4(F9(!4";
M=_!NZVRSWF2VWG:KW=-A`==6T/;]HUA=HJ'OB;&7AV!C#B006EP=1JQ^[OU*
MV&^[GW:@O>[6_P"V;#WL)987US\IV3Y`SM*&**=\PB+:%LSFMU!P>UCHP7CI
M(3GS79N)QM<BX-S''8NR=D1IC"%R=(!32P1+/)3CV`B^S%MK"YGI*+=NV*@F
M=$032)T'(45%""369>^!U_9W6X[2=ZVF3O+MM@Z\DLV]OVG8LC;*^KS$(V/:
MUPHPN)-03I:05J]K^JO:-UL-F[Q,[L=XH>Y&][LS;8=RD^4[#YF29\,>F-L[
MII(G.8XF0,:T:7,:9'M+53UE\R[#,!89=NUK4_/4.N7$*/.Y#86G'C54DJ60
M2BW4E`XWD+*AD6S5AD\5V/((,B)F(43D`P`&^?MWT[=[KZPBDEN((-[N+3YB
M.U=#=.&C27ADMVV$VL,SFC")TA()`)!6HWGZT/#G:MYN+>"SNKKNQ:;A\G-?
MLNK!KNUUMC=)!MS[@7]S;,<[&=D+6EH<6@X5NI(<O2O+):8_%^!<RYKI]"M8
MTF[Y%Q\R@5H9A9&ZJ"4K'5F$D9)M8+LI`G<E!X9HB0B7IZA+L8>9@\*C#M]M
M/WDWO:-GW:^M?F+>UNG2"1T1!+'S2-88K<24/9A[B7<JU`[J[^H$7&\7UKW)
M[K=XN\G=[:K\V=[?V#(71,N&EHECMH7O$]X82X=J8VM#,ZZ2'&V,5SH?1ENY
M#J9#QC8HG'>,+[7<78^/!MHN2NULR3)HI)EH#B*3L[@S^T659<'C`K=!!JP8
MI*%>JD<`"8]'<^"T%SM6PMV'<K>7?]RL9;RZ[0O9;P6C"3\T'F$:880.SD+G
M.?)(6F%ICJX<38_4]>67>#O<_O=LEW;]S]DW2#;;`PMBDO+K<)!3Y%T0NG&2
MYN'?O8`QD<<,+'MN'B;2PU7(\Y8>EGR-&9CPODK$5MH&,QRZUJLW(U"=6N-,
M"=9UH3P4S!2BL0WF4YE\FB=JX.3H'J#KZB"76L@\%[K>&[?<]TMXV_==KOMQ
M^1,T;)XQ!<=DZ;]Y'(P/,9C:7![0:X84(*WUU]3FW]W9-WV_Q#[N;SL&_P"U
M;-_BK;::2UG-W9]NVV!AFAD,39NV>UIB>13W@7:FEJDEA_)K_+-74MKK&E\Q
MBP7>(D@8_(K1A&ST_$+QC"01L2,4R=O%(Z,<*O#(HE7,59043'$A2B`:\\[U
M]W(.Z^Y#:XMQL=QG:P]HZU<Y\43P]S3$7N:T/>`T.<6C2-0%205[)X>]];KO
M[L9[P3;-NFRVKY`((]P8R.>:(QL>)Q$QSS'&XO+6AYU.T%U`"`KJZYE=TFB)
MHB:(FB)HB:(FB)HB:(FB)HB:(FB+%WYVJ15O**\Q(AB`H`<7KXKTF`!`#(&C
MEB'V'UIG3`P#ZA#?6'>_P?3_`&7+*L_X[>L>T+\=/6B6_31$T1-$5QL28CR+
MG7(=8Q3BBK2=ROEOD$XZ$@XILLX5.8PAWWSPR1#@SBX]$15<N#[)HI%$1'T`
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M),D>W3M#55!^82?8(5,7`L5CK`7I\0$``>KIW#4]MNFPNE#!?0:W8_$03RQ(
MHH9MLW1@)=;2AK>%,NL#%==-0=M9E%S(5J7%JD`)F>(MT'+8Z72<X.B+,%'*
M;@.UXD$OB(%$3=(CK>.PC;,T:HJ9UU>RN"U3(R7%E0UU<J$>1Z%Q(RSUZ`JY
ME8V:>GE&#ULV78/HXI$'"2O[=*+25;"4@).5^X=10H]0["!S%#IWTUU(7GLZ
MBN?ET+;01@8D>[U^6/E1:VY8*:?G7FJ:Y0N/?^\DY5,701B*JS3XEN8)=N*C
MY2/%0!$6@$4!J;?P$H;AHI712'2T-[0?BQSZ#F>H9+:1LD'O:CV9PIQI[,N/
M%5(O.JHLH61>PGQ\@#%^NY9FG(QK#'!-9-!XDW66_8NG!44R+H>(G#N#Z`ZM
M8#W!U&@BF-:<>?WK*9&27"I::BF&(Y=0X*U4@D#E1G(3B)FKZ054<,CHN>Z5
M,BQURDC)<A%D4BJ!TIB4I2J$34+MX`81U![FK0T^Z#ZUG-)H"10\E2TY+(0Y
M$8R?13,BBZ!BS>I>!VC:2CGZA46QCKK=I-M(I`D<AB%`@*#L&X>$XC8YU&CW
M2:'S@_:**UTFD5.>?EYE%#(U@AW[WH9)*MPV,=\NW,!WKSK5<`9(01.W3%L!
M3](^`[G`/$"CX6/A8\T;0.IGA4XGU=*QWS.:=7X>7W*-;J<<Q[I5U%+NV)G3
M,C*02;J"F<5-Q*]2,J<-P1743W,7Q+T_9W$!#6'=,CD&@AKFG,'G2ASIRK]J
MN@D<WWFZ@:9]'D5:.<>+$1<.$TBN%G`D4."*?4)#$,5,%133V*D0"[]2N_7X
M>L-<;>!K9FQMPC:TEO*I-,<<!^BBZ*U<7,))%2:'T5PZ?TY*RMR.?L-UGF_Q
M15#J-A*!-P*)-E1`!Z3&.*8AU;AOX![-<K<&.*L@TN(]9QI2G0MY;%\CM)J&
M4]7,K'7SNYO(\(\/%LL49G*9FR0J\B<:UYR4B23!N@F45[7+LMU3GB(=,Q!Z
M1`"O%S%)X`)A#?\`A_W/G[U;PZXNR6[;#1TA'2?=C!YG''@*GDL7O+O4.SV-
M0`Z9WNL;7-U,2>@9GS-XU7B\MUML=]M-@NMOEG4[:;3+/)N>F'I^MS(23]4R
MSA=0?04O4/20@;%(0`*```!KZU@@AM8&6UNT,@C:&M:,@!@`O#[BXENIW7$[
MBZ9YJ3T^67(*FS#L4??X?+\6I5"M@1V#?1%Q%#>GYQT55P5#;CM\^J*Y;>BJ
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+]Y;75+DDT1-$31$T1-$31$T1-$31%
M:'.6&H#/F/E\;6B6F8B!>6&KS\@I!?`@\?!59EO.-HI<9!L[0"/>O&B8+;$[
MG27[(@/CKJNY?>Z^[C[ZWO#ML4,M\R":)HDU:6]M&8R\:2TZFM<=.-*G$+S_
M`,3O#K:O%3NF_N;OD]Q!M4MU;SR&'1J?\M*V9L9UM<-#GM;JH*X"A"H3*O%#
M%V7,S8ISI.EDXRZXIDXY^U"'^`)'6QM"21)>`BK6BZ:+K.FD&_`YFYT3I+%3
M5,03"4"`7=]V/$_O+W5[H[IW+LC')L^Z1O:[M-6N`R,+)7PEK@`Z1M-0<"TE
MH=2M:\MW[\!^X_?_`,1=B\3]T$T/>389XY&=EH$=TV&4301W(<USG-A?J[,L
M<UP:]S22`W3:VJ<#*=4)=-O%93R.GC)M<G-X9XL094ED@E(NY)256AG.06U=
M#(+NI'=J#U1X/$BJ)[E.<PB8P]-N?C?NVZVIDN=LV\]XW6@MW7A=<.)8U@8)
M!:F7Y5L^D82]F2#B`*`#AMC^E?NWL&X"*RWO=QW+9N+KUFVMCLV`2.D,IA=?
MMM_GGVI<:&`2M#FU#G.)<XR#Q7@RK8JKN1:VP?RMB;92OM[R!;7,^#'XAW)9
M!(FC+QR96#5J@$6V9I`B@4Q3'!/](PZX/O-WTW/O/N&W[A.R*WDVRQMK6`1:
MJ-9:U,;SJ).LN.IQ!`KD`O6NXWA?L/<3:-XV:TDGNX-\W6]O[MT^C4^2_`;,
MP:&M'9A@TL!!(%:DJPU0X!85J6#,D8(^\KE.Q&4%8E2?N,N_CS71HE5Q9GI+
M&)>H1Y&#:-IBS(#LVYD#I"*B@'`0/L';[KXY]\-T[Z;?WV[.T@NMM#Q%`QKO
MEW&;5\PY[2[47W`=21P<'8-H01CY;L'TI>&VQ>&.\^%YFW&ZL-\=$;B[E?&;
MQHMM!LV1O$>AL=HYFJ*,L<RKGAP(<`+B8=XS-\6V8+E.91NN3;"T@S5R&^^H
MFFU&!AXPX@"KD*]1X.':R]A<(AVU)%\=PX$@F`.D3".M!WL\1G]Y=N_PBRVV
MSVZP?-VLG9OGGED>,AVMQ)(8X@<1%&&MK2M:476^'G@I!W&WL=Y-RWK<=YW>
M.U-O#VL5I:011DXN^7LX8FRW#A[KKB9TDA;6E"25OYOXT1.8;;0\EPU_NV(\
MKXV0DH^KY`HIHQ=Y]RRXG-(04S#S+9Q'2\8J=900(?HV[RA3=9#B74?<WQ$N
MNZ>UWW=V\L;/=>[&X.8Z:UN=8;VC*:9(Y(R'L>*#$5^%I%"*J?Q+\&;#Q!W[
M:^^>W;KN6P=^]F;(RVOK+LW.[*6NN&:*4%DL9+G$-);\;P[4UVE6^>\&,=V>
MJ9(C,DWO)N2KYE)&`2L&7+%,L6UNB`J<BVF*PWID;',4:U5XN(E&B:WPJ38Y
M5]NE0PE`H%WT/C3O^W;GM]SW>LMNV[9-L,IBL8HW&!_;L,<QN'O<99GO8XMU
MEX+<VBM:\E=?3!W0WO8]YL^^.Z;UO'>G?&0-N-UGE8VZB%K(V6W;9QQL$%M%
M%(T/[)K'!_PN=ITAN^IPRC[$2V2>5,UY3RS=[!C2R8E@[M8TZM&+X_J%N;G9
MV,U1@(:(1A26&:9J&2=2#HKA=5,PAX;B(V-\79]O-K;]V=GVS:]F@W&*]DMX
MC,\74\!#HNWED>9#%&X:F1,+6M(&=`IG?3I:;P+^\[]=Y-\W[O)=[-<;7#=W
M`MHS8VETTLN/E8(HQ$)YF$LDGDUO>TG(DDU_.\8J;-_Y#IA/V:+:<>:K8:Q2
M&4>,4"#D\_0T<?ISTMWF"AC2\+&H`Y:]@4D@="(G*8OV=:.R\1]WL_\`&W&"
MWDEWZZBFN'.UU'97)NC$RCA[DCSH?JU.T8`@XKJ=S\$^[NY?[K,;=WL%OW1L
M+BULV1]EI=V]BVQ$\M6$F6&-HDBT:6]KBX%N"ZUKQ-H33'7'?&"<[9C5GCC=
M:Y?*\0XQ0KVV:K*LJY8DMH`P!`[55],++J%:E0,)Q#80`-9$GBCO<N_[_P!Y
M#!;#<>\%G+;2_'2".8,:[L/>KJ#8VM&LN%,PL2/P&[JQ]TNZ7<MMS>?X-W0W
M2WO[<?NZW,]NZ5[/FO<H6%\SWN$88:G`A6WJG`ZH4^730B<K9(1QHTN3F\,,
M7H,:0R1;R3N34EU8=QD%M70R`\J8O5!$8_XQ(JA-RG.;<QAZ'<_&[==UM2^Z
MVS;SWB=:"W=>%UPXEC6!@D%J9?E6SZ1_%[,D'$`4`'&;)]+'=W8=P;'9;YN[
M>YL>XNO6;:V.S8!(Z0RF)U^VW^>?:ZSC!VK0YN#W.)<X]_$\-F-<LMA7JN=<
MVU#&5HR"[RA,8>JDY&04&K:Y%ZC(2:;6W,6"=TCJY).T"BNP;ND@4(`$,H(`
M`ZP+KQ;FW#;H&;GLNS7?>.VL&V<=_-&^200-:6L+H'.-N^5C2=,KF&AQ#5M[
M#Z=K;:-ZNY=C[T=Y=O[F7V[.W*;:K6:."$W3WM?(&W;&"[CMY'-&N"-[=3<"
M\T!'637!2BS*.2T_\R\HQZM^S+'Y_@G+-[``MC/*L>X=K%L54,:&[CX'*#HK
M91)^=<`;H)`02*%%0V39^->]6C]N=_AVVO98[0[;)`YLM+NR<&CLIOWE&T+=
M8=&&^\YVH%ITC!W'Z7>ZVX1;TS_&=[BDW7O(S?H7-?!7;MS8Y[A<6I,57AS7
M",MF+J1L9H+7@R';GN"]5O4/>PREEC)N2KWD6/J==L&29LE6CY=E2JC96%L;
M4BL0,7#(UZ`@9:9C4U7PD2477,`CUE$1WNLO&G<]EN[(]V=KV[;MDV^2>6*T
MC[9S'7$\+H#<32/D,LLK(WD1U<&M&%#04LW7Z7]A[T[;NC>_6^[SO/>C>(;6
MWGW"86T<K+.UN([IMG;0QQ""""6:-KY@&N<\U.H5=6<8%*0I2)E`B:9"IIIE
M_1333*!$R%W_`))"%``]P:\8))-7&KB:D\R<ROIP!K0&M%&```<@,`/,$T1-
M$31$T1-$31$T1-$31$T1-$31$T1-$6._S=8@\[Y5_F)Q:8"91?AUGA<@`4IA
MZHVBRDIX`<0+N`,M]]]P](>.L:Z%83T`_P!DJ>V-)V']8>U?C.$'J(0WZQ2C
M\X`.N?71+7HB:(N^JM7G[Q::U2JG&+S5IN$_#U:M0[84RN)6?GY!O%1$<B=8
MZ:)%'C]TFF!CF*0O5N(@`".F&9H!TY#I1>Z/A%Q'HGE585?2-=8PL[S?L=4+
M_F]F&7*29A:$[<D2D!Q?BP1**2<=`JD3^)=IH?$2CU,5%%BHE1;I^#]\N_UQ
M=S?);+6.T8XCM0*N>[B65^'B&$8\2:X#T?NSW5BD<V?<AK+J'LZT`;^MU\?0
M!Q7QWRMRC;#1D]:<DV"S2,G-_&2</(.SJ+,V"<0HDBN)%5TVBJ2ZZYE2D*4$
M0!,O4;J#I'SN5KYY"9W/DDQ]XN)]ZHP)-2:9=>2]*9M]I$-$$;(XJ"E!PKR&
M5:9J*,>V=7>WQK6W)($7FWTLLQDGX-$(]\^,U?F;G%1`4@1*[<$2#?I`Q5>H
MH`8I@WWAC=;V<L5N-!,8#B<2/AKTG,U(%!4#FJ.<SM&O)<6-=[H%<A7T#D#B
M<25<O&<<A7YN6CSV*6V814NN,*Y>LG<0]>L?B&<DDU223=NVDT#9<JJ)Q`X"
M("'2)!`Q8[EL3+!K=#-;R#4#'2:`8#A7!5K))-KQTY>?/&OK65?C1G?/N-K#
M6&V+<U7-A6W<,Q33H=CEWEDKC:03`A))-&#F#R#(47KE$!*9L9("%4`2F(!N
MD%MO&X;=[EG-)$X.)P)TFIRTY4'5CS6GO]LLKUCG7<+'FN#@`'4X'4*&O6LX
M$%G:FY`9%;9=AUJO(LTBM0M%26!.#<K/CD.HXE:VX%1%,H/R@8RB8',(ATCL
M&X:ZRS[T13?N]XCK+3"6/#^LWEST^A<7<[$^$:]O?5GY']')WV'TJ\DU)S30
M[,T>E^\U2>HLTFT^Q43507;N&QD5'\<ZC%A^'51[7V6Y2)@7?<?$VLE[VDB:
M'0;8Y%IK4<Z\#Z_.H8F`C1(7"<9AV%#TCB.E<-W$&G6<>:/;.UHN+E4#2#HT
M:+(BBZ29$5CBW<*&*>1!-%,_[+N)J&_O"$#PU8]O9M[0#/`5\LU)4$]F3[W7
MPY\Z<%5:M93:"074:Y;.1C'Y&[E9;K:E<N=CE9&,KU)HO@-]@AR]1=E?#;H#
M>QM0ZHP=CRRZNCFKQ,R0480X"G7U^?ET=*BSE5)K7&9927,]F@1^'<-BH.0<
M,CLET5#R#,ZAF!43K).P2.+CJ%0_VP$!\!UE0R!L@<['F.%.-.>*CN*]F2!0
M\#QKP\R@S:Y1,QR.%Q144<L#JH`V4(FF&ZX_M$RE.`H@MVA`PFZ1Z1V'PU9,
MV*.3WG"A&'3YOO6*USW1U#>*M._D$U440(FF=4#$(=)!4ZZBFP`94_8$#`FN
M"I]P`Y@``$?'8-M:'<KUC(@PZ?C`-,2>9IGZZ+96=N[M-8U?"3R%>&*Z8RP`
MU>`#?;8#'!5V5))F10IC)BHY$"""A0$QC%*7P'U;>&N'W>Z[67LV`AF(Z74X
MTY+H["#2S6?BP\WZ5#G/.5*CC^`L>2<E23&N8_I4.[DY*7,@9L1-NAU)M0:H
MIF[SR1EUNA)LD0>I18Y2^/CMIX;"ZWC<(MMV]IDN'NTM'`N/'H`%23P&*W+9
MHK2V?<SNTM:*DG(-&?7T#B<`O#/R]Y-6GEGG*TY:L)G;6+7.$)1*ZY6*J%5H
MT8HH2"AP[8%1%X=(PKNU"@'==*G'T`&WUWW7[O6W=G9HMK@H7@:I'?GD/Q.Z
MN#1P:`O$=\W>3>;]UTZHA'NL;^5HR\YS/2>0"C'KH5IULG'<=O4'Y=$6PH.W
MA^/157`4-Z?GT5>E<4?'QU17)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(OWE
MM=4N231$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-
M$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$49^:M6&\<,N7M,(EWE+5Q;Y!
MP"20!U"HO*8EMS5`@`'B(F64+M[]0W!I"[I%/3@I8?XK3R-?1BOQ(D/[E'_S
M2?\`S`USBZ0YK=T1-$657R5,?,<@^8]@H))JD\:4-ED7*9$5^D4RRU"H,_+5
MQR)3?IF8V06BY0]/4F`^K7+]];I]GW7O)8CID,6D'*FMP:?42MKLD+9]TAC?
MBW6"1SIBO3)F8)YC"7&$DYB:FH"=DYI9Z\02=_'Q%NC^S(+BZ4<+*"L62*L8
MY.KH!(0!0H`4?#YDMZ.GB<30-<'$G)K0:&@)S)P'+->_6_9TUAC1,&4`!^(.
MK3$#`"F//)1E9Q\NRKR\R_628,9<D0P@GQ6C-8[P#13=I(.DW)0*Y1=Q[[M_
M$@F!TA6`X"4`$1UT#2TO:R,%K6O>[34'#42''GJ\ZH7T+@3J?I:"<<,*::>O
M@NL;*3;-PT`7+1E'%ES-)]5X]9J-V<JP2,2-G(Q-8@MD#+J',)R`7X=8BA^K
MQ,)0R@TR=HUO!G[LG-P)]\'[.15#1N@D5<3[W(888J]N*JO$R$L=5>&616`4
M9IW,1I".U%)9959J<Z30%R-5D5"*&'I:&24Z/T$S["73<G:6B*"E=.G'`Z0`
M:5SK7GZE8T.:"\GC6G"N.(Y>55D=PXTA*JR=BT*X5=H)&^&60:-S.RR"#A5,
M#&8](+H,72*HF,W(!0$?M%';P+S<KC+*"X8D>8='33@L:7M'#WLO/CY^:O[=
M,NM1IA95]+-$X\\>BFNT,KTM!5:KB=!I)(J`<%HXSA$J:@*JHB7P`3>`&UD@
MW,UP+>,'42,,Z\^GI6"(FM!=3+U*D,`^8+::#9/W8E6SJUX[?$:HRM+=2R"`
M$61,HH:3HT\"J)V+I0@E[2"AU2B8`+]@?M:[B#:KFUM?F(CJ!))9C2G(BGNG
M/(+1W363/HZC7@8/IE7HXCT+/7B2YU+--01GL47$[R#^&02=1LJ[43M%86(0
MCDL)/,5O]\.LR.)R_$D,<RR8A]LQ2EUDMM_F">SUB9H]YCOB'2/S-Y%M1U+1
MNF%J1V[037!S15KN&=<*\C2BI&_JC'09WSBQRI6*'2[*P,=V\>#*M7!E56P.
M'`@7X,X%4`@=)1Z1(.VL0G3F`7#K^U9P;2I%`.A07LMOD':LH9K,2P-RH-]A
M54(`+$(*33H;HE,=N#D2JF[@=("/2(]0[^%M7C0<2X@@`$<!4DU(KZ>D*!SZ
MEY#O<&)K7CRIDH[R,A]HR8D4<%3ZTQ.<ZA>A$SG]L0A3](=13'\2[%#<?L^`
MZBNI6QLUD-TM-`14`-K0X'U@^8JV&/M'Z`7$N&1%36E?+UJCRF*_=%*B`)(&
M6/NIWR@N;H$_:3`IA,F5$?1L4>KVCKD=RN0]_ND".I-3QQH!EET>M;ZTA+6T
M<"2.60PQ)Z?LX+K;5)LP[$5$N5CL%D1-,.ETDQ)VVQ!,N5%P8Q2_"LRE,`FZ
MB]9Q`-PURUP[LRXNQEH`!R\N2W<32X`-I2OG*\7/F^<[VF><B.N/V))M=_AG
M&$TNUG+*W=#V,GV^-4*C\6":1Q34K=973.DS*(F!5?J5'T$'7T/X:=R?\"M?
M\9W$?_EKAGN@C&)CL?,]^%>3:-YKSOO=O_S3SM5H?]&8[WR,G.'X<.#3GP+L
M<@%A6UZJN&7P?#QT1;&B+B*&]/O_`":*JZ\X[CM^/\>J*Y:-%5-$31$T1-$3
M1$T1-$31$T1-$31$T1-$31%^\MKJER2:(FB)HB:(FB)HB:(FB+4!1,(`4!$3
M"!0``W$1'P``]HCJB*TU=SGB6VV)&JUVZL9.8>+O6L4)8V?:PMA=QJ3I=^TJ
MMJ?Q+6JVUVU;,5U13C'KLYD6ZJA0,FDH8M@D:3055Y8X"I5U]2*Q-$31$T1-
M$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31%]T1?-$31$T1-$31$T1-$7
M6S4*A98.<K3DI3MK)!S-><$-^B="<C'44L4V_AL9-V(:CD`+#JP:,?1BKFDA
MPIFOPO[57G51M5HJ3XADGE6LD_6W:1]^M-Q`RSR*63/OX]9%&@@/OUS=*&BZ
M?/%=#JB)HBRB>3/E2(Q/YBV!'U@>MXZ$OBEPQ&[>NC)D;HO<E5.5KU<!8ZH@
MF0B]J68I;F$``3AOX;ZY3OQ:R7?=6\9"*RMCU@?S'!Q_9!6XV&5L.[0N<:-+
MJ>D$>TKT>WY[-S4;>7KG=!]1,F"S53!4&LJLHL^>%=-WL0L999V](U!0B.QS
M)"5`NP;#L7YDAC:^2W>ZAA>QWJ%1Z3F5]",<(]43!^\+!TCAB#P%.`YJAY1C
M&S;N*LR-4<3D-'I/&!8V&=MV<=)F5BUU6AI6':HHFBADBJD$W;*4Q'27[390
M`-K96TLNI[)C20M`Q.6.-#QT^L8C!4?&&M#6NIC7+'U\_(K?QYCQY:1EC0M1
M<-B;G63;F<',HFB+MP=,4&3Q8Q7A&[5`.HQT%!`?$?LZV;[TQB,N(#6D`<M(
M`KEP))ZUCO;&RNLU<ZM<\SSZ5/W&]039,HY!@S$LY,E2A21CF$`H2CLA`041
M,B=N#-)TN"7<0(`#N?J+MOMOK;JY?.7.#JG544X5RZUCN&@X?"!G7+RXJZI6
M\_`KJ1*S]NT9&:EBG+M=+N2)"MB%22,NY6=.%4Y5@8>PHET%$"@`>`B&\#6M
MT:@"'`U/GSH.G-8[WMZSP'#U*,][G)-1\K$M7CF!?+N'**(R?5',II$3D*1-
M5\D`-D7+M(Y@3^,0!$P_I')MN/5[;;1/`F#>TA:`7:<7-ZAF1STXK#F?1E'4
MJ3@*^7M5K*/'2,3:TXR9KG>>+H.462,A*-F3%?J,KU@Z,Z<I-$^M,0[)2J`4
M_5]D!'80]1BB9=6;'Q/&AK@:BHJ<*8X&@XKC+F4,<]]34@\*D#CAS/!9!>-^
M7LCXJ63L-7IBJ;0'*+>RLEI-259+(M3F30C#"Y<)/&"(HK"5,43J"!MC`)BB
M&HMPV>SOY`\2-9.T>XX5J#F0:8$$]`\Q6H9?R6A+':G1D^\"!0]->:R:VZ^A
M:ZQ`V>,=+IM'C503-70*IO8YR!6R+F-D415$R<HR*!BB82]*R`$4`P[CKBKF
M.:#4R1K>W9@:&H/(CG7/](HMN)62QM=&2(WGCPZ^K+KZ%$&QV%98%VZ1&BZ(
ME.8AVZ``)SD6,"ISF,?OKJBF7JZ1`PI@`]/MUK9W#1I&+W4<*=&%1CY<%+"T
MZB:T:VHQZ<:%6>?W(%'.X*$:B<A.LH?%G;@*13&!5$R9@ZQ42_D>`;@`&W'6
MBO\`<0YCHB!0@88D4SKY8<UL[6SH0\$Z@3CA7E0KKF;UPN_2*CVP24`3D_W0
M.\(E3'J`RJICK'%+J^V80`>D-@]>N=?<@1$5]P<*"M>O/RHMO''[U/Q'C7"G
M4L&7G-<]5,*8Y1X]XLFDVN5\MQ<HA='K-<H2%$Q@Z_W=5/\`9`'PDS=5!,1L
M(]*B#0BB@`'4F.NV\-.ZC-^W`[W?LKMEJ\%E1A),#4#I;'@7#(N('-:CO1O+
MMJM/EX'`7TP('-C,B[K/PM\YX!>0H``H``!L`!L`>X-?2B\C7W5$6@X[!^'P
MT1;!AV`=$"X*H_+Y>_17!<(1W$1U17+YHB:(FB)HB:(FB)HB:(FB)HB:(FB)
MHB:(FB+]Y;75+DEA;\WG._)2,4P'Q+X4YAC<)<F<QL,X9[<W]^I`@C"8DXQ8
MW?SS>KNPL(_`()9OSC9*G4BG'[?PKEZ<H"5%3;7WDCJB-F?I](Z,/2LZTC::
MR2?"!3EGT]5?/17B-YG-.8\4N'/.>6H:ZG$KD)5:G+Y[R]$3:KE?B4]ND&T;
M1-@O5*:PC]U.8RALJE=5:RRC=ZBM6'/8<K-W#47"C>[YND;7TJ#G[:8\:4K]
MU2+!:DR.B!HX95X^75ZZ`\5EY@&:;M&<?J]C/B:DVS;RU>9GON!L<YHRN\QM
M%P?%##HU@P\B^0$M%8VM]EQQ+7A&[P)HVE1L/-RJ)YUJF[<H'2>@VJ+ES@`U
MM"33[.1YC@1PYT&V:VI<[!H%>=2*X5('.F.-,L16PF5N>N=\T'P-Q+QHW'A_
MRJS!S?R'PTY!6UFZKF9`P%&X2P$]Y09"MF#9RP5Z.K5XELKXC<P1Z9)S<"C]
MWEG%%7<9\4Q,D$;IY)0&-%"33U5X]%,QQRPHKVP1QDR/.I@;7#KIPPSKD>&?
M%=_B;)6&./W(7-%`IWFE<C.4F2,*8:S;:LJ\+.1UHIN0I=U-8RK["QK6JMY"
M0PQ2+'1GU:5Z&KQNP?24,NG*D_W0ADB#J-CVPN(8:Y5P`KB.L\?T*]S'SL!<
MT"N1%<,"3T<%+:G<X6]M6\M1(,:K,1\Q3%]DR4U']ZB./\IB5[C;$\AAAE0&
M!0"Z&=I2GW3WP&+`AB?$]`@/9#*^:&IHT_$`<\JD]"QC;FCS7X21EG0C[U%S
MCQYL:&5.7&*.*5UAN+C^7S:_RQ`5::XJ\IYODHOCRW8EJDK>9.L9@,[P;C*E
M('EJW`OTTW==G)D&<LU%HNB!#@X+8+HUX$4)H#R%>0IZSP4CK4AI(K4$9BF9
MIAB:K@X]\UC,5OXY1'*Z=X-O:OAS(+J,QO@E)'D?2IS)&;>1ETSPQP#BS'4-
M2F]*;-*9CR\69XHY4M,U)(.XUFR<*K0XD!(RH7A(/N]6>>`IR.?,=2JZT#2!
MJZ^@8FN=>'+SJK\+9%Y97_S%\\8/Y,151Q3!F\N3&%CA,?84S?:\PXY1F[KR
M`S93I?)4<XMF,<2.H3(1(EBE%KF^[%@60CD#D<BF8$D[=4CYPQU1@.?ZQY#D
M*X(61-M];,2''$C^;TE5!BO@W>JGR+=Y=E#P,86:DZ4YNT@S=5]Y!.X_%S;$
M!:6AB.)BH:'NU<>SKK#C,DL2S.I%I&1CYRTB2D'O+OKFPNUX^SHY\:\58Z9I
MCTC/'UU^]=QYOU_S+CSA>#K`67;#@C)MWY,\/<.QF5ZHVC'D]4(?,W)#'F-;
M,_8M)EC(QKDPP5C7`R:J)@.7</#??5UV7:0P9'_*:/M5+6G:U(J`TGT`J*.*
M_,)R+*\F..3;--M<T6O8MX&^85*<YL:1*#=W"1/)/A3E/!-/O5P38)-ADU&I
M(1_)SE=(DJ1-U`6)HH!3@J0P8[9W@ZW&M`>7-@]&)\V.*R'6[=!8SXB1G4<'
M88\:`>?!5=QG\YRH9[S-@+'3^$XWI0G*AA;%<3QV&.7E;SMG+&TO`8VG,M0D
M!R=Q/"T*!BL?+6JG5QVBH[@9VQLH2?(G&.U#&5(XU.RX<YS1[IU<CEYN'I/+
M!0OMM+7'WO=SJ*#E@>/JPQ7;8^\U+.-BXP8NYPY#X.(XHXCW]M@67E[^_P"2
M]9MM^JM*S%D"OT"P92=XSKN.A32QSC\UG;3!G#R7:2+J&2<+.6<<HF"(T;=N
M+=9;[N'/CTTH>>&-.&"N=:M#^S#JOQX<O/4<LO/BKI\EO-,HO'"R<EHF4H\5
M)UWC_=N-6`X^^V3*4'CBD7+E9R39/K4WQ+-VRPPKBNX[IN),8N(>RVNSNG+L
MS1G*B@A'K.42IK5-X*T:.6>'EF,Z9]%%1EHYS=1//(5^WH.5<1TU55\$_,-@
MN85_SAAYV7!+W(.$(#&UW>6SB_GU/DC@NX4C*3BV1D.K#WU:CXYGH&[UJ>I;
MUI,P<E$I*HIJM':"RR#H.W)%/K>6&E>@UY]`Y'EYZJ.6'LVAPK0US%#AT>=6
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MMW&&#?\`)'%7/;"7`>VX@I.<B.,=SMQS^TQK/X\R#2,PVO&]>=GJSVI97BW3
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MR=0LK6R>B[7C"7E+1QCC;52W#V3CV47+R*<*L5%A(`^C5EU4%&NHY9I1IKAB
M.'5Q+>&`RX^97110NU8D@`\L".IU#7//@K\27,7EM8,A9`PYA7B'BC(F5N.F
M.<<7#E%&3G*24I],@KYE.!EKE4<%8)MW^0TJ^R?>G='BTY-:4FXNJ0;4)%BB
M=03K*F0D^8D<XM:!4"O'S_A^P<Z\K.PC#!(YQTDT&`].?D<*<Z!BO,\ON;+K
MA^F\,N)CG/W^<_##'7-&,L%_SG5L"0E%J=YR/9,=O*5D$9&J7F33M<-)5M5%
M(D0VE2.9`BJ2PM&R0.U;?G"YP:QM3^BO`'[?M5WRFEI=(Z@!/J-*YCCAP4K.
M>F87&">-$EDE%>[LEV^7.+]2,ICJTPU0M*?^9O);$>-W""-@GJC>8PL(H2V&
M3EFXQIEI&*%PU079K+)O$,F8@1U.51[0H(6ETE!R/L/4H^UKS#[ADWF+E'C-
MC#'7'51KA;.B.%\@U7)?+%EC+EM)Q;>(KD]8\V8RXRNL83:=JQ''1=B%>(65
ML;9Q86[%PH@*`]!#8\=T7$#G3#CD,3ATYU`*G?:]FTDDX5X88$BE21CT`&BE
MORMY$I<8,;53(BM3/=26CD!QMP26)3F0@3,U.0^;J5AI*SB\-&2W?)5#W$)$
MS3M$%Z#?L]U'K[I<F23LZ85J?M`^U8T<?:$BM*`GT`G[%&;D[YCL-QFF^:T5
M+XI?69MP\PSQ3RJO+HW!"#C+6KRJR)D3&\:E:'CBNR*&-*%C%]12RECL:HR9
M&D(JY=?"_P"Z="T)N:`D`84X\R1]E>JIX*5EOKTX_$3PY`>VN'3UJU=O\T=_
MA_CJVS?F&`XA/O\`,/-E'P3QYMV#><-<R)QER5:;G!SECDI>^Y\L.,:87#E;
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MMS@6-1`O04D+,WZ:L,%T%V#]D:'ET!)[2"`ZYR6G:.IE4TZETD))B:3GI"@E
MJ-2)HB[&&F9:N3$188%^O%3L!*1TY"2C80*YC9B(>(R$8_;B8IB@LS?-TU"[
M@(=10W`=6R1LEC=%*`Z-P((.1!P(/6%<Q[HWA[#1P-1UA>S&HY1)S0Q;B+E3
M'BYBJKEBPUZE9^9QS9`%JOFVLQ!JU;"/7;7MDC4)YPX1F(U7IZ%&#\"F+UI'
M#7S%N.S2;!O4^R2BK&-?);N.3HG.U`=)%',=QJ*C->];)N[-PVF.YA(^9:*/
M;U9^L@CHHKM9'X\N:5:*C-4FP*PM:FH]JQ^*?6-TY%.=8M53RK919F)W2WQ"
M10.HF1+I4.)C%`H%$H:2"\-RZ:UG8"\.+QI'X3@13AIR'%;N.6D0?B9!0$4]
M!QPSS4P<+PL_`K5F26CB+NV2)4WLN+0H(2";07+<.EP@1145`2<J)B<4^A<!
M\?M>F.XDC?*^..H9RXBHRQX9>=8D@UM-3AY<.G/H4N0:)C((R\N/W&+`J4K#
MC#@51RV5.<RSQOW6RZ:B?Q*>_0H":8#U"&P'UC1N<P4<3U>Q8CFT;I9B36M5
M%/)UH8N).TEA7L>0ST7=@.Q048$<P!UND7G>)(N0?+IF`>LQDS'(<0V`I#`.
MNAV^%QT32"H+M(P-,3@,*^M65T-Q!P&>.-/4HCQ+UI857B=EE%%6@/!.Q6:=
M+@Y2=0AVW3A0R[APFL!PZDNC<#%V*8!$=>CP[7V+F3Q:1(6^\*$#HITX9Y4Q
MHM%<WI<'-:RN.9I578K32*>*DJLS!-IN&=E<DB3JO&R"Z`LA*HCVG+L&\HQ$
MP[=!DA662ZR[CL&VNIM"&6XECJU[2"<_LP/GP.:Y*],QD-'@.(/"N'L5^,=Q
M593EI9`&Y(V";IMQ.XM\RZ^"35$@BT;JO"HJG67.=/H;_$%,?[`B<`#<=;*.
M9S0"\-[1Q(!8*FG0*8=.?.H6EN(I)0"'$@`$@T`_3ZLU(R@6"R*OWM=E'$0W
MK4J`_=3F/E6;MNS75^T@]*"/@D*JFZ:Q15\$CCX"(!KG.]=G:OM/FX`1N$;@
M32M'-`%0:BM>(Y$467LUQ()C;RD_+O%,0,'<#GYE2=NL3RM/7<=(,R,W+5^Y
M2<BNV3(";@H;'*BX0,!0VW'J$?3U`.XZ\EN[\P@S-;5IJW(=)SY\UVUM8F8Z
M*^^*'`^NGEU*USV7?'8IE0.F#05/VSE$X"D*Y=A$$U#'ZU5";"'0(;>&W5X:
MXZXNY`T-)QTXT)I[?,%OH;>,O/+@",?T>91=Y4\LZ%PWP'8,OV8Y9&?<$5BJ
M#5_C2!(W2V2:3@L2R11.Z^))#-U"*N'ZQ0V0:^H#"7?/[O[!==YMV9M-G5K"
M-4K^#&<7']8Y-'%QZU;N-[#M=JZ]N_X;,`T8%SN#1]IX`$\%X2<FY(N&8+_;
M,G7^65FK?=)IY.33]03`3ONU3'39LTA$P-8V/1$J+9$OV4D2%*'HU];;=M]I
MM-C%MMBP,M(6!K1T#B>9)Q<>))*\3OKVXW&Z?>7)K,\U/(#@!R`&`')4-K-6
M(FB+8,.YA]WA\OQZ(MH_H#\.B+KU1]/X/I'5%>N+HJIHB:(FB)HB:(FB)HB:
M(FB)HB:(FB)HB:(FB+]Y;75+DEC[OOEL\;<Y<I\D\G^3]"QSR@<63%F*L/XK
MQEFO%%,O%)P15,>R5NLEE=4Q&S(SJ;RQY0M]N.]E'XMVBJ:#-NU+UID$PXWR
MX=*7OH0<J@'GS'E0*<3N;$(XR6XDFAS5HJUY3F-X/'D;QK?Y,E)C@]'<G<O<
MC5N'Q*+!Q%`GH+(DD2X4[C;9)EI,*+27'7%>4GTE9&]?(Q00EUUV;-X'P3`$
MG$0M'?"7>Y7+A3/*E.?/AGDI?FL=>D=K0"O'[\NKBNYC?+ENM$KV!%L2<M;C
M`96XF2N7JOQNR9DK'$3EM.(XQ9?+7TGW%G,D`^MU<D\Q52HMZC#)PUB++P=A
M;A!QXJJK"FY%V%HX`>]B#T]'GX#"OGSK3YEIJ"P4(QZ^?+B<:<>JFW(^5U6[
M#B%[$6'D#D\G*EYRC5YN-N9]1@:A5[[6^4'[LL<?L;%5<<.&L]1&N*F&*8IM
M3C4U_P#>+-]6TS).W*SI0SO5?E#V6BOO5KT94Y<N=<,*'-/FCVNL`:*4IT5K
MPIQQPICE3)=E3.`66+-G.'SYS'Y=N.3%AIV!\V<=*%5*/Q_I7'.F0U"Y"$J"
M&4).=2AK5D.PV.VRS:CQY&RQ'S)BR$IQ3:CUB&J-M#K+GFN'3G4'&M:Y#B%<
M;NC:1M#?NH>5/S'@J)Q?Y8-WKLCQ489?Y?V'+V-N&>+,JX-PQ0H7"E1Q0_=8
MRR5@UQQ_0=W^^0]KL4[/9/KE#%NF688I1<:X.W[GW4DNH9<+19NJ-1P%.?#+
MR%.I5^<H':&@%Q/KS\C5=O@+RW,AXDL_!Q>Z<M5LCXU\O1*RPG'W%L!QZHN*
MVDA5YK"=IP5&+Y1LT/:IY_9;_#5.R`924C6\-&/5TU5%(H%W'?1-LR"*D?"1
M7&N((X\J]'4C[S4T@"E37SU!Z.73UJOV/ET56.X%X^X0,<KVR.<XBL-9R%BO
M.D?7H,ELIF6L?9N<9]QM?DJB_<2->E4ZU<S)(.HQPL9O)QI5D3G2%?K3D%K2
M+37WZU'1E]PX*,W),W:$>[2A',8U]JK+`_$O*-"Y)7KE;G/DBEG;*5[P'2^/
MJL57<*U_"V/JI5J/D:W9'CW-5A(ZX7B?46D9.X.?BPE)216,J(G3621[;5*K
M('-EUN-:=?3SKSYE4DG#F:&-H":^SE0<.2G1K+6,HQ<N>,L5RUQ1!8JF;;(4
MIG!YPX^YM3F8R);33EP^P!F"I9=CJ^=FZ?1Z2;2S/*F1BLX!03MDEQ5*10Q0
M(:&6+M*4S!^T'[%+%)V;B>@CT@A1OM?E?87N//3*/-Z7L<^HRSAQ7R)QAR]@
M$&2):%<"90:4RM7')J<TC(H24+;;!CK'L+`OR(MC%>(1C9<52J)[&Q_DQJS]
MW33SU!]&'/+!3"[>(]/X]5:^8_?7K55\?.)O)/"*V-J3-\UQR;Q_Q'6'-*JM
M%D^-&.J]EVVU%C4G=-HL+EW.[&SOPM!J/'G:K?&PM;K;^8<L$C/ECE.X*M)'
M#(QP)=5N(S/FZ/0!3I5LDT;VFC0'&F.'W5])*N'B?AGCK'W!*H<`[6_=9/Q5
M`\<E>-%CE)F-;1#ZYTUY5'M0DW[N,;.7[:*D'D>^.H0J:RH(+%*8I]R@.JM@
M`A[)W1Z@!]BL=,3,9AGJJHZ4[RN*E4^&E2XQ&SMDR7RS3,X1O*F+Y?OXFN/<
ML/>4L!;!L=?S!8JS-!-U2RIMH=%O6WD,]%9H_K:0LS*)B8JJ<8M:,S_>\_+V
MTRP4IN:RZJ#LZ4IT>73FI<X"QER%HCZX2N?.1U9SDXGFT`QK4%1./=9P!3:4
ME#FDSR<FBQ97/(]KLE@M1GR(.U7TR+)L1FF5HU0$ZQE)HHWQDZC48<_MK[5%
M+(Q]-+:''E]@'L5E>0W"RZWS/4!RQXS<D)GBMR/9XS3PG>)U;&-9S;BK,^)&
M%A>6VLUC*.*K),U55U-4.RR;QS!3D7,QLBR3?.6Z@KMU>V6R6W+Y!(PZ3Y<O
MO&9Q(P5\4^AAC>-3/+K]AQ`.>*HR4X+9WE4\0Y2DN<=IL/,?"MPRG.5+/]FP
M-C@^.5:!FBO5.MY`P#(<>*K+5)@.'725&B9%B"=D+8F<XS!X:46[BJ)[/EGD
M`N=[P/W=1X#CP&/.X7#!4!HT$9>51Q.0\V5-ZD>7+&P$MB:_7+-MGR)F:J<V
MY/G?ES)3RF0->0S'E-_@*X\<8ZI,*C%22C#&F.:=C>PQ[*&:(.)1R@A"I@X7
M<KN7#D:BU.G23QJ?01UY4SY><T=<:B:-`&F@](/5GY<NWMGEY5>UW#*5O6R=
M/LU\H\_.,//=XR2K<<LC#V3C)3\/U")QNV6/*D.[A+:AB%!=Q(F*1=H=\H4B
M"@)E$U3;'M-8.3@?[/\`DHVX+8NSIAII_:_REIS3Y=%&S9<>4E[E<FW2J6KD
M/(</[A3[%58J!";P)E7A0\GIO$F2*DK-EEXBV.5;),$</XV48_`N6B:K,X'3
M<&.2UUK5SG@^\<O37VHVZ<&M90:1F.>%/95<&T\(<VYOQAD;&_*#E^6\_?ZF
M+;#B>:PCQQH6`CX2ROAF_P`9E&@YKBT'MIRQ(W2\,KK7XU9=G(/DZ^JT:G;$
M8I@X5.-?EY"TM<ZN5,\QUUXTQ'+).W8'!S&"N->H]5!S&7Z-C(?"SDEF[&CV
MO9OYKQ]HR75\Q<?L[8#NU+XOT^@4C$61N.]O6N4++36-5,BVJ6R@AD%\M\/8
M6[NR,$`:)D+&D8'`RAZ&V<6T<:G"F>'/B>7/T(+AC75:V@-:CG7S`8<,/2MF
M;X2\CVMYNF7,2\V&6(,MY[QM0*+RHL$?QDJ]MJ>0[-C.*F:U3LS8AIEAR6*V
M$<G0]-FS0Y?BI*UPKEJR8J.6*RS7K5&U>"7-=1Q'3GZ3GTU&0H<U<+AE`US:
MM&67W#[ZU-<5<OCUP,Q?QBR;1+OBZ=GV]9QOPIQKPFJ]'F$F\BK^ZF-<D6/)
M#:_3-K[R+J5MUBDK*L60)\(DB=83+E,'7VRW1VHCD#P<`/L(5C[E\C"QW$D^
MG'VJ['*SCM%\J<+OL,S-H?TY@^R'A#()IZ,C&\N[3<X3S70,TQ\85BZ=L43(
M3[^@I,%E.X!D$7)E2E.8@$-/*S6S2.8]1!44;^S?JZ#ZP0HJYF\ONZ<AL^4S
M).9.0M4MV,L9\A*5R'QG54>+N-X7D!1)''=G:7.I8M@.5<?8BV!EBQ"P,B)O
MBI5Y*=DX<ZL<O(BBLJ8V*VT<'`D@AI'/AZL\Q3^DLDW0T%C6TJ#Z_7ZZ="E%
MRZXY->5V$)C$JEVE,:3R=UQ9E.@Y$AH:.L;FCY1PIDNKY:QQ9%ZO++-8NT0[
M&WU%J#^,66;E?,3JI`LB<Q529$L7:,H,'<_.#]@6-$_LWZJ5&->HBBC75^$.
M?8*V<GLSON:SA[R/Y+T'CW1%\AQW&O';''F.8SC]9,C33*"K^'IBTV1"RTB\
M1F2W\;*,Y>9<RQ45554)0BAFX-(!;/:UP!%32F?`D]?'GYU.;AA+3IP;7##B
M!YN'*G,%6=K_`)1L/&P^1K:MG%C4.2MRY!8BY.U/+6",`4'#V+<697PC1;%C
M6J/:]QQ--7&MV2.N5'NDY&W49>8<O[,UE!+\4S%JR,A;\F0#1WO5J,3Z>)!\
MY^Z\WFIPJT%M*8^S@*9<.'76\MRX2YYRY0!99CYALIC,5(S-B?/G'/(V-.,]
M(QE2\#9&Q&E8&K-R7&+B[7.6RA#9`B;5(1ME:S-F#OQSDR3`\><`5&YUL]S2
MUSJBN&?VU(])XY9JQMPUC@YC0,,?*@'JX<5<SC7Q1ON'<V\@N1.6^0*N=\I\
MBZ?@RG646&)Z_B*ET^,P2.3@@(^CUR'LEKDB0[\F37!CEE)&2?D51$QGBI%"
M)(2PPNB<XN-:_I^_F5'+*)&M:!0-_1]W)38UD*!-$31$T1-$31$T1-$7Y4'\
M45B4<7><GR!ETT!;L,STK#.96`=/218\UCV)J$VX3]0@K9J0]ZA#PZ]_7OKG
MKD!LQ`%!]V'V+?V9U6XJ:D$_?]J\]VL=92:(FB+)WY8?/Y_PORNXK.0'4K,<
M6<PNF,+FZHM2*O7$#L`MH?+5,:`?_<KO2%CE5$Z11,^8%4;F*<12$G%=]NZK
M>\FW]I:@-WJ`$PNK2O$QN/Y7TICDZARJ#T?=S>W;1=ALN-D\^\,Z'+53HX\Q
MTT7K[D\!7MD-,F*%D"#OV#[$,=:*=:'LA&(+V%M+LW$PSFT`%;N2"::3H"+%
M%,JP$,4!`-E"C\[B>*&Y?%=1OCO`QS3AITN:0',(S#AQQK7H7M<=U%-#JI[Y
M(P%2"#\)!Y$9<%*JE0Z\6P=LWA6+1\8C=,D4V5<K@7[:RBLBV06#L)-B$0*0
M3)&V$B@E$I>HHZPG'4X2$FF=?O4+C^753S>A6_M5_.16,:`)Y9%P$DR<E!$K
M9>/&,!<#H&4*VV*JFN@98!2.H)TS%$VPZV5M;-DC+JXBAKPQ/)1/#@37`^FO
M2H?V"9KKZW1@*2;HK!V#AD,@3X%W,5-NNL8P@KW#-UE$0<.RF4#M"J!2"3KV
M$V_<[;;O^6<!\8((&37D#CAR'5BM==%[<V@^FOH!\N2V0@ZY5+;+L6=Q)/IF
M5(S5?I1BC<S\Y6@./B`>LD9"'<-05,)`Z"^(E`1VV$-=7:32W5FQ_9.9CJSK
MA6@P-'#HZ%SMR'M?I=0&E*>WRS5PXZ%2=*&:N'`RC9-ZV?,B/UTVT07P%-RH
MV=[M1(EL4I5$S%4Z=MB[!K<VDP<T/8"QVFAY]%1["M%=^[6H!.66.'W*2%15
M7353(PBZRQ(BFU,LW9)@^B3J-S'+UKR!!26D7[90/LE62$@E'P'66P/;^^>7
M]H*XDT.G^;P!YK33:'#035I/KIZ%<-=,7#ALVDX]NXCCN#/$F0-V4:T4^(,)
M7)Q3;%:F[9C"54>D3B(E*`E`?`=#N6Y=BXL8XY5J>'6.7H!698VA>T..!K3#
MK\AT+:R<Z;IGBIY9B>P*NV!V"RJBY@1([B$P*#@R"AD3.EE6QD]E#`)@`-A$
M1\=>);E*ZWN'1-JX-J6XX`$UK3B?L7HEBSM8M1.AYI7GZ>"B?<<HP\'#2$W8
MY9.O4^N(/9&P2[LB#2.A8=FV,Y?.Y-P!!01001((%``.8YMBB.YMAY8NGN[N
M.WMVO?<2/`:P8EQ)P:*<SPX"M5T<=NV*$O>6AK6DDG``#,^88E>*GS!N7S[F
M+GZ5N,:=ZSQ73T3T_#M==E[7W94F:NZTNLWV`4Y2V/RF?+]>ZA"J$2$=DP#7
MUIW([L-[K[*VVDH=RF.N=PQJ\Y-!_+&/=%,"03Q7BG>7>?\`&+^L1/R47NQ@
M\>;STN./0*#@H-:[!<ZFB)HBX^B+:4'P_``C\OFT51]JZU7U_BU17+8T54T1
M-$31$T1-$31$T1-$31$T1-$31$T1-$31%^\MKJER2Q;97YBYQQEYAEQX^4S!
MN7^2M*0X.XLS9!8QPW&X@B92%ODSGC,=-M=JL>0\LWC&D/'LY.J5..9QT4>5
M<'>O$3_"M0-\0L7#EF>R<-'PZ:\.FN9'7GP65%"V2'5D[73CT4R!XFGG"O;@
MKS`,!\A+AB"H4LMUACYUX\VKD7C>=O$"SJ\/*0^-,AH8OS3C:0!Q++R</EW!
MUL>MD[/$JM^PU0<`JBY<%36%.X749YY>0QI4Y><]=+76TC03@:'ACY\.&!./
M!7KXS9^J/*W#%*SSCB(M470,DK6%S05KC'L8F4M-4B+5,UB#OK!BQDI0J52O
M[:'"7@U%E$W+B'>-EU443*=LLC)FO89,FCR]F*C?&YC^S/Q*P."^=C3D5/L7
M^,^,_(F2X^S=DRC4JURN5)AP<22TSB*1M4%9W$A5FF676:ZE7I&S4Q]&13^5
MK#4KUX"/6F@DNDJ:QEP'/#:8&M,N%>FO#DI'0%K22144J,<*Y8TIZUWM%YVX
M>R#CS@ADN$A+^A`>8;/1M>PDWD8J#1E*^]E,/9"S:W4R.@WL+IM#MB5/&S]$
MXQZLF8'RB)`**9CJD?-1Z==#3_\`=+N?((+=YD,51J!IZP/:58*L>;9A.RX^
MNN9CX&Y<5_!%##(4/)9OGL30"%!L>2Z'EU3!S##.-DFM]=W#)>1\D9&[4=7`
MAXIS"NWBX-5I!NZ2<(HV_-MQH#AU<Z=>?*OIP5WRK\!45/7Q%>K)5I%>9+1H
M&U9/IW)/`V=^(,MB3C+/<N[0XS,IAVT0Z^$Z_;4*4^?P\A@[*V5%7EP).K@B
M,(=%)YWMDB=Q0Z8'I\VT'2X>]2O#*E>!/#]"&UDI5M"*TXCC3B!QP7'@/,WQ
M4PEY^+Y"XDS-Q&;Q^",E\EZS,YN-B>:CKMAS#C6%D<I2+0F%LGY4?U2^4:*L
ML<[>U6<1CYLR#PO82643732N^8+3^\:0*5]G2?/QZ,Z6F!Q%6$.Q`PKF<LP/
MN7>T'S":]/6J$I^6>-_)'C%*Y"Q3?\T80_SOB<8%2S33,85YK;KM%0?^763;
MXI1\G052?H2BU6M)8:4!@<ZI2F%L[*A:+H`@/!`.67.G/GU=6=+OE7D580X`
MXYX4%3F!PY?<NBP+YF%`SE9>.D>^P!R.PG2N7>+Y_*7&C*>8X7&D=5LI,*EC
M]AE.T0'W)2LF76]4R;9X]>*R[`TU%LFDRQ9.%6:J@%3[IMVTD88.RR^_VTXX
ME4=:O:":@Z30Y_;AZ*G)7!XO\VQY7&IEHI'&'D56L!Y4J4O>,0<F+<&&5<79
M`KD<HG]VNG,+4<MV?*./G5Q:*"YAFU@@6"[A(ABN"M5]D1NCN-;@*9CH^^M.
M.0P5)(#&TN)&!H<\^5:4]:G(4`,8I1,!`,8`$YM^DH".PF-T@([%]([`(ZR2
MH%@<P9YBF875TYG<A.1L%R(IO'_#7(O)'%/#N":_BGC;,P%ZR+!94I&&,94"
MFV*K9$L?(*[\GKY=Y145FKP\;1$F\D`$<E(R.XUKVW#@YSG&H!R!'.F52?LQ
M\ZSGV[=+0RE2*UQZSC0#`>?V*6MD\SO&^+Z+R/L7(3!>?^/E]XOXIKN=KUA2
MZL<8VF]VK#5KLB]/ALA8KG,8Y)NF.+W&I6IDXC)!JE,HR,9((@BX0**[4R\O
MS;6FCP:]%.1/`GAT^C"L3;5[P"P@M/'$<0.(YGRQ4N<"9L?YVAK)//,%9\P.
MPAK(2%@6_(6FP=#GKY"+QS21:7JMUF*MEIG(NM.0="B+><1B)MNX2.FX8(F`
M-YHYNT!(!J.K[_;3IHH9(^S(!(-?+RI58[,$^9[9GL7SENG)O`64L8X@XI<E
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MO62D'G8T[VMSK:,FP1DFYRH")E")4;<@UPR%>&7I_3T*CK=P`((-7`<<SEF.
M/H5O\A^8+;&_%'//("3XY\EN+=4I7'YOGC'>9\@5#C[F2O6:JRSJ'")=P-,Q
M]R)D6KRYA&S"#P]<GY"",+14Q_B>M%1,MC[FH(-0?,>!/!U1ZE(RV.H&K2*T
MXC&M*8C'/I5R,R>895L5W7,]9J_'GD=GNL\7XV%DN4^3\,P>.W]0P8,S46>0
MU(5Q&W+(U/NN4KC7L<23:PS$-3XN;>QL6[0ZRF=+)M1O?<AKB`,&YY??U9`Y
MJ-ENYX!J!JRSQ]`Z\Z9+H<D>9A0ZQ;,AU3$W'[D5RB+BWC]BGE/<K;@V/Q2%
M&:X(S!#7BQU6V15AR7E/'YYZ;<5_'[YVW@VC=65DD^GX1)7I5%.ANV?A&%*\
M.=.?1[,"KA:R8:R&DFE,>0/`'@?O5&R?F#52`Y)R]OF\E,FG"1MY4M(YV,Y4
M:P162<+V[-4O$Q=H9_#QJER?R$]CX6+-I!)F/WGZI")H"Y/N,1NG"6O^;Y?T
M2?T]7H5[;8NB.'[P.IZP%4J/FBXJJG^8/_$7AG.O%<U*X\Y(Y41"64T<3VU?
M(&%L0_<O^9;VNHX1REE'[ER%2_WHBA?U6;-&RR9))(Y"J$(X,A/\P6UUM(P)
MX9#SGS\>A1?+DTT$.JX#"N9RS`50RGF$HT'$-\S5GGB7R?P'4*O'8L>THUO_
M`,A;<?,\EFNZ1./,:4W'LKB[-UTK3"\S-OL48V=,K`^AFL:E()N%W8-R+JI/
MF0*U&(IQ'$TX$_R]%2*_+$D4<*&O!W#/,#+RQHI/X/RU><JL;6.0N-N:.-%@
MJDPQC!KF8'F*9LEH9R,<$@WL%*M.'LC9*JD]#MQZFSH#.F[IJ[+T'1$IB*&O
MBE[2HIB.JGJ)4<D?9T-00149_:`K!6/GS48KDW>^*=4P!R=RM?<6/L*CE*W8
MYH-5=XEQM5<X0ZD[!7RYY"L]\J\9&0-<C4%5I-FD1Q.]ANLNT8.D$CJA8;I@
MD[.ASIPYT\N/0I!;/,?:5%*5X\J\/Y.E41COS.<4Y$N>&6B6(LVU;"7)*^DQ
MCQVY06='%Q,698N4BRGI"FI(5&&R7+YPHM;RBSK+P]4E[%5HQE,[(^*/Q37N
MT-T`-;@>S/'T^VG(=:J+5Q.EI!DY>KJPKC0E4]0O-4QU>X[&>0#\;^4%,XZ9
M1S4IQWB.3EU@<4Q^,(K+KC*<YA:N1DU`Q>5YC*2%)MN3H4L,RM!($\(60>MD
MEE4P.<Z=!=`G`>[6G#.O7]E,L4=;.;F1JTUICEZ*?R%5Q;/,0K6,\_4[!^8<
M`9EQ+$Y*S9'8`QMEFUVKCJ^@;A?;))/H>BR!,7U;-L]GZ"Q_D.58]B)G7U51
M:@=PW%X5HFJ!PN-R`[(EA-`<,>&%":^A6]@2PN!%0VM,<O13UJA7'F2T/&4)
M/R-VB<VYHDI_S#\[\'<=U;$6#HE>ZH7K'->M=PC:6QJ\1D"67N,`QBZ0\:)6
ME92/6>*+D<R#&,:).%T8FW36@DDG'E3/5TG##J"D^5>[2105'/JZ!C[PYK(1
MBJ\R>2\>5:]S6-,B8<E;(Q<.WV,,LLZVPR+3ED)%ZP^[;4TI]FN582?+$9@Y
M3%E*/43METS=SJ$2ES(WB1NH`@>;["5C/;H=IJ#3RXJX&KU8FB)HB:(FB)HB
M:(FB)HB_/\_C1<*&C<R<'^1K1C^PN6,<EX4GI$A-@"0QW:8Z[UU!P<`^T=>/
MR.^[>X[]*`[>`#MIMP:1('&F/LP^VJW&W.JQS.1KY>I>)+6O6Q31$T1?-$6?
MCRA/-S;<5G2O''E;)35GXHV=85(&:"+&UV'!]H=.D2&F(=NX<E=N:&]255-)
M1Z7<.D8.XW)N90IO,._7<)N]ZMVVAK6[OAK;DV9HY\!(!@UQH'#W7'(CL^[G
M>5UE2QOG'Y4?`[BP_E/'0?/I.6%5ZU,D+5QI#U"\4>>BK3CB[P3.0IEWI\HL
MO`SD6[3;*M)>NS31)9-3N-_'MF/WTQ`"&(`D$`\.9`63.MG-<R=I((+:4(P<
M"#D1Q&?F7I\4XFCUM(/',&H.1Z0>!&!45LE'K4E',IS_`/*)C8XEX#E!U+')
M(0Z0)@<7!5BI+N7JY7S<Q3*N.D@*'`>KU&UTNUPSL)A8&NB?A2M#C[*<%"Z=
MPKB-/0/(*-=^J[B<DFDE'M`CC&:MMW$;))."3Y$W0E4"-,[(B,?+QR2H?LQ5
M.54IP$F_2(%[/891"]]N[%H-3J&(PXTJ2TTI6F'%:F_D(8#4ZN`IE_)FKRW)
M.X?#TROV9`JJM=@=X*8!.,0/)QS\43+)EDDFY&J+F,.CV7(%`#"L7TAN(#MM
ML^5URW4!<8WO]YM3AG3#D?PX#U+27+G:0PT#QQZ>/G]*EEAB@12QV#N4,U>)
M/$JM(S;=Q(H)QZ:K]U\/$)S;.1'O+)/UQ.4-D"G*)]Q`Q=AU-\W5Y#6@-:32
MN!\Q%5I[AC\W$U(Z\./D%<"^P#^LW9Y+MH*)8Q4JW(,>$1%HJ19VH))-C/DE
M$1&*10,D0!6(0RY@<`;]#;PAFNI6^Z'.R)<7$\L`W/S\`HXHHI&>\!5IH!QK
MQKQ6FMQ,G/+1SZ.3;NRR2B;!P_3%F],U4`XD*"34JB`MS+$-U`/05/H`3[&W
MZ1Y/<;X2N`CQ-=-./"A)Y<>I;:W@$.K74#,</-]G7Q7!S57UJ[3U$$A!-0MM
M9D210ZCNU3N&3ENKN5-0`*=<42G)MT[I!U`&VVO,N]DC;>1KY2`0T@^8_I)!
MXA=AL%926@5'EY=:\=OFM\\U<B.7'%O%%A^(H==ESNLL6.)7_P!VNEH:&`6U
M20<ICUN("JK`(.PZA3<OR;>)4?M>N^$_<F2R@'>O>F$;C.VL#'#&*,C!Y!R>
M\9<6M-<W8<OWZ[Q,=([8]O=[C329PR<1^`$<`<7=-&\#7!YKVY>9)HB:(FB+
MCCX>&B+;4]`?CT55UJH>GY]45WWKCZ*J:(FB)HB:(FB)HB:(FB)HB:(FB)HB
M:(FB)HB_>6UU2Y)8X,OX(Y?P/-"?Y<\77'&*?_>SBAC_`(V2E+Y!V#+-6/$2
MU&R[D[)S*]1TGC:FV].5BTOW_316BU2M5G@MS`5VU#8Y\*>&1\FIF6FG#IZ^
M!_2LN&6-D6A^>NOLZ1R_0H`\Q/+VL-9X;\".)6*KWD%YR75Y0S]4-R*Q[4EH
MP(BN<JV>8I[S#KM9"$+,L,=XLL>,,@6<T6V<NC*HS2=?;H+G>D36"":!P:UM
M"7]`\_\`E'KICDI8KBLCWG!FG*O4![!YJK/]2ZC5<=U2H4"DP[>N4>@UNNTN
MH5^-*5!M`U*IQ3."KT.Q('V4D8R'CT44_8!`UL&LT1Z!2H'F_D^Q8+G:G%QX
ME8>\0^7/ER`YI5+D[/U7B!Q_""M66Y_+MMX;O<X5*S\QXK(54M-5B*WF[#5B
M:Q.(*Z9I(S[2RRLL=U:I9S/Q"!FBS5-98XXC+>02:S3,\O-7CTYD](69)<1F
M'LVU)PSX<Z&OFP`\ZX7'_@!S`QX7RWL79!R#QF=8'\M3*,G.TR9I;?*KG,&;
M:8UP?FG"E(>6:/G(N-I6-K+$0F36IY..:N)UM(.4%ETG[0A2-5K/EIJ:#\-#
MR_*6CI]JO^9A#C(`=9()_K`GGRPP'355C9>$KC&'E86GCC?,CR#6QXLOMVY*
M5K)N*L8V_+[ZNWBN<Q+#S"Q3)1F'8=HC=<GI5V97C6DO!1Z97LH@D[39G`YD
M5`F=$1;Z3\52<B>->%>7V854`E#KC6/A(IG3\-#B5"VJX-S!YJ.8N64CG.RQ
M1</Y#\N%7B(RROCGB[GOC]28;*%QSPKE)JA3ZMRMD$[_`)D<5!*LLY:>5^"C
MH%N#MO$%466,Y6#$9"^9V-<L:X<"!]F7GQJLQ\S+=NEE/BR!KA4'//.N>/FH
MI"USRL[!>*/E[$F6>./E@<>(#*?'#*&#)[-_"?#EBAL\3MAO\7'Q3*Z0J5BI
M5'A<75)HNT-(2-:^\;-]X+%1;?'$02,=6<6\AJ'!HJT\!]E.'2X9<E`ZY8"'
M-+R0X&A)Y=-:X]`X^:^9>*/,G.^0\3W?EY<^-$8EQMQ7GFL8M:\?$\H/U<I9
M?SKB)]A"3R]DH,A0T.GCBM0=%E9$6M4B33Y_CY515244(U034&WF>X.><13E
MP->'Z<\U07$,;2V-IH?N\_''AU"JJ:@<&+Y2ZSY2D/\`O]3U9+RYL<3=-NKU
M-C.*M+[+2'#N4XVL9*GMSMVRI&#:T/B2:B;\S10\>0Q`$%A`NI!"_4P_E:`?
M,#7CTJ,S-(D'YC4>D'[%9KB+Y=^6,+\L8KD?.5+B+QNCF='R=7\HTCA!)YMB
MJ1RLN.07,$O$WG)>(KVQK^-L8%H;V,=2C).,2GIA:2D#D/*`W(<J\<5O*V0.
M/NCC2G/+#].>?.2:X8^/0!4US/\`*?LZN69D/`0'WZV"P5BBF?+QOCW`V<*)
M#90I\'EB;\R.V^8W@*X.X&;G:95;LUS=!YDQO3LF0!5H:5F81RG$KPU@^[ER
M*)MWQEV:IU4B`.O%HX`N_%P\QK]RS/F![K2/<TT/HIZE;#.GE[<G^8%?Y67/
MD#<^/N/LSYDXK5[B)ARHX>>9*MN*L<49IEV/S1=;C>+O<JO6+C;K7>K5&,TD
M6S."9M(9A'))E,Z5776"U]K*\ES_`(O-CA3H'LRXJ1EU''1C`='LQ!Z?:<UF
MP6."JJB@;@!SF/X^G[0B/C[];!HH`.06O6%K(?ENYFR72>?_`!@GK7A#_AEY
MB9OMW*FD9!=-;=/9AQWFF<G<17R"I=YP_)UXN+LBXGB,BXN[S\_[PM',K!NA
M8F:)*"=QK!%K(`Y@/NFG+AT4/3Q%<LL5G_-,JUY!UM!]>&=?LPSQP"I17RT<
MG7#"7+;%;CCAY5O%6=SWQ%RSQW@L@\1L97=A;I6XY+9,F'[PVVP2..Z,[J&)
M4"M!77K+1&P/%70-SB_,#4`6""72X$#%ARTY\L`/1B.E4=<1ES2"X@/!Q)R\
MY/IP4WLG\6LA6?D)C+/%.LN,TW.,^"G([BVPKF1J[-VBMS5_S%8<%V"KS]GK
M\>I'DG<9,#XD<-YN/!VV>NVSTJ:/I.8LA@=J)SJ#Z3IIQZ/TA0LD:&:<1[X/
MFQK[5C/B_)\RV\Q7S2HT*VXL\1H;DYQ>#`L5@+B]9<Z63C8ODE6[,[6OR$LE
M9OD'68V@3C&):'A8^)J\!X,7BXO'KHQ6Y4<?Y26AX898<B.%!Q_25EF\CJ,*
MXY\1B#Q+B<N?Z9AY(XF<QJM=.9C+BK?>.##%_/*6_?.^2V;6>2C9"X]9-G\.
M5+`V0KECB"ID;(5G,D//4RCQLG'0TQ(5K[NG$U04=N6:P)IROMY:N:S^&:'V
M<ZY4'$?8(&314:9`=;13K&/HQ/(_?6&'>`*F#[!R(9TZXQSC'>1^!W%'A9B]
MA+)OU+17DN,N.\Y8]0LUS70:$CG+><9Y/CU2@S,HJ!FCCJ(7=,#59;/:TMZ&
M^IQ-/7T*C[AKBUU*$$D^<`>W%1GFO*"DLAXGCL-Y&RI7&]>'RAL)>7))S%=@
MGTP\:91P[>V%^C\KM8&?;LHJ?Q^,U$-3FB7BJ+A\B11NL5,B@G",VCW$5RTC
MU-IY<.E2-O`S5I&)>3YJ@_H59X6X*YCQ\>_R2/$WR;<.6Q_@J_XXA[=A;`UX
MD39-N=M1BF0IY(A7-/QTM3<"V-@S<IV&ILW]C=O2N$2%?=ML(+WLAD`.IK<6
M\FY^:GM(Z5:^>,TH7T#AQ.7G)]@ZN5ML.^61F/%E3Y2H5W&/`NA5?/&/,68_
M9<%&CW/N6^"$\\J-XE;#D7(UT@KM#UYU2+=D&IRI(*/;U>L$CX<(]J\=$E%B
M`0E@MI`UPYTH,*=/`#U>9RO?=1N<TT.%<<:]'$GU^A2\\NKAM=>'\)G%K8E<
M?4JKY7O];ME`XUX6N>5+_@[CS&0-/:5N;98]LV848RSJN\D32)I>5:LXJ%A6
M:I$4VK3J!9=6>WA?$3J.'+T=7L&?IAN)FS$%HQIGY$^TJ[^.>,TC5>2G.+,M
MCG8J7IW+B$X\0$=68W[Q;3M?C\18CLV,[629=K($9`I8#V#NLCM3JBFF414Z
M3[`-&VY$CG'(U]9J/1YE:^;5&Q@S:L>?#KRM+7Q7M?'RF(<>/*TM%'P!9H)&
M&Y9J8/G(WF1:*)42+MZ<[?5]E2FE0KF=T69&B,I<4[:^0>+)+O"1R:SCMI8Y
MMY6L(TM(`(R%<L.%?77H65\S&YX<2\$D',TSJ>-/-0#IXJT'"+BWS#S=P[X[
MX)R]'88Q7Q7J/*JZYTM*+A#*X<H;Q$8@YU9%SK0<8RM$L=8@Z+18RUWRNQ;Q
M[84I>05=5P0(U8)J.2N$[HHIG"F3-9.-.!!&&!IAS]&8I+)`QY<,9"T9=5#C
MB*TZ*9=(-10OE+YM8W&B$?-N$SU*@^8)6>:%@Y9OJ;?9GFSGNN1/(5]FHE$O
MMD?5M-A39^#@7Z=>(X;STY%R#"-;()-(I$YNT;:R"0/.0=7AS\WFSPX#`(;M
MAC+!4592G(TIT^?`>?&LK*SY>]\@K]CJWJY!IJ[6E>;-R,\Q!XT1:SQ7+V@9
MKQ-E['</CUJ8[$$BW2&?Y(;N':IQ"/,@V4!-4QQ(`U;:O&!Y^P.%?6.GH5C[
MEKH]%,=-/6W_`"5E:UL5@IHB:(FB)HB:(FB)HB:(FB+S)?Q9V`C9;\J-[DUB
MS.YF>,F=,:Y/%9%/K71JMN4D,2VDH]("8&GQ-UC7"OCL`-0,/H#6NW!E6:P,
MLSY\O65G[>_3-I)S!^_[%^7YK3K=)HB:(FB)HBRB^7[YJ>;.#1SX]?1S;-G%
M^Q2Y9"[X"MTBZ;,T55=BN+!C*R$!=YCJWI?WA%VQ#M7"G@X14`=PY+O%W0V_
M?C\R/W.Z`4$C1G3(2-PU#@#@YH.!I@>@VCO!<[92%U7VE<N+?YI/"N):<#T'
M%>I#%-\P]S?K#"^<*L@UK(:+=!%[<L%7`8JH<A<;$474(X9VRO+N#-+?%LN@
MP)3\49=)=,W4?H$>@/,GV$NPS&VWL.9))72\5,9(_(ZF.%#0T(XM&:]!@W6"
M_@[6V-6MS_\`WFYMZLCP)7:6'$JT#'N:O<(>5J\\UD5R0[Q:4BW<*],FB0?N
MT))=Z1<T<9-3MI+D$1;J`4!*)=AUL[*]UW#;BT<V2,LHYH!#QCBZ@%*C.GX@
M:U"Q9W/+""<C4'KQHJZKCY[(R+"K7&0M<K+1I#5Y+X.?B(F781"QP250467B
MY).19.RK]*G;.F*A1*)@'8HAN+>WBTNN+%K&P$!U'!S@7#E0C33@"#0K43O>
MW&0BIY>OSK(''878L:_,5YNO)1A$+%`,[`+]B*=EG$DV\0XB#E<&*1KM&,E2
MB=4RIBE,H8!\3`(:UUT6O<YQTD@X#($DDX'`9X^98SM3J&E:>SR]BXQ9QE'1
MSEH@Q7GE0WC32UH9NA@6C=VFLV7=LVR1A21(]45%7[2P(E.D)B]8"<!T6X[I
MIC<V,>\`"3UC#SGK\Q69;6>J0/>?=J:`<P?7Z%4`6&,"MPK:F,41.Y;MBE62
MZI`6_>>_=H.>^E]EN]5=D(*('/UF`P"`D*'4/.W-R]UDPPT$KN7O.&-/,2<J
MX\<%M([<BY<):Z1YAE7CPH5@-\[GS$TN.M*;\8L5SRXY[M*!Y.X3B2G4_I$/
M+,U6;F:5=IG42+899$ZK9D0AA[*8"L`_9+U9'<ON>>]V]'=-S:YW=ZRDH`X@
M_,3MH2T\V,=B\Y$@,YJ;=]Y;W?VW1;%HW6X;[@`_AL-1KZ#3!@/&KN&/BT$3
M&$QCF,<YC&.<YS"<YSF$3'.<YA$QSG,(B(CXB([CKZ87D9))J<24T5$T1-$3
M1%LG#8?</R'1%M'#P_!HBX"H?+\.BN"X>J*Y-$31$T1-$31$T1-$31$T1-$3
M1$T1-$31$T1?O+:ZI<DHG9ZYM<?..%MCZ#D.6R'-WQY3762G])P[A3+V>;74
ML8,9!>)<Y.OL'AVEW-]1J"$HT7;HR,F5L1XLV7(U*N9!8$X7S-8[3B3U'+S`
M_=TJ5D3WC4*4K3$@8^=0YS+YE4@\Y7\6^,G%N2IEA@<]83B.2<AFZ:P=R4SI
MCVSXPL^1:;1J+`X\D<%L8VN0?[SI3SQ](7.P2O[MU8$&J3]'O.BD"`W&N0!F
M5*Y5Y#S9YUI3'$$*86^F-SI,P:4J!TX_=2M>I9$L\<@L5<<*Q%6W*,O.,VEG
MM\90*/6ZC3;=DO(>0;U-MY%]$4K'^.\?0EBN-TLSJ,AWCLS=@R5!!DS7<K&2
M;HJ*%R'R"-H+LSRY^76?6L=C'2&C>'EFK+.^?G&UCC>IY)=/<O)#?+U8L8TK
M%)^.F>2<B[5D&H,UI*V5:"XYJ8])F)^XK,0@9\_>%B/NMLP$KD[H$3D.:PW+
M`,:ZN5#T]%>!X>I2?+R=&GG44X<:TXA5!C3F]QCR[)8E@Z1D5RXL.;9/,-=H
M5:L%)O=-LG[[<?T&CK,N-KC`VVMPTGCK*%!9N_B'==GDH^65:I++MT5D$5%"
MU;/&XAM?>/#CY=?V%4=!(T%Q'NCCP\QX^;H7`MG/'C#3$;89Q>K%8YJG9RE^
M-9Z=CG&>3,D9"M>=ZW5(V\6C'&,Z-2*I-V;)<O3ZQ*$=3+F$;O(Z&!)<CUR@
MHW7*G:ZYAIAC_)7R\_(TK\O+2I%&TK4X>7\G,*DYOS-.%4!C*F9AN&:755J%
MZRM:,#1*%MQUE2'O<7G&EUZ?M%DPW<,8O*;_`)CTS)C")K;D4H:1BV[QZL=L
MDT(NH\:%6H)X6MH,,<J4QQ^XYT*K\O,32E<,ZX4PX^<+@V+S,>)%;A:_.JS>
M9YU&9QTCE^8B:;Q;Y*7"VXNQ0YDIJ);Y%SG28#%CVW8/K+I[6Y'L&M#*,=.4
M8]RLB@HB@HH6IN6`T%3YC]WW=>!5/EY..G^L,_3Y><*HLL<_^-.+E*_$M[3;
M<H6>Y8B;YTK,/@3$66>0YVN()MHX4J67+D.%J?<PIF,;2Z0,2.DY$[4DD"*X
MM05!!8R8W#?P8\<CEY@?NZ4;`]V)H!6F)`QY8D*N.#^;[+RBX=\5>15MB8.#
MMV>\#8NRK88.L%?)5R+G;Y5XZ<?1T$25?24BG$MG3T2(`X<KJ@F`=9S#N.KX
MY=47:.P%*^H%6R1Z9C&W&CJ!6@H/F><,,G6>AUNF9!O#]CDW(,CB"DY'D<$Y
MRKF%)G,49-3E=4Q$7-=DQ[$XS;9(?3=<>-646I)%4>N4RH(B==1-(]OS+*\=
M-:5H<_1]M>A7.MY&@DTP%:5%:<Z9JJ7WF$\4X[*)<5.;K<`=?YIM\$KY-1P[
MEUQQU99S=R1(-MAJ0Y(H4I3";+)"MC5)$_=YYL.W-'+&G.5^/PVJ&Y8'4QIE
MD<Z]7VUX4JJ=A)IU895I45ISIFK=7KS0.)<6YSS0Z+E=C-YBP5$<A&EQBY3%
M^>Y#'.-KSQZI=GMUNC,TWVD8RL,51X5HVK#A<G[8\A-,TC##(/E3H$4?,1N!
M##B`<:&F74?7YJJX6\@TEPP)'$5Q/7_)QHJFN'F-<9L:2,32[C8+]:<JFP=C
M;D!8:+@G`'(+-\A'XOR,RF3Q^1D&=`QK.R#2B`]K$CNL_(V>-D4DP<($6633
M-07+*4S=T`\R.71R^Q#;2=`%>)`X`\^1"M'=O-`Q?3>3.*:$Q5>Y/P)FG@VZ
MY8XQMN"<5Y:SODV_27^;$#5F)*M4\4PEID7%&3Q_*J2CQ5:+14:+D*55PF80
M;FC^;)DTM%6>>N0/"O$\!]ZO^5/9:B:/K3'`9D9GJ4BY[GKQ?B,<X3R?"W6S
MY0A.2%?<VS!-<P?BS)^:<FY/J\;'LY.?L5>Q7CBI6"_(0E1;2+<DT[?,&B$0
MZ73:NSI.E$T33&YCH"W$D>5:5\L\U%V$E2'"E.>'K*I"S^9QP=IU%PYD:?S>
M"%:Y`)Y)2Q`A'XZRK/6^YS^'W;*.R90FN.X"D2>06&4:=+O@8O*N[C$)XCU%
MPB#43MEP3?,Q4&=3PICY>OHK@JBWE)(IEGY_+/);LKYD/%N`DHE"Q.,[UJK2
MAL;(KY;LO%/DK7<&5A]EYA6G^/HN]9DFL7,:%1Y&8_?&,:N"2CQL6*D796<@
M9JZ*HD0;AC7`8T/0?NIQ''UH()"*BGI%?16O`JN\&9_M.4>1_.G#$Y"P,;!<
M5\G80HU.DHQ.0),SS#)W'6B9BFG-I.Z?NF2KZ/L%J7:MA:(M4P9ID`Y3J=2A
MC)B^8L%-%*@^9I^U'Q!L37XZCGZ2/L5-9Q\PKBSQXOETQAD6S9%>9!QQC^N9
M:R#5<:8'S?F"0I&*+0-E^!R9:%L84"U1T-2&)*A('?O5ERE9%0_:%`3D`U73
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M-,B0#Z,_4I@:R%"FB+48QCCU',8QAV`3&$3"(```'B.X^`!MJ@`&`R55IU54
M31$T1-$31$T1-$31$T1-$31$T11?YM\?FO*WAUR@XVND4UE,TX+R11(CN``@
MWM,G6GRM,?%W`VRL=;FS%P0?2!DP$-07#`^(BE3Y"OF!JI87F.4/Y%?B:NF3
MV-=.HV2;+,Y*.<N(^19N""DX:/V2QVKQLNF;84UF[E(Q#!ZC`.N=72+9T1-$
M31$T1-$5:XYR/>\0WFM9*QE:IJDWNGRK2:KEGK[Y>/E(U^R7(X1.1=`Y!50.
M=,`51/U)*D$2G*)1$-8]W:6U];/M+QC9+9XHYKA4$?8>1&(.(Q4]M<SVDPGM
MG%DK>(]A&1!X@X%>G3B3_$BMEXACB[S(>.,#GFI.CJMGN;<6LXFK9:C2.D3M
M`EI.J.4DZG:7S1%7<RJ*D<Z6`@=1CF]/"7?<E]L[MMFE-!2D<A((I^645=U-
M>U_\X!=+#WBCFPNVEDOYF"K3UL-*=):>IJSO\8<S^61RFDH!UQ_Y8X5:V0EC
M92+.AW1L]Q!DQPT17;BDQEJY<5464FM')H`!"M'CI$#G,)`,`ZT-P[<=J8X[
MCVT3!4:I&ZF8_KLU,`/,N&>-%L&$7;O]'+96D?@=4]>DT?\`LK.:;#!)%.PS
MB+IE8W\T+8KP(RSQ"Z`))LF#5->.*V<*(MTG!690,KMW?`!)X@(CJ9;JWN@3
M#+&\G`T>WU8X=>?)7LC=$:2-<VF56D>G!1BO].R"#M63DZ_6ZY"HO4Q4:OIJ
M#8TFNQD>V3:L73S[W<D-*/"%3ZNI4IDA`!-T;AMK07TUSK,LAAC8'`TU,#10
M4&9J[T&O*JV-NR-PT,$CGD<`XN-<\LE@HYU><UQ)X?P5XJF&[96<[\HAB'C6
M$C\=)J2N)J997`I,P?6FWMEV\;)OV0=:YT&Q%3G!,$Q[74&VPVKN;NN_.;)&
MSY7;Y'#M)B"TEOXNP8X:G.=D)'-:P5J-5*)=;K9;8#\T[M)V#W8J@DD9=H14
M,:#FVNKH&:\*^3<E7?,5_MF4,D3[NSWB[3+N=L4V\Z04=OW9Q.8J*)`!%HS;
MDV3003`J:*12E*``&O>=MVZRVBQBVW;HQ%90L#6-'`#F<R2<7$XDDDXE>=7U
M[<[C=OO;MVJ>0U/`#D`.``P`X!4-K-6(FB)HB:(FB+28-P]_JT1;`AZOQ:(N
M$J'R_!HKA]JX)@V$=450M.BJFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB_>6
MUU2Y)8R;U4.4G';F;G7DW@GCRVY5U/D[A;`5(DJU'YEQ_A^WXFR5QS<92:0'
MWNYR:LQAYG#E^B,F%7=.(E9W,0\DR7,6,>%<D,77RQ2,>XM&H.!X5I4DGJSZ
M>HK-CDC<QH>=+FG#D<ONZ.L*U'!;@1F7BIE[C#+6V2JUBKF+/+KRC@:_V*LR
MADXM#.64N5]7Y`RE7IT'(%;3KC'L"P-(LHU\J@B7X-FW(<B2AP3+2"W>R4.>
M,*?8`JW%PV6*C:@AWJ][[QYU)[S!L.O\SXIH43&<>+ER$D:CEN#O,8GB;DBG
MQ5SOB&5BZ[:(UAEW"&55YNI-2W2)-+FC7$:O-Q*#Z)E'0**K%*+9:>Y:YS1I
M!+J]/V4]H^PPV[FM>2\T;3T]&1]A^U8NI?@;S>LD%Q6S-G)AEGDI9L"VSEW3
ME,$#S4D\0\H(WC)R#E<;R.*$9/E5B2?Q'1\IYMQ,MC!-*;:OY9M#3<3,"@,B
MZ=QJ3AQBB&9K6FG/F#B>0(Y#C3,DY5RS/`7.%:`@<B,!AF#SY<,!CA?:3X29
M-3X>OK#QYXW_`/#CR[Q9R_C^;V!:%EOE)-\C;#>\J5EI7J;82YISE8+/:21;
MGD'AL)FIS+!K.R,?&LG#=07AU`.)+G0N=$7!M'@GB<>>=3EA@3F:*-LS6S"K
MJL+:9##CT#`XXCA14#D+RQLF5'%OE^6&#KMEY"7[C8ER*EN4>/:!R3N?%7(>
M:,B\S"0=XSEEK'&:*?;:$DK;:]F2,641AIR7CXF:KKM1L=PDH@V`1@E:&N`J
M[CG7'J(/2*Y5-3DJMN&.<YKL&&E..66!!X4R'`8*Y>*^%%XC[5PYO]3XRRG'
M)GCSS"\F\GLTUC)?*R1Y092FZY.<*\D\?(+*%OR%9;7=Q>WN8L$S#1QH&*FI
MA*.C&23CXDQA6*G<(WN`#FT&HUK7\I&-:]'$CDK72@%Q:ZIT``C#\0.%*=)R
M!5/<DN$N36W,CDCR!8\?<S<K\>\H*GAE1K$X0Y]W[AQ:L67K$N/W.,)2M7VK
MMLO8HHV0<;72%29R+2:15DIN)=*/VQV*J"R1AH^*1DAT#W3RJ/4"/OK7!5CF
M8Z,"0T<WF`?603]@PQ528MX]<FN&U\R&XX_\0:U><<<B.*7$W%4318+DW6X=
MAQ+O?&_%]OQ:;&=HN^4V:=OR7A=.'M"#N.L,*QE9HSYN^%:*W=)J#:8I&NJ!
M5I:.%:8C#GAE7//!4[2*1M)'8AQ->=>/$=8P'(J?_EXX=O''CA+PQP+DUK'L
M<C89X]X;QI>V43)-IF+:6RGU6)AIQO'2[,QFDFR2?M3@FNF(D5(`&#P'60UI
M9:$.ST?\FBA<X/NBX9%_VK"1P>IW)?E#P-XE<;X[`!:/@VL<P'.;;=RFG\N8
M^>Q<E0^._F"WS.[>!QQBZ$=O,HIY,N-LI2$"`2;%A$QC)9P\%ZX$J;=3$B:]
MXTM`TZR:TID0<_-R].2S)G1L>7%QUZ*4K7,$9>?*OMJ*HQMY;5[QD\-@O(O#
MS)W):J-.3D]DVMYZ:>97E3'''J1H-CY&R.?*Y;LC\7W66$%XC)V+'DLDHM7X
M6GR<'/S<0D[*]1^,5.C*(WM=I<TEFK];B:USIZB.95AFC<W4':7Z>0Y4Y=>9
MKCEAC.**XDYJ9<*/-3P:>,A"W[EMEWS);EB)BG8HP(V;AN3$386>)7-@E"*`
MR@7,@K(H@Z3=&*>/+_>](%TBMW-C>'-&K30>O+CQ\ZMDN`Z6,U)`()X<N'F4
M:<?6ODCQ[\P?-%5Q+Q@?\CKK"^5YY:-0LD3#YIQ?BV(IUOJ5GY;148M8I3(,
M@R++4V0F$G1'3V&))/V:+?J28N16(!8=+P[2!4Z3PJ<2_CPPZ^I3/=%(P/+J
M#5[&LX<<1T=85\N!O`G+7$C-?&B6L\K6[-4<4^7#,<>;Q:Z_(BBR5SG;.5$=
MGBQ0U5KKX$9XU!BV;Q\A%NU44P!HW03.4BINV%[;:0.Q'X3ZVT]OJ4<MTU[!
MIJ"'>H$G[O.H1U+RQ>0>+*9PAO-FQ/<LWR^%\`<@^.^9,%8-YC6GBYD.#1R1
MR5>9TH>2L<Y-IN2,84S(31)HB6/GJ[,SC)`4W#5TV,HY8BD-&P2L]X`XGIZ.
M1'+B0%>^YB?5A-``,:`U./,'GP%<U,WC[PON]$S/P-RA7>/J7':F8@=>8K:<
MM4"?Y'2?(V]0MOY2%QP-3M$[DVS2LW,7>ZY"D:P^D9T&+Z1:1#IP9(':Y![R
MEX@<Y[7::#CGP=4UK7VX]*C=<`,>T.)Y8`9BG"G0,N"ASSCX!<P>2<CS/K4[
M@ZQ9]NF3<O0-KXL\A+/S1>4;!6%<!QLKC27B<7Q'&<ML;,VF4*FO7I@'2CFL
MKL+$[=`^<3A!,5LG&^&>NDUI49`T.`\L!Y^4D4\#6C@:$=-:Y^1\W/,5Q_PI
M?,><J_,4RU9F<>WIG)#+V`;CBUTUE&CU](P>/>,&.\5V9:5CD#F<PB[>WUIT
MDDDX`IUD2E5*`D,`ZRH8GLDJ[+2!ZF_<5B2R-=$UHSQ]I^]4&OQURBIRF\PS
M*I6,7^Y7(_AMQSPMC-P,VQ!W)WS&L1RG9VAE+Q@J?$0T>V6RS#@BZ<%*BN"R
MHD$02/M:Z!Q<^H%32G]8GV*K96AC!7(NKYP`L8\/Y<V><12'&K(<[@_*/(HC
M#RY>&W$_*6.>//.FX\3,@XCS#Q:KMC:*3,;*P&6\08[S%C&XK7=RBJHYECR$
M,_C0<LD%T7ZW3'V4K-):"?='$\*G@6TSXGJZ)^VB=J!('ODC`',]3CD.'V8S
M=XD\.KCA'D9Q]R3#87K^`L2T#R[\A<?W.-(K-$AFF2QWE"\\I:QFD]3+?[%V
M[5?D5H5H\=/9LX&;'?',B0YB]L1K%`>U#G-`92M,3P`X]//%63SAT6D.)<'=
M7YN76J5NW`K+TYYB3&Z1;BM!P+ON5,7<Z<T5-6631L3OFUQ_HTOC"B0[&M`<
M/BZ3>EV]-N\JY[9B!/T=,#B!W/[0ZV<9J"O9Y\J994PPPIQ]U59<@0U-#*,,
M<:C/&N/,'K43C^6Y?JA8,YXEO/#W)_+>@Y8Y.Y4S)5<HP_F6Y4P7@Y[1,V9G
M>YE=PV>..XY7B$XVU8MF9M9!1*N5.?86@L:U='41<KK=NACD#BUS26EU<W4Q
M->!`]#3TTX7":,M#@[2\-ID.`IAA[2.CIOV[XQ\J83F\&0N.6*,O\6JS8N6A
M<H9^O4;S*K%ZX:<B\-.Y$?\`,BRRG#^75E;35.0F8JPU014^Z(2!3CI\WW@O
M-.B)&^)M$,@D!:V@#NL>GU5T^<\1GB,)#C5Y;3D?Y.C4>I9:\4V',-A_S,_S
M@QK6\;?<>7+I7<5A7+PC>/W^PS&?=O[BY,GQ19,OW0LUJ!=U\7!'[IX_L%W4
M-W/#81EQKJ%*.-.KT#RXK!>&BFDUJ,>ODKKZD5B:(FB)HB:(FB)HB:(FB)HB
M:(FB)HB:(M:9S)*$4(.QTSE.4?88@@8H_B$-4(#@6G(JH-,1FOQ_O/9XN#Q&
M\UCE]C9A&FCJA;LB+9PQZ0I.AH>F9N;IY#;-V`!L`-(.<F7\8`!X$,Q,7U;!
MSD[2V5P//^7UX+HK=^N!KNBGH6(W42F31$T1-$31$T1-$7P/`Y%"B)5$S`=-
M0HB51,Y1`2G3.40.0Q1#<!`0$!TX4X*H)!J,"KHQ^<<VQ*)&T5F;+48V3(5)
M-O'Y(N3-!-,A1*1,B3>93(4A"CL``&P!K6NV;9WNUOM+4O/$PQU].FJSQNVZ
M@`"YN*#_`)Q_WK@3.7,LV-D,98<J9*GHT=]X^:OMKE&/COU;M'TLNW'JW\?L
M^.I8MLVV!_:0V\#)!Q;&P'T@*Q^Y;C(-+[B9P/-[C]JMX!0*&Q0`H>P```\?
M3X![=9RPEJ]6W^O5$31$T1-$7T`$?0`CL`C^(/2/X`U5%\U1$T1;)_TA_%^0
M-$7#5#T_+P'1577*!X_+U:HKEHT54T1-$31$T1-$31$T1-$31$T1-$31$T1-
M$7[RVNJ7))HB:(FB)HB:(FB)HB:(FB+Z`B`@("("'B`AX"`^T!]0ZHBXS1DR
MCVZ;..9,X]FD*@I,X]HW9-$A65.NL*35JFD@F*RZIE#B4H=9S&,.XB(B``%!
MDJDUS7(U5431%QRLV9':S\C-F1^Y0;M7+\C5N1^Y:M#K*-&KEZ5,'*[9HHY4
M,DF<XD3,H<2@`F-O2@K7BJ]"Y&JJB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+PG_P`9KQ.,HWXC\XH&,`>P,_QAR?((
MMQ$P%.,CD?$CEXJF7[)-_P!YVO6IX;]D@#Z`UJ-PC(<).'E^DGK6VVZ04=%Q
MS'V_8O!_K6K9IHB:(FB)HB:(FB)HB:(FB)HB:(GNT1-$31$_T>CW>O\`+HB:
M(FB+9/\`I#^+\FB+CJA](?DT50NN5#T_/JBN"V-%5-$31$T1-$31$T1-$31$
MT1-$31$T1-$31%^\MKJER2:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+&S
MYOG#\O.KRXN4W'AC'DD+M*8]=WS%!1)NX3RSBU0MZH[=H<`$Z*T^_ACQ!S!O
MNA(J%$!`1UB7<?:0FGQ#R]M/,LBUE[*8./P\?+J7XU#U95N':,0Z+CJ,15-0
MHE50.F(D52.0P`8BJ:@"40$`$!`=_'6A71@8]"ZCK/OOU&W]._4.^_MWWWU1
M7+E?&K=L";_:_P"L])MO9MZ-_?I54TA;)7"Y1Z@5.(_SC"8!_$.X:)0+N6ZW
M>3`_H,`])@]@A[/<(:JK2*%;^BHMLZJ:?Z9RE]PB`#\WIT1:/B$/^M)\^BK0
MK;,\0+_*$P^PH"/TCL'TZ)0K:&02V\"*;^_I`/GZATJJZ5M'D#C^@F4OO,/5
M]`=(:532N.+QP/\`TFWX"E#_`$:HJT"T&<KG_25/^(>GY^G;?1*!:>\K_P!:
MI_7-]>BK0)WE?^M4_KF^O1*!;R";YTH"+4CIRJ;?I20*LLH;8HF'8B8&,.Q0
M$?1Z`U>QDDCM,8+G<@*GU*.22*%NN5S6L'$D`>DJOHK%.79D2C"XVR-+"80`
MOW;3;+(`81$@``?#1JP#N90H?A,'MUN;?NQWEN_]4V^^E_F02N]C#S"YR[[Z
M=S;#_7MVVR&G]Y=0,Y_F>.1]"NQ"<1>6E@*12+X\Y<73/^B=U0YZ-3,'=%$=
MSR+-F4NR@;#N(;!XCX>.NBM/"SQ(O0'6^Q[F6GB;>1HSI^-K>/WY+D+_`,</
M!S;"6WG>;9&N'!MW"\Y5R8YW#[LU<N.\O3FG*]';X_VMKU$ZMY.1J\20`!3M
MCO\`><\T.4VX[](AU=(;@`AXZWL/@5XM3TT;)<MK^=T+.C\<@_DQ7,7/U/>`
MMK77WDLW4_NV7$G"O^;A=Z<JX9JX;'RK.:+_`&[U`K$7^T,3>1R+3PZ0*4#=
MP09R;PW;,(](;`([^K;QUO8/IN\69OCLK>/'\=S!Z?=>[!<Q<_6+X#6X/9[E
M=S&E?<LKGT>]&W'BJG9^4!RZ>]/Q!L3Q0&3,<1?7U1;H,`[`B<(N#D1$Y@\0
M$-R;>D0'6TA^EWQ/DIVAVV/#\5Q6G1[D;_NZ5I+CZW/!2&O9#>9L:>Y9@5Z1
MVDK,.NAZ%5K#R7N1J_9&1R)AF.ZTQ,N5.6N#XZ"G2(@D';IR2:P=7AU`;;U^
M.MM!]*/?M].WOMJCJ,:/G=0\L(!7TK17'UW>%\>H6VU[[+0X5CMF5'/&Y)'5
M15(W\E#,9T]W69\6(*]1@Z$6%Q<D$FQ>DW=-#MQ`PCON'3X>T=9S/I+[TEM9
M-VVX.Z&SGUZ![%JY?KU[CM=2'8=X<RF9?;-/H[5WIJN[+Y)&0!*43Y^HA3B4
MO64M1LIRE-L'4!3"Y()B@/H$0#?V!K,'TC[W3'>K*O\`T,OWK7GZ^N[53I[M
M[B1P_P!)@'V'VE=R'DA3VP;\D('?8-]L92@AOZ]A_?$-PWUE?\(M[_Y]#_LC
M_P#QU@_\?NW?^EKC_;X__MD_\$*>_P#F0@O_`(92?_VY:?\`"+>_^?0_[(__
M`,=/^/W;O_2UQ_M\?_VR?^"%/?\`S(07_P`,I/\`^W+3_A%O?_/H?]D?_P".
MG_'[MW_I:X_V^/\`^V3_`,$*>_\`F0@O_AE)_P#VY:?\(M[_`.?0_P"R/_\`
M'3_C]V[_`-+7'^WQ_P#VRZQ;R1[P"IP;\@Z6H@!OV2B]*L2"QB>HRB"<DY33
M/[@4.'OUCN^D?>-1T;W:%G`F"4'S@.('I/6LMGU]]WRP&3NU?B2F(%U"17H)
M8TD=.D=2Z%SY)^7R$.+3-6+G!P-LF5>-N#4IR=6W4<Y(ISVS='CL`&\?#?UZ
MPY/I+[T`'LMVVYQX59./^05L8OKV[DN<!-L.[M;3$A]LZAZ!VC:X](YT5*2?
MDP<D6Y51B\@89E1**?9(I-6Z..L!NGN"(KTY1-+M[CZ3#U;>'IUK;CZ4>_C`
M3;WNU24I2LDS:\\X"!3K6XM?KM\+)2!=[;OL(-:D16SP.65R":]6"H21\H3F
M$RZ_AF6-)@"BH!1CL@,TNX!`W*8@2S&+,`*CX%Z@*._Z0%UII_IA\48J]FS;
MY:5^&Y:*_P!=K,^%:=-%T5K];'@A<4[63=H*T^.S<:5Y]F^3+C2O156WF_+#
MYLPNXEPZ:9(7KW/`7*C2>X$*0VY426--T;J$^P`"8F$0'8/#6AN_IZ\6[3+:
MNU'_`#<]N_U=J#ZEU-A]6G@'?X'?!`[#":VNV9UXF`MX5.-!4*U,[PCY<5M-
M165X\95!)$#"HI'U5_-I@!`4$Q@/"DD"F*`)B.X;@/AMZ0WYN\\(_$VP!=<[
M'N6D9EL+I,O^CU<EV.W>/W@MNK@RS[S[/K=2@?<,B.-/[W1SX_8592;Q?DNL
M@H-CQY>:^"0B"HS=2GXH$Q`=A`XOH]`"[#X>.N2N^[O>#;ZF_L;R`#/M(9&?
MVFA=[M_>WNINQ`VO<]ON2<NRN(9*]6AY5#]!_P!4WIZ?T1_2]GH].M10KH-0
MYA?O*:ZE<FFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB^E,HFL@LFH8@HJ
M=SI`J9BJ"`?8`_64Q@!,^Q@Z1#<0V'</#5"`X%IR*J#3$9K\AG^(.X3%X-^:
M'GREP$7]V8MS"_3Y$X@322.FQ0J&6'TE*R\$Q`2@DFWJ%_;S,2FF41[:#-+T
M`8`USMPPQRD'R_1RZ%T=I+VL`/$8'RZEA.U`LE-$31%R$')T-P``,!O$0'?T
M^X0T5"*K49XX,.X'`H>PI2[!\X"(Z)0+C@!U#@``8YSF````$QC&$=@``#<1
M$1U4`DT&)0D-%3@`KCUC#67KJ)0I^+<B6@#"``>`IEBEDMQVVZE6,<ND4/'T
MB(!K>[?W5[S[L:;7MU]<5_NX)7CTM:0N6W;OSW*V$'_&]WVRT(X374$9]#W@
M^I2)K?EW\S[21-5C@2W1Z"NP@M9EX.I@4#;["=*R2T6Y`/#]3?7=6'@;XK;B
M`Z'9;IC#QE,</JE>P^I>9;K]3?@3M!++CO'92R#A`);CUP1R-]:O_7O)\Y;2
MY$E9=;%M2*<`$Z4Q=E'[I'?U&2K,/.HB8/8"FNUL?I=\3+H!UT=NM0>#Y]1'
MFB9(/6O-MS^MSP7LG.;9-W>](R,5J&-/GGDA/[*OS`>21<UB)'M.?ZC&J#XK
M(5ZF3DZ!?<FYDI.N`8?>*8:[.R^DC=7`'<=[M8SQ$4$DGH+WQ>Q>=;E]?6Q,
M<YNS]V[V5O`S744/I:R.?^TKZ07DIX7;$3&RYFR;,*EV%4(6'JU>1.(#N(%!
MZE9%2%$OA^D(AZ==A9_29W3C`^?W7<)7<>S9#$/VA*5Y[N'UZ=^Y7'_"MBVF
M!G#M9+B8C^J8!ZE>Z"\I/AM$IIED8/(5G4*`=2LU?7;7N#X[B*==8092@(CZ
M`'U![]^NL_IG\*[9H$\-]<.'&2Y<*^:)L:X'</K/\<KUY-M<;9:,.0BLVNIY
MYGRJ]$!Y?'#&N$*1G@&I/Q*`!W+"^LUD4-L)A`3??4Z\3$1ZO'[/CL&NKLO!
M'PIL!2+9;5_3*Z64_P#>2.'J7![E]2OCKNCBZ?O)>Q@\(600#_NHFGUJ[]?X
MV\=ZKL-<P1B"(.7;95MCNJG7W`-M_B',8NX$=A_6UU%EW"[C;::V&S;7$>8M
MH:^DL)]:XG<O%/Q-WC#=.\6]S#DZ]N`/ZK9`/4KJ1\#`1``$1`0,2!?`H14+
M&1O2&Q@\/@FJ&VP','X!'VCKHX+*RM<+6&&(?J1L;_9`7'W.X[C>XWMS<35_
MO)9'_P!IQY#T+O/B'&VW?6V]G=/M\W5K,[1_YCZ5@=E%GI;7J"VA,8WB8QC#
M[1$1_+JVI.:O``R"TZHJIHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(OH"(#N`
MB`^T!V'Z-*D9*A`.:W#++'*)#JJ'((;"0YS'(8/88AA$HA[A#5Q>XBA)(5HC
M8TZF@!W,"A]*Z?[C@O\`ZPP7]]\1_P#4:,_[3_B/^R_]H_G_`*?OUB_)V?\`
M<PYU^!F?/+/IS6=_B&X__,7&5/XLF7+XLNC+H7O-U^2B_?I-$31$T1-$31$T
M1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$3
M1$T1-$31$T1-$31$T1-$31%]`!,.Q0$1]@`(C\P:IDJ@$Y+Q0_QD?"BU9$Q=
MQ;YFT6MJ2[[%,Q-X$R8DQ5<KV!:N9"D$+'BYTRKZ;14[]C%6QK--5U45`6(K
M+MRBD<@B=+`GLKB]E:VQCDFF/X6-+SP&`:"?Y5F1;A:;9$^3<IHK>W`KJD>V
M-HSK4N("\,U-X5<L+\FFO6<`Y+7;*FZ4WDK7G%99&_G`]LPQ#42!^MU[>_74
M[5X3>)6]-#]OV7<#&?Q/B,3?ZTN@>>JX3??'KP;[N.,>[=Y-J;*!BV.9L[_Z
ML':.KT4JI35/RA>75@%`\XVQU14%.DRPV&ZMW[IN4WI`6E4:6(QU2_J]0![]
M>B[9],/B=>EIO&V-FPY]K.'$?T86RX]%5Y!O/UK^"NVZF[>[=-PD&78VKF-/
M]*X=#ATT\RD]4O)(D#"12^\@(YN78.MG3:0\D#[_`,H`D9V9B"E]@?[J;7H6
MV?21.3JWK>XVC\L%NYW[4CV?V%Y-O7U]6P!;W<[MRN/!UU=-9^Q#%)_\0*3-
M4\G3BU"@F:R6#*UU6#I%0'-@AJ^R.(;=0%;0T"#Q-,WL^*,8/UM>@;;]+7AU
M:`&_GW*[?QK+'&T^:./4/ZYZUY/O'UP^+U^2-JMMFL(^&F&69X_I2S:2?^K`
MZ%)6K>7MPRJ()"PP+5I11+806MCZQ6TYQ#QZE49^8>LE-Q]("ET^[;7?;=X(
M^%6V4['9;:1PXS.EF](D>YI_JT7E>[_4MXZ[T3\SWCO(6'A;LAM@.HPQ,</Z
MU>E2.K&*L6TH`"G8SQ[51*``!Z]2JW$+``!L'[=C&(KCL'\[7>;?W<[N[2*;
M7M]C;?\`101,/I:P'UKR[=N^'>_?C7?-VW.\Z)KJ>0>A[R/4K@`JJ!`3!0Y4
MP\`(4PE(`>P"`(%`/Q:W>IU-()T\N"YK0PG40-7/CZ5HU:KE\T54T1-$31%]
M`!'T`(^KP#?5:%4J!FMP$%S?HHJC^!,X_D#50QYR!]"M,D8S<!YPOHMUP]**
MH>OQ3.'A^,-5[-_(J@EC.3F^D+84.FD`&5422*([`955-,HCMOL`G,4!';4;
MBUF+B`.D@*1H<\T8"X]`)]BZUQ.P310$G<]!-%1*!P2=3,8V5$AA$"G!-=TF
M<2&$!V';8=M8[[RRB=IEFA:[D9&`^@D++BV_<9VZX+:X>RM*MBD<*\JAI%5N
MLI6*DE3(1DK%R:Y=NI&-D6;]8NX`(;I-%UCAN`@(>'H'6%-W@[OV[M%QN%A&
M\<'7$+3Z"\%9\/=GO-<,$EOMFXR1G(MM9W`TZ1&0JE0@)]SO\-`S;C8-Q[$1
M(+;!OMO^S;&\-]8LG>WNG"`9=UVQH.5;NW%?3(LJ+N9WSG);!L^[/<,Z6=R:
M>B)=PEC[("Z7>1H=V61VW[R52L"B.WM[I(XQ-OQZM'>_NB[%N[;6>J[M_P#Q
M%*>XG?D9[)O'^Q77_A+JC5NQD.9,]>GB'(/2<AH:2*<A@'82G*+8#%$!]0ZR
MV]X-@<T/;?V18<B)XJ'SZUBN[I]ZVO,;MKW(2`X@VL]1UCLZA?/W=L0@8P5^
M=$"AU&$(>1$"E#TB80;"``&H3WI[KM>(W;GMPD)I0W4`->KM*J;_`'*[Z=F9
M?\&W;L@*D_)W-*=?9474NR'8`(R!#,`#Q$7Q19@4/>+D$@#\>IO]X>[W_F%A
M_M,/^6L?_=;O3E_A>YU__5+C_P`-=4,U"%,4AIR$*<XE*0AI>-*<YCB`$*0A
MG(&.8PCX``;CK+;N.VOH&7-LXG*DL9K7*E'8UX<UA/VC=XZF2SNVAM:U@E%*
M9UJS"G&N2YZ:J*PB"*Z"PE#<P)+I*B4!\`$P)G,)0$?;K+:YKL&D$]!"P7L?
M'B]KF@\P1[0N2#=<WZ**IMPW`2IG$!#VAL`[AJ01O.0)4)EC&;FCSA?#(K%_
M224+_23,'H]/I#U:M+7#,%5$C'9.!\ZV]A#T^&J*Y?-%5-$31$T1-$31$T1>
MRS!O+7C_`,B6Z08QR%%O)XR15'%)G1_=V[LQ$H&,0U>DCIKR!4]]A58F=(?S
M]?F'WL\..^7<IY_QZRD;9UPGC_>0._ZQM0WJD#'="_;CN#XQ>'/B5&!W5W*)
M^X$5=:R_N;IO1V+Z%]/S1&1GZRD>("41`0$!#P$!#80'V"`^(:X=>G$$8'-?
M-55$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$
MT1-$31$T1-$31$T1-$31$T1;A$U%/!-,Y]O3T%,;;Y@'5I<UN9`5P:YWP@E6
M[N66<5X[1%Q?<ET&FI@(AM9+;!12PF*&YBD:NGQ':A@#U%((ZW>V=W.\.]NT
M;/87ET[_`)J&1X](;0><KFM[[X]T>[3.T[P[IMUBW_G[B*,^9KGAQ\P41;KY
MF_#2F@X31R<]NSQ`1*#2@U6=G"+'`=NE&4>-8F$,&_\`+!ST>P1UZ1M?@-XG
M[II+K!MI&>-Q+''3K8TO?YM-5XWOOU4^".R:FLW62_F;^&TMY9:GD)'-CB\^
MNBB9<?.DH+054L?8-M\\(%$$7UQL\/66YC>/28S"&:V5UT>CP%4H_@UZ-MGT
MM[Q(`[>=VMH1Q;#$^4_UGF(>HKQW>_KD[O0DL[M[!>W!X.N9XX&G^A&V=U/Z
M0*B9<_."Y.3Z:[>I5W%V/4E2G(1RR@Y*T2J!3@(%.DZL<FM'=Y/?<#"S$-_Y
M/JUZ+MGTT=PK0AVXS[A>.'`R-B:?-&P._;7C^]_6EXJ;@"S9[7:-N8<BV)]P
M\?TII"RO3V?F45;ASHY>7GNEF\_7YLV6)VU&-9?-::RZ!*)3%!&J,X<0ZP$=
MQ$PB.^O0]L\)?#;:`/E-GLW/'XI6F=WIE+_8O(M[\?O&;?RX7_>+<61.S9`Y
MMLST6[8_:HTRUDLD^Z%[/6.P3KP3&.+N;FY27<]9_$YN_(NG*H&,/I'?QUWE
MK:6=@W18PQ0,'"-C6#T-`7E=]N&X;H\R[I<7%U*36LTCY37K>YQ73F.<X]1S
M&.;VF,)A^<1$=9)).)S6$&AHHT`!:BHJG_024/\`T2&-^0!U4-<<@2J%[&_$
M0/.NN?R<7%%,>6E(N*(4!$QY2291Q"@`=0B8SU=```"^(^[6//<6]J*W4D<0
M_7>UO]HA9=M:7EZ=-E#-,X\(XWO_`+(*M+/\C^/56.=*Q9TQ'$JI"(*(N<@U
M<RY!*8Q1*9!O)+K`8#%$!#IW`0US%[W^[C;:XMO]YVN)XS!N8:CS!Y/J7:;;
MX5^)V\-#MK[N[W.PY%ME<4/G=&!ZU9J=\POAC7C"1UGFLR!RAOT5Z+M-AW_0
M\"JQ4$X;F'8_J/ZA]@ZY2]\<O">P-)=ZMWG_`)IDTOK9&1ZUW>V_3%X\[H-4
M/=N[B;SFDMX>?"29KN'+ES5HISS8^'D2`_=\SD6S&#U0N/WK<@_W?H4L#^$]
M1Q]7\D?=OR]Y]3/A7;#]Q+?W!_YNV(_^*Z/V<.JO;[?]%WCE>G_28-KM!_SM
MXUQX\(62\N?$=-+33'G,X*;%.$%B?+,RH`#VQ?KU&"1..Q!#J.26F5B!XF`?
MV8^@/;X<Q=?5CW,C!^3VS<Y7?K&&,?VY#ZEVEC]!_B+*1_B.];+`WCH%S,1G
MSCB!X<>/1C:N6\ZQ$.L('CHJ8?M=I2;R20H?](!142CJD(C_`"!$`/\`K!OZ
M!US=S]7,8J++82>1DN_:&P=7'GBNRLOH$D-#N7>D`<1%8GHR+[GKQIRPS5KY
M?SGLRN!/]QX;Q9%D'JZ/O&1MTRH7<I`+U&2D8A,XE,!A\"%W`0#U;CSMU]6?
M>I]?D]JVZ,<-3IY#ZGL!]"ZZR^@SN)&!_B&^[Q,>.AEM$#Z62$<.)]=!;F7\
MWOE<_P"L(V.Q)7RF`X%^#IDA(*I]1@$ABJ3-B?$,=,H;!N02B`[B&^VV@N?J
ME\2IJ]A'M<`_5@<XC_M)7##JIT+JK+Z(/!FVI\W+O=R13XKIC`>BD4##0YYU
MY%6ZDO-%YIR'7VLEPD4!^[L$5CVEHBF"@AL"9W4.\.44=OL"(B(>O?6BN/J-
M\6IZZ=PABK7X+:W%*\JQN.'!=1:?2!X!VU->TW$Q%/XE[=&M.>F5HQX^JBH&
M2\P;F=*G,9?D!<6W4<%.B);5R&3*8"=&Q"Q<&UZ4Q#Q$N_2)O';?6DN/'+Q9
MN35^]W3<:^X(HQR_!&W#HRKCFNEM/IE\!K,4C[LV+\*5D=/*<ZX]I*['ISIA
MDJ&?<PN5DD42/.1.8#E,F=(Q4KO,M`,F<1$Q1^#<(#N._I_2#U"&M-/XJ^)5
MP*2[[NE*4PN)&Y_S2%T-MX&^#5H:P=U]C!J#C:1.Q'\X'[E1$EGG.<R)QELT
M99D>XB#=0'>1;>L51`!$024(:8Z#I@)A\!`=::?OKWRNJ_,[ON<E10ZKJ8U'
M(^_DNAM/#CP[L*"RV#98J.U#396PH>8/95!5*.;]?7ANMW>KHZ/T=OJ<VN?7
M-V_$>CJ5D##T;F'P]'CK72;YO<IK+>7;C2F,TAPY8N6YB[M=VX!2';K!@K7W
M;>$8\\&9KH5Y65<E*1S+2KDA!ZBD<2;Y<A3;;=12JKG*4VP[;AX[:P7W5U**
M22R.'2YQ^U;&.RLH270P0L<>(C8/8%+CBOQ$O')"T,#)Q[D*VFY1*N]<$44.
M\(4X"*21E!Z@0\?$V^VN8WS?[?;8R'.U7%.=:?I6VL;*6=VF$:8Z\*`>@>U>
MW[@=PNQ]B2I1T>WAV!))!NEW5D6Z9#;]!-R`8``3"4P>(CKR2XN&;E.;B8-)
M.0(!\YJNOA9);1B%CG#I!/H69_%N,VKF0(F9M_N*0%$XB`](=/B81`QM]M@U
MG;981R25+&Z!T!075U*T4UN+CTE5AFW(!*K$&J527,1RHB**QVZ@E!JCML8P
M](_I>[7KG=/8+2YN!+=M:VRCH3AGT??T+@N\V^7MG:.99ESKU^`Q/NUS=YN"
MBA2Z!.75U\*S26,0ZG4[?*@<P`(FZC]2FXB<1'78]ZN^5G8P_);;I+Z4%`*`
M4HN0[J]SKJXD^>W,NH7:CJ)J3GB3B:JO\DP$/BFJNP%4@.P;F%5<3;'.8"CO
MXCZ`WUXY([YB4W-[0N.-"O662/CC^6L]38QA4$BB\IWF&\D6S4TNT1D`$X"L
M7;N[C_*#T;ZN;-%(\-8UOF`4S8YF-J7.])7EDRUD!Q9I9XKW3&ZU5!*;?[0#
MN.P@(>)1#?\`%KI[&V#:/(`(6LN97$%E20<#TJR3>7E6HF,UDY!L8X`4XMWK
ME$3E`=P*84U"B8`'U#KH&7-S&28Y'M)Y.(]A6EDLK.8`30Q/`RJUIIU5"J%K
MD3(#';X*\W%GLF"(?"V::;[)!MLD'9>DV3#I#[/H\-9L>^;W#_"O+IN%,)9!
MARP=DM9-W8[MW'^L;?8R8U]Z")V//%AQZ57,5R1Y#09BFB,Z9?C^DR)BE;9'
MMZ:>[<!!$!2^]Q3$J11V`!#8`\-;BV[^]^+,UM=XW1E*974U,,L-=,%S]YX6
M>&>X`B][O;)+6OQ65L3[V>/9UQXE7%B^=',&'Z/@N1643`F)1*5_9'$L0>E0
M50`Y)4'I5`$P^(&`0,7P'</#6]MO&'Q0M:=CONXX?FE+^-?QZJ^0R7,7?T]^
M"5]7M^[&T"OY(&Q\*8&/33S9'$8XJYT/YGW-F(`A39A^]R$```LW3*+(F,``
M?]-8];(X4$1/N(B<1'I#V:Z&U^H7Q;MJ`[IVH']Y!;N]?9`^ODN2O?I*\`[V
MI&Q]BX_W5U=LY9#MRT9<!Q*NY!^<3RQC0*65C\3V4@?I&D:8\CUS!N8?TX">
MB4BCX@']WZ"^T1$>GM/JE\2H*"YCVRX'ZT#FG_NY&#U+BMP^A_P:NJFSEWFT
M=^I=->/1-#(?7Q5Z*]YVM_0$I;7@:D2Q=PZU*]:K#7E`#J'J$I)%M9DQ'IVV
M#P\0UU=C]6V],PW+9K24<XII8C^V)0N$W/Z!N[<E3LW>/<(3RFMX9AZ6.@*O
MO6O.MQ`[`A;?A?(L$H(@!U*_.UNS($#UFZ)`M66V#V!N.NRL/JS[KRT&Y[3?
MPGG%)%*/VNQ*\\W7Z"^^T!)V7?MKN&\!-#/`3YV?,!2(JWFM<,;&5(']SMM,
M<*F`HHVJB30D3$0])W=9_>1J4@#ZQ,&NXV[ZD/"F_`[:[N;1YX36\F']*+M1
MZUYCN_T=>.NUDFVL+*^C'&WNXJG^C/V#J^8J351Y8\8KV=!*JY\Q7(N7/3V6
M+BW1D)(G,?\`1)]W6!2*?`H(_P`D4]]_5KT#;/$KP^WDM;MN];;)([)IF;&[
M^K*6.KT47E&]>#7BSW>#G[QW<WB*)N;VVSY6#IUPB1E.G517I_>6L_\`V35K
M^Y^(_P#:"'_[/_B/^V_]G_G_`*/OUUGS^W__`#%OE7^(S+G\673DN#_PK=?_
M`)2Z^+3_``9?B_+\.?1FN]166;.$';999J[:JE7:NVRJC=TU7((&(LV<HF(L
MW6(8-RG(8#`/H'62YK7L,<@#HW"A!`((Y$'`CH*PV/?%(V:)SF3,-6N:2US2
M,BUPH01P((*R#X/\S;D_ATK.*F+"US!4FO;2""R0+A]+-VQ/`$8RZ-3IV)N)
M2_H_%'?)AL'V-O#7C/>SP'[@]YBZXMH7;9N3L>TMJ-83S=`?W9_H",]*^CNX
M7U4>*_<H,M+VY9O6SLH.RO=3I`T<&7+:3-Z-9E`_*LNV&_-?XSY&!K'WU2<P
MI850*10ML1&8J)UMB@;X>W0B"@-TC&$>D7S1F`!Z3:^;N\_T[=^]D+IMG$.Z
MV0R[$Z)J=,,A%3_T;W]2^R^Y/U?^%G>8,MN\)N-BW(Y_,#M+>OZMQ$#0<C+'
M'TE9(*[8Z[;XE"?J4_"6F#=%`[>9KDLPFXM8I@W#H?1J[EMU;>DHF`P>L->'
M7MC>[;<FSW*&6WNVYLE8Z-X_HN`/J7T[MNY[9O5FW<=FN8+NP>,)(9&2QGJ>
MPN;ZUW.L99J:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB
M:(FB)HB:(FB)HB^@`B.P`(B/H`/$=45<\`NALEJJU,9FD+C9ZY4F!"B8SRSS
ML7`-NDH;F$%95VT(;8/8(ZS+';]PW27L=LMY[F8_ABC?(?0P%:[=-WVG9(#<
M[U=VUG;@?%/+'"WTR.:#YE#N]^8]PWH0+)KY?9V]\B<R9H_'D-+V]4QR>`E"
M0:-4(+;?T&%WTCZAUZ;M'@?XG;Q1S=M=;1'\5R]D(_JDF3S:*KQ7O!]3G@EW
M>U,DWIE[.TTT6<<EP:_SVM$7G[2BAC>O.CHK/XA#&>$K58%2F$K>2O%BBZRQ
M.`>A4T9!HV)^(&]1163'VB&O4-H^ES=Y:/W[=;>%O%L$;Y7=6J0QM\^DKP_O
M!]<>P0:H^ZNPW=R\'!]U-'`P])9$)G^;4%#>\>;ERLLPN$JLECK&S-8.E+[B
MJYI^5;EVVW+*6QY+(&5']8&I-O4`:]-VGZ;_``\L-+MP-[?2C/M)>S8?Z$+6
M&G1K*\3W_P"LGQ>W4N9M(VS:X#EV4';2#_K+AT@KT]F.I0XO7*KDEDGNA=\Y
MY+F&RI#)J,$[2_A8D4C;]28Q,`>*C!((#L("D.X>G7IVT>'O<;8Z?X5M-A$\
M&NKLFO?7^?)K=ZUXEW@\7/$_O17_`!_?]TGB(H6"=\4=.79PF-E/Z*L.@DM*
M.O\`=DEY1^J?IV;IK2+U50P^C9(J[A4YA'WB(ZZ][FV\?[PB.$#B0UH'GH`O
M/HVONYJ1!TUPX\`7N)\U22KT57C7R'NYR$J>#<KS?7L)54*+86S78WH,9](,
M6;(A1]HJ`&N6W#OSW+VH5W'=MNBIP-Q&3_5:YSO4NYVCPO\`$G?G!NS[!O$]
M>(M9FM_K/:UOK4AZQY9G-*S"41Q(E6$C;#WKC;ZI";`/K%L25?/]P]G9WUQ=
M_P"._A;8##<C<.Y0PS2>O0UO[2])VKZ6?'+=:$[,+1G.YN;>+]D2/?\`LJ05
M:\FSD-)$*>T9$Q+4MQ#J0;NK+:7)0'T[_!0L<S$0#U`L.X^O7&7WU.]RX#2P
MLMRN>DB*(?M/<?V5Z/M?T2^)-T-6[;EL]GT!T\[OV8F-_:5_JYY*D"0B9KCR
M%F7*NP=U&IT)@Q1`?'<$W4Y.R*@A[Q1#\&N.OOJFNR2-LV6)K>!FN'./HCC;
M[5Z)MGT+[>UH.]]Y)W/XBWM&-'F=+*\_L^98]/.KPOQR\K?R_P"WYPJUBOEG
MS]<+;5L38)2N$Y"&A%+O87"TO-S[VL1<`S3E&-3HD')O!144,B9T#<BGV3[#
MPV[_`%.^(;FGY*+;;8'*D+GD>>21W3CIIADO2]C^BGPBC<&[C-O-X0*DNN&1
M`^:&%II_3KCFO!U/>8SS1L!U!6SC-1*:F_["M053KR28".^R9XZ"2<EV]0]S
M?;UZ\]O?'KQ:O7$NWB6)IX11PQ`=19&#ZUZKMWTM>`FV-`9W>MYG#C/-<3$]
M8?,6_LJQ<_R,Y!6HQS6+.&6I?N"(G3=9`M`("(B(C_NR,FDW`-Q'P`NVN-O>
M_O?G<B3?;QN<M<P;F:GH#P/4O1-M\+/#/9V@;7W>V6"F1;96]?ZQC+O6K2/G
M[^45.O)OWTDNH;J.M(O'+Y4YM@#J,HZ55.8=@](CKEYIY[E_:7#WR//%SBX^
MDDKMK>VMK-@CM(XXHQD&-:P#S-`"X0)D+XE(0!]H%`/R!J*@4Y<XYDK7HJ)H
MB:(FB)HB:(FB)HB:(FB)HBEYQ4XMV;/UOC2#'NBU=)VD+QP5,P?%E*<O4FD;
M;P3]H^@?P:Y_?=\@VN`C4.W(]'Z5G65E+=R`-!+%[5^&O%6HX^@Z_6H"'1*X
M[+9-9=-!,N_24-@+L'H+Z]_3X^.O'WNEW6Z^8E)))PKP^Q=@!'90]@R@''IY
M#FLZ=`P&E$LFQ&A`3<+$(!]@+L`B!1'T>`;;[^GU:VT>UN)IQ6&ZZ`Z5=>V3
MT?B*M&:IJ$7EW)#$3*&PG%4Q?TAVW,4@&\1UWW=GN^^]G$0P@;BYQR`'$_8N
M8WS>(MOMW3/QF=@UHS)/`#VJ-E$H5IR;-NY&0!8K%TL91T[4`?M`<X'[:)C!
M]DNWAX>@-=%WHW^SM&-VO9_ACP)'$\^E:CNWL]]*7[GO'QR&H:>`X`<E,I52
MFXGJBB*(-4%6Z`B<P=`'$Q2_:,81V'??7E\]]'`#+,[5.3Q*[IEK),X1QC3!
M3AY9+SA^9'SV@:M'S3!"51,[$CA-!NDJ!E!$>HH`4I1'UCKGO\7GO;CL;>I/
MJ'6M]#M+88NTD&E@]/F'VKQ0\CLY67*-BDG)SN#-U%EC`4#&$`*)A_2\1\==
M]LUB(F"29U7E:/<)L=$0HS'R*@K)&4[JG<WZ]QWZM]_I_#KM(@*"F2YF0DE=
M3K(4*:(FB)HB:(FB)HB:(FB)HB^]1O:/HZ?2/Z/L_!I4JE`O>V`@8`$!`0$-
MP$!W`0]H"'@(:_9W+-?SF@@XC)-%5-$5:43)&0L7RI9S&]XM5$E@'<SVJSDA
M#'6\0$2NDF:Z;9ZF(AXE6(H4?6&M7N^Q[-O]O\IOEI;W=M^66-KZ=1<"6];2
M"MYW?[S]Y.Z=W\_W8O[S;[S\UO*^*O\`.#2&N'0X$+(]BGS<^25*!NRR)&5#
M,,4D)"J.)9E^Z5K[12@4>F=KB)(UPL.V_4XCE3&'TFUXAWA^F_N-NNJ797W.
MV7!R#'=M#7_HY3J`_FR#J7TWW1^LKQ0V+3!WEBLM[LQF9&_+W%/^EA&@GC5\
M+B>)61O&?FZ<9+@5NVOD?=\22:A2@JI+Q/[UUPBHCL8$YJK@XD"I`/B!EH]+
MP].O$=^^F[OYMI=)L[[3<H`<`Q_8RT_F2T;7H;(5],]UOK*\*]Z#8N\,=_LU
MV0*F2/YB&O1+!5].ET+>E9`*!FO#V5D".,;91H=V*<";-Z_9HMW(D$Y0,4BT
M09PG+(*"`_HG0*8!\-M>-[SW5[S=WGZ-]V^\M".,D3PWS/H6'S.*^B^[O?ON
M5WNC$O=?=MOOP>$,\;GBO`QU$@/06A70.0Z8])R&(/L.42C\P@`ZT`(.(-0N
ML+7--'`@K1JJM31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31%K(
MFHH.R9#G'V$*)A^8`'5I(&9`5P:YQHT$E6[NV6L58U;F<Y"R51*4D3JW"RVJ
M%BG(B7](J;%P\*^6.'L(F8=;O:N[G>'?7]GLMC>73C_=1/>/ZP;I'G*YK?>^
M7='NO&9>\FZ;?8L']_<11N\S7.UGJ#2H3Y!\U'B#2>\C#6FS9-?I&,0&]"JS
MT[!0Q?6$[93U^+,D(^`'2,J`^H!#7JFS?3YXE;K1]U;V]A">-Q*W4/\`JXNT
M?7H("\)[Q_5QX,;%J98W=UNMP#33:0.+#_UL_8QTZ6ER@GD?SH[>Y[S?%&&:
MY7$.HY49G(<\\L;[HV$"'^Y8(L#'(J;^.QG2Y0]'CZ=>N;']+FVLH_O%ND\[
M^++:-L3?Z\G:.(_H-7S_`-Y_KDWJ75'W0V.UMHZX2WDKIGTX?NHNR8#UR/'!
M0UL'-WG7G!Q\!$9"R(JD\,=).$P[6%H)`X*C_<%4IT6:86``\`[CDY@#U[^.
MO3[/PI\).Z<?;7-E9!S<==[*)#AQI,_0/,T!>([CX\>/_?V7Y>SW+<BQY($6
MVP&(&O"MM'VA\[RJ;B>$W-C+#S[R=88RA)N%Q$YIO([HL*814'J,<SZ]RS-X
M83";<>D##K.N?%3PK[NQ]A'NEA&P?YNV&O\`9MV.:M99^!/CKWPG^9EV/=99
M'8]K>N[+/CJNY&N]"D74O*!Y2SA$E;+,8KH:9Q#K1D+,_L+](GAN)FU:AWS,
M3!^K\5Z?6&N)W+ZE?#^T);81;A>.'%L38VGSRO:[]E>E[/\`1AXM7X#]TFVC
M;VG@^=\SP/YL$;V^;6I-57R5(L@HJ7KD'(.`#I%PTIE$;,^K]<B,C/S;X2AO
MZ#"U'^CK@]P^J:<@MVC96-/`SW!=Z6QQM]&OSKU3:/H7M6EKM_[R2.'XFVUH
MUM>@/FE?Z='F4E*IY2'$B`Z#SJ>2[TN7;J^_;I]U-#C[VE6C80^PCZA5'7"[
MA]1_B/>5%H;"T;_S<&L^F5TGL7J&T?1OX.;?1VX#=-P>/[VZ[-O]6W9%_:4D
MJKP>XB4TJ?W+Q\QRLJD8IBN[#%KVUX)B^(&.XM#N7,8=_5L`>[7#;AXL>).Y
MD_-;S?!IX1O$+?1$&+U#:/`3P9V0#Y'NWMCGC\4T9N'>F=TBD5!U2J5=%-"L
MU6L5M%(I2))5^O0\*1,I0V*4@1K)MT@`:XF[W'<;]Q??W$\[CF9)'OK_`%G%
M>E6&S[/M3!'M5G:6K&C`0PQQ`?U&M51'554_34.?^F<QORB.L(-:,@`MF7N=
M\1)6WJY6IHB:(OS?OXP/E\?*?-C$W$*ORHK53BKC5*Q6]DW<"*!LP9J1C["\
M([1(/;.Y@L;Q\$FF)MS)'?."^'4.M'>R:Y:<!Y?I\ZW=@S3#KXN/L\O4O(AK
M"6<FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB*3'&?C=:^0=S81$8S<E@TW299!Z
MFD8>Z`'*)FZ`[=(B8!^T/J#6GWC=H=K@+G$=J<@LFUMI+J30S+BO8]P]X2ML
M9P$9&1L40CCX='N+@D0QB"!0#8PE#Q,;???T>S7BFYW5WNTYDDJ&57<6<,.W
MQZ1BXC-9Y^.^%CPSZ-5=I$<F0Z1$Y2>!1V#;<0\3``>T-;C:[301GIXK`NY=
M2GG:K'!T.-$R1N_(*I@FBV)L93NB78"$('KWVWUV%K9B:4-CP'$\!YUIY9BQ
MFIV7`<2K.PN)9G(<P6VW4RC:*$06;LE1$JADP'J+N0VPID,`_A'6ZO=Y,%H=
MMV@Z8/\`.29:C]W(+60;:Q]R+_<AJN!\#.#1]YXE=EE?-5!PS#&9-7+!G\.@
M8H['23`@)D'<1'<OB&WIUYGNV\V]F"&NJ_B5V>WV%Q=D%P]T\*+S3<WO-"4;
MJ3D!3I4KI02.$?BTU0.D10>HOV.D?$Q!$/=OKAC->;M+@2V$GSG[@NYM]MAL
M6!TH!DX#"GGYE>9Z]O\`)^?K*]EY!23<M5EUCG=K]P4SD,IN8J74(=)`#PW]
M>NMLWV&T1A@+3,:89FJUUVZ>[Q:':17'(4Y>960O.*D*NP6!9N`K=!NH3%^U
MOMX^.WMUU^TW,ERX/-0U<?N+615:,7<U`2YQZ:+Q8Q``-C&]&N^MZAH7+RFI
M*M[K+4*:(FB)HB:(FB)HB:(FB)HB:(OVM<K^7/Q)RRHY?/,:)46=='.JI/8Q
M>GIRYUCEV[J\.W2<UAR/5]H>IB`B/K\1U]`]W?&WQ'[N!L45^;NS:*".Z;VP
MIR#R1*/^T\R^6.]_TS^#G?!SIYMK&W[@XU,MB[Y8DGB8P'0.YXQ>=8X,F^3!
M;6?Q#O#F8X2P(E*)V\%D:(<5V2..X[(EL$`$K%JCT[;&4:-P$?3MKW#8?JAV
MV73'WGVR6%W&2V>)&]?9R:'CJ#W+YB[U?0]O,&J;N3O<%RP#"*]C,+^KMH>T
MC/68V#J6/[(_`_EKB[XA:Q84M,K&-C&`TW2"-KU$F(7T+`>L+2#]%(P>M9ND
M(>L`U[)LGB[X<=X-+;+=;>.=W^;GK;OZOWH:TGJ<5\Z]YOI]\8NZ>I^Y;%=S
M6K3_`!;4-NXZ<_W!>\#^<QO2HG/FKN+=J,)1H[BWZ)S)K,))JO'O45"#L8BK
M1XFBX3.4?2!B@(:]%BDCN(Q-;N;)"14.:0YIZBTD'TKQZ>*:TF-O=L?%<--"
MQ[2QP/(M<`0>L+CZO5B:(M21CH+INFYU&[I$P'1=-SG0<HG*.Y3HN$A(LD<H
MAN`E$!#5'`/88W@.C.8.(/6#@483'()8R6RM-0X&C@>@C$>8J2U`YD\IL8`F
ME3\Z9`;LDS$$L5-RXVZ)V3V`I/NZV)33=-,0#803`FX:X7>/#'P^WXEVY[19
M.E/XXV=B_']:$L->NJ]1[N^-OBUW5`9LO>#<6P`C]W+)\Q'APT7`E`'0**9]
M(\XCD?!=I*[4_&&0FY>D#K_=LI394X!L!C?$P;YQ&"<_I_[%MOZMO#7EVZ_3
M-W'NZNVJYO[)_+4R9GHD:'?MKW'8?K5\3MOHS?;+:MRC&9T26TA_I1/+*_\`
M5*6]/\Z#%3X4$K[AB_UDYM@</*Q-P%M9I&V\3D;/PK#XR>_J^T;;VZ\XW/Z7
M>\,-7;/NEG..#9620N/G;VK?L7L>R_7%W1N-+.\.Q[C:N.;H)8;AHZFO[!]/
M25)ZJ>9[PPM(`5?)DG3UAVW1NM+LL44!'U?&1[&8CO#U_M@UP6X^`?BAM^++
M".Y;S@GB?^RYS'?LKU;:/JM\#]V%'[I+92<KFVGC_:8R1G[2D76>3W&^Y$3/
M6,\XEE15_01+>H!BZ'W&92CQB\(8-_0)`'7$W_<'OQM9(O\`9]RCIQ^7D</Z
MS&N;ZUZ9M7BMX8[VT.VKO#L\U>'S<+7?U9'-</.%>>/DXR71(XB)2,EVZ@`*
M:\5(LI)$X#L("15DNNF8!`0]`^L-<O-!<6SM%S')&\<'M<T^AP!7;VUU:7C!
M)9RQ31G(QO:\'J+205V1D%R?I(JE_I)G#\H:@#V'(CTK*,<@S:?0MK80](;:
MJK5\U5431$T1-$31%]U156HJ:AO`I#F'V%*8?R!H2!F54-<<@2BB9T0ZEBBB
M7T]2W[(NWIWZE.D-4:X.-&XGHQ]B/:Z,5D&D=.'M5!3N4L7U8#C9LF8\KW;`
M14+-7:LQIR```8>I)W*)*!L!@'T>O6XM.[^_[A3Y"PO9J_D@E</2&$+GMP[V
M]T]I!.Z;IMMM3/M;J!A'F=("K#V3G;P]JIE4Y3D)CYRNCOUH5]W(VI7<NX"4
MO[M1TJF<VX>@##KK['PB\3-P`=;[+>M8>,@;$/\`O7,/J7GNY_4#X*[02V[[
MR;:YXS$+GW!_[AD@]:CQ9_-OXC08+%A5LF759/J!,L)1S1C9<P`.W2ZM$G""
M0AA]8I_BUVMA].'B1=T-T+"U:?SSZR/-$V3VKS;=?K'\&]O!%B[=;YXR[*UT
M-/\`2G?%ATT\RC3:?.ICUE!9XVX^R+]X<PD1/<+HB4YA$=D^F(J\.^<*',/\
MD'(>X==UM_TLS-':[YO+&1C/L8#Y_?E>T#KTKR[=OKGMY'=AW7[N2R3$T!N;
MH5/+]W!&\D]&M4F7F5YH>:.X7$^!5JG'.";(O8?%$JH")%/`JI;'DIV>*,?8
M?`P)@'KVUL3X8^`/=:A[Q;P+B9N;7W;!7H[*U&OS56F'C=]5_?FH[G]WG6=L
MX8.CV^0T!X]M>N,=>FG31<=;BAYJ^;BI#D[,CVHQCG<56,[E@8Q-N13<#`K6
M\7M7+4QND=N@WH#P\-2-\1/IY[J$C8=L;<SMR='::B>J6Z(/G"C?X/\`U=]_
M&M_WKWM]E:.S9+N'9@`\X;%I;YBJGJGDKJ.%_CLF<@S+N5!`ZY*73#N'*AS#
MNKW)JU2YE3B/J,+41$?$0]6M?N/U2M8SLMAV:C!EV\]!T>Y$RGFUK:[/]#+I
M']OWI[QZI3F+:V)<>=9;B2IZ^S4J:AY2W$:N?#J3K/(=_<HB!E!L=T6C6+DP
M#O\`M(^J,H'9,?U>Z/X=>?;E]1OB1?:FVCK*SC.79P!SAU.E=)CTT7KFR_1W
MX-;9I=N#-SW&5N?;7)8UW6RW;%AT:E*BF\0N+E`$JE4P'C!BX)T[/7]9:6)_
MN7;8WQUE^^'0&W`!W`P>.O/=S\2N_P#O(T[CO%^]GY6RF-O]6+0/4O6]D\&/
M";NX0[:.[NU1R#\3X&S/_KS]H[UJ0C!JTB6Y&<2S9Q31,O0FTBVC>.:IE`-@
M*1NR301(7;U`7;7%S227+^TN7.DD/%Y+CZ7$E>D6\,-G&(;-C(81DV-H8T=3
M6@#U+D"(CXB(B/M$=]69*4DG-?-55$T1-$31$T1-$31$T1=;-SL-5H2:M-D>
MI1M<J\-*V2PR*YP30CX&`CW$M,/ECF$`*FTC6:JAA$?`"ZLD=I879'[>'K5S
M1J<!FOQ,^8W(F=Y<<K>1/)JQJN#R.<,P7G(2*+D?VD=!S<XZ4J\(4/Y"$#6$
MV;)(O\E-N4/5MKFW'4XNX+I6-T,#.04;=6JY-$31$T1-$31$T1-$31$T1-$3
M1$T12YXH\2+]R<M[./A8UTG64'*82DJ!!*10A3`*J#<Y@V$>D!ZC!Z-:C==V
MAVV$DD=KPZ%D6]N^XD#6"J]FG#3@WC_#,#&1\5$D&00;(_$K%0`HBKL43@!Q
M`#;F,7<3^OZ->27][<;A,99M197!==;6\5K'1A]_B?L&*S88KHC@ZC6/BHL@
MJ"F0@'$F_P!GP\1';?[(!JEO!+*X,:W$J]\K65<_(!3'%_$XUCD(IB@I*VN1
M*":+!J3NK@N8`#8"E\2%`1\1'P#740PQPM$8^+C7@M4XNE<7NR7<0E*;1G5>
MLC.DA>@7XA*.7.`M(XOZ92CW!V.L7U^H!UFW%W';6U''1;<>#G_<%`V-\LNF
M,:YO4U8^>8_F7T##\=)0E?D$WLJD@H5-JQ.51;J`.@.L$Q$$D^H0\1V#;7G&
M\]ZI+AWRFW`:0:88`=9YKL=H[MN(^8NZUI6O$]0\@%Y7.0W-'+V>IE^4CY\D
MT<K*)-(YD98W5U"8J?=Z#=2IA`=_4&N;;;-+_F+YVI^9J<!SI5=2PQQ1F"U!
M;PK3,Y#+'I5&82X86G)DHG8LABX*P4,"Z3!4YRF/N/\`TQA'8W5^J.M9?]Y&
M,/R>TTUY%W!9K;/36XW'!F&E@..5!6GK^]3@LG&RN4BOG:Q44@D5)`2EV1(4
M1`"[!L8`\=_;Z=9^S6\UQ*)IB7./-<_N5_[ACC`8WD/M6&CE!5DXXK_I3`@`
M*H;?J@&XZ]FV6+LV@="X*]?4E83L@I`1\Z`!V^TI_IUW=N<`M%(,5:'66H4T
M1-$31$T1-$31$T1-$31$T1?O+:ZI<DFB+44QB"!BF$I@]`E$0$/P"&PZH0#@
M<E4$@U&!5'V['U!R`T.QOE&I]T:*!L=&TUJ&G0_Y*DDS<*IB'M*8!UL]MWG>
M-FD$VT7=S:R#C%*^/^RX`^<+2[SW;[N]XX3!W@L+*^A.8G@CE];VDCS%0^NW
MEI<-+J9RM_E0-.>.0$1=T"R3M:*DH(?WB,8+Q]!)CO\`R0:='NUZ7M7CKXG[
M4&M_Q'YJ)O"XBCEKT%VELGGUUZ5XMOOTM^"&^ES_`/!_DIW?BM)Y8*'F(]3X
MAU=G3H44;?Y+V*WW4I1,TW^M'^T)6MG@J_;6H;_H!WX\:L[*`#Z1'K$=>B;;
M]47>"+W=WVNSG'.*22$^AW:CV+R'>?H=[I3^]W?WS<;4_EGBAN&]&+/EW>U1
MHL_DRYR8*+#4<K8KL[<NXH%ED;14WBGL*HF$=8&:9A_\^(:[JP^I_NE,`-RV
M[<+=_'08IFCSZHR?ZJ\MW;Z(>_\`;N)V;=]HNXN':">W<>L:)FC^M11\L'E>
M<TH$511QG#V5),1`%:O?*D^[H!_*2;R$E%.Q`0]0I@;W:[.S\?O"V\IJOY8'
M'A+;S-IUEK7CUKSC<OI0\<MNJ6;5!=-'&"[MWUZ@]\;O4"K(3?#?E?7>X,OQ
MVRTB1+JZU6=1?S".Q1,`F*K"A(IG+]D?$HB`^KTAOU=IXG>'=[06V][<2?S3
M-8?0_2N"O_!/Q?VROSO=K>&@9EMN^0>F+6#EP5GI7'&1H)0Z4WCR^PZB8B4Y
M)2F65@)1*8Y1`WQ48D`;&2,'_)'V#KIK??-DNQJM+VSE!_)/$[V//,+B[ONQ
MWFV]Q9?[;N,#AGVEM.SG^:,<CZ"J/734:B)722K4P;;E=)*-C!U!U%W*L4A@
MZB^(>T/'6S86R"L9#AT$'V+2R-=$:3`L/ZP+?;1<0RC-3]-1LI_2,D;\HCJ0
M-D;D'#TJ$OA=F6GT+GL9)W'&`T7)O(XY1`P&C9!PQ,`@(;&`6BR0@("`>/N#
M44L$<XI<1M>/UFAWM!61!=36QK:2OB(_(]S/[)"N;!YWS?6@`M>S/E2'*7]%
M./R';$$@_N_0B$L*6W[$O\GT%`/1K07?=#NI?8WNU[?*>;K:$GCQT5XE=38>
M('?S:\-MWS=X!R9>7`'#AVE.`X<%<J.YK<NHH-F7([+!0Z3$V=6=:1#8Y^X;
M_P"J23S[77Z_2`>`#MX:T4WA7X;7&,NQ[=YH@W^R0NIMO'3QEM,(.\V\`4_%
M.7]/XP[TY^95XT\QSFJRZML\3;GK*4O^_P!<H[SIZ-]A3[U9$2F-O]H?2/KU
MJ9/!#PLE_P#Y/$VGY99V^FDJZ"'ZF_'2"O\`_L,[J_GAM79<JP>GFNZ3\SOF
MJBD1,<P,E`('3W7%#H)U3^(CNHI^[Q0,;Q]@>`:Q'>`GA:YQ(VQXKP%Q<4_^
M(L]GU6>.<;`T[TPTXFTM"3UGL5]'S0^:(>G+\4'X:'0`_P#Q#I_[!>%W_ELG
M^T7'_B*O_%AXXC/>H?\`9+3_`,%?2>:%S2.8"IY>BU#"/@4E!H)S"/IV`I8`
M1'PU0^`7A<!CML@'_P"L7'_B*K?JO\<G&C=YB)Z+2T_\%;B?F"\]YPITX[)]
MO<BX$HD-!XWK"B@=P_4F#91E35CE*<2B!=A'<-P\=4/@UX/VA#I]OMFZ?[RY
ME`PSJ'3!5;]1WU#[@TLM=VO7ZO[JR@)Q.&DMMB<>%,PNU:YP\S^^"8T18.4$
MF1?LF_[@I<W%MOLI]Q(4C1=7CT$BG3+U#TB`*>(COOK'D[I^`>T"ES#L$9%?
MXD['G.AKKE<3RQRX+*B[^_5;W@)-G<][)0ZG\&UEC;E44+(&`5&.!QXU7?-\
M5^:W?/V3A#E$9)4WVCSU\DJJVW[AE=S#*6:'`I053W#8-@'8`\!`!PW]X?IX
MVCWF'8`X?W=NV4Y4_#$_@MC'W1^KSO![LC>]A8?[V[?;MSK^.>/B/*H7:,_+
M2Y\W18IK0JRCB*C^U<7;,XRAB`(@`BHWC7MD<'\##X`4?0/X\>7QU\'MK;2P
M#WD9""RT>@N;$%EP?2Y]0^^/!W4QQ-.9NMS[3TACIB?0KHUOR6<M/5BJ6_,6
M,(%,?%7[CA;-:7HCZ^D7;>MH"/O%0=:"^^J3NY$W3MNV7\SN':/BB;^R93ZE
MUFV?0UWQG?JWK>]JMV\>RBGG=^T(1ZU(^I^2]B5CTGNV9\B6,P=.[:MPE<J;
M40#;J+W7H6AUL/M`2B&N'W'ZHN\<N&U;790#G*^68^AO9#VKT[9_H=[GV]';
M]OFY73ORP10V[?2[MW>Q2PI7EL<,Z2+=4F(T[<[0*'^]WZPSUH[IP#^]5C57
MK2#,81\=OA>D/4&O.MU\<_$_=:M.Y&VC/X;>..*G0'!ID_;JO7]C^E[P0V(M
M>-F%[,W\5W-+/4\RPN;%_P!W3H4M*GC3&]";IM:/CVCT]!(=TR5JJ04,8H[;
M=7>8,45S&]YC".O.=QWW?-X>9-VO;NY>?[V:1_J<XCU+V+9^ZW=CN]&(=@VV
MPLHQD(+>*+UL8#YZJN#J**#NH<YQ]IS&,/TB.M2&@9`!;]SG.^(D]:T:N5J:
M(FB)HB:(FB)HB:(FB)HB:(FB)HB:(L+_`/$(<D5.,7E%\N;/&OC,;3E&JQ?'
MBH'16[#D\GFR51J<^9JH`E,59GCX\TY`2CU`".X>C6%>R:(J`D./\A]M?,LN
MR9KG%<ACZ,5^1<``4`*`;````![``-@#YM:-;Y?=$31$T1-$31$T1-$31$T1
M-$31$T133XC<-;_R;M<<BPBGR=5*[3!T[*D<II`A#`*B+4^P;)[>!C_-[=:/
M=]Z@VV,BH,WL65:VDER_2P8+VD\,N$$;A:KQ$;'P8QG;121.!4=C'$NPG$^V
MXB!A#Q'U^O7F-R^YW.<S3$Z-6"Z:!L5FS1&/?(H5E^HN,01%(Q4DP`A2$'[/
M;ZA-L`^`[=7X_5K-ALVM`U8J)\IK5V?EZE.VDTU6KP17L='`>9>)=B-*8OV0
M44`0,NH;^0D7?YM;6"+L&ZVC]Z[X0.*Q97"4Z'&D8&*X<F_H>!XF5N]_FV*T
M^HBL\>R;Y1,@(%`HJ&0:%4-L@@F&X>&PCZ]8MY?6NRQFXOW-=<4J!R/WK(@A
MN-SD$%HTB&M*\UYKN=WFL6C(DZ^HF&5G#>O'.HT<3Z/<(D<1.9/:.,7P5ZMO
M$_B`>H->9;CNEYO<CI9G.9;<&Y$_<.2]"VS9K7;&-U@/E(QQP'6>)ZLN2Q8I
MTJYY+$YR*NY:1DUMG[][W5U=U.DAQ%4Y^I0VYS;``;!MK03WUMMS=,F#P*@`
MY^72M\V)]Q[\=.RR)(`H,L.K')3]X]\*X.%*V?S#$KV0/VA.=9(!\0*`[E$Q
M1Z1*(^@-<]+<W^[/TDEL/Y1AGS^Y4DNK>R;2W`[3B_/+ER\RRCTC!40V9$;F
M8E:III@4`*CT@/JW*/M';T:WFV[*RHU!<Y>;A(\DDU-<U'+/U7:0;*0;@`=)
M$E=A-["[@&_AX"`>SPUW^V6[82&8+G[F0O&I>8CF9(()+R2)!+]DRX;;^\=O
M=L.VO0]L-*!<]=8K`OD%R"K]SZ/$QP\/QAX[>_796V06FDYJTNLY0)HB:(FB
M)HB:(FB)HB:(FB)HB_>6UU2Y)-$31$T1-$31$T1-$6H#&+XE$0_`(A^35*`Y
MJH)&2W!77,'2994Q?U3*'$/F$1#5NA@R`KU*XR2$4+B1UKJ'L-"R0=,E"0LD
M'4!]I&(CGP=92B0I]G;9;[12"(`/I`!V]&LF*ZNH,8)98_YKW-]A"PI[&PNA
M2Z@@E%:^_&Q^/])I5&NL08B?"`O,48Q="4IB`+C']15$"'\3E`3PXB`&'T^W
M6TC[R]Y(L(MQOVCHN)A_RUI9>YG<V?&;9]J>:4QL[<Y_]6J6><:>.4@D5%[@
M/#;A(IP4*0V-JB4`.!3%`VZ420VX%,(>G;QUL(N_??>%VJ+>-T#J?_-3?Y:U
M,WA=X9W+`R?N[L;F`UI\E;Y^:,+I'7$7BN]1,W<\=,-'1,8IA*G08!L;<@]1
M=EFC1!<``?4!@`?7OK*C\2/$&)VN/>]T#NFXD/J)(]2P)O!OPDN(^RE[L[&6
M'E:0M.'2UH/K75_\%?$3_P"6[$7_`+IM?[>LC_W2\2/_`#S<O^V*P_\`V,\&
MO_3&S?[.W[USF7#WBC'"H+/CEAU,5@*"G=H\.\W`@B)>D'J+D$]A,/Z.PCZ]
M0R^)?B'/3M=[W,TRI.]O]DBOG63;^"WA#:DF'NSL@U9UM8W9?S@ZGFHNZ9\7
M^-4>J*[+C]AENJ8@IB<N-ZH81(82F$NRD6<NPB4/5OX:Q9>_W?J9NF7>=T+:
MU_UF;_+6=#X4^%UL_7!W<V-KZ4K\E;Y>>,JHV>#\)QX$*QPWBAH5-3NI@WQS
M3T^A7<#=PO3#>!]P`=]84O>SO5,29MTW%Q(H:W,V7+XUM(>X?<6V`%OLFSL`
M-12RMA0\_P"'FJK84JE10E&+I=.C#$.94AHZJP#$Q%#EZ3*$,UCDA(H8O@(A
ML(AX:UTVZ;K<?ZQ=74E13WI9'8<L7%;:WV+8K0@VEC91$&HT6\+*'G[K!CTJ
MI4MFX`5N4K<I0`I2MR%0*4I?T0*5("%`"[^`!Z-8+O?-7^\>G'VK:,`B%(@&
MCH%/8MTRRQ_TU53?TE#&_*(ZM#6C(`*\R/=F2?.MO558OFJHFB)HB:(FB)HB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+Q"_QH>>S1V,.$G%Q@\,![;=LCY\
MM+)-42_[E28>/Q]2CN4RB'6FN_N,V*?4`AUMQ$/$NM3N#ZD,!ZQU?R^I;7;F
M?%(1T#R\R\!.M8MHFB)HB:(FB)HB:(FB)HB:(FB)[@\1'P``\1$1]``'K$=$
M63O@MY<]]Y.6:+E[0S<5O'Y%DW!E7Z*K=671(('V*4P%.1JIZ/4)_<&N8WKO
M%!8M,-NX.N2.'!9]I82W)U'"+F5[8.(7#?'N'HB"CZY"MD3,4VY2O"(!VE>D
M"DZ1(4I0]OS^O7`!TM]-VUQ7.M:K?M:VW;V4/+%9C("EL2($!JS:$.<B8#TH
ME`/L!^G]H1Z!$-];-@8UM!0A8Y+G.Y!7GH%,C7DIWG:*1&C0@G,80V2$Y?#<
MP!ZQV'6;8Q,EDHXC3Q/)0SO<QM>*Z'DURLQ;QIHS^R6:59,2,&JI6R9UD_B5
MU0*/;1:H`;K,8YM@`"@(ZP=^[S6>U1=E;4=<G`4S\WE@LK:=DN]SEU/!$0Q/
M`>?D%XY^5G.#*G-VS3J,'+NH&D0C[LLJX@N<BTPEW`$%7YB*%,9-0A@`"``A
MX_:UY9=333S?.[F:O=4@<&_>>GAP7I=G:06D'R]H`7`BIIB>KHZ,SFJ:Q1@*
M2MQV/WXU48D251Z$S$Z#*#N`@)A`A1#?<?LE$?#7)W^^AK^PLZ.DRU</Y5NO
ME61L[:ZJ!F&#/^19;,,8#A8(C9%-BD8P%2`3]KI$1(`;AX_:*._S^W6-9;?)
M>3=I.2YW2M3?;B2W2WW6<`/M61RD8UKR2#?J0(BY+MMN40+Z`#[)=@W``]6N
M[L-JMF,%0`Y<O<W<IKQ5QK3#H0D4<R0)[%3ZBG``#T>'@`"'IW]>MSV+81@`
M%@-E=*[B5ATY>VM-&-?@54"J@14#``].^V^PAX[^K63;.J01@D@P(7DPY;6H
M7<C)@*G5N=;<VX^/VC?CUW.TDFE5H[JE<%APMSCO/%Q`?#J./T_3KM[<>Z.:
MTLF=%0.LY8Z:(FB)HB:(FB)HB:(FB)HB:(OWEM=4N231%3ULM,-2:Y+6JPN#
MMH>&;@Y>*))"NN8#JIH(H-D`$IEW+A=4I$R`("8PZM>X,:7.R"O8QTCPQGQ%
M6)C>6N'962CXML[LQ',F^9QS8[BO'1;E</G";5`5UOBS=I$%50ZC;#TAXZ@%
MU$33%9)L;AH+CIH!S5];A:(VCUV6M,TE(*14(D5Q(_=C07[M)N*Z:!W!6Q5$
MA41;F5`R@@/V"`)O0`ZF>\,;J.06-&QTCPQOQ%6SH'(7&N2[`6L5EW,A+G8N
MY!%*5B#1Z*Z+($S.2(K&<*@=<B:G7T;`(D*8?5J-D\<CM+<U-+:S0MUOIIKP
M-56&1,FU'%L.UF[>\<MVSY\6.9-V+47S]VY%(ZRG8:%.F8R+9$G4J<1`I-RA
MZ3``WR2-B%7*.*&29VF/.BZC'69*;E).9<58LX5A`)IGE)29B@B8Q`RI3J@@
M#Q9R=,RZ;=,RIP\`32#J,(`(;TCF9)4MK0*Z6WDAH'TJ>`-5:Z9Y+#+S3FLX
M7HLQE259F%-W*M>ZRK+8W5T]178)&4<(=0>"IS-D3^DACAXZB=<5-(@7'GP4
MS;32W7<.#&\N*XY[[RQCR_&O\'5F09E#K481,UO*%3#Q$I"ISKY0Z@%]0(G$
M1]6J&6X`U%K=/7^E.RLC@)'5Z1^A5QC?/U7ODJ>J2D=*42^("9-2I69,6[AR
MJF43*)Q;I1)M\4J4H";LJ)HKB7Q*0P;CJ2.=KSI-6OY%62VKXQK:0Z/F/M5]
MM3K%7634W"UJ*>SMBEXR!A(Y(5G\O,OFT;&LT@_E.'CM1)!/J'P*`FW,/@`"
M/AJTN#14X!5`+C1HJ5#6S>89QCKKQ1DTL=EMITCB0[FJ55ZYCA$H["*+^75A
MD7)/89/K*/J$=0&ZB!YA93;.=PK0#K*YU%Y\\=;[/Q-88REOA9F=D6<3$-YZ
MH/BHO9&0<)M&30CF&6F2)*.7"I2%%0"$`1\1`-QU5MS&YVD55'VDS&ZC0@=*
MN!FKE9B+`-@B:QD-U9$Y>9AQG6:4#`'F4BQX/G,<4[E8CMN"*IW+13I+L.Y2
M[[ZNDF;&:.S5D5O),"YE*`\U>*A7:#R33*W?:U\?^[]KC22T0,HS&/?F9**J
MHIG<LC**BW,H*(F`!,.Y1`?7J]C@]NH9*-["QQ8[X@K1YKY28FP!+0,)D1U8
MDI"QQCF8CDH*!/,D!BT>?`J'=*$=-P;G.X`0(78>H"B/JU9),V,T.:DB@DF!
M+*4'2KJ8YO\`7\ITFOY`JGWB-=LS9=Y$FEF)HU^HW;O74>91=D918R('7:'$
MFYAZB;#Z]7L>'MU#)1O8Z-Q8[X@H]Y*YO8#Q3=IO']ID[2M8JZHV0ERP594E
MH]L[<M$'OP?QQ'J!3NFR+@@+%`O[-3<HCN`ZB?<,8[2IF6LTC0]H&D\RKQX=
MS/1<[5-Q<\?N)->&:S3R`<A,1IHI^C(L4&;I4AV9EEQ!$Z#Y,Q#]7V@$?9J2
M.02-U-44D3XG:7YT74YHY"XOP"T@G>29.49?O*K()0K:'A'DTZ>&BB-#OC&(
MVZ4FR:(/4OM*G(!A-L&^PZI)*V(#5Q5T4+YB0S@HW#YE'&T%.@"9)$F^PK!3
M6X$`/;T#.@KL']'?47S<7353?)3_`*OI4A\1\EL+9P6688]N*3Z<;-S.W%:E
MF3N"L1&B>P*ND8V133%^V1$0[BC8ZQ4]_M"4-2QS,DR.*AD@EBQ>,.:V\T\E
M<38!6@VN1Y28:OK(U?/8=C"P+R:<.6L<LBW=+*&0%-NU(5=P4I>XH43COMOL
M.J23,CP.:10235T#`*/G_B4<;>YT=O)/1OMWOW.;=`![>C[^[NW_`"=]1_-Q
M=-5-\E/^KZ5?'%_+/`.7I)O!T^^-D[$['I9URR,7E:F7RFPCV8Y*422:2:^P
M?W;=950?474C)XWX`XJ*2WFC%7#W>8Q5WIN^T^MR*<3-SK5A(*))KG;G2=K`
MU;K&$J3B06;-UF\<@?I$>I<Z8`0!..Q`$VI"YH-"H@QSA4#!5?\`C`?8("`@
M(>H0$-P$!U547S551-$31$T1-$31$T1-$31$T1-$31$T1?EX_P`65FH<G^;9
M8*"W>BXC..^"<08N3;%4ZD&DS/QLAEJ?V*'@5P9;(:*:GKW1`/5K07CBZ<UX
M?RCU46]L6AMN"/Q&OV+S.ZQ5F)HB:(FB)HB:(FB)HB:(FB+6FFHLHFBBF=59
M4Y4TDDBF.HJH<0*1-,A0$QSF,.P`'B(Z$@"IP`19QO+Y\L:PWV4@,G9=A'",
M2"J+Z!J[I`1!QT&(=)U)%'[)O#Q`@[E+Z]QUY_WB[TAA-C88N.!</L6\V_:C
M*.WN#1@Q`/%>O[`/&MC6V3864<T9QR0HMRM&J`())D3('6B4I0`"%-MZ?3OK
M@HF"275/J+SC4XKH7ES&%D-`WD!0+*-0ZXSC&#5LVC6Z!@`I"`=,H]L@_H%$
MP>`CX>G6\B]S`4T^7K6ND-30*\T0R.1Q\.DF<%5=BF32#N&'<?``$N^V^WH]
MFI6FKNS;Q*HT`?%ATJ%7/+S&L3\+*TI3F<DSG,JO&X*)5EHX3[K55PF(HJ2J
MH"8&3<!V$>K[0AZ`\=:O>MY=9C_"MM!??$5>>#1T_=F5M]HV<WI-]=D,LP<*
MD5/5]IR"\B&9^0F=N<.1DSRCV2D5%W"Q6\4S54&$C2'4`$0(7Q3*1(#>*A@Z
MC#Z-</<F+;VNO=P?KN",SGU-'W+L[9G:@6UDW1#QQP/2X\AZ"5.[C)PD5H;9
M.8L3OXVPR?;%9(H&^$;CL'@0GIZB[^(CXCKD=QW*[W=W91`QVPR'XCU\NI9S
M)+>PKV?OS$8N_"*<JY]?H"R?4_!B;9)'NI@()B0X&(7I'\&P>'S:DLMATD22
M9K67.Y&04QJI4U.C/(Y9HN@'V$NCJ(</$0*.^X[B.Y=B^&VNHMK'L:&/)::6
M?M#5ROZP7;HB!E1`@DZ=S;?JCXAL&_VA#U@.MW$YHQ=F%KWAYP;D50V5[:U2
MASD2=!N1N8-NL.H!'^48!'W:K/.PBC#BJ11:27.&"\]O-2[*)LWYTW'5X+`(
M]7K\2AMZ]AUE6A)("LE-*DKRR<D+.9S)/]S]6YU=]QW](_AUZ%M#30+278H"
ML;TZZ!9RIL.^YA^D1UW,#:-6AE.."I_60H4T1-$31$T1-$31$T1-$31$T1?O
M+:ZI<DFB*`7-;((%)7L:,5M]P):;&5,=QZ2]U"!8JE#QW$06<B4?8D.L"[?E
M&.M;3;XLY3U#[5$;)%(?8RF*VP7[I))S3JO:W`'$0,WE)%-5TNV)X`)?@G*`
M)[>HQ!UBR-[,@<:`K-AD$S2>&HCS+,LP6C[E4V+AXD1W%VNM-%7B!MC$<,IV
M*3.Y2'U?;2=&#W#K;"CV8Y$+0FL;Z#XFGV+$,FC*8&S>W36,H*E)MB.Z@]10
MDJZY.`=[U=1)*OO-Q]7480]6M7C#-U'U?R+>5;<V_P#.;Z_Y56V5;+-\C,S-
M:]3^IY$MW)Z_42F!0K1..1/W):SO`V`44'0IF<*'$`,#=-,GZ0``W2.=<2T;
MEP^TJ.%C;2W+Y/BS/V!7^OM9%BIC?B=CIVI'-9MM]_Y#GDRE*\=193G5>NGO
M2(;FD!9*KG3$>D2E;H_W>X#.]NG3;,XXE8T3ZZ[V7$C!HZ?T?>J<<V(\I'VJ
MNXXM47@WCIBA)5.[9/<+%:.IAPW_`&3QXI*];=RZ</5`_9@15,ZH&()C#W$4
M-9FV;;N.][A%L^RPR37LSPR-D;=3WN/!H'I)P``+G$!:S?-[V7NOM$_>/O/<
MPVVVV\1DEEF<&11,'%Q.`Q(``JYSB&M!<0#'FCY6X-Y#N+2DQG)?*J<_)O"1
M\;*V=M)5B`G9)90$446<U+1`-VJCU8P%1!X9N"AC`4!$P@`^M;S]/'BGL6T.
MWJ^V\OM8V:Y&PS1S2L:!4ET;"7$-&+M&N@J3@*KYW[L?69X`=[>\;.[&U;RV
M/<)I!'$^XMIK>"5Y-&M;-*UK6EQP;VW9!Q(`Q("O#=*)QWH%L<PMOO&:V5HA
ME&BY79F;=PJ0H`1Q'OHZ3"-.95`HAU)*$-]DQ1#P,40#Q5S8&NH2ZO/R"^H6
M/NWMJUD>G*GM!%5.*@Y.IERICJTQ%@>/82MI.6L]-3S,L:^2&&C4G[^2DFY2
M))%[C$>^8Y"E(?[72`;;:S8Y&O9J!P"ULL,D<FAX`<<@%@>S#ES)O-+,L34:
ML1V:OOYT\3C2D_$&;1C-F45!&SV`"[HFDU6")W;QTJ!OA$`%-,`*38^O?(^=
M]!EP"VD<<=K%J=G3$_8LB./_`"S\,0L2V#(<Q:KW8C)$-(*QLHI5J\BX$H"H
ME&,F"0RBC=,VX%4<.1.<`W$A-^D,EMHVGO9K#??2D^X`&^E71HW!+!V-\DU;
M)E2+;6[ZIN';YE!2TRE-PJT@LQ<,V;\QGC$LDBXBSN!62V7,452E$0\-7MMF
M-<'*-]W*]A8ZE"L8OF03WWER4E&1#]1*O1*A$@&^X$67:/)]8H`'H'>8+O[]
M8ET:RX\`LZR%(*\R5FZPO`A5\/8JKH$[8P^.J:S4((;"5<(!@HYW#]87"AQ'
MWZV$8`C`'):N4ZI'.YDK"[YE\]\?R%910*=2=7QO7&HD`=P37E'DS.+`/L,9
M)XD(^[;6!=.K)U!;.Q%(:\W+*72K)%X!X?TRTS12@VHN&Z]+':G$""^F7\0V
M>,(L@#MNM)SLHF@`>G=3?U:S&D10!W0L![3-<EHXN*P55NA6++=2Y#YJG'#E
MTO2&$;:)-]N82R5KN5S8E=I',._4DWAU'RXE_D`"7H#;6N`+PYYS"VKGB-S(
MF\</,`LAWE86CN168Z0HIN+61JUO:)"/B!'S9_!R)BE]@'CVN_O$-95H1BWR
M\L%AW[<6OZPK>^:7."XR)BBME/N6)H\S,JI[_HJST_\`"$,(>H3(P/A[M6W9
M.L#H5]@/<<[I\O:K\\<^%.`[YQ^QQ8[S37;JV6^LFFI2PM++8(UZB$B^?*L7
M#5!&0"*;"SB^SMU-S)CT[G`VX[WQPQF+4X>]11374S9BUA]T'DL8N'&+Z"Y3
M4&)Q])KRRL3F=G#P$NUV`\K!,[,I'N7JG8$$S-)"M)+'<;?LC(G/_)UBLPF`
M;^;R]2SI2'6Y+^+?73[U)?S/9TK[.]8A"'W2K6-HX1+O^@K.3DW('\/4(MD4
M?Q;:ENB#(.I06(I$3S=]BESAC@OQ\L^%L;S5QITJYMEEI$#.SDNVMEC8.!D)
ME@G("HV;(/PCVH)I.2`4@(B3[/B`^.\T=O&Z,%P]XCI^]8\MU,V5P:?=!Y!8
MX.77&T.-=]A6L!,2$K3[6R7FJE(OC$2FXMU%.T4I"*>NF96Z:KR,67050=)$
M2,=-4H])3E,(XLT79.IPX+-MY^W8:_$,UDIXUL9CD7B>H9'GK`F-GC'4A5)^
M0?M7+IX:9KJM;9#8T$T':#&5>35<@8P%47Z:B*3L%5R[F.!2Y<596AQS6#/2
M&0L:/=S\O/59"FC5%BT:,6X&!NQ:MF3<#G%0X-VB";=$#J#L*AP23#<P^(CX
MZRA@L,FIJM_551-$31$T1-$31$T1-$31$T1-$31%NHIBLJDD'I54(F'X3F`H
M?2.K7.#6EQR`JJ@$F@S7XS'FVY<'.GF=\\\G%6%RTF^4668B(7$W7W("D65U
M0Z]T&W'=(L)64`)MX=`!MKG):=JX#(&GHP720BD+1QTCUXK'CJ-2)HB:(FB)
MHB"(CXCXC[]5SQ.:)JB)HB:(N9'1S^7?M(N+9N9&2?KIM63%FB=PZ=.%3`5-
M%!%,#'.<YA]6K7O;&TO>0&`5)*`$F@S7H@\NWRPGZ#F,R;F.#*K8NI![!5]V
MD#QI")&`#D5>MR@(*/Q`0W$?`F_A[_+N\G>SYEQL=N=^X_$X8$_H74[9M/9@
M7-V/?X-./IZ5ZR\(X%%M&LE%TSD1:H%32%#L(H;)D`4BI-_LBFF4@;>`;CMK
MFH+?6!+(,:^=;&64XQM/NCT#DLC-,JC1A!)H`T5*=42%,44P^P8OI,'A]H#A
MZPULW".-NEK?0L(DDYJXZ:+5BV*@FB8[@OV42$*)3B?<`*'V=S&$!VUCOD:!
MV;,7$^M2M;4U=FHZ<RN7M*X'8%F\I6Q=`^3K2V=PV**0LH99[.6(Z!@1<+M2
M"9=*,8"<%5UA`"@4.G?J,`:R'R';+7M#AN$H]P<AQ<>0'/G@KK:W-]/H%?EF
MGWC]@Z3Y9+QHPV*<Z\OKI.Y.R4Y?NBV.:>6">LDJFL"C@[U<51;,R']"3=,P
M$2*'V"$``#T`&O/-PWRUVH/=$>UO#F:XEW$GK7>164L[&,D'96P`TCA3D.?7
MQYK,IQGXLURB13,(^"%AW.DQI!R@(KOQ)MNIWE/$PB(^&WH#7%LCW#>)Q=79
M=I-:5R'4LZZNH+9AM[4!L8SIF>ORP61"N5$K-5$B30JAR@`!TDZ^K;T!MZ=_
M7OKI[2QCB(#1YUS\LY<TU/K4CX"!:H%2[R`$.)2F$=O1[ND?9MZ-;Z*$9TP6
MN>\XBN*N0O\`=C!FBNB!.LH"41W#[7N$?'I$!UFO$;(ZMI@L9I>7%KLE86\V
MYM'J=M)R!05,(FZ#;>)A$1`-O=K1W=RQKL%L(8G.%.*AKE>_""3M+XLQ"&1$
M=Q$?'?JV$`$=P\`'6N^;J^E<%D=C[N/Q+`KRWNACMY-,'8*)[KB7<P^H!V'Q
M-MMOKHMKE)<`2L:>$G&F"\U&?;<BK+.VZ2P**&4.`B4V^XB(^_7LFP6KG1AY
M&"X_<Y6QG0WXE$A10RAQ.8=Q$1'Y]=>``*!:$FIJM&JJB:(FB)HB:(FB)HB:
M(FB)HB:(OWEM=4N27$D9%E$1[^6DERMHZ+9.I%^X.(`5%FR0.Y<J"(^'V4DQ
MV]H^&J$@"IR"J`7$-&9*PSC>X:V9D#(60$I!:`=V<LY(1S!!)V[&,CS=</"H
MH+N&R0HD2:MT%-S@`)@<?$1VUJ-8=+VC\J_R+?\`9.9;]E'352GWE5CR0RG4
M,M6.N3]5;338\?".(F4"99-F9U!+(*/&1FX-GKP%"$*Z5`VXEZ?#;?U73R-E
M<'-KDH[2%\#"U],34460'C7-#/83HBHF[BT<Q=5];QW-W(60<LD2CZ]_A");
M>X=9]N:PCH6LNVZ;AW2:^E0(Y1W&`O>4U2U9H5U^[L9^[S^8:=2WWZ]C573E
MTJB1,#`=G#D,=$JH;]94S&WZ"E'6%<N#Y?=X8+9V;'1P5?Q-:<OY5<OA'*UU
M"S7"(<M$"VF0B6SN&DSFW64B&2P_?$2W*;[*9A551<'$OVE")COX$#5]F6AQ
M!^)0[B'Z&N'P5QZ^!5Q).3:0W)W+;B6DF$2Z<X<.WK#R3>MV"(NEH>(*@BV<
M.U4DP<*K)J=)0'J,)3;>O4CB!<.K^7#U*(`NLV``D=ICZUCHY=MY]WY>U+/4
MRNCPL5FY=;*Z;(3").ZSDTZXYF2I_:&/(^<,@*)_L`L=`?2!=OIWZ29MHC\0
M9V7I8-Q?MT@MM6>OM&&4,_7,0/3H#^%5\(?_`+1:V[QS^#5M)M`E.S1;S`Z]
M#*T[(Q2M@=)3_-B<@8X=JZ+C18/P(9003(0ZAU#%3(FF4QU%#G$"D33(4!,=
M0YA`"@'B(CL&OT<+@T:B0`,:\!TE?B+&Q\DC8X@72.(``Q))R`"]4M98V3]^
MN%$3<4A<Y*88?KQ,D)/DRN793)5U3O)S)%BG$SQ+MN05[FX][J'TZ_&SOU)M
M4_?C=)=BT_X.[<+DPZ?A[(ROTEM/PG-M/PTHOZ;/"F'O#:^%&QV_>W7_`+RL
MV:R;<ZZZ^W%O&)`\G'6#@^N.L&N*MY9)1S$<=N<+^!-VHUQ95HJ/,W^RFFUE
MYX8F4^'[>Q2IC%/RE\/`"F#U:Y8&D<I&6I>@N`,T`=\6E1N\LMI%KY_GG#SM
M?>3#&4\M!D/MU]]>8@&DBH@`^/=3C%CE';Q!,YO5OJVUIVF/)77Q/8BF6K["
MLA/,^M<D+5$4!CQX6L;)PSD[`_MSZMVUA4U_A?@6"$0T=+NY6,.\0,J=PH!2
M]92&(`CL.VLF<2FG956%;.@:29J=&%5C+XOY>SK=N16)ZG-9=R/+1+JXIGFX
MQ[;YAXP?1T*U?2C]H[0.[.BY:+)QXD.4=R'*/K`=8D4DKI`*DX\UG3QQ-A<X
M-;6G)6]Y2N%+GRXR>T,;_MN36%21ZA\"(LAAZPF'CZ"@#??5LM72FN=:?8K[
M?W;9I'Y:_:O261N1H1-FD&R31--HD4/0";8A4$P`/<1,-;48BH6E7F]YB/SW
MKECDYFP'XLZEMA:.Q*D/<[B\;&PU;%!/IWW,$B10NP?RM:J8ZYCZ%NK8:+=M
M>55,7S*LGIP\3CSCS".`(G'Q\7:+>DB?[)&T6U&'I\2L!?4)D'#PQ1_40-[-
M37+Q01MR6/8QU+ICU#[59C%O(_`U#XJ7+![Z$O;BXW^$MQ[),M(6%/$*66::
M':0?0Y5GDGBD9#-VC,@&%$#@)5#`3<=AM9)&V(L-=1!5\D,S[@2@C2".>2X'
MEM6@83D5]Q*J`1*ZT6QQ`DW^RH^BA96-F4-]MS`G%K@7^EJEJZDM.85;YM8:
M\B/N73>8K.!+<G)]F!^I*M5"FP>P;CT'-&*3C@H`&X@/<FO$/3OJER?WIKP5
MUDVD`/,E=+DUES7QCC&$B\A2^0H#$SJ/C*]&-6-AC%*\C'+,0^ZX%^:M.SN6
M:#AB3I(@[,4JH%$@]1MPU:X2L;C@T]7V*L9M7O)8`9,\OO4P/+-IF'Y&-LMW
M9LY-YF&L+$B)-2:.T4CX*$G$G'P3ZG-FZ9>T261:JMW2Z_6Y(9,R91*DI]O(
MM&L-7#XPL:^=*"&&G9'RQ4,.=<J>R\J,F-T3BH,<M6JFV`!WZ5(^MQ+<R1?P
M/G*@;?K".L><ATIIDLJT&F!OG/K7H=K<22!KE<@DR]*<)7X.'(4`VV+%Q;1B
M`;>K;L:VC1I:`M,XZG$\RL-_FBW*/DK[C.B-%DUGU2K<Q.3)2&`QF:]K>,2Q
MK1;;?H6/'PO?Z1\>VL0?Y0:P;MU7!O);*P:0QS^9]BFWP"J3RJ<8J<J_2.@X
MMTK8[HFFH42G"/EWY6D2H)1V$`<QL8DL7VD4`=3VS2(NM8MXX.G-.%`IG:R5
MBIHB:(FB)HB:(FB)HB:(FB)HB:(FB+H[19&U-JUIN+TY4V=/K%BM;LY_T2-J
MW#/9I<QM_#I!)B.^HY2&L.KX<O3@KF`EP`S7X8UGL3ZX6>RVZ3.961M=BG+,
M_4./4=1[/RCN6='..X[G,L\,(C[=<V34U73Y8+I-41-$31$T1-$31$T1-$54
M4NE6O(EFBJ=28-_8K)-.2-8Z+CD3++JJ'$`$Z@E`2H-T@'<ZAQ`I`\1'4%U=
M6]E`ZYNGM9`P5))HKXXI)I!%$TND<:`#->JCR[O+`9X6^'N>28AE9<G/VJ"O
M?51*Z8U0JP$.1C&(J;@=SU&`JJVW4(^C8`VUXWWA[TW6]S&SL=4=BTY\7]/5
MT+M-NVB&P8+BZH^Y(R_+^GV+T?88P\[['=&#*+D1,43!N3MMRF(!W!DP$I3F
MV*)0Z>H0VUK[#:B`'D>^#CSIU*6YO=1TM^#U>7%9!*ACOX1LS.*/;1#8!.B/
M2!Q)XE[A3[JE`"^`"/@.MVRVT.U.'NK"[4N;I;_*KR*@VCF9.T38VX)$V#K#
MK`-B@)=]RB(CJ&9P#?=&%54`>>B[1-W5L>U.>RC?#*H1L"V.L@AL"SIVX/\`
M]F9QR!P(9=X_<"5-,GM'??;QUE6K+/;K23>=S]V&,8#F>`'.N5%`_P"8NIF6
M5KC(XX]`Z5YI^0]+M'*OD0]S1G`H20,_^[L;8P9K&<QE.K:2O4R;.S!^Q%ZX
M_O72@!NHJ80WZ0``\;WOO7>WUS)(P%KY#0`9AO!HY#GS*]&V_;;2QMF1-]XM
M%23EJXGIY"N04OL.XB18)LD)=BP+%*J$128MT"HD8%\`2(9'I`#%`-@]&^L'
M:-KDF>)KVA:3DJ7]Z#5L5=7-2MD:$ZB`9E;&*:)1.'93*F0@-BB.P@'A]H@@
M;P_#KM)+`P!K10PA:%MP)2:?&KIU^`23;%,GVR=`=74)0ZO'QW-X>/IUGP0-
MTAYSX+%FEH=`R7</#(LB'!<2@8H`<BI0`I0+[!'P'P`=7R$1U)I1482\4&85
MA+W?21B:[8BQ>T;<Q=QZ?1Z0W$?'?;?QVUH+V\$8+:^ZMA!`7FO%1`R/D0#D
M3!N<IE3"4YMC^(`8=MP]'CM]&N9OKROO<%M[2U).D'K*@ME7(R^SHBRWB5`W
MVQ-NF`!OZ!-[!#6K;=O,H#.:W,>WM<VN-*>7\J\Z7.3D;%1`OH6->@ZDUQ,0
MQ$U`,?J-U%$FP#N5,OI'TZ]E[D[#<[@\3R@B`<3Y9E<;WAW*&R88HR#,1EQZ
MOO6#F:E'DR]6?/5#**JJ&,.XB(%`P[@`;Z]VAA9;QB*,4:%YG)(Z5^MV973Z
ME5B:(FB)HB:(FB)HB:(FB)HB:(FB+]Y;75+DE$#F-D(E<HC.DLW)4Y2\.!!X
M4IP*HE6XM1-9X)@W`0)(OA20#]8A5`]NL2[DTLT#,^Q9]A%KE[0_"WVJVO%[
M`]0M]*D;C?8!*;3EY4S.N(.7#YNFA'Q0'1>OD_@G345!>R!S)@)A,`%;^'I'
M4=M"Q[-;Q6N2FO+F2.3LXC2@Q\ZX7*S#E%H51K-AI5=;0(FL:L5+G;N7ZY7"
M+R-6<,>Y\<[=%)VEV)P#IZ=^OQW\-4NHF,:',%,56RN)99"R0DX5"L]3<[NJ
M/A.Q4"%640LDY979F<BF82A$5Z3C&9)9RW6`0Z9%PX;F21V\4P4,IZ2EWB9,
M61%@^(E3R6O:7`E=\`'I(R\ROQP_Q`V<,)')ED9%7;2360KE7:+DW*I'.4E&
M%@EP*;T@Z3.=FB;]7O"'I`=36L0([1WF6-?3D$0LS&)Z^`46G)I7`N95@;F,
M+NB6@PH%,82?>D$<W4FF;T=24M`.@*/JW4]VL8U@EPS!]7\BS!2ZM\<G#U_R
MK(5F:#Q?8*JQS!)XV=9.;%AHU;O0TR\C'Z%6<)JOF\B=%LY22>H1YW8][8HJ
MHE,(C]DAML^9L;F]J6ZL/4M7;NF8\P->&&O$<586C99Q>UAK/$4GCC=)NMV1
ML6.ML*D\6M\!)MCI*$!O+1CU*6CQ!9NJ8H]1`$Y!V'<`#:MCN$^WW++W;C+#
M=Q/#F/C<6O8YN(<UP-6N'`@@JS==HM=XLI=KWIMO<[=/&Z.2*9C7QR1N%',>
MQX+7M(S:X$*W-/QEABK6M*V8>X(23+(*#KXN#D;2-C?P%?D.OK0DF,7,JKP\
M>JT5^TD8GPXHB`"0Y!`!#T?>/&KQ1W_:7;'N>ZW<FW/;I>T".,O;D6R21L8]
M[2,'`NH[\55XGW:^F#P%[H=X6]ZMD[O[?#O,<FN-Y=-.V)X-0^&*>62*-[3B
MQS8ZL-"PM("NE(/9G$SFP6BURJ-SY/Y/;_<D%7H422'[ELI,"($,8C?J31<D
M(4A4$B;%'ME(3J3[RH^7XQ5)QG=@!R7O`I<4:P:;1F))XG[5?RHX"C6V`9G#
MMF4W<7F#F4[>_0$JYT)N?;E`'#<X^#@T`=%N"9M]E#M^H/`VLED($/9NS.?6
ML26X+KCM6Y`X=0^]8'IFNYKX>Y9823INZK%IK3]<\!8P:'<U:U1JA5&RJC)R
MH4K*7AIED<2.&IC`LF!Q(<J:A0$,`A\+^16S#HKF.@Q:>'$*:1O-+L#FM/6#
M_$$&6?=QCQC][1MQ?-8M%RZ:*MBOTXQU#/71`1.H"@)?%&WVVZ_7J?YMQ;2F
M/ET+%^0&JH<:=7Z597RXJ\K,\DHF7!%9PSJU/M\HJ]*B<[9)XX8)0;8%7!2B
MBFNJ:6.)2B;J-L(@'@.H[8$RU'`*6]-(*<20NMYUXKL^,L_V6[@T=H5C(,RE
M<ZM8TDSBR2F52MUY6*.Z`HHH2\9,(G5*D<0,=`Z9R@(;[)V.9(3P.*K:R-DA
M#/Q#`A7Y<^:7;/W**R0QE#M\@C'`U4MB\^JM722`)=HTXE6QCDW)EA4_;`V.
M\%$%/`3&)]D9/FCHTT]Y1?(-UUU>YRX^E6WX;X*G+==E.2664WD;C#'[B5R*
M]L,^F9$]TL<;\3-&=LP<E(+V,C7I3/73D`[)UDR(D$QC&`D<+"YW:.^$8J^Y
ME#6=A'B\X4Y!6>JC>6YB\L$%I,51;W^Y+SLVF10QC0N/X0`<*L@.4W4B#*M,
M$F9!`0_;J%$/$VK16:7H)]2D<1;6^&8'K\L5F@4X0<5W`*(I8?AFYURJ))*D
MF;6)FYU2F(FJ7JGA`3(F,!@W`0W#QUGF"(#):SYJ?\WL6#3`4T?%_)S&RSY8
M&ZE:RJVK,MU'*4Q47,LXJ,H50-P\.T\/U!K7QU;*!QK3[%M9AVD#J<6U^U5'
MR#7#(/,3(,<FL1<9G,[2G(`4Y3"*3*6BZB5,H`/B!2LQ#;57U=,1QK3[%;#[
MEL#R;7[5FTYH5XLWQ?S)'HI%4^ZJTWFVI.D![85>8C)7K)^J*3-B?Q]0;ZSI
M\83AC3]*UEL:3M/3[5C2\KN?3;9KNU;[Y-K+CI1=)(%"CW'%?L$4N`@4!\3$
M:R2P_@WUBVI`>:\EFWXK$#R<H@Y5N+21Y&7Z[ND0E62>8YJ;49$<$1&080UM
M.8C(K@2+%1^*9L`3`XD,!0-OL.VVHGN':EW#4LF-I$`;QT_8IXW/S3[#(,7+
M6A8JB*],.P4(A*V6QJ60K)57J`BK6%8Q<.D\73,.Y2JJBF)@^T0P>&IW71TZ
M6BF"Q&V`!J]U1T"BL_@OB;E[DO>SY'R^G88>E2\K]^VJTV5):/L-V$QRG4C*
MTP<IHN2H.TR`B+OM)LVC<-D>HQ2)A9'`^1U7X-4LMQ'`S1'0NIA3(+/8Q8LH
MMBRC(UH@PC8UFUCXYBV(";9DP9($;,VC=,/`B+9ND4A0]0!K9`4%!DM022:G
M-<G551-$31$T1-$31$T1-$31$T1-$31$T10N\R&\&QKY>7.J^D5[*M7XB<AI
M!NJ!ND4W:F++,Q9&*;TE.#MX38?;J"X+1"[5R/I`K]BF@%9FC]8+\5Q(!*DF
M`^D$R`/X0*`#KG5T:W-$31$T1-$31$T1-$57T&A6W)]O@J)185Y8+18WR,?%
MQC%$ZJBBJQP**JHD*8$6R!1ZE%#;%(4!$=07-S#9P.N+AP;$T5)\N*OCC?*\
M1QBKR:!>T'RUO*ZC./\`5DY*X)D<7B=225M5I28%4=D,*(+)URNBN05?@DSC
ML=0G27P$QA'T:\>WN[N.\EP'W&N/:V$Z6?FY$CB?4%V5@R/:8CV6E]\X8N_*
M.(!^WCU+T$8VXV5UD1,C<)#O%3!P#DZP*)G(8=P+V5"&0*?</$-M_3MK)LMJ
MMHVUB;B!C^C#-07%Y+([WSF<O6IA5'&X0":1VZ9RI%Z@(HL7L+=8#U*=H2AT
M&Z@_``ZSRQL3?<%#7RQ4#-;SC3+@KE'*=JB*9";+J?H)*B('/UA]G<X;$V'6
MNDD>XD.SSH5.``*#(K=K,%+2SL#R"+=-DT3,Z=.5CAV6K8H"8RBAS?9*8B9!
M$1#<H>T-5LK:>[D.L`1M%2>`'$E63RLA:*5+C@!S*QX<D<VR&<;BGCK%2+QW
M4:BH=DTD4$C@SE)-$!2>S**1@Z77:W$B)Q`2D+N(>)M>;][.\,N_7XVG9FEU
MA!@#0T<X9NZ>CTKK-GVUNW6IO+UP%S)B<J@'AT+K*E@UM%199%^HLZLZQTUE
MDU^CMF2)^D0RQ0$X."B'CK%L>[\<,0EEJZZY'+^527&Y.>_0R@B5[8.GN$`[
MY6(`DN<I4R]/44AM@`>D?$2COK?163A[S6T:M?)<,`I6I4DJC$1[J)5C;&DC
MT%2$X*B7<X;?H_;\1V#;T^G73V+(Y8##<@4`S6GF>]K]<//^54DZ&%C.^S`>
MTW*)@35`>LQ@\=AW](!X>G6M?V;"6M(TCV+(9K=[QS*CS?+:W9B9BFJ4G7UB
MFH<1$HE#_3M[1UI+ZY'P-RX?>MI;1'-V:@)DFV+FFDTQ6!PF!5/L)GZB!T@&
MW@`@`CKCKZ<]IG5;VVAU-(R41KW:E%7KA5=X5JS0(/<.8W;[9@$0-U&W*!2D
M]'OUH;EQ<[2*U71V-NT-I0')8->=?.&!H:#RGU"0++6!T59#K;+@H"8;"0RB
MJA1^P1,1\->B]P^XMYO-P+Z\;HLVTS&?5S)XK0]Z.\UKMEO\I;'5<D&E#Y4I
M^A>=RTV69MLN[G)QXJ\?/%3J*'4.8Q4^H1$")@81Z2AOKZ;L[.WL8&VULT-B
M:/(E>+7%S+=2F:8U>52:A/3]/UZR5"N(("'UZHKE\T1-$31$T1-$31$T1-$3
M1$T1-$7[RVNJ7)+HI2K5B<7(ZFZW`3+E)($$G,K#1TBNF@!C'!%-9XV64(D!
MSF$"@(%W$1V\=6EK2:D`GJ5[7O:*-)`Z"NT9,F4:U081S-K'L6I.VV9,6Z+1
MHW3ZA-VT&S<B:*).HPCL4H!N(CJH`&`R5I))J<2MB3B8J::_!3,9'2[+ND7^
M#E&+:0:]Y+J!-;X=VDLCW4P./2;;<-QV].A`.!`(50YS35I(/0J?_P`O,?\`
M_P!@M-_]UX/_`.D=6Z&?E;Z`KNUE_,[TE52U:M6+9!DQ;-V3-JD5!JT:()-F
MK9$@;$1;MT"$112('H*4``-7``"@R5A))J<UTLC4*E,.SOY>K5N5?*$334>R
M4%%OG9R)%`B1#N73558Y$B!L4!-L4/`/#5"UI-2`3U*X/>T4:X@=97<,F3*.
M:(L(]FT8L&R8HMV+-LBV9H(B)A%%%JB0B":0B<=R@4"CN/AXZJ``*#)6DDFI
MQ*CE9^,U=<S2UIQS9K!B>R+F.HNK5UE"P[A0XB<QC1:3AF=J50X[F(BJ5$1'
M?M[ZQW6S2=3"6NZ%ELNW!NB5H>SIS]*Z4^%\_2)/@)CDI+?=0AT*#&0ZS>24
M2'P,`N$W3-0#B7UBL;\>K!!+^>@Z`KOF+88MB%>DX*Y6,L$4;&+A25CDGL_:
MW0'!U;;"J5[+G%8-EP9AT@A'E7WV.8@"L</`ZA@\-2QPLBQ&+N94,US)-[IP
M9R&2I_''*3#V5,LY&PE5)I^.0\8NY!I.1<HP38-Y7[GD314RYJ[L';C[Z;1#
MX"D<?824(4Y3]`DZC%]$[P>&O>SNSW7V_OCN<+/\!W)C71O8XN+.T9KC$S=(
M[,O;4MQ<#0BM:`^-]SO'#P\[]=_=X\-=BN9?][=DDD9-%(QK&R]C)V4SK9P>
MXRMB?025:QP#@X-+:D=W2<M8OS@AE.*8-"RL'BB^2>.KFM<H:+)65+)$$`9$
M8U22</&3Z/;=8%%=4B(]1@#I\0'6J[Q=R]Z[M,VT[HV,R[K9,NH&1DOD[)_P
M:VZ06N.)TC5A7%;WN9XF]U^_,F]C8I)6P=W]TDV^ZEF#(HOF(?XG9R=H0Z-N
M`+W]F:D>[0@KD-,,<>U4R3S'%^'%VZAA,G,-:M3W#`YRG`H]#U)JHQ$P*"`"
M`&W`P[>G7,OLI(IC!+"]MR,V%A#Q_1(U>I=U%N5O<6PO(+F.2R.4C96NC/#!
MX<6YX9YX9JYL8G7HQ((F$+7XU%%4Z`14,$4Q3371(4RB`1\?VBE713.`F)T=
M9"F`1``$-5^7F8P/,;Q'2M2UU*'(U(I0TP.1I@J"[MI)#$V:)TP<6EH>TNU#
M$MI6NH`@D4J`02,5HFFE;F8R2B[&WKTM#$3*:9CITD6_BT4A_NSRK61!5HW+
MX_9,L4ON'5!!+(6M$;W%YHT!I.H\FX>]U"JJZZMX@][Y8V"(5>2]H[,<WDD:
M!TNHK8P6"^/2:J4_6\48D7,943MY:)J]9D6_>3-N86[A%!TS!5,P^/1XE'V:
MMEM'VTIBN(G1S#-KVEKA7H<`1T*^WOXKV`7%G.R>V=4!\<C9&&F8#F$M-...
M'%4=FOD9C#&%FKN(;72[_D2?O=5DIQA1\?X\#(0NJO%.CL7OWC!I.D?]Q(=N
M<>WV5$@32$3;```/?=UO#;>^]NS7._VMQMMILUI.R&26\N!;L[1[0YK0YS2T
MU!`Q(-2``5Y%X@>-O=?PY[R6/=*_LM\W+O+N%I)<Q0;99F\E[&-SF.>YC9&/
M`!:XU#7`!I)(X]1@#+7'K(EGNT-CG'JN+\A4)*+9VVO6_%D?BZY,F%D_:QA>
MUV2K.&<D=J4>UW0.803,*?28AAB[V>'&_P#<VSL]TO765UM-\).QGLYFW$3C
M%3M!J8!0MKB::<"*U:0)_#SQL[H^)NX[CL>ULW2P[P;28OF;3<K9UE<1B<$Q
M.[-[G5UTP%0_%ITZ7-)D\XFH5DS^\WDW#,HTJYVWWF[EXYK'@Z2.9-1M\>NY
M3:_$I*%$ID^OK*8!`0`0UQT=G>33?+0PS/N:5T-8]SZ'$'2`74(Q!I0A>F3;
MEMMM;?.W-S;1V6HM[1\L;8]0-"W6YP;J!!!;6H(((JK(9!<<:,='J]BOT#BV
M+<7^XQ5?JTPK2X:6>6.X3ZZKF.%J\C(9^Y56=N4C*&?',""9_M**E$0$=KLG
M=/?N\<MU#LUH^:6RMWSSCW6=E%'36YVLMQ%1[@J\\&E<]WI\0^Z/<JWL+GO-
MN,=M;;I>Q6EH??D$\\]>R8SLFO\`==0UD-(F_B>*A5XZI&((V;:R3ZI8NC[*
M]D`E&$@\A:@TG7TJ9S\2638NUVZ<@\?G>#W`72,90ROV@,)O'6FBL[B=CI8(
M9'QL^)S6.<&_SB`0WST737&Y6=I(RWN[F"*67X&OE8QS^`T-<X%]>&D&O!5E
M-K0C>/<IV9Q#-HA\56.=DL3B/;1CTCE,R2[!R6543:.BN$CB4Z1NKK*(@("`
MZ06\]V_LK6.2:2E=+&N>:<Z-!-.G)+N\L]OC[>_FAMX=5-4LC8VZN6IY:*]%
M:JT$G)<?,/6O'S!>+Q[1[ADN4<UK'ZD)4XYE)S;PS5-PZ;-Y*!B1%A'*-5""
M=PX51:'`0#K$?#6XVKNMOF]6=]N.UVKI;/;8>UN7>ZWLF$EN(<07.J#[C`Y^
M'PT7.=X._P!W5[L;EM6S;_?L@W'>[@P63"'O[>0-#C0L:YK&4<#VLA9'B!KJ
M:+GS.)./CF43;6#'6&_ON44%=%K*5VFMI>257,)A51:K((O7JBZ@B/44IA.8
M=_$=:>.PGGA=<Q02/MV?$]L;G,;SU.`+1TU(713;M9VMPRRN+N&*\DIHC?,Q
MDCZY:&.<'.KPT@U7?P^.<1TM8SB#HN-:JZ;`F8SEE7:O$/&P*J`D@<S@&J+E
M#NK&`A!Z@ZCB`!N/AJR.V>^AAC<ZM::6DUH*FE!C08GD,3@I9KV&*OS,S&::
M5UO:VE305U$4J<!7,X#%7%,)C"(G$PF]`B81$WAX;#OX^&K>K)2+3JJHFB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB+$KY\-B-5_)W\P>2*?H%U@1S7=_'Q"W7&I
M54Y/`IA^VG,&#T;>/I#TZP[VO8U'/["%EV=/F&CRYK\?C6B6^7W1$T1-$31$
MT1-$5V,*81R/R#O\3C7%T`M.V25-UG'Q2CHA@0?]YEIEYTB1E'-2^)C#N8P_
M9(!C"`:P[_<+7;+9UW>.TQ-])/(#B5+!!+<2B&$5D/ECR"]G_EQ<"L3\1JK\
M65H%KR[/MFQ;/D*4B$B.T`4%,RD-545A4-#Q+=4HEW`Y'"X#N?V!Y5>[]/OE
MP2066P^!OVGAJ]BZJ#;V6#*DATU,3PZAQI[5GGQW6C)LFY$$'2R@*[]P032(
M+8YCB<4BD.<>D!$HAN`#TCZQU/;L;&P`M-1SS43R7NU`T]BF36(88]`BPK*I
MJ`"9DB',7I6W#805(8#=(G`/;Z/1J<S]F,Z'EP`4?9ZC5W\JN']Y$<I$:F$P
MN5%@!(HK#V>LNW47]0@[>C?V:QWW#7BA)UDX8X*4-(.&#?6JDA*\,L^,U?(+
M'`2E41,"RG<`0,)!2$I#G(`;C^B/SZEM+,7D_9/!I2N>/4H;B;L8M32,UP<S
M,/B:FXQW&V$*[$2R`(VJ5C034F7:":A1-7V10,!VJ#DH=#E41W$OV`](CJ[O
M"R-M@=GAE[*W>/WKF_&[]0<@<G'S!-L+OF!?3,UR@^X#D/UO-P"L'7:K68!@
ME#5:!9,%&R`D4E%BIG>J(@`@<.[L"J1C>D0+N'CKE[2TM+>+Y6RB:P`?%AJ]
M/!;:>>>1QDG>3CEP6V2#Z'!>E!0X`03&\!^R?VJ&'U[_`(AU3L&ZJC@JF7W<
M3FJUBF#@$>\`@4IQ`W4&W2'0&_0*8_H^_61%')354!JB>1Q!H%VKDRC=DX7*
M!"@8BI5P$?#[)!,42>SJ#5[@\-+A2M#51-J2%%ZQV0SIG(?#'!55-LL<2@80
M.F5$QMP`?1X"'X=M<S-.7!U,2`MW'$&T6/3)&0I!02*+F4(+=8P)G!0!*(@<
M2F*80\`V#TZY6\NWG&N*WEK`T\QTJ)=PO36.,\G9%Z1K'MD5E5W"JA0(4P`(
MCOU;;AMZM]MO3K2!LEQ,&BKG$B@6[AB:R,UP`!)*\Z7/'S%%';J4Q]BF1$[D
M%5$)"70.84FY3=93@!R&Z#K#MX`'HU[+W*\.^W<-RWAG[G,-.9/5R7%]X^]O
M8M-CMCO?&;AD.BO\JP73$K)3C]Q*R[UQ(2#HXJ.'3I0RJIS&$1])A'I+N/H#
MPU[I###;Q"&!H9$W(`4"\SEEDF>9)7%SSQ*ZH0W\-2*-;!R?F'15]BXIT_`?
MP#HJ^M</5%<FB)HB:(FB)HB:(FB)HB:(FB+]Y;75+DDT1-$31$T1-$31$T1-
M$31%]!7L_MNV9440%8$B!N=44@%0$B`(@`G4$O2'O'5-.OW*TKA7E7"OF50_
ML_WE"[3C09FF-!TG(+#G0^(N7FN"VF:HB!=4'F74\WY,SC6F4B+--Y/Q\_,(
MIOL9V11%THT<Q=MA(X3MR*+=!%5Q3,)"+JB'UIO?BIW4E[Z.[GW<[;[PCNMF
MM-NE<S46Q.B82V[BJ`X/@D?1Q#:D-U`$L:OSQ[K_`$_]_H/#%GB3MMJ_:OJ)
ML>\NX;U;L?H#IV3R-$FW7!#BUT=U%&71ASP`Z0L):V:0JQ#CC-R2;8_PL[O&
M.,@R%4FLEYERCFO'%-KE9OT_'WVT3A$:E+6+',_.L(>ZPY86/0%!-9=0C8#J
MB8`.<`/VT?B+X>R;[O$6S;A8,W.';K"SV^[N)9K:)UM#'6=D5W%&Z2WD[1[M
M1:T%]&TJ`2WRV?P7\9(>Z7=RY[R[1NTNR7&\[MN>\;?9VUO?SLOKB4-M99MO
MN)F17D9BCC+&O>1&#+J(<X-?5YN(^8WN(;C4X''N1:]7\[Y_P\,Y29!M0:FG
M4\?51S)OK)D12B4F0<0F/OBSF:$49IKN%S&0*?HV*7?5#Q3[I0]ZK3=+Z_L)
M[[9-BONSN&FYG[:ZF#&Q6HN;AHDNM(UD/+6M&HBM25T'_L%XAW7A_N.P;=M.
M[VNT]Z>]6U=M:2-L;46UA:F1\^X&RLWNAL*N,371-?(\F,&E`VLJ^1?&ISBA
MA@#('$?$(S5GP?E^7M!J7&2;I=_9X>ZP/W?9WLO+S\DX?/U7;F$9%=**+B<2
M*F$`#QV\Q[@>(<?>>??=C\5-U[';=YVID/S#V-#89+>35"UC(F!K0T22%@#:
M5:`5[MXO>#,W<2T[I]ZO`+N^+G>^[._RW'RC)7NDN(;R$,N7RRS/?(\O=!"V
M1Q>3I>X@#%1DROQ$S56X+"SZ3B;EE1M:[-:LH\L$Z#!P%\G)C+,^5%S73O*'
M9)6)B[O3*8V5,P9M#J_#(G!RL!2BX(`^C=U_%7N?N-[O$%O+:;8^UMH;/93<
MR2VT<=E%42Z;F)CWV]Q<$"21X;K<.S94]F2/%._O@!XD[-M7=R[O+?<=[AOK
MVYW/O.+&""_GEW2:CX-5C<211WEK:`]C%&7")I^8DHWMFM,NN"V#;1BY_E^X
MRU<N./H'(;^!""H5GC:-4T=X5%P16V(8XH+F0AJ$\?IK@@HV%P=18"]1@``+
MKROQJ[Z;;WE@VK:;6XM+^]L(Y>TN87W$Y_>$4A-W<M;)<M:1J#]`#:T&-5[_
M`/2_X8[YW(N>\/>'<+/<-JVS=YH.QLKF.SM0>Q:0;D;?8NDAL7.!##'K+G4+
MC@&KK+QQVR1F#FU;,@O++EC#U#I6%:S3Z)D7'4Q#0LC8YE_(A)V.(8NW[&:.
M$<D,FY!T7X=(QE$2;'Z?`<G9>_W=[NIX.6NPQ6^U[MO=YO$T]S:W4<DC8HVM
MT1/<UKH_?.AFCWB`''"N6!WI\'N^'B']2=]WMGO]_P"[O=C;N[EO:65_M\L,
M,EQ,^0231,=)'-^[!EF$@T-)<QOO4P-O<O<%&CJY85KL(WREDV,OV;FE_P"2
MV7[G;0D+4K7J-7U6-7BY&<8%A%XQHL65=H-"L4053.(&ZP$B0DWO=3QKEBVG
M>+^\=MFW7%CLSK;:+&W@TPB6YE#IGLC=V@>X:&.>9':2,*&KJ\GW_P#I;M+C
M?^[FS;<W?-[M-T[R,O\`O#NUY==I=.@LH=%M%)/&(3&TMEF9%V3`]IH=8+8]
M/36W`S#&_(2="V<2+KGOCA%T.$A./%'QXW9VNG8^EW:WWE>23U6L-D9E9SEA
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MA[DQ]ZNZS]S[NL[T;E?76WQ/@NCM5A<_+?*[<]\L@:^`/;)/<!KG1UU:CVI(
M-&V3BYFVPV/,T+DC#^4;WD&X7>6;U>W0U!Q3/T8M'(Y(VJBU5S'<K"C)8KC(
M2+(`(LVC/=NF0A.@!`Q";?;_`!*[G6&W[1>=W]VVVRV*TLV&:"2YO8KGY@@F
M836$$19>OD>?>D?)[Q+C6E''G-Z\$/$O=]Z[Q[=WNV#?-S[U;CN4K;:ZBL-K
MGL?D@0VV^7W>[G$FV1Q1BC(HH3V;`QA:VCF-OO-X6O-7S!(EY`<=LH<RJ7'X
M?QS1<'NXI]$V6#KDE#UQHRN)+:TD)F$81%@F)M(YEIM1$Q^DO=3*;K#M\39]
M[]DW+NI&>XN_[;W1WB3=KNYW%KVOBDE9)*YT'8%L<CGQ1QD!MN'`5.EQ%#J]
M2W'PY[T;%XARCQ6[H[WXA]W(N[^WV.ROB?'<0V\D5NQEW\VU\T+(II9FDNO'
M,+J#M&-=K&CN)WB\[_SBX;N0XIF;XWJ5&N,?;JXG:6>58>@VFR2$DK5XVY62
MS2"#N7JM'?O2RPI-R*MT5%EDVA5#!L;$LO$F+_=/O;'_`+SZN\-U>P.@E,+K
M*2YAA:P3/MX86EK)KAK3!5Q#G!K'2EH.&?N7@=,?$'PZG_W%[/NAMVV7;+JW
M^:;ND5C<W+Y3;Q7=Q</#I;:RD>VZTL#HV.?*V!KR*&R(<?,B6?$M]QI?N(&0
M+OR^O%KF7#WDS:I&%4I$:J]LB:\7<8C)"MA,[C(B"@TP*E&,FNRHAL)1ZNV7
MLCW[V#;N]%CWBV/O786?A396L8;M$+9/F'AL1#X'V@BTO?)(:NFD?[O/#4?-
MV^%'>_>NX>Z=R^]?A_NVY_4!N=_*Z3O%<OA-DPON08[J+<#/JCCA@``MXHJ/
MIB#7LQ*W$W$=U:>165<@\BJI)W%C1X#!E'Q)/V21D$8VX/\`'E28M9[()8]C
M*)&E1-8X<KAN,@0P%4<G.*8G,(AYAWH\5(MM[@;9L7<"ZCM)KV?<;B^BB8PO
M@;=3N=%:ZW,.C]U(6N[(BH8`'!H`/NW<'P"N=Z\7]\[V^+ME-N-MMEILMGM4
M\\DC674EC:,CN+[0R4=K6>$21]L"`97$M+B2,G1C"8QC&$1,81,81](B([B(
M^\1U\X@`"@R7VJ27$N.96G551-$31$T1-$31$T1-$31$T1-$31$T1-$6#7^)
M-DU(KR4N;"B0"(OHK#D2?8QB[)2&?<7IJ&^SZ0`I?0/@._CK$O3_`*.X>686
M79?ZRWS^PK\EG6A6^31$T1-$31$T173PWAC(N>[W%8[QE7W4]/R:A!74(DJ$
M7!1PJ%3<3=@?D3.E%Q#/JW.JIMU#L4@&.(%'#O\`<+7;+5UY>.#86CSD\@.)
M/)306\MS*(807//E4]"]K'E^>7]4N../4(.!BFU@O#EFA)7V^?#`FZGI`ADR
MG39&?&,LWB&AC]MLT2*`F`.X("(B.O%=SO[WO)?.N)-0M&?PV<`,JGF3_(NU
MMK:';(!&VAG=\3O8!R'M6;/'^*4'35`KMBQC71R'2ZS)+JK(.FQU12,[1,JB
M("ZZB"/1TE3\`VWUGVD<+?W<H#7$=.&?M\W4L69SG5<S%JF53(QO&PS,%F96
MRZ22/<,B8!$"IG'I(&P@)RF,41W,&P!K,,XC=0944.@.'G5PQD%%S@N1J*Z9
M`*)ED"$4^QN($\#`<@%/ZC>)0'P';6*^8DA[15O/RP4FC"AP78QD<TD5S.&I
MSM@$>V;<@'(L3T@)P'8X"<Q?'I$1)X#T[:B9$R22K*M/EY&F7)'O+6XXCR\L
M575HM*>.:\D=FY1&TS;4R$?W#&[\<S$#$7>'3V'K,4OV4C"&W6&_B`:W=U>#
M9+)O9D'<)FT'-K>)/L'3U+"A@-_<$OK\LPY#(G]/'H4;Q-(.E1^-%5Z!S'44
MW+U/!!0>L[LP@<QENHYA'T[^O7(!LLKB7U<X^G]*W/[MH&G##R]"Y[6-*@NF
M85^CO"44C["JD<NYND_<#PW.(;"4=MM9+8PT@DTKZ%87UR&2KY!,"I@F<ANL
MI#;=0'`.D/$3%$=P%,WI`!]6LP"@IQ4.)*VG#QJFDAV%`3$I#F.EU%*7J*;T
M@41``V`?'U>.H72-#06GS*\--<,E:BQ7U%%^,.X?(-&[I-9,IS@`F[P$,`!L
M`_9*8/7Z]:J:_':]A(0UI'K67%:G0)!B:^I0`R!>',#&2ZR+\.Z9R_;MR)%`
M2J)=8E^UTB`E`-]P]'IUQ5[>&)CR'<2%T%O"9'M:!BL?F0[(5I75[),N4XN)
MC#*N7[I9?H0V\3"?[8AU&'?T;ZYTNFG(8T5<3@!QKP'2NAM88HW$G*E2>725
MY?.>GF%2EXD);&&)I4S>N(K*MI:;;'\5Q`.A5NT5*.QS&V'J/Z`WV#7N_</N
M`VUC9NV\-K.<6L/J)'V+@>]/>HSEVW;>:0#!SN)YXA8;U%%%3G55.=550PG4
M44,)SG.8=S'.8PB)C&'TB.O9``!08!>>$UQ.:T:(MHQ1#\'MT1:!#?TZ(MI0
MGV#B'ZIOR#HJBE5T^J*]-$31$T1-$31$T1-$31$T1-$7[RVNJ7))HB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HBP%_Q/!SD\E'ECT"8.NP<?4S])A+NF;/F/>H
M#;?I%$0#[(^`ZPK[^">K[0LRQ_UAOG]A7Y0>M&MZFB)HB:(FB*1W%WBSECEQ
MDQIC3%44599-,C^SV:0!1.NTV"!4I%Y>9=%#[2@@(@W:D$7#M0.D@;`8Q=;N
MNZVNT6QN;DXG!K1\3SR`]IR"R;6UENY1%$.L\`.97MUX(^7'2>+U'BZU68Y:
M;=23EL^NUU<I$3E;9*H`4AG9A.!B1L>0Z92M&0&.5$#;AUF$YC>1W\][OUX+
MV^%+<5#&`U#17AP+CQ)&/5@NNM^QVZ`P6V,AIJ<134?L'0/:LSM-Q.G"*HJM
MV;A@T5Z`>%</`=."G*`CWDUT6Y4RD,10VQ1+L41$-9MM;QQLJT.TC.I]=:+&
MEE+W$DC5R4C8:+;QR22;(Q>T"FQU3@<Y550V(4RA3D.8.KP\/#<?1X!JAD`.
M%,^E6T)SR`]2K)JS.NY2(1/[*G482F(FGTD`?M$ZCF(4#%$VW2(;[:D[-LKQ
M3[O,J!VG!RJ&&AG#5955J`IAWM@,3I17./B!B]P"F15!/?T&`0'?4,44C'DQ
MX&OG].2O<]M/?R\ZNG'0#*";?O1*MW"S<BBA6\8V``>R3DB(KD;$:E,"?6!B
MB`B```%W]`>&M]9[:RW:+ZX#G8^ZP?$YU*THM;-<NEK;Q$##%W`"N=5&2PNY
M"Q3KB8D4"F<'77_9+&<)%;MRF,FDR;)^)4#,RB7H(8``1WW].^N3NS-=W3KF
M4?O-1K6N'ZHY4Y+=0]G#"(F'W*</:>=5WD1!B0&SEN91,#]2:ICB!E$U#``E
M4314`/`IMA^R/2(^L=M2QP%H;(W^3I4;GZC0Y*HVL65F<Z2X)[*$!9)=)N42
M'5(8!.8Z6W:4%0?M`/240$1*(!JX,TG2:4.6"NSZ_+!<:7ET&2:B;MP4@)D.
M8AS#ML!1]!>C;P.`[;>(;:MEF9&*..("N8UQ=I&)49+[D5$C5(8]P85U3E,@
MD(B5/<AMC"4VP_I](@("/CMKF;N^:QE(JUKU+:6]KC[X%%"W).17CYP#G^X=
MG`4RJ=W8A!`>DXBF7?;8`\!`=<?>;@Z:2I-*E;F&WT"@%2%#W-&5(2FUI_8)
MJ5;LXIBS4<23M=P4$=@(910=U!+L;[.^P#Z=:\LENI&VT`<Z5YH`,:E;2VC;
M'6:<AD3,R<@.?#T+R.\Z_,9N6<9*5QSCN7=P^-&3I9LLY:K*)+3O;,)#"0Q3
M`(-#;#]KTF]7AKZ`[D^']OM43-QW5HDW$@$-.(9^E>>=XN]$EZ]UGMYT60)J
M1@7]?1T+%%[Q\1'Q$1\1$1\1$1'Q$1'7J:XM-$31%\T1:!(`^CP_)^;1%M*$
M-T'\/Y!O7_-'1`NBU12)HB:(FB)HB:(FB)HB:(FB)HB_>6UU2Y)=<YF(=E(1
MD0]F(AE+S?QGW)$O)-BUE9K[N1*YD?N>-7<)O93[N;F!1Q\.13LIB!C])1WU
M:7`$-.950"02,@NQU<J)HBZ2R6>LTR#?V>Y66NT^LQ1"*2ECMDY%5JOQI%#=
M"9I":FG;&,9E4/X%%14O4/@&K'/:P5<5<UKG&C<UQZG<J=?81O9:'<*G>JV[
M,<C6Q4NRPEL@7*B6W<30F*^^D8Y51/<.HI5!$-_'1CVO&IN7G'M1S7,.EV!5
M1ZO5J:(FB*WLGEC',6AD0XVZ&E'V)E89GD2OUUXA8;55)>S1D=,5.NRU:BE'
M,NSLMQCIEDK$,5$B.)`KU`R)3%5*88W2,;45&H<.*O#'&F&!5H<*<M,9YRLL
MO4*\A*Q%@BCR296DD[KLDB[7AU5DI6-^,K<U,MV4VQ*V65["H@@\0;.5&+AX
M1F\%O:V5KC3R\O:KGQN8*G)2+E)Z!@S1I)R>@X,\S(HP\,2:F(Z)-,2[G?X:
M(B2R#EL,G*N=A[;9#N+'V^R4=2.<UOQ<2K`TNRX+D%DXP\DXAB24<>9:,V\D
M[AB/FAY=K&O%EV[21<QA5A?-X]VX;*II+G3*DHHF<I3"8I@!45T\52AI7@N;
MJY431$T1-$5*2M]H4#,LZW/7ND05CD2MS1U>F[?78B>D"NU#I-#,8:1DFTD[
M*Z53,1(4TC`H<H@7<0$-1ND8UVDUKU%7ACB*C)5:8IB&$IBB4Q1$#%,`@8HA
MX"`@/B`@.KP0149*U:=55%M)+MW`*"W<-W`(K*-EQ;KI+@@Y1$`6;+"D<_9<
MHB(`=,VQR"/B`:H#556[JJHMI=PW:I'<.W#=HW3Z>XX=+I-FZ?6<J9.XNN=-
M)/K4.!0W$-S"`!XB&J$T%2JK>$-O`?`0\!`?5JJHOFB)HBX:DE&HOV<2M(QZ
M,K(MWKN/BEGS5*3D&D:+<))VPCU%2O'C6.,\1!PHF0Q$!63ZQ+UEWMJ`:<2J
MT-*\%S-7*B:(FB)HB^@&_@'B(^``'KT14W5[C4;NRD9*EVFO6V.A[)8Z=+/Z
MU,,)MG&6ZG2SF`MU7D',<NX19V&KSK-9E(,U!*X9NDCI*E*<H@%H<UV1!HJD
M$9A=\DNW7%8J#ANN9LL+9R5!=)8S9R4A%#-G)4CG%NY*FH4PIGZ3@4P#ML(;
MUK546[JJ)HB:(FB)HB:(FB+!1_$MQZDCY*/,T$T2K&8IX1DQZ@*/:(SS_C(3
MKEZA#8R95/2'CX^&L2]'^CN/1]H678_ZRWS^PK\F;6A6^31$T1-$4X."O`?-
M_/7)X4O%\2#"FUY5D[R?E&8.DRJ&/H)=8I3+2$BZ.DV6FWB8&!DR`W6L<.HW
M2D4YRZW<]SAVR`RR>])3!M0*]))P:T<2<NM9%M;/N9-#,!S\LSR'%>WOC9A;
MAUP*QO%XTQNA+WB1CFRKJR+5-@R6=VJQ"V_WNR6:\2+9I][NTNDY4_AT5&S5
M/8J!"D#Q\5W?O1M\ETZYNY'W-U3!D8]Q@/!KG4%!S`-3BN[L-DO.R$<;6PPG
M-S_B=TD#'J!IA@%(9'G@PJ==5-3<#PGW.#EN`+6.XS3]^JIN=/[0QC-FF19<
M@;@1/JW,.XB(B&L*'O@X-$-G8MT$@`.>YQ)Y>Z`/,%F/[N1AY-Q=$.`J2&@`
M#GB2LBO'G([O(-,>9%R+BV&Q;5VS11<9-*U23S[8@`MFA&,@P3^->.`VZ4DC
M;EZMA$==WVD%G9?-;JR.&335P:XD-KDVI^)W``"N?!<MH=<7/86#GR,)HTEH
M!=3,T&31S/M5P*W>\:W232;T^VLRR:JXI)UN>:JP<FZ.4%#=N+6="+1\J9-,
MXE3(KUF#<.G6DMMRVC=7_P#X^8=I6FB1I8ZN.#2?=)SP!KT+-FLKVS;6YC]R
MGQ-.H#I(S`Z2**[*,*LD(I"BJ@LF<15;J]2+DH^(E`=Q,`@<GZ!@'U;>/AK,
M="6>[B'@Y'-8S7M/O?AYJ[<*QC6T2XE)9ZDRBHQ`[]VY63`@$21V`2B4`W.X
M4+L4H!XJ'V#81UT%E!"VU-S<N#8F#42>0^WES/!:NX?))-V,8JYQH!7RP]BC
MU9LB2=OG5'<4JXCF$<J/W.P3Z0.T:*$%,XKF*8047=D$3J[_`,K[(>`!KG;O
M=[B\N>WMR8V,-&`<!]YS=TK;064=M%V<H!+LSS/W#@MR.9.Y$"N5NE954W0H
MBY`B:FQBFW!,$Q(03`382]0?:ZO3XZL>Z2<]HXZG'G@<<\J*]K6,%&Y*I&K)
M!JV,FT3ZB=20&:J"(F!(-P4*V.(CVU$S;?9^UMMX>`ZM:UK64;Z/N^Y7$$FO
MK703<^UCE?L*`=8BH)N!4Z``2=/0``8=ME`3'QV^R?81]FL2XN&L((.-?+%2
M,8YPRQ"BY>,CM3K+QR#TJ:S=RXW4$"F*0%#="B8E.8`.F`[@&X@!=]<]>7S7
M#0#B*XK:6]N6C53WCP4&;[=4TUUXQ)P)E$W"IQ.139,J'2<Q>STCL4Q3*".W
MMUQM_=Z?<;BZOJ6]MH"?>.5/+U*$>;\Q5;$]0?W.]6=O&5^.:+++KOG($74.
M`&$J;8AC;J*J?H^'KUKK2UN[^[9;6C723O/N@"M?T<^"VM8+>%T\Y:R%F;B<
MJ_:<@O(MS>\P6]<FYQ_6ZV\>UW%;1PJBSC4E#HN9U),PE(Z?](@8J"H!U`3T
MFW\?#PU]']S>X=IW?C%Y>@2[J1F<0SH'2.:\O[P=YIMT<;>UK'8#AQ=3B>OD
ML;VO1%RB^Z(FB)HB:(FB+0I_=J?T#?\`-'1%3FJ*1-$31$T1-$31$T1-$31$
MT1-$7[R^NJ7)+QP^9/R1;6;G7G[EU5J9R5N-L\HZS\?*9Q=>XJP)F[(6&INQ
M4VT%RCYE,9?,JT:H3&,Z6O,8@MB5.=!,OVXL_N855>RD8J@Z:5W:2.E`)`/#
M5Y^&&%`<0MM"P-B$1+??K6M/-QQQQR-5E(\P7S`LO<5KYB"VX7ROBR^8=YV8
ME@H+$#7(3-JWA^']KDI2I,8#G#=)JK5]Q+V;B$O#9.CB6Q.<<$3868D0@S>)
M-Y1T1":2XDJ-+L"/,.?4/72F..$$4#'-.L'4TGS]'7G3J-<L;HSCSECE/D'R
M"XTU;FS>,)$X0<5^.=O5R=&8KP)+6+D7F;,D#E6;DLM9EB[=C^<K$9AB"'%Q
M&BE>JB%?*L[=OP&13!!L";M9'$ASJ$#H`K4CE]QSQ&0=G&UH<&:@XGG@``>?
M3T@#GQB#A&[57S*^8O$:R<Q\85"Y5R9\H/#_`#&XY\9KM'-9O#MGY&Y-O]BA
M^0M^A:5<#/:Y=+;0JXPKK&#-*(OE:_"3XNR@0RQG`6:@^5IEQ!:":Y"M>>5,
M/3A0E7Z'11.$=:ZR*\:"GZ:TY="Z]7DC7>/='Y\EX^<"X/RR^4N)LB^64AFV
M&@'6!K?5[U4.2/(Z&I4),!$8B"5Q,E+EQS+V-D[>`U))$!\D<ZG<;H&2OAEH
MQ[F4!!;D.FG,UXXI)$2]C7DN:0XXDURKR'0I^<J^8$W@#E'RHJ=VR=-XWP#B
M?RO67(Y&1JM#KEVNE0RG-Y_R=C%K=JI#S$6Z6M]C-%Q$:VBX2044AG3XB?>2
M`JBQQ&Z?4>][NGHSTD\N:L9;!S3@=0?3S5:.CFH35/E1SRPK>^3^-<N..1$7
M&-O*OY(\R\/O>6SGAK9LSUG*N$I.%@F<JQ0XFUJ-HL-59`MT:K.ZY8TI=5M(
M,2@BN9`SA$;1.[WNS)H!QIS`X8<>E7NMV4:2`"7TPJ,,<ZXY@\E=Q*_<Z8#$
M7!5G:^::]@R1YE=_P#0UK_$<>L-TVO\`%:#=<;LF<B<E.<,P2D98B6B_Y,CJ
M2A`QKBYK3[-C(K'?-V12@5D6X2S=E5QP<<ZY4U5X89=(\V"H8X3*6M:?=&69
M-:`<<:5X4KS5>\(\0SK7DCYP>*;UF+(N4IU#D!P_<M\OW&-Q[$Y)3D8SA]A>
MV4N6?M*%3*=0G<O2Y6/9&1.6&;IOB-"?%)J"=43W1L#IG"M<Z'S-Y4]BLE=2
M%A`IT>=WG4PN.W#*MX#M\G;F$K$D!XZEIDE8I\-88&LR%YL"4BPL&49YM:;K
M>GZETEH.578=ABX912#=4YA06<&*N3)9!I=4FHS\Z@DFUBE*8*!OG/X%KG)^
MZ^5I@6T24E!,,D<U<FQ$=:(58Z$Y2;<SX6<C)FA9`@5B'3,G/8_O$9'33$>H
M`^*8)[^&^L>[`+Q7*GL#RIK1Q;K(ID,\OB;GT*`E&\P/(=5SCYF'+&PT^*DN
M4W$SR>\)4O/.-%BJ%@H7E+@?D/RNK5Q!^@W78+EQ[.S2#2VLS%6;]^J2K90J
MR93]TN,)"UP</B#?L>?1]BRNP#F:#@PNKYB6#CQY]*F+6<K^9[C".R5?+?$<
MHYS$:'#+DSD6YY$Y11?E[QD5C_/5!Q?^_6';7QYB^*=WLLVYI-HD&DFV>UVQ
MM;`T;MDV*X2!Q!R"\KI9&XL<33.I;S`R!/3GCTJ(0PN-'@#'"FO'`G&HZLE4
MZ.5.<>!N)?&?GUF#ENKG&C2Z_$3)?*?$S#`.)<<4:F<><PU1K5\LV*D2,!&R
M60U7>-YK)L)<9!V^F%!4;UEZ"2;9FY.S3N$L[8Q*3[I/W@X4KTY\%:8X'2.A
M:WWJ8=>?/S9<?31>6N>'*Z8J3Z_X8>V68H/+GS(R\+^(J^,JS@^2N56P7A7'
MV14,HYBQG*9IFZ=BVT9!Y"98PY96]67MTDZA6D89DY9M72O0T=4[>5PU$D,+
MJ<,..>`PH<^!%:\:M@BKIP+PVO'HI4`$\1EC4$*>W`B8YI*2&>JMRIJ>:F-`
M@9S'TGQSN_)13C`GGRR0EAKTJ7)=7OC?B;9);&DG'4BVQ*)X:6.QB'[UE*"@
MNDJ=H*QLFW<XEV-8^&1/[)H%CSM8T-TT#SG2M.CXA7^18GN9V,(W+GFO<QJ6
MOY:U6\Q:;G?+?XEP59:7.7X_UBNX4F)W(?*"/;6B4N>9YR,M-.93;DZ0JR%.
M:R$RW+&]8)`<K<1PY6ETI#0">H'\3^9]@)P65`YK(`YSBT:CE7DWD,?/08YJ
M1G'?'_/R(S1C+R]E>=+B@1O%ORV^#UORC>H/#V/\P7;).8)[(^=J!;U8>[Y?
M82+AE4I6*QFS8/'#]@]DWC5H@LU/&N#NCKWETL=&-)]UM3U^]7GG3ETX%1_Z
M.ZLCA\4A`Z![O2.=<#T9+J8?E/RO4PC0_,9<Y]F'-5NW/J+XX.^#9Z!BXF*X
M[#%AYL/>%[2H1=G1J2>;O^(VO()$MKJ85L:C)9^DNQ&*(RZ>AVLF8=[VJG"M
M*TK2GGSIT*[LV:BW1[H;6N-*TU4K7+ASXU5F\3W/.O"[BSYPO,B`SOD;+`X0
MYL>8":"P1;:5@YKC&:R&ZR#3H>$R?;)NNX]J&0TS0#J73?/6*5EC815BU4ZD
MVY1,N6&.4L:YS<">%1TD<*X4IF,^"GDB:Y[8W4+0*5QX4'.E37D<A6M:*ZZ_
M(OS*^*E3Y`YSR-COD]D_"6->%/(;,UBDN7S7@C"I1G(C%M?B+1C%'$3?A;>Y
M&R'Q3D%J:83FXB5;R0Q+5DU7;2HF.MW,@2/;5S"2`TDUTG$=#3ZSD>.8..8H
MR6M<`"7`"FH8'^<.HX9\EU/F28(Y,POE=9[N.0_,`RIF-&[X[X[6">B76(^-
MT%46UQ?<@L(R[R:Q&^J^,8V7@<:K-))1%.)D7$ZX[1&BWWD!RN/BHY:F($N!
M->8P...7(4QJ<<^=T)9V]`S3Z<13(X]-<,^6.$P;PRY0N.5^&>`K+FQFF!2E
MN/\`G3E9?N2:.-.-*.><@A6<L8VQ=2L/U!A_DJ&&:Y5:@M>EI>:=H51>7>MP
M8MQ<(D564/5LKCI;JHRG,4R!&.FG&F1RPXJAC;0OT5>74I1U<R"::J\.>9-:
MX*)]+Y6<W.0<GP)PM4^1==Q!;\E9+\T?!^=<Y5["%"NZ>46O!>YI8\J.6,=T
MJUG7JE.L]P&+-(;%%[!-'[MT4S!V@FV12H9YBYL8.?\`E$9^:OJHKA;PM:Z1
MPPS`Y>Z#CZ:<%GJI,-/5RFU2OVJXO\B6>#KL/$V*_P`K#P=>E+O-Q[!!K)VR
M2@:RT85N%?S[M(SI9K'H(LD%%!(BF1,"E#9MU!HU8NHM<ZE3IP;58^N3E\R7
M!<\.*%*Q=$XYDK7:.&OF-VBJ&O5:KZI_\Q*,GQB#'T:ID)6-4NU+H\I.6+IG
MVL4_:-I-`B1W9%C-&PI8MR]S7-#:5IRZ6^?T>U9$#8W,<9*AM1['?;3-62\O
M#.6;YK,8X>Y8Y1YHU[DH]P"ID*X\;^56!^.--QM(SL%9:;!9$R=Q3R_QVK98
M2U8UIEFL*<2,2[GY5X5A,,'3A--8#*'LMI2^0M)KAS&>'(?:2I+F$1LU!H%7
M=.6-*U-?4`IAVK,&0XWS)>.?'EC,D3Q1D+AKRARW9JU]UQ:B\ID#&F9.,]4J
M4PC,J,SSC4L17<C2R1VJ#@C9;XH%%DSG32,21\Q9*6D@-H<_Z/WE0LCUQ$M!
M+]0&'4?N6-)QR.Y^92P/1[Y25L_6VAQG-OS%,6\B+/PVH7':R\K*UC#"?(+)
MF,^-<=CBB9I8?N)-4^/3KJ3.TO&$;(VE9-NU,D50SATJ./)/)F3^[J>0XN''
M#(#@3RXK*9!$7:0/WFEIIB1B`2<//QISI@J;DN;'(+,TYQ(P/QCR)R\S;6[K
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MVV18<M,CMGM@EXRKQ\/78Z2F%DC+.$8]JU:)JG,"*29`*0)+6OO8X\_Z3E%<
MTJV@H-(_LA02QK.YKXJ5CSVN9,#GC).0F''3ECRWOK/CO/4O#*.,;U;HCB=@
M2S5.=N-B@<:1N563>I?><>W.A%SC!LXBX5,ZZ:CA5TLMCLD<QCG--!4X8'\(
M/*M*"E:K(>UKW1QD#$`5Q_,1SI[5-[%=JY)8#Y;\4\&Y3Y16/EO5.8''C.F1
MYUW;\?XDISS%F2<%L<1V-2W8K6Q+3Z=V<'WUCDY>+)$S8S3I@[08*(R2AE7!
M5)&2O;*!74#G0C.H'(>O'+%1/C:Z-S@W06G#/$$$\2>7#/DJJ\P3EY:>$%RX
MT9JG9@@\:)P.1^-\R5(\9%J*RV3$<$V',?'!U'3IV1YR-E9RTXAEJHU:-W";
M>0>V9L11-14B`EEN99(R-)HWRZ.0])"LMXF2AS377P]GHJ<>@*'_`!)YA<U;
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M'#+&7:WC_F9D?#$%9XW)`8.@:_@?("T?'V63&..U8,WQ&;TB*ZXN$4W6K1</
M(<UIPYGK:.'#$Y*0VT?NO(S&0K3)Q&>/`+)G@6TYRQ=SNS)P]R7GFX\F:83B
MUC/E%5;OD:I8OK-^QI8[%ER_XFLV/)!?$5*Q_6I.D6U.KHS->3=QOWBQ%J^1
M^)<H@022P3.,H;6K2!RY$\`..'IKPICS1-$>L#2X.(ICCEP)-#SQ62'6P6&L
M/?\`$`0`V3R:N?S`J8*&9X?AK"4!*!ND*OD^@V%10`,8H`*:,:8V_I#;P`?1
MK#O21`0./W$_8LNR_P!8:>7\GVK\A/6B6^31$T13R\NO@U8^>V?T,8M9\E+Q
M[48<E]S'>C-U'3NNX^92\?&O&U;9%3,E*76Q.WY&<4U4,FF9<XJG-VT3ZP-S
MW&#:[-]Y<'W6C+B3P`'%36\$ES.V",5<[T"G/D%[;0I-(Q+B6+P9AZB%PIA6
MF$;EC:C"1;95V_!@<6,C;\BR"/PC^Y6UR*`KR4H[55,JY4$I``"@`?/'>7>M
MPWG5\R9(X-5=.8`!H2X"GP\3E7`957INRV%M8/;V08^6E*GB3D&G'/@,Z9JP
MTE+OC2[Z$CW9I9!=)RB,@CUD-*`V,1F@*:ZP)N"H'1,40(80#I``UQL>N340
M_4T/`KSPIGG3H73N:QK6$LTR4)H<FXURR\ZN=QNF>-R&=J7AW-N1)%C99^N3
MN0,?T2)KTN_5R$>D$.\L4.A+-FKEA&N(1OUG[;DZ(KC]I,3]LQ1[SNQ96L(N
M-XN@]_R89I:UNH:GU`=_1`PKQ(/!<UODT[VQ6,(##<%P<7&AHT@TZ=7&G`'F
MLDUKNV0\Z3Q:G5H9>I4>!*#&!BCQ[E*"8&,`IE*HJF9M][3"R?2)S$,80,.P
M@7T#J]RGW+O%>F`A[6`G2VAT@GF>+CA4Y\*#)+6.TVJW[3W2XYGB:<AP:.`R
MZ2I(5#CH6DQY7$I)/',@Y,V<O):9:D[1CH-@00*@W*L+:/20((E13()1#<3'
M$3B(CU%KW+DM8@;B4C$'$8`@4RK04QIZ2:U6FGWYDSOW3!Q&!QYYTQZ?5@I/
MX\G':"",19)-&>:)%4^$D#B@:0@DDP'9-^H<V[N-$H@)=S',D;T#MKJ;!KXF
M-AOI!,P9.PU,Z''BWK)HM/=%LKC);-,;N(QH>KD53V4[X6S.$J]7%#C7HTZ@
M@("*/WM(@;?[PZ`3%06R.XD2W`0#<3[>C6!O6Y?-O%I:U^48>K4[\W4.'I63
MM]GV#3--3MG>H<OO]"ZVLPB:[4H+G`''0<`42Z%DT55")'!LZZ2]8_$>``;Q
MZ3CN&P[ZP8(VN90FA]G0>M3RNJ2:>[Y8^95>V;+,DB%V*F8I#%.03]*B`@!5
M4'*?6(F4(.PD$@ATE-MMZ]3M:YO73R/4HR0<%3\E8$TDC#U=H[94%%')DP!)
M8C@Q@(HCN<#*`F4Q0.'B)#>O;T033MIAF,^7ES4D;"<!Q]*C-D*YMW$:]6;.
M2',603*4$@`J@"!3&-T]77N":91`=@$``-]@'7-7MTQT+BTXZEMK>W+'@.Y*
M#%HN[527E/BW`B*R2H)JMU@$B*SP"E2ZU``5`*<"?AZ_'7*R70)<79X\5NFQ
M'2`P>06//DKR(Q[QWI4WD+(E@%&*C`4:P[`%R!*3D@("=-DP0$"JN3G.'3OL
M(]/B.M?8;9N&^;C'MUBPOG?Z`.+G'@T<ULWW%K86;KR[=HB&?,G@UHXD\O2O
M'IS!YK9*Y:6Y5Y-N7$)1(]<X5NFMUS?"MT"G,*3J1Z!`KIZ<H[CON4GJW'QU
M],]TNYMAW7MZBDNY/'OR$?LMY-'K7E&^]X+G>9=/P63?A8/:[F3S4,==DN?3
M1$T1-$31$T1-$6A3^[4_H&_YHZ(J<U12)HB:(FB)HB:(FB)HB:(FB)HB_>9(
M<R9RG(.QB&*<H[`.QBB`@.P@(#L(>O74D`BAR*Y)6CQU@C$&)J':,88\H4-7
M*%=[)DFX7.M$4D95G:[1F&:E;#DZ;L+B<?2DA+O;I+S;I5X*ZQR]*O:3`B1"
M)EB$,8!%*U/VU]JE,LA(=4U&7HI[%:VD<'.)..X.?K55P334H"T8%JW%J=B9
MY6?NC1[QQI;&:C:WA0I+K-6$S+'C!K87G<CVXI)NU5NZY[RI$SDM^7CI0XX`
M=5.2J9Y3QIC7SX?<J2R)Y<W#'+,3CR#OF%_OACC'&3'"-8.RR3EZN2LAA:/%
M$6>'L@3]9O\`#S^6L7I'1`PP5J<S,>8QU!%(165ZQMXR,:Y4S\O1ET()Y6FH
M.9KEQ\N.:K_//#/B[R8J%(HF;,*U2U0.+5D%L5GBSS5`LN)UFD<VAD?\K;KC
MF5J5TQRF6(9(M#)0[]FBHV132.0Q$R%+<Z"-X`(P'+R]F*HR:1A):<3GY?>J
M&HOEU<)L<8LR_ABL<?*JI0.03)G'YS;6J:NM_M.6VT6DNC!C?<C7VSV7(U@<
MUH')SQ*RLKWHE8W=9F04`#A06\8:6TP/G]?WU53/*7!U<1YO5DM5-\N_AA1F
MF2VD7@R)G3YHQ@KA?,$KD>W9'RY8\HXN5>O7Y:=?+1E2Y7&PV2.:N)!7X91P
MY,Y:)B5-!1-,A"EI\M%B34U\OMXU5?F)L,:4/##V+10/+LX;8U<6U_5\,BZG
M+]A^U<?KK:;ID?+F3+I:L*74T>-@QE,7/(]^M=H=55<L6@1J@#LHQQ"B5H9`
M%%.M\O'CGB*8^5>"H9Y2`*Y&O+%7;R7QAP/E[#L#@+(>.V,WBFI)T<*;7FTQ
M9J[)T=[C))HACV<H]TK,W#7JG6FFI,4RL):-DFTDB4#!WQ!10#W&&,M#:8#^
M7RIYE:)9&N+P?>*VL"\6\!\86UV;8+QVUHALESL5:<B2'[P6^U3MZM,+!-JT
MQL]LL5WL-EGIRQFAFB:3AZNY.Y=F+W%SJ*B)QK'"R,EPS/E]G'%'RODH''`*
M_P!L.PCL.P;;CMX!OZ-Q]6^VI%&K=73$6.<DV;%%NNM18V2T8/NSW(V)99TO
M)).:5=Y*I3]$?6&,28/6K9V[<5&T2#$2.TW"`)N3&`@*`0Y8WQL<=3^'Z1]I
M5[7N:"!D13[50\9Q:X[0^5LVYO88?IB>4N25.KV/L]VEPQ</_P#-FF5:*6@H
M2OW2!D'3JKRC-O".#,UC?`E5>-=DG)U2%*`6]A%J+J8GR^U7=K)H#*^ZW)6;
MQUY;7"W%:\NXI.&7;9K)XZN&($8:>RKFN\56IXLR''EB+EC['=3N^1K%6,7U
M>PQ216JC:O-(P"-DR))"FF0I0M^6BP::Y<_LZ.B@Z%?\S+G7&O+S>?SJ3CG$
MF-'N(U<"/:;#O<-N,:_Y.N,>/2.'<`YQA^ZP4D:8X*X<*/5XHU5*#(1.L*XI
M^(J=?V]2]DSL^S_"HM;M?:5]^M5;B:XB\9[%QWKG$V:PS4'_`!UIT#4:Y3\7
M&))H15184%1JO1WE5F&LDA:J[9:D\9).8^99OT9AL[)WR.@6,8XVF",L#*8#
MT^7Z.05W;2!_:5]XKF8%XNX0XSM[>EAVK34.]R!(Q,K>;%;<C9.RQ<[8]@&3
MB-@!G+MEJXWBV.VL&P>+(LVWQA6S8BI^A,!.81JR)C"7-K4\\?TJCY'R4#N'
MF]BKN-Q%CB(RM<,ZQE28M,LWVD4O&EQO*:\D:2G:-CV4LLW2JVZ;*O5(A%I`
M2EODUDCHMTESF=F!10Y2D`E1&P/U_B_E^\JFMQ9H_"#7R]"Y#'&%`C<H63-+
M&L,6V4[?1:EC.RW0BS\9.7H=$G+39:C6G"!W9HQ-E!3MVE7*1TT"+F.].!U#
ME`A25T-UZ_Q?R_>534=.C\-:^7H4?VO`GB&RSC_Q&-<*Q"652WMYE9%W^\U\
M/16N79&/4BI#,3'#BEJ/AQAE]\Q64*K:$8$DX<ZAU1<]XYE!C^7CU:C7.O1Z
M/MSZ5)V\FC17"E.FG7GYLEW33A9QB993RCF-OBU`MPS=&V*,S#%JVV^N<79,
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M7)"!SP.5`S8Q@[3%M46C^*"?&+<MD$DSMQ*DF!;C!&:9X=)\O+DJ">0$D4QZ
M![**\=3XQ\?J%_D6%(Q-4JDEQFK5PI^!6M?;NXQCC*MY!BXV'N\;!,&SPC)Q
M^]+")0!ZN]3=.5EBF7%3OJ*J'"WB!!`Q"H9I#6I/O9J^FIU$K4WK!6(\HV:'
MMV0*##6ZRP>/LHXHB9&5&04,VQUFQK7F.5J@+-N]08.HN\-*I').^ZDHL4K4
MH)'3W/U121,DQ?P'W'[`I&2/C^`T\C]Y5K<!\)^,O&.>D;5AK'4A"VJ1JS6A
MA:+=DC*N6K)#4!C()RK7'U3G,O7B]2=+HB<H@DY-#Q*K)@JN@DHHD<R*0DHR
M%D9U-K6E,_+[NA5?*^04=2E:Y4]BJ#/7%#`/)IQ1I#,]&=6&;QHZGG%$M-=O
M&0\97.M(6QFTCK?"L+KBVV4NUFJ]P8,&Z4M$JO%(R1*W2^(04%),2U?$R0@N
MK4=/EY9JC)'QU#<CYU:F0\N#A8[H./L8QF%AHU-Q/8LCVK&C+%&3,PX?EJ3,
M9?FAL.4/N&U8OR#4K6VBKS,[+OXXST\><Q"`5`@)D`M@MHQ3/#S>RGJ\ZN[>
M6I-:DTS`.66:[^W<!>(%TQ[B/%\AA.'@JI@-*20PDOCNS7S%-TQ6E.IBG9DZ
M7DW&=JJ>28@EP$PJ3@!+&";<#WG_`,0M^TU7Y>.@'+S>S[*()Y`2ZN)\X]!P
M7`F?+UX>3N-<9XG=8@58U+#=BM-LQB^KN2LNU3(=0L=\5?+9!EF.8JS?HG+K
MIQD5227_`'A!U.+IS?7_`+X5;H)TT^7CH!C4<>/'CY_OJJ]O)4FN?H]&7!7S
MPC@;#W&VA)8MP30(3&6/$+#:+6WJ5>/)'BT+#=9IS8K3)H_>K^1=$5F9MXJX
M4*"G;*<X]!2AX:DCB;&*-\O*JC?(Z0ZGFI5`_P#!SQN#-ESY"DQMVLGY)BW<
M3DM9"XW]O0<EHOZ:&.WC_(V&D;43#EZL#BAD+#GDY2!=2(QZ::0K;)DZ;3!&
M233/T>CR]"N[:0,#*X#T^G-=7Q^X/<5^+=@E+5@S%"-1LDG5F=!1FY2YY$R!
M(5K'4=(!+,,94!?)-NMYL;8R9RA".$Z]`?=L0"J*1A;CV4>@R%D9JVM:4\ON
MRZ$?-)(*..%:^7WG%7<R]A/$V?:O%TK,U#@LBU2%N])R1%P5A3=*,65YQQ/M
M;12;$F5FZ:*F=P,ZS36(0YC(+`!DEDU$3G3-<^-DE-7#^7[%:Q[F&K33!:66
M$<2QV6\@YX8T*":YARM1JOC3(N042.RSMMHE+7F7-7KDF/Q0L@:1"T^ZZ5$D
M4G"A3D*JH<J*`)VM@B:[4`/*OWJIE>YH82:`^7L5`67AYQLM7'VF\6)O%,8.
M",=,*,SQQ28V;MT`[Q[_`):J-UL>2U#NT%8([(-1LE-4;$-'RS"50DT/M`"X
M@<X&=C&6!G`>G"GW#)5$L@>9`?>.?G42L]>5?@&X\;LL8%P54*[BE?.N6>+V
M1,R6:<L&2+5*Y,:<>\RX^OKX;A:I>S3UVEKA/TJIO(E*7,\!\9R[3677$4P4
M)$^V;I.FNHD>BH)]G&I4K+EX>"\^Z`</,0/:IE8+XMX%XTC=U<+T9S7I/)$M
M'2]\MEEN=]R=D*Y+P31:.K3:SY'RE:;I>I>)JT:X4;Q;!61,QC4E5`;))]U0
M3RQ1"/'$N(%5#)*Z3/(9#DK^ZF4:@'YK=.4O_EC>8)44$A6<2O#_`#TNU3*&
MYC.X3'\S86HE`-]S%<1)1#WAK'N6ZH3T`GU$?:I[=VF=I_6'M7XQ"9NI,AOU
MB%-\Y0'7/+HEKT1?!$``1$=@`-Q$?4`>D=$7M<\H;"##CUPWH;I%".B,J\B7
M[?-M^L#A5J=V-,2;*%Q+4S.4D%3M(R)C2_>!D%-S_>,LKN``4-O$^_N^ON]R
M&UVK@UENZKB3@2/N.'.J[KN[MHCM77TS23(*-'+^48]2D5>)V8G)%RL[D%EW
M@=H5^ZH<_;;*/5F_21$`,F1$JR@@)>D`W$1]^O(IIIKG]Z]Q<22,?4!T9^=>
MA6T4%N-``;A4=?$])R7=8MP]:<B6)F[;NG457F+QTE+2PMQ6%<%69#*,(U$5
M$T'$DT4`%5>I0C=LF(&5,&Y2FW6T;:^Y8XOJVU=AJICJ&/NC"IH<<:-&)*Q=
MSW"*V<-/O3C\/`C+WCC094XFE`,U7EWH6(@ME#D,75)B[R/C`UF-5<RRZAY:
MPP\[.Q_P,HC%."FCDWT4\%%,7*(=EJL5/H2*4!%8VWEW-MD#:[+K9&"PR$O)
M[4--0"0`"!S:!@2!AB=9':.NOW^ZEKGD'0P#X*C/,D=1)-:$\EVT)GGS"4)-
MFC*\D:C5V:"1TB-*CC-JO'.3)*$!0SF,M`R2;!43?:`A7"Y$_$I3&](["'O'
MO!E>^UN'L&)$5(Z"N(`!::TR'$K'=LNU/C#)(@ZAIK)=4BE*UU#/CPZ%-6G\
MW.05:C/@,BDKV3F`.5&\L68KC6NOG30QB@B>.&`55:H`8I1.4>V;<!W$-PV#
M.C[Y[F&AMVV*:!V#@YM#Z1DL9_=:Q>:VSGQR<*&H/F/KQ\ZFIB_+^*,K-6[6
MMO'F-[\N)P2K5IE47$/,G\0%"(F1,<I5OM;%15'[8!Z"ZV-M<[=N0_T%SK>\
M/X)#5CN@.X'H.?0M3<V-Y9'_`$AHD@'XFC$=)'VJ\H4-XFX5+*+(HN3J&%,B
MAD_B2G,&PJ=)"]E5L/1N4Z8B8OIV,`ZNELI8G:9:`GT]?*G5ZU`RX:15@PZ,
MOY?+!5&S9.(M$#@NB4P%*V54450.F[7,80*142I]H@"`@8##T>/CMU`(:`.C
M%213+@:GRZO2A<UQID<^/E[?0J&N-O3;]1#!VC-5#'4*<1$[=OW#D636Z#E$
MZ:#D1`Y1'Q(;?;UZP;N[`J,B/4*XCS'-3P0EV)QJHOV/)[)TE(@9R44$I%5)
M($UR`J4ZA`(8R>YB&!ND`@80$-S&-X:Y^:_UAV/NU\O,MM%;:"",Z*+\W>"-
MPG`F$UG2C=-ZN@@LN=%N#L4!30ZE6I0.D"@+CX?B\-<V^\`+Q)C@>HGS9+9-
M@)TEAP)'!8H>6'+_`!SQFHDA?KPN!5G(.&-0K;!0B<S9Y=$1.5%`BQC.3MR&
M#[:Q@Z4R>O4>Q[+?]X[YMC8-':'%SC72QOYG'V#BLZ\N;;9[0W5V3V=<!Q<>
M3>GGR7CJY/\`*G*'*N^.KA?Y-5.-077"LU)JNJ,+7&)SCT)-T1-TK/#$V[JY
M@ZSCZ-@\-?3/=KNOMW=FS["T&JY<!VDI'O//V-'!HP\Z\IWC>KO>9M<YTP-/
MN,'PM'VGF3BHTZZ1:=-$31$T1-$31$T1-$6A3^[4_H&_YHZ(J<U12)HB:(FB
M)HB:(FB)HB:(FB)HB_>7UU2Y)8'>4/FDY8X_YJR$:G2N(LZ8:Q3R$Q)A?(U!
MQSQAY93,[C]AD.[8ZQ]8V^1>:;"8=<7:5E^F2M]!\>NK1BR0)D0CW*S=ZX*8
M,!UP\$T(H'`9'HXY>G%9K+=CFBN#BTG,=/X:5.68J%6^>><G-6I_^)QD3%57
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M<3&6<*G,)CG'<3&$1'6=$?W+3^J/8L2;^,^GYC[5`#C]Y@?,:VXQX%<ILT5'
MC"VX]\U\QT7`KO'V+H[*R&7L9SN6Y.XUK%V2/WVMELD:E98M];JNW:3-=)"H
M*1K60^(0E78MSE4P/FY6M#CB,>7``_:.'G*S/E(W.,;2=0ICYSPIT<_T;$-Y
MC?,1GQNSYS9N^(.,J7'7#EVY/8FJ5%K-MRFKG7+&1<9<F;-QHPT]=OY!@?'>
M,JC9;HP8MIXBAIQZ1`ZT@W%`HIL"7FXF%7'X*D<,P33D>'2,CS"M%O"2&5/:
M$`\L"`>D&E>CB.174<QN3?.;#^&^9_'G+\[Q\CLX3'EG<HN6.`LX\=XG+]%A
MZFO@]E#UC,E'DX2R7VQ6YO=ZBGD"+?TVVL)9BDZ=F%1U&MQ:]M>AFG<QP&>B
MM<N%<,<\1]P.9D4.MKA6@D`(SS.'+D>?7R[[(G./E)Q<PYP]HN69G!5HSMRL
M0<+T?(U*P+RNRA2\<XDQIAFGW2\7')&(\;3F2,SY9R8\E["R9($C'D##J*2/
MQ3UTV(V.5Q1L\S&AIJ7$\JX5QR.0->FE*%5[&*1[B,&@#C3&G2./G%:X46_C
MWS(N2N2:ACS%L#BNCL.3>7.7URXPXRRGD+$O(S#'':WX\H6!U^2-JY-,,.Y9
M:U/.QX^(H[)S`?NI]Y@5Q;FQR)S/P`"L$@GF<T`#WRZ@PITY'APS\_%6&"(/
M))_=AM30UXTS'IRRX+K<TV7S/HCFSY?V-VV6.(L1:K=CKGPYFF\53^1(80R0
MQHK+`[RKVJ[XT1RQ'S+.Q1$-8A3CV(RTJ2(D#/ET7BZ3PB*%DSKD/:*D$URI
MS%./5Q.''-71"W+'FF``SZCT>CS*<WF1Y*?X:\OGE+E)>*)8I6B8:<3CJ(B[
M7?,>HRL@C(P3=XC'V['UDK61*NU4<.#F27C95J^33`"BL.Y^K(N'%D53B:GF
M.!Y%06[=<H`P\P/$<U&;./+_`)L(90\Q.O8!@N*L;1?+]H.-<CKN,OP^6[#<
MLPGL_'E?.\[C]`M-N%6@*(55O'+M6EB-]YBV.HF4\2OT'6/`^YE#WAN3:\N8
M'1S'/J4T5O$YC'/)J[]/0:Y='6N5)<HLBV#ECP?MX05,#$'(C@9R-Y#XNB6\
M[EF,R#2YVOXSX^WZQ062X^.O+;#.2HF7"_LD(MRO7/O6#!FY,U<I"]6$[MI"
MYKR/=.7]8#@?;[%5L#-+V`G4W/+\I/+#$<U76.^=E^N6'O)^R0^I5,:2?F/3
MN/HK)<>T-._`4!&X<1,J<BWBM`%>45<BJULE!;L$OO([T/@%U>H#+="A;W7#
MVQ->,R*_LD_8K&6[73.BJ:-=3]H-^U1?@/,PY=1'#_)_/_*V(N-3/CS3'V9,
M>T;'M$GLS36<\C91KW*:5XQXADI0R<%+5BE4BQ69LB69CV+:RSH)=3IEU**I
MQI+>VG#3)_F\1PSK3H/HJ.O$*_L(-8B!/:?9IKU>SB,,UUM?\V7+^-8OD;/Y
MNQ_'YHIV(^*UMY#P60,3<6.8O$JLLLD56W52DM.-UM-RU@7368D;U+7I@O!V
M.,>$4^#8R)GD2B**0G-N9!4O&`;Q%,>7&I^XFG.CK:.K0QPJ74S!PYX4Y>L8
M\KF47_B\8^:]Q:9\K+-@"3E97R].94Q%P7'JL9-JT#6I`N;>'@3E?L*^0[U<
MOWY5KZ[HB$=.((0QW28N#*,$.LA=(W2.F!?^7[6])X4Y=2H\1"W/9_G'L=T#
M[>M2LY<<@N0&.\Y<../7'F*PQ^\W*F7Y!QLO=,V,KU,0./HO"^+6.0TYV+KE
M#G*[(6J0<*.#HC&K/6*3H.D/C&O2)S23S2,E;&SC3UDCC]XZU9#"Q\;I'DT"
MA%=O-1RWC''08XOE1QHVY;,N<V1>#DW:ZGCO/N3<%-C8WPU&\CY+/L7AS%;2
M[9]GHV0PU8XH$ZBT>J*MK`[43<S",<V5>!'\U(65`QK^G+JIQ\_%2?+,+\#[
MFFO+C3,TXUX>;@NKC?-!Y5+8W;M(?"./[WEASSTXZ\1J/?KEC+D]Q-P7F^E<
M@ZG(V)OD*OU;-E8D,N8^G<?2T<YB9Q$J5H8`X9"HU,N#I--&QUU,,Q05/"F&
M'7SZ2KVVD;O>U<,J@FN/&M.'1FJIRSRTY&\;+UR3G\RU7"EHSO@3RB<N<LEE
M\56?/#3!T])T/.6124VGH8ZNER^"02=0\"T&5F_@TK$HN=9NB^*P!%N09I&.
MHZO:`&N/($C`'3E3@J-@C>WW#^[U`9"N)`S(KQ*JZW\GN5M4D(C$_)V.X]/*
MYS"X6\J,DXDD^/T=DV(G<27K$&(8&Y6"@7:1R!9)E#),-.4N^_%1]@8LJVJA
M(1JB"K#H724*?/(0&/XT_M`</T998U2.")Q)CK[N=?YI/13U]!5L>!/(CE;B
MK%_D_4#."7'^P80Y>\::9C^ECCV.R<3+V+Y_&?#A'.%9LU\NEKL;JL9+;W:F
MT.02EVS*!@SQ,HNB#=P_2*=4]\4LS=#"*U;T<JC'S'@.FJMFCB=VCVDZFN^V
MGV\SYE2.`?-YS5G:[<=;Q6<;1EDP?R/S35\?LL.UGBGS:;9<QAB/(-E>5>H9
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M\;;3DM@U;2,GCSCY-Y`8LI#O&92$C3<6N;,T:/\`L+(.3-'CN,*1;H434$AC
M=)BFV,&6YYCA+QG7_E46$QFN72>*QQ8'YJ\MW=N\OF:Y(0/&A+%/F&XCL]PK
ML)A6+RHVN^#+76>."?)AH6PVN\6B3ALG5ZR4V.DFKA)M"P;B)D`;D36?I=Q8
MV.RYEJT.R/.@Y\17D>`\ZR)((@QQ83J::>P='/F>*CYQR\W3-N?+UQEN4)C2
M,L>$N4&5ZO3&V(:IQ4YM1V5\-8KR,]?Q]$SC:>4UGIR/&&^,X@H1[^TL(]FP
MBV3!\J,=+OQ9@=U9\U-IU`$C$Y8988\O*IXR&TB'NEP#AQJ#UX9^OB,,Z5]5
M^=7F,73BUF?FE7\(\2WN(<.2')L&6,8J;S1/9VRI`<8^1%PH%IEH9%)2,I%.
MDY7%^.YM1C&'<3*[F<2;+]:;=<6"5YFN*&3_`#8KRX&G7T<59V,&H1ZCK-/6
M`>KV85Z%<K/GFIQN-0Y'9+Q=4(/+G'?C=Q*P-E^5MK%Q8`G+WGOF!;H=KQBQ
M-7W,(UER-*VZQU+,K#9%T(J5E4FE@C!9H*'/V5J&[>22T#33U^W/`=8-$9:@
MT#S1Q=ZAZJ]9&1"L[3?,TY8-2Y_BU\'(<J)VB\3LD<A<=/,*\2N;O&&(+E''
M,M78MQQVL[#DQ5I*1OCZT,;3]ZP4E7%22\@TA))`T.FX%KUU;<3D'`X-XBF/
M1G4FOW#F=;P@CW@`74S!PY\*##UCII+_`,O7EO8N5;;)SV5Y$\0\]L:>G3DC
ML^.N/\V89R1C2QSJ4PYEZMF?#^=;7:;C`-5$&B(PL@L6,7?&2=D59D,D`ZFM
MYG2DU.`IT<^%3ZZ=2CN(6Q:=-<:]/KH/57K5NN>_-C,.`<EEQ_@6ZX>FK?!X
M1>Y<F<(+\4>6W*K,$L5&4L;>*D[*[XVST37,"XIL2<$+-G.V!)VX7?).U$&Z
MR+4Y1MEF<UY:T\.1./F]I%.&=4BA8YFI]?BIF![<_,5T%.YQ\I>4>0>+./\`
MB_6^/.,$.1_EP47GC,6O/4;DC)*^/I"ZW.K5AK08:LX\M6/6]V:==F*D9RXD
MH@R`)F<@*^X--0_-2%PIE2O[(=T>HA3"UC:*R$UU4Y?B(Y'E7++I778O\P?D
M5R7I7"6CX4I>$\>\DN3-+Y,7_*EBR2WO5[PMB&J\/LJQ^"LHR50J5<L5&NF0
M9#(&59R/2KK)S-1@1\4NNX>K+J($27N;<2O`:T>]7'S4KRXD<?N-CK>.,N<X
MG0*4\]2.?+E]XNAY23J].<%\E`R9)P,M?&GF1>8''VE[4TIQM4%)=CR%L3=V
M6HL+*_E9V,K)52#\$U=.7"S9`2IF4.)>H;[75J?K^*O_`"G*VZT^[IRTC^RU
M92-9JQ$T1-$5O,OTU+(V(<MX\63!9*_8LR-2%$3!N54MLIDW`=H0]8*?>&VW
MOU%,TOC+1T>T*^-VAX=R7X:JK1PP678.TS(NV"ZS%TD8!`R3EFJ=LX3,`@`@
M)%DA#\6N;73+1HBVE_[E;_S2G_,'1!FO>_C\%&V.\+10"BV:53`^*68_=Q#N
M`$(_&].,L8`[A>ON#U&Z`V`!';T[FU\K=X;@3[W=S5HULSJ<<C3'KX^A>T;'
M`8=K@92I<P5K@,0<L%<^!KB-NO$3]\2J<!&3+HD=.S[AB7X:/9%,HX*Y3*&V
MRRB:@=)3@)0.8HB.W5K5V,++JY;#/(V*%[P7.(R`Q)X5)&72MC<2?+6SGQ-,
MDS&U8T'$G`4RRKB>A2GM$LQD&:%'H+)6N41@S"+,Y045"0FG`&`ZQG*@@FLW
M8KKD%4P"`"Z4-UK;@)2EZ*[W"&=HL[%G9[<QH`IB7#C7D"<3Q<<3R6CM+1['
M&[O#VEX\ZC7)N>7,@4`_+PYJEXNFMXQ4RI6HI*%.FH^Z$@,4ZW0`%,40*)$U
M@`0\0#I,(^K?6"&#6`?@X$9X8TZ5F.<S0=%=7"OE@J^4@(J7:H`9LD1XV2Z#
M`($%%1<P]L`6W#<JI4QZ3@(AX])M3R&'W7`4DI0_93J6-'VK:\6UP/ES7#>P
M7P[,$'3/K=M54@3=@.XMDS%[J(."`&ZA?$`W'[([B`>W5`_W33201[P^T<BL
MJ-Q#P032N'EZE1:\&LV6(Z(D4%!7!PW%!50BB"B9RG(JCT^!3I*%\``0\-A`
M=PU"UNH:"ZC\*<#U_I"GJPN)IP-3@1U+*'QSS<O:FT)CR_R1%+6W:E-4;.Z,
M`GE$D0,L:N3@',1163*4`.W4$0,8`,`B)A$3=OM6Z"\8-OO'?Z8S^&\YN`_`
M[F?RD9\>GD-QV\6Y==6P_P!&/Q-Y5_$.0YCA@J^OUU;Q)'QOARF.;N_$-FW[
M-HF=10&ZR2F_;*9P"@%,`F#I`P&]`#XX=_<-:#ACC4#`<CYU';0%],<LCF5#
M#(V96[[XD"/&R*4J@D@BV<+"5;J:(&(=R44$S'5,X<`(F`=]@'8!VWVY:\W%
MS\`:`TPKC0#-;BWL]`QX?;P45)B1F8P73R0$'*RB!7Z`=X`*LS^PH5)@83@!
ME""OL5'T@(#L`#Z-++*]C2YQX5&/#A3U8+8QM#R&CJ\_EQ4!^;7-S'G%+&3V
MQ75PD^N%C25)2*"FN8+'9'A>V*:ZB8'.>-B69R`+IPIX;?9#<P@&LW8.[^Y=
MY[[Y6T:1'4&20CW8VGB>9(R;F3T54=Y?6>T0?,SN!.(:T9O(X"O3F<@.97B_
MY#<B\F\FLA/\AY,F%'CI4RJ,'"-SG+"5>)%03(1,,T$>A)%,NW6H(=Q8P=1A
MU],[!W?V[NY8BRV]N)IK>?B>[FX^P9#(+R[<]UN]VN.WNG8#X6_A:.0'M.95
MBM;M:U-$31$T1-$31$T1-$31%H4_NU/Z!O\`FCHBIS5%(FB)HB:(FB)HB:(F
MB)HB:(FB+]Y<!$!`0\!#Q#\.NJ7)+&)?O*PQ7?S94K;C/W*&KX.R_G5KR9M/
M'"G7#',3BLN;_P#,:M98G;4VDGF+)/)Z\!:\@U=*5?5UU8%X('SA99%LD84@
M2Q#:,+JUXUX5].?KIG@LIMU(UH%!4-IQRZJT]7)7^M'"C$%MIG.JBRDA=TX7
MS"W=B>9U49S$4D_BE;-@FH<>)$,=+JP*Z4"0E$I+-5('J<F)9(RJHB9,Q42W
MBWC#2P5H13U`>P*QT[W2"0TU`U]9/VJW.3O+OHE^N%IM]2SMR/P,.4L-4[`^
M>8/"EJH<-&9TH>/(.:K5%=6UU;L<7.:JEWKM>L3V/+.U=U!R+B.6!LJH8B2`
MI1NM&$D@G'/+G7ESZNO*E[;N04K0T.&>&%.'1SK[5+_"V+ZS@K$N)<*TY646
MIN&L<4/%E47FW#=Y-+5C'E8BZE!*S#IFSCVCJ54BXA(SA1)N@F=83"5,A1`H
M9(:&L#!D!18[G%SB\YDU6*GR]_+/M>(,(<+T>4V7,S7BU<7FSBZT[C1.6G%4
MI@'$69U7-SCV%PA'6/J!"VZ_NZG7K6Y"`3GK).,89=ZHL@3XA-$Z&%%:ZFCM
M,!CRQJ,>%>C&N7#"F9+=G63%QXX\#UTZ<AF?/-^&X0X&C^+V3.'\O&V*WX4R
MY.9UL%SCK%.`G8%WW(+*5NS%<#Q-@@&<(YA%X*[W)=Q!.6Y2NXSX9J?NJ+)=
MTV2Z!AC+.!)/IK]Y_EQ6/VS^T$GXA3U4'V*WM1\O+'"*F6)+.F7L\\MK1EWC
M[8.*,M;\_P!BI`S-9XZ6U-P%MQO3VV*:!C*"CG-S>*I.YR?<,W4_+NV30[AV
M)6R:86"U:*DDXBG+V4K7R.5+G7#S0-``!KASK7C7IZ,3ABNG+Y=<6ZQSBFHS
M_*[E98LB<>;4E9.-O(Q>9PU"YNP?'DHC?&CRC0[ZLX:AJ)?Z+9:8@+2=8VZ"
MGAFS'[SE05DFZB-/E&%H!.1Y#[O;7,Y\+A=/#BX`8C'$_?[*9`#"M:CL/`V-
MNV/:]7LA<G^5-ZRW1<SI9_Q?R>FK=CEEF;$N2$:HO1!3QQ%P&+HC#T)CU_2Y
M%_&2%77J[N'E&TH\%VFLLL"I'RK=-*XUKD.753GPICB"J?,NU:J"FFE,<O37
MUKI[-Y?H6=GB&PN^8'+=//\`A2UY6LU.Y/J3>&)7*'W=FV#B*YDG'SJIS6&)
M#"2&-)2*KD;\%$M*LV"*<QZ+ENJ5?NG5&V!()<=0ZO92GJX!5%R0"T-:&GAC
M[:U]?$\U)?D+Q_IG)OC[DGC=DR3M`T?*U*"C6Z8@'\;&V]:.,K'KN)%E(.(E
M]$M9=TXCBJ'.+$Z/4<W2D4!`"S/B;(W0XFG\H^U0QR.C?K;2JI1WQ+Q@]F^8
ML^L]MP/N<-5K=/S&4DI'%;QT55L./<'1JE%3&&,>&>GIS\ZJIW9I`AGX`H!2
MI@*0QFVC)<<:N^\'ET*X3O:&@4HW+U_>HETGC5E1SS"XR+.\0_N'Q;X&<7,Y
M<:J#=;ED^EW>U<C6N5(+`=&J[]G3::DG)4Z)@J;AYPK,K3A8YRX?/$TFK44N
MI4L#8I'.$9!#&Y>D'/(Y?H4YF:V,N::ROSZ,"/MZ>M5'B/RP,;XDG^,3Q/D+
MRFOE'X6V]Y9N+&';S<\>+8SQ/&N,>WG%["H*-:WBZNVK($57*7?G3&+?6*5D
MIE@U0012=@F+@'$@LV9$FE".'$4^WC7K5OS;P=0#=1()SQH0>?,8THKV0O!C
M`4;Q(LO":6CK/;<&6U7)SF9:SUA.UMP/,IY7L^:I.3B;566M?>04U5L@V@[V
M!?,R(NXQ1FT4!0ZJ(J'E,##'V?#$^<U^_P`CBHNV?VHE_$*>H45'LN"#6PTW
M*&->0_*GE=RSQIE/#UBP9*8_S=:\81U;BZ79A9?'S;4F'L3XND9K*3<D<D5K
M:95P^E&@@<Z(D455.>,6C0".BF0^P#[\<PI#=/)!I0AU<SGYR5R<-<%HS%V;
MZAR*NO);D[R.RM0\-7;`=2E\Y67&CB'A\:7JP8^LDJT3KF-\6X[C7-H&1QI&
MBO-K`I)20]9GJBX@AV;H[=K':ZDFE.'V`<A^E6/G+V=F``VM<*]/,GF517,[
MBQF#D%R5X%WW&>1KMAROX%F>4DK?LL8UD<:%O50-DG"["GTEO%US*E2OM:ML
M98Y]N=J_;&AGG:0_:"9#8JH1SQ/?.US1@`/MY@Y5K[%)#,V.%S#F>O'+D1Y<
MUW!O+;PF3$%<QTPO><8C)%4SK.<I8?E9&W>(2Y+AR6M;.2A[?F&0M"U57H\H
M]MM5EUZ_(0"]?/5E:T*<66-(U11*G=\I'HT\:Y_HR^SHI0*GS<O::^BE/+'A
M6M:]*JAOP@C9N-HZ>9N1_)7D+8\?\E<7<I:];,HV/'+1>/O6((^0CZC5H:JX
M]QE2:+6L<JDDUEI!A'QK=Z^=J"LH\ZAU3Y1A^(GS4&=.0Z.2?-/I0`#"G$X8
M\STJAN=?"XF=,:\Q[SC9"5E^1F:/+LS)PHI%=D+!#P]&DF-K&WVVL)NE)%JU
M&+FGEXL((*R"\@FS29"`&3*)15U6:W:[5(*ZZ'^R0J0SF,AAIV>H$^D'[%R\
M2^7_``D"JQN.:\XY\Y#9%;<<IOCG4'N6YS&9V6#*!D:O0,?E.'QA&XRQIC^"
M<66TN(!BB\LDPA,2[EK&-D/B.QW2K49:M(J_/S<#7@.-.OI577+@?W=`*]..
M%.)//]"NW`\-<35V(X.0K"0NAVGE^,FS#!IG,M%*K2J#7`$[QO3_`,Q#%@DT
MYXXT"PKK&^#+&@,D!%=NT`H&F[!E0<?=%/41]JB[9_O9>\<?2#]BMIBG@''8
M-GZNRQ)RIY:43C_2\@K9'JW$R&NF.!PO"/'$^YM"]%8S[W%CO."6&3SKQ54M
M1"V?=:2!_@TP(Q`K8(?DVY5PKR%?32N733HI@I3=/(H0":4X^RM/5Z\54;O@
M+@Q]Q1OW#MP^R#_EC?\`(61,KK3S>QL&>0ZOD;(.?I7DVC:ZC8&L&E'1\A1<
MP22<A!E<,72*23)!%T1V3N]V5T#3&8ZFA-?77[5&)GB02BFH`>H4]BMA(^61
MCJZ)<BWV:>07)O.]TY2\6'O#[*5[R%9L8Q\DTQ$\F+--E)CZMT+%-/HM%FVS
MRVNS`=M&*-5E#=YP@LN8ZAHA9QXDDU/*@X$<!TG@."E^<D`H`*5KQ/$'B:YC
MVJ>-KH$'<<96;$\LK()UBUX[F\8R:[)=%&7)79^JNJ>]6:.E6Z[9*4+%.S&3
M4,B=,JVQA3$OV1R'1M<S0:Z:_;58[7N:_6,U8Z*X?8IB"\)R-GMP4+P)@WE>
MPH5S*12Q9:/?8&>\=5_\PR?<A23ZHT%^=7_=`CB_>.RHE%+=`8Q;Q@@XX#[_
M`+RKS,\APP]XU/I!^Q6LQ#P%C\#3E.CL3\J^6U/X^X]NRMYI/$QA=<<J89KQ
MU)5W-IT!O8G.+5\Y.,,LY-ZH9M4U;:>,;H`1H39DF1L6/Y-F5<.H>VE<NGS<
M%+\V_,@$TXUQXXBM,^CUXJ1O'K`%#XTXK;X=H1YJ5IZ%QRS=C%N+IC,/W4GF
MC*%SRW<F3Q1G&Q;->(_>6]OD6R(H;D8`FDH94Y3*'R!&T1]G^''UFO\`(L=S
MR]VLYX>H449</>6#Q)PMQ0RYPN@:U;+%@[-U@MM@OC2W6UT\N"I["2$95J-@
MKE#-H.6KS##\!4X2,IAFPE=0#.#8]M8ZJ(JGA%K&&%E3CZO++JIRJI77$CI!
M(?B"J6M<,KO&0]QA[;S[YWY("P8X=XTJDI.Y"Q'5YO%[1>4A95O>ZM(8VPI3
M/WARW'JP""*5@LA)M46BKE$Z1BNW/<HVU#:@',4R'V`?;[:W.N7.()`P=7,Y
M^<GU4588!XE16$\B9&S5:,QY@Y$9SRE4*)CBS9;S.ICAI.(8UQG(VF9I5$@Z
M]B3'N,:1&1,;.W64?N'(QJTD^=NQ,LY,F1)(E\<#8W:O1EAGR`YGAQ.:LEG=
M**'+SGES)/`<52.8^"]9RMEZZYDKV>>1.!IS+N+:OAG/$/A"S42$B<T4.BK6
M]6C-YY];\=W2S4NQ59"^R[5"8JS^$D5&3TR2BIA(DHG:^U8]Q=E7JZ^/3RIU
MJL=P^-NG,`UX\J>SG55+@?A/A_CM:\*W&A/[NYE,#</:APBI*-BF(M^Q<8=I
M-F@+7#R$\BR@HU5[>3R5;;E7>(J-VAT1.4K4IA`Q:BUC!K4Y4_9T\N2.N9'B
MAI\5?63[2K3)>6KBRMTO`L!B++^><'WGC;/9WDL7YJH$SCI_D=&O\E[W+9$S
M/CNT,;WC:WXYMM$M%CD6ZR+5Y!'7CUXI@X;K$<('55H;5F&DFH/1QZQ3U<`@
MN'U)(!#@,,>&'`U4BN+_`!EI/$['<_C>B6;(MS96G*^4LT6*T96LK2W7B;O>
M8;2YN5UD)6?9PT$F^(ZG7BBB74W[A"FV,<VP;210MB&&)/Z3]JLEE=*:F@I_
M)]BD7J91)HB:(M]J<J;ENH;]$BZ1S>\I5"B8/Q@&K'@N86C,@JH-#5?B=<]L
M7*X3YQ\Q,1JMA:%QUR<SC56:&PE`L7&Y'L18<Y0$"_85B3(G+ZMC>'AKG91I
MD<W@"5TL3M4;7<VCV*)NHU>MM4HF34*'I,0Y0_")1`-$7Z%6+7M,O?'+B9DN
MK`Y3:9`PGBN630<LB]T(Z-I\)6IULLJA^Q/(1D]`&2.([%.!AV]>WS%WKM8[
M/>98CA*Z1Q.!I2M01Z*^=>N[!/)-8-)-8FL`'7CAZ"<N2O\`P5,&5KZ`ID,F
M0KP#*I&3*`J"W%9)(5#"7K3_`.B/U>/B'LUH!$7QAP)I6HY+9ND[.0TIJI3R
M]BO#%5(21ZPCNHX:MP=E$$MC@79`RPD#8W44A"B/3L(F`=_?K<6L'O:7'`UQ
MX+7RRN)J,\!P54K55V=,ITCIE./0X<%5*50RQ#`*1E/4!TER@`ATCU%,)1]`
M#J8P%GNR5`'E6JM$@<?>XKXC"(M'G>[P(QI@^(65`ICB1<H]"J8]1B@([B&W
M5XB'AO\`9U9)&T4K@1Y55S7%U<EMN(M-RRG9$\G\&X*=1!E%.B*%6E6HI]2K
ME`Q"BD*"0EV$H_:$1\/?%$R-MN99'@/K0`X./Z.2O=)^_;&UM12I.8"I90\2
M4S9)H@=MNV*)U'9NH%5T_%00*)0*)#CXAOL?I#;65$896BGO$<#FK'F4'$X'
MDN&[:.&[AI)QQW+)VV>HNF3YLL4!3>-S$5;.DME"J$424VVWW``#6;#9O!$L
M3LL@YI!'4['S*-T\9!C<*-ICCGYE<W-&4Y24A8RWF6)\3:DT&E@;%[;9-A-P
MJ:2,@L)#]PBS6041!=("EW+U=([^`ZQ-\G>7_,/(U28$#"C@,2.@Y^U06,#6
MGL&CW65IQP.741DH'R=G!V=V8#JN7(*%<-'3@3&*5N8`*XV1$A035(J(%3Z0
M^R'B/L'BRXNFQ-30^8+?"(@#AP/25`;GYYC-6XJ5J'15%M<\O2=>394NC`\!
M,K(B`KF+9K41-,JD?`-WJH=)``JKXY!(F(%`QPZSNQW4O^]=QIKV=A'0/D(K
M0?E9P+SRR;F>`.KW7=+78X=3AKN)"2U@.?"KN(;T\<AT>/G,V:LE\@+_`#.3
M,KV9Y:+7-*F,==P8Q&4:T`PBWB85@!A0C(IF4>E-%,```\1$3"(C](;3M%AL
MEDVPVYFB!N9S<X\7./%QY^84"\LOKZYW&X-Q=.U/.0R#1R:.`'\JM9K9+#31
M$T1-$31$T1-$31$T1-$6A3^[4_H&_P":.B*G-44B:(FB)HB:(FB)HB:(FB)H
MB:(OWEM=4N26,V*\QI_+9#Y)1Y.+63H[C]P]RMF+&_)+E;-Y`Q9%8YI$?AS&
M$;E":M59H[B<_P`ULCF-&RB+=TPC(G=@HLD/Q#@QE$T<%MTYQJ![@SZ,*C*M
M.NGL*S'6P:!4^^ZE!S-:'A3UJT&#/-_H>:LF8ZQE+4"HT0G(2B9*M.")>C\J
ML`Y[OR3VA8YE\I*UG-N*\<O7[_"5TE,?PSN18D,YLD2F\9*1[QTBZ%-)6UEV
M7OTTSRH,?7AER5TEF6,UU&'EPQSPQI[2NSQ!YB.2+S4>&F/,+\>LA\G<N\A^
M`M-YDI6;(N6,087;-*PYEJ74GRN6IZ)J1()G;IJ6MR!^FJUI=FH\4%--DU:@
M99)\TX"C14Z:XCH!X4Y\`?0JNM`#5Q`!=04ZR./2.)]:B]R%YL\B>7#GRUZM
MQ;Q_G&D4KEDGRQGLLU['7(/'&`\W,;OQ8!6CVG#'^:TE7[@TAH.CWXCY^]DX
MCM!8TV+9%)1-$RR:D$\SY-+3@TC*E<<N'3A3,4Y%3001QZG.-7#IIAGQZ,>6
M-,PIC+^92K60E[M_P[WR<X6XSSTQXF7;F&_RE2E9Q+)$1D6+P%8\@?Y,&C4[
M19\/5S-[PM?F;.21;/SNDW+]"(58)]\<@7#F.TT_=AU*X\Z9Y>;/KS6-\M5M
M:CM"*T]?7ET4Z>"JUCYB<G)92Y)UUKQ9R:WP1P[RODG'/);E9,Y!Q7"8SH41
MC/$%?S%-V^OT][.%RED11K"V%%%]&Q<48S#K2/\`$K&4,BE5MTYQJUON#/JH
M"*FN'73V(ZV:RC7N_>'(=-2.5.&&*X+#S#[O5,)7#E5R/XAW7CWQ8B,&N,]5
M7)+[,F+KY>I.$>K5T*'0[[B2*-"/<;9-R:TM+,\8T)*S,6S7$[>3D&*I-A,N
MG$%[P!'3#A7HS]E?,J.MAJ#&.K(32GV]773HJMKBCYF-9Y%Y\+QOM%)QQ1<C
M3^*;'F:@#B?E;A;E?7YBJTJ=J\#=ZW=Y;$2B`XWR35UKK%KF8+)OXF1;*KG8
M2CH6BQ0K!==H_2^GK'MZQ]Z3VIB;K!J*_P`GEGT!</E7REY9XHY[\4,$8)P:
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M+T9_-&0F]!>M9)9`?N*&*J^;,229WIED6\LMV6.T@4ISQ/JP^SIX*.&T,K-=
M<#EY?=4]"R)Q.:Z99^/\?R2IZKJP8[G\)H9YJZ@HC&/YNER-`#(L,4Z#DJAH
MV0D8-5,IB*`;L*G$#;]([Y)E'9=K3`T]9I^GJ6,(SVG9G,'V9J#&`O,<MN6K
M1PZ+D3B9;L$XNYZ4=Y9^-^1IO,./+Y+/9V/PTIGD:QDNA5%F"M`;V#&T=(OH
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M6MM9'-_6KZN?K&7-4#Q2\S*L\B\^)\;[12<<47(UAQ39,RT`<3\K<*\KH"7J
MU)G*O!7>M7B4Q$HB.-LDUA6ZQ:XL%DW\3(ME5S,)1T+18H4ANNT=I?2O4>KC
MUC+TJL]J8FZQB*_R?;R/0%=KE#S)LN`\QX0P#CCC+DKDSEC/V/LX7VEUZ@W+
M&]$CHEM@UWC%M.#=;1D^;K]?KD`_+DU`?O'OKJHJH%1(T<*."`62:9T;@UHJ
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MDLOY`8\;+C9^&_'?.`\>\Y\J&V2*9%O:O>(FRP%(R)9ZI@UVS5M5ZQ1A^[65
M",LDR238O$U6KY5C'OD&9U#T==D/I0:`:<>GCEPZ\\"KFVNI@-??(J!Z/OZN
MD+J\S^9E<\7R?-.4J_#FZY*Q%Y?EN2AN2>54<SXWJ!RUEMAW'><+/.XHH4JR
M?V._6"H4;(`.744[/"-ER-.EM(+.%OATCKI]:M'NYY'*@///'C15;:@T!<`X
M](SJ1[1PJJMO'F'S1^3-MXQ<>N/\?GFW8VIF(KY>TIWD;BS`UMEX'-$0O9JN
M.$\>9`9O)?+9XZL-_B)%TJX@HM!X8&";M5T18B1UV[7IC&6>!/&AZ*==/;0V
MT.C7(:?R5'D*GHR5H,5<ZN4[?+WF?!D_CRC8./G#K-.56L)D",RYC.*E*90,
M:<2,;9OB*8-*9UQ.S7*2R)(2IY$DDNX5/$?O$5HN)RQARC:VYE#G:L8QQH>0
MI]GI5QMXC&PM/[QP'$<S7#/^17.H7F.V^R5OCG?[[PRRYA7''*_+G''$^#;#
M?,EX@E)^RJ\@Z-=[P6U3-&HT[9YFFQ-.94Y(!;2BC9])H2:"I4VQTUT"7"[=
MIUD>Z<NG#'&OERSI8;8!QC!]\`U](IPZ?M5>98\Q#'N(;%RSJLQCN\V*Q<89
MWBA1H6OU9U!NI[.V4>9+=)KAS'5":2;F*CX24>VIZUC7+N3=ILFY%3NU#D11
M.`WNNJ.<VF(R\QISYGRS5K;5SF-?44.?1@3[`5&'E)S6\P3%R/%1NPX5,L=6
M_(_.;$N%;!6DN2.'<A57*^.[KC#*EI6JE;OCNGQCVI33N?J::$@Z<1#!:,48
MD^&<.V[SK+!+<3M:#\))Y'*F>/+J]BFAMX'/+2=5!S`QKZ//4CGP5U;%S[)A
MFX<KIO.E3RC7Y'!'&;AIDB8X^P$OC&_QC#)/)&_YDQQ4,;8IMD)"5J4MF0LA
M7NNQD.\=RTJ:OE,=DJT39$*^46F%P6M+G5+J#A2A)/GX4QZ.=5%V`<0&TH7'
M&O`4\V1KATK5;/,HG\*5/E$/*'BY8\,9<XU\5IOF4SQ?7LNTS+D-E_"=?>R4
M#.GI>2H.$@&,7=JG<(].*FHN0C$TVBT@S7;.'K5<%2VMO#I.H>]2HP/*O']'
M#/-7?*5<-)JRM#Z:?;PKD5=K$',F_6WD36..V;.,%CX\SV5L*7//F#9=]EFA
MY3+<Z7C>PT.OWZ`O$?26J3?&V0J]_F="/`8HO9Z.=-72@)R`K('3&2.=SI-#
MQ0<,".('3S&6'2HY(`QFMK@<17SC]!SH>A7@R[R:JF$\S<?,57F'?1\#R!C\
M['C\HJ2#-"KTV=P5CE/+4C7K&S63!VHM9\>QL[(-%TU"D2+`N"G*/640OEG[
M-X;G4?R8^FO0%9'$9&.<"*CR^X#I*B5QY\TG'/)RN\7'-'Q9D.O6?E!:^353
M<TVU.8Z.LV$H[C92G]RGKI?6GPW6NPLD5+U)6,;H%25$EQCU#&Z0-U0LNP\M
M:<"3CAU@<>=.>?HF=:.8'.S`&'J)]5?05';RZO,$SO*<>/+%;\GL%W=6O\O*
MG2\55CE98<OT>V6?(&<U\6V[)+.7OF*H9!:?KM/R7$X_E_NR8/+.)#XA-$KZ
M-8]X#%BBN'L8-7P4SIE[M<#EPJ/712S6S7R.[,C77*OZU.L9C/K!*[S'W+B[
MY#S/Y<KF.R9D=''^1.3/FV8[RJTO"]-CS6>(XR,<RP-586%O0:]6Z^[J5`G*
M2"T"91L,@1@W;J/EW+X7#A4^9W;-H32O1^9P]=*>U#`!`Z@&K#*O)I^TKL</
M>=1AS+V3<$PK&FTN/P]R>R6SQ1A&_P`7RCP==LQN;%96TNXQQ.Y3XK5E^XR)
MBVE9+-#"FQ<'?R4E%J/699AA'&64!"YM[5^(&CS^W+RX*QUDYL9=7WAY'R.'
M25FDUL5@IHB:(FB)HB:(OR>/XF/$!\2><KRG63;_``\7EMMB_-<1LF!"+%O&
M.:\A/+$V`.L#V^$DNHWI%0#:YVX:&S$-R'V8>T+H;1Q=;M)S\C]JP+:@60FB
M+VR>0GF.L<@N%!<$2[P"Y#XCWR3049F6ZWKW#669-Y/UR?9)``KBA7+J+Z/6
M$H"FEW6P'$.X77C'B%L[3N+;UU0V0`AW`$"A!\]#_27>]V+ZEL8&_&TY5\X]
M(KZ%G^I='"*(*3D!,14JB2@'1!,/ABB8B;HB1@`B:Y2])B@.P=`_BUQ45O1E
M'8&GJ_DR6^DEUN-,<?+UYJME8I*..L/3WG`H&ZA'MHB9FH00!TW*`"!SE'<0
M``$0*)@V$`V&]L>@Z<CY8JA?J'1Y8*ENIHP*1,ZB::/?(*+A538J9G/6)2"0
M#`!3%4\`']$W4.WCMK.;'\R--!VO$<_O\R@)+?>S!]*[MM#1BL8[D#-D7KLJ
MBJ*S$RP)-$E3G(0KU1D<.ZLIT[&3VV3,(;[>G:?Y(MC$KAJ;R)J&^7!1=N=1
M:TX\^)\N*M99TVG?:%(;8C9,$W#DY%`5,H!@(BFZ()^@H$*7T;["(^GV5=M[
M7N#8=+FD5H17'SY*2&X<&N[0T(X\^:ZDSTZO<2!NDHB).Z'25!UL4VQ1(4H@
M5=$">`@7<?1J7_#@UGOQ`$?JD'TBH(4;KAI?0.SZ1[/:J*?).5WA3II(;$$2
M@BW.=,1`?`0!$!`>L?67U[:SH+1C1E(T<J:A_(H9)L<*$]=#_*K29ND9:,AJ
MG#.3F9@L^G7IF(D,#@I&YHHQ12*KT&(FN8=S](_;'I#?PUQG>J2EVV*ONZ<J
M`4RY=?E1;G96B1KI,SSKAC584_,"\Q"#XILG]$IJ<;9<^3<,!(N"==3J'QXP
MDFJA&EMM)6ZQ.J90Z@781ISB*RI2JKE[/V3YO<CN;<=XYS>W@+-H8ZA.1D(_
M"W_E.R'25#O^^0[1;B"$A]^\5`S#1^8_8./4O*%=+O;\CVB7NM]LDO;;9/.3
M.Y>?G'BKZ0>K#X%`RJHB"2")?LI)$`J21``I"@`;:^C;.SM=OMVVEE&V*V8,
M&M%`/O)XDXGBO*KBYGNYC/<O<^9V9/E@.0&`5+ZR5"FB)HB:(FB)HB:(FB)H
MB:(FB+0I_=J?T#?\T=$5.:HI$T1-$31$T1-$31$T1-$31$T1?O+:ZI<DH2TO
MA-48W'/.S$N0K&O>:%SKS3GW)5SCH^./67]9J>?L9T[&,]2&<@,A+_'2,5&5
MA5=&4`B`"JY+_NQ>UN?%CM]#',)J'"F7\N:R'SETC9`*%OWU5F^/7"KD3B)S
M4*K<<P<2[3C*@8_LN/F5EHO"IEC?DADMD_H\E2*K*Y,R8EE29JD++P:+Q)[*
MJUN"8A/.D!+TLD%E$1C9;R-<,:4XXX_M?8/L4C[ECP10X]6%.7NU]?I54<3>
M`IN+]SXJVTV4T[K_`,,_EWUG@89@2GJ0(W(]=O6/KI_F@1R:Q2P02;L*+\-]
MT"1T8@NNOXLW;Z3U;:4-=7X:9?JAO/HJJ2W7:`#32CJY])/VKHL#>76IA&Q<
M,[`&74[$;B/:>?5F^')2E(L;V/."^S5W3:$5-9GX5P<:#+_#&.)7OWMV^L"M
M>KH"ORM2"3@.C]8GGTT5#<U#A3X@./(45OYWRULERL?=N/#3D-3V7`?)')UY
MRDMF'E</23K/:,A.9I8\CKC@RO9H+D9"G,L-V[-S,\DJY7JB]A:13QQ&).1*
M9-TG:;9Y.FON5KZZ\^DY#C2O*HN&BCJ?O0VG1E2N7+IZ5*&E<+ZM%5'GICV^
MV)6[T;GCF;,F2+C$,HTU<>5>IYHPMC_"]@H[:0-(2OWD^:Q5+6=)28)MPZWA
M2_#AV>I26.W#(C%4T/W`=.=%9)<&242THX>VI/VJ/:O`SD;E3CE;N''*;E1C
MO)/'=U@IKA>H2N-N/CS'^=7LS57]1>XJS'DFW67*5^HDC<\='I;1=2,AX".A
MIU^8ZSE--'I:A$+>0L[-QP&76>.9Z<QQK2F"O^88).U8TZJ]%.K+[?/7%7KX
MT<=^1>+[X%DS#?N'T]`QM)?U5HTXY<.38$N5RGGCV'5)>[]<Y/*V0!9'39QJ
MY3P,(U:1JSEZ94RHE111+?#"YCZG++CCTXN/V*V:9LC=(!&->'HP:%SN3'&G
M+^0\W<>.2W'K*F.,;Y?P)5LW8V&/S'C2RY0QM<\;Y\)CMQ:VCJ,IN0L:6>%M
M=?G,6Q+R->(OU6ZA.^W71$JI5"731/<YKV9C[P>8Y#RRMBD8UKF/!+3YLJ]!
MYJU5X\NY:Z\9/,3X[*9<08+\^<S93R\>WDI*JZ.+U<FUO%<`I!?<(VA-2V%B
M%,:&6!<';#O%>@3H**0F4C^4&@M!-">701SZ5?\`,_O!(1B!3UU7494X"Y,)
MR!S?GGCE?>,$.MR8+2Y;+-2Y5<53<B&E;R11J1$8U891Q%.P62\9S$0ZF:16
MXMO)U^5,_BG#R.3=(J-C+.2*I+=Q>7-R/J]!;EAS/VW1W(:P,</AY4]!J"I]
MR./7TOA*3Q+)V!FO*3&(I'&4E;&%980$>M)2M'7J+ZSLJ9$N$XR$9*NW)WB4
M4U6*W;)B#=-0"%*;4YC+HNS)QP]1JL<24D[0#B<.M1-J_!C]W:QY7U;5R0C(
MI^7#&,XQPL>IJ(IYD2;<2+;Q:4$J'[P*C22.`M(S(E,>4V*B+7<1/WRV=@06
MD'%K0,N0(KZ^E2=MB\T^,_:#]BLOQP\O'+O%N1QCCG&V4N*[WC5B.^-IVG+V
M_APRFN7#7&;*QKV"-PRXS>ADUA2EPAVZP1;2WC6/OTD:DF8Z1WI1=F@%J\'2
M#0<\</VA[/O4KKIKP=33J(H<J=?PD^O[E,#BUQ@B^.^"K#@JPSC+*$%:<K<G
M<A3JKR`^YX^3A.2N;\E9=E*8^B%I*9*Y:PT=D52'66%7I?%0,MVD04[1,EL(
M$98>->'23ZJK'=*7/$@P(`'H%/6H0X6\G['^/^&/)OA]D?,UTRP')!6)KQLQ
M.H6,B[UC[%.(82LU+B/CV%:R#FP1<TCQKK%*C`;*O0,WFGX.UW*!0=JDU`+,
M!A%:NX</+T9X]"G==N=(V0"E.'/GZ?9@I-<:.._(O%]\"R9BOW#V>@8VDOZL
MT:<<^'!L"7.YSSQY#JDO=_N<GE?(`L3I,XU<IX&$:-(U9R],J942(HHEOAA<
MQU3U<<>G%Q^Q633MD;I`.)KP]&#0KKW3CP-NY;<>^4?[VE8%P3ASD?B<:2,*
M9R>SCR`E<+299TL^$FB6)+5?\H1(+<6C@7GQX""B/9V4E?%K>'5R^]I^Q1-D
MTQN93,CU5^]0XO/E\Y5A<R\@LE<;LC<5X"!Y0W1ME*_P7)WB$ER&L>-,LK4^
MN4:S7G#-JC,GXX.K%VR*J,>]7KMA1?L&LPDJX06*DY5;:QG6I#O<^$]>'[0^
MW[%DLNAI`>"2.K'KJ"J[DN(G)K'68\Q9,XH\E<4XTB.3!L7SF<:]EOCQ(Y07
MA,G8TQW7<2*Y9PC^ZN5L:P=?D[CCNHQ35Y`SC.6AFSR.1<M]B&6;J7=A*UY+
M'9^7,<@*XDTKSK9VT;F!KV_#E0^VH/$D\!ZE:[(7EK9,MK7/.!8'D54Z]P9Y
M0Y]E>0>9<4/L024MGAE(7>Y0.1<RXIQKF%#(L;3(7&F8;S!J/'2\C59"9AV\
MJ_;-%C@=NJVM=:N+R*^X34^5>D\./52YMT&M%1^\#:`^0KA0<?MK>*\<"SW/
M%_FEXX_S12CA\RF3N<BG+_N@HY+AP+=Q:QQQK!%1C^\2(W@&`T#[XW*K%]PK
MKX78HI]\\HMZ,<VN8I^R!SZ*J/M_?8^@]TY<,R?-G161YA>6CD'EVHPI%JR%
MQ8-B9E5\85NJW:T<1CV+F-Q^5HK.ODGYSC9R(8Y7A4*A/VB8@SR,>\?1#A2O
MO'9Q*#U,A$M1/MGEW`@UQIEQYX=8%?-@I67+6#`.KUX'KPQZB:4]*N?8>$&8
MAOW.=G1\W8WB^/O/N)N,KDZGV[$UGL.7Z'E"T<7H?C/]^4'(D5DV`JKVFJM:
MA"3+J/DX%9[WD';=%T0KDBR%QMWEQ;7]V>0ZJ<>@??RL$[:-+@3(WC7/$G'#
M/'-5EE_A;9+MQBXJX>H.58:HY8X;VOC1DG$F2;/1GEJHTU?N.%4"EHI7S'\=
M:J],NZ9?:X_DFSINQFFSY@+PBR+@ZB``>K[:L36`U+:^>IKS\V85&W&F4R4P
M=Y=73DK"2/EFY+R(ERSM^9>3<`^SCR/R!P]S-0[]BS"1J=5>/>6>%:B$MBA[
M`TJT9&NSS(=1+8H]N+YK*RB#U^P.Y1.X3,LD=O9\H\DO)]\_>#SYC[E)\V`U
MK`W]V,^D4(Y#@?M5Q,H<3N9&=:34I#*W)GCXGG##')/#O)3C\\H'&RZP>$ZO
M/8HB[9!2M<R-5IW.M@R/?(W)L1>)`CM9K8(H\*<K<61#BFH*U7P2R-JXXCAY
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M$]QN&;Y4<<N2_P"^!6Q<`\?<]8+&FC!F5-:1S;+8,E`LQ9W[T3+#EK?^3`D%
MH+5P+K[Q`>ZEV-E<@PU>'5RK[0?L6*)*1F.F9!]%?O5N/,&X21W//"E9Q(XR
M+*XFDZOEJH9%C[W!Q0R\NC`(1MCHF5J4T1+*0ZC5/*N&+Y8JTJZ!809EDP<"
MDN"7:,GA[8#&E/+V5]*NAE[%Q=2M1_)ZZ'S+J*#P$J&.N=6:>9D!;E6\/E'"
M47C&M831@2(5S&ER>QV/JODS)L%*DDA35=Y'H>$:)%N&9&3<40KYU#+J_$]"
M=C+8MDUEU?,/(9#T=*O=/JB$=*4.=?+F?2J9H'E[GH_'[RRL%CE=.2'RZLDX
MMR"I9@IJC0N7`QMB#*V*ABDHD;(X-2AF!R=\<"QG$GV`9"ET'[O<)0VU8A%7
MU?JZ>?G5S;G3.Z;3F<J](/V+I<6>6VTQ[-\8)&4RDWM4;QWSGYAF89.&/2UH
MQ._QW/66RI(.:>+DMG='@`QVVR:9!1WTNOO4&HF*DT[@`G0VE7AU<C7+]8GG
MTJINR6%@%"1G7H:/L]:ISC%Y?69N+KK#N-:GE?BO-<<<&R[%"GR4OPU8?\7L
MMC"`!RE4L763-[;)J%(!_7X\6K$]O:5=*:?-&93G1([45<C:VV>UU`:`9''_
M`"J?LT]JK)<M>TU!U$=%.OX:^O[EEBUGK"31$T1-$31$T1?GO?QG^$!A>1/#
M#D>T8F!MD?#5YP[-R"9/V9IC$]Q2M4.DY.`>*ZT+E%0J>_\`(;"'JUI;]I$@
M=A0^7M)6XVYP,;F<0:^G^1>+#6`MBFB*87!+F;D;@=R0IN?\>IEEVT=WJ[D6
MBNG`MXC)F,YM1$EKI,JH!%/AQ>H(D78N@*8["2;H."`(I[#KMUVV#=;-UK,!
M7-I/!W`_8>A95G=26DPE833CU+]-C".9<5<C\&X[SOB&:_>#'64:TRL%9>&4
M:C+19U6Y1DZG9&S511.*MM6?`9K(-#"`D63Z@#MJ)&-XS?;?):3NMYFTD96H
MSP^X^Q=Y;7#9V"6,^X5IM#]1$R(%W[^Z@%3*.W>2(!1[+?<"G(NMM]D``1`2
M`(^O6I[,EV(JRF?+S_?P6=J:T$DT)5(/T6KQNU6E&A?ATE4S?LS.4"KG`Q3J
M-W0)E(<Z/64#&VW`1#<`\=9,%N\8Q>=IR/2#ZZJ%\V-"<3QY8+HF\NZCI%8K
MAX*:QA,LV**Q313YNJ/4B*;C]LDD.QQZ0ZR@8-MRB.MU:N,Q,3XP7CI(?Z./
MK6%/I8!(QU&^KSG@J,F)8X.%EE`42!Z[.)R'("GPRYR&Z2HJ"4I%4U"AN&YA
MV`1]7CJYEBQV`HXCD:.\XS\]%5\Y%.`ZJCTKH%)QMN/V0#I4*194C94_V@)N
M8WH,GUCZ?T@`/4.MHQO9``OIT%P.'+GZE@/)<XT%3SH<U2;A\N[>$38E!8SA
MT4B)BDV<*KKF(1$J:0$-VC#Z-Q/X:QKB^B@:=3G&3D*T^\UZED1V[GZ30!E*
MU.)/V!8+?-E\U&,X^VJ3XZX-D8R[Y@IR!X:U6!X0DM5<86&01([L`I*"`!/W
M)!=1-`C3N&9QXH;K@9011UA[7W-N.\=W\]NKG,VEKB0!0.D<<"&\6L``:3QH
M=.=5)=;[%M4!@M6@WSO0QO`GF[&H'"N.&"\C5@L$Y:YR7L]GEY"?L4_(.96;
MFY9TH]DI22>*&6<O'KI83*++*J&](^`!L`````:]DM[>"T@9;6S&LMV-`:T8
M``<`N$FFEN)733.+I7&I)S)74:E4::(FB)HB:(FB)HB:(FB)HB:(FB+0I_=J
M?T#?\T=$5.:HI$T1-$31$T1-$31$T1-$31$T1?O+:ZI<DL==Q\T7B_1[7DNO
MS,7GY>M8/S)_D1GG,L3@*_R.",(7\YZLDV+D?*9&1(-E755;I&]^18!((1:3
M@%Y'X-OLJ.&;M@(I\-?L!Y=//#BLL6DA:3QI6GD>C#GP5P)'G[Q\9<D+1Q.C
MVV:+?FFAW;'U(R)&T'`V4[Q3<:JY.J4%=:C;,D9+KE<?4"AT%U"6)OWI:4D&
MJ2*I5P$HD;K*$D^8&K2`2!3@<B*\O4HQ`[1K)`!K3$8T-,,53M%\R#CQD.[4
M>K0<'GEC5\NS4W5\$9QLV#;K6N/^?[;"0L[8PJ^'\GRK=!C892S0=7D75<5=
MH1[&TH,SGB'#THIB>-MVPNTX4Z_;P'IZJJ1UI*&!^9Y>6?V<5<.O\W..]KQ9
MQAS!7+/-S%2YA7ZK8PP.U9U68-:K%>+,UM+YQ!S56.D24JJU(94>:5LQGI4R
MP)(IS\2)13V&_P":C#0ZN?7AQ/#DH_EY"\Q@>\/Y!Z50%;\QSCI:LB4^E1D=
MFU&F9(R4XPQC'DA*85N<9Q<R5EI&0DX5O1:5F=RW+%RKJ;GX5W&Q$F=LC`3<
MD@+6/?N5CI%4L^<CUZ3\/K]%/MZL5)\G+H#Z8GA^GRIQ5-0'FD\7K)9:Y$QT
M7G]&F6//,OQ@#.<M@*_0V`(3/L9DJ8Q`VQM.Y1DF;>,2?3^1H4T4QD&J3N%,
M]<-D%WB"ZQ4@K\VW7IIACSKG3`4Q^_!4^5DT:^@'ARKSY8]6*LE4O-+<6EGY
MB3&9P]E/&2O#:^\H*S7,P6CC[EN:P*RK''W#-<R0G8\NV*,>L51LCY]).E@@
M(MRS>R\1\"9D*:CU,^HX[LN+FFE17$8C`<!3$>=226@;H(KC3#`'$]9H?8K_
M`%Y\Q_"6.)YSCUS4>0>8,H5G!6*>0=ZKO'CCQD/)#>#Q=E*/LSB+OCARU*$9
M#Q!EZ5)F"-=/S39B)D2;MWBO6!;W78:.!/G'$CD>7G5C;20XG`>8\`>?(^;B
MJON//[C_``$7@QY1D,J\AI?D?C1'-F(Z5QNQ=8LKW:<PD=K`.5LP3$*S",1I
M]`;'M,>U!U++LUW,@Y*R:HKNRJ(DNDNF,:"W'U>685K+:1[BTBE,//T<\CER
M5\N.^>\<\I</4K.N('4\_P`?7_\`>`*\K9JW*U"Q`O5[;/4>=93%7G$6\Q"2
M#"RUIXW.W<ID5**7VBAOMJ6.5LC-?#CY&BA>PL?H.:LECWG=B7*V4D<<8\Q_
MR0M5==Y`N^*6'(**P'=7'&=]D3'#^?AKO74<O$2%B@U@+)5I&(-,.&J,`O+M
M#LT'RJPE*:(7+72]F!@*\R<.@!3&U>V,2'"M,\,^DE4[C'S(N-.6<AT^C5E'
M,K."RE/7&J8-S19<,W*NX%Y#6N@,YV2L]7P?E"0;%B[E-#&5:4<Q)54F2%C;
MQKA6(5?)IB;5HNV%Q%,.OVX8#IQPQ%0JFTD:T..9X>KGCU<\%B4H/G'<AW-7
MKW)2SXKS-8,4YAYGUWC#2<%1W![)D$C0J5*<C;OB,;#7,YHVV0D<VYM"KX]7
M*\@"1K)FVM,@6-(B!F^RN)\V\.UU%"<JGGU$=9&*R_E(R.S%=0&>!X5YCS`^
ME>@N(RLTG,-K9F;47*T,S+2K#<T\>6W',_7,Q)IP#24<C`/,8/2%L;>U2(Q@
M@TCA*#ASWDNC^\+K8MEU1=I3AY</L6N+*2=G7C18S^-7FB.N0W%SB1F^<QW;
M<"VG.^1N)M$L?^:."<M-<57*8Y%R,DP6J_'JV&E&1[0LX6C138V%=9Y$1954
M%GR:J:Y"ZQ8[LN95Q:*4KF3Z!3RHLJ6TTO+6`G/U>FOJXJ6%*YXXAR/E13&M
M$H7(VTUY/(MTQ$;D'#X&NCSC*3)..7LW$7JM+9?22%BT:5BQ5M_$.9I9HG7A
MEVBC--^=8`*,PNFF4Q@5`KE4G#H`^U1&U>(Q(<*TSPSZ253V,_,8P9EAK(V:
MJT+DVCB4F/;]E.J<@I_CM?87`V2Z)C>)=3M@GJ#D)PW.D[;R,,Q5=0@23:+&
MP-R=V.^(3$##:V[:2</='''B:"N&'E2JN=:2-`_,>&'WXTZ%>N+Y4X9F`XEB
MPFIA7_C<BUIGCT!Z]()#8V#?#CO/*BD]UE`*HH&-F2CD"N^D1<@#?^\'4HG8
M:8YBO'IZ.@\E"8G`.)R:?MI]JLM4_,>XYW/(-*IL3&YM;4[*.0'F)L2\BYO"
MMRAN,.6,GM%9=LC2Z!F-ZW)&2[J>?0#YK"R*K=M!V!VV,C&/G9SI`I$+QA?I
M.77]E/MZJJ5UK(V+M#Y>7)2FS!E%EAJA2=^?4?*V2$X]]#1J%+PICV9RCD>9
M>SLFWBF9(:GP?2Z<-6RS@%7CI51!FP:D.NX532(8P3RR=DPNI7RYT*AC89'A
M@S*QO\@_-<IN.>.5TS%C;$.:)C(V+>37&CCKEG`>1<-W>OY8QJ\SW?\`'[!*
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MQ'EQKBN=_P`=N&ELXO\`"-=IG(;(YZQE2OX2R-EC&&![S>,#XQRU8%H5)+'U
M[RE#-5(Z.F(8UA8EG'#1![&UL[LA95TR."A2'77O:(Q4TPZ^'#[>NBHVW.C7
M(=(^SRK3"IX54.>&7FJ5W)>/</->0=<RQ"W;*/(3,G'AIF:-P'<:_P`9%,GP
MO(;+.-\38Q#)JR7W)^]-FK%0CF1'C8CB&<3B@M5'J;U06Y;8[JA#'CB>=<R,
MJ?;T9X*26U(!>S(`<N0)_DY8J]MY\UGBCCN8R4A9&'(+]R<)9I?\?LXYJB..
M^3)O".'\HLY>"@&L)<L@1D4X;ND)B=L\<T;K0S>6!)9\@#HK;O)">XWC*X"K
M?/\`=]N'-6BTD(X!U,O3]QZU<^@\_,`7%3.#6V(96X_2/'C',9FG)D/R9Q99
M<+3#+"$W^]!(?,<1&V$BSF6HKUW2Y1J<2@23:/F9FKIF@X.FF>YMTPUU84\]
M?9R/53&BM?;2-IIQK^C[Q0\:X*G*SYC^`9@UX2MU1Y%X0>4[".0>2,9'<@,!
M7;$LCDW!^*V#23R%>L5L["EW+.I464FQ4D(5?X"PLB2+4[A@DFL!PM;=L.JM
M!3KZN6'#I5SK25NFF-?+T=.2T8V\R'`>4['!U>`IO)*"?Y`PW;\Z8->9`X[Y
M#H<;R,HM$K\-9;8&#?WA9-)2X66(B;''KEB5VL>^?-W9%V1'#<>\`7;:D$4P
M\N&'EA14-K(`#GCCT>OH^Q1_XN^;=1<M\.\/<E,PX8Y`8WM63HK%,1#4R%P%
MDEVPS#EO+(3YJ_CSC`I(D7<Y>6%O6GCM==)P5K'QR)G;QPBW`QRQQWE8M3Z5
M%./MP]E?M4DEF1+H8:@U]`-.>/JQP61S"698S.=.<V^.H&9,8*QUBE*K+TO.
MV,9[%%^BY>(18.5SJ5Z<!5*4A';:214:2D<Y>QCP!,"*YS)J%+E0R]JW52GE
MSH*K%EC,3]!-?+U*[^IE&FB)HB:(FB)HB:(FB)HB:(O+]_%N8!-E;RL6N6&#
M,R\OQCSYCR_+KI)]Q9"GWTDABFRD,)0$Q6HRUHAUE1_1`&X&'T:UVX,JS6!E
MF>K^7U+8;>^DN@G,?I^Q?F(:TZW*:(FB+*;Y8OFKYM\MR]OD(5!3)7'>^R35
M?+N"960%G'RZA"$:!<Z-**).0IN1XQF4"I/")F;/DB%;O4ED@(*>HW7:(-SC
MX-N`,'?8>CV>I9UE?26CZBICY>7L]B]]/'OD5QUYM8T-F3C1D>&RE6&$>T7L
M%.20199&QU(.BM%U*UDFC.%TYR(=LU'()'=-B.(]QV^XU<'3\0X&?99K.0ES
M2+@#,?"[AD2/0*^A=-%N<=P``:,/`\..'Z5V*YTS`JH+APJU*#A)HU^(*J1@
MJ"G4W%`QP57230`H@4H#N8/`QMP'6(S;HY'Z9XW,EX:33#J.!'1A13R7CF-#
MXBTCC7CZ%2QW!$.A-VFLFFJ50'`MBD?)+).2AUK))*JH"L(KE-[`\-]]_`<A
MNUU=_$#F'(OJ'#E2E:4ZU"Z_`'PD.Y-Q!^]4=*MF[HRHH.GBX`<VQD4%FH@?
M82]TP'4[13[&$NVQ@\-]2BSN6'5(^.@YNU5'H^U4%U;N;I8'8\A2BZEG".GR
MPHH(NG)2H*.UDG+L/AF;1JD99Y(/7:XH-6#)!ND*BJZRB:*9"B8Q@`!'4%U*
MYK0TAKCPTM#?(#F5+`QGQ'4,<03J\B>07GD\QWSG8K%IYG"G"6X15BR&=%>*
MNG(.OC\;7Z`;K%)Y`XC>J`=A9+,<I1(XGRE58LP$2LA64'OIYNQ]V)[Z47NY
M`LLABUF3G]?%K/0YW0,\;<MVCMV&"W.JX.!.;6_83T9#CC@/*4Z=.GSIT^?.
MG+Y\^<KO7KUXNJZ>/7CI4Z[IV[=+G47<NG*ZACJ*',8YSF$1$1'7IC6M8T,8
M`&`4`&0`R`7(.<7.+G&KB<2MC551-$31$T1-$31$T1-$31$T1-$31$T1:%/[
MM3^@;_FCHBIS5%(FB)HB:(FB)HB:(FB)HB:(FB+]Y;75+DEYNJ_C#E+R;K7F
M]\/,:8RQI'X8Y%^8SR&QYD7DK;LON&$YB^GV?'_'MIE$(3!;7'CZ1NMN"I(*
M)5M5*?:L3R+LJKT[9-J)7&FB:]X+&Y&E<.BF=*<3]_/:R&.-S97'W@,!YSTU
MY8T]/#++AOC':*?F+S&K';7[!''O+N[XI=T`T#,+NK3&U"J<2,<\?[*M/HKL
M6R$58"3U6=JM`(JY*J@"2QC%,84RYO8.=(YSJ5H/2-)Y95"PS-^[:UM</O=]
MA6-3AAY95LXY6'B]0[IP>XUV9;C/.58A>:2'+O-4FXL,5C>%?PE+RC3.+,Y7
M)%I6<URS`K4'L<ZD"P$6Y7>*-'BR'90'&CMY->APJT#C6F7.GL/G65)=,+"Y
MIHX\LQ^UZZ>928X_>7ID+%O.S(V5K39ZI(\0J).YSRQPUQE$.'Y;;CK-/-0:
MN]Y42,ZU4:I14;"UZ2@YT*@+910R+>]RQ3%(``74K+9XF+L-(RSZ^@9Y@<"1
MR4+[D&$,`]\Y\N73PIZ`5%/B=Y65DXVSN`\76;A-QTR[$X%RQ59^%YG3'+O-
M$<^D*-1+P-II-^-Q6<5N7CFG(6OQR#4GP*;X*P::0%ZD\20.#8D3;>5K](KA
MERZ,=)'EGP4S[F-["3@2*'#''/\`$/+"G%232X%9Q+P0A^-9W]"-D-AYC;;E
M>LY_>-^-:'%Z/F<N>89VJ4I]Q_$#;/\`*E8$@9_#`E]\[MN_V_V^LCL7:.G5
M7C^>O+DL;MF]KKQIHIY]-/:NON_$[EB%>\V'CI5,>XOL6*?,`5Y.9-QGG9_F
M4U=E:-=LX<6:AA^+QI?,2*T&1DUF[._4PIS3D?*K-B1+T%C(BNB9N>-D<L;7
M04]TMSH<Z`9TZ.M2OEBD>V<U#FN&'1J)^WJ4DL%\6LF8WY$9YRG8'=54J^2^
M#_"_CM7D8V8=N91/(''YAR#;7EQ*,E8QLDUKJRF4HW[O=%544<@5?J22Z"]<
MD4+FDUI7#^TX\ND*.>9D@:&UP/\`R6C["L:<'4;9Y5K'@-<+=G?@]3,KP/EQ
M4[A+E2B\HLXVK#E$F0X_V:)OQ,F8/R1$8ZN"]T=5>PW)ZVE*XM%Q[N:8NF2C
M9=%5`Q#8SH3'1SB,6<P/P@<1GB>'*I"R62B;4&@TU@Y$YNKB!D,`#GQH.61#
MR=ZS<JAY;W%QED.)=U^TS,=D_(+^/6AY6NN4XW*6=LGY-KDBE7[`(3T$C,5B
MVLWS=F_V>MD'!"+_`+4I]95J'=@:C$DY\:@>16)=:3.:'W</4**,6.>#_(B"
MYA0N2Z5B.L\.<>.LQ99NG).:POS6RMD/#'*O'=[@;Y&_=#+A;/TV&Q_C7*]W
MLM@B;#+V!/X!:&DV#H[=Q)G==0PB*7M2`,`2<:TKPY#/D*])4[IHNR`=4F@'
M"HI3CB>>>!Y!<C!_#'F`PK/E]\3LLUC#->X]>71EB@Y%CN0].RE*V*\<AH;`
M50O5+P+`Q.&%J'#+8JG)AG;6CNZN'\X_;$4CEV\>+M-[W$+/EYGCLB!1H..6
M8IG3'(9>OA<+B&-QF;4O<:D>>OW^K*F/;$X(\BJIP%PGA^N(8UL^>N/'/0>:
M,%47UVD*_1,BQ,'S>R7R*CL>J9"&K22U4F[#CB\$;E>*Q3EJRF2=I4#(`9;4
MSX7F($?$TGUNKU\.2B$S#*ZOP.:!7E[M%EMH<C=;7C^%?Y.I++%UWGH9X2TT
M:)N3/)#2I.W9WK0K%M=&,/7&%F.1@*2QE4F;=,%3F2#J`G<-E,+WQU<*.\X]
MN(]:Q7AK7D,-6@K#7B#AKS$:<4N#?$C(>/<255#@-R<X6VV,RO`YK5MD;G3$
M_'*Z3[RSVF+IPX^AIK'MG=55*.6;Q$@NY[[]TN@"Y$FY5UL`02N;H-*M-!@<
M<AG3H]?IS3-"UY>"[WP:Y5!QR]/JKQP["B\+.2E;YH068,:8AI_$"K$SWD7)
MN?[7BCFEE>_8/Y88]LD9=D4X"5X035+B\?4K*>2+!+PTO8)X@,U8A^R=KMG<
MFHX+U7B&3MM(J&5)KCZ<1IKYJ])5'31=CCBZ@`&&%*<?B]=.%`J,X^^7OR)K
M^2+!'Q6-Z_P3P!:\&\B,99HP[BWF;E3E!@++5RS#6A@:79L*\?KU4JS6>.\)
MCZ=?OYPZS`L2Z63<!%@Q41.=P2QL$KCIR:.OF#QH.'`#IYJ1US$T:OB>>H4P
M(',X=)//!5OA'BUSBD++Y7-<S=B[!..L;^7C5[OCV[V^EY]FL@VW,1'G#ZS<
M9*_=J!4QQ35F=/@)-R_0?K,I625EFQW!B]/0VZW%T<4NIM<--1QY&G#F3T4P
MSSBDEAT/#:DOQ]8//H\JT%E^)'E:6?CA+<>,6VCA+QRR>QX]Y$J<C%<TG_+O
M-#=[*T['M@4E*-D=GQ6?5R5CXOD%&QK=H51A\>%92ER*NT'I6YB-BVQV\C90
M,:-]&'3I(\L^"DDN8WQDC`N%*4Y^<>GU<5DR\Q+!.7N0^"*Y2\1D:V/[FS7C
M*^93PY(93LN$8WD=AJKNY0]WP3(Y9J3-_,4UG:5GK)\83)&8R0Q01[T2M':Q
M@RKIDCV>YP\LO+ED2L6V>QDM7C#R\NC/@L9,#Y76>(O$?/5C0\,<8^.DIG7.
MO`CD/Q\X_P"/<F3LYCV-D.'4]C6\3U(R1D!/&T$,-8\CS=`4;.)AC$R#1)P^
M!?\`;II&44Q6V\H!<`.'1Q:<J?JY9]966ZZB-&8D8U/F<.9_-U=2FO/4SFDM
MRPP7S<BN-.,7D\^XWY)XNYGP#(<G8QC(8UCK#GJD94J>3JYDY+%;RM9&9GB*
MNZ2E(=)FP=ME7"!4%G'2H8*B.9NF0?$13(X8`99Y"N-/.HM4!:8B3H!J,L<\
M*^?SJ!D_Y7_).UY-KTW;L*8!R!E.G>8ECKE')\_\B\AKM9<M7?`M/Y2,\NPF
M-<=X<DL?RJ>'I6H8B;M:J:$;R[2N]B+'X45CO!.D[&4R@G@X'+IKR/#"@-![
M)/F(A%I&%6D4\U.?.IJ14U60K`>-.9/%3)^3,74+$V%\I\>,L<P\H<DF&=)[
M.<M1;IC>B\@\BADS+E+L^'4L96*0O=[J$Y+2Z%9=,)QO&2C-5D5\=B*"P*7B
M.4.<P@$/SSZ\Z$#,TKT9<8G21.8'U(>T"@ZA0<1R%:#GGA2T]<X$9PB>"O&?
MC<Z?T(^0,/\`F"T3E!:'"=B?J5M7&E:\P*W<H'[6'E!@RN'EH-C><133:&;H
MI&E.I`5@('>&X0NTMZ'5X_F!Y<@K3,PR.=C0LI^S3VK3D'@/G*T<1?,#P9&2
M%!)=.3_/NQ<G,:+NK'((P37',KGC`62VK>SR!8-1>(LX5_&4D!FB2#E,KHR)
M.\(*&.2(6KQ&0:5JWGPK7ATJ5URQTK7XZ0#Z_.JKYL>7I=.8&6>7[T;=7Z;C
MSD7Y<5:XF5JP*K2$A.P66*[G[)67F4M8*PR39*.J`#:QQA'9F\@1VY)\2B0J
M9@(H-TEM(Z@%,&`>@$?;_(J1738P<"27D^8EI^Q1JJGEXY!F:IFZ&/P"XR\<
M,E6GAWR8P;#9KA^:>9<_.I;).:L;'I#=ICZK7*EH!0\5620,#F8?2RH3*#=!
ML@1HX,0ZH1-MI'!P.8'&O,9>[CYO0I3=1@M()I6N`Z_UCY5Q4Y"\4,F'RAY6
M-N6>U8(;AIB#,%!S$))=T>0=3%^XT4C$$.K26YHPJ<^S3M-><'7.NHS$C02*
M`4QC"0)?EG@L(IAU\'%W+#/TJ'YEE'YU=]U%#2D<0.4$5Y?^,N#&9N%O'WD%
M`\8W^.*W39@W,6V8L?9<K]%?W0T+F7%-LJ6+V=XX[9FJ2"L.Z:)NGQ>Z=Y(M
M"/T4R$6<6B*01EA%2TBF!Y4Y8Y#*G7Q5QEB[82M)&H&N6%3U^VO.G!2DXHXE
MYV\?<)5.H2;VI7Q_/\MU9Z2I><>0>1LZ6;CIPGL+5LE(8_K?(&:@X^V9SRY3
M9.-4?18S*8L$TI<[#XMPDQ274FB;,Q@KF7#GEYP3YSCPK0"L4KX7R$BND-H.
MOS4'HZZ8K)]K-6(OFB)HB:(FB)HB:(FB)HB:(HH<[N/3?ECPLY4\;5D"+N<Q
MX)R-3X(#E`W8N"U>=R-'>$`P"'=87./8+$]ADPU!<1]I$6TJ>'L]5:J:!_9R
MM?6@!7XH2[9TR779/D%6KYFNLT>M5TS)+MGC50R#ILLD8`,FJ@NF8ABCX@8!
M#7.KHUMZ(FB)HBN-BO,.6<&6YK?L+Y+O>*+LR*5)"TX]M,Q4YOX<KA!T+)P^
MAG;15Y'J.&R9SMUNX@H)`ZB#MJR2*.9NB5H<P\"*JK7.::M)!6<7%G\2%S>J
MD>PB\LT/`>?2,BHE/8['4YG'][>@FGVSJ2%BQI.UZ,DG:^P&.LYC5CB<-QWW
M$-:V79[5^#:@<`<0.JN/K64R\F9QJI<?_P!R[2'RPGD>%5J8I?`B0"1?(")>
M=#U40,N4@R6)"G^[^H1$@&,90-@WW$1'6`[8*$]F8Z'F#PZB%D#<74`=6OET
M*VTW_$AJ)E$:EPMA%77=$?B;WFZ;DFW9#JZ2C&U2DU@QE=A\3"YZ?#]$=4'=
MXN;I?(UH_4;3UDGV*O\`B1::M:21^8U^P+$GRX\T;E_S'*_@+Y?B4;%;LX`G
MA?$R+FE8[.@GU%1+8&S9VM-7=T5,0`RTR[>[F#J*4GHUG66R6-F[M*&2?#WG
MT-*<A2@ZP*\RH9]PN)QIKICQP'3G4YGV+'@`````````;``>```>@`#U`&MN
ML%?=$31$T1-$31$T1-$31$T1-$31$T1-$31%H4_NU/Z!O^:.B*G-44B:(FB)
MHB:(FB)HB:(FB)HB:(OWEM=4N26@B220J"DBBD*RAEEA2232%98X%`ZZPIE*
M*JQP*`"<VYA``W'P#5$6O5431$T1-$31$T1-$6PX:,WA4R/&;-Z1%8CA$KQH
MW=E1<)^*;A$KA-4$ETQ_1.78P>H=4(!S5:T7),8QS"8QA,8PB8QC"(F,(CN(
MB([B(B.@``H,D6G551-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1
M-$31$T1-$31$T1-$31$T1-$31$T1;B:ADE$U2>!TSE4*/L,0P&+](:M(#@6G
M(A5!H:C-?CV>>-Q<'B'YJ/,+%C&./'5&>R:\S)CQ,$P(U-1LUH)9(BF\?L`%
M%G"/I]U&``>!#L3%_D[!SLS2R4@TK7R]>"Z*!_:0M=T4]"Q/:B4R:(FB)HB:
M(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(M"G]VI_0-_P`T=$5.
M:HI$T1-$31$T1-$31$T1-$31$T1?O+:ZI<DFB)HB:(FB)HB:(FB)HB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(OS5OXQ;_P#Z9X;_`/9C_P#PUQ[_`/4K_P!I_P#])V6__;#_
M`/%O_P!Y[ZT=]_&&67#K/KY]*W6W?P#_`#OL"\G&L)9Z:(FB)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(M"G]VI_0-_P`T=$5.:HI$T1-$
131$T1-$31$T1-$31$T1?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g532389g42z24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g532389g42z24.jpg
M_]C_X0]]17AI9@``34T`*@````@`"`$2``,````!``$```$:``4````!````
M;@$;``4````!````=@$H``,````!``(```$Q``(````>````?@$R``(````4
M````G`$[``(````&````L(=I``0````!````N````.0`+<;````G$``MQL``
M`"<0061O8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q,SHP-3HQ-"`P
M.3HP-#HU-P!E<FEC:``````#H`$``P````$``0``H`(`!`````$```#'H`,`
M!`````$```"N``````````8!`P`#`````0`&```!&@`%`````0```3(!&P`%
M`````0```3H!*``#`````0`"```"`0`$`````0```4("`@`$`````0``#C,`
M````````2`````$```!(`````?_8_^T`#$%D;V)E7T--``'_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`",`*`#`2(``A$!`Q$!_]T`!``*_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U5))))2DDDDE*22224I4L$DYG49)(%[(!/'Z#'X5U4L'^F=1_X]G_
M`)XQDE-U))))2DDDDE*22224I))))2DDDDE*22224__0]522224I))))2DDD
MDE*5+!_IG4?^/9_YXQE=5+!_IG4?^/9_YXQDE-U))))2DDDDE*22224I))))
M2DDDDE*22224_P#_T?54DDDE*220;,S%JW;[6@LC>`9(W$,;N:WW-]SDE)DD
M+[3CR!ZK)+?4'N&K/])_4_EIVWT/V[+&N]20R'`[MOTMO[VU)214L'^F=1_X
M]G_GC&5U9^+8RK(ZI;8X,8RYKGN/``Q\<N)24Z"2I_M7``87V>F;&66M;8US
M';*?Y][J[&ML9Z?\MJ7[7P/LOVO>[T@XUN'IV;VN'TFV4;/7JV-][_4K]E?Z
M3^;0XAW">$]BW$E3?U?IU8N=9<&-QX]1[@X-U/I_HWENV[]+^B_0^I^E_1?S
MB)=G8M%S:;;-CWB>#M`U@VV`>G3OV_H_5<SU?\&EQ#N%4>Q;"2I5]8Z?8*B+
M'`7$AI=6]@!:-WZ;U&-^S[VG]#Z_I^O_`('U$;$S,?,J];'<7,F#N:YA!@.]
MU=K6/;N8YMC/;[Z_TGT$A('8A1B1N"G22210I))))2DDDDE/_]+U5))))2E0
M'2]U]EMCXW6;V-;$032YV^1[M_V=7TDE.9=TW%8(LN+&VDM`.T398+*V;=/W
M+GM]+Z'_`((C?LW'.0+]P=#]^T@$<AS-O[NRQGTT7+Q?M'I0X--3R\$MW:['
MUCG_`(S<JE?2',MIL-C3Z+R\,#(:=Q]S=N[Z+/IT?Z.[](DITUEBBG(_;%%[
MME-MFVQX.V&G&QPYVX_1VK466,89?[8Q2XL%]@K+V\C=C8[=P0.QZI&XZ-;'
MHPZ\6EU?465V;<BVJR&L:"6[+K*L:SVUTXGTW5_0_P!-_.)-^S-Z,(ZA3]GL
M=L=>ZH.;8YQ<VUN17:]_J6/:=UO\W^D9ZO\`,;Z58JZ/DLJK=]H9]HK%Q!],
MFL&UNUE==;K/4;C4N]_H^M[_`/@TW[+SOV<_$%U/J7$F^TUO/J;]S+G61<VS
M>]CO\':ST]GI?S'Z-1\)_=Z=_P#T)DL?O=?Y?HM-M72L8Y['Y\%]1JN<YOZ0
M!TM^T95D?K3JW#91>[]'35^B5O+Q<3)R\7)ORZXL:XTL<ULNK`-Q^S.L)V;J
MG;<US/Z3C?H[$9W22^J^M][G'(-37O(U]&H,:_']FQFV_;D;_397_2K/8C7X
M=M]E5KK&M?0][F.:R3M>Q]36^]Q^CO\`4?\`Z38CPFJK^7%_>1Q#>_Y4Y&+1
MTZ,2MO46/&18;"-HFU[`VEOI/M=;;1^A8S%LWOL]>A_H?X5:'0J,:K$>['M^
MT"U^Y]H#F@EK64LV-L+W;&TUU_X1_P#P?Z/V(-?2,\/8;<FI[#:ZZ^KTW!KK
M"6[+&3:_^:V>HRF[UZ_M#_4_P./55;Z5@VX-#JK+&OW/W-96TLK8T!K&LIK>
M^YU;?9ZCF^I_.OL0A$@CTTJ4@0?5;=2224K&I))))2DDDDE/_]/T<]6J!(]#
M),$B119&AC]Q+]KT_P#<?*_]A[?_`""O))*:/[7I_P"X^5_[#V_^02_:U/\`
MW'RO_8>S_P`@I9E699=4<<[&MU+]Y'<;MU,;+6[%2_9V>ZI['0?5/Z1IL<9.
MRJOU;+-OO9[+?T'_``B2FW^UZ?\`N/E?^P]O_D$OVO3_`-Q\K_V'M_\`(*#<
M7J`L83<[;+RZ'3#BYSF_3:YOI^EMKV[/T*C5C=2:<<N>2&/.\&PD%A(]UGYS
M[?I;/\"DI+^UZ?\`N/E?^P]O_D%#I5K;K^H6M:YH=D-]KVECA%&./=6_:Y:*
MS&,-AZQ6VL7E]D"ESMC7DXV/^C?8`_8U_P!'?L24Z/J5G;#A[]6:C7O[?WDX
M(<`6F0>"%SC>AYD5"JEF,[T[6/<'-+&>H;2^O'I97OQV6>K^@?C9#/2K_G_5
M_P`/:P.E75VXE[J*\84V7.&/6Z6TUVM#?2JVM96_?:SU7>SV;_T:8)R/Z*\Q
MC^\[,A.L%W0;CDEP97Z/K&OZ3@?L=A^VWLV@;?5=G_H__"JEZ77&V!CW.;]I
ML#3L>7[&D/\`M5S7NKVU[-E7V7=^_P#S"7&1O$JX!TD'<26&S#ZVZMC2YU;G
M/WV;KB\-#BQME%9:/TE->/O95;9^E?D?IOU;]&B8N%U1K]CSMQ_LSJ=CK762
MX-I90^8W?FY/K/;^_P#X?_!+B/[I5PC]X.LUS7B6D.'$@SPI+F\+I'5L7'+:
M&^@26#8U[`=[:_29<]V/512_'J?_`(#T?6O_`,-99_159LPNLV.WN<)ITK=O
M]SI=9ZSZH:/1?=C/935N?^A_\%>A,U\I48"_F#MI+(&-UD`-+R^O:UQ'J187
M$BJVK<UC?97C-]6O]+OLRO\`#?X55[^F]<MPG4VV^K9:STK&BTM;/IUL9;N]
M/^;]7[3Z]7I_I_5_ZVD9G]TJ$!^\'?2223UC_]3U5)43G9H)'[.O(!(!#Z-0
M#]+^D?G)?;\S_P`K;_\`/H_]Z4E-Y)4OMV7_`.5V1_GT?^]*7V[+_P#*[(_S
ML?\`]Z4E-U)4OMV7_P"5V1_G8_\`[TI?;LO_`,KLC_.Q_P#WI24W5DOJLNKZ
MW34'&RQVQ@8[8Z78U#?99+=C_P!U^Y6?MV7_`.5V1_G8_P#[TJ'2WNLR.H/?
M6ZEQR&S6\M+A%&/SZ3K*_=_72.H4#1MH_9>M,=ZK-[K0P4-<][7@-I-M;,KT
MW/\`3];+]3UW?]LV?01K!]81O-3MQ9N96UXK`<!]HV7V%ON]33$]K?3K_P"#
M_P!#L))G!XR^U?Q^`^QPLG(ZY50;&[]K&6.+W-K^ALO=4Y]3?=]IK>W&^@[T
M[/\`0_SGI.\=>L!J(L]-X<&']&UQ8=P><A]<>EE-;L^R_9OT?^G_`."W$DN#
M^M+[5<?]4.7BV=3IOC(J<:"T`-8&PUSG-8/HFRRW=N?98_?7Z+/\&@WXG4SF
M9!K%GHW757@BP``X_P!FVUL;OW-JRH?ZS/\`NM;_`-REM)(\&E64<>MT'(Z3
MB]0Q\@5Y`L=170T5VV6>H=SW%[\>WW;G68T?H\C_``M%E?\`A*G^I3R\#/?9
MG13<^NVQKB1Z9>_:Z:F5;KZVVX>S^>JM^R6L_P"'_2+HTD#C!%64B9NZ#S]N
M)U:PO.;CFW'=74+*<6\@D,=;^AH;8<;TW?I*[;[/7_3;/3]3_!(O3\;JE.>Z
MRRO>7U5B^^UPC<&U-VXKJW/>]GLMWLOQZ?T_^$_2K;22]L7=G17&:J@X&#A9
M@H!%>3CD9E=WH66@PS1MOJ6BZ[[1N_G[V>IL^T?0]3Z=HL7HV<]K:\@6&O[0
MP[WO+;6AH=9DY$U7V?TVVNJKV6?GV6,HJ72))>U'3P5[AU\7_]7U5))))35S
MLF[':PU5BPV'8T&1[R/T6[:';:]P][E3LZIDOK>ZJL,'HFZMQG?M/OJ?Z+AN
M=[?9<S_!O6LDDIRG]5OVZ,;!9:0YDDDLW[+&-V_S+MG\[_ZC]:;,_*&2*'-8
M[=:YI.K(:'`-8W?].UM9];^76M)))2EFU66UV=5LI9ZEC+FN:S]Z,?&.T1^<
M[\U:2I8/],ZC_P`>S_SQC)*:AZQG`FW[&[T`[;`:_P!30?:O4V>G]#[!_P##
M#]1_EJ=?5,T6"N_&V0X^I;#_`$VM`]=VI9_W&LJ;_P"&_6I_P2U4DWAE^\NX
MA^ZX'[1ZH'.I)<7NVD`5Q8T;G;K&[F"E]3MOH_U[$1G6\USJQZ`<7/`+`UX)
MDM:_&8YX:W[1B-<ZS(?_`#/Z/_COLVVDAP2_>*>(?NAQ;^MY+;;&LK8RH.:&
M6/:]P:PM]1N7<ZOV>AD._0T,9^D]3_K_`*$Z^J=2<ZI[\45UV.:#60_U&@V,
MQ7;SM]/>UUOK_P#%5_\`7:]=)+AE^\CBC^ZI)))/6J22224I))))3__6]522
M224I))))2DDDDE*5+!_IG4?^/9_YXQE=5+!_IG4?^/9_YXQDE-U))))2DDDD
ME*22224I))))2DDDDE*22224_P#_U_54DDDE*22224I))))2E2P?Z9U'_CV?
M^>,9752P=OVSJ,3/KLW3$3Z&/]"/Y/[R2FZDDDDI22222E))))*4DDDDI222
M22E))))*?__9_^T7=%!H;W1O<VAO<"`S+C``.$))300$``````!1'`%:``,;
M)4<<`@```@``'`)0``5E<FEC:!P"!0`S0T].4T5.5"!/1B!)3D1%4$5.1$5.
M5"!#15)4249)140@4%5"3$E#($%#0T]53E1!3E13`#A"24T$)0``````$#'M
MDJ'\;NZ4SQ#(\14^4V0X0DE-!#H``````.4````0`````0``````"W!R:6YT
M3W5T<'5T````!0````!0<W138F]O;`$`````26YT965N=6T`````26YT90``
M``!#;')M````#W!R:6YT4VEX=&5E;D)I=&)O;VP`````"W!R:6YT97).86UE
M5$585`````$```````]P<FEN=%!R;V]F4V5T=7!/8FIC````#`!0`'(`;P!O
M`&8`(`!3`&4`=`!U`'````````IP<F]O9E-E='5P`````0````!";'1N96YU
M;0````QB=6EL=&EN4')O;V8````)<')O;V9#35E+`#A"24T$.P`````"+0``
M`!`````!```````2<')I;G1/=71P=71/<'1I;VYS````%P````!#<'1N8F]O
M;```````0VQB<F)O;VP``````%)G<TUB;V]L``````!#<FY#8F]O;```````
M0VYT0V)O;VP``````$QB;'-B;V]L``````!.9W1V8F]O;```````16UL1&)O
M;VP``````$EN=')B;V]L``````!"8VMG3V)J8P````$```````!21T)#````
M`P````!29"`@9&]U8D!OX````````````$=R;B!D;W5B0&_@````````````
M0FP@(&1O=6)`;^````````````!"<F1456YT1B-2;'0```````````````!"
M;&0@56YT1B-2;'0```````````````!2<VQT56YT1B-0>&Q`<L``````````
M``IV96-T;W)$871A8F]O;`$`````4&=0<V5N=6T`````4&=0<P````!09U!#
M`````$QE9G15;G1&(U)L=````````````````%1O<"!5;G1&(U)L=```````
M`````````%-C;"!5;G1&(U!R8T!9````````````$&-R;W!7:&5N4')I;G1I
M;F=B;V]L``````YC<F]P4F5C=$)O='1O;6QO;F<`````````#&-R;W!296-T
M3&5F=&QO;F<`````````#6-R;W!296-T4FEG:'1L;VYG``````````MC<F]P
M4F5C=%1O<&QO;F<``````#A"24T#[0``````$`$L`````0`"`2P````!``(X
M0DE-!"8```````X`````````````/X```#A"24T$#0``````!````'@X0DE-
M!!D```````0````>.$))30/S```````)```````````!`#A"24TG$```````
M"@`!``````````(X0DE-`_4``````$@`+V9F``$`;&9F``8```````$`+V9F
M``$`H9F:``8```````$`,@````$`6@````8```````$`-0````$`+0````8`
M``````$X0DE-`_@``````'```/____________________________\#Z```
M``#_____________________________`^@`````____________________
M_________P/H`````/____________________________\#Z```.$))300(
M```````0`````0```D````)``````#A"24T$'@``````!``````X0DE-!!H`
M`````SD````&``````````````"N````QP````(`,``R`````0``````````
M```````````````!``````````````#'````K@`````````````````````!
M`````````````````````````!`````!````````;G5L;`````(````&8F]U
M;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P``````````
M3&5F=&QO;F<``````````$)T;VUL;VYG````K@````!29VAT;&]N9P```,<`
M```&<VQI8V5S5FQ,<P````%/8FIC`````0``````!7-L:6-E````$@````=S
M;&EC94E$;&]N9P`````````'9W)O=7!)1&QO;F<`````````!F]R:6=I;F5N
M=6T````,15-L:6-E3W)I9VEN````#6%U=&]'96YE<F%T960`````5'EP965N
M=6T````*15-L:6-E5'EP90````!);6<@````!F)O=6YD<T]B:F,````!````
M````4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG````````
M``!"=&]M;&]N9P```*X`````4F=H=&QO;F<```#'`````W5R;%1%6%0````!
M````````;G5L;%1%6%0````!````````37-G951%6%0````!```````&86QT
M5&%G5$585`````$```````YC96QL5&5X=$ES2%1-3&)O;VP!````"&-E;&Q4
M97AT5$585`````$```````EH;W)Z06QI9VYE;G5M````#T53;&EC94AO<GI!
M;&EG;@````=D969A=6QT````"79E<G1!;&EG;F5N=6T````/15-L:6-E5F5R
M=$%L:6=N````!V1E9F%U;'0````+8F=#;VQO<E1Y<&5E;G5M````$453;&EC
M94)'0V]L;W)4>7!E`````$YO;F4````)=&]P3W5T<V5T;&]N9P`````````*
M;&5F=$]U='-E=&QO;F<`````````#&)O='1O;4]U='-E=&QO;F<`````````
M"W)I9VAT3W5T<V5T;&]N9P``````.$))300H```````,`````C_P````````
M.$))3004```````$`````CA"24T$#``````.3P````$```"@````C````>``
M`0:````.,P`8``'_V/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;
M`(0`#`@("`D(#`D)#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01
M#`P,#`P1$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``
M$0@`C`"@`P$B``(1`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,`
M`0($!08'"`D*"P$``04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#
M`@0"!0<&"`4###,!``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"
MT4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6T
ME<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$
M!08'!P8%-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,5
M8W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3T
MI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]522
M224I))))2DDDDE*5+!).9U&22!>R`3Q^@Q^%=5+!_IG4?^/9_P">,9)3=222
M24I))))2DDDDE*22224I))))2DDDDE/_T/54DDDE*22224I))))2E2P?Z9U'
M_CV?^>,9752P?Z9U'_CV?^>,9)3=22224I))))2DDDDE*22224I))))2DDDD
ME/\`_]'U5))))2DDD&S,Q:MV^UH+(W@&2-Q#&[FM]S?<Y)29)"^TX\@>JR2W
MU![AJS_2?U/Y:=M]#]NRQKO4D,AP.[;]+;^]M24D5+!_IG4?^/9_YXQE=6?B
MV,JR.J6V.#&,N:Y[CP`,?'+B4E.@DJ?[5P`&%]GIFQEEK6V-<QVRG^?>ZNQK
M;&>G_+:E^U\#[+]KWN](.-;AZ=F]KA])ME&SUZMC?>_U*_97^D_FT.(=PGA/
M8MQ)4W]7Z=6+G67!C<>/4>X.#=3Z?Z-Y;MN_2_HOT/J?I?T7\XB79V+1<VFV
MS8]XG@[0-8-M@'IT[]OZ/U7,]7_!I<0[A5'L6PDJ5?6.GV"HBQP%Q(:75O8`
M6C=^F]1C?L^]I_0^OZ?K_P"!]1&Q,S'S*O6QW%S)@[FN808#O=7:UCV[F.;8
MSV^^O])]!(2!V(48D;@ITDDD4*22224I))))3__2]522224I4!TO=?9;8^-U
MF]C6Q$$TN=OD>[?]G5]))3F7=-Q6"++BQMI+0#M$V6"RMFW3]RY[?2^A_P""
M(W[-QSD"_<'0_?M(!'(<S;^[LL9]-%R\7[1Z4.#34\O!+=VNQ]8Y_P",W*I7
MTAS+:;#8T^B\O#`R&G<?<W;N^BSZ='^CN_2)*=-98HIR/VQ1>[93;9ML>#MA
MIQL<.=N/T=JU%EC&&7^V,4N+!?8*R]O(W8V.W<$#L>J1N.C6QZ,.O%I=7U%E
M=FW(MJLAK&@ENRZRK&L]M=.)]-U?T/\`3?SB3?LS>C".H4_9[';'7NJ#FV.<
M7-M;D5VO?ZECVG=;_-_I&>K_`#&^E6*NCY+*JW?:&?:*Q<0?3)K!M;M9776Z
MSU&XU+O?Z/K>_P#X--^R\[]G/Q!=3ZEQ)OM-;SZF_<RYUD7-LWO8[_!VL]/9
MZ7\Q^C4?"?W>G?\`]"9+'[W7^7Z+3;5TK&.>Q^?!?4:KG.;^D`=+?M&59'ZT
MZMPV47N_1TU?HE;R\7$R<O%R;\NN+&N-+'-;+JP#<?LSK"=FZIVW-<S^DXWZ
M.Q&=TDOJOK?>YQR#4U[R-?1J#&OQ_9L9MOVY&_TV5_TJSV(U^';?95:ZQK7T
M/>YCFLD[7L?4UOO<?H[_`%'_`.DV(\)JJ_EQ?WD<0WO^5.1BT=.C$K;U%CQD
M6&PC:)M>P-I;Z3[76VT?H6,Q;-[[/7H?Z'^%6AT*C&JQ'NQ[?M`M?N?:`YH)
M:UE+-C;"]VQM-=?^$?\`\'^C]B#7TC/#V&W)J>PVNNOJ]-P:ZPENRQDVO_FM
MGJ,IN]>O[0_U/\#CU56^E8-N#0ZJRQK]S]S65M+*V-`:QK*:WON=6WV>HYOJ
M?SK[$(1((]-*E($'U6W4DDE*QJ22224I))))3__3]'/5J@2/0R3!(D461H8_
M<2_:]/\`W'RO_8>W_P`@KR22FC^UZ?\`N/E?^P]O_D$OVM3_`-Q\K_V'L_\`
M(*695F675''.QK=2_>1W&[=3&RUNQ4OV=GNJ>QT'U3^D:;'&3LJK]6RS;[V>
MRW]!_P`(DIM_M>G_`+CY7_L/;_Y!+]KT_P#<?*_]A[?_`""@W%Z@+&$W.VR\
MNATPXN<YOTVN;Z?I;:]NS]"HU8W4FG'+GDACSO!L)!82/=9^<^WZ6S_`I*2_
MM>G_`+CY7_L/;_Y!0Z5:VZ_J%K6N:'9#?:]I8X11CCW5OVN6BLQC#8>L5MK%
MY?9`I<[8UY.-C_HWV`/V-?\`1W[$E.CZE9VPX>_5FHU[^W]Y."'`%ID'@A<X
MWH>9%0JI9C.].UCW!S2QGJ&TOKQZ65[\=EGJ_H'XV0STJ_Y_U?\`#VL#I5U=
MN)>ZBO&%-ESACUNEM-=K0WTJMK65OWVL]5WL]F_]&F"<C^BO,8_O.S(3K!=T
M&XY)<&5^CZQK^DX'['8?MM[-H&WU79_Z/_PJI>EUQM@8]SF_:;`T['E^QI#_
M`+5<U[J]M>S95]EW?O\`\PEQD;Q*N`=)!W$EALP^MNK8TN=6YS]]FZXO#0XL
M;9166C])37C[V56V?I7Y'Z;]6_1HF+A=4:_8\[<?[,ZG8ZUUDN#:64/F-WYN
M3ZSV_O\`^'_P2XC^Z5<(_>#K-<UXEI#AQ(,\*2YO"Z1U;%QRVAOH$E@V->P'
M>VOTF7/=CU44OQZG_P"`]'UK_P##66?T56;,+K-CM[G":=*W;_<Z76>L^J&C
MT7W8SV4U;G_H?_!7H3-?*5&`OY@[:2R!C=9`#2\OKVM<1ZD6%Q(JMJW-8WV5
MXS?5K_2[[,K_``W^%5>_IO7+<)U-MOJV6L]*QHM+6SZ=;&6[O3_F_5^T^O5Z
M?Z?U?^MI&9_=*A`?O!WTDDD]8__4]525$YV:"1^SKR`2`0^C4`_2_I'YR7V_
M,_\`*V__`#Z/_>E)3>25+[=E_P#E=D?Y]'_O2E]NR_\`RNR/\['_`/>E)3=2
M5+[=E_\`E=D?YV/_`.]*7V[+_P#*[(_SL?\`]Z4E-U9+ZK+J^MTU!QLL=L8&
M.V.EV-0WV62W8_\`=?N5G[=E_P#E=D?YV/\`^]*ATM[K,CJ#WUNI<<ALUO+2
MX11C\^DZROW?UTCJ%`T;:/V7K3'>JS>ZT,%#7/>UX#:3;6S*]-S_`$_6R_4]
M=W_;-GT$:P?6$;S4[<6;F5M>*P'`?:-E]A;[O4TQ/:WTZ_\`@_\`0["29P>,
MOM7\?@/L<+)R.N54&QN_:QECB]S:_H;+W5.?4WW?::WMQOH.].S_`$/\YZ3O
M'7K`:B+/3>'!A_1M<6'<'G(?7'I936[/LOV;]'_I_P#@MQ)+@_K2^U7'_5#E
MXMG4Z;XR*G&@M`#6!L-<YS6#Z)LLMW;GV6/WU^BS_!H-^)U,YF0:Q9Z-UU5X
M(L``./\`9MM;&[]S:LJ'^LS_`+K6_P#<I;22/!I5E''K=!R.DXO4,?(%>0+'
M45T-%=MEGJ'<]Q>_'M]VYUF-'Z/(_P`+197_`(2I_J4\O`SWV9T4W/KML:XD
M>F7OVNFIE6Z^MMN'L_GJK?LEK/\`A_TBZ-)`XP15E(F;N@\_;B=6L+SFXYMQ
MW5U"RG%O()#'6_H:&V'&]-WZ2NV^SU_TVST_4_P2+T_&ZI3GNLLKWE]58OOM
M<(W!M3=N*ZMSWO9[+=[+\>G]/_A/TJVTDO;%W9T5QFJH.!@X68*`17DXY&97
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MH_\`'L_\\8R2FH>L9P)M^QN]`.VP&O\`4T'VKU-GI_0^P?\`PP_4?Y:G7U3-
M%@KOQMD./J6P_P!-K0/7=J6?]QK*F_\`AOUJ?\$M5)-X9?O+N(?NN!^T>J!S
MJ27%[MI`%<6-&YVZQNY@I?4[;Z/]>Q$9UO-<ZL>@'%SP"P->"9+6OQF.>&M^
MT8C7.LR'_P`S^C_X[[-MI(<$OWBGB'[H<6_K>2VVQK*V,J#FAECVO<&L+?4;
MEW.K]GH9#OT-#&?I/4_Z_P"A.OJG4G.J>_%%==CF@UD/]1H-C,5V\[?3WM=;
MZ_\`Q5?_`%VO722X9?O(XH_NJ2223UJDDDDE*22224__UO54DDDE*22224I)
M)))2E2P?Z9U'_CV?^>,9752P?Z9U'_CV?^>,9)3=22224I))))2DDDDE*222
M24I))))2DDDDE/\`_]?U5))))2DDDDE*22224I4L'^F=1_X]G_GC&5U4L';]
MLZC$SZ[-TQ$^AC_0C^3^\DINI)))*4DDDDI22222E))))*4DDDDI22222G__
MV0`X0DE-!"$``````%4````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O
M`',`:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``
M0P!3`#8````!`#A"24T$!@``````!P`(`````0$`_^$0@&AT='`Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7
M-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T82!X;6QN<SIX
M/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XS
M+6,P,3$@-C8N,30U-C8Q+"`R,#$R+S`R+S`V+3$T.C4V.C(W("`@("`@("`B
M/B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N=S,N;W)G+S$Y.3DO
M,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(B!X;6QN<SIX;7`](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"\B('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(@
M>&UL;G,Z9&,](FAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B!X
M;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+VUM+R(@
M>&UL;G,Z<W1%=G0](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]297-O=7)C945V96YT(R(@>&UL;G,Z<W12968](FAT='`Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM;&YS.G!H;W1O
M<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W`O,2XP+R(@>&UP
M.D-R96%T941A=&4](C(P,3,M,#4M,314,#DZ,#(Z-3<B('AM<#I#<F5A=&]R
M5&]O;#TB36EC<F]S;V9TPJX@3V9F:6-E(%=O<F0@,C`P-R(@>&UP.DUO9&EF
M>41A=&4](C(P,3,M,#4M,314,#DZ,#0Z-3<K,#4Z,S`B('AM<#I-971A9&%T
M841A=&4](C(P,3,M,#4M,314,#DZ,#0Z-3<K,#4Z,S`B('!D9CI0<F]D=6-E
M<CTB36EC<F]S;V9TPJX@3V9F:6-E(%=O<F0@,C`P-R(@9&,Z9F]R;6%T/2)I
M;6%G92]J<&5G(B!X;7!-33I);G-T86YC94E$/2)X;7`N:6ED.D9%-SA#138W
M-#-"0T4R,3%!-C1#0D$X,CA$0S9&,#,V(B!X;7!-33I$;V-U;65N=$E$/2)X
M;7`N9&ED.D9$-SA#138W-#-"0T4R,3%!-C1#0D$X,CA$0S9&,#,V(B!X;7!-
M33I/<FEG:6YA;$1O8W5M96YT240](GAM<"YD:60Z1D0W.$-%-C<T,T)#13(Q
M,4$V-$-"03@R.$1#-D8P,S8B('!H;W1O<VAO<#I#;VQO<DUO9&4](C,B('!H
M;W1O<VAO<#I)0T-0<F]F:6QE/2)S4D="($E%0S8Q.38V+3(N,2(^(#QD8SIC
M<F5A=&]R/B`\<F1F.E-E<3X@/')D9CIL:3YE<FEC:#PO<F1F.FQI/B`\+W)D
M9CI397$^(#PO9&,Z8W)E871O<CX@/&1C.G1I=&QE/B`\<F1F.D%L=#X@/')D
M9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY#3TY314Y4($]&($E.1$5014Y$
M14Y4($-%4E1)1DE%1"!054),24,@04-#3U5.5$%.5%,\+W)D9CIL:3X@/"]R
M9&8Z06QT/B`\+V1C.G1I=&QE/B`\>&UP34TZ2&ES=&]R>3X@/')D9CI397$^
M(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)S879E9"(@<W1%=G0Z:6YS=&%N8V5)
M1#TB>&UP+FEI9#I&1#<X0T4V-S0S0D-%,C$Q038T0T)!.#(X1$,V1C`S-B(@
M<W1%=G0Z=VAE;CTB,C`Q,RTP-2TQ-%0P.3HP-#HU-RLP-3HS,"(@<W1%=G0Z
M<V]F='=A<F5!9V5N=#TB061O8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W<RDB
M('-T179T.F-H86YG960](B\B+SX@/')D9CIL:2!S=$5V=#IA8W1I;VX](F1E
M<FEV960B('-T179T.G!A<F%M971E<G,](F-O;G9E<G1E9"!F<F]M(&%P<&QI
M8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W`@=&\@:6UA9V4O:G!E9R(O/B`\
M<F1F.FQI('-T179T.F%C=&EO;CTB<V%V960B('-T179T.FEN<W1A;F-E240]
M(GAM<"YI:60Z1D4W.$-%-C<T,T)#13(Q,4$V-$-"03@R.$1#-D8P,S8B('-T
M179T.G=H96X](C(P,3,M,#4M,314,#DZ,#0Z-3<K,#4Z,S`B('-T179T.G-O
M9G1W87)E06=E;G0](D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I(B!S
M=$5V=#IC:&%N9V5D/2(O(B\^(#PO<F1F.E-E<3X@/"]X;7!-33I(:7-T;W)Y
M/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12968Z:6YS=&%N8V5)1#TB>&UP+FEI
M9#I&1#<X0T4V-S0S0D-%,C$Q038T0T)!.#(X1$,V1C`S-B(@<W12968Z9&]C
M=6UE;G1)1#TB>&UP+F1I9#I&1#<X0T4V-S0S0D-%,C$Q038T0T)!.#(X1$,V
M1C`S-B(@<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/2)X;7`N9&ED.D9$-SA#
M138W-#-"0T4R,3%!-C1#0D$X,CA$0S9&,#,V(B\^(#PO<F1F.D1E<V-R:7!T
M:6]N/B`\+W)D9CI21$8^(#PO>#IX;7!M971A/B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(#P_>'!A8VME="!E;F0](G<B/S[_X@Q824-#7U!23T9)3$4``0$`
M``Q(3&EN;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5```
M``!)14,@<U)'0@```````````````0``]M8``0````#3+4A0("``````````
M`````````````````````````````````````````````````````!%C<')T
M```!4````#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R
M6%E:```"&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5```
M`'!D;61D```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#
M^````!1M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#
M```$/```"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY
M."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)
M14,V,3DV-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````
M````````````````````````````````````````````````````````````
M6%E:(````````/-1``$````!%LQ865H@`````````````````````%A96B``
M``````!OH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````
M)*````^$``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```
M````````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````
M``````````````````````````````````````````!D97-C`````````"Y)
M14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`
M`````````````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S
M<&%C92`M('-21T(`````````````````````````````9&5S8P`````````L
M4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``
M````````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V
M,3DV-BTR+C$``````````````````````````````````'9I97<``````!.D
M_@`47RX`$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G
M;65A<P`````````!`````````````````````````H\````"<VEG(`````!#
M4E0@8W5R=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%
M`$H`3P!4`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`
MMP"\`,$`Q@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R
M`3@!/@%%`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!
MV0'A`>D!\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B
M`JP"M@+!`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#
MH@.N`[H#QP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$
M!-,$X03P!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&
M)P8W!D@&609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L
M![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)
M>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI
M"X`+F`NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-
MJ0W##=X-^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)
M$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2
MPQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;
M%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8
MU1CZ&2`911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ
M'%(<>QRC',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?
MZB`5($$@;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"
M(_`D'R1-)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH
M#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN
M+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q
M2C&",;HQ\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W
M-G(VKC;I-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[
MJCOH/"<\93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I
M06I!K$'N0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'
M-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*
M39--W$XE3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3
M]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF
M6O5;15N56^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A
M]6))8IQB\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#
M:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q
M.G&5<?!R2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ
M>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!
MS8(P@I*"](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HID
MBLJ+,(N6B_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3
MMI0@E(J4])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SW
MG62=TIY`GJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF
M_:=NI^"H4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#J
ML6"QUK)+LL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[
MI[PAO)N]%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&
MQL/'0<>_R#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1
MOM(_TL'31-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0
MW9;>'-ZBWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI
M1NG0ZEOJY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50
M]=[V;?;[]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@`.061O
M8F4`9$`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!`0$!`0$"
M`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P/_P``1"`"N`,<#`1$``A$!`Q$!_]T`!``9_\0!H@````8"`P$`
M````````````!P@&!00)`PH"`0`+`0``!@,!`0$````````````&!00#!P((
M`0D`"@L0``(!`P0!`P,"`P,#`@8)=0$"`P01!1(&(0<3(@`(,11!,B,5"5%"
M%F$D,Q=2<8$88I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$5'-%1C='8RA55E<:
MLL+2XO)D@W23A&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI:G9W>'EZA8:'B(F*
ME)66EYB9FJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V
M]_CY^A$``@$#`@0$`P4$!`0&!@5M`0(#$00A$@4Q!@`B$T%1!S)A%'$(0H$C
MD152H6(6,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V160G"G.#DT9TPM+B
M\E5E=58WA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=79CAVAI:FML;6YO9G
M=X>7I[?'U^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*
MVNKZ_]H`#`,!``(1`Q$`/P#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=%<^%555UOQ9Z8JJZLK,A5S;6D:>LR%74U];4/_&,FNNHK
M*N6:IG?2`+NQ-@!]![]U[HT?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K_]#?X]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%6^$7_9*72G_AJ2?^
M[G*>_=>Z-3[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__T=_CW[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T5;X1?]DI=*?^&I)_[N<I[]U[HU/OW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[K__2W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW15OA%_V2ETI_X:DG_NYRGOW7NC4^_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO_]/?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=%6^$7_9*72G_AJ2?^[G*>_=>Z-3[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__U-_C
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T5;X1?]DI=*
M?^&I)_[N<I[]U[HU/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__5W^/?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW15OA%_V2ETI_X:DG_NYRGOW7
MNC4^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO_];?X]^Z]U[W[KW7O?NO=1:Z5X**LGCM
MY(:6HECU6(UQQ.ZW!(!&H>_=>ZKGQ'=':W8&'V8D.ZJ>2IR>YNA,G59_;&V\
MKA:/:^<W;NG*8K<77V=QYR,C[DQRX>B3(2!IH5",!/\`L30GW[KW2NHN_P#M
MB5MJQU4>(CR:OB*&BP`VEEHJCNG(2=EYS8FZDP5>]8]/LV7:^%Q,61E1A4>-
MZCS2_P"1*"?=>ZPS][]T8W$9++&/#Y],MMO=^7QD,&TLAC#M"EVMW-2=>29R
MNG?(U$>6IX]K9+^(U"2+`B/3>0?Y-Y2/=>Z-=U!N/<>Z]A8C-[IDP%3DZB?*
MPQY+;5>F0Q.9QM%E:RCQF722&-::"KKJ*!&J8H6EIXZC6(7:+0??NO="9[]U
M[JL3;^[MY[%_EB83=.P*BKH=S8W8.,2'*T3>*HP.(R._X,7NC<@JQB\X<9#M
MK:];65\M:**K-#%3-4"&0QZ"'.;;N\L>7=SNK!BMRJK1AQ52ZJ[UTMIT(68M
MI;2!JH:4Z/N6+:TO-]V^VO0#;LS8/!F",46E5KK<*H74-1.FHK7IJZ\[$[$R
MNR_CED\+VCN2;:N-^666ZNSE31[IC[3P/<NW*FFW5)BZ[`=R9W"T.Z=V]9XF
M1/'3S2QM7U-?1/%/D*J"`&8);?N&X2V?+TL.YR&U7=6A8A_'6X0A])6X90[P
MKP!(U%E(:1E7(GOK&QCN]]CEVZ,7+;:LR@IX+0,"E0T"L424\2`=(5@0BEL*
MOXN]I;>S_;_;.4V_\HJOM/KM8DV_4T._]\[0RF7SG;4G8&<Q$N;ZTV3B&HJ_
M8G75`8_[L4%+%2TU-N#(4ODI896B-;7J^6-TMY]VW66WYF-UM_P$2RQLS3^*
MRZH8UH8HA_8JH4"5UJH)&N1-S#MT\.V;;'/R\+:^^(&.-PJP^&K:99&J))3_
M`&K$DF-31B*Z$+#N?N&OCAW?L[8'R?SFZ-A;EW?L'<J]L;X[]J]B;9V?]UMW
ML:IW5L7M'O"BZN?+?&K=NX=SX?'O1;-I\54M$*&&E_R-,I401AFYW>0+=V=A
MS,\MA++$_CR71B2.J3%XIKD0ZK.1W5--N$--(7L$K*!#;[6A-K=7O+R1WL<4
MB>#';"1WHT022&W,VFZ149M4Y<5U%NXQJ2<KK7L/?];NOXO[SWIV1GJ;9.\_
MBUN_/;IVMNC;N&V;2Q;GVC1=75^=[-WC6%5J/OZ],U.\$6NAQM!1.[B!GD,B
M##;=POWNN6;R\W&064VV2,Z.BQC7&(2TTAXU.HD"JHJU.FIJ`M?V-DEMS#:V
ME@ANXMQ14=&9SH<S!8D'H-(J>YF:@K04)7]^]U]I3=Y]_4VS.XJC!R)M?M_$
M;9Q&7WH\J[2P6W.I]J;JVYV!F>H%VI78;8/6$%9%DJS"=EQ5^1FS5=E*.GK*
M%Z)1'&&;_>=T;>]^6SW<H?"N%16D_LU2!'25K?05BA!UM'>!G,C.BNA3`$%G
MM.W#9]E:ZVL./$@9V6/XV:9T:-9M8:24C2LEJ501JCLCA\E-4?=&87JRGS=3
MWOV5M6IVCVEE,A\>\?F.Y,'NS,]R;&Q%3UC-O+!56]-MX/=NS?DQV'ALYE\M
MA<'M>',5%/6_=^.2JE>E2NI$R;S-^ZUF;?+F)H;IC:AKA9&N(U,/B*9$62.\
ME5F>..$2$-JH7)4.BA]IB_>+0KL]O(LML!<E8&18)&$OAL(W9'M8F54DDE*`
MK2H4!BC&&^-_8G9N6^6'8>T:_?&2WSB%@[DK>R8&W_@=T;1VEDL+V3A:#J#'
M[0V%1J=S]+U%)L[(5F,R6+S7VM7E:V@FJ4BK8X?XG*(.7=PW*7FK<+1[UIXJ
M7!F'BJ\<9691`(XAWVY$99'232SLI8!POB$DWZQV^+ENQNDM%AEK`(OTV1W#
M1,9B\A[)P7"NKQU5%8*2A/ABSCW)74?=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U_]??X]^Z]U[W[KW7O?NO=8Y8HYXI(95#Q31O%(AO9XY%*.IL
M0;,I(]^Z]TV8#`X?:V$Q6W-OT$.+PF$H:?&8K'4YD,%%0TD:PTU-$97DD*11
MJ`-3$_U/OW7ND1W'V+)U1UWG]\P[?K=T5&)%!#2X6AE%.]75Y3)4F*I//5-'
M/]K1QU-8K2R".1@H]*DD#W[KW28D[_VAC)\[C-PT&Z,7F-JX"FW'GJ<;9S$D
M!PL61QF'W'GL3JIDK*[`[4R.34UL[0QLM*K5$:R0JSCW7NA.V=NW$[ZV[0;J
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M:^@$LCUAIXHXGJ2&TYG>2WV4_NU"9[LP.8W_`$X2NJE1(D<H<E0!$8E9:DOI
M`!8ZN>74CN-W'[P8""U$R!T[Y0=-:%'DCT@$GQ!*RM0!=1)"JCJ;M+<>Y.W]
M\]:;TZ3VUL/*8?;%!OS'U^VMU8;>M?0X6JW-D\+MW#=H'&X/&8[:.^\]!C/X
MQC*.EK<M3RT)E/W*R4SZU6U;I<7&[WNVWFRQP2I$)04=9"%+LJ+-15$<K`>(
MBAG!6O=535/N6W00;79W]INTDT;2&,AT:,%@@9FBJQ+QJ3H=BJ$-3MHPH%F9
M^2O8V,VAWO/ENI>FL%F^EZW;NX]]X;+]GYJOVS5;>W;@\OFJ'#'+8OJN:KR?
M<5/6XNAII<?#CZC#U,V0@6ERT\R20H5S<Q[A':;ZTNU6:3691Y5:9BA6168+
MJ6"K7`*J"@4QDLNF5F!4&,6P6$EULPBW.[>*[#+&RPJ'#(RJ6H9J"`@L0Q8.
M`IU1@$$B#CNY.\ZCM3ISKG=74/6-"G9FRJK=V\,=0]G9S-[PZOP>,VW0S;NG
MS^*?K:EP62Q\.^,M0[?HFBR"#)S3/*`D=/*%7Q[QO;;IL^W76TVR_4PF20"9
MFDA54'B%E\$*1XC+$M'[R2<!3TB?:MG7;MTO[;<[@FWE"(3$JI*Q8Z`I\4L#
MX:M(U5[``,EATL\SVYGZ#N/>/5FVNFZG*Y;"=)R;^VON.NW#MS;U%O[*4F=@
MP\.QL8S+7Y#$X?'5.2A^YR5='%%%),PIZ>I",Q63;M/'O%YM=MLY:5++Q4<N
MB"5@P7PEXE5!(J[``$]JM0])(MLA?:K7<9]U"QO=^&ZA68Q@KJ\0\`S$`T5:
MD@=S+7H`Y_E5OVEZQH=]4O1G7V1QVP]^[FV9ODT/:4,&%?/;:W3A-GX?!]$Q
M5NQ*;<.]=Y;SJ,_,,52Y'&;<A:>CDIS4?Y132RD3<T7R[8E\FR6[1P3O')2:
MBZD=8U6VK$'DDD+'0KI$*J5U=RDG2\N63;@]FV\3J\T*21UA[M+(SEKBDA6.
M.,*-95Y31@VGM8`6.G/D#6]B=U]L==Y';6TMG1;8K]R0X&GJ*G?E#V1O.BV=
MN5=G56[*G$;CZSVQM.OVY)/"#'/B,YFGI8:BC$XB^Y2QKM&_ON&\[KM\EM%"
M(F<*"91-((W\,N5>%$*5X&.632"FJFH=%NZ;(MCM.VWT<\LID5-1`C,49=-8
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M(*&A*L""&5E89#*P#*1P8`]++"^N-MNX+VU($T9Q4`@@@AE8'!5E)5AY@D="
MWMKXT;`VYMW:^#;)[RW!6[<[67NRLW;N'/I5;JWCV3]O74<NX-WUM%08['UZ
MST=:(/M::EI*2."G@CBBC2)5]EEMRW86]O;0&2:1X[KZ@N[5>2:A&N0@`'!I
MI"JH`4``#HPGW^]GGN)A'$B26W@!%6B)%4'2@))&16I+,22223TS]6_%[$]3
M56X9L)V]WCG:7=&Z)=WYG&[RW=@=Q4]9FJW<<FX<S)55T^T8<YD(,W&ZXR5*
MJKG$&(ABI*7[>.*/2UM?+,6U-<-#NU[(LLOB,))$<%B^MJGP]1U?`=3&D8"+
MI`'3FX\PR;DL`FVNS1HX]"E$92%"Z5H->D:?C%%%7)9M1)ZA[>^(/6F$.4DR
M6X>R]\5&1RW7=1!7=@;REW9D<3M?JK>?]_\`9'6^/R.0H?OIMAXW=)-1/!62
M55=D.%JZJ<)'HI;\I;;#XADN+F=F>(@RR>(52"3Q8X02*^$'R0Q9G_&S4%+S
M\SW\OAB."WA55E%(TT`O,GAR2D`T\0I@%0%7\*BIJ,M9UE@:K=F[M]15F:Q^
M[=W;"Q?74N<H*Z)*O`X##UFY<E12[:6>EJ*?&9+^)[IGJ9)6259988"ZD1`$
MX?;8&N[N^#NMW-`L6H'*JI<C14$`ZG))S4A:C'14NX3+;6UF51K:*8RZ2,,S
M!`==""11``,4!:ASTG]R]&[0W=75.5SF2WA+EJSJNOZBJ,MC]TY'!Y4[>R.3
MQV9J,O3Y+!-C:S'[M3*8N*>/(4SPR1.#I`!M[3W.R6EV[2SR3&4VI@+!RK:"
M0Q8%:$2:E!#BA!X=/V^[W5JBQPQQ",7(F"E`PU`%0I#5!2A(*FH/GT"4OPCV
M@V1VMN&G[E^0E'N_;>8W%N6LW>F^L!69;>&Z]R46#PE1NO=U!E=F9':];N'%
M;0V[2X+&5--CZ1L7B!)#2B)IYY)"4\EVADM;A=XW`7<;NYD\52TCN%4O(&C*
M%EC18T*HNB.JK34Q)L.;;K1<0-M5B;6150)X;!412S!$(D#A2[&1P6;6]"U:
M``7-F_'W:>S>QLKV8NY.P]U9>>GSU%M?$[YWA6;JV_UK0;LR5'F-V4'7U)D8
M6KL/3;CR6.IVF^XJ:QZ>"GCI*5J>C1:<&UGL%K9[A+N7U-Q+*0P199"ZPB1@
MSB('*AR!6I:@`1=*#3T676]W-U81[?X$$<0*ES&@1I2@*H9",,5!-*!:DEFU
M.=70[>SSHGZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K_T=V.K^8W
MQ=H*RMQ]9WEU_3UN.K:S'5U-)F5$M+78^IEHZVEE7QG3+354#HP_#*??NO=1
M_P#9T/BI_P`_WZ\_\_2_]>O?NO=>_P!G0^*G_/\`?KS_`,_2_P#7KW[KW7O]
MG0^*G_/]^O/_`#]+_P!>O?NO=>_V=#XJ?\_WZ\_\_2_]>O?NO=>_V=#XJ?\`
M/]^O/_/TO_7KW[KW7O\`9T/BI_S_`'Z\_P#/TO\`UZ]^Z]U[_9T/BI_S_?KS
M_P`_2_\`7KW[KW7:_,_XJL0H[XZ[N38:LVBCG^K-&%4?XD^_=>Z@?!YTE^)O
M1L\3!X:G9J54$B_IEIJK)Y&HIYD/%XYH)593^01[]U[HU?OW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[K__TM_CW[KW7O?NO=>]^Z]T0ZC^4VYZW)YBBHJK8U5AI<CLLT6\
MZG$9S%XS8^'W#V!N/9V6J=\X*KSZ9,+C8\)`J-4SX5Q55L;3QPP/$S^Z]T@%
M[Z[$J.N\5BWWIC<975ZXW*P;HJ$J?[S[X?.?(?)[2JL;U[-*]-1146U=N44:
M3":DKIC2U47D6%!]PWNO="/E_D1VKC]O[2R\&,V))4;VSO:0Q;Y%VV_M^BH>
MN\]+@<1M6LS6=W/14K;EW@\;3_<>5/`D4@@HZHJQ7W7NG"M^1._J7,]I89H.
MO(<AMC#Y/);;I9:^63!TO\)W'@L/5P;JWE%F!287,0T^6:/[++46%CJ<BJK3
MU,E+KJ%]U[HP_36^JKL78&,W+7F,Y%ZW-XS(F#$U6'I35X;,UV,<TD$^1S5-
M50Z*9?\`*:2NK:&H?4]/,\14^_=>Z%+W[KW5=O5FY]N;,_ER[:W/N_M')]+[
M8Q'6D\^=[-PB8Y\[M?'2;DJJ>HFP(RF-S%*,[DDF^RHF%+/.E54QM`AF$?LF
MYAN;>SV7<;F[W-K.V2.K3+34@J`=.H,-1^%>TG41I%:=&VQ6\]WN]A;VNW+=
MW#/VQ-72YH2-5"ITCXFR!0&II7HK\/:VZL5#T3D:GOFKWQ@*/.[DK]L]44G?
M^5INYM\T>9[RVSA-L;,J]U["QNX-H=_=A=?[9A-#F-OSYCS4QR#Q5DALN3>,
M5W2ZB78Y&WTSP"1RD`NF%Q(&N45(R\0>.ZEB3MDB,E1K(<\)3(;;;;2'>(UV
M80S%$#S&V!@C*V[L\@20J]M%(_<D@2AT@J.,84FP>RNT=Q8KY"T.V/D3O.MW
MTW079F^.S):JFQ>Y(?COW)MCL/<.&QNU-L;;R=$]'UU75>T\=74U+AJ[S+HQ
M4&3:GJ&>:2J46&Y;G<1<P);<PS-??032S5"N+2X25U"(C"D1*!@L;5^!9=+$
MDLQ>V&W02;(]QL<0L_K8HXJ$I]3`\2L7=@:R@.5)=:?&T>H4`4RO<?:F]>M^
ME?CMWI19_<%3#!C=M;?W?@XT2NH-UYGN+8"[5V!DMR1B$3S-0]QY+!+Y$\86
M.NG9N./8DW?=+W;MFY>WQ+B0J%19%XB1KB+1$7Q7%P8LBF&;H@VO;K2_W;?-
MG:!`2SLC<"BP2:Y`OVP"3C7X1T#O7W;W:W6PWOMS>W9F:W3FOC1C]G]![BR^
M_,955E+V/VEVYO[;^:VCV/EH,+#@XZV=.K*_&FG\E;C,?'49&6.IJZ2,O4Q%
M&W[MNFW?6V][N3RS;:L=J[2@D33SRJT<S!=-?T"E*LB`N0S(*L#6]VS;;_Z2
M>TV](XMP9[E1&0#%##&RO$NK53]8-6BNU%!56-%*NV_\X-V9+`[.FS&(Z_P-
M;OY=YQX3<V0K,A2[1P]%T9V5O[;OR'WCNB.?,!*##;/ZYVQC]PTE$N2U2'(&
MG^]F1%G=5;\ZW4D%FTT-O&\_B:7)(C46TTJ7<CU;"QPHLJKKSJTZR!J*6?E&
MVCFNA%+.Z0^'J0`%V-Q%&ULB47+/*[1,VC&FN@$T"8S'SOWYM[K6HW]6#J/,
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M.X>4[+<)T$4<T,#P1A6JK#Q/I/&=Z:265G%*?IJ*D"0L-`3OS"[0WIM/OK=X
MPW<LFR&V;U[T?G]H[2/><NP\OE,AF>P-ZP[F;8W1G]Q]RXGY$[ASV.Q<-"N.
MR%;CX6J/#2JR-,)XT_-VYWEKOMWX.\>`8;>V:./ZGPF8M+('\*V\-UNV8*%T
M.RBNE12NH/\`*^WVESLUKXNU>-XL]PKO]/XB@+'&4\2X\1#;*I);4JL:5;-*
M$5LK\UMYXG,91I\%L(XA<[O:CKL"]5F(MX=-X#K_`+?VCUY4Y_N[QUU528>G
MWKMW.U&4QS""B@I&6`>2NIGEJHC27G.\AFE+00>#KD!6K>);K%<1Q%KG)"B1
M&+IA0O;EU)8%L?*=K)%'IFF\71&0U%T3M)`\H6WP"WALH1LL6SA&`4IBN^8.
M^'W]N;([=DV_58#([JJNJMNY*LR-/4=5;9IMH=B]UX[_`$@YZLR.>V?22YK?
M-)M&#%TX.:H:&:KBC$4K$)'.F?FZ^-_<R6YC-NTI@1B08$$<MP/%8EHQJE$8
M0?J*I8"A.`RA.5[065NDX<3K&)F`!$SEXH#X:@*YTQERY_39@I-1Q(5E=\VM
MW8NA6'-[0VC@LY_HMQO?M6SY#<.;P./Z9R>RJ.CI\L*O"X^?(YC,R=VUBX:.
M.EIV#XUEJ2B*'F16_.EU%&!-:1)/]*+HY=E%N8P`U5!+-]2?#`4?!W4`JP3)
MRE;2/6&ZE>'Z@VPPJL9Q(25HQHJ^`-9).&[:G`*:C^;O:\E%O&2BV;LC,3=6
M_P"FU]YS4M/G5.>H^N-U=6;:PF3PU!AL_NJEVWC(*?LN7(YR?^(YZ*"DP\II
MFE\VJG3#G7=2EV4LX7-K]3XE`W<(7@164*SA%`F+R'7*`L9TUKVJ#RCMH>U#
MW4R"X^GT5T]IE29V#%E0L28@L8TQDLXU4I1C+?$_?^Y>P\;W=D-R;TP&_#@^
M_P#=VV,)G=HR3/M'^`8O:FQ9:*DVU'/4Y&6EQZ5%9-)+#][7K%623JM3(H%A
M)RK?W.X1;U)<WD<Y2_D16C_L]*I%0)4F@J22-348MW$=$',EE;V,FT);VCPZ
M[)'97^/47DJ7P*F@`!TK50.T=&N]BGH-]>]^Z]U__]/?X]^Z]U[W[KW7O?NO
M=130T1$JFCI2L_D\X-/$1-YF5IO*"EI/*R`M>^H@7]^Z]UR-'2-XM5+3MX?)
MX;P1'Q>8WE\5U_;\I_5:VK\^_=>Z\])2R1I%)34\D4<JSQQO#&T<<R/Y4F1&
M4JLJ2'4&`N&Y^OOW7NO?:4NNID^VI]=8B1U;^&/751QHT:)4MIO.B1N5`:X`
M)'T]^Z]UEBBB@CCAACCAAB18XHHD6...-`%2.-$`5$118```#W[KW7/W[KW5
M=75_:$?2O\N/;G:<NR:KLG^Y76=1EX=@T%504=?NZK&XZNEHL#05.4BFQ\5=
MD*RI1(?*I4RE1^;^R?F#<EV?9K_<FM/'$*5\.H!<U`"BH.23C!^SHVV+;CNV
M[V&W"[$'BOI\0@D(*$EB!0T`&:>72_?Y.=;XSLO9_7^$V)BJ;;]=USM/M./?
ME;4XK;V!VW7=@[GVY@,7M:''08JMR)WCE=M;BDR2^%$AE2-*:26-JA64D/,N
MW1[E:6$%BHMVMTG\4E45#*Z*J4"D^(R.7Q@T"DC57HV'+]_)M]U>S7C&<3O#
MX8!9G$:,Q>M0-`=0F<C+`$+TNL?\JOC=4XI,]BMWQ5%/N:NV_'20X_8V]9<Y
MNV;=>SLSO';.0Q.WJ?:IW#NC'9[9NU:^JI*ZFIJBEG@H)D64M$R!='S3RZT0
MGBNZK(RT`BDU2:XVD0J@36X:-&*L`5(4@&HITC?ES?ED\&2U(:,-6LD>E-#J
MC@L7TH5=U!4D$%@:9KTH%^2?0=158W$IV!@ZA,GA\3F\;4)0Y2;`U%+D]JS;
M^P5'%G%QK8%<]D=G43Y:DQAG&2FHH_-'`4`/M1_6/8F>.(7Z$,BL#1M)!3Q5
M&JFG48QK5*ZRHJ%ITQ^X=Z59)/HG!5BI%1J!#^&QTUU:0YT,]-(8T)KTPYKY
M2?'*&BFI=P[H$8R=1N7&9;;N7V!OC^-0+M';F"W1NJ3=.TZO:AS>'Q&$V?N2
M@R=559&E@HX\751U)D\!UA/-S/RZ$9;BZ^(N&1HI-0\-%=]:%-2JL;J[,ZA0
MC!JZ<]/Q<N[Z75H+?X0A5EDCT][,B:'#Z69G5D`4EM8*TKCI&[W[B^/V*WI4
M;LQSG?W86UJ"+K["X"CDRD>W30[@WALC$;^&RJW(T:[`R^X\-3;KQDVX/X=-
M49*+'PQ4]1XX_3[27N[[!%>-=1GQ]PB7PE45T4>2-9?#)'A,ZAT,N@EP@"M0
M=*K/:]ZEM5MG_1L9&\1F--5521H_$`/B*K%'$>H!2Q++4]+WK/M7H[>^2H=L
M;9CV=/NH?[GJ[';0PM9G-O8?,UF$2M_=WC3;7QN!I]PUVUZZ.=(:AJ7(S4,V
MKQ&,GVNV[=-EO)([:V$)N?C(C4LBL5K_`&@0*'*&M#I<J>%.D5_MN[V<;W%P
M91;_``@NP5F4-3X"Y8J'!%150PXUZP[^[AVML;OOI_J7*[!BJAVGB=_YE>QK
MX6'&[1SF$I<'38[$92GJ(?XE/6;]I'J((JB%M*''K%-<21VU?;O:V6^[3M4M
MB#]4DK>+VTC90H"D$5K**@$'\(!XCJUEM=Q>;-NFYQWM/IFC7PNZKJQ8E@1B
MD9H2#_%4<#T!>S/FQLO?F[]GT^<Z;S6WI-QTO<2;/W?FY]OUT-/GNN-^Y?:V
MS-L5E8L0JMNY7NK;N*GS6W]3>.0!J)F-68TE);3G*RO;NT6;:F0R"?PW;2>Z
M*1DC0FG8TZJ7CJ:'X,M2IQ=<I7=G:W1AW1'$9@UHNH566-7=P.#"!F"2>8^/
MX:D&2J^SMLTG0.3^0E=M!4HLOT[2]G9O;R0455E\I0'9?]X:;:]=60TSQY2I
M2GJ31(SJ\(+FP"$CV(7W.V389=_>T['LQ,R4!9AX>L(33N-#I%<9].B%=ON&
MWJ/9$NN];HQ*U2%!\327`K@5&HTS^?12*[YO8==@=75N0ZWZ:=.S]Q;LVQ7T
M51W92MUIM#'[$7;*5%#NC>51U.D=!N@Y3<U+30X>MQ-'#&ZF5JM8-,K!.3G6
M(6&V/)MMG_C,DB$&Y'@QB+14/(8,/J=0(V10#G7IH>A*G*,IO=P1+Z[_`,7C
M1P1`?%<R:Z%$$V4HA)=78GAIKCH<.P/D]1;=WAO_`&1@>J\SOC(;;VQLFDP5
M>V1PN"P6_M\]@=E-U=2];8S(99)##28#/5-.V:R;QR45&DTD:I//3SQ*=W_,
MR6]Y?V4&UO/)'%&%-559999O!$*EO)6(\1R"JU(`9E8`HLN7GGM;*[FW%(4D
MDD+"C,T<<<7C&4A?-E!\-,,U`20&!Z#;&_,R@I]V]5=;S=6;3V+GMSRYO:^]
M,?NWLC&;<Q&R,YM?L=.KZ[9.T,KCMF9;#;_R]55T<M;C:9Y<)'6T"TP4I45"
M4Z%L7.$:W>U[<=KB@GE+)('F5%C9)O!,<;"-EE8D%D%8PRZ>#,%"^3E5VMMR
MOAN,DT,85XRD19I%>+QA(X+JT:@$*YI(5;5Q52Q&OMKN?-](9S96(Q'2U7F^
MMLCEME[=SN\,3N/;F`7"Y7?F[J39>W=O[)V)X)\WO[/4U54K6U])3K0QT^,&
MN&6IG!IE.MVWF;99[*&+9B^W,\:-(KHNEI9!&B1Q4+2L"=3*--$RI9NWHIVS
M:H=WANY9=V"7ZK(RH59M0C0R,TDF%C4@:5)U5;!"CNZ0^\OF!-MZKWW@<5U-
MFY]U[=[JVKTAM'';UW9MOK_#;SS>Y]H5.]8-UU6X*LYG^Z6RGQ6+K$HIJBEF
MK\E/%"D-)_E4)9%><W-;M?00[4YNH[U+:,2.D2R,\9D#ESJ\./2&TDJ6<@`)
MW#I9:<KB=;.:3<T%M):/<.8T:1HU1Q'H"C3KDJ5U`$*H)JW:>@\S'SSS--M[
MK_L7;O2<&Z.JNP-@[L[%I=PP=L8+%;HQ.WNM=H9O<O:62R6ULEMV/"_P79F3
MQ=/BQ7QYQZ:OJ<G2/"?%+J!?-SU,MO8;A;[*)=KN('E#B=5=4AC9YB4*:=,9
M4)J$FEBZ$8/2Z+DV)IKVQGW8Q[C!,D17P6*,TKJL(#AM6J0$OI,=5",#D=?_
MU-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T1OXV=?
MXKM#X/\`5.R,U6Y3'8[+;<Q-3+6X::GI\E!-@M['<-$U-+54M;3KJK<5&KZH
MFO&6`L2"$.Y6$6YV<ME,[+&Y4U6@(TLKBE01Q4>7#I987LFW7<=W"BM(H84:
MI'<I4UH0>!/GQZ50^&'5J)H@R^](%&\-\[PCT93&,T,F^-];6WXVWH&DPKM%
MM?:E7M*FH<-1@Z:#&O)"&8L'4A_J=M8%%EF`\:63XEQXDJ2Z!V_`AC"QK^%"
M1\^CK^M>XG)BB)\*-.!_T.-X]7Q?&X<L[?B:A^72RVW\:=C[7W1UWNV@RVZ9
MLCUKM;9>TL'#5UV/DI*O';%V/O[8.)FRD<>+BEFK*C$=B5LM0T;Q(]3%"RJB
MJZ.LMN6[*VNMONXY93);11QK4BA$44L2ZNW)*RL32F0*4%04L^_WEQ;WUL\<
M82XDD=J`U!DDCD:F<`-$H%:X)^1`9XSX-=9X0?;X/<^]\+0/@*+'SOBI]N46
MY_[R8[8T?7M-O?';[AVZN\MOYHX*"*:2#'5E+0/D($J/`"94E+8^2=MA[8+F
M=(_#`.G0'UB/PA()0GB(VD`D(RJ7`;3Q!,).;]PF[IK>%WUDBNHII,GBF,QZ
MM#+JJ`64MI)6O`A(GX,4^,W/05&U^R=T8+;NX*+L=.TI,<NV,;E<N^\]C]<=
M>PX;:^*@V=/@<)M^HP&RI):A@%KJ6O=:BGFU22`)#R0L=S&UKN,L=O(LWC4T
M!F\2.&+2B^&452L9)_$K=RG)Z4_UP,ENZW%A&\Z&+P:ZR%T22RZG)<,S!I`!
M^$J-+#`Z$./X7];0U>/IX,]O*FV?MC)UF;Z\V+3UV-3!=?9C,Y7!9/<55@ZF
M3%RYFN@RPP?@2GR%15PT4-=5_;A'DB:`P')VW!XU6>86D3%HH@5TQ,S*7*G3
MJ(;32CE@H9]-"051'FN_*NS0Q&ZD4++(0=4BJ&"AA72"NJM5"EBJZJ@&N3&_
M$C#[6S&*W/LOL#=^)W+M+8^8VIL;(UD6W:E\/6Y';N3P%%69VJH\'C\EO?;.
M(GR1R5/M[+S5F&@RB"IA@BD`MN+E2&UFBN;._F6YB@9(R=!TDHR@L0H,B*3K
M$4A:,/W*H/6I.9I;B*2WN[*)K>697D`U#4`P8A06(C=J:3*@5RG:21TL.W_C
M5M+NU'DW=N/>..R4FPYMBC+;3R%!@ZZC2HW5M;=TNXL1-)C*]\7N%:_:J01S
M1G0E'5U$6D^34JO=N7+3>@3=W$RR>!X6I"%(JZ2:U[3I>J``C\+,*9Z2[7OU
MSM)I;01-'XWB:7!8&B.FELBJT>M#^(*?+I.9SX<]3[CQ'9N`R]1NJ;#=H[>W
M1MW*4-)E:3&+M^#<>[7WK19+9\^-QM+48#,[-SPAEPE0C,U`U+"P#.FHIIN4
M-JN(MR@E:4PW4;HP#!=`>3Q`8Z*"K1M0QG\.D>8KT_#S3N4$NWS1+'XMNZ,"
M03JTIX9#U)#*ZU$@_%4^1Z&>GZUQ]-U10=24^X=WT6-QNQ<=L2CW7BLXV%WS
M2TV*PM/A:+/TF>Q,%&E'N2):5*CS10K":@<Q&,F,G*[;&NU1[2MQ,(U@$0=6
MTR@*H4.&4"CXK4"E?*F.BHW[MN3[FT$1D:8R%"NJ,DL6*E6)JF:4)K3SKGH!
MZKXBTU=B\Q2U?>7=3YG?-=F9.X-R05VP:*J[?PV<PN"VS4[?W1A*3846T\)2
MX_;&VZ3'8^LP-!B<G04OF$-2K5$SL1MRFKQ2J^]WOC3LWU#@Q`W"LJH4=1%H
M4!$5$:)4=5K1JL23E>9F22)EVBT\*$+X"TD(@969PR,9-;$NQ9ED9T8TJO:!
MTRS?`#X\X_.Y/=&P<1FNK-PU6UZ';V&R6Q,HM,NTLCB]\T?8N-W=MO'9NES>
M)I-PT^Y\?%(_D@EHZB$R12P.LTVMAN0N7TGENK&)[6X,016B:GAE91*)$#!E
M#AP#D%2*@J035T<Z;V\,=O>R)<P"0LPD%=8,9B*.5*DJ4)X$,#0AA04=YOAO
MMBLP^+VSE.TNV\MM2KKJK,=I[7KLKM1L)W7GZW?,W8]7GM[4T.T(7P>3K-US
M?OOMIL$)L:D>/<&DBBB1X\H6SPQ6TNYW;VI8M.A9--RQD\8M(/#[27X^#X54
MI&>P`!H<TW"RR7$>W6RW(`6%P'U0*(_""QG7W`)P\7Q*-5QW$DN^=^*F$J>Q
M-D;_`-G=@[RZY@V%3Y"/![(V]C-@9?945?N'<-1G=X;EAQN\]F[FK*#>.[J6
MI?%U.5IJB&LI\4SP4;TWEF:1Z?E>%]PLK^SW":W$`.F-%B:.KN6D>DD;D22`
MZ"X(8)54*U)+4/,<JV-Y975E%.9B-4C&19**H5$JCH"B$:PA!4O0L&H*/?8/
MQIVYOQ.RW&[=U;=K>T-Q;$W+G)Z*AV-N+'Q5?7^&HL)B:`;9W[L[=NU<MAZN
MGH(YJBGR-%6#[I$FB,4D<95[<.6[>_&Y'ZN6-[F2)V($3BL2A5&B6.1&4@`D
M.K=U&%"!1JRW^>R.WCZ:-TMTD1:F1321BS'7&Z.K`D@%67&#4$UBXKXG=5X;
M%5&"QYW%#B9NALC\>8Z4Y2%VH]F9W(9/*[DRE)+)0L8MT[CR&2$M74V,#/30
MZ855-)I%RKM<,301^((C8FTIJ&(V+,[#'QN35CPP***=6DYEW&619GT&47HN
M:TXR*`$!S\"@4`XY.<]?_]7=1K)OFT*ZO_A^-^+#XT5];_"S69OMJ*N;%BJE
M_AWWZP;?F@2O-%H\_C+1B75INMO?NO=8!4_.,?7"?%%C_ANCMY/]A_QZ#_[?
MW[KW7,5GS?\`SM[XJ'_6WCVZO_RBO?W[KW645OS9_.V?BR?];?/;2_\`S.VO
M[]U[KO[[YL?\\O\`%K_T/.V?_M<>_=>Z]]]\V/\`GE_BU_Z'G;/_`-KCW[KW
M7OOOFQ_SR_Q:_P#0\[9_^UQ[]U[KWWWS8_YY?XM?^AYVS_\`:X]^Z]UV*[YK
M7&K:WQ;*W%P-^]L@D?FQ/6Y`/^P]^Z]U&^#OE/Q-Z-,XB6H.S5-2L#.T"U)R
MF2-2M.\BI*].L^H1LP5BEB0#<>_=>Z-;[]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z_];?
MX]^Z]U[W[KW7O?NO=%`WQ\F\KLG>6X]G56T,=4U>WZ^:DFJ%S,Z((]V4&-@Z
M6>5#0,1+V!N^IJ<5*JEOM'I&=3)^@>Z]TE=S_)7?\VV=^U^+VHFU(=MY:BQ5
M#NJMFI9,=19C`=I[<V)NC!Y^/*PM'#'G?NJLTU3!%**.G'[VF?0#[KW2@J?D
M[G:"HQ<>2VOMRCQV.WMG]G[ZW.F?K<AMO'2X7<^`P$=5BI:'%RYE,?5P;BC=
MJ^JHEHJ>MB:BE=)75_?NO=)>7Y(;YP.1R>0JHL-FMN46V=TM18>65%W'7;E3
MY"9'J/#UTE30T-/3C!XN-8ONHXXS)'``2\L["_NO=&VZVW3F=X[3H\UN#;=5
MM7,&LRN/K<7421RQR28K)56.7)4+I(\JX[*QTPJ(8YPE1"LGCE42(WOW7NEW
M[]U[HA'0>_JKJWX)=7=AQXQ,KBMH;8H,UN^(O,D]!L.EW;4'?6X*)88Y#45F
MU]JM5Y)(&TK/]H8]2Z@P+=WOVVRPFW`1:HH2K2>HB##Q7'J434]//33%>C#:
M[)=QO8K$R:9)053YR$'PU/H'>B5\JUZ9*GYM[M26OJJ3J:DJ,;M^LFV'N"E&
MY:U\P_<N_0,G\<-H8(Q8!\=D,'VSMNOPU349%I$7%R[DH$*2!:AHP@_.EV#(
MR;2#'&?"8:SJ^HE[K2->VA6=#&2]>PS1BA[J"E>4K4A%;<B)''B*=`T^!'BZ
M=NZH:%PX"T[Q$YJ.VN>7YTKC:>?=65V?C3UUEM5=LO.T&:K9<CD]M=7Y>DQ/
MRFW)7T3XK1]ET[#)5U]&M.9'R]#C9R/$^E3L\[^&K74MHO[O?,;!B2R0L%O7
M(T\+?N9:5\14;@:#JHY/\0BWCNF^N7$BE10/*I-HH->,^%:M-#,O$5Z3?R`^
M1W9&'ZSV7O/#Y["]>9[)]9]P[OS6"ILWAJ['8>;'83;&Y>OFW/E\IBJI\*\6
MVLO#6UA,`$$=3*VB5$0E/OW,6XQ;;97D,Z6\[6UQ(RAE(6BH\6MF4Z>Q@S8P
M&)H0!THV78;"7<+NUEA>>%;B!%8JP+59TDT*"-7>I5<YH!4$GJ'7_+3LFE[/
MJL,DNS7JXVI^JJ:GBRKU'3/]\\MV918JB[+JMUBCAW&,5BL/4?P>LHE(']X2
MM`KAY!.M).:]Q7<WA!AU"D`&JMOXC3!1,7IKTJI\-E_W[^G6IU=63EJP;;UE
M(ETYF)TTGT+$28@E=-2PUJW^^N^E!0KO:_S0R&=W7M."?$==5&T,MO3!=89>
M3:^^*K<&XI<]E=A56_*SM3:25&'Q%%F^AL?3T4L29>5*>6HI:>IKK1Q4YBD7
M6W.+SW5JK16YM'F6%M$A9]31&4SQU50UL`"/$-"5#/@+0H[GE1(;:Y(EG%TL
M32KKC"KI$@C$+T9BMP20=`J`2J9+5&'=?S0S&#W1O6@I,-UO2X?%]BS=.[6Q
M^ZM[UN$WK-NB,;,D_P!*.X\1!AZ^CI.C(:3>D5;59*.59J;&)3U(,HKXXX-7
M7.,T-S>QK#;B%+@VZ!Y"LFO]/]9U"D"VI(&9P:A`K9U@+NVY4BFM[1VEG,K0
M>.Y2,-'H[_T5;4";BL94(10OJ7&@DMV-^8/:6=KJK&X/8_6E2=I;SV5UMO#+
MU6\<Y!B<]N??G<^4Z3Q.X>O33X.L:MV539:"'(/)4OYYG@K,;'^_"M2S<?-V
MYSNT<-E;'PIHX9&,C!7>6X:V5XJ*:QA@'))J:/&.Y=1<DY7VZ%%DFO+@"6*2
M5%"+J5(X!<,LE6%)"I*@`4%5D.#IZ-]T=V'DNTNM,+O#-8S&XC.2Y/>&W,Y0
MX6OFR>'3.;%WIN'8N9J,365-/2U4F,KLGMN6>G6:-9HHI522[JQ(MV3<)-TV
MV&\FC5)BTB,%.I=44CQ,5)`.DE"145`-#D=!?=[&/;K^6UBD9H=*,I84;3)&
MLBA@"14!@#0T)%1CH6?9KT6]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_
MU]_CW[KW7O?NO=>]^Z]TRU6V]O5U3-6UN!PM965+XB2HJZK%T-14SR8"KEK\
M$\T\L#RROA*Z=YJ0L2::5V>/2Q)]^Z]U`EV-LJ>IS%;/L_:TU9N%8$S]7+M_
M$R5.<2FEBGIDS$[TAER:T\\".@F+A'12+$#W[KW7!-A;&C7!I'LS::)MB22;
M;2)MW#JNWII:@5<LN#5:,#$R252B5FI_&3(-1YY]^Z]U(FV;M"I"K4;5VW.J
M4V;HE$V#Q<H6CW+4&KW'2*'I6`IL_5$RUL8]-5(=4H8\^_=>Z=,5B,5@<?2X
MC!XS'X;%42-'18S%45-CL?21L[RM'2T5'%#34Z-([,0B@%B3]3[]U[IP]^Z]
MT5'X4P0U/Q,Z9IJF&*HIZC9]1!/!/&DL,\,N6RT<L,T4@9)(I$8JRL""#8^]
M,H8%6`*D4(/GUL$J0RDA@<'HSXQ6+5648V@"M44=6RBCIPK56/6G2@J6`CL:
MBA2DB$+_`*HA$@4C2+4\*+AX:TJ#P'$4H?M%!3TH*=6\23_?C<".)X&M1]AJ
M:^M3UA."PC0Q4[8?%-!!'6PP0''TAAAAR89<C%%&8=$<>05V$Z@`2@G5>_O7
M@0D!3"ND`TP//C^WS]?/K?C3`EA*VHT\SY</V>7IY=1)MI[5J'KY)]M;?G?*
MQK%E'FPV.E?)1+0)BUCKV>F8UD:XR):8"34!`HC_`$`#W0VMJQ<M;1DMQ[1G
M&G.,]N,^6.'5Q<W*Z`MPX"\.XXS7&<9SCSSQZ@'K[8385]MMLC:#;=DQTV'D
MP)VUACA9,145AR$^+?%FB^Q;'3U[&=X#'XFF.LJ6Y]T_=]AX)MOHH?I].G3H
M73I)J5TTI0G-*4KGCU?ZV]\43_5R^/JU:M;:M0%`:UK6F*\:8ZS3;'V54UBY
M"HV?M:HKTP$NU5KIMOXF6L7:\Z&.?;:U+TC3#`31L5:C#?;L#8I;WMK*R9_$
M:TB,GAZ*E%KH/%*T^$_P\/EU47EVJZ%NI`FO734U-?\`'2OQ?TN/SZ\=C;):
MHKZL[.VL:K*X&+:V3J3M_$FHR.V($:.#;E?,:3R5F!AC8JE'(6IU!("6]^^A
MLM4C_1Q:FCT,="U*#@AQE1_"<?+KWUEWI1?JI-*OK`U-0/\`Q#.&_I#/SZET
M.U=L8RDI*#&[<P./H<?3XRDH**AP^/I*2BI<)5/78:FI*:"GCAIJ?$5TC34J
M(JK3RL70*QO[NEK;1(D<=O&L:A0`%``"FJ@`#`4Y6G`Y'57N;B1F>2=V=B22
M6))+"C$DG)88/J,'IUI:.DH8134-+34=.):B804L$5/")JJ>6JJI1%"J)Y:F
MJF>21K7>1V8W))]NJB(-**`M3@"G$U/[3D_/IMG9SJ=B6QDYX"@_8,#Y=2?=
MNJ]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_0W^/?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW15OA%_V2ETI_X:DG_NYRGOW7NC4^
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO_]'?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=%6^$7_9*72G_AJ2?^[G*>_=>Z-3[]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z__TM_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]T5;X1?]DI=*?^&I)_[N<I[]U[HU/OW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__3
MW^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW15OA%_V2
METI_X:DG_NYRGOW7NC4^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_]3?X]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%<^%4`IOBSTQ`M71UPCVM
M(HJ\>:XT4_\`N8R9UTYR5!BZ[1S;]RGB:X/%K$^Z]T:/W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
(O=>]^Z]U_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g532389g54c00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g532389g54c00.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!X17AI9@``24DJ``@````&`#$!`@`1
M````5@````$#!0`!````:`````,#`0`!`````$O8`!!1`0`!`````0```!%1
M!``!````Q`X``!)1!``!````Q`X```````!-:6-R;W-O9G0@3V9F:6-E`$2@
MA@$`C[$``/_;`$,`"`8&!P8%"`<'!PD)"`H,%`T,"PL,&1(3#Q0=&A\>'1H<
M'"`D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T,O_;`$,!"0D)#`L,&`T-
M&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,O_``!$(`24"*`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0``
M`````````0(#!`4&!P@)"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%
M$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U
M-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*
MDI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:
MX>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#
M!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q
M$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%
M1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8
MF9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?H
MZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`+']L:I_T$KW_P`"'_QH_MC5/^@E
M>_\`@0_^-4J*^KY(]CX7VD^[+O\`;&J?]!*]_P#`A_\`&C^V-4_Z"5[_`.!#
M_P"-4J*.2/8/:3[LN_VQJG_02O?_``(?_&K,6HZB(_-EU.]"]A]H?G]:RE&6
M`]36M!;1W5X8YM_DQ0/,50X+;1T![5Q8O64:4=+W;?6R[>IV87F:E4>MK)+I
M=]R&;6+F9LO++)CH9)"33X=9N47RQ<W$2G_GG*P'Z&K2^'!-?7D,=VL202*B
M^8I);<A<#CT`-2_\(D_R9U&$>8%9?W3<JS!0?S8<5D\)@TK+1]];FRK8UN^Z
M^5C/GU'5(B&74[TH>A^T/_C4/]L:I_T$KW_P(?\`QHVL+::)\9C8K^56-#T^
MVOY9DN"V0%$2A]FYV;`!.#6N&G[DE4U<7:]M^S,:T).<?9NW,KVOMW*_]L:I
M_P!!*]_\"'_QH_MC5/\`H)7O_@0_^-7=/\.O?P>8;N.`EV0(R%C\I4'D>["G
MR>&)8[.2<WD1>./S&BV'/3=C/3H#71ST4[?H9*EB&N;6WJ9_]L:I_P!!*]_\
M"'_QH_MC5/\`H)7O_@0_^-4JU]+TNWU"V4M)*DOVN*%CQMVMGI[\5<E"*NT9
MTW4J2Y8O7U*O]L:I_P!!*]_\"'_QH_MC5/\`H)7O_@0_^-:(T"*[NU6WG-O$
M\$<H$P+,"[;0IQ[T\^%2(5F;480C*74^4W(4`M^6?TJ/:4>OY&OL<0]OS,O^
MV-4_Z"5[_P"!#_XT?VQJG_02O?\`P(?_`!J&\M6LKV>U=@S0N4)'0XJ?3+2"
M\-TLK2!X[=Y4VXQE?6K:@ES6,DZCER7U]1/[8U3_`*"5[_X$/_C1_;&J?]!*
M]_\``A_\:TKS0H#?6D%G)MBF+J9G8M\R#+9&`1^O6I%\).X+#48=@95W>6W5
MMNT8]]X^E1[2C;7\C7V&(NTM;>?S,G^V-4_Z"5[_`.!#_P"-']L:I_T$KW_P
M(?\`QI-1L#ITT<9F659(Q(KJ".#D=#[@TNE6T=YJ"02I*ZL#\L9`/XD]!ZFK
M]SEYK:&7[WGY+Z^H?VQJG_02O?\`P(?_`!H_MC5/^@E>_P#@0_\`C6CJ&C6<
M%@TUK-)(5\MUD;[KJ[E0,>HQFI7\(R*>-0A8!RC'RV&,$@GWY6H]I1M=_D:^
MQQ%[+7YF3_;&J?\`02O?_`A_\:/[8U3_`*"5[_X$/_C4VJZ.VEI`YN4G6;."
MJE<8`/?V85GPJKSQH^_:S`'8,MC/8>M7%0DN9+0RDZL)<LF[^I:_MC5/^@E>
M_P#@0_\`C1_;&J?]!*]_\"'_`,:V9M#T\0W`A,K7**2(6EQL(7<PR%PQ'X>E
M5;?PT]Q8)<K>Q!FB$OEE&R`0Q`STZ*:S52E:[7X&KHXA.R=_F4/[8U3_`*"5
M[_X$/_C1_;&J?]!*]_\``A_\:NZCX=?3[*2Y^V13"-]C*J%3G<5/7W%8M:0]
MG-7BC*I[6F[3;7S+O]L:I_T$KW_P(?\`QH_MC5/^@E>_^!#_`.-;,&@V,EC'
M=L+H#A73>N2Q*C/3Y<;LX/;'K5:U\-FZ:<"^CC$<\D0W(3NV8R>/J*S]I2UT
M_`V='$:)/?S,_P#MC5/^@E>_^!#_`.-']L:I_P!!*]_\"'_QK3;PK*D$CF^A
M\R-"YCV-V#'&?^`&N?ZBK@Z<_A,JBK4[<S:OYEW^V-4_Z"5[_P"!#_XT?VQJ
MG_02O?\`P(?_`!K1TG2+*]LO.N#.A1QO8,,%2<<#&<?[7KQ0/#HN;^:**=((
ME$1C+DR;_,^[R`/Y5+G23::V\C14J[BI)[^9G?VQJG_02O?_``(?_&C^V-4_
MZ"5[_P"!#_XUJ_\`"*'8CG4H0DB"1#Y3<K\O/_CPXK!N(6M[F6!B"T3LA(Z$
M@XJH.E/X?R(J1KT_CNOF6?[8U3_H)7O_`($/_C1_;&J?]!*]_P#`A_\`&KWA
MW0AK4MQYC.L<49P4ZER#M_#CFGW6A0F^AAMY7A1UF+&;YBOE,P)X]=N:ESI*
M7*T4J5=P4T]'Y_(SO[8U3_H)7O\`X$/_`(T?VQJG_02O?_`A_P#&M?\`X1"3
M_H(P8\SRL^6WW^,#]1S6+J%D;"Y$/FK*&C6174$9##(X-.$J4W:/Y"J4Z]-7
ME=?,?_;&J?\`02O?_`A_\:/[8U3_`*"5[_X$/_C4^@:4-8U5+=RRPCYI"GWL
M9QQ[Y-6;[1(H;:V\C=YS2)%,SO\`<9LX&W`].N30Y4U+EMJ$:=:4.=/3U,_^
MV-4_Z"5[_P"!#_XT?VQJG_02O?\`P(?_`!K4?PHZKN&H0L@W;V\MAM"[LG'?
M[C5GZOI#Z3)$K3I,)`2&52,8.".:(SI2=E^03IXB$>:5[>I'_;&J?]!*]_\`
M`A_\:/[8U3_H)7O_`($/_C45A!'<ZA;P2L5B>15<KU"YYK=N]!LXK.2:,R@M
M"\\+"3<NU0O7Y0>=WMC%$G3BTF@IPK3BY1>WF8_]L:I_T$KW_P`"'_QH_MC5
M/^@E>_\`@0_^-:4?A:66V65;V+>R*_E[&XW`'&?H:KZGH#:=9_:1=QSKOV$*
MA4CEAW]U-"G1;LOR&Z6(2YG>WK_P2K_;&J?]!*]_\"'_`,:/[8U3_H)7O_@0
M_P#C5*NEL=$TZ?3XKF5Y/EB$D[>:1M)SM&-AX..HS3FX05VB:4:M5VC+\3'_
M`+8U3_H)7O\`X$/_`(T?VQJG_02O?_`A_P#&K\?AYI[J]C,Z6PMY?+"OE\_*
M6ZC'93VJQ_PB+@H#J,(+[2O[MN0S;5/XDBI=2BM_R+5'$O57^\R/[8U3_H)7
MO_@0_P#C1_;&J?\`02O?_`A_\:INI1V0]5)!K6T/2H=2^T-,S8CV*JJ^TLS'
M`YP:N2A%<S1E3]K.7(GJ5?[8U3_H)7O_`($/_C1_;&J?]!*]_P#`A_\`&M2X
M\/1![>""5UF:98':3E263?D`=`.G>E7PHSQ^8NHPF,!26\IN`P!7CWS6?M*-
MK_H;>PQ-[+\S*_MC5/\`H)7O_@0_^-']L:I_T$KW_P`"'_QI=4TUM,FCC,R3
M!U+!E!&,,5(Y]U-58(O.N(H@<;W"Y],G%:I0:ND82=6,N5MW]2S_`&QJG_02
MO?\`P(?_`!H_MC5/^@E>_P#@0_\`C6]<^&[*))_*,DDF&$"F;`8KNW'.WMMZ
M''?FL^U\-O=V"7*WD2L\?F"(H<X^;'/3^`UDJE)J]OP-Y4,0GRWO\RC_`&QJ
MG_02O?\`P(?_`!H_MC5/^@E>_P#@0_\`C5Z^\./8V,MS]LBE\HX=%0@CD`\G
MTW"L>$!ID!Z9JN:GR.:6B,W&M&:A)M-^9J)J6H1())M3O<GHOVA_\:KRZM<2
MON>21SZNY)K5L].L;^!FN5N$D#[$99!AR%+D8QZ#KGN*@3P^EUJ$D,%R(8Q%
M#(OF@L<R8PO'H3UKS:-&E6C[3$:MZ^27E8]"K*O3]RB]-O-OSN01:S=%!%]L
MNHAVV3,`/R-13:EJL+X_M.](/0_:'_QK0_X14B%)6U&$(ZEU/E-RHVY/_CU9
MU]`]LLD$I!DAD,9([X.*I1IT*L?9?#)V:[>:O^),_;5*<O:Z22NG^CM^!<T/
M5=1DU_34?4+MD:ZB#*T[$$;AP1FBJF@?\C'IG_7W%_Z&**SS-)3C8[LFDY4Y
M7?4SJ***]H^;"BBC!]#^5`!6A%+(VR>WE:*XCZ,IP15#!]#^5*I=#E=P/TKF
MQ%!U;2B[26WZI^3.BA6]G=25T]_\UYD_VJ\A=V\^96=M[G<?F;!&3^!/YU(E
MYJ,A4"ZG^4``ESP`01^H!_"BWGDDD".N>.N*G>.5N%?:/9:\^OCYTI^SJ12?
M?5K\%<[J.$C4CSPDVNVS_,K7#B.+RMVYV.6-16]W<6C,UM/)"6&UBC8R/2IC
M8L3DN?\`OFC[`?[Y_P"^:JAC,'2ARN=V]6[/5_<16PV*J3YE&UM%JM%]Y%%>
MW4"A8KB5%&2`K8QG!/\`(?E3CJ%ZRLINIB&&U@7/(QC'Y<4_[`?[Y_[YH^P'
M^^?^^:W_`+2P?\WX/_(R^I8OM^*_S*=2)/-&A2.5U4L'PIQ\PZ'ZC-6/L!_O
MG_OFC[`?[Y_[YI_VGA/Y_P`'_D)8#$K:/XK_`#&'4+PSO,;J8ROC<^XY.#D?
MD0*#J-Z4"&[F*`%0N\X`/44_[`?[Y_[YH^P'^^?^^:G^TL'_`#?@_P#(KZEB
M^WXK_,JR2/-*TDKL\C'+,QR2:6.62(L8W9"RE25.,@]15G[`?[Y_[YH^P'^^
M?^^:K^T\)_/^#_R)^H8F]^7\5_F,DU"]EE262ZF>2,%49G)*CI@4HU*^`P+R
M<#(.-YZC&#^&!^0IWV`_WS_WS1]@/]\_]\U/]I8/^;\'_D5]2Q?9_>O\RM+-
M+,5,LC.5&U=QS@>E.M[J>SF\VVF>*3!&Y#@X/45/]@/]\_\`?-'V`_WS_P!\
MT_[3P=K<WX/_`")^H8J]^77U7^9'+?7<T8CEN97C#;PK-QN]:=_:=_S_`*9/
MR23\YY)Y/\S^=.^P'^^?^^:/L!_OG_OFE_:6#_F_!_Y%?4L7V_%?YD$UU<7"
MJLTTD@7[H9LXX`_D!^5,CD>*19(V*.A#*P."".AJU]@/]\_]\T?8#_?/_?-/
M^T\)MS?@_P#(EX#%-W<?Q7^82:KJ$JR+)>SLLHPX+GYOK4:7]Y&@1+J95"A0
M`QP``0!^1/YU)]@/]\_]\T?8#_?/_?-+^T<%_-^#_P`BOJ>+WL_O7^9')?7<
MT;1RW,KHQRRLV03G.?SYJO5S[`?[Y_[YH^P'^^?^^::S/"+:7X/_`")>`Q3W
MC^*_S$&JZ@&1A>SAD78IWG@>E1QWEU"NV*XE09)PK$<G&?SP/RJ7[`?[Y_[Y
MH^P'^^?^^:7]I8/^;\'_`)%?4L7V?WK_`#&G4KX[LW<QW#!^<\CD?U/YFJM7
M/L!_OG_OFC[`?[Y_[YIK,\&MI?@_\B7@<4]X_BO\QD>H7L,2117<R1HVY55R
M`I]11_:%YYSR_:IO,<AF;><DCH?PI_V`_P!\_P#?-'V`_P!\_P#?-+^TL'_-
M^#_R*^I8OM^*_P`QG]HWI55^US;57:HWG@<<?H/R%0.[2.SNQ9V)9F/4D]35
MK[`?[Y_[YH^P'^^?^^::S+!K:7X/_(3P.*>\?Q7^96BFE@?=%(R,01E3C@C!
M%2O?7<LPFDN96D";-Y8YVXP1]*D^P'^^?^^:/L!_OG_OFC^T\'_-^#_R!8'%
M)62_%?YC?[3O\?\`'Y/][?\`?/WO7Z\"H))9)F#2.SD*%!8YP!T%6?L!_OG_
M`+YH^P'^^?\`OFA9E@UM+\'_`)`\#BGNOQ7^95CD>&19(W9'4@JRG!!]:F>^
MNY4B22YE9(CF,%B0I]14GV`_WS_WS1]@/]\_]\T?VG@W]K\'_D"P.*2LH_BO
M\QG]HWQ4K]KFVG.1O/.<Y_\`0F_,U'/=3W)4SS/*5SC>V<5/]@/]\_\`?-'V
M`_WS_P!\T?VE@U]K\'_D#P6+:LU^*_S*J.\4BR1L4=3E64X(-3RZC>S)*DMW
M,ZRD&16<D-CUI_V`_P!\_P#?-'V`_P!\_P#?-#S+!O>7X/\`R!8'%)62_%?Y
MC%U&]486[F`P!@.>@&!^E-EO+J:/RY;B1TSNVLV1G).?S)_,U+]@/]\_]\T?
M8#_?/_?-']I8/^;\'_D'U+%[6_%?YE.K<6J:A#'''%>SHD?W%5R`OTI?L!_O
MG_OFC[`?[Y_[YH>98-[R_!_Y!'`XJ.T;?-?YD2WMTA<K<2@NVYB&/S'!&3[X
M)'XT_P#M.^)4F\GRH`'SG@`Y'Y'FG?8#_?/_`'S1]@/]\_\`?-']I8/^;\'_
M`)!]2Q:Z?BO\RH2222<D\DU)!=7%JS-;S21%EVL4;&1Z5/\`8#_?/_?-'V`_
MWS_WS0\SPCT<OP?^0E@,4G=1_%?YD9O[P^3FZE_<?ZKYC\GTI1J-ZJ%!=S!2
M`"-YQQT_+`I_V`_WS_WS1]@/]\_]\TO[2P?\WX/_`"*^I8OM^*_S*\T\UP09
MI7D*YP6.<9))_4D_C4?0Y'6KGV`_WS_WS1]@/]\_]\U7]IX3^?\`!_Y$O`8E
MZN/XK_,1]5U"02![VX82*%<%S\P]#3$O[N)`D=S*JA=H`8@`<\?J?S-2?8#_
M`'S_`-\T?8#_`'S_`-\U/]HX/^;\'_D5]2Q>]G]Z_P`R.2_NY8W22YE='Y96
M8D'IU_(?E4"DJP8=0<U;^P'^^?\`OFC[`?[Y_P"^:?\`:6#M;F_!_P"0OJ.*
M;NX_BO\`,E,T\D<;V\SJ8VWJH;&UO4>]5_MMZD[R_:)EE<@N^XY8@Y&?H:E2
MTDC.5D(/^[4Q\Q(V+?,0,CY:X(8Z%#W*;4X]-TUY;69VRPLZWOSO%]=FO7<A
MCN=0E54^TS"-05&6.`#C('Y#\J9>SF1MI<NQ.78G))]ZC>YF<8P5'L*AP?0_
ME7HPH5)U%4K65MDOS;."=>$8.G3;=]V_T-#0/^1CTS_K[B_]#%%&@@_\)%IG
M!_X^XNW^V**Y,T^./H>MDG\.?J9U%%%>R?.A7K?P_4'PG#D#_6R?^A5Y)7K?
MP^_Y%.'_`*ZR?^A5P9E_!^?^9ZN3_P"\/T?Z'4;5_NC\J-J_W1^5+17@GU`F
MU?[H_*C:OH/RI:*`$VKZ#\J-J^@_*EHH`3:OH/RHVKZ#\J;--%;PO--(L<4:
MEG=S@*!U)-<3X2^)=EXP\57^D6-C.EO;0>?%=R'`G7<%RJXS@YX/M0!W&U?0
M?E1M7T'Y5"E[:R7)MTN(WF')16!(^OI4]-IK<2:>PFU?0?E1M7T'Y4M%(8FU
M?0?E1M7T'Y4M%`";5]!^5&U?0?E2T9H`3:OH/RHVKZ#\J6B@!-J^@_*C:OH/
MRI:*`$VKZ#\J-J^@_*EHH`3:OH/RHVKZ#\JYG_A+3)XP'AN.Q*7"L7DEED`C
M,6W(*$9RYS]S@@9/2NGH`3:OH/RHVKZ#\J6B@!-J^@_*C:OH/RKF+[Q@+7Q9
M!X<6R/VN=E9)I)0(C&023D<A_E("$<]>E=10`FU?0?E1M7T'Y4M%`";5]!^5
M&U?0?E2T4`)M7T'Y4W='OV93=_=XS6)+9ZZWBV.ZCO4&D"/#0=R<>F.N><YK
M"U%776[QX@#.MV'54B(EVB(?,'_N@]N]:1II]3*52W3J=SA<D8&1VH`4C(`(
M]JXR%[N#F6ZN_+D6U-Q<'[ZJ5<G!QP,X'M5"QO[RVL[2.*YN%N58K#;8XDC\
MMV!(QU+"J]CYB]LNQZ'M7T'Y4;5]!^5<SI]YJ)\,:A.'=Y4#&!G;<WW03R0,
MX.?Y5COJMS'<R_9=0O)X8YU\MG)P1^[R#QENIX.!U-)4FW8;JI),[[:OH/RH
MVKZ#\JX7^T+UX7:"_N6`=_M);.V/$N%`('R@C(R,]*UVU"XAL-&N9I+A(WW>
M>77)/R-MW8'KBDZ30*JF='M7T'Y4@V$D#:2.OM7&:%J%[<7ELKW=S)/YJK+$
M^=HB\H$DC'7=3+F26TUG5%%S=PHSO(-A/,FQ-@Z=#\W'?&*?LM;![56O8[5F
MB3&]D7/3)`I04)P-I/7%8&KVRZA9:9;WEJCW-RRI(S)DQC&Y\>G3'XU6TR(I
MXB"K&RS))<>>=I'[LD>6,^F.GTI*"M<;GK:QU.U?0?E1M7T'Y5Q5Q-J2FXF6
M[O01]I<(#\H*2*$`&.F">.]%S-J2_:)DN[T,!<N%!^4%)%"`#'3!/'>G[+S)
M]JNQVNU?0?E1M7T'Y4M%9&PFU?0?E1M7T'Y4M%`";5]!^5&U?0?E2T4`)M7T
M'Y4;5]!^5+10`FU?0?E1M7T'Y4M%`";5]!^5&U?0?E2T4`)M7T'Y4;5]!^5+
M10`FU?0?E1M7T'Y4M%`";5_NC\J-J_W1^5+10`FU?0?E12T4`?/=%%%?6GP0
M5ZW\/O\`D4X?^NLG_H5>25ZW\/O^13A_ZZR?^A5P9E_!^?\`F>KD_P#O#]'^
MAU-%%%>"?4!1110`R66.&)I975(U&69C@`5BG7Y[T-_8]@UQ&/\`EZG;RH?J
M">6'T%'B2WFF2RD^S/=6<,V^YMX_O.,<''\6#SBL7Q0(?%NE1Z39>(X](MI&
M`O%,969X_P#GFI8C9GG/!K>,+1YDK_H<\YMSY'+E_-^ESF'?6_BKJ5SI27T<
M/A6TDVW5U;1D"\D'_+)"3ED'<]#6'K*2>'/'GBF:.[E8Z=X=B>-4Q$K`,H"$
M*!A?I7M&D6VDZ1I=OI^F&WBM+=`D:1N,`?X^]<7XC\`?VUK'B/4DUN"+^U]-
M2Q6-TR(<,I+9W<_=/&!UJ.:2>B_`OD@UJ[_,FA\4V7AKP=H\T.F+)K6K0));
MZ;:<O-(R@Y)/(49Y8]*CO?%VM6$$4>HZWX3T^[\O=,A>29U?NH12"<=,YY/:
MJ<7@BRL/"=];'Q1#_P`)%=VJVS:J[C,4:X`CC4'Y$P,8'/.:I0Z-/'X2N="M
M+_0+&2:)83<Z;9RR2LO1V9NI8C(_$\T<E23O9L%.E!<J:1!;?%_69_#(G@TJ
MVO-4N]0-GI:0APMXJ_?DVGYE4<=^I]C6MXJ\9>.?"ND6^JW>E:&8Y)8X?L:7
M$C3,[=@<`$_3/XTOAGPU;Z)XC;5!;WMY%:VJV6EP1VC(+:(?>)+$9=CR3[FK
M6K:/J>O>-['5]0T^Z;2M-B8VEHNP-Y[<&1LMC@=/I1[*0_:P)U\<:OKVIS:=
MX3TFWN3:82]OKR8I;Q2XYC4J"78=\<5GZE\1M5\-W_\`8VLPZ1/K$P5H5M;A
MTBB0YR\S./E[8`R3^54/"6F>,O!=@=&MX[673!.T@NIK21I@&.3E4)!/XU8C
MTJ^L?'NK:_HNJ:1*-41/-M=722)XBHP-A`Y'^>U+V<^P>UAM<MZ7\0M2N?%F
MFZ+,NCWT6H"3]]I4TCFV*KG+[E`P?6K'@WP)JWASQ+>ZE>ZRUU%,&`3>QWDM
MD$@\+]!GGVXKJM">Y:P\W49=.>ZW'<UB"(E'8`GD_6M!+NWDF\I)D=^N%.<?
M7'2ILR[HFHHHI#,:7PEH$TKRR:5;M([%F8KR2>2:9_PAWAW_`*!%M_WS5B3Q
M+H44C1R:WIJ.A*LK72`@CJ",TW_A*/#_`/T'=,_\"X_\:`(?^$.\._\`0(MO
M^^:/^$.\._\`0(MO^^:F_P"$H\/_`/0=TS_P+C_QH_X2CP__`-!W3/\`P+C_
M`,:`/!OC7HI\)WNGG2KVYAL+Z66Z-GNS'%,BJ-R=QE3C'M[U['H7A[P]JWA_
M3M0;1[4-<VT<K#81@LH)_6O'?CGXAMO$E]IMKIADFL[&22*:[5<P&9PI55<=
M2`/UKV?P_K.A:7X<TVPEU[3#);VT<3G[9&?F"@'OZT`6_P#A#O#O_0(MO^^:
M/^$.\._]`BV_[YJ;_A*/#_\`T'=,_P#`N/\`QH_X2CP__P!!W3/_``+C_P`:
M`/$_C?HG_",6EM-I$\UK8:E.#/;(WR+-&OR.O<?+GC/;->B^!=%T77O`^CZG
M=Z3:&YN+96E(4\L."?QQ7G?QY\00:[96UGI6Z[M=.E$EU=0C?"DCKA%W#C.-
MWZ"O2/`&IZ-HG@+1=.N]:TM+B&V42*+N/ACR0>>O-`&[_P`(=X=_Z!%M_P!\
MT?\`"'>'?^@1;?\`?-3?\)1X?_Z#NF?^!<?^-'_"4>'_`/H.Z9_X%Q_XT`0_
M\(=X=_Z!%M_WS6O;6T-G;1V]M&L<,8VHB]`*SO\`A*/#_P#T'=,_\"X_\:TH
M+B&Z@2>WFCFA<922-@RL/4$=:`(FU"S6^6Q:YB%TR[A#N&XCUQ5>;6K>&\:W
M\J=PCJDDJ)E(V;H"<Y].W&>:C?P[ITFOIK31,;Q%P#N^7IC./7%5[G2]2$U\
M+&X@BCNW$C/(NYD.T*1C&"#@?K6B4#-N99D\0Z7$L+FZ1HI9#&)%.55@N[G\
M*8+W1WO#<R>3'<+*;=9)``6(`Z'TY'-9"^&M21BZO:$ENC.Q`'E&,_P^^1V[
M4/X2NMS*MTIC?=&PWE?D.WGH<GY>G';FKY8=R.:?8Z*]OK"VQ!>SQ)YHP$D/
MW@>/ZXJM:ZEHEO&L5K<VJ(SE0J$#+=_Z5G>(+*]GU#;:VYE2XBCB=ST3;)NS
M^6:BE\-7YM+:!);?$484\E?F$F\]!D@C'![\\U*C&RNQN4KNR+5IXITCYH;=
M'1%W,`$"@_/M)'/<G-:*ZYI;)(ZWT!6/&X[NF3C^?%8\GAN],6Q98#N1T8DG
MC,PD&..>.*AGT*]L5L+N)4N)+)`OE)GYSO)_+!_.J<:;V8E*HMT=`M[8QQ17
M$!1UO)!M>+'[PXZY]@.OH*C.NZ=^Z*W*/'(S)YBD;5*KN.3VXK-M]+NTTC1U
M>,"6`L)4`!"AU89QWQN'%43X2U"6/;+<6X/F+)G<S9*IMQT&!D#CL#248=6-
MRGT1T1US2P$)OH!O^[\WOC^=68;VVN)I889XWDB.)%4Y*_6N=;PW>S3ZC<R2
M6ZR7L178I)"'*XYQR,+^=6])T*:PO+F668.KJZ(0Q/#.6Z8XZ^])QA;1C4IW
MU1?.M:8L;2&^@"*_ED[OXO3]#2W.KV5G<F"YF6([%8%CP<D@`=\\&L>U\.W4
M=S92RR08M?+0!<_.B!QD\?>RP_+K5R\T>:Y\0VVH+)&(H@F5.<G&_P#^*%+E
MA?<.:=MC0DU*RAM$NY+J);>3&R0MPV?2F2:QIT3R))>PJT0#."W0<?XC\ZS/
M[$NXM+TZ&)[=Y[0ME9,^6VX,/3WJK-X8O)8T@$MN(HIC,C`$%BQ!((Q@`8/Z
M>E-1AU8.4^B-:7Q#I<=M+.MTDJQ`%Q&<D`L%SCZFGOKNG(R;KE!&Z;UDR-IY
MVX^N:R;CPY=R(WER6^[=,PW9P=\RN,\>BD4L?AR[%Y;7#2P?)+YLBC/!,A<@
M<>^*?+#N+FJ=C7_MK3>`MY"Q,9D`5LDKC/\`(&H+7Q)IMS:_://$4?RC,A`Y
M9=V/RK)MO#-_;WT4IFMS$D[2X!(X(8=,<GYNI^E-A\,:A%&&$ML91%Y.TLVW
M;Y80MTZ\9HY:?<.:IV.DBU.RGNWM8KJ)YTSNC#<C'7^8IAU;3QG-Y",*6/S=
M@VTG\^*S=/T&>RO8)3+&R1/*>^2&50/Q^7FJDGA6=]5:Y$\0A-R'"<Y\H_,R
M_B_-+EA?<?-.VQ>'BS3"V"TB\Q@DKP-^<=_:M&74[&&UCNI+J)8)/N2%N&^E
M8=KX<O(&MPTL!1&@9CDYS&7R`,=]PJ2XT"\?0K.QCFA$D(97;)&001P<9'7\
M>E-QA?1B4JEM4:=YK5A96LMQ)<(5CSE5.22%W8'O@@_C3DUC3I`<7<0*Q^:P
M+8(7&<G\ZP6\-:@\9A,ML(RK'=EL[C"(\=.G&:2[\.WTD,A+1'8[7"K&269R
M%^3D#Y?E_E1RP[ASS[&ZNNZ4Q`%_!DY(^?TZ_E52]\5Z59A"96E#QM)F(9``
M..?QK-L-%U"X^WWDR0V\EVDJI&Z[MI9@02".G'_UJ5?#%^T-RKS0AI4F`^=F
MY<H1DD?[)HY::>K%S5&M$=)9WL-]$TD).%<H01@@C_.?QJQ6=I-O-%]LFG3R
MWN+@R!,YP,!?UVY_&M&LI))Z&T6VM0HHHI#"BBB@#Y[HHHKZT^""O6_A]_R*
M</\`UUD_]"KR2O6_A]_R*</_`%UD_P#0JX,R_@_/_,]7)_\`>'Z/]#J:***\
M$^H"BBB@`J*:V@N!B>".4>CH&_G4M%"=@:ON9SZ!I$A^;3;7\(@/Y4T>'=&!
MR--MO^^!6G15^TGW9G[*G_*ON*D>EZ?#CRK&V3']V)1_2K)0;"JX7(P,#I3J
M*EMO<M12V1YG9_#+7;';%;^-+Z.UW?-&@(.-J#&[.?X3CTS6A;^!=<2:^%QX
MOO;BVN+66W2)Q_JRQ.T]><#`]3S7>44AGF;?#GQ&;..V7Q?+%'DB2.-&5-FT
MC:HW<=?T%='H_@RWL?#T^C7L@NX#,\D+MDL@.,#DG!'M74T4TW%W0I)25GL<
M_;^&8H;1(6%O*`,%98`P_`C!J_9:2EDJB!F@`/,<;$H?P.<5HT5<JLY;LSC1
MA'9!11169J1F"$G)BC)/^R*/L\'_`#QC_P"^14E%`$?V>#_GC'_WR*/L\'_/
M&/\`[Y%244`<E<>$)KKQ:NM_:(((X9$*6J1[XYL*07D!Q^\`)"D=!Z]NI^SP
M?\\8_P#OD5)10!']G@_YXQ_]\BC[/!_SQC_[Y%244`<EJWA";5/$D.IQW$%I
M%;&-EB2/<+DJ<_OEX!V\[<<@DG/:NI^SP_\`/&/_`+Y%244`1_9X/^>,?_?(
MH^SP?\\8_P#OD5)10!']G@_YXQ_]\BGA0H`4``=`*6B@#"E\1M'XLCT/[!,R
MNF[[0.@XSTQT[9SUJC>:Y?6NJS_.3;Q7(BVM$!'M\L-C?UW9Z?A75UFRZ%83
MW,D\L;L9&WLAD;86QMW;<XSCO6D90ZHRE&?1]3,M_$-Y))M>U02S"'R(?,X&
M\,V2V/1:@LO%5S]@AGN;97C#&.>57P0X5G.%QR,`#K6VVB6#)M\I@=L:AE<@
MKL!"X.>",FJ(\)VBWD+K(XM8A_Q[<D,=I7).>>"??WJE*GU1/+474ELM?%WI
M%U>^2FZW)!5)058X!&&.!W`I(]?>31;B^6V4RPS>28Q)\K'<!D,1T^;TJZ-(
MLQI\ED4=H9.6W2,6/3').>,#\J@FT&V?3+FQB>2-;B02.Y<LV[().2>^*F\"
M[3L43XH99H8VM%!,ODR_O<D-OV?*,<CODXJF_B34I&\X0Q0VY@$BKOW-_K0F
M>GH3Q6T?#FF_*1'(",$D2L-Q!W`GGD@DG)IS^'].>..,PML2/RP!(W*[@V#S
MSR,U2E370EQJ/J8T_BFXDF$,,21,&)R&#Y7:^`>P.5!XS5[3->DN[JWLI(!Y
M[1AY'#<;=BL&QCN6QCVJ=/#6F(ZN(I"478H,K$!>0`.>@W'\ZFL](BM-0DNU
M8$F%+>-0N-D:]`3W/O0Y4[:($JE]69<OBSRC.CVJ1RI*$C22;;D9/+<<#Y<\
M9'(I+CQ>D"@_9"<JD@!?'[MDR&/''S'%:)\.Z:=Q\IP2?E82L#'R3A3GY1DG
M@5++HFGS2>9);@MY`M\[CP@.0/KGOUI7I]@M4[F.WBYE5F%I&RQ(S3.)OE&'
M"C:<<@DCFFW7BBXDL)C901_:(HW>1O,W(H5@N5X^;.<]JV?[#L-KAHF<NAC9
MGD8D@MNZD]<@'-,F\/Z?<0K%*DK`!@6\UMS`G)#'.2,@=:?-3[`XU.Y#J>N2
M:=>21BU62&&*.65_,P0&<KP,<],]:IP>*WNVBCMK2.269U$8\_@*P8_,<<$;
M>1[UM7.EVEX\KSQ;C*BQO\Q&55MP'YU%#HEC`T;)&^8G#Q[I&.S`(`&3P.3Q
M23A;5:C:G?1Z&1)XOV.(OLJ+)DHYDFVJK@ME2<>BY'U%=%:7*WEG#<H"JRH'
M`/49&:IOH.GN\S^4R22R^<SI(RMNQMR"#QQQ6A'&L421H,(@"J/0"IDXM>ZB
MHJ2?O,=1114%A1110`4444`%%%%`!1110`4444`%%%%`!1110!\]UV'A:YM;
M'0KFYU)D>P^T;&A-MYA9BH_B[?\`UJX^NR\(7EE%IEQ:W5QIZ^=./W5U$7W<
M#!ZXZU]+BOX9\=@7:MOT>YCZ_)HEQ]GN='C:`R;A-`V?DP>#^//2KVA^-KG0
MM,2QBLHI55F;>SD'DYK)\0Q"'Q#?1*L2A),;8DVH.!T':LVFJ4*E-1EJM]29
M5ZE*M*4-'MH=S_PLV]_Z!MO_`-_&_P`*<GQ*OY&PNEP$_P#71O\`"N$JX[?9
MHE1/OMU-<>(HT:=H0A>4MM_FWZ'70QF)G>4ZC45OHONV.V_X6#?@?-86J_\`
M;1O\*&^(6H`973K9OI*W^%>?$ECEB2?>E21HSE3BL_[-FE=23?:VGYW+_M5M
MV=[=[Z_E8[@_$R^!P=,@!_ZZ-_A2?\+-O?\`H&V__?QO\*Y&8+/;B8###K50
M`GH":VP]&A5C=PLUHUYF5?&8JE*RJ73U3LMON.Y_X6;>_P#0-M_^_C?X4?\`
M"S;W_H&V_P#W\;_"N&HKH^I4/Y?S,?[1Q7\_Y?Y'<_\`"S;W_H&V_P#W\;_"
MC_A9M[_T#;?_`+^-_A7#44?4J'\OYA_:.*_G_+_([G_A9M[_`-`VW_[^-_A1
M_P`+-O?^@;;_`/?QO\*X:BE]2H?R_F']HXK^?\O\CN?^%FWO_0-M_P#OXW^%
M'_"S;W_H&V__`'\;_"N&HI_4J'\OYA_:.*_G_+_([G_A9M[_`-`VW_[^-_A1
M_P`+-O?^@;;_`/?QO\*X;!'4&BE]2H?R_F']HXK^?\O\CN?^%FWO_0-M_P#O
MXW^%'_"S;W_H&V__`'\;_"N&HH^I4/Y?S#^T<5_/^7^1W/\`PLV]_P"@;;_]
M_&_PH_X6;>_]`VW_`._C?X5PU%'U*A_+^8?VCBOY_P`O\CN?^%FWO_0-M_\`
MOXW^%'_"S;W_`*!MO_W\;_"N&HI_4J'\OYA_:.*_G_+_`".Y_P"%FWO_`$#;
M?_OXW^%'_"S;W_H&V_\`W\;_``KA\'T/'M24OJ5#^7\P_M'%?S_E_D=S_P`+
M-O?^@;;_`/?QO\*/^%FWO_0-M_\`OXW^%<-13^I4/Y?S#^T<5_/^7^1W/_"S
M;W_H&V__`'\;_"C_`(6;>_\`0-M_^_C?X5PV#Z&BE]2H?R_F']HXK^?\O\CN
M?^%FWO\`T#;?_OXW^%'_``LV]_Z!MO\`]_&_PKAJ*?U*A_+^8?VCBOY_R_R.
MY_X6;>_]`VW_`._C?X4?\+-O?^@;;_\`?QO\*X;'M001U&*7U*A_+^8?VCBO
MY_R_R.Y_X6;>_P#0-M_^_C?X4?\`"S;W_H&V_P#W\;_"N&HI_4J'\OYA_:.*
M_G_+_([M/B5?R-A=+@)_ZZ-_A4__``L&_`^:PM5_[:-_A7$NWV6%57[[=351
MB6.6))/K7GPPRQ/O4THQZ/=O\=CMECJE#W9R<I==DE^!Z"WQ"U`#*Z=;-])6
M_P`*KGXF7P.#ID`/_71O\*X=)&C.5.*LRXGM_.`PR]:?U>-":C52E%Z7VL_-
M7%]>JUHMTY--:VT>GEH==_PLV]_Z!MO_`-_&_P`*/^%FWO\`T#;?_OXW^%<-
M1@XS@XKN^I4/Y?S./^T<5_/^7^1W/_"S;W_H&V__`'\;_"C_`(6;>_\`0-M_
M^_C?X5PU%/ZE0_E_,/[1Q7\_Y?Y'<_\`"S;W_H&V_P#W\;_"C_A9M[_T#;?_
M`+^-_A7#48(Z@TOJ5#^7\P_M'%?S_E_D=S_PLV]_Z!MO_P!_&_PH_P"%FWO_
M`$#;?_OXW^%<-13^I4/Y?S#^T<5_/^7^1W/_``LV]_Z!MO\`]_&_PH_X6;>_
M]`VW_P"_C?X5PU+@GL?RI?4J'\OYA_:.*_G_`"_R.X_X6;>_]`VW_P"_C?X4
M?\+-O?\`H&V__?QO\*X:BCZE0_E_,/[1Q7\_Y?Y'<_\`"S;W_H&V_P#W\;_"
MC_A9M[_T#;?_`+^-_A7#44?4J'\OYA_:.*_G_+_([G_A9M[_`-`VW_[^-_A1
M_P`+-O?^@;;_`/?QO\*X:BCZE0_E_,/[1Q7\_P"7^1W/_"S;W_H&V_\`W\;_
M``H_X6;>_P#0-M_^_C?X5PU%/ZE0_E_,/[1Q7\_Y?Y'<_P#"S;W_`*!MO_W\
M;_"C_A9M[_T#;?\`[^-_A7#X/H?RI*7U*A_+^8?VCBOY_P`O\CN?^%FWO_0-
MM_\`OXW^%'_"S;W_`*!MO_W\;_"N&HI_4J'\OYA_:.*_G_+_`".Y_P"%FWO_
M`$#;?_OXW^%'_"S;W_H&V_\`W\;_``KAL'&<&BE]2H?R_F']HXK^?\O\CN?^
M%FWO_0-M_P#OXW^%'_"S;W_H&V__`'\;_"N&HI_4J'\OYA_:.*_G_+_(]#T[
MXB7=[JEI:-I\"K/,D982$D!F`ST]Z*XW0/\`D8],_P"ON+_T,45Y>/HPI22@
MK'MY5B*E:$G4=[,SNU=YX87[/:21:=KH`)6211IYE(8J,C/MC'X5P==[X8M[
MJST26&>WUB$SRB9)+*,<KM&.3ZUZ>+_A_P##?J>+E_\`%V_/]&C`\4:>+6\6
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M3MW`G:5[_P`ZRIY6F/W2%'08J+:?0_E71AZ3Y).IHY._IV_(Y:M?EJ1=-745
M;U.ATJ70TME6\C@>0NY+2AMP&Y=O3V+?E4DTGAXV,T4<=OY@B_=R`-O+;2>O
MKNP*YK:?0_E1M/H?RK=THMWYG]Y"Q$E'EY%]PE;>CZA;6]FL5VRE%O890A7)
MVC=N/3GM6+M/H?RHVGT/Y5I-1FK-F-.<J<N9(Z87>E2ZD7OG@NBL$,;2N&VN
M^\;V'?A2>?:GFX\.K:HRV]H9F1RRE6X8`;1^)S^M<MM/H?RHVGT/Y5E[&/\`
M,_O-_K,OY5]Q8U'[/_:5S]DQ]F\P^5CIMSQ5C2+N.V:[65U6.6V=.5SENPK/
MVGT/Y4;3Z'\JU:BX\K9@I24^=(Z>_OM-N]3L99YHYXU$GF*&=HPNWY!@\@YZ
M@<=*E2?PT5+/!:!M\8"[7QM.S>?P^?\`*N3VGT/Y4;3Z'\JR]C&R2D_O.CZU
M*[;BG?R\K%[5FLGGA>R6-%,0\Q8\X#Y/K[8I^A2QPZJDDMTMJ@5LR$>W0'!P
M3TSVK.VGT/Y4;3Z'\JTLN7EN8<\O:<]CI-4U*TNM,9!+"6=DQ#$#A'#L78<=
M"".>]67G\,L21!:+MD;:`K_,H+!<_4;:Y+:?0_E1M/H?RK/V,;64OQ-OK4V[
MN*?R-?6WTN2*V;3TA1^?-$0(_A4]_?=^59MJ=MY`3(L>)%.]QD+SU([@5%M/
MH?RHVGT/Y5K%*,>6YA.;E/GM;T.PNM5LY+>\A:^B9"I`>-W$DN$PI/`!R>H/
M053M9=`_LV..>*V\_P`A=SX;=OVMG]0GYUS>T^A_*C:?0_E62HQ2LI'1+%3E
M+F<4_D=#JTNAR:=,+**W2X$G[LQA@2N\CO\`[.#7.GI2[3Z'\J-I]#^5:02@
MK7N859NH[VMZ'8VNJV*:;#&^HQB[4+LDP<(OREE^[\O"D8YSD^M4;&YT/]^U
MS!;MON)67S%;*I\I0<?\"KG-I]#^5&T^A_*LU1@KV>YN\7-VO%:'4O+X<^SS
M1K%;9$9"/AMQ;#]_J$_.N5'2EVGT/Y4;3Z'\JTA%0ZW,:M1U+>ZE;LCIM$U&
MVL]-1)KV(/Y@9(V!PAR>3@?^/`^V*%N=&DU6XENVCN%;R5W2EV`_YZ%3UP.V
M:YG:?0_E1M/H?RJ'2C=N^YJL5-14>5-(ZK[1X<$43"WLS(T0:12K85_DX^GW
M_P`JYJZ\I;Z?R,&`2MY?^[GC]*BVGT/Y4;3Z'\JJ$(QZW^9G5JRJ6]U+T1TF
MBW>GV5^;B^+`/&41]FY5!!S^)X`I][?Z9<7T+2R17$:"=U!!VJ"/W2'Z$=/>
ML"&;">7*I*?3I3_LD;\I(<>F*\J$H87W:UTEHFM5;Y;,]*4YUX_NDG?5I[W_
M`%1T4D_A@)N2"T+%B"-K\+M8@CWSM%9&H_95>9[0*L$@4JJYP"5&0,^^:IB&
M"(YDDW>U0SSF4X`PHZ"M%'ZQ.*IWY4[MORZ(B=7V4&YI*71+]31\.75E9:S%
M<7Q(1"-C;=P5L]2/0#-7]2O=/N;2RB^TATCF0!%+8$?.XNIX!^E<U17HRI*4
M^>YPPQ$HT_9V5CK/M'ALI,?L]H&5&:,!7^9@S@#\MA_&LG76TQY86TU8E7#!
MQ&"!UXZ^U9-%$:/*[W85,2YQY>5+Y%K39DM]4M9I"H6.56)8'`P>^*Z2_P!4
ML)+"X1;M9':)Q)'EF\R0A-I4D9(7#=>E<C13G24Y*3Z"IXB5.#@EN=1#)X=-
MJD<L=N'$:9?#;BVT%O\`Q[(JKJ\FC2Z?_H44$=P)?^608$KEQW]@A_&L&BI5
M&SO=E2Q+<>7E7W!78:;J]I#IELC7D*31Q;(T+R`!N=V_`X]B*X^BJJ4U45F1
M0KRHMN)T4-QHWVN_><1SJ\_[IY]Q;9L;G/\`O;1S5PS^&@T8$%H0P1G)5^"7
M&X?0*3^5<C14.@GU?WFD<4TK<J^X=)M$C[/N[CM^G:MKPY>6EF;K[3*(G=5"
MOD@@`_,`1WQVZ&L.BM9P4X\K,:=1TY\Z.IN;[2KF2Q266.2V$RML*G]U&(\%
M3CIEN<"G)<>'#`7>WM!*!&0NUL$D#?\`D<URE%9>P5K)LW^MRNVXK[C2UEK!
MYXFT]8U38P<1YQD.P!Y]5VFJ,#(MS$THS&'!8>HSS4=%:QC96.>4^:7-8[6\
MU?398KI%O5"RJ=VQW#$?/L"\<]1D'@5FV,NA#38H[F*W\\P_.Y#;@YWY_P#9
M/SKG**R6'25DV=$L9*4N9Q1T>I2:$^G7"VD=NLZG]TR!@Q`*^OL6_*N<HHK2
M$.16O<PJU/:.]DO0Z+1-7CLK!8);H@23$%&R1$H4D-C_`'R/RI\=UI$NK3R7
MOD3J4@3S'#89@0)&&/;)S7-45#H1;;ON:K%245%I-(ZK[1X=6VC86]F9FC+.
MI5OE8;<#\?FKG;\6XU"Y%J0;?S&\K']W/%5Z*J%/D=[MD5:_M%;E2]$:.@?\
MC'IG_7W%_P"ABBC0/^1CTS_K[B_]#%%>5FGQQ]#W,D_AS]3.K>TZZ\3WEM(;
M&]O#!;J`Q$N%0=A_]:L&NT\(><^C7D7V!KR#S"=L,P60$J`>#U&,5Z6(ERPY
MK)^IX^#CSU.6[7H<E>FZ-[-]M,AN=V)3(<MD<<UVGA7P=IFM:%'>W37`E9W4
M^7(`,`X':N2UJXGN]:O+BY@,$TDA+1'JGM^6*]-^'W_(IP_]=9/_`$*L,94G
M"@I1=GIL=67T:=3%2C-76N_J1?\`"N-#_OWG_?T?X4?\*XT/^_>?]_1_A774
M5Y'UNO\`S,][ZCAOY$<G'\/-%C?<KW>?>4?X5-_P@FD?W[K_`+^#_"NFHK"J
MW5?-4U9M3H4Z:M!61S/_``@FD?W[K_OX/\*/^$$TC^_=?]_!_A7345G[*'8O
ME1S/_"":1_?NO^_@_P`*/^$$TC^_=?\`?P?X5TU%'LH=@Y4<S_P@FD?W[K_O
MX/\`"C_A!-(_OW7_`'\'^%=-11[*'8.5',_\()I']^Z_[^#_``H_X032/[]U
M_P!_!_A7344>RAV#E1S/_"":1_?NO^_@_P`*/^$$TC^_=?\`?P?X5TU%'LH=
M@Y4<S_P@FD?W[K_OX/\`"C_A!-(_OW7_`'\'^%=-11[*'8.5',_\()I']^Z_
M[^#_``H_X032/[]U_P!_!_A7344>RAV#E1S/_"":1_?NO^_@_P`*/^$$TC^_
M=?\`?P?X5TU%'LH=@Y4<S_P@FD?W[K_OX/\`"C_A!-(_OW7_`'\'^%=-11[*
M'8.5',_\()I']^Z_[^#_``H_X032/[]U_P!_!_A5Z[\4Z-97TME/=D7,.TR1
MI"[E,C(SM4]147_"8:)_S\S?^`DW_P`31[*'8.5%;_A!-(_OW7_?P?X4?\()
MI']^Z_[^#_"K/_"8:)_S\S?^`DW_`,31_P`)AHG_`#\S?^`DW_Q-'LH=@Y45
MO^$$TC^_=?\`?P?X4?\`"":1_?NO^_@_PJS_`,)AHG_/S-_X"3?_`!-(WC+0
ME4LUU*`!DDVLO'_CM'LH=@Y45_\`A!-(_OW7_?P?X4?\()I']^Z_[^#_``KH
MK>XAN[:*XMY%EAE4.CH<AE/((J2CV4.P<J.9_P"$$TC^_=?]_!_A1_P@FD?W
M[K_OX/\`"NFHH]E#L'*CF?\`A!-(_OW7_?P?X4?\()I']^Z_[^#_``KIJ*/9
M0[!RHYG_`(032/[]U_W\'^%)_P`()I']^Z_[^#_"NGHH]G#L'*CD?^%<:'_?
MO/\`OZ/\*/\`A7&A_P!^\_[^C_"NNHKK^MU_YF<WU'#?R(Y'_A7&A_W[S_OZ
M/\*/^%<:'_?O/^_H_P`*ZZBCZW7_`)F'U'#?R(Y'_A7&A_W[S_OZ/\*/^%<:
M'_?O/^_H_P`*ZZBCZW7_`)F'U'#?R(Y'_A7&A_W[S_OZ/\*/^%<:'_?O/^_H
M_P`*ZZBCZW7_`)F'U'#?R(Y'_A7&A_W[S_OZ/\*/^%<:'_?O/^_H_P`*ZZBC
MZW7_`)F'U'#?R(Y'_A7&A_W[S_OZ/\*/^%<:'_?O/^_H_P`*ZZBCZW7_`)F'
MU'#?R(Y'_A7&A_W[S_OZ/\*/^%<:'_?O/^_H_P`*ZZBCZW7_`)F'U'#?R(Y'
M_A7&A_W[S_OZ/\*/^%<:'_?O/^_H_P`*ZZBCZW7_`)F'U'#?R(Y'_A7&A_W[
MS_OZ/\*/^%<:'_?O/^_H_P`*ZZBCZW7_`)F'U'#?R(Y'_A7&A_W[S_OZ/\*/
M^%<:'_?O/^_H_P`*ZZBCZW7_`)F'U'#?R(Y'_A7&A_W[S_OZ/\*/^%<:'_?O
M/^_H_P`*ZZBCZW7_`)F'U'#?R(Y'_A7&A_W[S_OZ/\*/^%<:'_?O/^_H_P`*
MZZBCZW7_`)F'U'#?R(Y'_A7&A_W[S_OZ/\*/^%<:'_?O/^_H_P`*ZZBCZW7_
M`)F'U'#?R(Y'_A7&A_W[S_OZ/\*/^%<:'_?O/^_H_P`*ZZBCZW7_`)F'U'#?
MR(Y:T\`Z/9WD%U$]UYD,BR+ND!&0<C/'M174T5E.K.IK-W-J5&G25J:L?/==
MMX/AN?["O+G3K>T;44N`L<MQV7:,X]_\:XFNL\*:/::EIEZQMHKF\5MJH[XV
M+MR"![GC/:OHL5;V>O\`7Y'R>`O[96WL_P"MF8.L_;/[9NO[09&N]_[TH1M)
MP.F/;%>F_#[_`)%.'_KK)_Z%7F6M06UMK=Y!9L&MDE(C(.>/K]<UZ;\/O^13
MA_ZZR?\`H5<N/_W:/R_([,KTQDK]G^:.IHHHKQ#Z4****`"BBB@`HJ!KVU23
MRVN(@_\`=+C-3]1D4`%%(2%&20![T9&,Y&*`%HHSBC(H`**"0!DG`I`P;H0?
MI0`M%(64'!89],TM`!1110`C,%4LQ``&23VJ#[?9_P#/W!_W\%321I+&T<B*
M\;@JRL,A@>H(KD&.@&_O+.V\&FZ:TD$4KPV4`4,5#<;F!/!':@#J?M]G_P`_
M<'_?P4?;[/\`Y^X/^_@KF/*TK_H09O\`P#MO_BZ/*TK_`*$&;_P#MO\`XN@"
M:VU;2H?&NKEK^UC_`-#M0^Z95R^Z4]SS\I6MG^W='_Z"MC_X$)_C6!Y6E?\`
M0@S?^`5M_P#%T>5I7_0@S?\`@%;?_%T`;_\`;NC_`/05L?\`P(3_`!H_MW1_
M^@K8_P#@0G^-8'E:5_T(,W_@%;?_`!=7=)T_PUK%E]I@T&RCVR-%)%+9QJ\;
MJ<%6&#@T`:7]NZ/_`-!6Q_\``A/\:/[=T?\`Z"MC_P"!"?XU'_PC6@_]`33?
M_`1/\*/^$:T'_H":;_X")_A0!D^#[ZQALM0LXKN`V]KJ$T<&)5P$)#@#GH-Q
M'X5T7V^S_P"?N#_OX*I_\(UH/_0$TW_P%3_"C_A&M!_Z`FF_^`J?X4`:,<T4
MREHI$<`XRK`T^J]I8V>GQ&*RM(+:-CN*PQA`3ZX'>K%`&#+<:^/%L<,=O$=&
M,>6D.,YQ]<YSVKG-1U&_M-2N84GFV6TDD/WSR9_]7GZ=J[_>N_9N&XC.W/.*
MSIM2TA'OC-)"&M`KW)9.5[J3QS^%;0GY&,X>9@W.K:C9Q7")>KB*=X8E,0+;
M8T!R6)QG/7/\ZLZ1K=Y>:A")+B*1)I'0PJH!C`C#!L]>IQ^-;4<VFWD(<>0\
M9?<-Z@9;`YY[\CFF6,6EVKS/:K#&[R-O.,'(X(Y[<?2AR5M@47=:Z'.RZQJ$
M-]JB0W*K';&27:R;MV&48R>@P3TI+77[N*VN$:=`RSQK$'Y)#2N&Z]>`/I74
M,^G^8Z-Y(9D#,Q``*L?7H<D?I3;;3].BCCABBA?RQE2V'8`G.<GGD\T<\;:H
M7)*^C.<BU[5$.G!Y%F::&.9]L2J&#MC;UXP!GCK5K1+^YNK^6::[$I:Q27RU
MP!$2S?+CU]SS6XSV"W$,9$/FH#Y?RCY`.O/\-)%)IZ7+QP^0LK()'VJ!N!)`
M.>^2#2<DUL-1:>YR?_"1ZK':QAIUDDECBE#K$OR[D9B,$@8RHY^M69->U*WL
M9]3EEC,$5SY30",?*"G'/?YB*Z6:.PC1EF2W"JH8JRKPJ]#CT%)#+8W5DLZ>
M4UM-AP67`;T.#3YX_P`H<DOYCEVU_58YY[=GC$B*8]SHJJ'`3G.>Y8]1@<5I
M1ZS.='L+DR*'>[6"9G0`8W$'OCMU'%:=W-IMM'<7%R;<`)^^8@$E?0]S4A^P
MFW\D_9S`,?(=NT>G'2DY)K8:BT]SFM/U^_N+NSW7$3+)Y0,(09</ORP/MM%.
MNKZ\M==OXEOQ&DDJ@-(H*Q`1;N![D8_^O7016FGP7DEQ&D*S;`I(Q\JC.,#L
M.:D9+&X9BR6\I8`L2%;('3/TI\\;Z(2A*VK,#7=5NSX5AEC6:":Y@WO)&C'R
M@%W'D=,GC\:ALKQY=3MY1<RF9[PQ&(N?]3Y61\A]\'..]=2TMNT85I(BCC`!
M(PP_K4-G)97@^V6HB<G*>:JC/!P1G\*2DE'8;@W*]SFKS6-42YNS'=QJD;7.
MU#$#@1*&`S[YYIL^M:IYEP\=W&B+]H94\H'`C16`S[YQ77&W@.<PQG.<Y4<Y
MZ_G2&V@.<PQ\YS\H[]?SH]I'L'LY=QT+F6".0C!90V/J*?0``,`8%%9&H444
M4`%%%%`!1110`4444`%%%%`!1110`4444`?/1Z&O5M'T9!H\5S<:#8.[0KL2
M#&]P1U8M@<UY4>E=6G@W4[G3H+O3KY+I9`IV++MV`KDYYZ@\8KZ+%I-).7*?
M(X"4HRDXPYON_P`F8>MH8M:NT:T2T*OC[.A!$?`X!''_`.NO3/A]_P`BG#_U
MUD_]"KRR]M9[&]EM;H8GB;#_`#;N<>O>O4_A]_R*</\`UUD_]"K''_[NOE^1
MTY5_O<KJVC_-'4T445X9]*(S!5+,<`#)-<5=7$T\YU4.PC^T!$7=V'/2NHU>
M.ZFT]X;109)/E)+8P.]9-SX:4:8JVZ9NP!DE^#ZTQ"ZZ6LKZTU.)B03AEW?>
M_P`BJJ"98!>32L);PLQ*G[D8&2![G@5;BT>\OIP=1"K'%%LC56SSC&?ZTD&D
MWG]E-;W$*L\+$P_O<9!ZC(H`YZXUNTM-1&G3QR*N0LAB5=J$]N1ENHR:W;75
M/[*L;I620K$C-&'<'D'&/IFLV738)KQ+F>P2.Z3`Y61B2.A(QAC^-;$>BF\L
M;B.Y)B\V,I&&P6'.2S>Y-:U72:CR+7J<]%5E*7M6FKZ>AB16L-[IJZQX@U&X
M5)FQ&D9(`].`#[U%J'V0V>DV>FW,TL,MRWSN2"3D#'./6K<>G>([;37TM;>U
MN+<@A)"X^4'TITOAG4(=,TQ[;RVO+1BS(6X.6SUK(Z2QXS=WDTNT1F!EF_A.
M,]!_6LOQ)<2ZIJ%Z892MOI\>.&QN;//^?:M";3]9O[P:E?QP0O;H?L\"R#E^
MV2??G\*2T\'*VCRM>*3J+AF!$G`/;V-`BKK]\;CPUHW[PKYN"Y![*,'^=-TQ
M(/\`A)H3HD]P]G&FZX:1CMQSZ_A4MMX>U9CI45S!&(;20LY\P'@L#T_"KQT2
M^MO$-]=6L*"VG@95VN!\Q7CCZT#,SP_HL.O17MU<RSJWG$(R/C'?^HJ?PREU
M>7DMK->S-'82Y0AOO<D8/MQ2Z98>);#3WL;>VMX0[%C.T@)&>.*Z#0=%31;-
MH]_F32'=*_J?0>U`&K1112`9*[1PNZQM(RJ2$7&6/H,D#/U-<==7&N6^OKJV
MF>&;YA.BPWMO+-;H'5<[9%(D/S+DC!Z@]L"NTHH`YW_A*+O_`*%77?\`OB'_
M`..TG_"4W?\`T*FN_P#?$/\`\=KHZ*`.<_X2F[_Z%37?^^(?_CM'_"4W?_0J
M:[_WQ#_\=ID/B/5[RYO8K/P]YJVEPUNS->HI)&#G&.A!!J?^U?$7_0LK_P"#
M!/\`"@"/_A*;O_H5-=_[XA_^.U@WNH:Q::G+JNA>&=76>?'VJSG2$17!`P&W
M"0E'`XS@@@#(XKH1J_B%LX\-(<''&H)_A2_VKXB_Z%E?_!@G^%`$-GXGU*XC
M03^$=8@F(RR[H"H_X$9!5S^V[_\`Z%K5/^^[?_X[4/\`:OB+_H65_P#!@G^%
M17.OZY96TEU<^&6\B)2\ABO4=@HZD+CDX[=Z`+?]MW__`$+6J?\`?=O_`/':
M/[;O_P#H6M4_[[M__CM:MO<175M%<0.'AE0.CCHRD9!_*I*`*MC=37<+/-8W
M%FP;`2<H21Z_(S#'XU:HHH`PY?#,,OBJ/7C<S"1$V^4#\IXQ^7M63JGAW4+K
M4KR2&-?)NY2LV7'S1A%*_P#CRX_&MJ3Q+81>(TT-A+]J==P(7Y>F<9^E4;WQ
M/)8W]RCI#)#!+Y9A0DS%=FXN!TP/\FMXNI?Y?@825.WS_$HQ>'+UHI!/:1LW
MV>=4W,IP[*@7'IRIY]J(/#=XTC-<VD;DR1G+,IX$Q9O_`!TUK2^)HT@=Q9W"
ME1C,@4`.5W*IY[C'YTD7BFV6")KN&2$F-6D88*JY3?MZYSBGS5.PN6GW,QM%
MU&*VFB6R619(Q"`&0[%\UR2`3C(5ACZ^U6])T:ZM=>-R8?)M@&V+\O"E5"J2
M"2<8Z=*O0:W-/K$%E]@FB1XW9S+@%2-N,<\C#=O7ZTC>)(%D=#:W/#ND9"C]
MXRD!@.>.O4X%)RF]+#48+6^QDS^';EP[+:(7DDN6D*N%9@S`IS]!_C3+70M3
MBOK6[>!"D."8,J`_[QCD@'`90P;CC/2M"Z\5H+4/96<TSE%D.=H509-F"<]<
M@],U-'XEC614GMY5+3F'<H&U3OV`')Y.?3-.]2VPK4[[E/4]&O+J^N2ENKF6
M02)<EE^5!'M,>.O)_#FGZIH]W/H>FVL$2Y@4"6(!3SL*\`D#@G/ZTMGXK#1M
M)>P;%"Y5H^1G86P<]^#BM*ZUN&TFMHI(9B\Z;\`#*C('//)&>@R:5YII6&E!
MINYSEYX9O9+.14MHWG::0LY9<NIC`&3[D5)=Z!=20SM%IT8>:YE?JFY5*87J
M<8SGUQV%:Z>*+)MI:.9%;E68#!4AB&Z]#M(]:C/BRS$+2&WN<;<J,+ER"H*@
M9ZC<*?-4["Y:?<P1HU_>+=QK9%)D&UY&8`R?N479GN,C.>E6[KPW>;KC[);Q
MQ;Y)\%2HRC;-H^AP>*V&\36D<DL<D,Z-&IX('+#&4&#U&X>WO2PZZ?[-O+RX
MM73[/<&'REP6/(`[XSD^M'//L')#N8G_``CEZ\5P7MD8M`XA5M@\MC(&P`#A
M>!G@UT.@V<EAIIMY(%B999#A<88%B0>/8BJX\3VFZ-6AG1BQ20$#]V=Q49Y[
ML,<9I(_$]L\4;O:W,7FHCQ*ZKEPS!1CGWS]*F7/)6:*BH1=TS<HK!/BRR$6_
MR9R2X"KA<LI!(;KCD`\=?:MT'<H(Z$9K)Q:W-%)/86BBBD4%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`'SW77^%+&*[TBX9K%M2=;E5^R^=L$:D<R?7M
M^%<A6WHFCRWMI/>C5H-.AC<1%Y)"NXD9QP17T^(5X;V_KRU/B\(VJNBOOV_7
M0IZU;06>MWEM;/OABE*H2<\>F?;I^%>F?#[_`)%.'_KK)_Z%7E=[;K:WDL"7
M$=PJ-@31'*O[BO5/A]_R*</_`%UD_P#0JY,?_NZ^7Y'=E7^]RTMH_P`T=311
M17AGTP4444`%%%%`!6+JVB2ZC=_:8KHP2)"8XB!G!)^;([@CBMJBJA-P=XD5
M*<:BY9',V_AS4HG*'5Y?L_RJ%4D'8".!Z<#'%/NM`U*42B'6)47S,Q(6/"'D
M@GJ3G]!71T5K]8G>_P"B,OJM.UM?O9BW>A-?Q6$5U=,ZVZMYAP,R,1C/.?>J
MC^&KQ(%BMM2F1`S?*96`5?X,8/\`#^M=+125>:T3'+#4Y.[1S">'-3BF5H]7
M=5\PN_7+9.<D9Y..,=*/^$=U-X8_,U3,R.7\S+G)VD`XS@')'`XKIZ*?UBI_
M2)^J4_/[V86G:)>6]TDMSJ,LD:$L(1(Q&XXZD\D<$X]ZW:**SG-S=V;4Z<::
MM$****@LK7UV;&V,PM;BY(('EVZ!F^N"167_`,)*_P#T`-:_\!U_^*K=KD=.
MU'Q1JQO##+I$)MKJ2W>&2*1F3:>,D-W4J?QH`T?^$E?_`*`&M?\`@.O_`,51
M_P`)*_\`T`-:_P#`=?\`XJF>5XN_Y^M%_P"_$O\`\51Y7B[_`)^M%_[\2_\`
MQ5`&-I&O36%]K$USX>UT&ZO#*@2RW#8$50<@_P"R:PO&/B_41<&31;?7K.X2
MW+7J36VV-;?GYP#G:Y((#?GG%=MY7B[_`)^M%_[\2_\`Q58&O^#O$>OSQ3OJ
MMA:3)L#M;1R`2HK;E5U8D,`W(R/YT`3^'?%VE)H=NFD^']>^R*"!BR9CNS\V
MXDY+9SDGO6I_PF"_]"_X@_\```_XU5TS1_%.D6!MK:\TF0EFD:2:*4M([')9
MCNZDUMZ!JZZUI:7#)Y5RA,5U!WAE7AE/X]/48-`&=_PF"_\`0O\`B#_P`/\`
MC2'Q>C*0?#WB`@\$?8#_`(UTM%`'&>&M7N-,\/6EE-H&M;H0RC_1UX7<=O\`
M%_=Q6M_PDK_]`#6O_`=?_BJW:*`*]C=F]M5G-M<6Y)(\N=0KC'L":L444`1&
MVMS<BY,$9G`VB78-P'IGK55M)@:+4$+/_IV=YXRN5"\?@*HRR>(?^$MC2..+
M^Q?+^9CC.<?GG/X8K'O9Y[?6;FZ59,1WZ)YHF/3RP?+V=,$]_>M8P?<RE-=5
MU-Z7P];32DM++Y389X<C:SA=H;IG./Y56'A&R)_>RR2`H%;<JY)"[0<XR.,<
M#BL*;7]1;3HKHR@2*[%'(7O#N((!(X)[\^M2WE]J$6L3;KUY#9+($&Q0.?+^
M8@=<!S^56H3[F;G!ZV.E@T?R;R&[>\N)ID#@F0@A@V.,8X^Z.E4D\,"03&ZN
MI"3-))$$QB/<V[N.>@R#D=:SO[;U,R7/EW2R1VL,TBL(U/G[6P#QT`SSCKBE
M?7;Z*\C@BO$NT4J1*D:J)<R;2I)(Z#^[[4E&?<IRAV-2/PQ;1VTL(N)SYB!-
MWRY&)"XQQCJ:;)X6MWF$OVJ<.)/,SA3\V_?Z<<^E1ZOJUU::C,D5Q''Y,*O'
M`Z;C<$A\XQSQM']:R;KQ)?0"6*/4(Y3'")Q*(T^;Y<E,].#CC[W-"51ZW!NF
MNAJS>%8_LR6T4FZ)IHY)#*>0$[+@=^G/K6EJ6CPZG+$TTLJJF,HI&&P0?P/'
M48-<OJ&KWMS!J$(O1M*R_+&H!A"A"ISUYR>M,O=:NKE9X%U',)&Y9%5%("2H
MO;GN<D_AQ3Y)NSN+G@KZ&[_PB5C]@FL]\@CD*8*A5*A3D#('/4C)YI[>%K)I
MIW5G02G=A57Y26#'!QG''0GBLBWUF\CDNE6Y7]S<XCB(!-SNE*G!]AZ5?T75
M+ZX$OVBX24M:"X4F,#82SKCCJ/E'O2:FM;C3IMVL6I?#-E+=74Y9PUQDG`7*
ML<<@XS_"."<5,NB1C3Y[22XFD\^;SGD.`Q;(/88Q\HKDKO5KV\LF62];S%AE
M)>,`?P*>".".?J.];FEZQ>7.NM;-(9(`9$Y"#`7&UA@Y.>>V.1BB49I7N$9P
M;M8LGPO9F[%P7D+[V<Y"G.6+8R1Q@D]*F_X1^T/]F[FD/]G@B/)'S#;CYOY_
M6M:BLN>7<UY(]CGU\)6D=JUO'/*BM\IPJ8*XQ@C&#UZGGWK=AB6"".),[44*
M,G)P!BGT4.3>X**CL%%%%24%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M'SV>E>D:9)K,F@6LL<VA)$VU0DJ_PA>"3G[WM7F]=IX/NBFC7-M!>6$%S]I6
M0K>#Y2FT`D>_%?1XR-X)]CY'+Y6J.+ZHYS7B#KU[B6&7]YC?"NU#P.@KTKX?
M?\BG#_UUD_\`0JXKQE?V-_<P-:/#)(C2*SQ)M&W(V@^IZUTG@O7])T[PW%;W
ME_##,)')1SR`6XKFQ2E/#1LM=#KP3A2QLKR5K/7UL=U16+_PEWA__H*VW_?5
M'_"7>'_^@K;?]]5Y7L:G\K^X]WZQ1_G7WHVJ*R%\4:&PR-2@/XTC>*M"3[VI
MP#\:S46WRI:ENK!*[:L;%%8O_"7>'_\`H*VW_?5'_"7>'_\`H*VW_?5:>QJ?
MRO[B/K%'^=?>C:HK('BC1&&1J4'YTC>*]"3[VIVX^IK-1;?*EJ6ZL$KMJQL4
M5B_\)=X?_P"@K;?]]4?\)=X?_P"@K;?]]5I[&I_*_N(^L4?YU]Z-JBL7_A+O
M#_\`T%;;_OJC_A+O#_\`T%;;_OJCV-3^5_<'UBC_`#K[T;5%8O\`PEWA_P#Z
M"MM_WU1_PEWA_P#Z"MM_WU1[&I_*_N#ZQ1_G7WHVJ*Q?^$N\/_\`05MO^^J/
M^$N\/_\`05MO^^J/8U/Y7]P?6*/\Z^]&U16+_P`)=X?_`.@K;?\`?5'_``EW
MA_\`Z"MM_P!]4>QJ?RO[@^L4?YU]Z-&^^W?9C_9YM_M&1C[1NVX[].:Y6;0_
M%@UDZK8WNCVD\BA+E/*E>.X`^Z67(PPZ!ASCCFMG_A+O#_\`T%;;_OJC_A+O
M#_\`T%;;_OJCV-3^5_<'UBC_`#K[T5?*\:_\_6@_^`\W_P`71Y7C7_GZT'_P
M'F_^+JU_PEWA_P#Z"MM_WU1_PEWA_P#Z"MM_WU1[&I_*_N#ZQ1_G7WHJ^5XU
M_P"?K0?_``'F_P#BZ/*\:_\`/UH/_@/-_P#%U:_X2[P__P!!6V_[ZH_X2[P_
M_P!!6V_[ZH]C4_E?W!]8H_SK[T5?*\:_\_6@_P#@/-_\761>>&_%\VH_VE9Z
MIH]A?$!9)8+>0K,HZ"1"V&QV/!'K70_\)=X?_P"@K;?]]4?\)=X?_P"@K;?]
M]4>QJ?RO[@^L4?YU]Z*MM%XUC3%S=:%.W]Y8)8_TW&I\>*_[VB_E+_C3_P#A
M+O#_`/T%;;_OJC_A+O#_`/T%;;_OJCV-3^5_<'UBC_.OO0S'BO\`O:+^4O\`
MC1CQ7_>T7\I?\:?_`,)=X?\`^@K;?]]4?\)=X?\`^@K;?]]4>QJ?RO[@^L4?
MYU]Z-*Q^V_95^WFW^T9.[[/G9CMUYJQ6+_PEWA__`*"MM_WU1_PEWA__`*"M
MM_WU1[&I_*_N#ZQ1_G7WHVJ:8XSG**<G<>._K6/_`,)=X?\`^@K;?]]4?\)=
MX?\`^@K;?]]4>QJ_RO[@^L4?YU]Z-;[/`%V^3'MR3C:,9/6E\J,L6,:9;@G:
M.:R/^$N\/_\`05MO^^J/^$N\/_\`05MO^^J/8U?Y7]P?6*/\Z^]&NL,2`!8T
M4`;0`H&!Z4@MX1LQ#&/+^Y\H^7Z>E9/_``EWA_\`Z"MM_P!]4?\`"7>'_P#H
M*VW_`'U1[&K_`"O[@^L4?YU]Z-@QH9%D**77@,1R/QJ/[+;[0OV>+:"2!L&,
M^M9?_"7>'_\`H*VW_?5'_"7>'_\`H*VW_?5'L:O\K^X/K%'^=?>C1@L+6W,Q
MB@1?.8M)QG<3_3VIXM+89Q;Q#(P?D'-9?_"7>'_^@K;?]]4?\)=X?_Z"MM_W
MU1[*K_*_N8O;T/YE]Z-800AE(BCRN2IVCC/I3EC1/NHJ\8X&.*Q_^$N\/_\`
M05MO^^J/^$N\/_\`05MO^^J/8U?Y7]P_K%'^=?>C6%O`J[1#&%YX"COU_.E2
M&*-BR1(K$`$JH!P.U9'_``EWA_\`Z"MM_P!]4?\`"7>'_P#H*VW_`'U1[&K_
M`"O[@^L4?YE]Z-JBL7_A+O#_`/T%;;_OJC_A+O#_`/T%;;_OJCV-3^5_<'UB
MC_.OO1M45B_\)=X?_P"@K;?]]4?\)=X?_P"@K;?]]4>QJ?RO[@^L4?YU]Z-J
MBL7_`(2[P_\`]!6V_P"^J/\`A+O#_P#T%;;_`+ZH]C4_E?W!]8H_SK[T;5%8
MO_"7>'_^@K;?]]4?\)=X?_Z"MM_WU1[&I_*_N#ZQ1_G7WHVJ*Q?^$N\/_P#0
M5MO^^J/^$N\/_P#05MO^^J/8U/Y7]P?6*/\`.OO1M45B_P#"7>'_`/H*VW_?
M5'_"7>'_`/H*VW_?5'L:G\K^X/K%'^=?>C:HK%_X2[P__P!!6V_[ZH_X2[P_
M_P!!6V_[ZH]C4_E?W!]8H_SK[T;5%8O_``EWA_\`Z"MM_P!]4?\`"7>'_P#H
M*VW_`'U1[&I_*_N#ZQ1_G7WHVJ*Q?^$N\/\`_05MO^^J/^$N\/\`_05MO^^J
M/8U/Y7]P?6*/\Z^]&U161#XHT.XGCABU.!Y9&"(H;DDG`%%1*$H_$K%PJ0G\
M+N>)5VG@ZZAATB\1;Z*TNC,&+M:F8[`._MFN+KJ_"NJV-OI]UI]U/+;O.^5>
M./=ORN`OU!Y'UKZ/%1;IV2/D,#)1K)MVW_K=&'K4OG:U=R?:%N-S_P"N6/8'
MX'.WM5"M'7YOM&OWTWD/;[Y2?*==K+]1V/?\:SJVI_`O0PJ_Q)>K"K:(EO$)
M)!ECT%55QN&>F:U8;6.[OBLQ?RHH'F(0X+;1G`/:N/%MRG"C>R=V_1=#IPD;
M1E42NU9+Y]2@UW*3P0H]J<EXX.)`&7Z5J+X<\Z^O(8[M(T@D5%\Q22VY"X''
ML#4W_")2?)G48!O"LO[MN5+!0?S8<4I4,'R\KBONU^\TB\;?F3?WZ&)<0J%$
ML?W#VJ152VC#N,N>@]*=$ACBDCD_@?;^1JY8V5O?7\J73E46,%`&VY8L``3@
MXZ^E<:J2G/ZM.3Y4W=]6E:R_'4W]DDO;07O.UET3UN_PT,QKN4G@@#V%.2[;
MI(`RGVK2M/#KWGG$W,=N8YI(MCJ6/R8SR/K4K>%)EAD<WL'F(A8Q[6[;N_\`
MP!J[)4,';EY4OEK]YSQEC+\R;?S_`$,:XA"8=/N-^E05:4YT\Y]>*NZ7I5OJ
M-LI,DJ3&ZBA;IMVMGD=\\56%JM4Y*H[\K:N9UZ//4C[-6YE>QD45O#0([N[5
M;:X\B)X(Y0)P68%VVA3CWI__``BKB$2MJ,`1E+J?+;D*`6_+/Z5T>WAU9G]5
MJO9?D<]14]Y;/97LUK(0SQ.4)'0XJ?3+2"\-TLK2!XX'E3;C!*^M:.22YC%0
M;ER=2C16_>:%!]NM8+.7;%,74S.^X;D&6R-H(_7K4B^$I'!8:C!L#*N[RVZM
MMVC\=XK/V\+:LV^J5;M)7L<Y15S4;!M.GCC,J2K)&)%=00"#D=#[@T:5;1WF
MH)!*DKJP/RQ$`D^Y/`'J:OG7+S=#+V<N?DZE.BMW4-&LX+%YK:>20KL=9#C:
MZNY48'J,9J;_`(1&0R,BZC`Q3=N_=L,!20Q_,5'MX6NV:_5:M[)7.<HK2U71
MVTM('-Q',LV<%%(Q@`]_9A5"%5>>-'W[68`[!EL9[#UJXR4ES+8RE3E"7++<
M9172S:%8+#<>2TK7**2(6E`*$+N8$A<,1^'I5:W\-27%@ERM["&:(2^64;(!
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M.Z#_`&U+<;V=8XD."G4N0=H^G'-.NM"A-[##;S-$CK,6,W)7RF8$\#H=N12=
M:"ERE+#5'!32T?\`PQA45T?_``B$N?\`D(08\SRL[&^_Q@?J.:QM0LC87(A,
MJRAHUD5U!`(89'!HC5A-VBQ5,/4IJ\E8JT5J:!I/]L:JENY981\TK)]X#../
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MFK'_``B,@*@ZC`"^TJ/+;D,VU3^)(J77IK=EK"UGJD<Y12NI1V0]5)!K6T/2
MHM2^T-,S;8MBJJN%+,QP.2#_`)]*N4U%<S,J=.4Y<JW,BBM^[T")&MH(9'$S
MW"6[M)RI9E#9`'0#..]/'A*1HA,NHP&(@'=Y;<9Z<5'MZ=KMFOU2M=I+8YVB
MKVIZ:VF31QM,DH=2P9`1T8J1S[@U5@B,UQ%$#@NX7/IDXK1235T8RA*,N5[D
M=%=5<^&[*%)_*:223#"!3,!O*[MQ^[VV].._-4+7PW)=V*7*WD*L\?F"(JV<
M?-CGI_":R5>#5S>6$JI\MKF)16U?>')+&REN?MD4OE'#HJL".0#R?3<*Q:TA
M.,U>)C4ISINTU8**W=(TNPOK$O<"X27S"BLKC:Y"ER`,?W1USU(H3P^MUJ$D
M,%R(8Q'#(OF@L?WF,+Q[GK4.M%-I]#18:HXJ2UN85%=#_P`(JPA65M1@".I=
M3Y;<J-N3_P"/5B7=N]I>36SD%XG*$CH2#BJC4C/2+)J4*E-7DBWH'_(QZ9_U
M]Q?^ABBC0/\`D8],_P"ON+_T,45Y.:?''T/=R3^'/U,X].*ZFRN?!T"V\LL.
MIFYCVLQ7&W>,$XYZ9KEJ*]:=/G5KM>AX5*JZ;NDGZJYH:[?1:EKEY>P!A%,^
MY0XP<8`Y_*L^BMG3?"NKZM9K=V<$;PL2H)E"G(.#P:&X4HJ[LD)1J5IMQ5V]
M=#&J_;7+Y1HY6BN$^ZZG!K6_X0+Q#_SZ1?\`?]:/^$"\1?\`/K%_W_6N3$.A
M62]])K9W1UT*6)I-_NVT]U9F/YFH1.[)-+N=M[,K?>;!&3[X)_.I4N-2<KNN
MYE"@`9?H`01C\0#^%;,7@KQ(KKNMX]G?]\M6&\%:TXPUM&1_UV%>?7QM:FU#
MW7YI7_7<[J.!YUS6DO)Z'+7,P(\M#GG+-ZFK%K>3+\UO</!/C:60X)%;W_""
M:M_SYQ?]_A_C1_P@FK?\^<?_`'^'^-8O$T/9J,8R4EK>RW>]]=;FBPF*YW*5
MK/2VNW2VG0YQ9-0MP5CFE4$D_*W4GJ?QP*E2XU)R3)>3*",-E^HY_P#BC^9K
MHAX,UL#`MH_^_P`*J2^"/$DC'-O&5SP//6MZ.-JU[Q?+'S:_+4SJX+V-I)2E
MY(YZXE4@11_<6HTGFB0I'*Z*6#X4X^8=#]1FNA_X0+Q#_P`^D7_?]:/^$"\0
M_P#/I%_W_6O2HRP]*"@I+[_Q//JT<54GSN#^YF&=1O3.\YNI?-?;N?=R<'(_
M(@4IU&]*!#=S%`"H7=P`>HK;_P"$"\0_\^D7_?\`6C_A`O$/_/I%_P!_UJ_;
M4/YE^!/U?%?RR^YG.2RR32M+*[/(YRS,<DGUI8Y9(2QC=D+*48J<9!ZBNB_X
M0+Q#_P`^D7_?]:/^$"\0_P#/I%_W_6J^L4=N9?>3]4Q-[\C^YF')J-[++'+)
M=S/)&"J,6Y4$8.*4:G?JNT7DP&0V-_<8P?PP/R%;?_"!>(?^?2+_`+_K1_P@
M7B'_`)](O^_ZU/ML/_,OP*^KXK^67XG/2SRSE3+(SE5VKN.<#TIUM=7%G-YU
MM,\4F"-R'!P>HK?_`.$"\0_\^D7_`'_6C_A`O$/_`#Z1?]_UI_6*%K<R^]$_
M5<3>_([^C,*6_NYXA%+<R/&&WA2W&[UIXU2_!8B\GRV03OZY.3^9K:_X0+Q#
M_P`^D7_?]:/^$"\0_P#/I%_W_6E[:A_,OP*^KXK?EE^)@375Q<*JS3/(J?=#
M'..`/Y`?E4<<CQ2))&Q1T(96'4$=#71_\(%XA_Y](O\`O^M'_"!>(?\`GTB_
M[_K3^L4=N9?>2\+B6[N#^YF-)JVHRK*LE[.RR\2`M][ZTQ-0O(T")=2JH4*`
M&X``(`_(G\ZW/^$"\0_\^D7_`'_6C_A`O$/_`#Z1?]_UI>VP_P#,OP*^KXN]
M^67XF%+?W<T;1RW,KHQRRLV03G.?SYJO72_\(%XA_P"?2+_O^M'_``@7B'_G
MTB_[_K36(HK:2^\EX7$O>#^YF,NK:B@0+?3C8NU</T'I445[=0KMBN)4&2<*
MW<XS^>!^5;W_``@7B'_GTB_[_K1_P@7B'_GTB_[_`*TO;4/YE^!7U?%?RR_$
MQ#J=\=V;R8[A@_/U'(_J?S-5:Z7_`(0+Q#_SZ1?]_P!:/^$"\0_\^D7_`'_6
MFJ]!;27WHEX7$O>#^YF'%J-[#$D45W,D:-N55;`4^HH_M&]\YYOM<WF.P9FW
M<DCH?PK<_P"$"\0_\^D7_?\`6C_A`O$/_/I%_P!_UI>VH?S+\"OJ^*_EE]S,
M3^TKXJJ_:YMJKM4;N@XX_0?E5=W:21I'8L[$LS'J2>IKH_\`A`O$/_/I%_W_
M`%H_X0+Q#_SZ1?\`?]::KT%M)?@)X7$O>$ON9SL4TL#EX9&C8@KE3C@C!%2O
M?WDLPFDN96D"%-Y;G:1@CZ<UN_\`"!>(?^?2+_O^M'_"!>(?^?2+_O\`K1[>
MAOS+\`6&Q*5E"7W,Q?[4O_\`G]G^]O\`O_Q>OUX'Y57DEDF8-*[.0H4%CG`'
M05T7_"!>(?\`GTB_[_K1_P`(%XA_Y](O^_ZT*O06TE^`/#8I[QE]S.=CEDAD
M62)V1U(*LIP0:E>_O)4B22ZE9(CNC!;[I]16[_P@7B'_`)](O^_ZT?\`"!>(
M?^?2+_O^M'MZ#^TOO0+"XE*RA+[F8G]I7V&'VN;#@JPW=0221^9/YU'-=7%S
MCSYGDP2PW'/)QD_H/RK?_P"$"\0_\^D7_?\`6C_A`O$/_/I%_P!_UH5>@OM+
M\`>&Q35G&7W,YR.1XI%DC8HZG*LIP0:L2ZE?3)*DMW,Z2D&16;AL>M;?_"!>
M(?\`GTB_[_K1_P`(%XA_Y](O^_ZT.O0>KDOP!8;$I64)?<S$74KY!A;N8#`&
M`W8#`_2F2WMU/%Y4MQ(\>=VUFR,Y)S^9/YFM[_A`O$/_`#Z1?]_UH_X0+Q#_
M`,^D7_?]:/;T/YE^`?5\5MRR^YG-5;BU74((XXXKV=$C^XJN<+6U_P`(%XA_
MY](O^_ZT?\(%XA_Y](O^_P"M#KT'O)?@$<-B8[0DODS!6^ND9V6YE!=M[G=]
MXX(R?P)'XU(=4OR5)O)LJ`!\_0`Y'Y'FMK_A`O$/_/I%_P!_UH_X0+Q#_P`^
MD7_?]:/;4/YE^`?5\4OLR^YG-DEB23DDY)J6WNKBT9FMYY(BZ[6*-C(]*W_^
M$"\0_P#/I%_W_6C_`(0+Q#_SZ1?]_P!:;Q%%Z.2^\2PN)3NH/[F81O[MO(S<
MRGR.8LM]SZ4X:G?"/RQ>3!.!MW\<=*V_^$"\0_\`/I%_W_6C_A`O$/\`SZ1?
M]_UI>VH?S+\"OJ^*_EE]S.>FN)K@@S2O(5R`6.<9))_4D_C48.#D=:Z7_A`O
M$/\`SZ1?]_UH_P"$"\0_\^D7_?\`6G]8H_S+[R7A,0]7!_<S&?5M1D$@>^G8
M2+M<%S\P]*C2_O(D"1W4JJ%V@!N`.>/U/YUN_P#"!>(?^?2+_O\`K1_P@7B'
M_GTB_P"_ZU/ML/\`S+\"OJ^+WY9?B84E_>2QO')<RNCG+*6R#TZ_D/RJO72_
M\(%XA_Y](O\`O^M'_"!>(?\`GTB_[_K36(H+:2^\EX7$O>#^YF!'=7$2HL<S
MH(W\Q`#C:WJ/>G"_O!,\PN91+(07<-RQ!R/R-;O_``@7B'_GTB_[_K1_P@7B
M'_GTB_[_`*T>WH?S+\!_5L5_++[F89U&]**ANYMBJ55=W`!QD?H/RJ"21YI6
MDD<O(YW,S'))]:Z/_A`O$/\`SZ1?]_UH_P"$"\0_\^D7_?\`6A5Z"VDOP!X;
M$O>$ON9EZ!_R,>F?]?<7_H8HKH-)\%:[::S8W,UM&(HKB.1R)E.`&!-%>5F-
M2$Y1Y7<]S**4Z<)*::UZG'4445[A\R%>M_#[_D4X?^NLG_H5>25ZW\/O^13A
M_P"NLG_H5<&9?P?G_F>KD_\`O#]'^AU-%%%>"?4!1132Z!MI8`^F:`'44F]=
MVW<-WIGFDWIDC<N1U&:`'452;5]/5]INH\YQG/'Y]*N*RNH92&4\@@]:`%HI
MDDT47^LE1,_WF`H\Z+:&\Q-IZ'<.:`'T4UG1,;W5<],G%#2(F-[JN?4XH`=1
M37D2-=SNJCU8XI(YHI1F.1''^RP-`#Z*B^U6X;;Y\6[TWC-29''(YZ4`+111
M0`4444`%%<;XH\6W^@:C]A2VMG^U(#;W)<[;49"M)<#'"`GAAP3QQUKHK.\@
M@LX8KC5(+B95`>8LB[SW.!P/I0!H456_M&Q_Y_+?_OZO^-']HV/_`#^6_P#W
M]7_&@"S15;^T;'_G\M_^_J_XT?VC8_\`/Y;_`/?U?\:`+-%9NH:FB6$S6-W8
M&Z5<QB>8!"?0D<CZUS_A3Q9+XMU!YXY(K*UMTVFR9@TLS'_EIG_GGP=I'WN2
M<=*`.RHHHH`****`"BL*75-77Q9'IZ:;NTUDRUUSP<>O3KQBLJ_U&^M=5N9U
MFF$,5V(@3(#'CRP=FSKR>_O6BIMF;J)'945REOK.I-,$D>#SKD6X0[6\N/>K
ML>,YSQCK56Q\2:A%IL,\IAECC<Q2AL[W(1GW`YQC@#I3]E(7MHG:T5@6NNW#
M:%?7L\(,EMG;A&0/\H8<'D#G'X51E\1ZC;7<L$OV20PS*K>4K993LYZ_+]\\
MGVXI*G)C=2*U.MHKDV\1:DJ)A+:1IF<($4Y0+)LY!;YB1T`QSFM*/697@TJ0
M>2PNP^]ES@80MQGIR.])TY(%4BS:HKE]*\0WU[);/*MOY4LRPE$4[@3'OW9S
MT[5&VKZE!JNI0)-`RHTDJ>:APJHB':,'ON_G3]D[V#VJM<ZRBN;U>\GD@L;I
M&GCM_(:XF2&94?&%/?KC)XJ;7-8N[%D-H(2GV9YV\U22=I4`#!&/O4E!NPW4
M2N;U%<G<^(M2@$R!;4R6XF,A*-A]A0#'/'WO?I6YI-Y/=Q7"W`C\V"=H2T8(
M#8QS@].M#@TK@JB;LC0HHHJ"PHHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@#Y[HHHKZT^""O6_A]_R*</\`UUD_]"KR2O6_A]_R*</_`%UD
M_P#0JX,R_@_/_,]7)_\`>'Z/]#J:***\$^H&NZQHSL<*HR3[5P]S*9Y3JI<;
MC<`(F>0HZ&NLU:WN;NP>"V*AG.&+''%9UUX;A;35BMT070`S(2>?6F(AU_%I
M>VFIPE?,/!']X?\`ZC5"2-X+..Z<>;+>;I)"#_`.V?J1FM6#1+B><R:BZ,%B
M\N-5.<<8S4<>A79TLVTKIOB<M"RL>0>JGV-`'+3:K#::NFF-!(PC<(9?,Z,<
M<JO3'/?K6Y;:I+I5A?\`SK(8U+*H'"ONV_EWJ)M+NOM)D.G'ST`$<S1AGR.G
MS=./7K6E%HT']GW%K?2Q13W$716&55>_OSR36U25.2CR*W<YZ,:L')U973>G
MDC%BL+`:3%J^O27-S)<MP%).WK_A4=W]AN&T&TT]'%L9F8"3[Q^89_D:O1Z)
MX@CTYM.ANK26R<85FSD*?3TJ:?PO>Q6FFO9SQ"\LQ@YSM8YSQ6)TAXL`N-9T
M:TQD&7<?ID#^AK#U^8:Q=ZA=B51':;8X5+#YN>2!^=:UUIM^)FU+5;ZTCN]A
MCMD+[54^N?;)-6(/"%M_8!C:.)[]D)$VXX!/3'M1:RN*ZO8S?$=Y'=V&A"0D
MQNH>3`R<<`_UINDK;G7YKS2$>&PMH2TH=OO?*>,9SUJ_9>&]12\TI[EH#%9@
M@@,23R2.WN*G;P_?1ZIJL\!A$5Y"R(-V,$XZ\?6@9F>&_#UCJNC37%VC>8TC
M!9`Q!4`#\.N:L>$H&U"%A<32LEE-F$AN.>H^G`_.EL=%U]-,_L^*[M(;0DY=
M,LQR>>:Z72=+@TBP6VA);G<SGJQ]:&!>HHHI`%9MYI=Q=7)ECUK4+52`/*A$
M.T?]]1D_K6E10!Y3-X8U75_%6MRQW3:KIR[+5XKR98LRJF<G;'AU7?PI&,Y.
M#72:3\/=/L=%MK6Y,3SQ11JTBVT)`*]<;D)P>ASZ<8K2\+L-^MQ='CU2;</]
M[:P_0BMR='DMY4C?8[(0K8S@XX..]`'$P>'[8V<VIQ:=8W<$<TLD,"V\!^TP
MX^4!L`+@Y(YSZUT2>&O#\B*ZZ-IQ5@""+=#Q^5+9W,$?A-9YE,<,-J?-$D&S
M`52&R@Z#@\"K>DQ^3HUC$1&-EO&N(E*J,*/N@\@>@-`&/JVB:'96B^1H^D"Z
MF<0VZSP*J-(>@)"D]`3^%,7P1IH=2R0%0[L5^Q0\ANB_<_A[?KFM;5"Z7&G.
M&N-@N0'$2*P.5(&_/1<]QSG%:-`'GGC#PAIT'AF:"T2/[;=K'96Y:VAQYKN`
M'.U`<XSG'&`>*R-+^$4GVZ![V46@B5S)<6LJ&:5V[JWE`H`>1R<<`8KNO$^%
MN=!E?`C34XPQ/8E'4?J0/QKH*`,5="NU4*/$FKG`QR+<G_T56K;Q-!;I$\\D
M[*,&67;N;W.T`?D!4M%`!1110`5ES1:(NJ8F6U%]+V;&YLC'YXXJK+X?GD\6
MQZT-1E6%(]IMAG!XQZ]._2JM_:WRRZI!!8F>:[D62"9L;$P@`)/8J1D?6M(Q
M71F<I/JC>?3;%XVC:UB*,JJ05'(7[H_#M6?-H6DVMRFHR*(H[9,!.!&H`(Z8
M]"?SKG;O3K]K>3[-8720E0$1B25E"'+;<]SCYO49I'L;G4?[4$5K,[?OA*6Z
M2':FU1SU!S6BA_>,W/\`NG826MC9Z9/%M2VM2IWE?E`!ZFJ5CX?T>.W*)`EP
M!(Q+R`,=W`(Z>P_*N>N-,O)Y;](].G6&6"4*C#(8Y4IR3UP#@8&.E2QZ=J&\
M%+6X0F4FV)X$/[W)+<\`IC^5+ELOB'S7?PG20:#IMO!+"+5'$K%I#(`2Q+%N
M3]34MQ9Z?)%!:3P0E,XBC91@$#M^&:QM!L;NQ9RT$B[[0%@S?>EWO^1QMK$C
MTS5R2L-M<1$IN!.0`WEL&Y)Y))`SWZTN6[?O!S62]TZRTT_2;*XNKJ%8E>,_
MO&X_<X4<>PP`?QJ8Z=IE_P#Z2UK!-YN'WE`=W'!_*L6WTXOH6NP1V$L4<Y8P
MP2#EOW:@=_[PK-N-'OS"8([6<2[SYLBG"O$2NU1SV_3!]:?+=_$'-9?"=C>V
MMC+$);R&%HX`7#2*,(!U-#0V6H;F:.*?`,3$C/!P2O\`*L/Q'ISO!'##:2SV
MRVTL:1Q<[9"!L)Y^O-9_]D:B]UJ$@MY0XAD-LQ;`WG:..>N,XJ8Q35[CE)IV
ML=8VFV3ERUK$3)NWY4?-NQG/UP/RI]H;9HWEM=A21V9F3^)LX)^N17*6NG7J
MO:^?:W+P;F,*1DIY!+J<G))`V@]<]QWJS#I<@\-K8BTD0_;@9$7Y<IYN200>
MFVAQ7<%-]CJ:0D`$GH*X*>QO+42FX@E\GSU1T0']\#,-H!W<_+QP!Z5/]@U.
M.XL&^RW&4V_,"6*H6?Y3SQ@%<]<_A3]DNX>U?8[6.1)HEDC8,C#*L.A%.KEO
M#5L^FE?MMM,MS<,L2,W.%6-3SSP,@_C61>PO>:K/;1QS27?F3>:Z,<%"Z;1U
MXP/Y&DJ:;M<;J-1O8[V66."%Y975(T!9F8X`%10W]K<,%BG1R25`![C&1^HK
MB]0TB\DNKN.+3YO*998PH!8$?+LY)Z<'`QQ3KK1;E9IXK:QE5#<2'*<!D)CQ
M@Y]`U-4X]R75E?8[JBO/[VVEM+V>WEAF"O.HL%!.$_>@L1ST(-=)J;MJ6G6\
ML=O/+;K<?OX`,.ZC<.F>1G!J73M;4I5+WT-RBN;\/Z;=027,]W&XN3%&B.[9
M_@&1U]<9^E8T^FWYTQ4CT^[$P0B1B^X&;8?F"Y]?XL_A35--VN#J-*]CMC>V
MRPRS&>,1PL5D;=PI'4&IZX2?3+Z9KPQ6-PLLCRO([=)4(7:HYY.?Y&M?0+/4
M(-5O9;I656W`D@X=MY*G.>?EP.`*)4TE>X1J-NUCI*BN+F&UC$D\JQJ6"@L<
M9)Z"N#M+8W^HQPK%-(Z,GVQ@QVN1*V3G/I^E30:/=S7BI/I\HA$\3E7&0,,X
M8Y)YX*\\?I3]DENQ>U;V1VL%W;W./)F23*AQM/522,_H:FKAK31KGR[6!K"5
M(E\E9E(P"0\A8]>1@K^=16J2Q:AIUM<I,;Q98-F6R4C`;<#S^/Y4.DM;,%5>
MET=]1116)L%%%%`'SW1117UI\$%>M_#[_D4X?^NLG_H5>25ZW\/O^13A_P"N
MLG_H5<&9?P?G_F>KD_\`O#]'^AU-%%%>"?4!1110`4444`%8^J^'XM5G:=YY
M(Y?*$<;)U09.?KD'!K8HJH3E!WB1.G&HN62NCG(?"4<<[,]]/)"SAC$W0@'(
M!.?I^5)/X22:/:NH7"D2$KSD*G90,]LGFNDHK3ZQ5O>YE]5HVMRF5=:.\UU%
M/%=;&2`P'?&),J>_/0U3'A5#<O(]Y*RLV2H&-RY!VGGD<8&,8KH:*2K32LF5
M+#TY.[1@#PM&`2+R=7S\CJ<%%^;Y1[?-^E0P>$C!Y7_$QE<(Q)5URO..0,\'
MCKSUKI:*?UBIW)^JTNQS"^#E555;^50JX!5<$<$''/0YR?>NBMK>.TMHX(5Q
M&@P!G-2T5,ZLY_$RZ="G3^!6"BBBLS4*R[W3M2N+II+;6YK2(@8B6WC<#\6!
M-:E%`'&7&B>(M'U?^V-/U%]268J+^S:**-I54$*R'``89P<]0!Z4JZKXC$:@
MZ=JQ81.I;R+?ER?E;&_MZ=Z[*B@#AUFU(S,\VBZR8S+'.4A\F+=(HP2Q5\L&
MP,@\<8K8_P"$BU#_`*%?5/\`OJ+_`.+KH**`.7O=5N-1LY+2[\):I)!(,,I:
M(9YR.C^HJLFJ^(5P#IVK-CS,YAM^=WW/X_X?U[UV-%`'`:PVNZQI%Q8RZ?JR
MM)"@CE$$&8YE8,)1\_7('':H[/6OB/-$89-"LTN1PLDD>(F']XD39'J0%^F:
M]#HH`Q%A\4;1NU#1PV.0+&4C/_?VM:V$ZVZ"Z>-YP/G:)"JD^P))'YFI:*`"
MBBB@#,?7].CUQ-':?%ZZ[@FTXZ9QGUQS5:7Q`T6IO;M;Q^2MP+<OYOSY*AMV
MW'09]:T6TRQ;45U!K6(WBKM$VWY@*S[GPW!<S3S&3;++<+-Y@0;E`4*4SUP0
M#^=:+DZF;Y^G]()?%%C'%'-B3RBS*Y9"&`";@0.X(QCZU&_BFV2^6`6TZHJN
MT[NA7R\8P,=R=P_,5`?!T7V(6XNBI#$[UCZC9L&>?3_(JU<^&H[F\NKAKEAY
MX;Y0OW2=F#[X,8_.J_=$_O27_A)+`,%/G!MKNX,1_=A3AMWI3D\16#M&N9E9
MFVL&B(,7.T;_`$R>*KKX90FZ::Z9Y+J)TE8)MRS,#N'IC`&*;+X:-S=1W-U>
MF>48#EH^"`VX!1GY?QS2M3'>H:%WK-E8W0@N)&4[=S-M)5!SC<>V<''TJLWB
M;3TC+,)U8<E#$=P7&=Q']W'>GWNB_;+J:07<D45Q&(YXT49<`,!SV^\:S[CP
MF]T7>7469Y(O);,(V[0,*=N?O#GGWZ415/JPDZG1%F\\3VMO#=F*.666W#87
M80'*XS@]\9%)=^*+:WAE,<%Q)+&1^[,97/S!6P?8D9JO'X9FF^UBZN@%<R"$
M(GW=P4%C_P!\]/UI3X5D=WDDU$O(RLI<P\DEU;GGL5QCTIVIDWJ="Y#XBM'<
MI(LB$2F-B%)"?,5&X]LD5/9:W9WZRM$9%$:>83(A7*Y(W#U&0?RJBOAD*\W^
MF'R[F427">6/GPY8`'/'7'TJU8:(MB<BX9O]&%OG:`1AF;/_`(]^E)J%M"DZ
ME]2G=^++>*U\^WMY9<HSA2I4D``@CCH0>M:5OJ]K<WAM4\Q9,'[Z$`D8W`'U
M&1FLH>$E\ID:];+*Z_+$`HW*!D+G@\9/J3VJW8>'TLM3:^:82.2[#Y,$,V-W
M.3Q[?SH:IVT$G4OJ;.,]:***R-@I`H!)`&3U-+10`4444`(0"02`2.E+110`
M4444`%%%%`"!0,X`&>N*6BB@`I-HW;L#/K2T4`%%%%`!1110!\]T445]:?!!
M7JW@*ZMX?"L223Q(WFR<,X!^\:\II"H/4"L,105>'(W8ZL)B7AJG.E?2Q[[]
MOL_^?N#_`+^"C[?9_P#/W!_W\%>!;5_NC\J-J_W1^5</]EQ_F_`]+^VY?R?C
M_P``]]^WV?\`S]P?]_!1]OL_^?N#_OX*\"VK_='Y4;5_NC\J/[+C_-^`?VW+
M^3\?^`>^_;[/_G[@_P"_@H^WV?\`S]P?]_!7@6U?[H_*C:O]T?E1_9<?YOP#
M^VY?R?C_`,`]]^WV?_/W!_W\%'V^S_Y^X/\`OX*\"VK_`'1^5&U?[H_*C^RX
M_P`WX!_;<OY/Q_X![[]OL_\`G[@_[^"C[?9_\_<'_?P5X%M7^Z/RHVK_`'1^
M5']EQ_F_`/[;E_)^/_`/??M]G_S]P?\`?P4?;[/_`)^X/^_@KP+:O]T?E1M7
M^Z/RH_LN/\WX!_;<OY/Q_P"`>^_;[/\`Y^X/^_@H^WV?_/W!_P!_!7@6U?[H
M_*C:O]T?E1_9<?YOP#^VY?R?C_P#WW[?9_\`/W!_W\%'V^S_`.?N#_OX*\"V
MK_='Y4;5_NC\J/[+C_-^`?VW+^3\?^`>^_;[/_G[@_[^"C[?9_\`/W!_W\%>
M!;5_NC\J-J_W1^5']EQ_F_`/[;E_)^/_``#WW[?9_P#/W!_W\%'V^S_Y^X/^
M_@KP+:O]T?E1M7^Z/RH_LN/\WX!_;<OY/Q_X![[]OL_^?N#_`+^"C[?9_P#/
MW!_W\%>!;5_NC\J-J_W1^5']EQ_F_`/[;E_)^/\`P#WW[?9_\_<'_?P4?;[/
M_G[@_P"_@KP+:O\`='Y4;5_NC\J/[+C_`#?@']MR_D_'_@'OOV^S_P"?N#_O
MX*/M]G_S]P?]_!7@6U?[H_*C:O\`='Y4?V7'^;\`_MN7\GX_\`]]^WV?_/W!
M_P!_!1]OL_\`G[@_[^"O`MJ_W1^5&U?[H_*C^RX_S?@']MR_D_'_`(![[]OL
M_P#G[@_[^"C[?9_\_<'_`'\%>!;5_NC\J-J_W1^5']EQ_F_`/[;E_)^/_`/?
M?M]G_P`_<'_?P4?;[/\`Y^X/^_@KP+:O]T?E1M7^Z/RH_LN/\WX!_;<OY/Q_
MX![[]OL_^?N#_OX*/M]G_P`_<'_?P5X%M7^Z/RHVK_='Y4?V7'^;\`_MN7\G
MX_\``/??M]G_`,_<'_?P4?;[/_G[@_[^"O`MJ_W1^5&U?[H_*C^RX_S?@']M
MR_D_'_@'OOV^S_Y^X/\`OX*/M]G_`,_<'_?P5X%M7^Z/RHVK_='Y4?V7'^;\
M`_MN7\GX_P#`/??M]G_S]P?]_!1]OL_^?N#_`+^"O`MJ_P!T?E1M7^Z/RH_L
MN/\`-^`?VW+^3\?^`>^_;[/_`)^X/^_@H^WV?_/W!_W\%>!;5_NC\J-J_P!T
M?E1_9<?YOP#^VY?R?C_P#WW[?9_\_<'_`'\%'V^S_P"?N#_OX*\"VK_='Y4;
M5_NC\J/[+C_-^`?VW+^3\?\`@'OOV^S_`.?N#_OX*/M]G_S]P?\`?P5X%M7^
MZ/RHVK_='Y4?V7'^;\`_MN7\GX_\`]]^WV?_`#]P?]_!1]OL_P#G[@_[^"O`
MMJ_W1^5&U?[H_*C^RX_S?@']MR_D_'_@'OOV^S_Y^X/^_@H^WV?_`#]P?]_!
M7@6U?[H_*C:O]T?E1_9<?YOP#^VY?R?C_P``]]^WV?\`S]P?]_!1]OL_^?N#
M_OX*\"VK_='Y4;5_NC\J/[+C_-^`?VW+^3\?^`>^_;[/_G[@_P"_@H^WV?\`
MS]P?]_!7@6U?[H_*C:O]T?E1_9<?YOP#^VY?R?C_`,`]]^WV?_/W!_W\%'V^
MS_Y^X/\`OX*\"VK_`'1^5&U?[H_*C^RX_P`WX!_;<OY/Q_X![[]OL_\`G[@_
M[^"C[?9_\_<'_?P5X%M7^Z/RHVK_`'1^5']EQ_F_`/[;E_)^/_`/??M]G_S]
MP?\`?P4?;[/_`)^X/^_@KP+:O]T?E1M7^Z/RH_LN/\WX!_;<OY/Q_P"`>^_;
M[/\`Y^X/^_@H^WV?_/W!_P!_!7@6U?[H_*C:O]T?E1_9<?YOP#^VY?R?C_P#
MWW[?9_\`/W!_W\%'V^S_`.?N#_OX*\"VK_='Y4;5_NC\J/[+C_-^`?VW+^3\
M?^`>_+>VKL%6YA+$X`$@R317B.@*O_"1Z7P/^/N+M_MBBN+%X94&DG>YZ>!Q
MCQ47)JUCL_\`A5__`%&/_);_`.SH_P"%7_\`48_\EO\`[.BBCZ_B/YOP7^0O
M[+PG\GXO_,/^%7_]1C_R6_\`LZ/^%7_]1C_R6_\`LZ**/K^(_F_!?Y!_9>$_
MD_%_YA_PJ_\`ZC'_`)+?_9T?\*O_`.HQ_P"2W_V=%%'U_$?S?@O\@_LO"?R?
MB_\`,/\`A5__`%&/_);_`.SH_P"%7_\`48_\EO\`[.BBCZ_B/YOP7^0?V7A/
MY/Q?^8?\*O\`^HQ_Y+?_`&='_"K_`/J,?^2W_P!G111]?Q'\WX+_`"#^R\)_
M)^+_`,P_X5?_`-1C_P`EO_LZ/^%7_P#48_\`);_[.BBCZ_B/YOP7^0?V7A/Y
M/Q?^8?\`"K_^HQ_Y+?\`V='_``J__J,?^2W_`-G111]?Q'\WX+_(/[+PG\GX
MO_,/^%7_`/48_P#);_[.C_A5_P#U&/\`R6_^SHHH^OXC^;\%_D']EX3^3\7_
M`)A_PJ__`*C'_DM_]G1_PJ__`*C'_DM_]G111]?Q'\WX+_(/[+PG\GXO_,/^
M%7_]1C_R6_\`LZ/^%7_]1C_R6_\`LZ**/K^(_F_!?Y!_9>$_D_%_YA_PJ_\`
MZC'_`)+?_9T?\*O_`.HQ_P"2W_V=%%'U_$?S?@O\@_LO"?R?B_\`,/\`A5__
M`%&/_);_`.SH_P"%7_\`48_\EO\`[.BBCZ_B/YOP7^0?V7A/Y/Q?^8?\*O\`
M^HQ_Y+?_`&='_"K_`/J,?^2W_P!G111]?Q'\WX+_`"#^R\)_)^+_`,P_X5?_
M`-1C_P`EO_LZ/^%7_P#48_\`);_[.BBCZ_B/YOP7^0?V7A/Y/Q?^8?\`"K_^
MHQ_Y+?\`V='_``J__J,?^2W_`-G111]?Q'\WX+_(/[+PG\GXO_,/^%7_`/48
M_P#);_[.C_A5_P#U&/\`R6_^SHHH^OXC^;\%_D']EX3^3\7_`)A_PJ__`*C'
M_DM_]G1_PJ__`*C'_DM_]G111]?Q'\WX+_(/[+PG\GXO_,/^%7_]1C_R6_\`
MLZ/^%7_]1C_R6_\`LZ**/K^(_F_!?Y!_9>$_D_%_YA_PJ_\`ZC'_`)+?_9T?
M\*O_`.HQ_P"2W_V=%%'U_$?S?@O\@_LO"?R?B_\`,/\`A5__`%&/_);_`.SH
M_P"%7_\`48_\EO\`[.BBCZ_B/YOP7^0?V7A/Y/Q?^8?\*O\`^HQ_Y+?_`&='
M_"K_`/J,?^2W_P!G111]?Q'\WX+_`"#^R\)_)^+_`,P_X5?_`-1C_P`EO_LZ
M/^%7_P#48_\`);_[.BBCZ_B/YOP7^0?V7A/Y/Q?^8?\`"K_^HQ_Y+?\`V='_
M``J__J,?^2W_`-G111]?Q'\WX+_(/[+PG\GXO_,/^%7_`/48_P#);_[.C_A5
M_P#U&/\`R6_^SHHH^OXC^;\%_D']EX3^3\7_`)A_PJ__`*C'_DM_]G1_PJ__
M`*C'_DM_]G111]?Q'\WX+_(/[+PG\GXO_,/^%7_]1C_R6_\`LZ/^%7_]1C_R
M6_\`LZ**/K^(_F_!?Y!_9>$_D_%_YA_PJ_\`ZC'_`)+?_9T?\*O_`.HQ_P"2
MW_V=%%'U_$?S?@O\@_LO"?R?B_\`,/\`A5__`%&/_);_`.SH_P"%7_\`48_\
MEO\`[.BBCZ_B/YOP7^0?V7A/Y/Q?^8?\*O\`^HQ_Y+?_`&='_"K_`/J,?^2W
M_P!G111]?Q'\WX+_`"#^R\)_)^+_`,P_X5?_`-1C_P`EO_LZ/^%7_P#48_\`
M);_[.BBCZ_B/YOP7^0?V7A/Y/Q?^8?\`"K_^HQ_Y+?\`V='_``J__J,?^2W_
M`-G111]?Q'\WX+_(/[+PG\GXO_,/^%7_`/48_P#);_[.C_A5_P#U&/\`R6_^
MSHHH^OXC^;\%_D']EX3^3\7_`)A_PJ__`*C'_DM_]G1_PJ__`*C'_DM_]G11
M1]?Q'\WX+_(/[+PG\GXO_,/^%7_]1C_R6_\`LZ/^%7_]1C_R6_\`LZ**/K^(
M_F_!?Y!_9>$_D_%_YEBP^'/V'4;6[_M7?Y$R2[?L^-VT@XSNXZ4445C5K3JN
-\W<Z*&&I4$U35KG_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g532389g60e21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g532389g60e21.jpg
M_]C_X0J017AI9@``34T`*@````@`"`$2``,````!``$```$:``4````!````
M;@$;``4````!````=@$H``,````!``(```$Q``(````>````?@$R``(````4
M````G`$[``(````&````L(=I``0````!````N````.0`+<;````G$``MQL``
M`"<0061O8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q,SHP-3HQ-"`P
M.3HP,SHS-P!E<FEC:``````#H`$``P````$``0``H`(`!`````$```"-H`,`
M!`````$````R``````````8!`P`#`````0`&```!&@`%`````0```3(!&P`%
M`````0```3H!*``#`````0`"```"`0`$`````0```4("`@`$`````0``"48`
M````````2`````$```!(`````?_8_^T`#$%D;V)E7T--``'_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``R`(T#`2(``A$!`Q$!_]T`!``)_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U5))))2DDDDE*22224I))))2DDDDE*22224I))))3C2[_`)SD28]'
MB3''[JV52_9P_:G[0]0SLV>G&GQW*ZF8XD<5]9$CR7S(/#72("DDDD]8_P#_
MT.UZ/U^W]@YG5>IN]1N'=DAWIM`/ITO<UC6L_.?L:K.1]9^FX[,E]C;8Q!CF
MW:R2?M7]'],3[_\`A%BXW2OK`WHW4NB/P6L9E_:WU9?K,(W6N<^FMU+??[]W
MTTS^B=<R:<Y[\5M-F0[IWI5^JUVF*\'(+GCV[FM"9<J^BZ@ZQ^L%%659=DV6
MXV/5@G+LQ;J=KF@6.K]5UFYUGJNV[?LVQ7>E]8Q^I&YC*K<>_&<UMV/D-V6-
MWCU*G%H+V[;&?REE=>Z%U#J.;G.H#6UY'3?LU5CB(]86FYK'-^GLV_GJQ]6>
MFW80RK+,&OIXN<S94VUUUA#&PY]]SG/9]-S_`$MG^#1!-^"-*<EGUBZM^VW8
MXRJKA^TG88Z<*QZOV<#<[+;8UV_;3^=O9L]BW:?K)@7=2/3VMM!]1]+,@LBE
M]M3?4OHKMG^<K8U_YGYBPQT'K+^J6#[)754>J?;V]0-C=XJ&V:&5-'J_IMFW
MWN]/](C8/U>S*.O/O?A4NK&5?DMSW6N)V6!SJ::<5KF[+6/L].VQ[/YI`&7X
MI--F[ZU8F3TO)R<9V1B"IM5E>0^C>'UV6"IEV.QSMEK+/H>Y[+*_YSTU/#Z_
M8.J9F#E3:\YHQ\.JIHW-8*:[[;;=?YFMS_?<[_BUD_L+KS\#J6,S$9B4Y+:7
M,PVW!]7VAMS;,J_#G^C8UM3=_HO_`,(K)Z#U*CKMW6J*9O.<V/T@]^$^IE.0
M-A.UKZ[OTW[_`.B2N6BJ#HL^M>#:ZYE%-[RQES\=WI^W(^SGT\AN(=WZ7TW_
M`-1"Z+U3J.3]5+.IY%A=EFJVUKW5AC00TOK]%C?YW';_`(.QW\ZJ?3.A=7IR
M,6FZEK,?I;,UM60+`[USE.W4[:OI4[&?SOJ+1Z9TW-H^J-?3+6!N8W#=2:]P
M(WECF[=X]OTDA9W[*-,L3K9J^KN#U+.#[[\FNKV4,W.LMM`AE=;?:W<[][]&
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M6>WZ*5R_EY*H.YD?6;`H-S/3NMMIR1ABFM@+[+C6,G91+FM=^A]_NV+1Q,JK
M,QJLJG=Z=S0YH>TM<`>SV/AS'+E[>C]5NQNHG)Z<V[[=FMO^SMO:RQC!2RME
M^+DB&UY=-[&_270]&KZA5TO%KZF\69K*P+W@S+A_*_.=^\B";00&R<B@$@V,
M!&A!<$OM&/SZK/\`."H6_5[IMMK[7M=OL<7.]QY.J8?5SI@:6[7PX@GW'\W=
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M]NW=^=Z?TDB<NNG:E`8^[8?U3'8Y[7-L&P;@=NC@"UA]/][W/:DSJF,_2'M=
MN#=A;KN+_1V_V7_20'=(>ZQ[S=.^0"6^Z"ZNQN]^[W;/3]-B:WI]_P!I8^O4
MUFZUMA@-WV:U5[9W.]-_O2XLO958^[;MR+&9U&.`-EK'N<>\MV;8_P`Y4W=3
MR/LF+;NJJ=>][7O>#L:&^I'YS?W%9NQ,FRVB]EK66TM+7RW<#NV[X]S=OT$&
MGI5K/099<U]6.]SV,V03N#_:X[G?Z1&7N$FKK_T3_P!#0."A=?RXO_06W@Y#
MLG$JO>W8ZQLEO]THZ22D%@"S?BL.YK12BZNMSFN<T.<PRPD`D$Z>W]U2210I
M))))2#[9C?:OLF_]8V[MD'CQGZ*.L;_UJ#_Q/\%LID)&7%?21C]BZ<0.&NH!
M4DDDGK7_TO54E\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27
MRJDDI^JDE\JI)*?I3_UHS_-?S/\`UWC_`*E:R^54E'B_3_OR7Y/T?[H?JI)?
M*J2D6/\`_]G_[1*H4&AO=&]S:&]P(#,N,``X0DE-!`0``````%$<`5H``QLE
M1QP"```"```<`E``!65R:6-H'`(%`#-#3TY314Y4($]&($E.1$5014Y$14Y4
M($-%4E1)1DE%1"!054),24,@04-#3U5.5$%.5%,`.$))300E```````0,>V2
MH?QN[I3/$,CQ%3Y39#A"24T$.@``````Y0```!`````!```````+<')I;G1/
M=71P=70````%`````%!S=%-B;V]L`0````!);G1E96YU;0````!);G1E````
M`$-L<FT````/<')I;G13:7AT965N0FET8F]O;``````+<')I;G1E<DYA;654
M15A4`````0``````#W!R:6YT4')O;V93971U<$]B:F,````,`%``<@!O`&\`
M9@`@`%,`90!T`'4`<```````"G!R;V]F4V5T=7`````!`````$)L=&YE;G5M
M````#&)U:6QT:6Y0<F]O9@````EP<F]O9D--64L`.$))300[``````(M````
M$`````$``````!)P<FEN=$]U='!U=$]P=&EO;G,````7`````$-P=&YB;V]L
M``````!#;&)R8F]O;```````4F=S36)O;VP``````$-R;D-B;V]L``````!#
M;G1#8F]O;```````3&)L<V)O;VP``````$YG='9B;V]L``````!%;6Q$8F]O
M;```````26YT<F)O;VP``````$)C:V=/8FIC`````0```````%)'0D,````#
M`````%)D("!D;W5B0&_@````````````1W)N(&1O=6)`;^````````````!"
M;"`@9&]U8D!OX````````````$)R9%15;G1&(U)L=````````````````$)L
M9"!5;G1&(U)L=````````````````%)S;'15;G1&(U!X;$!RP```````````
M"G9E8W1O<D1A=&%B;V]L`0````!09U!S96YU;0````!09U!S`````%!G4$,`
M````3&5F=%5N=$8C4FQT````````````````5&]P(%5N=$8C4FQT````````
M````````4V-L(%5N=$8C4')C0%D````````````08W)O<%=H96Y0<FEN=&EN
M9V)O;VP`````#F-R;W!296-T0F]T=&]M;&]N9P`````````,8W)O<%)E8W1,
M969T;&]N9P`````````-8W)O<%)E8W12:6=H=&QO;F<`````````"V-R;W!2
M96-T5&]P;&]N9P``````.$))30/M```````0`2P````!``(!+`````$``CA"
M24T$)@``````#@`````````````_@```.$))300-```````$````>#A"24T$
M&0``````!````!XX0DE-`_,```````D```````````$`.$))32<0```````*
M``$``````````CA"24T#]0``````2``O9F8``0!L9F8`!@```````0`O9F8`
M`0"AF9H`!@```````0`R`````0!:````!@```````0`U`````0`M````!@``
M`````3A"24T#^```````<```_____________________________P/H````
M`/____________________________\#Z`````#_____________________
M________`^@`````_____________________________P/H```X0DE-!`@`
M`````!`````!```"0````D``````.$))300>```````$`````#A"24T$&@``
M```#6P````8``````````````#(```"-````$P!!`'@`;P!'`&4`;@`@`"T`
M(`!%`'@`:`!I`&(`:0!T`"``,@`S`````0`````````````````````````!
M``````````````"-````,@`````````````````````!````````````````
M`````````!`````!````````;G5L;`````(````&8F]U;F1S3V)J8P````$`
M``````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<`````
M`````$)T;VUL;VYG````,@````!29VAT;&]N9P```(T````&<VQI8V5S5FQ,
M<P````%/8FIC`````0``````!7-L:6-E````$@````=S;&EC94E$;&]N9P``
M```````'9W)O=7!)1&QO;F<`````````!F]R:6=I;F5N=6T````,15-L:6-E
M3W)I9VEN````#6%U=&]'96YE<F%T960`````5'EP965N=6T````*15-L:6-E
M5'EP90````!);6<@````!F)O=6YD<T]B:F,````!````````4F-T,0````0`
M````5&]P(&QO;F<``````````$QE9G1L;VYG``````````!"=&]M;&]N9P``
M`#(`````4F=H=&QO;F<```"-`````W5R;%1%6%0````!````````;G5L;%1%
M6%0````!````````37-G951%6%0````!```````&86QT5&%G5$585`````$`
M``````YC96QL5&5X=$ES2%1-3&)O;VP!````"&-E;&Q497AT5$585`````$`
M``````EH;W)Z06QI9VYE;G5M````#T53;&EC94AO<GI!;&EG;@````=D969A
M=6QT````"79E<G1!;&EG;F5N=6T````/15-L:6-E5F5R=$%L:6=N````!V1E
M9F%U;'0````+8F=#;VQO<E1Y<&5E;G5M````$453;&EC94)'0V]L;W)4>7!E
M`````$YO;F4````)=&]P3W5T<V5T;&]N9P`````````*;&5F=$]U='-E=&QO
M;F<`````````#&)O='1O;4]U='-E=&QO;F<`````````"W)I9VAT3W5T<V5T
M;&]N9P``````.$))300H```````,`````C_P````````.$))3004```````$
M`````CA"24T$#``````)8@````$```"-````,@```:@``%+0```)1@`8``'_
MV/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)
M#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`,@"-`P$B``(1
M`0,1`?_=``0`"?_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$`
M`04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!
M``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]522224I))))2DDDDE*2
M2224I))))2DDDDE*22224XTN_P"<Y$F/1XDQQ^ZME4OV</VI^T/4,[-GIQI\
M=RNIF.)'%?61(\E\R#PUTB`I)))/6/\`_]#M>C]?M_8.9U7J;O4;AW9(=Z;0
M#Z=+W-8UK/SG[&JSD?6?IN.S)?8VV,08YMVLDG[5_1_3$^__`(18N-TKZP-Z
M-U+HC\%K&9?VM]67ZS"-UKG/IK=2WW^_=]-,_HG7,FG.>_%;39D.Z=Z5?JM=
MIBO!R"YX]NYK0F7*OHNH.L?K!15E679-EN-CU8)R[,6ZG:YH%CJ_5=9N=9ZK
MMNW[-L5WI?6,?J1N8RJW'OQG-;=CY#=EC=X]2IQ:"]NVQG\I977NA=0ZCFYS
MJ`UM>1TW[-58XB/6%IN:QS?I[-OYZL?5GIMV$,JRS!KZ>+G,V5-M==80QL.?
M?<YSV?3<_P!+9_@T03?@C2G)9]8NK?MMV.,JJX?M)V&.G"L>K]G`W.RVV-=O
MVT_G;V;/8MVGZR8%W4CT]K;0?4?2S(+(I?;4WU+Z*[9_G*V-?^9^8L,=!ZR_
MJE@^R5U5'JGV]O4#8W>*AMFAE31ZOZ;9M][O3_2(V#]7LRCKS[WX5+JQE7Y+
M<]UKB=E@<ZFFG%:YNRUC[/3ML>S^:0!E^*339N^M6)D]+R<G&=D8@J;597D/
MHWA]=E@J9=CL<[9:RSZ'N>RRO^<]-3P^OV#JF9@Y4VO.:,?#JJ:-S6"FN^VV
MW7^9K<_WW._XM9/["Z\_`ZEC,Q&8E.2VES,-MP?5]H;<VS*OPY_HV-;4W?Z+
M_P#"*R>@]2HZ[=UJBF;SG-C](/?A/J93D#83M:^N[]-^_P#HDKEHJ@Z+/K7@
MVNN913>\L9<_'=Z?MR/LY]/(;B'=^E]-_P#40NB]4ZCD_52SJ>18799JMM:]
MU88T$-+Z_18W^=QV_P"#L=_.JGTSH75Z<C%INI:S'Z6S-;5D"P.]<Y3MU.VK
MZ5.QG\[ZBT>F=-S:/JC7TRU@;F-PW4FO<"-Y8YNW>/;])(6=^RC3+$ZV:OJ[
M@]2S@^^_)KJ]E#-SK+;0(976WVMW._>_1L3?\ZL`TT6-IR'V9%MM#<=M<VMM
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M:<D88IK8"^RXUC)V42YK7?H??[MBT<3*JS,:K*IW>G<T.:'M+7`'L]CX<QRY
M>WH_5;L;J)R>G-N^W9K;_L[;VLL8P4LK9?BY(AM>73>QOTET/1J^H5=+Q:^I
MO%F:RL"]X,RX?ROSG?O(@FT$!LG(H!(-C`1H07!+[1C\^JS_`#@J%OU>Z;;:
M^U[7;['%SO<>3JF'U<Z8&ENU\.()]Q_-W1_U:;>6_EC7][_T%=6.OF-^3__1
M]'PLR_(R;ZWM`KJ<6`C2'`G]'S^D_1;;?[:BS/R3?<][&##I>]EC]=S=C19Z
MCOWFO^CM:U1QND.HRVY'K;@TNAFWG=/O>[=_/>[9ZO\`HU)_22^R[=>[T+B]
MQJ`CW6-]-VYWYS6_F-VJ$>Y0T-WW#+Z+.HJNS)W5\9K-SF6`C<7L+?<T-#;'
M.?K]'TWM>D[JV.QI<YE@VEVYNW4!@:Y[W?R-EC7(;NDO>VS?=+[66,<X-@>]
MC*60W=^8VM1R.F766EK'Q7<+!8^`=H>VJO;MW?G>G])(G+KIVI0&/NV']4QV
M.>US;!L&X';HX`M8?3_>]SVI,ZIC/TA[7;@W86Z[B_T=O]E_TD!W2'NL>\W3
MOD`EON@NKL;O?N]VST_38FMZ??\`:6/KU-9NM;88#=]FM5>V=SO3?[TN++V5
M6/NV[<BQF=1C@#9:Q[G'O+=FV/\`.5-W4\C[)BV[JJG7O>U[W@[&AOJ1^<W]
MQ6;L3)LMHO9:UEM+2U\MW`[MN^/<W;]!!IZ5:ST&67-?5CO<]C-D$[@_VN.Y
MW^D1E[A)JZ_]$_\`0T#@H77\N+_T%MX.0[)Q*KWMV.L;);_=*.DDI!8`LWXK
M#N:T4HNKK<YKG-#G,,L)`)!.GM_=4DD4*22224@^V8WVK[)O_6-N[9!X\9^B
MCK&_]:@_\3_!;*9"1EQ7TD8_8NG$#AKJ`5))))ZU_]+U5)?*J22GZJ27RJDD
MI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZ4_]:,_S7\S_
M`-=X_P"I6LOE5)1XOT_[\E^3]'^Z'ZJ27RJDI%C_`/_9.$))300A``````!5
M`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````$P!!
M`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`$,`4P`V`````0`X0DE-
M!`8```````<`"`````$!`/_A#MAH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C`O`#P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53
M>DY48WIK8SED(C\^(#QX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T
M82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V
M,2P@,C`Q,B\P,B\P-BTQ-#HU-CHR-R`@("`@("`@(CX@/')D9CI21$8@>&UL
M;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D9BUS>6YT
M87@M;G,C(CX@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z
M>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SIP9&8]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B('AM;&YS.F1C/2)H='1P
M.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(@>&UL;G,Z>&UP34T](FAT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T179T/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V5%=F5N
M=",B('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T
M;W-H;W`O,2XP+R(@>&UP.D-R96%T941A=&4](C(P,3,M,#4M,314,#DZ,#(Z
M-3<B('AM<#I#<F5A=&]R5&]O;#TB36EC<F]S;V9TPJX@3V9F:6-E(%=O<F0@
M,C`P-R(@>&UP.DUO9&EF>41A=&4](C(P,3,M,#4M,314,#DZ,#,Z,S<K,#4Z
M,S`B('AM<#I-971A9&%T841A=&4](C(P,3,M,#4M,314,#DZ,#,Z,S<K,#4Z
M,S`B('!D9CI0<F]D=6-E<CTB36EC<F]S;V9TPJX@3V9F:6-E(%=O<F0@,C`P
M-R(@9&,Z9F]R;6%T/2)I;6%G92]J<&5G(B!X;7!-33I$;V-U;65N=$E$/2)X
M;7`N9&ED.D9!-SA#138W-#-"0T4R,3%!-C1#0D$X,CA$0S9&,#,V(B!X;7!-
M33I);G-T86YC94E$/2)X;7`N:6ED.D9!-SA#138W-#-"0T4R,3%!-C1#0D$X
M,CA$0S9&,#,V(B!X;7!-33I/<FEG:6YA;$1O8W5M96YT240](GAM<"YD:60Z
M1D$W.$-%-C<T,T)#13(Q,4$V-$-"03@R.$1#-D8P,S8B('!H;W1O<VAO<#I#
M;VQO<DUO9&4](C,B('!H;W1O<VAO<#I)0T-0<F]F:6QE/2)S4D="($E%0S8Q
M.38V+3(N,2(^(#QD8SIC<F5A=&]R/B`\<F1F.E-E<3X@/')D9CIL:3YE<FEC
M:#PO<F1F.FQI/B`\+W)D9CI397$^(#PO9&,Z8W)E871O<CX@/&1C.G1I=&QE
M/B`\<F1F.D%L=#X@/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY#3TY3
M14Y4($]&($E.1$5014Y$14Y4($-%4E1)1DE%1"!054),24,@04-#3U5.5$%.
M5%,\+W)D9CIL:3X@/"]R9&8Z06QT/B`\+V1C.G1I=&QE/B`\>&UP34TZ2&ES
M=&]R>3X@/')D9CI397$^(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)D97)I=F5D
M(B!S=$5V=#IP87)A;65T97)S/2)C;VYV97)T960@9G)O;2!A<'!L:6-A=&EO
M;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+VIP96<B+SX@/')D9CIL
M:2!S=$5V=#IA8W1I;VX](G-A=F5D(B!S=$5V=#II;G-T86YC94E$/2)X;7`N
M:6ED.D9!-SA#138W-#-"0T4R,3%!-C1#0D$X,CA$0S9&,#,V(B!S=$5V=#IW
M:&5N/2(R,#$S+3`U+3$T5#`Y.C`S.C,W*S`U.C,P(B!S=$5V=#IS;V9T=V%R
M94%G96YT/2)!9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S*2(@<W1%=G0Z
M8VAA;F=E9#TB+R(O/B`\+W)D9CI397$^(#PO>&UP34TZ2&ES=&]R>3X@/'AM
M<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(B\^(#PO
M<F1F.D1E<V-R:7!T:6]N/B`\+W)D9CI21$8^(#PO>#IX;7!M971A/B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#P_>'!A8VME="!E;F0](G<B/S[_X@Q824-#
M7U!23T9)3$4``0$```Q(3&EN;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q
M``!A8W-P35-&5`````!)14,@<U)'0@```````````````0``]M8``0````#3
M+4A0("``````````````````````````````````````````````````````
M`````````!%C<')T```!4````#-D97-C```!A````&QW='!T```!\````!1B
M:W!T```"!````!1R6%E:```"&````!1G6%E:```"+````!1B6%E:```"0```
M`!1D;6YD```"5````'!D;61D```"Q````(AV=65D```#3````(9V:65W```#
MU````"1L=6UI```#^````!1M96%S```$#````"1T96-H```$,`````QR5%)#
M```$/```"`QG5%)#```$/```"`QB5%)#```$/```"`QT97AT`````$-O<'ER
M:6=H="`H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P``
M```````2<U)'0B!)14,V,3DV-BTR+C$``````````````!)S4D="($E%0S8Q
M.38V+3(N,0``````````````````````````````````````````````````
M````````````````6%E:(````````/-1``$````!%LQ865H@````````````
M`````````%A96B````````!OH@``./4```.06%E:(````````&*9``"WA0``
M&-I865H@````````)*````^$``"VSV1E<V,`````````%DE%0R!H='1P.B\O
M=W=W+FEE8RYC:```````````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```
M``````````````````````````````````````````````````````````!D
M97-C`````````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S
M<&%C92`M('-21T(``````````````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@
M4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````````````````````````
M9&5S8P`````````L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0``````````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$`````````````````````````````````
M`'9I97<``````!.D_@`47RX`$,\4``/MS``$$PL``UR>`````5A96B``````
M`$P)5@!0````5Q_G;65A<P`````````!`````````````````````````H\`
M```"<VEG(`````!#4E0@8W5R=@````````0`````!0`*``\`%``9`!X`(P`H
M`"T`,@`W`#L`0`!%`$H`3P!4`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`
MF@"?`*0`J0"N`+(`MP"\`,$`Q@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-
M`1,!&0$?`24!*P$R`3@!/@%%`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!
MJ0&Q`;D!P0')`=$!V0'A`>D!\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G
M`G$">@*$`HX"F`*B`JP"M@+!`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#
M6@-F`W(#?@.*`Y8#H@.N`[H#QP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q
M!'X$C`2:!*@$M@3$!-,$X03P!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%
MQ075!>4%]@8&!A8&)P8W!D@&609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]
M!T\'80=T!X8'F0>L![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(
M^PD0"24).@E/"60)>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<
M"O,+"PLB"SD+40MI"X`+F`NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-
M#0TF#4`-6@UT#8X-J0W##=X-^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>
M#WH/E@^S#\\/[!`)$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2
M!Q(F$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.
M%/`5$A4T%585>!6;%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7
M]Q@;&$`891B*&*\8U1CZ&2`911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[
M&V,;BANR&]H<`APJ'%(<>QRC',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>
MZ1\3'SX?:1^4'[\?ZB`5($$@;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O
M(MTC"B,X(V8CE"/"(_`D'R1-)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<F
MZ"<8)TDG>B>K)]PH#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV
M*VDKG2O1+`4L.2QN+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O
M_C`U,&PPI##;,1(Q2C&",;HQ\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38
M-1,U336'-<(U_38W-G(VKC;I-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ
M-CIT.K(Z[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B
M/^)`(T!D0*9`YT$I06I!K$'N0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%
MFD7>1B)&9T:K1O!'-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:
M2^),*DQR3+I-`DU*39--W$XE3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92
M,5)\4L=3$U-?4ZI3]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+
M61I9:5FX6@=:5EJF6O5;15N56^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@
M!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]
M9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O
M'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X
M=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_
MA'_E@$>`J($*@6N!S8(P@I*"](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$
MB&F(SHDSB9F)_HIDBLJ+,(N6B_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1
M/Y&HDA&2>I+CDTV3MI0@E(J4])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IH
MFM6;0INOG!R<B9SWG62=TIY`GJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D
M5J3'I3BEJ:8:IHNF_:=NI^"H4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XM
MKJ&O%J^+L`"P=;#JL6"QUK)+LL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FX
MT;E*N<*Z.[JUNRZ[I[PAO)N]%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8
MP]3$4<3.Q4O%R,9&QL/'0<>_R#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.
MML\WS[C0.="ZT3S1OM(_TL'31-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQ
MVG;:^]N`W`7<BMT0W9;>'-ZBWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F
M#>:6YQ_GJ>@RZ+SI1NG0ZEOJY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_
M\HSS&?.G]#3TPO50]=[V;?;[]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^
MW/]M____[@`.061O8F4`9$`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#
M`0$!`0$!`0$!`0$"`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"``R`(T#`1$``A$!`Q$!_]T`!``2
M_\0!H@````8"`P$`````````````!P@&!00)`PH"`0`+`0``!@,!`0$`````
M```````&!00#!P((`0D`"@L0``(!`P0!`P,"`P,#`@8)=0$"`P01!1(&(0<3
M(@`(,11!,B,5"5%"%F$D,Q=2<8$88I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$
M5'-%1C='8RA55E<:LL+2XO)D@W23A&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI
M:G9W>'EZA8:'B(F*E)66EYB9FJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8
MV=KDY>;GZ.GJ]/7V]_CY^A$``@$#`@0$`P4$!`0&!@5M`0(#$00A$@4Q!@`B
M$T%1!S)A%'$(0H$CD152H6(6,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V
M160G"G.#DT9TPM+B\E5E=58WA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=7
M9CAVAI:FML;6YO9G=X>7I[?'U^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI
M^2HZ2EIJ>HJ:JKK*VNKZ_]H`#`,!``(1`Q$`/P#?X]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5
M;<=56_\`#FT])_$,G]C_`*%DD_AW\2K_`.%^7[!?WOX9]Q_#_/?^WX]?^/N!
MA)+_`,$`T?CR>#^Z:Z=;:*Z1G1737YTKU+I2/_6=#^$GB?O'XM*ZOBX:J:J?
M*M.K)/<\]1%U[W[KW7O?NO=?_]#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1:U^.T*_)U_DC
M_?&J,S[*&SO[E_P6F^T"BG$'\1_C?WWW)DXOXO!;_:O8"'(RCW!//G[T;4;3
MP/`\,4X4U>)JK7Y:?SZ%_P#6MOZFCE'Z!=/U'B^+K->-=.BE/SU?ET93V/>@
MAU[W[KW7O?NO=?_1V??B#\]=TR?`_P"2OR\^5.4GW3C_`(_]V_+^AR\G7NS,
M?19C_1;T;V=NC";>Q>*VW2UU)2Y?/46VL1'$9'GB>LF&IV!)/LAV_=2^VW=_
M=5TQ22`_#6B&G]$>1(KP&"QH6)K=V*B]MK6V%#(B<2>+"OSZ&C?O\SOXX]<8
MKN[,[@Q?;,M)T#0_%7(;WCP^P_XK6UD7S$GCI^I(-J4%-ES5[AKH9I57+4\2
M+-2.0D2U#D*79=\LH5NF=9*0B(M1:_VWP4SGY^GE7II-MN)#`%*5DUTS_OOX
MJ^GRZ0M7_,$V-M7M/=V].U-U=N=-]8;,^"-?\HMV]#=I]!4NV]S;,PF&[AW#
MLV;?F=W;3;@R>[H]\YJFQ"T-+LH4#`P3050F^XE,"M'=XH[B26XDDB@6T\4Q
MO'0J`Y&HFI.HTH$IZ&M<=7%@[Q(D2(\K3Z`RM4'M!H!2E!QU5^71G?B_\P-A
M?*6;LW!X39/;74W8O3>9VUB.R^I.\=FQ;(['VI#OC;D.[=BYJNQ5#E]PXF;"
M[PV]*T]))!72NCP30SI#-$Z!=8[C#?\`CJL4D<T9`9'&EAJ%5-*D4(X9]0:'
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MI)76R!RO8SH*L@:O$`'RH:$`FG16^WSI;BX+)32&*U[@K&BL1Z$T\ZY%>BT[
MR_FJ=4=I?&+NCM+JO*_(#H&FV9@>G]_;*[;W9\;:;>E'V!U5V9W!A^OMO]F=
M1[:RVYZ3:V_=K;KR,-7C98:W(XW-XBGJ4KYZ",&F$R2;?(9=ON;F%I80NDJQ
MC#%E+A=2J6RI)IG21DTQTICVR6.YABE$<E2P*AZ4(6I#$"H(XX!!X5Z4G3_S
MYSU+\I/DKT+VM-DM^9JH^:]!T!\:NO\`K7:&*J-T[?Z]H/COUQVGO??G8#KD
MZ!Z?K39N3W!52Y/<M:P2&>LI\?"D]2\,+N6^ZDWM[:2U9Q<:$4::Z="L6I@Z
M5U"I[CY\,"LMBOTUO/%VKX.IR2:5U%0!QR:8'Y]*[%?S6.CMW9/L3!;#ZW[^
MW%6X+8_?6\^G<TO6:P[4^48^-F>@VCV_BOCUD9-P15N]LIL[=-7%3RT]33XR
M2LAUU%']Q`C2C:[_`&LC3)%#,Q"R%#IQ+X9HXC->XJ?6E>(J.J':YE$;/)&`
M64-G*:\KKQBH^WY]![\+/D_\A>S_`.53O'Y5=F;MRF;[LJNK>\.S\+G\[U9M
MO8FT\=6X;:V9SVT8.O<!A:B:GWOU)AZBDB7#YFO<5^=HT,M4%=B`UME]>3[!
M)?SR$W/ANP)4*,`D:0/B0>3'+#CTY>6UO'NB6L:`0ZE!`8DY-#4^3>H&!Y="
MYU/\VI=I?R\/BQ\HN^J'>?8_8O<76G1D#[9Z9ZXK,_N_LON/MC"XO^';=V;L
MO",N,Q#YW-54C"6MJZ'$8Z!6DJ:N"%"X56NY$;18WUR&>:2-310*LQ6M`,"I
M\L@$X&2!TS+9ZK^YMH"%C1FRQH`JGB3\OS/47_AU'H2;9_4^X,7UQ\C-P[M[
M=[/[IZ0Q73>W.J3E^WMM=R_'[$9_,=H];[OVO#GUH\=G<##MJK43T]958V30
M)?N5I[S"G[^M#';NL,S22.Z!`M7#Q@EE(KQ%#P)'SIGJW[LGURJ9(PB*K:BW
M:58@*0:<#7[?SZ1&%_F3=.;SWEU-W+A.WM[8+X];G^"/?GRSS?7N7Z4QGA7:
M_3N\=HX?=V[MT=D'<4FX-J;TZ[J*JJQ#[7I**MILG--),*J\$7D;3>;>5X+M
M;EA9&U>4J4'!2*L374"N05`(J>/"MFV^5$EA:(&X$ZH"&\V!H`*4(/'57'IT
M"W7W\V":7L[Y;=L=G;7[:V5\6NH^A?AGOG:/5FZ^HL9@.],+N/Y#[^W?LFIS
MU50T^XZQ=Q[:W')-A9Z:1:YJ>G@BJ2EY$D3VFBY@4RW]Q-%*MG'%"P4J`_ZC
M%0:>8.#7413@`0:O2;7^G:Q1LAN7>0%@U5H@!IPP1GRZ-_V)_,QZ*Z^F[,PZ
M;+[LWQO;KOY,X?XC8WKK8FQL;E=Y=I]W9CJ>@[N7`]74N1W/A\5FL=C>M:N7
M(U5975>-BC%%/&NN41)*93;Q;PB>D,KR),(]*@%F<C50"N,9[M/RXK5)'MTT
MGAG6BHT>NI-`%KIJ<>N,5Z.;U)VCM7NOK/9';&R?XVNU=_[>Q^Y,+#N;;V9V
MEN.DI:^+4U!N#;&X:/'YO`9O'3AX*JDJH8Y8)XV0CBY,8)DN(8YXZZ&%144/
MY@^?226)H9'B>FI33!J/R(X].]1O[8E)45%)5[UVE2U=+-)3U5+4;CP\-135
M$+%)8*B&2L62&:)Q9E8!E/!'M"^];/$[Q2;M;+(I((,J`@CB""U01Y@]*DVO
M<Y$62/;IV1A4$1N00>!!ID=<!V'L!D>5=\[/,<3Q))(-S84I&\XF:!'<5NE'
MF6GD*`\L(VM^DVU^_-E(+#>+72*5/BQXK6GXO.AIZT/IUO\`=6Z`@';;BIK_
M`*&_E2OEY5%?M'KU_]*Z_K3XJ_/W'_#3YN_`G.?%W;."P?>Z_.G>/7_?\_R#
MV!D,54;E[GW?N?='66S\MUQBZ.KW%C8<]%FD@FR1J_'0LNJ:(7-@7#8;N-MW
M3:6L%"2^.5D\1:5<DJ"HR*UXUQZ="*2ZL#=V5\MT2T?A@KH/!0`Q!X8]//K#
MG/A1\WNS=F?*W,9WH3!]?[J[=W!_*5DV+LI^Y]A[HJ3A/B)O[%5O;U;FMR8V
M2BP]!EL+A,>]9%3IKBJ]214LT\NJVCM>YSQ7[26@1Y#::1K5L0GNJ:@#A_FJ
M>M"\LXVM56<LJ">ITD?V@[:#_5\Z=&?^>'P8[]^3?=GRFR&PJ+;>)VIVQ_++
M'Q[V/O3<&>HDH6[QQO?60[*QFV,U@J8S[@HL!6XJ.G\^42!X8A,P75(FDKMV
MVJ[OKJ_:(*(Y+'PU8G\8DU`$<:4\^D]C>P6T-J')+)<ZR!_#II4'A7Y=#5_+
M2^.&[.BX>^-Q;E^*G7WQ*H^Q\_UW%MO9&#[@W)WOV;G<?LO9K465W%VUV3E-
MS;CV]7SR[IS-?%@J3%^$4F(1/N09GTQJ]ELFM!<NUBMOK*]H8NW:"*L^I@<G
MMI2@P1Y],[C<+/X"K<M+I!SI"C)X**`\.-?/AU7O3?`SYCY?Y1[OA7H#KG9>
MR<A_-7A^<>$^8U3VELVH[!PO36#GPDE?U7MK9.!Q-=ON:;LJ@V_)05-)7U]/
MB8Z;+3^>G+!F),-IW%K^0?1HL1O_`!Q-J74$%.P*!J[@*4)IDU'2_P"NM%ME
M_78O]+X?AZ334?Q$G&*UQG'0D]'_`,O?MWKWYVY_L+-?&+J')[;I?E;\COD9
MAOEMN3N#=.4RU/LGM+#;JR?6/7?6W1.!W!BZ#:W8.W-T;N.*S^9R=!+25&"I
MZAH'J*BJC\+UKL]S#NKS-8QE/J))!*7).E@2JK&"*,":,Q%-(-*DX:FOXI+$
M1K<OJ\)$,84<5I4EB,@@5`!X]`2OP5^>69Z$^:W5>!^/&S^B-C]Q8/H'<&W?
MC9@/D!@=]=35'R<V]\AL+O'O3M3XYRY+[5ND>D-];'PT>3;;&5-+4-F=1BI8
M7:0RIFVO=GM-SMDLUBA=8],8=2ID$NIW3^!&7.EC6N!PZ?%[8K/92M<%W0L"
MY4AM!2BJ_P#$P.*CRZ'.3X'?(_8GSJ[%^=?7_6L%9V//\]MEFFE3LS;E/!V'
M\`-^=![4ZU[EH/X!6Y&#&8K<>SNQ@^YZ2EJVBR60FP4,<5P\-U1VF[BW67=H
M(:SFZ'X@-4#(%<`5X@T?-"2*4X$L_76[V4=E))^GX!\CB4,2N?0CM]!7K'\:
M/@U\MMC]A]"['WUUSM7;_6/PDV5_,'P&Q>W*3LO"9V7Y&UGRUWO'E^N/X-L.
MCIXLUUK_`'8VV\G\<;,2`??A8Z0RP7E&K':MPBFM(9856"U6X"OJ!\3Q6JM%
MXK0?%7SX8Z]<WMH\<\B2$RS-$2M*:-`SGSJ>%/+CT=#XU?'#N7K[^4?LSXL;
MQVS08OO3$_#G<O4F1VG!N3#9+&T^_LCL'/X*CPZ;IHZB3!34KY*NBC-6LIIU
M5M1;2"?9I9V5Q#R^FWLO^,BW*4J..D@9!(_F0/7I'<7$,FZM=*U8#,&K0\*@
M\./1)]N==?S0/^&^NK_BE2?&:LZ<S/2-!\7-@[MR?7ORPZU@W[\B.F=JU!Q7
M>FT^M]X8ZDHH>CMRY;"8.D7^(U60$[4&1J8J*HBJ460%<<6^#:(+#]WZ&B$:
MG3*NJ1!API%-!H`:D^9`Z6-)MOU\ET;G6KER*H:(Q^$D?B%?*GV]%BVIU#WC
M\-=Z?RZ]O97H/;.%['RO\P7^83V1U'\<L)W5@:NAJMC;Z^/785=L[:&.[=SD
M5525.6PNUIV,E1E8TGKJBC83-$U0L@116MWMTFT*+(>+]7<.L8<4TM&:#6:C
M%:5;B>-">E3S07B7["<F/Z>)6?2>(<5.G[?3A^70C["_EA_+:AZ(ZVZ>S^V=
MH8S*2?RD_G3\7]U9Z'>V%R&&VCWW\DNUMN=A[&VA/!%(,CG,10T<,]/79>CB
MDHDDIV96(>/4[#L5^+.&W=%#_N^:(FH(#R,&`.:XX5`(XYX5:DW*U,\DRL2/
MJHG`H:E44@G_`#`]9MX_"CYV=P=:?,_)Y_X\X#8&]NVOBW_+RZVZ[V%-W=L'
M<LFX-V?%CM+)[M[#Q-9N;'21X7;U17XDJ:"2H9Z)WFC#5)/E$6I=KW6Y@W-G
MLPDLEO;JJZU-3$Y+"O`5'"N/GQZ\EY8Q2686X+(DLI)TD4#K08\_GY]+W='Q
M`^4^]NN?FE6=G_"_;/8;?)WYM[/[E3J3$?)?;6SNR]A]>XCX[[2V=@.V>AN[
M\>N/Q>S/D!UOVQM:BJ(WK#CX9*!*R.&6:.2/[A0=OOWCW*2?;%=IKI9`GB+J
M`$:@,CG`=6`.10BHR#EL7=JLEF(KPJ(X2NK02"=1)5E\U*GR\Z=7)_#G;OR`
MVE\6^BML?*C<=!NWY"X+KG`8SM?<>.JX<C%E=T4E.8IIZK*4U)0TN7RZ4BPI
M7UD4,<596K+,@T./8CVY+N.QM4OW#7@0!R,Y^WS/J?,YZ*+MH&N9VM5(MRQT
MCY?ZN'0;[H_E]?'#=^Z-R;OS6(W3)FMUYW*;CS$D&Z\A3P29/+U4E96O!3HN
MB"%IY250<*.![C'<?9/D3=-PO]SN[6Y-W<S/*Y$S`%W)9J#R%3P\NA]9>Z?-
MNWV5G86\\`MX(EC2L2DZ5%!4^9H./3?#_+G^,T&/R.,CPV[!2Y2LPU?5J=W9
M$NU1@8,]3X\H^FZ*D>XZK4!^HLM_TCVROL7R`D,\"VMSX<C1LWZS<8Q(%_E*
M]?7'ITZWNSSBTL4QN(-:*ZC])>#E"W_5M:>F?7K_T]U7I3N+?G8G8G;&W\_@
M\11;8V1N7+[6IZZCIZNCJ,3N?&9O)0TVT*FMJZ^IIMU9&MV/3T.?GJ*.*GCH
MDR20,K<-[CSE/FG>=\WSF2RO;.)-OM+AX0R@J4E21@("Q8B9FMQ'<,R!0@E"
M$'!Z&G,7+^V;3M.QW5M<R->7,*R$$@AHV1290`H,2B8O`%<L7,98$<.F7"][
M=BS;W[&S6;P&T:+H;KC=W8NS-U[@AJJY-U;07KW:./W6-YY4SU1I<SB-P25<
ME$*&AHS4TC^*0R2*T@5):<X[X^[;[=W=E;)R;875U!-("WC0_30K-X[U-'20
MDQ^'&FM#I.I@311<<M;2NW;3;VUU.W,UW!!+$A`\.7QY6B\):"J.E`^MVTL-
M0H"!5WKOESUQB\-+ELGMSLN@J*!-RU6>P$^SV.X-L8G:>W]N[MR^=W!119"6
M"BPR;4W519".999#)!(5"^96B"J;W,V*WM6N;BPW!'02F2,P?J1)#'%,\DBA
MB%3P9HY`P8U4T`U@KTQ%R)NT]PL$-W9LK>&$<2]DC2O)$B(2H)?Q8W0B@H16
MNDANLV3^677F'H*^NR.W.RZ>3$5>\8\UC'V=*,IA,7L7%[8SVX-RY:E-:!1;
M?AV]O"@KXY6;RO3RV\8E!C]VN/<G8[6&::>POU:)IQ(G@'7&END4DDKC5VQB
M*>.0$FI5OAU=O58>1MVN)8HHKNS(D6+0WBC2[3-(B1J:9<R1.A`P&'&F>G3,
M?)[K_`Y'<6/RN'W[2#!8F;.4%;+M&K%)O+%4FX=O;5KJW9BF85N8IJ7.;IHH
M5D>&".J$I>F:>-68*+KW!V2SGOH+FUO5\&(R*QA:DZ++%"S09U.!)-&M2JAZ
MUC+J"0Q!R;NMS%:2P7%JWBR!&'BBL3%'D`EQ1"4C<T!)6E'TD@=<\/\`)WKG
M+G[8T>[\7EQFL)MQL#EMO/39=<[F^PJ[K/\`A8AAJJFFEJ,1N*@9Z\QRNE+1
MLLS,02!NU]P=BNNSPKJ.Y\6.+PWBH_B27+6NB@)!*2J3)0D(A#$TZ]/R;NT`
MU^);O!X;R:UDJNA(!<:JD`@-&U$J`6:JTZ4>Y>P<YB.\>K>MZ6GQKX#>FSNR
ML_EZF>*H;*0UVT)MH1XN.@F2H2FCIIESTWG#Q.S%4TE;&Z^_WN\M>;N7=AC2
M,V5W:W4CD@ZPT!AT:36@!\1M502<4(S5'9[5;3\M[UN[L_U5O<6Z*`1I(E$N
MK4*5J-`I0CSK7HM5;\F=_MU/T1O&3+]6[(R79^]M\[=W+N7>='EO[D;=QVUT
MWY-CZADCW%C*FGER+;6IJ8O+5Z//4W%@0``9N?\`>OZM\G;HUSMUI/N%W<12
MRSJ_T\2Q?4%33Q4(+>"J5+TU-T,(^3MK&^<S;>L%[<Q65M#)''$5\:1I/!##
M^S8'3XC-0+6B]&GZ0W_D^T^IMA]A9G!C;F4W7@8,I68A#4M3P2M)+#]Q0M61
M05;8S(I"*FE,J+(:>9-7-_<B\H[U<<Q<M;-O=W:>!<7,(=DS0&I%5U`-H:FI
M*BNEA7/0*YCVN'9=\W/:K>Y\6&"4J&Q4C!H:$C4M=+4--0-.A4]B/HDZ][]U
M[IHK\!@<K7X;*Y3"8C)93;M34UFW\E7XVCK*_!5=9224%758:LJ(9*C&5-50
MS/#(\#(SQ,48E21[J41BK,H++P-.'V>G6PS`$!B`>/SZ=_=NM=>]^Z]T&@[@
MZX/9[=,C<T'^DQ<(-Q-M;['*_<#"F/RBN^_^Q_A.CQF^C[CR?[3[(/ZT;%_6
M$\J_O`?O_P`'Q?!TO7P^.K5IT?EJK\NCC]P;O^YOZP?1G]S^)X?B56FOAITZ
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MNUW>[YXW,,XV2]>ZE-NJA3XUW"('9Y`U)(XU&N*-H^US5F8*!TU!SNMO:[3X
M>RQ'=;5((Q,S%AX=O*94"I2J.Y.F1P^4%`!4GIJR'Q,S.:QFZ_XWV73UNX]Y
M[-[+VEF<Q2[.CQU`B[SZXV;UGMVJH,,F>J/MH]MX?9R3SQM42&MJ:B2SPH$4
M)I_;6[N[?<A=[^KWUW:W4+N(-*_KVL%K$5C\0T$20!F&H^(S-0H`!T_%SS;V
M\UC]-LY6TM[BWE13+J;]*XEN)`SZ!7Q'E*@Z1H51AC4]-'87QHWCN#=-9B\-
MGX(=M]BX[MNDWCN2?"45<-M8K>.Q^H]EK@J?%3YNCJ:ROS$&RJF:"NC)6D?T
MR1,MBR;>^0=TO=QEM[6]`L;Z.]6>4QJWA)/;V4'AA#(I9G$#LL@PAPRD<7]J
MYPV^ULHYKBU)O+1[4Q1AROB-%-=3:RP0@*AF4,A^(9!'DX5GQ%RU?G=U9>L[
M*IZPYZ+)T--6U6T/-N;^&UF]-A[NQE+N'<4FX7?.0[9H]DKBL;3Q04=+24<N
MM8_*9"[\OMG<S7FXW4N_JQF#J&,%9=+3V\R"67Q/U!$MN(8E"HB(:A=6JK4?
M/<$5M96\>SE?"*L0):1ZA#-$Q2/1V&0S>)(Q+LSBA-*4;=R_'_?,?9.`R^UA
M'6U&U*SY$]HXG=>4CQU+MU-X=HUE76]?[-J\*N5ERN<FVGN*;^(23R)3T8B6
MX=99="IK_DK>%WZRNMN`=[9]SNTF<*(O'NV9K:!H]9>0PRGQ"Q"I08(9J!ZS
MYIVUMHNH+TE4G6PMFB749/"M@%GE#Z0J"6,:`H+-4\"HJ1DWCU/V)N/=?4W8
M>'W[MW;V\]A;7SNWL^:S9\^XL)GCNP;6EW#+CZ89_!U&+O4;=/VS%Y"BR^I3
M8@BK=.6]\O\`<>6M[M=Y@@W6RMY(Y-4!ECD\;P3*5'B1E,Q=N30-D8Z#]AOF
MTVEEOFU3[9++M]U,CI241NGA>)H#'0X;$G=PK3!Z#K9OQ:W-@CU?B-Q=B8#<
MVR^IMZ[CW;MW`G8"TE96Q;EH-Y4E9C,WD:K<>3I:X0S;N,L<JTL94P+Z=5F4
MBVKV[W"S/+UM?;Y#<;5MEW+-%']/1F$JSJR2,97#4,U0=`II&*Y!MN'.MG<_
MOJXM-IEAW&^MHXI'\>H'AM$0R*(U(J(J$:C\1\L$YRJJJ%4!54!550`JJ!8`
M`<``>Y6````&.H])KD\>N_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U6I'_P!O/9__
M`!"B?^X"^X$'_B0;?]*G_GT=2^?^G-C_`*6/_/W5E?N>^H@Z][]U[KWOW7NO
M_]7?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW5>R?]O&9O^96_\R@3Z?\`,U_^`*_J_P"K%_T3
M[A(?]/S;_DG?\DO_`*C/A_ZM_P"3J5/_``4P_P!S?]S_`/J&X_\`'^K"?<V]
-17U[W[KW7O?NO=?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g532389g90w05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g532389g90w05.jpg
M_]C_X``02D9)1@`!`@$!+`$L``#_X0LX17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````4````<@$R``(````4````AH=I``0````!````G````,@```$L````
M`0```2P````!061O8F4@4&AO=&]S:&]P(#<N,``R,#$R.C$Q.C`Y(#`Y.C$Q
M.C`S``````.@`0`#`````0`!``"@`@`$`````0```-&@`P`$`````0```#L`
M````````!@$#``,````!``8```$:``4````!```!%@$;``4````!```!'@$H
M``,````!``(```(!``0````!```!)@("``0````!```*"@````````!(````
M`0```$@````!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`"0`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`/54._(IQJG7WO%=58ESW&`%'*R:<3'?D7NV55B7._@/
MY3OHM7"=4ZQD=2R/5M&VJLS12=6M_P"$>/HV7*?E^7EE/:(W/_<AJ\WS<<$1
MUG+Y8_\`=2=O-^L[W_T=WV.@ZLM>SU+[!^]CXFC:Z_\`ALKV+/9UKIOJ3DXV
M3F"?YS(OW.CRQALQ6_V%E>E<X>L_VMLU%EA@O\V[O?9_93&EXJ%P(=7N],N:
M>'1O#7M=M<W<WZ"T(\OBB*^FAK_G!R9\YGD;-=_4.+3^Y+T/?].;A645Y6#+
M:+1(:"0WP/Z(^UCVN5U8_P!5*WLZ+47<6/L>T?R2YT?YWTEIY.13BT/R+W;*
MJFESW>067DC62403*I&([EV\,[PPF0(7$3/2,=$J2H=/ZU@=1>]F*YQ=6`YP
M<TMT=('TOZJOILHRB:D"#V*^$XS'%$B43U&H4DDD@N4DJ/5>M=,Z10+^H7MI
M:XQ6W5SWG]VJIFZRS^RU9&)_C"^K.3>VCUK*=[@QMEU;FU[CH-UFK:_^N[$E
M/2I)))*4DDDDI__0Z+ZV=2=D9OV)A_08IET:[K2/_137;/ZZ#A=+L&0,?TQ9
MU#TS<ZMT%M#8FKU&/_1VY=VYGILL_18^_P!7WJWT#`&1U-^;E"7>I=96T_O,
M?M<_^S99[?\`BU7KOZSTOK&5>,5]UE[WAPV/+7M+MU;JK*VN_-6F#43AQD7"
M-ZGAXYGYO_0G$,>*8YC,)$9)T*'%[6./R_X7[C6IZ)UO,N)=CV->X_I+L@[1
M\7.=[W_];:K#L&N^ZGH.`_U0VPVYN6!H7`>F[;_P>/6[8SW_`,\]7,C,Z]U!
MS<6UOV06B1B4G].]OC?8[=]DQ_W[;/3_`.)O6UT?I%73:-H#3<^/5>T0-/HU
MUS[O2K_]2)F3F)1%R,>(?)"'R@_ORE_59,/*0G*H"?"?YS+D],C'_-PA^CQ_
MI-VBFNBEE-3=M=30QC?`-&UJY_K^0_J'4L?H=!]I>VS*([`>_;_UNO\`2_U_
M06SU3/KZ=A695FNP0QO&YYTK9_G+ENE=*ZYE,=U/%R&4OR"_=8XG<Z7>]P]E
MGL=8U0<O'YLLB(UZ82EM[I_[UM<Y,GAP0B9<7JR1A\WLQZ?X:7ZM#TNMYN,P
M[!LM8PG6/3LVL_K;6N2J^M74<9V35FM;;=6#74UC2W]*UWID.@N]GYRHXF8>
ME=:MNRW>I93ZK;BT_3>X3Y?3L4<JS/QLO'ZSE,:RS)><AC`(T86C86G]ZGZ'
MY_Y_\XK9Q"60F41(3A'@[RG'I'_NFA'/*&("$I0./)/C`%QACG^E,?WY>AUK
MNO=9Q15A/#+>IY&TENV&U!_MJIVAWZ2]_P#.6>[TJE*CK/6</K%?3^HNKO%C
MF-<:Q$>I]!['>SZ+OI[V*B,G'J^M3LK+L`HWFUMG(+'5?JK]/S=I8IXM=G7.
MOWY=(_5V;HL,@"*_1Q_[;G_IMBC..`B28#A]KW#*O\I+Y80++'+DE,".61F,
MPQ1A=_J8?/DR1_2XG`Z>S_GC]<GVYDOPV![Q7,`8]3O3QZ!^[Z]EC+K_`/2?
MI%>^LV)]3.K.H;A=4P>F&H/JO-=8.]I]C&>G4ZEOZ-ZR?J9UG$^KO4\EO56O
MJ)J^SV[6ESZ[*W>YKZV_I-K_`-]JCBT]+S_K3TUG1\1V-TNR]@H#]Q]7[.?M
M.7;-KK=WT?3>W?[&?SGZ19[KO39OUEZL>I4_5?ZO"NW+H:*LC/R`2W=6T>LY
MM;3_`(/_``KW^I^E_0UUINE?6OK6'UC,Z-UXTWV8M5EHR*1MUKK;E;7?FNK?
M2[]RM]:Y7I#.B6]6SV_6JU]!:ZPN`=8P^N;'OO#W4?I-W^C9_A4<6=(;T7J?
M4NG]/MPJW-^P8V7=DOM]7[0]M=S64V#8U[<1CG6O]1_I?S/O24Z?3/K9]=>I
M=.SLBAN*1B5MMNR'-V"L!K[;&55ES_7O>S_2?HZO^NK=^H?U@ZGUK'R_V@66
M'&>P5W-;L+@]N]S'L'LW5_R?WUS^*6=/_P`6>5>7!K^JW.:PSR+'MQ(G_P`+
MTOL6S]078W3_`*N,R;WAIZA?98P@$RUI&,SZ(/M_0_\`324__]'N\K[%O9]B
M]?[5ZUWI?98G=+?MN_[1^K?9_7V>MZW^'_F_TB<_;]H^U?;8[^GZ,?\`LI^F
M7S<DI^@V_P`/^<_P6H?FEOT_F_YK;]/^7R/TYTO]F>B[[!MB?TO[^[_A]WZ3
M?_75U?*R2BE\QW_POF;&+Y!\O^!\GT?J+,^P;&_;O2]/=[/7VQN@_1]3\_:B
M4^CZ3/0V^C`]/9&W;^;LV^W:OEE)#]$;_P#<I'SGY=O\-^FKOV#ZS_7^R>MN
M]^_T]V[^7N]VY'S/V=M;]N]';)V>OMB8UV>JOEY)..\?F_E^XQ])_P`W_+_.
M/TSD?\W_`$ZOM/V7T]H]#?Z<;/S?2G_!_P!16\;[+Z+?LNST-=GI1L_L[/:O
MEM)*7RCYM_TOE^B8?.?DV_1^?_"_JOTGU7_FG]I;^U_L'VF!M^U>EZD?F_SW
MOV*VS]D>KB;/L_J['?8(V;MD#UOLGYWI[-OJ>BOF%),97Z2ZG_S1^UC]K?8/
MM<#^D^EZD?FSZWOVJUE_L7['5]M^S?8I;Z/K>GZ4P?3]+U/T7T/H;%\QI)*?
MIFW_`)O_`+/I];[)^SI'V??Z?H3#MGH[OT.[Z?T$0?L?[+1L]#[)_P!IMFWT
MX_X+9[-G]5?,222G_]G_[0_F4&AO=&]S:&]P(#,N,``X0DE-!"4``````!``
M````````````````````.$))30/M```````0`2P````!``$!+`````$``3A"
M24T$)@``````#@`````````````_@```.$))300-```````$````'CA"24T$
M&0``````!````!XX0DE-`_,```````D```````````$`.$))300*```````!
M```X0DE-)Q````````H``0`````````!.$))30/U``````!(`"]F9@`!`&QF
M9@`&```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!
M`#4````!`"T````&```````!.$))30/X``````!P``#_________________
M____________`^@`````_____________________________P/H`````/__
M__________________________\#Z`````#_________________________
M____`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X`````
M``0`````.$))300:``````-I````!@``````````````.P```-$````:`$4`
M>`!H`&D`8@!I`'0`(``Y`#D`7P`Q`"``7P!%`&$`<@!N`&D`;@!G`',`(`!2
M`&4`;`````$``````````````````````````0``````````````T0```#L`
M`````````````````````0`````````````````````````0`````0``````
M`&YU;&P````"````!F)O=6YD<T]B:F,````!````````4F-T,0````0`````
M5&]P(&QO;F<``````````$QE9G1L;VYG``````````!"=&]M;&]N9P```#L`
M````4F=H=&QO;F<```#1````!G-L:6-E<U9L3',````!3V)J8P````$`````
M``5S;&EC90```!(````'<VQI8V5)1&QO;F<`````````!V=R;W5P241L;VYG
M``````````9O<FEG:6YE;G5M````#$53;&EC94]R:6=I;@````UA=71O1V5N
M97)A=&5D`````%1Y<&5E;G5M````"D53;&EC951Y<&4`````26UG(`````9B
M;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L;VYG````````
M``!,969T;&]N9P``````````0G1O;6QO;F<````[`````%)G:'1L;VYG````
MT0````-U<FQ415A4`````0```````&YU;&Q415A4`````0```````$US9V54
M15A4`````0``````!F%L=%1A9U1%6%0````!```````.8V5L;%1E>'1)<TA4
M34QB;V]L`0````AC96QL5&5X=%1%6%0````!```````):&]R>D%L:6=N96YU
M;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F875L=`````EV97)T06QI9VYE
M;G5M````#T53;&EC959E<G1!;&EG;@````=D969A=6QT````"V)G0V]L;W)4
M>7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP90````!.;VYE````"71O<$]U
M='-E=&QO;F<`````````"FQE9G1/=71S971L;VYG``````````QB;W1T;VU/
M=71S971L;VYG``````````MR:6=H=$]U='-E=&QO;F<``````#A"24T$%```
M````!`````(X0DE-!`P`````"B8````!````@````"0```&````V````"@H`
M&``!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N``Y!9&]B
M90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,
M#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.
M#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#/_``!$(`"0`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!!0$!`0$!
M`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'
M"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"
M(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#
MTW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W
M$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P
M,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S
M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$`
M`A$#$0`_`/54._(IQJG7WO%=58ESW&`%'*R:<3'?D7NV55B7._@/Y3OHM7"=
M4ZQD=2R/5M&VJLS12=6M_P"$>/HV7*?E^7EE/:(W/_<AJ\WS<<$1UG+Y8_\`
M=2=O-^L[W_T=WV.@ZLM>SU+[!^]CXFC:Z_\`ALKV+/9UKIOJ3DXV3F"?YS(O
MW.CRQALQ6_V%E>E<X>L_VMLU%EA@O\V[O?9_93&EXJ%P(=7N],N:>'1O#7M=
MM<W<WZ"T(\OBB*^FAK_G!R9\YGD;-=_4.+3^Y+T/?].;A645Y6#+:+1(:"0W
MP/Z(^UCVN5U8_P!5*WLZ+47<6/L>T?R2YT?YWTEIY.13BT/R+W;*JFESW>06
M7DC62403*I&([EV\,[PPF0(7$3/2,=$J2H=/ZU@=1>]F*YQ=6`YP<TMT=('T
MOZJOILHRB:D"#V*^$XS'%$B43U&H4DDD@N4DJ/5>M=,Z10+^H7MI:XQ6W5SW
MG]VJIFZRS^RU9&)_C"^K.3>VCUK*=[@QMEU;FU[CH-UFK:_^N[$E/2I)))*4
MDDDDI__0Z+ZV=2=D9OV)A_08IET:[K2/_137;/ZZ#A=+L&0,?TQ9U#TS<ZMT
M%M#8FKU&/_1VY=VYGILL_18^_P!7WJWT#`&1U-^;E"7>I=96T_O,?M<_^S99
M[?\`BU7KOZSTOK&5>,5]UE[WAPV/+7M+MU;JK*VN_-6F#43AQD7"-ZGAXYGY
MO_0G$,>*8YC,)$9)T*'%[6./R_X7[C6IZ)UO,N)=CV->X_I+L@[1\7.=[W_]
M;:K#L&N^ZGH.`_U0VPVYN6!H7`>F[;_P>/6[8SW_`,\]7,C,Z]U!S<6UOV06
MB1B4G].]OC?8[=]DQ_W[;/3_`.)O6UT?I%73:-H#3<^/5>T0-/HUUS[O2K_]
M2)F3F)1%R,>(?)"'R@_ORE_59,/*0G*H"?"?YS+D],C'_-PA^CQ_I-VBFNBE
ME-3=M=30QC?`-&UJY_K^0_J'4L?H=!]I>VS*([`>_;_UNO\`2_U_06SU3/KZ
M=A695FNP0QO&YYTK9_G+ENE=*ZYE,=U/%R&4OR"_=8XG<Z7>]P]EGL=8U0<O
M'YLLB(UZ82EM[I_[UM<Y,GAP0B9<7JR1A\WLQZ?X:7ZM#TNMYN,P[!LM8PG6
M/3LVL_K;6N2J^M74<9V35FM;;=6#74UC2W]*UWID.@N]GYRHXF8>E=:MNRW>
MI93ZK;BT_3>X3Y?3L4<JS/QLO'ZSE,:RS)><AC`(T86C86G]ZGZ'Y_Y_\XK9
MQ"60F41(3A'@[RG'I'_NFA'/*&("$I0./)/C`%QACG^E,?WY>AUKNO=9Q15A
M/#+>IY&TENV&U!_MJIVAWZ2]_P#.6>[TJE*CK/6</K%?3^HNKO%CF-<:Q$>I
M]!['>SZ+OI[V*B,G'J^M3LK+L`HWFUMG(+'5?JK]/S=I8IXM=G7.OWY=(_5V
M;HL,@"*_1Q_[;G_IMBC..`B28#A]KW#*O\I+Y80++'+DE,".61F,PQ1A=_J8
M?/DR1_2XG`Z>S_GC]<GVYDOPV![Q7,`8]3O3QZ!^[Z]EC+K_`/2?I%>^LV)]
M3.K.H;A=4P>F&H/JO-=8.]I]C&>G4ZEOZ-ZR?J9UG$^KO4\EO56OJ)J^SV[6
MESZ[*W>YKZV_I-K_`-]JCBT]+S_K3TUG1\1V-TNR]@H#]Q]7[.?M.7;-KK=W
MT?3>W?[&?SGZ19[KO39OUEZL>I4_5?ZO"NW+H:*LC/R`2W=6T>LYM;3_`(/_
M``KW^I^E_0UUINE?6OK6'UC,Z-UXTWV8M5EHR*1MUKK;E;7?FNK?2[]RM]:Y
M7I#.B6]6SV_6JU]!:ZPN`=8P^N;'OO#W4?I-W^C9_A4<6=(;T7J?4NG]/MPJ
MW-^P8V7=DOM]7[0]M=S64V#8U[<1CG6O]1_I?S/O24Z?3/K9]=>I=.SLBAN*
M1B5MMNR'-V"L!K[;&55ES_7O>S_2?HZO^NK=^H?U@ZGUK'R_V@66'&>P5W-;
ML+@]N]S'L'LW5_R?WUS^*6=/_P`6>5>7!K^JW.:PSR+'MQ(G_P`+TOL6S]07
M8W3_`*N,R;WAIZA?98P@$RUI&,SZ(/M_0_\`324__]'N\K[%O9]B]?[5ZUWI
M?98G=+?MN_[1^K?9_7V>MZW^'_F_TB<_;]H^U?;8[^GZ,?\`LI^F7S<DI^@V
M_P`/^<_P6H?FEOT_F_YK;]/^7R/TYTO]F>B[[!MB?TO[^[_A]WZ3?_75U?*R
M2BE\QW_POF;&+Y!\O^!\GT?J+,^P;&_;O2]/=[/7VQN@_1]3\_:B4^CZ3/0V
M^C`]/9&W;^;LV^W:OEE)#]$;_P#<I'SGY=O\-^FKOV#ZS_7^R>MN]^_T]V[^
M7N]VY'S/V=M;]N]';)V>OMB8UV>JOEY)..\?F_E^XQ])_P`W_+_./TSD?\W_
M`$ZOM/V7T]H]#?Z<;/S?2G_!_P!16\;[+Z+?LNST-=GI1L_L[/:OEM)*7RCY
MM_TOE^B8?.?DV_1^?_"_JOTGU7_FG]I;^U_L'VF!M^U>EZD?F_SWOV*VS]D>
MKB;/L_J['?8(V;MD#UOLGYWI[-OJ>BOF%),97Z2ZG_S1^UC]K?8/M<#^D^EZ
MD?FSZWOVJUE_L7['5]M^S?8I;Z/K>GZ4P?3]+U/T7T/H;%\QI)*?IFW_`)O_
M`+/I];[)^SI'V??Z?H3#MGH[OT.[Z?T$0?L?[+1L]#[)_P!IMFWTX_X+9[-G
M]5?,222G_]DX0DE-!"$``````%4````!`0````\`00!D`&\`8@!E`"``4`!H
M`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`
M;P!P`"``-P`N`#`````!`#A"24T$!@``````!P`(`````0$`_^$22&AT='`Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2?ON[\G
M(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC.60G/SX*/#]A9&]B92UX87`M
M9FEL=&5R<R!E<V,](D-2(C\^"CQX.GAA<&UE=&$@>&UL;G,Z>#TG861O8F4Z
M;G,Z;65T82\G('@Z>&%P=&L])UA-4"!T;V]L:VET(#(N."XR+3,S+"!F<F%M
M97=O<FL@,2XU)SX*/')D9CI21$8@>&UL;G,Z<F1F/2=H='1P.B\O=W=W+G<S
M+F]R9R\Q.3DY+S`R+S(R+7)D9BUS>6YT87@M;G,C)R!X;6QN<SII6#TG:'1T
M<#HO+VYS+F%D;V)E+F-O;2]I6"\Q+C`O)SX*"B`\<F1F.D1E<V-R:7!T:6]N
M(&%B;W5T/2=U=6ED.F8T,SEA-3<Q+3)A,&8M,3%E,BTX9#,P+6%A860U.3-C
M9#-D9B<*("!X;6QN<SIX87!-33TG:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O
M,2XP+VUM+R<^"B`@/'AA<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO
M=&]S:&]P.F8T,SEA-39F+3)A,&8M,3%E,BTX9#,P+6%A860U.3-C9#-D9CPO
M>&%P34TZ1&]C=6UE;G1)1#X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*/"]R9&8Z
M4D1&/@H\+W@Z>&%P;65T83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"CP_>'!A8VME="!E;F0])W<G/S[_X@Q824-#
M7U!23T9)3$4``0$```Q(3&EN;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q
M``!A8W-P35-&5`````!)14,@<U)'0@```````````````0``]M8``0````#3
M+4A0("``````````````````````````````````````````````````````
M`````````!%C<')T```!4````#-D97-C```!A````&QW='!T```!\````!1B
M:W!T```"!````!1R6%E:```"&````!1G6%E:```"+````!1B6%E:```"0```
M`!1D;6YD```"5````'!D;61D```"Q````(AV=65D```#3````(9V:65W```#
MU````"1L=6UI```#^````!1M96%S```$#````"1T96-H```$,`````QR5%)#
M```$/```"`QG5%)#```$/```"`QB5%)#```$/```"`QT97AT`````$-O<'ER
M:6=H="`H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P``
M```````2<U)'0B!)14,V,3DV-BTR+C$``````````````!)S4D="($E%0S8Q
M.38V+3(N,0``````````````````````````````````````````````````
M````````````````6%E:(````````/-1``$````!%LQ865H@````````````
M`````````%A96B````````!OH@``./4```.06%E:(````````&*9``"WA0``
M&-I865H@````````)*````^$``"VSV1E<V,`````````%DE%0R!H='1P.B\O
M=W=W+FEE8RYC:```````````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```
M``````````````````````````````````````````````````````````!D
M97-C`````````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S
M<&%C92`M('-21T(``````````````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@
M4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````````````````````````
M9&5S8P`````````L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0``````````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$`````````````````````````````````
M`'9I97<``````!.D_@`47RX`$,\4``/MS``$$PL``UR>`````5A96B``````
M`$P)5@!0````5Q_G;65A<P`````````!`````````````````````````H\`
M```"<VEG(`````!#4E0@8W5R=@````````0`````!0`*``\`%``9`!X`(P`H
M`"T`,@`W`#L`0`!%`$H`3P!4`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`
MF@"?`*0`J0"N`+(`MP"\`,$`Q@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-
M`1,!&0$?`24!*P$R`3@!/@%%`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!
MJ0&Q`;D!P0')`=$!V0'A`>D!\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G
M`G$">@*$`HX"F`*B`JP"M@+!`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#
M6@-F`W(#?@.*`Y8#H@.N`[H#QP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q
M!'X$C`2:!*@$M@3$!-,$X03P!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%
MQ075!>4%]@8&!A8&)P8W!D@&609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]
M!T\'80=T!X8'F0>L![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(
M^PD0"24).@E/"60)>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<
M"O,+"PLB"SD+40MI"X`+F`NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-
M#0TF#4`-6@UT#8X-J0W##=X-^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>
M#WH/E@^S#\\/[!`)$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2
M!Q(F$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.
M%/`5$A4T%585>!6;%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7
M]Q@;&$`891B*&*\8U1CZ&2`911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[
M&V,;BANR&]H<`APJ'%(<>QRC',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>
MZ1\3'SX?:1^4'[\?ZB`5($$@;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O
M(MTC"B,X(V8CE"/"(_`D'R1-)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<F
MZ"<8)TDG>B>K)]PH#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV
M*VDKG2O1+`4L.2QN+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O
M_C`U,&PPI##;,1(Q2C&",;HQ\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38
M-1,U336'-<(U_38W-G(VKC;I-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ
M-CIT.K(Z[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B
M/^)`(T!D0*9`YT$I06I!K$'N0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%
MFD7>1B)&9T:K1O!'-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:
M2^),*DQR3+I-`DU*39--W$XE3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92
M,5)\4L=3$U-?4ZI3]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+
M61I9:5FX6@=:5EJF6O5;15N56^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@
M!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]
M9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O
M'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X
M=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_
MA'_E@$>`J($*@6N!S8(P@I*"](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$
MB&F(SHDSB9F)_HIDBLJ+,(N6B_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1
M/Y&HDA&2>I+CDTV3MI0@E(J4])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IH
MFM6;0INOG!R<B9SWG62=TIY`GJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D
M5J3'I3BEJ:8:IHNF_:=NI^"H4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XM
MKJ&O%J^+L`"P=;#JL6"QUK)+LL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FX
MT;E*N<*Z.[JUNRZ[I[PAO)N]%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8
MP]3$4<3.Q4O%R,9&QL/'0<>_R#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.
MML\WS[C0.="ZT3S1OM(_TL'31-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQ
MVG;:^]N`W`7<BMT0W9;>'-ZBWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F
M#>:6YQ_GJ>@RZ+SI1NG0ZEOJY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_
M\HSS&?.G]#3TPO50]=[V;?;[]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^
MW/]M____[@`.061O8F4`9$`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#
M`0$!`0$!`0$!`0$"`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"``[`-$#`1$``A$!`Q$!_]T`!``;
M_\0!H@````8"`P$`````````````!P@&!00)`PH"`0`+`0``!@,!`0$`````
M```````&!00#!P((`0D`"@L0``(!`P0!`P,"`P,#`@8)=0$"`P01!1(&(0<3
M(@`(,11!,B,5"5%"%F$D,Q=2<8$88I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$
M5'-%1C='8RA55E<:LL+2XO)D@W23A&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI
M:G9W>'EZA8:'B(F*E)66EYB9FJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8
MV=KDY>;GZ.GJ]/7V]_CY^A$``@$#`@0$`P4$!`0&!@5M`0(#$00A$@4Q!@`B
M$T%1!S)A%'$(0H$CD152H6(6,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V
M160G"G.#DT9TPM+B\E5E=58WA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=7
M9CAVAI:FML;6YO9G=X>7I[?'U^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI
M^2HZ2EIJ>HJ:JKK*VNKZ_]H`#`,!``(1`Q$`/P#?X]^Z]U[W[KW75Q_4?[?W
MJHK2N>M5'KTC-][]V?UQMVMW5OC<F&VOM['Q225F5S60@H:9`BAA'&9;O4U#
M_P!B*-7D<\*I/LPVW:]QWF\BV_:K%[B[<_"@+$?.@\OF:#Y]$N_\P[/RQML^
M[[]N45IM<2DO*[`::?P@Y8GT`)^758V=_F%[\[=SU?L[X;=.5^^EI&:GR';&
M_6EV_P!?X'0S))75,<XI(XJ6)1K4U=732NI&F%OI[G.U]GMGY<L[?=/<[FF.
MP#KJ2T@4S74J\!0+735JKD8(/6*6Y?>6Y@YPW"YV/V2Y/EOV4Z6W"Y80V4?J
MSEPHU`4-"V00:9Z1,NW)MV5T3_*W^8_BL?45#:J[K?IK?&!V1@J*5B2:1\S1
M5+5LBQ?H+-`E[?J)Y]KX[MK195]N_9*>.V4=L]Y`T\K$<7&H::,<JHX#H/R;
M?'NEZB^[_P!Y2!I'(K96,P@AC-/AUH23\R30^6.C3]>_$'XLYO&1YO8VY]X;
MQ3T_[^S$=_;\RU8\]O1*U?A=U+!#47%[!%'^%O8!WWW%]P(C]+OMO%:GAX36
M<4?Y`-&#3\SU+W+7LM[07@_>G+FY7E\XH2Z;M=R`GU(28J*^E`/0=&>V3L;.
M[%FCQ\&^MS;KVN;+%CM[3KG,[B9+CQ_9;I"4V1K:(`6,5<*F0?591^DQY=WB
M;@3))8)'-QJE`I^>FO\`@IU,VS[/=[(BPINDDNVUH%N*O(/0*XS]FKH7O9?T
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MLW+V_N0]@_)/,5NZ,M'^YL_I/`U,^$P&(IY`LM/+GGBDF?;>(=7!,<?DS=:+
MZY($TO[S;Y9Y+LN7+2/8?;NQCM[>@\7<YUUSAN'Z28\0@@T)HJ5K1JD=<Q>=
M/<;=.=]R/,_N9>/=RU/@[;%*T4"KQ[F%0*BE10EZ4J./00[Y[V['WYBZ7:]5
MEH=L["QJB/$=<;(@?;.Q,9".0!A:.4'+5;'U2U5?)554K\M(?8QV;V[Y:VBX
MDO[BW>_W]VU27=R1)*[?(\%7T50`/MST`-\]T>:-YM4VFWW&2QY;C71':6R"
M&*-/0@$F1O61R6/K2@Z!H1QIPL2`?[2J@?ZP```'L>:FH!A0/)>`ZCL-HJJ-
M(XJ35\L2>-?EZ=#]\;>^]W_'3M+;6^-KY*KI\4F4H:?>&WXZB5,7N7;<]0L>
M2H\A1J3#+/#3.TE/*5UPRJI7@L#'WN3R%M//7+&\VEU;0_O.*'5;RD=WB4KI
M!]:\?+J5_:'W-W[VTYSV#=[#<)EV9Y@EU;@]K)6FLCA0^7GUN3X^OI<E0T60
MHY!+2U]+35E-(/I)!5PI40./^#Q2`_['WRPE1HI987Q(C$'Y$&G7=.WN([FW
MMKF)JQRH&7Y@BH_EU-]TZ?Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z__1W]R;`G^@)_VWOU0,DXZT30$]$*^;_P`R,+\7]E"BP[4F7[6W;252
M;0P,A$L>,B%X9-TYR*_[>+H9C^U&;-53KH7TAV65_:/VKG]R]Z9+K7%R]"P,
MTG"JC(6/^)B:5SA<]8\_>%]\K/VBV`164J2<U7,1\"(4)6M!XD@KVHH)(-#5
M@!UJ^9_?^Z-V;GRV^]UYBLW)O;-UK5]9GLL_W4Z5)Y%3!&UH%FAX2G0*(:95
M'C0$+;HY8;!MNU[59;+M>WQV]E"@2B8+CU;YGSZX\;KS-N>][[N7,>ZM)>;]
M<.2\[L27!_H<$"<!3CTBY96=Y)YY))997,DLLKO++++(Q9WDD<M)++([7+$E
MB?J?9\L$-I;I&@5$7U(%?VT`I\R.B"1KB>X$L[DS28"Y/#T`J<_(=*Y=A;O&
M/ARU7A9\1BJGFFR.?GI-OTM4MKZJ1LS444E6EC^J)7'^/L.S\V<O02-"=S1Y
MEXJ@9R#Z$J"*_GT?KRES(8TFDVEXHF%5,C1QZA_$`[AJ?,@=2AUQNZ;`Y?=&
M.Q]-G=O;>2GEW#E=O93&YN#`0U4JP4]1FHL=4SU>-I)IW$:S2QK"7].J_'MF
MUYRY>NMPM-M:^\&XGDT1F56C5VIJHK,,T'Y_+I^3DOF./:[[>A8:]MM8]<SH
MRR"(5T@/H)H6/#Y<2.'24QN-JLQE,;AZ*%JBNRV1H,71PH"SRU=?5PT=/$JK
MZF:264#CG^GLXW&^MK3:-POIY--M"A9C\A7AZ]%.SVD^Y;QM&WVJUN[B41JO
M]*OGZ=;OFU,.V"VQMS".=;8;!8?&,^HDLV/Q]/2L3_6[1>^0M[()[V_G0]DD
MI8?83U]!FS6SV.T;79OF2.!%;Y$*`:=*,FPN?;%0./1CT%G:7=O5G2>'H\_V
MIO+%[,Q&0R"8J@K,F*F05F0>%ZC[:G@H8*NJE9(8V9V":$`]1%Q<_P"7>5^8
M.;;N:QY<VN2[NXU+,J4!"@@$U8J*5('&N>@=SA[@<G\@6<.X<X[[#86<D@1&
MDU4=B">T*&)%`:FE!Y](;K;Y;?'7M_=$>R^MNT,)NS=$M!692/$4%+EX:AJ#
M'^+[RH#U^.I("L'F6XU:N>![,N8_;[G/E*P&Y\Q\OSVMB6"ZVT$5/EVLU/SZ
M(^4O>3VSYZW3]R\I\VVU[N6@OH36#I'$]RK7\J]&+5@X)'T!M[!WF13J2U97
M4,IJ.N7OW5NO>_=>Z][]U[KWOW7NO>_=>Z`ON_Y-?'_XV8&GW+WQVYLCJS$5
MKR1X^3=F:IZ&MRLD0)E3$8A#-E\N\87U"F@E(_/O8!/`=:)`X]$*C_GC?RRI
M,PN'_P!F+B35*L7\5DZ_['3"C4VD2MD#M32(1]2VFP'U]VT-UK4.K&>HNZNI
MN_-F4/8?3'8.UNRME9"6:GIMQ;2RM/E*`5=/;[BBJ3"WFH:^GU#R03I',EQJ
M47'NA%,'JW'H4/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?__2WD^]
M^ZMK="=7;J[-W;*!C\#0L*.B1U%3F<U5#PXC"T2GEZG(UC*G'Z$U.?2I/L0<
MH<MWW.7,&W\NV$9,\S@.:5$:5[F/J`*GH$^X'.^U>WW*>Y\T;LP\&%#H6H!D
M>ATJ">!)Q\N/6GUVOVEO'N??^X.Q]^9*3);BW%6--,2W^2XZCB+1T&'QL7"T
M^-Q=-:*)0.0"QNS$GJ7R?RGM7)?+]GL.VQJ(X?B<+E_4D<:GCQ^77#+W!YVW
MSG_F?<N:]_G>7<YI-,8KVQP5Q%3A5<584%!PZ>>J>D]Z=N/FJW"QT&%V;M.E
M_B&^.Q-SU)Q>R]G8T69JC*9-E;[BMDC_`,Q14XDJJA[*B\W]E_-/N)L7)YBM
MKAI)]YNQIM;>-:RRL<#6O^@BO%GJ!T:<C>VF]\_-N5Y9'P.6MN.J[O)#X<,:
MC)T,?[7'DN2<`=*K<.\M@]:5*X3I?$5&3RM)&AJ^WM^X:+^\U?/+$#Y]F[0K
MC58G9.+:.0-3S31U&592',D5]`(-JY?YBYG#W?.U\R6#/FPC8Z,9I+,I!D_T
MJZ5!]>A'OF_\L\FLMER)MVO<BG^Y]P`9*'`>W@:OAJ37]1BVL<`*=`3E<ME,
M]7SY7.9*OS&2JI"]3D<I5U-?6S,Q)_<J*J265E6]@+V`]R98V6W[3;K;V$)@
MLT^%(T5](^P@L17)8D]1-?7E_O5P\NX7GU%_)EFF([OL8X7Y*HIY^?5A/Q%Z
MTKMF],?(_P"3.]Z44?72].[QZTVQ19`>*/>^X]V?9T""E@D4&KH,=6>%(Y1=
M6J7.F_B8C'CW>YCBYAYQY#Y!V%UN.91N$=VSH`-$:#*/IH*D"IX4&#QZRM]A
MN3+CE'V^]T_=#F5&AY8_=KV<<$O]C++(0-8CQ4JS"A\SD=,_\MCHJO[<^0^W
MMRUE)Y-G]1M3;RW#5SQ%J6HS,'D7:N(O8*\U3DU^Y9?J(J8D\'E?]X?G&#EW
MDE]EBE'[ZW$:%5332GF_V$8`^?1?]TWVW?G/W)M-]DM2=CV>4O,S`D&5LQQC
MAEL&O``<.MJL?0?ZP]\[_MX]=B/RZPU,@BA=R%(4`G6XC0"XNS.>%"CGWZBD
MJ&\R!ZY)Q_/JCL$4LQ`C'Q$F@"?C8GY+4_EUJ]_-[N+</RP^1&0VGL$R9C9G
M6U%N+&[7IJ9K4E2FW<;497?6[974$&%_X9(D4QN&IH([?K-^@'M)RWM?M;R'
M'S'S'$J;IN+QE=0!(5V"K'0URU0U1\^N1'WAN>-W]Y/<M]AY8<S['MD=P(-)
M.DQP)JEF.FARPTBO`'Y=)C^6MFDQ'S!ZVU2:8LWC=X8,@M82&NVW65,2$W^O
MDHU/'Y'LY^\-`EW[6;R@C3PEN83A`"VDUXC@*-Y]$GW2;Q[3WSY<,[A6>VG2
MI+$`O&&I0GCBGV];$G8'RP^/?46Y)=F]E=G8':&YHJ*CR38G*1Y3[@T&0C+T
M=4KP8^>%XIE0V(<V((-B"/>"&Q\C\X<S6GUVP<O7-W9@Z2T:Z@A`&&/K_GZZ
MF\S>[GM]R;N"[9S7S/:V.X/&LBI(2I=7X$"GVC\NE_L3N3K?L_:DF^=@[LQ&
MY=GPR9*&;<-)4/#CH)<.JME$J)*N&!J?[)6!<N%`4WO;V5[OL.\['?IM.Y[=
M+#NS%:0LI#G5\./GY="'8.<N6>:-DEYCV'>(+G8XW99)E;L30M6.>-.!Z#'9
M_P`R/C;V!NK%[)V5VE@MS;HS50]+C,/B8,Q4U=5-$KO-ITXP0K#"D99Y6<1J
MHN6`]G&X<A<X;18?O7==BEM]MX>(]`I/H*\?RZ#&R^\GMQS'O<7+FQ\QI=;T
MPKX<:LQ`]21@?GUR[3^8GQSZ:KYL/OWL_;^/SM.0)\!CI*C/9JG)(!6JQV$I
MZ^>E=;_ID"M_A[4<N^W/.G-*B39M@GEA/!M-%_::#\ZTZ3\X^]GMGR)=/9<Q
M<T0K>+QCBK-*H]61`2HZA=7_`#5^-'<68@V[L7L_$5FX:IBE'@LK3Y#;V4KF
M`OIH:7.4E`:U[?18B[G^GMSF'VSY[Y7MWNMXY<GCMEXOVLHS3)4FG[.DG*/O
MW[3\[W2V&P<W0/?M\,3AXY&H*FBNHX`9ST'G\PWYL[2^"OQMW-W!F(X,KO"N
M<[5ZIVC)(0=U=AY.CJ9,135*1LLXP6)2%JW(RK^BEA90?(Z`@2*LFK%*&AZF
M`L**:X(J/LZT8NI^M?EI_-R^6DF,R6[ZK>78^XHI\_O3?NZI9DVIUEL6DJX(
M:FJI\;1+]MA\!C9*I*?'8NB2,U%0Z(/4TDH>!\/!S7JOQ=6;_.'^07!\7/B[
MO#O[KSOK.=CYOJS$0[DW]MK<NTL9M_'Y3;JU$%/FLAM2IQU=5UE'58A9_/\`
M;5;3B>&-_P!Q'"@^\3Y=>T_/H&_^$]O?&[]@?.:BZ9Q^8JCL+O+96\:?<FV_
M.TF.;<6S<'4;FV]N6&C+>.#*4T-!/2/,H#M3U#*Q("@-DU)/5A@=;I_=?R&Z
M1^..U1O/O+M#9O6&VV<PT^0W;F:;'/7SKIO2XJ@O)DLO5@,"8J6&9P.2`/>N
MM]$?VA_.?_EL;UW33;1Q?R7V]CLC65*T='7;HV[O+:FW:BI=_'%&-R;@V]C\
M+"LK?I>69(S_`*KW<H0">JA@>K#-W=F;"V'U[F^U]W;KPN$ZYVYMZ;=N:WE/
M6I-@:+;4%,*R3-_?4?W$=1CS2$2(\7D$BD:=5Q[J!4TZV<=%6ZS_`)E/P4[C
MW93;&ZR^3'6^[=UU>,S6:BQ-'5Y.D*X?;F+J,WG<K4UV3QE#CJ+'XK%4DD\T
MTTL<:1K];V!WH/GUK4.@<SO\Y_\`EK;?W;)LZL^3>VZJNAJ?M)\OA]O;SS>T
MX9PYC?5NO%;=J\$\,;BQE29XN+AB.?>_#;KVH=61[0W?M??^U\%O79.X,1NK
M:6Y\92YG;VX\!7T^4PV9Q5;&):6OQU?2/)3U--,AX93P;@V((]U(H:=;!KTH
M_>NM]?_3O#_FW=Z2[L[1V]TAB*N7^!=;T:9O<L4,K_;UV[\]3I)2P5$0]$CX
M/"Z=-[E7JW^A'O-[[KO)R6%A?<W7<'^-7<I2-B!B!0:LIXU+"A\L=<N?OL^X
M<^]<U[;[;;9<@0V4`ED`)TM.Q!T,*\`E/G7HD_Q4^+VY_DYOYL)25/\`=[8N
MVH(\SV'O6H0BEP>"21S)3TKM:.7+Y"."585)T1A'DD]*$&9/=#W-V_VYV8,%
M$_,EQJ6WB!Q4BB,WG@D'!S2@Z@#V5]H=Q]W^9)HXYWLN6[$:[NX<"@502X0D
M4R`5SZUZ/;UA2[1^6?R(VM\?>K\<-K?$+HO[C=61VU0F2-.S:O;M=3TPW1NR
M6/3+F*W=&7>)8FJ2Y6A5VX:2RP)S&N[^V7(-SSIS/(UU[G[["`DQ[F@5ZETC
M!^!E`%*4-3UDYRI#MWN[[H;;[<\EPBT]F.60)YDCPETZ85IJ8D9R3A@4IQ&!
MTU=Q_P`J_P"0V:[6WAF-C9/8N=VCN3<N7SF+R&3S<^#K\9196OGJX<96XLT$
MZEL9%((E-.6C9$72%'I!IRA]Y7D^PY<V>SW6QO$O8K95=1I8/(/B<$Y#-YZN
MB3G_`.YM[B;CS?O.X\N3V4NT7-P7B9GT&&$_"A4^2YHB4`\N/0Y].?RJMA]9
M^3L#Y-;_`,1N/%[<@;,U^V\69L'LFEI:)1.\NZ,YDC!7Y&B@8>N*-::-[`$L
MI((.YO\`O-;_`+](VR<@;3/97<_Z8FRTQ5O)0.P`_836N>I'Y`^YMROR>C\S
M^[&_0WUA:CQ&C`$=M$5%2TI>KM3AVLH.,=%!^8?R3K?E)NO:'17Q[P%12]1;
M=S>/VWL[;^&HEQ=/OO=CLU)CZRFQ4*PQT^(Q\&K[.%E'BB+U$@74NF4?:3V_
M7VXL-VYXY\O5/,D]LTXE=@6@115E4G\<GXOF:#J%/?3W3D]V=TV3VS]L+*O)
M\=XEJEO`"!=RM1A.`.WZ>(<:C54<>KT/A]\;L;\9^FL+L<&CK-TY`_QW?>=I
M8E_W+[EK$7S11R,"[T&'@TTM-<_YN,M8%S[Q!]R.>YO<;FB\YA[EL#5;="3V
M1#"\?Q'B?*IQCKH3[+^V-I[4<EVG+ZZ'W*0"2YE4#]28C^8C^%*^0R3T:\FR
MD_T%_P#;#V`J&E!\74O$T!)\AU7)_,B^2S])=*5.U-N9`4O87:BU.W,(]-(1
M68G`Z%&YL\FEM<+0T4HIX'_X[3@C]!]S3[$\A/SSS='<7$%=DL3K<D89U!T*
M:X(+`5'&@ZQ?^])[IMR'R)/L6V7*IS1NJ^#'DC0CD!VP01VDBOS/1)?Y:_QP
M2?J;N+OC<-&'EW1LG>G7^P$FCU.N+&)K(-T9B-G#?\7&M5*1&')6"6W#>Y/^
M\)S[%+S1R_RGM\SFVAGMWF7&E75@%1*<%`-37SIU`/W3O:UCR5SO[C[I%^K<
MV-U:6ZD94"-EF<$Y[V`TGJM[XB9H[;^3O0^4\AA6+LK;F/G:X4^'+U#8:6,D
MVL)%K-)_P]Y$>[4$5_[7\S1JM5,*NOJ"D8/\_/K%7V6O9-I]Y.1Y9(WC_P!V
MBHQ)XAB\=,?):]6R?S?>H%K-K=>]UXRFUUFWLA/LC=52J`DX7,L]9@)9B`+1
MTF826%6/T-4`/K[QF^ZYS>EAO.]<JWDKB*\M_P!,!V4!P2#0`@5(`K]G6:GW
MW^0EW#8M@Y\V^S1[JRFT2U16'A`=M32N#7SIGJI'8_=O;-!U5FOCAL.;(-B>
MS-YT&1JJ/"_<R9S+35%''BFVM0K"P,=!G*F.!ZE5YD\85O0S7R=YGY)Y1CYE
MM_<3?;A`NVVNAU?N&H#M:K5)8#AZ5ZPAY1]Q^=HN3KWVMY/2;5NNY"5=%5JK
M@*R46@">H'$\>C];YV7+_+J^/6-7'U=*_P`H>^DJ,17[JHW5Y^M=GT=/!4Y?
M';6G(#PU8>IBIWJUMY:ERZ^F)![@W9=XN??OG5Q=L[>W>R5=8:468UHOB#@1
MZ`9I]O63&_['%]U;VNM4L:2^ZW,!"/.M#+;1$5(B)R&'PL345K04IT$7P$^'
M^%^5.X=\[D[*KL^FR-J/24U4<56BGRNX]U9@RUC0U&7J(ZJ<1T5(GGG87ED:
M5!J`O<5^]WNM<^VMKM.Q<J"**\F3O&D:57TH*5!X4/ET!ONT>Q=E[S;AO^^\
MX75R=FMFTJ5<B1I">#3-5S^WHI_?VR:#IGOGLK8VS\KD9*'K[>M71;=RTU1I
MRU(*%J>KH9'JZ98/\NQTD@7RQA-3)?@W]RER3NHYVY"V*_YAL;>22\L&=QX2
M@`\.TTK\\GC\NH4]SMI'ME[E\S[1RKNES'9[9>T0Z]3-I&H!V.:$]K4(QT6W
M^>9\FLWW7VK\<.O*NLJ&INL_CML3=6XZ03'[*?L3MC#T.XLOD#3`Z$JH<!3T
M,0)NP$C@$!B/?,_?K2"PWW>[*#^RBNG5?]*&:G\NNV'(^Y3[MRCRY?W@I=R6
M4+-Z$L@)X_/JW'_A-STWC]F?&'NKY"9BFHZ:N[+[(GP%#F)XHTJ(=E]88J)*
MA?N2-<5!+N/*5KR`'2S4X8_I%B23B.A:OGUE[*_X4(?`/L3;6\.L.P>B.\=[
M[(W%#D]L[EPE;MW9-3@=RX@5,E-403Q2;YIY9\;D%A#:6"EHV`(Y(]Z5-0K7
MKQ:G2@^)W\PO^6C)LSY#]Q_'OX<4?30^+?4E7V1F=UU?6/6FU<CD7RU1)M[;
M^R\+N;;]=F,U%F]WY604D8=@C(Y!)_2?%*4SUL'K7`VGN#LK^:[\\=GT_P`B
M.V*?:E%V)N'*5.7S^5RU)C]K=3]:8*BKL]6;:V13YRJ@PV*\.-I/LZ)7]557
M3+-/Y&+7L4`SGJNHUIT=G^<)\$/@Q\5.JNF-X?%'>R9;<N>WE6;,W=@1VCC^
MR/XQB8MNUN63<]5##554N(KJ:OHDBE,0AI)A4A1$I47V"7!!Z\0!GJ=UU\G]
MU4W_``G^[XZ_W-F\ID91\A,%T+L.JKZZ>IJ*?:>Y:G:O8-;MJA>9VD3%XC'X
MK))'$IT113B,`(`/?@H#"G7B:@]$K_E6_!G)_/+Y`;BZXJ=Z;CZ]ZWVUU_D,
M]VGN#:9A&?R&WJ^OHL9CMFXUJI):'5N3*E#.)UDB%+32,8W(4>]LVD`CK0%>
M@^_F5?%CKOX9?+?>GQ_ZPW?N#>>V=LX#9N6:NW0<<^=QF2W-A(<O4X.MJ,52
MT-%5&C@GBD2188VT3!6!*W/E;57KQ%.MSO\`DA;;S&V_Y9_QS&9JZFH.=H]Z
M;FQ=/4R.XQN#S6^]QSXFAIE<GPTOVJB9$`"KYN![;?XNK+PZMB]TZMU__]0Z
MV]J?.]\?)+M*ODDE<Y7?&_=R9ROYMC=LX'(UK3RLQU!63'4D5+3K]&J)(D'Z
M@/?4"SOK/VY]L-IM)4'C6UG';Q_\.DEI(S#UT!JGY`]<,-]M=T]UO=SFV>/4
M&FW"6=IC_H,<;-$J'R[RM!7S/5W':77LGQ*_EU]@8_:-!'B=W9W;^(BW7D<?
M'IJJ:KWG7XO$Y.-JI+3/#@\1D'HHF8@<-(1J=B</>5M]?W(][MGDWQS)9QW-
M$#?"RQJS)0"@XJ&/KP..NAO.6PK[+_=LYAAY>LP+V:U196458>.%60LQJ3AB
M,\*U%.J@?A3\I8?BCV?DMTY/`5NY-K;FP']V]QX[%3T\.4@@AK(JW'Y#&/5%
M:>>6AF1@T3L@E1S9@0/>6/O%[8W_`+C;);6>W7:C<89_%C+$A14$,M!Y&HH.
M`].L$?N\>[\/LSS)=7FX6<]WMES`(G2+3J"H08ZZJ@E<U)[F\SU:[NC^<1TM
MCJ!Y=H==]B[DRK1L8J7+KA-M8Z&;2=`J*W[_`#%24##GQPM?\>\9MH^ZSSU>
M3M%NE[:VULK5:5C6B^H%`.LSM^^_-[9V-NTFU;+N4U\%_LY=$,2L>%9*,0"?
M(#\NJ^.W^[?D5\L\='NKM'*5/7'2-1DDH-L;)VU!6QS=@9HSJ:3;^R\!*ZY7
ML;<<[E1]U4#^&T-];%"`C2_RURW[>^V<CV6PB+=^;*'Q+F4GP;-0*&64FJK$
M/)5[R>L<>=^?/=3WLM?WAS<+K9/;[Q%$4$*N);XL?TX+=*_XRKL0'E8>&HK@
M$=6I?!KX6TW4L-/VUV)MVAQ?8-?0_:;-V@'7(?Z+]OU<2^;[ZM9-&1[`S:F^
M3K0!XU_8B"(I7WCK[O>Z-YS0\W*^V;C+/M`E!FF':LSKBL=*%8!3]-1\0[FJ
M>LO?N_>PZ<AQ_P!<.9MI@MN9YH]%M;IW_1PMD@DX:9^+MG0256@P+.XUM&@(
M((6UM1)']>?R?<+&@)"_#UEF0NJH-0.'_%=-V4RU#A\97Y;*UD./QF-HJK(9
M"NJ66."CHJ."2HJJF>1O2D4$$;,Q_H/?K:"YO)XH;52\SN%50*EB30`>=2<=
M([V_M;"QN-QO9UAM8T9F9N"JH))-<4`%>M2#Y1]S;B^57?VX]TX"@S>7Q;NV
M`Z]V]04M7DZZ#:F&#^*>GQ]%'+,)<HR2U\^E.#+ZN%%NEWMKROMGMIR)M]KN
M-U%;7$H$\TY.E79S_9$G@4J!QS3KBI[V<[[K[T>Y&^;EM%G<7%E&_A6L*(SO
MX$:Z&E18Z,=35:HX<>EIM7O+YT['VCC=A;47M#![1P^-;#X["476#"EIL>ZR
M>6+4VV&ED,HE<R2.Q=F8DDGGV0[CR;[);QN5YO-]N%H^ZR,)"WU+Y<$4H-=!
M]@%.A'M7N/\`>*V38;7ES:K7<;;:$B\%47;M`"%6#59T-2035CW$YK7HIVS,
MM4;=WWM+-WD@J\)O';^4DU*T<T,^.SM)52@H0#'*KQD$$#2?<K\S;>EWRIO4
M$:*]FU@S+I:NHZ*`_D`,=0ORC>7=MSMRY?&/08]UA!+L:HZN2Q(/J6..KP_Y
MG'RXVW#M:M^-FR4QNY=P[HAQDN_JV2"*OIMKT#205^.Q%$`'#;KKITC<$7:D
MCL;>1AIPU]@O;6\GW7^ON]N;;9K!B035=1J>ZN.P?S/RX]"/O6^]NSQ[`GM;
ML+_4;S?P"261`L@@09"*I!#2RL"M.*CAQZIXZ*[#K^B^\M@[]JZ&6&396[J9
M=P8ZLIUBJHL;)*^+W!2RPU2!J:LAH:B6VH*Z2(/H?>5O/^RV_-O(^_;?83B>
M&:$S(Z_B:E5-1Q`P*<.L$?:SF&Z]O_<3E3>+N`Q_XW$CJXS"C4J&!^%Z&IX$
M'HYW\UO=C[B^1V`Q\$PGP^"ZNVS-B)$<M%41[DJ,AF):N(7*E9T:(!A]0@'X
M'N*/NP;8=OY*WR>9*74URT4GE54---!@$$'AGJ>_OJ[\VZ^YVU06\C-8Q[;;
M2Q%33^V?+`C)#*1\O,=66_RR\9A=B_#FEWGD)(Z.'-Y[?&\\[7NVD)1X>JEQ
MD<LDEP`M/C\(/J;`$^\>/?>[N=Z]U;[;H(RTJZ8HQ2M"?\-2P`ZRQ^ZE9[7R
MS[#6N^W;:!/)<SSO4C48I6"GCBBK2@P?/K7OS4V>[X[JRM1C:>6NW#VSV16R
MT%-&&>1JC=.??[5`%N5CI:6I4M^$1"3P/><MA)9\C^W-DMV1%;6.VD$'B&*X
MR<_'Y?EPZYE;D=S]R?<S>$V^(W-UN^[,@('&K4!QPTKG''SZKF_F^[2K=C?S
M"N^=K54$D%'BHNM:;;Z.NE#MJEZNV?0X=H%/T@,=(VFWIN"!]/?+R\O#N%]=
MWK(?$F=G8^I+$_9Y]=UMJL4VC:=HVB.C);VD4>H<*Q($8?MSUM2?R.JSKSM+
M^5OM;K&BRJRST%1V_L#LW'8;(?9;@PM?NO<FY*R1VDIF^]QM7D=MYZ"HHZ@"
M]F#(24-D4GQ=&:\.M=3^<A\9_@Y\0=\];=)_%>BSLG8L-#DMQ]NU>3[$R6](
M=N8R=::BVGM:JHJR26/&9ZND$];*"5FCIDBU+:53[M'P/IUIN/03[:V]E>NO
MY.G9N_:4O3CY)?-'8?7E?/&ACEEV?TUL[.[DCH99OI)0U^\\@6TWTF2DY%['
MW?%>M5-.E;_*3_EM['_F);K[KQO9&]]V[(VSU;MW:-93U&S(\)+E<CG-U93*
MQ0P52YW'Y*F&.IZ'"3,=**_D9?5:X/F-*4Z\,]'.^2'\L?\`E&?$+L:@ZK[V
M^:W?.R][9+;5)NM<;1[,Q6XEI<'7U=71T,^2J-L=?96*@EJY:&5HXI;2-&NL
M#202SK;UZO3HM?\`,GVKT+\>OB/\//CU\8NP]W=G=5=I;N[3^6(WIO/&?P/-
M;ACRE+@^MMM3R8E\)MZJAQ<$>)KOLGEI5,B7=2RL";(Q+9ZT0`.K=/\`A,[U
M*<+T-\@.ZZNF`G["[-Q.R,14M'ID.(Z[P?W58L4AY:&7,;LD#6XU0_X>]R>0
MZTOGUK1?S!>R#WI\Z/D_OG#2R9&FW/W9N;`[9-S*U1C=OUL&R=OQ0@7U+-3X
M>,H!QZ^/?H^!Z\WEU]%'XQ=74_2?QUZ/ZDIHA$O7G5FR-JSJJZ`]?BMO4$&3
MFT?53/DA*YOS=N>?;;9)ZL.'0Z>]=;Z__]6_3!?&S<_6&4^?\]/MZKS.XMOY
MGK[=.S:*&D+5.XNM:GL*7LO-#"J%U5;5N.V^:258R2TU.T9%_>6>]^XMAS;M
MOLQ#->,L;P7,=TM>V*X\(P1&G`%JC/IUSCV/VFWKDJ[^\%=PV(EOH+ZVEMDI
M_;6`F^HD?YM74/RZM\VWO7I?Y0]:5T>'R^V=][(WI@UHLYA1D(9ZJ&ER,`-3
MC<QC4F%;B,C3-=2DB1RQ2QZE/`/O'*ZM>:>2-]$D@:TW&UDK#)0CN&*UX,".
M%#0@Y'EUFE8[QR'[I\IRV27MO?;%>6X$\*%?$C<T/AR"M04.!48(QCJL3LK^
M6#\3]FUD^2S/R&SG7&$F9Y:;#9S,[,FJ8HKG334%3E(X,I7E20J*4FE8@#U$
M^\@MG^\A[E7%O#:VW+%O>3*E/$$9/^V:F*_/'6)_,WW/_9FPN;B]N>>YMNLY
M)-1C:1,<<+W`ZO0T/V'I%[5Z*Z&V9N"GP7QVZ7W5\@.Q(Y8FI-[=QP5*[1PL
MTO--E:?9\]%B*.2AATB1*O*0TE%8?MRSO:,I]T]P>==_A9N=.9EL-CXO!:D)
M,X\T5A4@^H!..D.S>V/MURU>1Q>U')L_,',RXCO+]]=M$3^,QL%5_4!D`%!Q
MZL1Z(^(\.S=VKW-W+N#_`$G]Y55.M/29>H@BCVMUY0.A7^`]?87Q04>,IJ=7
M*?<1P0,1<1I&I.J)N:.?IMRL_P"KO+UH;3EM*@@8DFS77<.,R/\`;7%.LC^0
M/9JWV;>HN=N;[IMRYU*XH@2VLPPS%;QTTJ!DZA3CCH\$2*$MI'#&U['Z'CW'
M"KX8TJQ(ZGE0$%$8:?EY?+\NLWOP%,#AU[HAWSXVEWYV5U`>L>BML)EYMZ5R
M4^]<K)N'%X/^'[8HRE1+BH1D:JF>J;/5&F.31PM.C@_J`]R;[2[SR=R]S-'O
MW-TU+6SRJ::@R<58^0T\0?6G6/OWBMD]Q.:>0KKE7V^MM<U\X660-1E@)I(H
M->#"H(\QCHLW\N7X1;]Z.WKNGL_N;!46&W3#CO[M;)Q=/E<=F/MJ#(HLV=S4
MD^.FGAAFJ$BCI8TN'">0D68>Y(]\?>#:>=]NVGEKEN0G:(F,KU!&ICPJ#Z'-
M?7J)?NO_`'?]^]O-[W3FSG2V1-S$`@M1BJ(?CT^E16H''/5PLBZE`_Q_V_!X
M]XRNL?:"*$L,_P`_\G6;;`D&GH<>N".M8+>O\MWY<Y#>^\<GA.O,9/BZ[=VX
MLCB:G^^FUZ=Y,=59NMJ\=.(I<BDD3O32(VD@,IX-C[S^Y?\`O!>V=GR_M%A<
MWT\4\5HD4BI#X@8JH#5J",_S\^N1G,OW4/>'<.9^8MPL-E@DM9]QEGC+2^&1
MJ<E2*<2/+T\N/1SOA-_+QWCM'L*K[>^2V-I9MP8+(_>[.VQ-E:'<B5F<DO/+
MO'<%=3S5<%1/22FU+"SLWFO*X]*>XJ]W???:]UV&+E7D.1EV:4?XS(8Q`R)4
MT156G:>)-/.G4\^P'W7MYV+F)^=_="V1MYM)=5M"9/'21](`D<M7N7\/I0'H
M(?F%_+Q[TWK\@]^;VZ>V?CL[LW>]13;D>6?<N!Q#T>X,A3C^\-(:3)5E-/HE
MR$;3JP721,1]1[$7M5[^<I<O\CV6Q<R7$BWD!*=H9JQZB4J?FA%1T#??7[KW
M/^_>XVZ<Q<@[-;3;3?N)I`T_AZ92BZR$!`!U@T(SY].O:/P&^0O;?2_56?RN
M(Q.*[RZSVW)UOG-MY#<&-J*?>VR<#52R;.R]!GJ2>JHJ?/4%#4FF>*=T22.,
M>I2!J2<H^]O*O*7-G,]K!(S\C7UPTX;31H7D-6`&*"OGQSZ=+N=?NU>XO._(
M/)&XSPA.?]KL9+*\7547%NI_Q5HG/&:)0*.36O#HOF!^-G\Q^GV/6](8S;&_
M<)UM6SU3U^W:G<FVL?MB9:VH\]=&]?\`Q)I3CJR<>66%'\<C$DH;FX\O^=/N
M\3;I_7.YN(I=^)#$*D^L$9!0M@/Z$\.HTV[VT^]A:\O1<@66T7\/+(U+I$T*
MHP<]P95()5B26`XYZLL^#O\`+RIOC[F:;L[M'(XG<W9GV<]-A,7BD:HV_LN&
ML@9*R:&JJ8HI<GGYXW,1G")%#&6$8);7[@KW;]\-QY]1MGVF$6O+JT%.$DH4
M@KK(X@$`D'K*;[NOW8[7VJDCYAYGF6]YKUL\>@#P[5F4AJXR^2`WD<@UZ+G_
M`#?/Y1^0^<4F"[JZ5S>"VWW[L_;[[9J,)N`?8;:[.VS2SU&0Q>-R&:AAE?";
MEPT]1+'1U4JO320S&*4QJJ.L`HQ`TU[>LPFX$>I)_,\3]IZUL\!_*6_FP;*W
M/5X':'1_96U*RM=*"MSVT>T=M8';]?$&*+]YN#"[TH8*JB4$F\EP%_`^GNY*
M'C3JN>CNI_PGB^1M%\;NP-];FSN(WG\JLO6[;?8/56!W?CX-MXR"HS^/?=^2
MWOO_`'']I1Y_<#8+[@Q1PR+3(P!\L[L`K;&A[<#JP'KU<%LG^5&^\?Y1NR_@
M_P!G5%)LCMBDI:KL0YVFEI-P4.TNZJC<69W'2RSSXUYJ?*X9(LD<96-3NQ>D
MDD:,E@GNM3QKUN@].J!-A?RZ?YT/PF['SM?\>]E[PQ.7S-#)@<CO'J#>>R<S
MM?=.$2H,U)]_2YVOIR8DG'FA6MH8JBE<DC2;W=JI7/5*$'HX7QE_D5_*3Y`]
MQ#O/^8YO6HI<77YBDSVZ]KU&[X=Z]J=E34WB^WQ>?S^.FJL+M3;TD$*PS)#4
M2U*4X\,,4-PZL=>7545/2L_FQ_RM?G!\IOE>F[>@>H-K572&QNI^N.K^MXY.
MQ=C;6IZ/%;:H*ZKKZ.AV]E<O2UF,HJ/)Y5X(E,2!HX5*\>]@TX=.=72?!#XY
M=I_$7^7)M+IJ+;-%#\@,'UYV)G:_;U'G,34T4_;FY9]PYC%8X[ABJ/X*\`K:
MFCIVJ?+X%2/46L/>R2>)Z]UK4?&'^1U\^,;\F^C]W]Y]8[7PW7&&[;VIO7LC
M-4_9NQ,_5QXK"YZ/<V3\>*QN8J*W(29&LI!`4C1F_>U'T@^_`D<#UZ@/6T_\
MI<)WYD]Y;=GZ]K-[+M.+'8M11[%K)Z>:;(KDLBVXZ/)I25U!44>3RF.:B7%Y
M2H9L=CVBF$H1I`S:Z]TB_P"[/SJ_YZ^E_P#/[M#_`.MOOW7NO__6WRGM_>.?
M_BQ:OX$+7U?Q^WWLU_-_NO\`@E_TWY\NNWMT<$^+CY?Y/GZ=$LNGZN?_`''K
MX1^*M?\`;_T/7\^J#^U_]'O^ES>/]XO]D(^\_C-5?_1__LS_`/?#];?\?G_H
MN_W`_P`7M_G=/%]7^/O*OE;]Z_U=M_I_ZU>'0?\`1N\+\O&_4IZ?/KGYS5_5
M_P#KGO7U/^M_XFHU\/\`?/C\?]$\#].OKHZ$[I/^[/\`>BE_@G^R8_PFS_=_
MZ//]+G^F31?^S_I!_P!_I;_CI]C^Y["G,WUFF3Q_W_JQ_;_2^'_U2[?LKT/N
M2?W9]4OTO]2_"\)O[+Z_Q>(X_4?J4]:8ZM>Z&^W_`+KUOVG^C3[;^*U7A_T:
M_P`4^UT:VM_>'^-_[EO[Q?\`*QY_7J^ON$-WU>.-7CUS_::?Y:<4ZRKY*\/Z
M&3P_W=2H_P!Q==//X]>?L_/H<3_L/K^?]]]?93T-.N_?NM=>]^ZWUU_MO=3P
M;A_J]>MCAUW[WY^7#K77O>^O=>]U'GPZ]UT?]A_L?>SY\.'7O3KW^V]Z\CPZ
M]Y]>_I]/]]_3WOR/#KPX==^]]>ZZ_/X_XG\>_=:'GUW[]U[KWOW6^O'Z'_B?
MI_L??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[^O\`K_\`$#Z_X^_=>Z][]U[KWOW7
+NL?_`%+]^Z]U_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
